Metadata_SMILES,Metadata_InChI,Metadata_InChIKey,Metadata_pert_iname,Metadata_clinical_phase,Metadata_moa,Metadata_target,Metadata_disease_area,Metadata_indication
CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3,"InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3",VMWNQDUVQKEIOC-UHFFFAOYSA-N,(r)-(-)-apomorphine,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A,neurology/psychiatry,Parkinson's Disease
COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,"InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)",HJORMJIFDVBMOB-UHFFFAOYSA-N,(r)-(-)-rolipram,Phase 1,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,,
NCC(CC(=O)O)c1ccc(Cl)cc1,"InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)",KPYSYYIEGFHWSV-UHFFFAOYSA-N,(r)-baclofen,Phase 3,benzodiazepine receptor agonist,GABBR1|GABBR2,,
COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,"InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)",HJORMJIFDVBMOB-UHFFFAOYSA-N,(s)-(+)-rolipram,Phase 1,phosphodiesterase inhibitor,PDE4B|PDE4D,,
CC(C)CC(NC(=O)CN(C)C(=O)C(Cc1ccccc1)NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C1CCCN1C(=O)C(N)CCCN=C(N)N)C(=O)NC(CCS(C)(=O)=O)C(N)=O,"InChI=1S/C64H100N18O15S/c1-38(2)34-46(57(89)74-42(54(69)86)28-33-98(4,96)97)73-53(85)37-80(3)62(94)48(36-40-18-9-6-10-19-40)79-58(90)47(35-39-16-7-5-8-17-39)78-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-59(91)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-60(92)49-22-14-31-81(49)61(93)41(66)20-13-30-72-64(70)71/h5-10,16-19,38,41-50H,11-15,20-37,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,85)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,88)(H,79,90)(H4,70,71,72)",OUPXSLGGCPUZJJ-UHFFFAOYSA-N,"[sar9,met(o2)11]-substance-p",Preclinical,tachykinin antagonist,TACR1,,
ClC=CC[N+]12CN3CN(CN(C3)C1)C2,"InChI=1S/C9H16ClN4/c10-2-1-3-14-7-11-4-12(8-14)6-13(5-11)9-14/h1-2H,3-9H2/q+1",LDLCEGCJYSDJLX-UHFFFAOYSA-N,"1-((z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",Preclinical,,,,
c1ccc(CC(c2ccccc2)N2CCCCC2)cc1,"InChI=1S/C19H23N/c1-4-10-17(11-5-1)16-19(18-12-6-2-7-13-18)20-14-8-3-9-15-20/h1-2,4-7,10-13,19H,3,8-9,14-16H2",JQWJJJYHVHNXJH-UHFFFAOYSA-N,"1-(1,2-diphenylethyl)piperidine-(+/-)",Preclinical,glutamate receptor antagonist,,,
Cc1ccc(Cl)c(OCC(O)CNC(C)C)c1,"InChI=1S/C13H20ClNO2/c1-9(2)15-7-11(16)8-17-13-6-10(3)4-5-12(13)14/h4-6,9,11,15-16H,7-8H2,1-3H3",NJEIOWSBPCZKTL-UHFFFAOYSA-N,1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol,Preclinical,,,,
CC(=O)N1CCN(C)CC1,"InChI=1S/C7H14N2O/c1-7(10)9-5-3-8(2)4-6-9/h3-6H2,1-2H3",YSDBJKNOEWSFGA-UHFFFAOYSA-N,1-acetyl-4-methylpiperazine,Preclinical,acetylcholine receptor agonist,,,
O=c1cc2c([nH]c3ccc(Br)cc32)c2c(n1)CCC=N2,"InChI=1S/C15H10BrN3O/c16-8-3-4-11-9(6-8)10-7-13(20)18-12-2-1-5-17-15(12)14(10)19-11/h3-7,19H,1-2H2",NHJLKJABMYANGP-UHFFFAOYSA-N,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,
OCC1NCC(O)C(O)C1O,"InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2",LXBIFEVIBLOUGU-UHFFFAOYSA-N,1-deoxymannojirimycin,Preclinical,alpha mannosidase inhibitor,MAN2A1,,
CCn1c(=O)[nH]c2ccccc21,"InChI=1S/C9H10N2O/c1-2-11-8-6-4-3-5-7(8)10-9(11)12/h3-6H,2H2,1H3,(H,10,12)",CXUCKELNYMZTRT-UHFFFAOYSA-N,1-ebio,Preclinical,potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,
CCN1CCCC1=O,"InChI=1S/C6H11NO/c1-2-7-5-3-4-6(7)8/h2-5H2,1H3",ZFPGARUNNKGOBB-UHFFFAOYSA-N,1-ethyl-2-pyrrolidone,Preclinical,transdermal absorption-enhancing compound,,,
CCCCCCCCCCCCCCCC=O,"InChI=1S/C16H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h16H,2-15H2,1H3",NIOYUNMRJMEDGI-UHFFFAOYSA-N,1-hexadecanal,Preclinical,sphingosine 1-phosphate receptor substrate,DBI|RHO,,
CCCCCCCCCCCCCCCCO,"InChI=1S/C16H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h17H,2-16H2,1H3",BXWNKGSJHAJOGX-UHFFFAOYSA-N,1-hexadecanol,Launched,,,dermatology,cosmetic
CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(=N)[nH]cnc21,"InChI=1S/C19H19N5/c1-19(2,3)24-18-15(17(20)21-11-22-18)16(23-24)14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H2,20,21,22)",XSHQBIXMLULFEV-UHFFFAOYSA-N,1-naphthyl-pp1,Preclinical,SRC inhibitor,SRC,,
CCCCCCCCCCCCCCCCCCCCCCCCCCCCO,"InChI=1S/C28H58O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29/h29H,2-28H2,1H3",CNNRPFQICPFDPO-UHFFFAOYSA-N,1-octacosanol,Phase 2,,,,
CCCCCCCCO,"InChI=1S/C8H18O/c1-2-3-4-5-6-7-8-9/h9H,2-8H2,1H3",KBPLFHHGFOOTCA-UHFFFAOYSA-N,1-octanol,Phase 2,,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1,,
N=C(N)N=C(N)Nc1ccccc1,"InChI=1S/C8H11N5/c9-7(10)13-8(11)12-6-4-2-1-3-5-6/h1-5H,(H6,9,10,11,12,13)",CUQCMXFWIMOWRP-UHFFFAOYSA-N,1-phenylbiguanide,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,
CCNCCCNCCCCNCCCNCC,"InChI=1S/C14H34N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h15-18H,3-14H2,1-2H3",PGMIWVSHZMWSSI-UHFFFAOYSA-N,"1,12-besm",Phase 2,polyamine biosynthesis inhibitor,,,
BrC1C(Br)C(Br)C(Br)C(Br)C1Br,InChI=1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H,QFQZKISCBJKVHI-UHFFFAOYSA-N,"1,2,3,4,5,6-hexabromocyclohexane",Preclinical,JAK inhibitor,JAK2,,
CCCn1c(=O)c2[nH]c(-c3ccccc3)nc2n(CCC)c1=O,"InChI=1S/C17H20N4O2/c1-3-10-20-15-13(16(22)21(11-4-2)17(20)23)18-14(19-15)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,18,19)",CLIGSMOZKDCDRZ-UHFFFAOYSA-N,"1,3-dipropyl-8-phenylxanthine",Preclinical,adenosine receptor antagonist,,,
OCCCCO,"InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2",WERYXYBDKMZEQL-UHFFFAOYSA-N,"1,4-butanediol",Phase 1,benzodiazepine receptor agonist,MAN1B1|PLA2G2A|PLA2G2E,,
OCCCCO,"InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2",WERYXYBDKMZEQL-UHFFFAOYSA-N,"1,4-butanediol",Phase 1,gamma hydroxybutyric acid agonist,MAN1B1|PLA2G2A|PLA2G2E,,
O=C(C=Cc1ccc(O)c(O)c1)OC1CC(OC(=O)C=Cc2ccc(O)c(O)c2)(C(=O)O)CC(O)C1O,"InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)",YDDUMTOHNYZQPO-UHFFFAOYSA-N,"1,5-dicaffeoylquinic-acid",Phase 1,,,,
CC(=O)OC12COC1CC(O)C1(C)C(=O)C(=O)C3C(C)C(O)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,"InChI=1S/C29H36O10/c1-14-17(31)12-29(36)24(38-25(35)16-9-7-6-8-10-16)22-27(5,23(34)21(33)20(14)26(29,3)4)18(32)11-19-28(22,13-37-19)39-15(2)30/h6-10,14,17-20,22,24,31-32,36H,11-13H2,1-5H3",XGVBNFXVLFKPCO-UHFFFAOYSA-N,10-deacetylbaccatin,Preclinical,antitumor agent,,,
CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21,"InChI=1S/C20H25ClN2O/c1-3-22(4-2)13-7-8-14-23-17-9-5-6-10-19(17)24-20-12-11-16(21)15-18(20)23/h5-6,9-12,15H,3-4,7-8,13-14H2,1-2H3",GYBXAGDWMCJZJK-UHFFFAOYSA-N,10-debc,Preclinical,AKT inhibitor,PIM1,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)ccc3nc2-1,"InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3",HAWSQZCWOQZXHI-UHFFFAOYSA-N,10-hydroxycamptothecin,Preclinical,topoisomerase inhibitor,TOP1,,
CCc1ccc(C=C2SC(=S)NC2=O)cc1,"InChI=1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)",SVXDHPADAXBMFB-UHFFFAOYSA-N,10058-f4,Preclinical,c-Myc inhibitor,,,
CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C(C=C(CO)CC3(O)C(=O)C(C)=CC32)C2C(C)(C)C12OC(C)=O,"InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3",PHEDXBVPIONUQT-UHFFFAOYSA-N,12-o-tetradecanoylphorbol-13-acetate,Phase 2,PKC activator,KCNT2|TRPV4,,
CC(=N)NCc1cccc(CN)c1,"InChI=1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)",RODUKNYOEVZQPR-UHFFFAOYSA-N,1400w,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
CCCCC(C)(C)C(O)C=CC1C(O)CC(=O)C1CC=CCCCC(=O)O,"InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)",QAOBBBBDJSWHMU-UHFFFAOYSA-N,"16,16-dimethylprostaglandin-e2",Phase 2,prostanoid receptor agonist,HPGD,,
CCCCCC(=O)OC1(C(C)=O)CCC2C3CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h9,21-23H,5-8,10-17H2,1-4H3",VPEJMHYFGCNXLM-UHFFFAOYSA-N,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR,obstetrics/gynecology,spontaneous preterm birth
CC12CCC3C(CCC4CC(O)CCC43C)C1CC=C2c1ccccc1,"InChI=1S/C25H34O/c1-24-14-12-19(26)16-18(24)8-9-20-22-11-10-21(17-6-4-3-5-7-17)25(22,2)15-13-23(20)24/h3-7,10,18-20,22-23,26H,8-9,11-16H2,1-2H3",SINAMTXBCYKFDL-UHFFFAOYSA-N,17-pa,Preclinical,glucocorticoid receptor agonist,,,
CCCCCCCCCCCC(=NO)c1cc(C)ccc1O,"InChI=1S/C19H31NO2/c1-3-4-5-6-7-8-9-10-11-12-18(20-22)17-15-16(2)13-14-19(17)21/h13-15,21-22H,3-12H2,1-2H3",OOXQDZTUGOJLHK-UHFFFAOYSA-N,1e-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime,Preclinical,,,,
CC(N)C(O)c1ccccc1,"InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3",DLNKOYKMWOXYQA-UHFFFAOYSA-N,"1s,2r-phenylpropanolamine",Withdrawn,adrenergic receptor agonist,,,
O=C(O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C18H21NO3/c20-16(21)14-3-1-2-4-15(14)19-17(22)18-8-11-5-12(9-18)7-13(6-11)10-18/h1-4,11-13H,5-10H2,(H,19,22)(H,20,21)",XKZLSYWCDJZTMW-UHFFFAOYSA-N,2-(1-adamantylamino)benzoic-acid,Preclinical,,,,
O=C(O)CCC(CCCS)C(=O)O,"InChI=1S/C8H14O4S/c9-7(10)4-3-6(8(11)12)2-1-5-13/h6,13H,1-5H2,(H,9,10)(H,11,12)",FNLNSQHJKVQCBP-UHFFFAOYSA-N,2-(3-mercaptopropyl)pentanedioic-acid,Phase 1,glutamate carboxypeptidase inhibitor,FOLH1,,
O=c1[nH]c(CCl)nc2sc3c(c12)CCCC3,"InChI=1S/C11H11ClN2OS/c12-5-8-13-10(15)9-6-3-1-2-4-7(6)16-11(9)14-8/h1-5H2,(H,13,14,15)",GDHMBNWVLWMONW-UHFFFAOYSA-N,"2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3h)-one",Preclinical,,,,
c1ccc2sc(N3CCN(Cc4ccc5c(c4)OCO5)CC3)nc2c1,"InChI=1S/C19H19N3O2S/c1-2-4-18-15(3-1)20-19(25-18)22-9-7-21(8-10-22)12-14-5-6-16-17(11-14)24-13-23-16/h1-6,11H,7-10,12-13H2",BYHKGNWKJMGHGE-UHFFFAOYSA-N,2-[1-(4-piperonyl)piperazinyl]benzothiazole,Preclinical,serotonin receptor agonist,HTR4,,
Nc1ccccc1S(N)(=O)=O,"InChI=1S/C6H8N2O2S/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)",YAZSBRQTAHVVGE-UHFFFAOYSA-N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA6|CA9,,
NCCOB(c1ccccc1)c1ccccc1,"InChI=1S/C14H16BNO/c16-11-12-17-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10H,11-12,16H2",BLZVCIGGICSWIG-UHFFFAOYSA-N,2-apb,Preclinical,"1,4,5-trisphosphate inhibitor",TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6,,
c1ccc2oc(C3=NCCN3)cc2c1,"InChI=1S/C11H10N2O/c1-2-4-9-8(3-1)7-10(14-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)",YTJOHEUHUVBKSB-UHFFFAOYSA-N,2-bfi,Preclinical,imidazoline receptor ligand,ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB,,
OCC1OC(n2cnc3c(=NC4CCCC4)[nH]c(Cl)nc32)C(O)C1O,"InChI=1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)",XSMYYYQVWPZWIZ-UHFFFAOYSA-N,2-chloro-n6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
N=c1[nH]c(Cl)nc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C10H12ClN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)",BIXYYZIIJIXVFW-UHFFFAOYSA-N,2-chloroadenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B,,
Clc1cnccn1,InChI=1S/C4H3ClN2/c5-4-3-6-1-2-7-4/h1-3H,GELVZYOEQVJIRR-UHFFFAOYSA-N,2-chloropyrazine,Preclinical,,,,
CN1CCN(C2=Cc3ccccc3Oc3ccc(Cl)cc32)CC1,"InChI=1S/C19H19ClN2O/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,12-13H,8-11H2,1H3",OTKUTGIVEREJLL-UHFFFAOYSA-N,2-cmdo,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,
CN(NO)C(=O)NC(C=O)C(O)C(O)C(O)CO,"InChI=1S/C8H17N3O7/c1-11(10-18)8(17)9-4(2-12)6(15)7(16)5(14)3-13/h2,4-7,10,13-16,18H,3H2,1H3,(H,9,17)",IRKFWNAFFNEDFV-UHFFFAOYSA-N,2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose,Preclinical,,,oncology|endocrinology,pancreatic cancer|hypoglycemia
OCC1OC(O)CC(O)C1O,"InChI=1S/C6H12O5/c7-2-4-6(10)3(8)1-5(9)11-4/h3-10H,1-2H2",PMMURAAUARKVCB-UHFFFAOYSA-N,2-deoxyglucose,Phase 2,glycolysis inhibitor,SLC2A1|SLC2A2|SLC2A3|SLC2A4,,
CCOc1ccccc1C(=O)O,"InChI=1S/C9H10O3/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3,(H,10,11)",XDZMPRGFOOFSBL-UHFFFAOYSA-N,2-ethoxybenzoic-acid,Phase 1,analgesic agent,,,
CCCC(O)C(CC)CO,"InChI=1S/C8H18O2/c1-3-5-8(10)7(4-2)6-9/h7-10H,3-6H2,1-2H3",RWLALWYNXFYRGW-UHFFFAOYSA-N,"2-ethyl-1,3-hexanediol",Preclinical,,,,
OCC1OC(O)C(F)C(O)C1O,"InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2",ZCXUVYAZINUVJD-UHFFFAOYSA-N,2-fluoro-2-deoxy-d-galactose,Phase 1,,LCT,,
CC1OC(O)C(F)C(O)C1O,"InChI=1S/C6H11FO4/c1-2-4(8)5(9)3(7)6(10)11-2/h2-6,8-10H,1H3",IRKXGKIPOMIQOD-UHFFFAOYSA-N,2-fluorofucose,Phase 1,,,,
O=C(C=Cc1ccc(O)cc1)C1C(=O)C(C2OC(CO)C(O)C(O)C2O)C(=O)C(O)(C2OC(CO)C(O)C(O)C2O)C1=O,"InChI=1S/C27H32O16/c28-7-12-16(32)19(35)21(37)23(42-12)15-18(34)14(11(31)6-3-9-1-4-10(30)5-2-9)24(39)27(41,25(15)40)26-22(38)20(36)17(33)13(8-29)43-26/h1-6,12-17,19-23,26,28-30,32-33,35-38,41H,7-8H2",DKEZDPGUJMMUCC-UHFFFAOYSA-N,"2-hydroxy-4-((e)-3-(4-hydroxyphenyl)acryloyl)-2-((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)-6-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)cyclohexane-1,3,5-trione",Preclinical,,,,
O=C(OCCO)c1ccccc1O,"InChI=1S/C9H10O4/c10-5-6-13-9(12)7-3-1-2-4-8(7)11/h1-4,10-11H,5-6H2",LVYLCBNXHHHPSB-UHFFFAOYSA-N,2-hydroxyethyl-salicylate,Launched,,,neurology/psychiatry,pain relief
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,"InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)",YPQLFJODEKMJEF-UHFFFAOYSA-N,2-hydroxyflutamide,Phase 2,androgen receptor antagonist,AR,,
NCC(O)(CS(=O)(=O)O)c1ccc(Cl)cc1,"InChI=1S/C9H12ClNO4S/c10-8-3-1-7(2-4-8)9(12,5-11)6-16(13,14)15/h1-4,12H,5-6,11H2,(H,13,14,15)",WBSMZVIMANOCNX-UHFFFAOYSA-N,2-hydroxysaclofen,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,
NC1=NC2C(CSC2CCCCC(=O)O)N1,"InChI=1S/C10H17N3O2S/c11-10-12-6-5-16-7(9(6)13-10)3-1-2-4-8(14)15/h6-7,9H,1-5H2,(H,14,15)(H3,11,12,13)",WWVANQJRLPIHNS-UHFFFAOYSA-N,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,NOS1|NOS2,,
O=C(O)CNC(=O)c1ccccc1I,"InChI=1S/C9H8INO3/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)",CORFWQGVBFFZHF-UHFFFAOYSA-N,2-iodohippuric-acid,Preclinical,,,,
COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,"InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)",FJDDSMSDZHURBJ-UHFFFAOYSA-N,2-iodomelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B|NQO2,,
COc1cc2c(cc1O)CCC1C2CCC2(C)C(O)CCC12,"InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3",CQOQDQWUFQDJMK-UHFFFAOYSA-N,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB,,
Cc1[nH]c2ccc(O)cc2c1CCN,"InChI=1S/C11H14N2O/c1-7-9(4-5-12)10-6-8(14)2-3-11(10)13-7/h2-3,6,13-14H,4-5,12H2,1H3",WYWNEDARFVJQSG-UHFFFAOYSA-N,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6,,
Cc1ccc([N+](=O)[O-])cc1O,"InChI=1S/C7H7NO3/c1-5-2-3-6(8(10)11)4-7(5)9/h2-4,9H,1H3",UMFDLIXUUJMPSI-UHFFFAOYSA-N,2-methyl-5-nitrophenol,Preclinical,,,,
Cc1ncc[nH]1,"InChI=1S/C4H6N2/c1-4-5-2-3-6-4/h2-3H,1H3,(H,5,6)",LXBGSDVWAMZHDD-UHFFFAOYSA-N,2-methylimidazole,Preclinical,cholesterol inhibitor,,,
CCCCCCCCCCC(CO)CCCCCCCC,"InChI=1S/C20H42O/c1-3-5-7-9-11-12-14-16-18-20(19-21)17-15-13-10-8-6-4-2/h20-21H,3-19H2,1-2H3",LEACJMVNYZDSKR-UHFFFAOYSA-N,2-octyldodecan-1-ol,Preclinical,,,,
CCCCCCCCC=CCCCCCCCC(=O)OC(CO)CO,"InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-20(18-22)19-23/h9-10,20,22-23H,2-8,11-19H2,1H3",UPWGQKDVAURUGE-UHFFFAOYSA-N,2-oleoylglycerol,Phase 1,glucose dependent insulinotropic receptor ligand,GPR119,,
O=C(O)CCC(=O)C(=O)O,"InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10)",KPGXRSRHYNQIFN-UHFFFAOYSA-N,2-oxoglutaric-acid,Preclinical,,OXGR1,,
CC(=O)C(=O)O,"InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)",LCTONWCANYUPML-UHFFFAOYSA-N,2-oxopropanoate,Preclinical,pyruvate dehydrogenase kinase inhibitor,ABAT,,
COc1ccc2[nH]c(-c3ccccc3)c(CCNC(C)=O)c2c1,"InChI=1S/C19H20N2O2/c1-13(22)20-11-10-16-17-12-15(23-2)8-9-18(17)21-19(16)14-6-4-3-5-7-14/h3-9,12,21H,10-11H2,1-2H3,(H,20,22)",OFCLARYYBGKCHN-UHFFFAOYSA-N,2-phenylmelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
O=c1nc2ccccc2c2n1CC(CN1CCN(c3ccccc3)CC1)N2,"InChI=1S/C21H23N5O/c27-21-23-19-9-5-4-8-18(19)20-22-16(15-26(20)21)14-24-10-12-25(13-11-24)17-6-2-1-3-7-17/h1-9,16,22H,10-15H2",ALPFEYWIGFAARN-UHFFFAOYSA-N,2-pmdq,Preclinical,adrenergic receptor antagonist,ADRA1A,,
NCCc1ccccn1,"InChI=1S/C7H10N2/c8-5-4-7-3-1-2-6-9-7/h1-3,6H,4-5,8H2",XPQIPUZPSLAZDV-UHFFFAOYSA-N,2-pyridylethylamine,Preclinical,histamine receptor agonist,HRH1,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)OCCc1cccs1,"InChI=1S/C16H13NO4S/c17-10-12(8-11-3-4-14(18)15(19)9-11)16(20)21-6-5-13-2-1-7-22-13/h1-4,7-9,18-19H,5-6H2",KCGLTUBCAGZLHP-UHFFFAOYSA-N,2-tedc,Preclinical,lipoxygenase inhibitor,ALOX12,,
O=c1cc[nH]c(=S)[nH]1,"InChI=1S/C4H4N2OS/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)",ZEMGGZBWXRYJHK-UHFFFAOYSA-N,2-thiouracil,Preclinical,,,,
CC1(C)C2CCC1(C)C(O)C2O,"InChI=1S/C10H18O2/c1-9(2)6-4-5-10(9,3)8(12)7(6)11/h6-8,11-12H,4-5H2,1-3H3",AYEOSGBMQHXVER-UHFFFAOYSA-N,"2,3-cis/exo-camphanediol",Phase 1,,,,
CC1(C)C2CC(O)C(C)(O)C1C2,"InChI=1S/C10H18O2/c1-9(2)6-4-7(9)10(3,12)8(11)5-6/h6-8,11-12H,4-5H2,1-3H3",MOILFCKRQFQVFS-UHFFFAOYSA-N,"2,3-cis/exo-pinanediol",Phase 1,,,,
OCCNCCCOc1cccc(Cl)c1Cl,"InChI=1S/C11H15Cl2NO2/c12-9-3-1-4-10(11(9)13)16-8-2-5-14-6-7-15/h1,3-4,14-15H,2,5-8H2",QVEIRCZEBQRCTR-UHFFFAOYSA-N,"2,3-dcpe",Preclinical,BCL-XL downregulator,BCL2L1,,
O=[N+]([O-])c1ccc(Cl)c([N+](=O)[O-])c1,InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H,VYZAHLCBVHPDDF-UHFFFAOYSA-N,"2,4-dinitrochlorobenzene",Phase 2,thioredoxin inhibitor,TXN,,
O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1,"InChI=1S/C6H4N2O5/c9-6-2-1-4(7(10)11)3-5(6)8(12)13/h1-3,9H",UFBJCMHMOXMLKC-UHFFFAOYSA-N,"2,4-dinitrophenol",Preclinical,ATP synthase inhibitor,APP,,
OCc1ccc(CO)o1,"InChI=1S/C6H8O3/c7-3-5-1-2-6(4-8)9-5/h1-2,7-8H,3-4H2",DSLRVRBSNLHVBH-UHFFFAOYSA-N,"2,5-furandimethanol",Phase 2,hemoglobin modulator,HBB,,
CC1CCCC(C)N1,"InChI=1S/C7H15N/c1-6-4-3-5-7(2)8-6/h6-8H,3-5H2,1-2H3",SDGKUVSVPIIUCF-UHFFFAOYSA-N,"2,6-dimethylpiperidine",Preclinical,,,,
CC1(O)C(O)C(CO)OC1n1cnc2c(=O)[nH]c(=N)[nH]c21,"InChI=1S/C11H15N5O5/c1-11(20)6(18)4(2-17)21-9(11)16-3-13-5-7(16)14-10(12)15-8(5)19/h3-4,6,9,17-18,20H,2H2,1H3,(H3,12,14,15,19)",NVKAMPJSWMHVDK-UHFFFAOYSA-N,2'-c-methylguanosine,Preclinical,HCV inhibitor,,,
CC1(O)C(O)C(CO)OC1n1cnc2c(=NC3CCCC3)[nH]c(Cl)nc21,"InChI=1S/C16H22ClN5O4/c1-16(25)11(24)9(6-23)26-14(16)22-7-18-10-12(19-8-4-2-3-5-8)20-15(17)21-13(10)22/h7-9,11,14,23-25H,2-6H2,1H3,(H,19,20,21)",MMPAUXMIDJWGFO-UHFFFAOYSA-N,2'-meccpa,Preclinical,adenosine receptor agonist,ADORA1,,
O=C(O)CCCC=CCC=CCC=CCC=CCCCCCO,"InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)",NNDIXBJHNLFJJP-UHFFFAOYSA-N,20-hete,Preclinical,ion channel antagonist,,,
CC(C)(O)CCC(O)C(C)(O)C1CCC2(O)C3=C(CCC12C)C1(C)CC(O)C(O)CC1C(=O)C3,"InChI=1S/C27H44O7/c1-23(2,32)9-8-22(31)26(5,33)21-7-11-27(34)16-12-18(28)17-13-19(29)20(30)14-24(17,3)15(16)6-10-25(21,27)4/h17,19-22,29-34H,6-14H2,1-5H3",LAFYUFZYMDYGLR-UHFFFAOYSA-N,20-hydroxyecdysone,Phase 2,ecdysone receptor modulator,,,
Cc1ccc(C=C2C(=O)C3(C)CCC2C3(C)C)cc1,"InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3",HEOCBCNFKCOKBX-UHFFFAOYSA-N,3-(4-methylbenzylidene)camphor,Launched,endocrine disruptor,,dermatology,sunscreen lotion
CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,"InChI=1S/C21H23F2NO/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15/h2-9,18-21H,10-13H2,1H3",MHNSOBBJZCWUGS-UHFFFAOYSA-N,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,CHRM1|SLC6A2|SLC6A3|SLC6A4,,
CC12CCC3C(CCC4CC(O)CCC43C)C1CCC2=O,"InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3",QGXBDMJGAMFCBF-UHFFFAOYSA-N,3-alpha-hydroxy-5-beta-androstan-17-one,Preclinical,,HSD17B11|IGHG2|SULT2A1,,
NC(=O)c1cccc(N)c1,"InChI=1S/C7H8N2O/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,8H2,(H2,9,10)",GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-amino-benzamide,Phase 2,PARP inhibitor,PARP1,,
OCCCNc1ccccc1,"InChI=1S/C9H13NO/c11-8-4-7-10-9-5-2-1-3-6-9/h1-3,5-6,10-11H,4,7-8H2",GZYBSURBYCLNSM-UHFFFAOYSA-N,3-anilinopropan-1-ol,Preclinical,,,,
C=CCN1CCN(c2nc3ccccc3nc2C#N)CC1,"InChI=1S/C16H17N5/c1-2-7-20-8-10-21(11-9-20)16-15(12-17)18-13-5-3-4-6-14(13)19-16/h2-6H,1,7-11H2",IDOXKFDPDOIUMG-UHFFFAOYSA-N,3-aqc,Preclinical,serotonin receptor agonist,HTR3A,,
O=[N+]([O-])c1cccc2c(Br)[nH]nc12,"InChI=1S/C7H4BrN3O2/c8-7-4-2-1-3-5(11(12)13)6(4)9-10-7/h1-3H,(H,9,10)",NFSTZPMYAZRZPC-UHFFFAOYSA-N,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
CC12CCC(C(Br)C1=O)C2(C)C,"InChI=1S/C10H15BrO/c1-9(2)6-4-5-10(9,3)8(12)7(6)11/h6-7H,4-5H2,1-3H3",NJQADTYRAYFBJN-UHFFFAOYSA-N,3-bromocamphor,Launched,,,,
O=C(O)C(=O)CBr,"InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)",PRRZDZJYSJLDBS-UHFFFAOYSA-N,3-bromopyruvate,Preclinical,hexokinase inhibitor,HK2,,
NC(C(=O)O)c1ccc(O)c(C(=O)O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-6(11)5(3-4)8(12)13/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",CHZBCZTXSTWCIG-UHFFFAOYSA-N,3-carboxy-4-hydroxyphenylglycine-(r),Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,
NC(C(=O)O)c1ccc(O)c(C(=O)O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-6(11)5(3-4)8(12)13/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",CHZBCZTXSTWCIG-UHFFFAOYSA-N,3-carboxy-4-hydroxyphenylglycine-(s),Preclinical,glutamate receptor antagonist,GRM1|GRM5,,
N=c1[nH]ccc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C11H14N4O4/c12-10-7-5(1-2-13-10)15(4-14-7)11-9(18)8(17)6(3-16)19-11/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13)",DBZQFUNLCALWDY-UHFFFAOYSA-N,3-deazaadenosine,Phase 2,adenosylhomocysteinase inhibitor,AHCY,,
N=c1[nH]ccc2c1ncn2C1C=C(CO)C(O)C1O,"InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)",OMKHWTRUYNAGFG-UHFFFAOYSA-N,3-deazaneplanocin-a,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=c1cc(O)ccn1C1OC(CO)C(O)C1O,"InChI=1S/C10H13NO6/c12-4-6-8(15)9(16)10(17-6)11-2-1-5(13)3-7(11)14/h1-3,6,8-10,12-13,15-16H,4H2",CBOKZNLSFMZJJA-UHFFFAOYSA-N,3-deazauridine,Preclinical,cytidine deaminase inhibitor,,,
CCC(O)(CC(N)=O)c1ccccc1,"InChI=1S/C11H15NO2/c1-2-11(14,8-10(12)13)9-6-4-3-5-7-9/h3-7,14H,2,8H2,1H3,(H2,12,13)",MOHYRCCDARWQRM-UHFFFAOYSA-N,3-hydroxy-3-phenylpentanamide,Phase 1,GABA receptor modulator,,,
O=C(O)CCCc1c[nH]c2ccccc12,"InChI=1S/C12H13NO2/c14-12(15)7-3-4-9-8-13-11-6-2-1-5-10(9)11/h1-2,5-6,8,13H,3-4,7H2,(H,14,15)",JTEDVYBZBROSJT-UHFFFAOYSA-N,3-indolebutyric-acid,Preclinical,,B2M|HLA-A|TRAC|TRBC1,,
Cc1cc(C(=O)O)sc1C(N)C(=O)O,"InChI=1S/C8H9NO4S/c1-3-2-4(7(10)11)14-6(3)5(9)8(12)13/h2,5H,9H2,1H3,(H,10,11)(H,12,13)",KOMWRBFEDDEWEP-UHFFFAOYSA-N,3-matida,Preclinical,glutamate receptor antagonist,GRM1,,
CC(CN)CC(=O)O,"InChI=1S/C5H11NO2/c1-4(3-6)2-5(7)8/h4H,2-3,6H2,1H3,(H,7,8)",CZGLBWZXGIAIBU-UHFFFAOYSA-N,3-methyl-gaba,Preclinical,GABA aminotransferase activator,ABAT,,
Cn1cnc(=N)c2[nH]cnc21,"InChI=1S/C6H7N5/c1-11-3-10-5(7)4-6(11)9-2-8-4/h2-3,7H,1H3,(H,8,9)",ZPBYVFQJHWLTFB-UHFFFAOYSA-N,3-methyladenine,Preclinical,PI3K inhibitor,PI3,,
COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c([nH]c4ccccc43)c2=O)CC1,"InChI=1S/C23H25N5O3/c1-31-19-9-5-4-8-18(19)27-13-10-26(11-14-27)12-15-28-22(29)21-20(25-23(28)30)16-6-2-3-7-17(16)24-21/h2-9,24H,10-15H2,1H3,(H,25,30)",AQASGOHUMGAWJJ-UHFFFAOYSA-N,3-mppi,Preclinical,adrenergic receptor ligand,ADRA1A,,
Clc1cccc(C=NN=Cc2cccc(Cl)c2)c1,InChI=1S/C14H10Cl2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H,XMOVWXSCYLINBJ-UHFFFAOYSA-N,"3,3'-dichlorobenzaldazine",Preclinical,glutamate receptor modulator,GRM5,,
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1,"InChI=1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2",VFTRKSBEFQDZKX-UHFFFAOYSA-N,"3,3'-diindolylmethane",Phase 3,CHK inhibitor,AR|HIF1A|IFNG|PI3,,
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1,"InChI=1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2",VFTRKSBEFQDZKX-UHFFFAOYSA-N,"3,3'-diindolylmethane",Phase 3,cytochrome P450 activator,AR|HIF1A|IFNG|PI3,,
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1,"InChI=1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2",VFTRKSBEFQDZKX-UHFFFAOYSA-N,"3,3'-diindolylmethane",Phase 3,"indoleamine 2,3-dioxygenase inhibitor",AR|HIF1A|IFNG|PI3,,
NC(C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)",IJVMOGKBEVRBPP-UHFFFAOYSA-N,"3,4-dcpg-(+/-)",Preclinical,glutamate receptor agonist,GRM8,,
NC(C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)",IJVMOGKBEVRBPP-UHFFFAOYSA-N,"3,4-dcpg-(r)",Preclinical,glutamate receptor antagonist,,,
NC(C(=O)O)c1ccc(C(=O)O)c(C(=O)O)c1,"InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)",IJVMOGKBEVRBPP-UHFFFAOYSA-N,"3,4-dcpg-(s)",Preclinical,glutamate receptor agonist,GRM8,,
O=[N+]([O-])C=Cc1ccc2c(c1)OCO2,"InChI=1S/C9H7NO4/c11-10(12)4-3-7-1-2-8-9(5-7)14-6-13-8/h1-5H,6H2",KFLWBZPSJQPRDD-UHFFFAOYSA-N,"3,4-methylenedioxy-beta-nitrostyrene",Preclinical,SRC inhibitor,SRC|SYK,,
O=[N+]([O-])C=Cc1ccc2c(c1)OCO2,"InChI=1S/C9H7NO4/c11-10(12)4-3-7-1-2-8-9(5-7)14-6-13-8/h1-5H,6H2",KFLWBZPSJQPRDD-UHFFFAOYSA-N,"3,4-methylenedioxy-beta-nitrostyrene",Preclinical,SYK inhibitor,SRC|SYK,,
NC(C(=O)O)c1cc(O)cc(O)c1,"InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)",HOOWCUZPEFNHDT-UHFFFAOYSA-N,"3,5-dhpg-(s)",Preclinical,glutamate receptor agonist,GRM1,,
O=C(CCCN1CCC2(CC1)C(=O)N(Cc1cccc(F)c1)CN2c1ccccc1)c1ccc(F)cc1,"InChI=1S/C30H31F2N3O2/c31-25-13-11-24(12-14-25)28(36)10-5-17-33-18-15-30(16-19-33)29(37)34(21-23-6-4-7-26(32)20-23)22-35(30)27-8-2-1-3-9-27/h1-4,6-9,11-14,20H,5,10,15-19,21-22H2",DXZKTRNEOISOCA-UHFFFAOYSA-N,3'-fluorobenzylspiperone,Preclinical,dopamine receptor ligand,DRD2,,
O=C(C=Cc1cccnc1)c1ccncc1,InChI=1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H,UOWGYMNWMDNSTL-UHFFFAOYSA-N,3po,Preclinical,phosphofructokinase inhibitor,PFKFB3,,
O=C(c1ccc(F)cc1)C1CCN(CCCCc2ccccc2)CC1,"InChI=1S/C22H26FNO/c23-21-11-9-19(10-12-21)22(25)20-13-16-24(17-14-20)15-5-4-8-18-6-2-1-3-7-18/h1-3,6-7,9-12,20H,4-5,8,13-17H2",FTJXZACAQRDRNT-UHFFFAOYSA-N,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Preclinical,serotonin receptor antagonist,HTR2A,,
NCc1ccc(C(=O)O)cc1,"InChI=1S/C8H9NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4H,5,9H2,(H,10,11)",QCTBMLYLENLHLA-UHFFFAOYSA-N,4-(aminomethyl)benzoic-acid,Preclinical,hemostatic agent,,,
CC(=O)N1CC[N+](C)(C)CC1,"InChI=1S/C8H17N2O/c1-8(11)9-4-6-10(2,3)7-5-9/h4-7H2,1-3H3/q+1",MSBLMBWXUVQCDY-UHFFFAOYSA-N,"4-acetyl-1,1-dimethylpiperazinium",Preclinical,acetylcholine receptor agonist,,,
Nc1ccc(C(=O)NCC(=O)O)cc1,"InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)",HSMNQINEKMPTIC-UHFFFAOYSA-N,4-aminohippuric-acid,Launched,,SLC22A6,nephrology,renal diagnostic agent
NC(C(=O)O)c1ccc(C(=O)O)c(O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",GXZSAQLJWLCLOX-UHFFFAOYSA-N,4-carboxy-3-hydroxyphenylglycine-(rs),Preclinical,glutamate receptor agonist,GRM1,,
NC(C(=O)O)c1ccc(C(=O)O)c(O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",GXZSAQLJWLCLOX-UHFFFAOYSA-N,4-carboxy-3-hydroxyphenylglycine-(rs),Preclinical,glutamate receptor antagonist,GRM1,,
NC(C(=O)O)c1ccc(C(=O)O)c(O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",GXZSAQLJWLCLOX-UHFFFAOYSA-N,4-carboxy-3-hydroxyphenylglycine-(s),Preclinical,glutamate receptor agonist,GRM1|GRM2,,
NC(C(=O)O)c1ccc(C(=O)O)c(O)c1,"InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)",GXZSAQLJWLCLOX-UHFFFAOYSA-N,4-carboxy-3-hydroxyphenylglycine-(s),Preclinical,glutamate receptor antagonist,GRM1|GRM2,,
N=C(N)Nc1ccc(Cl)cc1,"InChI=1S/C7H8ClN3/c8-5-1-3-6(4-2-5)11-7(9)10/h1-4H,(H4,9,10,11)",ZSJNJAJDBNFVCA-UHFFFAOYSA-N,4-chlorophenylguanidine,Preclinical,urokinase inhibitor,PLAUR,,
CC(C)C(C(=O)N=c1[nH]ccs1)c1ccc(Cl)cc1,"InChI=1S/C14H15ClN2OS/c1-9(2)12(10-3-5-11(15)6-4-10)13(18)17-14-16-7-8-19-14/h3-9,12H,1-2H3,(H,16,17,18)",AZYDQCGCBQYFSE-UHFFFAOYSA-N,4-cmtb,Preclinical,free fatty acid receptor agonist,FFAR2,,
C[N+]1(C)CCC(OC(=O)C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C21H26NO2/c1-22(2)15-13-19(14-16-22)24-21(23)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-20H,13-16H2,1-2H3/q+1",HYJRTXSYDAFGJK-UHFFFAOYSA-N,4-damp,Preclinical,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
OCC1OC(OC2C(CO)OC(OC3C(CO)OC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2",FYGDTMLNYKFZSV-UHFFFAOYSA-N,4-galactosyllactose,Preclinical,,,,
O=c1[nH]cnc2ccccc12,"InChI=1S/C8H6N2O/c11-8-6-3-1-2-4-7(6)9-5-10-8/h1-5H,(H,9,10,11)",QMNUDYFKZYBWQX-UHFFFAOYSA-N,4-hqn,Preclinical,PARP inhibitor,PARP1,,
Cc1c(O)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C11H12N2O2/c1-8-10(14)11(15)13(12(8)2)9-6-4-3-5-7-9/h3-7,14H,1-2H3",SKVPTPMWXJSBTF-UHFFFAOYSA-N,4-hydroxy-phenazone,Preclinical,,,,
O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(I)cc1,"InChI=1S/C19H21IN2O/c20-17-8-6-16(7-9-17)19(23)21-18-10-12-22(13-11-18)14-15-4-2-1-3-5-15/h1-9,18H,10-14H2,(H,21,23)",HELCSESNNDZLFM-UHFFFAOYSA-N,4-ibp,Preclinical,sigma receptor agonist,SIGMAR1,,
Ic1cc(-c2ccccc2)ncn1,InChI=1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H,ZTCJXHNJVLUUMR-UHFFFAOYSA-N,4-iodo-6-phenylpyrimidine,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
NC(Cc1ccc(I)cc1)C(=O)O,"InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)",PZNQZSRPDOEBMS-UHFFFAOYSA-N,4-iodo-l-phenylalanine,Preclinical,,DPP4,,
COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1,"InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3",WUADCCWRTIWANL-UHFFFAOYSA-N,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,CYP19A1|ESRRA|ESRRB|ESRRG|FASN,,
Cc1[nH]cnc1CCN,"InChI=1S/C6H11N3/c1-5-6(2-3-7)9-4-8-5/h4H,2-3,7H2,1H3,(H,8,9)",UGYXPZQILZRKJJ-UHFFFAOYSA-N,4-methylhistamine,Preclinical,histamine receptor agonist,HRH4,,
Cc1cc(=O)oc2c(C=O)c(O)ccc12,"InChI=1S/C11H8O4/c1-6-4-10(14)15-11-7(6)2-3-9(13)8(11)5-12/h2-5,13H,1H3",RTHHSXOVIJWFQP-UHFFFAOYSA-N,4-mu-8c,Preclinical,IRE1 inhibitor,ERN1,,
CCC(=O)NC1Cc2ccccc2C(c2ccccc2)C1,"InChI=1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21)",RCYLUNPFECYGDW-UHFFFAOYSA-N,4-p-pdot,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,
O=S(=O)(O)c1ccc(O)cc1,"InChI=1S/C6H6O4S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4,7H,(H,8,9,10)",FEPBITJSIHRMRT-UHFFFAOYSA-N,4-phenolsulfonic-acid,Preclinical,,,,
c1ccc(C2CNCc3ccccc32)cc1,"InChI=1S/C15H15N/c1-2-6-12(7-3-1)15-11-16-10-13-8-4-5-9-14(13)15/h1-9,15-16H,10-11H2",OSZMNJRKIPAVOS-UHFFFAOYSA-N,"4-phenyl-1,2,3,4-tetrahydroisoquinoline",Preclinical,dopamine release inhibitor,,,
c1ccc(CCCCN2CCC(c3ccccc3)CC2)cc1,"InChI=1S/C21H27N/c1-3-9-19(10-4-1)11-7-8-16-22-17-14-21(15-18-22)20-12-5-2-6-13-20/h1-6,9-10,12-13,21H,7-8,11,14-18H2",HQGDPZPNAXRCSA-UHFFFAOYSA-N,4-ppbp,Preclinical,sigma receptor ligand,SIGMAR1,,
CCCc1ccc(C(=O)O)cc1,"InChI=1S/C10H12O2/c1-2-3-8-4-6-9(7-5-8)10(11)12/h4-7H,2-3H2,1H3,(H,11,12)",ATZHGRNFEFVDDJ-UHFFFAOYSA-N,4-propylbenzoic-acid,Preclinical,,,,
N#Cc1ccncn1,"InChI=1S/C5H3N3/c6-3-5-1-2-7-4-8-5/h1-2,4H",ZIEWSZYVEDTXGH-UHFFFAOYSA-N,4-pyrimidinecarbonitrile,Preclinical,,,,
CC(C)(C)c1ccc(O)cc1,"InChI=1S/C10H14O/c1-10(2,3)8-4-6-9(11)7-5-8/h4-7,11H,1-3H3",QHPQWRBYOIRBIT-UHFFFAOYSA-N,4-tert-butylphenol,Preclinical,,,,
C1CCC2(CC1)CCNCC2,"InChI=1S/C10H19N/c1-2-4-10(5-3-1)6-8-11-9-7-10/h11H,1-9H2",LIZKZVQBLDHKCY-UHFFFAOYSA-N,"4,4-pentamethylenepiperidine",Preclinical,M2 channel blocker,,,
Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,"InChI=1S/C14H9Cl5/c15-11-5-1-9(2-6-11)13(14(17,18)19)10-3-7-12(16)8-4-10/h1-8,13H",YVGGHNCTFXOJCH-UHFFFAOYSA-N,"4,4'-ddt",Preclinical,,,,
Brc1c(Br)c(Br)c2[nH]nnc2c1Br,"InChI=1S/C6HBr4N3/c7-1-2(8)4(10)6-5(3(1)9)11-13-12-6/h(H,11,12,13)",OMZYUVOATZSGJY-UHFFFAOYSA-N,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,
NS(=O)(=O)c1ccc2c(c1)C1C=CCC1C(c1ccc(Br)cc1)N2,"InChI=1S/C18H17BrN2O2S/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(24(20,22)23)8-9-17(16)21-18/h1-2,4-10,14-15,18,21H,3H2,(H2,20,22,23)",YNCXHXYZTLIZTO-UHFFFAOYSA-N,4bp-tqs,Preclinical,nicotinic receptor agonist,CHRNA7,,
O=C(O)c1ccc(N2C(=O)C(=Cc3ccc(-c4ccc([N+](=O)[O-])cc4)o3)C=C2c2ccccc2)cc1,"InChI=1S/C28H18N2O6/c31-27-21(16-24-14-15-26(36-24)19-6-12-23(13-7-19)30(34)35)17-25(18-4-2-1-3-5-18)29(27)22-10-8-20(9-11-22)28(32)33/h1-17H,(H,32,33)",BBQRBOIMSKMFFO-UHFFFAOYSA-N,4e1rcat,Preclinical,protein synthesis inhibitor,EIF4E|EIF4G1,,
O=C(O)C(Cc1ccccc1[N+](=O)[O-])=NN=c1[nH]c(-c2ccc(Cl)c(Cl)c2)cs1,"InChI=1S/C18H12Cl2N4O4S/c19-12-6-5-10(7-13(12)20)15-9-29-18(21-15)23-22-14(17(25)26)8-11-3-1-2-4-16(11)24(27)28/h1-7,9H,8H2,(H,21,23)(H,25,26)",KFRKRECSIYXARE-UHFFFAOYSA-N,4egi-1,Preclinical,protein synthesis inhibitor,EIF4E,,
Cn1cc(-c2ccc(S(=O)(=O)n3ccc(C=CC(=O)Nc4ccccc4N)c3)cc2)cn1,"InChI=1S/C23H21N5O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24/h2-16H,24H2,1H3,(H,26,29)",PRXXYMVLYKJITB-UHFFFAOYSA-N,4sc-202,Phase 1,HDAC inhibitor,HDAC1,,
CCn1c(-c2ccc(Cl)cc2)n[nH]c1=O,"InChI=1S/C10H10ClN3O/c1-2-14-9(12-13-10(14)15)7-3-5-8(11)6-4-7/h3-6H,2H2,1H3,(H,13,15)",PXINDYJACXPZIN-UHFFFAOYSA-N,"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3h-1,2,4-triazol-3-one",Preclinical,,,,
N=c1[nH]c(=O)c2sc(=O)n(C3OC(CO)C(O)C3O)c2[nH]1,"InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)",TZYVRXZQAWPIAB-UHFFFAOYSA-N,"5-amino-3-d-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3h,6h)-dione",Preclinical,,TLR7,,
NCC(=O)CCC(=O)O,"InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)",ZGXJTSGNIOSYLO-UHFFFAOYSA-N,5-aminolevulinic-acid,Launched,oxidizing agent,ALAD,oncology|dermatology,glioma|actinic keratosis (AK)
O=C1C=NC(c2cccc(Br)c2)c2oc3ccccc3c2N1,"InChI=1S/C17H11BrN2O2/c18-11-5-3-4-10(8-11)15-17-16(20-14(21)9-19-15)12-6-1-2-7-13(12)22-17/h1-9,15H,(H,20,21)",HZEOFUOTRXBYRR-UHFFFAOYSA-N,5-bdbd,Preclinical,purinergic receptor antagonist,P2RX4,,
NCCc1c[nH]c2ccc(C(N)=O)cc12,"InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)",WKZLNEWVIAGNAW-UHFFFAOYSA-N,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
OCc1cncc(F)c1,"InChI=1S/C6H6FNO/c7-6-1-5(4-9)2-8-3-6/h1-3,9H,4H2",GGGJYJXAFSEWNM-UHFFFAOYSA-N,5-fluoro-3-pyridyl-methanol,Preclinical,,,,
Fc1cncnc1,InChI=1S/C4H3FN2/c5-4-1-6-3-7-2-4/h1-3H,KSPDSMOWMQFPBL-UHFFFAOYSA-N,5-fluoropyrimidine,Phase 3,kinase inhibitor,,,
O=c1[nH]cc(F)c(=O)[nH]1,"InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)",GHASVSINZRGABV-UHFFFAOYSA-N,5-fluorouracil,Launched,thymidylate synthase inhibitor,DPYD|TYMS,oncology,colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma
O=c1ncc(F)c[nH]1,"InChI=1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)",HPABFFGQPLJKBP-UHFFFAOYSA-N,5-fp,Phase 1,thymidylate synthase inhibitor,TYMS,,
O=Cc1ccc(CO)o1,"InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2",NOEGNKMFWQHSLB-UHFFFAOYSA-N,5-hmf,Phase 2,,,,
CCCCCC(O)CCCC(=O)O,"InChI=1S/C10H20O3/c1-2-3-4-6-9(11)7-5-8-10(12)13/h9,11H,2-8H2,1H3,(H,12,13)",LMHJFKYQYDSOQO-UHFFFAOYSA-N,5-hydroxydecanoic-acid,Preclinical,,,,
CC1=NC(C(=O)O)C(O)CN1,"InChI=1S/C6H10N2O3/c1-3-7-2-4(9)5(8-3)6(10)11/h4-5,9H,2H2,1H3,(H,7,8)(H,10,11)",KIIBBJKLKFTNQO-UHFFFAOYSA-N,5-hydroxyectoine,Preclinical,,,,
CC(C)N(CCC(c1ccccc1)c1cc(CO)ccc1O)C(C)C,"InChI=1S/C22H31NO2/c1-16(2)23(17(3)4)13-12-20(19-8-6-5-7-9-19)21-14-18(15-24)10-11-22(21)25/h5-11,14,16-17,20,24-25H,12-13,15H2,1-4H3",DUXZAXCGJSBGDW-UHFFFAOYSA-N,5-hydroxymethyl-tolterodine,Phase 1,acetylcholine receptor antagonist,CHRM3,,
NC(Cc1c[nH]c2ccc(O)cc12)C(=O)O,"InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)",LDCYZAJDBXYCGN-UHFFFAOYSA-N,5-hydroxytryptophan,Launched,neurotransmitter,SLC36A1|SLC36A2,neurology/psychiatry,insomnia
Ic1cncc(OCC2CCN2)c1,"InChI=1S/C9H11IN2O/c10-7-3-9(5-11-4-7)13-6-8-1-2-12-8/h3-5,8,12H,1-2,6H2",RKVRGRXOYDTUEY-UHFFFAOYSA-N,5-iodo-a-85380,Phase 2,acetylcholine receptor agonist,,,
Cc1ccc(C[N+](C)(C)C)o1,"InChI=1S/C9H16NO/c1-8-5-6-9(11-8)7-10(2,3)4/h5-6H,7H2,1-4H3/q+1",KOWVJDFMEZKDDT-UHFFFAOYSA-N,5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
Cc1[nH]c(=O)[nH]c1O,"InChI=1S/C4H6N2O2/c1-2-3(7)6-4(8)5-2/h7H,1H3,(H2,5,6,8)",VBPFHJBRXZWCDM-UHFFFAOYSA-N,5-methylhydantoin-(d),Preclinical,,,,
Cc1[nH]c(=O)[nH]c1O,"InChI=1S/C4H6N2O2/c1-2-3(7)6-4(8)5-2/h7H,1H3,(H2,5,6,8)",VBPFHJBRXZWCDM-UHFFFAOYSA-N,5-methylhydantoin-(l),Preclinical,,,,
CCCCCCCC(=O)c1ccc(O)c(C(=O)O)c1,"InChI=1S/C15H20O4/c1-2-3-4-5-6-7-13(16)11-8-9-14(17)12(10-11)15(18)19/h8-10,17H,2-7H2,1H3,(H,18,19)",IXIGWKNBFPKCCD-UHFFFAOYSA-N,5-octanoylsalicylic-acid,Preclinical,protein kinase activator,,,
O=C(O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1,"InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)",BGKFPRIGXAVYNX-UHFFFAOYSA-N,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
OC1C(CCl)OC(n2cnc3c(=NC4CC5CCC4C5)[nH]cnc32)C1O,"InChI=1S/C17H22ClN5O3/c18-5-11-13(24)14(25)17(26-11)23-7-21-12-15(19-6-20-16(12)23)22-10-4-8-1-2-9(10)3-8/h6-11,13-14,17,24-25H,1-5H2,(H,19,20,22)",PVJGDYDNVNCGBT-UHFFFAOYSA-N,5'-chloro-5'-deoxy-enba-(+/-),Preclinical,adenosine receptor agonist,ADORA1,,
Nc1cc2c3ccccc3ccc2c2ccccc12,"InChI=1S/C18H13N/c19-18-11-17-13-6-2-1-5-12(13)9-10-15(17)14-7-3-4-8-16(14)18/h1-11H,19H2",KIVUHCNVDWYUNP-UHFFFAOYSA-N,6-aminochrysene,Phase 2,transferase inhibitor,,,
CC1(C)SC2C(N)C(=O)N2C1C(=O)O,"InChI=1S/C8H12N2O3S/c1-8(2)4(7(12)13)10-5(11)3(9)6(10)14-8/h3-4,6H,9H2,1-2H3,(H,12,13)",NGHVIOIJCVXTGV-UHFFFAOYSA-N,6-aminopenicillanic-acid,Preclinical,,,,
c1ccc(CN=c2[nH]cnc3[nH]cnc23)cc1,"InChI=1S/C12H11N5/c1-2-4-9(5-3-1)6-13-11-10-12(15-7-14-10)17-8-16-11/h1-5,7-8H,6H2,(H2,13,14,15,16,17)",NWBJYWHLCVSVIJ-UHFFFAOYSA-N,6-benzylaminopurine,Preclinical,purinergic receptor activator,,,
COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,"InChI=1S/C13H15ClN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)",LUINDDOUWHRIPW-UHFFFAOYSA-N,6-chloromelatonin,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
N#[N+]CC(=O)CCC(N)C(=O)O,"InChI=1S/C6H9N3O3/c7-5(6(11)12)2-1-4(10)3-9-8/h5H,1-3,7H2/p+1",UUTYCZUIECRVAL-UHFFFAOYSA-O,6-diazo-5-oxo-l-norleucine,Preclinical,glutamate receptor antagonist,,,
N#[N+]CC(=O)CCC(N)C(=O)O,"InChI=1S/C6H9N3O3/c7-5(6(11)12)2-1-4(10)3-9-8/h5H,1-3,7H2/p+1",UUTYCZUIECRVAL-UHFFFAOYSA-O,6-diazo-5-oxo-l-norleucine,Preclinical,glutaminase inhibitor,,,
CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,"InChI=1S/C17H26INO3/c1-3-4-5-6-7-8-9-17(21)19-12-13-10-16(22-2)15(20)11-14(13)18/h10-11,20H,3-9,12H2,1-2H3,(H,19,21)",AAORACFZMYMFCG-UHFFFAOYSA-N,6-iodo-nordihydrocapsaicin,Preclinical,TRPV antagonist,TRPV1,,
CC(=O)OC1(C(C)=O)CCC2C3=CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C23H30O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h5-6,19-20H,7-13H2,1-4H3",KBFVVRPWBOFOKF-UHFFFAOYSA-N,"6,7-dehydro-17-acetoxy-progesterone",Preclinical,steroidal progestin,,,
CC(=O)OC=C1CSC2C(N)C(=O)N2C1C(=O)O,"InChI=1S/C10H12N2O5S/c1-4(13)17-2-5-3-18-9-6(11)8(14)12(9)7(5)10(15)16/h2,6-7,9H,3,11H2,1H3,(H,15,16)",FLIJLHAXSUEBCW-UHFFFAOYSA-N,7-aminocephalosporanic-acid,Preclinical,beta lactamase inhibitor,,,
O=C(O)c1cc(=O)c2ccc(Cl)cc2[nH]1,"InChI=1S/C10H6ClNO3/c11-5-1-2-6-7(3-5)12-8(10(14)15)4-9(6)13/h1-4H,(H,12,13)(H,14,15)",UAWVRVFHMOSAPU-UHFFFAOYSA-N,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,
CCCN(CCC)C1CCc2ccc(O)cc2C1,"InChI=1S/C16H25NO/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3",BLYMJBIZMIGWFK-UHFFFAOYSA-N,7-hydroxy-dpat,Preclinical,dopamine receptor agonist,DRD2|DRD3,,
CCCN(CC=CI)C1CCc2ccc(O)cc2C1,"InChI=1S/C16H22INO/c1-2-9-18(10-3-8-17)15-6-4-13-5-7-16(19)12-14(13)11-15/h3,5,7-8,12,15,19H,2,4,6,9-11H2,1H3",RTMIJLQPWFKAFE-UHFFFAOYSA-N,7-hydroxy-pipat,Preclinical,dopamine receptor ligand,DRD3,,
CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4O,"InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)",PBCZSGKMGDDXIJ-UHFFFAOYSA-N,7-hydroxystaurosporine,Phase 2,CDK inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,,
CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4O,"InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)",PBCZSGKMGDDXIJ-UHFFFAOYSA-N,7-hydroxystaurosporine,Phase 2,CHK inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,,
CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4O,"InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)",PBCZSGKMGDDXIJ-UHFFFAOYSA-N,7-hydroxystaurosporine,Phase 2,PKC inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,,
CC(=O)OC1C=C2CC(=O)C3C4CCC(=O)C4(C)CCC3C2(C)CC1,"InChI=1S/C21H28O4/c1-12(22)25-14-6-8-20(2)13(10-14)11-17(23)19-15-4-5-18(24)21(15,3)9-7-16(19)20/h10,14-16,19H,4-9,11H2,1-3H3",PXFPHBRENKMNBG-UHFFFAOYSA-N,7-keto-dhea,Launched,steroid,,,
COc1ccc2[nH]c3c(c(=N)c2c1)CCCC3,"InChI=1S/C14H16N2O/c1-17-9-6-7-13-11(8-9)14(15)10-4-2-3-5-12(10)16-13/h6-8H,2-5H2,1H3,(H2,15,16)",APQPVVOYBLOJDY-UHFFFAOYSA-N,7-methoxytacrine,Phase 2,acetylcholinesterase inhibitor,ACHE,,
Cn1cnc2[nH]c(=O)[nH]c(=O)c21,"InChI=1S/C6H6N4O2/c1-10-2-7-4-3(10)5(11)9-6(12)8-4/h2H,1H3,(H2,8,9,11,12)",PFWLFWPASULGAN-UHFFFAOYSA-N,7-methylxanthine,Phase 2,adenosine receptor antagonist,,,
O=[N+]([O-])c1cccc2c[nH]nc12,"InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)",PQCAUHUKTBHUSA-UHFFFAOYSA-N,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
O=c1c2ccccc2nc2n1CCCCC2,"InChI=1S/C13H14N2O/c16-13-10-6-3-4-7-11(10)14-12-8-2-1-5-9-15(12)13/h3-4,6-7H,1-2,5,8-9H2",HTLIIBRHXAULMB-UHFFFAOYSA-N,"7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6h)-one",Preclinical,,,,
N=c1[nH]cnc2c1nc(Br)n2C1OC2CO[PH](=O)(=O)OC2C1O,"InChI=1S/C10H10BrN5O6P/c11-10-15-4-7(12)13-2-14-8(4)16(10)9-5(17)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,17H,1H2,(H2,12,13,14)",NBOLKVNBILJYTB-UHFFFAOYSA-N,8-bromo-camp,Preclinical,PKA activator,,,
N=c1[nH]c(=O)c2nc(Br)n(C3OC4CO[PH](=O)(=O)OC4C3O)c2[nH]1,"InChI=1S/C10H10BrN5O7P/c11-9-13-3-6(14-10(12)15-7(3)18)16(9)8-4(17)5-2(22-8)1-21-24(19,20)23-5/h2,4-5,8,17H,1H2,(H3,12,14,15,18)",WZDDIIOSSFYOPQ-UHFFFAOYSA-N,8-bromo-cgmp,Preclinical,PKA activator,PRKG1,,
CCCN(CCC)C1CCc2cccc(O)c2C1,"InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14/h5-7,14,18H,3-4,8-12H2,1-2H3",ASXGJMSKWNBENU-UHFFFAOYSA-N,8-hydroxy-dpat,Preclinical,serotonin receptor agonist,HTR5A|HTR7,,
CCCN(CC=CI)C1CCc2cccc(O)c2C1,"InChI=1S/C16H22INO/c1-2-10-18(11-4-9-17)14-8-7-13-5-3-6-16(19)15(13)12-14/h3-6,9,14,19H,2,7-8,10-12H2,1H3",QBXHUZJZYDSLRH-UHFFFAOYSA-N,8-hydroxy-pipat,Preclinical,dopamine receptor ligand,DRD2|DRD3,,
CCC(=O)NC1CCc2cccc(OC)c2C1,"InChI=1S/C14H19NO2/c1-3-14(16)15-11-8-7-10-5-4-6-13(17-2)12(10)9-11/h4-6,11H,3,7-9H2,1-2H3,(H,15,16)",RVIGBTUDFAGRTQ-UHFFFAOYSA-N,8-m-pdot,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,
Cc1oc(=O)oc1CCl,"InChI=1S/C5H5ClO3/c1-3-4(2-6)9-5(7)8-3/h2H2,1H3",QCLFSYYUWPUWQR-UHFFFAOYSA-N,80841-78-7,Preclinical,,,,
N=c1c2ccccc2[nH]c2ccccc12,"InChI=1S/C13H10N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H,(H2,14,15)",XJGFWWJLMVZSIG-UHFFFAOYSA-N,9-aminoacridine,Preclinical,,,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(N)cccc3nc2-1,"InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3",FUXVKZWTXQUGMW-UHFFFAOYSA-N,9-aminocamptothecin,Phase 2,topoisomerase inhibitor,TOP1,,
O=C(O)c1c2ccccc2cc2ccccc12,"InChI=1S/C15H10O2/c16-15(17)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-9H,(H,16,17)",XGWFJBFNAQHLEF-UHFFFAOYSA-N,9-anthracenecarboxylic-acid,Preclinical,,ANO1|CLCN1,,
COc1ccc2c(=NC(=O)N=c3cccc(C(F)(F)F)[nH]3)cc[nH]c2c1,"InChI=1S/C17H13F3N4O2/c1-26-10-5-6-11-12(7-8-21-13(11)9-10)22-16(25)24-15-4-2-3-14(23-15)17(18,19)20/h2-9H,1H3,(H2,21,22,23,24,25)",VQPBIJGXSXEOCU-UHFFFAOYSA-N,a-1070722,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1,"InChI=1S/C20H19F3N2O3/c21-20(22,23)16-7-3-1-5-14(16)13-9-11-25(12-10-13)19(28)24-17-8-4-2-6-15(17)18(26)27/h1-8,13H,9-12H2,(H,24,28)(H,26,27)",MEAQCLPMSVEOQF-UHFFFAOYSA-N,a-1120,Preclinical,retinoid receptor ligand,RBP4,,
O=C(O)c1cc(C(=O)O)c(C(=O)N(Cc2cccc(Oc3ccccc3)c2)C2CCCc3ccccc32)cc1C(=O)O,"InChI=1S/C33H27NO8/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41)",VQGBOYBIENNKMI-UHFFFAOYSA-N,a-317491,Preclinical,purinergic receptor antagonist,P2RX3,,
CC(=O)N=C1NC(c2ccccc2)c2ccccc2NC1=O,"InChI=1S/C17H15N3O2/c1-11(21)18-16-17(22)19-14-10-6-5-9-13(14)15(20-16)12-7-3-2-4-8-12/h2-10,15H,1H3,(H,19,22)(H,18,20,21)",ZUVMUPKZNWVSLV-UHFFFAOYSA-N,a-33903,Phase 2,,,,
COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,"InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)",BKCDJTRMYWSXMC-UHFFFAOYSA-N,a-366,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
Cc1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)cc1C,"InChI=1S/C20H24N4/c1-15-7-8-17(13-16(15)2)24-11-9-23(10-12-24)14-20-21-18-5-3-4-6-19(18)22-20/h3-8,13H,9-12,14H2,1-2H3,(H,21,22)",SAQMCVDGOIRQTC-UHFFFAOYSA-N,a-381393,Preclinical,dopamine receptor antagonist,,,
Cc1cccc(NC(=O)CN2CCC(c3ccccn3)CC2)c1,"InChI=1S/C19H23N3O/c1-15-5-4-6-17(13-15)21-19(23)14-22-11-8-16(9-12-22)18-7-2-3-10-20-18/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,21,23)",JFCDMGGMCUKHST-UHFFFAOYSA-N,a-412997,Preclinical,dopamine receptor agonist,DRD4,,
Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,"InChI=1S/C13H9Cl2N5/c14-11-5-1-4-10(12(11)15)13-17-18-19-20(13)8-9-3-2-6-16-7-9/h1-7H,8H2",MMPAULQSJLVKHP-UHFFFAOYSA-N,a-438079,Preclinical,purinergic receptor antagonist,P2RX7,,
CNC(=O)Nc1ccc2c(c1)CCC21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)C(C)C(F)(F)F)C1=O,"InChI=1S/C25H24F4N4O5/c1-14(25(27,28)29)32(12-15-3-5-17(26)6-4-15)20(34)13-33-21(35)24(38-23(33)37)10-9-16-11-18(7-8-19(16)24)31-22(36)30-2/h3-8,11,14H,9-10,12-13H2,1-2H3,(H2,30,31,36)",VRVJKILQRBSEAG-UHFFFAOYSA-N,a-485,Preclinical,histone acetyltransferase inhibitor,,,
CN1CC2CN(c3ccc(-c4ccccc4)nn3)CC2C1,"InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3",GTMRUYCIJSNXGB-UHFFFAOYSA-N,a-582941,Preclinical,nicotinic receptor agonist,CHRNA7,,
CS(=O)(=O)Nc1c(O)ccc2c1CCCC2C1=NCCN1,"InChI=1S/C14H19N3O3S/c1-21(19,20)17-13-10-3-2-4-11(14-15-7-8-16-14)9(10)5-6-12(13)18/h5-6,11,17-18H,2-4,7-8H2,1H3,(H,15,16)",OQFCXJDXHCDLHX-UHFFFAOYSA-N,a-61603,Preclinical,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,,
Cc1[nH]nc2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12,"InChI=1S/C22H22N4O/c1-15-21-11-17(7-8-22(21)26-25-15)18-10-20(13-24-12-18)27-14-19(23)9-16-5-3-2-4-6-16/h2-8,10-13,19H,9,14,23H2,1H3,(H,25,26)",BPNUQXPIQBZCMR-UHFFFAOYSA-N,a-674563,Preclinical,AKT inhibitor,AKT1|PKIA|PRKACA,,
NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,"InChI=1S/C20H29ClN2O2S/c21-19-13-9-12-18-17(19)11-10-14-20(18)26(24,25)23-16-8-6-4-2-1-3-5-7-15-22/h9-14,23H,1-8,15-16,22H2",JLUUJHIQVIXTGT-UHFFFAOYSA-N,a-7,Preclinical,calmodulin antagonist,,,
N#Cc1c(O)[nH]c2scc(-c3ccc(-c4ccccc4O)cc3)c2c1=O,"InChI=1S/C20H12N2O3S/c21-9-14-18(24)17-15(10-26-20(17)22-19(14)25)12-7-5-11(6-8-12)13-3-1-2-4-16(13)23/h1-8,10,23H,(H2,22,24,25)",CTESJDQKVOEUOY-UHFFFAOYSA-N,a-769662,Preclinical,AMPK activator,,,
O=C(Nc1ccc(S(=O)(=O)C(F)(F)F)cc1)C1=CCN(c2ncccc2C(F)(F)F)CC1,"InChI=1S/C19H15F6N3O3S/c20-18(21,22)15-2-1-9-26-16(15)28-10-7-12(8-11-28)17(29)27-13-3-5-14(6-4-13)32(30,31)19(23,24)25/h1-7,9H,8,10-11H2,(H,27,29)",SDUAWRFBHRAFBM-UHFFFAOYSA-N,a-784168,Preclinical,transient receptor potential channel antagonist,TRPV1,,
COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1,"InChI=1S/C19H16ClNO4/c1-23-15-9-14(10-16(11-15)24-2)21-19(22)18-8-7-17(25-18)12-3-5-13(20)6-4-12/h3-11H,1-2H3,(H,21,22)",VHKBTPQDHDSBSP-UHFFFAOYSA-N,a-803467,Preclinical,sodium channel blocker,SCN10A,,
CC(N=C(NC#N)Nc1cccc2ncccc12)c1ccccc1,"InChI=1S/C19H17N5/c1-14(15-7-3-2-4-8-15)23-19(22-13-20)24-18-11-5-10-17-16(18)9-6-12-21-17/h2-12,14H,1H3,(H2,22,23,24)",PQYCRDPLPKGSME-UHFFFAOYSA-N,a-804598,Preclinical,purinergic receptor antagonist,P2RX7,,
Clc1cccc(-n2[nH]nnc2=NCc2ccccc2Oc2ccccn2)c1Cl,"InChI=1S/C19H14Cl2N6O/c20-14-7-5-8-15(18(14)21)27-19(24-25-26-27)23-12-13-6-1-2-9-16(13)28-17-10-3-4-11-22-17/h1-11H,12H2,(H,23,24,26)",GMVNBKZQJFRFAR-UHFFFAOYSA-N,a-839977,Preclinical,purinergic receptor antagonist,P2RX7,,
CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C,"InChI=1S/C20H19ClN2O3S/c1-3-20(24)18-12-19(14-4-6-15(21)7-5-14)23(13(18)2)16-8-10-17(11-9-16)27(22,25)26/h4-12H,3H2,1-2H3,(H2,22,25,26)",ABACVOXFUHDKNZ-UHFFFAOYSA-N,a-867744,Preclinical,acetylcholine receptor allosteric modulator,CHRNA3|CHRNA4|CHRNA7,,
CCCCOc1ccc(-c2cncc(C(=O)NCc3cccnc3N3CCOCC3)c2)cc1Cl,"InChI=1S/C26H29ClN4O3/c1-2-3-11-34-24-7-6-19(15-23(24)27)21-14-22(17-28-16-21)26(32)30-18-20-5-4-8-29-25(20)31-9-12-33-13-10-31/h4-8,14-17H,2-3,9-13,18H2,1H3,(H,30,32)",JPJGFWKHSMUKFO-UHFFFAOYSA-N,a-887826,Preclinical,sodium channel blocker,SCN10A,,
O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)C3CCCC3C(=O)O)cc2)cc1,"InChI=1S/C26H24N2O4/c29-24(22-7-4-8-23(22)25(30)31)19-11-9-17(10-12-19)18-13-15-21(16-14-18)28-26(32)27-20-5-2-1-3-6-20/h1-3,5-6,9-16,22-23H,4,7-8H2,(H,30,31)(H2,27,28,32)",BOZRFEQDOFSZBV-UHFFFAOYSA-N,a-922500,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CNC(=O)c1cccc(NC(=O)N2CCC(Oc3ccccc3Cl)CC2)c1,"InChI=1S/C20H22ClN3O3/c1-22-19(25)14-5-4-6-15(13-14)23-20(26)24-11-9-16(10-12-24)27-18-8-3-2-7-17(18)21/h2-8,13,16H,9-12H2,1H3,(H,22,25)(H,23,26)",DPYTYQFYDLYWHZ-UHFFFAOYSA-N,a-939572,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,
CCC(=NO)C(C)=Cc1ccc(F)cc1,"InChI=1S/C12H14FNO/c1-3-12(14-15)9(2)8-10-4-6-11(13)7-5-10/h4-8,15H,3H2,1-2H3",HKROEBDHHKMNBZ-UHFFFAOYSA-N,a-967079,Preclinical,transient receptor potential channel antagonist,TRPA1,,
N=c1nc(N2CCNCC2)c2c([nH]1)C1=C(CC2)OC2CCCCC12,"InChI=1S/C18H25N5O/c19-18-21-16-12(17(22-18)23-9-7-20-8-10-23)5-6-14-15(16)11-3-1-2-4-13(11)24-14/h11,13,20H,1-10H2,(H2,19,21,22)",DJKJVWJQAVGLHJ-UHFFFAOYSA-N,a-987306,Preclinical,histamine receptor antagonist,ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2,,
Cc1c(C)c(O)c(C=CC(C)(O)CCCC(C)CCCC(C)CCCC(C)C)c(C)c1O,"InChI=1S/C29H50O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h17,19-22,30-32H,9-16,18H2,1-8H3",ISGNBHKSNFKMFU-UHFFFAOYSA-N,a0001,Phase 2,,,,
CCCCCCCCCCC(O)C1C=Cc2c(c(O)n(-c3ccccc3)c2O)N1Nc1ccc([N+](=O)[O-])cc1,"InChI=1S/C30H38N4O5/c1-2-3-4-5-6-7-8-12-15-27(35)26-21-20-25-28(30(37)32(29(25)36)23-13-10-9-11-14-23)33(26)31-22-16-18-24(19-17-22)34(38)39/h9-11,13-14,16-21,26-27,31,35-37H,2-8,12,15H2,1H3",CUSVHPBRTJKJMM-UHFFFAOYSA-N,a12b4c3,Preclinical,polynucleotide kinase/phosphatase inhibitor,PNKP,,
Cc1ccc(Sc2cncc3sc(C(N)=O)cc23)cc1,"InChI=1S/C15H12N2OS2/c1-9-2-4-10(5-3-9)19-13-7-17-8-14-11(13)6-12(20-14)15(16)18/h2-8H,1H3,(H2,16,18)",QQGWEXFLMJGCAL-UHFFFAOYSA-N,a205804,Preclinical,ICAM1 expression inhibitor,ICAM1|SELE,,
CS(=O)(=O)Nc1c(O)ccc2c1CCCC2C1=NCCN1,"InChI=1S/C14H19N3O3S/c1-21(19,20)17-13-10-3-2-4-11(14-15-7-8-16-14)9(10)5-6-12(13)18/h5-6,11,17-18H,2-4,7-8H2,1H3,(H,15,16)",OQFCXJDXHCDLHX-UHFFFAOYSA-N,a61603,Preclinical,adrenergic receptor agonist,ADRA1A,,
Cc1[nH]c(=NC(=O)N2CCCC2C(N)=O)sc1-c1csc(C(C)(C)C)n1,"InChI=1S/C17H23N5O2S2/c1-9-12(10-8-25-14(20-10)17(2,3)4)26-15(19-9)21-16(24)22-7-5-6-11(22)13(18)23/h8,11H,5-7H2,1-4H3,(H2,18,23)(H,19,21,24)",HBPXWEPKNBHKAX-UHFFFAOYSA-N,a66,Preclinical,PI3K inhibitor,PIK3CA,,
COc1ccc(CC(=O)NC(N=C(NC#N)Nc2cccc3ncccc23)C(C)(C)C)cc1OC,"InChI=1S/C26H30N6O3/c1-26(2,3)24(31-23(33)15-17-11-12-21(34-4)22(14-17)35-5)32-25(29-16-27)30-20-10-6-9-19-18(20)8-7-13-28-19/h6-14,24H,15H2,1-5H3,(H,31,33)(H2,29,30,32)",PUHSRMSFDASMAE-UHFFFAOYSA-N,a740003,Preclinical,purinergic receptor antagonist,P2RX7,,
NCC1OC(C23CC4CC(CC(C4)C2)C3)Cc2c1ccc(O)c2O,"InChI=1S/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2",QLJOSZATCBCBDR-UHFFFAOYSA-N,a77636,Preclinical,dopamine receptor agonist,CALY,,
O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)C3CCCC3C(=O)O)cc2)cc1,"InChI=1S/C26H24N2O4/c29-24(22-7-4-8-23(22)25(30)31)19-11-9-17(10-12-19)18-13-15-21(16-14-18)28-26(32)27-20-5-2-1-3-6-20/h1-3,5-6,9-16,22-23H,4,7-8H2,(H,30,31)(H2,27,28,32)",BOZRFEQDOFSZBV-UHFFFAOYSA-N,a922500,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N,"InChI=1S/C19H25N3O2/c1-5-24-19(23)22-18-7-6-15(10-17(18)20)21-11-16-13(3)8-12(2)9-14(16)4/h6-10,21H,5,11,20H2,1-4H3,(H,22,23)",SCOOTUMXCXKEAD-UHFFFAOYSA-N,aa-29504,Preclinical,GABA receptor positive allosteric modulator,GABRA1|GABRA4|GABRB3,,
C[n+]1ccn(CC2(C)C(C(=O)O)N3C(=O)CC3S2(=O)=O)n1,"InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/p+1",HFZITXBUTWITPT-UHFFFAOYSA-O,aai101,Phase 3,lactamase inhibitor,,,
CCC(C)NS(=O)(=O)c1ccc(F)c(C(=O)Nc2ccc(F)c(F)c2)c1,"InChI=1S/C17H17F3N2O3S/c1-3-10(2)22-26(24,25)12-5-7-14(18)13(9-12)17(23)21-11-4-6-15(19)16(20)8-11/h4-10,22H,3H2,1-2H3,(H,21,23)",BBLXLHYPDOMJMO-UHFFFAOYSA-N,ab-423,Preclinical,HBV capsid assembly inhibitor,,,
N=c1[nH]c(=NC2CC2)c2ncn(C3C=CC(CO)C3)c2[nH]1,"InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)",MCGSCOLBFJQGHM-UHFFFAOYSA-N,abacavir,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
Cc1ccc(Oc2ccccc2-c2csc(=NC3=NCCCN3)[nH]2)c(C)c1,"InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)",TYBHXIFFPVFXQW-UHFFFAOYSA-N,abafungin,Phase 3,sterol methyltransferase inhibitor,,,
COC1CC(OC2C(C)OC(OC3C(C)=CCC4CC(CC5(C=CC(C)C(C(C)C)O5)O4)OC(=O)C4=CC(C)C(O)C5OCC(=CC=CC3C)C45O)CC2OC)OC(C)C1O,"InChI=1S/C47H70O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,16-18,24-25,27-30,32-33,35-44,48-49,51H,15,19-23H2,1-10H3",YURGWJYGVQETQF-UHFFFAOYSA-N,abamectin,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,infectious disease,gastrointestinal parasites
Cc1ccc(-c2ccc(C)cn2)nc1,"InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3",PTRATZCAGVBFIQ-UHFFFAOYSA-N,abametapir,Phase 3,metalloproteinase inhibitor,MMP9,,
CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)N(C)C(Cc1ccc(O)cc1)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,"InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)",AIWRTTMUVOZGPW-UHFFFAOYSA-N,abarelix,Phase 3,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,
CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,"InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)",OEDSFMUSNZDJFD-UHFFFAOYSA-N,abbv-744,Phase 1,bromodomain inhibitor,,,
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,"InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)",CAOTVXGYTWCKQE-UHFFFAOYSA-N,abc-294640,Phase 2,sphingosine kinase inhibitor,SPHK2,,
CCN1CCN(Cc2ccc(N=c3nc(-c4cc(F)c5nc(C)n(C(C)C)c5c4)c(F)c[nH]3)nc2)CC1,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,abemaciclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3",GZOSMCIZMLWJML-UHFFFAOYSA-N,abiraterone,Launched,androgen biosynthesis inhibitor,CYP11B1|CYP17A1,oncology,prostate cancer
CC(=O)OC1CCC2(C)C(=CCC3C2CCC2(C)C(c4cccnc4)=CCC32)C1,"InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3",UVIQSJCZCSLXRZ-UHFFFAOYSA-N,abiraterone-acetate,Launched,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer
COc1c(C=Cc2ccc(NS(C)(=O)=O)cc2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,"InChI=1S/C24H27N3O5S/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31/h6-15,26H,1-5H3,(H,25,28,29)",XMZSTQYSBYEENY-UHFFFAOYSA-N,abt-072,Phase 2,RNA polymerase inhibitor,,,
NC1CCN(c2cccnc2)C1,"InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2",LVGMMVAWLISWJD-UHFFFAOYSA-N,abt-202,Phase 1,acetylcholine receptor agonist,,,
CC1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1,"InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3",KFHYZKCRXNRKRC-UHFFFAOYSA-N,abt-239,Phase 1,histamine receptor antagonist,HRH1|HRH2|HRH3,,
C#Cc1cccc2c1c(C(=O)c1ccc(Cn3c(C)nc4cnccc43)c(F)c1)cn2C(=O)N(C)C,"InChI=1S/C28H22FN5O2/c1-5-18-7-6-8-25-26(18)21(16-34(25)28(36)32(3)4)27(35)19-9-10-20(22(29)13-19)15-33-17(2)31-23-14-30-12-11-24(23)33/h1,6-14,16H,15H2,2-4H3",GDLNHSUSOZEAOR-UHFFFAOYSA-N,abt-491,Phase 1,platelet activating factor receptor antagonist,PTAFR,,
O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCCC2C1,"InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2",AGPIHNZOZNKRGT-UHFFFAOYSA-N,abt-639,Phase 2,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,
N=c1[nH]cnc2nc(-c3ccc(N4CCOCC4)nc3)cc(-c3cccc(Br)c3)c12,"InChI=1S/C22H19BrN6O/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29/h1-5,10-13H,6-9H2,(H2,24,26,27,28)",RQCXKDWOCUJWQZ-UHFFFAOYSA-N,abt-702,Preclinical,adenosine kinase inhibitor,ADK,,
c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1,"InChI=1S/C17H19N5/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17/h1-8H,9-13H2,(H,19,20)",FRPJGTNLZNXQEX-UHFFFAOYSA-N,abt-724,Phase 2,dopamine receptor agonist,DRD4,,
CN(C)CCC(CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],"InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)",HPLNQCPCUACXLM-UHFFFAOYSA-N,abt-737,Phase 1/Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,
COc1ccc(S(=O)(=O)Nc2ccc[nH]c2=Nc2ccc(O)cc2)cc1,"InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)",URCVCIZFVQDVPM-UHFFFAOYSA-N,abt-751,Phase 2,tubulin polymerization inhibitor,TUBB,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1,"InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2",SQZJGTOZFRNWCX-UHFFFAOYSA-N,abx-1431,Phase 2,monoacylglycerol lipase inhibitor,,,
FC(F)(F)Oc1ccc(N=c2ccc3cccc(Cl)c3[nH]2)cc1,"InChI=1S/C16H10ClF3N2O/c17-13-3-1-2-10-4-9-14(22-15(10)13)21-11-5-7-12(8-6-11)23-16(18,19)20/h1-9H,(H,21,22)",OZOGDCZJYVSUBR-UHFFFAOYSA-N,abx464,Phase 2,antiviral,,,
Oc1ccc(C2(c3ccccc3F)CCC(F)(F)CC2)cc1,"InChI=1S/C18H17F3O/c19-16-4-2-1-3-15(16)17(9-11-18(20,21)12-10-17)13-5-7-14(22)8-6-13/h1-8,22H,9-12H2",HSMUKSLNDJOZQG-UHFFFAOYSA-N,ac-186,Preclinical,estrogen receptor agonist,ESR2,,
CCCCOCCOc1nc(-c2ccc(C(=O)O)c(F)c2)sc1C,"InChI=1S/C17H20FNO4S/c1-3-4-7-22-8-9-23-15-11(2)24-16(19-15)12-5-6-13(17(20)21)14(18)10-12/h5-6,10H,3-4,7-9H2,1-2H3,(H,20,21)",HSAOETBFVAWNRP-UHFFFAOYSA-N,ac-261066,Preclinical,retinoid receptor agonist,RARB,,
CC(=NNC(=O)C1C(=O)NCC1c1ccccc1)c1cccc(Br)c1,"InChI=1S/C19H18BrN3O2/c1-12(14-8-5-9-15(20)10-14)22-23-19(25)17-16(11-21-18(17)24)13-6-3-2-4-7-13/h2-10,16-17H,11H2,1H3,(H,21,24)(H,23,25)",RQKXQCSEZPQBNZ-UHFFFAOYSA-N,ac-264613,Preclinical,PAR agonist,F2RL1,,
CC(=NNC(=O)C(NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1,"InChI=1S/C25H20BrN5O3/c1-15(17-10-7-11-18(26)14-17)28-31-25(34)22(27-23(32)16-8-3-2-4-9-16)21-19-12-5-6-13-20(19)24(33)30-29-21/h2-14,22H,1H3,(H,27,32)(H,30,33)(H,31,34)",UCUHFWIFSHROPY-UHFFFAOYSA-N,ac-55541,Preclinical,PARP inhibitor,PARP2,,
CCCCCCCCc1ccc(-c2ccc(C(=O)O)cc2)cc1,"InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)",HXBKPYIEQLLNBK-UHFFFAOYSA-N,ac-55649,Preclinical,retinoid receptor agonist,RARA|RARB,,
CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)N=c4cc(C(C)(C)C)o[nH]4)cc3)nc2)CC1(C)C,"InChI=1S/C31H42N6O4/c1-9-37-30(5,6)17-23(18-31(37,7)8)40-22-14-15-24(32-19-22)27(38)33-20-10-12-21(13-11-20)34-28(39)35-26-16-25(41-36-26)29(2,3)4/h10-16,19,23H,9,17-18H2,1-8H3,(H,33,38)(H2,34,35,36,39)",JVCWPUFNLFSKFS-UHFFFAOYSA-N,ac-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,
CN(C)CCC1(c2ccc(Cl)cc2)Cc2ccccc2C(=O)O1,"InChI=1S/C19H20ClNO2/c1-21(2)12-11-19(15-7-9-16(20)10-8-15)13-14-5-3-4-6-17(14)18(22)23-19/h3-10H,11-13H2,1-2H3",HIVBATDUVFEJFZ-UHFFFAOYSA-N,ac-7954-(+/-),Preclinical,urotensin receptor agonist,UTS2R,,
CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC,"InChI=1S/C30H53O2S/c1-4-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23-27-33(26-5-2)29-25-22-21-24-28(29)30(31)32-6-3/h21-22,24-25H,4-20,23,26-27H2,1-3H3/q+1",VZXULFIUJKSVJY-UHFFFAOYSA-N,ac1ndss5,Phase 1,,,,
CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc32)CC1,"InChI=1S/C20H29FN2O2/c1-2-3-5-16-8-12-22(13-9-16)10-4-11-23-18-7-6-17(21)14-19(18)25-15-20(23)24/h6-7,14,16H,2-5,8-13,15H2,1H3",BWAKMLKESHKOHK-UHFFFAOYSA-N,ac260584,Preclinical,cholinergic receptor agonist,,,
NC(=O)c1ncn(C2OC(CO)C(O)C2O)c1N,"InChI=1S/C9H14N4O5/c10-7-4(8(11)17)12-2-13(7)9-6(16)5(15)3(1-14)18-9/h2-3,5-6,9,14-16H,1,10H2,(H2,11,17)",RTRQQBHATOEIAF-UHFFFAOYSA-N,acadesine,Phase 3,AMPK activator,,,
CC#CC(=O)N1CCCC1c1nc(-c2ccc(C(=O)N=c3cccc[nH]3)cc2)c2c(=N)[nH]ccn12,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)",WDENQIQQYWYTPO-UHFFFAOYSA-N,acalabrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BTK,hematologic malignancy,mantle cell lymphoma (MCL)
CC(N=c1[nH]cnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,"InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)",DOCINCLJNAXZQF-UHFFFAOYSA-N,acalisib,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,
CC(=O)NCCCS(=O)(=O)O,"InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)",AFCGFAGUEYAMAO-UHFFFAOYSA-N,acamprosate,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5,neurology/psychiatry,abstinence from alcohol
CC1OC(OC2C(CO)OC(OC3C(CO)OC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1NC1C=C(CO)C(O)C(O)C1O,"InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3",XUFXOAAUWZOOIT-UHFFFAOYSA-N,acarbose,Launched,glucosidase inhibitor,AMY2A|MGAM,endocrinology,diabetes mellitus
CN(C)c1[nH]c(=N)c(C(=O)Nc2cccnc2)nc1Cl,"InChI=1S/C12H13ClN6O/c1-19(2)11-9(13)17-8(10(14)18-11)12(20)16-7-4-3-5-15-6-7/h3-6H,1-2H3,(H2,14,18)(H,16,20)",RNGRUHWJJPTYNR-UHFFFAOYSA-N,acdpp,Preclinical,glutamate receptor antagonist,GRM5,,
O=C(O)c1ccc(CN2CC3CC2CN3Cc2ccc(Oc3ccc(-c4ncco4)cc3)cc2)cc1,"InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)",GERJIEKMNDGSCS-UHFFFAOYSA-N,acebilustat,Phase 2,leukotriene inhibitor,,,
CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1,"InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)",GOEMGAFJFRBGGG-UHFFFAOYSA-N,acebutolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension|ventricular arrhythmias
CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,"InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)",KEECCEWTUVWFCV-UHFFFAOYSA-N,acecainide,Phase 3,polarization inhibitor,SCN5A,,
CC(=O)OC1CN2CCC1CC2,"InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3",WRJPSSPFHGNBMG-UHFFFAOYSA-N,aceclidine,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology,glaucoma
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,"InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)",MNIPYSSQXLZQLJ-UHFFFAOYSA-N,aceclofenac,Launched,prostanoid receptor antagonist,PTGS2,rheumatology,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia
CC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(C)=O)cc2)cc1,"InChI=1S/C16H16N2O4S/c1-11(19)17-13-3-7-15(8-4-13)23(21,22)16-9-5-14(6-10-16)18-12(2)20/h3-10H,1-2H3,(H,17,19)(H,18,20)",AMTPYFGPPVFBBI-UHFFFAOYSA-N,acedapsone,Launched,,,infectious disease,leprosy
CC(=O)Nc1ccc(C(=O)O)cc1,"InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)",QCXJEYYXVJIFCE-UHFFFAOYSA-N,acedoben,Phase 2,,,,
Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O,"InChI=1S/C9H10N4O4/c1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15/h4H,3H2,1-2H3,(H,14,15)",HCYFGRCYSCXKNQ-UHFFFAOYSA-N,acefylline,Launched,adenosine receptor agonist,ADORA1,pulmonary,asthma
CC(=O)NC(CCC(N)=O)C(=O)O,"InChI=1S/C7H12N2O4/c1-4(10)9-5(7(12)13)2-3-6(8)11/h5H,2-3H2,1H3,(H2,8,11)(H,9,10)(H,12,13)",KSMRODHGGIIXDV-UHFFFAOYSA-N,aceglutamide,Launched,,,gastroenterology,peptic ulcer disease (PUD)
CC(NP(=O)(OCC1OC(n2ccc(=N)[nH]c2=O)C(F)(F)C1O)Oc1ccccc1)C(=O)OCc1ccccc1,"InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)",NHTKGYOMICWFQZ-UHFFFAOYSA-N,acelarin,Phase 2/Phase 3,anticancer agent,,,
COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,"InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)",FSQKKOOTNAMONP-UHFFFAOYSA-N,acemetacin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis
CC(=O)NC1C(O)CC(O)(C(=O)O)OC1C(O)C(O)CO,"InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)",SQVRNKJHWKZAKO-UHFFFAOYSA-N,aceneuramic-acid,Phase 3,,CES1|SELE|SELP,,
CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,"InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3",VABCILAOYCMVPS-UHFFFAOYSA-N,acenocoumarol,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT)
CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2,"InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3",NOSIYYJFMPDDSA-UHFFFAOYSA-N,acepromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,sedative
CC1=CC(=O)NS(=O)(=O)O1,"InChI=1S/C4H5NO4S/c1-3-2-4(6)5-10(7,8)9-3/h2H,1H3,(H,5,6)",YGCFIWIQZPHFLU-UHFFFAOYSA-N,acesulfame-potassium,Phase 3,,,,
CC(=O)Nc1ccccc1,"InChI=1S/C8H9NO/c1-7(10)9-8-5-3-2-4-6-8/h2-6H,1H3,(H,9,10)",FZERHIULMFGESH-UHFFFAOYSA-N,acetanilide,Preclinical,hydrogen peroxide decomposition inhibitor,,,
CC(=O)Nc1cc([As](=O)(O)O)ccc1O,"InChI=1S/C8H10AsNO5/c1-5(11)10-7-4-6(9(13,14)15)2-3-8(7)12/h2-4,12H,1H3,(H,10,11)(H2,13,14,15)",ODFJOVXVLFUVNQ-UHFFFAOYSA-N,acetarsol,Launched,,,gastroenterology,diarrhea
CC(=O)N=c1[nH]nc(S(N)(=O)=O)s1,"InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)",BZKPWHYZMXOIDC-UHFFFAOYSA-N,acetazolamide,Launched,carbonic anhydrase inhibitor,AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7,ophthalmology,glaucoma
CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,"InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)",VGZSUPCWNCWDAN-UHFFFAOYSA-N,acetohexamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus
CC(O)=NO,"InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)",RRUDCFGSUDOHDG-UHFFFAOYSA-N,acetohydroxamic-acid,Launched,urease inhibitor,MMP12,infectious disease,urinary tract infections
CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,"InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3",WNTYBHLDCKXEOT-UHFFFAOYSA-N,acetophenazine,Launched,dopamine receptor antagonist,DRD1|DRD2,neurology/psychiatry,psychosis
CC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I,"InChI=1S/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)",GNOGSFBXBWBTIG-UHFFFAOYSA-N,acetriazoic-acid,Preclinical,,,,
CC(=O)OC1CCC2(C)C(CCC3(C)C2C(=O)C=C2C4C(C)C(C)CCC4(C)CCC23C)C1(C)C(=O)O,"InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)",HMMGKOVEOFBCAU-UHFFFAOYSA-N,acetyl-11-keto-beta-boswellic-acid,Phase 2,lipoxygenase inhibitor,HSD11B1|HSD11B2,,
CC(=O)NC(CSCC=C(C)CCC=C(C)CCC=C(C)C)C(=O)O,"InChI=1S/C20H33NO3S/c1-15(2)8-6-9-16(3)10-7-11-17(4)12-13-25-14-19(20(23)24)21-18(5)22/h8,10,12,19H,6-7,9,11,13-14H2,1-5H3,(H,21,22)(H,23,24)",XTURYZYJYQRJDO-UHFFFAOYSA-N,acetyl-farnesyl-cysteine,Launched,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV)
CC(=O)NC(CC(C)C)C(=O)O,"InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)",WXNXCEHXYPACJF-UHFFFAOYSA-N,acetyl-l-leucine,Launched,,,neurology/psychiatry,vertigo
CC(=O)OCC[N+](C)(C)C,"InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1",OIPILFWXSMYKGL-UHFFFAOYSA-N,acetylcholine,Launched,acetylcholine receptor agonist,ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,neurology/psychiatry|gastroenterology|pulmonary,drowsiness|fatigue|headache|indigestion|chest congestion
CC(=O)NC(CS)C(=O)O,"InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)",PWKSKIMOESPYIA-UHFFFAOYSA-N,acetylcysteine,Launched,mucolytic agent,ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11,gastroenterology,acetaminophen overdose|hepatic injury
CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(=O)O,"InChI=1S/C16H12O6/c1-10(17)21-14-9-5-3-7-12(14)16(20)22-13-8-4-2-6-11(13)15(18)19/h2-9H,1H3,(H,18,19)",DDSFKIFGAPZBSR-UHFFFAOYSA-N,acetylsalicylsalicylic-acid,Preclinical,cyclooxygenase inhibitor,,,
COC1C(OC(C)=O)CC(=O)OC(C)CC=CC=CC(OC2CCC(N(C)C)C(C)O2)C(C)CC(CC=O)C1OC1OC(C)C(OC2CC(C)(O)C(O)C(C)O2)C(N(C)C)C1O,"InChI=1S/C45H76N2O15/c1-25-22-31(20-21-48)41(62-44-39(51)38(47(10)11)40(28(4)58-44)61-37-24-45(7,53)43(52)29(5)57-37)42(54-12)34(59-30(6)49)23-35(50)55-26(2)16-14-13-15-17-33(25)60-36-19-18-32(46(8)9)27(3)56-36/h13-15,17,21,25-29,31-34,36-44,51-53H,16,18-20,22-24H2,1-12H3",ZPCCSZFPOXBNDL-UHFFFAOYSA-N,acetylspiramycin,Preclinical,other antibiotic,,,
CC(=O)NCCCCCC(=O)O,"InChI=1S/C8H15NO3/c1-7(10)9-6-4-2-3-5-8(11)12/h2-6H2,1H3,(H,9,10)(H,11,12)",WDSCBUNMANHPFH-UHFFFAOYSA-N,acexamic-acid,Launched,5 alpha reductase inhibitor,GAST,dermatology,wound healing
CC1(c2ccccc2)OC(C(=O)O)=CC1=O,"InChI=1S/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15)",DFDGRKNOFOJBAJ-UHFFFAOYSA-N,acifran,Phase 3,cholesterol inhibitor,HCAR2|HCAR3,,
Cc1cnc(C(=O)O)c[n+]1[O-],"InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)",DJQOOSBJCLSSEY-UHFFFAOYSA-N,acipimox,Launched,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia
O=C(O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,"InChI=1S/C9H7N5O3/c15-8(9(16)17)10-6-3-1-2-5(4-6)7-11-13-14-12-7/h1-4H,(H,10,15)(H,16,17)(H,11,12,13,14)",VWQZJJZGISNFOE-UHFFFAOYSA-N,acitazanolast,Launched,mediator release inhibitor,,allergy,allergic rhinitis
COc1cc(C)c(C=CC(C)=CC=CC(C)=CC(=O)O)c(C)c1C,"InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)",IHUNBGSDBOWDMA-UHFFFAOYSA-N,acitretin,Launched,retinoid receptor agonist,RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3,dermatology,psoriasis
NC(C(=O)O)C1CC(Cl)=NO1,"InChI=1S/C5H7ClN2O3/c6-3-1-2(11-8-3)4(7)5(9)10/h2,4H,1,7H2,(H,9,10)",QAWIHIJWNYOLBE-UHFFFAOYSA-N,acivicin,Phase 2,gamma glutamyltransferase inhibitor,CTPS1,,
CCC1(O)C=C(OC2CC(N(C)C)C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)c2c(cc3c(O)c4cccc(O)c4c(O)c3c2O)C1C(=O)OC,"InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,17-20,24,27,29-31,35,39-40,45-49,51H,8,12-13,15-16H2,1-7H3",DRWZHURZYBIXHX-UHFFFAOYSA-N,aclarubicin,Launched,topoisomerase inhibitor,TOP1|TOP2A,hematologic malignancy,acute myeloid leukemia (AML)
O=C(OC1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,"InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1",ASMXXROZKSBQIH-UHFFFAOYSA-N,aclidinium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)
CC1=C(c2ccc(O)cc2)C(c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21,"InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3",DUYNJNWVGIWJRI-UHFFFAOYSA-N,acolbifene,Phase 3,estrogen receptor antagonist,,,
CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc21,"InChI=1S/C17H14BF4NO3/c1-16(2)12-6-4-10(8-14(12)18(25)26-16)23-15(24)11-5-3-9(19)7-13(11)17(20,21)22/h3-8,25H,1-2H3,(H,23,24)",PTYGDEXEGLDNAZ-UHFFFAOYSA-N,acoziborole,Preclinical,antitrypanosomal,,,
NC1(C(=O)O)CC1,"InChI=1S/C4H7NO2/c5-4(1-2-4)3(6)7/h1-2,5H2,(H,6,7)",PAJPWUMXBYXFCZ-UHFFFAOYSA-N,acpc,Phase 1,glutamate receptor antagonist,,,
C[n+]1c2cc(N)ccc2cc2ccc(N)cc21,"InChI=1S/C14H13N3/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17/h2-8H,1H3,(H3,15,16)/p+1",XSIOKTWDEOJMGG-UHFFFAOYSA-O,acriflavine,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection
C[n+]1c2cc(N)ccc2cc2ccc(N)cc21,"InChI=1S/C14H13N3/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17/h2-8H,1H3,(H3,15,16)/p+1",XSIOKTWDEOJMGG-UHFFFAOYSA-O,acriflavinium,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection
CCCCCCc1ccc(O)cc1O,"InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3",WFJIVOKAWHGMBH-UHFFFAOYSA-N,acrisorcin,Launched,other antifungal,,infectious disease,fungal infection
Cc1ccc(C(=CCN2CCCC2)c2cccc(C=CC(=O)O)n2)cc1,"InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)",PWACSDKDOHSSQD-UHFFFAOYSA-N,acrivastine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
C=CC(=O)O,"InChI=1S/C3H4O2/c1-2-3(4)5/h2H,1H2,(H,4,5)",NIXOWILDQLNWCW-UHFFFAOYSA-N,acrylate,Phase 3,mucus protecting agent,,,
NS(=O)(=O)N=c1[nH]cnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,"InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)",DKULOVKANLVDEA-UHFFFAOYSA-N,act-132577,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
COc1ccc(S(=O)(=O)N2CCCC2C(=O)Nc2cc(C)cc(C)c2)cc1,"InChI=1S/C20H24N2O4S/c1-14-11-15(2)13-16(12-14)21-20(23)19-5-4-10-22(19)27(24,25)18-8-6-17(26-3)7-9-18/h6-9,11-13,19H,4-5,10H2,1-3H3,(H,21,23)",NHPQGZOBHSVTAQ-UHFFFAOYSA-N,act-462206,Phase 1,orexin receptor antagonist,HCRTR1|HCRTR2,,
CC(=O)Nc1ccc(CC(=O)O)cc1,"InChI=1S/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)",MROJXXOCABQVEF-UHFFFAOYSA-N,actarit,Launched,interleukin receptor agonist,,rheumatology,rheumatoid arthritis
COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(=N)[nH]cnn2c1CN1CCOCC1,"InChI=1S/C27H26F5N7O3/c1-41-13-17-22(12-38-6-8-42-9-7-38)39-24(25(33)34-14-35-39)23(17)15-2-5-20(19(29)10-15)36-26(40)37-21-11-16(27(30,31)32)3-4-18(21)28/h2-5,10-11,14H,6-9,12-13H2,1H3,(H2,33,34,35)(H2,36,37,40)",GZPJCJKUZPUFAL-UHFFFAOYSA-N,actb-1003,Phase 1,FGFR inhibitor,KDR|TEK,,
COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(=N)[nH]cnn2c1CN1CCOCC1,"InChI=1S/C27H26F5N7O3/c1-41-13-17-22(12-38-6-8-42-9-7-38)39-24(25(33)34-14-35-39)23(17)15-2-5-20(19(29)10-15)36-26(40)37-21-11-16(27(30,31)32)3-4-18(21)28/h2-5,10-11,14H,6-9,12-13H2,1H3,(H2,33,34,35)(H2,36,37,40)",GZPJCJKUZPUFAL-UHFFFAOYSA-N,actb-1003,Phase 1,VEGFR inhibitor,KDR|TEK,,
Cc1ccc(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c2c1Oc1c(C)c(O)c(N)c(C(=O)N=C3C(=O)NC(C(C)C)C(=O)N4CCCC4C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC3C)c1N2,"InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-44,48-49,64,77H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)",GSADSJFVCHVKRH-UHFFFAOYSA-N,actinomycin-d,Launched,RNA polymerase inhibitor,,oncology,Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma
CCOc1ccc(S(=O)(=O)O)c2cccnc12,"InChI=1S/C11H11NO4S/c1-2-16-9-5-6-10(17(13,14)15)8-4-3-7-12-11(8)9/h3-7H,2H2,1H3,(H,13,14,15)",YAMVZYRZAMBCED-UHFFFAOYSA-N,actinoquinol,Preclinical,,,,
Cc1ccc(C(=O)NC2CC2)cc1-n1[nH]cc(C(=O)c2cccc(C#N)c2)c1=N,"InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17,24-25H,7-8H2,1H3,(H,26,29)",FUKKFSDRLRCEKO-UHFFFAOYSA-N,acumapimod,Phase 1,p38 MAPK inhibitor,,,
O=C(NCCCCCCC(O)=NO)c1cnc(N(c2ccccc2)c2ccccc2)nc1,"InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)",QGZYDVAGYRLSKP-UHFFFAOYSA-N,acy-1215,Phase 1/Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6|HDAC8,,
N=c1[nH]c(=O)c2ncn(COCCO)c2[nH]1,"InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)",MKUXAQIIEYXACX-UHFFFAOYSA-N,acyclovir,Launched,DNA polymerase inhibitor,PNP,infectious disease,genitial herpes|shingles|chicken pox
CC(C)c1cccc2c1OC(C(C)C)C(=S)N2CC(=O)O,"InChI=1S/C16H21NO3S/c1-9(2)11-6-5-7-12-15(11)20-14(10(3)4)16(21)17(12)8-13(18)19/h5-7,9-10,14H,8H2,1-4H3,(H,18,19)",CLDJCRWXLDLJLO-UHFFFAOYSA-N,ad-5467,Phase 2,aldose reductase inhibitor,AKR1B1,,
COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,"InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)",LZCDAPDGXCYOEH-UHFFFAOYSA-N,adapalene,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRA|RXRB|RXRG,dermatology,acne vulgaris (AV)
O=[PH](=O)(O)OCC1OC(O)C(O)C(O)C1O,"InChI=1S/C6H12O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H,11,12,13)",FILRQECQUCCKHI-UHFFFAOYSA-N,adaprev,Phase 3,TGF beta receptor inhibitor,AKR1B1|GPI|HK1|M6PR|PYGM,,
CC(=O)C(NC(=O)C(CO)NC(=O)C(C)N)C(O)NC(C(=O)NC(C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(C(N)=O)C(C)O)C(C)O)C(C)O,"InChI=1S/C35H56N10O15/c1-13(36)29(54)41-22(12-46)32(57)43-26(16(4)49)34(59)45-27(17(5)50)35(60)44-25(15(3)48)33(58)40-21(11-23(37)52)30(55)39-20(10-18-6-8-19(51)9-7-18)31(56)42-24(14(2)47)28(38)53/h6-9,13-15,17,20-22,24-27,34,45-48,50-51,59H,10-12,36H2,1-5H3,(H2,37,52)(H2,38,53)(H,39,55)(H,40,58)(H,41,54)(H,42,56)(H,43,57)(H,44,60)",HWPWTUQOPNVEFW-UHFFFAOYSA-N,adaptavir,Phase 2,CC chemokine receptor antagonist,CCR5,,
O=C(O)C=Cc1ccc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)cc1,"InChI=1S/C25H26O3/c26-23-7-6-21(20-4-1-16(2-5-20)3-8-24(27)28)12-22(23)25-13-17-9-18(14-25)11-19(10-17)15-25/h1-8,12,17-19,26H,9-11,13-15H2,(H,27,28)",QAWBIEIZDDIEMW-UHFFFAOYSA-N,adarotene,Phase 1,retinoid receptor agonist,RARB|RARG,,
O=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C21H31N5O/c27-19(21-13-16-10-17(14-21)12-18(11-16)15-21)22-4-5-25-6-8-26(9-7-25)20-23-2-1-3-24-20/h1-3,16-18H,4-15H2,(H,22,27)",HPFLVTSWRFCPCV-UHFFFAOYSA-N,adatanserin,Phase 2,serotonin receptor agonist,HTR1A|HTR2A,,
O=C(NCCN1CCN(c2ncccn2)CC1)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C21H31N5O/c27-19(21-13-16-10-17(14-21)12-18(11-16)15-21)22-4-5-25-6-8-26(9-7-25)20-23-2-1-3-24-20/h1-3,16-18H,4-15H2,(H,22,27)",HPFLVTSWRFCPCV-UHFFFAOYSA-N,adatanserin,Phase 2,serotonin receptor antagonist,HTR1A|HTR2A,,
CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5c(-c6cccc(F)c6)cncc5[nH]4)c3c2)c1,"InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)",AQDWDWAYVBQMAM-UHFFFAOYSA-N,adavivint,Phase 1,WNT pathway inhibitor,,,
O=c1[nH]c(N2CCOCC2)cn1-c1ccc(Cl)cc1,"InChI=1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4,9H,5-8H2,(H,15,18)",OKVOKULYZXODKU-UHFFFAOYSA-N,add-233089,Phase 1,benzodiazepine receptor agonist,,,
N=c1[nH]cnc2c1ncn2CCOC[PH](=O)(=O)O,"InChI=1S/C8H11N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H,14,15,16)",QBOMMLNIIUVYAH-UHFFFAOYSA-N,adefovir,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(=N)[nH]cnc21)OCOC(=O)C(C)(C)C,"InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)",WOZSCQDILHKSGG-UHFFFAOYSA-N,adefovir-dipivoxil,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
O=C(CCCCCCCC(=O)NCCO)NCCO,"InChI=1S/C13H26N2O4/c16-10-8-14-12(18)6-4-2-1-3-5-7-13(19)15-9-11-17/h16-17H,1-11H2,(H,14,18)(H,15,19)",PAHZPHDAJQIETD-UHFFFAOYSA-N,adelmidrol,Launched,anti-inflammatory agent,,dermatology,dermatitis
C[S+](CCC(N)C(=O)O)CC1OC(n2cnc3c(=N)[nH]cnc32)C(O)C1O,"InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/p+1",MEFKEPWMEQBLKI-UHFFFAOYSA-O,ademetionine,Launched,methyltransferase stimulant,,neurology/psychiatry,depression|attention-deficit/hyperactivity disorder (ADHD)
C[S+](CCC(N)C(=O)O)CC1OC(n2cnc3c(=N)[nH]cnc32)C(O)C1O,"InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/p+1",MEFKEPWMEQBLKI-UHFFFAOYSA-O,ademetionine,Launched,phosphodiesterase inhibitor,,neurology/psychiatry,depression|attention-deficit/hyperactivity disorder (ADHD)
N=c1[nH]cnc2[nH]cnc12,"InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)",GFFGJBXGBJISGV-UHFFFAOYSA-N,adenine,Preclinical,protein synthesis stimulant,ACACB|ACP1|APRT|MTAP|PECR|SRPK2,,
N=c1[nH]cnc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)",OIRDTQYFTABQOQ-UHFFFAOYSA-N,adenosine,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4,cardiology,Wolff-Parkinson-White Syndrome (WPW)
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O)C(O)C1O,"InChI=1S/C10H13N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H,18,19,20)",KKFNWXDXVGCEMI-UHFFFAOYSA-N,adenosine-phosphate,Launched,adenosine receptor agonist,ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4,,
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)O)C(O)C1O,"InChI=1S/C10H13N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H,18,19,20)",HHQVIDHPNWPJBM-UHFFFAOYSA-N,adenosine-triphosphate,Phase 2,adenosine receptor agonist,ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7,,
CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,"InChI=1S/C20H25NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,19H,3-4,15-16H2,1-2H3",JGOAIQNSOGZNBX-UHFFFAOYSA-N,adiphenine,Launched,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms
O=C(O)CCCCC(=O)O,"InChI=1S/C6H10O4/c7-5(8)3-1-2-4-6(9)10/h1-4H2,(H,7,8)(H,9,10)",WNLRTRBMVRJNCN-UHFFFAOYSA-N,adipic-acid,Preclinical,solute carrier family member inhibitor,SLC22A6,,
O=C(COc1ccc(C(=O)c2ccccc2)cc1)NC1CCN(Cc2ccccc2)CC1,"InChI=1S/C27H28N2O3/c30-26(28-24-15-17-29(18-16-24)19-21-7-3-1-4-8-21)20-32-25-13-11-23(12-14-25)27(31)22-9-5-2-6-10-22/h1-14,24H,15-20H2,(H,28,30)",SHHUPGSHGSNPDB-UHFFFAOYSA-N,adiporon,Preclinical,adiponectin receptor agonist,ADIPOR1|ADIPOR2,,
CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cccc(O)c32)cc1,"InChI=1S/C24H28N2O3/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21/h5-11,16,25,27H,3-4,12-15H2,1-2H3",OPIKUXLJQFYMSC-UHFFFAOYSA-N,adl5859,Phase 2,opioid receptor agonist,OPRD1,,
Cc1cc(OC(CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,"InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)",FASLTMSUPQDLIB-UHFFFAOYSA-N,adomeglivant,Preclinical,glucagon receptor antagonist,,,
Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1,"InChI=1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2",IUVSEUFHPNITEQ-UHFFFAOYSA-N,adoprazine,Phase 2,dopamine receptor antagonist,DRD2|HTR1A,,
Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1,"InChI=1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2",IUVSEUFHPNITEQ-UHFFFAOYSA-N,adoprazine,Phase 2,serotonin receptor agonist,DRD2|HTR1A,,
[O-][S+](CC(O)=NO)C(c1ccccc1)c1ccccc1,"InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17)",CGNMLOKEMNBUAI-UHFFFAOYSA-N,adrafinil,Launched,adrenergic receptor agonist,,neurology/psychiatry,fatigue
CNCC(=O)c1ccc(O)c(O)c1,"InChI=1S/C9H11NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,10-12H,5H2,1H3",PZMVOUYYNKPMSI-UHFFFAOYSA-N,adrenalone,Launched,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage
CC12CC(=O)C3C(CC=C4CC(=O)CCC43C)C1CCC2=O,"InChI=1S/C19H24O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h3,13-14,17H,4-10H2,1-2H3",KIEUSUVLMCIWSA-UHFFFAOYSA-N,adrenosterone,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1|HSD11B2,,
Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1,"InChI=1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3",MEDCLNYIYBERKO-UHFFFAOYSA-N,adx-10059,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,
O=C(c1ccc(F)cc1)N1CCCC(c2nc(-c3ccc(F)cc3)no2)C1,"InChI=1S/C20H17F2N3O2/c21-16-7-3-13(4-8-16)18-23-19(27-24-18)15-2-1-11-25(12-15)20(26)14-5-9-17(22)10-6-14/h3-10,15H,1-2,11-12H2",VXQCCZHCFBHTTD-UHFFFAOYSA-N,adx-47273,Preclinical,glutamate receptor modulator,GRM5,,
CCN1CCN(Cc2ccc(-c3cc4c(=NC(C)c5ccccc5)[nH]cnc4[nH]3)cc2)CC1,"InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)",OONFNUWBHFSNBT-UHFFFAOYSA-N,aee788,Phase 1/Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR,,
CCN1CCN(Cc2ccc(-c3cc4c(=NC(C)c5ccccc5)[nH]cnc4[nH]3)cc2)CC1,"InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)",OONFNUWBHFSNBT-UHFFFAOYSA-N,aee788,Phase 1/Phase 2,VEGFR inhibitor,EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR,,
NS(=O)(=O)c1nn2cc(-c3ccccc3)nc2s1,"InChI=1S/C10H8N4O2S2/c11-18(15,16)10-13-14-6-8(12-9(14)17-10)7-4-2-1-3-5-7/h1-6H,(H2,11,15,16)",MQUYTXDAVCOCMX-UHFFFAOYSA-N,aeg3482,Preclinical,HSP inducer,,,
Cc1cccc(=NC(=O)c2ccc(C(F)(F)F)cc2C(=O)O)[nH]1,"InChI=1S/C15H11F3N2O3/c1-8-3-2-4-12(19-8)20-13(21)10-6-5-9(15(16,17)18)7-11(10)14(22)23/h2-7H,1H3,(H,22,23)(H,19,20,21)",JWCUSQCZMQIBMR-UHFFFAOYSA-N,af38469,Preclinical,sortilin inhibitor,SORT1,,
CC(=O)NC(Cc1ccccc1)C(=O)O,"InChI=1S/C11H13NO3/c1-8(13)12-10(11(14)15)7-9-5-3-2-4-6-9/h2-6,10H,7H2,1H3,(H,12,13)(H,14,15)",CBQJSKKFNMDLON-UHFFFAOYSA-N,afalanine,Phase 3,dopamine receptor agonist,DRD2,,
CCCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(C)=O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCN=C(N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(N)=O)C(C)C,"InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)",UAHFGYDRQSXQEB-UHFFFAOYSA-N,afamelanotide,Launched,melanocyte-stimulating hormone mimetic,,,
CN(C)C=CCC(=O)Nc1cc2c(=Nc3ccc(F)c(Cl)c3)[nH]cnc2cc1OC1CCOC1,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3,5-6,8,10-12,14,16H,4,7,9,13H2,1-2H3,(H,30,32)(H,27,28,29)",HSPXNODNUFUFPA-UHFFFAOYSA-N,afatinib,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,oncology,non-small cell lung cancer (NSCLC)
CCC(=C(c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,"InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3",TXUZVZSFRXZGTL-UHFFFAOYSA-N,afimoxifene,Phase 2,estrogen receptor antagonist,ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ,,
Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O,"InChI=1S/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3",VDOSWXIDETXFET-UHFFFAOYSA-N,afloqualone,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,sedative
Cc1c(CN(C)C(=O)CC=c2cnc3c(c2)CCC(=O)N=3)oc2ccccc12,"InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,11-12H,8-10,13H2,1-2H3",YDPWZYNWWCAEFH-UHFFFAOYSA-N,afn-1252,Phase 2,FABI inhibitor,,,
CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,"InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)",WWNUCVSRRUDYPP-UHFFFAOYSA-N,afobazole,Launched,anxiolytic,,neurology/psychiatry,anxiety
CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,"InChI=1S/C14H13BrN2O/c1-14(2,3)11-5-9(4-10(7-16)8-17)6-12(15)13(11)18/h4-6,18H,1-3H3",ABBADGFSRBWENF-UHFFFAOYSA-N,ag-1024,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,
CN(C)Cc1ccc(-c2nc3cccc4c3n2CCNC4=O)cc1,"InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)",SEKJSSBJKFLZIT-UHFFFAOYSA-N,ag-14361,Preclinical,PARP inhibitor,PARP1,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)",TUCIOBMMDDOEMM-UHFFFAOYSA-N,ag-490,Preclinical,EGFR inhibitor,EGFR|JAK2|JAK3,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)",TUCIOBMMDDOEMM-UHFFFAOYSA-N,ag-490,Preclinical,JAK inhibitor,EGFR|JAK2|JAK3,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1,"InChI=1S/C19H18N2O3/c20-13-16(11-15-8-9-17(22)18(23)12-15)19(24)21-10-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-9,11-12,22-23H,4,7,10H2,(H,21,24)",GSQOBTOAOGXIFL-UHFFFAOYSA-N,ag-555,Preclinical,tyrosine kinase inhibitor,CDK2,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,"InChI=1S/C20H20N2O3/c21-14-17(12-16-9-10-18(23)19(24)13-16)20(25)22-11-5-4-8-15-6-2-1-3-7-15/h1-3,6-7,9-10,12-13,23-24H,4-5,8,11H2,(H,22,25)",GWCNJMUSWLTSCW-UHFFFAOYSA-N,ag-556,Preclinical,tyrosine kinase inhibitor,,,
Cc1ccccc1C(C(=O)NC1CCCCC1)N(C(=O)Cn1ccnc1C)c1cccc(F)c1,"InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10,13-17,22,26H,3-5,11-12,18H2,1-2H3,(H,30,34)",FNYGWXSATBUBER-UHFFFAOYSA-N,agi-5198,Preclinical,isocitrate dehydrogenase inhibitor,IDH1,,
O=C(Nc1cccc(C(F)(F)F)c1)Nc1cc(S(=O)(=O)NC2CC2)ccc1-c1ccsc1,"InChI=1S/C21H18F3N3O3S2/c22-21(23,24)14-2-1-3-16(10-14)25-20(28)26-19-11-17(32(29,30)27-15-4-5-15)6-7-18(19)13-8-9-31-12-13/h1-3,6-12,15,27H,4-5H2,(H2,25,26,28)",CCAWRGNYALGPQH-UHFFFAOYSA-N,agi-6780,Preclinical,isocitrate dehydrogenase inhibitor,IDH2,,
COC1C(OC(=O)NC(=O)CCl)CCC2(CO2)C1C1(C)OC1CC=C(C)C,"InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)",MSHZHSPISPJWHW-UHFFFAOYSA-N,agm-1470,Phase 2,cell cycle inhibitor,METAP2,,
N=C(N)NCCCCN,"InChI=1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)",QYPPJABKJHAVHS-UHFFFAOYSA-N,agmatine,Phase 3,nitric oxide synthase inhibitor,ADRA2C|ASIC3|CACNA1B|CHRNA1|GRIN1|KCNJ1|NISCH,,
CC(C)C1C2CCC(C2)C1N,"InChI=1S/C10H19N/c1-6(2)9-7-3-4-8(5-7)10(9)11/h6-10H,3-5,11H2,1-2H3",SHXVJSFOJHMEEQ-UHFFFAOYSA-N,agn-192403,Preclinical,imidazoline receptor ligand,NISCH,,
CCc1ccc(C2=CC(C)(C)Sc3ccc(C#Cc4ccc(C(=O)O)cc4)cc32)cc1,"InChI=1S/C28H24O2S/c1-4-19-7-12-22(13-8-19)25-18-28(2,3)31-26-16-11-21(17-24(25)26)6-5-20-9-14-23(15-10-20)27(29)30/h7-18H,4H2,1-3H3,(H,29,30)",LHUPKWKWYWOMSK-UHFFFAOYSA-N,agn-194310,Phase 3,retinoid receptor antagonist,RXRA|RXRB|RXRG,,
CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,"InChI=1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)",PNAWUIKCVQSLFG-UHFFFAOYSA-N,agn-195183,Phase 1/Phase 2,retinoid receptor agonist,RARA,,
COc1ccc2cccc(CCNC(C)=O)c2c1,"InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)",YJYPHIXNFHFHND-UHFFFAOYSA-N,agomelatine,Launched,melatonin receptor agonist,HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B,neurology/psychiatry,depression
COc1ccc2cccc(CCNC(C)=O)c2c1,"InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)",YJYPHIXNFHFHND-UHFFFAOYSA-N,agomelatine,Launched,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B,neurology/psychiatry,depression
CCCCCCCCCCCCCCCCCCCCCC(=O)O,"InChI=1S/C22H44O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h2-21H2,1H3,(H,23,24)",UKMSUNONTOPOIO-UHFFFAOYSA-N,agp-103,Launched,membrane permeability inhibitor,,,
Cc1ccc(S(=O)(=O)NC2c3ccccc3Oc3ccccc32)cc1,"InChI=1S/C20H17NO3S/c1-14-10-12-15(13-11-14)25(22,23)21-20-16-6-2-4-8-18(16)24-19-9-5-3-7-17(19)20/h2-13,20-21H,1H3",OZCQEUZTOAAWDK-UHFFFAOYSA-N,ah-7614,Preclinical,free fatty acid receptor antagonist,FFAR4,,
N=C(CC(O)COc1ccccc1-c1ccccc1)N1CCCCC1,"InChI=1S/C21H26N2O2/c22-21(23-13-7-2-8-14-23)15-18(24)16-25-20-12-6-5-11-19(20)17-9-3-1-4-10-17/h1,3-6,9-12,18,22,24H,2,7-8,13-16H2",HSVZQQYIMKLNLN-UHFFFAOYSA-N,ah11110,Preclinical,adrenergic receptor ligand,ADRA1B,,
CC(C)Oc1ccc2c(=O)c3cc(C(=O)O)ccc3oc2c1,"InChI=1S/C17H14O5/c1-9(2)21-11-4-5-12-15(8-11)22-14-6-3-10(17(19)20)7-13(14)16(12)18/h3-9H,1-2H3,(H,19,20)",AQFFXPQJLZFABJ-UHFFFAOYSA-N,ah6809,Preclinical,prostanoid receptor antagonist,PTGDR|PTGER1|PTGER2|PTGER3,,
FC(F)(F)Oc1ccc2[nH]c(-c3ccc(OCCOCCOc4ccc(-c5nc6cc(OC(F)(F)F)ccc6[nH]5)nc4)cn3)nc2c1,"InChI=1S/C30H22F6N6O5/c31-29(32,33)46-17-1-5-21-25(13-17)41-27(39-21)23-7-3-19(15-37-23)44-11-9-43-10-12-45-20-4-8-24(38-16-20)28-40-22-6-2-18(14-26(22)42-28)47-30(34,35)36/h1-8,13-16H,9-12H2,(H,39,41)(H,40,42)",WJBSSBFGPKTMQQ-UHFFFAOYSA-N,ai-10-49,Preclinical,core binding factor inhibitor,CBFB,,
c1ccc(-c2oc3[nH]cnc(=NCC4CCCO4)c3c2-c2ccccc2)cc1,"InChI=1S/C23H21N3O2/c1-3-8-16(9-4-1)19-20-22(24-14-18-12-7-13-27-18)25-15-26-23(20)28-21(19)17-10-5-2-6-11-17/h1-6,8-11,15,18H,7,12-14H2,(H,24,25,26)",XNFHHOXCDUAYSR-UHFFFAOYSA-N,aim-100,Preclinical,tyrosine kinase inhibitor,TNK2,,
CCCNC1CCc2c(OC)cccc2C1C,"InChI=1S/C15H23NO/c1-4-10-16-14-9-8-13-12(11(14)2)6-5-7-15(13)17-3/h5-7,11,14,16H,4,8-10H2,1-3H3",YGHLYBIUVOLKCV-UHFFFAOYSA-N,aj76-(+),Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,
CCC1C2CC3C4N(C)c5ccccc5C45CC(C2C5O)N3C1O,"InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3",CJDRUOGAGYHKKD-UHFFFAOYSA-N,ajmaline,Launched,sodium channel blocker,,cardiology,Wolff-Parkinson-White Syndrome (WPW)
O=C(Nc1cccc(Br)c1)c1cccc(S(=O)(=O)N2CCCCCC2)c1,"InChI=1S/C19H21BrN2O3S/c20-16-8-6-9-17(14-16)21-19(23)15-7-5-10-18(13-15)26(24,25)22-11-3-1-2-4-12-22/h5-10,13-14H,1-4,11-12H2,(H,21,23)",IYAYHZZWYNXHEQ-UHFFFAOYSA-N,ak-7,Preclinical,SIRT inhibitor,SIRT2,,
CC(=O)OC1CCC2(C)C(CCC3(C)C2C(=O)C=C2C4C(C)C(C)CCC4(C)CCC23C)C1(C)C(=O)O,"InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)",HMMGKOVEOFBCAU-UHFFFAOYSA-N,akba,Phase 3,lipoxygenase inhibitor,ALOX5,,
NC(=O)c1ccc([N+](=O)[O-])cc1Cl,"InChI=1S/C7H5ClN2O3/c8-6-3-4(10(12)13)1-2-5(6)7(9)11/h1-3H,(H2,9,11)",GFGSZUNNBQXGMK-UHFFFAOYSA-N,aklomide,Launched,,,infectious disease,coccidiosis
Cc1c(F)cc(C(=O)NC2CC2)cc1-c1c(F)cn2c(C(C)(C)C)nnc2c1F,"InChI=1S/C21H21F3N4O/c1-10-13(7-11(8-14(10)22)19(29)25-12-5-6-12)16-15(23)9-28-18(17(16)24)26-27-20(28)21(2,3)4/h7-9,12H,5-6H2,1-4H3,(H,25,29)",ZVBTZTQYHOXIBC-UHFFFAOYSA-N,al-8697,Preclinical,p38 MAPK inhibitor,MAPK14,,
CC(=O)SCC(C)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(=O)O,"InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)",FHHHOYXPRDYHEZ-UHFFFAOYSA-N,alacepril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
CC(N)C(=O)NC(C)[PH](=O)(=O)O,"InChI=1S/C5H12N2O4P/c1-3(6)5(8)7-4(2)12(9,10)11/h3-4H,6H2,1-2H3,(H,7,8)(H,9,10,11)",NOELPILGONARSV-UHFFFAOYSA-N,alafosfalin,Phase 1,bacterial cell wall synthesis inhibitor,,,
Cc1sc[n+](CC(=O)c2ccccc2)c1C,"InChI=1S/C13H14NOS/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12/h3-7,9H,8H2,1-2H3/q+1",LYLFQLCLUXOFOL-UHFFFAOYSA-N,alagebrium,Phase 2/Phase 3,glycosylation inhibitor,,,
CC(N)C(=O)O,"InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)",QNAYBMKLOCPYGJ-UHFFFAOYSA-N,alanine,Launched,,,,
NC(CN(O)[N+][O-])C(=O)O,"InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,10H,1,4H2,(H,7,8)",MLFKVJCWGUZWNV-UHFFFAOYSA-N,alanosine,Phase 2,antimetabolite,,,
C=C1C(=O)OC2CC3(C)CCCC(C)C3=CC12,"InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h7,9,11,13H,2,4-6,8H2,1,3H3",PXOYOCNNSUAQNS-UHFFFAOYSA-N,alantolactone,Preclinical,apoptosis stimulant,STAT3,,
C=C1C(=O)OC2CC3(C)CCCC(C)C3=CC12,"InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h7,9,11,13H,2,4-6,8H2,1,3H3",PXOYOCNNSUAQNS-UHFFFAOYSA-N,alantolactone,Preclinical,STAT inhibitor,STAT3,,
CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1,"InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3",FZSPJBYOKQPKCD-UHFFFAOYSA-N,alaproclate,Phase 2,serotonin receptor antagonist,SLC6A4,,
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,"InChI=1S/C56H78N16O12/c1-5-60-54(83)45-13-9-21-72(45)55(84)39(12-8-20-61-56(57)58)66-50(79)40(22-30(2)3)67-47(76)31(4)64-49(78)41(23-32-14-16-35(74)17-15-32)68-53(82)44(28-73)71-51(80)42(24-33-26-62-37-11-7-6-10-36(33)37)69-52(81)43(25-34-27-59-29-63-34)70-48(77)38-18-19-46(75)65-38/h6-7,10-11,14-17,26-27,29-31,38-45,62,73-74H,5,8-9,12-13,18-25,28H2,1-4H3,(H,59,63)(H,60,83)(H,64,78)(H,65,75)(H,66,79)(H,67,76)(H,68,82)(H,69,81)(H,70,77)(H,71,80)(H4,57,58,61)",QLGKMLRGKPKGKI-UHFFFAOYSA-N,alarelin,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRH1,,
CCCSc1ccc2[nH]c(=NC(=O)OC)[nH]c2c1,"InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)",HXHWSAZORRCQMX-UHFFFAOYSA-N,albendazole,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis
CCC[S+]([O-])c1ccc2[nH]c(=NC(=O)OC)[nH]c2c1,"InChI=1S/C12H15N3O3S/c1-3-6-19(17)8-4-5-9-10(7-8)14-11(13-9)15-12(16)18-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)",VXTGHWHFYNYFFV-UHFFFAOYSA-N,albendazole-oxide,Launched,anthelmintic agent,,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3",NDAUXUAQIAJITI-UHFFFAOYSA-N,albuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,"InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3",MWTBKTRZPHJQLH-UHFFFAOYSA-N,alcaftadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis
C=CCOc1ccc(CC(=O)O)cc1Cl,"InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)",ARHWPKZXBHOEEE-UHFFFAOYSA-N,alclofenac,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis
CCC(=O)OCC(=O)C1(OC(=O)CC)C(C)CC2C3C(Cl)C=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C28H37ClO7/c1-6-22(33)35-14-21(32)28(36-23(34)7-2)15(3)10-18-24-19(29)12-16-11-17(30)8-9-26(16,4)25(24)20(31)13-27(18,28)5/h8-9,12,15,18-20,24-25,31H,6-7,10-11,13-14H2,1-5H3",MCKDVEPRTDUOEQ-UHFFFAOYSA-N,alclometasone-dipropionate,Launched,glucocorticoid receptor agonist,CYP3A4|NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses
O=C(NCc1ccc2c(c1)OCO2)c1c(Cl)cccc1Cl,"InChI=1S/C15H11Cl2NO3/c16-10-2-1-3-11(17)14(10)15(19)18-7-9-4-5-12-13(6-9)21-8-20-12/h1-6H,7-8H2,(H,18,19)",NMKJFZCBCIUYHI-UHFFFAOYSA-N,alda-1,Preclinical,aldehyde dehydrogenase activator,ALDH2,,
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(O)C(C)O1)CC(O)(C(C=O)NNC(=O)CCCCCN1C(=O)C=CC1=O)C=4,"InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,14,16-17,20,23,27,32,39,46-51H,3-5,9,12-13,15,38H2,1-2H3,(H,40,43)",JYJLNZYTWBYUKE-UHFFFAOYSA-N,aldoxorubicin,Phase 3,topoisomerase inhibitor,TOP2A,,
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,alectinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC)
NCCCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C4H11NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H,7,8,9)(H,10,11,12)",COORKQZSNQLSLX-UHFFFAOYSA-N,alendronate,Launched,bone resorption inhibitor,ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS,orthopedics,osteoporosis
CCCCC(CC)CN=C(N)N=C(N)NCCCCCCN=C(N)N=C(N)NCC(CC)CCCC,"InChI=1S/C26H56N10/c1-5-9-15-21(7-3)19-33-25(29)35-23(27)31-17-13-11-12-14-18-32-24(28)36-26(30)34-20-22(8-4)16-10-6-2/h21-22H,5-20H2,1-4H3,(H5,27,29,31,33,35)(H5,28,30,32,34,36)",LFVVNPBBFUSSHL-UHFFFAOYSA-N,alexidine,Preclinical,phosphatidylglycerophosphatase inhibitor,PTPMT1,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCCC(C)C)CC(O)CC1O,"InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3",OFHCOWSQAMBJIW-UHFFFAOYSA-N,alfacalcidol,Launched,vitamin D receptor agonist,CYP27B1|VDR,endocrinology,vitamin D deficiency
CC(=O)OCC(=O)C1CCC2C3CCC4CC(O)CCC4(C)C3C(=O)CC12C,"InChI=1S/C23H34O5/c1-13(24)28-12-20(27)18-7-6-17-16-5-4-14-10-15(25)8-9-22(14,2)21(16)19(26)11-23(17,18)3/h14-18,21,25H,4-12H2,1-3H3",QRJOQYLXZPQQMX-UHFFFAOYSA-N,alfadolone-acetate,Phase 2,benzodiazepine receptor agonist,,,
COc1cc2[nH]c(N(C)CCCNC(=O)C3CCCO3)nc(=N)c2cc1OC,"InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)",WNMJYKCGWZFFKR-UHFFFAOYSA-N,alfuzosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,urology,benign prostatic hyperplasia (BPH)
CC(=O)C12OC(C)(c3ccccc3)OC1CC1C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-10,22-25H,11-17H2,1-4H3",RDTZJWYGGFSECH-UHFFFAOYSA-N,algestone-acetophenide,Launched,,,endocrinology,contraceptive
C=CCc1cc(OC)c(O)c(C(=O)NCCO)c1,"InChI=1S/C13H17NO4/c1-3-4-9-7-10(13(17)14-5-6-15)12(16)11(8-9)18-2/h3,7-8,15-16H,1,4-6H2,2H3,(H,14,17)",UMJHTFHIQDEGKB-UHFFFAOYSA-N,alibendol,Launched,antispasmodic,,gastroenterology,bile stimulation
CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,"InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3",ZZHLYYDVIOPZBE-UHFFFAOYSA-N,alimemazine,Launched,histamine receptor agonist,HRH1,neurology/psychiatry|allergy|pulmonary,sedative|urticaria|itching|cough suppressant
CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,"InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3",ZZHLYYDVIOPZBE-UHFFFAOYSA-N,alimemazine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|allergy|pulmonary,sedative|urticaria|itching|cough suppressant
C=CCN(C1=NCCN1)c1c(Cl)cccc1Cl,"InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16)",OXTYVEUAQHPPMV-UHFFFAOYSA-N,alinidine,Phase 3,bradycardic effect ,,,
COc1cc(N=c2nc3c(c[nH]2)CN=C(c2c(F)cccc2OC)c2cc(Cl)ccc2-3)ccc1C(=O)O,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,alisertib,Phase 3,Aurora kinase inhibitor,AURKA,,
COCCCOc1cc(CC(CC(N)C(O)CC(C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,"InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)",UXOWGYHJODZGMF-UHFFFAOYSA-N,aliskiren-hemifumarate,Launched,renin inhibitor,REN,cardiology,hypertension
CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)C(C)C(=O)N(CC)C(C(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,"InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)",OLROWHGDTNFZBH-UHFFFAOYSA-N,alisporivir,Phase 3,cyclophilin inhibitor,,,
C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC,"InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20)",KSEYRUGYKHXGFW-UHFFFAOYSA-N,alizapride,Launched,dopamine receptor antagonist,,gastroenterology,nausea
O=C1C=Cc2c(c(O)c3ccccc3c2O)C1=O,"InChI=1S/C14H8O4/c15-10-6-5-9-11(14(10)18)13(17)8-4-2-1-3-7(8)12(9)16/h1-6,16-17H",GADFHZPEJJBGDD-UHFFFAOYSA-N,alizarin,Preclinical,,,,
NC(=O)Nc1[nH]c(=O)[nH]c1O,"InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h9H,(H3,5,6,10)(H2,7,8,11)",MLVVTNIFHMERMU-UHFFFAOYSA-N,allantoin,Launched,cosmetic,,dermatology,skin protectant
C=CCS[S+]([O-])CC=C,"InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2",JDLKFOPOAOFWQN-UHFFFAOYSA-N,allicin,Phase 2,cytokine production inhibitor,TRPA1|TRPV1,,
O=c1[nH]cnc2[nH]ncc12,"InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)",OFCNXPDARWKPPY-UHFFFAOYSA-N,allopurinol,Launched,xanthine oxidase inhibitor,XDH,rheumatology|urology,gout|kidney stones
O=c1[nH]cnc2c1cnn2C1OC(CO)C(O)C1O,"InChI=1S/C10H12N4O5/c15-2-5-6(16)7(17)10(19-5)14-8-4(1-13-14)9(18)12-3-11-8/h1,3,5-7,10,15-17H,2H2,(H,11,12,18)",KFQUAMTWOJHPEJ-UHFFFAOYSA-N,allopurinol-riboside,Phase 2,anti-leishmanial agent,,,
O=c1[nH]cnc2c1cnn2C1OC(CO)C(O)C1O,"InChI=1S/C10H12N4O5/c15-2-5-6(16)7(17)10(19-5)14-8-4(1-13-14)9(18)12-3-11-8/h1,3,5-7,10,15-17H,2H2,(H,11,12,18)",KFQUAMTWOJHPEJ-UHFFFAOYSA-N,allopurinol-riboside,Phase 2,phosphorylase inhibitor,,,
C=CCC1(O)CCC2C3CCC4=CCCCC4C3CCC21C,"InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3",ATXHVCQZZJYMCF-UHFFFAOYSA-N,allylestrenol,Launched,steroidal progestin,ESR1|PGR|SLC6A9,obstetrics/gynecology,premature labor
C=CCN=C=S,"InChI=1S/C4H5NS/c1-2-3-5-4-6/h2H,1,3H2",ZOJBYZNEUISWFT-UHFFFAOYSA-N,allylisothiocyanate,Preclinical,TRPV agonist,TRPA1,,
C=CCNC(N)=S,"InChI=1S/C4H8N2S/c1-2-3-6-4(5)7/h2H,1,3H2,(H3,5,6,7)",HTKFORQRBXIQHD-UHFFFAOYSA-N,allylthiourea,Preclinical,nitrification inhibitor,,,
C=CCN=c1nc(N2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)[nH]c(=NCC=C)[nH]1,"InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)",OBDOVFRMEYHSQB-UHFFFAOYSA-N,almitrine,Launched,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD)
CNC(=O)C(c1ccccc1)N1CCc2cc(OC)c(OC)cc2C1CCc1ccc(C(F)(F)F)cc1,"InChI=1S/C29H31F3N2O3/c1-33-28(35)27(20-7-5-4-6-8-20)34-16-15-21-17-25(36-2)26(37-3)18-23(21)24(34)14-11-19-9-12-22(13-10-19)29(30,31)32/h4-10,12-13,17-18,24,27H,11,14-16H2,1-3H3,(H,33,35)",DKMACHNQISHMDN-UHFFFAOYSA-N,almorexant,Phase 3,orexin receptor antagonist,HCRTR1|HCRTR2,,
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,"InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3",WKEMJKQOLOHJLZ-UHFFFAOYSA-N,almotriptan,Launched,serotonin receptor agonist,HTR1B|HTR1D,neurology/psychiatry,migraine headache
O=Cc1cc(O)c2c(O)c3c(O)cccc3c(O)c2c1,"InChI=1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-6,17-20H",LVYBASRFZOCHFE-UHFFFAOYSA-N,aloe-emodin,Preclinical,anticancer agent,CASP8,,
Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O,"InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3",ZSBOMTDTBDDKMP-UHFFFAOYSA-N,alogliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
OCc1cc(O)c2c(O)c3c(O)cccc3c(C3OC(CO)C(O)C(O)C3O)c2c1,"InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13,17,19-29H,6-7H2",UBCKYWKJKPMKAA-UHFFFAOYSA-N,aloin,Preclinical,angiogenesis inhibitor,,,
C1=C2CCCNC2C2CC1C1CCCCN1C2,"InChI=1S/C15H24N2/c1-2-7-17-10-13-9-12(14(17)5-1)8-11-4-3-6-16-15(11)13/h8,12-16H,1-7,9-10H2",SKOLRLSBMUGVOY-UHFFFAOYSA-N,aloperine,Preclinical,,,,
Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,"InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)",JSWZEAMFRNKZNL-UHFFFAOYSA-N,alosetron,Withdrawn,serotonin receptor antagonist,HTR3A,,
Cc1cn(C2CC(F)C(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)",UXCAQJAQSWSNPQ-UHFFFAOYSA-N,alovudine,Phase 2,DNA synthesis marker,,,
CCOC(=O)C1OC1C(=O)NC(CC(C)C)C(=O)NCCC(C)C,"InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)",SRVFFFJZQVENJC-UHFFFAOYSA-N,aloxistatin,Phase 3,protease inhibitor,CTSG,,
Cc1[nH]c(=NC(=O)N2CCCC2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)",STUWGJZDJHPWGZ-UHFFFAOYSA-N,alpelisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,oncology,breast cancer
CC=Cc1cc(OC)c(OC)cc1OC,"InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3",RKFAZBXYICVSKP-UHFFFAOYSA-N,alpha-asarone,Preclinical,cytochrome P450 inhibitor,HMGCR,,
CC=Cc1cc(OC)c(OC)cc1OC,"InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3",RKFAZBXYICVSKP-UHFFFAOYSA-N,alpha-asarone,Preclinical,HMGCR inhibitor,HMGCR,,
OCC1OC(O)C(O)C(O)C1O,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2",WQZGKKKJIJFFOK-UHFFFAOYSA-N,alpha-d-glucopyranose,Preclinical,,,,
COc1ccc(C2CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(OC5OC(CO)C(O)C(O)C5O)C(O)C4O)cc3O2)cc1O,"InChI=1S/C34H44O20/c1-11-23(39)25(41)28(44)32(49-11)48-10-21-31(54-34-29(45)26(42)24(40)20(9-35)52-34)27(43)30(46)33(53-21)50-13-6-15(37)22-16(38)8-18(51-19(22)7-13)12-3-4-17(47-2)14(36)5-12/h3-7,11,18,20-21,23-37,39-46H,8-10H2,1-2H3",IMMBLRJLSYJQIZ-UHFFFAOYSA-N,alpha-glucosyl-hesperidin,Preclinical,antioxidant,,,
CCC=CCC=CCC=CCCCCCCCC(=O)O,"InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)",DTOSIQBPPRVQHS-UHFFFAOYSA-N,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1,,
CC(N)Cc1c[nH]cn1,"InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)",XNQIOISZPFVUFG-UHFFFAOYSA-N,alpha-methylhistamine-dihydrobromide-(r)-(-),Preclinical,histamine receptor agonist,HRH3,,
CC(N)Cc1c[nH]cn1,"InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)",XNQIOISZPFVUFG-UHFFFAOYSA-N,alpha-methylhistamine-dihydrobromide-(s)-(+),Preclinical,histamine receptor agonist,HRH3,,
CC(N)Cc1c[nH]c2ccc(O)cc12,"InChI=1S/C11H14N2O/c1-7(12)4-8-6-13-11-3-2-9(14)5-10(8)11/h2-3,5-7,13-14H,4,12H2,1H3",LYPCGXKCQDYTFV-UHFFFAOYSA-N,alpha-methylserotonin,Preclinical,serotonin receptor agonist,HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4,,
CC(N)Cc1c[nH]c2ccc(O)cc12,"InChI=1S/C11H14N2O/c1-7(12)4-8-6-13-11-3-2-9(14)5-10(8)11/h2-3,5-7,13-14H,4,12H2,1H3",LYPCGXKCQDYTFV-UHFFFAOYSA-N,methyl-5-hydroxytryptamine,Preclinical,,,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3",GVJHHUAWPYXKBD-UHFFFAOYSA-N,alpha-tochopherol,Launched,antioxidant,,endocrinology,vitamin E deficiency
CC(=O)Oc1c(C)c(C)c2c(c1C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C31H52O3/c1-21(2)13-10-14-22(3)15-11-16-23(4)17-12-19-31(9)20-18-28-26(7)29(33-27(8)32)24(5)25(6)30(28)34-31/h21-23H,10-20H2,1-9H3",ZAKOWWREFLAJOT-UHFFFAOYSA-N,alpha-tochopheryl-acetate,Launched,antioxidant,,endocrinology,vitamin E deficiency
CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12,"InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3",JRTIDHTUMYMPRU-UHFFFAOYSA-N,alpidem,Withdrawn,benzodiazepine receptor agonist,GABRA1,,
C=CCc1ccccc1OCC(O)CNC(C)C,"InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3",PAZJSJFMUHDSTF-UHFFFAOYSA-N,alprenolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,angina pectoris
CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(=O)O,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)",GMVPRGQOIOIIMI-UHFFFAOYSA-N,alprostadil,Launched,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR,cardiology,congenital heart defects
O=C(O)CN1C(=O)c2cccc3cccc(c23)C1=O,"InChI=1S/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17)",GCUCIFQCGJIRNT-UHFFFAOYSA-N,alrestatin,Preclinical,aldose reductase inhibitor,AKR1B1,,
N=c1ccn(C2OC(CO)(CCl)C(O)C2F)c(=O)[nH]1,"InChI=1S/C10H13ClFN3O4/c11-3-10(4-16)7(17)6(12)8(19-10)15-2-1-5(13)14-9(15)18/h1-2,6-8,16-17H,3-4H2,(H2,13,14,18)",AWSRKKBIPSQHOJ-UHFFFAOYSA-N,als-8112,Phase 1,,,,
CC(C)C(=O)OCC1(CCl)OC(n2ccc(=N)[nH]c2=O)C(F)C1OC(=O)C(C)C,"InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)",MJVKYGMNSQJLIN-UHFFFAOYSA-N,als-8176,Phase 1,RNA polymerase inhibitor,,,
O=C(c1ccc(F)cc1)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,"InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)",SMYALUSCZJXWHG-UHFFFAOYSA-N,altanserin,Phase 2,serotonin receptor antagonist,HTR2A,,
C=CCSCC1Nc2cc(Cl)c(S(N)(=O)=O)cc2S(=O)(=O)N1,"InChI=1S/C11H14ClN3O4S3/c1-2-3-20-6-11-14-8-4-7(12)9(21(13,16)17)5-10(8)22(18,19)15-11/h2,4-5,11,14-15H,1,3,6H2,(H2,13,16,17)",VGLGVJVUHYTIIU-UHFFFAOYSA-N,althiazide,Launched,diuretic,,cardiology,hypertension
C#Cc1cncc(C2CCCN2C)c1,"InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3",NUPUDYKEEJNZRG-UHFFFAOYSA-N,altinicline,Phase 2,nicotinic receptor agonist,CHRNA4|CHRNB2,,
O=C(N=c1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)cc[nH]1)C1CC1,"InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)",GNNDEPIMDAZHRQ-UHFFFAOYSA-N,altiratinib,Phase 1,MET inhibitor,KDR|MET|TEK,,
O=C(N=c1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)cc[nH]1)C1CC1,"InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)",GNNDEPIMDAZHRQ-UHFFFAOYSA-N,altiratinib,Phase 1,VEGFR inhibitor,KDR|MET|TEK,,
C=CCC1(O)CCC2C3=C(C=CC21C)C1=C(CC3)CC(=O)CC1,"InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,19,23H,1,4-7,9-10,12-13H2,2H3",QYNNQWGHBJQOCT-UHFFFAOYSA-N,altrenogest,Launched,progestogen hormone,PGR,endocrinology,estrus
CN(C)c1nc(N(C)C)nc(N(C)C)n1,InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,altretamine,Launched,DNA synthesis inhibitor,,oncology,ovarian cancer
CCN(CCCc1ccccc1)CCCc1ccccc1,"InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3",ZPFXAOWNKLFJDN-UHFFFAOYSA-N,alverine,Launched,muscle relaxant,HTR1A,gastroenterology,irritable bowel syndrome|diverticular disease
COC1=CC=CC(C)C(=O)Nc2cc(O)c(N=CCN(C)C)c(c2O)CC(C)CC(OC)C(O)C(C)C=C(C)C1OC(N)=O,"InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-12,16-20,26,28,30,37-39H,13-15H2,1-8H3,(H2,33,41)(H,35,40)",FUGYCECNWWVFSN-UHFFFAOYSA-N,alvespimycin,Phase 2,HSP inhibitor,HSP90AA1,,
CC1CN(CC(Cc2ccccc2)C(=O)NCC(=O)O)CCC1(C)c1cccc(O)c1,"InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)",UPNUIXSCZBYVBB-UHFFFAOYSA-N,alvimopan,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,postoperative ileus
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3",BIIVYFLTOXDAOV-UHFFFAOYSA-N,alvocidib,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM,,
CC(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(N)=O,"InChI=1S/C56H113N37O10/c1-29(94)85-31(12-3-21-77-49(60)61)40(96)87-33(14-5-23-79-51(64)65)42(98)89-35(16-7-25-81-53(68)69)44(100)91-37(18-9-27-83-55(72)73)46(102)93-38(19-10-28-84-56(74)75)47(103)92-36(17-8-26-82-54(70)71)45(101)90-34(15-6-24-80-52(66)67)43(99)88-32(13-4-22-78-50(62)63)41(97)86-30(39(57)95)11-2-20-76-48(58)59/h30-38H,2-28H2,1H3,(H2,57,95)(H,85,94)(H,86,97)(H,87,96)(H,88,99)(H,89,98)(H,90,101)(H,91,100)(H,92,103)(H,93,102)(H4,58,59,76)(H4,60,61,77)(H4,62,63,78)(H4,64,65,79)(H4,66,67,80)(H4,68,69,81)(H4,70,71,82)(H4,72,73,83)(H4,74,75,84)",LGLVVVCSQBZONM-UHFFFAOYSA-N,alx-40-4c,Preclinical,CC chemokine receptor antagonist,,,
CN(CCC(Oc1ccc(-c2ccccc2)cc1)c1ccc(F)cc1)CC(=O)O,"InChI=1S/C24H24FNO3/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18/h2-14,23H,15-17H2,1H3,(H,27,28)",FDORQEIHOKEJNX-UHFFFAOYSA-N,alx-5407,Phase 1,glycine transporter inhibitor,SLC6A9,,
CN1CCCCC1Cn1cc(C(=O)c2cc([N+](=O)[O-])ccc2I)c2ccccc21,"InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3",ZUHIXXCLLBMBDW-UHFFFAOYSA-N,am-1241,Preclinical,cannabinoid receptor agonist,CNR1|CNR2,,
Oc1c(I)cc(I)cc1I,"InChI=1S/C6H3I3O/c7-3-1-4(8)6(10)5(9)2-3/h1-2,10H",VAPDZNUFNKUROY-UHFFFAOYSA-N,am-24,Phase 2,lipoxygenase inhibitor,ALOX5,,
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1,"InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)",BUZAJRPLUGXRAB-UHFFFAOYSA-N,am-251,Preclinical,cannabinoid receptor antagonist,CNR1|GPR18|GPR55,,
Cc1c(C(=O)NN2CCOCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(I)cc1,"InChI=1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)",AJFFBPZYXRNAIC-UHFFFAOYSA-N,am-281,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2|GPR55,,
CCCCCC=CCC=CCC=CCC=CCCCC(=O)Nc1ccc(O)cc1,"InChI=1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)",IJBZOOZRAXHERC-UHFFFAOYSA-N,am-404,Preclinical,cyclooxygenase inhibitor,CNR1|CNR2|FAAH|TRPV1,,
CCCCCC=CCC=CCC=CCC=CCCCC(=O)Nc1ccc(O)cc1,"InChI=1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)",IJBZOOZRAXHERC-UHFFFAOYSA-N,am-404,Preclinical,FAAH inhibitor,CNR1|CNR2|FAAH|TRPV1,,
CCCCCC=CCC=CCC=CCC=CCCCC(=O)Nc1ccc(O)cc1,"InChI=1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)",IJBZOOZRAXHERC-UHFFFAOYSA-N,am-404,Preclinical,TRPV antagonist,CNR1|CNR2|FAAH|TRPV1,,
CC1(C)CCC(C)(C)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc21,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",SZWKGOZKRMMLAJ-UHFFFAOYSA-N,am-580,Preclinical,retinoid receptor agonist,RARA,,
COc1ccc(C(=O)c2c(C)n(CCN3CCOCC3)c3cc(I)ccc23)cc1,"InChI=1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3",JHOTYHDSLIUKCJ-UHFFFAOYSA-N,am-630,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2,,
CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1,"InChI=1S/C19H24Cl2N2O4S/c1-23(10-9-14-3-8-18(20)19(21)11-14)12-16(24)13-27-17-6-4-15(5-7-17)22-28(2,25)26/h3-8,11,16,22,24H,9-10,12-13H2,1-2H3",BQBSHJUQVIWEFM-UHFFFAOYSA-N,am-92016,Preclinical,potassium channel blocker,GRIN1,,
Cc1noc(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)c1NC(=O)OC(C)c1ccccc1,"InChI=1S/C27H24N2O5/c1-17-25(28-27(32)33-18(2)20-6-4-3-5-7-20)26(34-29-17)23-14-12-22(13-15-23)21-10-8-19(9-11-21)16-24(30)31/h3-15,18H,16H2,1-2H3,(H,28,32)(H,30,31)",LNDDRUPAICPXIN-UHFFFAOYSA-N,am095,Preclinical,lysophosphatidic acid receptor antagonist,,,
CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)NCc1ccccc1,"InChI=1S/C27H27F3N2O4/c1-3-32(26(35)31-16-18-7-5-4-6-8-18)17-20-15-21(27(28,29)30)10-11-22(20)23-13-19(14-25(33)34)9-12-24(23)36-2/h4-13,15H,3,14,16-17H2,1-2H3,(H,31,35)(H,33,34)",OPXIRFWNLBDKQB-UHFFFAOYSA-N,am211,Preclinical,prostaglandin inhibitor,,,
COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCC5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1,"InChI=1S/C40H44N4O5S/c1-25(45)44-29(18-28-10-8-9-11-33(28)44)24-49-30-16-17-34-32(19-30)36(50-39(2,3)4)35(20-40(5,6)38(46)47)43(34)23-26-12-14-27(15-13-26)37-41-21-31(48-7)22-42-37/h8-17,19,21-22,29H,18,20,23-24H2,1-7H3,(H,46,47)",VYXWHVDEWWHDLH-UHFFFAOYSA-N,am679,Preclinical,cannabinoid receptor agonist,ALOX5AP|CNR1|CNR2,,
COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCC5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1,"InChI=1S/C40H44N4O5S/c1-25(45)44-29(18-28-10-8-9-11-33(28)44)24-49-30-16-17-34-32(19-30)36(50-39(2,3)4)35(20-40(5,6)38(46)47)43(34)23-26-12-14-27(15-13-26)37-41-21-31(48-7)22-42-37/h8-17,19,21-22,29H,18,20,23-24H2,1-7H3,(H,46,47)",VYXWHVDEWWHDLH-UHFFFAOYSA-N,am679,Preclinical,lipoxygenase inhibitor,ALOX5AP|CNR1|CNR2,,
NC12CC3CC(CC(C3)C1)C2,"InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2",DKNWSYNQZKUICI-UHFFFAOYSA-N,amantadine,Launched,glutamate receptor antagonist,DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A,infectious disease|neurology/psychiatry,influenza A virus infection|Parkinson's Disease
N=C(N)N=Nc1ccc(NNC(N)=S)cc1,"InChI=1S/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4,13H,(H3,9,10)(H3,11,15,16)",HQDSAVMTLKVTGJ-UHFFFAOYSA-N,ambazone,Phase 1,DNA damage inducer,,,
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,"InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2",OMHBPUNFVFNHJK-UHFFFAOYSA-P,ambenonium,Launched,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis
COC(c1ccccc1)(c1ccccc1)C(Oc1nc(C)cc(C)n1)C(=O)O,"InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)",OUJTZYPIHDYQMC-UHFFFAOYSA-N,ambrisentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1,"InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2",JBDGDEWWOUBZPM-UHFFFAOYSA-N,ambroxol,Launched,sodium channel blocker,CYP3A4,pulmonary,bronchitis
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(-c4csc(-c5ccccc5)n4)cc23)c1C,"InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-14,16,18,33-34,37H,5-6,15,17H2,1-4H3",WHZPEZIAUQWBEH-UHFFFAOYSA-N,amcasertib,Phase 2,kinase inhibitor,,,
CC(=O)OCC(=O)C12OC3(CCCC3)OC1CC1C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC12C,"InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h6,8,11,19-21,23,32H,4-5,7,9-10,12-15H2,1-3H3",QUYIFTUJECZGBB-UHFFFAOYSA-N,amcinonide,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
c1ccc(CNCc2ccc(CN3CCCNCCNCCCNCC3)cc2)nc1,"InChI=1S/C24H38N6/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2",CWJJHESJXJQCJA-UHFFFAOYSA-N,amd-3465,Preclinical,CC chemokine receptor antagonist,CXCR4,,
NCCCCN(Cc1nc2ccccc2[nH]1)C1CCCc2cccnc21,"InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)",WVLHHLRVNDMIAR-UHFFFAOYSA-N,amd11070,Phase 3,CC chemokine receptor antagonist,CCR5|CXCR4,,
CC1(C)SC2C(N=CN3CCCCCC3)C(=O)N2C1C(=O)O,"InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)",BWWVAEOLVKTZFQ-UHFFFAOYSA-N,amdinocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
Cc1cccc(C)c1NC(=O)c1ccc(N)cc1,"InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)",HZIWGOAXOBPQGY-UHFFFAOYSA-N,ameltolide,Preclinical,anticonvulsant,,,
Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1,"InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)",MNHNIVNAFBSLLX-UHFFFAOYSA-N,amenamevir,Phase 1,helicase primase inhibitor,,,
OCCN=CCNc1ccc(NCCNCCO)c2c(O)c3ccccc3c(O)c12,"InChI=1S/C22H28N4O4/c27-13-11-23-7-9-25-17-5-6-18(26-10-8-24-12-14-28)20-19(17)21(29)15-3-1-2-4-16(15)22(20)30/h1-7,24-30H,8-14H2",LBYBRYBVEMFWAN-UHFFFAOYSA-N,ametantrone,Preclinical,anticancer agent,,,
COc1cc(N)cn[n+]1-c1ccccc1,"InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1",VXROHTDSRBRJLN-UHFFFAOYSA-O,amezinium,Launched,adrenergic receptor agonist,ADRB2,cardiology,hypotension
Nc1c(CC(=O)O)cccc1C(=O)c1ccccc1,"InChI=1S/C15H13NO3/c16-14-11(9-13(17)18)7-4-8-12(14)15(19)10-5-2-1-3-6-10/h1-8H,9,16H2,(H,17,18)",SOYCMDCMZDHQFP-UHFFFAOYSA-N,amfenac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
Nc1c(-c2cccc(C(F)(F)F)c2)nsc1C(=O)O,"InChI=1S/C11H7F3N2O2S/c12-11(13,14)6-3-1-2-5(4-6)8-7(15)9(10(17)18)19-16-8/h1-4H,15H2,(H,17,18)",KVMCEGAWQYTFKC-UHFFFAOYSA-N,amflutizole,Phase 2,xanthine oxidase inhibitor,XDH,,
COC1C=CCC(C)C(C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(CC2CCC21)CC1(CCCc2cc(Cl)ccc21)CO3,"InChI=1S/C33H41ClN2O5S/c1-21-6-4-8-30(40-3)27-12-9-25(27)18-36-19-33(15-5-7-23-16-26(34)11-13-28(23)33)20-41-31-14-10-24(17-29(31)36)32(37)35-42(38,39)22(21)2/h4,8,10-11,13-14,16-17,21-22,25,27,30H,5-7,9,12,15,18-20H2,1-3H3,(H,35,37)",JQNINBDKGLWYMU-UHFFFAOYSA-N,amg-176,Phase 1,MCL1 inhibitor,,,
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3",HEAIZQNMNCHNFD-UHFFFAOYSA-N,amg-208,Phase 1,tyrosine kinase inhibitor,MET,,
CC(C)C(CS(=O)(=O)C(C)C)N1C(=O)C(C)(CC(=O)O)CC(c2cccc(Cl)c2)C1c1ccc(Cl)cc1,"InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)",DRLCSJFKKILATL-UHFFFAOYSA-N,amg-232,Phase 2,MDM inhibitor,MDM2,,
CC(N=c1[nH]cnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,"InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)",KWRYMZHCQIOOEB-UHFFFAOYSA-N,amg-319,Phase 2,PI3K inhibitor,PIK3CD,,
COCCOc1cnc2ccn(C(C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1,"InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3",DWHXUGDWKAIASB-UHFFFAOYSA-N,amg-337,Phase 2,MET inhibitor,MET,,
CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"InChI=1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3",WQTKNBPCJKRYPA-UHFFFAOYSA-N,amg-487,Phase 2,CC chemokine receptor antagonist,,,
CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"InChI=1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3",WQTKNBPCJKRYPA-UHFFFAOYSA-N,amg-487-(+/-),Phase 2,CC chemokine receptor antagonist,CXCR3,,
C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)C(C)C1,"InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3",NXQKSXLFSAEQCZ-UHFFFAOYSA-N,amg-510,Phase 1/Phase 2,K-Ras inhibitor,,,
CC(=O)N=c1[nH]c2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1,"InChI=1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16(18)30-19)29-17-9-14(24-10-25-17)12-5-7-13(8-6-12)20(21,22)23/h2-10H,1H3,(H,26,27,28)",YUTIXVXZQIQWGY-UHFFFAOYSA-N,amg-517,Phase 1,TRPV antagonist,TRPV1,,
Cn1c(=NCC(N)Cc2ccccc2)[nH]c(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,"InChI=1S/C29H27N5O/c1-34-28(35)26(24-12-11-21-9-5-6-10-23(21)18-24)27(22-13-15-31-16-14-22)33-29(34)32-19-25(30)17-20-7-3-2-4-8-20/h2-16,18,25H,17,19,30H2,1H3,(H,32,33)",RQVKVJIRFKVPBF-UHFFFAOYSA-N,amg-548,Phase 1,MAP kinase inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,
CC#CC(CC(=O)O)c1ccc(OCc2cccc(-c3ccc(C(F)(F)F)cc3)c2)cc1,"InChI=1S/C26H21F3O3/c1-2-4-21(16-25(30)31)20-9-13-24(14-10-20)32-17-18-5-3-6-22(15-18)19-7-11-23(12-8-19)26(27,28)29/h3,5-15,21H,16-17H2,1H3,(H,30,31)",ZOPNBMMVVZRSGH-UHFFFAOYSA-N,amg-837,Phase 1,free fatty acid receptor agonist,FFAR1,,
CC1CCC(n2c3c[nH]ccc3c3cnc(=Nc4ccc5c(n4)CCN(C(=O)CO)C5)nc32)CC1,"InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(24(35)15-34)11-9-21(17)29-23/h4,7-8,10,12-13,16,18,27,34H,2-3,5-6,9,11,14-15H2,1H3",AOJQBABIGYNZOY-UHFFFAOYSA-N,amg-925,Phase 1,CDK inhibitor,CDK4|CDK6|FLT3,,
CC1CCC(n2c3c[nH]ccc3c3cnc(=Nc4ccc5c(n4)CCN(C(=O)CO)C5)nc32)CC1,"InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(24(35)15-34)11-9-21(17)29-23/h4,7-8,10,12-13,16,18,27,34H,2-3,5-6,9,11,14-15H2,1H3",AOJQBABIGYNZOY-UHFFFAOYSA-N,amg-925,Phase 1,FLT3 inhibitor,CDK4|CDK6|FLT3,,
CC(C)(C)c1ccc(C=CC(=O)Nc2ccc3c(c2)OCCO3)cc1,"InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)",GZTFUVZVLYUPRG-UHFFFAOYSA-N,amg-9810,Preclinical,TRPV antagonist,TRPV1,,
Cc1ccc2cc(-c3c(C)ccc(C(=O)c4c(-c5ccccc5)n(C)n(-c5ccccc5)c4=O)c3N)ccc2n1,"InChI=1S/C34H28N4O2/c1-21-14-18-27(31(35)29(21)25-17-19-28-24(20-25)16-15-22(2)36-28)33(39)30-32(23-10-6-4-7-11-23)37(3)38(34(30)40)26-12-8-5-9-13-26/h4-20H,35H2,1-3H3",YPPSMYLMSKHYAY-UHFFFAOYSA-N,amg-perk-44,Preclinical,PERK inhibitor,EIF2AK4,,
CC(N=c1[nH]cnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,"InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)",KWRYMZHCQIOOEB-UHFFFAOYSA-N,amg319,Phase 2,PI3K inhibitor,PIK3CD,,
COc1ccc2c(Oc3ccc(=NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)[nH]c3)ccnc2c1,"InChI=1S/C30H29N5O5/c1-19-27(29(37)35(20-8-6-5-7-9-20)34(19)18-30(2,3)38)28(36)33-26-13-11-22(17-32-26)40-25-14-15-31-24-16-21(39-4)10-12-23(24)25/h5-17,38H,18H2,1-4H3,(H,32,33,36)",GLBZSOQDAOLMGC-UHFFFAOYSA-N,amg458,Preclinical,MET inhibitor,MET,,
Cc1csc(-c2n[nH]c(=Nc3ccc(Oc4ncccc4-c4cc[nH]c(=N)n4)cc3)c3ccccc23)c1,"InChI=1S/C28H21N7OS/c1-17-15-24(37-16-17)25-20-5-2-3-6-21(20)26(35-34-25)32-18-8-10-19(11-9-18)36-27-22(7-4-13-30-27)23-12-14-31-28(29)33-23/h2-16H,1H3,(H,32,35)(H2,29,31,33)",IVUGFMLRJOCGAS-UHFFFAOYSA-N,amg900,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
O=C(Nc1ccc2c(O)cc(S(=O)(=O)O)cc2c1)Nc1ccc2c(O)cc(S(=O)(=O)O)cc2c1,"InChI=1S/C21H16N2O9S2/c24-19-9-15(33(27,28)29)7-11-5-13(1-3-17(11)19)22-21(26)23-14-2-4-18-12(6-14)8-16(10-20(18)25)34(30,31)32/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32)",PCGISRHGYLRXSR-UHFFFAOYSA-N,ami-1,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,
CCOC(=O)COc1ccc2c(c1)CC(NCC(O)c1cccc(Cl)c1)CC2,"InChI=1S/C22H26ClNO4/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3",RDJQCOBTKKAQAH-UHFFFAOYSA-N,amibegron,Phase 3,adrenergic receptor agonist,ADRB3,,
Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3",RMMXTBMQSGEXHJ-UHFFFAOYSA-N,amidopyrine,Launched,analgesic agent,,dermatology,dermatitis herpetiformis (DH)
N=c1cc[nH]cc1N,"InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)",OYTKINVCDFNREN-UHFFFAOYSA-N,amifampridine,Launched,potassium channel blocker,,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS)
Cc1cc(N(C)C)ccc1CC(C)N,"InChI=1S/C12H20N2/c1-9-7-12(14(3)4)6-5-11(9)8-10(2)13/h5-7,10H,8,13H2,1-4H3",HFQMYSHATTXRTC-UHFFFAOYSA-N,amiflamine,Phase 1,monoamine oxidase inhibitor,MAOA|SLC6A2,,
NCCCNCCS[PH](=O)(=O)O,"InChI=1S/C5H14N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H,8,9,10)",LXDGFIQSXMEGBL-UHFFFAOYSA-N,amifostine,Launched,reducing agent,ALPPL2|ENPP1,nephrology,renal toxicity
NCCC(=O)C(O)NC1CC(N)C(OC2OC(CN)C(O)C(O)C2O)C(O)C1OC1OC(CO)C(O)C(N)C1O,"InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-7,9-22,27-28,30-36H,1-5,23-26H2",WZGFRDSZMKBKLU-UHFFFAOYSA-N,amikacin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
N=C(N)NC(=O)c1nc(Cl)c(=N)[nH]c1N,"InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)",XSDQTOBWRPYKKA-UHFFFAOYSA-N,amiloride,Launched,sodium channel blocker,AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2,cardiology,hypertension|congestive heart failure
O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21,"InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)",ONNOFKFOZAJDHT-UHFFFAOYSA-N,amineptine,Withdrawn,dopamine receptor agonist,SLC6A2|SLC6A4,,
NCCCCCC(=O)O,"InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)",SLXKOJJOQWFEFD-UHFFFAOYSA-N,aminocaproic-acid,Launched,plasminogen activator inhibitor,LPA|PLAT|PLG,hematology,fibrinolytic bleeding
CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,"InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)",ROBVIMPUHSLWNV-UHFFFAOYSA-N,aminoglutethimide,Launched,glucocorticoid receptor antagonist,CYP11A1|CYP19A1,endocrinology|oncology,Cushing's syndrome|breast cancer
N=C(N)NN,"InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)",HAMNKKUPIHEESI-UHFFFAOYSA-N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,AKR1B1|NOS2|TIMP3,,
NCC(O)CC(=O)O,"InChI=1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)",YQGDEPYYFWUPGO-UHFFFAOYSA-N,aminohydroxybutyric-acid,Launched,,,neurology/psychiatry,epilepsy
NCC(=O)CCC(=O)OCc1ccccc1,"InChI=1S/C12H15NO3/c13-8-11(14)6-7-12(15)16-9-10-4-2-1-3-5-10/h1-5H,6-9,13H2",AFFZCQDLQIEQGB-UHFFFAOYSA-N,aminolevulinic-acid-benzyl-ester,Phase 1,,,,
CC1CCN=C(N)S1,"InChI=1S/C5H10N2S/c1-4-2-3-7-5(6)8-4/h4H,2-3H2,1H3,(H2,6,7)",BATVOUKHGLKDGQ-UHFFFAOYSA-N,aminomethyltransferase,Preclinical,nitric oxide synthase inhibitor,NOS2,,
CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,"InChI=1S/C19H24N2O/c1-15(21(2)3)14-19(18(20)22,16-10-6-4-7-11-16)17-12-8-5-9-13-17/h4-13,15H,14H2,1-3H3,(H2,20,22)",NARHAGIVSFTMIG-UHFFFAOYSA-N,aminopentamide,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea
Cn1c(=O)c2[nH]cnc2n(C)c1=O,"InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)",ZFXYFBGIUFBOJW-UHFFFAOYSA-N,aminophylline,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary,asthma|bronchitis|emphysema
N=c1[nH]c(=N)c2nc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,"InChI=1S/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)",TVZGACDUOSZQKY-UHFFFAOYSA-N,aminopterin,Phase 3,dihydrofolate reductase inhibitor,DHFR|SLC46A1,,
CC(C)C(CO)N=c1[nH]c(=Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)",RAMROQQYRRQPDL-UHFFFAOYSA-N,aminopurvalanol-a,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5,,
CC(C)C(CO)N=c1[nH]c(=Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)",RAMROQQYRRQPDL-UHFFFAOYSA-N,aminopurvalanol-a,Preclinical,tyrosine kinase inhibitor,CDK1|CDK2|CDK5,,
Nc1ccc(C(=O)O)c(O)c1,"InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)",WUBBRNOQWQTFEX-UHFFFAOYSA-N,aminosalicylate,Launched,cyclooxygenase inhibitor,ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2,gastroenterology,inflammatory bowel disease|ulcerative colitis
N=c1[nH]ncs1,"InChI=1S/C2H3N3S/c3-2-5-4-1-6-2/h1H,(H2,3,5)",QUKGLNCXGVWCJX-UHFFFAOYSA-N,aminothiadiazole,Phase 2,inosine monophosphate dehydrogenase inhibitor,ADORA3|IMPDH1,,
N=c1[nH]ccs1,"InChI=1S/C3H4N2S/c4-3-5-1-2-6-3/h1-2H,(H2,4,5)",RAIPHJJURHTUIC-UHFFFAOYSA-N,aminothiazole,Preclinical,cyclin D inhibitor,NOS2,,
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,"InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3",IYIKLHRQXLHMJQ-UHFFFAOYSA-N,amiodarone,Launched,potassium channel blocker,ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2,cardiology,ventricular arrhythmias
CN(C)CCCOC1C(C(O)CO)OC2OC(C)(C)OC21,"InChI=1S/C14H27NO6/c1-14(2)20-12-11(18-7-5-6-15(3)4)10(9(17)8-16)19-13(12)21-14/h9-13,16-17H,5-8H2,1-4H3",YXBQLONCIPUQKO-UHFFFAOYSA-N,amiprilose,Phase 3,CD antagonist,,,
CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,"InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3",JVCPIJKPAKAIIP-UHFFFAOYSA-N,amiselimod,Phase 2,sphingosine 1-phosphate receptor modulator,,,
CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,"InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)",NTJOBXMMWNYJFB-UHFFFAOYSA-N,amisulpride,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,psychosis|bipolar disorder|schizophrenia
Clc1ccc(C23CNCC2C3)cc1Cl,"InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2",BSMNRYCSBFHEMQ-UHFFFAOYSA-N,amitifadine,Phase 3,serotonin transporter (SERT) inhibitor,SLC6A2|SLC6A3|SLC6A4,,
Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1,"InChI=1S/C19H23N3/c1-14-6-8-18(16(3)10-14)20-12-22(5)13-21-19-9-7-15(2)11-17(19)4/h6-13H,1-5H3",QXAITBQSYVNQDR-UHFFFAOYSA-N,amitraz,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,infectious disease,generalized demodicosis
CN(C)CCC=C1c2ccccc2CCc2ccccc21,"InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",KRMDCWKBEZIMAB-UHFFFAOYSA-N,amitriptyline,Launched,norepinephrine inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(C)CCC=C1c2ccccc2CCc2ccccc21,"InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",KRMDCWKBEZIMAB-UHFFFAOYSA-N,amitriptyline,Launched,norepinephrine reuptake inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(C)CCC=C1c2ccccc2CCc2ccccc21,"InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",KRMDCWKBEZIMAB-UHFFFAOYSA-N,amitriptyline,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(C)CCC=C1c2ccccc2CCc2ccccc21,"InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",KRMDCWKBEZIMAB-UHFFFAOYSA-N,amitriptyline,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CC(C)c1ccc2oc3[nH]c(=N)c(C(=O)O)cc3c(=O)c2c1,"InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)",SGRYPYWGNKJSDL-UHFFFAOYSA-N,amlexanox,Launched,histamine receptor modulator,FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13,dental|pulmonary|ophthalmology|allergy,aphthous ulcers|asthma|conjunctivitis|allergic rhinitis
CCOC(=O)C1=C(COCCN)N=C(C)C(C(=O)OC)C1c1ccccc1Cl,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,16-17H,4,9-11,22H2,1-3H3",YMDXSGBNCBQYGC-UHFFFAOYSA-N,amlodipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1,cardiology,hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)
CC1(C(=O)O)CCC2(C)CCC3(C)C(=C2C1)CC(=O)C1C2(C)CCC(OC4OC(C(=O)O)C(O)C(O)C4OC4OC(C(=O)O)C(O)C(O)C4O)C(C)(C)C2CCC13C,"InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h21-31,34-35,44-48H,8-17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)",QCQGNTXXPCJRFZ-UHFFFAOYSA-N,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,HSD11B1|HSD11B2|SLCO1B1|SLCO1B3,dermatology,cosmetic
CC(=O)C(O)O,"InChI=1S/C3H6O3/c1-2(4)3(5)6/h3,5-6H,1H3",UOQFZGVGGMHGEE-UHFFFAOYSA-N,ammonium-lactate,Launched,,HCAR1,dermatology,xerosis cutis|ichthyosis vulgaris
O=C(O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,"InChI=1S/C8HF15O2/c9-2(10,1(24)25)3(11,12)4(13,14)5(15,16)6(17,18)7(19,20)8(21,22)23/h(H,24,25)",SNGREZUHAYWORS-UHFFFAOYSA-N,ammonium-perfluorocaprylate,Phase 1,Pim kinase inhibitor,PIM1,,
c1ccc(C(NCCNC(c2ccccc2)c2ccccc2)c2ccccc2)cc1,"InChI=1S/C28H28N2/c1-5-13-23(14-6-1)27(24-15-7-2-8-16-24)29-21-22-30-28(25-17-9-3-10-18-25)26-19-11-4-12-20-26/h1-20,27-30H,21-22H2",DTZDSNQYNPNCPK-UHFFFAOYSA-N,amn-082,Preclinical,glutamate receptor modulator,GRM7,,
CCN(CC)Cc1cc(N=c2cc[nH]c3cc(Cl)ccc23)ccc1O,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)",OVCDSSHSILBFBN-UHFFFAOYSA-N,amodiaquine,Launched,histamine receptor agonist,HNMT,infectious disease,malaria
CN(C)CCN1C(=O)c2cccc3cc(N)cc(c23)C1=O,"InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3",UPALIKSFLSVKIS-UHFFFAOYSA-N,amonafide,Phase 3,topoisomerase inhibitor,TOP2A|TOP2B,,
CCC(C)(C)c1ccc(CC(C)CN2CC(C)OC(C)C2)cc1,"InChI=1S/C21H35NO/c1-7-21(5,6)20-10-8-19(9-11-20)12-16(2)13-22-14-17(3)23-18(4)15-22/h8-11,16-18H,7,12-15H2,1-6H3",MQHLMHIZUIDKOO-UHFFFAOYSA-N,amorolfine,Launched,membrane integrity inhibitor,,infectious disease,onychomycosis
Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,"InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2",QWGDMFLQWFTERH-UHFFFAOYSA-N,amoxapine,Launched,norepinephrine reputake inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
CC1(C)SC2C(NC(=O)C(N)c3ccc(O)cc3)C(=O)N2C1C(=O)O,"InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)",LSQZJLSUYDQPKJ-UHFFFAOYSA-N,amoxicillin,Launched,penicillin binding protein inhibitor,CYP2C19|SLC15A1|SLC15A2|SLC22A6,infectious disease|gastroenterology,skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections
Cc1o[nH]c(=O)c1CC(N)C(=O)O,"InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)",UUDAMDVQRQNNHZ-UHFFFAOYSA-N,ampa-(rs),Preclinical,glutamate receptor agonist,GRIN1,,
Cc1o[nH]c(=O)c1CC(N)C(=O)O,"InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)",UUDAMDVQRQNNHZ-UHFFFAOYSA-N,ampa-(s),Preclinical,glutamate receptor agonist,GRIA2|GRIN1,,
O=C(c1ccc2nccnc2c1)N1CCCCC1,"InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2",ANDGGVOPIJEHOF-UHFFFAOYSA-N,ampalex,Phase 2,glutamate receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,,
CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C23H29F2N3O/c1-2-26-23(29)28-16-14-27(15-17-28)13-3-4-22(18-5-9-20(24)10-6-18)19-7-11-21(25)12-8-19/h5-12,22H,2-4,13-17H2,1H3,(H,26,29)",NNAIYOXJNVGUOM-UHFFFAOYSA-N,amperozide,Launched,dopamine receptor antagonist,FAAH|HTR2A,neurology/psychiatry,psychosis
CC1C=CC=CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,"InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)",APKFDSVGJQXUKY-UHFFFAOYSA-N,amphotericin-b,Launched,membrane permeability enhancer,,infectious disease,fungal infection
CC1(C)SC2C(NC(=O)C(N)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)",AVKUERGKIZMTKX-UHFFFAOYSA-N,ampicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections
CCOC(=O)OC(C)OC1=C(C(=O)N=c2cccc[nH]2)N(C)S(=O)(=O)c2ccccc21,"InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)",LSNWBKACGXCGAJ-UHFFFAOYSA-N,ampiroxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OC1CCOC1)S(=O)(=O)c1ccc(N)cc1,"InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)",YMARZQAQMVYCKC-UHFFFAOYSA-N,amprenavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CCCc1nc(=N)c(C[n+]2ccccc2C)c[nH]1,"InChI=1S/C14H19N4/c1-3-6-13-16-9-12(14(15)17-13)10-18-8-5-4-7-11(18)2/h4-5,7-9H,3,6,10H2,1-2H3,(H2,15,16,17)/q+1",IPZFPROOBOUEIG-UHFFFAOYSA-N,amprolium,Launched,thiamine uptake blocker,,infectious disease,coccidiosis
Cc1c(N)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C11H13N3O/c1-8-10(12)11(15)14(13(8)2)9-6-4-3-5-7-9/h3-7H,12H2,1-2H3",RLFWWDJHLFCNIJ-UHFFFAOYSA-N,ampyrone,Preclinical,cyclooxygenase inhibitor,,,
Nc1cc(-c2ccncc2)c[nH]c1=O,"InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)",RNLQIBCLLYYYFJ-UHFFFAOYSA-N,amrinone,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B|PDE4B|TNF,cardiology,congestive heart failure
CC(=O)C1(N)C=C(OC2CC(O)C(O)CO2)c2c(c(O)c3c(O)c4ccccc4c(O)c3c2O)C1,"InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,8,14-15,17,28-33H,6-7,9,26H2,1H3",WESDNQPJIFLAIT-UHFFFAOYSA-N,amrubicin,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,small cell lung cancer
COc1cc(NS(C)(=O)=O)ccc1N=c1c2ccccc2[nH]c2ccccc12,"InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)",XCPGHVQEEXUHNC-UHFFFAOYSA-N,amsacrine,Launched,topoisomerase inhibitor,KCNH2|TOP2A,hematologic malignancy,acute lymphoblastic leukemia (ALL)
Cc1[nH]c(=N)sc1CCN,"InChI=1S/C6H11N3S/c1-4-5(2-3-7)10-6(8)9-4/h2-3,7H2,1H3,(H2,8,9)",LHVRFUVVRXGZPV-UHFFFAOYSA-N,amthamine,Preclinical,histamine receptor agonist,HRH2,,
COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,"InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27)",CWJNMKKMGIAGDK-UHFFFAOYSA-N,amtolmetin-guacil,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)",FOFDIMHVKGYHRU-UHFFFAOYSA-N,amuvatinib,Phase 2,FLT3 inhibitor,KIT|MET,,
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)",FOFDIMHVKGYHRU-UHFFFAOYSA-N,amuvatinib,Phase 2,KIT inhibitor,KIT|MET,,
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)",FOFDIMHVKGYHRU-UHFFFAOYSA-N,amuvatinib,Phase 2,PDGFR tyrosine kinase receptor inhibitor,KIT|MET,,
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)",FOFDIMHVKGYHRU-UHFFFAOYSA-N,amuvatinib,Phase 2,RAD51 inhibitor,KIT|MET,,
S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,"InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)",FOFDIMHVKGYHRU-UHFFFAOYSA-N,amuvatinib,Phase 2,RET tyrosine kinase inhibitor,KIT|MET,,
N#CC(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)c1ccccc1,"InChI=1S/C20H27NO11/c21-6-10(9-4-2-1-3-5-9)30-20-18(28)16(26)14(24)12(32-20)8-29-19-17(27)15(25)13(23)11(7-22)31-19/h1-5,10-20,22-28H,7-8H2",XUCIJNAGGSZNQT-UHFFFAOYSA-N,amygdalin,Phase 2,caspase activator,CASP3,,
CCCCCONO,"InChI=1S/C5H13NO2/c1-2-3-4-5-8-6-7/h6-7H,2-5H2,1H3",WZLHAIVCEJPCJH-UHFFFAOYSA-N,amyl-nitrite,Preclinical,atrial natriuretic peptide receptor agonist,,,
CCC(C)(CN(C)C)OC(=O)c1ccccc1,"InChI=1S/C14H21NO2/c1-5-14(2,11-15(3)4)17-13(16)12-9-7-6-8-10-12/h6-10H,5,11H2,1-4H3",FDMBBCOBEAVDAO-UHFFFAOYSA-N,amyleine,Preclinical,local anesthetic,,,
CCC(C)(C)O,"InChI=1S/C5H12O/c1-4-5(2,3)6/h6H,4H2,1-3H3",MSXVEPNJUHWQHW-UHFFFAOYSA-N,amylene-hydrate,Preclinical,local anesthetic,,,
N#CC(=Cc1cccn1S(=O)(=O)c1cccc([N+](=O)[O-])c1)S(=O)(=O)c1ccc(F)cc1,"InChI=1S/C19H12FN3O6S2/c20-14-6-8-17(9-7-14)30(26,27)19(13-21)11-15-4-2-10-22(15)31(28,29)18-5-1-3-16(12-18)23(24)25/h1-12H",GUCUORSUHTZMBW-UHFFFAOYSA-N,amz30,Preclinical,protein phosphatase inhibitor,,,
OB1OCc2cc(Cl)ccc21,"InChI=1S/C7H6BClO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2",HMAFTPZYFJFEHK-UHFFFAOYSA-N,an2718,Phase 1,leucyl-tRNA synthetase inhibitor,,,
O=C(Nc1ccccc1C(=O)NC1CCCCNC1=O)c1cc2ccccc2s1,"InChI=1S/C22H21N3O3S/c26-20(25-17-10-5-6-12-23-21(17)27)15-8-2-3-9-16(15)24-22(28)19-13-14-7-1-4-11-18(14)29-19/h1-4,7-9,11,13,17H,5-6,10,12H2,(H,23,27)(H,24,28)(H,25,26)",TUSCYCAIGRVBMD-UHFFFAOYSA-N,ana-12,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,
c1cncc(C2CCCCN2)c1,"InChI=1S/C10H14N2/c1-2-7-12-10(5-1)9-4-3-6-11-8-9/h3-4,6,8,10,12H,1-2,5,7H2",MTXSIJUGVMTTMU-UHFFFAOYSA-N,anabasine,Preclinical,acetylcholine receptor agonist,,,
COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)OC(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1C,"InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3",MZZLGJHLQGUVPN-UHFFFAOYSA-N,anacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N)cn2n1,"InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)",LDXYBEHACFJIEL-UHFFFAOYSA-N,anagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
Oc1cn2c(n1)Nc1ccc(Cl)c(Cl)c1C2,"InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2,4,16H,3H2,(H,13,14)",CUCMIJQKFCWAPD-UHFFFAOYSA-N,anagrelide,Launched,phosphodiesterase inhibitor,PDE3A,hematology|hematologic malignancy,thrombocythemia|myeloproliferative neoplasms
CN(C)N(C)C(=O)C1(Cc2ccccc2)CCCN(C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1,"InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)",VQPFSIRUEPQQPP-UHFFFAOYSA-N,anamorelin,Phase 3,growth hormone secretagogue receptor agonist,GHSR,,
CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO,"InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)",LGEQQWMQCRIYKG-UHFFFAOYSA-N,anandamide,Phase 2,cannabinoid receptor agonist,CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1,,
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,"InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3",YBBLVLTVTVSKRW-UHFFFAOYSA-N,anastrozole,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CC(=O)Nc1ccc(OCC(C)(O)C(=O)Nc2ccc([N+](=O)[O-])c(C(F)(F)F)c2)cc1,"InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)",YVXVTLGIDOACBJ-UHFFFAOYSA-N,andarine,Phase 1,androgen receptor modulator,AR,,
C=C1CCC2C(C)(CO)C(O)CCC2(C)C1C=CC1C(=O)OCC1O,"InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5-6,13-17,21-23H,1,4,7-11H2,2-3H3",CKZDDLBOPCFVJG-UHFFFAOYSA-N,andrographolide,Phase 2,tumor necrosis factor production inhibitor,IL1B|IL6|NFKB1|NFKB2|TNF,,
CC12C=CCC1C1CCC3CC(=O)CCC3(C)C1CC2,"InChI=1S/C19H28O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13,15-17H,4-8,10-12H2,1-2H3",HFVMLYAGWXSTQI-UHFFFAOYSA-N,androstenone,Preclinical,steroid,,,
CC12CCC3C(CCC4CC(O)CCC43C)C1CCC2=O,"InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3",QGXBDMJGAMFCBF-UHFFFAOYSA-N,androsterone,Preclinical,androgen receptor agonist,,,
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3=CCC21C,"InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h4,7,17,19,27H,5-6,8-13H2,1-3H3",UMWBOSAIPUDSKP-UHFFFAOYSA-N,anecortave-acetate,Launched,angiogenesis inhibitor,,ophthalmology,macular degeneration
CC=Cc1ccc(OC)cc1,"InChI=1S/C10H12O/c1-3-4-9-5-7-10(11-2)8-6-9/h3-8H,1-2H3",RUVINXPYWBROJD-UHFFFAOYSA-N,anethole,Launched,glutathione transferase stimulant,,,
COc1ccc(-c2cc(=S)ss2)cc1,"InChI=1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3",KYLIZBIRMBGUOP-UHFFFAOYSA-N,anethole-trithione,Launched,glutathione transferase stimulant,,dental,xerostomia
CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C12CO2,"InChI=1S/C19H26O7/c1-10-5-6-18(8-23-11(2)20)13(7-10)26-16-14(22)15(25-12(3)21)17(18,4)19(16)9-24-19/h7,13-16,22H,5-6,8-9H2,1-4H3",AUGQEEXBDZWUJY-UHFFFAOYSA-N,anguidine,Phase 2,protein synthesis inhibitor,SLC5A1,,
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)c5ccc(O)cc5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)cc3)cc2)cc1,"InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)",JHVAMHSQVVQIOT-UHFFFAOYSA-N,anidulafungin,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|fungal infection|esophageal candidiasis
COc1ccc(C(=O)N2CCCC2=O)cc1,"InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3",ZXNRTKGTQJPIJK-UHFFFAOYSA-N,aniracetam,Launched,glutamate receptor agonist,DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A,,
COc1ccc(C2C(=O)c3ccccc3C2=O)cc1,"InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3",XRCFXMGQEVUZFC-UHFFFAOYSA-N,anisindione,Launched,vitamin K antagonist,GGCX,hematology,deep vein thrombosis (DVT)
COc1ccc(CC2NCC(O)C2OC(C)=O)cc1,"InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3",YKJYKKNCCRKFSL-UHFFFAOYSA-N,anisomycin,Preclinical,DNA synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,
CCCC(CCC)C(=O)OC1CC2CCC(C1)[N+]2(C)C,"InChI=1S/C17H32NO2/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4/h13-16H,5-12H2,1-4H3/q+1",XGGHHHBGPSNXFE-UHFFFAOYSA-N,anisotropine,Launched,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,"InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3",KSMZEXLVHXZPEF-UHFFFAOYSA-N,anlotinib,Launched,PDGFR tyrosine kinase receptor inhibitor,KDR|PDGFRB,,
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,"InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3",KSMZEXLVHXZPEF-UHFFFAOYSA-N,anlotinib,Launched,VEGFR inhibitor,KDR|PDGFRB,,
Clc1cccc(SC2CCNCC2)n1,"InChI=1S/C10H13ClN2S/c11-9-2-1-3-10(13-9)14-8-4-6-12-7-5-8/h1-3,8,12H,4-7H2",GGALEXMXDMUMDM-UHFFFAOYSA-N,anpirtoline,Phase 1,serotonin receptor agonist,HTR1B,,
CCOc1nc2c(=N)[nH]cnc2n1CC,"InChI=1S/C9H13N5O/c1-3-14-8-6(7(10)11-5-12-8)13-9(14)15-4-2/h5H,3-4H2,1-2H3,(H2,10,11,12)",QUGDTMONBLMLLD-UHFFFAOYSA-N,anr-94,Preclinical,adenosine receptor antagonist,ADORA2A,,
COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)C)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,"InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)",OPQNCARIZFLNLF-UHFFFAOYSA-N,ansamitocin-p-3,Preclinical,apoptosis stimulant,,,
CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccccc1)N(C)C(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(N)CCCN=C(N)N)C(N)=O,"InChI=1S/C49H66N12O6S/c1-29(2)23-39(45(64)57-38(43(51)62)20-22-68-4)58-46(65)40(25-31-27-55-36-18-10-8-15-33(31)36)59-47(66)42(24-30-13-6-5-7-14-30)61(3)48(67)41(26-32-28-56-37-19-11-9-16-34(32)37)60-44(63)35(50)17-12-21-54-49(52)53/h5-11,13-16,18-19,27-29,35,38-42,55-56H,12,17,20-26,50H2,1-4H3,(H2,51,62)(H,57,64)(H,58,65)(H,59,66)(H,60,63)(H4,52,53,54)",CUCSSYAUKKIDJV-UHFFFAOYSA-N,antagonist-g,Phase 1,neuropeptide receptor antagonist,MAPK8,,
CCCCN(CC)c1nc(C)nc2c1c(C)c(C)n2-c1c(C)cc(C)cc1C,"InChI=1S/C24H34N4/c1-9-11-12-27(10-2)23-21-18(6)19(7)28(24(21)26-20(8)25-23)22-16(4)13-15(3)14-17(22)5/h13-14H,9-12H2,1-8H3",IXPROWGEHNVJOY-UHFFFAOYSA-N,antalarmin,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,"InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)",REYFJDPCWQRWAA-UHFFFAOYSA-N,antazoline,Launched,antihistamine,HRH1,ophthalmology|otolaryngology,conjunctivitis|nasal congestion
Oc1cccc2cc3cccc(O)c3c(O)c12,"InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-7,15-17H",YUTJCNNFTOIOGT-UHFFFAOYSA-N,anthralin,Launched,DNA synthesis inhibitor,,dermatology,psoriasis
O=C1c2ccccc2C(=O)c2ccccc21,InChI=1S/C14H8O2/c15-13-9-5-1-2-6-10(9)14(16)12-8-4-3-7-11(12)13/h1-8H,RZVHIXYEVGDQDX-UHFFFAOYSA-N,anthraquinone,Preclinical,CDC inhibitor,CDC25B,,
O=C1O[SbH]23OC(=O)C(O2)C2O[SbH]4(OC(=O)C(O4)C1O3)OC2=O,"InChI=1S/2C4H4O6.2Sb.2H/c2*5-1(3(7)8)2(6)4(9)10;;;;/h2*1-2H,(H,7,8)(H,9,10);;;;/q2*-2;2*+4;;/p-4",ZCIXFSVENQDMCK-UHFFFAOYSA-J,antimony-potassium,Phase 2,,,,
O=C1O[SbH]23OC(=O)C(O2)C2O[SbH]4(OC(=O)C(O4)C1O3)OC2=O,"InChI=1S/2C4H4O6.2Sb.2H/c2*5-1(3(7)8)2(6)4(9)10;;;;/h2*1-2H,(H,7,8)(H,9,10);;;;/q2*-2;2*+4;;/p-4",ZCIXFSVENQDMCK-UHFFFAOYSA-J,antimonyl,Phase 1,,,,
CCCCCCC1C(=O)OC(C)C(NC(=O)c2cccc(NC=O)c2O)C(=O)OC(C)C1OC(=O)CC(C)C,"InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)",UIFFUZWRFRDZJC-UHFFFAOYSA-N,antimycin-a,Preclinical,ATP synthase inhibitor,CYCS,,
Cc1ccc(C(C)C)cc1O,"InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3",RECUKUPTGUEGMW-UHFFFAOYSA-N,antioxine,Launched,,,,
CC(=Cc1ccc(Cl)cc1)C(C)=NO,"InChI=1S/C11H12ClNO/c1-8(9(2)13-14)7-10-3-5-11(12)6-4-10/h3-7,14H,1-2H3",MHTJEUOFLVQMCL-UHFFFAOYSA-N,ap-18,Preclinical,transient receptor potential channel antagonist,TRPA1,,
CCC(C(=O)N1CCCCC1C(=O)OC(CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(C(CCc3ccc(OC)c(OC)c3)OC(=O)C3CCCCN3C(=O)C(CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,"InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)",GQLCLPLEEOUJQC-UHFFFAOYSA-N,ap1903,Phase 1/Phase 2,,MTOR,,
COc1cc(N2CCC(N(C)C)CC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccccc2P(C)(C)=O)[nH]1,"InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)",OVDSPTSBIQCAIN-UHFFFAOYSA-N,ap26113,Phase 2,ALK tyrosine kinase receptor inhibitor,ALK|EGFR,,
COc1cc(OC)c2c(=O)[nH]c(-c3cc(C)c(OCCO)c(C)c3)nc2c1,"InChI=1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)",NETXMUIMUZJUTB-UHFFFAOYSA-N,apabetalone,Phase 3,apolipoprotein expression enhancer,BRD3,,
Cc1nnc2n1-c1sc(CCC(=O)N3CCOCC3)cc1C(c1ccccc1Cl)=NC2,"InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3",JGPJQFOROWSRRS-UHFFFAOYSA-N,apafant,Phase 3,platelet activating factor receptor antagonist,PTAFR,,
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,"InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)",HJBWBFZLDZWPHF-UHFFFAOYSA-N,apalutamide,Launched,androgen receptor antagonist,,oncology,prostate cancer
CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O,"InChI=1S/C17H17FN2O4S/c1-17(2)16(21)20(13-7-4-11(18)5-8-13)14-9-6-12(10-15(14)24-17)19-25(3,22)23/h4-10,19H,1-3H3",AZNHWXAFPBYFGH-UHFFFAOYSA-N,apararenone,Preclinical,mineralocorticoid receptor antagonist,,,
N#CC1(c2ccc(NC(=O)c3ccc[nH]c3=NCc3ccncc3)cc2)CCCC1,"InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)",WPEWQEMJFLWMLV-UHFFFAOYSA-N,apatinib,Phase 3,RET tyrosine kinase inhibitor,CSK|KDR|KIT|RET,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,"InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3",SEBPXHSZHLFWRL-UHFFFAOYSA-N,apc-100,Phase 1/Phase 2,androgen receptor antagonist,AR,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,"InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3",SEBPXHSZHLFWRL-UHFFFAOYSA-N,apc-100,Phase 1/Phase 2,anti-inflammatory agent,AR,,
COc1cc(OC)cc(-c2ccc3c(-c4ccc(F)cc4)[nH]nc3n2)c1,"InChI=1S/C20H16FN3O2/c1-25-15-9-13(10-16(11-15)26-2)18-8-7-17-19(23-24-20(17)22-18)12-3-5-14(21)6-4-12/h3-11H,1-2H3,(H,22,23,24)",CAMGZGMEPKFVMF-UHFFFAOYSA-N,apck-110,Preclinical,KIT inhibitor,KIT|STAT3,,
COc1c(OC2CCN(C(=O)OC(C)C)CC2)[nH]cnc1=Nc1ccc(S(C)(=O)=O)nc1C,"InChI=1S/C21H29N5O6S/c1-13(2)31-21(27)26-10-8-15(9-11-26)32-20-18(30-4)19(22-12-23-20)25-16-6-7-17(24-14(16)3)33(5,28)29/h6-7,12-13,15H,8-11H2,1-5H3,(H,22,23,25)",WPDCHTSXOPUOII-UHFFFAOYSA-N,apd597,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,
CC(C)OC(=O)N1CCC(Oc2ncnc3c2cnn3-c2ccc(S(C)(=O)=O)cc2F)CC1,"InChI=1S/C21H24FN5O5S/c1-13(2)31-21(28)26-8-6-14(7-9-26)32-20-16-11-25-27(19(16)23-12-24-20)18-5-4-15(10-17(18)22)33(3,29)30/h4-5,10-14H,6-9H2,1-3H3",XTRUQJBVQBUKSQ-UHFFFAOYSA-N,apd668,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,
CC1(CO)C(O)CCC2(C)C1CCC1CC3CC12CCC3(O)CO,"InChI=1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3",NOFOAYPPHIUXJR-UHFFFAOYSA-N,aphidicolin,Phase 1,RNA synthesis inhibitor,,,
Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,"InChI=1S/C20H23N3O2/c1-16-14-20(25-13-10-22-8-11-24-12-9-22)21-23(16)19-7-6-17-4-2-3-5-18(17)15-19/h2-7,14-15H,8-13H2,1H3",DGPGXHRHNRYVDH-UHFFFAOYSA-N,api-001,Phase 2,sigma receptor antagonist,SIGMAR1,,
N=c1[nH]cnc2c1c(=O)c(C(N)=O)cn2C1OC(CO)C(O)C1O,"InChI=1S/C13H15N5O6/c14-10-6-7(20)4(11(15)23)1-18(12(6)17-3-16-10)13-9(22)8(21)5(2-19)24-13/h1,3,5,8-9,13,19,21-22H,2H2,(H2,15,23)(H2,14,16,17)",SPBWHPXCWJLQRU-UHFFFAOYSA-N,api-1,Preclinical,AKT inhibitor,AKT1|AKT2|AKT3,,
O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H",KZNIFHPLKGYRTM-UHFFFAOYSA-N,apigenin,Preclinical,casein kinase inhibitor,AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1,,
O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H",KZNIFHPLKGYRTM-UHFFFAOYSA-N,apigenin,Preclinical,cell proliferation inhibitor,AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1,,
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,"InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)",QNZCBYKSOIHPEH-UHFFFAOYSA-N,apixaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)
COc1cc(C(C)=O)ccc1O,"InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3",DFYRUELUNQRZTB-UHFFFAOYSA-N,apocynin,Phase 1,NADPH oxidase inhibitor,NOX4,,
O=C1C(=O)N(Cc2ccc(Cl)c(Cl)c2)c2ccccc21,"InChI=1S/C15H9Cl2NO2/c16-11-6-5-9(7-12(11)17)8-18-13-4-2-1-3-10(13)14(19)15(18)20/h1-7H,8H2",KGRJPLRFGLMQMV-UHFFFAOYSA-N,apoptosis-activator-ii,Preclinical,carboxylesterase inhibitor,BCHE|CES1,,
COCC1(CO)C(=O)C2CCN1CC2,"InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3",BGBNULCRKBVAKL-UHFFFAOYSA-N,apr-246,Phase 3,p53 activator,TP53,,
Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,"InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)",IEJXVRYNEISIKR-UHFFFAOYSA-N,apraclonidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C,ophthalmology,glaucoma|intraocular pressure
CNC1C(OC2OC(CO)C(N)C(O)C2O)OC2CC(N)C(OC3C(N)CC(N)C(O)C3O)OC2C1O,"InChI=1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3",XZNUGFQTQHRASN-UHFFFAOYSA-N,apramycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)C1C(O)=NO,"InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)",MAVDNGWEBZTACC-UHFFFAOYSA-N,apratastat,Phase 2,matrix metalloprotease inhibitor,ADAM17|MMP1|MMP13|MMP9,,
CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)C1C(O)=NO,"InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)",MAVDNGWEBZTACC-UHFFFAOYSA-N,apratastat,Phase 2,tumor necrosis factor production inhibitor,ADAM17|MMP1|MMP13|MMP9,,
CCOc1cc(C(CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,"InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)",IMOZEMNVLZVGJZ-UHFFFAOYSA-N,apremilast,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology|rheumatology,psoriasis|psoriatic arthritis
CC(OC1OCCN(Cc2n[nH]c(=O)[nH]2)C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)",ATALOFNDEOCMKK-UHFFFAOYSA-N,aprepitant,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
N=c1ccn(C2COC(CO)S2)c(=O)[nH]1,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)",RYMCFYKJDVMSIR-UHFFFAOYSA-N,apricitabine,Phase 3,nucleoside reverse transcriptase inhibitor,,,
CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,"InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3",NZLBHDRPUJLHCE-UHFFFAOYSA-N,aprindine,Launched,voltage-gated sodium channel blocker,CALM1|SCN5A,cardiology,cardiac arrythmia
C=CCC(C(=O)NC(N)=O)C(C)C,"InChI=1S/C9H16N2O2/c1-4-5-7(6(2)3)8(12)11-9(10)13/h4,6-7H,1,5H2,2-3H3,(H3,10,11,12,13)",KSUUMAWCGDNLFK-UHFFFAOYSA-N,apronal,Preclinical,cytochrome P450 modulator,,,
CCc1cccc(N(C)C(=N)Nc2cccc3ccccc23)c1,"InChI=1S/C20H21N3/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19/h4-14H,3H2,1-2H3,(H2,21,22)",BFNCJMURTMZBTE-UHFFFAOYSA-N,aptiganel,Phase 3,glutamate receptor antagonist,GRIN1,,
Cc1[nH]c2ccc(F)cc2c1-c1nc2c3cccnc3c3[nH]cccc3c2n1,"InChI=1S/C22H14FN5/c1-11-17(15-10-12(23)6-7-16(15)26-11)22-27-20-13-4-2-8-24-18(13)19-14(21(20)28-22)5-3-9-25-19/h2-10,24,26H,1H3",XHFARPUAMCYXFV-UHFFFAOYSA-N,apto-253,Phase 1,krppel-like factor expression enhancer,KLF4,,
c1cc(N=c2cc(C3CC3)[nH][nH]2)[nH]c(=Nc2ccc3[nH]cnc3c2)n1,"InChI=1S/C17H16N8/c1-2-10(1)13-8-16(25-24-13)22-15-5-6-18-17(23-15)21-11-3-4-12-14(7-11)20-9-19-12/h3-10H,1-2H2,(H,19,20)(H3,18,21,22,23,24,25)",WJNBSTLIALIIEW-UHFFFAOYSA-N,apy-29,Preclinical,serine/threonine kinase inhibitor,ERN1,,
Cc1cccc(C=NN=c2cc(N3CCOCC3)n3[nH]c(-c4ccncc4)cc3n2)c1,"InChI=1S/C23H23N7O/c1-17-3-2-4-18(13-17)16-25-27-21-15-23(29-9-11-31-12-10-29)30-22(26-21)14-20(28-30)19-5-7-24-8-6-19/h2-8,13-16,28H,9-12H2,1H3",DWFWRWOABQRHJO-UHFFFAOYSA-N,apy0201,Preclinical,phosphoinositide dependent kinase inhibitor,IL12A|IL12B|PIKFYVE,,
COc1ccc2c(c1)c(CC(=O)Oc1ccc(NC(C)=O)cc1)c(C)n2C(=O)c1ccc(Cl)cc1,"InChI=1S/C27H23ClN2O5/c1-16-23(15-26(32)35-21-10-8-20(9-11-21)29-17(2)31)24-14-22(34-3)12-13-25(24)30(16)27(33)18-4-6-19(28)7-5-18/h4-14H,15H2,1-3H3,(H,29,31)",KWUFTKVMXUYTBF-UHFFFAOYSA-N,apyramide,Preclinical,cyclooxygenase inhibitor,,,
CCN(CC)CCCN=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C16H22ClN3/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19)",NCPLTAGJJVCHOW-UHFFFAOYSA-N,aq-13,Phase 2,antimalarial agent,,,
CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,"InChI=1S/C27H37N5O2/c1-3-30(4-2)17-8-7-10-21-14-18-31(19-15-21)20-25(33)32-24-13-6-5-11-22(24)27(34)29-23-12-9-16-28-26(23)32/h5-6,9,11-13,16,21H,3-4,7-8,10,14-15,17-20H2,1-2H3,(H,29,34)",BCUGCHZRMKTPMU-UHFFFAOYSA-N,aq-ra741,Preclinical,acetylcholine receptor antagonist,CHRM2,,
Cc1ccc(-c2ccc(OC3CN4CCC3CC4)cn2)cc1,"InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3",NPDLTEZXGWRMLQ-UHFFFAOYSA-N,aqw-051,Preclinical,nicotinic receptor agonist,,,
NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,"InChI=1S/C26H19F3N4O/c27-26(28,29)24-14-23(33(32-24)20-10-8-19(9-11-20)31-25(34)15-30)18-7-12-22-17(13-18)6-5-16-3-1-2-4-21(16)22/h1-14H,15,30H2,(H,31,34)",YULUCECVQOCQFQ-UHFFFAOYSA-N,ar-12,Phase 1,phosphoinositide dependent kinase inhibitor,PDPK1,,
CC(C)C(C(=O)Nc1ccc(C(O)=NO)cc1)c1ccccc1,"InChI=1S/C18H20N2O3/c1-12(2)16(13-6-4-3-5-7-13)18(22)19-15-10-8-14(9-11-15)17(21)20-23/h3-12,16,23H,1-2H3,(H,19,22)(H,20,21)",LAMIXXKAWNLXOC-UHFFFAOYSA-N,ar-42,Phase 1,HDAC inhibitor,HDAC1,,
COc1ccc(CNC(=O)N=c2[nH]cc([N+](=O)[O-])s2)cc1,"InChI=1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)",YAEMHJKFIIIULI-UHFFFAOYSA-N,ar-a014418,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1CC(O)CO1)c(=O)n(C)c(=O)n2CC(C)C,"InChI=1S/C21H27N5O5S/c1-10(2)7-25-20-17(18(28)24(5)21(25)30)16(19(29)26-8-13(27)9-31-26)15(32-20)6-14-11(3)22-23-12(14)4/h10,13,27H,6-9H2,1-5H3,(H,22,23)",ISIVOJWVBJIOFM-UHFFFAOYSA-N,ar-c155858,Preclinical,monocarboxylate transporter inhibitor,SLC16A1|SLC16A7,,
CCCCCC=CCC=CCC=CCC=CCCCC(=O)O,"InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)",YZXBAPSDXZZRGB-UHFFFAOYSA-N,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2,,
CCCCCCCCCCCCCCCCCCCC(=O)NC1CCC2(C)C(C1)CC(O)C1C2CC(O)C2(C)C(C(C)CCC(=O)O)CCC12,"InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)",SHKXZIQNFMOPBS-UHFFFAOYSA-N,aramchol,Phase 2/Phase 3,stearoyl-CoA desaturase inhibitor,,,
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,"InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3",KCFYEAOKVJSACF-UHFFFAOYSA-N,arbidol,Launched,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection
OCC1OC(Oc2ccc(O)cc2)C(O)C(O)C1O,"InChI=1S/C12H16O7/c13-5-8-9(15)10(16)11(17)12(19-8)18-7-3-1-6(14)2-4-7/h1-4,8-17H,5H2",BJRNKVDFDLYUGJ-UHFFFAOYSA-N,arbutin,Phase 2/Phase 3,melanin inhibitor,TYR,,
COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,"InChI=1S/C24H29N3O3/c1-24(2)19-9-5-4-8-18(19)22(28)27(23(24)29)17-14-25-12-15-26(16-13-25)20-10-6-7-11-21(20)30-3/h4-11H,12-17H2,1-3H3",JFNKXGOEOQCXDM-UHFFFAOYSA-N,arc-239,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,
COc1cc(CC2C(=O)OCC2Cc2ccc(OC)c(OC)c2)ccc1O,"InChI=1S/C21H24O6/c1-24-18-7-5-13(11-20(18)26-3)8-15-12-27-21(23)16(15)9-14-4-6-17(22)19(10-14)25-2/h4-7,10-11,15-16,22H,8-9,12H2,1-3H3",NQWVSMVXKMHKTF-UHFFFAOYSA-N,arctigenin,Preclinical,MEK inhibitor,CHUK|MAP2K1,,
O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,"InChI=1S/C20H11N3O2/c24-19-15-13-9-5-1-3-7-11(9)21-17(13)18-14(16(15)20(25)23-19)10-6-2-4-8-12(10)22-18/h1-8,21-22H,(H,23,24,25)",KAJXOWFGKYKMMZ-UHFFFAOYSA-N,arcyriaflavin-a,Preclinical,CDK inhibitor,CCND1|CDK4,,
COC1OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC)C(O)C2OS(=O)(=O)O)C(O)C1NS(=O)(=O)O,"InChI=1S/C14H25NO20S3/c1-29-9-7(17)10(35-38(26,27)28)14(34-11(9)12(18)19)33-8-4(3-31-37(23,24)25)32-13(30-2)5(6(8)16)15-36(20,21)22/h4-11,13-17H,3H2,1-2H3,(H,18,19)(H,20,21,22)(H,23,24,25)(H,26,27,28)",HXSDFQWQRCUQHF-UHFFFAOYSA-N,ardeparin,Withdrawn,thrombin inhibitor,SERPIND1,,
CC#CCOC(=O)C1=CCCN(C)C1,"InChI=1S/C11H15NO2/c1-3-4-8-14-11(13)10-6-5-7-12(2)9-10/h6H,5,7-9H2,1-2H3",LBFWTPRSXIRKMZ-UHFFFAOYSA-N,arecaidine-but-2-ynyl-ester,Preclinical,acetylcholine receptor agonist,CHRM2,,
C#CCOC(=O)C1=CCCN(C)C1,"InChI=1S/C10H13NO2/c1-3-7-13-10(12)9-5-4-6-11(2)8-9/h1,5H,4,6-8H2,2H3",SPHRJZBOFYIKMC-UHFFFAOYSA-N,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
COC(=O)C1=CCCN(C)C1,"InChI=1S/C8H13NO2/c1-9-5-3-4-7(6-9)8(10)11-2/h4H,3,5-6H2,1-2H3",HJJPJSXJAXAIPN-UHFFFAOYSA-N,arecoline,Phase 1,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
CC1CNc2c(cccc2S(=O)(=O)NC(CCCN=C(N)N)C(=O)N2CCC(C)CC2C(=O)O)C1,"InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)",KXNPVXPOPUZYGB-UHFFFAOYSA-N,argatroban,Launched,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT)
CSCCC(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(C)=O)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(N)=O,"InChI=1S/C34H60N14O12S/c1-17(49)43-20(8-11-25(51)52)29(57)47-22(9-12-26(53)54)31(59)48-23(13-16-61-2)32(60)46-21(7-10-24(35)50)30(58)45-19(6-4-15-42-34(39)40)28(56)44-18(27(36)55)5-3-14-41-33(37)38/h18-23H,3-16H2,1-2H3,(H2,35,50)(H2,36,55)(H,43,49)(H,44,56)(H,45,58)(H,46,60)(H,47,57)(H,48,59)(H,51,52)(H,53,54)(H4,37,38,41)(H4,39,40,42)",RJZNPROJTJSYLC-UHFFFAOYSA-N,argireline,Phase 3,neurotransmitter release inhibitor,,,
C=C1C(=O)OC2C1CCC1(C)OC13CC=C(C)C23,"InChI=1S/C15H18O3/c1-8-4-7-15-11(8)12-10(9(2)13(16)17-12)5-6-14(15,3)18-15/h4,10-12H,2,5-7H2,1,3H3",UVJYAKBJSGRTHA-UHFFFAOYSA-N,arglabin,Launched,farnesyltransferase inhibitor,FNTA|NFKB1,,
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",CEUORZQYGODEFX-UHFFFAOYSA-N,aripiprazole,Launched,serotonin receptor agonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7,neurology/psychiatry,depression|schizophrenia|bipolar disorder
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,"InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)",CEUORZQYGODEFX-UHFFFAOYSA-N,aripiprazole,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7,neurology/psychiatry,depression|schizophrenia|bipolar disorder
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,"InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3",DDINXHAORAAYAD-UHFFFAOYSA-N,aripiprazole-lauroxil,Launched,serotonin receptor agonist,,neurology/psychiatry,schizophrenia
CCCn1c(=O)c2[nH]cnc2n(-c2ccc(Cl)cc2)c1=O,"InChI=1S/C14H13ClN4O2/c1-2-7-18-13(20)11-12(17-8-16-11)19(14(18)21)10-5-3-9(15)4-6-10/h3-6,8H,2,7H2,1H3,(H,16,17)",GVTLDPJNRVMCAL-UHFFFAOYSA-N,arofylline,Phase 3,phosphodiesterase inhibitor,PDE4A,,
CC(C)(C)NCC(O)CSc1nc(-c2ccc(C(N)=O)s2)cs1,"InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)",BHIAIPWSVYSKJS-UHFFFAOYSA-N,arotinolol,Launched,adrenergic receptor antagonist,ADRB3,cardiology|neurology/psychiatry,hypertension|tremors
N=c1[nH]cccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,"InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)",HNFMVVHMKGFCMB-UHFFFAOYSA-N,arq-092,Phase 1,AKT inhibitor,AKT2,,
C#CCC(c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)N(CCCN)C(=O)c1cccc(Cl)c1F,"InChI=1S/C28H24Cl2FN5O2/c1-2-8-24(35(16-7-15-32)27(37)21-11-6-12-22(30)25(21)31)26-33-23-17-18(29)13-14-20(23)28(38)36(26)34-19-9-4-3-5-10-19/h1,3-6,9-14,17,24,34H,7-8,15-16,32H2",UPJSUQWHUVLLNW-UHFFFAOYSA-N,arq-621,Phase 1,kinesin-like spindle protein inhibitor,KIF11,,
CC1COC(=Nc2ccc3[nH]cnc(=Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)N1,"InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)",UWXSAYUXVSFDBQ-UHFFFAOYSA-N,arry-334543,Phase 2/Phase 3,EGFR inhibitor,ERBB2,,
Nc1ccc([As](=O)(O)O)cc1,"InChI=1S/C6H8AsNO3/c8-6-3-1-5(2-4-6)7(9,10)11/h1-4H,8H2,(H2,9,10,11)",XKNKHVGWJDPIRJ-UHFFFAOYSA-N,arsanilic-acid,Phase 1,,LYZ,,
O=[As]O[As]=O,InChI=1S/As2O3/c3-1-5-2-4,IKWTVSLWAPBBKU-UHFFFAOYSA-N,arsenic-trioxide,Launched,apoptosis stimulant,AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1,gastroenterology,diarrhea
COC1OC2OC3(C)CCC4C(C)CCC(C1C)C24OO3,"InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3",SXYIRMFQILZOAM-UHFFFAOYSA-N,artemether,Launched,antimalarial agent,ATP1A1,infectious disease,malaria
CC1CCC2C(C)C(=O)OC3OC4(C)CCC1C32OO4,"InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3",BLUAFEHZUWYNDE-UHFFFAOYSA-N,artemisinin,Launched,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria
CCOC1OC2OC3(C)CCC4C(C)CCC(C1C)C24OO3,"InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3",NLYNIRQVMRLPIQ-UHFFFAOYSA-N,artemotil,Launched,,,infectious disease,malaria
CC1CCC2C(C)C(OC(=O)CCC(=O)O)OC3OC4(C)CCC1C32OO4,"InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)",FIHJKUPKCHIPAT-UHFFFAOYSA-N,artesunate,Launched,DNA synthesis inhibitor,,infectious disease,malaria
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,"InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)",QTGIAADRBBLJGA-UHFFFAOYSA-N,articaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
CCCCCCC(CCC)C(=O)O,"InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)",YCYMCMYLORLIJX-UHFFFAOYSA-N,arundic-acid,Phase 2/Phase 3,astrocyte modulating agent,PTGS2|S100B,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=NC(CC(=O)Nc1ccc(OCCOCCOCCOCC=Nc3cccc4c(O)n(C5CCC(=O)NC5=O)c(O)c34)cc1)c1nnc(C)n1-2,"InChI=1S/C46H47ClN8O9S/c1-26-27(2)65-46-39(26)41(29-7-9-30(47)10-8-29)50-35(42-53-52-28(3)54(42)46)25-38(57)49-31-11-13-32(14-12-31)64-24-23-63-22-21-62-20-19-61-18-17-48-34-6-4-5-33-40(34)45(60)55(44(33)59)36-15-16-37(56)51-43(36)58/h4-14,17,35-36,59-60H,15-16,18-25H2,1-3H3,(H,49,57)(H,51,56,58)",UKTJEYYXXYXUAQ-UHFFFAOYSA-N,arv-825,Preclinical,bromodomain inhibitor,BRD4,,
Cc1cc(=NCCO)[nH]c(-c2ccc(Br)cc2)n1,"InChI=1S/C13H14BrN3O/c1-9-8-12(15-6-7-18)17-13(16-9)10-2-4-11(14)5-3-10/h2-5,8,18H,6-7H2,1H3,(H,15,16,17)",DUKPGOOUJNUIOI-UHFFFAOYSA-N,as-1269574,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,
O=C(Nc1ccc(-c2ccncc2)cc1)NC(CO)c1ccccc1,"InChI=1S/C20H19N3O2/c24-14-19(17-4-2-1-3-5-17)23-20(25)22-18-8-6-15(7-9-18)16-10-12-21-13-11-16/h1-13,19,24H,14H2,(H2,22,23,25)",WDTFYYZHMRBVHK-UHFFFAOYSA-N,as-1892802,Preclinical,rho associated kinase inhibitor,ROCK1,,
CC(NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,"InChI=1S/C20H18ClNO2S/c1-14(16-5-3-2-4-6-16)22-20(23)19-18(11-12-25-19)24-13-15-7-9-17(21)10-8-15/h2-12,14H,13H2,1H3,(H,22,23)",RFZPGNRLOKVZJY-UHFFFAOYSA-N,as-1949490,Preclinical,SHIP2 phosphatase inhibitor,INPP5D,,
O=C(O)CCc1ccc(NCc2cccc3c2CCCN3CCOc2ccccc2)cc1F,"InChI=1S/C27H29FN2O3/c28-25-18-22(13-11-20(25)12-14-27(31)32)29-19-21-6-4-10-26-24(21)9-5-15-30(26)16-17-33-23-7-2-1-3-8-23/h1-4,6-8,10-11,13,18,29H,5,9,12,14-17,19H2,(H,31,32)",VENOXIKBBUVHRY-UHFFFAOYSA-N,as-2034178,Preclinical,free fatty acid receptor agonist,FFAR1,,
Cc1cc(-c2nc(C(=O)Nc3cn(C4CCOCC4)nc3C(N)=O)co2)ccn1,"InChI=1S/C19H20N6O4/c1-11-8-12(2-5-21-11)19-23-15(10-29-19)18(27)22-14-9-25(24-16(14)17(20)26)13-3-6-28-7-4-13/h2,5,8-10,13H,3-4,6-7H2,1H3,(H2,20,26)(H,22,27)",JANBIXNDYNRYQP-UHFFFAOYSA-N,as-2444697,Preclinical,interleukin inhibitor,IRAK4,,
O=C1NC(=O)C(=Cc2ccc(-c3ccc(F)cc3O)o2)S1,"InChI=1S/C14H8FNO4S/c15-7-1-3-9(10(17)5-7)11-4-2-8(20-11)6-12-13(18)16-14(19)21-12/h1-6,17H,(H,16,18,19)",OYYVWNDMOQPMGE-UHFFFAOYSA-N,as-252424,Preclinical,PI3K inhibitor,PIK3CG,,
O=C1NC(=O)C(=Cc2ccc3c(c2)OC(F)(F)O3)S1,"InChI=1S/C11H5F2NO4S/c12-11(13)17-6-2-1-5(3-7(6)18-11)4-8-9(15)14-10(16)19-8/h1-4H,(H,14,15,16)",SRLVNYDXMUGOFI-UHFFFAOYSA-N,as-604850,Preclinical,PI3K inhibitor,PIK3CA|PIK3CG,,
O=C(NCC(O)CO)c1ccncc1Nc1ccc(I)cc1F,"InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)",VIUAUNHCRHHYNE-UHFFFAOYSA-N,as-703026,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,
O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,"InChI=1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2",KINMYBBFQRSVLL-UHFFFAOYSA-N,as-77,Phase 1,potassium channel blocker,KCNA3|KCNA5|KCNN4,,
Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,"InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)",XGOYIMQSIKSOBS-UHFFFAOYSA-N,asa-404,Phase 3,angiogenesis inhibitor,,,
CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1,"InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)",ZMZNWNTZRWXTJU-UHFFFAOYSA-N,asapiprant,Preclinical,prostaglandin inhibitor,,,
COc1cc(OC)c(OC)cc1C=O,"InChI=1S/C10H12O4/c1-12-8-5-10(14-3)9(13-2)4-7(8)6-11/h4-6H,1-3H3",IAJBQAYHSQIQRE-UHFFFAOYSA-N,asaraldehyde,Preclinical,cyclooxygenase inhibitor,PTGS2,,
COc1ccc(C=CC(=O)CC(=O)C=Cc2ccc(OC)c(OC)c2)cc1OC,"InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-14H,15H2,1-4H3",HMJSBVCDPKODEX-UHFFFAOYSA-N,asc-j9,Phase 2,androgen receptor enhancer,AR,,
O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CCC(O)C2)c(-c2cc[nH]n2)c1,"InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)",VOVZXURTCKPRDQ-UHFFFAOYSA-N,asciminib,Phase 2,Bcr-Abl kinase inhibitor,,,
CCC1=CC(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,"InChI=1S/C43H69NO12/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)44-16-12-11-13-31(44)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-32(45)35(22-29)52-7/h18,20,24-25,27-29,31-33,35-39,45-46,51H,10-17,19,21-23H2,1-9H3",APOKBJZFCVDZMU-UHFFFAOYSA-N,ascomycin,Preclinical,calcineurin inhibitor,FKBP1A,,
OCC(O)c1oc(O)c(O)c1O,"InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,7-11H,1H2",LPYXWGMUVRGUOY-UHFFFAOYSA-N,ascorbic-acid,Launched,antioxidant,SLC23A1|SLC23A2,endocrinology,scurvy
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1,"InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3",VSWBSWWIRNCQIJ-UHFFFAOYSA-N,asenapine,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1,"InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3",VSWBSWWIRNCQIJ-UHFFFAOYSA-N,asenapine,Launched,serotonin receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(CO)C5CCC43C)C2C1C,"InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)",JXSVIVRDWWRQRT-UHFFFAOYSA-N,asiatic-acid,Preclinical,apoptosis stimulant,PYGM,,
CN(C(=O)C(c1ccccc1)c1ccccc1)C(CN1CCC(O)C1)c1ccccc1,"InChI=1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3",JHLHNYVMZCADTC-UHFFFAOYSA-N,asimadoline,Phase 3,opioid receptor agonist,OPRK1,,
CCC=c1nc(C(F)(F)F)ccc1=CCC(=O)NC(C)c1cc(F)c(NS(C)(=O)=O)c(F)c1,"InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h5-8,10-12,29H,4,9H2,1-3H3,(H,27,30)",AFXBOGBEMDMUSH-UHFFFAOYSA-N,asivatrep,Phase 3,transient receptor potential channel antagonist,,,
CC(C)c1nnc(-c2ccc(-c3ccccc3)nc2)n1-c1cccc2nonc12,"InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3",FQGLDGKVKDPVLO-UHFFFAOYSA-N,asp-2535,Phase 1,glycine transporter inhibitor,SLC6A9,,
COc1ccc(-c2nc(OC)nn2-c2ccc(OC)cc2)cc1,"InChI=1S/C17H17N3O3/c1-21-14-8-4-12(5-9-14)16-18-17(23-3)19-20(16)13-6-10-15(22-2)11-7-13/h4-11H,1-3H3",OBAICMYWONZOSZ-UHFFFAOYSA-N,asp-6537,Preclinical,cyclooxygenase inhibitor,,,
COc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1,"InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3",OXSCPDKUZWPWFR-UHFFFAOYSA-N,asp-9521,Preclinical,aldo-keto reductase inhibitor,,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1[nH]cnc(=Nc2ccccc2S(=O)(=O)C(C)C)[nH]1,"InChI=1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)",MGGBYMDAPCCKCT-UHFFFAOYSA-N,asp3026,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,
COC(=O)C(Cc1ccccc1)NC(=O)C(N)CC(=O)O,"InChI=1S/C14H18N2O5/c1-21-14(20)11(7-9-5-3-2-4-6-9)16-13(19)10(15)8-12(17)18/h2-6,10-11H,7-8,15H2,1H3,(H,16,19)(H,17,18)",IAOZJIPTCAWIRG-UHFFFAOYSA-N,aspartame,Launched,,TAS1R2|TRPV1,,
CC(=O)Oc1ccccc1C(=O)O,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",BSYNRYMUTXBXSQ-UHFFFAOYSA-N,aspirin,Launched,cyclooxygenase inhibitor,AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53,neurology/psychiatry|endocrinology|dental,headache|fever|toothache|muscle pain
C=CC(=O)Nc1ccc2[nH]cnc(=Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,"InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)",MVZGYPSXNDCANY-UHFFFAOYSA-N,ast-1306,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CC(C=CC=C(C)C=CC1C(C)C(=O)C(=O)CC1(C)C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)C(=O)C(=O)CC1(C)C,"InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,31-34H,25-26H2,1-10H3",IERBGNMOVQIRSJ-UHFFFAOYSA-N,astaxanthin,Launched,antioxidant,,,
COc1ccc(CCN2CCC(N=c3[nH]c4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,"InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)",GXDALQBWZGODGZ-UHFFFAOYSA-N,astemizole,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,,
CC1OC(OC2C(=O)c3c(O)cc(O)cc3OC2c2ccc(O)c(O)c2)C(O)C(O)C1O,"InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3",ZROGCCBNZBKLEL-UHFFFAOYSA-N,astilbin,Preclinical,nuclear factor erythroid derived,,,
CC1OC(OC2C(=O)c3c(O)cc(O)cc3OC2c2ccc(O)c(O)c2)C(O)C(O)C1O,"InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3",ZROGCCBNZBKLEL-UHFFFAOYSA-N,astilbin,Preclinical,like (NRF2) activator,,,
CC(C)(O)C1CCC(C)(C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C5C(C)(C)C(OC6OCC(O)C(O)C6O)CCC56CC46CCC23C)O1,"InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3",QMNWISYXSJWHRY-UHFFFAOYSA-N,astragaloside-a,Preclinical,anti-inflammatory agent,,,
CC1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc32)C(CN2CCOCC2C)CN1,"InChI=1S/C30H42FN5O3/c1-20-14-35(25(13-32-20)15-34-9-10-39-18-21(34)2)16-28(38)36-19-30(3,4)29-27(36)12-23(26(17-37)33-29)11-22-5-7-24(31)8-6-22/h5-8,12,20-21,25,32,37H,9-11,13-19H2,1-4H3",YCXOHEXZVKOGEV-UHFFFAOYSA-N,astx660,Phase 1/Phase 2,apoptosis inhibitor,,,
C=CC1CC1(NC(=O)C1CC(Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)C(NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,"InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)",XRWSZZJLZRKHHD-UHFFFAOYSA-N,asunaprevir,Phase 3,HCV inhibitor,,,
CN(C)C(=N)NCCCC(N)C(=O)O,"InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)",YDGMGEXADBMOMJ-UHFFFAOYSA-N,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,NOS2|NOS3,,
O=CN1CCC(C(=O)NCCN2CCC(=C3c4ccccc4C=Cc4ccccc43)CC2)CC1,"InChI=1S/C29H33N3O2/c33-21-32-18-13-25(14-19-32)29(34)30-15-20-31-16-11-24(12-17-31)28-26-7-3-1-5-22(26)9-10-23-6-2-4-8-27(23)28/h1-10,21,25H,11-20H2,(H,30,34)",BSPMYKLEFGUTSI-UHFFFAOYSA-N,at-1015,Preclinical,serotonin receptor antagonist,HTR2A,,
CNC(C)C(=O)NC1CN(C(=O)CC(C)C)CCC2CCC(C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O,"InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)",LSXUTRRVVSPWDZ-UHFFFAOYSA-N,at-406,Phase 1,IAP antagonist ,,,
O=C(NC1CCNCC1)c1[nH]ncc1NC(=O)c1c(Cl)cccc1Cl,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,at-7519,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK9,,
O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CC1,"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)",LOLPPWBBNUVNQZ-UHFFFAOYSA-N,at-9283,Phase 2,Aurora kinase inhibitor,AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A,,
O=C(Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1)NC1CC1,"InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)",LOLPPWBBNUVNQZ-UHFFFAOYSA-N,at-9283,Phase 2,JAK inhibitor,AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A,,
NCC(O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,"InChI=1S/C17H16ClN3O/c18-16-7-5-15(6-8-16)17(22,11-19)14-3-1-12(2-4-14)13-9-20-21-10-13/h1-10,22H,11,19H2,(H,20,21)",IIRWNGPLJQXWFJ-UHFFFAOYSA-N,at13148,Phase 1,protein kinase inhibitor,AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3,,
CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,"InChI=1S/C24H31N3O3/c1-16(2)20-11-21(23(29)12-22(20)28)24(30)27-14-18-5-4-17(10-19(18)15-27)13-26-8-6-25(3)7-9-26/h4-5,10-12,16,28-29H,6-9,13-15H2,1-3H3",IFRGXKKQHBVPCQ-UHFFFAOYSA-N,at13387,Phase 2,HSP inhibitor,HSP90AA1,,
Clc1ccc(C2(c3ccc(-c4cn[nH]c4)cc3)CCNCC2)cc1,"InChI=1S/C20H20ClN3/c21-19-7-5-18(6-8-19)20(9-11-22-12-10-20)17-3-1-15(2-4-17)16-13-23-24-14-16/h1-8,13-14,22H,9-12H2,(H,23,24)",LZMOSYUFVYJEPY-UHFFFAOYSA-N,at7867,Preclinical,AKT inhibitor,AKT2|GSK3B|PKIA|PRKACA,,
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,"InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)",OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,Launched,CFTR channel agonist,DMD,genetics|pulmonary,duchenne muscular dystrophy (DMD)|cystic fibrosis
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,"InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)",OOUGLTULBSNHNF-UHFFFAOYSA-N,ataluren,Launched,dystrophin stimulant,DMD,genetics|pulmonary,duchenne muscular dystrophy (DMD)|cystic fibrosis
COC(=O)NC(C(=O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C,"InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)",AXRYRYVKAWYZBR-UHFFFAOYSA-N,atazanavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
COc1ccc2cc(C(C)C(=O)Oc3ccc(C(N)=S)cc3)ccc2c1,"InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)",YCNMAPLPQYQJFC-UHFFFAOYSA-N,atb-346,Phase 2,cyclooxygenase inhibitor,PTGER2,,
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,"InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)",METKIMKYRPQLGS-UHFFFAOYSA-N,atenolol-(-),Launched,adrenergic receptor antagonist,,cardiology,hypertension
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,"InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)",METKIMKYRPQLGS-UHFFFAOYSA-N,atenolol-(+),Preclinical,adrenergic receptor antagonist,,,
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,"InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)",METKIMKYRPQLGS-UHFFFAOYSA-N,atenolol-(+/-),Launched,adrenergic receptor antagonist,ADRB1|ADRB2|LTF|PLA2G2E,cardiology,hypertension|angina pectoris
CN(C)C(=O)Nc1cccc(-c2ccc(N(C)C)cc2)c1,"InChI=1S/C17H21N3O/c1-19(2)16-10-8-13(9-11-16)14-6-5-7-15(12-14)18-17(21)20(3)4/h5-12H,1-4H3,(H,18,21)",AWOPBSAJHCUSAS-UHFFFAOYSA-N,atglistatin,Preclinical,adipose triglyceride lipase inhibitor,,,
Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1,"InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)",ZHPMYDSXGRRERG-UHFFFAOYSA-N,aticaprant,Phase 2,opioid receptor antagonist,,,
CCC1(c2c[nH]cn2)Cc2ccccc2C1,"InChI=1S/C14H16N2/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14/h3-6,9-10H,2,7-8H2,1H3,(H,15,16)",HSWPZIDYAHLZDD-UHFFFAOYSA-N,atipamezole,Launched,adrenergic receptor antagonist,,neurology/psychiatry,reverse sedative
CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,"InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3",SERHTTSLBVGRBY-UHFFFAOYSA-N,atiprimod,Phase 2,JAK inhibitor,JAK2|STAT3,,
CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,"InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3",SERHTTSLBVGRBY-UHFFFAOYSA-N,atiprimod,Phase 2,STAT inhibitor,JAK2|STAT3,,
COc1ccc(C2CNC(=O)NC2)cc1OC1CC2CCC1C2,"InChI=1S/C18H24N2O3/c1-22-15-5-4-12(14-9-19-18(21)20-10-14)8-17(15)23-16-7-11-2-3-13(16)6-11/h4-5,8,11,13-14,16H,2-3,6-7,9-10H2,1H3,(H2,19,20,21)",LITNEAPWQHVPOK-UHFFFAOYSA-N,atizoram,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,
CC(=O)N1CCCC1C(=O)NC(Cc1c[nH]cn1)C(=O)NC(C=O)C(O)NC(CS)C(=O)NC(CC(N)=O)C(N)=O,"InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7-8,10,13-17,21,31,38,41H,2-6,9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)",UTVUAEWFACYSGU-UHFFFAOYSA-N,atn-161,Phase 2,integrin antagonist,ITGA5|ITGAV|ITGB1|ITGB3,,
CNCCC(Oc1ccccc1C)c1ccccc1,"InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3",VHGCDTVCOLNTBX-UHFFFAOYSA-N,atomoxetine,Launched,norepinephrine transporter inhibitor,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD)
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CCC(O)CC(O)CC(=O)O,"InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)",XUKUURHRXDUEBC-UHFFFAOYSA-N,atorvastatin,Launched,HMGCR inhibitor,AHR|DPP4|HMGCR,neurology/psychiatry|cardiology,stroke|heart attack
CCOc1ccc(CC2NC(=O)CCSSCC(C(=O)N3CCCC3C(=O)NC(CCCN)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C(C)O)NC(=O)C(C(C)CC)NC2=O)cc1,"InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)",VWXRQYYUEIYXCZ-UHFFFAOYSA-N,atosiban,Launched,oxytocin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,neurology/psychiatry|cardiology|endocrinology,stroke|angina pectoris|myocardial infarction|hyperlipidemia
Oc1c(C2=CCC(c3ccc(Cl)cc3)CC2)c(O)c2ccccc2c1O,"InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,7,9-13,24-26H,5-6,8H2",JAUORDHNHDCTAS-UHFFFAOYSA-N,atovaquone,Launched,mitochondrial electron transport inhibitor,,infectious disease,pneumonia
CC(C)(C)c1o[nH]c(=O)c1CC(N)C(=O)O,"InChI=1S/C10H16N2O4/c1-10(2,3)7-5(8(13)12-16-7)4-6(11)9(14)15/h6H,4,11H2,1-3H3,(H,12,13)(H,14,15)",PIXJURSCCVBKRF-UHFFFAOYSA-N,atpa,Preclinical,glutamate receptor agonist,GRIK1,,
C=C1CCCC2(C)C=c3oc(O)c(C)c3=CC12,"InChI=1S/C15H18O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h7-8,12,16H,1,4-6H2,2-3H3",MEPMFBFJAVXDMR-UHFFFAOYSA-N,atractylenolide-i,Preclinical,JAK inhibitor,,,
COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC,"InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2",YXSLJKQTIDHPOT-UHFFFAOYSA-N,atracurium,Launched,acetylcholine receptor antagonist,,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
CCCCN(CCCC)C(=O)CN1CC(c2ccc3c(c2)OCO3)C(C(=O)O)C1c1ccc(OC)cc1,"InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)",MOTJMGVDPWRKOC-UHFFFAOYSA-N,atrasentan,Phase 3,endothelin receptor antagonist,EDNRA,,
C[N+]1([O-])C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2,"InChI=1S/C17H23NO4/c1-18(21)13-7-8-14(18)10-15(9-13)22-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3",HGWPFSBHDACWNL-UHFFFAOYSA-N,atropine-oxide,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
COc1cc(F)ccc1-c1nc(=Nc2cccc(CS(C)(=N)=O)c2)nc[nH]1,"InChI=1S/C18H18FN5O2S/c1-26-16-9-13(19)6-7-15(16)17-21-11-22-18(24-17)23-14-5-3-4-12(8-14)10-27(2,20)25/h3-9,11,20H,10H2,1-2H3,(H,21,22,23,24)",ACWKGTGIJRCOOM-UHFFFAOYSA-N,atuveciclib,Phase 1,CDK9 inhibitor,,,
CC(=O)OCC1OC(S)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O,"InChI=1S/C14H20O9S/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18/h10-14,24H,5H2,1-4H3",SFOZKJGZNOBSHF-UHFFFAOYSA-N,auranofin,Launched,NFkB pathway inhibitor,IKBKB|PRDX5|TRPA1,rheumatology,rheumatoid arthritis
CCN1CCN(C(=O)Cc2ccc(N=c3[nH]cc(F)c(=Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)[nH]3)cc2)CC1,"InChI=1S/C31H31ClFN7O2/c1-2-39-15-17-40(18-16-39)28(41)19-21-7-11-24(12-8-21)36-31-34-20-26(33)29(38-31)35-23-13-9-22(10-14-23)30(42)37-27-6-4-3-5-25(27)32/h3-14,20H,2,15-19H2,1H3,(H,37,42)(H2,34,35,36,38)",AKSIZPIFQAYJGF-UHFFFAOYSA-N,aurora-a-inhibitor-i,Preclinical,Aurora kinase inhibitor,AURKA,,
OCC1OC(S)C(O)C(O)C1O,"InChI=1S/C6H12O5S/c7-1-2-3(8)4(9)5(10)6(12)11-2/h2-10,12H,1H2",JUSMHIGDXPKSID-UHFFFAOYSA-N,aurothioglucose,Launched,PKC inhibitor,PRKCI,rheumatology,rheumatoid arthritis
CCc1[nH]c(=O)n(-c2ccc(Oc3ccc(C)c(OC)c3)nc2)c1O,"InChI=1S/C18H19N3O4/c1-4-14-17(22)21(18(23)20-14)12-6-8-16(19-10-12)25-13-7-5-11(2)15(9-13)24-3/h5-10,22H,4H2,1-3H3,(H,20,23)",XMLLPNNBUDCDLX-UHFFFAOYSA-N,aut-1,Preclinical,potassium channel activator,,,
CC(c1ccc2ccc(OC3CCC(C(F)(F)F)CC3)c(C(F)(F)F)c2c1)N1C2CCC1CC(C(=O)O)C2,"InChI=1S/C28H31F6NO3/c1-15(35-20-7-8-21(35)13-18(12-20)26(36)37)17-3-2-16-4-11-24(25(23(16)14-17)28(32,33)34)38-22-9-5-19(6-10-22)27(29,30)31/h2-4,11,14-15,18-22H,5-10,12-13H2,1H3,(H,36,37)",PZASAAIJIFDWSB-UHFFFAOYSA-N,autotaxin-modulator-1,Preclinical,autotaxin inhibitor,ENPP2,,
C=CC(=O)Nc1cc2c(=Nc3ccc(F)c(Cl)c3)[nH]cnc2cc1C#CC(C)(C)N1CCN(C)CC1,"InChI=1S/C27H28ClFN6O/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32)",ZAJXXUDARPGGOC-UHFFFAOYSA-N,av-412,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,
O=C(NC1CCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(Cc2ccc(Cl)cc2)C1)c1ccnc2ccccc12,"InChI=1S/C31H24ClF6N3O2/c32-22-7-5-18(6-8-22)13-24-17-23(40-28(42)26-9-11-39-27-4-2-1-3-25(26)27)10-12-41(24)29(43)19-14-20(30(33,34)35)16-21(15-19)31(36,37)38/h1-9,11,14-16,23-24H,10,12-13,17H2,(H,40,42)",NXLUTEDAEFXMQR-UHFFFAOYSA-N,av-608,Phase 2,tachykinin antagonist,TACR1,,
Cc1ccc(NC(=O)C2CCCN(C(=O)c3c(C)cccc3F)C2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F,"InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)",PUKBOVABABRILL-UHFFFAOYSA-N,avacopan,Phase 2,complement inhibitor,,,
Cc1nc2cccc(N)c2c(=O)n1C1CCC(=O)NC1=O,"InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)",RSNPAKAFCAAMBH-UHFFFAOYSA-N,avadomide,Phase 2,antitumor agent,,,
NC(=O)C(CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)",XEAOPVUAMONVLA-UHFFFAOYSA-N,avagacestat,Phase 2,gamma secretase inhibitor,PSEN1,,
COc1ccc(CN=c2[nH]c(N3CCCC3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,"InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)",WEAJZXNPAWBCOA-UHFFFAOYSA-N,avanafil,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction
Cn1cc(-c2cc3c(N4CCN(c5ncc(C(C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,"InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3",DWYRIWUZIJHQKQ-UHFFFAOYSA-N,avapritinib,Launched,KIT inhibitor,,,
CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,"InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)",PTQXTEKSNBVPQJ-UHFFFAOYSA-N,avasimibe,Phase 3,ACAT inhibitor,CES1,,
O=C(N=c1[nH]c(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,"InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)",OFZJKCQENFPZBH-UHFFFAOYSA-N,avatrombopag,Launched,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia
CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(-c3ccccc3)nc(OC)c2C=O)cc1,"InChI=1S/C29H32N4O5S2/c1-5-30-29(35)32-40(36,37)28-24(16-23(39-28)15-19(2)3)21-13-11-20(12-14-21)17-33-25(18-34)27(38-4)31-26(33)22-9-7-6-8-10-22/h6-14,16,18-19H,5,15,17H2,1-4H3,(H2,30,32,35)",QTOZBSNPDCWHPV-UHFFFAOYSA-N,ave-0991,Preclinical,angiotensin receptor agonist,MRGPRX1,,
O=C(NC1Cc2ccccc2C1)c1ccc2c(c1)OC(F)(F)O2,"InChI=1S/C17H13F2NO3/c18-17(19)22-14-6-5-12(9-15(14)23-17)16(21)20-13-7-10-3-1-2-4-11(10)8-13/h1-6,9,13H,7-8H2,(H,20,21)",OKCJNSDIVCXYAL-UHFFFAOYSA-N,ave-3085,Preclinical,nitric oxide synthase stimulant,,,
CN(C)CC1CCOC1(c1ccccc1)c1ccccc1,"InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3",BOTHKNZTGGXFEQ-UHFFFAOYSA-N,avex-73,Preclinical,sigma receptor agonist,,,
NC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O,"InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)",NDCUAPJVLWFHHB-UHFFFAOYSA-N,avibactam,Launched,beta lactamase inhibitor,,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis
C=CC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,"InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)",UOFYSRZSLXWIQB-UHFFFAOYSA-N,avitinib,Phase 2,EGFR inhibitor,,,
C=CC(=O)Nc1cccc(N=c2[nH]c(=Nc3ccc(OCCOC)cc3)[nH]cc2F)c1,"InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)",KXBDTLQSDKGAEB-UHFFFAOYSA-N,avl-292,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,BTK|YES1,,
CN=c1[nH]n2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1,"InChI=1S/C17H21N5O2S/c1-11-14(21(4)5)12(2)22-17(19-11)15(16(18-3)20-22)25(23,24)13-9-7-6-8-10-13/h6-10H,1-5H3,(H,18,20)",SNPPEHMSSOEYDH-UHFFFAOYSA-N,avn-492,Preclinical,serotonin receptor antagonist,,,
CCC(CC#N)OC(=O)NC(C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,"InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)",GYCPCOJTCINIFZ-UHFFFAOYSA-N,avn-944,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,
COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1,"InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3",XNEFYCZVKIDDMS-UHFFFAOYSA-N,avobenzone,Launched,topical sunscreen agent,,dermatology,cosmetic|sunscreen lotion
C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,"InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37)",TUWMKPVJGGWGNL-UHFFFAOYSA-N,avoralstat,Phase 3,kallikrein inhibitor,,,
CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO,"InChI=1S/C43H90N2O2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-44(38-35-39-45(40-42-46)41-43-47)37-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h46-47H,3-43H2,1-2H3",WXNRAKRZUCLRBP-UHFFFAOYSA-N,avridine,Preclinical,immunostimulant,,,
COc1ccc2c(c1)C(c1ccc(F)cc1)=C(CN1CCCC1)CO2,"InChI=1S/C21H22FNO2/c1-24-18-8-9-20-19(12-18)21(15-4-6-17(22)7-5-15)16(14-25-20)13-23-10-2-3-11-23/h4-9,12H,2-3,10-11,13-14H2,1H3",VMMKGVRPILDZML-UHFFFAOYSA-N,ax-024,Preclinical,cytokine production inhibitor,,,
CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)[nH]nc2c1,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)",RITAVMQDGBJQJZ-UHFFFAOYSA-N,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor,CSF1|FLT1|FLT4|KDR|PLK4,oncology,renal cell carcinoma (RCC)
CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)[nH]nc2c1,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)",RITAVMQDGBJQJZ-UHFFFAOYSA-N,axitinib,Launched,VEGFR inhibitor,CSF1|FLT1|FLT4|KDR|PLK4,oncology,renal cell carcinoma (RCC)
Clc1ccccc1CNCC1CCC(CNCc2ccccc2Cl)CC1,"InChI=1S/C22H28Cl2N2/c23-21-7-3-1-5-19(21)15-25-13-17-9-11-18(12-10-17)14-26-16-20-6-2-4-8-22(20)24/h1-8,17-18,25-26H,9-16H2",RZRPZWGIOOZIBE-UHFFFAOYSA-N,ay-9944,Preclinical,hedgehog pathway modulator,,,
C=CCNC(=O)c1cc([N+](=O)[O-])cc2c(=O)[nH]c(=Nc3ccc(Cl)c(Cl)c3)[nH]c12,"InChI=1S/C18H13Cl2N5O4/c1-2-5-21-16(26)11-7-10(25(28)29)8-12-15(11)23-18(24-17(12)27)22-9-3-4-13(19)14(20)6-9/h2-4,6-8H,1,5H2,(H,21,26)(H2,22,23,24,27)",VUBILPOZTRGZJK-UHFFFAOYSA-N,az-10417808,Preclinical,caspase inhibitor,CASP3,,
O=C(CC12CC3CC(CC(C3)C1)C2)Nc1cccc2[nH]c(=NCCNCCO)ccc12,"InChI=1S/C25H34N4O2/c30-9-8-26-6-7-27-23-5-4-20-21(28-23)2-1-3-22(20)29-24(31)16-25-13-17-10-18(14-25)12-19(11-17)15-25/h1-5,17-19,26,30H,6-16H2,(H,27,28)(H,29,31)",FQMZXMVHHKXGTM-UHFFFAOYSA-N,az-10606120,Preclinical,purinergic receptor antagonist,P2RX7,,
Cc1ccc(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1,"InChI=1S/C23H20N4O2/c1-16-5-6-18(22-25-12-13-26-22)14-21(16)27-23(28)17-7-9-20(10-8-17)29-15-19-4-2-3-11-24-19/h2-14H,15H2,1H3,(H,25,26)(H,27,28)",KMSKKYBHDQYHMC-UHFFFAOYSA-N,az-12080282,Preclinical,hedgehog pathway inhibitor,DHH,,
Cc1ccc(NC(=O)c2cccc(C(C)(C)C#N)c2)cc1Nc1ccc2ncn(C)c(=O)c2c1,"InChI=1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33)",ZGBGPEDJXCYQPH-UHFFFAOYSA-N,az-628,Preclinical,RAF inhibitor,BRAF|RAF1,,
COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C,"InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)",VDRYGTNDKXIPSK-UHFFFAOYSA-N,az-7371,Preclinical,antibacterial ,,,
COc1cc(N2CCN(C)CC2)ccc1N=c1nc(-c2cn(C)c3cnccc23)cc[nH]1,"InChI=1S/C24H27N7O/c1-29-10-12-31(13-11-29)17-4-5-21(23(14-17)32-3)28-24-26-9-7-20(27-24)19-16-30(2)22-15-25-8-6-18(19)22/h4-9,14-16H,10-13H2,1-3H3,(H,26,27,28)",ZYVXTMKTGDARKR-UHFFFAOYSA-N,az191,Preclinical,DYRK inhibitor,DYRK1B,,
CC1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1,"InChI=1S/C21H24N4O3S/c1-14-13-28-11-10-25(14)19-12-18(21(7-8-21)29(2,26)27)23-20(24-19)16-4-3-5-17-15(16)6-9-22-17/h3-6,9,12,14,22H,7-8,10-11,13H2,1-2H3",SCGCBAAYLFTIJU-UHFFFAOYSA-N,az20,Preclinical,ATR kinase inhibitor,ATR|MTOR,,
COc1cc(OC2CCN(C)CC2)ccc1N=c1nc2c(c[nH]1)n(C)c(=O)n2C1CCCC1,"InChI=1S/C24H32N6O3/c1-28-12-10-17(11-13-28)33-18-8-9-19(21(14-18)32-3)26-23-25-15-20-22(27-23)30(24(31)29(20)2)16-6-4-5-7-16/h8-9,14-17H,4-7,10-13H2,1-3H3,(H,25,26,27)",YUKWVHPTFRQHMF-UHFFFAOYSA-N,az3146,Preclinical,monopolar spindle 1 kinase inhibitor,,,
O=C1COc2c(CCNCCN(C(=O)CCNCCc3ccc(Cl)c(Cl)c3)C3CCCCC3)ccc(O)c2N1,"InChI=1S/C29H38Cl2N4O4/c30-23-8-6-20(18-24(23)31)10-13-32-15-12-27(38)35(22-4-2-1-3-5-22)17-16-33-14-11-21-7-9-25(36)28-29(21)39-19-26(37)34-28/h6-9,18,22,32-33,36H,1-5,10-17,19H2,(H,34,37)",LIBVHXXKHSODII-UHFFFAOYSA-N,az505,Preclinical,histone lysine methyltransferase inhibitor,SMYD2,,
C=CC(=O)Nc1cc(N=c2nc(-c3c[nH]c4ccccc34)cc[nH]2)c(OC)cc1N(C)CCN(C)C,"InChI=1S/C27H31N7O2/c1-6-26(35)30-22-15-23(25(36-5)16-24(22)34(4)14-13-33(2)3)32-27-28-12-11-21(31-27)19-17-29-20-10-8-7-9-18(19)20/h6-12,15-17,29H,1,13-14H2,2-5H3,(H,30,35)(H,28,31,32)",IQNVEOMHJHBNHC-UHFFFAOYSA-N,az5104,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cc(N=c2nc(-c3cn(C)c4ccccc34)cc[nH]2)c(OC)cc1N(C)CCNC,"InChI=1S/C27H31N7O2/c1-6-26(35)30-21-15-22(25(36-5)16-24(21)33(3)14-13-28-2)32-27-29-12-11-20(31-27)19-17-34(4)23-10-8-7-9-18(19)23/h6-12,15-17,28H,1,13-14H2,2-5H3,(H,30,35)(H,29,31,32)",ZROCWKZRGJYPTG-UHFFFAOYSA-N,az7550,Phase 1,insulin growth factor receptor inhibitor,,,
Cc1cc(=Nc2[nH]c(=NC(C)c3ccc(F)cc3)c(C#N)cc2F)[nH][nH]1,"InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)",SUNXHXDJOIXABJ-UHFFFAOYSA-N,az960,Preclinical,JAK inhibitor,JAK2,,
N=c1ncn(C2OC(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)",NMUSYJAQQFHJEW-UHFFFAOYSA-N,azacitidine,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)
OC(c1ccccc1)(c1ccccc1)C1CCNCC1,"InChI=1S/C18H21NO/c20-18(15-7-3-1-4-8-15,16-9-5-2-6-10-16)17-11-13-19-14-12-17/h1-10,17,19-20H,11-14H2",ZMISODWVFHHWNR-UHFFFAOYSA-N,azacyclonol,Preclinical,histamine receptor antagonist,HRH1,,
N=c1[nH]c(=O)c2[nH]nnc2[nH]1,"InChI=1S/C4H4N6O/c5-4-6-2-1(3(11)7-4)8-10-9-2/h(H4,5,6,7,8,9,10,11)",LPXQRXLUHJKZIE-UHFFFAOYSA-N,azaguanine-8,Preclinical,purine antagonist,PNP,,
CCC1C(C)OC(O)(C(C)C(O)C(C)C2OC(=O)C=CC=CC(C)C(C(C)C(O)C(C)C3(O)CC(OC4CC(O)C(O)C(C)O4)C(CC)C(C)O3)OC(=O)C=CC=CC2C)CC1OC1CC(O)C(O)C(C)O1,"InChI=1S/C54H88O18/c1-13-37-33(9)71-53(63,25-41(37)67-45-23-39(55)49(61)35(11)65-45)31(7)47(59)29(5)51-27(3)19-15-17-22-44(58)70-52(28(4)20-16-18-21-43(57)69-51)30(6)48(60)32(8)54(64)26-42(38(14-2)34(10)72-54)68-46-24-40(56)50(62)36(12)66-46/h15-22,27-42,45-52,55-56,59-64H,13-14,23-26H2,1-12H3",OSERMIPXNLXAPD-UHFFFAOYSA-N,azalomycin-b,Preclinical,bacterial 50S ribosomal subunit inhibitor,,,
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,"InChI=1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2",XTKDAFGWCDAMPY-UHFFFAOYSA-N,azaperone,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,sedative
CCCc1c(O)n2c(N(C)C)nc3ccc(C)cc3n2c1=O,"InChI=1S/C16H20N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h7-9,22H,5-6H2,1-4H3",VECZDVJCSZXAPJ-UHFFFAOYSA-N,azapropazone,Withdrawn,cyclooxygenase inhibitor,PTGS2,,
N#[N+]CC(=O)OCC(N)C(=O)O,"InChI=1S/C5H7N3O4/c6-3(5(10)11)2-12-4(9)1-8-7/h3H,1-2,6H2/p+1",YXEASJLRXGZRHS-UHFFFAOYSA-O,azaserine,Preclinical,purine antagonist,,,
CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21,"InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)",WUKZPHOXUVCQOR-UHFFFAOYSA-N,azasetron,Launched,serotonin receptor antagonist,HTR3A|HTR3B,infectious disease,genitial herpes
CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,"InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3",SEBMTIQKRHYNIT-UHFFFAOYSA-N,azatadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12,"InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)",LMEKQMALGUDUQG-UHFFFAOYSA-N,azathioprine,Launched,dehydrogenase inhibitor,HPRT1|IMPDH1|PPAT,transplant|rheumatology,renal homotransplantation|rheumatoid arthritis
CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,"InChI=1S/C26H31N5O3/c1-29(2)11-4-12-34-24-8-6-19(16-28-24)18-5-7-22-21(15-18)25-23(17-27-22)30(3)26(32)31(25)20-9-13-33-14-10-20/h5-8,15-17,20H,4,9-14H2,1-3H3",AOTRIQLYUAFVSC-UHFFFAOYSA-N,azd0156,Phase 1,ATM kinase inhibitor,,,
N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1,"InChI=1S/C19H18N4O2/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23/h1-4,9,11,22,24H,5-8,12H2",BLTVBQXJFVRPFK-UHFFFAOYSA-N,azd1080,Phase 1,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
NC1CCCN(c2c(C=C3SC(=O)NC3=O)cccc2-c2ccccc2)C1,"InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)",MCUJKPPARUPFJM-UHFFFAOYSA-N,azd1208,Phase 1,Pim kinase inhibitor,PIM1|PIM2|PIM3,,
CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C,"InChI=1S/C23H26N4O5S/c1-3-32-23(29)20-13-19(14-24)21(25-16(20)2)27-11-9-18(10-12-27)22(28)26-33(30,31)15-17-7-5-4-6-8-17/h4-8,13,18H,3,9-12,15H2,1-2H3,(H,26,28)",NEMHKCNXXRQYRF-UHFFFAOYSA-N,azd1283,Preclinical,purinergic receptor antagonist,P2RY12,,
CC(C)n1c(=O)n(C)c2cnc3cc(F)c(-c4ccc(OCCCN5CCCCC5)nc4)cc3c21,"InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3",VQSZIPCGAGVRRP-UHFFFAOYSA-N,azd1390,Phase 1,ATM kinase inhibitor,,,
O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,"InChI=1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2",GTUIQNHJSXQMKW-UHFFFAOYSA-N,azd1446,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2,,
Cc1cc(=Nc2[nH]c(=NC(C)c3ncc(F)cn3)ncc2Cl)[nH][nH]1,"InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)",PDOQBOJDRPLBQU-UHFFFAOYSA-N,azd1480,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O,"InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)",JWYIGNODXSRKGP-UHFFFAOYSA-N,azd1981,Phase 2,CRTH receptor antagonist,PTGDR2,,
CNC(=O)c1cccc(-c2ccc3c(N4CCOCC4C)nc(N4CCOCC4C)nc3n2)c1,"InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)",JUSFANSTBFGBAF-UHFFFAOYSA-N,azd2014,Phase 2,mTOR inhibitor,MTOR,,
COC1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1,"InChI=1S/C22H22FN3O3/c1-29-15-8-10-26(11-9-15)22(28)18-12-14(6-7-19(18)23)13-20-16-4-2-3-5-17(16)21(27)25-24-20/h2-7,12,15H,8-11,13H2,1H3,(H,25,27)",HYNBNUYQTQIHJK-UHFFFAOYSA-N,azd2461,Phase 1,PARP inhibitor,,,
CN1CCN(S(=O)(=O)c2ccc(-c3c[nH]c(=N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,"InChI=1S/C21H23N7O3S/c1-27-9-11-28(12-10-27)32(30,31)17-6-4-15(5-7-17)18-14-24-20(22)19(26-18)21(29)25-16-3-2-8-23-13-16/h2-8,13-14H,9-12H2,1H3,(H2,22,24)(H,25,29)",FHCSBLWRGCOVPT-UHFFFAOYSA-N,azd2858,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(OC2CCNC2)c1,"InChI=1S/C21H23N5O4S/c1-10-18(11(2)30-26-10)12-3-4-14(16(7-12)29-13-5-6-24-9-13)17-8-15(19(22)27)20(31-17)25-21(23)28/h3-4,7-8,13,24H,5-6,9H2,1-2H3,(H2,22,27)(H3,23,25,28)",NMFIXEFNQPDISY-UHFFFAOYSA-N,azd3264,Preclinical,IKK inhibitor,IKBKB,,
COc1cc(N2CCC(N)CC2)ccc1N=c1nc(-c2c[nH]c3ccccc23)c(Cl)c[nH]1,"InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30)",GCYIGMXOIWJGBU-UHFFFAOYSA-N,azd3463,Preclinical,ALK tyrosine kinase receptor inhibitor,ALK|IGF1R,,
COc1cc(N2CCC(N)CC2)ccc1N=c1nc(-c2c[nH]c3ccccc23)c(Cl)c[nH]1,"InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30)",GCYIGMXOIWJGBU-UHFFFAOYSA-N,azd3463,Preclinical,insulin growth factor receptor inhibitor,ALK|IGF1R,,
CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,"InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3",JMEYDSHPKCSIJC-UHFFFAOYSA-N,azd3514,Phase 1,androgen receptor modulator,AR,,
COc1cc2[nH]cnc(=Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)CC1C,"InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)",MXDSJQHFFDGFDK-UHFFFAOYSA-N,azd3759,Phase 2/Phase 3,EGFR inhibitor,EGFR,,
N=C1NC(c2cccc(-c3cncnc3)c2)(c2ccnc(C(F)F)c2)c2cccc(F)c21,"InChI=1S/C24H16F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22H,(H2,28,32)",MRXBCEQZNKUUIP-UHFFFAOYSA-N,azd3839,Phase 1,beta-secretase inhibitor,BACE1,,
Cc1[nH]nc(C(F)(F)F)c1Cc1sc2c(c1C(=O)N1CC(C)(O)CO1)c(=O)n(C)c(=O)n2C(C)C,"InChI=1S/C21H24F3N5O5S/c1-9(2)29-18-14(16(30)27(5)19(29)32)13(17(31)28-7-20(4,33)8-34-28)12(35-18)6-11-10(3)25-26-15(11)21(22,23)24/h9,33H,6-8H2,1-5H3,(H,25,26)",PRNXOFBDXNTIFG-UHFFFAOYSA-N,azd3965,Phase 1,monocarboxylate transporter inhibitor,SLC16A1,,
O=C(O)CC1CCC(c2ccc(NC(=O)c3n[nH]c(=Nc4ccc(F)c(F)c4)o3)cc2)CC1,"InChI=1S/C23H22F2N4O4/c24-18-10-9-17(12-19(18)25)27-23-29-28-22(33-23)21(32)26-16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-20(30)31/h5-10,12-14H,1-4,11H2,(H,26,32)(H,27,29)(H,30,31)",NGEBYTLALFOQKI-UHFFFAOYSA-N,azd3988,Preclinical,diacylglycerol kinase inhibitor,DGAT1,,
NCC(=O)O,"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)",DHMQDGOQFOQNFH-UHFFFAOYSA-N,azd4282,Phase 1,glutamate receptor antagonist,AGXT|AGXT2|ALAS1|ALAS2|BAAT|GARS|GATM|GCAT|GCSH|GLDC|GLRA1|GLRA2|GLRA3|GLRB|GLYAT|GLYATL1|GLYATL2|GNMT|GPR18|GPRC6A|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3B|GSS|PIPOX|SHMT1|SHMT2|SLC32A1|SLC36A1|SLC6A5|SLC6A9,,
COc1cc(CCc2cc(=NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)[nH][nH]2)cc(OC)c1,"InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)",VRQMAABPASPXMW-UHFFFAOYSA-N,azd4547,Phase 2/Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR,,
CC(=O)NC1CCCC(C(=O)N=c2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)c[nH]2)C1,"InChI=1S/C22H28ClN5O2/c1-13(29)26-15-6-4-5-14(7-15)21(30)27-20-8-16(18(23)11-24-20)17-10-25-28-12-22(2,3)9-19(17)28/h8,10-11,14-15H,4-7,9,12H2,1-3H3,(H,26,29)(H,24,27,30)",AVIWDYSJSPOOAR-UHFFFAOYSA-N,azd4573,Phase 1,CDK9 inhibitor,,,
Cc1cc(-c2n[nH]c(=N)nc2-c2ccc(F)cc2)cc(Cl)n1,"InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)",NCWQLHHDGDXIJN-UHFFFAOYSA-N,azd4635,Phase 1/Phase 2,adenosine receptor antagonist,,,
CC(Oc1cc(=NS(=O)(=O)N2CCC2)[nH]c(SCc2cccc(F)c2F)n1)C(O)CO,"InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)",QZECRCLSIGFCIO-UHFFFAOYSA-N,azd5069,Phase 2,CC chemokine receptor antagonist,CXCR2,,
COc1nnc2ccc(N3CCC(c4ccc(OCCN5CCN(C)C(=O)C5C)cc4)CC3)nn12,"InChI=1S/C25H33N7O3/c1-18-24(33)29(2)14-15-30(18)16-17-35-21-6-4-19(5-7-21)20-10-12-31(13-11-20)23-9-8-22-26-27-25(34-3)32(22)28-23/h4-9,18,20H,10-17H2,1-3H3",RSMYFSPOTCDHHJ-UHFFFAOYSA-N,azd5153,Phase 1,bromodomain inhibitor,,,
NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)",JDUBGYFRJFOXQC-UHFFFAOYSA-N,azd5363,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3,,
Cc1ncc(-c2cc[nH]c(=Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,"InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)",WJRRGYBTGDJBFX-UHFFFAOYSA-N,azd5438,Phase 1,CDK inhibitor,KCNH2,,
CNC(C)C(=O)NC(C(=O)N1CCCC1C(=O)NC1c2ccccc2CC1OCC#CC#CCOC1Cc2ccccc2C1NC(=O)C1CCCN1C(=O)C(NC(=O)C(C)NC)C1CCCCC1)C1CCCCC1,"InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)",WLMCRYCCYXHPQF-UHFFFAOYSA-N,azd5582,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,
Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13,"InChI=1S/C35H34ClN5O3S2/c1-20-31-29(38-40(20)3)19-45-17-22-15-23(41(4)37-22)18-46-24-14-21-8-5-6-9-25(21)30(16-24)44-13-7-10-26-27-11-12-28(36)32(31)33(27)39(2)34(26)35(42)43/h5-6,8-9,11-12,14-16H,7,10,13,17-19H2,1-4H3,(H,42,43)",KBQCEQAXHPIRTF-UHFFFAOYSA-N,azd5991,Phase 1,MCL1 inhibitor,,,
Cc1cc(C(C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,"InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)",IRTDIKMSKMREGO-UHFFFAOYSA-N,azd6482,Phase 1,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC1COCCN1c1cc(C2(S(C)(=N)=O)CC2)nc(-c2ccnc3[nH]ccc23)n1,"InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)",OHUHVTCQTUDPIJ-UHFFFAOYSA-N,azd6738,Phase 2,ATR kinase inhibitor,ATR,,
NC(Cc1ccccn1)c1ccccc1,"InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2",FWUQWDCOOWEXRY-UHFFFAOYSA-N,azd6765,Phase 2,glutamate receptor antagonist,GRIN1,,
CN(C)C(=O)c1ccc(S(=O)(=O)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,"InChI=1S/C19H18ClF3N2O5S/c1-18(28,19(21,22)23)17(27)24-15-9-8-13(10-14(15)20)31(29,30)12-6-4-11(5-7-12)16(26)25(2)3/h4-10,28H,1-3H3,(H,24,27)",DTDZLJHKVNTQGZ-UHFFFAOYSA-N,azd7545,Phase 1,pyruvate dehydrogenase kinase inhibitor,PDK1,,
CC(NC(=O)C(C)(F)F)C(Oc1ccc2c(cnn2-c2cccc(C(=O)NC3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,"InChI=1S/C32H32F2N4O6/c1-19(36-31(40)32(2,33)34)29(20-6-9-27-28(16-20)43-13-12-42-27)44-25-7-8-26-22(15-25)17-35-38(26)24-5-3-4-21(14-24)30(39)37-23-10-11-41-18-23/h3-9,14-17,19,23,29H,10-13,18H2,1-2H3,(H,36,40)(H,37,39)",ZZWJKLGCDHYVMB-UHFFFAOYSA-N,azd7594,Phase 2,glucocorticoid receptor modulator,,,
Cc1nc(C)c(-c2ccc(C3CCC(CC(=O)O)CC3)cc2)nc1C(N)=O,"InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)",YXFNPRHZMOGREC-UHFFFAOYSA-N,azd7687,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,
NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)NC1CCCNC1,"InChI=1S/C17H19FN4O2S/c18-11-4-1-3-10(7-11)14-8-13(22-17(19)24)15(25-14)16(23)21-12-5-2-6-20-9-12/h1,3-4,7-8,12,20H,2,5-6,9H2,(H,21,23)(H3,19,22,24)",IAYGCINLNONXHY-UHFFFAOYSA-N,azd7762,Phase 1,CHK inhibitor,CHEK1|CHEK2,,
Cn1c(=O)oc2ccc(-c3ccc(CC(C#N)NC(=O)C4CNCCCO4)cc3)cc21,"InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)",AEXFXNFMSAAELR-UHFFFAOYSA-N,azd7986,Phase 1,dipeptidyl peptidase inhibitor,,,
COc1ccc(-c2ccc3c(N4CCOCC4C)nc(N4CCOCC4C)nc3n2)cc1CO,"InChI=1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3",KVLFRAWTRWDEDF-UHFFFAOYSA-N,azd8055,Phase 1,mTOR inhibitor,MTOR,,
CC(Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,"InChI=1S/C24H25F2N3O4/c1-14(27-18-11-16(25)10-17(26)12-18)19-8-15(24(31)28(2)3)9-20-21(30)13-22(33-23(19)20)29-4-6-32-7-5-29/h8-14,27H,4-7H2,1-3H3",LMJFJIDLEAWOQJ-UHFFFAOYSA-N,azd8186,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,
Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,"InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)",RWEVIPRMPFNTLO-UHFFFAOYSA-N,azd8330,Phase 1,MEK inhibitor,MAP3K1,,
CC(C)CC(CO)N=c1[nH]c(SC(C)c2ccccc2)nc2[nH]c(=N)sc12,"InChI=1S/C19H25N5OS2/c1-11(2)9-14(10-25)21-16-15-17(22-18(20)27-15)24-19(23-16)26-12(3)13-7-5-4-6-8-13/h4-8,11-12,14,25H,9-10H2,1-3H3,(H3,20,21,22,23,24)",ZMQSLMZOWVGBSM-UHFFFAOYSA-N,azd8797,Preclinical,CC chemokine receptor antagonist,,,
CCn1nc(C2CCN(C(=O)CCO)CC2)nc1-c1c[nH]c(=N)c(-c2nnc(C(C)(C)C)o2)n1,"InChI=1S/C22H31N9O3/c1-5-31-19(26-18(29-31)13-6-9-30(10-7-13)15(33)8-11-32)14-12-24-17(23)16(25-14)20-27-28-21(34-20)22(2,3)4/h12-13,32H,5-11H2,1-4H3,(H2,23,24)",ZGRDYKFVDCFJCZ-UHFFFAOYSA-N,azd8835,Phase 1,PI3K inhibitor,PIK3CA|PIK3CD,,
CNC(=O)CN1CCC(Oc2cc3c(=Nc4cccc(Cl)c4F)[nH]cnc3cc2OC)CC1,"InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)",DFJSJLGUIXFDJP-UHFFFAOYSA-N,azd8931,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB3,,
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,"InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)",HSQAARMBHJCUOK-UHFFFAOYSA-N,azd9056,Phase 2,purinergic receptor antagonist,,,
N#Cc1cc(F)cc(-c2nc(-c3ccc(F)cn3)no2)c1,"InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H",RBSPCALDSNXWEP-UHFFFAOYSA-N,azd9272,Preclinical,glutamate receptor antagonist,GRM5,,
CC1Cc2c([nH]c3ccccc23)C(c2c(F)cc(C=CC(=O)O)cc2F)N1CC(C)(C)F,"InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32)",DFBDRVGWBHBJNR-UHFFFAOYSA-N,azd9496,Phase 1,estrogen receptor agonist,ESR1,,
Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1,"InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)",QNQZWEGMKJBHEM-UHFFFAOYSA-N,azd9668,Phase 2,elastase inhibitor,ELANE,,
O=C(O)CCCCCCCC(=O)O,"InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)",BDJRBEYXGGNYIS-UHFFFAOYSA-N,azelaic-acid,Launched,tyrosinase inhibitor,AKR1D1|SRD5A2|TYR,dermatology,rosacea
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,"InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3",MBUVEWMHONZEQD-UHFFFAOYSA-N,azelastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CCCCc1nc(-c2ccc(OCCCN(CC)CC)cc2)cn1-c1ccc(Oc2ccc(Cl)cc2)cc1,"InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3",KJNNWYBAOPXVJY-UHFFFAOYSA-N,azeliragon,Phase 3,RAGE receptor antagonist,AGER,,
CC1=NC(=N)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)C(c2cccc([N+](=O)[O-])c2)C1C(=O)OC(C)C,"InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26-30,34H,18-19H2,1-3H3",VWQKBXQRFVPFAL-UHFFFAOYSA-N,azelnidipine,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nc(=O)o[nH]2)cc1,"InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)",KGSXMPPBFPAXLY-UHFFFAOYSA-N,azilsartan,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension
CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2nc(=O)o[nH]2)cc1,"InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)",QJFSABGVXDWMIW-UHFFFAOYSA-N,azilsartan-medoxomil,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension
CN1CCN(CCCCn2c(O)cn(N=Cc3ccc(-c4ccc(Cl)cc4)o3)c2=O)CC1,"InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16-17,30H,2-3,10-15H2,1H3",AFGPVGJVUMWQDE-UHFFFAOYSA-N,azimilide,Phase 3,potassium channel blocker,KCNA5,,
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O,"InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3",MQTOSJVFKKJCRP-UHFFFAOYSA-N,azithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,pelvic inflammatory disease|pneumonia
CC1(C)SC2C(NC(=O)C(NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)",JTWOMNBEOCYFNV-UHFFFAOYSA-N,azlocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections
COc1ccc(Cl)c(N=c2[nH]cnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,"InChI=1S/C23H27ClN4O3/c1-28-8-6-15(7-9-28)13-31-22-12-19-17(11-21(22)30-3)23(26-14-25-19)27-20-10-16(29-2)4-5-18(20)24/h4-5,10-12,14-15H,6-9,13H2,1-3H3,(H,25,26,27)",WPOXAFXHRJYEIC-UHFFFAOYSA-N,azm-475271,Preclinical,SRC inhibitor,SRC,,
NC(=O)N=NC(N)=O,"InChI=1S/C2H4N4O2/c3-1(7)5-6-2(4)8/h(H2,3,7)(H2,4,8)",XOZUGNYVDXMRKW-UHFFFAOYSA-N,azodicarbonamide,Phase 2,DNA synthesis inhibitor,,,
O=[N+]([O-])c1ncc[nH]1,"InChI=1S/C3H3N3O2/c7-6(8)3-4-1-2-5-3/h1-2H,(H,4,5)",YZEUHQHUFTYLPH-UHFFFAOYSA-N,azomycin-(2-nitroimidazole),Preclinical,protein synthesis inhibitor,,,
NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl,"InChI=1S/C12H11ClN6O2S2/c13-9-5-10(15-6-7-2-1-3-22-7)8(12-16-18-19-17-12)4-11(9)23(14,20)21/h1-5,15H,6H2,(H2,14,20,21)(H,16,17,18,19)",HMEDEBAJARCKCT-UHFFFAOYSA-N,azosemide,Launched,electrolyte reabsorption inhibitor,SLC12A1|SLC12A2,cardiology,edema
CC1C(=NC(=O)C(NOC(C)(C)C(=O)O)c2csc(=N)[nH]2)C(=O)N1S(=O)(=O)O,"InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,8,17H,1-3H3,(H2,14,15)(H,21,22)(H,23,24,25)",FLMIOANAVARRAD-UHFFFAOYSA-N,aztreonam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections
CCOC(=O)OC(C)OC(=O)C1N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1(C)C,"InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)",PFOLLRNADZZWEX-UHFFFAOYSA-N,bacampicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections
CCC(C)C(=N)C1NC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)NC2CCCCNC(=O)C(CC(N)=O)NC(=O)C(CC(=O)O)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(Cc3ccccc3)NC(=O)C(C(C)CC)NC(=O)C(CCCN)NC2=O)C(C)CC)CS1,"InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,53-54,66,69,81H,9-11,15-17,20-30,32,67H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)",SFHRUUJDGPOFFI-UHFFFAOYSA-N,bacitracin,Launched,bacterial cell wall synthesis inhibitor,IDE,infectious disease,first-aid antibiotic
CCC(C)C(=N)C1NC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)NC2CCCCNC(=O)C(CC(N)=O)NC(=O)C(CC(=O)O)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(Cc3ccccc3)NC(=O)C(C(C)CC)NC(=O)C(CCCN)NC2=O)C(C)CC)CS1,"InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,53-54,66,69,81H,9-11,15-17,20-30,32,67H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)",SFHRUUJDGPOFFI-UHFFFAOYSA-N,bacitracin-zinc,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,first-aid antibiotic
NCC(CC(=O)O)c1ccc(Cl)cc1,"InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)",KPYSYYIEGFHWSV-UHFFFAOYSA-N,baclofen,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,neurology/psychiatry,multiple sclerosis|spasms
CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1,"InChI=1S/C21H24O4/c1-21(2,15-3-7-17(8-4-15)22-11-19-13-24-19)16-5-9-18(10-6-16)23-12-20-14-25-20/h3-10,19-20H,11-14H2,1-2H3",LCFVJGUPQDGYKZ-UHFFFAOYSA-N,badge,Preclinical,PPAR receptor antagonist,PPARG,,
Cc1ccc(NC(=O)c2ccc(CN3CCC(N(C)C)C3)c(C(F)(F)F)c2)cc1N=c1nc(-c2cncnc2)cc[nH]1,"InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)",ZGBAJMQHJDFTQJ-UHFFFAOYSA-N,bafetinib,Phase 2,Bcr-Abl kinase inhibitor,ABL1|BCR|LYN,,
Cc1ccc(NC(=O)c2ccc(CN3CCC(N(C)C)C3)c(C(F)(F)F)c2)cc1N=c1nc(-c2cncnc2)cc[nH]1,"InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)",ZGBAJMQHJDFTQJ-UHFFFAOYSA-N,bafetinib,Phase 2,LYN tyrosine kinase inhibitor,ABL1|BCR|LYN,,
COC1=CC(C)=CC(C)C(O)C(C)CC(C)=CC=CC(OC)C(C(C)C(O)C(C)C2(O)CC(O)C(C)C(C(C)C)O2)OC1=O,"InChI=1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3",XDHNQDDQEHDUTM-UHFFFAOYSA-N,bafilomycin-a1,Preclinical,ATPase inhibitor,,,
Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(C(C)(C)C#N)cc1,"InChI=1S/C28H21N5/c1-19-32-26-17-31-25-13-8-20(6-7-21-5-4-14-30-16-21)15-24(25)27(26)33(19)23-11-9-22(10-12-23)28(2,3)18-29/h4-5,8-17H,1-3H3",GVPAGJWVBUZHNQ-UHFFFAOYSA-N,bag-956,Preclinical,phosphoinositide dependent kinase inhibitor,PIK3CG,,
O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12,"InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H",FXNFHKRTJBSTCS-UHFFFAOYSA-N,baicalein,Preclinical,lipoxygenase inhibitor,ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH,,
O=C(O)C1OC(Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)C(O)C(O)C1O,"InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)",IKIIZLYTISPENI-UHFFFAOYSA-N,baicalin,Launched,beta glucuronidase inhibitor,PREP,neurology/psychiatry,anxiety
C=CC(C)(C=Cc1ccc(O)cc1)CCC=C(C)C,"InChI=1S/C18H24O/c1-5-18(4,13-6-7-15(2)3)14-12-16-8-10-17(19)11-9-16/h5,7-12,14,19H,1,6,13H2,2-4H3",LFYJSSARVMHQJB-UHFFFAOYSA-N,bakuchiol,Phase 2,DNA polymerase inhibitor,HIF1A,,
Cn1c(COc2ccc(Cc3sc(=O)[nH]c3O)cc2)nc2ccccc2c1=O,"InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,24H,10-11H2,1H3,(H,22,26)",BLWRISJFPSMOON-UHFFFAOYSA-N,balaglitazone,Phase 3,insulin sensitizer,PPARG,,
Cn1c(COc2ccc(Cc3sc(=O)[nH]c3O)cc2)nc2ccccc2c1=O,"InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,24H,10-11H2,1H3,(H,22,26)",BLWRISJFPSMOON-UHFFFAOYSA-N,balaglitazone,Phase 3,PPAR receptor partial agonist,PPARG,,
CC(C)C(=O)OCC1(N=[N+]=[N-])OC(n2ccc(=N)[nH]c2=O)C(OC(=O)C(C)C)C1OC(=O)C(C)C,"InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)",VKXWOLCNTHXCLF-UHFFFAOYSA-N,balapiravir,Phase 2,RNA polymerase inhibitor,,,
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1,"InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)",LLCRBOWRJOUJAE-UHFFFAOYSA-N,balicatib,Phase 2,cathepsin inhibitor,CTSK,,
CNC1CCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1,"InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)",MGQLHRYJBWGORO-UHFFFAOYSA-N,balofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
O=C1c2c(O)c(=O)ccn2N(C2c3ccccc3SCc3c2ccc(F)c3F)C2COCCN12,"InChI=1S/C24H19F2N3O4S/c25-16-6-5-13-15(20(16)26)12-34-18-4-2-1-3-14(18)21(13)29-19-11-33-10-9-27(19)24(32)22-23(31)17(30)7-8-28(22)29/h1-8,19,21,31H,9-12H2",FIDLLEYNNRGVFR-UHFFFAOYSA-N,baloxavir,Phase 3,endonuclease inhibitor,,,
COC(=O)OCOc1c2n(ccc1=O)N(C1c3ccccc3SCc3c1ccc(F)c3F)C1COCCN1C2=O,"InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3",RZVPBGBYGMDSBG-UHFFFAOYSA-N,baloxavir-marboxil,Launched,endonuclease inhibitor,,infectious disease,influenza A virus infection
O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1,"InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)",IPOKCKJONYRRHP-UHFFFAOYSA-N,balsalazide,Launched,cyclooxygenase inhibitor,ALOX5|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis
CCOc1ccccc1N=Nc1c(C)[nH]n(-c2nc(-c3ccccc3)cs2)c1=O,"InChI=1S/C21H19N5O2S/c1-3-28-18-12-8-7-11-16(18)23-24-19-14(2)25-26(20(19)27)21-22-17(13-29-21)15-9-5-4-6-10-15/h4-13,25H,3H2,1-2H3",WRLVHADVOGFZOZ-UHFFFAOYSA-N,bam7,Preclinical,BAX activator,BAX,,
CCCn1c(=O)c(CCCOC(=O)NC)nc2ccccc21,"InChI=1S/C16H21N3O3/c1-3-10-19-14-9-5-4-7-12(14)18-13(15(19)20)8-6-11-22-16(21)17-2/h4-5,7,9H,3,6,8,10-11H2,1-2H3,(H,17,21)",HNQSZPBGDAJIJO-UHFFFAOYSA-N,bamaquimast,Preclinical,proton pump inhibitor,,,
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,"InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3",ANZXOIAKUNOVQU-UHFFFAOYSA-N,bambuterol,Launched,adrenergic receptor agonist,ADRB2|BCHE,pulmonary,asthma
O=C(NCCCN1CCC2(CC1)OCc1ccccc12)C1CCCN1Cc1ccccc1,"InChI=1S/C27H35N3O2/c31-26(25-12-6-17-30(25)20-22-8-2-1-3-9-22)28-15-7-16-29-18-13-27(14-19-29)24-11-5-4-10-23(24)21-32-27/h1-5,8-11,25H,6-7,12-21H2,(H,28,31)",MAKMQGKJURAJEN-UHFFFAOYSA-N,ban-orl-24,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,
C[N+](C)([O-])CC=Nc1ccc(NCC[N+](C)(C)[O-])c2c(O)c3c(O)ccc(O)c3c(O)c12,"InChI=1S/C22H28N4O6/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30/h5-9,24,27-30H,10-12H2,1-4H3",XDGJJOUSKUZGSE-UHFFFAOYSA-N,banoxantrone,Phase 1/Phase 2,topoisomerase inhibitor,TOP2A,,
CCN(CCCOc1ccc2c(=Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)[nH]cnc2c1)CCO[PH](=O)(=O)O,"InChI=1S/C26H30FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H,36,37,38)(H2,28,29,31,32,33)",YTWPSLMSUODGDB-UHFFFAOYSA-N,barasertib,Phase 2/Phase 3,Aurora kinase inhibitor,AURKA|AURKB,,
CCN(CCO)CCCOc1ccc2c(=Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)[nH]cnc2c1,"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)",QYZOGCMHVIGURT-UHFFFAOYSA-N,barasertib-hqpa,Phase 2/Phase 3,Aurora kinase inhibitor,AURKB,,
CC1(C)CCC2(C(=O)O)CCC3(C)C(C(=O)C=C4C5(C)C=C(C#N)C(=O)C(C)(C)C5CCC43C)C2C1,"InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)",TXGZJQLMVSIZEI-UHFFFAOYSA-N,bardoxolone,Phase 1,nuclear factor erythroid derived,NOS2|PPARG,,
CC1(C)CCC2(C(=O)O)CCC3(C)C(C(=O)C=C4C5(C)C=C(C#N)C(=O)C(C)(C)C5CCC43C)C2C1,"InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)",TXGZJQLMVSIZEI-UHFFFAOYSA-N,bardoxolone,Phase 1,like (NRF2) activator,NOS2|PPARG,,
COC(=O)C12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C#N)C(=O)C(C)(C)C4CCC3(C)C1(C)CC2,"InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3",WPTTVJLTNAWYAO-UHFFFAOYSA-N,bardoxolone-methyl,Phase 3,nuclear factor erythroid derived,PPARG|STAT3,,
COC(=O)C12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C#N)C(=O)C(C)(C)C4CCC3(C)C1(C)CC2,"InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3",WPTTVJLTNAWYAO-UHFFFAOYSA-N,bardoxolone-methyl,Phase 3,like (NRF2) activator,PPARG|STAT3,,
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,"InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)",XUZMWHLSFXCVMG-UHFFFAOYSA-N,baricitinib,Launched,JAK inhibitor,JAK1|JAK2,rheumatology,rheumatoid arthritis
O=C(C(O)CO)C(O)C(O)CO[PH](=O)(=O)O,"InChI=1S/C6H12O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h3-4,6-9,11H,1-2H2,(H,12,13,14)",ACQISADZCWNNIO-UHFFFAOYSA-N,barium-6-o-phosphonato-d-glucose,Preclinical,,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OC2CCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,24-25H,12-13,15-16H2,1-3H3",QPOLEIZVZGWOJF-UHFFFAOYSA-N,barnidipine,Launched,calcium channel blocker,,cardiology,hypertension
CC1=CC(=C(c2ccc(N)cc2)c2ccc(N)cc2)C=CC1=N,"InChI=1S/C20H19N3/c1-13-12-16(6-11-19(13)23)20(14-2-7-17(21)8-3-14)15-4-9-18(22)10-5-15/h2-12,23H,21-22H2,1H3",YDCMWLQSPFTWCS-UHFFFAOYSA-N,basic-fuchsin,Preclinical,,,,
Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,"InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3",UPZWINBEAHDTLA-UHFFFAOYSA-N,basimglurant,Phase 2,glutamate receptor antagonist,GRM5,,
Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1,"InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3",VCGRFBXVSFAGGA-UHFFFAOYSA-N,basmisanil,Phase 2,GABA receptor inverse agonist,,,
COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNCC(O)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)",URWYQGVSPQJGGB-UHFFFAOYSA-N,batefenterol,Phase 2,acetylcholine receptor antagonist,,,
COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNCC(O)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)",URWYQGVSPQJGGB-UHFFFAOYSA-N,batefenterol,Phase 2,adrenergic receptor agonist,,,
CNC(=O)C(Cc1ccccc1)NC(=O)C(CC(C)C)C(CSc1cccs1)C(O)=NO,"InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)",XFILPEOLDIKJHX-UHFFFAOYSA-N,batimastat,Phase 3,matrix metalloprotease inhibitor,ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8,,
O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1,"InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2",BGBVSGSIXIIREO-UHFFFAOYSA-N,bavisant,Phase 2,histamine receptor antagonist,HRH3,,
OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,"InChI=1S/C19H21Br2N3O/c20-13-1-3-18-16(9-13)17-10-14(21)2-4-19(17)24(18)12-15(25)11-23-7-5-22-6-8-23/h1-4,9-10,15,22,25H,5-8,11-12H2",KUUJEXLRLIPQQJ-UHFFFAOYSA-N,bax-channel-blocker,Preclinical,cytochrome C release inhibitor,BAX,,
Cc1ccc(S(=O)(=O)C=CC#N)cc1,"InChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3",DOEWDSDBFRHVAP-UHFFFAOYSA-N,bay-11-7082,Preclinical,NFkB pathway inhibitor,RELA,,
CC(C)(C)c1ccc(S(=O)(=O)C=CC#N)cc1,"InChI=1S/C13H15NO2S/c1-13(2,3)11-5-7-12(8-6-11)17(15,16)10-4-9-14/h4-8,10H,1-3H3",VHKZGNPOHPFPER-UHFFFAOYSA-N,bay-11-7085,Preclinical,NFkB pathway inhibitor,NFKBIA,,
COc1cc(F)ccc1-c1cc(=Nc2cc(CS(C)(=N)=O)ccn2)[nH]cc1F,"InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)",YZCUMZWULWOUMD-UHFFFAOYSA-N,bay-1251152,Phase 1,CDK9 inhibitor,,,
CC1CC(n2c(=Nc3ccc(OC(F)(F)F)cc3)[nH]c3cc(CCC(=O)O)ccc32)CC(C)(C)C1,"InChI=1S/C26H30F3N3O3/c1-16-12-19(15-25(2,3)14-16)32-22-10-4-17(5-11-23(33)34)13-21(22)31-24(32)30-18-6-8-20(9-7-18)35-26(27,28)29/h4,6-10,13,16,19H,5,11-12,14-15H2,1-3H3,(H,30,31)(H,33,34)",RNMAUIMMNAHKQR-UHFFFAOYSA-N,bay-1436032,Phase 1,isocitrate dehydrogenase inhibitor,,,
CC1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3cc[nH]n3)c2n1,"InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)",YBXRSCXGRPSTMW-UHFFFAOYSA-N,bay-1895344,Phase 1,ATR kinase inhibitor,,,
CCn1c(CO)nn(-c2cc(OC(C)C(F)(F)F)c(C(=O)Nc3c(F)cccc3Cl)cc2F)c1=O,"InChI=1S/C21H18ClF5N4O4/c1-3-30-17(9-32)29-31(20(30)34)15-8-16(35-10(2)21(25,26)27)11(7-14(15)24)19(33)28-18-12(22)5-4-6-13(18)23/h4-8,10,32H,3,9H2,1-2H3,(H,28,33)",KNVJMHHAXCPZHF-UHFFFAOYSA-N,bay-2402234,Phase 1,dihydroorotate dehydrogenase inhibitor,,,
N=c1[nH]c(-c2nn(Cc3ccccc3F)c3ncccc23)ncc1C1CC1,"InChI=1S/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)",ATOAHNRJAXSBOR-UHFFFAOYSA-N,bay-41-2272,Preclinical,guanylyl cyclase activator,GUCY1A3|GUCY1B3,,
N#Cc1c(SCC(N)=O)[nH]c(=N)c(C#N)c1-c1ccc(OCC2CC2)cc1,"InChI=1S/C19H17N5O2S/c20-7-14-17(12-3-5-13(6-4-12)26-9-11-1-2-11)15(8-21)19(24-18(14)23)27-10-16(22)25/h3-6,11H,1-2,9-10H2,(H2,22,25)(H2,23,24)",ZTYHZMAZUWOXNC-UHFFFAOYSA-N,bay-60-6583,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc(Cc2nc(=O)c3c(C)nc(C(CCCc4ccccc4)C(C)O)n3[nH]2)cc1OC,"InChI=1S/C27H32N4O4/c1-17-25-27(33)29-24(16-20-13-14-22(34-3)23(15-20)35-4)30-31(25)26(28-17)21(18(2)32)12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,18,21,32H,8,11-12,16H2,1-4H3,(H,29,30,33)",MYTWFJKBZGMYCS-UHFFFAOYSA-N,bay-60-7550,Preclinical,phosphodiesterase inhibitor,PDE2A,,
COc1ccc(-c2cc3[nH]ccn3c(=Nc3ncccc3C(N)=O)n2)cc1OC,"InChI=1S/C20H18N6O3/c1-28-15-6-5-12(10-16(15)29-2)14-11-17-22-8-9-26(17)20(24-14)25-19-13(18(21)27)4-3-7-23-19/h3-11,22H,1-2H3,(H2,21,27)",OTRNSBDYYOXZBG-UHFFFAOYSA-N,bay-61-3606,Preclinical,SYK inhibitor,SYK,,
O=C(Nc1ccccc1C(=O)O)c1cc(S(=O)(=O)c2ccccc2)ccc1Cl,"InChI=1S/C20H14ClNO5S/c21-17-11-10-14(28(26,27)13-6-2-1-3-7-13)12-16(17)19(23)22-18-9-5-4-8-15(18)20(24)25/h1-12H,(H,22,23)(H,24,25)",CLAUJSRBKSRTGQ-UHFFFAOYSA-N,bay-8002,Preclinical,monocarboxylate transporter inhibitor,,,
NC(CC(F)C(=O)O)C(=O)O,"InChI=1S/C5H8FNO4/c6-2(4(8)9)1-3(7)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)",JPSHPWJJSVEEAX-UHFFFAOYSA-N,bay-85-8050,Phase 1,,,,
Cc1cc(-c2nc(-c3ccc(OC(F)(F)F)cc3)no2)nn1Cc1ccnc(N2CCN(C3CC3)CC2)c1,"InChI=1S/C26H26F3N7O2/c1-17-14-22(25-31-24(33-38-25)19-2-6-21(7-3-19)37-26(27,28)29)32-36(17)16-18-8-9-30-23(15-18)35-12-10-34(11-13-35)20-4-5-20/h2-3,6-9,14-15,20H,4-5,10-13,16H2,1H3",CDJNNOJINJAXPV-UHFFFAOYSA-N,bay-87-2243,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,
COC(=O)C1=C(C)N=C(C)C([N+](=O)[O-])C1c1ccccc1C(F)(F)F,"InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13-14H,1-3H3",HLQRHTWAVXFDBJ-UHFFFAOYSA-N,bay-k-8644-(+/-),Preclinical,L-type calcium channel blocker,,,
COC(=O)C1=C(C)N=C(C)C([N+](=O)[O-])C1c1ccccc1C(F)(F)F,"InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13-14H,1-3H3",HLQRHTWAVXFDBJ-UHFFFAOYSA-N,bay-k-8644-(s)-(-),Preclinical,L-type calcium channel activator,CACNA1C,,
COC(=O)C1=C(C)N(C)C(C)=C(C(=O)OC)C1c1ccc(C(F)(F)F)cc1,"InChI=1S/C19H20F3NO4/c1-10-14(17(24)26-4)16(15(18(25)27-5)11(2)23(10)3)12-6-8-13(9-7-12)19(20,21)22/h6-9,16H,1-5H3",AVFYPHPSIBAAME-UHFFFAOYSA-N,bay-w-9798,Phase 2,antioxidant,,,
NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1,"InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)",JBGYKRAZYDNCNV-UHFFFAOYSA-N,bay1125976,Phase 1,AKT inhibitor,,,
COc1ccc(Oc2cc(=NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3[nH]2)c(F)c1F,"InChI=1S/C27H24F5N5O3/c1-14-11-15(3-6-17(14)26(38)35-16-4-5-16)19-13-34-25-18(33-10-9-27(30,31)32)12-22(36-37(19)25)40-21-8-7-20(39-2)23(28)24(21)29/h3,6-8,11-13,16,36H,4-5,9-10H2,1-2H3,(H,35,38)",MENQSBGNBJBPAP-UHFFFAOYSA-N,bay1217389,Phase 1,kinase inhibitor,,,
Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,"InChI=1S/C20H19N7/c1-25-12-16(10-23-25)7-8-27-14-22-19(18-11-24-26(2)13-18)20(27)17-5-3-15(9-21)4-6-17/h3-6,10-14H,7-8H2,1-2H3",RRZVGDGTWNQAPW-UHFFFAOYSA-N,baz2-icr,Preclinical,bromodomain inhibitor,ZNF215,,
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,"InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3",UCJGJABZCDBEDK-UHFFFAOYSA-N,bazedoxifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|endocrinology,osteoporosis|menopause
N=C(N)SCc1ccc(B(O)O)cc1,"InChI=1S/C8H11BN2O2S/c10-8(11)14-5-6-1-3-7(4-2-6)9(12)13/h1-4,12-13H,5H2,(H3,10,11)",KDQVMGQHPAKJAN-UHFFFAOYSA-N,bc-11,Preclinical,urokinase inhibitor,PLAU,,
Cc1oc2[nH]c3c(c(=NC(=O)CN4CCCC4=O)c2c1C)CCCC3,"InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23)",PSPGQHXMUKWNDI-UHFFFAOYSA-N,bci-540,Phase 2,glutamate receptor agonist,,,
CC(C)(C)c1ccc(NC(=O)N2CCN(c3ncccc3Cl)CC2)cc1,"InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)",ROGUAPYLUCHQGK-UHFFFAOYSA-N,bctc,Preclinical,TRPV antagonist,TRPV1,,
N=C(N)c1cc2ccc(OC(=O)c3cccs3)cc2s1,"InChI=1S/C14H10N2O2S2/c15-13(16)12-6-8-3-4-9(7-11(8)20-12)18-14(17)10-2-1-5-19-10/h1-7H,(H3,15,16)",OTGQTQBPQCRNRG-UHFFFAOYSA-N,bcx-1470,Phase 1,complement inhibitor,CFD,,
N=C(N)c1cc2ccc(OC(=O)c3cccs3)cc2s1,"InChI=1S/C14H10N2O2S2/c15-13(16)12-6-8-3-4-9(7-11(8)20-12)18-14(17)10-2-1-5-19-10/h1-7H,(H3,15,16)",OTGQTQBPQCRNRG-UHFFFAOYSA-N,bcx-1470,Phase 1,serine protease inhibitor,CFD,,
CN(CCc1ccc(Cl)c(Cl)c1)CCN1CCCC1,"InChI=1S/C15H22Cl2N2/c1-18(10-11-19-7-2-3-8-19)9-6-13-4-5-14(16)15(17)12-13/h4-5,12H,2-3,6-11H2,1H3",ASGIQUHBAVIOTI-UHFFFAOYSA-N,bd-1008,Preclinical,sigma receptor antagonist,,,
CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,"InChI=1S/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3",MGVRNMUKTZOQOW-UHFFFAOYSA-N,bd-1047,Preclinical,adrenergic receptor antagonist,SIGMAR1,,
CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,"InChI=1S/C13H18Cl2N2/c1-16-6-8-17(9-7-16)5-4-11-2-3-12(14)13(15)10-11/h2-3,10H,4-9H2,1H3",SUIZRDJCBVPASY-UHFFFAOYSA-N,bd-1063,Preclinical,sigma receptor antagonist,SIGMAR1,,
O=C1c2ccccc2CCC1CNCCc1ccc(O)cc1,"InChI=1S/C19H21NO2/c21-17-9-5-14(6-10-17)11-12-20-13-16-8-7-15-3-1-2-4-18(15)19(16)22/h1-6,9-10,16,20-21H,7-8,11-13H2",PZZOEXPDTYIBPI-UHFFFAOYSA-N,be-2254,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CN=c1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(O)=NO)cn4)cc3n2)c[nH]1,"InChI=1S/C23H25N9O3S/c1-24-18-4-3-14(10-25-18)20-28-17-9-16(36-19(17)21(29-20)32-5-7-35-8-6-32)13-31(2)23-26-11-15(12-27-23)22(33)30-34/h3-4,9-12,34H,5-8,13H2,1-2H3,(H,24,25)(H,30,33)",TWJZFXHSPBBPNI-UHFFFAOYSA-N,bebt-908,Preclinical,PI3K inhibitor,,,
O=C(CCCl)NCc1ccccc1,"InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13)",JPYQFYIEOUVJDU-UHFFFAOYSA-N,beclamide,Launched,anticonvulsant,,neurology/psychiatry,sedative|seizures
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO,"InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h4,6-7,12,15-17,24,26,28H,5,8-11H2,1-3H3",CVZOZPYAZUVIDT-UHFFFAOYSA-N,beclomethasone,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
CCC(=O)OCC(=O)C1(OC(=O)CC)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC21C,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h8,10-11,16,19-21,31H,6-7,9,12-15H2,1-5H3",IBIIDGIPJPTFBZ-UHFFFAOYSA-N,beclomethasone-dipropionate,Launched,glucocorticoid receptor agonist,GPR97|NR3C1,allergy,allergic rhinitis
COc1nc2ccc(Br)cc2cc1C(c1ccccc1)C(O)(CCN(C)C)c1cccc2ccccc12,"InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3",QUIJNHUBAXPXFS-UHFFFAOYSA-N,bedaquiline,Launched,ATPase inhibitor,,infectious disease,tuberculosis
O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1,"InChI=1S/C20H20N2O2/c23-20(19-14-17-8-4-5-9-18(17)24-19)22-12-10-21(11-13-22)15-16-6-2-1-3-7-16/h1-9,14H,10-13,15H2",SRIJFPBZWUFLFD-UHFFFAOYSA-N,befuraline,Phase 2,,,,
O=S(=O)(NC(CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1,"InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2",PSXOKXJMVRSARX-UHFFFAOYSA-N,begacestat,Phase 1,gamma secretase inhibitor,PSEN1,,
NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)C(O)C1O,"InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2",SKKLOUVUUNMCJE-UHFFFAOYSA-N,bekanamycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
O=S(=O)(Nc1ccccc1)c1cccc(C=CC(O)=NO)c1,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)",NCNRHFGMJRPRSK-UHFFFAOYSA-N,belinostat,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
CC(C)NC(=O)C1CCC(n2c(=NC(=O)c3ccc(F)cc3)[nH]c3ccc(CN4CCC(C(C)(C)O)CC4)cc32)CC1,"InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)",WSTUJEXAPHIEIM-UHFFFAOYSA-N,belizatinib,Preclinical,receptor tyrosine protein kinase inhibitor,,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,"InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3",LNHWXBUNXOXMRL-UHFFFAOYSA-N,belotecan,Phase 3,topoisomerase inhibitor,,,
CCC1(C)CC(=O)NC(=O)C1,"InChI=1S/C8H13NO2/c1-3-8(2)4-6(10)9-7(11)5-8/h3-5H2,1-2H3,(H,9,10,11)",ORRZGUBHBVWWOP-UHFFFAOYSA-N,bemegride,Launched,chemoreceptor agonist,GABRA1,critical care,poison antidote
CCCCC(CC)COc1ccc(-c2nc(-c3ccc(OC)cc3)nc(-c3ccc(OCC(CC)CCCC)cc3O)n2)c(O)c1,"InChI=1S/C38H49N3O5/c1-6-10-12-26(8-3)24-45-30-18-20-32(34(42)22-30)37-39-36(28-14-16-29(44-5)17-15-28)40-38(41-37)33-21-19-31(23-35(33)43)46-25-27(9-4)13-11-7-2/h14-23,26-27,42-43H,6-13,24-25H2,1-5H3",XVAMCHGMPYWHNL-UHFFFAOYSA-N,bemotrizinol,Launched,,,dermatology,sunscreen lotion
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,"InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)",HYHMLYSLQUKXKP-UHFFFAOYSA-N,bempedoic-acid,Launched,AMPK inhibitor,ACLY,,
CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,"InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3",IVQOFBKHQCTVQV-UHFFFAOYSA-N,benactyzine,Preclinical,butyrylcholinesterase inhibitor,,,
O=C(O)c1ccc(NC2OC(CO)C(O)C(O)C2O)cc1,"InChI=1S/C13H17NO7/c15-5-8-9(16)10(17)11(18)12(21-8)14-7-3-1-6(2-4-7)13(19)20/h1-4,8-12,14-18H,5H2,(H,19,20)",VXMVXDITZWJXJN-UHFFFAOYSA-N,benaxibine,Phase 1,,,,
CCOC(=O)C(CCc1ccccc1)NC1CCc2ccccc2N(CC(=O)O)C1=O,"InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)",XPCFTKFZXHTYIP-UHFFFAOYSA-N,benazepril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,"InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)",YTKUWDBFDASYHO-UHFFFAOYSA-N,bendamustine,Launched,DNA inhibitor,,hematologic malignancy,chronic lymphocytic leukemia (CLL)|non-Hodgkin lymphoma (NHL)
O=C(O)COc1nn(Cc2ccccc2)c2ccccc12,"InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)",BYFMCKSPFYVMOU-UHFFFAOYSA-N,bendazac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
c1ccc(Cc2nc3ccccc3[nH]2)cc1,"InChI=1S/C14H12N2/c1-2-6-11(7-3-1)10-14-15-12-8-4-5-9-13(12)16-14/h1-9H,10H2,(H,15,16)",YTLQFZVCLXFFRK-UHFFFAOYSA-N,bendazol,Launched,nitric oxide synthase stimulant,,,
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O,"InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)",HDWIHXWEUNVBIY-UHFFFAOYSA-N,bendroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,SLC12A1|SLC12A3,cardiology,hypertension
c1ccc(CCNCc2ccccc2)cc1,"InChI=1S/C15H17N/c1-3-7-14(8-4-1)11-12-16-13-15-9-5-2-6-10-15/h1-10,16H,11-13H2",UPABQMWFWCMOFV-UHFFFAOYSA-N,benethamine,Preclinical,,,,
CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,"InChI=1S/C19H20F3NO2/c1-14(12-15-6-5-9-17(13-15)19(20,21)22)23-10-11-25-18(24)16-7-3-2-4-8-16/h2-9,13-14,23H,10-12H2,1H3",CJAVTWRYCDNHSM-UHFFFAOYSA-N,benfluorex,Withdrawn,gluconeogenesis inhibitor,HMGCR,,
CCCCN(CC)c1c([N+](=O)[O-])cc(C(F)(F)F)cc1[N+](=O)[O-],"InChI=1S/C13H16F3N3O4/c1-3-5-6-17(4-2)12-10(18(20)21)7-9(13(14,15)16)8-11(12)19(22)23/h7-8H,3-6H2,1-2H3",SMDHCQAYESWHAE-UHFFFAOYSA-N,benfluralin,Phase 3,,CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1,,
CC(=C(CCO[PH](=O)(=O)O)SC(=O)c1ccccc1)N(C=O)Cc1c[nH]c(C)nc1=N,"InChI=1S/C19H22N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H,26,27,28)",RBLDDFCEKGJPKQ-UHFFFAOYSA-N,benfotiamine,Launched,antioxidant,AGER,rheumatology,lumbago
COC(=O)C1=C(C)N=C(C)C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,25-26H,8,13-14,16-17H2,1-3H3",JEEWYTNVHFSNBZ-UHFFFAOYSA-N,benidipine,Launched,calcium channel blocker,CACNA1C|CACNA1G,cardiology,hypertension
O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,"InChI=1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)",FEBOTPHFXYHVPL-UHFFFAOYSA-N,benperidol,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia
CC(COc1ccccc1Cc1ccccc1)N1CCCCC1,"InChI=1S/C21H27NO/c1-18(22-14-8-3-9-15-22)17-23-21-13-7-6-12-20(21)16-19-10-4-2-5-11-19/h2,4-7,10-13,18H,3,8-9,14-17H2,1H3",JTUQXGZRVLWBCR-UHFFFAOYSA-N,benproperine,Launched,antitussive,SCN5A,pulmonary,cough suppressant
NC(C=O)C(O)NNCc1ccc(O)c(O)c1O,"InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,4,6,10,12-13,15-18H,3,11H2",RFEZFSCPUMTOGS-UHFFFAOYSA-N,benserazide,Launched,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease
O=C(O)c1ccc(NC(=O)C(Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1,"InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)",SPPTWHFVYKCNNK-UHFFFAOYSA-N,bentiromide,Launched,,HPN,gastroenterology,pancreas diagnostic agent
O=C(NCC(O)=NO)c1ccc(Cl)cc1,"InChI=1S/C9H9ClN2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(13)12-15/h1-4,15H,5H2,(H,11,14)(H,12,13)",JFZGBMJPJZDNNT-UHFFFAOYSA-N,benurestat,Phase 1,urease inhibitor,,,
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,"InChI=1S/C22H40N/c1-4-5-6-7-8-9-10-11-12-13-17-20-23(2,3)21-22-18-15-14-16-19-22/h14-16,18-19H,4-13,17,20-21H2,1-3H3/q+1",VVZBFOKBSDGVGZ-UHFFFAOYSA-N,benzalkonium,Launched,cationic surfactant,,dermatology,abrasions|superficial cuts
N=C(NCc1ccccc1)NC(=O)c1nc(Cl)c(=N)[nH]c1N,"InChI=1S/C13H14ClN7O/c14-9-11(16)20-10(15)8(19-9)12(22)21-13(17)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,15,16,20)(H3,17,18,21,22)",KXDROGADUISDGY-UHFFFAOYSA-N,benzamil,Phase 2,sodium channel blocker,ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1,,
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,"InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3",WHQCHUCQKNIQEC-UHFFFAOYSA-N,benzbromarone,Launched,chloride channel blocker,ABCC1,rheumatology,gout
Cc1ccc(C)c(C(O)CNC(C)C)c1,"InChI=1S/C13H21NO/c1-9(2)14-8-13(15)12-7-10(3)5-6-11(12)4/h5-7,9,13-15H,8H2,1-4H3",PHFWPIKQCFQPJY-UHFFFAOYSA-N,"benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]",Preclinical,,,,
CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,"InChI=1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1",SIYLLGKDQZGJHK-UHFFFAOYSA-N,benzethonium,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic
O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,"InChI=1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)",CULUWZNBISUWAS-UHFFFAOYSA-N,benznidazole,Launched,DNA synthesis inhibitor,,infectious disease,Chagas disease
S=c1[nH]c2ccccc2s1,"InChI=1S/C7H5NS2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4H,(H,8,9)",YXIWHUQXZSMYRE-UHFFFAOYSA-N,benzo[d]thiazole-2(3h)-thione,Phase 1,,,,
CCOC(=O)c1ccc(N)cc1,"InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3",BLFLLBZGZJTVJG-UHFFFAOYSA-N,benzocaine,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic
O=C(OC1CN2CCC1CC2)c1ccccc1,"InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2",AHKAOMZZTQULDS-UHFFFAOYSA-N,benzoclidine,Preclinical,,,,
O=C(O)Cc1ccc(OCc2ccccc2)c(Cl)c1,"InChI=1S/C15H13ClO3/c16-13-8-12(9-15(17)18)6-7-14(13)19-10-11-4-2-1-3-5-11/h1-8H,9-10H2,(H,17,18)",DFHBBMJTBBLQSA-UHFFFAOYSA-N,benzofenac,Phase 1,,,,
O=C(O)c1ccccc1,"InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)",WPYMKLBDIGXBTP-UHFFFAOYSA-N,benzoic-acid,Launched,food preservative,DAO|HRSP12|PRDX5|RAB9A,infectious disease,tinea pedis
O=C(c1ccccc1)C(O)c1ccccc1,"InChI=1S/C14H12O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13,15H",ISAOCJYIOMOJEB-UHFFFAOYSA-N,benzoin,Preclinical,,CES1,,
CCCCNc1ccc(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)cc1,"InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3",MAFMQEKGGFWBAB-UHFFFAOYSA-N,benzonatate,Launched,local anesthetic,SCN5A,pulmonary,cough suppressant
CC[N+](CC)(CCC=Nc1cc(O)c(NCCC[N+](CC)(CC)Cc2ccccc2)cc1O)Cc1ccccc1,"InChI=1S/C34H48N4O2/c1-5-37(6-2,27-29-17-11-9-12-18-29)23-15-21-35-31-25-34(40)32(26-33(31)39)36-22-16-24-38(7-3,8-4)28-30-19-13-10-14-20-30/h9-14,17-21,25-26,36H,5-8,15-16,22-24,27-28H2,1-4H3/p+2",LJJADZXWJYRULW-UHFFFAOYSA-P,benzoquinonium-dibromide,Preclinical,cholinergic receptor antagonist,CHRNA1,,
O=C(NC(Cc1c[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,"InChI=1S/C18H15ClN2O3/c19-13-7-5-11(6-8-13)17(22)21-16(18(23)24)9-12-10-20-15-4-2-1-3-14(12)15/h1-8,10,16,20H,9H2,(H,21,22)(H,23,24)",QJERBBQXOMUURJ-UHFFFAOYSA-N,benzotript,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,
O=C(Oc1cccc2cccnc12)c1ccccc1,InChI=1S/C16H11NO2/c18-16(13-6-2-1-3-7-13)19-14-10-4-8-12-9-5-11-17-15(12)14/h1-11H,BHKPHCKISVSDGV-UHFFFAOYSA-N,benzoxiquine,Preclinical,antiinfective drug,,,
O=C(OOC(=O)c1ccccc1)c1ccccc1,InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H,OMPJBNCRMGITSC-UHFFFAOYSA-N,benzoyl-peroxide,Launched,oxidizing agent,,dermatology,acne vulgaris (AV)
O=C(Nc1ccc(C(=O)O)c(O)c1)c1ccccc1,"InChI=1S/C14H11NO4/c16-12-8-10(6-7-11(12)14(18)19)15-13(17)9-4-2-1-3-5-9/h1-8,16H,(H,15,17)(H,18,19)",GNZCRYWFWKFIDM-UHFFFAOYSA-N,benzoylpas,Preclinical,,,,
NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O,"InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)",NDTSRXAMMQDVSW-UHFFFAOYSA-N,benzthiazide,Launched,carbonic anhydrase inhibitor,CA2,cardiology,hypertension|edema
CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,"InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3",GIJXKZJWITVLHI-UHFFFAOYSA-N,benztropine-mesylate,Launched,acetylcholine receptor antagonist,CHRM1|HRH1|SLC6A3,neurology/psychiatry,extrapyramidal symptoms (EPS)|Parkinson's Disease
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,"InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3",CNBGNNVCVSKAQZ-UHFFFAOYSA-N,benzydamine,Launched,prostanoid receptor antagonist,,dental|otolaryngology,mouth inflammation|throat inflammation
OCc1ccccc1,"InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2",WVDDGKGOMKODPV-UHFFFAOYSA-N,benzyl-alcohol,Launched,local anesthetic,,infectious disease,virus herpes simplex (HSV)
O=C(OCc1ccccc1)c1ccccc1,"InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2",SESFRYSPDFLNCH-UHFFFAOYSA-N,benzyl-benzoate,Launched,lipase inhibitor,LIPE,allergy,sweet itch
S=C=NCc1ccccc1,"InChI=1S/C8H7NS/c10-7-9-6-8-4-2-1-3-5-8/h1-5H,6H2",MDKCFLQDBWCQCV-UHFFFAOYSA-N,benzyl-isothiocyanate,Preclinical,methylazoxymethanol acetate inhibitor,,,
CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,"InChI=1S/C25H46N/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23-26(2,3)24-25-21-18-17-19-22-25/h17-19,21-22H,4-16,20,23-24H2,1-3H3/q+1",QDYLMAYUEZBUFO-UHFFFAOYSA-N,benzyldimethylhexadecylammonium,Preclinical,cationic surfactant,,,
CCCCCCCC[N+](C)(C)Cc1ccccc1,"InChI=1S/C17H30N/c1-4-5-6-7-8-12-15-18(2,3)16-17-13-10-9-11-14-17/h9-11,13-14H,4-8,12,15-16H2,1-3H3/q+1",SHFLYPPECXRCFO-UHFFFAOYSA-N,benzyldimethyloctylammonium,Preclinical,,,,
CC1(C)SC2C(NC(=O)Cc3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)",JGSARLDLIJGVTE-UHFFFAOYSA-N,benzylpenicillin,Launched,penicillin binding protein inhibitor,,infectious disease,celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia
C[N+](C)(CCOc1ccccc1)Cc1ccccc1,"InChI=1S/C17H22NO/c1-18(2,15-16-9-5-3-6-10-16)13-14-19-17-11-7-4-8-12-17/h3-12H,13-15H2,1-2H3/q+1",AVWWVJUMXRXPNF-UHFFFAOYSA-N,bephenium-hydroxynaphthoate,Launched,anthelmintic agent,,infectious disease,ascariasis
O=C(O)CCCN1CCC(OC(c2ccc(Cl)cc2)c2ccccn2)CC1,"InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)",YWGDOWXRIALTES-UHFFFAOYSA-N,bepotastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,"InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3",UIEATEWHFDRYRU-UHFFFAOYSA-N,bepridil,Launched,calcium channel blocker,KCNQ4,cardiology,angina pectoris
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,"InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1",YBHILYKTIRIUTE-UHFFFAOYSA-N,berberine,Launched,LDL receptor activator,LDLR,,
COc1c2ccoc2cc2oc(=O)ccc12,"InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3",BGEBZHIAGXMEMV-UHFFFAOYSA-N,bergapten,Phase 3,,,,
COc1c(O)cc2c(c1O)C1OC(CO)C(O)C(O)C1OC2=O,"InChI=1S/C14H16O9/c1-21-11-5(16)2-4-7(9(11)18)12-13(23-14(4)20)10(19)8(17)6(3-15)22-12/h2,6,8,10,12-13,15-19H,3H2,1H3",YWJXCIXBAKGUKZ-UHFFFAOYSA-N,bergenin,Preclinical,interleukin inhibitor,IL1B|TNF,,
NC1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,"InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)",QFFGVLORLPOAEC-UHFFFAOYSA-N,besifloxacin,Launched,bacterial DNA gyrase inhibitor,,ophthalmology,conjunctivitis
Cc1nnc(CC2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc32)o1,"InChI=1S/C22H18ClN5O/c1-13-24-27-22-16(12-21-26-25-14(2)29-21)11-19(15-7-9-17(23)10-8-15)18-5-3-4-6-20(18)28(13)22/h3-11,16H,12H2,1-2H3",AGYIAWHWIUZNSD-UHFFFAOYSA-N,bet-bay-002,Preclinical,bromodomain inhibitor,,,
Oc1cccc(N=c2ccc(=Nc3cccc(O)c3)[nH][nH]2)c1,"InChI=1S/C16H14N4O2/c21-13-5-1-3-11(9-13)17-15-7-8-16(20-19-15)18-12-4-2-6-14(22)10-12/h1-10,21-22H,(H,17,19)(H,18,20)",GYNDFOLSPPBBIK-UHFFFAOYSA-N,beta-amyloid-synthesis-inhibitor,Preclinical,beta amyloid synthesis inhibitor,APP,,
CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,"InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3",OENHQHLEOONYIE-UHFFFAOYSA-N,beta-carotene,Launched,,,,
CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc12,"InChI=1S/C16H16N2O2/c1-2-3-8-20-16(19)14-9-12-11-6-4-5-7-13(11)18-15(12)10-17-14/h4-7,9-10,18H,2-3,8H2,1H3",WGNGIELOOKACSB-UHFFFAOYSA-N,beta-ccb,Launched,benzodiazepine receptor ligand,GABRA1|GABRG2,,
C=CC1(C)CCC(C(=C)C)CC1C(=C)C,"InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3",OPFTUNCRGUEPRZ-UHFFFAOYSA-N,beta-elemene,Launched,apoptosis stimulant,MMP2|MMP9,,
COC(=O)CCC(=O)N=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5,"InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-5,14,18,23,28,31H,2-3,6-13H2,1H3",FFGCTXZVUKPBCR-UHFFFAOYSA-N,beta-funaltrexamine,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
O=[PH](=O)(O)OC(CO)CO,"InChI=1S/C3H8O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H,6,7,8)",QLCHHDJGGKVFCC-UHFFFAOYSA-N,beta-glycerophosphoric-acid,Preclinical,,,,
CC(C)(O)CC(=O)O,"InChI=1S/C5H10O3/c1-5(2,8)3-4(6)7/h8H,3H2,1-2H3,(H,6,7)",AXFYFNCPONWUHW-UHFFFAOYSA-N,beta-hydroxy-beta-methylbutyrate,Launched,protein synthesis stimulant,MTOR,,
CC(O)CC(=O)O,"InChI=1S/C4H8O3/c1-3(5)2-4(6)7/h3,5H,2H2,1H3,(H,6,7)",WHBMMWSBFZVSSR-UHFFFAOYSA-N,beta-hydroxybutyrate,Phase 1,,HCAR2,,
CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O,"InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3",QZPQTZZNNJUOLS-UHFFFAOYSA-N,beta-lapachone,Phase 2,topoisomerase inhibitor,TOP1,,
Oc1ccc2ccccc2c1,"InChI=1S/C10H8O/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7,11H",JWAZRIHNYRIHIV-UHFFFAOYSA-N,beta-naphthol,Preclinical,,,,
CNCCc1ccccn1,"InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3",UUQMNUMQCIQDMZ-UHFFFAOYSA-N,betahistine,Launched,histamine receptor agonist,HRH1|HRH3,neurology/psychiatry,Meniere's disease
CNCCc1ccccn1,"InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3",UUQMNUMQCIQDMZ-UHFFFAOYSA-N,betahistine,Launched,histamine receptor antagonist,HRH1|HRH3,neurology/psychiatry,Meniere's disease
C[N+](C)(C)CC(=O)O,"InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3/p+1",KWIUHFFTVRNATP-UHFFFAOYSA-O,betaine,Launched,nitric oxide donor,,metabolism,homocystinuria
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h4,6-7,12,15-17,24,26,28H,5,8-11H2,1-3H3",GJFCONYVAUNLKB-UHFFFAOYSA-N,betamethasone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC(=O)OCC(=O)C1(O)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h5,7-8,13,17-19,28,30H,6,9-12H2,1-4H3",PPDWQLSRZNCMRA-UHFFFAOYSA-N,betamethasone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)OC1(C(=O)COC(=O)CC)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C29H39FO7/c1-6-8-25(35)37-29(23(33)16-36-24(34)7-2)17(3)13-21-20-10-9-18-14-19(31)11-12-26(18,4)28(20,30)22(32)15-27(21,29)5/h9,11-12,17,20-22,32H,6-8,10,13-16H2,1-5H3",OGRGMWYPJCHTPR-UHFFFAOYSA-N,betamethasone-butyrate-propionate,Launched,,,rheumatology,rheumatoid arthritis
CCC(=O)OCC(=O)C1(OC(=O)CC)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h8,10-11,16,19-21,31H,6-7,9,12-15H2,1-5H3",JDUYIZFMBRCCHQ-UHFFFAOYSA-N,betamethasone-dipropionate,Launched,anti-inflammatory agent,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO[PH](=O)(=O)O,"InChI=1S/C22H29FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h4,6-7,12,15-17,25,27H,5,8-11H2,1-3H3,(H,28,29,30)",OMERPEOHSFCCJI-UHFFFAOYSA-N,betamethasone-phosphate,Launched,,,rheumatology,rheumatoid arthritis
CCCCC(=O)OC1(C(=O)CO)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h8,10-11,16,19-21,29,31H,5-7,9,12-15H2,1-4H3",CKHSUZOTJQWRKZ-UHFFFAOYSA-N,betamethasone-valerate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
O=C(O)CCNC(=O)c1ccccc1,"InChI=1S/C10H11NO3/c12-9(13)6-7-11-10(14)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,11,14)(H,12,13)",CWXYHOHYCJXYFQ-UHFFFAOYSA-N,betamipron,Launched,panipenem uptake inhibitor,,nephrology,renal toxicity
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,"InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3",NWIUTZDMDHAVTP-UHFFFAOYSA-N,betaxolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
NCCc1cc[nH]n1,"InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)",JXDFEQONERDKSS-UHFFFAOYSA-N,betazole,Launched,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic
CC(C[N+](C)(C)C)OC(N)=O,"InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1",NZUPCNDJBJXXRF-UHFFFAOYSA-O,bethanechol,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,urology,urinary retention
CC[S+]([O-])c1nc(-c2cccc(OCc3ccccc3)c2)cc(C(F)(F)F)n1,"InChI=1S/C20H17F3N2O2S/c1-2-28(26)19-24-17(12-18(25-19)20(21,22)23)15-9-6-10-16(11-15)27-13-14-7-4-3-5-8-14/h3-12H,2,13H2,1H3",NTDFYGSSDDMNHI-UHFFFAOYSA-N,betp,Preclinical,GLP receptor positive allosteric modulator,GLP1R,,
COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)N=c2ccc(Cl)c[nH]2)c1,"InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)",XHOLNRLADUSQLD-UHFFFAOYSA-N,betrixaban,Launched,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT)
C=C(C)C1CCC2(C(=O)O)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C12,"InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)",QGJZLNKBHJESQX-UHFFFAOYSA-N,betulinic-acid,Phase 1/Phase 2,apoptosis stimulant,GPBAR1,,
C=C(C)C1CCC2(C(=O)O)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C12,"InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)",QGJZLNKBHJESQX-UHFFFAOYSA-N,betulinic-acid,Phase 1/Phase 2,NFkB pathway inhibitor,GPBAR1,,
COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,"InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3",HXLAFSUPPDYFEO-UHFFFAOYSA-N,bevantolol,Launched,adrenergic receptor antagonist,,cardiology,angina pectoris|hypertension
COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,"InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25)",ZGCYVRNZWGUXNQ-UHFFFAOYSA-N,bevenopran,Phase 1,opioid receptor antagonist,,,
C=C(C)C1CCC2(C(=O)O)CCC3(C)C(CCC4C5(C)CCC(OC(=O)CC(C)(C)C(=O)O)C(C)(C)C5CCC43C)C12,"InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)",YJEJKUQEXFSVCJ-UHFFFAOYSA-N,bevirimat-dimeglumine,Phase 2,HIV capsid assembly inhibitor,,,
OCC1OC(c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)C(O)C(O)C1O,"InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2",BTCRKOKVYTVOLU-UHFFFAOYSA-N,bexagliflozin,Phase 3,solute carrier family member inhibitor,,,
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,"InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)",NAVMQTYZDKMPEU-UHFFFAOYSA-N,bexarotene,Launched,retinoid receptor agonist,RXRA|RXRB|RXRG,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,"InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)",IIBYAHWJQTYFKB-UHFFFAOYSA-N,bezafibrate,Launched,PPAR receptor agonist,PPARA|PPARD|PPARG,cardiology,cholesterol
O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12,"InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)",JNLSTLQFDDAULK-UHFFFAOYSA-N,bfh772,Phase 2,VEGFR inhibitor,,,
N=C(NOCC(O)CN1CCCCC1)c1cccnc1,"InChI=1S/C14H22N4O2/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17)",MVLOQULXIYSERZ-UHFFFAOYSA-N,bgp-15,Phase 2,PARP inhibitor,,,
COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,"InChI=1S/C28H25F3N6O2/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36/h3-8,13-16,32H,9-12H2,1-2H3",BMMXYEBLEBULND-UHFFFAOYSA-N,bgt226,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CG,,
CC(C)(C)c1cc(O)c(C(C)(C)C)cc1O,"InChI=1S/C14H22O2/c1-13(2,3)9-7-12(16)10(8-11(9)15)14(4,5)6/h7-8,15-16H,1-6H3",JZODKRWQWUWGCD-UHFFFAOYSA-N,bhq,Preclinical,ATPase inhibitor,ATP2A1,,
Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1C(OC(C)(C)C)C(=O)O,"InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)",MIXIIJCBELCMCZ-UHFFFAOYSA-N,bi-224436,Phase 1,HIV integrase inhibitor,,,
CCC1C(=O)N(C)c2c[nH]c(=Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)",XQVVPGYIWAGRNI-UHFFFAOYSA-N,bi-2536,Phase 2,PLK inhibitor,BRD4|PLK1|PLK2|PLK3,,
O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1,"InChI=1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22)",BZTIJCSHNVZMES-UHFFFAOYSA-N,bi-409306,Phase 1,phosphodiesterase inhibitor,,,
O=c1[nH]nc(Sc2ncc([N+](=O)[O-])s2)n1-c1ccc2c(c1)OCCO2,"InChI=1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19)",QFRLDZGQEZCCJZ-UHFFFAOYSA-N,bi-78d3,Preclinical,JNK inhibitor,MAPK8,,
CCNC(=O)C#Cc1ccc2c(C(=Nc3ccc(CN(C)C)cc3)c3ccccc3)c(O)[nH]c2c1,"InChI=1S/C29H28N4O2/c1-4-30-26(34)17-13-20-12-16-24-25(18-20)32-29(35)27(24)28(22-8-6-5-7-9-22)31-23-14-10-21(11-15-23)19-33(2)3/h5-12,14-16,18,32,35H,4,19H2,1-3H3,(H,30,34)",OCUQMWSIGPQEMX-UHFFFAOYSA-N,bi-847325,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC|MAP2K1|MAP2K2,,
CCNC(=O)C#Cc1ccc2c(C(=Nc3ccc(CN(C)C)cc3)c3ccccc3)c(O)[nH]c2c1,"InChI=1S/C29H28N4O2/c1-4-30-26(34)17-13-20-12-16-24-25(18-20)32-29(35)27(24)28(22-8-6-5-7-9-22)31-23-14-10-21(11-15-23)19-33(2)3/h5-12,14-16,18,32,35H,4,19H2,1-3H3,(H,30,34)",OCUQMWSIGPQEMX-UHFFFAOYSA-N,bi-847325,Phase 1,MEK inhibitor,AURKA|AURKB|AURKC|MAP2K1|MAP2K2,,
CC(C)CCN1c2[nH]c(=Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C,"InChI=1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)",DTEKTGDVSARYDS-UHFFFAOYSA-N,bi-d1870,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6,,
CN(C(=O)n1cnc(-c2ccc[n+]([O-])c2)c1)C1CCCCC1,"InChI=1S/C16H20N4O2/c1-18(14-7-3-2-4-8-14)16(21)19-11-15(17-12-19)13-6-5-9-20(22)10-13/h5-6,9-12,14H,2-4,7-8H2,1H3",DOWVMJFBDGWVML-UHFFFAOYSA-N,bia-10-2474,Preclinical,Fatty acid hydrolase inhibitor,,,
CC(O)C1C(=O)N2C(C(=O)O)=C(SC3Cn4cnc[n+]4C3)C(C)C12,"InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/p+1",MRMBZHPJVKCOMA-UHFFFAOYSA-O,biapenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,bacterial septicemia|pneumonia|urinary tract infections
NCCCCC(NC(=O)C(Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1,"InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)",ITIXDWVDFFXNEG-UHFFFAOYSA-N,bibn4096,Phase 2,calcitonin antagonist,CALCA|CALCRL|RAMP1,,
CC(=CC(=O)Nc1ccccc1C(=O)O)c1ccc2ccccc2c1,"InChI=1S/C21H17NO3/c1-14(16-11-10-15-6-2-3-7-17(15)13-16)12-20(23)22-19-9-5-4-8-18(19)21(24)25/h2-13H,1H3,(H,22,23)(H,24,25)",PGFQXGLPJUCTOI-UHFFFAOYSA-N,bibr-1532,Preclinical,telomerase inhibitor,TERT,,
CCN(CC)CC1CCN(c2ncc3[nH]cnc(=Nc4ccc(F)c(Cl)c4)c3n2)CC1,"InChI=1S/C22H27ClFN7/c1-3-30(4-2)13-15-7-9-31(10-8-15)22-25-12-19-20(29-22)21(27-14-26-19)28-16-5-6-18(24)17(23)11-16/h5-6,11-12,14-15H,3-4,7-10,13H2,1-2H3,(H,26,27,28)",JUGSLZCFNSTKBN-UHFFFAOYSA-N,bibu-1361,Preclinical,EGFR inhibitor,EGFR,,
CN1CCC(N=c2nc3c(=Nc4ccc(F)c(Cl)c4)[nH]cnc3c[nH]2)CC1,"InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)",FTFRZXFNZVCRSK-UHFFFAOYSA-N,bibx-1382,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)",LKJPYSCBVHEWIU-UHFFFAOYSA-N,bicalutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
Cc1ccc(C23CNCC2C3)cc1,"InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3",OFYVIGTWSQPCLF-UHFFFAOYSA-N,bicifadine,Phase 3,dopamine reuptake inhibitor,,,
Cc1ccc(C23CNCC2C3)cc1,"InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3",OFYVIGTWSQPCLF-UHFFFAOYSA-N,bicifadine,Phase 3,serotonin receptor antagonist,,,
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1C3CCC(C3)OC1C2,"InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)",SOLUWJRYJLAZCX-UHFFFAOYSA-N,bictegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CN1CCc2cc3c(cc2C1C1OC(=O)c2c1ccc1c2OCO1)OCO3,"InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3",IYGYMKDQCDOMRE-UHFFFAOYSA-N,bicuculline-(+),Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1,,
C[N+]1(C)CCc2cc3c(cc2C1C1OC(=O)c2c1ccc1c2OCO1)OCO3,"InChI=1S/C21H20NO6/c1-22(2)6-5-11-7-15-16(26-9-25-15)8-13(11)18(22)19-12-3-4-14-20(27-10-24-14)17(12)21(23)28-19/h3-4,7-8,18-19H,5-6,9-10H2,1-2H3/q+1",WDIQXKYUSINZME-UHFFFAOYSA-N,bicuculline-methochloride-(-),Preclinical,GABA receptor antagonist,,,
COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2,"InChI=1S/C19H18O9/c1-22-11-4-9(6-20)13(17-15(11)25-7-27-17)14-10(19(21)24-3)5-12(23-2)16-18(14)28-8-26-16/h4-5,20H,6-8H2,1-3H3",KXMTXZACPVCDMH-UHFFFAOYSA-N,bicyclol,Launched,NFkB pathway inhibitor,HSPA1A|HSPB1,infectious disease,hepatitis B|hepatitis C
CNCCCCOc1ccccc1Cc1ccccc1,"InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3",QSQQPMHPCBLLGX-UHFFFAOYSA-N,bifemelane,Launched,acetylcholine release enhancer,MAOA|MAOB,ophthalmology|neurology/psychiatry,glaucoma|senile dementia
COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,"InChI=1S/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3",JMZOMFYRADAWOG-UHFFFAOYSA-N,bifendate,Launched,,,infectious disease,hepatitis B|hepatitis C
c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,"InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H",OCAPBUJLXMYKEJ-UHFFFAOYSA-N,bifonazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris
COc1c(C)cnc(Cn2cnc3c(Cl)[nH]c(=N)nc32)c1C,"InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)",QULDDKSCVCJTPV-UHFFFAOYSA-N,biib021,Phase 2,HSP inhibitor,HSP90AA1,,
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,"InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)",ACCMWZWAEFYUGZ-UHFFFAOYSA-N,bilastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CC(C)(C)C1(O)CC2OC(=O)CC23C(=O)OC2OC(=O)C(O)C231,"InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3",MOLPUWBMSBJXER-UHFFFAOYSA-N,bilobalide,Preclinical,GABA receptor modulator,GLRA1|GLRA2|GLRB|HTR3A|HTR3B,,
CCNC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(O)CCc1ccccc1,"InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)",AQOKCDNYWBIDND-UHFFFAOYSA-N,bimatoprost,Launched,prostanoid receptor agonist,AKR1C3|PTGER1|PTGER3|PTGFR,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
CC(C)n1c(=O)n(C(=O)NC2CC3CCC(C2)N3C)c2ccccc21,"InChI=1S/C19H26N4O2/c1-12(2)22-16-6-4-5-7-17(16)23(19(22)25)18(24)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,12-15H,8-11H2,1-3H3,(H,20,24)",AFOFVIBWSLOHFR-UHFFFAOYSA-N,bimu-8,Preclinical,serotonin receptor agonist,HTR4,,
Cc1c(OCc2cccc(-c3ccc(C(=O)O)cc3)c2)cc2c(c1C)C(=O)C(C1CCCC1)C2,"InChI=1S/C30H30O4/c1-18-19(2)28-25(15-26(29(28)31)22-7-3-4-8-22)16-27(18)34-17-20-6-5-9-24(14-20)21-10-12-23(13-11-21)30(32)33/h5-6,9-14,16,22,26H,3-4,7-8,15,17H2,1-2H3,(H,32,33)",KMKBEESNZAPKMP-UHFFFAOYSA-N,bina,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,
CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(=O)O,"InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)",MTHORRSSURHQPZ-UHFFFAOYSA-N,bindarit,Phase 2,NFkB pathway inhibitor,CCL2|CCL7|CCL8,,
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,binimetinib,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)N2CCCC2C(=O)O)C(C)C)cc1,"InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)",NVVGCQABIHSJSQ-UHFFFAOYSA-N,bio-1211,Phase 2,integrin antagonist,ITGA4|ITGB1,,
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N(C)C(CC(C)C)C(=O)NCCC(NC(=O)C2CCCN2S(=O)(=O)c2cc(Cl)cc(Cl)c2)C(=O)O)cc1,"InChI=1S/C38H46Cl2N6O8S/c1-23(2)18-33(45(4)34(47)19-25-11-13-28(14-12-25)42-38(52)44-30-9-6-5-8-24(30)3)35(48)41-16-15-31(37(50)51)43-36(49)32-10-7-17-46(32)55(53,54)29-21-26(39)20-27(40)22-29/h5-6,8-9,11-14,20-23,31-33H,7,10,15-19H2,1-4H3,(H,41,48)(H,43,49)(H,50,51)(H2,42,44,52)",MNQBPRHHZPXCKZ-UHFFFAOYSA-N,bio-5192,Preclinical,integrin inhibitor,ITGA4|ITGB1,,
O=C(O)CCCCC1SCC2NC(=O)NC21,"InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)",YBJHBAHKTGYVGT-UHFFFAOYSA-N,biotin,Launched,vitamin B,ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6,,
NCc1ccccc1Sc1ccccc1CO,"InChI=1S/C14H15NOS/c15-9-11-5-1-3-7-13(11)17-14-8-4-2-6-12(14)10-16/h1-8,16H,9-10,15H2",HLAFSNJRKZLMPT-UHFFFAOYSA-N,bipenamol,Phase 2,dipeptidyl peptidase inhibitor,CTSC,,
OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,"InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2",YSXKPIUOCJLQIE-UHFFFAOYSA-N,biperiden,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,neurology/psychiatry,Parkinson's Disease
CCC(NC(=O)C(C)NC)C(=O)N1CC(O)CC1Cc1c(-c2[nH]c3cc(F)ccc3c2CC2CC(O)CN2C(=O)C(CC)NC(=O)C(C)NC)[nH]c2cc(F)ccc12,"InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)",PKWRMUKBEYJEIX-UHFFFAOYSA-N,birinapant,Phase 2,XIAP inhibitor,BIRC2|XIAP,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)C1(C)Cc1ccc(Br)cc1,"InChI=1S/C18H15BrCl2N2O2/c1-18(10-11-3-5-12(19)6-4-11)16(24)23(17(25)22(18)2)15-8-13(20)7-14(21)9-15/h3-9H,10H2,1-2H3",FJNJHZQMQRVZEE-UHFFFAOYSA-N,birt-377,Preclinical,lymphocyte function-associated antigen negative modulator,ICAM1,,
Cc1occc(=O)c1O,"InChI=1S/C6H6O3/c1-4-6(8)5(7)2-3-9-4/h2-3,8H,1H3",XPCTZQVDEJYUGT-UHFFFAOYSA-N,bis(maltolato)oxovanadium(iv),Phase 2,tyrosine phosphatase inhibitor,PTPN1,,
CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,"InChI=1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3",KHOITXIGCFIULA-UHFFFAOYSA-N,bisacodyl,Launched,laxative,,gastroenterology,constipation
C(=NNC1=NCCN1)c1c2ccccc2c(C=NNC2=NCCN2)c2ccccc12,"InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)",NJSMWLQOCQIOPE-UHFFFAOYSA-N,bisantrene,Phase 2,topoisomerase inhibitor,,,
Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C25H23N5O2S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32)",DSXXEELGXBCYNQ-UHFFFAOYSA-N,bisindolylmaleimide-ix,Preclinical,PKC inhibitor,AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1,,
O=C(O)C(=O)O,"InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6)",MUBZPKHOEPUJKR-UHFFFAOYSA-N,bismuth-oxalate,Preclinical,,,,
O=C(O)CC(O)(CC(=O)O)C(=O)O,"InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",KRKNYBCHXYNGOX-UHFFFAOYSA-N,bismuth-subcitrate-potassium,Launched,,,gastroenterology,duodenal ulcer disease
O=C(O)c1cc(O)c(O)c(O)c1,"InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)",LNTHITQWFMADLM-UHFFFAOYSA-N,bismuth-subgallate,Launched,nitric oxide synthase inhibitor,NOS1,gastroenterology,internal deoderant
O=C(O)c1ccccc1O,"InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",YGSDEFSMJLZEOE-UHFFFAOYSA-N,bismuth-subsalicylate,Launched,antacid,,gastroenterology,diarrhea
O=S(=O)(O)C(F)(F)F,"InChI=1S/CHF3O3S/c2-1(3,4)8(5,6)7/h(H,5,6,7)",ITMCEJHCFYSIIV-UHFFFAOYSA-N,bismuth(iii)-trifluoromethanesulfonate,Preclinical,direct substitution catalyst,,,
CC(C)(C)CC(C)(C)c1cc(Cc2cc(C(C)(C)CC(C)(C)C)cc(-n3nc4ccccc4n3)c2O)c(O)c(-n2nc3ccccc3n2)c1,"InChI=1S/C41H50N6O2/c1-38(2,3)24-40(7,8)28-20-26(36(48)34(22-28)46-42-30-15-11-12-16-31(30)43-46)19-27-21-29(41(9,10)25-39(4,5)6)23-35(37(27)49)47-44-32-17-13-14-18-33(32)45-47/h11-18,20-23,48-49H,19,24-25H2,1-10H3",FQUNFJULCYSSOP-UHFFFAOYSA-N,bisoctrizole,Phase 2,,,,
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,"InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3",VHYCDWMUTMEGQY-UHFFFAOYSA-N,bisoprolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,"InChI=1S/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H3",IISBACLAFKSPIT-UHFFFAOYSA-N,bisphenol-a,Phase 1,synthetic estrogen,AR|ESR1|ESR2|ESRRG|PPARG,,
Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,"InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H",JFIOVJDNOJYLKP-UHFFFAOYSA-N,bithionol,Withdrawn,autotaxin inhibitor,ESR1|ESR2|MCL1,,
CC(Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F,"InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3",YUUGYIUSCYNSQR-UHFFFAOYSA-N,bitopertin,Phase 3,glycine transporter inhibitor,SLC6A5|SLC6A9,,
S=C=Nc1ccc(N=C=S)cc1,InChI=1S/C8H4N2S2/c11-5-9-7-1-2-8(4-3-7)10-6-12/h1-4H,OMWQUXGVXQELIX-UHFFFAOYSA-N,bitoscanate,Preclinical,anthelmintic agent,,,
CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(N)Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)O,"InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)",OIRCOABEOLEUMC-UHFFFAOYSA-N,bivalirudin,Launched,thrombin inhibitor,F2,cardiology,angina pectoris
COc1cc2[nH]c(N3CCCN(C)CC3)nc(=NC3CCN(Cc4ccccc4)CC3)c2cc1OC,"InChI=1S/C28H38N6O2/c1-32-12-7-13-34(17-16-32)28-30-24-19-26(36-3)25(35-2)18-23(24)27(31-28)29-22-10-14-33(15-11-22)20-21-8-5-4-6-9-21/h4-6,8-9,18-19,22H,7,10-17,20H2,1-3H3,(H,29,30,31)",OSXFATOLZGZLSK-UHFFFAOYSA-N,bix-01294,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
CN(C)Cc1cccc(N=C(c2ccccc2)c2c(O)[nH]c3cc(C(N)=O)ccc23)c1,"InChI=1S/C25H24N4O2/c1-29(2)15-16-7-6-10-19(13-16)27-23(17-8-4-3-5-9-17)22-20-12-11-18(24(26)30)14-21(20)28-25(22)31/h3-14,28,31H,15H2,1-2H3,(H2,26,30)",WGPXKFOFEXJMBD-UHFFFAOYSA-N,bix-02188,Preclinical,MEK inhibitor,MAP2K5,,
CN(C)Cc1cccc(N=C(c2ccccc2)c2c(O)[nH]c3cc(C(=O)N(C)C)ccc23)c1,"InChI=1S/C27H28N4O2/c1-30(2)17-18-9-8-12-21(15-18)28-25(19-10-6-5-7-11-19)24-22-14-13-20(27(33)31(3)4)16-23(22)29-26(24)32/h5-16,29,32H,17H2,1-4H3",ZGXOBLVQIVXKEB-UHFFFAOYSA-N,bix-02189,Preclinical,MEK inhibitor,MAP2K5|MAPK7,,
O=C(O)c1cc2ccccc2s1,"InChI=1S/C9H6O2S/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5H,(H,10,11)",DYSJMQABFPKAQM-UHFFFAOYSA-N,bl-5583,Preclinical,hypercalcaemic agent,,,
Cc1ccc2c(c1)C(=O)C1(O)CCN(c3ccccc3)C1=N2,"InChI=1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3",LZAXPYOBKSJSEX-UHFFFAOYSA-N,blebbistatin-(-),Preclinical,ATPase inhibitor,,,
Cc1ccc2c(c1)C(=O)C1(O)CCN(c3ccccc3)C1=N2,"InChI=1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3",LZAXPYOBKSJSEX-UHFFFAOYSA-N,blebbistatin-(+/-),Preclinical,ATPase inhibitor,MYH14|MYH2,,
Cc1c(C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc2nc(-c3nc(C(=O)NCCCNCCCCN)cs3)cs2)C(C)O)C(OC2OC(CO)C(O)C(O)C2OC2OC(CO)C(O)C(OC(N)=O)C2O)c2c[nH]cn2)[nH]c(C(CC(N)=O)NCC(N)C(N)=O)nc1=N,"InChI=1S/C57H89N19O21S2/c1-22-35(73-48(76-46(22)61)27(14-33(60)80)68-15-26(59)47(62)86)52(90)75-37(43(28-16-65-21-69-28)95-56-45(41(84)39(82)31(17-77)94-56)96-55-42(85)44(97-57(63)92)40(83)32(18-78)93-55)53(91)70-24(3)38(81)23(2)49(87)74-36(25(4)79)51(89)67-13-8-34-71-30(20-98-34)54-72-29(19-99-54)50(88)66-12-7-11-64-10-6-5-9-58/h16,19-21,23-27,31-32,36-45,55-56,64,68,77-79,81-85H,5-15,17-18,58-59H2,1-4H3,(H2,60,80)(H2,62,86)(H2,63,92)(H,65,69)(H,66,88)(H,67,89)(H,70,91)(H,74,87)(H,75,90)(H2,61,73,76)",QYOAUOAXCQAEMW-UHFFFAOYSA-N,bleomycetin,Launched,EGFR expression inhibitor,,,
Cc1c(C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc2nc(-c3nc(C(=O)NCCC[S+](C)C)cs3)cs2)C(C)O)C(OC2OC(CO)C(O)C(O)C2OC2OC(CO)C(O)C(OC(N)=O)C2O)c2c[nH]cn2)[nH]c(C(CC(N)=O)NCC(N)C(N)=O)nc1=N,"InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1",OYVAGSVQBOHSSS-UHFFFAOYSA-O,bleomycin,Launched,DNA synthesis inhibitor,,hematologic malignancy|pulmonary|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|pleural effusion|testicular carcinoma|squamous cell carcinoma
CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,"InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3",XVGOZDAJGBALKS-UHFFFAOYSA-N,blonanserin,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,"InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3",XVGOZDAJGBALKS-UHFFFAOYSA-N,blonanserin,Launched,serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
C=CC(=O)Nc1cccc(C)c1N=c1nc2ccc(-c3c(Cl)c(OC)cc(OC)c3Cl)cc2c[nH]1,"InChI=1S/C26H22Cl2N4O3/c1-5-21(33)30-18-8-6-7-14(2)25(18)32-26-29-13-16-11-15(9-10-17(16)31-26)22-23(27)19(34-3)12-20(35-4)24(22)28/h5-13H,1H2,2-4H3,(H,30,33)(H,29,31,32)",TXEBNKKOLVBTFK-UHFFFAOYSA-N,blu9931,Preclinical,FGFR inhibitor,FGFR4,,
CNC(=O)c1cc(Oc2ccc3[nH]c(=NC4CCCCC4O)sc3c2)ccn1,"InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)",ADZBMFGQQWPHMJ-UHFFFAOYSA-N,blz945,Phase 1/Phase 2,CSF1R inhibitor,,,
COc1ccc2c(c1)c(CC(=O)N1CCOCC1)c(C)n2C(=O)c1ccc(Cl)cc1,"InChI=1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3",BJSDNVVWJYDOLK-UHFFFAOYSA-N,bml-190,Preclinical,cannabinoid receptor inverse agonist,CNR2,,
COc1cccc(-c2cc(=NCc3ccc4c(c3)OCO4)[nH]c(=N)[nH]2)c1,"InChI=1S/C19H18N4O3/c1-24-14-4-2-3-13(8-14)15-9-18(23-19(20)22-15)21-10-12-5-6-16-17(7-12)26-11-25-16/h2-9H,10-11H2,1H3,(H3,20,21,22,23)",FABQUVYDAXWUQP-UHFFFAOYSA-N,bml-284,Preclinical,WNT agonist,,,
Cc1[nH]oc(=NS(=O)(=O)c2cccc3c(N(C)C)cccc23)c1C,"InChI=1S/C17H19N3O3S/c1-11-12(2)18-23-17(11)19-24(21,22)16-10-6-7-13-14(16)8-5-9-15(13)20(3)4/h5-10,18H,1-4H3",OQWWCLIDHPGMBT-UHFFFAOYSA-N,bms-182874,Phase 2,endothelin receptor antagonist,EDNRA,,
O=c1oc(-c2ccc(C(F)(F)F)cc2)nn1Cc1cc(Cl)ccc1O,"InChI=1S/C16H10ClF3N2O3/c17-12-5-6-13(23)10(7-12)8-22-15(24)25-14(21-22)9-1-3-11(4-2-9)16(18,19)20/h1-7,23H,8H2",QKOWACXSXTXRKA-UHFFFAOYSA-N,bms-191011,Preclinical,potassium channel activator,KCNMA1,,
CC1(C)Oc2ccc(C#N)cc2C(N(Cc2ncc[nH]2)c2ccc(Cl)cc2)C1O,"InChI=1S/C22H21ClN4O2/c1-22(2)21(28)20(17-11-14(12-24)3-8-18(17)29-22)27(13-19-25-9-10-26-19)16-6-4-15(23)5-7-16/h3-11,20-21,28H,13H2,1-2H3,(H,25,26)",SMIKIPXIDLITMP-UHFFFAOYSA-N,bms-191095,Phase 1,KATP activator,,,
CC1(C)Oc2ccc(C#N)cc2C(N(Cc2ncc[nH]2)c2ccc(Cl)cc2)C1O,"InChI=1S/C22H21ClN4O2/c1-22(2)21(28)20(17-11-14(12-24)3-8-18(17)29-22)27(13-19-25-9-10-26-19)16-6-4-15(23)5-7-16/h3-11,20-21,28H,13H2,1-2H3,(H,25,26)",SMIKIPXIDLITMP-UHFFFAOYSA-N,bms-191095,Phase 1,potassium channel agonist,,,
Cc1o[nH]c(=NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)CC(C)(C)C)c1C,"InChI=1S/C28H32N4O5S/c1-18-19(2)37-30-26(18)31-38(34,35)24-10-8-7-9-23(24)22-12-11-20(27-29-13-14-36-27)15-21(22)17-32(6)25(33)16-28(3,4)5/h7-15H,16-17H2,1-6H3,(H,30,31)",ORJRYNKVKJAJPY-UHFFFAOYSA-N,bms-207940,Preclinical,endothelin receptor antagonist,,,
N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)C(Cc1ccccc1)CN2Cc1c[nH]cn1,"InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)",OLCWFLWEHWLBTO-UHFFFAOYSA-N,bms-214662,Phase 1,farnesyltransferase inhibitor,,,
CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)cnc2[nH]ncc12,"InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23)",SCFMWQIQBVZOQR-UHFFFAOYSA-N,bms-265246,Preclinical,CDK inhibitor,CDK1|CDK2,,
CC(c1ccc(F)cc1CCCC(=O)O)N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)",IZAOBRWCUGOKNH-UHFFFAOYSA-N,bms-299897,Phase 1,gamma secretase inhibitor,,,
CCc1c(-c2ccccc2)c(-c2ccccc2)nn1-c1ccccc1-c1cccc(OCC(=O)O)c1,"InChI=1S/C31H26N2O3/c1-2-27-30(22-12-5-3-6-13-22)31(23-14-7-4-8-15-23)32-33(27)28-19-10-9-18-26(28)24-16-11-17-25(20-24)36-21-29(34)35/h3-20H,2,21H2,1H3,(H,34,35)",SJRVJRYZAQYCEE-UHFFFAOYSA-N,bms-309403,Preclinical,fatty acid binding protein inhibitor,FABP4,,
Cc1ccc2[nH]c(=NCCN)c3ncc(C)n3c2c1,"InChI=1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18)",PSPFQEBFYXJZEV-UHFFFAOYSA-N,bms-345541,Preclinical,IKK inhibitor,CHUK|IKBKB,,
CC(C)(C)c1cnc(CSc2c[nH]c(=NC(=O)C3CCNCC3)s2)o1,"InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)",OUSFTKFNBAZUKL-UHFFFAOYSA-N,bms-387032,Phase 1,CDK inhibitor,CDK2|CDK7|CDK9,,
CC(C)(C)c1cnc(CSc2c[nH]c(=NC(=O)C3CCNCC3)s2)o1,"InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)",OUSFTKFNBAZUKL-UHFFFAOYSA-N,bms-387032,Phase 1,cell cycle inhibitor,CDK2|CDK7|CDK9,,
CC(C)(C)c1cnc(CSc2c[nH]c(=NC(=O)C3CCNCC3)s2)o1,"InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)",OUSFTKFNBAZUKL-UHFFFAOYSA-N,bms-387032,Phase 1,MCL1 inhibitor,CDK2|CDK7|CDK9,,
CCCC(=O)C1(c2ccccc2)CCN(C(=O)C(Cc2ccc(OC)cc2)NC(=O)C(N)Cc2cncn2C)CC1,"InChI=1S/C32H41N5O4/c1-4-8-29(38)32(24-9-6-5-7-10-24)15-17-37(18-16-32)31(40)28(19-23-11-13-26(41-3)14-12-23)35-30(39)27(33)20-25-21-34-22-36(25)2/h5-7,9-14,21-22,27-28H,4,8,15-20,33H2,1-3H3,(H,35,39)",GULVVTHHUIIMRL-UHFFFAOYSA-N,bms-470539,Preclinical,melanocortin receptor agonist,MC1R,,
Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)",ZWVZORIKUNOTCS-UHFFFAOYSA-N,bms-536924,Preclinical,IGF-1 inhibitor,AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB,,
CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1,"InChI=1S/C28H30FN5O2/c1-4-33-11-13-34(14-12-33)25-10-9-18(17-30-25)28(2,3)32-27(36)20-16-24-21(15-22(20)29)26(35)19-7-5-6-8-23(19)31-24/h5-10,15-17H,4,11-14H2,1-3H3,(H,31,35)(H,32,36)",XEVJUIZOZCFECP-UHFFFAOYSA-N,bms-566419,Preclinical,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,
CCCNC(=O)c1cn2[nH]cnc(=Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,"InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)",GDTQLZHHDRRBEB-UHFFFAOYSA-N,bms-582949,Phase 2,p38 MAPK inhibitor,,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)C12CN(Cc1cc(C(=O)O)cs1)CC2c1ccc(C#N)cc1,"InChI=1S/C26H20Cl2N4O4S/c1-30-25(36)32(20-8-18(27)7-19(28)9-20)24(35)26(30)14-31(11-21-6-17(13-37-21)23(33)34)12-22(26)16-4-2-15(10-29)3-5-16/h2-9,13,22H,11-12,14H2,1H3,(H,33,34)",NXNKJLOEGWSJGI-UHFFFAOYSA-N,bms-587101,Phase 2,integrin antagonist,ITGAL|ITGB2,,
Cc1c(NC(=O)OCC2COCCN2)cn2[nH]cnc(=Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)",LUJZZYWHBDHDQX-UHFFFAOYSA-N,bms-599626,Phase 1,EGFR inhibitor,EGFR|ERBB2|ERBB4,,
Cc1c(NC(=O)OCC2COCCN2)cn2[nH]cnc(=Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)",LUJZZYWHBDHDQX-UHFFFAOYSA-N,bms-599626,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2|ERBB4,,
COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,"InChI=1S/C24H23N7O4/c1-15-27-14-31(28-15)22-20-19(18(35-2)13-26-22)17(12-25-20)21(32)24(34)30-10-8-29(9-11-30)23(33)16-6-4-3-5-7-16/h3-7,12-14,25H,8-11H2,1-2H3",QRPZBKAMSFHVRW-UHFFFAOYSA-N,bms-626529,Phase 3,HIV attachment inhibitor,,,
Cc1ccc(C(=O)NC2CC2)cc1NC(=O)c1cnn(-c2ncccc2C(F)(F)F)c1C,"InChI=1S/C22H20F3N5O2/c1-12-5-6-14(20(31)28-15-7-8-15)10-18(12)29-21(32)16-11-27-30(13(16)2)19-17(22(23,24)25)4-3-9-26-19/h3-6,9-11,15H,7-8H2,1-2H3,(H,28,31)(H,29,32)",ZZZJRULMCGMYRH-UHFFFAOYSA-N,bms-626531,Phase 1,p38 MAPK inhibitor,,,
CC1(C)CCC(C)(C)c2cc(C3(c4ccc(C(=O)O)cc4)OCCO3)ccc21,"InChI=1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26)",ZZUKALQMHNSWTK-UHFFFAOYSA-N,bms-649,Preclinical,retinoid receptor agonist,RXRA,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)C12CN(c1ccc(C(=O)O)cn1)CC2c1ccc(C#N)cc1,"InChI=1S/C26H19Cl2N5O4/c1-31-25(37)33(20-9-18(27)8-19(28)10-20)24(36)26(31)14-32(22-7-6-17(12-30-22)23(34)35)13-21(26)16-4-2-15(11-29)3-5-16/h2-10,12,21H,13-14H2,1H3,(H,34,35)",LILGMDXLRPEBNH-UHFFFAOYSA-N,bms-688521,Preclinical,ICAM1 antagonist,ICAM1,,
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)C12CN(c1ccc(C(=O)O)cn1)CC2c1ccc(C#N)cc1,"InChI=1S/C26H19Cl2N5O4/c1-31-25(37)33(20-9-18(27)8-19(28)10-20)24(36)26(31)14-32(22-7-6-17(12-30-22)23(34)35)13-21(26)16-4-2-15(11-29)3-5-16/h2-10,12,21H,13-14H2,1H3,(H,34,35)",LILGMDXLRPEBNH-UHFFFAOYSA-N,bms-688521,Preclinical,leukocyte function-associated antigen receptor antagonist,ICAM1,,
COc1cccc(N=c2[nH]cnn3ccc(CN4CCC(N)C(O)C4)c23)c1,"InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)",CSGQVNMSRKWUSH-UHFFFAOYSA-N,bms-690514,Phase 2,EGFR inhibitor,EGFR|ERBB2|FLT3|KDR,,
COc1cccc(N=c2[nH]cnn3ccc(CN4CCC(N)C(O)C4)c23)c1,"InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)",CSGQVNMSRKWUSH-UHFFFAOYSA-N,bms-690514,Phase 2,VEGFR inhibitor,EGFR|ERBB2|FLT3|KDR,,
Cn1c(N2CCCCS2(=O)=O)nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O,"InChI=1S/C17H19FN4O5S/c1-21-16(25)14(23)13(15(24)19-10-11-4-6-12(18)7-5-11)20-17(21)22-8-2-3-9-28(22,26)27/h4-7,23H,2-3,8-10H2,1H3,(H,19,24)",VNIWZCGZPBJWBI-UHFFFAOYSA-N,bms-707035,Phase 2,HIV integrase inhibitor,,,
CC1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(=Nc2cc(C3CC3)[nH]n2)c2cccn2[nH]1,"InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)",LQVXSNNAFNGRAH-UHFFFAOYSA-N,bms-754807,Phase 2,IGF-1 inhibitor,AKT1|IGF1R,,
OC12CCC(c3nnc4c(Oc5ccccc5Cl)cccn34)(CC1)C2,"InChI=1S/C19H18ClN3O2/c20-13-4-1-2-5-14(13)25-15-6-3-11-23-16(15)21-22-17(23)18-7-9-19(24,12-18)10-8-18/h1-6,11,24H,7-10,12H2",HNXGIFYHJKEXNA-UHFFFAOYSA-N,bms-770767,Phase 2,11-beta-HSD1 inhibitor,,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,AXL kinase inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,c-Met inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,FLT3 inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,hepatocyte growth factor receptor inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,macrophage migration inhibiting factor inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2cc[nH]c(=N)c2Cl)c(F)c1,"InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)",VNBRGSXVFBYQNN-UHFFFAOYSA-N,bms-777607,Phase 1/Phase 2,tyrosine kinase inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,
CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,"InChI=1S/C28H29ClN2O3S/c1-27(2,23-11-6-7-12-24(23)29)26-30-25(28(3,4)32)18-31(26)21-15-13-19(14-16-21)20-9-8-10-22(17-20)35(5,33)34/h6-18,32H,1-5H3",JLPURTXCSILYLW-UHFFFAOYSA-N,bms-779788,Phase 1,LXR agonist,,,
COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3C)c12,"InChI=1S/C22H22N4O4/c1-14-13-25(21(28)15-6-4-3-5-7-15)10-11-26(14)22(29)19(27)16-12-24-20-18(16)17(30-2)8-9-23-20/h3-9,12,14H,10-11,13H2,1-2H3,(H,23,24)",OKGPFTLYBPQBIX-UHFFFAOYSA-N,bms-806,Phase 1,HIV attachment inhibitor,,,
CC(=O)NC1CC(NC(C)(C)C)CCC1N1CCC(N=c2[nH]cnc3cc(C(C)(C)C)nn23)C1=O,"InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)",CMVHFGNTABZQJU-UHFFFAOYSA-N,bms-813160,Phase 2,CC chemokine receptor antagonist,,,
N=c1[nH]ccc(Oc2ccc(NC(=O)c3cn(CO[PH](=O)(=O)O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,"InChI=1S/C24H17ClF2N4O7P/c25-21-20(7-8-29-23(21)28)38-19-6-5-15(9-18(19)27)30-24(33)17-11-31(12-37-39(34,35)36)10-16(22(17)32)13-1-3-14(26)4-2-13/h1-11H,12H2,(H2,28,29)(H,30,33)(H,34,35,36)",WXDLSLDFQWNSNX-UHFFFAOYSA-N,bms-817378,Phase 1,c-Met inhibitor,KDR|MET,,
N=c1[nH]ccc(Oc2ccc(NC(=O)c3cn(CO[PH](=O)(=O)O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,"InChI=1S/C24H17ClF2N4O7P/c25-21-20(7-8-29-23(21)28)38-19-6-5-15(9-18(19)27)30-24(33)17-11-31(12-37-39(34,35)36)10-16(22(17)32)13-1-3-14(26)4-2-13/h1-11H,12H2,(H2,28,29)(H,30,33)(H,34,35,36)",WXDLSLDFQWNSNX-UHFFFAOYSA-N,bms-817378,Phase 1,VEGFR inhibitor,KDR|MET,,
CNCc1ccc(C)c(NC(=O)c2ccc(N=c3nc(-c4ccccc4)c4ccccc4[nH]3)cc2)c1,"InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)",KLRRGBHZCJLIEL-UHFFFAOYSA-N,bms-833923,Phase 2,smoothened receptor antagonist,SMO,,
O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,"InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)",JJWLXRKVUJDJKG-UHFFFAOYSA-N,bms-863233,Phase 1/Phase 2,CDC inhibitor,CDC7|PIM1,,
Cn1c(=O)c(=NC(=O)C(CCC(F)(F)F)C(CCC(F)(F)F)C(N)O)nc(-c2ccccc2)c2ccccc21,"InChI=1S/C26H26F6N4O3/c1-36-19-10-6-5-9-18(19)20(15-7-3-2-4-8-15)34-22(24(36)39)35-23(38)17(12-14-26(30,31)32)16(21(33)37)11-13-25(27,28)29/h2-10,16-17,21,37H,11-14,33H2,1H3",YVDYVNVCEZNCJV-UHFFFAOYSA-N,bms-906024,Phase 1,gamma secretase inhibitor,,,
CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(=Nc3cc(C)n(C)n3)[nH]c21,"InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)",JCINBYQJBYJGDM-UHFFFAOYSA-N,bms-911543,Phase 1/Phase 2,JAK inhibitor,,,
Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O,"InChI=1S/C31H26N4O3/c1-17-19(8-6-10-26(17)35-16-33-24-9-5-4-7-22(24)30(35)37)20-13-14-23(29(32)36)28-27(20)21-12-11-18(31(2,3)38)15-25(21)34-28/h4-16,34,38H,1-3H3,(H2,32,36)",TVJRDCQUZMGBAB-UHFFFAOYSA-N,bms-935177,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
NC(O)C(CC1CC1)C(CCC(F)(F)F)C(=O)N=c1[nH]c(-c2ccccc2)c2cccc(F)c2nc1=O,"InChI=1S/C26H26F4N4O3/c27-19-8-4-7-17-20(15-5-2-1-3-6-15)32-23(25(37)33-21(17)19)34-24(36)16(11-12-26(28,29)30)18(22(31)35)13-14-9-10-14/h1-8,14,16,18,22,35H,9-13,31H2,(H,32,33,34,36,37)",SLNKNEMKNXKIRA-UHFFFAOYSA-N,bms-983970,Phase 1,notch signaling inhibitor,,,
Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)OC(C)c1ccccc1,"InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)",GQBRZBHEPUQRPL-UHFFFAOYSA-N,bms-986020,Phase 2,lysophosphatidic acid receptor antagonist,LPAR1,,
Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,"InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)",ZRYMMWAJAFUANM-UHFFFAOYSA-N,bms-986142,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n(C(c3ccccc3)C3CCOCC3)c2c1,"InChI=1S/C30H33N5O2/c1-19-28(34(4)33-32-19)22-16-26-27(31-18-22)24-11-10-23(30(2,3)36)17-25(24)35(26)29(20-8-6-5-7-9-20)21-12-14-37-15-13-21/h5-11,16-18,21,29,36H,12-15H2,1-4H3",KGERZPVQIRYWRK-UHFFFAOYSA-N,bms-986158,Phase 1/Phase 2,bromodomain inhibitor,,,
CC#CC(=O)NC1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,"InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)",VJPPLCNBDLZIFG-UHFFFAOYSA-N,bms-986195,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,,,
CC(C(=O)Nc1ccc(Cl)cc1)C1CCC(c2ccnc3ccc(F)cc23)CC1,"InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)",KRTIYQIPSAGSBP-UHFFFAOYSA-N,bms-986205,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",,,
CSc1ccc(C(=O)NC2CCCCC2NC(=O)CNC(=O)c2cc(C(F)(F)F)ccc2NC(=O)NC(C)C)cc1,"InChI=1S/C28H34F3N5O4S/c1-16(2)33-27(40)36-21-13-10-18(28(29,30)31)14-20(21)26(39)32-15-24(37)34-22-6-4-5-7-23(22)35-25(38)17-8-11-19(41-3)12-9-17/h8-14,16,22-23H,4-7,15H2,1-3H3,(H,32,39)(H,34,37)(H,35,38)(H2,33,36,40)",IBPXYDUJQWENPM-UHFFFAOYSA-N,bms-ccr2-22,Preclinical,CC chemokine receptor antagonist,CCR2,,
OC(CCCN1CCN(c2ncc(F)cn2)CC1)c1ccc(F)cc1,"InChI=1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2",ZXUYYZPJUGQHLQ-UHFFFAOYSA-N,bmy-14802,Phase 2,sigma receptor antagonist,HTR1A,,
O=C(O)COc1cccc(-c2ocnc2-c2nc(-c3ccccc3)c(-c3ccccc3)o2)c1,"InChI=1S/C26H18N2O5/c29-21(30)15-31-20-13-7-12-19(14-20)24-23(27-16-32-24)26-28-22(17-8-3-1-4-9-17)25(33-26)18-10-5-2-6-11-18/h1-14,16H,15H2,(H,29,30)",DSRSEEYZGWTODH-UHFFFAOYSA-N,bmy-45778,Preclinical,IP1 prostacyclin receptor agonist,PTGIR,,
COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,"InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3",AYYCFGDXLUPJAQ-UHFFFAOYSA-N,bmy-7378,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A,,
COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,"InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3",AYYCFGDXLUPJAQ-UHFFFAOYSA-N,bmy-7378,Preclinical,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A,,
COc1cc(C(=O)c2c(C)oc3c(O)c(OC)ccc23)cc(OC)c1OC,"InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3",RADMJHVVIZTENA-UHFFFAOYSA-N,bnc105,Phase 2,tubulin polymerization inhibitor,,,
O=C1C(=Cc2ccccc2)CC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5,"InChI=1S/C27H27NO4/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17/h1-5,8-9,12,17,21,25,29,31H,6-7,10-11,13-15H2",WXOUFNFMPVMGFZ-UHFFFAOYSA-N,bntx,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CC(C)(C)NC(=O)NC(C(=O)N1CC2C(C1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,"InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)",LHHCSNFAOIFYRV-UHFFFAOYSA-N,boceprevir,Launched,HCV inhibitor,CMA1|CTSA|CTSF|CTSK|CTSL|CTSS,infectious disease,hepatitis C
O=C1C=Cc2cc(Br)ccc2C1=O,InChI=1S/C10H5BrO2/c11-7-2-3-8-6(5-7)1-4-9(12)10(8)13/h1-5H,MXWZRRPNVLCHMY-UHFFFAOYSA-N,bonaphthone,Phase 3,,,,
Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,"InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3",UUOJIACWOAYWEZ-UHFFFAOYSA-N,bopindolol,Launched,adrenergic receptor antagonist,,cardiology,hypertension|coronary artery disease (CAD)
CC(=O)OC1CC2CCC1(C)C2(C)C,"InChI=1S/C12H20O2/c1-8(13)14-10-7-9-5-6-12(10,4)11(9,2)3/h9-10H,5-7H2,1-4H3",KGEKLUUHTZCSIP-UHFFFAOYSA-N,bornyl-acetate,Preclinical,,,,
NC(Cc1ccc(B(O)O)cc1)C(=O)O,"InChI=1S/C9H12BNO4/c11-8(9(12)13)5-6-1-3-7(4-2-6)10(14)15/h1-4,8,14-15H,5,11H2,(H,12,13)",NFIVJOSXJDORSP-UHFFFAOYSA-N,boronophenylalanine,Phase 2,,,,
CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)",GXJABQQUPOEUTA-UHFFFAOYSA-N,bortezomib,Launched,NFkB pathway inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)
CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)",GXJABQQUPOEUTA-UHFFFAOYSA-N,bortezomib,Launched,proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)
CCOc1cc(-c2nncn2C)ccc1N=c1nc2c(=NCC(C)(C)C)[nH]c(C)cc2c[nH]1,"InChI=1S/C24H30N8O/c1-7-33-19-11-16(22-31-27-14-32(22)6)8-9-18(19)29-23-25-12-17-10-15(2)28-21(20(17)30-23)26-13-24(3,4)5/h8-12,14H,7,13H2,1-6H3,(H,26,28)(H,25,29,30)",SGWLRDAOCLITOM-UHFFFAOYSA-N,bos-172722,Phase 1,monopolar spindle 1 kinase inhibitor,,,
COc1ccccc1Oc1c(OCCO)[nH]c(-c2ncccn2)nc1=NS(=O)(=O)c1ccc(C(C)(C)C)cc1,"InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)",GJPICJJJRGTNOD-UHFFFAOYSA-N,bosentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH)
COc1cc(N=c2c(C#N)c[nH]c3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,bosutinib,Launched,Abl kinase inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML)
COc1cc(N=c2c(C#N)c[nH]c3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,bosutinib,Launched,Bcr-Abl kinase inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML)
COc1cc(N=c2c(C#N)c[nH]c3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,bosutinib,Launched,SRC inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML)
c1ccc(N2CCN(CCCOc3ccc4c(c3)OCO4)CC2)cc1,"InChI=1S/C20H24N2O3/c1-2-5-17(6-3-1)22-12-10-21(11-13-22)9-4-14-23-18-7-8-19-20(15-18)25-16-24-19/h1-3,5-8,15H,4,9-14,16H2",VUSNBQDZGKZEDL-UHFFFAOYSA-N,bp-554,Preclinical,serotonin receptor agonist,HTR1A,,
COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,"InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)",MNHDKMDLOJSCGN-UHFFFAOYSA-N,bp-897,Phase 2,dopamine receptor agonist,ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B,,
CC(C)CC1NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC(=O)O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O,"InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)",VYCMAAOURFJIHD-UHFFFAOYSA-N,bq-123,Phase 2,endothelin receptor antagonist,EDNRA,,
CCCCC(NC(=O)C(Cc1cn(C(=O)OC)c2ccccc12)NC(=O)C(CC(C)(C)C)NC(=O)N1C(C)CCCC1C)C(=O)O,"InChI=1S/C34H51N5O7/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)",LPAHKJMGDSJDRG-UHFFFAOYSA-N,bq-788,Phase 1,endothelin receptor antagonist,EDNRB,,
Cc1nn(C)c2c1C(c1ccc(C(F)(F)F)cc1)C(C#N)C(=N)O2,"InChI=1S/C16H13F3N4O/c1-8-12-13(9-3-5-10(6-4-9)16(17,18)19)11(7-20)14(21)24-15(12)23(2)22-8/h3-6,11,13,21H,1-2H3",QFUFJOJDXRWBNA-UHFFFAOYSA-N,bqu57,Preclinical,Ras GTPase inhibitor,RALA|RALB,,
COC(=O)c1ccc2c(c1)[nH]c(=NC(=O)c1ccccc1)n2CCCc1ccccc1,"InChI=1S/C25H23N3O3/c1-31-24(30)20-14-15-22-21(17-20)26-25(27-23(29)19-12-6-3-7-13-19)28(22)16-8-11-18-9-4-2-5-10-18/h2-7,9-10,12-15,17H,8,11,16H2,1H3,(H,26,27,29)",UCGWYCMPZXDHNR-UHFFFAOYSA-N,brd4770,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
O=C1Nc2cccc3c(O)c4ccccc4c(c23)C1=NCCc1ccccc1,"InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,27H,13-14H2,(H,26,28)",ZPHLSQQEXXKIIA-UHFFFAOYSA-N,brd7389,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3,,
CC(C)(C)c1ccc2cc(C#N)c(C#N)cc2c1,"InChI=1S/C16H14N2/c1-16(2,3)15-5-4-11-6-13(9-17)14(10-18)7-12(11)8-15/h4-8H,1-3H3",MKILROQBJOOZKC-UHFFFAOYSA-N,brd9876,Preclinical,kinesin inhibitor,KIF11,,
CC1CCCC=CC2CC(O)CC2C(=O)CCC(=O)O1,"InChI=1S/C16H24O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6,11-14,17H,2-3,5,7-10H2,1H3",OKIFNFBLSKVOOO-UHFFFAOYSA-N,brefeldin-a,Preclinical,protein synthesis inhibitor,ARF1|CYTH2,,
CCCCC(NC(C)=O)C(=O)NC1CC(=O)NCCCCC(C(=O)O)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CCCN=C(N)N)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC1=O,"InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)",FFHBJDQSGDNCIV-UHFFFAOYSA-N,bremelanotide,Launched,melanocortin receptor agonist,MC1R|MC2R|MC3R|MC4R|MC5R,neurology/psychiatry,hypoactive sexual desire disorder
Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,"InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)",PHEZJEYUWHETKO-UHFFFAOYSA-N,brequinar,Phase 2,dihydroorotate dehydrogenase inhibitor,DHODH,,
CC(C)(C)OC(=O)c1ncn2c1C1CCCN1C(=O)c1c(Br)cccc1-2,"InChI=1S/C19H20BrN3O3/c1-19(2,3)26-18(25)15-16-13-8-5-9-22(13)17(24)14-11(20)6-4-7-12(14)23(16)10-21-15/h4,6-7,10,13H,5,8-9H2,1-3H3",LWUDDYHYYNNIQI-UHFFFAOYSA-N,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
CC[N+](C)(C)Cc1ccccc1Br,"InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1",AAQOQKQBGPPFNS-UHFFFAOYSA-N,bretylium,Launched,norepinephrine inhibitor,ATP1A1,cardiology,ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,"InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)",ZKIAIYBUSXZPLP-UHFFFAOYSA-N,brexpiprazole,Launched,dopamine receptor partial agonist,DRD2,neurology/psychiatry,depression|schizophrenia
COc1cc(OC)c(C=CS(=O)(=O)Cc2ccc(OC)c(O[PH](=O)(=O)O)c2)c(OC)c1,"InChI=1S/C19H22O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H,20,21,22)",VSVFLGPUZJTBSD-UHFFFAOYSA-N,briciclib,Phase 1,cyclin D inhibitor,CCND1,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccccc2P(C)(C)=O)[nH]1,"InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)",AILRADAXUVEEIR-UHFFFAOYSA-N,brigatinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|EGFR,oncology,non-small cell lung cancer (NSCLC)
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccccc2P(C)(C)=O)[nH]1,"InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)",AILRADAXUVEEIR-UHFFFAOYSA-N,brigatinib,Launched,EGFR inhibitor,ALK|EGFR,oncology,non-small cell lung cancer (NSCLC)
CCN(CC)c1ccc([C+](c2ccccc2)c2ccc(N(CC)CC)cc2)cc1,"InChI=1S/C27H33N2/c1-5-28(6-2)25-18-14-23(15-19-25)27(22-12-10-9-11-13-22)24-16-20-26(21-17-24)29(7-3)8-4/h9-21H,5-8H2,1-4H3/q+1",HXCILVUBKWANLN-UHFFFAOYSA-N,brilliant-green,Launched,,,infectious disease,antiseptic
Brc1c(NC2=NCCN2)ccc2nccnc12,"InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)",XYLJNLCSTIOKRM-UHFFFAOYSA-N,brimonidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
CCCCCCCCCCCCCCCCOCCCO[PH](=O)(=O)COC(CO)Cn1ccc(=N)[nH]c1=O,"InChI=1S/C27H51N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H2,28,29,32)",RFLLKQPAOJGESS-UHFFFAOYSA-N,brincidofovir,Phase 3,antiviral,,,
CCNC1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)",HCRKCZRJWPKOAR-UHFFFAOYSA-N,brinzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA5A|CA7,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1,"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3",WCWUXEGQKLTGDX-UHFFFAOYSA-N,brivanib,Phase 3,FGFR inhibitor,CYP3A4|FGFR1|FLT1|KCNH2|KDR,,
Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)O)c(C)c34)ccc2[nH]1,"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3",WCWUXEGQKLTGDX-UHFFFAOYSA-N,brivanib,Phase 3,VEGFR inhibitor,CYP3A4|FGFR1|FLT1|KCNH2|KDR,,
Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(C)N)c(C)c34)ccc2[nH]1,"InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3",LTEJRLHKIYCEOX-UHFFFAOYSA-N,brivanib-alaninate,Phase 3,FGFR inhibitor,FGFR3,,
Cc1cc2c(F)c(Oc3ncnn4cc(OCC(C)OC(=O)C(C)N)c(C)c34)ccc2[nH]1,"InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3",LTEJRLHKIYCEOX-UHFFFAOYSA-N,brivanib-alaninate,Phase 3,VEGFR inhibitor,FGFR3,,
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1C=CBr,"InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)",ODZBBRURCPAEIQ-UHFFFAOYSA-N,brivudine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,shingles
OC(CN1CCN(c2cccc(Cl)c2)CC1)C(c1ccccc1)c1ccccc1,"InChI=1S/C25H27ClN2O/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-13,18,24-25,29H,14-17,19H2",QJHCTHPYUOXOGM-UHFFFAOYSA-N,brl-15572,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,
O=C(O)C(Cc1ccccc1)NCc1ccc(Cl)cc1,"InChI=1S/C16H16ClNO2/c17-14-8-6-13(7-9-14)11-18-15(16(19)20)10-12-4-2-1-3-5-12/h1-9,15,18H,10-11H2,(H,19,20)",SAOHCSVJQIAGDD-UHFFFAOYSA-N,brl-26314,Phase 1,cholesterol inhibitor,LPL,,
CC(Cc1ccc(OCC(=O)O)cc1)NCC(O)c1cccc(Cl)c1,"InChI=1S/C19H22ClNO4/c1-13(21-11-18(22)15-3-2-4-16(20)10-15)9-14-5-7-17(8-6-14)25-12-19(23)24/h2-8,10,13,18,21-22H,9,11-12H2,1H3,(H,23,24)",ZGGNJJJYUVRADP-UHFFFAOYSA-N,brl-37344,Phase 2,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CC1c2ccccc2CN1CC1=NCCN1,"InChI=1S/C13H17N3/c1-10-12-5-3-2-4-11(12)8-16(10)9-13-14-6-7-15-13/h2-5,10H,6-9H2,1H3,(H,14,15)",SGOFAUSEYBZKDQ-UHFFFAOYSA-N,brl-44408,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)C,"InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3",IFIUFCJFLGCQPH-UHFFFAOYSA-N,brl-50481,Preclinical,phosphodiesterase inhibitor,PDE7A|PDE7B,,
O=C(Cc1ccc(Cl)c(Cl)c1)N1CCCCC1CN1CCCC1,"InChI=1S/C18H24Cl2N2O/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21/h6-7,11,15H,1-5,8-10,12-13H2",GHCCBWMZKJQGLS-UHFFFAOYSA-N,brl-52537,Preclinical,opioid receptor agonist,OPRK1,,
CN1CCC(c2c[nH]c3ccc(O)cc23)CC1,"InChI=1S/C14H18N2O/c1-16-6-4-10(5-7-16)13-9-15-14-3-2-11(17)8-12(13)14/h2-3,8-10,15,17H,4-7H2,1H3",WKNFADCGOAHBPG-UHFFFAOYSA-N,brl-54443,Preclinical,serotonin receptor agonist,HTR1E|HTR1F,,
O=C(C=Cc1ccccc1)NCCO,"InChI=1S/C11H13NO2/c13-9-8-12-11(14)7-6-10-4-2-1-3-5-10/h1-7,13H,8-9H2,(H,12,14)",OSCTXCOERRNGLW-UHFFFAOYSA-N,brolitene,Launched,muscle relaxant,RYR1,rheumatology,lumbago
Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1,"InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2",LWJALJDRFBXHKX-UHFFFAOYSA-N,bromantan,Launched,dopamine reuptake inhibitor,,neurology/psychiatry,neurasthenia
Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1,"InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2",LWJALJDRFBXHKX-UHFFFAOYSA-N,bromantan,Launched,serotonin reuptake inhibitor,,neurology/psychiatry,neurasthenia
COc1ccc(C(=O)C(Br)=CC(=O)O)cc1,"InChI=1S/C11H9BrO4/c1-16-8-4-2-7(3-5-8)11(15)9(12)6-10(13)14/h2-6H,1H3,(H,13,14)",UPZFHUODAYGHDZ-UHFFFAOYSA-N,bromebric-acid,Preclinical,DNA synthesis inhibitor,,,
COc1ccc(C(=O)C(Br)=CC(=O)O)cc1,"InChI=1S/C11H9BrO4/c1-16-8-4-2-7(3-5-8)11(15)9(12)6-10(13)14/h2-6H,1H3,(H,13,14)",UPZFHUODAYGHDZ-UHFFFAOYSA-N,bromebric-acid,Preclinical,purine antagonist,,,
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,"InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)",ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,bromfenac,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,"InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3",OJGDCBLYJGHCIH-UHFFFAOYSA-N,bromhexine,Launched,mucolytic agent,,pulmonary,chest congestion
O=C1c2ccccc2C(=O)C1c1ccc(Br)cc1,"InChI=1S/C15H9BrO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H",NPUZIGSOEWMFKK-UHFFFAOYSA-N,bromindione,Phase 2,anticoagulant,,,
CC(C)C(Br)C(=O)NC(N)=O,"InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)",CMCCHHWTTBEZNM-UHFFFAOYSA-N,bromisoval,Preclinical,anti-inflammatory agent,,,
CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3=CC4c5cccc6[nH]c(Br)c(c56)CC4N(C)C3)(C(C)C)C(=O)N12,"InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-17,20,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)",NUEAMYZABAMKDO-UHFFFAOYSA-N,bromocriptine,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,endocrinology|neurology/psychiatry,hyperprolactinemia|Parkinson's Disease|acromegaly
CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,"InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",GIYAQDDTCWHPPL-UHFFFAOYSA-N,bromopride,Launched,dopamine receptor antagonist,DRD2,gastroenterology,nausea|vomiting|gastroesophageal reflux disease (GERD)
CCOC(=O)N=c1cc(-c2ccc(C)c(NS(C)(=O)=O)c2)[nH]n2c(C)nnc12,"InChI=1S/C17H20N6O4S/c1-5-27-17(24)18-15-9-14(21-23-11(3)19-20-16(15)23)12-7-6-10(2)13(8-12)22-28(4,25)26/h6-9,21-22H,5H2,1-4H3",VMADELNZTBWIMN-UHFFFAOYSA-N,bromosporine,Preclinical,bromodomain inhibitor,,,
O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,"InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",RKLNONIVDFXQRX-UHFFFAOYSA-N,bromperidol,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia
CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,"InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",ZDIGNSYAACHWNL-UHFFFAOYSA-N,brompheniramine,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold
O=[N+]([O-])C(Br)(CO)CO,"InChI=1S/C3H6BrNO4/c4-3(1-6,2-7)5(8)9/h6-7H,1-2H2",LVDKZNITIUWNER-UHFFFAOYSA-N,bronopol,Launched,,,obstetrics/gynecology,mastitis
N=c1[nH]c(-c2ccccc2)c(Br)c(=O)[nH]1,"InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)",CIUUIPMOFZIWIZ-UHFFFAOYSA-N,bropirimine,Phase 3,interferon inducer,,,
Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,"InChI=1S/C17H11Br2NO2/c1-10-7-8-12-13(18)9-14(19)16(15(12)20-10)22-17(21)11-5-3-2-4-6-11/h2-9H,1H3",IJTPLVAAROHGGB-UHFFFAOYSA-N,broxaldine,Preclinical,,,,
CC(C)(C)NCC(O)c1cc(Br)no1,"InChI=1S/C9H15BrN2O2/c1-9(2,3)11-5-6(13)7-4-8(10)12-14-7/h4,6,11,13H,5H2,1-3H3",JBRBWHCVRGURBA-UHFFFAOYSA-N,broxaterol,Phase 3,adrenergic receptor agonist,ADRB2,,
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1Br,"InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)",WOVKYSAHUYNSMH-UHFFFAOYSA-N,broxuridine,Phase 2,antimetabolite,,,
Oc1c(Br)cc(Br)c2cccnc12,"InChI=1S/C9H5Br2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",ZDASUJMDVPTNTF-UHFFFAOYSA-N,broxyquinoline,Phase 1,antiprotozoal agent,,,
COC(=O)C12OCC34C(CC5C(C)C(=O)C(=O)CC5(C)C3C(O)C1O)OC(=O)C(OC(=O)C=C(C)C(C)C)C24,"InChI=1S/C28H36O11/c1-11(2)12(3)7-17(30)39-20-22-27-10-37-28(22,25(35)36-6)23(33)19(32)21(27)26(5)9-15(29)18(31)13(4)14(26)8-16(27)38-24(20)34/h7,11,13-14,16,19-23,32-33H,8-10H2,1-6H3",KMCZIPGKKBSLEX-UHFFFAOYSA-N,bruceantin,Phase 2,protein synthesis inhibitor,,,
COc1cc2c(cc1OC)C13CCN4CC5=CCOC6CC(=O)N2C1C6C5CC43,"InChI=1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3",RRKTZKIUPZVBMF-UHFFFAOYSA-N,brucine,Preclinical,glycine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
CC(C)c1c[nH]n2c(=NCc3ccccc3)cc(NCCCCCCN)nc12,"InChI=1S/C22H32N6/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23/h5-7,10-11,14,16-17,24,26H,3-4,8-9,12-13,15,23H2,1-2H3",VZOGFWHVKVYZIG-UHFFFAOYSA-N,bs-181,Preclinical,CDK inhibitor,CDK7,,
O=C(c1cccc(-c2nc3ccccc3[nH]2)n1)N1CCN(C(=O)c2cccc(-c3nc4ccccc4[nH]3)n2)CC1,"InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)",MVHWZNBAQIGPOQ-UHFFFAOYSA-N,bt-11,Phase 2,cAMP stimulant,,,
O=C(Oc1cc(S(=O)(=O)c2ccccc2)ccc1[N+](=O)[O-])c1ccc(Cl)cc1,"InChI=1S/C19H12ClNO6S/c20-14-8-6-13(7-9-14)19(22)27-18-12-16(10-11-17(18)21(23)24)28(25,26)15-4-2-1-3-5-15/h1-12H",WNDWKKPBLAKXMI-UHFFFAOYSA-N,btb06584,Preclinical,ATPase inhibitor,ATP5F1,,
O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)c1ccccc1,"InChI=1S/C12H8ClNO4S/c13-9-6-7-12(11(8-9)14(15)16)19(17,18)10-4-2-1-3-5-10/h1-8H",VZDUQPHKUBZMLW-UHFFFAOYSA-N,btb1,Preclinical,mitotic kinesin inhibitor,KIF18A,,
O=C(CNc1cccc(Cl)c1)NC1CCCN(c2ncnc3[nH]ccc23)C1,"InChI=1S/C19H21ClN6O/c20-13-3-1-4-14(9-13)22-10-17(27)25-15-5-2-8-26(11-15)19-16-6-7-21-18(16)23-12-24-19/h1,3-4,6-7,9,12,15,22H,2,5,8,10-11H2,(H,25,27)(H,21,23,24)",SPSNKQVUYDXOGY-UHFFFAOYSA-N,btk-in-1,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
Cc1ccc(S(=O)(=O)NCc2ccccc2)cc1,"InChI=1S/C14H15NO2S/c1-12-7-9-14(10-8-12)18(16,17)15-11-13-5-3-2-4-6-13/h2-10,15H,11H2,1H3",WTHKAJZQYNKTCJ-UHFFFAOYSA-N,bts,Preclinical,,,,
CC(C)CC(N)C1(c2ccc(Cl)cc2)CCC1,"InChI=1S/C15H22ClN/c1-11(2)10-14(17)15(8-3-9-15)12-4-6-13(16)7-5-12/h4-7,11,14H,3,8-10,17H2,1-2H3",WQSACWZKKZPCHN-UHFFFAOYSA-N,bts-54505,Withdrawn,dopamine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,,
CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1,"InChI=1S/C15H20ClN3/c1-15(2,13-4-6-14(16)7-5-13)18-8-3-10-19-11-9-17-12-19/h4-7,9,11-12,18H,3,8,10H2,1-2H3",GRKYRJREJPZXIU-UHFFFAOYSA-N,bts-71321,Phase 2,,,,
CC(Oc1ccc(Cl)cc1)c1ccnc2ncnn12,"InChI=1S/C13H11ClN4O/c1-9(19-11-4-2-10(14)3-5-11)12-6-7-15-13-16-8-17-18(12)13/h2-9H,1H3",FCEPUTGEUCVRRI-UHFFFAOYSA-N,bts-72664,Phase 1,GABA receptor antagonist,GABBR1,,
CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(-c2ccc(F)cc2)c1,"InChI=1S/C23H20FN5O3S/c1-28(33(31,32)22-15-25-29(16-22)21-11-7-17(24)8-12-21)20-13-9-19(10-14-20)27-23(30)26-18-5-3-2-4-6-18/h2-16H,1H3,(H2,26,27,30)",NSLIQOPYDUKWTA-UHFFFAOYSA-N,btt-3033,Preclinical,integrin inhibitor,ITGA2|ITGB1,,
CC1COC2(CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)O1,"InChI=1S/C17H16F3N3O5S/c1-9-8-27-16(28-9)2-4-22(5-3-16)15-21-14(24)11-6-10(17(18,19)20)7-12(23(25)26)13(11)29-15/h6-7,9H,2-5,8H2,1H3",GTUIRORNXIOHQR-UHFFFAOYSA-N,btz043-racemate,Phase 1/Phase 2,DPRE1 inhibitor,,,
c1ccc2nc(C3=NCCN3)ccc2c1,"InChI=1S/C12H11N3/c1-2-4-10-9(3-1)5-6-11(15-10)12-13-7-8-14-12/h1-6H,7-8H2,(H,13,14)",OSUVWJGCKQEMHK-UHFFFAOYSA-N,bu-224,Preclinical,imidazoline receptor ligand,MAOA|MAOB,,
c1ccc2nc(C3=NCCN3)cnc2c1,"InChI=1S/C11H10N4/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)",MQSSFHXQKUSFIW-UHFFFAOYSA-N,bu-239,Preclinical,imidazoline receptor agonist,,,
c1ccc2nc(C3=NCCN3)cnc2c1,"InChI=1S/C11H10N4/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)",MQSSFHXQKUSFIW-UHFFFAOYSA-N,bu-239,Preclinical,imidazoline receptor ligand,,,
c1ccc2cc(C3=NCCN3)ncc2c1,"InChI=1S/C12H11N3/c1-2-4-10-8-15-11(7-9(10)3-1)12-13-5-6-14-12/h1-4,7-8H,5-6H2,(H,13,14)",ZXRSVNHYTSSFMN-UHFFFAOYSA-N,bu226,Preclinical,imidazoline receptor ligand,,,
CCOc1ccc(NC(=O)CC(C)O)cc1,"InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)",LIAWQASKBFCRNR-UHFFFAOYSA-N,bucetin,Withdrawn,analgesic agent,,,
CC(C)(S)C(=O)NC(CS)C(=O)O,"InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)",VUAFHZCUKUDDBC-UHFFFAOYSA-N,bucillamine,Launched,immunosuppressant,,rheumatology,rheumatoid arthritis
CCCC(=O)N=c1[nH]cnc2c1ncn2C1OC2CO[PH](=O)(=O)OC2C1OC(=O)CCC,"InChI=1S/C18H23N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,19,20,22,24)",LWQOPFSCNLNNAR-UHFFFAOYSA-N,bucladesine,Launched,adenosine receptor agonist,PRKACA,dermatology,skin ulcer
CCCC(=O)N=c1[nH]cnc2c1ncn2C1OC2CO[PH](=O)(=O)OC2C1OC(=O)CCC,"InChI=1S/C18H23N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,19,20,22,24)",LWQOPFSCNLNNAR-UHFFFAOYSA-N,bucladesine,Launched,cAMP stimulant,PRKACA,dermatology,skin ulcer
CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,"InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3",MOYGZHXDRJNJEP-UHFFFAOYSA-N,buclizine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,migraine headache
CCCC1OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h6,8-9,16-18,20-22,26,28H,4-5,7,10-13H2,1-3H3",UNISKOOZAQCSPC-UHFFFAOYSA-N,budesonide,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology,Crohn's disease
CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,"InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3",QIHLUZAFSSMXHQ-UHFFFAOYSA-N,budipine,Launched,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease
CCCCOc1ccc(CC(O)=NO)cc1,"InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)",MXJWRABVEGLYDG-UHFFFAOYSA-N,bufexamac,Withdrawn,cyclooxygenase inhibitor,HDAC10|HDAC6,,
COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,"InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3",OWYLAEYXIQKAOL-UHFFFAOYSA-N,buflomedil,Launched,adrenergic receptor antagonist,ADRA1A,cardiology,peripheral artery disease (PAD)
COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,"InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3",OWYLAEYXIQKAOL-UHFFFAOYSA-N,buflomedil,Launched,calcium channel blocker,ADRA1A,cardiology,peripheral artery disease (PAD)
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,"InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)",MAEIEVLCKWDQJH-UHFFFAOYSA-N,bumetanide,Launched,solute carrier family member inhibitor,CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5,cardiology,edema|congestive heart failure
CCCC(=O)N1CCCN(c2nc(=N)c3cc(OC)c(OC)cc3[nH]2)CC1,"InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)",RHLJLALHBZGAFM-UHFFFAOYSA-N,bunazosin,Launched,adrenergic receptor antagonist,ADRA1A,ophthalmology,glaucoma|intraocular pressure
N=c1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)c[nH]1,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,buparlisib,Phase 3,PI3K inhibitor,PIK3CA|PIK3CG,,
CC(C)(C)C1CCC(=Cc2c(O)c(O)c3ccccc3c2O)CC1,"InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,12,14,22-24H,8-11H2,1-3H3",PPINWYOLRRJCPE-UHFFFAOYSA-N,buparvaquone,Launched,antiprotozoal agent,,infectious disease,protozoan infection
CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,"InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3",PTGXAUBQBSGPKF-UHFFFAOYSA-N,buphenine,Launched,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease
CCCCc1ccc(C(N)=O)nc1,"InChI=1S/C10H14N2O/c1-2-3-4-8-5-6-9(10(11)13)12-7-8/h5-7H,2-4H2,1H3,(H2,11,13)",VKSPIPWLHGKJQO-UHFFFAOYSA-N,bupicomide,Phase 1,adrenergic receptor antagonist,ADRB1,,
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)",LEBVLXFERQHONN-UHFFFAOYSA-N,bupivacaine,Launched,sodium channel blocker,KCNA5|SCN10A,neurology/psychiatry,peripheral nerve block|caudal epidural block|lumbar epidural block
Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1,"InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3",HQIRNZOQPUAHHV-UHFFFAOYSA-N,bupranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology|ophthalmology,hypertension|glaucoma
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,"InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3",SNPPWIUOZRMYNY-UHFFFAOYSA-N,bupropion,Launched,dopamine reuptake inhibitor,SLC6A2|SLC6A3,neurology/psychiatry,depression
O=C(NCc1ccccc1)OCCO,"InChI=1S/C10H13NO3/c12-6-7-14-10(13)11-8-9-4-2-1-3-5-9/h1-5,12H,6-8H2,(H,11,13)",YFLRYAVDPKONNX-UHFFFAOYSA-N,buramate,Preclinical,antiepileptic,,,
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,"InChI=1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)",CUWODFFVMXJOKD-UHFFFAOYSA-N,buserelin,Launched,gonadotropin releasing factor hormone receptor agonist,,oncology|obstetrics/gynecology,prostate cancer|endometriosis
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,buspirone,Launched,serotonin receptor agonist,DRD2|HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)
CS(=O)(=O)OCCCCOS(C)(=O)=O,"InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3",COVZYZSDYWQREU-UHFFFAOYSA-N,busulfan,Launched,DNA inhibitor,,hematologic malignancy,chronic myeloid leukemia (CML)
CCCCNC(=O)C1Cc2ccccc2N1C(=O)C(N)CC,"InChI=1S/C17H25N3O2/c1-3-5-10-19-16(21)15-11-12-8-6-7-9-14(12)20(15)17(22)13(18)4-2/h6-9,13,15H,3-5,10-11,18H2,1-2H3,(H,19,21)",HAQIRIMIVLFYIX-UHFFFAOYSA-N,butabindide,Preclinical,tripeptidyl peptidase inhibitor,TPP2,,
CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1,"InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3",HQFWVSGBVLEQGA-UHFFFAOYSA-N,butacaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1,"InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3",ZZJYIKPMDIWRSN-UHFFFAOYSA-N,butaclamol,Phase 2,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A,,
C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,"InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)",UZVHFVZFNXBMQJ-UHFFFAOYSA-N,butalbital,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,headache|muscle relaxant
CCCCOC(=O)c1ccc(N)cc1,"InChI=1S/C11H15NO2/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7H,2-3,8,12H2,1H3",IUWVALYLNVXWKX-UHFFFAOYSA-N,butamben,Withdrawn,sodium channel blocker,,,
CCCC1(C(O)CC=CC2C(O)CC(=O)C2CCCCCCC(=O)OC)CCC1,"InChI=1S/C24H40O5/c1-3-14-24(15-9-16-24)22(27)12-8-11-19-18(20(25)17-21(19)26)10-6-4-5-7-13-23(28)29-2/h8,11,18-19,21-22,26-27H,3-7,9-10,12-17H2,1-2H3",XRISENIKJUKIHD-UHFFFAOYSA-N,butaprost,Preclinical,prostaglandin receptor agonist,,,
O=C(C=Cc1ccc(O)c(O)c1)c1ccc(O)cc1O,"InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H",AYMYWHCQALZEGT-UHFFFAOYSA-N,butein,Preclinical,EGFR inhibitor,ACE,,
O=C(C=Cc1ccc(O)c(O)c1)c1ccc(O)cc1O,"InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H",AYMYWHCQALZEGT-UHFFFAOYSA-N,butein,Preclinical,SRC inhibitor,ACE,,
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12,"InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3",ABJKWBDEJIDSJZ-UHFFFAOYSA-N,butenafine,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis
CCCCS(=N)(=O)CCC(N)C(=O)O,"InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)",KJQFBVYMGADDTQ-UHFFFAOYSA-N,buthionine-sulfoximine,Phase 1,glutathione transferase inhibitor,GCLM,,
CCC(C(=O)O)c1ccc(CC(C)C)cc1,"InChI=1S/C14H20O2/c1-4-13(14(15)16)12-7-5-11(6-8-12)9-10(2)3/h5-8,10,13H,4,9H2,1-3H3,(H,15,16)",UULSXYSSHHRCQK-UHFFFAOYSA-N,butibufen,Withdrawn,cyclooxygenase inhibitor,,,
Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,"InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2",SWLMUYACZKCSHZ-UHFFFAOYSA-N,butoconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis
CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C,"InChI=1S/C17H26FNO3/c1-5-6-15(21)14-9-12(18)7-8-16(14)22-11-13(20)10-19-17(2,3)4/h7-9,13,19-20H,5-6,10-11H2,1-4H3",NMBNQRJDEPOXCP-UHFFFAOYSA-N,butofilolol,Phase 2,adrenergic receptor antagonist,,,
CCCCOC(=O)c1ccc(O)cc1,"InChI=1S/C11H14O3/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7,12H,2-3,8H2,1H3",QFOHBWFCKVYLES-UHFFFAOYSA-N,butyl-paraben,Preclinical,DNA synthesis inhibitor,,,
COc1ccc(O)c(C(C)(C)C)c1,"InChI=1S/C11H16O2/c1-11(2,3)9-7-8(13-4)5-6-10(9)12/h5-7,12H,1-4H3",MRBKEAMVRSLQPH-UHFFFAOYSA-N,butylated-hydroxyanisole,Preclinical,antioxidant,,,
Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"InChI=1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3",NLZUEZXRPGMBCV-UHFFFAOYSA-N,butylated-hydroxytoluene,Phase 1,carbonic anhydrase inhibitor,CA2,,
CCCC=C1OC(=O)c2ccccc21,"InChI=1S/C12H12O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h4-8H,2-3H2,1H3",WMBOCUXXNSOQHM-UHFFFAOYSA-N,butylidenephthalide,Phase 1/Phase 2,cyclooxygenase inhibitor,,,
CCCCC1OC(=O)c2ccccc21,"InChI=1S/C12H14O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h4-7,11H,2-3,8H2,1H3",HJXMNVQARNZTEE-UHFFFAOYSA-N,butylphthalide,Launched,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke
CC(C)N=c1cc(-c2c[nH]c(C(=O)NC(CO)c3cccc(Cl)c3)c2)c(Cl)c[nH]1,"InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)",KSERXGMCDHOLSS-UHFFFAOYSA-N,bvd-523,Phase 2,MAP kinase inhibitor,,,
Cc1c(Cl)cccc1S(=O)(=O)N=c1[nH]c(CC(=O)N2CCN(C)CC2)cs1,"InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20)",YDPRNGAPPNPYQQ-UHFFFAOYSA-N,bvt-2733,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,,
CC1(C)C(=O)N=C2c3ccccc3C(=O)C(=O)C21,"InChI=1S/C14H11NO3/c1-14(2)9-10(15-13(14)18)7-5-3-4-6-8(7)11(16)12(9)17/h3-6,9H,1-2H3",AJVXVYTVAAWZAP-UHFFFAOYSA-N,bvt-948,Preclinical,tyrosine phosphatase inhibitor,PTPN1|PTPN11|PTPN2,,
CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)C(C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)",ZHUJMSMQIPIPTF-UHFFFAOYSA-N,bw-180c,Phase 2,opioid receptor agonist,OPRD1|OPRM1,,
CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,"InChI=1S/C15H15ClN6S2/c1-10(12-7-4-5-9-17-12)19-21-15(24)22-20-14(23)18-13-8-3-2-6-11(13)16/h2-9H,1H3,(H2,18,20,23)(H2,21,22,24)",YYLKOELWSMRYHV-UHFFFAOYSA-N,bw-348u87,Preclinical,antiviral,,,
C=CCN1CC(C)N(C(c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)CC1C,"InChI=1S/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3",LBLDMHBSVIVJPM-UHFFFAOYSA-N,bw-373u86,Preclinical,opioid receptor agonist,OPRD1,,
CNC(=O)c1ccc2c(c1)S(=O)(=O)c1ccccc1C2=O,"InChI=1S/C15H11NO4S/c1-16-15(18)9-6-7-11-13(8-9)21(19,20)12-5-3-2-4-10(12)14(11)17/h2-8H,1H3,(H,16,18)",MLPSDBJCWIYSEA-UHFFFAOYSA-N,bw-616u,Preclinical,monoamine oxidase inhibitor,MAOA,,
CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,"InChI=1S/C16H18N2OS/c1-11(17)7-12-9-18-16-5-4-13(8-15(12)16)19-10-14-3-2-6-20-14/h2-6,8-9,11,18H,7,10,17H2,1H3",ALFGDCNSEBJYSP-UHFFFAOYSA-N,bw-723c86,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
CC(=O)N(O)CC=Cc1cccc(Oc2ccccc2)c1,"InChI=1S/C17H17NO3/c1-14(19)18(20)12-6-8-15-7-5-11-17(13-15)21-16-9-3-2-4-10-16/h2-11,13,20H,12H2,1H3",CEUDWZXMLMKPNN-UHFFFAOYSA-N,bw-a4c,Phase 1,lipoxygenase inhibitor,ALOX5,,
CC(C=Cc1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O,"InChI=1S/C17H17FN2O3/c1-12(20(22)17(19)21)5-6-13-3-2-4-16(11-13)23-15-9-7-14(18)8-10-15/h2-12,22H,1H3,(H2,19,21)",UAIYNMRLUHHRMF-UHFFFAOYSA-N,bw-b70c,Preclinical,lipoxygenase inhibitor,ALOX5,,
O=C(NCCCN=c1[nH]c(=Nc2cccc(NC(=O)N3CCCC3)c2)[nH]cc1I)c1cccs1,"InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)",VAVXGGRQQJZYBL-UHFFFAOYSA-N,bx-795,Preclinical,IKK inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,
O=C(Nc1cccc(N=c2[nH]cc(Br)c(=NCCc3c[nH]cn3)[nH]2)c1)N1CCCC1,"InChI=1S/C20H23BrN8O/c21-17-12-24-19(28-18(17)23-7-6-16-11-22-13-25-16)26-14-4-3-5-15(10-14)27-20(30)29-8-1-2-9-29/h3-5,10-13H,1-2,6-9H2,(H,22,25)(H,27,30)(H2,23,24,26,28)",DMMILYKXNCVKOJ-UHFFFAOYSA-N,bx-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,
Cn1cccc1C=C1C(=O)NC(=O)c2ccccc21,"InChI=1S/C15H12N2O2/c1-17-8-4-5-10(17)9-13-11-6-2-3-7-12(11)14(18)16-15(13)19/h2-9H,1H3,(H,16,18,19)",BTYSIDSTHDDAJW-UHFFFAOYSA-N,byk-204165,Preclinical,PARP inhibitor,PARP1,,
COc1cc2[nH]c(N3CCC(N4CCCCC4)CC3)nc(=NC3CCCCCC3)c2cc1OC,"InChI=1S/C27H41N5O2/c1-33-24-18-22-23(19-25(24)34-2)29-27(30-26(22)28-20-10-6-3-4-7-11-20)32-16-12-21(13-17-32)31-14-8-5-9-15-31/h18-21H,3-17H2,1-2H3,(H,28,29,30)",WYVBISCFCHREDA-UHFFFAOYSA-N,c-021,Preclinical,CC chemokine receptor antagonist,CCR4,,
O=S(=O)(c1cccc2cnccc12)N1CCNCC1,"InChI=1S/C13H15N3O2S/c17-19(18,16-8-6-14-7-9-16)13-3-1-2-11-10-15-5-4-12(11)13/h1-5,10,14H,6-9H2",UPTYCYWTFGTCCG-UHFFFAOYSA-N,c-1,Preclinical,protein kinase inhibitor,PRKCA,,
CCOC(=O)c1c[nH]cn1,"InChI=1S/C6H8N2O2/c1-2-10-6(9)5-3-7-4-8-5/h3-4H,2H2,1H3,(H,7,8)",KLWYPRNPRNPORS-UHFFFAOYSA-N,c-751,Preclinical,,,,
Cc1ccc(C(=O)OC(C(=O)O)C(OC(=O)c2ccc(C)cc2)C(=O)O)cc1,"InChI=1S/C20H18O8/c1-11-3-7-13(8-4-11)19(25)27-15(17(21)22)16(18(23)24)28-20(26)14-9-5-12(2)6-10-14/h3-10,15-16H,1-2H3,(H,21,22)(H,23,24)",CMIBUZBMZCBCAT-UHFFFAOYSA-N,c106,Phase 3,,,,
[Y+3],InChI=1S/Y/q+3,GRTBAGCGDOYUBE-UHFFFAOYSA-N,c11-acetate,Phase 3,,ABAT|ACE|AKR1C3|CA2|CELA1|ESR2|FFAR2|FFAR3|HPRT1|LTA4H|MMP12|NOS1|NOS3|PLA2G1B|PTPN1|SOD1|TXN,,
COc1ccc(S(=O)(=O)Nc2cc(-c3c(O)ccc4ccccc34)c(O)c3ccccc23)cc1,"InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3",QDCJDYWGYVPBDO-UHFFFAOYSA-N,c188-9,Preclinical,STAT inhibitor,,,
CC(=O)NC1C(OC(C)C)OC(COC(C)=O)C(OC(C)=O)C1OC(C)=O,"InChI=1S/C17H27NO9/c1-8(2)24-17-14(18-9(3)19)16(26-12(6)22)15(25-11(5)21)13(27-17)7-23-10(4)20/h8,13-17H,7H2,1-6H3,(H,18,19)",KMIQMFHPUJUDMC-UHFFFAOYSA-N,c34,Preclinical,toll-like receptor inhibitor,TLR4,,
C=c1[nH]n(-c2ccc(C(=O)O)cc2)c(=O)c1=Cc1ccc(-c2cc(C)c(C)cc2[N+](=O)[O-])o1,"InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12,25H,3H2,1-2H3,(H,29,30)",QZBUMRNGAHPCMI-UHFFFAOYSA-N,c646,Preclinical,histone acetyltransferase inhibitor,EP300,,
N=c1ccc(-c2cccc(C(=O)Nc3cnc4nc(N5CCOCC5)oc4c3)n2)c[nH]1,"InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29)",RWIMETUXCNDSLE-UHFFFAOYSA-N,ca-4948,Phase 1,kinase inhibitor,,,
C[S+](C)CCC(N)C(=O)O,"InChI=1S/C6H13NO2S/c1-10(2)4-3-5(7)6(8)9/h5H,3-4,7H2,1-2H3/p+1",YDBYJHTYSHBBAU-UHFFFAOYSA-O,cabagin,Launched,,,gastroenterology,dyspepsia
OCC1OC(OC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)9(19)11(21-3)23-12-10(20)8(18)6(16)4(2-14)22-12/h3-20H,1-2H2",HDTRYLNUVZCQOY-UHFFFAOYSA-N,cabaletta,Phase 2,pharmacological chaperone,,,
COC1=C2C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c3ccccc3)CC(O)(C(OC(=O)c3ccccc3)C3C4(OC(C)=O)COC4CC(OC)C3(C)C1=O)C2(C)C,"InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,24,28-30,32-33,35,37,48,53H,21-23H2,1-10H3,(H,46,52)",SUOGUKJEXYJHTD-UHFFFAOYSA-N,cabazitaxel,Launched,microtubule inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,prostate cancer
C=CCN1CC(C(=O)N(CCCN(C)C)C(=O)NCC)CC2c3cccc4[nH]cc(c34)CC21,"InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)",KORNTPPJEAJQIU-UHFFFAOYSA-N,cabergoline,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7,endocrinology,hyperprolactinemia
CC1COC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,"InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)",WCWSTNLSLKSJPK-UHFFFAOYSA-N,cabotegravir,Phase 3,HIV integrase inhibitor,,,
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,cabozantinib,Launched,RET tyrosine kinase inhibitor,KDR|MET|RET,oncology,medullary thyroid cancer (MTC)
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,cabozantinib,Launched,VEGFR inhibitor,KDR|MET|RET,oncology,medullary thyroid cancer (MTC)
CC(C)(C)C1CCc2c(sc(NC(=O)c3ccco3)c2C(=O)O)C1,"InChI=1S/C18H21NO4S/c1-18(2,3)10-6-7-11-13(9-10)24-16(14(11)17(21)22)19-15(20)12-5-4-8-23-12/h4-5,8,10H,6-7,9H2,1-3H3,(H,19,20)(H,21,22)",ACLUEOBQFRYTQS-UHFFFAOYSA-N,caccinh-a01,Preclinical,calcium-activated chloride channel inhibitor,CLCA1,,
O=C(O)c1cn(C2CC2)c2cc(N3CCC(O)(COc4ccc(N5CC(CO)OC5=O)cc4F)CC3)c(F)cc2c1=O,"InChI=1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)",XWFCFMXQTBGXQW-UHFFFAOYSA-N,cadazolid,Phase 3,antibacterial ,,,
CCOC(=O)NN=c1ccc(N(CC)CC(C)O)n[nH]1,"InChI=1S/C12H21N5O3/c1-4-17(8-9(3)18)11-7-6-10(13-15-11)14-16-12(19)20-5-2/h6-7,9,18H,4-5,8H2,1-3H3,(H,13,14)(H,16,19)",QLTVVOATEHFXLT-UHFFFAOYSA-N,cadralazine,Launched,adrenergic receptor antagonist,,cardiology,hypertension
CC12CCc3occc3C1CCC13CC(CCC12)C(O)(CO)C3,"InChI=1S/C20H28O3/c1-18-7-5-16-14(6-9-23-16)15(18)4-8-19-10-13(2-3-17(18)19)20(22,11-19)12-21/h6,9,13,15,17,21-22H,2-5,7-8,10-12H2,1H3",DNJVYWXIDISQRD-UHFFFAOYSA-N,cafestol,Launched,pregnane X receptor agonist,,,
O=C(O)C=Cc1ccc(O)c(O)c1,"InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)",QAIPRVGONGVQAS-UHFFFAOYSA-N,caffeic-acid,Preclinical,HIV integrase inhibitor,ALOX5|MIF,,
O=C(O)C=Cc1ccc(O)c(O)c1,"InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)",QAIPRVGONGVQAS-UHFFFAOYSA-N,caffeic-acid,Preclinical,lipoxygenase inhibitor,ALOX5|MIF,,
O=C(O)C=Cc1ccc(O)c(O)c1,"InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)",QAIPRVGONGVQAS-UHFFFAOYSA-N,caffeic-acid,Preclinical,nitric oxide production inhibitor,ALOX5|MIF,,
O=C(O)C=Cc1ccc(O)c(O)c1,"InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)",QAIPRVGONGVQAS-UHFFFAOYSA-N,caffeic-acid,Preclinical,tumor necrosis factor production inhibitor,ALOX5|MIF,,
O=C(C=Cc1ccc(O)c(O)c1)OCCc1ccccc1,"InChI=1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2",SWUARLUWKZWEBQ-UHFFFAOYSA-N,caffeic-acid-phenethyl-ester,Preclinical,HIV integrase inhibitor,RELA,,
Cn1c(=O)c2c(ncn2C)n(C)c1=O,"InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3",RYYVLZVUVIJVGH-UHFFFAOYSA-N,caffeine,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3,neurology/psychiatry,fatigue|drowsiness
Cn1c(=O)c2c(ncn2C)n(C)c1=O,"InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3",RYYVLZVUVIJVGH-UHFFFAOYSA-N,caffeine,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3,neurology/psychiatry,fatigue|drowsiness
C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)CCCC(C)(C)O,"InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3",JWUBBDSIWDLEOM-UHFFFAOYSA-N,calcifediol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC(O)C2CC2)CC(O)CC1O,"InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3",LWQQLNNNIPYSNX-UHFFFAOYSA-N,calcipotriol,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis
CC(C)CC(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1)C(C)C)C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NCC(=O)NC(C)C(=O)NCC(=O)NC(C(=O)N1CCCC1C(N)=O)C(C)O)C(C)C)C(C)O)C(C)O,"InChI=1S/C146H241N43O47S2/c1-66(2)47-88(175-140(231)112(72(13)14)184-137(228)100-64-238-237-63-81(149)119(210)178-97(60-190)135(226)174-94(54-105(152)200)132(223)172-92(51-70(9)10)130(221)180-99(62-192)136(227)187-115(76(18)195)143(234)181-100)120(211)159-58-107(202)163-82(27-20-22-42-147)121(212)169-91(50-69(7)8)129(220)179-98(61-191)134(225)167-85(36-39-103(150)198)123(214)165-87(38-41-109(204)205)124(215)171-90(49-68(5)6)128(219)173-93(53-79-56-156-65-161-79)131(222)164-83(28-21-23-43-148)122(213)170-89(48-67(3)4)127(218)166-86(37-40-104(151)199)126(217)186-114(75(17)194)142(233)177-96(52-78-32-34-80(197)35-33-78)144(235)189-46-26-31-102(189)138(229)168-84(29-24-44-157-146(154)155)125(216)185-113(74(16)193)141(232)176-95(55-110(206)207)133(224)183-111(71(11)12)139(230)160-57-106(201)162-73(15)118(209)158-59-108(203)182-116(77(19)196)145(236)188-45-25-30-101(188)117(153)208/h32-35,56,65-77,81-102,111-116,190-197H,20-31,36-55,57-64,147-149H2,1-19H3,(H2,150,198)(H2,151,199)(H2,152,200)(H2,153,208)(H,156,161)(H,158,209)(H,159,211)(H,160,230)(H,162,201)(H,163,202)(H,164,222)(H,165,214)(H,166,218)(H,167,225)(H,168,229)(H,169,212)(H,170,213)(H,171,215)(H,172,223)(H,173,219)(H,174,226)(H,175,231)(H,176,232)(H,177,233)(H,178,210)(H,179,220)(H,180,221)(H,181,234)(H,182,203)(H,183,224)(H,184,228)(H,185,216)(H,186,217)(H,187,227)(H,204,205)(H,206,207)(H4,154,155,157)",JDJALSWDQPEHEJ-UHFFFAOYSA-N,calcitonin,Launched,calcitonin agonist,,orthopedics,osteoporosis
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O,"InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3",GMRQFYUYWCNGIN-UHFFFAOYSA-N,calcitriol,Launched,vitamin D receptor agonist,VDR,endocrinology|orthopedics,hypocalcemia|hypoparathyroidism|osteoporosis
O=C(C(O)C(O)CO)C(O)C(O)C(O)O,"InChI=1S/C7H14O8/c8-1-2(9)3(10)4(11)5(12)6(13)7(14)15/h2-3,5-10,12-15H,1H2",CCYHUXJZAZZHSB-UHFFFAOYSA-N,calcium-gluceptate,Launched,,,,
N=c1[nH]c2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1)CN2,"InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)",VVIAGPKUTFNRDU-UHFFFAOYSA-N,calcium-levofolinate,Launched,,,,
CC(NC1CCCCC1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12,"InChI=1S/C25H27ClN2O/c1-17(21-10-6-8-18-7-2-3-9-22(18)21)27-23-11-4-5-12-24(23)28-25(29)19-13-15-20(26)16-14-19/h2-3,6-10,13-17,23-24,27H,4-5,11-12H2,1H3,(H,28,29)",YTFUQWWKTIWYEY-UHFFFAOYSA-N,calhex-231,Preclinical,calcium sensing receptor negative allosteric modulator,CASR,,
CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1,"InChI=1S/C20H30N2O4/c1-4-5-11-17(13-23)21-19(24)18(12-15(2)3)22-20(25)26-14-16-9-7-6-8-10-16/h6-10,13,15,17-18H,4-5,11-12,14H2,1-3H3,(H,21,24)(H,22,25)",PGGUOGKHUUUWAF-UHFFFAOYSA-N,calpeptin,Preclinical,calpain inhibitor,,,
CC1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,"InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3",RZKDEGZIFSJVNA-UHFFFAOYSA-N,camicinal,Phase 2,motilin receptor agonist,MLNR,,
Cc1c(Cl)cccc1S(=O)(=O)N=c1[nH]c(=NCCc2ccccc2)[nH]c2c1CN(Cc1ccccc1)CC2,"InChI=1S/C29H30ClN5O2S/c1-21-25(30)13-8-14-27(21)38(36,37)34-28-24-20-35(19-23-11-6-3-7-12-23)18-16-26(24)32-29(33-28)31-17-15-22-9-4-2-5-10-22/h2-14H,15-20H2,1H3,(H2,31,32,33,34)",LGUUETDTMQTHML-UHFFFAOYSA-N,camkii-in-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,AKT1|CAMK2A|CAMK4|MYLK,,
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1,"InChI=1S/C33H50O4S2/c1-29(2,3)22-15-20(16-23(27(22)36)30(4,5)6)38-33(13,14)39-21-17-24(31(7,8)9)28(37-19-26(34)35)25(18-21)32(10,11)12/h15-18,36H,19H2,1-14H3,(H,34,35)",FGBGXESDYFKUFX-UHFFFAOYSA-N,camobucol,Preclinical,anti-inflammatory agent,,,
CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(N=C(N)N)cc2)cc1,"InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)",XASIMHXSUQUHLV-UHFFFAOYSA-N,camostat-mesilate,Launched,protease inhibitor,PRSS1,gastroenterology,pancreatitis
CC12CCC(CC1=O)C2(C)C,"InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3",DSSYKIVIOFKYAU-UHFFFAOYSA-N,camphor-(+),Phase 2,,,,
CC12CCC(CC1=O)C2(C)C,"InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3",DSSYKIVIOFKYAU-UHFFFAOYSA-N,camphor-(1r),Phase 1,TRPV activator,TRPV1,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1,"InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3",VSJKWCGYPAHWDS-UHFFFAOYSA-N,camptothecin,Phase 3,topoisomerase inhibitor,TOP1,,
CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1,"InChI=1S/C19H32N2O2/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4/h7-11,16,18,20H,5-6,12-15H2,1-4H3",RYOOHIUJEJZCFT-UHFFFAOYSA-N,camylofine-chlorhydrate,Launched,,,gastroenterology,abdominal pain
Cc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,"InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3",XTNGUQKDFGDXSJ-UHFFFAOYSA-N,canagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)",HTQMVQVXFRQIKW-UHFFFAOYSA-N,candesartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure
CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)",GHOSNRCGJFBJIB-UHFFFAOYSA-N,candesartan-cilexetil,Launched,angiotensin receptor antagonist,,cardiology,hypertension|congestive heart failure|hypertension
CC1C=CC=CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(O)C2N)CC(O)C(C(=O)O)C(O)CC(=O)CC(O)CC(O)CC(O)CC(=O)CCCC(=O)CC(=O)OC1C(C)CC(C)C(O)CC(=O)c1ccc(N)cc1,"InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-54(61)56(74)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)",HYIZCDMXFDRDFE-UHFFFAOYSA-N,candicidin,Launched,fungal ergosterol inhibitor,,infectious disease,vulvovaginal candidiasis
C=CC(=O)Nc1cc2c(=Nc3ccc(F)c(Cl)c3)[nH]cnc2cc1OCCCN1CCOCC1,"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)",OMZCMEYTWSXEPZ-UHFFFAOYSA-N,canertinib,Phase 3,EGFR inhibitor,AKT1|EGFR|ERBB2|ERBB4,,
CSCCN=c1[nH]c(SCCC(F)(F)F)nc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)C(Cl)(Cl)[PH](=O)(=O)O)C(O)C1O,"InChI=1S/C17H22Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,23,25,26)(H,30,31,32)",YKINTJYLFZRURY-UHFFFAOYSA-N,cangrelor,Launched,purinergic receptor antagonist,,cardiology,myocardial infarction
CC12CCC(=O)C=C1C=CC1C2CCC2(C)C1CCC21CCC(=O)O1,"InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3",UJVLDDZCTMKXJK-UHFFFAOYSA-N,canrenone,Withdrawn,mineralocorticoid receptor antagonist,NR3C2,,
CC12C(=O)OC(=O)C1(C)C1CCC2O1,"InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3",DHZBEENLJMYSHQ-UHFFFAOYSA-N,cantharidin,Launched,protein phosphatase inhibitor,,dermatology,blisters
N#Cc1c(SCc2csc(-c3ccc(Cl)cc3)n2)[nH]c(=N)c(C#N)c1-c1ccc(OCCO)cc1,"InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)",CITWCLNVRIKQAF-UHFFFAOYSA-N,capadenoson,Phase 2,adenosine receptor agonist,ADORA1,,
CCCCCOC(=O)N=c1[nH]c(=O)n(C2OC(C)C(O)C2O)cc1F,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)",GAGWJHPBXLXJQN-UHFFFAOYSA-N,capecitabine,Launched,DNA synthesis inhibitor,TYMS,oncology,breast cancer|colorectal cancer
CCCCCOC(=O)N=c1[nH]c(=O)n(C2OC(C)C(O)C2O)cc1F,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)",GAGWJHPBXLXJQN-UHFFFAOYSA-N,capecitabine,Launched,thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer
COc1cc(C(=O)NCCCCCC(=O)O)cc(OC)c1OC,"InChI=1S/C16H23NO6/c1-21-12-9-11(10-13(22-2)15(12)23-3)16(20)17-8-6-4-5-7-14(18)19/h9-10H,4-8H2,1-3H3,(H,17,20)(H,18,19)",MPTXLVRHYGBOQY-UHFFFAOYSA-N,capobenic-acid,Preclinical,,,,
CC1=NC(=O)C(N)CNC(=O)C(C2CCN=C(N)N2)NC(=O)C(CNC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O,"InChI=1S/C25H44N14O7/c1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h12-16,18H,2-10,26-28H2,1H3,(H,32,40)(H,33,45)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)",AVYQDPREEYDUCJ-UHFFFAOYSA-N,capreomycin,Launched,protein synthesis inhibitor,,infectious disease,tuberculosis
CN1N=C2CCN(C(=O)C(COCc3ccccc3)NC(=O)C(C)(C)N)CC2(Cc2ccccc2)C1=O,"InChI=1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)",KVLLHLWBPNCVNR-UHFFFAOYSA-N,capromorelin,Preclinical,growth hormone secretagogue receptor agonist,,,
CCCCCCCC(=O)O,"InChI=1S/C8H16O2/c1-2-3-4-5-6-7-8(9)10/h2-7H2,1H3,(H,9,10)",WWZKQHOCKIZLMA-UHFFFAOYSA-N,caprylic-acid,Launched,,,,
COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,"InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)",YKPUWZUDDOIDPM-UHFFFAOYSA-N,capsaicin,Launched,TRPV agonist,CFTR|TRPV1,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis
Oc1cc2c(cc1O)CN(C(=S)NCCc1ccc(Cl)cc1)CCC2,"InChI=1S/C19H21ClN2O2S/c20-16-5-3-13(4-6-16)7-8-21-19(25)22-9-1-2-14-10-17(23)18(24)11-15(14)12-22/h3-6,10-11,23-24H,1-2,7-9,12H2,(H,21,25)",DRCMAZOSEIMCHM-UHFFFAOYSA-N,capsazepine,Preclinical,TRPV agonist,TRPV1|TRPV4,,
CN(C)CCS,"InChI=1S/C4H11NS/c1-5(2)3-4-6/h6H,3-4H2,1-2H3",DENMGZODXQRYAR-UHFFFAOYSA-N,captamine,Preclinical,,,,
Oc1c2c(c(O)n1SC(Cl)(Cl)Cl)CC=CC2,"InChI=1S/C9H8Cl3NO2S/c10-9(11,12)16-13-7(14)5-3-1-2-4-6(5)8(13)15/h1-2,14-15H,3-4H2",YHILKALTPHRGSY-UHFFFAOYSA-N,captan,Phase 1,,,,
CC(CS)C(=O)N1CCCC1C(=O)O,"InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)",FAKRSMQSSFJEIM-UHFFFAOYSA-N,captopril,Launched,angiotensin converting enzyme inhibitor,ACE|LTA4H|MMP2|MMP9,cardiology|endocrinology|nephrology,hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy
CNC(=O)ON(C(C)=O)C(=O)NC,"InChI=1S/C6H11N3O4/c1-4(10)9(5(11)7-2)13-6(12)8-3/h1-3H3,(H,7,11)(H,8,12)",JURAJLFHWXNPHG-UHFFFAOYSA-N,caracemide,Phase 2,ribonucleotide reductase inhibitor,RRM1,,
CCN(CC)CCOC(=O)C1(c2ccccc2)CCCC1,"InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3",OFAIGZWCDGNZGT-UHFFFAOYSA-N,caramiphen,Launched,cholinergic receptor antagonist,CHRM1|CHRM2,neurology/psychiatry,Parkinson's Disease
CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,"InChI=1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3",BQXQGZPYHWWCEB-UHFFFAOYSA-N,carazolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|cardiac arrythmia|hypertension|myocardial infarction
C[N+](C)(C)CCOC(N)=O,"InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1",VPJXQGSRWJZDOB-UHFFFAOYSA-O,carbachol,Launched,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,ophthalmology,intraocular pressure
COC(=O)NN=Cc1c[n+]([O-])c2ccccc2[n+]1[O-],"InChI=1S/C11H10N4O4/c1-19-11(16)13-12-6-8-7-14(17)9-4-2-3-5-10(9)15(8)18/h2-7H,1H3,(H,13,16)",OVGGLBAWFMIPPY-UHFFFAOYSA-N,carbadox,Launched,other antibiotic,,infectious disease|gastroenterology,dysentry|enteritis
NC(=O)N1c2ccccc2C=Cc2ccccc21,"InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)",FFGPTBGBLSHEPO-UHFFFAOYSA-N,carbamazepine,Launched,carboxamide antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CNC(=O)Oc1cccc2ccccc12,"InChI=1S/C12H11NO2/c1-13-12(14)15-11-8-4-6-9-5-2-3-7-10(9)11/h2-8H,1H3,(H,13,14)",CVXBEEMKQHEXEN-UHFFFAOYSA-N,carbaril,Launched,acetylcholinesterase inhibitor,,,
NC(=O)Nc1ccc([As](=O)(O)O)cc1,"InChI=1S/C7H9AsN2O4/c9-7(11)10-6-3-1-5(2-4-6)8(12,13)14/h1-4H,(H3,9,10,11)(H2,12,13,14)",WWXBHTZSYYGCSG-UHFFFAOYSA-N,carbarsone,Launched,antiprotozoal agent,,infectious disease,amebiasis
CN1c2cc(O)c(N=NC(N)=O)cc2CC1S(=O)(=O)O,"InChI=1S/C10H12N4O5S/c1-14-7-4-8(15)6(12-13-10(11)16)2-5(7)3-9(14)20(17,18)19/h2,4,9,15H,3H2,1H3,(H2,11,16)(H,17,18,19)",OQVRCWUMFBNYKF-UHFFFAOYSA-N,carbazochrome,Launched,,,hematology,hemorrhage
COC(=O)N=c1[nH]c2ccccc2[nH]1,"InChI=1S/C9H9N3O2/c1-14-9(13)12-8-10-6-4-2-3-5-7(6)11-8/h2-5H,1H3,(H2,10,11,12,13)",TWFZGCMQGLPBSX-UHFFFAOYSA-N,carbendazim,Launched,microtubule inhibitor,TP53|TUBB,infectious disease,fungicide
COC(=O)N=c1[nH]c2ccccc2[nH]1,"InChI=1S/C9H9N3O2/c1-14-9(13)12-8-10-6-4-2-3-5-7(6)11-8/h2-5H,1H3,(H2,10,11,12,13)",TWFZGCMQGLPBSX-UHFFFAOYSA-N,carbendazim,Launched,tubulin polymerization inhibitor,TP53|TUBB,infectious disease,fungicide
CC1(C)SC2C(NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)",FPPNZSSZRUTDAP-UHFFFAOYSA-N,carbenicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CC1(C(=O)O)CCC2(C)CCC3(C)C(=C2C1)CC(=O)C1C2(C)CCC(OC(=O)CCC(=O)O)C(C)(C)C2CCC13C,"InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h23-24,27H,8-19H2,1-7H3,(H,36,37)(H,39,40)",WTRSDYASGDJGGB-UHFFFAOYSA-N,carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3,gastroenterology|dental,peptic ulcer disease (PUD)|mouth inflammation
CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,"InChI=1S/C20H31NO3/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3",CFJMRBQWBDQYMK-UHFFFAOYSA-N,carbetapentane,Launched,acetylcholine receptor antagonist,CHRM2,otolaryngology|pulmonary,common cold|nasal congestion|bronchitis
CCC(C)C1NC(=O)C(Cc2ccc(OC)cc2)NC(=O)CCCSCC(C(=O)N2CCCC2C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC1=O,"InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)",NSTRIRCPWQHTIA-UHFFFAOYSA-N,carbetocin,Launched,oxytocin receptor agonist,OXTR,hematology,hemorrhage
CC(Cc1ccc(O)c(O)c1)(NN)C(=O)O,"InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)",TZFNLOMSOLWIDK-UHFFFAOYSA-N,carbidopa,Launched,aromatic L-amino acid decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease
CCOC(=O)n1ccn(C)c1=S,"InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3",CFOYWRHIYXMDOT-UHFFFAOYSA-N,carbimazole,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism
CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,"InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3",OJFSXZCBGQGRNV-UHFFFAOYSA-N,carbinoxamine,Launched,histamine receptor antagonist,HRH1,allergy|ophthalmology|otolaryngology|dermatology,allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism
O=C(O)C1(C(=O)O)CCC1,"InChI=1S/C6H8O4/c7-4(8)6(5(9)10)2-1-3-6/h1-3H2,(H,7,8)(H,9,10)",CCQPAEQGAVNNIA-UHFFFAOYSA-N,carboplatin,Launched,DNA alkylating agent,,oncology,ovarian cancer
O=C(O)C1(C(=O)O)CCC1,"InChI=1S/C6H8O4/c7-4(8)6(5(9)10)2-1-3-6/h1-3H2,(H,7,8)(H,9,10)",CCQPAEQGAVNNIA-UHFFFAOYSA-N,carboplatin,Launched,DNA inhibitor,,oncology,ovarian cancer
N=c1c(C(N)=O)n[nH]n1Cc1cc(Cl)c(C(=O)c2ccc(Cl)cc2)c(Cl)c1,"InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6,21,24H,7H2,(H2,22,27)",DLVKUJBXDDMSSY-UHFFFAOYSA-N,carboxyamidotriazole,Phase 3,calcium channel blocker,CXCL8,,
CCCCc1nc(Cl)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C22H21ClN6O2/c1-2-3-8-18-24-20(23)19(22(30)31)29(18)13-14-9-11-15(12-10-14)16-6-4-5-7-17(16)21-25-27-28-26-21/h4-7,9-12H,2-3,8,13H2,1H3,(H,30,31)(H,25,26,27,28)",ZEUXAIYYDDCIRX-UHFFFAOYSA-N,carboxylosartan,Phase 1,angiotensin antagonist,AGTR1,,
O=C(O)c1ccc(SSc2ccc(C(=O)O)cn2)nc1,"InChI=1S/C12H8N2O4S2/c15-11(16)7-1-3-9(13-5-7)19-20-10-4-2-8(6-14-10)12(17)18/h1-6H,(H,15,16)(H,17,18)",GSASOFRDSIKDSN-UHFFFAOYSA-N,carboxypyridine-disulfide,Phase 2,,,,
COc1ccc(N=c2[nH]ccc(=NCCO)[nH]2)cc1,"InChI=1S/C13H16N4O2/c1-19-11-4-2-10(3-5-11)16-13-15-7-6-12(17-13)14-8-9-18/h2-7,18H,8-9H2,1H3,(H2,14,15,16,17)",LKBSMPFEKIBRGC-UHFFFAOYSA-N,cardiogenol-c,Preclinical,cardiomyogenesis inducer,,,
c1coc(-c2nnc3sc(C4CCCCC4)nn23)c1,"InChI=1S/C13H14N4OS/c1-2-5-9(6-3-1)12-16-17-11(10-7-4-8-18-10)14-15-13(17)19-12/h4,7-9H,1-3,5-6H2",SWTUPSNBTSPBIH-UHFFFAOYSA-N,cardionogen-1,Preclinical,WNT signaling inhibitor,CTNNB1,,
CC(C)(C(=O)O)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36)",XGHOVGYJHWQGCC-UHFFFAOYSA-N,carebastine,Phase 1,histamine receptor antagonist,HRH1,,
CC(C)CC(NC(=O)C(CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)NC(Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)",BLMPQMFVWMYDKT-UHFFFAOYSA-N,carfilzomib,Launched,proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9,hematologic malignancy,multiple myeloma
NC(=O)NC(CCC(=O)O)C(=O)O,"InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)",LCQLHJZYVOQKHU-UHFFFAOYSA-N,carglumic-acid,Launched,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia
NC(=O)CN1C=CCC(C(N)=O)=C1,"InChI=1S/C8H11N3O2/c9-7(12)5-11-3-1-2-6(4-11)8(10)13/h1,3-4H,2,5H2,(H2,9,12)(H2,10,13)",WEJRSYKFMCUCRQ-UHFFFAOYSA-N,caricotamide,Phase 2,NADPH quinone oxidoreductase inhibitor,NQO2,,
CC(C)c1ccc(C(=O)N=C(N)N)cc1S(C)(=O)=O,"InChI=1S/C12H17N3O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18/h4-7H,1-3H3,(H4,13,14,15,16)",IWXNYAIICFKCTM-UHFFFAOYSA-N,cariporide,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,
CN(C)C(=O)NC1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,"InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)",KPWSJANDNDDRMB-UHFFFAOYSA-N,cariprazine,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,schizophrenia
CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,"InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)",AOCCBINRVIKJHY-UHFFFAOYSA-N,carmofur,Launched,thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer
COc1ccc(CC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,"InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)",IHOXNOQMRZISPV-UHFFFAOYSA-N,carmoterol,Phase 2,adrenergic receptor agonist,ADRB2,,
O=C(O)c1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1,"InChI=1S/C24H26N2O2/c27-24(28)20-9-10-23-22(16-20)21(17-25-23)8-4-5-13-26-14-11-19(12-15-26)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,25H,4-5,8,12-15H2,(H,27,28)",AFSOIHMEOKEZJF-UHFFFAOYSA-N,carmoxirole,Phase 2,dopamine receptor agonist,DRD2,,
O=C(NCCCl)N(CCCl)NO,"InChI=1S/C5H11Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h9,12H,1-4H2,(H,8,11)",NANCADMWZWLLJE-UHFFFAOYSA-N,carmustine,Launched,DNA alkylating agent,GSR,hematologic malignancy|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma
O=C(NCCCl)N(CCCl)NO,"InChI=1S/C5H11Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h9,12H,1-4H2,(H,8,11)",NANCADMWZWLLJE-UHFFFAOYSA-N,carmustine,Launched,DNA inhibitor,GSR,hematologic malignancy|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma
C[N+](C)(C)CC(O)CC(=O)O,"InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/p+1",PHIQHXFUZVPYII-UHFFFAOYSA-O,carnitine-(d/l),Phase 3,,,,
NCCC(=O)NC(Cc1c[nH]cn1)C(=O)O,"InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)",CQOVPNPJLQNMDC-UHFFFAOYSA-N,carnosine,Phase 2,antiglycating agent,,,
CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21,"InChI=1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3",MSPRUJDUTKRMLM-UHFFFAOYSA-N,caroverin,Phase 3,cytochrome P450 inhibitor,,,
NC(=O)CN1Cc2ccccc2OC1=O,"InChI=1S/C10H10N2O3/c11-9(13)6-12-5-7-3-1-2-4-8(7)15-10(12)14/h1-4H,5-6H2,(H2,11,13)",KYCBWEZLKCTALM-UHFFFAOYSA-N,caroxazone,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,,
CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12,"InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)",PUXBGTOOZJQSKH-UHFFFAOYSA-N,carprofen,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
O=c1[nH]c(=O)c2ccccc2o1,"InChI=1S/C8H5NO3/c10-7-5-3-1-2-4-6(5)12-8(11)9-7/h1-4H,(H,9,10,11)",OAYRYNVEFFWSHK-UHFFFAOYSA-N,carsalam,Preclinical,analgesic agent,,,
CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2,"InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)",LWAFSWPYPHEXKX-UHFFFAOYSA-N,carteolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,intraocular pressure|glaucoma|ocular hypertension
N=c1[nH]c(C(=NOCC(=O)O)C(=O)NC2C(=O)N(S(=O)(=O)O)C2COC(N)=O)cs1,"InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)",UIMOJFJSJSIGLV-UHFFFAOYSA-N,carumonam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,"InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3",OGHNVEJMJSYVRP-UHFFFAOYSA-N,carvedilol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,myocardial infarction|hypertension
NS(=O)(=O)c1ccc(C(=O)O)cc1,"InChI=1S/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)",UCAGLBKTLXCODC-UHFFFAOYSA-N,carzenide,Preclinical,,CA1|CA12|CA14|CA2|CA6|CA9,,
OCc1cc(O)c2c(O)c3c(O)cccc3c(OC3OC(CO)C(O)C(O)C3O)c2c1,"InChI=1S/C21H22O10/c22-6-8-4-10-15(12(25)5-8)17(27)14-9(2-1-3-11(14)24)20(10)31-21-19(29)18(28)16(26)13(7-23)30-21/h1-5,13,16,18-19,21-29H,6-7H2",XMCJWIFCIIXRGI-UHFFFAOYSA-N,casanthranol-variant,Launched,,,gastroenterology,constipation
OCCNC1CCCc2c1[nH]c1ccc(-c3ccccc3)cc21,"InChI=1S/C20H22N2O/c23-12-11-21-19-8-4-7-16-17-13-15(14-5-2-1-3-6-14)9-10-18(17)22-20(16)19/h1-3,5-6,9-10,13,19,21-23H,4,7-8,11-12H2",RXIUMAOXORBRCY-UHFFFAOYSA-N,casin,Preclinical,GTPase inhibitor,CDC42,,
CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(C(O)CCN)NC(=O)C(C(O)C(O)c2ccc(O)cc2)NC(=O)C2CC(O)CN2C(=O)C(C(C)O)NC1=O,"InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)",JYIKNQVWKBUSNH-UHFFFAOYSA-N,caspofungin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,candidemia|esophageal candidiasis|aspergillosis|peritonitis|fungal infection
CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(C(O)CCN)NC(=O)C(C(O)C(O)c2ccc(O)cc2)NC(=O)C2CC(O)CN2C(=O)C(C(C)O)NC1=O,"InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)",JYIKNQVWKBUSNH-UHFFFAOYSA-N,caspofungin,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|esophageal candidiasis|aspergillosis|peritonitis|fungal infection
OC1CN2CCC(O)C2C(O)C1O,"InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2",JDVVGAQPNNXQDW-UHFFFAOYSA-N,castanospermine,Phase 2,glucosidase inhibitor,GAA|GBA,,
CCC1=CC2CN3CCc4c([nH]c5ccccc45)C(C(=O)OC)(C2)C13,"InChI=1S/C21H24N2O2/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18/h4-7,10,13,19,22H,3,8-9,11-12H2,1-2H3",CMKFQVZJOWHHDV-UHFFFAOYSA-N,catharanthine,Preclinical,tubulin polymerization inhibitor,,,
Cn1nc(C(C)(C)C)cc1C(=O)NC(Cc1cccc(Cl)c1)C(=O)NCC#N,"InChI=1S/C20H24ClN5O2/c1-20(2,3)17-12-16(26(4)25-17)19(28)24-15(18(27)23-9-8-22)11-13-6-5-7-14(21)10-13/h5-7,10,12,15H,9,11H2,1-4H3,(H,23,27)(H,24,28)",MZRVIHRERYCHBL-UHFFFAOYSA-N,cathepsin-inhibitor-1,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSV,,
O=C1NC(=O)C(=Cc2ccc(-c3ccc(F)cc3)o2)S1,"InChI=1S/C14H8FNO3S/c15-9-3-1-8(2-4-9)11-6-5-10(19-11)7-12-13(17)16-14(18)20-12/h1-7H,(H,16,17,18)",UFBTYTGRUBUUIL-UHFFFAOYSA-N,cay10505,Preclinical,PI3K inhibitor,PIK3CG,,
CCC(=O)OC1(C(=O)CO)CCC2C3CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h5,17-19,25H,4,6-14H2,1-3H3",LQEJQTUNPIYXOR-UHFFFAOYSA-N,cb-03-01,Phase 3,androgen receptor antagonist,AR,,
CN(C)N=Nc1ccc(C(=O)O)cc1,"InChI=1S/C9H11N3O2/c1-12(2)11-10-8-5-3-7(4-6-8)9(13)14/h3-6H,1-2H3,(H,13,14)",GUAZPUYTLMUTMA-UHFFFAOYSA-N,cb-10-277,Phase 1,DNA synthesis inhibitor,,,
Cc1cc2c(C(N)=O)cccc2n1-c1nc(=NCc2ccccc2)c2c([nH]1)CCOC2,"InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)",RDALZZCKQFLGJP-UHFFFAOYSA-N,cb-5083,Phase 1,valosin-containing protein inhibitor,VCP,,
O=C(Cc1cccc(OC(F)(F)F)c1)N=c1ccc(CCCCc2n[nH]c(=NC(=O)Cc3ccccn3)s2)n[nH]1,"InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)",PRAAPINBUWJLGA-UHFFFAOYSA-N,cb-839,Phase 2,glutaminase inhibitor,GLS,,
CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2ccc(C#N)cc2)c1,"InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3",HDVYXILCBYGKGU-UHFFFAOYSA-N,cbipes,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,
CC(=O)c1ccc2c(c1)c1cc(C(C)=O)ccc1n2CCNC(C)C,"InChI=1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3",JKCSODVERGVDLT-UHFFFAOYSA-N,cbl0137,Phase 1,histone chaperone inhibitor,,,
N=C(NNc1ccccc1)c1ccccc1,"InChI=1S/C13H13N3/c14-13(11-7-3-1-4-8-11)16-15-12-9-5-2-6-10-12/h1-10,15H,(H2,14,16)",ZOBKPJRHDMKXQG-UHFFFAOYSA-N,cbs-1114,Phase 1,lipoxygenase inhibitor,ALOX5,,
CCn1c(=O)cnc2c1=NC(c1ccc(-c3nc[nH]n3)nc1C)CN=2,"InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-5,7-8,12H,3,6H2,1-2H3,(H,19,20,23)",DISSYWHTRARGQK-UHFFFAOYSA-N,cc-115,Phase 2,DNA protein kinase inhibitor,MTOR,,
CCn1c(=O)cnc2c1=NC(c1ccc(-c3nc[nH]n3)nc1C)CN=2,"InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-5,7-8,12H,3,6H2,1-2H3,(H,19,20,23)",DISSYWHTRARGQK-UHFFFAOYSA-N,cc-115,Phase 2,mTOR inhibitor,MTOR,,
COC1CCC(n2c(=O)cnc3c2=NC(c2ccc(C(C)(C)O)nc2)CN=3)CC1,"InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-10,12,14-16,28H,5-8,11H2,1-3H3",AJNVQLKCRNIWCV-UHFFFAOYSA-N,cc-223,Phase 2,mTOR inhibitor,MTOR,,
c1cc(OCCN2CCCCC2)cc(-c2[nH]nc3ccc(-c4nc[nH]n4)cc23)c1,"InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)",XDJCLCLBSGGNKS-UHFFFAOYSA-N,cc-401,Phase 1,JNK inhibitor,MAPK8,,
C=CC(=O)Nc1cc(C)ccc1N=c1[nH]c(=Nc2cc(OC)ncc2C)[nH]cc1C(F)(F)F,"InChI=1S/C22H21F3N6O2/c1-5-18(32)28-17-8-12(2)6-7-15(17)29-20-14(22(23,24)25)11-27-21(31-20)30-16-9-19(33-4)26-10-13(16)3/h5-11H,1H2,2-4H3,(H,28,32)(H2,26,27,29,30,31)",ILUKRINUNLAVMH-UHFFFAOYSA-N,cc-90003,Phase 1,MAP kinase inhibitor,,,
OC1CCC(N=c2nc3c(c[nH]2)[nH]c(=Nc2c(F)cc(F)cc2F)n3C2CCOC2)CC1,"InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)",IBGLGMOPHJQDJB-UHFFFAOYSA-N,cc-930,Phase 2,JNK inhibitor,,,
O=c1cccc2n1CC1CC2CN(CCN2CC3CC(C2)c2cccc(=O)n2C3)C1,"InChI=1S/C24H30N4O2/c29-23-5-1-3-21-19-9-17(13-27(21)23)11-25(15-19)7-8-26-12-18-10-20(16-26)22-4-2-6-24(30)28(22)14-18/h1-6,17-20H,7-16H2",LEXDAVFCJPDCNA-UHFFFAOYSA-N,cc4,Preclinical,nicotinic receptor agonist,CHRNB2,,
CC(ONC(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc(Cl)cc1,"InChI=1S/C18H13ClF6N2O3/c1-9(15(28)26-14-4-2-13(19)3-5-14)30-27-16(29)10-6-11(17(20,21)22)8-12(7-10)18(23,24)25/h2-9H,1H3,(H,26,28)(H,27,29)",DSMXVSGJIDFLKP-UHFFFAOYSA-N,ccg-1423,Preclinical,apoptosis stimulant,RHOC|SRF,,
Cc1ccc(-n2sc(=O)n(Cc3ccc(F)cc3)c2=O)cc1,"InChI=1S/C16H13FN2O2S/c1-11-2-8-14(9-3-11)19-15(20)18(16(21)22-19)10-12-4-6-13(17)7-5-12/h2-9H,10H2,1H3",QUIIIYITNGOFEI-UHFFFAOYSA-N,ccg-50014,Preclinical,G protein signaling inhibitor,RGS4|RGS8,,
Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2C=C(C#N)c2nc3ccccc3s2)c1,"InChI=1S/C26H18N4O2S/c1-16-7-5-9-19(13-16)32-24-20(26(31)30-12-6-8-17(2)23(30)29-24)14-18(15-27)25-28-21-10-3-4-11-22(21)33-25/h3-14H,1-2H3",VFSVKVQMZDJFQX-UHFFFAOYSA-N,ccg-63802,Preclinical,G protein signaling inhibitor,RGS4,,
Cc1cccn2c(=O)c(C=C(C#N)c3nc4ccccc4s3)c(Oc3ccc(F)cc3)nc12,"InChI=1S/C25H15FN4O2S/c1-15-5-4-12-30-22(15)29-23(32-18-10-8-17(26)9-11-18)19(25(30)31)13-16(14-27)24-28-20-6-2-3-7-21(20)33-24/h2-13H,1H3",IPZHFKHGSYRBNT-UHFFFAOYSA-N,ccg-63808,Preclinical,G protein signaling inhibitor,RGS4,,
Cc1cc(C(C=Nc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1,"InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,17H,1H3,(H,23,25)",YFDGNBSGIOPFET-UHFFFAOYSA-N,ccmi,Preclinical,acetylcholine receptor allosteric modulator,CHRNA7,,
O=C(O)Cc1cc2ccccc2nc1C(=O)O,"InChI=1S/C12H9NO4/c14-10(15)6-8-5-7-3-1-2-4-9(7)13-11(8)12(16)17/h1-5H,6H2,(H,14,15)(H,16,17)",IFXJDEHFADWURH-UHFFFAOYSA-N,ccmq,Preclinical,homoquinolinic acid binding inhibitor,,,
O=C(CN1C2=NCCN2c2ccccc21)c1ccc(-c2ccccc2)cc1,"InChI=1S/C23H19N3O/c27-22(19-12-10-18(11-13-19)17-6-2-1-3-7-17)16-26-21-9-5-4-8-20(21)25-15-14-24-23(25)26/h1-13H,14-16H2",JPCYSKNELCOPKJ-UHFFFAOYSA-N,cct-031374,Preclinical,WNT signaling inhibitor,CTNNB1,,
CCc1cc(-c2[nH]nc(C)c2-c2ccc3c(c2)OCCO3)c(O)cc1O,"InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)",OWPMENVYXDJDOW-UHFFFAOYSA-N,cct018159,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,
NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,"InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23)",RZIDZIGAXXNODG-UHFFFAOYSA-N,cct128930,Preclinical,AKT inhibitor,,,
CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)N=c5[nH]ccs5)CC4)c(Cl)cnc3[nH]2)cc1,"InChI=1S/C23H25ClN8OS/c1-30(2)16-5-3-15(4-6-16)21-28-19-20(17(24)13-26-22(19)29-21)32-10-8-31(9-11-32)14-18(33)27-23-25-7-12-34-23/h3-7,12-13H,8-11,14H2,1-2H3,(H,25,27,33)(H,26,28,29)",QYKHWEFPFAGNEV-UHFFFAOYSA-N,cct129202,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(-c5ccc(N6CCN(C)CC6)cc5)nc34)CC2)no1,"InChI=1S/C26H31BrN8O/c1-18-15-20(31-36-18)17-33-9-13-35(14-10-33)24-22(27)16-28-26-23(24)29-25(30-26)19-3-5-21(6-4-19)34-11-7-32(2)8-12-34/h3-6,15-16H,7-14,17H2,1-2H3,(H,28,29,30)",GFLQCBTXTRCREJ-UHFFFAOYSA-N,cct137690,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CC(C)(C)c1cc(=NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)cnc34)cc2F)n(-c2ccccc2)[nH]1,"InChI=1S/C27H24FN7O3/c1-27(2,3)21-14-22(35(34-21)16-7-5-4-6-8-16)32-26(37)31-19-10-9-17(13-18(19)28)38-20-11-12-29-25-24(20)30-15-23(36)33-25/h4-15,34H,1-3H3,(H,31,37)(H,29,33,36)",OKAXXRRMIPBHQT-UHFFFAOYSA-N,cct196969,Preclinical,RAF inhibitor,,,
N#Cc1c[nH]c(=Nc2cc(=NCC3CNCCO3)c(C(F)(F)F)c[nH]2)cn1,"InChI=1S/C16H16F3N7O/c17-16(18,19)12-8-25-14(26-15-9-22-10(4-20)5-24-15)3-13(12)23-7-11-6-21-1-2-27-11/h3,5,8-9,11,21H,1-2,6-7H2,(H2,23,24,25,26)",YBYYWUUUGCNAHQ-UHFFFAOYSA-N,cct245737,Preclinical,kinase inhibitor,,,
O=C(O)c1ccc(-c2ccc3cc(O)c(C45CC6CC(CC(C6)C4)C5)cc3c2)cc1,"InChI=1S/C27H26O3/c28-25-12-22-6-5-21(19-1-3-20(4-2-19)26(29)30)10-23(22)11-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)",VCQGNUWOMLYNNG-UHFFFAOYSA-N,cd-1530,Preclinical,retinoid receptor agonist,RARG,,
O=C(O)c1ccc2cc(-c3ccc(O)c(C45CC6CC(CC(C6)C4)C5)c3)ccc2c1,"InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)",LDGIHZJOIQSHPB-UHFFFAOYSA-N,cd-437,Preclinical,retinoid receptor agonist,RARG,,
OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,"InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2",WHGYBXFWUBPSRW-UHFFFAOYSA-N,cdba,Phase 3,,,,
N=c1[nH][nH]c2nc3ccccc3nc12,"InChI=1S/C9H7N5/c10-8-7-9(14-13-8)12-6-4-2-1-3-5(6)11-7/h1-4H,(H3,10,12,13,14)",DWHVZCLBMTZRQM-UHFFFAOYSA-N,cdk1-5-inhibitor,Preclinical,CDK inhibitor,CDK1|CDK5|GSK3B,,
N=c1[nH][nH]c2nc3ccccc3nc12,"InChI=1S/C9H7N5/c10-8-7-9(14-13-8)12-6-4-2-1-3-5(6)11-7/h1-4H,(H3,10,12,13,14)",DWHVZCLBMTZRQM-UHFFFAOYSA-N,cdk1-5-inhibitor,Preclinical,glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3B,,
COCC(C)NC1CCC(N=c2cc(-c3cccc(=NCC4(C#N)CCOCC4)[nH]3)c(Cl)c[nH]2)CC1,"InChI=1S/C27H37ClN6O2/c1-19(16-35-2)32-20-6-8-21(9-7-20)33-26-14-22(23(28)15-30-26)24-4-3-5-25(34-24)31-18-27(17-29)10-12-36-13-11-27/h3-5,14-15,19-21,32H,6-13,16,18H2,1-2H3,(H,30,33)(H,31,34)",XWQVQSXLXAXOPJ-UHFFFAOYSA-N,cdk9-in-6,Preclinical,CDK inhibitor,CDK9,,
N#Cc1cccc(C(=O)N=c2cc(-c3ccccc3)[nH]n2-c2ccccc2)c1,"InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15,26H",DVADPMKDYVQEFR-UHFFFAOYSA-N,cdppb,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
CC1CCc2c(cc(Br)c(F)c2Br)N1C=O,"InChI=1S/C11H10Br2FNO/c1-6-2-3-7-9(15(6)5-16)4-8(12)11(14)10(7)13/h4-6H,2-3H2,1H3",ZZLQPWXVZCPUGC-UHFFFAOYSA-N,ce3f4,Preclinical,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,,
CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(F)cc12,"InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3",CSMVOZKEWSOFER-UHFFFAOYSA-N,cebranopadol,Phase 3,opioid receptor agonist,OPRL1|OPRM1,,
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,cediranib,Phase 3,KIT inhibitor,CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB,,
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,cediranib,Phase 3,VEGFR inhibitor,CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB,,
CC1CCC2C(C)(C)C3CC12CCC3(C)O,"InChI=1S/C15H26O/c1-10-5-6-11-13(2,3)12-9-15(10,11)8-7-14(12,4)16/h10-12,16H,5-9H2,1-4H3",SVURIXNDRWRAFU-UHFFFAOYSA-N,cedrol,Phase 2,,,,
CC1CCC2C(C)(C)C3CC12CCC3(C)O,"InChI=1S/C15H26O/c1-10-5-6-11-13(2,3)12-9-15(10,11)8-7-14(12,4)16/h10-12,16H,5-9H2,1-4H3",SVURIXNDRWRAFU-UHFFFAOYSA-N,cedrol-(+),Phase 2,sedative,,,
NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CSC12)c1ccccc1,"InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)",QYIYFLOTGYLRGG-UHFFFAOYSA-N,cefaclor,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis
CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1,"InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)",BOEGTKLJZSQCCD-UHFFFAOYSA-N,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,SLC15A1|SLC15A2|SLC22A6|SLC22A8,infectious disease|otolaryngology,urinary tract infections|skin infections|tonsillitis|pharyngitis
NC(=O)c1cc[n+](C=C2CSC3C(NC(=O)Cc4cccs4)C(=O)N3C2C(=O)O)cc1,"InChI=1S/C20H18N4O5S2/c21-17(26)11-3-5-23(6-4-11)9-12-10-31-19-15(18(27)24(19)16(12)20(28)29)22-14(25)8-13-2-1-7-30-13/h1-7,9,15-16,19H,8,10H2,(H3-,21,22,25,26,28,29)/p+1",KFHBBILFIRUCOW-UHFFFAOYSA-O,cefalonium,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Cn1nnnc1SC=C1CSC2C(NC(=O)C(O)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,8,11-13,16,25H,7H2,1H3,(H,19,26)(H,28,29)",JDFBTIJUBZEOLI-UHFFFAOYSA-N,cefamandole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|urinary tract infections|respiratory tract infections
Cn1nnnc1SC=C1CSC2C(NC(=O)C(OC=O)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,8-9,12-14,17H,7H2,1H3,(H,20,27)(H,29,30)",TUEAWFAFHDFWRC-UHFFFAOYSA-N,cefamandole-nafate,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|urinary tract infections|respiratory tract infections
CC(=O)OC=C1CSC2C(NC(=O)CSC(=NC(C)C)NC(C)C)C(=O)N2C1C(=O)O,"InChI=1S/C19H28N4O6S2/c1-9(2)20-19(21-10(3)4)31-8-13(25)22-14-16(26)23-15(18(27)28)12(6-29-11(5)24)7-30-17(14)23/h6,9-10,14-15,17H,7-8H2,1-5H3,(H,20,21)(H,22,25)(H,27,28)",RHWWNTPUZPSQAS-UHFFFAOYSA-N,cefathiamidine,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Cc1nnc(SC=C2CSC3C(NC(=O)Cn4cnnn4)C(=O)N3C2C(=O)O)s1,"InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h4-5,9-10,12H,2-3H2,1H3,(H,16,23)(H,25,26)",ZQRBOBGLJZHCAN-UHFFFAOYSA-N,cefazolin,Launched,bacterial cell wall synthesis inhibitor,PON1,infectious disease,urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections
CCCC(C(=O)N=C1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(COC(N)=O)CSC12)c1csc(=N)[nH]1,"InChI=1S/C23H29N5O8S2/c1-5-6-12(13-9-38-21(24)26-13)16(29)27-14-17(30)28-15(11(7-34-22(25)33)8-37-18(14)28)19(31)35-10-36-20(32)23(2,3)4/h9,12,18H,5-8,10H2,1-4H3,(H2,24,26)(H2,25,33)",QUHCHUHSFDMLAB-UHFFFAOYSA-N,cefcapene-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|pneumonia|urinary tract infections
C=CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(=NO)c3csc(=N)[nH]3)C2SC1,"InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)",RTXOFQZKPXMALH-UHFFFAOYSA-N,cefdinir,Launched,bacterial cell wall synthesis inhibitor,MPO,infectious disease|otolaryngology|pulmonary,pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis
CON=C(C(=O)NC1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(C=Cc3scnc3C)CSC12)c1csc(=N)[nH]1,"InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)",AFZFFLVORLEPPO-UHFFFAOYSA-N,cefditoren-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CSC12)c1csc(=N)[nH]1,"InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/p+1",HVFLCNVBZFFHBT-UHFFFAOYSA-O,cefepime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|urinary tract infections|skin infections|intra-abdominal infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C)CSC12)c1csc(=N)[nH]1,"InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)",MQLRYUCJDNBWMV-UHFFFAOYSA-N,cefetamet,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,ear infections|pneumonia|otitis|sinusitis|bronchitis|urinary tract infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(C)CSC12)c1csc(=N)[nH]1,"InChI=1S/C20H25N5O7S2/c1-9-6-33-16-12(23-14(26)11(24-30-5)10-7-34-19(21)22-10)15(27)25(16)13(9)17(28)31-8-32-18(29)20(2,3)4/h7,12,16H,6,8H2,1-5H3,(H2,21,22)(H,23,26)",DASYMCLQENWCJG-UHFFFAOYSA-N,cefetamet-pivoxil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CSC12)c1csc(=N)[nH]1)C(=O)O,"InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/p+1",DBPPRLRVDVJOCL-UHFFFAOYSA-O,cefiderocol,Launched,antibacterial ,,,
C=CC1=C(C(=O)O)N2C(=O)C(=NC(=O)C(NOCC(=O)O)c3csc(=N)[nH]3)C2SC1,"InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,9,14,20H,1,3-4H2,(H2,17,18)(H,22,23)(H,26,27)",FACRSCOHUPSUMI-UHFFFAOYSA-N,cefixime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CSC12)c1csc(=N)[nH]1,"InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)",HJJDBAOLQAWBMH-UHFFFAOYSA-N,cefmenoxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
COC1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CSC21,"InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)",SNBUBQHDYVFSQF-UHFFFAOYSA-N,cefmetazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|skin infections
COC1(NC(=O)CSCC(N)C(=O)O)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CSC21,"InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)",JSDXOWVAHXDYCU-UHFFFAOYSA-N,cefminox,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nc(C)c(CC(=O)O)s3)CSC12)c1csc(=N)[nH]1,"InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)",XDZKBRJLTGRPSS-UHFFFAOYSA-N,cefodizime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|skin infections|gonorrhea
O=C(NC1C(=O)N2C(C(=O)O)C(=CSc3nnnn3CS(=O)(=O)O)CSC12)C(O)c1ccccc1,"InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,7,11-13,16,25H,6,8H2,(H,19,26)(H,28,29)(H,30,31,32)",CXAFPLYCBNPHSG-UHFFFAOYSA-N,cefonicid,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CCN1CCN(C(=O)NC(C(=O)NC2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CSC23)c2ccc(O)cc2)C(=O)C1=O,"InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)",GCFBRXLSHGKWDP-UHFFFAOYSA-N,cefoperazone,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
NCc1ccccc1CC(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nnnn3CC(=O)O)CSC12,"InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)",SLAYUXIURFNXPG-UHFFFAOYSA-N,ceforanide,Launched,penicillin binding protein inhibitor,,infectious disease,gram-negative bacterial infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cn3ccc(=N)n3CCO)CSC12)c1csc(=N)[nH]1,"InChI=1S/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32)",ZINFAXPQMLDEEJ-UHFFFAOYSA-N,cefoselis,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(C)=O)CSC12)c1csc(=N)[nH]1,"InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)",GPRBEKHLDVQUJE-UHFFFAOYSA-N,cefotaxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections
COC1(NC(O)=c2sc(=C(C(N)=O)C(=O)O)s2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CSC21,"InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h15,19,26H,3-4H2,1-2H3,(H2,18,25)(H,27,28)(H,29,30)",SMRZELGKBINBNK-UHFFFAOYSA-N,cefotetan,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|respiratory tract infections|skin infections|gynecologic infections|chlamydia|intra-abdominal infections|bone and joint infections|surgical prophylaxis
CN(C)CCn1nnnc1SC=C1CSC2C(NC(=O)Cc3csc(=N)[nH]3)C(=O)N2C1C(=O)O,"InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h7-8,12-13,15H,3-6H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)",ZERZWIVZXKRPMQ-UHFFFAOYSA-N,cefotiam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,bacterial septicemia|bone and joint infections|respiratory tract infections|skin infections|urinary tract infections
CC(OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CSC2C(NC(=O)Cc3csc(=N)[nH]3)C(=O)N12,"InChI=1S/C27H37N9O7S3/c1-15(42-27(40)43-18-7-5-4-6-8-18)41-24(39)21-16(13-46-26-31-32-33-35(26)10-9-34(2)3)12-44-23-20(22(38)36(21)23)30-19(37)11-17-14-45-25(28)29-17/h14-15,18,20,23H,4-13H2,1-3H3,(H2,28,29)(H,30,37)",VVFDMWZLBPUKTD-UHFFFAOYSA-N,cefotiam-cilexetil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
COC1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC21,"InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)",WZOZEZRFJCJXNZ-UHFFFAOYSA-N,cefoxitin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[n+]3ccn4ncccc43)CSC12)c1nc(=N)s[nH]1,"InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/p+1",QDUIJCOKQCCXQY-UHFFFAOYSA-O,cefozopran,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cc1cc(=O)c(C(=O)NC(C(=O)NC2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CSC23)c2ccc(O)cc2)c[nH]1,"InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)",PWAUCHMQEXVFJR-UHFFFAOYSA-N,cefpiramide,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[n+]3cccc4c3CCC4)CSC12)c1csc(=N)[nH]1,"InChI=1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/p+1",DKOQGJHPHLTOJR-UHFFFAOYSA-O,cefpirome,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
COC=C1CSC2C(=NC(=O)C(NOC)c3csc(=N)[nH]3)C(=O)N2C1C(=O)OC(C)OC(=O)OC(C)C,"InChI=1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h6,8-10,13,15,18,25H,7H2,1-5H3,(H2,22,23)",HRMIDAMMEUSCLH-UHFFFAOYSA-N,cefpodoxime,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology|infectious disease|pulmonary,pharyngitis|pneumonia|bronchitis|gonorrhea|skin infections|urinary tract infections|sinusitis|tonsillitis
CC=CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1,"InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)",WDLWHQDACQUCJR-UHFFFAOYSA-N,cefprozil,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology|infectious disease|pulmonary,pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis
CC1=C(C(=O)O)N2C(=O)C(=NC(=O)C(N)C3C=CCCC3)C2SC1,"InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h3,5,9-10,15H,2,4,6-7,17H2,1H3,(H,22,23)",AHUXISVXKYLQOD-UHFFFAOYSA-N,cefradine,Launched,bacterial cell wall synthesis inhibitor,CYP3A4,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia
NC(=O)c1cc[n+](C=C2CSC3C(NC(=O)C(c4ccccc4)S(=O)(=O)O)C(=O)N3C2C(=O)O)cc1,"InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-10,15-17,21H,11H2,(H4-,23,24,27,28,30,31,32,33,34)/p+1",GEAPRUYBJDONRS-UHFFFAOYSA-O,cefsulodin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CCON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CSC12)c1nc(=N[PH](=O)(=O)O)s[nH]1,"InChI=1S/C22H20N8O8PS4/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10/h4-8,14,19H,3,9H2,1-2H3,(H3-,24,25,27,28,31,33,34,35,36,37)/p+1",RQMZBLHBGVXCCX-UHFFFAOYSA-O,ceftaroline-fosamil,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|pneumonia
CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[n+]3ccccc3)CSC12)c1csc(=N)[nH]1)C(=O)O,"InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/p+1",ORFOPKXBNMVMKC-UHFFFAOYSA-O,ceftazidime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis
N=c1[nH]c(C(CCC(=O)O)C(=O)N=C2C(=O)N3C(C(=O)O)=CCSC23)cs1,"InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h3,5-6,13H,1-2,4H2,(H2,16,17)(H,20,21)(H,24,25)",LLLXKOHOTQDYHM-UHFFFAOYSA-N,ceftibuten,Launched,bacterial cell wall synthesis inhibitor,,pulmonary|otolaryngology,bronchitis|otitis|pharyngitis|tonsillitis
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSC(=O)c3ccco3)CSC12)c1csc(=N)[nH]1,"InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)",ZBHXIWJRIFEVQY-UHFFFAOYSA-N,ceftiofur,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|respiratory tract infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=CCSC12)c1csc(=N)[nH]1,"InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)",NNULBSISHYWZJU-UHFFFAOYSA-N,ceftizoxim,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis
N=c1[nH]c(C(=NO)C(=O)NC2C(=O)N3C(C(=O)O)=C(Cc4ccn(C5CCNC5)c4O)CSC23)ns1,"InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h2,4,10,12,18,22,30,34H,1,3,5-7H2,(H,23,29)(H,32,33)(H2,21,24,26)",SYXFXSRBMUIWBI-UHFFFAOYSA-N,ceftobiprole,Phase 3,antiinfective drug,,,
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CSC12)c1csc(=N)[nH]1,"InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)",VAAUVRVFOQPIGI-UHFFFAOYSA-N,ceftriaxone,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,gonorrhea|pneumonia|otitis|skin infections|urinary tract infections|pelvic inflammatory disease|bacterial septicemia|bone and joint infections|intra-abdominal infections|meningitis|surgical prophylaxis
CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1,"InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)",JFPVXVDWJQMJEE-UHFFFAOYSA-N,cefuroxime,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections
CON=C(C(=O)NC1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CSC12)c1ccco1,"InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)",KEJCWVGMRLCZQQ-UHFFFAOYSA-N,cefuroxime-axetil,Launched,bacterial cell wall synthesis inhibitor,,otolaryngology,pharyngitis|tonsillitis|otitis|sinusitis
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,celecoxib,Launched,cyclooxygenase inhibitor,CA12|PDPK1|PTGS2,rheumatology|endocrinology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)
CCCC(=O)OC1CN2CCC(O)C2C(O)C1O,"InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3",HTJGLYIJVSDQAE-UHFFFAOYSA-N,celgosivir,Phase 2,glucosidase inhibitor,,,
CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,"InChI=1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)",JOATXPAWOHTVSZ-UHFFFAOYSA-N,celiprolol,Launched,adrenergic receptor antagonist,ADRA2A|ADRB1|ADRB2,genetics,Ehlers-Danlos syndrome (EDS)
CCc1cc(-c2noc(-c3cc(OC)nc(C4CCCC4)c3)n2)cc(C)c1OCC(O)CO,"InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3",KJKKMMMRWISKRF-UHFFFAOYSA-N,cenerimod,Phase 2,sphingosine 1-phosphate receptor modulator,,,
CCCCOCCOc1ccc(-c2ccc3c(c2)C=C(C(=O)Nc2ccc([S+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,"InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)",PNDKCRDVVKJPKG-UHFFFAOYSA-N,cenicriviroc,Phase 3,CC chemokine receptor antagonist,,,
NC(=O)OC(Cn1ncnn1)c1ccccc1Cl,"InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)",GFHAXPJGXSQLPT-UHFFFAOYSA-N,cenobamate,Launched,GABA receptor modulator,,,
NC(=O)OC(Cn1ncnn1)c1ccccc1Cl,"InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)",GFHAXPJGXSQLPT-UHFFFAOYSA-N,cenobamate,Launched,voltage-gated sodium channel blocker,,,
c1ccc2cc(C34CNCC3C4)ccc2c1,"InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2",HKHCSWPSUSWGLI-UHFFFAOYSA-N,centanafadine,Phase 3,dopamine reuptake inhibitor,,,
Nn1cnc2cc3ccccc3cc2c1=O,"InChI=1S/C12H9N3O/c13-15-7-14-11-6-9-4-2-1-3-8(9)5-10(11)12(15)16/h1-7H,13H2",CZXUQBVMAUWSBX-UHFFFAOYSA-N,centazolone,Phase 1,monoamine oxidase inhibitor,,,
Cc1cccc(N2CCN(CCc3ccc4ccccc4n3)CC2)c1,"InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3",UJNWGFBJUHIJKK-UHFFFAOYSA-N,centhaquin,Phase 1,analgesic agent,,,
CCC(=O)c1ccc(OCC(O)CN2CCN(c3ccccc3)CC2)cc1,"InChI=1S/C22H28N2O3/c1-2-22(26)18-8-10-21(11-9-18)27-17-20(25)16-23-12-14-24(15-13-23)19-6-4-3-5-7-19/h3-11,20,25H,2,12-17H2,1H3",ZQPXSRTZFYHSFB-UHFFFAOYSA-N,centpropazine,Phase 3,inositol monophosphatase inhibitor,,,
COc1cc2ncnc(Oc3cccc(NC(=O)N=c4cc(C(C)(C)C(F)(F)F)o[nH]4)c3)c2cc1OC,"InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)",DKNUPRMJNUQNHR-UHFFFAOYSA-N,cep-32496,Phase 1/Phase 2,RAF inhibitor,BRAF|RAF1,,
CN1CCN(c2cccc(N=c3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4[nH]3)c2)CC1,"InChI=1S/C24H26N6O2S/c1-28-13-15-29(16-14-28)20-6-3-5-19(17-20)25-24-26-23-22(7-4-12-30(23)27-24)18-8-10-21(11-9-18)33(2,31)32/h3-12,17H,13-16H2,1-2H3,(H,25,27)",RFZKSQIFOZZIAQ-UHFFFAOYSA-N,cep-33779,Preclinical,JAK inhibitor,JAK2,,
CNC(=O)c1ccccc1N=c1[nH]c(=Nc2ccc3c(c2OC)CCCC(N2CCN(CCO)CC2)C3)[nH]cc1Cl,"InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)",BCSHRERPHLTPEE-UHFFFAOYSA-N,cep-37440,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,
COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC,"InChI=1S/C31H26F2N4O6/c1-17(2)36-16-22(30(39)37(31(36)40)20-8-5-18(32)6-9-20)29(38)35-19-7-10-26(23(33)13-19)43-25-11-12-34-24-15-28(42-4)27(41-3)14-21(24)25/h5-17H,1-4H3,(H,35,38)",FKCWHHYUMFGOPY-UHFFFAOYSA-N,cep-40783,Preclinical,AXL kinase inhibitor,,,
CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1,"InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)",ZAIPMKNFIOOWCQ-UHFFFAOYSA-N,cephalexin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections
CCC(C)C(=O)NC(C(=O)C(=O)OC1CC2(O)C(OC(=O)c3ccccc3)C3C4(OC(C)=O)COC4CC(O)C3(C)C(=O)C(OC(C)=O)=C(C1C)C2(C)C)c1ccccc1,"InChI=1S/C45H53NO14/c1-9-23(2)39(52)46-33(27-16-12-10-13-17-27)34(50)41(54)58-29-21-45(55)38(59-40(53)28-18-14-11-15-19-28)36-43(8,30(49)20-31-44(36,22-56-31)60-26(5)48)37(51)35(57-25(4)47)32(24(29)3)42(45,6)7/h10-19,23-24,29-31,33,36,38,49,55H,9,20-22H2,1-8H3,(H,46,52)",GXAHUZMCACKPFI-UHFFFAOYSA-N,cephalomannine,Preclinical,DNA polymerase inhibitor,,,
CC(=O)OC=C1CSC2C(NC(=O)CCCC(N)C(=O)O)C(=O)N2C1C(=O)O,"InChI=1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h5,9,11-12,14H,2-4,6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)",CMQZTLIDOSHMLO-UHFFFAOYSA-N,cephalosporin-c-zn,Preclinical,bacterial cell wall synthesis inhibitor,,,
CC(=O)OC=C1CSC2C(NC(=O)Cc3cccs3)C(=O)N2C1C(=O)O,"InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,6,12-13,15H,5,7H2,1H3,(H,17,20)(H,22,23)",RPYOSGKJIBAQNU-UHFFFAOYSA-N,cephalothin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|surgical prophylaxis
CC(=O)OC=C1CSC2C(NC(=O)CSc3ccncc3)C(=O)N2C1C(=O)O,"InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-6,13-14,16H,7-8H2,1H3,(H,19,22)(H,24,25)",ASUSRJLYZAZXFH-UHFFFAOYSA-N,cephapirin,Launched,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis
COc1ccc2cc1Oc1ccc(cc1)CC1c3c(cc4c(c3Oc3cc5c(cc3OC)CCN(C)C5C2)OCO4)CCN1C,"InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3",YVPXVXANRNDGTA-UHFFFAOYSA-N,cepharanthine,Phase 2,NFkB pathway inhibitor,,,
CC1=C(C(=O)O)N2C(=O)C(=NC(=O)C(N)C3C=CCCC3)C2SC1,"InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h3,5,9-10,15H,2,4,6-7,17H2,1H3,(H,22,23)",AHUXISVXKYLQOD-UHFFFAOYSA-N,cephradine,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|respiratory tract infections|urinary tract infections
CCCCCCCCCCCCCC=CC(O)C(CO)NC(C)=O,"InChI=1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)",BLTCBVOJNNKFKC-UHFFFAOYSA-N,ceramide,Launched,phosphoenolpyruvate carboxylase activator,,dermatology,cosmetic
CCCCCCCCCCCCCC=CC(O)C(CO)NC(C)=O,"InChI=1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)",BLTCBVOJNNKFKC-UHFFFAOYSA-N,ceramide,Launched,serine/threonine protein phosphatase activator,,dermatology,cosmetic
Cc1cc(N=c2[nH]cc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FLT3|IGF1R|INSR|TSSK1B,oncology,non-small cell lung cancer (NSCLC)
CC=CCC=CCCC(=O)C1OC1C(N)=O,"InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)",GVEZIHKRYBHEFX-UHFFFAOYSA-N,cerulenin,Launched,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection
CSCCC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)C(NC(=O)C(Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C1CCC(=O)N1)C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O,"InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)",YRALAIOMGQZKOW-UHFFFAOYSA-N,ceruletide,Preclinical,CCK receptor agonist,CCKAR,,
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1,"InChI=1S/C23H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26/h16-19,24H,2-15,20H2,1H3,(H,25,26)",QXWKHSSBFQDQPR-UHFFFAOYSA-N,cetaben,Phase 2,ACAT inhibitor,PPARA,,
CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1,"InChI=1S/C23H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26/h16-19,24H,2-15,20H2,1H3,(H,25,26)",QXWKHSSBFQDQPR-UHFFFAOYSA-N,cetaben,Phase 2,cholesterol inhibitor,PPARA,,
CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1,"InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3",MVCQKIKWYUURMU-UHFFFAOYSA-N,cetilistat,Phase 3,triacylglycerol lipase inhibitor,PNLIP,,
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)",ZKLPARSLTMPFCP-UHFFFAOYSA-N,cetirizine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
CCCCCCCCCCCCCCCC[N+](C)(C)C,"InChI=1S/C19H42N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4/h5-19H2,1-4H3/q+1",RLGQACBPNDBWTB-UHFFFAOYSA-N,cetrimonium,Launched,,,dermatology,cosmetic
CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCCNC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,"InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)",SBNPWPIBESPSIF-UHFFFAOYSA-N,cetrorelix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR|LHCGR,endocrinology,premature luteinizing hormone surges
CCCCCCCCCCCCCCCC[n+]1ccccc1,"InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1",NEUSVAOJNUQRTM-UHFFFAOYSA-N,cetylpyridinium,Launched,,,dental,gingivitis|mouth inflammation
CC1OC2(CS1)CN1CCC2CC1,"InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3",WUTYZMFRCNBCHQ-UHFFFAOYSA-N,cevimeline,Launched,acetylcholine receptor agonist,CHRM3,rheumatology,sjogren's syndrome
CNCCCOc1cc(F)c(-c2c(Cl)[nH]c3ncnn3c2=NC(C)C(F)(F)F)c(F)c1,"InChI=1S/C18H18ClF5N6O/c1-9(18(22,23)24)28-16-14(15(19)29-17-26-8-27-30(16)17)13-11(20)6-10(7-12(13)21)31-5-3-4-25-2/h6-9,25H,3-5H2,1-2H3,(H,26,27,29)",ODTBOKDHTIXRKH-UHFFFAOYSA-N,cevipabulin,Phase 1,microtubule stimulant,TUBB,,
CNCCCOc1cc(F)c(-c2c(Cl)[nH]c3ncnn3c2=NC(C)C(F)(F)F)c(F)c1,"InChI=1S/C18H18ClF5N6O/c1-9(18(22,23)24)28-16-14(15(19)29-17-26-8-27-30(16)17)13-11(20)6-10(7-12(13)21)31-5-3-4-25-2/h6-9,25H,3-5H2,1-2H3,(H,26,27,29)",ODTBOKDHTIXRKH-UHFFFAOYSA-N,cevipabulin,Phase 1,tubulin polymerization inhibitor,TUBB,,
CNC(=O)C1OC(n2cnc3c(=NCc4cccc(I)c4)[nH]c(Cl)nc32)C(O)C1O,"InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)",IPSYPUKKXMNCNQ-UHFFFAOYSA-N,cf102,Phase 2,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc2c(c1)C1(CC1c1ccc3c(C=Cc4ccc(CN5CC(C)OC(C)C5)cc4)[nH]nc3c1)C(=O)N2,"InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)",DADASRPKWOGKCU-UHFFFAOYSA-N,cfi-400945,Phase 2,serine/threonine kinase inhibitor,,,
Cc1cc(-c2c[nH]n3c(=NCC4CC(C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,"InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,31,36H,6-7,12-14H2,1-2H3,(H,32,35)",RQYNWCPANZJZKP-UHFFFAOYSA-N,cfi-402257,Phase 1/Phase 2,dual specificity protein kinase inhibitor,,,
COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1,"InChI=1S/C23H28N4O3/c1-26(2)14-7-15-30-22-16-21(27(25-22)17-18-8-5-4-6-9-18)23(28)24-19-10-12-20(29-3)13-11-19/h4-6,8-13,16H,7,14-15,17H2,1-3H3,(H,24,28)",YZCSJBGQLATPMH-UHFFFAOYSA-N,cfm-1571,Preclinical,guanylate cyclase activator,,,
COc1cc2c(cc1OC)C(c1ccc(N)cc1)=NNC(=O)C2,"InChI=1S/C17H17N3O3/c1-22-14-7-11-8-16(21)19-20-17(13(11)9-15(14)23-2)10-3-5-12(18)6-4-10/h3-7,9H,8,18H2,1-2H3,(H,19,21)",MJKADKZSYQWGLL-UHFFFAOYSA-N,cfm-2,Preclinical,glutamate receptor antagonist,,,
O=C(O)c1ccc(C=C2SC(=S)N(c3cccc(C(F)(F)F)c3)C2=O)cc1,"InChI=1S/C18H10F3NO3S2/c19-18(20,21)12-2-1-3-13(9-12)22-15(23)14(27-17(22)26)8-10-4-6-11(7-5-10)16(24)25/h1-9H,(H,24,25)",JIMHYXZZCWVCMI-UHFFFAOYSA-N,cftrinh-172,Preclinical,chloride channel blocker,CFTR,,
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O,"InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3",YCLREGRRHGLOAK-UHFFFAOYSA-N,cg-400549,Phase 2,FABI inhibitor,,,
N=c1[nH]c(-c2ccc(Cl)c(Cl)c2)c(-c2ccncc2)s1,"InChI=1S/C14H9Cl2N3S/c15-10-2-1-9(7-11(10)16)12-13(20-14(17)19-12)8-3-5-18-6-4-8/h1-7H,(H2,17,19)",BEPGKLOHQTXUHX-UHFFFAOYSA-N,cgh2466,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,
O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,"InChI=1S/C23H18Cl3FN4O3S/c24-23(25,26)21(30-22(35)28-16-11-12-17(27)18(13-16)31(33)34)29-20(32)19(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13,19,21H,(H,29,32)(H2,28,30,35)",HLCDNLNLQNYZTK-UHFFFAOYSA-N,cgk-733,Preclinical,ATM kinase inhibitor,ATM|ATR,,
O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1,"InChI=1S/C23H18Cl3FN4O3S/c24-23(25,26)21(30-22(35)28-16-11-12-17(27)18(13-16)31(33)34)29-20(32)19(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13,19,21H,(H,29,32)(H2,28,30,35)",HLCDNLNLQNYZTK-UHFFFAOYSA-N,cgk-733,Preclinical,ATR kinase inhibitor,ATM|ATR,,
COc1cc2c(cc1OC(C)C)C(c1ccc(Cl)cc1)N(c1ccc(N(C)CC3CCC(N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2,"InChI=1S/C38H47ClN4O4/c1-25(2)47-35-22-33-28(20-34(35)46-5)21-36(44)43(38(33)27-8-10-29(39)11-9-27)32-16-14-30(15-17-32)41(4)23-26-6-12-31(13-7-26)42-19-18-40(3)37(45)24-42/h8-11,14-17,20,22,25-26,31,38H,6-7,12-13,18-19,21,23-24H2,1-5H3",CLRSLRWKONPSRQ-UHFFFAOYSA-N,cgm097,Phase 1,MDM inhibitor,MDM2,,
CC(C)(C)NCC(O)COc1cccc2[nH]c(=O)[nH]c12,"InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)",UMQUQWCJKFOUGV-UHFFFAOYSA-N,cgp-12177,Phase 1,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CC(C)(C=O)Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"InChI=1S/C19H30O2/c1-17(2,3)14-9-13(11-19(7,8)12-20)10-15(16(14)21)18(4,5)6/h9-10,12,21H,11H2,1-8H3",XGWATTXMMMANFJ-UHFFFAOYSA-N,cgp-13501,Preclinical,GABA receptor modulator,GABBR1,,
Cn1cc(C(F)(F)F)nc1-c1ccc(OCC(O)CNCCOc2ccc(O)c(C(N)=O)c2)cc1,"InChI=1S/C23H25F3N4O5/c1-30-12-20(23(24,25)26)29-22(30)14-2-4-16(5-3-14)35-13-15(31)11-28-8-9-34-17-6-7-19(32)18(10-17)21(27)33/h2-7,10,12,15,28,31-32H,8-9,11,13H2,1H3,(H2,27,33)",GKJZEKSHCJELPL-UHFFFAOYSA-N,cgp-20712a,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB3,,
CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC,"InChI=1S/C15H20ClN3O2/c1-4-19(5-2)7-6-18-15(20)12-8-11(10-17)13(16)9-14(12)21-3/h8-9H,4-7H2,1-3H3,(H,18,20)",JEMKCYHUYUPGFN-UHFFFAOYSA-N,cgp-25454a,Preclinical,dopamine receptor antagonist,,,
O=C1CSC(c2ccccc2Cl)c2cc(Cl)ccc2N1,"InChI=1S/C15H11Cl2NOS/c16-9-5-6-13-11(7-9)15(20-8-14(19)18-13)10-3-1-2-4-12(10)17/h1-7,15H,8H2,(H,18,19)",KQEPIRKXSUIUTH-UHFFFAOYSA-N,cgp-37157,Preclinical,mitochondrial Na+/Ca2+ exchanger antagonist,SLC8A1,,
O=C1CSC(c2ccccc2Cl)c2cc(Cl)ccc2N1,"InChI=1S/C15H11Cl2NOS/c16-9-5-6-13-11(7-9)15(20-8-14(19)18-13)10-3-1-2-4-12(10)17/h1-7,15H,8H2,(H,18,19)",KQEPIRKXSUIUTH-UHFFFAOYSA-N,cgp-37157,Preclinical,sodium/calcium exchange inhibitor,SLC8A1,,
CC(CC(=N)C(=O)O)C[PH](=O)(=O)O,"InChI=1S/C6H11NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h4,7H,2-3H2,1H3,(H,8,9)(H,10,11,12)",NDGGFXMTACACBA-UHFFFAOYSA-N,cgp-37849,Phase 1,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CCOC(=O)C(=N)CC(C)C[PH](=O)(=O)O,"InChI=1S/C8H15NO5P/c1-3-14-8(10)7(9)4-6(2)5-15(11,12)13/h6,9H,3-5H2,1-2H3,(H,11,12,13)",QUSMRQRZOOWLHV-UHFFFAOYSA-N,cgp-39551,Preclinical,NMDA receptor antagonist,,,
O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21,"InChI=1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25)",AAALVYBICLMAMA-UHFFFAOYSA-N,cgp-52411,Preclinical,EGFR inhibitor,EGFR,,
O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,"InChI=1S/C20H13F2N3O2/c21-11-1-5-13(6-2-11)23-17-9-15-16(20(27)25-19(15)26)10-18(17)24-14-7-3-12(22)4-8-14/h1-10,23-24H,(H,25,26,27)",RONQPWQYDRPRGG-UHFFFAOYSA-N,cgp-53353,Preclinical,EGFR inhibitor,EGFR|PRKCB,,
O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,"InChI=1S/C20H13F2N3O2/c21-11-1-5-13(6-2-11)23-17-9-15-16(20(27)25-19(15)26)10-18(17)24-14-7-3-12(22)4-8-14/h1-10,23-24H,(H,25,26,27)",RONQPWQYDRPRGG-UHFFFAOYSA-N,cgp-53353,Preclinical,PKC inhibitor,EGFR|PRKCB,,
CC(NCC(O)C[PH](=O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,"InChI=1S/C18H27Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h7-9,13-14,16,21-22H,2-6,10-12H2,1H3",XZNTZLXFIYAHRM-UHFFFAOYSA-N,cgp-54626,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
CC(NCC(O)C[PH](=O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,"InChI=1S/C18H21Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h2-9,13,16,21-22H,10-12H2,1H3",FMNCOFMWTVTFHT-UHFFFAOYSA-N,cgp-55845,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
N=c1[nH]cnc2[nH][nH]c(=Nc3ccc(F)cc3)c12,"InChI=1S/C11H9FN6/c12-6-1-3-7(4-2-6)16-11-8-9(13)14-5-15-10(8)17-18-11/h1-5H,(H4,13,14,15,16,17,18)",UQPMANVRZYYQMD-UHFFFAOYSA-N,cgp-57380,Preclinical,MAP kinase inhibitor,AURKB|LCK|MKNK1|MKNK2|SGK1,,
OCCCN=c1cc(-c2cc[nH]c(=Nc3cccc(Cl)c3)n2)cc[nH]1,"InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)",IYNDTACKOAXKBJ-UHFFFAOYSA-N,cgp-60474,Preclinical,CDK inhibitor,CDK1|CDK2,,
N=c1[nH]c(=NCC2CCC(CNS(=O)(=O)c3cccc4ccccc34)CC2)[nH]c2ccccc12,"InChI=1S/C26H29N5O2S/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31)",UULIGRNKXHCLQN-UHFFFAOYSA-N,cgp-71683,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCn1cnc2c(=Nc3cccc(Cl)c3)[nH]c(=NC3CCCCC3N)[nH]c21,"InChI=1S/C19H24ClN7/c1-2-27-11-22-16-17(23-13-7-5-6-12(20)10-13)25-19(26-18(16)27)24-15-9-4-3-8-14(15)21/h5-7,10-11,14-15H,2-4,8-9,21H2,1H3,(H2,23,24,25,26)",UTBSBSOBZHXMHI-UHFFFAOYSA-N,cgp-74514,Preclinical,CDK inhibitor,CDK1,,
CC(NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)[PH](=O)(=O)O,"InChI=1S/C11H12BrN3O5P/c1-5(21(18,19)20)13-4-6-2-7(12)3-8-9(6)15-11(17)10(16)14-8/h2-3,5,13H,4H2,1H3,(H,14,16)(H,15,17)(H,18,19,20)",CFZRFLVNQYQCMT-UHFFFAOYSA-N,cgp-78608,Preclinical,glutamate receptor antagonist,,,
CC(C)(CO)Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"InChI=1S/C19H32O2/c1-17(2,3)14-9-13(11-19(7,8)12-20)10-15(16(14)21)18(4,5)6/h9-10,20-21H,11-12H2,1-8H3",XLWJPQQFJNGUPA-UHFFFAOYSA-N,cgp-7930,Preclinical,GABA receptor modulator,GABBR1,,
N=c1[nH]c2ccc(Cl)cc2c2nc(-c3ccco3)nn12,"InChI=1S/C13H8ClN5O/c14-7-3-4-9-8(6-7)12-17-11(10-2-1-5-20-10)18-19(12)13(15)16-9/h1-6H,(H2,15,16)",MSJODEOZODDVGW-UHFFFAOYSA-N,cgs-15943,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1ccc(-n2[nH]c3c4c(ncc3c2=O)CCCCC4)cc1,"InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3",UBLXQFIFWUEVGJ-UHFFFAOYSA-N,cgs-20625,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
COc1ccc(-n2[nH]c3c4c(ncc3c2=O)CCCCC4)cc1,"InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3",UBLXQFIFWUEVGJ-UHFFFAOYSA-N,cgs-20625,Phase 1,GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
CCNC(=O)C1OC(n2cnc3c(=N)[nH]c(=NCCc4ccc(CCC(=O)O)cc4)[nH]c32)C(O)C1O,"InChI=1S/C23H29N7O6/c1-2-25-21(35)18-16(33)17(34)22(36-18)30-11-27-15-19(24)28-23(29-20(15)30)26-10-9-13-5-3-12(4-6-13)7-8-14(31)32/h3-6,11,16-18,22,33-34H,2,7-10H2,1H3,(H,25,35)(H,31,32)(H3,24,26,28,29)",PAOANWZGLPPROA-UHFFFAOYSA-N,cgs-21680,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
O=c1c2cnc3ccccc3c2[nH]n1-c1ccc(Cl)cc1,"InChI=1S/C16H10ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h1-9,19H",QCBUAKLOWCOUCR-UHFFFAOYSA-N,cgs-9896,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,
Cc1nc(Cn2cnc3c2c(=O)n(C)c(=O)n3C)no1,"InChI=1S/C11H12N6O3/c1-6-13-7(14-20-6)4-17-5-12-9-8(17)10(18)16(3)11(19)15(9)2/h5H,4H2,1-3H3",JBXSBZBZASARMY-UHFFFAOYSA-N,ch-170,Phase 1,,,,
Cc1nc2cc(-n3[nH]cc(C(=O)c4cc5ccccc5[nH]4)c3=N)ccc2[nH]1,"InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,21-22,25H,1H3,(H,23,24)",VOBHSEZBXFNLOQ-UHFFFAOYSA-N,ch-5183284,Phase 2,fibroblast growth factor inhibitor,FGFR1|FGFR2|FGFR3,,
Cc1ccccc1N=Nc1ccc(NC(=O)c2ccnn2C)c(C)c1,"InChI=1S/C19H19N5O/c1-13-6-4-5-7-17(13)23-22-15-8-9-16(14(2)12-15)21-19(25)18-10-11-20-24(18)3/h4-12H,1-3H3,(H,21,25)",LKTNEXPODAWWFM-UHFFFAOYSA-N,ch223191,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,
CS(=O)(=O)N1CCc2c(-c3cnc(=N)[nH]c3)nc(N3CCOCC3)nc21,"InChI=1S/C15H19N7O3S/c1-26(23,24)22-3-2-11-12(10-8-17-14(16)18-9-10)19-15(20-13(11)22)21-4-6-25-7-5-21/h8-9H,2-7H2,1H3,(H2,16,17,18)",JEGHXKRHKHPBJD-UHFFFAOYSA-N,ch5132799,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)(C)c1cc(C(=O)C=Cc2ccc(C(=O)O)cc2)cc(C(C)(C)C)c1,"InChI=1S/C24H28O3/c1-23(2,3)19-13-18(14-20(15-19)24(4,5)6)21(25)12-9-16-7-10-17(11-8-16)22(26)27/h7-15H,1-6H3,(H,26,27)",FOUVTBKPJRMLPE-UHFFFAOYSA-N,ch55,Preclinical,retinoid receptor binder,RARA|RARB,,
N#CC(=Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C10H7NO3/c11-6-8(10(13)14)5-7-1-3-9(12)4-2-7/h1-5,12H,(H,13,14)",AFVLVVWMAFSXCK-UHFFFAOYSA-N,chc,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,
CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)",RUDATBOHQWOJDD-UHFFFAOYSA-N,chenodeoxycholic-acid,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1|NR1H4,cardiology|gastroenterology,cerebral cholesterosis|gallstones
CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)",RUDATBOHQWOJDD-UHFFFAOYSA-N,chenodeoxycholic-acid,Launched,FXR agonist,HSD11B1|NR1H4,cardiology|gastroenterology,cerebral cholesterosis|gallstones
O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1,"InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)",LIYLTQQDABRNRX-UHFFFAOYSA-N,chf5074,Phase 2,gamma secretase modulator,PSEN1,,
COc1cc(-c2ccc(N=Nc3ccc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4c3O)c(OC)c2)ccc1N=Nc1ccc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2c1O,"InChI=1S/C34H28N6O16S4/c1-55-23-11-15(3-7-19(23)37-39-21-9-5-17-25(57(43,44)45)13-27(59(49,50)51)31(35)29(17)33(21)41)16-4-8-20(24(12-16)56-2)38-40-22-10-6-18-26(58(46,47)48)14-28(60(52,53)54)32(36)30(18)34(22)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",OHMJKMNGYYWCHB-UHFFFAOYSA-N,chicago-sky-blue-6b,Preclinical,glutamate inhibitor,MIF,,
COc1cc(-c2ccc(N=Nc3ccc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4c3O)c(OC)c2)ccc1N=Nc1ccc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2c1O,"InChI=1S/C34H28N6O16S4/c1-55-23-11-15(3-7-19(23)37-39-21-9-5-17-25(57(43,44)45)13-27(59(49,50)51)31(35)29(17)33(21)41)16-4-8-20(24(12-16)56-2)38-40-22-10-6-18-26(58(46,47)48)14-28(60(52,53)54)32(36)30(18)34(22)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",OHMJKMNGYYWCHB-UHFFFAOYSA-N,chicago-sky-blue-6b,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)C=Cc2cccnc2)cc1,"InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)",WXHHICFWKXDFOW-UHFFFAOYSA-N,chidamide,Launched,HDAC inhibitor,HDAC10|HDAC3,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
O=S(=O)(O)c1cc(I)c(O)c2ncccc12,"InChI=1S/C9H6INO4S/c10-6-4-7(16(13,14)15)5-2-1-3-11-8(5)9(6)12/h1-4,12H,(H,13,14,15)",ZBJWWKFMHOAPNS-UHFFFAOYSA-N,chiniofon,Launched,antiprotozoal agent,,infectious disease,amebiasis
O=c1[nH]c2ccc(Cl)cc2c(NC2CN3CCC2CC3)c1-c1nc2ccccc2[nH]1,"InChI=1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)",MOVBBVMDHIRCTG-UHFFFAOYSA-N,chir-124,Preclinical,CHK inhibitor,CHEK1,,
N=c1[nH]c(NCCN=c2nc(-c3ccc(Cl)cc3Cl)c(-n3ccnc3)c[nH]2)ccc1[N+](=O)[O-],"InChI=1S/C20H17Cl2N9O2/c21-12-1-2-13(14(22)9-12)18-16(30-8-7-24-11-30)10-27-20(29-18)26-6-5-25-17-4-3-15(31(32)33)19(23)28-17/h1-4,7-11H,5-6H2,(H3,23,25,28)(H,26,27,29)",MDZCSIDIPDZWKL-UHFFFAOYSA-N,chir-98014,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
Cc1c[nH]c(-c2c[nH]c(=NCCN=c3ccc(C#N)c[nH]3)nc2-c2ccc(Cl)cc2Cl)n1,"InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32)",AQGNHMOJWBZFQQ-UHFFFAOYSA-N,chir-99021,Preclinical,glycogen synthase kinase inhibitor,CDK1|GSK3A|GSK3B|MAPK1,,
OCC(O)C1OC2OC(C(Cl)(Cl)Cl)OC2C1O,"InChI=1S/C8H11Cl3O6/c9-8(10,11)7-16-5-3(14)4(2(13)1-12)15-6(5)17-7/h2-7,12-14H,1H2",OJYGBLRPYBAHRT-UHFFFAOYSA-N,chloralose,Preclinical,,,,
O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,"InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)",JCKYGMPEJWAADB-UHFFFAOYSA-N,chlorambucil,Launched,DNA inhibitor,,hematologic malignancy,chronic lymphocytic leukemia (CLL)|Hodgkin's lymphoma
Cc1ccc(S(=O)(=O)NCl)cc1,"InChI=1S/C7H8ClNO2S/c1-6-2-4-7(5-3-6)12(10,11)9-8/h2-5,9H,1H3",NXTVQNIVUKXOIL-UHFFFAOYSA-N,chloramine-t,Launched,,,infectious disease,bacterial gill disease
O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,"InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)",WIIZWVCIJKGZOK-UHFFFAOYSA-N,chloramphenicol,Launched,bacterial 50S ribosomal subunit inhibitor,CD55,infectious disease|endocrinology,meningitis|fever|cholera
CCCCCCCCCCCCCCCC(=O)OCC(NC(=O)C(Cl)Cl)C(O)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C27H42Cl2N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-24(32)37-20-23(30-27(34)26(28)29)25(33)21-16-18-22(19-17-21)31(35)36/h16-19,23,25-26,33H,2-15,20H2,1H3,(H,30,34)",PXKHGMGELZGJQE-UHFFFAOYSA-N,chloramphenicol-palmitate,Launched,protein synthesis inhibitor,,infectious disease|endocrinology,meningitis|fever|cholera
O=C(O)CCC(=O)OCC(NC(=O)C(Cl)Cl)C(O)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C15H16Cl2N2O8/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21)",LIRCDOVJWUGTMW-UHFFFAOYSA-N,chloramphenicol-sodium-succinate,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
N=c1[nH]cnc(=Nc2ccc(Cl)cc2)[nH]1,"InChI=1S/C9H8ClN5/c10-6-1-3-7(4-2-6)14-9-13-5-12-8(11)15-9/h1-5H,(H3,11,12,13,14,15)",YRZQHIVOIFJEEE-UHFFFAOYSA-N,chlorazanil,Preclinical,,,,
CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3",WFNAKBGANONZEQ-UHFFFAOYSA-N,chlorcyclizine,Launched,histamine receptor antagonist,,allergy,allergic rhinitis
O=S(=O)(Oc1ccc(Cl)cc1)c1ccc(Cl)cc1,"InChI=1S/C12H8Cl2O3S/c13-9-1-5-11(6-2-9)17-18(15,16)12-7-3-10(14)4-8-12/h1-8H",RZXLPPRPEOUENN-UHFFFAOYSA-N,chlorfenson,Phase 2,other antifungal,,,
N=C(N=C(N)NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)Nc1ccc(Cl)cc1,"InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)",GHXZTYHSJHQHIJ-UHFFFAOYSA-N,chlorhexidine,Launched,membrane integrity inhibitor,,dermatology|infectious disease|dental,cosmetic|skin infections|gingivitis
Oc1ccc(Cl)c2c1CCC2,"InChI=1S/C9H9ClO/c10-8-4-5-9(11)7-3-1-2-6(7)8/h4-5,11H,1-3H2",ATAJVFBUUIBIEO-UHFFFAOYSA-N,chlorindanol,Preclinical,,,,
O=C1c2ccccc2C(=O)C1c1ccc(Cl)cc1,"InChI=1S/C15H9ClO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H",NJDUWAXIURWWLN-UHFFFAOYSA-N,chlorindione,Preclinical,,,,
C[N+](C)(C)CC[N+]1(C)Cc2c(Cl)c(Cl)c(Cl)c(Cl)c2C1,"InChI=1S/C14H20Cl4N2/c1-19(2,3)5-6-20(4)7-9-10(8-20)12(16)14(18)13(17)11(9)15/h5-8H2,1-4H3/q+2",IXWDUZLHWJKVPX-UHFFFAOYSA-N,chlorisondamine-diiodide,Preclinical,acetylcholine receptor antagonist,CHRNA1,,
CC(=O)OC1(C(C)=O)CCC2C3=CC(Cl)=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h12,17-18H,5-11H2,1-4H3",GBFMXJIPEWEABS-UHFFFAOYSA-N,chlormadinone-acetate,Launched,5 alpha reductase inhibitor,PGR,endocrinology,hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea
CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1,"InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3",WEQAYVWKMWHEJO-UHFFFAOYSA-N,chlormezanone,Withdrawn,GABA receptor modulator,GABRA1,,
Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,"InChI=1S/C15H13ClN2/c1-11-17-14-4-2-3-5-15(14)18(11)10-12-6-8-13(16)9-7-12/h2-9H,10H2,1H3",WNAQOLSMVPFGTE-UHFFFAOYSA-N,chlormidazole,Launched,fungal lanosterol demethylase inhibitor,,infectious disease,fungal infection
CC(C)(O)C(Cl)(Cl)Cl,"InChI=1S/C4H7Cl3O/c1-3(2,8)4(5,6)7/h8H,1-2H3",OSASVXMJTNOKOY-UHFFFAOYSA-N,chlorobutanol,Launched,,,neurology/psychiatry,anesthetic|sedative
Cc1cc(O)ccc1Cl,"InChI=1S/C7H7ClO/c1-5-4-6(9)2-3-7(5)8/h2-4,9H,1H3",CFKMVGJGLGKFKI-UHFFFAOYSA-N,chlorocresol,Launched,ryanodine receptor activator,,infectious disease,first-aid antiseptic
O=C(C=Cc1ccc(O)c(O)c1)OC1CC(O)(C(=O)O)CC(O)C1O,"InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)",CWVRJTMFETXNAD-UHFFFAOYSA-N,chlorogenic-acid,Launched,antioxidant,SLC37A4,neurology/psychiatry|pulmonary|allergy,headache|chest congestion|allergic rhinitis
CC=c1c(C)c2[nH]c1=Cc1[nH]c(c(C(=O)O)c1C)C(=CC(=O)O)c1[nH]c(c(C)c1CCC(=O)O)C=c1[nH]c(c(CC)c1C)=C2,"InChI=1S/C34H36N4O6/c1-7-19-15(3)23-12-25-17(5)21(9-10-29(39)40)32(37-25)22(11-30(41)42)33-31(34(43)44)18(6)26(38-33)14-28-20(8-2)16(4)24(36-28)13-27(19)35-23/h8,11-14,35-38H,7,9-10H2,1-6H3,(H,39,40)(H,41,42)(H,43,44)",KZNLCJFZBATBSY-UHFFFAOYSA-N,chlorophyllin,Preclinical,,,urology,urinary incontinence
CC=c1c(C)c2n3c1=Cc1[nH]c(c(CC)c1C)C=c1c(C)c(C(=O)O)c(n1[Cu]3)=C(CC(=O)O)c1[nH]c(c(C)c1C=CC(=O)O)C2,"InChI=1S/C34H34N4O6.Cu/c1-7-19-15(3)23-12-25-17(5)21(9-10-29(39)40)32(37-25)22(11-30(41)42)33-31(34(43)44)18(6)26(38-33)14-28-20(8-2)16(4)24(36-28)13-27(19)35-23;/h7,9-10,13-14,36-37H,8,11-12H2,1-6H3,(H,39,40)(H,41,42)(H,43,44);/q-2;+2",MPUNIOSVWMMHNW-UHFFFAOYSA-N,chlorophyllin-copper,Phase 1,cytochrome P450 inhibitor,,,
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,"InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3",VDANGULDQQJODZ-UHFFFAOYSA-N,chloroprocaine,Launched,sodium channel blocker,ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3,neurology/psychiatry,local anesthetic
CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,"InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3",ICKFFNBDFNZJSX-UHFFFAOYSA-N,chloropyramine,Launched,histamine receptor antagonist,HRH1,cardiology|ophthalmology|allergy|pulmonary,edema|conjunctivitis|allergic rhinitis|asthma
CCN(CC)CCCC(C)N=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)",WHTVZRBIWZFKQO-UHFFFAOYSA-N,chloroquine,Launched,antimalarial agent,MRGPRX1,infectious disease,malaria|amebiasis
NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,"InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)",JBMKAUGHUNFTOL-UHFFFAOYSA-N,chlorothiazide,Launched,diuretic,CA1|CA2|CA4|SLC12A3,cardiology,hypertension
Cc1cc(O)c(C(C)C)cc1Cl,"InChI=1S/C10H13ClO/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6,12H,1-3H3",KFZXVMNBUMVKLN-UHFFFAOYSA-N,chlorothymol,Launched,,,,
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1,"InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3",BFPSDSIWYFKGBC-UHFFFAOYSA-N,chlorotrianisene,Launched,estrogenic hormone,ESR1|ESR2,endocrinology|oncology,menopause|prostate cancer
Oc1c(Cl)cc(Cl)c2cccnc12,"InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",WDFKMLRRRCGAKS-UHFFFAOYSA-N,chloroxine,Launched,opioid receptor antagonist,OPRK1,gastroenterology|infectious disease|dermatology,diarrhea|inflammatory bowel disease|giardiasis|dandruff
O=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C9H6ClNO/c10-6-1-2-7-8(5-6)11-4-3-9(7)12/h1-5H,(H,11,12)",XMFXTXKSWIDMER-UHFFFAOYSA-N,chloroxoquinoline,Launched,,,,
Cc1cc(O)cc(C)c1Cl,"InChI=1S/C8H9ClO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,1-2H3",OSDLLIBGSJNGJE-UHFFFAOYSA-N,chloroxylenol,Launched,ATP synthase inhibitor,,infectious disease,skin infections
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,"InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",SOYKEARSMXGVTM-UHFFFAOYSA-N,chlorphenamine,Launched,histamine receptor antagonist,,allergy,allergic rhinitis|urticaria
OCC(O)COc1ccc(Cl)cc1,"InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2",MXOAEAUPQDYUQM-UHFFFAOYSA-N,chlorphenesin,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant|sedative
CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,"InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3",KKHPNPMTPORSQE-UHFFFAOYSA-N,chlorphenoxamine,Preclinical,histamine receptor antagonist,,,
NC(=O)OCC(O)COc1ccc(Cl)cc1,"InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)",SKPLBLUECSEIFO-UHFFFAOYSA-N,chlorphensin-carbamate,Launched,muscle relaxant,,neurology/psychiatry,spasms
CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,"InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)",ISZNZKHCRKXXAU-UHFFFAOYSA-N,chlorproguanil,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,"InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3",ZPEIMTDSQAKGNT-UHFFFAOYSA-N,chlorpromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5,neurology/psychiatry|gastroenterology|hematology|infectious disease,schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)",RKWGIWYCVPQPMF-UHFFFAOYSA-N,chlorpropamide,Launched,ATP channel blocker,ABCC8|KCNJ10,endocrinology,diabetes mellitus
CC(C)OC(=O)Nc1cccc(Cl)c1,"InChI=1S/C10H12ClNO2/c1-7(2)14-10(13)12-9-5-3-4-8(11)6-9/h3-7H,1-2H3,(H,12,13)",CWJSHJJYOPWUGX-UHFFFAOYSA-N,chlorpropham,Phase 1,antiviral,,,
CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,"InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3",WSPOMRSOLSGNFJ-UHFFFAOYSA-N,chlorprothixene,Launched,dopamine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C,neurology/psychiatry,schizophrenia|bipolar disorder
CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,"InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3",SBPBAQFWLVIOKP-UHFFFAOYSA-N,chlorpyrifos,Launched,acetylcholinesterase inhibitor,ACHE,,
Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,"InChI=1S/C10H7Cl2NO/c1-5-2-3-6-7(11)4-8(12)10(14)9(6)13-5/h2-4,14H,1H3",GPTXWRGISTZRIO-UHFFFAOYSA-N,chlorquinaldol,Launched,other antibiotic,,infectious disease,fungal infection
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)C3C(=O)c4c(O)ccc(Cl)c4C(C)(O)C3CC12,"InChI=1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,11,13,15,26,32-33H,6H2,1-3H3,(H2,24,31)",RNPLSXLZRGPQCU-UHFFFAOYSA-N,chlortetracycline,Launched,protein synthesis inhibitor,,ophthalmology,conjunctivitis
NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl,"InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)",JIVPVXMEBJLZRO-UHFFFAOYSA-N,chlorthalidone,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1,cardiology|gastroenterology|rheumatology|nephrology,hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure
O=c1[nH]c2cc(Cl)ccc2o1,"InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)",TZFWDZFKRBELIQ-UHFFFAOYSA-N,chlorzoxazone,Launched,bacterial 30S ribosomal subunit inhibitor,KCNMA1|KCNN4,neurology/psychiatry,muscle relaxant
C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)CCCC(C)C,"InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3",QYSXJUFSXHHAJI-UHFFFAOYSA-N,cholecalciferol,Launched,,VDR,endocrinology,vitamin D deficiency
CC(C)CCCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3",HVYWMOMLDIMFJA-UHFFFAOYSA-N,cholesterol,Preclinical,,RORA,,
CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,"InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)",BHQCQFFYRZLCQQ-UHFFFAOYSA-N,cholic-acid,Launched,bile acid,ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B,gastroenterology|neurology/psychiatry|genetics,bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome
C[N+](C)(C)CCO,"InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1",OEYIOHPDSNJKLS-UHFFFAOYSA-N,choline,Phase 3,acetylcholine precursor,ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2,,
C[N+](C)(C)CCO[PH](=O)(=O)OCC(O)CO,"InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/q+1",ORESXOWGWRZOHX-UHFFFAOYSA-N,choline-alfoscerate,Launched,acetylcholine precursor,,,
NC(C(=O)O)c1cc(O)ccc1Cl,"InChI=1S/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)",UNIDAFCQFPGYJJ-UHFFFAOYSA-N,chpg,Preclinical,glutamate receptor agonist,GRM5,,
CCCN=c1ccc2ncc(-c3ccc4[nH]ncc4c3)n2[nH]1,"InChI=1S/C16H16N6/c1-2-7-17-15-5-6-16-18-10-14(22(16)21-15)11-3-4-13-12(8-11)9-19-20-13/h3-6,8-10H,2,7H2,1H3,(H,17,21)(H,19,20)",CZZCAOGIEGXMBZ-UHFFFAOYSA-N,chr-6494,Preclinical,serine/threonine kinase inhibitor,GSG2,,
CCS(=O)(=O)N(C)C1c2cc(C#N)ccc2OC(C)(C)C1O,"InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3",HVSJHHXUORMCGK-UHFFFAOYSA-N,chromanol-(+/-),Preclinical,potassium channel blocker,,,
CCS(=O)(=O)N(C)C1c2cc(C#N)ccc2OC(C)(C)C1O,"InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3",HVSJHHXUORMCGK-UHFFFAOYSA-N,"chromanol-293b-(-)-[3r,4s]",Preclinical,potassium channel blocker,,,
O=C(O)c1ccccn1,"InChI=1S/C6H5NO2/c8-6(9)5-3-1-2-4-7-5/h1-4H,(H,8,9)",SIOXPEMLGUPBBT-UHFFFAOYSA-N,chromium-picolinate,Launched,insulin sensitizer,,endocrinology,diabetes mellitus
O=C(O)c1cc(=O)c2ccccc2o1,"InChI=1S/C10H6O4/c11-7-5-9(10(12)13)14-8-4-2-1-3-6(7)8/h1-5H,(H,12,13)",RVMGXWBCQGAWBR-UHFFFAOYSA-N,chromocarb,Launched,antispasmodic,,,
O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H",RTIXKCRFFJGDFG-UHFFFAOYSA-N,chrysin,Phase 1,breast cancer resistance protein inhibitor,AKR1B1|CDK6|CYP19A1|CYP1B1,,
Cc1cc(O)c2c(c1)C(=O)c1cccc(O)c1C2=O,"InChI=1S/C15H10O4/c1-7-5-9-13(11(17)6-7)15(19)12-8(14(9)18)3-2-4-10(12)16/h2-6,16-17H,1H3",LQGUBLBATBMXHT-UHFFFAOYSA-N,chrysophanic-acid,Preclinical,EGFR inhibitor,EGFR|MTOR,,
Cc1nc(C)c(C)nc1C,InChI=1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3,FINHMKGKINIASC-UHFFFAOYSA-N,chuanxiongzine,Phase 2,,,,
c1ccc(Oc2cccnc2)cc1,InChI=1S/C11H9NO/c1-2-5-10(6-3-1)13-11-7-4-8-12-9-11/h1-9H,KDGUIKPOZGYLQJ-UHFFFAOYSA-N,ci-844,Phase 2,,,,
CCNC(C)CN1CCc2c(c(=O)oc3ccccc23)C1,"InChI=1S/C17H22N2O2/c1-3-18-12(2)10-19-9-8-13-14-6-4-5-7-16(14)21-17(20)15(13)11-19/h4-7,12,18H,3,8-11H2,1-2H3",MJRICTKAEYTJAV-UHFFFAOYSA-N,ci-923,Phase 1,acetylcholine receptor antagonist,,,
Cc1cccc(Cl)c1NC(=O)N=c1cc[nH]cc1,"InChI=1S/C13H12ClN3O/c1-9-3-2-4-11(14)12(9)17-13(18)16-10-5-7-15-8-6-10/h2-8H,1H3,(H2,15,16,17,18)",ZSBWDKCIIZYQIR-UHFFFAOYSA-N,ci-953,Phase 1,voltage-gated sodium channel blocker,,,
O=C(O)C1=CCCN(CCOC(c2ccc(C(F)(F)F)cc2)c2ccc(C(F)(F)F)cc2)C1,"InChI=1S/C23H21F6NO3/c24-22(25,26)18-7-3-15(4-8-18)20(16-5-9-19(10-6-16)23(27,28)29)33-13-12-30-11-1-2-17(14-30)21(31)32/h2-10,20H,1,11-14H2,(H,31,32)",CMHQDSBIBSKHFP-UHFFFAOYSA-N,ci-966,Phase 1,GAT inhibitor,SLC6A1,,
CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,"InChI=1S/C23H39NO4/c1-7-8-9-10-11-12-13-14-15-23(2,3)22(25)24-21-19(27-5)16-18(26-4)17-20(21)28-6/h16-17H,7-15H2,1-6H3,(H,24,25)",WAFNZAURAWBNDZ-UHFFFAOYSA-N,ci-976,Phase 1,ACAT inhibitor,ACAT1|CES1,,
c1ccc2c(c1)C1=NC2=Nc2c3ccccc3c3n2[Zn]n2c(c4ccccc4c2=NC2=NC(=N3)c3ccccc32)=N1,InChI=1S/C32H16N8.Zn/c1-2-10-18-17(9-1)25-33-26(18)38-28-21-13-5-6-14-22(21)30(35-28)40-32-24-16-8-7-15-23(24)31(36-32)39-29-20-12-4-3-11-19(20)27(34-29)37-25;/h1-16H;/q-2;+2,PODBBOVVOGJETB-UHFFFAOYSA-N,ciaftalan-zinc,Phase 1,reactive oxygen species stimulant,,,
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,"InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2",PFTAWBLQPZVEMU-UHFFFAOYSA-N,cianidanol,Withdrawn,fatty acid synthase inhibitor,PTGS1,,
c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1,"InChI=1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)",IPOBOOXFSRWSHL-UHFFFAOYSA-N,cibenzoline,Launched,sodium channel blocker,,cardiology,cardiac arrythmia
CC(C)C(=O)OCC(=O)C12OC(C3CCCCC3)OC1CC1C3CC=C4CC(=O)C=CC4(C)C3C(O)CC12C,"InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h10,12-13,18-19,22-24,26-27,29,34H,5-9,11,14-17H2,1-4H3",UGGUCACMQFGWAH-UHFFFAOYSA-N,ciclesonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
Cc1cc(C2CCCCC2)n(O)c(=O)c1,"InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3",SCKYRAXSEDYPSA-UHFFFAOYSA-N,ciclopirox,Launched,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis
CC(C(=O)O)c1ccc2c(c1)Cc1ccccc1-2,"InChI=1S/C16H14O2/c1-10(16(17)18)11-6-7-15-13(8-11)9-12-4-2-3-5-14(12)15/h2-8,10H,9H2,1H3,(H,17,18)",LRXFKKPEBXIPMW-UHFFFAOYSA-N,cicloprofen,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,,
Cc1ccc(-c2[nH]nc3c2C(c2cccc(O)c2)N(c2ccc(C(=O)O)cc2)C3=O)cc1,"InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)",VGUQVYZXABOXCX-UHFFFAOYSA-N,cid-16020046,Preclinical,G protein-coupled receptor antagonist,GPR55,,
O=C(Nc1ccc(CN2CCOCC2)cc1)c1ccc(-c2cccc(Cl)c2)o1,"InChI=1S/C22H21ClN2O3/c23-18-3-1-2-17(14-18)20-8-9-21(28-20)22(26)24-19-6-4-16(5-7-19)15-25-10-12-27-13-11-25/h1-9,14H,10-13,15H2,(H,24,26)",XQJWTJLJEYIUDZ-UHFFFAOYSA-N,cid-2011756,Preclinical,protein kinase inhibitor,PKD1,,
COC(=O)c1cnn(-c2ccc(F)cc2F)c1C=NNC(=S)NC(C)(C)C,"InChI=1S/C17H19F2N5O2S/c1-17(2,3)22-16(27)23-20-9-14-11(15(25)26-4)8-21-24(14)13-6-5-10(18)7-12(13)19/h5-9H,1-4H3,(H2,22,23,27)",CYNLZIBKERMMOA-UHFFFAOYSA-N,cid-2745687,Preclinical,G protein-coupled receptor antagonist,GPR35,,
O=C1c2ccccc2C(=NC2CCCCC2)C1Cc1ccccc1,"InChI=1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-14,17,20H,2,5-6,11-12,15H2",GDUJQLWBXWRZAA-UHFFFAOYSA-N,cid-5458317,Preclinical,MAP kinase phosphatase inhibitor,MAPK3,,
N=c1ccn(CC(CO)OC[PH](=O)(=O)O)c(=O)[nH]1,"InChI=1S/C8H13N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H,14,15,16)",RBLWGWDMUXGUPI-UHFFFAOYSA-N,cidofovir,Launched,DNA polymerase inhibitor,,infectious disease,acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis
CC1(COc2ccc(Cc3sc(=O)[nH]c3O)cc2)CCCCC1,"InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,20H,2-4,9-12H2,1H3,(H,19,21)",YNQLJZYIOAPXMU-UHFFFAOYSA-N,ciglitazone,Phase 2,PPAR receptor agonist,PPARG,,
CC1(C)CC1C(=O)N=C(CCCCCSCC(N)C(=O)O)C(=O)O,"InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h10-11H,3-9,17H2,1-2H3,(H,20,21)(H,22,23)",UUNQYGUCVSFAME-UHFFFAOYSA-N,cilastatin,Launched,dehydropeptidase inhibitor,DPEP1,,
CCOC(=O)C(CCc1ccccc1)NC1CCCN2CCCC(C(=O)O)N2C1=O,"InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)",HHHKFGXWKKUNCY-UHFFFAOYSA-N,cilazapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
CC(C)C1C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(Cc2ccccc2)C(=O)N1C,"InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)",AMLYAMJWYAIXIA-UHFFFAOYSA-N,cilengitide,Phase 3,integrin antagonist,ITGAV|ITGB3,,
COCCOC(=O)C1=C(C)N=C(C)C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,23,25H,14-16H2,1-3H3",BYAAPSQQRDMOAQ-UHFFFAOYSA-N,cilnidipine,Launched,calcium channel blocker,CACNA1B,cardiology,hypertension
O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1,"InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)",KZSKGLFYQAYZCO-UHFFFAOYSA-N,cilofexor,Phase 3,FXR agonist,,,
COc1ccc(C2(C#N)CCC(C(=O)O)CC2)cc1OC1CCCC1,"InChI=1S/C20H25NO4/c1-24-17-7-6-15(12-18(17)25-16-4-2-3-5-16)20(13-21)10-8-14(9-11-20)19(22)23/h6-7,12,14,16H,2-5,8-11H2,1H3,(H,22,23)",CFBUZOUXXHZCFB-UHFFFAOYSA-N,cilomilast,Phase 3,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4D,,
CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1,"InChI=1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23)",UIAYVIIHMORPSJ-UHFFFAOYSA-N,cilostamide,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE3B,,
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,"InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)",RRGUKTPIGVIEKM-UHFFFAOYSA-N,cilostazol,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B,cardiology,claudication
COc1ccc2c(OC3CC4C(=O)NC5(C(=O)O)CC5C=CCCCCCC(NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(=NC(C)C)[nH]3)nc2c1,"InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)",PJZPDFUUXKKDNB-UHFFFAOYSA-N,ciluprevir,Preclinical,serine protease inhibitor,,,
Cc1cc(=NC(=O)C(c2ccccc2)N2CCCc3ccccc32)[nH]o1,"InChI=1S/C21H21N3O2/c1-15-14-19(23-26-15)22-21(25)20(17-9-3-2-4-10-17)24-13-7-11-16-8-5-6-12-18(16)24/h2-6,8-10,12,14,20H,7,11,13H2,1H3,(H,22,23,25)",KSEXDSJYVSEVGF-UHFFFAOYSA-N,cim-0216,Preclinical,transient receptor potential channel agonist,TRPM3,,
CC(C)NCC(O)c1ccc(N)c(C#N)c1,"InChI=1S/C12H17N3O/c1-8(2)15-7-12(16)9-3-4-11(14)10(5-9)6-13/h3-5,8,12,15-16H,7,14H2,1-2H3",BUXRLJCGHZZYNE-UHFFFAOYSA-N,cimaterol,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CN=C(NC#N)NCCSCc1[nH]cnc1C,"InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)",AQIXAKUUQRKLND-UHFFFAOYSA-N,cimetidine,Launched,histamine receptor antagonist,HRH2|SLC29A4|SLC47A1|SLC47A2,gastroenterology|hematologic malignancy|endocrinology,duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma
CC(NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,"InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3",VDHAWDNDOKGFTD-UHFFFAOYSA-N,cinacalcet,Launched,calcium channel activator,CASR,endocrinology|nephrology|oncology,hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia
O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,"InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)",WPYWMXNXEZFMAK-UHFFFAOYSA-N,cinaciguat,Phase 2,guanylate cyclase activator,GUCY1A3|GUCY1B3,,
CCC(CC)(CC(=O)Nc1cccc(C=Cc2nc(C3CCC3)cs2)c1)C(=O)O,"InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)",BZMKNPGKXJAIDV-UHFFFAOYSA-N,cinalukast,Phase 2,leukotriene receptor antagonist,CYSLTR1,,
CN(C)CCCSc1ccccc1NC(=O)C=Cc1ccccc1,"InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)",RSUVYMGADVXGOU-UHFFFAOYSA-N,cinanserin,Preclinical,serotonin receptor antagonist,HTR2A,,
CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,"InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)",PUFQVTATUTYEAL-UHFFFAOYSA-N,cinchocaine,Launched,sodium channel blocker,CALM1|SCN10A|SCN5A,neurology/psychiatry,local anesthetic
C=CC1CN2CCC1CC2C(O)c1ccnc2ccccc12,"InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2",KMPWYEUPVWOPIM-UHFFFAOYSA-N,cinchonidine,Phase 1,P glycoprotein inhibitor,,,
C=CC1CN2CCC1CC2C(O)c1ccnc2ccccc12,"InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2",KMPWYEUPVWOPIM-UHFFFAOYSA-N,cinchonine,Preclinical,P glycoprotein inhibitor,CYP2D6,,
O=C(O)c1cc(-c2ccccc2)nc2ccccc12,"InChI=1S/C16H11NO2/c18-16(19)13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H,(H,18,19)",YTRMTPPVNRALON-UHFFFAOYSA-N,cinchophen,Launched,analgesic agent,,rheumatology,gout
CCOC(=O)CN1CCN(C(=O)C=Cc2cc(OC)c(OC)c(OC)c2)CC1,"InChI=1S/C20H28N2O6/c1-5-28-19(24)14-21-8-10-22(11-9-21)18(23)7-6-15-12-16(25-2)20(27-4)17(13-15)26-3/h6-7,12-13H,5,8-11,14H2,1-4H3",XDUOTWNXVDBCDY-UHFFFAOYSA-N,cinepazet,Launched,vasodilator,,,
COc1cc(C=CC(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC,"InChI=1S/C22H31N3O5/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24/h6-7,14-15H,4-5,8-13,16H2,1-3H3",RCUDFXMNPQNBDU-UHFFFAOYSA-N,cinepazide,Withdrawn,calcium channel activator,,,
O=C(C=Cc1cccc(F)c1)NC1CC1,"InChI=1S/C12H12FNO/c13-10-3-1-2-9(8-10)4-7-12(15)14-11-5-6-11/h1-4,7-8,11H,5-6H2,(H,14,15)",NCOOUEIQXVWKTO-UHFFFAOYSA-N,cinflumide,Phase 2,muscle relaxant,,,
O=CC=Cc1ccccc1,InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H,KJPRLNWUNMBNBZ-UHFFFAOYSA-N,cinnamaldehyde,Preclinical,aldose reductase inhibitor,TRPA1,,
O=CC=Cc1ccccc1,InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H,KJPRLNWUNMBNBZ-UHFFFAOYSA-N,cinnamaldehyde,Preclinical,TRPV agonist,TRPA1,,
C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2",DERZBLKQOCDDDZ-UHFFFAOYSA-N,cinnarazine,Launched,calcium channel blocker,,neurology/psychiatry|gastroenterology|ophthalmology,Meniere's disease|nausea|vomiting|Cogan's syndrome
CC(=O)OC1C(c2ccc(=O)oc2)C2(C)CCC3C(CCC4(O)CC(O)CCC34C)C23OC13,"InChI=1S/C26H34O7/c1-14(27)32-21-20(15-4-5-19(29)31-13-15)24(3)10-7-17-18(26(24)22(21)33-26)8-11-25(30)12-16(28)6-9-23(17,25)2/h4-5,13,16-18,20-22,28,30H,6-12H2,1-3H3",KBKUJJFDSHBPPA-UHFFFAOYSA-N,cinobufotalin,Phase 1,anticancer agent,,,
COc1cc(C=CC(=O)N2CCCCCCC2)cc(OC)c1OC,"InChI=1S/C19H27NO4/c1-22-16-13-15(14-17(23-2)19(16)24-3)9-10-18(21)20-11-7-5-4-6-8-12-20/h9-10,13-14H,4-8,11-12H2,1-3H3",MDGVCMGGLSOVIQ-UHFFFAOYSA-N,cinoctramide,Preclinical,,,,
CCn1nc(C(=O)O)c(=O)c2cc3c(cc21)OCO3,"InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)",VDUWPHTZYNWKRN-UHFFFAOYSA-N,cinoxacin,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
CCOCCOC(=O)C=Cc1ccc(OC)cc1,"InChI=1S/C14H18O4/c1-3-17-10-11-18-14(15)9-6-12-4-7-13(16-2)8-5-12/h4-9H,3,10-11H2,1-2H3",CMDKPGRTAQVGFQ-UHFFFAOYSA-N,cinoxate,Launched,,,dermatology,sunscreen lotion
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(CC)CC)c1ccccc1CC2,"InChI=1S/C23H29N3O3/c1-4-25(5-2)16-22(27)26-20-10-8-7-9-17(20)11-12-18-13-14-19(15-21(18)26)24-23(28)29-6-3/h7-10,13-15H,4-6,11-12,16H2,1-3H3,(H,24,28)",AYQBYSPEGRYKFA-UHFFFAOYSA-N,cinpa-1,Preclinical,CAR antagonist,NR1H4|NR1I3|PPARG,,
CCNC(=O)C=Cc1cccc(Br)c1,"InChI=1S/C11H12BrNO/c1-2-13-11(14)7-6-9-4-3-5-10(12)8-9/h3-8H,2H2,1H3,(H,13,14)",LDCXGZCEMNMWIL-UHFFFAOYSA-N,cinromide,Phase 3,,,,
CC(C)(CC1CN(S(=O)(=O)c2cccc(C(F)(F)F)c2)c2cc(-c3cc(F)cc(OC(F)F)c3)ccc2O1)C(=O)O,"InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)",GULSIMHVQYBADX-UHFFFAOYSA-N,cintirorgon,Phase 1/Phase 2,ROR agonist,,,
COc1cc(C=CC(N)=O)cc(OC)c1OC,"InChI=1S/C12H15NO4/c1-15-9-6-8(4-5-11(13)14)7-10(16-2)12(9)17-3/h4-7H,1-3H3,(H2,13,14)",LRLKZVMLJBNNPE-UHFFFAOYSA-N,cintriamide,Preclinical,,,,
N=c1[nH]c2c(=O)n(CC3CC3)c(=O)n(CC3CC3)c2[nH]1,"InChI=1S/C13H17N5O2/c14-12-15-9-10(16-12)17(5-7-1-2-7)13(20)18(11(9)19)6-8-3-4-8/h7-8H,1-6H2,(H3,14,15,16)",KSPYMJJKQMWWNB-UHFFFAOYSA-N,cipamfylline,Phase 2,phosphodiesterase inhibitor,,,
CC1Cc2c([nH]c3cc(Cl)c(F)cc23)C2(N1)C(=O)Nc1ccc(Cl)cc12,"InChI=1S/C19H14Cl2FN3O/c1-8-4-11-10-6-14(22)13(21)7-16(10)23-17(11)19(25-8)12-5-9(20)2-3-15(12)24-18(19)26/h2-3,5-8,23,25H,4H2,1H3,(H,24,26)",CKLPLPZSUQEDRT-UHFFFAOYSA-N,cipargamin,Phase 2,antimalarial agent,,,
CN1C(=O)N(CC(C(O)=NO)C(CC2CCCC2)C(=O)N2CCCCC2)C(=O)C1(C)C,"InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)",GFUITADOEPNRML-UHFFFAOYSA-N,cipemastat,Phase 3,metalloproteinase inhibitor,ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9,,
CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O,"InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)",KPSRODZRAIWAKH-UHFFFAOYSA-N,ciprofibrate,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,"InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)",MYSWGUAQZAJSOK-UHFFFAOYSA-N,ciprofloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis
O=C(c1ccc(OCCCc2c[nH]cn2)cc1)C1CC1,"InChI=1S/C16H18N2O2/c19-16(12-3-4-12)13-5-7-15(8-6-13)20-9-1-2-14-10-17-11-18-14/h5-8,10-12H,1-4,9H2,(H,17,18)",ACQBHJXEAYTHCY-UHFFFAOYSA-N,ciproxifan,Preclinical,histamine receptor antagonist,ADRA2A|ADRA2C|HRH3|HRH4|HTR3A,,
COc1ccc(OCC2c3cc(OC)c(OC)cc3CCN2C(=O)c2cccc(Cl)c2)cc1,"InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-22-15-25(32-3)24(31-2)14-17(22)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3",VYMILMYEENZHAR-UHFFFAOYSA-N,ciq,Preclinical,glutamate receptor potentiator,GRIN2C|GRIN2D,,
c1ccc(C2CC2)c(OCC2=NCCN2)c1,"InChI=1S/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15)",YAORIDZYZDUZCM-UHFFFAOYSA-N,cirazoline,Preclinical,adrenergic receptor agonist,ADRA1A,,
CCCCCCC=CC=CCCCCCCCC(=O)O,"InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-10H,2-6,11-17H2,1H3,(H,19,20)",JBYXPOFIGCOSSB-UHFFFAOYSA-N,"cis-9,trans-11-conjugated-linoleic-acid",Launched,,,,
O=C(O)C=C(CC(=O)O)C(=O)O,"InChI=1S/C6H6O6/c7-4(8)1-3(6(11)12)2-5(9)10/h1H,2H2,(H,7,8)(H,9,10)(H,11,12)",GTZCVFVGUGFEME-UHFFFAOYSA-N,cis-aconitic-acid,Preclinical,,ACO2,,
NC1(C(=O)O)CCC(C(=O)O)C1,"InChI=1S/C7H11NO4/c8-7(6(11)12)2-1-4(3-7)5(9)10/h4H,1-3,8H2,(H,9,10)(H,11,12)",YFYNOWXBIBKGHB-UHFFFAOYSA-N,cis-acpd,Preclinical,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM7|GRM8,,
CC1(C)C2CCC1(C)C(O)C2O,"InChI=1S/C10H18O2/c1-9(2)6-4-5-10(9,3)8(12)7(6)11/h6-8,11-12H,4-5H2,1-3H3",AYEOSGBMQHXVER-UHFFFAOYSA-N,"cis-exo-camphanediol-2,3",Phase 1,nitric oxide stimulant,NOS3,,
O=C(O)C=Cc1c[nH]cn1,"InChI=1S/C6H6N2O2/c9-6(10)2-1-5-3-7-4-8-5/h1-4H,(H,7,8)(H,9,10)",LOIYMIARKYCTBW-UHFFFAOYSA-N,cis-urocanic-acid,Phase 2,serotonin receptor agonist,HTR2A,,
COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,"InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)",DCSUBABJRXZOMT-UHFFFAOYSA-N,cisapride,Withdrawn,serotonin receptor agonist,HTR2A|HTR3A|HTR4|KCNH2,,
COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC,"InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2",YXSLJKQTIDHPOT-UHFFFAOYSA-N,cisatracurium,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry|critical care,muscle relaxant|endotracheal intubation
N,InChI=1S/H3N/h1H3,QGZKDVFQNNGYKY-UHFFFAOYSA-N,cisplatin,Launched,DNA alkylating agent,XIAP,oncology,testicular carcinoma|ovarian cancer|bladder cancer
N,InChI=1S/H3N/h1H3,QGZKDVFQNNGYKY-UHFFFAOYSA-N,cisplatin,Launched,DNA synthesis inhibitor,XIAP,oncology,testicular carcinoma|ovarian cancer|bladder cancer
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,"InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3",WSEQXVZVJXJVFP-UHFFFAOYSA-N,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
O=C(NCCCCCCC(O)=NO)c1cnc(N(c2ccccc2)c2ccccc2Cl)nc1,"InChI=1S/C24H26ClN5O3/c25-20-12-7-8-13-21(20)30(19-10-4-3-5-11-19)24-27-16-18(17-28-24)23(32)26-15-9-2-1-6-14-22(31)29-33/h3-5,7-8,10-13,16-17,33H,1-2,6,9,14-15H2,(H,26,32)(H,29,31)",VLIUIBXPEDFJRF-UHFFFAOYSA-N,citarinostat,Phase 1,HDAC inhibitor,,,
Clc1ccc(-c2nc3sccn3c2C=NOCc2ccc(Cl)c(Cl)c2)cc1,"InChI=1S/C19H12Cl3N3OS/c20-14-4-2-13(3-5-14)18-17(25-7-8-27-19(25)24-18)10-23-26-11-12-1-6-15(21)16(22)9-12/h1-10H,11H2",ZQWBOKJVVYNKTL-UHFFFAOYSA-N,citco,Preclinical,constitutive androstane receptor (CAR) agonist,NR1I3,,
C[N+](C)(C)CCO[PH](=O)(=O)O[PH](=O)(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(O)C1O,"InChI=1S/C14H24N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H-,15,16,21)/p+1",BDFKEJPTFCHVFQ-UHFFFAOYSA-O,citicoline,Launched,glutathione transferase stimulant,ACHE|SLC1A2,neurology/psychiatry|ophthalmology,stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma
C[N+](C)(C)CCO[PH](=O)(=O)O[PH](=O)(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(O)C1O,"InChI=1S/C14H24N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H-,15,16,21)/p+1",BDFKEJPTFCHVFQ-UHFFFAOYSA-O,citicoline,Launched,membrane permeability enhancer,ACHE|SLC1A2,neurology/psychiatry|ophthalmology,stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma
CC(=O)NC1CCSC1=O,"InChI=1S/C6H9NO2S/c1-4(8)7-5-2-3-10-6(5)9/h5H,2-3H2,1H3,(H,7,8)",NRFJZTXWLKPZAV-UHFFFAOYSA-N,citiolone,Preclinical,lipotropic,,,
CC(=O)NC1CCSC1=O,"InChI=1S/C6H9NO2S/c1-4(8)7-5-2-3-10-6(5)9/h5H,2-3H2,1H3,(H,7,8)",NRFJZTXWLKPZAV-UHFFFAOYSA-N,citiolone,Preclinical,mucolytic agent,,,
O=C(O)CC(O)(CC(=O)O)C(=O)O,"InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",KRKNYBCHXYNGOX-UHFFFAOYSA-N,citric-acid,Preclinical,coagulation factor inhibitor,AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2,,
Cc1cn2c(=N)c(Cl)cc(C(=O)NCC3CCN(CC(C)C)CC3)c2[nH]1,"InChI=1S/C19H28ClN5O/c1-12(2)10-24-6-4-14(5-7-24)9-22-19(26)15-8-16(20)17(21)25-11-13(3)23-18(15)25/h8,11-12,14,21,23H,4-7,9-10H2,1-3H3,(H,22,26)",VFMLAMXNKQWUKP-UHFFFAOYSA-N,cj-033466,Preclinical,serotonin receptor agonist,HTR4,,
Cc1nccn1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1,"InChI=1S/C22H23N3O2S/c1-16-24-11-12-25(16)18-5-7-19(8-6-18)28-20-4-2-3-17(15-20)22(21(23)26)9-13-27-14-10-22/h2-8,11-12,15H,9-10,13-14H2,1H3,(H2,23,26)",VPTONMHDLLMOOV-UHFFFAOYSA-N,cj-13610,Phase 2,lipoxygenase inhibitor,,,
C=CC(=O)Nc1cccc(-c2cccc3c[nH]c(=Nc4ccc(N5CCN(CCO)CC5)c(F)c4F)nc23)c1,"InChI=1S/C29H28F2N6O2/c1-2-25(39)33-21-7-3-5-19(17-21)22-8-4-6-20-18-32-29(35-28(20)22)34-23-9-10-24(27(31)26(23)30)37-13-11-36(12-14-37)15-16-38/h2-10,17-18,38H,1,11-16H2,(H,33,39)(H,32,34,35)",IDRGFNPZDVBSSE-UHFFFAOYSA-N,ck-101,Preclinical,EGFR inhibitor,,,
Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,"InChI=1S/C16H16N2OS/c1-11-12(13-5-2-3-6-14(13)18-11)8-9-17-16(19)15-7-4-10-20-15/h2-7,10,18H,8-9H2,1H3,(H,17,19)",ACAKNPKRLPMONU-UHFFFAOYSA-N,ck-636,Preclinical,actin related protein inhibitor,ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5,,
Oc1cc2c(cc1O)C(Cc1cccc3ccccc13)NCC2,"InChI=1S/C20H19NO2/c22-19-11-15-8-9-21-18(17(15)12-20(19)23)10-14-6-3-5-13-4-1-2-7-16(13)14/h1-7,11-12,18,21-23H,8-10H2",YGCQFKVNIBDJFW-UHFFFAOYSA-N,ckd-712,Phase 1,NFkB pathway inhibitor,JAK2|STAT1,,
NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12,"InChI=1S/C11H12ClN3O2S/c12-10-1-2-11(18(16,17)15-6-4-13)9-7-14-5-3-8(9)10/h1-3,5,7,15H,4,6,13H2",OGKYMFFYOWUTKV-UHFFFAOYSA-N,cki-7,Preclinical,casein kinase inhibitor,CSNK1G2,,
Cc1nnc2ccc(-c3cccc(C(F)(F)F)c3)nn12,"InChI=1S/C13H9F3N4/c1-8-17-18-12-6-5-11(19-20(8)12)9-3-2-4-10(7-9)13(14,15)16/h2-7H,1H3",GUOQUXNJZHGPQF-UHFFFAOYSA-N,cl-218872,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,
N#CCC(=O)c1ccccc1,"InChI=1S/C9H7NO/c10-7-6-9(11)8-4-2-1-3-5-8/h1-5H,6H2",ZJRCIQAMTAINCB-UHFFFAOYSA-N,cl-225385,Phase 2,,,,
CC(Cc1ccc2c(c1)OC(C(=O)O)(C(=O)O)O2)NCC(O)c1cccc(Cl)c1,"InChI=1S/C20H20ClNO7/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27)",JEDJMKTVUPSHFW-UHFFFAOYSA-N,cl316243,Phase 2,adrenergic receptor agonist,ADRB3|UCP1|UCP2|UCP3,,
N=c1[nH]c(Cl)nc2c1ncn2C1CC(O)C(CO)O1,"InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)",PTOAARAWEBMLNO-UHFFFAOYSA-N,cladribine,Launched,adenosine deaminase inhibitor,ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B,hematologic malignancy,hairy cell leukemia
N=c1[nH]c(Cl)nc2c1ncn2C1CC(O)C(CO)O1,"InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)",PTOAARAWEBMLNO-UHFFFAOYSA-N,cladribine,Launched,ribonucleotide reductase inhibitor,ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B,hematologic malignancy,hairy cell leukemia
CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC,"InChI=1S/C19H22ClN3O5S2/c1-21-19(29)23-30(25,26)17-10-12(4-6-16(17)28-3)8-9-22-18(24)14-11-13(20)5-7-15(14)27-2/h4-7,10-11H,8-9H2,1-3H3,(H,22,24)(H2,21,23,29)",VXTKXGKPBOLHRY-UHFFFAOYSA-N,clamikalant,Preclinical,ATP-sensitive potassium channel antagonist,,,
CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1,"InChI=1S/C16H15ClFN3O2/c1-21(2)13-5-3-4-12(18)14(13)15(22)20-16(23)19-11-8-6-10(17)7-9-11/h3-9H,1-2H3,(H2,19,20,22,23)",SRLPZQAEBMZCIJ-UHFFFAOYSA-N,clanfenur,Preclinical,anticancer agent,,,
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C(O)C1(C)O,"InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3",AGOYDEPGAOXOCK-UHFFFAOYSA-N,clarithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,CYP3A4,otolaryngology|pulmonary|infectious disease,pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis
O=C(O)C1=C(CCO)OC2CC(=O)N12,"InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h6,10H,1-3H2,(H,12,13)",UHZZNJMZGMUGFB-UHFFFAOYSA-N,clavulanate,Launched,beta lactamase inhibitor,,otolaryngology,otitis
COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,"InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)",BVPWJMCABCPUQY-UHFFFAOYSA-N,clebopride,Launched,dopamine receptor antagonist,ACHE|DRD2,gastroenterology,nausea
CN1CCCC1CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,"InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3",YNNUSGIPVFPVBX-UHFFFAOYSA-N,clemastine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1,"InChI=1S/C19H20ClN3/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22/h1-2,5-10H,3-4,11-14H2",CJXAEXPPLWQRFR-UHFFFAOYSA-N,clemizole,Launched,HCV inhibitor,,allergy,allergic rhinitis
CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,"InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3",STJMRWALKKWQGH-UHFFFAOYSA-N,clenbuterol,Launched,adrenergic receptor agonist,ABCC8|ADRB2|KCNJ11,pulmonary,chronic obstructive pulmonary disease (COPD)|asthma
CCCC(=O)OCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1c1cccc(Cl)c1Cl,"InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,16,18H,5,7,10H2,1-4H3",PLWGSEYKEKXMIX-UHFFFAOYSA-N,cleviprex,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension
Cc1cn(C2OC(CO)C(O)C2F)c(=O)[nH]c1=O,"InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)",GBBJCSTXCAQSSJ-UHFFFAOYSA-N,clevudine,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1,"InChI=1S/C15H17ClN2O2/c1-15(2,3)13(19)14(18-9-8-17-10-18)20-12-6-4-11(16)5-7-12/h4-10,14H,1-3H3",OWEGWHBOCFMBLP-UHFFFAOYSA-N,climbazole,Launched,enzyme inducer,,dermatology,dandruff|eczema
NC1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,"InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)",QGPKADBNRMWEQR-UHFFFAOYSA-N,clinafloxacin,Phase 3,bacterial DNA gyrase inhibitor,,,
CCCC1CC(C(=O)NC(C(C)Cl)C2OC(SC)C(O)C(O)C2O)N(C)C1,"InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)",KDLRVYVGXIQJDK-UHFFFAOYSA-N,clindamycin,Launched,protein synthesis inhibitor,,infectious disease,respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections
CCCCCCCCCCCCCCCC(=O)OC1C(SC)OC(C(NC(=O)C2CC(CCC)CN2C)C(C)Cl)C(O)C1O,"InChI=1S/C34H63ClN2O6S/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-21-27(38)42-32-30(40)29(39)31(43-34(32)44-5)28(24(3)35)36-33(41)26-22-25(20-7-2)23-37(26)4/h24-26,28-32,34,39-40H,6-23H2,1-5H3,(H,36,41)",OYSKUZDIHNKWLV-UHFFFAOYSA-N,clindamycin-palmitate,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,intra-abdominal infections|skin infections|pneumonia|peritonitis|gynecologic infections
CCCC1CC(C(=O)NC(C(C)Cl)C2OC(SC)C(O[PH](=O)(=O)O)C(O)C2O)N(C)C1,"InChI=1S/C18H33ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H,25,26,27)",XDJGZAFTCTYHSZ-UHFFFAOYSA-N,clindamycin-phosphate,Launched,protein synthesis inhibitor,,obstetrics/gynecology,bacterial vaginosis
CCC(C)(Oc1ccc(C2(c3ccc(OC(C)(CC)C(=O)O)cc3)CCCCC2)cc1)C(=O)O,"InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)",BMOVQUBVGICXQN-UHFFFAOYSA-N,clinofibrate,Launched,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia
Oc1c(I)cc(Cl)c2cccnc12,"InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",QCDFBFJGMNKBDO-UHFFFAOYSA-N,clioquinol,Withdrawn,chelating agent,OPRK1,,
N=C(NCc1ccc(Cl)cc1)SCCCc1c[nH]cn1,"InChI=1S/C14H17ClN4S/c15-12-5-3-11(4-6-12)8-18-14(16)20-7-1-2-13-9-17-10-19-13/h3-6,9-10H,1-2,7-8H2,(H2,16,18)(H,17,19)",UCAIEVHKDLMIFL-UHFFFAOYSA-N,clobenpropit,Preclinical,histamine receptor antagonist,HRH1|HRH2|HRH3|HRH4,,
CCC(=O)OC1(C(=O)CCl)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h6,8-9,14,17-19,29H,5,7,10-13H2,1-4H3",VTWNBHBLWRWSOB-UHFFFAOYSA-N,clobetasol-propionate,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)OC1(C(=O)CCl)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(=O)CC21C,"InChI=1S/C26H32ClFO5/c1-5-6-22(32)33-26(21(31)14-27)15(2)11-19-18-8-7-16-12-17(29)9-10-23(16,3)25(18,28)20(30)13-24(19,26)4/h7,9-10,15,18-19H,5-6,8,11-14H2,1-4H3",HUYVOKGTJJWNAG-UHFFFAOYSA-N,clobetasone-butyrate,Launched,corticosteroid agonist,NR3C1,dermatology,eczema|psoriasis|dermatitis
CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,"InChI=1S/C14H22ClNO/c1-11(10-16(3)4)14(2,17)9-12-5-7-13(15)8-6-12/h5-8,11,17H,9-10H2,1-4H3",KVHHQGIIZCJATJ-UHFFFAOYSA-N,clobutinol,Withdrawn,antitussive,,,
CC1CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1C(=O)COC(=O)C(C)(C)C,"InChI=1S/C27H36ClFO5/c1-14-9-16-17-11-19(29)18-10-15(30)7-8-26(18,6)27(17,28)21(32)12-25(16,5)22(14)20(31)13-34-23(33)24(2,3)4/h7-8,14,16-17,21-22,32H,9-13H2,1-6H3",KSRXSZHGKMBEGY-UHFFFAOYSA-N,clocortolone-pivalate,Launched,steroid,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
O=[PH](=O)(O)C(Cl)(Cl)[PH](=O)(=O)O,"InChI=1S/CH2Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H,4,5,6)(H,7,8,9)",SMDQENAKEXGVHN-UHFFFAOYSA-N,clodronic-acid,Launched,bone resorption inhibitor,SLC25A4|SLC25A5|SLC25A6,orthopedics|endocrinology|hematologic malignancy,osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma
N=c1[nH]c(Cl)nc2c1ncn2C1OC(CO)C(O)C1F,"InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)",WDDPHFBMKLOVOX-UHFFFAOYSA-N,clofarabine,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,acute lymphoblastic leukemia (ALL)
CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3[nH]c-2cc1=Nc1ccc(Cl)cc1,"InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,32H,1-2H3",LWOJLHGUZZEVRZ-UHFFFAOYSA-N,clofazimine,Launched,GK0582 inhibitor,,infectious disease,leprosy
CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl,"InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3",WRCHFMBCVFFYEQ-UHFFFAOYSA-N,clofedanol,Launched,histamine receptor antagonist,HRH1,pulmonary,cough suppressant
CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,"InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3",KNHUKKLJHYUCFP-UHFFFAOYSA-N,clofibrate,Launched,PPAR receptor agonist,LPL|PPARA,endocrinology|cardiology,hyperlipidemia|cholesterol
CC(C)(Oc1ccc(Cl)cc1)C(=O)O,"InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)",TXCGAZHTZHNUAI-UHFFFAOYSA-N,clofibric-acid,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia
CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1,"InChI=1S/C21H37ClN/c1-4-7-8-9-11-18-23(5-2,6-3)19-12-10-13-20-14-16-21(22)17-15-20/h14-17H,4-13,18-19H2,1-3H3/q+1",WPSYTTKBGAZSCX-UHFFFAOYSA-N,clofilium,Phase 2,potassium channel blocker,KCNA5|KCNH1,,
CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1,"InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3",HQVZOORKDNCGCK-UHFFFAOYSA-N,clofoctol,Launched,protein synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CS(=O)(=O)CS(=O)(=O)OCCCl,"InChI=1S/C4H9ClO5S2/c1-11(6,7)4-12(8,9)10-3-2-5/h2-4H2,1H3",SEHSPJCWCBQHPF-UHFFFAOYSA-N,clomesone,Phase 1,DNA inhibitor,,,
Cc1ncsc1CCCl,"InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3",PCLITLDOTJTVDJ-UHFFFAOYSA-N,clomethiazole,Launched,GABA receptor antagonist,GABRA1,neurology/psychiatry,Parkinson's Disease|sedative|muscle relaxant
Cc1ncsc1CCCl,"InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3",PCLITLDOTJTVDJ-UHFFFAOYSA-N,clomethiazole,Launched,GABA receptor modulator,GABRA1,neurology/psychiatry,Parkinson's Disease|sedative|muscle relaxant
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,"InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3",GKIRPKYJQBWNGO-UHFFFAOYSA-N,clomifene,Launched,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,"InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3",GDLIGKIOYRNHDA-UHFFFAOYSA-N,clomipramine,Launched,serotonin transporter (SERT) inhibitor,GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD)
Clc1cccc(Cl)c1NC1=NCCN1,"InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)",GJSURZIOUXUGAL-UHFFFAOYSA-N,clonidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|neurology/psychiatry,hypertension|attention-deficit/hyperactivity disorder (ADHD)
Cc1c(Cl)cccc1N=c1[nH]cccc1C(=O)O,"InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)",CLOMYZFHNHFSIQ-UHFFFAOYSA-N,clonixin,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|infectious disease,rheumatoid arthritis|soft tissue infection
Cc1c(Cl)cccc1N=c1[nH]cccc1C(=O)O,"InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)",CLOMYZFHNHFSIQ-UHFFFAOYSA-N,clonixin-lysinate,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,"InChI=1S/C14H20ClN3O3S/c1-9-4-3-5-10(2)18(9)17-14(19)11-6-7-12(15)13(8-11)22(16,20)21/h6-10H,3-5H2,1-2H3,(H,17,19)(H2,16,20,21)",LBXHRAWDUMTPSE-UHFFFAOYSA-N,clopamide,Launched,sodium/chloride cotransporter inhibitor,,cardiology,hypertension
Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1,"InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2",FLNXBVJLPJNOSI-UHFFFAOYSA-N,cloperastine,Launched,antitussive,,pulmonary,cough suppressant
Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1,"InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2",FLNXBVJLPJNOSI-UHFFFAOYSA-N,cloperastine-fendizoate,Preclinical,potassium channel antagonist,,,
COC(=O)C(c1ccccc1Cl)N1CCc2sccc2C1,"InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3",GKTWGGQPFAXNFI-UHFFFAOYSA-N,clopidogrel,Launched,purinergic receptor antagonist,P2RY12,cardiology|neurology/psychiatry,myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)
Cc1[nH]c(C)c(Cl)c(=O)c1Cl,"InChI=1S/C7H7Cl2NO/c1-3-5(8)7(11)6(9)4(2)10-3/h1-2H3,(H,10,11)",ZDPIZLCVJAAHHR-UHFFFAOYSA-N,clopidol,Launched,,,infectious disease,coccidiosis
O=C(O)CCCC=CCC1C(O)CC(O)C1C=CC(O)COc1cccc(Cl)c1,"InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)",VJGGHXVGBSZVMZ-UHFFFAOYSA-N,cloprostenol-(+/-),Launched,prostaglandin receptor agonist,PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R,obstetrics/gynecology,endometriosis
CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,"InChI=1S/C13H19Cl2NO2/c1-13(2,3)16-7-10(17)8-18-12-6-9(14)4-5-11(12)15/h4-6,10,16-17H,7-8H2,1-3H3",XYCMOTOFHFTUIU-UHFFFAOYSA-N,cloranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,hypertension
C#CCN(C)CCCOc1ccc(Cl)cc1Cl,"InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3",BTFHLQRNAMSNLC-UHFFFAOYSA-N,clorgiline,Phase 2,monoamine oxidase inhibitor,MAOA,,
CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C19H21ClN2S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,13,17H,8-12H2,1H3",XRYLGRGAWQSVQW-UHFFFAOYSA-N,clorotepine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6,neurology/psychiatry,psychosis
CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C19H21ClN2S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,13,17H,8-12H2,1H3",XRYLGRGAWQSVQW-UHFFFAOYSA-N,clorotepine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6,neurology/psychiatry,psychosis
CC(C)NCC(O)c1ccccc1Cl,"InChI=1S/C11H16ClNO/c1-8(2)13-7-11(14)9-5-3-4-6-10(9)12/h3-6,8,11,13-14H,7H2,1-2H3",SSMSBSWKLKKXGG-UHFFFAOYSA-N,clorprenaline,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,asthma
Nc1cc(C(Cl)=C(Cl)Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,"InChI=1S/C8H8Cl3N3O4S2/c9-7(8(10)11)3-1-4(12)6(20(14,17)18)2-5(3)19(13,15)16/h1-2H,12H2,(H2,13,15,16)(H2,14,17,18)",QOVTVIYTBRHADL-UHFFFAOYSA-N,clorsulon,Launched,glycolysis inhibitor,,infectious disease,gastrointestinal roundworms|lungworms|liver flukes|lice|mites
Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,"InChI=1S/C22H14Cl2I2N2O2/c1-11-6-15(17(10-27)12-2-4-13(23)5-3-12)18(24)9-20(11)28-22(30)16-7-14(25)8-19(26)21(16)29/h2-9,17,29H,1H3,(H,28,30)",JMPFSEBWVLAJKM-UHFFFAOYSA-N,closantel,Launched,chitinase inhibitor,,infectious disease,liver flukes
Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,"InChI=1S/C22H14Cl2I2N2O2/c1-11-6-15(17(10-27)12-2-4-13(23)5-3-12)18(24)9-20(11)28-22(30)16-7-14(25)8-19(26)21(16)29/h2-9,17,29H,1H3,(H,28,30)",JMPFSEBWVLAJKM-UHFFFAOYSA-N,closantel,Launched,NFkB pathway inhibitor,,infectious disease,liver flukes
CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",KAAZGXDPUNNEFN-UHFFFAOYSA-N,clotiapine,Launched,,,neurology/psychiatry,psychosis
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,"InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H",VNFPBHJOKIVQEB-UHFFFAOYSA-N,clotrimazole,Launched,cytochrome P450 inhibitor,CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8,infectious disease,vulvovaginal candidiasis|oropharyngeal candidiasis
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,"InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H",VNFPBHJOKIVQEB-UHFFFAOYSA-N,clotrimazole,Launched,imidazoline receptor ligand,CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8,infectious disease,vulvovaginal candidiasis|oropharyngeal candidiasis
Cc1onc(-c2ccccc2Cl)c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)",LQOLIRLGBULYKD-UHFFFAOYSA-N,cloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
Oc1ccc(Cl)c2cccnc12,"InChI=1S/C9H6ClNO/c10-7-3-4-8(12)9-6(7)2-1-5-11-9/h1-5,12H",CTQMJYWDVABFRZ-UHFFFAOYSA-N,cloxyquin,Preclinical,potassium channel activator,KCNK18,,
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3",QZUDBNBUXVUHMW-UHFFFAOYSA-N,clozapine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia
CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3",QZUDBNBUXVUHMW-UHFFFAOYSA-N,clozapine,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia
Cc1cccc(F)c1C(=O)N=c1cnc(-c2cc3c(cc2Cl)OC(F)(F)O3)c[nH]1,"InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27)",QQMKTHUGOQDEIL-UHFFFAOYSA-N,cm-4620,Phase 2,calcium release activated channel modulator,,,
O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1,"InChI=1S/C22H20FNO2/c23-21-6-2-1-5-20(21)17-10-8-16(9-11-17)4-3-7-22(26)24-18-12-14-19(25)15-13-18/h1-2,5-6,8-15,25H,3-4,7H2,(H,24,26)",ODYAQBDIXCVKAE-UHFFFAOYSA-N,cmpd-1,Preclinical,p38 MAPK inhibitor,GNRHR|MAPK14,,
N#Cc1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+](=O)[O-],"InChI=1S/C9H4N4O4/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5/h1-2H,(H,11,14)(H,12,15)",RPXVIAFEQBNEAX-UHFFFAOYSA-N,cnqx,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
C=CC(=O)Nc1cccc(N=c2[nH]c(=Nc3ccc(NC4CN(CCF)C4)cc3OC)[nH]cc2C(F)(F)F)c1,"InChI=1S/C26H27F4N7O2/c1-3-23(38)33-16-5-4-6-17(11-16)34-24-20(26(28,29)30)13-31-25(36-24)35-21-8-7-18(12-22(21)39-2)32-19-14-37(15-19)10-9-27/h3-8,11-13,19,32H,1,9-10,14-15H2,2H3,(H,33,38)(H2,31,34,35,36)",BFSRTTWIPACGMI-UHFFFAOYSA-N,cnx-2006,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cccc(N=c2[nH]c(=Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)[nH]cc2F)c1,"InChI=1S/C26H22FN7O3/c1-3-23(35)31-17-5-4-6-18(13-17)32-24-21(27)15-30-26(34-24)33-16-7-9-19(10-8-16)37-20-11-12-29-22(14-20)25(36)28-2/h3-15H,1H2,2H3,(H,28,36)(H,31,35)(H2,30,32,33,34)",VVLHQJDAUIPZFH-UHFFFAOYSA-N,cnx-774,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,"InChI=1S/C21H27NO3/c1-17-2-4-18(5-3-17)16-21(24)10-12-22(13-11-21)14-15-25-20-8-6-19(23)7-9-20/h2-9,23-24H,10-16H2,1H3",VKMFDKYCIKEDMR-UHFFFAOYSA-N,co-101244,Preclinical,glutamate receptor antagonist,GRIN2B,,
NC(=O)NN=Cc1ccc(Oc2ccc(F)cc2)cc1,"InChI=1S/C14H12FN3O2/c15-11-3-7-13(8-4-11)20-12-5-1-10(2-6-12)9-17-18-14(16)19/h1-9H,(H3,16,18,19)",MHUUDVZSPFRUSK-UHFFFAOYSA-N,co-102862,Phase 1,sodium channel blocker,SCN4A|SCN9A,,
CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)",ZCIGNRJZKPOIKD-UHFFFAOYSA-N,cobicistat,Launched,cytochrome P450 inhibitor,CYP3A4|CYP3A43|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)(C2CCCCN2)C1,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2",BSMCAPRUBJMWDF-UHFFFAOYSA-N,cobimetinib,Launched,MEK inhibitor,MAP2K1,oncology,melanoma
CC(C)(CO[PH](=O)(=O)O[PH](=O)(=O)OCC1OC(n2cnc3c(=N)[nH]cnc32)C(O)C1O[PH](=O)(=O)O)C(=O)C(O)NCCC(=O)NCCS,"InChI=1S/C21H33N7O16P3S/c1-21(2,16(31)19(32)24-4-3-12(29)23-5-6-48)8-41-47(38,39)44-46(36,37)40-7-11-15(43-45(33,34)35)14(30)20(42-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-15,19-20,24,30,32,48H,3-8H2,1-2H3,(H,23,29)(H2,22,25,26)(H,33,34,35)",GBZKZQGETAQRBG-UHFFFAOYSA-N,coenzyme-a,Launched,,ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5,,
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)OCC2OC(N3C=CCC(C(N)=O)=C3)C(O)C2O)C(O)C1O,"InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H2,22,24,25)",MWBVNIMORFEJDU-UHFFFAOYSA-N,coenzyme-i,Phase 2,,AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH,,
COc1c(O)c(C)c(C=CC(C)=CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)c(O)c1OC,"InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40-43,60-61H,15-23,25,27,29,31,33,35,37,39H2,1-14H3",IWWNJJYZVFOLBL-UHFFFAOYSA-N,coenzyme-q10,Launched,,,,
O=C(N=c1[nH]c(-c2ccc(O)c(O)c2)c(-c2ccccc2)s1)c1ccc(O)c(O)c1,"InChI=1S/C22H16N2O5S/c25-15-8-6-13(10-17(15)27)19-20(12-4-2-1-3-5-12)30-22(23-19)24-21(29)14-7-9-16(26)18(28)11-14/h1-11,25-28H,(H,23,24,29)",LGGDLPSXAGQFSG-UHFFFAOYSA-N,coh29,Phase 1,ribonucleotide reductase inhibitor,,,
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,"InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)",IAKHMKGGTNLKSZ-UHFFFAOYSA-N,colchicine,Launched,microtubule inhibitor,GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,rheumatology|endocrinology,gout|fever
C=CC1(C)CC(=O)C2(O)C(C)(O1)C(OC(C)=O)C(O)C1C(C)(C)CCC(O)C12C,"InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3",OHCQJHSOBUTRHG-UHFFFAOYSA-N,colforsin,Phase 2,adenylyl cyclase activator,ADCY2|ADCY5,,
C=CC1(C)CC(=O)C2(O)C(C)(O1)C(OC(C)=O)C(OC(=O)CCN(C)C)C1C(C)(C)CCC(O)C12C,"InChI=1S/C27H43NO8/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24/h10,17,20-22,30,33H,1,11-15H2,2-9H3",RSOZZQTUMVBTMR-UHFFFAOYSA-N,colforsin-daproate,Launched,adenylyl cyclase activator,,,
CCCCCCCCCCCCCCCC(=O)OCC(CO[PH](=O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,"InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/q+1",BRKCUXAPDJKJSF-UHFFFAOYSA-N,colfosceril-palmitate,Launched,pulmonary surfactant,,pulmonary,respiratory distress syndrome (RDS)
CC(C)CCCC(=O)NC(CCNCS(=O)(=O)O)C(=O)NC(C(=O)NC(CCNCS(=O)(=O)O)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)O)NC1=O)C(C)O,"InChI=1S/C56H106N16O28S5/c1-31(2)10-9-11-44(75)63-36(12-18-57-26-101(86,87)88)51(80)72-46(35(8)74)56(85)68-39(15-21-60-29-104(95,96)97)48(77)66-41-17-23-62-55(84)45(34(7)73)71-52(81)40(16-22-61-30-105(98,99)100)65-47(76)37(13-19-58-27-102(89,90)91)67-53(82)42(24-32(3)4)70-54(83)43(25-33(5)6)69-50(79)38(64-49(41)78)14-20-59-28-103(92,93)94/h31-43,45-46,57-61,73-74H,9-30H2,1-8H3,(H,62,84)(H,63,75)(H,64,78)(H,65,76)(H,66,77)(H,67,82)(H,68,85)(H,69,79)(H,70,83)(H,71,81)(H,72,80)(H,86,87,88)(H,89,90,91)(H,92,93,94)(H,95,96,97)(H,98,99,100)",PTQGBRPUALXNCZ-UHFFFAOYSA-N,colistimethate,Launched,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections
CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,"InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)",YKQOSKADJPQZHB-UHFFFAOYSA-N,colistin,Launched,bacterial permeability inducer,,infectious disease,gram-negative bacterial infections|gram-negative bacterial infections
COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1O,"InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3",HVXBOLULGPECHP-UHFFFAOYSA-N,combretastatin-a-4,Phase 2,tubulin polymerization inhibitor,,,
O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12,"InChI=1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2",BVRDQVRQVGRNHG-UHFFFAOYSA-N,compound-401,Preclinical,DNA dependent protein kinase inhibitor,MTOR|PRKDC,,
COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1,"InChI=1S/C14H25NO2Si2/c1-16-14-8-6-7-13(9-14)10-15-11-18(2,3)17-19(4,5)12-15/h6-9H,10-12H2,1-5H3",CUYLJVJMQPPTOS-UHFFFAOYSA-N,compound-58112,Preclinical,,,,
O=C(O)c1cc(Oc2ccc([N+](=O)[O-])cc2)cc(Oc2ccc([N+](=O)[O-])cc2)c1,"InChI=1S/C19H12N2O8/c22-19(23)12-9-17(28-15-5-1-13(2-6-15)20(24)25)11-18(10-12)29-16-7-3-14(4-8-16)21(26)27/h1-11H,(H,22,23)",JOSXKPZXMVHRKU-UHFFFAOYSA-N,compound-w,Preclinical,beta-secretase inhibitor,BACE1,,
Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2,"InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)",IKENVDNFQMCRTR-UHFFFAOYSA-N,conivaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology,hyponatremia
CC1OC(OC2CCC3(C=O)C4CCC5(C)C(c6coc(O)c6)CCC5(O)C4CCC3(O)C2)C(O)C(O)C1O,"InChI=1S/C29H42O10/c1-15-22(32)23(33)24(34)25(38-15)39-17-3-8-27(14-30)19-4-7-26(2)18(16-11-21(31)37-13-16)6-10-29(26,36)20(19)5-9-28(27,35)12-17/h11,13-15,17-20,22-25,31-36H,3-10,12H2,1-2H3",APGBLEASYXGLCD-UHFFFAOYSA-N,convallatoxin,Preclinical,cardiac glycoside,,,
COc1c(OCCCN2CCOCC2)ccc2c3n(c(=NC(=O)c4cnc(=N)[nH]c4)nc12)CCN3,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)",MWYDSXOGIBMAET-UHFFFAOYSA-N,copanlisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,follicular lymphoma
NC(Cc1c[nH]cn1)C(=O)O,"InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)",HNDVDQJCIGZPNO-UHFFFAOYSA-N,copper-histidine,Phase 3,,SLC15A3|SLC15A4|SLC38A5,,
CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(-c3ccccc3)ccc21,"InChI=1S/C31H36N2O2/c1-2-3-7-12-33-20-27(30(35)32-31-17-21-13-22(18-31)15-23(14-21)19-31)29(34)26-16-25(10-11-28(26)33)24-8-5-4-6-9-24/h4-6,8-11,16,20-23H,2-3,7,12-15,17-19H2,1H3,(H,32,35)",MSJISJDTJJYBFT-UHFFFAOYSA-N,cor-170,Preclinical,cannabinoid receptor inverse agonist,CNR2,,
N=c1[nH]cnc2c1ncn2C1OC(CO)CC1O,"InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)",OFEZSBMBBKLLBJ-UHFFFAOYSA-N,cordycepin,Phase 1/Phase 2,DNA inhibitor,,,
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C)C5CCC43C)C2C1C,"InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)",HFGSQOYIOKBQOW-UHFFFAOYSA-N,corosolic-acid,Phase 2,PKC inhibitor,HSD11B1|PTPN1,,
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C)C5CCC43C)C2C1C,"InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)",HFGSQOYIOKBQOW-UHFFFAOYSA-N,corosolic-acid,Phase 2,protein tyrosine kinase inhibitor,HSD11B1|PTPN1,,
CCOCC12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2,"InChI=1S/C26H25F4N3O3S/c1-2-36-17-25-14-18-15-31-33(22-7-5-21(27)6-8-22)24(18)13-20(25)11-12-32(16-25)37(34,35)23-9-3-19(4-10-23)26(28,29)30/h3-10,13,15H,2,11-12,14,16-17H2,1H3",SLKURXRZHJOZOD-UHFFFAOYSA-N,cort-108297,Preclinical,glucocorticoid receptor antagonist,,,
CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12,"InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3",OMFXVFTZEKFJBZ-UHFFFAOYSA-N,corticosterone,Preclinical,mineralocorticoid receptor agonist,HSD11B1|NCOA1|NR3C2,,
CC12CCC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO,"InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3",MFYSYFVPBJMHGN-UHFFFAOYSA-N,cortisone,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology|rheumatology|dermatology,ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3C(=O)CC21C,"InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h4,16-17,20,28H,5-12H2,1-3H3",SLEIAHSDXRGERW-UHFFFAOYSA-N,cortisone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease,asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis
CC12CCC(=O)C=C1CCC1C2CCC2(C)C1CCC2(O)C(=O)CO,"InChI=1S/C21H30O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h11,15-17,22,25H,3-10,12H2,1-2H3",WHBHBVVOGNECLV-UHFFFAOYSA-N,cortodoxone,Phase 3,androgen receptor antagonist,AR,,
C=C1C(=O)OC2C=C(C)CCC=C(C)CCC12,"InChI=1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3",HRYLQFBHBWLLLL-UHFFFAOYSA-N,costunolide,Preclinical,telomerase inhibitor,,,
N#Cc1c[nH]c2c(Cl)cc(NCc3cn(CCN4CCCCCC4)nn3)cc2c1=Nc1ccc(F)c(Cl)c1,"InChI=1S/C27H27Cl2FN8/c28-23-12-19(5-6-25(23)30)34-26-18(14-31)15-33-27-22(26)11-20(13-24(27)29)32-16-21-17-38(36-35-21)10-9-37-7-3-1-2-4-8-37/h5-6,11-13,15,17,32H,1-4,7-10,16H2,(H,33,34)",ZWFKJFUFYPOTKL-UHFFFAOYSA-N,cot-inhibitor-1,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,
CCN1CCC(n2cc(CNc3cc(Cl)c4[nH]cc(C#N)c(=Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1,"InChI=1S/C26H25Cl2FN8/c1-2-36-7-5-20(6-8-36)37-15-19(34-35-37)14-31-18-9-21-25(33-17-3-4-24(29)22(27)10-17)16(12-30)13-32-26(21)23(28)11-18/h3-4,9-11,13,15,20,31H,2,5-8,14H2,1H3,(H,32,33)",PHNZIIMWDVXPGG-UHFFFAOYSA-N,cot-inhibitor-2,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,
S=C(NN=C1CCCc2cccnc21)N1CCN(c2ccccn2)CC1,"InChI=1S/C19H22N6S/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26)",UTDAKQMBNSHJJB-UHFFFAOYSA-N,coti-2,Phase 1,anticancer agent,,,
CN1C(=O)CCC1c1cccnc1,"InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3",UIKROCXWUNQSPJ-UHFFFAOYSA-N,cotinine,Phase 2,nicotine metabolite,,,
O=c1ccc2ccccc2o1,InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,coumarin,Launched,vitamin K antagonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6,gastroenterology|pulmonary,ulcerative colitis|asthma|celiac disease
CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1,"InChI=1S/C14H16ClO5PS/c1-4-17-21(22,18-5-2)20-10-6-7-11-9(3)13(15)14(16)19-12(11)8-10/h6-8H,4-5H2,1-3H3",BXNANOICGRISHX-UHFFFAOYSA-N,coumophos,Preclinical,cholinesterase inhibitor,,,
O=C(O)C1(c2ccc3c(c2)OCC(Cc2ccc(-c4ccccc4)cc2)C3O)CCCC1,"InChI=1S/C28H28O4/c29-26-22(16-19-8-10-21(11-9-19)20-6-2-1-3-7-20)18-32-25-17-23(12-13-24(25)26)28(27(30)31)14-4-5-15-28/h1-3,6-13,17,22,26,29H,4-5,14-16,18H2,(H,30,31)",KMNLXCBYBKHKSK-UHFFFAOYSA-N,"cp-105,696",Preclinical,leukotriene receptor antagonist,,,
CON(C)C(=O)C(O)C(Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,"InChI=1S/C21H22ClN3O4/c1-25(29-2)21(28)19(26)17(10-13-6-4-3-5-7-13)24-20(27)18-12-14-11-15(22)8-9-16(14)23-18/h3-9,11-12,17,19,23,26H,10H2,1-2H3,(H,24,27)",WEQLRDLTRCEUHG-UHFFFAOYSA-N,cp-316819,Preclinical,glycogen phosphorylase inhibitor,PYGL,,
CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12,"InChI=1S/C21H24N2/c1-2-3-9-15-22-20-14-16-23(17-18-10-5-4-6-11-18)21-13-8-7-12-19(20)21/h4-8,10-14,16H,2-3,9,15,17H2,1H3",MMGAVKCAGQCFHS-UHFFFAOYSA-N,cp-339818,Preclinical,potassium channel blocker,KCNA3,,
CCC(CC)N=c1cc(C)[nH]c(Oc2c(C)cc(C)cc2C)c1C,"InChI=1S/C21H30N2O/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3,(H,22,23)",VIZBSVDBNLAVAW-UHFFFAOYSA-N,cp-376395,Phase 1,corticotropin releasing factor receptor antagonist,CRHR1,,
CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(O)=NO,"InChI=1S/C16H17FN2O5S/c1-16(2,15(20)18-21)19-25(22,23)14-9-7-13(8-10-14)24-12-5-3-11(17)4-6-12/h3-10,19,21H,1-2H3,(H,18,20)",QCOQJYRPDUMCNP-UHFFFAOYSA-N,cp-471474,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,
CCC1CC(N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(C)=O)c2cc(C(F)(F)F)ccc2N1C(=O)OC(C)C,"InChI=1S/C27H27F9N2O3/c1-5-20-12-23(21-11-17(25(28,29)30)6-7-22(21)38(20)24(40)41-14(2)3)37(15(4)39)13-16-8-18(26(31,32)33)10-19(9-16)27(34,35)36/h6-11,14,20,23H,5,12-13H2,1-4H3",TUPKOWFPVAXQFP-UHFFFAOYSA-N,cp-532623,Phase 1,cholesteryl ester transfer protein inhibitor,CETP,,
NC(=O)c1c(OCc2c(F)cc(Br)cc2F)[nH]sc1=NC(=O)NCCCCN1CCCC1,"InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10,27H,1-8,11H2,(H2,24,29)(H,25,30)",SRHFGYWCTGXMQW-UHFFFAOYSA-N,cp-547632,Phase 2,kinase inhibitor,,,
O=C(c1c2ccccc2cc2ccccc12)N1CCC(N2CCCC(C(=O)N3CCOCC3)C2)CC1,"InChI=1S/C30H35N3O3/c34-29(32-16-18-36-19-17-32)24-8-5-13-33(21-24)25-11-14-31(15-12-25)30(35)28-26-9-3-1-6-22(26)20-23-7-2-4-10-27(23)28/h1-4,6-7,9-10,20,24-25H,5,8,11-19,21H2",LDQKDRLEMKIYMC-UHFFFAOYSA-N,cp-640186,Preclinical,acetyl-CoA carboxylase inhibitor,ACACA|ACACB,,
COCCOc1ccc2c(c1)ncn2-c1ccc2cccc(N3CCC(N)CC3)c2n1,"InChI=1S/C24H27N5O2/c1-30-13-14-31-19-6-7-21-20(15-19)26-16-29(21)23-8-5-17-3-2-4-22(24(17)27-23)28-11-9-18(25)10-12-28/h2-8,15-16,18H,9-14,25H2,1H3",DEEOXSOLTLIWMG-UHFFFAOYSA-N,cp-673451,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA|PDGFRB,,
COCC(=O)NCC=Cc1ccc2[nH]cnc(=Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,"InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)",LLVZBTWPGQVVLW-UHFFFAOYSA-N,cp-724714,Phase 2,EGFR inhibitor,ERBB2,,
COCC(=O)NCC=Cc1ccc2[nH]cnc(=Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,"InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)",LLVZBTWPGQVVLW-UHFFFAOYSA-N,cp-724714,Phase 2,protein tyrosine kinase inhibitor,ERBB2,,
CC(C)c1ccc(CC(=O)N2CCCC(c3cccc(OC(C)(C)C(=O)O)c3)C2)cc1,"InChI=1S/C26H33NO4/c1-18(2)20-12-10-19(11-13-20)15-24(28)27-14-6-8-22(17-27)21-7-5-9-23(16-21)31-26(3,4)25(29)30/h5,7,9-13,16,18,22H,6,8,14-15,17H2,1-4H3,(H,29,30)",OISHBINQIFNIPV-UHFFFAOYSA-N,cp-775146,Preclinical,PPAR receptor agonist,PPARA,,
CN(C)C(=O)C(O)C(Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,"InChI=1S/C21H22ClN3O3/c1-25(2)21(28)19(26)17(10-13-6-4-3-5-7-13)24-20(27)18-12-14-11-15(22)8-9-16(14)23-18/h3-9,11-12,17,19,23,26H,10H2,1-2H3,(H,24,27)",HINJNZFCMLSBCI-UHFFFAOYSA-N,cp-91149,Preclinical,glycogen phosphorylase inhibitor,PYGL,,
O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,"InChI=1S/C12H13N3O/c16-11-2-1-10-12(15-11)9(7-14-10)8-3-5-13-6-4-8/h1-3,7,13-14H,4-6H2,(H,15,16)",PJYVGMRFPFNZCT-UHFFFAOYSA-N,cp-93129,Preclinical,serotonin receptor agonist,HTR1A,,
CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1,"InChI=1S/C15H19N3O/c1-2-9-19-14-4-3-13-15(18-14)12(10-17-13)11-5-7-16-8-6-11/h3-5,10,16-17H,2,6-9H2,1H3",KWQWBZIGHIOKIO-UHFFFAOYSA-N,cp-94253,Preclinical,serotonin receptor agonist,HTR1B,,
CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1,"InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)",UNAZAADNBYXMIV-UHFFFAOYSA-N,"cp-945,598",Phase 3,cannabinoid receptor antagonist,CNR1,,
COc1ccccc1CNC1CCCNC1c1ccccc1,"InChI=1S/C19H24N2O/c1-22-18-12-6-5-10-16(18)14-21-17-11-7-13-20-19(17)15-8-3-2-4-9-15/h2-6,8-10,12,17,19-21H,7,11,13-14H2,1H3",DTQNEFOKTXXQKV-UHFFFAOYSA-N,cp-99994,Phase 2,tachykinin antagonist,TACR1,,
O=C(O)C(Cc1ccccc1)CN(O)C(=O)Cc1ccccc1,"InChI=1S/C18H19NO4/c20-17(12-15-9-5-2-6-10-15)19(23)13-16(18(21)22)11-14-7-3-1-4-8-14/h1-10,16,23H,11-13H2,(H,21,22)",PONANXDRJJIGPG-UHFFFAOYSA-N,cpa-inhibitor,Preclinical,carboxypeptidase inhibitor,CPA1|CPA2,,
CCOC(=O)C12CC1C(=NO)c1ccccc1O2,"InChI=1S/C13H13NO4/c1-2-17-12(15)13-7-9(13)11(14-16)8-5-3-4-6-10(8)18-13/h3-6,9,16H,2,7H2,1H3",FXCTZFMSAHZQTR-UHFFFAOYSA-N,cpccoet,Preclinical,glutamate receptor antagonist,GRM1,,
Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=NC2CC(N)=O,"InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)",GCWIQUVXWZWCLE-UHFFFAOYSA-N,cpi-0610,Phase 2,bromodomain inhibitor,BRD4,,
CC(=O)Nc1ccc(C(=O)NC(C)(C)C)cc1,"InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)",DJKNRCWSXSZACF-UHFFFAOYSA-N,cpi-1189,Phase 2,tumor necrosis factor release inhibitor,TNF,,
COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n(C(C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,"InChI=1S/C27H33F3N4O3/c1-16-13-23(37-4)21(25(35)32-16)14-31-26(36)24-18(3)34(22-8-6-5-7-20(22)24)17(2)19-9-11-33(12-10-19)15-27(28,29)30/h5-8,13,17,19H,9-12,14-15H2,1-4H3,(H,31,36)(H,32,35)",HPODOLXTMDHLLC-UHFFFAOYSA-N,cpi-1205,Phase 1/Phase 2,EZH2 inhibitor,,,
CCS(=O)(=O)N1CCC(C(C)n2c(C)c(C(=O)NCc3c(OC)cc(C)[nH]c3=O)c3ccccc32)CC1,"InChI=1S/C27H36N4O5S/c1-6-37(34,35)30-13-11-20(12-14-30)18(3)31-19(4)25(21-9-7-8-10-23(21)31)27(33)28-16-22-24(36-5)15-17(2)29-26(22)32/h7-10,15,18,20H,6,11-14,16H2,1-5H3,(H,28,33)(H,29,32)",LHGUZCKPFXXVPV-UHFFFAOYSA-N,cpi-169,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=NC(CC(N)=O)c1nnc(C)n1-2,"InChI=1S/C19H18ClN5OS/c1-9-10(2)27-19-16(9)17(12-4-6-13(20)7-5-12)22-14(8-15(21)26)18-24-23-11(3)25(18)19/h4-7,14H,8H2,1-3H3,(H2,21,26)",QECMENZMDBOLDR-UHFFFAOYSA-N,cpi-203,Preclinical,bromodomain inhibitor,BRD4,,
COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n(C(C)C2CCOCC2)c2ccccc12,"InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)",PFPSFENQCNMITC-UHFFFAOYSA-N,cpi-360,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
Cc1ccc(-c2[nH]c(=N)nc3c2nnn3Cc2cccc(COC3CCOC3)n2)o1,"InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)",KURQKNMKCGYWRJ-UHFFFAOYSA-N,cpi-444,Phase 1/Phase 2,adenosine receptor antagonist,,,
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,"InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)",ZYRLHJIMTROTBO-UHFFFAOYSA-N,cpi-613,Phase 3,pyruvate dehydrogenase inhibitor,PDHA1,,
O=C(O)C1CN(CCC[PH](=O)(=O)O)CCN1,"InChI=1S/C8H16N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h7,9H,1-6H2,(H,11,12)(H,13,14,15)",NIHWOYIGRLJWKF-UHFFFAOYSA-N,cpp,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
O=C(CC1CC(c2ccc(F)cc2F)=NO1)N1CCOCC1,"InChI=1S/C15H16F2N2O3/c16-10-1-2-12(13(17)7-10)14-8-11(22-18-14)9-15(20)19-3-5-21-6-4-19/h1-2,7,11H,3-6,8-9H2",GUWOSEVHCSNYFK-UHFFFAOYSA-N,cpsi-1306-(+/-),Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
Nc1ccc(S(=O)(=O)N=c2cnc3c(Cl)cccc3[nH]2)cc1,"InChI=1S/C14H11ClN4O2S/c15-11-2-1-3-12-14(11)17-8-13(18-12)19-22(20,21)10-6-4-9(16)5-7-10/h1-8H,16H2,(H,18,19)",CTSNHMQGVWXIEG-UHFFFAOYSA-N,cqs,Preclinical,,,,
CCC(CO)N=c1[nH]c(=NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C24H29N7O/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30)",HOCBJBNQIQQQGT-UHFFFAOYSA-N,cr8-(r),Preclinical,CDK inhibitor,CCNA2,,
CN(CC(=O)O)C(=N)N,"InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)",CVSVTCORWBXHQV-UHFFFAOYSA-N,creatine,Launched,,CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8,,
Cn1cc(O)[nH]c1=N,"InChI=1S/C4H7N3O/c1-7-2-3(8)6-4(7)5/h2,8H,1H3,(H2,5,6)",BTXYOFGSUFEOLA-UHFFFAOYSA-N,creatinine,Preclinical,,,,
CN(CCO[PH](=O)(=O)O)C(=N)N,"InChI=1S/C4H11N3O4P/c1-7(4(5)6)2-3-11-12(8,9)10/h2-3H2,1H3,(H3,5,6)(H,8,9,10)",SAWKLNILBIUDSA-UHFFFAOYSA-N,creatinol-phosphate,Launched,,,,
CC(NC(=O)CCC(F)(F)F)C(=O)NC1C(=O)N(CCO)c2ncccc2-c2ccccc21,"InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)",YCBAQKQAINQRFW-UHFFFAOYSA-N,crenigacestat,Preclinical,notch signaling inhibitor,,,
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,"InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3",DYNHJHQFHQTFTP-UHFFFAOYSA-N,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,
Cc1ccc(O)cc1,"InChI=1S/C7H8O/c1-6-2-4-7(8)5-3-6/h2-5,8H,1H3",IWDCLRJOBJJRNH-UHFFFAOYSA-N,cresol,Launched,,,,
CC(=O)Oc1c(C)cccc1C(=O)O,"InChI=1S/C10H10O4/c1-6-4-3-5-8(10(12)13)9(6)14-7(2)11/h3-5H,1-2H3,(H,12,13)",XRBMKGUDDJPAMH-UHFFFAOYSA-N,cresopirine,Preclinical,,,,
O=C(O)Cn1c2ccccc2c(=O)c2ccccc21,"InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)",UOMKBIIXHQIERR-UHFFFAOYSA-N,cridanimod,Launched,progesterone receptor agonist,PGR,infectious disease,influenza A virus infection
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,"InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2",USZAGAREISWJDP-UHFFFAOYSA-N,crisaborole,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology,dermatitis
O=C(O)c1cc(NCCc2ccc(C(F)(F)F)cc2)ccc1O,"InChI=1S/C16H14F3NO3/c17-16(18,19)11-3-1-10(2-4-11)7-8-20-12-5-6-14(21)13(9-12)15(22)23/h1-6,9,20-21H,7-8H2,(H,22,23)",UTMVACIBQLDZLP-UHFFFAOYSA-N,crisdesalazine,Preclinical,free radical scavenger,,,
CC(Oc1cc(-c2cnn(C3CCNCC3)c2)c[nH]c1=N)c1c(Cl)ccc(F)c1Cl,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)",KTEIFNKAUNYNJU-UHFFFAOYSA-N,crizotinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC)
CC(Oc1cc(-c2cnn(C3CCNCC3)c2)c[nH]c1=N)c1c(Cl)ccc(F)c1Cl,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)",KTEIFNKAUNYNJU-UHFFFAOYSA-N,crizotinib-(s),Preclinical,MTH1 inhibitor,NUDT1,,
C=C(c1ccccc1OCc1cccc(Cl)c1)n1ccnc1,"InChI=1S/C18H15ClN2O/c1-14(21-10-9-20-13-21)17-7-2-3-8-18(17)22-12-15-5-4-6-16(19)11-15/h2-11,13H,1,12H2",WHPAGCJNPTUGGD-UHFFFAOYSA-N,croconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,fungal infection
COc1cc(C2c3ccc(N)c(N)c3OC(=N)C2C#N)cc(Br)c1OC,"InChI=1S/C18H17BrN4O3/c1-24-13-6-8(5-11(19)17(13)25-2)14-9-3-4-12(21)15(22)16(9)26-18(23)10(14)7-20/h3-6,10,14,23H,21-22H2,1-2H3",ANTUWCUHGWGJQS-UHFFFAOYSA-N,crolibulin,Phase 1/Phase 2,tubulin polymerization inhibitor,,,
CC1(C)Oc2ccc(C#N)cc2C(N2CCCC2=O)C1O,"InChI=1S/C16H18N2O3/c1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h5-6,8,14-15,20H,3-4,7H2,1-2H3",TVZCRIROJQEVOT-UHFFFAOYSA-N,cromakalim,Phase 2,,KCNJ8,,
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,"InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)",IMZMKUWMOSJXDT-UHFFFAOYSA-N,cromoglicic-acid,Launched,immunosuppressant,KCNMA1|S100P,pulmonary|ophthalmology|allergy|gastroenterology,asthma|conjunctivitis|urticaria|ulcerative colitis
CC=CC(=O)N(CC)c1ccccc1C,"InChI=1S/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3",DNTGGZPQPQTDQF-UHFFFAOYSA-N,crotamiton,Launched,antipruritic,,infectious disease,scabies
O=C(O)c1cc2cccc([N+](=O)[O-])c2[nH]1,"InChI=1S/C9H6N2O4/c12-9(13)6-4-5-2-1-3-7(11(14)15)8(5)10-6/h1-4,10H,(H,12,13)",BIUCOFQROHIAEO-UHFFFAOYSA-N,crt0044876,Preclinical,,,,
Cc1coc2c1c(O)c(O)c1c3c(ccc12)C(C)(C)CCC3,"InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9,20-21H,4-5,8H2,1-3H3",ICAXIVZVKMILFF-UHFFFAOYSA-N,cryptotanshinone,Preclinical,acetylcholinesterase inhibitor,STAT3,,
Cc1coc2c1c(O)c(O)c1c3c(ccc12)C(C)(C)CCC3,"InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9,20-21H,4-5,8H2,1-3H3",ICAXIVZVKMILFF-UHFFFAOYSA-N,cryptotanshinone,Preclinical,STAT inhibitor,STAT3,,
CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,"InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1",LGLFFNDHMLKUMI-UHFFFAOYSA-N,crystal-violet,Launched,other antibiotic,,,
c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1,"InChI=1S/C19H25NS/c1-5-11-19(12-6-1,20-13-7-2-8-14-20)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2",RGSVXQJPSWZXOP-UHFFFAOYSA-N,cs-110266,Preclinical,dopamine receptor agonist,SLC6A3,,
CC(C)Cc1sc(=N)[nH]c1-c1ccc([PH](=O)(=O)O)o1,"InChI=1S/C11H14N2O4PS/c1-6(2)5-8-10(13-11(12)19-8)7-3-4-9(17-7)18(14,15)16/h3-4,6H,5H2,1-2H3,(H2,12,13)(H,14,15,16)",NGQIKHLRDKUYQG-UHFFFAOYSA-N,cs-917,Phase 2,fructose biphosphate inhibitor,FBP1,,
O=C(O)C(Cc1ccc(N=c2[nH]ccc3ccncc23)cc1)N=C1C(Br)C(=O)C12CCCCC2,"InChI=1S/C26H25BrN4O3/c27-21-22(26(23(21)32)10-2-1-3-11-26)31-20(25(33)34)14-16-4-6-18(7-5-16)30-24-19-15-28-12-8-17(19)9-13-29-24/h4-9,12-13,15,20-21H,1-3,10-11,14H2,(H,29,30)(H,33,34)",UXSWXYHTBXXKFZ-UHFFFAOYSA-N,ct-7758,Phase 2,integrin antagonist,ITGA4,,
CC(C)c1c[nH]n2c(=NCc3ccccc3)cc(NCC3CCNCC3O)nc12,"InChI=1S/C22H30N6O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29/h3-7,10,13,15,17,19,23-24,26,29H,8-9,11-12,14H2,1-2H3",WPTDFQICNWPUPP-UHFFFAOYSA-N,ct7001,Phase 1/Phase 2,CDK inhibitor,,,
Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,"InChI=1S/C19H13ClF3N3O/c1-12-17(8-3-14-9-10-24-18(20)11-14)25-13(2)26(12)15-4-6-16(7-5-15)27-19(21,22)23/h4-7,9-11H,1-2H3",GOHCTCOGYKAJLZ-UHFFFAOYSA-N,ctep,Preclinical,glutamate receptor antagonist,GRM5,,
O=S(=O)(CC1(C(O)=NO)CCOCC1)c1ccc(Oc2ccc(Cl)cc2)cc1,"InChI=1S/C19H20ClNO6S/c20-14-1-3-15(4-2-14)27-16-5-7-17(8-6-16)28(24,25)13-19(18(22)21-23)9-11-26-12-10-19/h1-8,23H,9-13H2,(H,21,22)",ROSNVSQTEGHUKU-UHFFFAOYSA-N,cts-1027,Phase 2,metalloproteinase inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,
CC(C)CC(NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CCC(=O)O)C(C)C)C(O)CC(C)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O,"InChI=1S/C41H64N8O14/c1-20(2)16-27(46-39(60)28(19-31(43)51)47-40(61)34(21(3)4)49-37(58)25(42)12-14-32(52)53)30(50)17-22(5)35(56)44-23(6)36(57)45-26(13-15-33(54)55)38(59)48-29(41(62)63)18-24-10-8-7-9-11-24/h7-11,20-23,25-30,34,50H,12-19,42H2,1-6H3,(H2,43,51)(H,44,56)(H,45,57)(H,46,60)(H,47,61)(H,48,59)(H,49,58)(H,52,53)(H,54,55)(H,62,63)",NIOCOJFPGCXNKL-UHFFFAOYSA-N,cts21166,Phase 1,beta-secretase inhibitor,BACE1,,
O=C(NC(Cc1ccccc1)C(=O)O)c1sc2cc(F)ccc2c1Cl,"InChI=1S/C18H13ClFNO3S/c19-15-12-7-6-11(20)9-14(12)25-16(15)17(22)21-13(18(23)24)8-10-4-2-1-3-5-10/h1-7,9,13H,8H2,(H,21,22)(H,23,24)",IAASQMCXDRISAV-UHFFFAOYSA-N,cu-cpt-4a,Preclinical,toll-like receptor inhibitor,TLR3,,
CNc1ccc([N+](=O)[O-])cc1-n1cnc(-c2ccc(C(F)(F)F)cc2)c1,"InChI=1S/C17H13F3N4O2/c1-21-14-7-6-13(24(25)26)8-16(14)23-9-15(22-10-23)11-2-4-12(5-3-11)17(18,19)20/h2-10,21H,1H3",LITXVDAFEYLWQE-UHFFFAOYSA-N,cu-t12-9,Preclinical,toll-like receptor agonist,TLR1|TLR2,,
C#Cc1cccc(N=c2[nH]cnc3cc(OC)c(OCCCCCCC(O)=NO)cc23)c1,"InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)",PLIVFNIUGLLCEK-UHFFFAOYSA-N,cudc-101,Phase 1,EGFR inhibitor,EGFR|ERBB2,,
CNC(C)C(=O)NC(C(=O)N1CCCC1C(=O)Nc1sc(-c2ncco2)nc1-c1ccccc1)C1CCCCC1,"InChI=1S/C29H36N6O4S/c1-18(30-2)24(36)32-23(20-12-7-4-8-13-20)29(38)35-16-9-14-21(35)25(37)34-27-22(19-10-5-3-6-11-19)33-28(40-27)26-31-15-17-39-26/h3,5-6,10-11,15,17-18,20-21,23,30H,4,7-9,12-14,16H2,1-2H3,(H,32,36)(H,34,37)",HSHPBORBOJIXSQ-UHFFFAOYSA-N,cudc-427,Phase 1,apoptosis inhibitor,XIAP,,
COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(O)=NO)cn4)cc3n2)cn1,"InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)",JOWXJLIFIIOYMS-UHFFFAOYSA-N,cudc-907,Phase 2,PI3K inhibitor,HDAC2|PIK3R1,,
COc1cccc(CN(C(=O)CC(C)(C)C)C2CC(C(=O)N3CCNCC3)N(Cc3ccc4c(c3)OCO4)C2)c1,"InChI=1S/C31H42N4O5/c1-31(2,3)17-29(36)35(19-22-6-5-7-25(14-22)38-4)24-16-26(30(37)33-12-10-32-11-13-33)34(20-24)18-23-8-9-27-28(15-23)40-21-39-27/h5-9,14-15,24,26,32H,10-13,16-21H2,1-4H3",WPHXYKUPFJRJDK-UHFFFAOYSA-N,cur-61414,Phase 1,smoothened receptor antagonist,DHH|IHH|SMO,,
COc1cc(C=CC(=O)CC(=O)C=Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3",VFLDPWHFBUODDF-UHFFFAOYSA-N,curcumin,Launched,cyclooxygenase inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,
COc1cc(C=CC(=O)CC(=O)C=Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3",VFLDPWHFBUODDF-UHFFFAOYSA-N,curcumin,Launched,histone acetyltransferase inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,
COc1cc(C=CC(=O)CC(=O)C=Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3",VFLDPWHFBUODDF-UHFFFAOYSA-N,curcumin,Launched,lipoxygenase inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,
COc1cc(C=CC(=O)CC(=O)C=Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3",VFLDPWHFBUODDF-UHFFFAOYSA-N,curcumin,Launched,NFkB pathway inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,
C=C1CC2(O)OC3(CC2C(C)C)C(C)CCC13,"InChI=1S/C15H24O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h9,11-13,16H,3,5-8H2,1-2,4H3",QRMPRVXWPCLVNI-UHFFFAOYSA-N,curcumol,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,"InChI=1S/C23H32N2O2/c1-26-22-11-10-21(19-23(22)27-2)12-14-25-17-15-24(16-18-25)13-6-9-20-7-4-3-5-8-20/h3-5,7-8,10-11,19H,6,9,12-18H2,1-2H3",UVSWWUWQVAQPJR-UHFFFAOYSA-N,cutamesine,Phase 2,sigma receptor agonist,SIGMAR1,,
N=c1[nH]c(=Nc2ccccc2)[nH]c2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)",SCNILGOVBBRMBK-UHFFFAOYSA-N,cv-1808,Preclinical,adenosine receptor agonist,ADORA2A,,
CS(=O)(=O)Nc1ccc(-c2coc3cc(OCc4cccc(C(=O)O)c4)ccc3c2=O)cc1,"InChI=1S/C24H19NO7S/c1-33(29,30)25-18-7-5-16(6-8-18)21-14-32-22-12-19(9-10-20(22)23(21)26)31-13-15-3-2-4-17(11-15)24(27)28/h2-12,14,25H,13H2,1H3,(H,27,28)",YYOOFJZTRCPVFD-UHFFFAOYSA-N,cvt-10216,Phase 1,aldehyde dehydrogenase inhibitor,ALDH2,,
COc1ccn2ncc(-c3nc4[nH][nH]c(=NC(=O)c5ccc(F)cc5)c4cc3F)c2c1,"InChI=1S/C21H14F2N6O2/c1-31-13-6-7-29-17(8-13)15(10-24-29)18-16(23)9-14-19(25-18)27-28-20(14)26-21(30)11-2-4-12(22)5-3-11/h2-10H,1H3,(H2,25,26,27,28,30)",KCIMKTNQCUDTFI-UHFFFAOYSA-N,cw-008,Preclinical,PKA activator,PRKACA,,
O=C(O)c1ccc2c(c1)[nH]c(=Nc1cccc(Cl)c1)c1ccncc12,"InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)",MUOKSQABCJCOPU-UHFFFAOYSA-N,cx-4945,Phase 1/Phase 2,casein kinase inhibitor,CSNK2A1|CSNK2A2|DAPK3|HIPK3,,
O=C(c1ccc2c(c1)OCO2)N1CCCCC1,"InChI=1S/C13H15NO3/c15-13(14-6-2-1-3-7-14)10-4-5-11-12(8-10)17-9-16-11/h4-5,8H,1-3,6-7,9H2",BXBNADAPIHHXJQ-UHFFFAOYSA-N,cx-516,Phase 2/Phase 3,glutamate receptor modulator,,,
Cc1cnc(CNC(=O)c2c(=O)c3ccc(N4CCCN(C)CC4)nc3n3c2sc2ccccc23)cn1,"InChI=1S/C27H27N7O2S/c1-17-14-29-18(15-28-17)16-30-26(36)23-24(35)19-8-9-22(33-11-5-10-32(2)12-13-33)31-25(19)34-20-6-3-4-7-21(20)37-27(23)34/h3-4,6-9,14-15H,5,10-13,16H2,1-2H3,(H,30,36)",XGPBJCHFROADCK-UHFFFAOYSA-N,cx-5461,Phase 1,RNA polymerase inhibitor,,,
Cc1nn(C)cc1CN1CCC(c2ccc(C(=O)Nc3ccccc3N)cc2)CC1,"InChI=1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)",JHDZMASHNBKTPS-UHFFFAOYSA-N,cxd101,Phase 1/Phase 2,HDAC inhibitor,,,
CN1Cc2ccccc2C2c3cccc4[nH]cc(c34)CC21,"InChI=1S/C19H18N2/c1-21-11-12-5-2-3-6-14(12)19-15-7-4-8-16-18(15)13(10-20-16)9-17(19)21/h2-8,10,17,19-20H,9,11H2,1H3",WRNKIDLXXXIELU-UHFFFAOYSA-N,cy208-243,Phase 2,dopamine receptor agonist,CALY,,
N#CCC(=O)NN,"InChI=1S/C3H5N3O/c4-2-1-3(7)6-5/h1,5H2,(H,6,7)",HPHBOJANXDKUQD-UHFFFAOYSA-N,cyacetacide,Preclinical,,,,
CC(CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,"InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3",SLFGIOIONGJGRT-UHFFFAOYSA-N,cyamemazine,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C|HTR7,neurology/psychiatry,schizophrenia|anxiety
CC1=C2N=C(C=C3N=C(C(C)C4=NC(C(CC(N)=O)C4(C)CCC(=O)NCC(C)O[PH](=O)(=O)OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O,"InChI=1S/C62H89N13O14P/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56/h20-21,23,28,31-32,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)",BFOWVMZUKTYNPH-UHFFFAOYSA-N,cyanocobalamin,Launched,methylmalonyl CoA mutase stimulant,MUT,hematology|infectious disease|gastroenterology,anemia|fish tapeworm infestation|celiac disease
CC1=C2N=C(C=C3N=C(C(C)C4=NC(C(CC(N)=O)C4(C)CCC(=O)NCC(C)O[PH](=O)(=O)OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O,"InChI=1S/C62H89N13O14P/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56/h20-21,23,28,31-32,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)",BFOWVMZUKTYNPH-UHFFFAOYSA-N,cyanocobalamin,Launched,vitamin B,MUT,hematology|infectious disease|gastroenterology,anemia|fish tapeworm infestation|celiac disease
CC(C)(C)NCC(O)COc1cccc2[nH]c(C#N)cc12,"InChI=1S/C16H21N3O2/c1-16(2,3)18-9-12(20)10-21-15-6-4-5-14-13(15)7-11(8-17)19-14/h4-7,12,18-20H,9-10H2,1-3H3",QXIUMMLTJVHILT-UHFFFAOYSA-N,cyanopindolol,Phase 2,adrenergic receptor antagonist,ADRB1|HTR1A|HTR1D,,
CCC(N=c1[nH]c(=NCc2cnc(C)cc2C)c2ncn(C(C)C)c2[nH]1)C(C)O,"InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)",DLPIYBKBHMZCJI-UHFFFAOYSA-N,cyc065,Phase 1,CDK inhibitor,,,
Cc1[nH]c(=N)sc1-c1cc[nH]c(=Nc2ccc(N3CCOCC3)cc2)n1,"InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)",GPSZYOIFQZPWEJ-UHFFFAOYSA-N,cyc116,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|KDR,,
O=S(=O)(O)NC1CCCCC1,"InChI=1S/C6H13NO3S/c8-11(9,10)7-6-4-2-1-3-5-6/h6-7H,1-5H2,(H,8,9,10)",HCAJEUSONLESMK-UHFFFAOYSA-N,cyclamic-acid,Preclinical,,,,
CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1,"InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3",WZHCOOQXZCIUNC-UHFFFAOYSA-N,cyclandelate,Launched,calcium channel blocker,,cardiology|rheumatology,claudication|arteriosclerosis|Raynaud's disease
N=c1[nH]cnc2c1ncn2C1OC2CO[PH](=O)(=O)OC2C1O,"InChI=1S/C10H11N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H2,11,12,13)",DNLSQHSVOPMSOH-UHFFFAOYSA-N,cyclic-amp,Preclinical,,CNGA3|TRPM7,,
CN1CCN(C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3",UVKZSORBKUEBAZ-UHFFFAOYSA-N,cyclizine,Launched,histamine receptor modulator,HRH1|SULT1E1,gastroenterology|neurology/psychiatry,nausea|vomiting|vertigo|motion sickness
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,"InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3",JURKNVYFZMSNLP-UHFFFAOYSA-N,cyclobenzaprine,Launched,adrenergic receptor agonist,HTR2A,neurology/psychiatry,spasms
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,"InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3",JURKNVYFZMSNLP-UHFFFAOYSA-N,cyclobenzaprine,Launched,serotonin receptor agonist,HTR2A,neurology/psychiatry,spasms
NC1=NCCN1CC(=O)O,"InChI=1S/C5H9N3O2/c6-5-7-1-2-8(5)3-4(9)10/h1-3H2,(H2,6,7)(H,9,10)",AMHZIUVRYRVYBA-UHFFFAOYSA-N,cyclocreatine,Phase 1,creatine kinase substrate,,,
N=c1ccn2c(n1)OC1C(O)C(CO)OC12,"InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2",BBDAGFIXKZCXAH-UHFFFAOYSA-N,cyclocytidine,Preclinical,DNA synthesis inhibitor,,,
N=c1ccn2c(n1)OC1C(O)C(CO)OC12,"InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2",BBDAGFIXKZCXAH-UHFFFAOYSA-N,cyclocytidine,Preclinical,RNA synthesis inhibitor,,,
CC1CC(C)C(=O)C(C(O)CC2CC(=O)NC(=O)C2)C1,"InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)",YPHMISFOHDHNIV-UHFFFAOYSA-N,cycloheximide,Preclinical,protein synthesis inhibitor,RPL3,,
CC1=C2CC3C(CC=C4CC(O)CCC43C)C2CCC12OC1CC(C)CNC1C2C,"InChI=1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3",QASFUMOKHFSJGL-UHFFFAOYSA-N,cyclopamine,Preclinical,hedgehog pathway inhibitor,,,
NS(=O)(=O)c1cc2c(cc1Cl)NC(CC1CCCC1)NS2(=O)=O,"InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)",BKYKPTRYDKTTJY-UHFFFAOYSA-N,cyclopenthiazide,Launched,thiazide diuretic,,cardiology,hypertension|congestive heart failure
CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,"InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3",SKYSRIRYMSLOIN-UHFFFAOYSA-N,cyclopentolate,Launched,acetylcholine receptor antagonist,,ophthalmology,mydriasis|cycloplegia
O=P1(N(CCCl)CCCl)NCCCO1,"InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)",CMSMOCZEIVJLDB-UHFFFAOYSA-N,cyclophosphamide,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7,hematologic malignancy|oncology,Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer
CC(=O)c1c(O)c2n(c1O)C(C)(C)C1Cc3cccc4[nH]cc(c34)C21,"InChI=1S/C20H20N2O3/c1-9(23)14-18(24)17-16-11-8-21-13-6-4-5-10(15(11)13)7-12(16)20(2,3)22(17)19(14)25/h4-6,8,12,16,21,24-25H,7H2,1-3H3",QMBUCWVILCOIEG-UHFFFAOYSA-N,cyclopiazonic-acid,Preclinical,ATPase inhibitor,ATP2A1,,
NC1CONC1=O,"InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)",DYDCUQKUCUHJBH-UHFFFAOYSA-N,cycloserine-(d),Launched,bacterial cell wall synthesis inhibitor,GRIN1,infectious disease,tuberculosis|tuberculosis
CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,"InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)",PMATZTZNYRCHOR-UHFFFAOYSA-N,cyclosporin-a,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis
NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O,"InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)",BOCUKUHCLICSIY-UHFFFAOYSA-N,cyclothiazide,Launched,glutamate receptor modulator,CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3,cardiology,hypertension
COc1cc(C=C2CCCC(=Cc3ccc(O)c(OC)c3)C2=O)ccc1O,"InChI=1S/C22H22O5/c1-26-20-12-14(6-8-18(20)23)10-16-4-3-5-17(22(16)25)11-15-7-9-19(24)21(13-15)27-2/h6-13,23-24H,3-5H2,1-2H3",DHKKONBXGAAFTB-UHFFFAOYSA-N,cyclovalone,Launched,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation
CNC(C)C1C(O)CC2(C)C3CCC4C(C)(C)C(NC)CCC45CC35CCC12C,"InChI=1S/C26H46N2O/c1-16(27-6)21-17(29)14-24(5)19-9-8-18-22(2,3)20(28-7)10-11-25(18)15-26(19,25)13-12-23(21,24)4/h16-21,27-29H,8-15H2,1-7H3",GMNAPBAUIVITMI-UHFFFAOYSA-N,cyclovirobuxin-d,Preclinical,calcium channel modulator,,,
O=C(O)C1CSC(c2nc3cc4cc[nH]c4cc3s2)N1,"InChI=1S/C13H11N3O2S2/c17-13(18)9-5-19-11(16-9)12-15-8-3-6-1-2-14-7(6)4-10(8)20-12/h1-4,9,11,14,16H,5H2,(H,17,18)",JOYYUASGJAHBEA-UHFFFAOYSA-N,cycluc1,Preclinical,,,,
FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1,"InChI=1S/C14H11Cl3FNO2/c15-9-1-3-12(11(16)7-9)20-5-6-21-13-4-2-10(8-18)19-14(13)17/h1-4,7H,5-6,8H2",FHPOTBQOUBMMCI-UHFFFAOYSA-N,cym-50260,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR4,,
Cc1cc(CN)cc(C)c1NC(=O)c1ccc(-c2cc(Cl)ccc2Cl)o1,"InChI=1S/C20H18Cl2N2O2/c1-11-7-13(10-23)8-12(2)19(11)24-20(25)18-6-5-17(26-18)15-9-14(21)3-4-16(15)22/h3-9H,10,23H2,1-2H3,(H,24,25)",QWJOPXDAQCDRRM-UHFFFAOYSA-N,cym-50358,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR4,,
COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc43)c2=O)cc1,"InChI=1S/C24H17ClN2O3/c1-29-15-10-12-16(13-11-15)30-23-21(25)14-26-27(24(23)28)22-19-8-4-2-6-17(19)18-7-3-5-9-20(18)22/h2-14,22H,1H3",QHVSQUYCVUHYKT-UHFFFAOYSA-N,cym-50769,Preclinical,neuropeptide receptor antagonist,NPBWR1,,
CCOc1ccc(-c2nc(-c3cccc4c3CCC4NCCO)no2)cc1OCC,"InChI=1S/C23H27N3O4/c1-3-28-20-11-8-15(14-21(20)29-4-2)23-25-22(26-30-23)18-7-5-6-17-16(18)9-10-19(17)24-12-13-27/h5-8,11,14,19,24,27H,3-4,9-10,12-13H2,1-2H3",NUIKTBLZSPQGCP-UHFFFAOYSA-N,cym-5442,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
Cc1cc(C(=O)Cn2cc(C#N)ccc2=O)c(C)n1Cc1ccccc1,"InChI=1S/C21H19N3O2/c1-15-10-19(16(2)24(15)13-17-6-4-3-5-7-17)20(25)14-23-12-18(11-22)8-9-21(23)26/h3-10,12H,13-14H2,1-2H3",FMYGNANMYYHBSU-UHFFFAOYSA-N,cym-5520,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR2,,
O=C(c1cc(C2CC2)on1)N(C1CCCCC1)C1CCCCC1,"InChI=1S/C19H28N2O2/c22-19(17-13-18(23-20-17)14-11-12-14)21(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h13-16H,1-12H2",NDKGACIWVAOUQH-UHFFFAOYSA-N,cym-5541,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR3,,
CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)c1cccc(Oc2ccccc2)c1,"InChI=1S/C22H19Cl2NO3/c1-22(2)17(12-19(23)24)20(22)21(26)28-18(13-25)14-7-6-10-16(11-14)27-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3",KAATUXNTWXVJKI-UHFFFAOYSA-N,cypermethrin,Launched,,,infectious disease,flea control
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,"InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3",JJCFRYNCJDLXIK-UHFFFAOYSA-N,cyproheptadine,Launched,histamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7,allergy|otolaryngology|ophthalmology|dermatology,allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism
CC(=O)OC1(C(C)=O)CCC2C3=CC(Cl)=C4CC(=O)C5CC5C4(C)C3CCC21C,"InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10,15-18H,5-9,11H2,1-4H3",WZXZCWIUJRKDJF-UHFFFAOYSA-N,cyproterone-acetate,Launched,androgen receptor antagonist,ADORA1|AR,oncology,prostate cancer
N=c1[nH]c(=N)[nH]c(=NC2CC2)[nH]1,"InChI=1S/C6H10N6/c7-4-10-5(8)12-6(11-4)9-3-1-2-3/h3H,1-2H2,(H5,7,8,9,10,11,12)",LVQDKIWDGQRHTE-UHFFFAOYSA-N,cyromazine,Launched,,,,
NCCS,"InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2",UFULAYFCSOUIOV-UHFFFAOYSA-N,cysteamine,Launched,tissue transglutaminase inhibitor,NPY2R|SST,metabolism,cystinosis
CCCC(N=c1[nH]c(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,"InChI=1S/C24H30N6O2/c1-5-8-19(18-9-7-12-25-15-18)28-22-16(3)14-27-23(30-22)17-10-11-20(21(13-17)32-4)29-24(31)26-6-2/h7,9-15,19H,5-6,8H2,1-4H3,(H2,26,29,31)(H,27,28,30)",MTJHLONVHHPNSI-UHFFFAOYSA-N,cyt-997,Phase 2,tubulin polymerization inhibitor,TUBB,,
N#CCNC(=O)c1ccc(-c2cc[nH]c(=Nc3ccc(N4CCOCC4)cc3)n2)cc1,"InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)",ZVHNDZWQTBEVRY-UHFFFAOYSA-N,cyt387,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3,,
N=c1ccn(C2OC(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)",UHDGCWIWMRVCDJ-UHFFFAOYSA-N,cytarabine,Launched,ribonucleotide reductase inhibitor,POLA1|POLB|POLD1|POLE,hematologic malignancy,acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)
N=c1ccn(C2OC(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)",UHDGCWIWMRVCDJ-UHFFFAOYSA-N,cytidine,Launched,,,,
O=c1cccc2n1CC1CNCC2C1,"InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2",ANJTVLIZGCUXLD-UHFFFAOYSA-N,cytisine,Launched,acetylcholine receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4,neurology/psychiatry,nicotinism
C=C1C(C)C2C(Cc3ccccc3)NC(=O)C23OC(=O)CCC(=O)CCCC(C)CC=CC3C1O,"InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14,18-19,23-24,26-27,33H,3,7,9-10,13,15-17H2,1-2H3,(H,30,34)",WXIPPGRNMKMGML-UHFFFAOYSA-N,cytochalasin-b,Phase 2,microtubule inhibitor,ACTB,,
N=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1Cl,"InChI=1S/C9H12ClN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)",NGGRGTWYSXYVDK-UHFFFAOYSA-N,cytochlor,Phase 1,,,,
COc1cc(N2CCOCC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccccc2NS(C)(=O)=O)[nH]1,"InChI=1S/C22H25ClN6O4S/c1-32-20-13-15(29-9-11-33-12-10-29)7-8-19(20)26-22-24-14-16(23)21(27-22)25-17-5-3-4-6-18(17)28-34(2,30)31/h3-8,13-14,28H,9-12H2,1-2H3,(H2,24,25,26,27)",CLGWUCNXOBLWFM-UHFFFAOYSA-N,czc-54252,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(=N)[nH]n3c2)c1,"InChI=1S/C15H17FN6O2S/c1-15(2,3)21-25(23,24)11-4-9(6-18-7-11)10-5-12(16)13-19-14(17)20-22(13)8-10/h4-8,21H,1-3H3,(H2,17,20)",RXRZPHQBTHQXSV-UHFFFAOYSA-N,czc24832,Preclinical,PI3K inhibitor,PIK3CG,,
OCC1OC(OC2C(CO)OC(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2",GUBGYTABKSRVRQ-UHFFFAOYSA-N,d-(+)-maltose,Preclinical,,MGAM,,
N=c1[nH]c(=N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2[nH]1,"InChI=1S/C21H23Cl2N5O/c22-15-3-1-4-16(23)14(15)11-28-9-7-13(8-10-28)12-29-18-6-2-5-17-19(18)20(24)27-21(25)26-17/h1-6,13H,7-12H2,(H4,24,25,26,27)",MNLHFGXIUJNDAF-UHFFFAOYSA-N,d-157495,Preclinical,decapping scavenger enzyme inhibitor,,,
COc1ccc2c(c1)n(CCN)c(=O)n2C(=O)C1CC(C)CCC1C(C)C,"InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3",ZGTYTFYRCIRWBL-UHFFFAOYSA-N,d-3263,Phase 1,transient receptor potential channel agonist,,,
NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,"InChI=1S/C23H18N4O3/c24-22(28)14-4-6-15(7-5-14)23-26-20(21(27-23)17-3-1-2-10-25-17)16-8-9-18-19(13-16)30-12-11-29-18/h1-10,13H,11-12H2,(H2,24,28)(H,26,27)",DPDZHVCKYBCJHW-UHFFFAOYSA-N,d-4476,Preclinical,TGF beta receptor inhibitor,CSNK1A1|CSNK1D|TGFB1,,
COc1ccc2[nH]c(C(=O)c3ccccc3)cc2c1,"InChI=1S/C16H13NO2/c1-19-13-7-8-14-12(9-13)10-15(17-14)16(18)11-5-3-2-4-6-11/h2-10,17H,1H3",ICMIJSRDISNKOC-UHFFFAOYSA-N,d-64131,Preclinical,microtubule inhibitor,TUBB,,
CC(=O)NC(CSSCC(NC(C)=O)C(=O)O)C(=O)O,"InChI=1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)",YTPQSLLEROSACP-UHFFFAOYSA-N,d-7193,Phase 2,,,,
Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)O)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C33H54O5/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-20-33(8)21-19-28-27(7)31(25(5)26(6)32(28)38-33)37-30(36)18-17-29(34)35/h22-24H,9-21H2,1-8H3,(H,34,35)",IELOKBJPULMYRW-UHFFFAOYSA-N,d-alpha-tocopheryl-succinate,Launched,,,,
Cc1cc(O)cc2c1OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CC2,"InChI=1S/C27H46O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h18-22,28H,7-17H2,1-6H3",GZIFEOYASATJEH-UHFFFAOYSA-N,d-delta-tocopherol,Launched,,,,
C=C(C)C1CC=C(C)CC1,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3",XMGQYMWWDOXHJM-UHFFFAOYSA-N,d-limonene,Phase 1,,,,
NC(Cc1ccccc1)C(=O)O,"InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)",COLNVLDHVKWLRT-UHFFFAOYSA-N,d-phenylalanine,Preclinical,enkephalinase inhibitor,CCBL1|CRH|HCAR3,,
NC(C=O)C(O)O,"InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h1-3,6-7H,4H2",AFNIGYOBGXVNEF-UHFFFAOYSA-N,d-serine,Launched,glutamate receptor agonist,GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3,,
CC1(O)CCOC(=O)C1,"InChI=1S/C6H10O3/c1-6(8)2-3-9-5(7)4-6/h8H,2-4H2,1H3",JYVXNLLUYHCIIH-UHFFFAOYSA-N,"d,l-mevalonic-acid-lactone",Preclinical,,,,
S=C(S)OC1CC2CC1C1CCCC21,"InChI=1S/C11H16OS2/c13-11(14)12-10-5-6-4-9(10)8-3-1-2-7(6)8/h6-10H,1-5H2,(H,13,14)",PWLXJBSAUKKGCM-UHFFFAOYSA-N,d609,Preclinical,phospholipase inhibitor,,,
COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1,"InChI=1S/C23H22FNO4/c1-16(26)25(15-17-13-20(27-2)10-12-22(17)28-3)21-14-18(24)9-11-23(21)29-19-7-5-4-6-8-19/h4-14H,15H2,1-3H3",DCRZYADKQRHHSF-UHFFFAOYSA-N,daa-1106,Preclinical,benzodiazepine receptor agonist,TSPO,,
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,"InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)",YBSJFWOBGCMAKL-UHFFFAOYSA-N,dabigatran,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
CCCCCCOC(=O)N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,"InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)",KSGXQBZTULBEEQ-UHFFFAOYSA-N,dabigatran-etexilate,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2cc[nH]c(=N)n2)s1,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,dabrafenib,Launched,RAF inhibitor,BRAF|LIMK1|NEK11|RAF1|SIK1,oncology,melanoma
CN(C)N=Nc1[nH]cnc1C(N)=O,"InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)",FDKXTQMXEQVLRF-UHFFFAOYSA-N,dacarbazine,Launched,DNA alkylating agent,PGD|POLA2,oncology|hematologic malignancy,melanoma|Hodgkin's lymphoma
OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(C=CC(O)=NO)cc1,"InChI=1S/C22H25N3O3/c26-14-13-25(12-11-19-15-23-21-4-2-1-3-20(19)21)16-18-7-5-17(6-8-18)9-10-22(27)24-28/h1-10,15,23,26,28H,11-14,16H2,(H,24,27)",BWDQBBCUWLSASG-UHFFFAOYSA-N,dacinostat,Phase 1,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
COC(=O)NC(C(=O)N1CCCC1c1nc(-c2ccc(-c3ccc(-c4c[nH]c(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)n4)cc3)cc2)c[nH]1)C(C)C,"InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)",FKRSSPOQAMALKA-UHFFFAOYSA-N,daclatasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COc1cc2[nH]cnc(=Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN1CCCCC1,"InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)",LVXJQMNHJWSHET-UHFFFAOYSA-N,dacomitinib,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,,
Cc1ccc(C(=O)NC2C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC2C)c2c1Oc1c(C)c(O)c(N)c(C(=O)N=C3C(=O)NC(C(C)C)C(=O)N4CCCC4C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC3C)c1N2,"InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-44,48-49,64,77H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)",GSADSJFVCHVKRH-UHFFFAOYSA-N,dactinomycin,Launched,RNA polymerase inhibitor,POLR2A,oncology,testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD)
O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,"InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H",ZQSIJRDFPHDXIC-UHFFFAOYSA-N,daidzein,Phase 2,estrogen receptor agonist,ESRRA|ESRRB|ESRRG|TRPC5,,
O=c1c(-c2ccc(O)cc2)coc2cc(OC3OC(CO)C(O)C(O)C3O)ccc12,"InChI=1S/C21H20O9/c22-8-16-18(25)19(26)20(27)21(30-16)29-12-5-6-13-15(7-12)28-9-14(17(13)24)10-1-3-11(23)4-2-10/h1-7,9,16,18-23,25-27H,8H2",KYQZWONCHDNPDP-UHFFFAOYSA-N,daidzin,Phase 1,antioxidant,ALDH2,,
CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)C(C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)NC(CCCN=C(N)N)C(=O)O,"InChI=1S/C35H51N9O8/c1-20(2)16-27(32(49)43-26(34(51)52)10-7-15-39-35(37)38)44-33(50)28(18-22-8-5-4-6-9-22)42-29(46)19-40-30(47)21(3)41-31(48)25(36)17-23-11-13-24(45)14-12-23/h4-6,8-9,11-14,20-21,25-28,45H,7,10,15-19,36H2,1-3H3,(H,40,47)(H,41,48)(H,42,46)(H,43,49)(H,44,50)(H,51,52)(H4,37,38,39)",GDPHPXYFLPDZGH-UHFFFAOYSA-N,dalargin,Phase 2,opioid receptor agonist,OPRM1,,
CNC1C(=O)NC2Cc3ccc(cc3)Oc3cc4cc(c3OC3OC(C(=O)O)C(O)C(O)C3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)C(O)c3[nH]c(O)c(c5ccc(O)c(c5)c5c(OC6OC(CO)C(O)C(O)C6O)cc(O)cc5c(=C(O)NCCCN(C)C)[nH]c3O)NC(=O)C4NC(=O)C(NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O,"InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64,66,68,70-76,78,87-88,91-92,98-99,101-105,107-112,114,116,119H,6-14,25-27,37H2,1-5H3,(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,120,121)",LQERMDXPGNOJCT-UHFFFAOYSA-N,dalbavancin,Launched,bacterial cell wall synthesis inhibitor,PNLIP,infectious disease,skin infections
CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1,"InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)",YZQLWPMZQVHJED-UHFFFAOYSA-N,dalcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
N=c1cc[nH]cc1,"InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",NUKYPUAOHBNCPY-UHFFFAOYSA-N,dalfampridine,Launched,potassium channel blocker,KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2,neurology/psychiatry,multiple sclerosis
CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,"InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)",SUYRLXYYZQTJHF-UHFFFAOYSA-N,dalfopristin,Preclinical,antibacterial ,,,
O=C(O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,"InChI=1S/C16H16ClNO4S/c17-14-5-7-15(8-6-14)23(21,22)18-10-9-12-1-3-13(4-2-12)11-16(19)20/h1-8,18H,9-11H2,(H,19,20)",IULOBWFWYDMECP-UHFFFAOYSA-N,daltroban,Phase 3,thromboxane receptor antagonist,TBXA2R,,
CN(C)NC(=O)CCC(=O)O,"InChI=1S/C6H12N2O3/c1-8(2)7-5(9)3-4-6(10)11/h3-4H2,1-2H3,(H,7,9)(H,10,11)",NOQGZXFMHARMLW-UHFFFAOYSA-N,daminozide,Preclinical,KDM2A inhibitor,KDM2A|KDM7A|PHF8,,
C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C,"InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3",POZRVZJJTULAOH-UHFFFAOYSA-N,danazol,Launched,estrogen receptor antagonist,AR|CCL2|ESR1|GNRHR|GNRHR2|PGR,obstetrics/gynecology|cardiology,endometriosis|angioedema
C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C,"InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3",POZRVZJJTULAOH-UHFFFAOYSA-N,danazol,Launched,progesterone receptor agonist,AR|CCL2|ESR1|GNRHR|GNRHR2|PGR,obstetrics/gynecology|cardiology,endometriosis|angioedema
NCC(=O)N1CC(NC(=O)c2ccccc2)CC1C(=O)O,"InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)",BIZKIHUJGMSVFD-UHFFFAOYSA-N,danegaptide,Phase 2,gap junction modulator,,,
Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCNC2)c1O,"InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)",NGYNBSHYFOFVLS-UHFFFAOYSA-N,danirixin,Phase 2,CC chemokine receptor antagonist,CXCR2,,
CN1CC2CC1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1,"InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)",QMLVECGLEOSESV-UHFFFAOYSA-N,danofloxacin,Launched,bacterial DNA gyrase inhibitor,,pulmonary,bovine respiratory disease (BRD)
CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(C(=O)NS(=O)(=O)C2CC2)NC(=O)C2CC(OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O,"InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)",ZVTDLPBHTSMEJZ-UHFFFAOYSA-N,danoprevir,Phase 3,HCV inhibitor,,,
O=c1[nH]c(O)cn1N=Cc1ccc(-c2ccc([N+](=O)[O-])cc2)o1,"InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-8,19H,(H,16,20)",IMVWGCIUSSJUAA-UHFFFAOYSA-N,dantrolene,Launched,calcium channel blocker,RYR1|RYR3,neurology/psychiatry|endocrinology,spasms|malignant hyperthermia (MH)
O=C1c2cccc(O)c2C(=O)c2c(O)cccc21,"InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H",QBPFLULOKWLNNW-UHFFFAOYSA-N,dantron,Withdrawn,laxative,,,
COC(C(=O)n1cc2[nH][nH]c(=NC(O)c3ccc(N4CCN(C)CC4)cc3)c2c1)c1ccccc1,"InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,16-17,23,25,28,33H,12-15H2,1-2H3,(H,27,29)",KRBSMMVJJVHVCB-UHFFFAOYSA-N,danusertib,Phase 2,Aurora kinase inhibitor,AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK,,
COC(C(=O)n1cc2[nH][nH]c(=NC(O)c3ccc(N4CCN(C)CC4)cc3)c2c1)c1ccccc1,"InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,16-17,23,25,28,33H,12-15H2,1-2H3,(H,27,29)",KRBSMMVJJVHVCB-UHFFFAOYSA-N,danusertib,Phase 2,growth factor receptor inhibitor,AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK,,
CCOc1ccc(Cc2cc(C3OC(CO)C(O)C(O)C3O)ccc2Cl)cc1,"InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3",JVHXJTBJCFBINQ-UHFFFAOYSA-N,dapagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
CS(=O)(=O)CCC#N,"InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3",LQFRYKBDZNPJSW-UHFFFAOYSA-N,dapansutrile,Phase 2,anti-inflammatory agent,,,
O=c1ccc2ccc(O)c(O)c2o1,"InChI=1S/C9H6O4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12H",ATEFPOUAMCWAQS-UHFFFAOYSA-N,daphnetin,Preclinical,protein kinase inhibitor,,,
Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,"InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3",RFWZESUMWJKKRN-UHFFFAOYSA-N,dapiprazole,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,ophthalmology,mydriasis
Cc1cc(C)c(N=c2cc[nH]c(=Nc3ccc(C#N)cc3)[nH]2)c(C)c1,"InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)",ILAYIAGXTHKHNT-UHFFFAOYSA-N,dapivirine,Phase 3,non-nucleoside reverse transcriptase inhibitor,CYP3A4|CYP3A5,,
CN(C)C(CCOc1cccc2ccccc12)c1ccccc1,"InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3",USRHYDPUVLEVMC-UHFFFAOYSA-N,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),HTR1A|HTR1B|HTR2C|SLC6A4,urology,premature ejaculation (PE)
O=C(O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O,"InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,26H,1-11H2,(H,20,25)(H,23,24)",NVTKJBXOBFRPLQ-UHFFFAOYSA-N,daprodustat,Phase 3,hypoxia inducible factor inhibitor,EGLN1,,
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,"InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2",MQJKPEGWNLWLTK-UHFFFAOYSA-N,dapsone,Launched,bacterial antifolate,DHFR,dermatology|infectious disease,dermatitis herpetiformis (DH)|leprosy
CC(NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC(C(=O)OC(C)(C)C)c1ccccc1,"InChI=1S/C23H26F2N2O4/c1-14(26-19(28)12-15-10-17(24)13-18(25)11-15)21(29)27-20(16-8-6-5-7-9-16)22(30)31-23(2,3)4/h5-11,13-14,20H,12H2,1-4H3,(H,26,28)(H,27,29)",DWJXYEABWRJFSP-UHFFFAOYSA-N,dapt,Preclinical,gamma secretase inhibitor,,,
CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C,"InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)",DOAKLVKFURWEDJ-UHFFFAOYSA-N,daptomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|endocarditis
CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,"InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3",WDPFJWLDPVQCAJ-UHFFFAOYSA-N,darapladib,Phase 3,phospholipase inhibitor,PLA2G7,,
Cc1oc(-c2ccccc2)nc1CCC(=O)c1ccc(Cc2sc(=O)[nH]c2O)cc1,"InChI=1S/C23H20N2O4S/c1-14-18(24-22(29-14)17-5-3-2-4-6-17)11-12-19(26)16-9-7-15(8-10-16)13-20-21(27)25-23(28)30-20/h2-10,27H,11-13H2,1H3,(H,25,28)",BUWFKENPFXXWGV-UHFFFAOYSA-N,darglitazone,Phase 2,PPAR receptor antagonist,PPARG,,
NC(=O)C(c1ccccc1)(c1ccccc1)C1CCN(CCc2ccc3c(c2)CCO3)C1,"InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)",HXGBXQDTNZMWGS-UHFFFAOYSA-N,darifenacin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence
CC(=O)c1cc(C(O)NC(C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)[nH]n1,"InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11,19,22,28H,10H2,1-2H3,(H,23,24)",UNCRTZNMCJCUDV-UHFFFAOYSA-N,darolutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)OC1COC2OCCC12)S(=O)(=O)c1ccc(N)cc1,"InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)",CJBJHOAVZSMMDJ-UHFFFAOYSA-N,darunavir,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
COc1cc(OC)nc(OC(C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,"InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)",FEJVSJIALLTFRP-UHFFFAOYSA-N,darusentan,Phase 3,endothelin receptor antagonist,EDNRA,,
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,"InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)",NBRBXGKOEOGLOI-UHFFFAOYSA-N,dasabuvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,Bcr-Abl kinase inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,ephrin inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,KIT inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,PDGFR tyrosine kinase receptor inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,SRC inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1nc(=Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)[nH]1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,dasatinib,Launched,tyrosine kinase inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
NC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21,"InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2",SRPXSILJHWNFMK-UHFFFAOYSA-N,dasotraline,Phase 3,dopamine-norepinephrine-serotonin reuptake inhibitor,,,
CN1C2CCC1CC(OC(=O)N1Cc3ccccc3NC1=O)C2,"InChI=1S/C17H21N3O3/c1-19-12-6-7-13(19)9-14(8-12)23-17(22)20-10-11-4-2-3-5-15(11)18-16(20)21/h2-5,12-14H,6-10H2,1H3,(H,18,21)",NWXCDQHBVVPPTL-UHFFFAOYSA-N,dau-5884,Preclinical,acetylcholine receptor antagonist,CHRM3,,
CCC(CCC(C)C1CCC2C3CC=C4CC(OC5OC(CO)C(O)C(O)C5O)CCC4(C)C3CCC12C)C(C)C,"InChI=1S/C35H60O6/c1-7-22(20(2)3)9-8-21(4)26-12-13-27-25-11-10-23-18-24(14-16-34(23,5)28(25)15-17-35(26,27)6)40-33-32(39)31(38)30(37)29(19-36)41-33/h10,20-22,24-33,36-39H,7-9,11-19H2,1-6H3",NPJICTMALKLTFW-UHFFFAOYSA-N,daucosterol,Phase 2,apoptosis stimulant,,,
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(O)C(C)O1)CC(O)(C(C)=O)C=4,"InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,8,10,14,17,22,30-35H,7,9,28H2,1-3H3",FMKMZSSCGDCUTK-UHFFFAOYSA-N,daunorubicin,Launched,RNA synthesis inhibitor,TOP2A|TOP2B,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(O)C(C)O1)CC(O)(C(C)=O)C=4,"InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,8,10,14,17,22,30-35H,7,9,28H2,1-3H3",FMKMZSSCGDCUTK-UHFFFAOYSA-N,daunorubicin,Launched,topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)
Cc1c(Cn2ccnc2)c2ccccc2n1CCC(=O)O,"InChI=1S/C16H17N3O2/c1-12-14(10-18-9-7-17-11-18)13-4-2-3-5-15(13)19(12)8-6-16(20)21/h2-5,7,9,11H,6,8,10H2,1H3,(H,20,21)",DEQLGSOHGTZKFB-UHFFFAOYSA-N,dazmegrel,Phase 2,thromboxane synthase inhibitor,TBXAS1,,
O=C(O)c1ccc(OCCn2ccnc2)cc1,"InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)",XQGZSYKGWHUSDH-UHFFFAOYSA-N,dazoxiben,Phase 2,thromboxane synthase inhibitor,TBXAS1,,
c1ccc(CN=c2[nH]c(=NCc3ccccc3)c3ccccc3[nH]2)cc1,"InChI=1S/C22H20N4/c1-3-9-17(10-4-1)15-23-21-19-13-7-8-14-20(19)25-22(26-21)24-16-18-11-5-2-6-12-18/h1-14H,15-16H2,(H2,23,24,25,26)",QAIMUUJJAJBPCL-UHFFFAOYSA-N,dbeq,Preclinical,ATPase inhibitor,CASP3,,
O=C(NN1CCCCC1)c1nn(-c2ccc(Cl)cc2Cl)c(-c2ccc(C#Cc3ccc(C(F)(F)F)cc3)s2)c1CNS(=O)(=O)N1CCCC1,"InChI=1S/C33H31Cl2F3N6O3S2/c34-24-11-14-28(27(35)20-24)44-31(29-15-13-25(48-29)12-8-22-6-9-23(10-7-22)33(36,37)38)26(21-39-49(46,47)43-18-4-5-19-43)30(40-44)32(45)41-42-16-2-1-3-17-42/h6-7,9-11,13-15,20,39H,1-5,16-19,21H2,(H,41,45)",KAIYFJUWIBTYPK-UHFFFAOYSA-N,dbpr-211,Preclinical,cannabinoid receptor antagonist,,,
CC(C)(CC(=O)N1CCCC1)NCC(=O)N1CC(F)CC1C#N,"InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3",VQKSCYBKUIDZEI-UHFFFAOYSA-N,dbpr108,Phase 1,dipeptidyl peptidase inhibitor,DPP4,,
CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1,"InChI=1S/C16H18FNO2S/c1-2-3-4-13-5-9-15(10-6-13)18-21(19,20)16-11-7-14(17)8-12-16/h5-12,18H,2-4H2,1H3",CNGHPXKWPGIDSK-UHFFFAOYSA-N,dc-260126,Preclinical,free fatty acid receptor antagonist,FFAR1,,
Cn1cc(-c2cc(Oc3cc(F)c(NC(=O)C4(C(=O)Nc5ccccc5)CC4)cc3F)ccn2)cn1,"InChI=1S/C26H21F2N5O3/c1-33-15-16(14-30-33)21-11-18(7-10-29-21)36-23-13-19(27)22(12-20(23)28)32-25(35)26(8-9-26)24(34)31-17-5-3-2-4-6-17/h2-7,10-15H,8-9H2,1H3,(H,31,34)(H,32,35)",WWOXKWLDMLMYQY-UHFFFAOYSA-N,dcc-2618,Phase 1,KIT inhibitor,KIT|PDGFRA,,
Cn1cc(-c2cc(Oc3cc(F)c(NC(=O)C4(C(=O)Nc5ccccc5)CC4)cc3F)ccn2)cn1,"InChI=1S/C26H21F2N5O3/c1-33-15-16(14-30-33)21-11-18(7-10-29-21)36-23-13-19(27)22(12-20(23)28)32-25(35)26(8-9-26)24(34)31-17-5-3-2-4-6-17/h2-7,10-15H,8-9H2,1H3,(H,31,34)(H,32,35)",WWOXKWLDMLMYQY-UHFFFAOYSA-N,dcc-2618,Phase 1,PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA,,
CCn1c(=O)[nH]c2cc(Cl)c(Cl)cc21,"InChI=1S/C9H8Cl2N2O/c1-2-13-8-4-6(11)5(10)3-7(8)12-9(13)14/h3-4H,2H2,1H3,(H,12,14)",LKHRMULASXZCLG-UHFFFAOYSA-N,dcebio,Preclinical,potassium channel activator,KCNN2|KCNN3|KCNN4,,
CCCCCC1CC1CC1CC1CCCCCCCC(=O)O,"InChI=1S/C20H36O2/c1-2-3-7-10-16-13-18(16)15-19-14-17(19)11-8-5-4-6-9-12-20(21)22/h16-19H,2-15H2,1H3,(H,21,22)",CONYTTFKIUJZOF-UHFFFAOYSA-N,dcp-la,Preclinical,protein kinase activator,,,
CCCCC1(C2CCCC2)Cc2cc(OCCCC(=O)O)c(Cl)c(Cl)c2C1=O,"InChI=1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)",KHKGTPJPBOQECW-UHFFFAOYSA-N,dcpib,Preclinical,chloride channel blocker,SLC1A2,,
CCCCC1(C2CCCC2)Cc2cc(OCCCC(=O)O)c(Cl)c(Cl)c2C1=O,"InChI=1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)",KHKGTPJPBOQECW-UHFFFAOYSA-N,dcpib,Preclinical,gap junction modulator,SLC1A2,,
CCCCC1(C2CCCC2)Cc2cc(OCCCC(=O)O)c(Cl)c(Cl)c2C1=O,"InChI=1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)",KHKGTPJPBOQECW-UHFFFAOYSA-N,dcpib,Preclinical,glutamate inhibitor,SLC1A2,,
CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Oc4ccc5[nH]c(O)cc5c4)c3)cc2C(F)(F)F)CC1,"InChI=1S/C30H31F3N4O3/c1-3-36-10-12-37(13-11-36)18-21-6-5-20(15-25(21)30(31,32)33)29(39)34-23-7-4-19(2)27(17-23)40-24-8-9-26-22(14-24)16-28(38)35-26/h4-9,14-17,35,38H,3,10-13,18H2,1-2H3,(H,34,39)",UXUQIRNFBFRPAC-UHFFFAOYSA-N,ddr1-in-1,Preclinical,discoidin domain receptor inhibitor,DDR1|DDR2,,
Nc1cc2[nH]cnc2c(=O)[nH]1,"InChI=1S/C6H6N4O/c7-4-1-3-5(6(11)10-4)9-2-8-3/h1-2H,(H,8,9)(H3,7,10,11)",KXBCLNRMQPRVTP-UHFFFAOYSA-N,deazaguanine,Preclinical,DNA synthesis inhibitor,,,
CN(C)c1cc2c(cc1Sc1nc3c(=N)[nH]ccc3n1CCNCC(C)(C)C)OCO2,"InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25)",RVJIQAYFTOPTKK-UHFFFAOYSA-N,debio-0932,Phase 1,HSP inhibitor,,,
N=C(N)N1CCc2ccccc2C1,"InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)",JWPGJSVJDAJRLW-UHFFFAOYSA-N,debrisoquin,Launched,adrenergic neuron blocker,SLC6A2,cardiology,hypertension
C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,"InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2",MTCUAOILFDZKCO-UHFFFAOYSA-N,decamethonium,Launched,acetylcholine receptor agonist,ACHE|CHRNA2,neurology/psychiatry,muscle relaxant
CC1CCC(C(C)C)C(OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)OC2CC(C)CCC2C(C)C)C1,"InChI=1S/C38H74N2O4/c1-29(2)33-21-19-31(5)25-35(33)43-37(41)27-39(7,8)23-17-15-13-11-12-14-16-18-24-40(9,10)28-38(42)44-36-26-32(6)20-22-34(36)30(3)4/h29-36H,11-28H2,1-10H3/q+2",ZADGGFKUEYIBJC-UHFFFAOYSA-N,decamethoxine,Phase 2,antiseptic,,,
CCC(C)(N=c1cc[nH]c(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,"InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)",ASUGUQWIHMTFJL-UHFFFAOYSA-N,decernotinib,Phase 2/Phase 3,JAK inhibitor,JAK3,,
N=c1ncn(C2CC(O)C(CO)O2)c(=O)[nH]1,"InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)",XAUDJQYHKZQPEU-UHFFFAOYSA-N,decitabine,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)
CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1,"InChI=1S/C13H20ClN3O/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18)",YEYAKZXEBSVURO-UHFFFAOYSA-N,declopramide,Preclinical,cell cycle inhibitor,,,
OCCOCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C21H28N2O2/c24-16-18-25-17-15-22-11-13-23(14-12-22)21(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-10,21,24H,11-18H2",OXBBIHZWNDPBMQ-UHFFFAOYSA-N,decloxizine,Preclinical,histamine receptor antagonist,,,
CCCCCCCCCCOc1cc2c(=O)c(C(=O)OCC)c[nH]c2cc1OCC,"InChI=1S/C24H35NO5/c1-4-7-8-9-10-11-12-13-14-30-21-15-18-20(16-22(21)28-5-2)25-17-19(23(18)26)24(27)29-6-3/h15-17H,4-14H2,1-3H3,(H,25,26)",JHAYEQICABJSTP-UHFFFAOYSA-N,decoquinate,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CNC(=O)c1ccc(N=c2[nH]cc(C(F)(F)F)c(=NCc3nccnc3N(C)S(C)(=O)=O)[nH]2)cc1,"InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)",FWLMVFUGMHIOAA-UHFFFAOYSA-N,defactinib,Phase 2,focal adhesion kinase inhibitor,PTK2,,
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",BOFQWVMAQOTZIW-UHFFFAOYSA-N,deferasirox,Launched,chelating agent,CYP3A4,hematology,transfusional hemosiderosis|thalassemia|iron overload
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,"InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)",BOFQWVMAQOTZIW-UHFFFAOYSA-N,deferasirox-iron-chelate,Launched,,,,
Cc1c(O)c(=O)ccn1C,"InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3",TZXKOCQBRNJULO-UHFFFAOYSA-N,deferiprone,Launched,chelating agent,UGT1A6,hematology,transfusional hemosiderosis|thalassemia|iron overload
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,"InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)",UBQYURCVBFRUQT-UHFFFAOYSA-N,deferoxamine-mesylate,Launched,chelating agent,,hematology,acute iron intoxication|iron overload
CC(=O)OCC(=O)C12N=C(C)OC1CC1C3CC=C4CC(=O)C=CC4(C)C3C(O)CC12C,"InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h5,7-8,17-19,21-22,29H,6,9-12H2,1-4H3",CHSYXJNUOMUPOG-UHFFFAOYSA-N,deflazacort,Launched,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation
COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OP(C)(C)=O)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,35-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3",MTTQXNQOEINTQC-UHFFFAOYSA-N,deforolimus,Phase 3,mTOR inhibitor,MTOR,,
CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(O)c2cc(=O)[nH]c(=O)[nH]2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,"InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,42-43,45-47,59-65,67-68,71,87,90,102,106H,9-10,12,16-17,33-35,37-41,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)",ZUFHFTCQPLPMAL-UHFFFAOYSA-N,degarelix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer
CC(=O)c1c(O)cc(C)oc1=O,"InChI=1S/C8H8O4/c1-4-3-6(10)7(5(2)9)8(11)12-4/h3,10H,1-2H3",PKLPQOJFHFGVBS-UHFFFAOYSA-N,dehydroacetic-acid,Preclinical,,,,
CC(CCC(=O)O)C1CCC2C3C(=O)CC4CC(=O)CCC4(C)C3CC(=O)C12C,"InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)",OHXPGWPVLFPUSM-UHFFFAOYSA-N,dehydrocholate,Preclinical,,,,
CC(CCC(=O)O)C1CCC2C3C(=O)CC4CC(=O)CCC4(C)C3CC(=O)C12C,"InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)",OHXPGWPVLFPUSM-UHFFFAOYSA-N,dehydrocholate-acid,Preclinical,,,,
COc1cc2c(cc1OC)-c1c(C)c3ccc(OC)c(OC)c3c[n+]1CC2,"InChI=1S/C22H24NO4/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23/h6-7,10-12H,8-9H2,1-5H3/q+1",RFKQJTRWODZPHF-UHFFFAOYSA-N,dehydrocorydaline,Phase 3,acetylcholinesterase inhibitor,ACHE,,
CC12CCC3C(CC=C4CC(O)CCC43C)C1CCC2=O,"InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3",FMGSKLZLMKYGDP-UHFFFAOYSA-N,dehydroepiandrosterone,Launched,protein synthesis stimulant,ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1,endocrinology,menopause
CC12CCC3C(CC=C4CC(OS(=O)(=O)O)CCC43C)C1CCC2=O,"InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)",CZWCKYRVOZZJNM-UHFFFAOYSA-N,dehydroepiandrosterone-sulfate,Launched,androgen receptor agonist,AR|ESR1|ESR2,endocrinology,menopause
CC12CCC3C(CC=C4CC(OS(=O)(=O)O)CCC43C)C1CCC2=O,"InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)",CZWCKYRVOZZJNM-UHFFFAOYSA-N,dehydroepiandrosterone-sulfate,Launched,estrogen receptor agonist,AR|ESR1|ESR2,endocrinology,menopause
N=c1[nH]c(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F,"InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)",DYDCPNMLZGFQTM-UHFFFAOYSA-N,delafloxacin,Phase 3,antiinfective drug,,,
CC1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1,"InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3",XDAOLTSRNUSPPH-UHFFFAOYSA-N,delamanid,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis
CC(=O)C(NC(=O)c1cccc(-c2ccccc2)n1)C(O)NC(CC(C)C)B(O)O,"InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13,18-19,21,24,28-30H,12H2,1-3H3,(H,25,27)",XUZQTIZWMHMWOC-UHFFFAOYSA-N,delanzomib,Phase 1/Phase 2,proteasome inhibitor,CMA1|CTSG|CYP3A4|ELANE,,
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,"InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)",WOUOLAUOZXOLJQ-UHFFFAOYSA-N,delapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,"InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3",WHBIGIKBNXZKFE-UHFFFAOYSA-N,delavirdine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
CC(C)CC(NC(=O)C(CO)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(Cc1ccccc1)NC(=O)C(CO)NC(=O)C(N)CSSCC(N)C(=O)NC(Cc1ccc(O)cc1)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)O)C(=O)O,"InChI=1S/C120H199N45O34S2/c1-61(2)48-80(96(179)145-55-92(174)148-86(56-166)110(193)163-85(114(198)199)49-62(3)4)159-106(189)78(37-39-93(175)176)156-107(190)83(52-65-30-34-67(170)35-31-65)161-112(195)88(58-168)165-109(192)84(53-90(126)172)162-108(191)82(50-63-18-6-5-7-19-63)160-111(194)87(57-167)164-95(178)69(124)60-201-200-59-68(123)94(177)158-81(51-64-28-32-66(169)33-29-64)97(180)146-54-91(173)147-70(22-12-42-139-115(127)128)98(181)149-71(20-8-10-40-121)99(182)150-72(21-9-11-41-122)100(183)151-73(23-13-43-140-116(129)130)101(184)152-75(25-15-45-142-118(133)134)103(186)155-77(36-38-89(125)171)105(188)154-74(24-14-44-141-117(131)132)102(185)153-76(26-16-46-143-119(135)136)104(187)157-79(113(196)197)27-17-47-144-120(137)138/h5-7,18-19,28-35,61-62,68-88,166-170H,8-17,20-27,36-60,121-124H2,1-4H3,(H2,125,171)(H2,126,172)(H,145,179)(H,146,180)(H,147,173)(H,148,174)(H,149,181)(H,150,182)(H,151,183)(H,152,184)(H,153,185)(H,154,188)(H,155,186)(H,156,190)(H,157,187)(H,158,177)(H,159,189)(H,160,194)(H,161,195)(H,162,191)(H,163,193)(H,164,178)(H,165,192)(H,175,176)(H,196,197)(H,198,199)(H4,127,128,139)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)",XPXZTVWPRKJTAA-UHFFFAOYSA-N,delcasertib,Phase 1,PKC inhibitor,,,
CC1CN(C(=O)CC#N)C12CCN(c1ncnc3[nH]ccc13)C2,"InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)",LOWWYYZBZNSPDT-UHFFFAOYSA-N,delgocitinib,Phase 2,JAK inhibitor,,,
CCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(N)CC(=O)O)C(C)C)C(=O)NC(Cc1c[nH]cn1)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(=O)O,"InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)",CZGUSIXMZVURDU-UHFFFAOYSA-N,delivert,Launched,angiotensin receptor agonist,AGTR1|AGTR2,critical care,sepsis
CN1CCN(c2ccc(N3CC(CO)OC3=O)cc2F)C=N1,"InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3",QLUWQAFDTNAYPN-UHFFFAOYSA-N,delpazolid,Phase 2,antibacterial,,,
Oc1cc(O)c2cc(O)c(-c3cc(O)c(O)c(O)c3)[o+]c2c1,"InChI=1S/C15H10O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-5H,(H5-,16,17,18,19,20,21)/p+1",JKHRCGUTYDNCLE-UHFFFAOYSA-O,delphinidin,Phase 2,membrane permeability inhibitor,GLO1,,
CC(C)=CCCC(C)=CCCC(C)=CCCC1(C)CCc2cc(O)cc(C)c2O1,"InChI=1S/C27H40O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h10,12,14,18-19,28H,7-9,11,13,15-17H2,1-6H3",ODADKLYLWWCHNB-UHFFFAOYSA-N,delta-tocotrienol,Phase 1,HMGCR inhibitor,HMGCR,,
c1ccc(Cn2c(-c3ccc(OCC(C4CCNCC4)n4c(-c5ccccc5)nc5ccccc54)cc3)nc3ccccc32)cc1,"InChI=1S/C40H37N5O/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31/h1-22,30,38,41H,23-28H2",LTZKEDSUXKTTTC-UHFFFAOYSA-N,deltarasin,Preclinical,phosphodiesterase inhibitor,KRAS,,
CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1,"InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2",RWZVPVOZTJJMNU-UHFFFAOYSA-N,demecarium,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,ophthalmology,intraocular pressure|glaucoma
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(O)c3c(c(O)c4c(Cl)ccc(O)c4c3O)CC12,"InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,7,13-14,18,25-27,29,32H,5H2,1-2H3,(H2,23,31)",STSZYJMXQQPUNU-UHFFFAOYSA-N,demeclocycline,Launched,bacterial 30S ribosomal subunit inhibitor,,endocrinology|infectious disease|ophthalmology|urology,fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|cholera|syphilis|listeria|anthrax|actinomycosis|tularemia|brucellosis
CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1,"InChI=1S/C21H28N2O/c1-5-23(6-2,15-19-13-8-7-9-14-19)16-20(24)22-21-17(3)11-10-12-18(21)4/h7-14H,5-6,15-16H2,1-4H3/p+1",ZFQMTVNLDNXRNQ-UHFFFAOYSA-O,denatonium-benzoate,Preclinical,,,,
COc1ccc(CCNCC(O)c2ccc(O)cc2)cc1OC,"InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3",VHSBBVZJABQOSG-UHFFFAOYSA-N,denopamine,Launched,adrenergic receptor agonist,,cardiology,angina pectoris
Cc1[nH]sc(=NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1,"InChI=1S/C18H14ClN3O2S/c1-11-15(17(24)20-14-9-7-13(19)8-10-14)18(25-22-11)21-16(23)12-5-3-2-4-6-12/h2-10,22H,1H3,(H,20,24)",NJLVQZSKJRZBCP-UHFFFAOYSA-N,denotivir,Launched,antiviral,,infectious disease,virus herpes simplex (HSV)|skin infections
Oc1ccc(OC2CCCCO2)cc1,"InChI=1S/C11H14O3/c12-9-4-6-10(7-5-9)14-11-3-1-2-8-13-11/h4-7,11-12H,1-3,8H2",GFBCWCDNXDKFRH-UHFFFAOYSA-N,deoxyarbutin,Preclinical,tyrosinase inhibitor,,,
CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,"InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)",KXGVEGMKQFWNSR-UHFFFAOYSA-N,deoxycholic-acid,Launched,biliverdin reductase A activator,FPR1|GPBAR1,endocrinology,submental fat
CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,"InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)",KXGVEGMKQFWNSR-UHFFFAOYSA-N,deoxycholic-acid,Launched,G protein-coupled receptor agonist,FPR1|GPBAR1,endocrinology,submental fat
CC(=O)OCC(=O)C1CCC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h4,17-20H,5-13H2,1-3H3",HJMATBDGCKEHQI-UHFFFAOYSA-N,deoxycorticosterone-acetate,Preclinical,progestogen hormone,NR3C2,,
CNCCc1ccc(O)c(O)c1,"InChI=1S/C9H13NO2/c1-10-5-4-7-2-3-8(11)9(12)6-7/h2-3,6,10-12H,4-5H2,1H3",NGKZFDYBISXGGS-UHFFFAOYSA-N,deoxyepinephrine,Preclinical,adrenergic receptor agonist,ADRA1A|DRD1|DRD2,,
CNCCc1ccc(O)c(O)c1,"InChI=1S/C9H13NO2/c1-10-5-4-7-2-3-8(11)9(12)6-7/h2-3,6,10-12H,4-5H2,1H3",NGKZFDYBISXGGS-UHFFFAOYSA-N,deoxyepinephrine,Preclinical,dopamine receptor agonist,ADRA1A|DRD1|DRD2,,
Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21,"InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2",PCSWXVJAIHCTMO-UHFFFAOYSA-P,dequalinium,Launched,PKC inhibitor,KCNN1|KCNN3,infectious disease,first-aid antiseptic
COc1ccc(-c2cc(C(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1F,"InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)",WAZQAZKAZLXFMK-UHFFFAOYSA-N,deracoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
COCCNCCc1cccc(N=c2nc3c(c[nH]2)CC(c2ccccc2F)c2ccccc2-3)c1,"InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)",KPJDVVCDVBFRMU-UHFFFAOYSA-N,derazantinib,Phase 2,tyrosine kinase inhibitor,,,
COC(=O)C1C2CC3c4[nH]c5ccccc5c4CCN3CC2CC(OC(=O)c2cc(OC)c(OC)c(OC)c2)C1OC,"InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3",CVBMAZKKCSYWQR-UHFFFAOYSA-N,deserpidine,Launched,angiotensin converting enzyme inhibitor,ACE|SLC18A2,cardiology,hypertension
O=C(O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O,"InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)",IKRKQQLJYBAPQT-UHFFFAOYSA-N,desidustat,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
CNCCCN1c2ccccc2CCc2ccccc21,"InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3",HCYAFALTSJYZDH-UHFFFAOYSA-N,desipramine,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1,neurology/psychiatry,depression
CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CC1OC(C3CCCCC3)OC12C(=O)CO,"InChI=1S/C28H38O6/c1-26-11-10-18(30)12-17(26)8-9-19-20-13-23-28(22(32)15-29,27(20,2)14-21(31)24(19)26)34-25(33-23)16-6-4-3-5-7-16/h10-12,16,19-21,23-25,29,31H,3-9,13-15H2,1-2H3",OXPLANUPKBHPMS-UHFFFAOYSA-N,desisobutyryl-ciclesonide,Launched,cytochrome P450 inhibitor,,allergy,allergic rhinitis
CC1OC(OC2CCC3(C)C(CCC4C3CC(O)C3(C)C(c5coc(O)c5)CCC43O)C2)CC(O)C1OC1CC(O)C(OC2CC(O)C(OC3OC(CO)C(O)C(O)C3O)C(C)O2)C(C)O1,"InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,19-22,24-33,35-44,48-57H,6-11,13-18H2,1-5H3",PMYGXMBKYBGIEC-UHFFFAOYSA-N,deslanoside,Launched,Na/K-ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,"InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2",JAUOIFJMECXRGI-UHFFFAOYSA-N,desloratadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,"InChI=1S/C64H83N17O12/c1-4-68-62(92)53-16-10-24-81(53)63(93)46(15-9-23-69-64(65)66)74-56(86)47(25-35(2)3)75-58(88)49(27-37-30-70-43-13-7-5-11-41(37)43)77-57(87)48(26-36-17-19-40(83)20-18-36)76-61(91)52(33-82)80-59(89)50(28-38-31-71-44-14-8-6-12-42(38)44)78-60(90)51(29-39-32-67-34-72-39)79-55(85)45-21-22-54(84)73-45/h5-8,11-14,17-20,30-32,34-35,45-53,70-71,82-83H,4,9-10,15-16,21-29,33H2,1-3H3,(H,67,72)(H,68,92)(H,73,84)(H,74,86)(H,75,88)(H,76,91)(H,77,87)(H,78,90)(H,79,85)(H,80,89)(H4,65,66,69)",GJKXGJCSJWBJEZ-UHFFFAOYSA-N,deslorelin,Phase 2,gonadotropin releasing factor hormone receptor agonist,,,
Clc1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,"InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2",JNNOSTQEZICQQP-UHFFFAOYSA-N,desmethylclozapine,Phase 2,acetylcholine receptor agonist,HTR2C,,
N=C(N)NCCCC(NC(=O)C1CCCN1C(=O)C1CSSCCC(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)",NFLWUMRGJYTJIN-UHFFFAOYSA-N,desmopressin-acetate,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,endocrinology|urology,central diabetes insipidus|nocturnal enuresis
C#CC1(O)CCC2C3CCC4=CCCCC4C3C(=C)CC21CC,"InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3",RPLCPCMSCLEKRS-UHFFFAOYSA-N,desogestrel,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
CC1(C)OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h5,7-8,15-17,19-20,25,27H,6,9-12H2,1-4H3",ZMUSCGJNJYXJBP-UHFFFAOYSA-N,desonide,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,gastroenterology,Crohn's disease
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1C(=O)CO,"InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h4,6-7,12,15-16,18-19,24,27H,5,8-11H2,1-3H3",RAKDWPCGCPYIRC-UHFFFAOYSA-N,desoximetasone,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CC(C)(C)C(=O)OCC(=O)C1CCC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h6,18-21H,7-15H2,1-5H3",QCZFFZQOVRRUFF-UHFFFAOYSA-N,desoxycorticosterone-pivalate,Launched,corticosteroid agonist,NR3C2,endocrinology,Addison's disease
CC12CCC(=O)C=C1CCC1C2CCC2(C)C(C(=O)CO)CCC12,"InChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3",ZESRJSPZRDMNHY-UHFFFAOYSA-N,desoxycortone,Preclinical,mineralocorticoid receptor agonist,NR3C1|NR3C2,,
c1ccc2c(c1)CN1CCCC1=N2,"InChI=1S/C11H12N2/c1-2-5-10-9(4-1)8-13-7-3-6-11(13)12-10/h1-2,4-5H,3,6-8H2",WUFQLZTXIWKION-UHFFFAOYSA-N,desoxypeganine,Phase 1,acetylcholinesterase inhibitor,ACHE,,
c1ccc2c(c1)CN1CCCC1=N2,"InChI=1S/C11H12N2/c1-2-5-10-9(4-1)8-13-7-3-6-11(13)12-10/h1-2,4-5H,3,6-8H2",WUFQLZTXIWKION-UHFFFAOYSA-N,desoxypeganine,Phase 1,monoamine oxidase inhibitor,ACHE,,
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,"InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3",KYYIDSXMWOZKMP-UHFFFAOYSA-N,desvenlafaxine,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
Cc1cccc(Cc2c[nH]cn2)c1C,"InChI=1S/C12H14N2/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12/h3-5,7-8H,6H2,1-2H3,(H,13,14)",RHDJRPPFURBGLQ-UHFFFAOYSA-N,detomidine,Launched,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative
CN1C(=O)C(NC(=O)c2cc3ccccc3[nH]2)N=C(c2ccccc2)c2ccccc21,"InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)",NFHRQQKPEBFUJK-UHFFFAOYSA-N,devazepide,Preclinical,CCK receptor antagonist,,,
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h4,6-7,12,15-17,24,26,28H,5,8-11H2,1-3H3",GJFCONYVAUNLKB-UHFFFAOYSA-N,dexamethasone,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR0B1|NR3C1|NR3C2,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
CC(=O)OCC(=O)C1(O)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h5,7-8,13,17-19,28,30H,6,9-12H2,1-4H3",PPDWQLSRZNCMRA-UHFFFAOYSA-N,dexamethasone-acetate,Launched,glucocorticoid receptor agonist,,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,"InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",SOYKEARSMXGVTM-UHFFFAOYSA-N,dexchlorpheniramine,Launched,histamine receptor antagonist,,allergy|cardiology,allergic conjunctivitis|allergic rhinitis|urticaria|angioedema
NC(CO[PH](=O)(=O)O)C(=O)O,"InChI=1S/C3H7NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)",QDYSNGVNNVDCTC-UHFFFAOYSA-N,dexfosfoserine,Preclinical,membrane integrity inhibitor,CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2,,
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,"InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)",MJIHNNLFOKEZEW-UHFFFAOYSA-N,dexlansoprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)
CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,"InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)",QNQZBKQEIFTHFZ-UHFFFAOYSA-N,dexloxiglumide,Phase 3,CCK receptor antagonist,CCKAR,,
Cc1cccc(C(C)c2c[nH]cn2)c1C,"InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)",CUHVIMMYOGQXCV-UHFFFAOYSA-N,dexmedetomidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,32-33H,11,18-23H2,1-3H3",DCOAXFMVFWUZET-UHFFFAOYSA-N,dexniguldipine,Phase 2,calmodulin antagonist,ADORA3,,
CC(C)(CO)C(=O)C(O)NCCCO,"InChI=1S/C9H19NO4/c1-9(2,6-12)7(13)8(14)10-4-3-5-11/h8,10-12,14H,3-6H2,1-2H3",ZIZYJTNDTBOCRC-UHFFFAOYSA-N,dexpanthenol,Launched,,,gastroenterology,paralytic ileus
CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,"InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)",BMKDZUISNHGIBY-UHFFFAOYSA-N,dexrazoxane,Launched,chelating agent,TOP2A|TOP2B,cardiology,cardiomyopathy
CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,"InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)",BMKDZUISNHGIBY-UHFFFAOYSA-N,dexrazoxane,Launched,topoisomerase inhibitor,TOP2A|TOP2B,cardiology,cardiomyopathy
O=C(C(O)CO)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C18H32O16/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18/h5-8,10-22,24-30H,1-4H2",BYMPKULJRANZCQ-UHFFFAOYSA-N,dextran,Launched,,,hematology|critical care,thrombosis|hypovolemia
COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3,"InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3",MKXZASYAUGDDCJ-UHFFFAOYSA-N,dextromethorphan,Launched,glutamate receptor antagonist,CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4,pulmonary,cough suppressant
COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3,"InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3",MKXZASYAUGDDCJ-UHFFFAOYSA-N,dextromethorphan,Launched,sigma receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4,pulmonary,cough suppressant
Cc1ncc([N+](=O)[O-])n1CC(CN1CCOCC1)O[PH](=O)(=O)O,"InChI=1S/C11H18N4O7P/c1-9-12-6-11(15(16)17)14(9)8-10(22-23(18,19)20)7-13-2-4-21-5-3-13/h6,10H,2-5,7-8H2,1H3,(H,18,19,20)",JJEYFUNLMISKKH-UHFFFAOYSA-N,dextrorotation-nimorazole-phosphate-ester,Preclinical,antiinfective drug,,,
O=C(C(O)CO)C(O)C(O)CO,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-5,7-11H,1-2H2",DWJZKGYQNOQQEZ-UHFFFAOYSA-N,dextrose,Launched,,,endocrinology,hypoglycemia
Fc1cccc(C=NN=Cc2cccc(F)c2)c1,InChI=1S/C14H10F2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H,YYMCVDNIIFNDJK-UHFFFAOYSA-N,dfb,Preclinical,glutamate receptor agonist,GRM5,,
CN1CCN(c2ccc(C=C(C#N)c3ccccc3Br)cc2)CC1,"InChI=1S/C20H20BrN3/c1-23-10-12-24(13-11-23)18-8-6-16(7-9-18)14-17(15-22)19-4-2-3-5-20(19)21/h2-9,14H,10-13H2,1H3",ZJMDTBBCNMGFMS-UHFFFAOYSA-N,dg-172,Preclinical,PPAR receptor inverse agonist,PPARD,,
O=C(O)CCCN1CCCC1COc1ccc(Oc2ccc(Cl)cc2)cc1,"InChI=1S/C21H24ClNO4/c22-16-5-7-19(8-6-16)27-20-11-9-18(10-12-20)26-15-17-3-1-13-23(17)14-2-4-21(24)25/h5-12,17H,1-4,13-15H2,(H,24,25)",PVCTYSQBVIGZRU-UHFFFAOYSA-N,dg051,Preclinical,leukotriene synthesis inhibitor,,,
CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,"InChI=1S/C22H26N2O/c1-2-3-13-22(25)23-15-14-19-18-11-7-8-12-20(18)24-21(19)16-17-9-5-4-6-10-17/h4-12,24H,2-3,13-16H2,1H3,(H,23,25)",HDOIPCLEKCEANF-UHFFFAOYSA-N,dh-97,Preclinical,melatonin receptor antagonist,MTNR1B,,
CCCCCCC[n+]1ccc(-c2cc[n+](CCCCCCC)cc2)cc1,"InChI=1S/C24H38N2/c1-3-5-7-9-11-17-25-19-13-23(14-20-25)24-15-21-26(22-16-24)18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18H2,1-2H3/q+2",XJGZGUSMZSXHJI-UHFFFAOYSA-N,dhbp,Preclinical,ryanodine receptor blocker,,,
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,"InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)",TYNLGDBUJLVSMA-UHFFFAOYSA-N,diacerein,Launched,interleukin inhibitor,IL1B,rheumatology,osteoarthritis
CC(=O)Nc1ccc(OC(C)=O)cc1,"InChI=1S/C10H11NO3/c1-7(12)11-9-3-5-10(6-4-9)14-8(2)13/h3-6H,1-2H3,(H,11,12)",UJAOSPFULOFZRR-UHFFFAOYSA-N,diacetamate,Preclinical,,,,
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)OCC2OC(n3cnc4c(=N)[nH]cnc43)C(O)C2O)C(O)C1O,"InChI=1S/C20H24N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-50(35,36)47-52(39,40)49-53(41,42)48-51(37,38)44-2-8-12(32)14(34)20(46-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H2,21,23,25)(H2,22,24,26)",QGCUYEGBMUQFHB-UHFFFAOYSA-N,diadenosine-tetraphosphate,Phase 1,adenosine kinase inhibitor,P2RY13|P2RY2,,
OC(C1CO1)C(O)C1CO1,"InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2",AAFJXZWCNVJTMK-UHFFFAOYSA-N,dianhydrogalactitol,Phase 3,DNA alkylating agent,,,
N#CC(Cc1ccc(O)cc1)c1ccc(O)cc1,"InChI=1S/C15H13NO2/c16-10-13(12-3-7-15(18)8-4-12)9-11-1-5-14(17)6-2-11/h1-8,13,17-18H,9H2",GHZHWDWADLAOIQ-UHFFFAOYSA-N,diarylpropionitrile,Preclinical,estrogen receptor agonist,ESR2,,
CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I,"InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)",YVPYQUNUQOZFHG-UHFFFAOYSA-N,diatrizoic-acid,Launched,,,radiology,contrast agent
COc1ccc(Cc2c[nH]c(=N)[nH]c2=N)cc1OC,"InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17)",LDBTVAXGKYIFHO-UHFFFAOYSA-N,diaveridine,Launched,dihydrofolate reductase inhibitor,,infectious disease,coccidiosis
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,"InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)",GDLBFKVLRPITMI-UHFFFAOYSA-N,diazoxide,Launched,potassium channel activator,ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3,endocrinology,hypoglycemia
NCC1CCC(N)C(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)O1,"InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2",JJCQSGDBDPYCEO-UHFFFAOYSA-N,dibekacin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,"InChI=1S/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3",QPGGEKPRGVJKQB-UHFFFAOYSA-N,dibenzepine,Preclinical,norepinephrine reputake inhibitor,,,
c1ccc2c(c1)sc1ccccc12,InChI=1S/C12H8S/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11/h1-8H,IYYZUPMFVPLQIF-UHFFFAOYSA-N,dibenzothiophene,Preclinical,,,,
CCCCOC(=O)c1ccccc1C(=O)OCCCC,"InChI=1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3",DOIRQSBPFJWKBE-UHFFFAOYSA-N,dibutyl-phthalate,Preclinical,,TRPA1,,
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(Cl)CC21C,"InChI=1S/C23H28Cl2O5/c1-13(26)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(27)6-8-20(14,2)23(17,25)18(24)11-21(16,22)3/h4,6,8,16-18,29H,5,7,9-12H2,1-3H3",MVHXUCZGVIIWIV-UHFFFAOYSA-N,dichlorisone-acetate,Phase 2,,,,
O=C(O)C(Cl)Cl,"InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)",JXTHNDFMNIQAHM-UHFFFAOYSA-N,dichloroacetate,Phase 3,pyruvate dehydrogenase kinase inhibitor,,,
Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O,"InChI=1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2",MDNWOSOZYLHTCG-UHFFFAOYSA-N,dichlorophen,Launched,anticestodal agent,,infectious disease,hookworm|tapeworm
COP(=O)(OC)OC=C(Cl)Cl,"InChI=1S/C4H7Cl2O4P/c1-8-11(7,9-2)10-3-4(5)6/h3H,1-2H3",OEBRKCOSUFCWJD-UHFFFAOYSA-N,dichlorvos,Launched,acetylcholinesterase inhibitor,,,
N#CC(c1ccc(Cl)cc1)c1c(Cl)cc(-n2ncc(=O)[nH]c2=O)cc1Cl,"InChI=1S/C17H9Cl3N4O2/c18-10-3-1-9(2-4-10)12(7-21)16-13(19)5-11(6-14(16)20)24-17(26)23-15(25)8-22-24/h1-6,8,12H,(H,23,25,26)",ZSZFUDFOPOMEET-UHFFFAOYSA-N,diclazuril,Launched,antiprotozoal agent,,infectious disease,equine protozoal myeloencephalitis (EPM)
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,"InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)",DCOPUUMXTXDBNB-UHFFFAOYSA-N,diclofenac,Launched,cyclooxygenase inhibitor,AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A,rheumatology|neurology/psychiatry,rheumatoid arthritis|osteoarthritis|migraine headache
NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,"InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)",GJQPMPFPNINLKP-UHFFFAOYSA-N,diclofenamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA4|CA7,ophthalmology|neurology/psychiatry,glaucoma|epilepsy
COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1,"InChI=1S/C17H17Cl2NO/c1-20-9-12-7-13(21-2)4-5-14(12)15(10-20)11-3-6-16(18)17(19)8-11/h3-8,15H,9-10H2,1-2H3",ZJDCGVDEEHWEIG-UHFFFAOYSA-N,diclofensine,Phase 3,dopamine reuptake inhibitor,DRD1|MAOA|MAOB,,
O=C(NC(O)C(Cl)(Cl)Cl)NC(O)C(Cl)(Cl)Cl,"InChI=1S/C5H6Cl6N2O3/c6-4(7,8)1(14)12-3(16)13-2(15)5(9,10)11/h1-2,14-15H,(H2,12,13,16)",PPJXIHLNYDVTDI-UHFFFAOYSA-N,dicloralurea,Preclinical,,,,
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)",YFAGHNZHGGCZAX-UHFFFAOYSA-N,dicloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
O=c1c(Cc2c(O)oc3ccccc3c2=O)c(O)oc2ccccc12,"InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,22-23H,9H2",KSKRYQVHJQRUNC-UHFFFAOYSA-N,dicoumarol,Launched,NADPH inhibitor,CRYZ|NQO1|VKORC1,hematology,deep vein thrombosis (DVT)
C1CCC(NC2CCCCC2)CC1,"InChI=1S/C12H23N/c1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h11-13H,1-10H2",XBPCUCUWBYBCDP-UHFFFAOYSA-N,dicyclohexylamine,Preclinical,,,,
CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,"InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3",CURUTKGFNZGFSE-UHFFFAOYSA-N,dicycloverine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,irritable bowel syndrome
O=c1[nH]cnc2c1ncn2C1CCC(CO)O1,"InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)",BXZVVICBKDXVGW-UHFFFAOYSA-N,didanosine,Launched,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1)
N=c1[nH]cnc2c1ncn2C1CCC(CO)O1,"InChI=1S/C10H13N5O2/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(3-16)17-7/h4-7,16H,1-3H2,(H2,11,12,13)",WVXRAFOPTSTNLL-UHFFFAOYSA-N,dideoxyadenosine,Phase 1,nucleoside reverse transcriptase inhibitor,,,
ON=C(O)c1ccc(O)c(O)c1,"InChI=1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)",QJMCKEPOKRERLN-UHFFFAOYSA-N,didox,Launched,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer
CC=C(C(=CC)c1ccc(O)cc1)c1ccc(O)cc1,"InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3",NFDFQCUYFHCNBW-UHFFFAOYSA-N,dienestrol,Launched,estrogen receptor agonist,ESR1,endocrinology,menopause
CC12CC=C3C4=C(CCC3C1CCC2(O)CC#N)CC(=O)CC4,"InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h6,17-18,23H,2-5,7-10,12H2,1H3",WUQMVSOZWZOUJR-UHFFFAOYSA-N,dienogest,Launched,progesterone receptor agonist,PGR,endocrinology|obstetrics/gynecology,contraceptive|endometriosis
CCN(CC)C(=O)N1CCN(C)CC1,"InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3",RCKMWOKWVGPNJF-UHFFFAOYSA-N,diethylcarbamazine,Launched,lipoxygenase inhibitor,ALOX5|PTGS1,infectious disease,filariasis
CC=C(c1ccc(O)cc1)C(CC)c1ccc(O)cc1,"InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3,5-12,18-20H,4H2,1-2H3",CEHDRGBLVBQUPH-UHFFFAOYSA-N,diethylstilbestrol,Withdrawn,estrogen receptor agonist,ESR1|ESR2|ESRRB|ESRRG,,
CCN(CC)C(=O)c1cccc(C)c1,"InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3",MMOXZBCLCQITDF-UHFFFAOYSA-N,diethyltoluamide,Launched,ionotropic receptor IR40a activator,,dermatology,sunscreen lotion
O=C(Cc1ccc(-c2ccccc2)cc1)N=c1cccc[nH]1,"InChI=1S/C19H16N2O/c22-19(21-18-8-4-5-13-20-18)14-15-9-11-17(12-10-15)16-6-2-1-3-7-16/h1-13H,14H2,(H,20,21,22)",PWHROYKAGRUWDQ-UHFFFAOYSA-N,difenpiramide,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
O=C(Cc1ccc(-c2ccccc2)cc1)N=c1cccc[nH]1,"InChI=1S/C19H16N2O/c22-19(21-18-8-4-5-13-20-18)14-15-9-11-17(12-10-15)16-6-2-1-3-7-16/h1-13H,14H2,(H,20,21,22)",PWHROYKAGRUWDQ-UHFFFAOYSA-N,difenpiramide,Launched,prostaglandin inhibitor,,neurology/psychiatry,pain relief
CC(=O)OCC(=O)C1(OC(C)=O)C(C)CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C26H32F2O7/c1-13-8-17-18-10-20(27)19-9-16(31)6-7-23(19,4)25(18,28)21(32)11-24(17,5)26(13,35-15(3)30)22(33)12-34-14(2)29/h6-7,13,17-18,21,32H,8-12H2,1-5H3",PZKVKZCJORWNJM-UHFFFAOYSA-N,diflorasone-diacetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,"InChI=1S/C21H19F2N3O3/c1-24-6-8-25(9-7-24)19-11-18-15(10-17(19)23)20(27)16(21(28)29)12-26(18)14-4-2-13(22)3-5-14/h2-5,10-12H,6-9H2,1H3,(H,28,29)",NOCJXYPHIIZEHN-UHFFFAOYSA-N,difloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,skin infections|urinary tract infections
O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,"InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)",HUPFGZXOMWLGNK-UHFFFAOYSA-N,diflunisal,Launched,prostanoid receptor antagonist,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
CCCC(=O)OC1(C(=O)COC(C)=O)CCC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,17-18,21,32H,5-6,8,10-14H2,1-4H3",NMGOGMOURXLOOY-UHFFFAOYSA-N,difluprednate,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis
O=C1c2ccccc2CN2C(=O)c3ccccc3CN12,"InChI=1S/C16H12N2O2/c19-15-13-7-3-1-5-11(13)9-17-16(20)14-8-4-2-6-12(14)10-18(15)17/h1-8H,9-10H2",CXSJGNHRBWJXEA-UHFFFAOYSA-N,diftalone,Launched,cyclooxygenase inhibitor,,endocrinology,thyroiditis
CC12CCC(O)CC1CCC1C2CCC2(C)C(c3coc(O)c3)CCC12O,"InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,13,15-19,24-26H,3-10,12H2,1-2H3",VIODKXLQVXBZPE-UHFFFAOYSA-N,digitoxigenin,Preclinical,ATPase inhibitor,ATP1A1,,
CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC5(C)C(c7coc(O)c7)CCC65O)C4)OC3C)OC2C)CC(O)C1O,"InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,19-22,24-31,33-38,42-47H,6-13,15-18H2,1-5H3",KFSMYZHQQKRKMN-UHFFFAOYSA-N,digitoxin,Launched,ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia
CC12CCC(O)CC1CCC1C2CC(O)C2(C)C(c3coc(O)c3)CCC12O,"InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,12,14-19,24-27H,3-8,10-11H2,1-2H3",QWANRZGATYQPEL-UHFFFAOYSA-N,digoxigenin,Preclinical,steroid,,,
CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(c7coc(O)c7)CCC65O)C4)OC3C)OC2C)CC(O)C1O,"InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,18-21,23-31,33-38,42-48H,6-11,13-17H2,1-5H3",IJJIUSOIKBRXAK-UHFFFAOYSA-N,digoxin,Launched,ATPase inhibitor,ATP1A1,cardiology,congestive heart failure|atrial fibrillation (AF)
CCCCCC=CCC=CCC=CCCCCCCC(=O)O,"InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)",HOBAELRKJCKHQD-UHFFFAOYSA-N,dihomo-gamma-linolenic-acid,Phase 2,prostanoid receptor agonist,PTGS1|PTGS2,,
Oc1cc2c(cc1O)C1c3ccccc3CNC1CC2,"InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2",BGOQGUHWXBGXJW-UHFFFAOYSA-N,dihydrexidine,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|DRD5,,
CC1CCC2C(C)C(O)OC3OC4(C)CCC1C32OO4,"InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3",BJDCWCLMFKKGEE-UHFFFAOYSA-N,dihydroartemisinin,Launched,antimalarial agent,,infectious disease,malaria
CC(C)C1(NC(=O)C2CC3c4cccc5[nH]cc(c45)CC3N(C)C2)OC2(O)C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O,"InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)",DEQITUUQPICUMR-UHFFFAOYSA-N,dihydroergocristine,Launched,adrenergic receptor antagonist,ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7,neurology/psychiatry,senile dementia|cerebrovascular insufficiency
CC(C)C1(NC(=O)C2CC3c4cccc5[nH]cc(c45)CC3N(C)C2)OC2(O)C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O,"InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)",DEQITUUQPICUMR-UHFFFAOYSA-N,dihydroergocristine,Launched,prolactin inhibitor,ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7,neurology/psychiatry,senile dementia|cerebrovascular insufficiency
CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)CC2c3cccc4[nH]cc(c34)CC21,"InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)",LUZRJRNZXALNLM-UHFFFAOYSA-N,dihydroergotamine,Launched,serotonin receptor agonist,ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache
O=C1C(O)c2c(O)cc(O)cc2OC1c1cc(O)c(O)c(O)c1,"InChI=1S/C15H12O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,13,15-21H",AWMNMVKFFWMAAM-UHFFFAOYSA-N,dihydromyricetin,Preclinical,,,,
CNC1C(OC2C(OC3C(O)C(O)C(N=C(N)N)C(O)C3N=C(N)N)OC(C)C2(O)CO)OC(CO)C(O)C1O,"InChI=1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)",ASXBYYWOLISCLQ-UHFFFAOYSA-N,dihydrostreptomycin,Withdrawn,bacterial 30S ribosomal subunit inhibitor,,,
CC1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)C,"InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3",ILYCWAKSDCYMBB-UHFFFAOYSA-N,dihydrotachysterol,Launched,vitamin analog,VDR,orthopedics|endocrinology,rickets|hypocalcemia|osteomalacia
O=C(CO)CO,"InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2",RXKJFZQQPQGTFL-UHFFFAOYSA-N,dihydroxyacetone,Launched,,,dermatology,skin protectant
NC(C(=O)O)c1cc(O)cc(O)c1,"InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)",HOOWCUZPEFNHDT-UHFFFAOYSA-N,dihydroxyphenylglycine,Preclinical,glutamate receptor agonist,GRM1|GRM5,,
O=C(O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1,"InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)",WONYMNWUJVKVII-UHFFFAOYSA-N,diiodothyropropionic-acid,Phase 2,thyroid hormone stimulant,,,
COc1cc(C(=O)OCCCN2CCCN(CCCOC(=O)c3cc(OC)c(OC)c(OC)c3)CC2)cc(OC)c1OC,"InChI=1S/C31H44N2O10/c1-36-24-18-22(19-25(37-2)28(24)40-5)30(34)42-16-8-12-32-10-7-11-33(15-14-32)13-9-17-43-31(35)23-20-26(38-3)29(41-6)27(21-23)39-4/h18-21H,7-17H2,1-6H3",QVZCXCJXTMIDME-UHFFFAOYSA-N,dilazep,Launched,adenosine reuptake inhibitor,SLC29A1,cardiology,coronary heart disease
Cc1cc(F)ccc1-c1[nH]c(=NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F,"InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)",ORVNHOYNEHYKJG-UHFFFAOYSA-N,dilmapimod,Phase 1,p38 MAPK inhibitor,,,
CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,"InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3",BDYYDXJSHYEDGB-UHFFFAOYSA-N,diloxanide,Launched,protein synthesis inhibitor,,infectious disease,amebiasis
COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1,"InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3",HSUGRBWQSSZJOP-UHFFFAOYSA-N,diltiazem,Launched,calcium channel blocker,CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5,cardiology,hypertension|angina pectoris
COC(=O)c1ccc(C(c2c[nH]c3ccccc23)c2c[nH]c3ccccc23)cc1,"InChI=1S/C25H20N2O2/c1-29-25(28)17-12-10-16(11-13-17)24(20-14-26-22-8-4-2-6-18(20)22)21-15-27-23-9-5-3-7-19(21)23/h2-15,24,26-27H,1H3",BBAOKSZCULLDIW-UHFFFAOYSA-N,dim-c-pphco2me,Preclinical,nuclear receptor antagonist,,,
CN(C)CCCSC(=N)N,"InChI=1S/C6H15N3S/c1-9(2)4-3-5-10-6(7)8/h3-5H2,1-2H3,(H3,7,8)",OLHQOJYVQUNWPL-UHFFFAOYSA-N,dimaprit,Preclinical,histamine receptor agonist,HRH2|HRH3|HRH4,,
Cc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3,"InChI=1S/C18H25N/c1-13-6-7-14-12-17-15-5-3-4-8-18(15,16(14)11-13)9-10-19(17)2/h6-7,11,15,17H,3-5,8-10,12H2,1-2H3",KBEZZLAAKIIPFK-UHFFFAOYSA-N,dimemorfan,Launched,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant
CN(C)CCOC(c1ccccc1)c1ccccc1,"InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3",ZZVUWRFHKOJYTH-UHFFFAOYSA-N,dimenhydrinate,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|gastroenterology,motion sickness|nausea|vomiting
OCC(S)CS,"InChI=1S/C3H8OS2/c4-1-3(6)2-5/h3-6H,1-2H2",WQABCVAJNWAXTE-UHFFFAOYSA-N,dimercaprol,Launched,chelating agent,,neurology/psychiatry,metal toxicity
O=C(O)C(S)C(S)C(=O)O,"InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)",ACTRVOBWPAIOHC-UHFFFAOYSA-N,dimercaptosuccinic-acid,Launched,chelating agent,DNMT1,neurology/psychiatry,metal toxicity
O=S(=O)(O)CCSSCCS(=O)(=O)O,"InChI=1S/C4H10O6S4/c5-13(6,7)3-1-11-12-2-4-14(8,9)10/h1-4H2,(H,5,6,7)(H,8,9,10)",BYUKOOOZTSTOOH-UHFFFAOYSA-N,dimesna,Phase 3,tubulin polymerization inhibitor,,,
CC1(C)OC(=O)NC1=O,"InChI=1S/C5H7NO3/c1-5(2)3(7)6-4(8)9-5/h1-2H3,(H,6,7,8)",JYJFNDQBESEHJQ-UHFFFAOYSA-N,dimethadione,Preclinical,oxazolidine antiepileptic,,,
C[Si](C)(C)O[Si](C)(C)C,"InChI=1S/C6H18OSi2/c1-8(2,3)7-9(4,5)6/h1-6H3",UQEAIHBTYFGYIE-UHFFFAOYSA-N,dimethicone,Launched,,,dermatology,cosmetic
CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,"InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3",MVMQESMQSYOVGV-UHFFFAOYSA-N,dimethindene-(s)-(+),Preclinical,acetylcholine receptor antagonist,HRH1,,
CCCCc1cc2ccccc2c(OCCN(C)C)n1,"InChI=1S/C17H24N2O/c1-4-5-9-15-13-14-8-6-7-10-16(14)17(18-15)20-12-11-19(2)3/h6-8,10,13H,4-5,9,11-12H2,1-3H3",XNMYNYSCEJBRPZ-UHFFFAOYSA-N,dimethisoquin,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
COC(=O)C=CC(=O)OC,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3",LDCRTTXIJACKKU-UHFFFAOYSA-N,dimethyl-fumarate,Launched,nuclear factor erythroid derived,KEAP1,neurology/psychiatry,multiple sclerosis
COC(=O)C=CC(=O)OC,"InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3",LDCRTTXIJACKKU-UHFFFAOYSA-N,dimethyl-fumarate,Launched,like (NRF2) activator,KEAP1,neurology/psychiatry,multiple sclerosis
COC1COC2C(OC)COC12,"InChI=1S/C8H14O4/c1-9-5-3-11-8-6(10-2)4-12-7(5)8/h5-8H,3-4H2,1-2H3",MEJYDZQQVZJMPP-UHFFFAOYSA-N,dimethyl-isosorbide,Preclinical,cosmetic moisturizer,,,
CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,"InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3",MVMQESMQSYOVGV-UHFFFAOYSA-N,dimetindene,Launched,cholinergic receptor antagonist,HRH1,allergy,allergic rhinitis
CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,"InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3",MVMQESMQSYOVGV-UHFFFAOYSA-N,dimetindene,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
Cc1ncc([N+](=O)[O-])n1C,"InChI=1S/C5H7N3O2/c1-4-6-3-5(7(4)2)8(9)10/h3H,1-2H3",IBXPYPUJPLLOIN-UHFFFAOYSA-N,dimetridazole,Launched,bacterial DNA inhibitor,,infectious disease,protozoan infection
N=C(N)c1ccc(N=NNc2ccc(C(=N)N)cc2)cc1,"InChI=1S/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)",XNYZHCFCZNMTFY-UHFFFAOYSA-N,diminazene-aceturate,Phase 3,angiotensin converting enzyme activator,AOC1|PRDX5|PRSS1,,
CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,"InChI=1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3",FHIVAFMUCKRCQO-UHFFFAOYSA-N,dimpylate,Launched,acetylcholinesterase inhibitor,ACHE,infectious disease,flea control
CCc1c[nH]n2c(=NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12,"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,23,28H,2-4,7-8,10-11,13H2,1H3",MWOYBUQZKNAXAU-UHFFFAOYSA-N,dinaciclib,Phase 3,CDK inhibitor,CDK1|CDK2|CDK5|CDK9,,
Cc1c(C(N)=O)cc([N+](=O)[O-])cc1[N+](=O)[O-],"InChI=1S/C8H7N3O5/c1-4-6(8(9)12)2-5(10(13)14)3-7(4)11(15)16/h2-3H,1H3,(H2,9,12)",ZEFNOZRLAWVAQF-UHFFFAOYSA-N,dinitolmide,Launched,,,infectious disease,coccidiosis
CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(=O)O,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)",PXGPLTODNUVGFL-UHFFFAOYSA-N,dinoprost,Launched,prostacyclin analog,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,obstetrics/gynecology,labor induction
CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(=O)O,"InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)",XEYBRNLFEZDVAW-UHFFFAOYSA-N,dinoprostone,Withdrawn,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,,
CC1CCC2(OC1)OC1CC3C4CC=C5CC(OC6OC(CO)C(OC7OC(C)C(O)C(O)C7O)C(O)C6OC6OC(C)C(O)C(O)C6O)CCC5(C)C4CCC3(C)C1C2C,"InChI=1S/C45H72O16/c1-19-9-14-45(54-18-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(52)34(50)32(48)22(4)56-41)37(53)38(29(17-46)58-42)59-40-35(51)33(49)31(47)21(3)55-40/h7,19-22,24-42,46-53H,8-18H2,1-6H3",VNONINPVFQTJOC-UHFFFAOYSA-N,dioscin,Preclinical,apoptosis stimulant,CXCR3,,
CC1CCC2(OC1)OC1CC3C4CC=C5CC(O)CCC5(C)C4CCC3(C)C1C2C,"InChI=1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3",WQLVFSAGQJTQCK-UHFFFAOYSA-N,diosgenin,Preclinical,steroid,,,
COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,"InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3",MBNGWHIJMBWFHU-UHFFFAOYSA-N,diosmetin,Launched,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic
COc1ccc(-c2cc(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3o2)cc1O,"InChI=1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3",GZSOSUNBTXMUFQ-UHFFFAOYSA-N,diosmin,Launched,aryl hydrocarbon receptor agonist,AHR,cardiology|hematology|dermatology,chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome
COc1ccc(-c2cc(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3o2)cc1O,"InChI=1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3",GZSOSUNBTXMUFQ-UHFFFAOYSA-N,diosmin,Launched,capillary stabilizing agent,AHR,cardiology|hematology|dermatology,chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome
COc1ccc(C(=O)c2ccccc2O)c(O)c1,"InChI=1S/C14H12O4/c1-18-9-6-7-11(13(16)8-9)14(17)10-4-2-3-5-12(10)15/h2-8,15-16H,1H3",MEZZCSHVIGVWFI-UHFFFAOYSA-N,dioxybenzone,Preclinical,topical sunscreen agent,,,
CC(N)C(=O)NC(CCC(N)=O)C(=O)O,"InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)",HJCMDXDYPOUFDY-UHFFFAOYSA-N,dipeptamin,Launched,,,,
O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1,"InChI=1S/C22H27N3O4/c26-21(23-18-10-4-1-5-11-18)28-17-20(16-25-14-8-3-9-15-25)29-22(27)24-19-12-6-2-7-13-19/h1-2,4-7,10-13,20H,3,8-9,14-17H2,(H,23,26)(H,24,27)",YUGZHQHSNYIFLG-UHFFFAOYSA-N,diperodon,Preclinical,local anesthetic,,,
C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C20H24N/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12H,13-16H2,1-2H3/q+1",LCTZPQRFOZKZNK-UHFFFAOYSA-N,diphemanil,Launched,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms
O=c1c(-c2ccccc2)c1-c1ccccc1,InChI=1S/C15H10O/c16-15-13(11-7-3-1-4-8-11)14(15)12-9-5-2-6-10-12/h1-10H,HCIBTBXNLVOFER-UHFFFAOYSA-N,diphencyprone,Phase 2,immunostimulant,,,
CN(C)CCOC(c1ccccc1)c1ccccc1,"InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3",ZZVUWRFHKOJYTH-UHFFFAOYSA-N,diphenhydramine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,headache
OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,"InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2",OGAKLTJNUQRZJU-UHFFFAOYSA-N,diphenidol,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,vertigo
c1ccc2c(c1)[I]c1ccccc1-2,InChI=1S/C12H8I/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11/h1-8H,ZSZPLBNCHKXQRY-UHFFFAOYSA-N,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,
N=C(Nc1ccccc1)Nc1ccccc1,"InChI=1S/C13H13N3/c14-13(15-11-7-3-1-4-8-11)16-12-9-5-2-6-10-12/h1-10H,(H3,14,15,16)",OWRCNXZUPFZXOS-UHFFFAOYSA-N,diphenylguanidine,Preclinical,,,,
CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3",OWQUZNMMYNAXSL-UHFFFAOYSA-N,diphenylpyraline,Launched,dopamine reuptake inhibitor,HRH1|SLC6A3,allergy,allergic rhinitis
CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,"InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3",OCUJLLGVOUDECM-UHFFFAOYSA-N,dipivefrine,Launched,adrenergic receptor agonist,,ophthalmology,glaucoma|intraocular pressure
Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,"InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2",LZXMUJCJAWVHPZ-UHFFFAOYSA-N,dipraglurant,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,
CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,"InChI=1S/C16H24N2/c1-12(2)18(13(3)4)10-9-14-11-17-16-8-6-5-7-15(14)16/h5-8,11-13,17H,9-10H2,1-4H3",ZRVAAGAZUWXRIP-UHFFFAOYSA-N,dipt,Launched,dopamine reuptake inhibitor,HTR1A|HTR2A|HTR2C,,
CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,"InChI=1S/C16H24N2/c1-12(2)18(13(3)4)10-9-14-11-17-16-8-6-5-7-15(14)16/h5-8,11-13,17H,9-10H2,1-4H3",ZRVAAGAZUWXRIP-UHFFFAOYSA-N,dipt,Launched,serotonin reuptake inhibitor,HTR1A|HTR2A|HTR2C,,
OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,"InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2",IZEKFCXSFNUWAM-UHFFFAOYSA-N,dipyridamole,Launched,phosphodiesterase inhibitor,ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1,cardiology,coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension
CC(=O)Oc1cccc(C(=O)O)c1OC(C)=O,"InChI=1S/C11H10O6/c1-6(12)16-9-5-3-4-8(11(14)15)10(9)17-7(2)13/h3-5H,1-2H3,(H,14,15)",NYIZXMGNIUSNKL-UHFFFAOYSA-N,dipyrocetyl,Launched,chelating agent,,endocrinology|neurology/psychiatry,fever|pain relief
O=c1ccn(C2OC(CO[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)OCC3OC(n4ccc(=O)[nH]c4=O)C(O)C3O)C(O)C2O)c(=O)[nH]1,"InChI=1S/C18H22N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,19,23,29)(H,20,24,30)",AHTBQAVYNLUCPB-UHFFFAOYSA-N,diquafosol,Phase 3,purinergic receptor activator,,,
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C2NC(COCCOC)OC(C2C)C1(C)O,"InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3",WLOHNSSYAXHWNR-UHFFFAOYSA-N,dirithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis
COC(=O)C=CC(=O)OCCn1c(O)ccc1O,"InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h2-5,13-14H,6-7H2,1H3",ZXGIHWUHYINXLE-UHFFFAOYSA-N,diroximel-fumarate,Phase 3,anti-inflammatory agent,,,
O=C(O)CCCCCCCCC(=O)O,"InChI=1S/C10H18O4/c11-9(12)7-5-3-1-2-4-6-8-10(13)14/h1-8H2,(H,11,12)(H,13,14)",CXMXRPHRNRROMY-UHFFFAOYSA-N,disodium-sebacate,Phase 1,,HBB,,
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,"InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)",UVTNFZQICZKOEM-UHFFFAOYSA-N,disopyramide,Launched,sodium channel blocker,CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A,cardiology,ventricular tachycardia (VT)|ventricular arrhythmias
CCN(CC)C(=S)SSC(=S)N(CC)CC,"InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",AUZONCFQVSMFAP-UHFFFAOYSA-N,disulfiram,Launched,aldehyde dehydrogenase inhibitor,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol
CCN(CC)C(=S)SSC(=S)N(CC)CC,"InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",AUZONCFQVSMFAP-UHFFFAOYSA-N,disulfiram,Launched,DNA methyltransferase inhibitor,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol
CCN(CC)C(=S)SSC(=S)N(CC)CC,"InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",AUZONCFQVSMFAP-UHFFFAOYSA-N,disulfiram,Launched,TRPV agonist,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol
Oc1cccc2cc3cccc(O)c3c(O)c12,"InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-7,15-17H",YUTJCNNFTOIOGT-UHFFFAOYSA-N,dithranol,Launched,DNA synthesis inhibitor,,dermatology,psoriasis
CCN(CC)C(=S)S,"InChI=1S/C5H11NS2/c1-3-6(4-2)5(7)8/h3-4H2,1-2H3,(H,7,8)",LMBWSYZSUOEYSN-UHFFFAOYSA-N,ditiocarb-sodium-trihydrate,Phase 3,immunostimulant,CA1|CA2|CA4,,
Cc1ccccc1N=C(N)Nc1ccccc1C,"InChI=1S/C15H17N3/c1-11-7-3-5-9-13(11)17-15(16)18-14-10-6-4-8-12(14)2/h3-10H,1-2H3,(H3,16,17,18)",OPNUROKCUBTKLF-UHFFFAOYSA-N,ditolylguanidine,Preclinical,sigma receptor agonist,GRIN1|GRIN2A|GRIN2B|SIGMAR1,,
CCOC(=S)SSC(=S)OCC,"InChI=1S/C6H10O2S4/c1-3-7-5(9)11-12-6(10)8-4-2/h3-4H2,1-2H3",FVIGODVHAVLZOO-UHFFFAOYSA-N,dixanthogen,Preclinical,,,,
CC(CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc21,"InChI=1S/C24H33N3O2S/c1-20(18-26-12-10-25(11-13-26)14-16-29-17-15-28)19-27-21-6-2-4-8-23(21)30-24-9-5-3-7-22(24)27/h2-9,20,28H,10-19H2,1H3",MSYUMPGNGDNTIQ-UHFFFAOYSA-N,dixyrazine,Preclinical,antipsychotic,,,
CC12NC(Cc3ccccc31)c1ccccc12,"InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3",LBOJYSIDWZQNJS-UHFFFAOYSA-N,dizocilpine-(-),Phase 1,glutamate receptor antagonist,,,
CC12NC(Cc3ccccc31)c1ccccc12,"InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3",LBOJYSIDWZQNJS-UHFFFAOYSA-N,dizocilpine-(+),Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CN(C)c1ccc(C=C2CCCN=C2c2cccnc2)cc1,"InChI=1S/C19H21N3/c1-22(2)18-9-7-15(8-10-18)13-16-5-4-12-21-19(16)17-6-3-11-20-14-17/h3,6-11,13-14H,4-5,12H2,1-2H3",KHUUTHZSRXABAC-UHFFFAOYSA-N,dmab-anabaseine,Preclinical,adrenergic receptor agonist,CHRNA7,,
COc1cccc(C=NN=Cc2cccc(OC)c2)c1,"InChI=1S/C16H16N2O2/c1-19-15-7-3-5-13(9-15)11-17-18-12-14-6-4-8-16(10-14)20-2/h3-12H,1-2H3",FBNPHFBYHYNMHC-UHFFFAOYSA-N,dmeob,Preclinical,glutamate receptor modulator,GRM5,,
CC(C)Oc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1,"InChI=1S/C24H20N4O/c1-16(2)29-19-9-7-17(8-10-19)18-13-26-24-22(14-27-28(24)15-18)20-11-12-25-23-6-4-3-5-21(20)23/h3-16H,1-2H3",JMIFGARJSWXZSH-UHFFFAOYSA-N,dmh1,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1,,
c1ccc(-c2cnn3cc(-c4ccc(OCCN5CCOCC5)cc4)cnc23)cc1,"InChI=1S/C24H24N4O2/c1-2-4-20(5-3-1)23-17-26-28-18-21(16-25-24(23)28)19-6-8-22(9-7-19)30-15-12-27-10-13-29-14-11-27/h1-9,16-18H,10-15H2",SKZQZGSPYYHTQG-UHFFFAOYSA-N,dmh4,Preclinical,VEGFR inhibitor,KDR,,
COc1cc(C=O)c([N+](=O)[O-])cc1OC,"InChI=1S/C9H9NO5/c1-14-8-3-6(5-11)7(10(12)13)4-9(8)15-2/h3-5H,1-2H3",YWSPWKXREVSQCA-UHFFFAOYSA-N,dmnb,Preclinical,DNA dependent protein kinase inhibitor,,,
O=C1c2ccccc2C(Cc2ccnc(F)c2)(Cc2ccnc(F)c2)c2ccccc21,"InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2",MUJBUUDUXGDXLW-UHFFFAOYSA-N,dmp-543,Phase 2,acetylcholine release enhancer,,,
CCCC(NC(=O)N1C(=O)C(CC)(CC)C1Oc1ccc(C(=O)N2CCN(C)CC2)cc1)c1ccc2c(c1)OCO2,"InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)",ZSDCIRYNTCVTMF-UHFFFAOYSA-N,dmp-777,Phase 2,elastase inhibitor,MPO,,
O=S(=O)(O)CC(S)CS,"InChI=1S/C3H8O3S3/c4-9(5,6)2-3(8)1-7/h3,7-8H,1-2H2,(H,4,5,6)",JLVSRWOIZZXQAD-UHFFFAOYSA-N,dmps,Phase 1,chelating agent,,,
C[S+](C)[O-],InChI=1S/C2H6OS/c1-4(2)3/h1-2H3,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,dmso,Preclinical,control vehicle,,,
O=c1[nH]c2cc([N+](=O)[O-])c([N+](=O)[O-])cc2[nH]c1=O,"InChI=1S/C8H4N4O6/c13-7-8(14)10-4-2-6(12(17)18)5(11(15)16)1-3(4)9-7/h1-2H,(H,9,13)(H,10,14)",RWVIMCIPOAXUDG-UHFFFAOYSA-N,dnqx,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B,,
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,"InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3",JRWZLRBJNMZMFE-UHFFFAOYSA-N,dobutamine,Launched,adrenergic receptor agonist,ADRB1|ADRB2,cardiology,congestive heart failure
Cc1c(C)c(O)c(C=CCCC#CCCCC#CCO)c(C)c1O,"InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h12,14,22-24H,5,7-10,15H2,1-3H3",YJJCOKZDOWPHHH-UHFFFAOYSA-N,docebenone,Phase 2,lipoxygenase inhibitor,ALOX5,,
CC(=O)OC12COC1CC(O)C1(C)C(=O)C(=O)C3C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)c4ccccc4)CC(O)(C(OC(=O)c4ccccc4)C21)C3(C)C,"InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,22,26-30,32-33,35,46,48,53H,19-21H2,1-8H3,(H,44,52)",ROQZUJKOMJECOM-UHFFFAOYSA-N,docetaxel,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)
CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O,"InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)",MBMBGCFOFBJSGT-UHFFFAOYSA-N,doconexent,Launched,PPAR receptor agonist,FFAR1|PTGS1|PTGS2,,
CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC,"InChI=1S/C24H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26-4-2/h5-6,8-9,11-12,14-15,17-18,20-21H,3-4,7,10,13,16,19,22-23H2,1-2H3",ITNKVODZACVXDS-UHFFFAOYSA-N,doconexent-ethyl-ester,Launched,omega 3 fatty acid stimulant,,endocrinology,hypertriglyceridemia
CCCCCCCCCCCCCCCCCCCCCCO,"InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3",NOPFSRXAKWQILS-UHFFFAOYSA-N,docosanol,Launched,lipase clearing factor inhibitor,TLR7,dental,cold sore
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,"InChI=1S/C20H38O7S/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2/h16-18H,5-15H2,1-4H3,(H,23,24,25)",HNSDLXPSAYFUHK-UHFFFAOYSA-N,docusate,Launched,laxative,,gastroenterology,constipation
CCCCCCCCCCCCOS(=O)(=O)O,"InChI=1S/C12H26O4S/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H,13,14,15)",MOTZDAYCYVMXPC-UHFFFAOYSA-N,dodecyl-sulfate,Preclinical,,LYZ,,
O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2cccc3ncccc23)CC1,"InChI=1S/C30H31N3O3/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24/h1-16,25,29,34H,17-22H2",KLWUUPVJTLHYIM-UHFFFAOYSA-N,dofequidar,Phase 3,MRP inhibitor,ABCB1,,
O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2cccc3ncccc23)CC1,"InChI=1S/C30H31N3O3/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24/h1-16,25,29,34H,17-22H2",KLWUUPVJTLHYIM-UHFFFAOYSA-N,dofequidar,Phase 3,P glycoprotein inhibitor,ABCB1,,
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,"InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3",IXTMWRCNAAVVAI-UHFFFAOYSA-N,dofetilide,Withdrawn,potassium channel blocker,KCNH1|KCNH2|KCNJ12|KCNK2,,
O=C(OC1CC2CC3CC(C1)N2CC3=O)c1c[nH]c2ccccc12,"InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2",UKTAZPQNNNJVKR-UHFFFAOYSA-N,dolasetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(Cc1ccccc1)c1nccs1)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C,"InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)",OFDNQWIFNXBECV-UHFFFAOYSA-N,dolastatin-10,Phase 2,tubulin polymerization inhibitor,TUBB,,
CC1CCOC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,"InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)",RHWKPHLQXYSBKR-UHFFFAOYSA-N,dolutegravir,Launched,HIV integrase inhibitor,CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1,infectious disease,human immunodeficiency virus (HIV-1)
CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,"InChI=1S/C22H40NO/c1-4-5-6-7-8-9-10-11-12-16-19-23(2,3)20-21-24-22-17-14-13-15-18-22/h13-15,17-18H,4-12,16,19-21H2,1-3H3/q+1",YXUPZGKORWTXID-UHFFFAOYSA-N,domiphen,Preclinical,,,,
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,"InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)",FGXWKSZFVQUSTL-UHFFFAOYSA-N,domperidone,Launched,dopamine receptor antagonist,DRD2|DRD3,infectious disease,fescue toxicosis
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,"InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3",ADEBPBSSDYVVLD-UHFFFAOYSA-N,donepezil,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,Alzheimer's disease
N#Cc1ccc(N2CCN(C(=O)COc3ccc4[nH]cc(CCN)c4c3)CC2)cc1,"InChI=1S/C23H25N5O2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26H,7-12,16,24H2",SOHCKWZVTCTQBG-UHFFFAOYSA-N,donitriptan,Phase 2,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6,,
NCCc1ccc(O)c(O)c1,"InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2",VYFYYTLLBUKUHU-UHFFFAOYSA-N,dopamine,Launched,dopamine receptor agonist,DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4,cardiology|neurology/psychiatry,ventricular arrhythmias|depression|headache|tremors
Cc1ccc(-n2[nH]c(C(C)(C)C)cc2=NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,"InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21,34H,15-20H2,1-4H3,(H,32,37)",ZOCLDDFPKNVTNQ-UHFFFAOYSA-N,doramapimod,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,
COC1CC(OC2C(C)OC(OC3C(C)=CCC4CC(CC5(C=CC(C)C(C6CCCCC6)O5)O4)OC(=O)C4=CC(C)C(O)C5OCC(=CC=CC3C)C45O)CC2OC)OC(C)C1O,"InChI=1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34,47)54)48(53)60-36-22-35(63-49(25-36)20-19-29(3)45(64-49)33-14-10-9-11-15-33)18-17-28(2)44(27)61-41-24-39(56-8)46(32(6)59-41)62-40-23-38(55-7)43(52)31(5)58-40/h12-13,16-17,19-21,27,29-33,35-36,38-47,51-52,54H,9-11,14-15,18,22-26H2,1-8H3",VZOJDURAMSCPBY-UHFFFAOYSA-N,doramectin,Launched,,,infectious disease,gastrointestinal roundworms
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,"InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)",ZIAOVIPSKUPPQW-UHFFFAOYSA-N,doravirine,Launched,non-nucleoside reverse transcriptase inhibitor,,,
CC(O)C1C(=O)N2C(C(=O)O)=C(SC3CNC(CNS(N)(=O)=O)C3)C(C)C12,"InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)",AVAACINZEOAHHE-UHFFFAOYSA-N,doripenem,Launched,bacterial cell wall synthesis inhibitor,DPEP1,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis
c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1,"InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2",XHBVYDAKJHETMP-UHFFFAOYSA-N,dorsomorphin,Preclinical,AMPK inhibitor,ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC,,
CCNC1CC(C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,"InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)",IAVUPMFITXYVAF-UHFFFAOYSA-N,dorzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,intraocular pressure|glaucoma
CN(C)CCC=C1c2ccccc2CSc2ccccc21,"InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",PHTUQLWOUWZIMZ-UHFFFAOYSA-N,dosulepin,Launched,norepinephrine reuptake inhibitor,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(C)CCC=C1c2ccccc2CSc2ccccc21,"InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",PHTUQLWOUWZIMZ-UHFFFAOYSA-N,dosulepin,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(C)CCC=C1c2ccccc2CSc2ccccc21,"InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",PHTUQLWOUWZIMZ-UHFFFAOYSA-N,dosulepin,Launched,tricyclic antidepressant,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression
O=[PH](=O)(O)CN1CCN(C[PH](=O)(=O)O)CCN(C[PH](=O)(=O)O)CCN(C[PH](=O)(=O)O)CC1,"InChI=1S/C12H28N4O12P4/c17-29(18,19)9-13-1-2-14(10-30(20,21)22)5-6-16(12-32(26,27)28)8-7-15(4-3-13)11-31(23,24)25/h1-12H2,(H,17,18,19)(H,20,21,22)(H,23,24,25)(H,26,27,28)",CGTVJRMVKTWXMH-UHFFFAOYSA-N,dotmp,Preclinical,,,,
CN1CCN(c2ccc3[nH]c(-c4c(N)c5c(F)cccc5[nH]c4=O)nc3c2)CC1,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,Phase 3,EGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CN1CCN(c2ccc3[nH]c(-c4c(N)c5c(F)cccc5[nH]c4=O)nc3c2)CC1,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,Phase 3,FGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CN1CCN(c2ccc3[nH]c(-c4c(N)c5c(F)cccc5[nH]c4=O)nc3c2)CC1,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,Phase 3,FLT3 inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CN1CCN(c2ccc3[nH]c(-c4c(N)c5c(F)cccc5[nH]c4=O)nc3c2)CC1,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CN1CCN(c2ccc3[nH]c(-c4c(N)c5c(F)cccc5[nH]c4=O)nc3c2)CC1,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,dovitinib,Phase 3,VEGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,
CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,"InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3",XFDJYSQDBULQSI-UHFFFAOYSA-N,doxapram,Launched,potassium channel blocker,,pulmonary|neurology/psychiatry,respiratory depression|central nervous system depression|acute hypercapnia (AHC)
COc1cc2[nH]c(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(=N)c2cc1OC,"InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)",RUZYUOTYCVRMRZ-UHFFFAOYSA-N,doxazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
CN(C)CCC=C1c2ccccc2COc2ccccc21,"InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",ODQWQRRAPPTVAG-UHFFFAOYSA-N,doxepin,Launched,histamine receptor antagonist,HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression|anxiety
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC(C)C(C)C)CC(O)CC1O,"InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3",HKXBNHCUPKIYDM-UHFFFAOYSA-N,doxercalciferol,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperparathyroidism
CC1OC(n2cc(F)c(=O)[nH]c2=O)C(O)C1O,"InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)",ZWAOHEXOSAUJHY-UHFFFAOYSA-N,doxifluridine,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O,"InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3",HWXIGFIVGWUZAO-UHFFFAOYSA-N,doxofylline,Launched,adenosine receptor antagonist,ADORA1|PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,asthma
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(O)C(C)O1)CC(O)(C(=O)CO)C=4,"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,7,10,13,17,22,29,31-36H,6,8-9,28H2,1-2H3",OEMKXOUYUCIRSC-UHFFFAOYSA-N,doxorubicin,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy|oncology,acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma
CC1c2cccc(O)c2C(=O)C2C(=O)C3(O)C(=O)C(C(N)=O)C(=O)C(N(C)C)C3C(O)C21,"InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,12-15,17,25,27,32H,1-3H3,(H2,23,31)",VXVNYCRICCVPTD-UHFFFAOYSA-N,doxycycline,Launched,bacterial 30S ribosomal subunit inhibitor,MMP8,dental,periodontitis
CC1c2cccc(O)c2C(=O)C2C(=O)C3(O)C(=O)C(C(N)=O)C(=O)C(N(C)C)C3C(O)C21,"InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,12-15,17,25,27,32H,1-3H3,(H2,23,31)",VXVNYCRICCVPTD-UHFFFAOYSA-N,doxycycline,Launched,metalloproteinase inhibitor,MMP8,dental,periodontitis
CN(C)CCOC(C)(c1ccccc1)c1ccccn1,"InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3",HCFDWZZGGLSKEP-UHFFFAOYSA-N,doxylamine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,sedative
CN(C(=S)NN=C(c1ccccn1)c1ccccn1)C1CCCCC1,"InChI=1S/C19H23N5S/c1-24(15-9-3-2-4-10-15)19(25)23-22-18(16-11-5-7-13-20-16)17-12-6-8-14-21-17/h5-8,11-15H,2-4,9-10H2,1H3,(H,23,25)",GNLZNQJBZNOUBM-UHFFFAOYSA-N,dpc,Phase 1,,,,
CC(C)CN(CC(O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1,"InChI=1S/C35H48FN5O5S/c1-24(2)22-41(47(45,46)29-16-10-15-28(37)19-29)23-31(42)30(18-25-11-7-6-8-12-25)39-34(44)33(35(3,4)5)40-32(43)21-38-20-26-13-9-14-27(36)17-26/h6-17,19,24,30-31,33,38,42H,18,20-23,37H2,1-5H3,(H,39,44)(H,40,43)",PNIFFZXGBAYVMQ-UHFFFAOYSA-N,dpc-681,Phase 1,HIV protease inhibitor,,,
CCCn1c(=O)c2[nH]c(C3CCCC3)nc2n(CCC)c1=O,"InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)",FFBDFADSZUINTG-UHFFFAOYSA-N,dpcpx,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
N#Cc1cc2c(OCC(O)CN3CCN(C(c4ccccc4)c4ccccc4)CC3)cccc2[nH]1,"InChI=1S/C29H30N4O2/c30-19-24-18-26-27(31-24)12-7-13-28(26)35-21-25(34)20-32-14-16-33(17-15-32)29(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-13,18,25,29,31,34H,14-17,20-21H2",BYBYHCOEAFHGJL-UHFFFAOYSA-N,dpi-201106,Phase 2,sodium channel activator,ADRB2,,
CC1CCC(C(C)C)C(P(=O)(c2ccccc2)c2ccccc2)C1,"InChI=1S/C22H29OP/c1-17(2)21-15-14-18(3)16-22(21)24(23,19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,17-18,21-22H,14-16H2,1-3H3",BPCNGVCAHAIZEE-UHFFFAOYSA-N,dpo-1,Preclinical,potassium channel blocker,KCNA5,,
CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,"InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3",NFIXBCVWIPOYCD-UHFFFAOYSA-N,dppe,Phase 3,histamine receptor antagonist,ABCB1|HRH1,,
Cc1ccc2[nH]c(=O)c(C3=NN(C(=O)CCC(=O)O)C(c4ccc(Br)cc4)C3)c(-c3ccccc3)c2c1,"InChI=1S/C29H24BrN3O4/c1-17-7-12-22-21(15-17)27(19-5-3-2-4-6-19)28(29(37)31-22)23-16-24(18-8-10-20(30)11-9-18)33(32-23)25(34)13-14-26(35)36/h2-12,15,24H,13-14,16H2,1H3,(H,31,37)(H,35,36)",MVYNQMRZRULRIE-UHFFFAOYSA-N,dqp-1105,Preclinical,glutamate receptor antagonist,GRIN2C|GRIN2D,,
Cc1nc(=O)c2c([nH]1)CCSC2,"InChI=1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)",HRYKZAKEAVZGJD-UHFFFAOYSA-N,dr-2313,Preclinical,PARP inhibitor,PARP1|PARP3,,
O=C1Nc2ccc(Cl)c3c2C1(CCCCN1CC=C(c2ccc(Cl)cc2)CC1)CCC3,"InChI=1S/C26H28Cl2N2O/c27-20-7-5-18(6-8-20)19-11-16-30(17-12-19)15-2-1-13-26-14-3-4-21-22(28)9-10-23(24(21)26)29-25(26)31/h5-11H,1-4,12-17H2,(H,29,31)",SBTRHJHOLCAPFT-UHFFFAOYSA-N,dr-4485,Preclinical,serotonin receptor antagonist,HTR7,,
CCC(CO)N=c1[nH]c(=Nc2cccc(-c3ccccn3)c2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C23H27N7O/c1-4-17(13-31)27-23-28-21(20-22(29-23)30(14-25-20)15(2)3)26-18-9-7-8-16(12-18)19-10-5-6-11-24-19/h5-12,14-15,17,31H,4,13H2,1-3H3,(H2,26,27,28,29)",LWANFAFTTOKZAX-UHFFFAOYSA-N,drf053-(r),Preclinical,CDK inhibitor,CSNK1A1,,
CCN(CC)CCOC(=O)C(c1ccccc1)C1CCCCC1,"InChI=1S/C20H31NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5,7-8,11-12,18-19H,3-4,6,9-10,13-16H2,1-2H3",AGJBLWCLQCKRJP-UHFFFAOYSA-N,drofenine,Launched,,,neurology/psychiatry,spasms
CCC(=C(c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,"InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3",ZQZFYGIXNQKOAV-UHFFFAOYSA-N,droloxifene,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,
CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C,"InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3",NOTIQUSPUUHHEH-UHFFFAOYSA-N,dromostanolone-propionate,Launched,androgen receptor modulator,AR,oncology,breast cancer
CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,"InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3",ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,dronedarone,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A,cardiology,atrial fibrillation (AF)
O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,"InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)",RMEDXOLNCUSCGS-UHFFFAOYSA-N,droperidol,Launched,dopamine receptor antagonist,ADRA1A|DRD2|DRD3|DRD4|HTR2A,gastroenterology,nausea|vomiting
OCC(O)CN1CCN(c2ccccc2)CC1,"InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2",PTVWPYVOOKLBCG-UHFFFAOYSA-N,dropropizine,Launched,antitussive,,pulmonary,cough suppressant
CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,"InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3",METQSPRSQINEEU-UHFFFAOYSA-N,drospirenone,Launched,mineralocorticoid receptor antagonist,AR|NR3C2|PGR,endocrinology,contraceptive
CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc32)cc1OCC,"InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,14-16H,5-8,11-13H2,1-4H3",NCVXEYAKRVJMTQ-UHFFFAOYSA-N,drotaverine,Launched,phosphodiesterase inhibitor,,obstetrics/gynecology,labor induction
CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O,"InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3",OEHFRZLKGRKFAS-UHFFFAOYSA-N,droxicam,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis|osteoarthritis
NC(C(=O)O)C(O)c1ccc(O)c(O)c1,"InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)",QXWYKJLNLSIPIN-UHFFFAOYSA-N,droxidopa,Launched,norepinephrine precursor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH,cardiology|neurology/psychiatry,hypertension|Parkinson's Disease
Cc1cc(Cl)ccc1OCCCC(O)=NO,"InChI=1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)",JHSXDAWGLCZYSM-UHFFFAOYSA-N,droxinostat,Preclinical,HDAC inhibitor,HDAC6|HDAC8,,
O=C(Nc1c(-c2cccs2)nc2ccccn12)c1ccc(Cl)cc1,"InChI=1S/C18H12ClN3OS/c19-13-8-6-12(7-9-13)18(23)21-17-16(14-4-3-11-24-14)20-15-5-1-2-10-22(15)17/h1-11H,(H,21,23)",AZKMWHRDICVYEI-UHFFFAOYSA-N,ds2-(806622),Preclinical,,,,
Cc1cc(=Nc2ccc(S(F)(F)(F)(F)F)cc2)n2[nH]c(C(C)(F)F)nc2n1,"InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7H,1-2H3,(H,22,24,25)",MZZIFDNSYYGDOU-UHFFFAOYSA-N,dsm265,Phase 2,dihydroorotate dehydrogenase inhibitor,,,
CCCCCCCCCCCCCCCCCC(=O)OCC(CO[PH](=O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC,"InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/q+1",FTKAZVHITCHFQB-UHFFFAOYSA-N,dspc,Preclinical,,,,
CCCCN=c1[nH]c(=N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2[nH]1,"InChI=1S/C19H28N8O2/c1-4-5-8-21-18-24-16(20)15-17(25-18)27(19(28)23-15)12-13-6-7-14(22-11-13)29-10-9-26(2)3/h6-7,11H,4-5,8-10,12H2,1-3H3,(H,23,28)(H3,20,21,24,25)",SSZHESNDOMBSRV-UHFFFAOYSA-N,dsr-6434,Preclinical,toll-like receptor agonist,TLR7,,
N=C(N)NCCCC(N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(C=O)C(O)O,"InChI=1S/C15H27N7O8/c16-7(2-1-3-19-15(17)18)12(27)20-5-10(24)21-8(4-11(25)26)13(28)22-9(6-23)14(29)30/h6-9,14,29-30H,1-5,16H2,(H,20,27)(H,21,24)(H,22,28)(H,25,26)(H4,17,18,19)",VJRIJBYNKMFWQP-UHFFFAOYSA-N,du-728,Phase 1,structural glycoprotein antagonist,ITGA2B|ITGB3,,
CNCCC(Oc1cccc2ccccc12)c1cccs1,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3",ZEUITGRIYCTCEM-UHFFFAOYSA-N,duloxetine,Launched,norepinephrine reuptake inhibitor,HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
CNCCC(Oc1cccc2ccccc12)c1cccs1,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3",ZEUITGRIYCTCEM-UHFFFAOYSA-N,duloxetine,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy
CS(=O)(=O)c1ccc(-c2cc(Br)sc2-c2ccc(F)cc2)cc1,"InChI=1S/C17H12BrFO2S2/c1-23(20,21)14-8-4-11(5-9-14)15-10-16(18)22-17(15)12-2-6-13(19)7-3-12/h2-10H,1H3",AJFTZWGGHJXZOB-UHFFFAOYSA-N,dup-697,Phase 1,cyclooxygenase inhibitor,PTGS2,,
CC12C=CC(=O)NC1CCC1C2CCC2(C)C(C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CCC12,"InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)",JWJOTENAMICLJG-UHFFFAOYSA-N,dutasteride,Launched,5 alpha reductase inhibitor,SRD5A1|SRD5A2|SRD5A3,urology,benign prostatic hyperplasia (BPH)
CC(N=c1[nH]cnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,"InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)",SJVQHLPISAIATJ-UHFFFAOYSA-N,duvelisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CCOC(=O)CNC(=O)C1CCCN1C(=O)Cc1ccccc1,"InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)",PJNSMUBMSNAEEN-UHFFFAOYSA-N,dvd-111,Phase 2,,,,
COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1,"InChI=1S/C20H22O4/c1-21-10-4-5-14-6-8-17-16(11-14)13-19(24-17)15-7-9-18(22-2)20(12-15)23-3/h6-9,11-13H,4-5,10H2,1-3H3",CUEPJIGXQLIOIK-UHFFFAOYSA-N,dwk-1339,Preclinical,beta amyloid aggregation inhibitor,,,
CCN(CC)c1ccc(C=NNC(=O)c2ccc(O)cc2)cc1,"InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)",WLKOCYWYAWBGKY-UHFFFAOYSA-N,dy131,Preclinical,estrogen-related receptor agonist,ESRRB|ESRRG,,
CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1,"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3",BZEWSEKUUPWQDQ-UHFFFAOYSA-N,dyclonine,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,local anesthetic
CC(=O)C1CCC2C3=CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,17-19H,6-12H2,1-3H3",CCTOEXCQYMSSED-UHFFFAOYSA-N,dydrogesterone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility
O=C(NN=Cc1ccc(O)c(O)c1)c1cc2ccccc2cc1O,"InChI=1S/C18H14N2O4/c21-15-6-5-11(7-17(15)23)10-19-20-18(24)14-8-12-3-1-2-4-13(12)9-16(14)22/h1-10,21-23H,(H,20,24)",SYNDQCRDGGCQRZ-UHFFFAOYSA-N,dynasore,Preclinical,dynamin inhibitor,DNM1|DNM1L|DNM2,,
CCCCCCCCNC(=O)C(C#N)=Cc1cn(CCCN(C)C)c2ccccc12,"InChI=1S/C25H36N4O/c1-4-5-6-7-8-11-15-27-25(30)21(19-26)18-22-20-29(17-12-16-28(2)3)24-14-10-9-13-23(22)24/h9-10,13-14,18,20H,4-8,11-12,15-17H2,1-3H3,(H,27,30)",MYIMRONQBLZJFI-UHFFFAOYSA-N,dynole-34-2,Preclinical,dynamin inhibitor,DNM1,,
Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,"InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3",KSCFJBIXMNOVSH-UHFFFAOYSA-N,dyphylline,Launched,adenosine receptor antagonist,PDE4A,pulmonary,asthma|bronchitis|emphysema
Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,"InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3",KSCFJBIXMNOVSH-UHFFFAOYSA-N,dyphylline,Launched,phosphodiesterase inhibitor,PDE4A,pulmonary,asthma|bronchitis|emphysema
O=C(CN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc2ccccc2c1,"InChI=1S/C24H22FNO2/c25-22-9-7-18(8-10-22)24(28)19-11-13-26(14-12-19)16-23(27)21-6-5-17-3-1-2-4-20(17)15-21/h1-10,15,19H,11-14,16H2",WPFPDSUMDURRRW-UHFFFAOYSA-N,e-2001,Preclinical,antioxidant,,,
COc1cc(C=C2CCCN(C(C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,"InChI=1S/C25H26FN3O2/c1-17-15-28(16-27-17)23-11-6-19(14-24(23)31-3)13-21-5-4-12-29(25(21)30)18(2)20-7-9-22(26)10-8-20/h6-11,13-16,18H,4-5,12H2,1-3H3",PUOAETJYKQITMO-UHFFFAOYSA-N,e-2012,Phase 1,gamma secretase modulator,APH1A|APH1B|PSENEN,,
Cc1cccc(CCN2CCC(C(=O)c3ccc(NS(C)(=O)=O)cc3)CC2)n1,"InChI=1S/C21H27N3O3S/c1-16-4-3-5-19(22-16)12-15-24-13-10-18(11-14-24)21(25)17-6-8-20(9-7-17)23-28(2,26)27/h3-9,18,23H,10-15H2,1-2H3",SRUISGSHWFJION-UHFFFAOYSA-N,e-4031,Phase 1,potassium channel blocker,KCNH1|KCNH2,,
CC(C)CC(NC(=O)C1OC1C(=O)O)C(=O)NCCCCN=C(N)N,"InChI=1S/C15H27N5O5/c1-8(2)7-9(20-13(22)10-11(25-10)14(23)24)12(21)18-5-3-4-6-19-15(16)17/h8-11H,3-7H2,1-2H3,(H,18,21)(H,20,22)(H,23,24)(H4,16,17,19)",LTLYEAJONXGNFG-UHFFFAOYSA-N,e-64,Preclinical,calpain inhibitor,CTSS,,
CC(C)CC(NC(=O)C1OC1C(=O)O)C(=O)NCCCCN=C(N)N,"InChI=1S/C15H27N5O5/c1-8(2)7-9(20-13(22)10-11(25-10)14(23)24)12(21)18-5-3-4-6-19-15(16)17/h8-11H,3-7H2,1-2H3,(H,18,21)(H,20,22)(H,23,24)(H4,16,17,19)",LTLYEAJONXGNFG-UHFFFAOYSA-N,e-64,Preclinical,cysteine protease inhibitor,CTSS,,
CCCCCCCC=CC(=Cc1c(C)c(O)c(OC)c(OC)c1O)C(=O)O,"InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h11-13,22-23H,5-10H2,1-4H3,(H,24,25)",OJHBQWRSUJOFQB-UHFFFAOYSA-N,e3330,Preclinical,NFkB pathway inhibitor,,,
CC(NC(=O)c1c(C(F)F)nn(C)c1Oc1cccc(C(F)(F)F)c1)c1ccc(C(=O)O)cc1,"InChI=1S/C22H18F5N3O4/c1-11(12-6-8-13(9-7-12)21(32)33)28-19(31)16-17(18(23)24)29-30(2)20(16)34-15-5-3-4-14(10-15)22(25,26)27/h3-11,18H,1-2H3,(H,28,31)(H,32,33)",MKLKAQMPKHNQPR-UHFFFAOYSA-N,e7046,Phase 1,prostanoid receptor antagonist,,,
O=c1[nH]nc2[nH]c(=CN3Cc4ccccc4C3)[nH]c3cccc1c32,"InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7,10,19H,8-9H2,(H,20,21)(H,22,24)",SBPPRRMBDWXAEO-UHFFFAOYSA-N,e7449,Phase 2,PARP inhibitor,PARP1|PARP2|TNKS|TNKS2,,
Cc1ccc(NS(=O)(=O)c2cccc(C#N)c2)c2[nH]cc(C#N)c12,"InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3",LWGUASZLXHYWIV-UHFFFAOYSA-N,e7820,Phase 2,angiogenesis inhibitor,,,
COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(-c2ccccc2)cs1,"InChI=1S/C22H24N2O5S/c1-26-11-10-24(22-23-17(14-30-22)15-8-6-5-7-9-15)21(25)16-12-18(27-2)20(29-4)19(13-16)28-3/h5-9,12-14H,10-11H2,1-4H3",ZUXNHFFVQWADJL-UHFFFAOYSA-N,eact,Preclinical,calcium-activated chloride channel inhibitor,ANO1,,
N=c1[nH]cnc2c1ncn2C1OC(C(=O)N2CCN(CC(=O)Nc3cccc4c3CNC4=O)CC2)C(O)C1O,"InChI=1S/C24H27N9O6/c25-20-16-21(28-10-27-20)33(11-29-16)24-18(36)17(35)19(39-24)23(38)32-6-4-31(5-7-32)9-15(34)30-14-3-1-2-12-13(14)8-26-22(12)37/h1-3,10-11,17-19,24,35-36H,4-9H2,(H,26,37)(H,30,34)(H2,25,27,28)",DDFLFKTXUWPNMV-UHFFFAOYSA-N,eb-47,Preclinical,PARP inhibitor,PARP1,,
CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3",MJJALKDDGIKVBE-UHFFFAOYSA-N,ebastine,Launched,histamine receptor antagonist,CYP3A4|HRH1,allergy,allergic rhinitis|urticaria
CCOC(=O)c1cn(Cc2ccccc2)c(O)c1O,"InChI=1S/C14H15NO4/c1-2-19-14(18)11-9-15(13(17)12(11)16)8-10-6-4-3-5-7-10/h3-7,9,16-17H,2,8H2,1H3",BEUOVVHUBYBSPI-UHFFFAOYSA-N,ebpc,Preclinical,aldose reductase inhibitor,AKR1B1,,
N=C(N)N=c1[nH]c(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,"InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)",ZQHFZHPUZXNPMF-UHFFFAOYSA-N,ebrotidine,Withdrawn,histamine receptor antagonist,HRH2,,
O=c1c2ccccc2[se]n1-c1ccccc1,InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H,DYEFUKCXAQOFHX-UHFFFAOYSA-N,ebselen,Phase 2/Phase 3,cyclooxygenase inhibitor,ALB,,
O=c1c2ccccc2[se]n1-c1ccccc1,InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H,DYEFUKCXAQOFHX-UHFFFAOYSA-N,ebselen,Phase 2/Phase 3,glutathione peroxidase agonist,ALB,,
O=c1c2ccccc2[se]n1-c1ccccc1,InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H,DYEFUKCXAQOFHX-UHFFFAOYSA-N,ebselen,Phase 2/Phase 3,H+/K+-ATPase inhibitor,ALB,,
O=c1c2ccccc2[se]n1-c1ccccc1,InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H,DYEFUKCXAQOFHX-UHFFFAOYSA-N,ebselen,Phase 2/Phase 3,nitric oxide synthase inhibitor,ALB,,
COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)[nH]c(=N)nc32)c1C,"InChI=1S/C21H24ClN5O2/c1-12-9-24-15(13(2)17(12)29-5)11-27-10-14(7-6-8-21(3,4)28)16-18(22)25-20(23)26-19(16)27/h9-10,28H,8,11H2,1-5H3,(H2,23,25,26)",VOASEWXFCTZRDF-UHFFFAOYSA-N,ec-144,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,
CC1(C)CCC(C)(C)c2cc(C#Cc3ccc(C(=O)O)cc3)ccc21,"InChI=1S/C23H24O2/c1-22(2)13-14-23(3,4)20-15-17(9-12-19(20)22)6-5-16-7-10-18(11-8-16)21(24)25/h7-12,15H,13-14H2,1-4H3,(H,24,25)",OQVLOWLEEHYBJH-UHFFFAOYSA-N,ec-23,Preclinical,retinoid receptor agonist,RARA|RARB|RARG,,
CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,"InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)",JTAGHJPZEDNHHA-UHFFFAOYSA-N,ecabapide,Phase 3,,,,
CC(C)c1cc2c(cc1S(=O)(=O)O)C1(C)CCCC(C)(C(=O)O)C1CC2,"InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)",IWCWQNVIUXZOMJ-UHFFFAOYSA-N,ecabet,Launched,gastrin inhibitor,NOXO1,ophthalmology,dry eye syndrome
CC(C)c1cc2c(cc1S(=O)(=O)O)C1(C)CCCC(C)(C(=O)O)C1CC2,"InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)",IWCWQNVIUXZOMJ-UHFFFAOYSA-N,ecabet,Launched,urease inhibitor,NOXO1,ophthalmology,dry eye syndrome
CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1,"InChI=1S/C28H34O8S2/c1-25(2)21-9-11-27(25,15-37(31,32)33)23(29)19(21)13-17-5-7-18(8-6-17)14-20-22-10-12-28(24(20)30,26(22,3)4)16-38(34,35)36/h5-8,13-14,21-22H,9-12,15-16H2,1-4H3,(H,31,32,33)(H,34,35,36)",HEAHZSUCFKFERC-UHFFFAOYSA-N,ecamsule-triethanolamine,Launched,,,dermatology,skin protectant|sunscreen lotion
CSC1SCC2C(=O)N(C)C(C(C)C)C(=O)OCC(NC(=O)c3cnc4ccccc4n3)C(=O)NC(C)C(=O)N(C)C1C(=O)N(C)C(C(C)C)C(=O)OCC(NC(=O)c1cnc3ccccc3n1)C(=O)NC(C)C(=O)N2C,"InChI=1S/C51H64N12O12S2/c1-25(2)38-49(72)74-22-36(59-42(65)34-21-53-30-17-13-15-19-32(30)57-34)44(67)55-28(6)46(69)63(10)40-48(71)62(9)39(26(3)4)50(73)75-23-35(58-41(64)33-20-52-29-16-12-14-18-31(29)56-33)43(66)54-27(5)45(68)60(7)37(47(70)61(38)8)24-77-51(40)76-11/h12-21,25-28,35-40,51H,22-24H2,1-11H3,(H,54,66)(H,55,67)(H,58,64)(H,59,65)",AUJXLBOHYWTPFV-UHFFFAOYSA-N,echinomycin,Phase 2,DNA intercalating agent,,,
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",LEZWWPYKPKIXLL-UHFFFAOYSA-N,econazole,Launched,lanosterol demethylase inhibitor,NPY1R|NPY2R|TRPM2|TRPV5,infectious disease,tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",LEZWWPYKPKIXLL-UHFFFAOYSA-N,econazole,Launched,sterol demethylase inhibitor,NPY1R|NPY2R|TRPM2|TRPV5,infectious disease,tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis
CC1=NC(C(=O)O)CCN1,"InChI=1S/C6H10N2O2/c1-4-7-3-2-5(8-4)6(9)10/h5H,2-3H2,1H3,(H,7,8)(H,9,10)",WQXNXVUDBPYKBA-UHFFFAOYSA-N,ectoine,Launched,anti-inflammatory agent,,,
Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2sc(=O)[nH]c2O)c2sccc12,"InChI=1S/C24H20N2O4S2/c1-14-18(25-23(30-14)15-5-3-2-4-6-15)9-11-29-19-8-7-16(21-17(19)10-12-31-21)13-20-22(27)26-24(28)32-20/h2-8,10,12,27H,9,11,13H2,1H3,(H,26,28)",ZXHQSLBKYSKYLQ-UHFFFAOYSA-N,edaglitazone,Phase 2,PPAR receptor agonist,PPARG,,
Cc1cc(=O)n(-c2ccccc2)[nH]1,"InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-7,11H,1H3",KZQYIMCESJLPQH-UHFFFAOYSA-N,edaravone,Launched,nootropic agent,BCL2,neurology/psychiatry,stroke
CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)NCCNC(=O)c1ccccc1O,"InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)",JQLBBYLGWHUHRW-UHFFFAOYSA-N,edasalonexent,Phase 3,NFkB pathway inhibitor,,,
CCCCCCCCCCCCCCCCCCOCC(CO[PH](=O)(=O)OCC[N+](C)(C)C)OC,"InChI=1S/C27H58NO6P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-23-32-25-27(31-5)26-34-35(29,30)33-24-22-28(2,3)4/h27H,6-26H2,1-5H3/q+1",SJHKGZLJPMSEOR-UHFFFAOYSA-N,edelfosine,Phase 2,phospholipase inhibitor,,,
CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O,"InChI=1S/C14H32N2O4/c1-11(17)7-15(8-12(2)18)5-6-16(9-13(3)19)10-14(4)20/h11-14,17-20H,5-10H2,1-4H3",NSOXQYCFHDMMGV-UHFFFAOYSA-N,editol,Preclinical,,,,
Cn1c(CCCCCCC(O)=NO)nc2cc(N(CCCl)CCCl)ccc21,"InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)",GISXTRIGVCKQBX-UHFFFAOYSA-N,edo-s101,Phase 1/Phase 2,HDAC inhibitor,,,
OC1CN(CCCOCCc2ccc3sccc3c2)C1,"InChI=1S/C16H21NO2S/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2",HQNACSFBDBYLJP-UHFFFAOYSA-N,edonerpic-maleate,Preclinical,beta amyloid inhibitor,,,
CN1CCc2nc(C(=O)NC3CC(C(=O)N(C)C)CCC3NC(=O)C(=O)N=c3ccc(Cl)c[nH]3)sc2C1,"InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)",HGVDHZBSSITLCT-UHFFFAOYSA-N,edoxaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF)
CCc1cn(C2CC(O)C(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)",XACKNLSZYYIACO-UHFFFAOYSA-N,edoxudine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV)
CC[N+](C)(C)c1cccc(O)c1,"InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1",VWLHWLSRQJQWRG-UHFFFAOYSA-O,edrophonium,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis
O=[PH](=O)(O)CN(CCN(C[PH](=O)(=O)O)C[PH](=O)(=O)O)C[PH](=O)(=O)O,"InChI=1S/C6H16N2O12P4/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20/h1-6H2,(H,9,10,11)(H,12,13,14)(H,15,16,17)(H,18,19,20)",IVCUTQNVXVKOBR-UHFFFAOYSA-N,edtmp,Preclinical,chelating agent,,,
CS(=O)(=O)c1ccc(-c2c[nH]c(=NCc3ccco3)n3cnnc23)cc1,"InChI=1S/C17H15N5O3S/c1-26(23,24)14-6-4-12(5-7-14)15-10-19-17(22-11-20-21-16(15)22)18-9-13-3-2-8-25-13/h2-8,10-11H,9H2,1H3,(H,18,19)",DYIRSNMPIZZNBK-UHFFFAOYSA-N,eed226,Preclinical,polycomb protein inhibitor,EED,,
O=C(Cn1ccnc1[N+](=O)[O-])NCC(F)(F)C(F)(F)F,"InChI=1S/C8H7F5N4O3/c9-7(10,8(11,12)13)4-15-5(18)3-16-2-1-14-6(16)17(19)20/h1-2H,3-4H2,(H,15,18)",JGGDSDPOPRWSCX-UHFFFAOYSA-N,ef5,Phase 2,cytochrome P450 activator,,,
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1,"InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)",BNFRJXLZYUTIII-UHFFFAOYSA-N,efaproxiral,Phase 3,hemoglobin oxygen release stimulant,HBA1|HBB,,
CCC1(C2=NCCN2)Cc2ccccc2O1,"InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)",RATZLMXRALDSJW-UHFFFAOYSA-N,efaroxan,Phase 2,adrenergic receptor antagonist,ADORA2A,,
Cc1cc(Oc2ccc3nc(COc4ccc(Cc5sc(=O)[nH]c5O)cc4)n(C)c3c2)cc(C)c1N,"InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,32H,12,14,28H2,1-3H3,(H,30,33)",MBOKSSYXJPVPOA-UHFFFAOYSA-N,efatutazone,Phase 2,PPAR receptor agonist,PPARG,,
O=C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1,"InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)",XPOQHMRABVBWPR-UHFFFAOYSA-N,efavirenz,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
C=C1CCN(C(C)C(O)(Cn2cncn2)c2ccc(F)cc2F)CC1,"InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3",NFEZZTICAUWDHU-UHFFFAOYSA-N,efinaconazole,Launched,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis
O=C(O)COCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C21H24F2N2O3/c22-18-5-1-16(2-6-18)21(17-3-7-19(23)8-4-17)25-11-9-24(10-12-25)13-14-28-15-20(26)27/h1-8,21H,9-15H2,(H,26,27)",BAWMMJAUVBLLEE-UHFFFAOYSA-N,efletirizine,Phase 3,antihistamine,,,
NCCCC(N)(C(=O)O)C(F)F,"InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)",VLCYCQAOQCDTCN-UHFFFAOYSA-N,eflornithine,Launched,ornithine decarboxylase inhibitor,ARG2|ODC1,dermatology,facial hair reduction
CCOC(=O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1,"InChI=1S/C19H16O5/c1-2-22-19(21)12-23-14-8-9-15-16(20)11-17(24-18(15)10-14)13-6-4-3-5-7-13/h3-11H,2,12H2,1H3",ZVXBAHLOGZCFTP-UHFFFAOYSA-N,efloxate,Preclinical,vasodilator,,,
CC1=NC(C)=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C1P1(=O)OCC(C)(C)CO1,"InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31-32H,18-19,21-23H2,1-4H3",YDJXRHCTKNMBAT-UHFFFAOYSA-N,efonidipine,Launched,calcium channel blocker,,cardiology,hypertension
N=C(N)NCCCC(NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(=O)O,"InChI=1S/C17H19N7O5S3/c18-17(19)20-7-2-4-11(16(26)27)21-15(25)14-10(6-8-30-14)24-32(28,29)12-5-1-3-9-13(12)23-31-22-9/h1,3,5-6,8,11,24H,2,4,7H2,(H,21,25)(H,26,27)(H4,18,19,20)",ZWWMEDURALZMEV-UHFFFAOYSA-N,eg00229,Preclinical,neuropilin receptor antagonist,NRP1,,
Cc1cc(C(=O)N=c2[nH]c3cccc(Cl)c3n2C2CCCCN(C(=O)C=CCN(C)C)C2)ccn1,"InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)",IOMMMLWIABWRKL-UHFFFAOYSA-N,egf816,Phase 2,EGFR inhibitor,EGFR,,
NC1(C(=O)O)CCC2C(C(=O)O)C21,"InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)",VTAARTQTOOYTES-UHFFFAOYSA-N,eglumetad,Phase 2,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM8,,
CCn1c2ccccc2c2cc(N=c3cc[nH]c(=NCCCN4CCOCC4)[nH]3)ccc21,"InChI=1S/C25H30N6O/c1-2-31-22-7-4-3-6-20(22)21-18-19(8-9-23(21)31)28-24-10-12-27-25(29-24)26-11-5-13-30-14-16-32-17-15-30/h3-4,6-10,12,18H,2,5,11,13-17H2,1H3,(H2,26,27,28,29)",AFTZZRFCMOAFCR-UHFFFAOYSA-N,ehop-016,Preclinical,Ras GTPase inhibitor,RAC1|RAC3,,
CCC(CC)n1ccc2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(C#N)cc21,"InChI=1S/C23H26N4O2/c1-5-17(6-2)27-8-7-18-19(10-16(12-24)11-21(18)27)22(28)25-13-20-14(3)9-15(4)26-23(20)29/h7-11,17H,5-6,13H2,1-4H3,(H,25,28)(H,26,29)",PFHDWRIVDDIFRP-UHFFFAOYSA-N,ei1,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCN(c1[nH]c(=N)c(C(=O)N=C(N)N)nc1Cl)C(C)C,"InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)",QDERNBXNXJCIQK-UHFFFAOYSA-N,eipa,Preclinical,sodium/hydrogen exchanger inhibitor,ADRA2A|ASIC1|PKD2L1,,
CCN(c1[nH]c(=N)c(C(=O)N=C(N)N)nc1Cl)C(C)C,"InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)",QDERNBXNXJCIQK-UHFFFAOYSA-N,eipa,Preclinical,transient receptor potential polycystic inhibitor,ADRA2A|ASIC1|PKD2L1,,
CCSC(=N)N,"InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)",VFIZBHJTOHUOEK-UHFFFAOYSA-N,eit-hydrobromide,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,
CCNCCc1ccc(CN(CC)c2cc(OC)ccc2C2CCc3cc(O)ccc3C2)cc1,"InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3",SIFNOOUKXBRGGB-UHFFFAOYSA-N,elacestrant,Phase 3,estrogen receptor degrader,,,
COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cccc4c(=O)c5cccc(OC)c5[nH]c34)cc1)CC2,"InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)",OSFCMRGOZNQUSW-UHFFFAOYSA-N,elacridar,Phase 1,P glycoprotein inhibitor,ABCB1,,
CCC(C=CC1OC(=O)C=CC1C)=CC(C)CC=CC(C)=CC(C)C(=O)C(C)C(O)C(C)C=C(C)CC(=O)O,"InChI=1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-19,22,24-27,29,33,38H,9,12,20H2,1-8H3,(H,34,35)",XBDMWBDVYWZRSE-UHFFFAOYSA-N,elactocin,Phase 1,exportin antagonist,XPO1,,
CCCCCCCCC=CCCCCCCCC(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(O)C1O,"InChI=1S/C27H45N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(31)35-20-21-24(32)25(33)26(36-21)30-19-18-22(28)29-27(30)34/h9-10,18-19,21,24-26,32-33H,2-8,11-17,20H2,1H3,(H2,28,29,34)",FLFGNMFWNBOBGE-UHFFFAOYSA-N,elacytarabine,Phase 3,antineoplastic agent,DCK,,
CSc1ccc(C(=O)C=Cc2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1,"InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)",AFLFKFHDSCQHOL-UHFFFAOYSA-N,elafibranor,Phase 3,PPAR receptor agonist,PPARA|PPARD|PPARG,,
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F,"InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)",HEAUOKZIVMZVQL-UHFFFAOYSA-N,elagolix,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,
COC(=O)NC(C(=O)N1CCCC1c1nc(-c2ccc3c(c2)OC(c2ccccc2)n2c-3cc3cc(-c4c[nH]c(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C,"InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)",BVAZQCUMNICBAQ-UHFFFAOYSA-N,elbasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)C(OCCCO)C1O,"InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3",FZEXGDDBXLBRTD-UHFFFAOYSA-N,eldecalcitol,Phase 3,bone formation stimulant,VDR,,
O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,"InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2",YNUAEEJQYHYLMS-UHFFFAOYSA-N,eleclazine,Phase 3,late sodium current inhibitor,,,
C=CC1(C)CCC(C(=C)C)CC1C(=C)C,"InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3",OPFTUNCRGUEPRZ-UHFFFAOYSA-N,elemene,Phase 3,VEGFR inhibitor,,,
CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,"InChI=1S/C19H20N4O2S2/c1-22(18(26)14-9-5-3-6-10-14)20-16(24)13-17(25)21-23(2)19(27)15-11-7-4-8-12-15/h3-12H,13H2,1-2H3,(H,20,24)(H,21,25)",BKJIXTWSNXCKJH-UHFFFAOYSA-N,elesclomol,Phase 3,oxidative stress inducer,HSPA1A,,
CN1CCCC1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,"InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3",PWVXXGRKLHYWKM-UHFFFAOYSA-N,eletriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache
CCCCCCCC(=O)NC(CN1CCCC1)C(O)c1ccc2c(c1)OCCO2,"InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)",FJZZPCZKBUKGGU-UHFFFAOYSA-N,eliglustat,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,"InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)",LGSDFTPAICUONK-UHFFFAOYSA-N,elinogrel,Phase 2,purinergic receptor antagonist,P2RY12,,
OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,"InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2",GGUSQTSTQSHJAH-UHFFFAOYSA-N,eliprodil,Phase 3,glutamate receptor antagonist,GRIN1|GRIN2B,,
O=c1c(O)cc2c(O)oc3c(=O)c(O)cc4c(O)oc1c2c43,"InChI=1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-16,19-20H",CYFXRGFESOFDNS-UHFFFAOYSA-N,ellagic-acid,Phase 2,glutathione transferase inhibitor,CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK,,
O=c1c(O)cc2c(O)oc3c(=O)c(O)cc4c(O)oc1c2c43,"InChI=1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-16,19-20H",CYFXRGFESOFDNS-UHFFFAOYSA-N,ellagic-acid,Phase 2,non-nucleoside reverse transcriptase inhibitor,CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK,,
O=C(c1cccc(N2Cc3cccc(Cl)c3C2=O)c1)N1CCC2(CC1)CCN(c1ccncc1)CC2,"InChI=1S/C29H29ClN4O2/c30-25-6-2-4-22-20-34(28(36)26(22)25)24-5-1-3-21(19-24)27(35)33-17-11-29(12-18-33)9-15-32(16-10-29)23-7-13-31-14-8-23/h1-8,13-14,19H,9-12,15-18,20H2",ARYQHSWJGHCGJS-UHFFFAOYSA-N,eln-441958,Preclinical,bradykinin receptor antagonist,BDKRB1,,
NC(=O)C(=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)c1cncnc1,"InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)",JFBAVWVBLRIWHM-UHFFFAOYSA-N,eltanexor,Preclinical,exportin inhibitor,,,
CC(=O)C1CCC2C3CCC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3",AURFZBICLPNKBZ-UHFFFAOYSA-N,eltanolone,Phase 3,GABA receptor positive allosteric modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,
c1cc2c(c(N3CCNCC3)c1)OCCO2,"InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2",WVLHGCRWEHCIOT-UHFFFAOYSA-N,eltoprazine,Phase 2,serotonin receptor agonist,HTR1A|HTR1B,,
Cc1ccc(-n2[nH]c(C)c(N=Nc3cccc(-c4cccc(C(=O)O)c4)c3O)c2=O)cc1C,"InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)",SVOQIEJWJCQGDQ-UHFFFAOYSA-N,eltrombopag,Launched,thrombopoietin receptor agonist,MPL,hematology|infectious disease,anemia|hepatitis C|thrombocytopenia
COc1ccc(CN(C(=O)C(N)Cc2c(C)cc(C(N)=O)cc2C)C(C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)",QFNHIDANIVGXPE-UHFFFAOYSA-N,eluxadoline,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome
COc1ccc(CN(C(=O)C(N)Cc2c(C)cc(C(N)=O)cc2C)C(C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O,"InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)",QFNHIDANIVGXPE-UHFFFAOYSA-N,eluxadoline,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C(CO)C(C)C,"InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)",JUZYLCPPVHEVSV-UHFFFAOYSA-N,elvitegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CNC1C(C)OC(OC2C(C)OC(OC3C(C)=CCC4CC(CC5(C=CC(C)C(C(C)C)O5)O4)OC(=O)C4=CC(C)C(O)C5OCC(=CC=CC3C)C45O)CC2OC)CC1OC,"InChI=1S/C48H73NO13/c1-25(2)42-28(5)17-18-47(62-42)23-34-20-33(61-47)16-15-27(4)43(26(3)13-12-14-32-24-55-45-41(50)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-11)44(31(8)57-39)60-38-21-36(53-10)40(49-9)30(7)56-38/h12-15,17-19,25-26,28-31,33-34,36-45,49-50,52H,16,20-24H2,1-11H3",KFIRUDJQMBQTHC-UHFFFAOYSA-N,emamectin,Preclinical,GABA receptor agonist,,,
CCCCCCCC=CCCc1c(O)c(O)cc(O)c1O,"InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h8-9,12,18-21H,2-7,10-11H2,1H3",LQEIDFGJVUFQAZ-UHFFFAOYSA-N,embelin,Preclinical,HCV inhibitor,XIAP,,
CCCCCCCC=CCCc1c(O)c(O)cc(O)c1O,"InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h8-9,12,18-21H,2-7,10-11H2,1H3",LQEIDFGJVUFQAZ-UHFFFAOYSA-N,embelin,Preclinical,XIAP inhibitor,XIAP,,
CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,"InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3",AHYMHWXQRWRBKT-UHFFFAOYSA-N,emd-1214063,Phase 2,hepatocyte growth factor receptor inhibitor,MET,,
Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,"InChI=1S/C14H15ClN2/c1-9-14(10-4-6-16-7-5-10)12-8-11(15)2-3-13(12)17-9/h2-4,8,16-17H,5-7H2,1H3",BPPGPYJBCVXILI-UHFFFAOYSA-N,emd-386088,Preclinical,serotonin receptor agonist,HTR6,,
COc1ccc(C(=O)N2CCCc3cc(C4=NNC(=O)SC4C)ccc32)cc1OC,"InChI=1S/C22H23N3O4S/c1-13-20(23-24-22(27)30-13)15-6-8-17-14(11-15)5-4-10-25(17)21(26)16-7-9-18(28-2)19(12-16)29-3/h6-9,11-13H,4-5,10H2,1-3H3,(H,24,27)",IZLRMTJLQCLMKF-UHFFFAOYSA-N,emd-53998,Phase 1,phosphodiesterase inhibitor,TNNC1,,
CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C28H30N8O2/c1-4-5-10-24-29-23-15-16-35(18-25(37)34(2)3)28(38)26(23)36(24)17-19-11-13-20(14-12-19)21-8-6-7-9-22(21)27-30-32-33-31-27/h6-9,11-16H,4-5,10,17-18H2,1-3H3,(H,30,31,32,33)",CQVJTTOZTTVVBK-UHFFFAOYSA-N,emd-66684,Preclinical,angiotensin receptor antagonist,AGTR1,,
CN(C)CCNC(=O)NCC1CCC2C(c3ccccc3)Nc3ccc(C(F)(F)F)cc3C2O1,"InChI=1S/C25H31F3N4O2/c1-32(2)13-12-29-24(33)30-15-18-9-10-19-22(16-6-4-3-5-7-16)31-21-11-8-17(25(26,27)28)14-20(21)23(19)34-18/h3-8,11,14,18-19,22-23,31H,9-10,12-13,15H2,1-2H3,(H2,29,30,33)",MARIUIDCPUZLKZ-UHFFFAOYSA-N,emd534085,Preclinical,kinesin inhibitor,,,
CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,"InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3",KBUZBQVCBVDWKX-UHFFFAOYSA-N,emedastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
O=C(NCCS)c1cccc(C(=O)NCCS)c1,"InChI=1S/C12H16N2O2S2/c15-11(13-4-6-17)9-2-1-3-10(8-9)12(16)14-5-7-18/h1-3,8,17-18H,4-7H2,(H,13,15)(H,14,16)",JUTBAVRYDAKVGQ-UHFFFAOYSA-N,emeramide,Phase 2,antioxidant,,,
CCC1CN2CCc3cc(OC)c(OC)cc3C2CC1CC1NCCc2cc(OC)c(OC)cc21,"InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3",AUVVAXYIELKVAI-UHFFFAOYSA-N,emetine,Phase 2,protein synthesis inhibitor,RPS2,,
CCOC(=O)c1ccc(OCCN2CC(O)C(O)C(O)C2CO)cc1,"InChI=1S/C17H25NO7/c1-2-24-17(23)11-3-5-12(6-4-11)25-8-7-18-9-14(20)16(22)15(21)13(18)10-19/h3-6,13-16,19-22H,2,7-10H2,1H3",NWWORXYTJRPSMC-UHFFFAOYSA-N,emiglitate,Preclinical,alpha glucoside inhibitor,,,
NCCC(O)c1cccc(OCC2CCCCC2)c1,"InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2",WJIGGYYSZBWCGC-UHFFFAOYSA-N,emixustat,Phase 3,retinoid isomerohydrolase inhibitor,,,
CC(C)CC1C(=O)OC(Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)C(CC(C)C)C(=O)OC(C)C(=O)N(C)C(CC(C)C)C(=O)OC(Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)C(CC(C)C)C(=O)OC(C)C(=O)N1C,"InChI=1S/C60H90N6O14/c1-37(2)31-47-57(71)77-41(9)53(67)61(11)50(34-40(7)8)60(74)80-52(36-44-17-21-46(22-18-44)66-25-29-76-30-26-66)56(70)64(14)48(32-38(3)4)58(72)78-42(10)54(68)62(12)49(33-39(5)6)59(73)79-51(55(69)63(47)13)35-43-15-19-45(20-16-43)65-23-27-75-28-24-65/h15-22,37-42,47-52H,23-36H2,1-14H3",ZMQMTKVVAMWKNY-UHFFFAOYSA-N,emodepside,Phase 1,nematocide,,,
Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O,"InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3",RHMXXJGYXNZAPX-UHFFFAOYSA-N,emodin,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,,
CCOc1c(N2CCOCC2)cnn(C)c1=O,"InChI=1S/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3",URJQOOISAKEBKW-UHFFFAOYSA-N,emorfazone,Launched,anti-inflammatory agent,,dental,mouth inflammation
CCOc1c(N2CCOCC2)cnn(C)c1=O,"InChI=1S/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3",URJQOOISAKEBKW-UHFFFAOYSA-N,emorfazone,Launched,cyclooxygenase inhibitor,,dental,mouth inflammation
CCc1nc(C)ccc1O,"InChI=1S/C8H11NO/c1-3-7-8(10)5-4-6(2)9-7/h4-5,10H,3H2,1-2H3",JPGDYIGSCHWQCC-UHFFFAOYSA-N,emoxipin,Phase 3,,,,
OCC1OC(c2ccc(Cl)c(Cc3ccc(OC4CCOC4)cc3)c2)C(O)C(O)C1O,"InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2",OBWASQILIWPZMG-UHFFFAOYSA-N,empagliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus
CC(NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)NC(CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F,"InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)",SCVHJVCATBPIHN-UHFFFAOYSA-N,emricasan,Phase 2,caspase inhibitor,CASP1|CASP3|CASP7,,
N=c1[nH]c(=O)n(C2CSC(CO)O2)cc1F,"InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)",XQSPYNMVSIKCOC-UHFFFAOYSA-N,emtricitabine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
O=C(O)c1cc(N2N=C(C(F)(F)F)C(=Cc3ccc(-c4ccccc4)o3)C2=O)ccc1Cl,"InChI=1S/C22H12ClF3N2O4/c23-17-8-6-13(10-15(17)21(30)31)28-20(29)16(19(27-28)22(24,25)26)11-14-7-9-18(32-14)12-4-2-1-3-5-12/h1-11H,(H,30,31)",RSLFQCNAOMQAIH-UHFFFAOYSA-N,en460,Preclinical,endoplasmic reticulum oxidation inhibitor,ERO1A,,
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1CCCC1C(=O)O,"InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)",GBXSMTUPTTWBMN-UHFFFAOYSA-N,enalapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)
CC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O,"InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)",LZFZMUMEGBBDTC-UHFFFAOYSA-N,enalaprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
CC(C)(O)CN=c1[nH]c(-c2cccc(C(F)(F)F)n2)nc(=Nc2ccnc(C(F)(F)F)c2)[nH]1,"InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)",DYLUUSLLRIQKOE-UHFFFAOYSA-N,enasidenib,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML)
C=C(C#N)C(=O)OCCCC,"InChI=1S/C8H11NO2/c1-3-4-5-11-8(10)7(2)6-9/h2-5H2,1H3",JJJFUHOGVZWXNQ-UHFFFAOYSA-N,enbucrilate,Launched,,,dermatology,skin lacerations|tissue adhesive
COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1,"InChI=1S/C23H32N2O6/c1-27-20-8-6-5-7-19(20)25-11-9-24(10-12-25)15-17(26)16-31-18-13-21(28-2)23(30-4)22(14-18)29-3/h5-8,13-14,17,26H,9-12,15-16H2,1-4H3",KSQCNASWXSCJTD-UHFFFAOYSA-N,enciprazine,Phase 3,GABA receptor modulator,GABRA1,,
COC(=O)NC(C)CN=c1nc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)cc[nH]1,"InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)",CMJCXYNUCSMDBY-UHFFFAOYSA-N,encorafenib,Launched,RAF inhibitor,BRAF,oncology,melanoma
O=C(Nc1cccc2cccnc12)c1ccc(-n2c(O)c3c(c2O)C2C=CC3C2)cc1,"InChI=1S/C25H19N3O3/c29-23(27-19-5-1-3-14-4-2-12-26-22(14)19)15-8-10-18(11-9-15)28-24(30)20-16-6-7-17(13-16)21(20)25(28)31/h1-12,16-17,30-31H,13H2,(H,27,29)",OGYSABKWWQZOIU-UHFFFAOYSA-N,endo-iwr-1,Preclinical,PARP inhibitor,TNKS|TNKS2,,
CCC(=C(c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1,"InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3",MHJBZVSGOZTKRH-UHFFFAOYSA-N,endoxifen,Phase 2,estrogen receptor antagonist,ESR1,,
FC(F)OC(F)(F)C(F)Cl,"InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H",JPGQOUSTVILISH-UHFFFAOYSA-N,enflurane,Launched,membrane permeability inhibitor,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,anesthetic
C=CCOC(Cn1ccnc1)c1ccc(Cl)cc1Cl,"InChI=1S/C14H14Cl2N2O/c1-2-7-19-14(9-18-6-5-17-10-18)12-4-3-11(15)8-13(12)16/h2-6,8,10,14H,1,7,9H2",PZBPKYOVPCNPJY-UHFFFAOYSA-N,enilconazole,Launched,sterol demethylase inhibitor,CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2,infectious disease,skin infections
C#Cc1c[nH]c(=O)[nH]c1=O,"InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)",JOZGNYDSEBIJDH-UHFFFAOYSA-N,eniluracil,Phase 3,dihydropyrimidine dehydrogenase inhibitor,AOX1|DPYD|XDH,,
Cc1cc(-n2cccc2)c(S(C)(=O)=O)cc1C(=O)N=C(N)N,"InChI=1S/C14H16N4O3S/c1-9-7-11(18-5-3-4-6-18)12(22(2,20)21)8-10(9)13(19)17-14(15)16/h3-8H,1-2H3,(H4,15,16,17,19)",UADMBZFZZOBWBB-UHFFFAOYSA-N,eniporide,Preclinical,sodium/hydrogen antiport inhibitor,,,
C[n+]1ccc(C(=O)NCc2ccccc2)cc1,"InChI=1S/C14H14N2O/c1-16-9-7-13(8-10-16)14(17)15-11-12-5-3-2-4-6-12/h2-10H,11H2,1H3/p+1",QOEJDHLJOKRPJG-UHFFFAOYSA-O,enisamium-iodide,Launched,,,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)[nH][nH]1,"InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)",BLQYVHBZHAISJM-UHFFFAOYSA-N,enmd-2076,Phase 2,Aurora kinase inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)[nH][nH]1,"InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)",BLQYVHBZHAISJM-UHFFFAOYSA-N,enmd-2076,Phase 2,FLT3 inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)[nH][nH]1,"InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)",BLQYVHBZHAISJM-UHFFFAOYSA-N,enmd-2076,Phase 2,VEGFR inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,,
CCCCCCCCCCCCCCCCCCCCCC(=O)N=c1ccn(C2OC(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)",SAMRUMKYXPVKPA-UHFFFAOYSA-N,enocitabine,Launched,DNA synthesis inhibitor,CMPK1|RRM1|TYMS,hematologic malignancy,acute myeloid leukemia (AML)
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,"InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)",IDYZIJYBMGIQMJ-UHFFFAOYSA-N,enoxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease,urinary tract infections|gonorrhea
CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1,"InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)",ZJKNESGOIKRXQY-UHFFFAOYSA-N,enoximone,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
CC1(C(=O)O)CCC2(C)CCC3(C)C(=C2C1)CC(=O)C1C2(C)CCC(O)C(C)(C)C2CCC13C,"InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h21-23,32H,8-17H2,1-7H3,(H,33,34)",YLHIVIHHVKLKEI-UHFFFAOYSA-N,enoxolone,Launched,gap junction modulator,HSD11B1,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|common cold
CCCn1c(=O)[nH]c(=O)c2[nH]cnc21,"InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)",SIQPXVQCUCHWDI-UHFFFAOYSA-N,enprofylline,Phase 3,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B,,
CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1,"InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)",SPFYMRJSYKOXGV-UHFFFAOYSA-N,enrofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,"InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3",JRURYQJSLYLRLN-UHFFFAOYSA-N,entacapone,Launched,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease
O=C(Nc1ccc2ncccc2c1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,"InChI=1S/C26H18ClN3O2/c27-19-9-7-17(8-10-19)15-30-16-22(21-5-1-2-6-24(21)30)25(31)26(32)29-20-11-12-23-18(14-20)4-3-13-28-23/h1-14,16H,15H2,(H,29,32)",LJIUXAHLYIPHOK-UHFFFAOYSA-N,entasobulin,Preclinical,tubulin polymerization inhibitor,,,
C=C1C(CO)C(O)CC1n1cnc2c(=O)[nH]c(=N)[nH]c21,"InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)",QDGZDCVAUDNJFG-UHFFFAOYSA-N,entecavir,Launched,DNA replication inhibitor,,infectious disease,hepatitis B
C=C1C(CO)C(O)CC1n1cnc2c(=O)[nH]c(=N)[nH]c21,"InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)",QDGZDCVAUDNJFG-UHFFFAOYSA-N,entecavir,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis B
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,entinostat,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC9,,
CN1CCN(c2ccc(C(=O)N=c3[nH][nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,"InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)",HAYYBYPASCDWEQ-UHFFFAOYSA-N,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK|NTRK1|NTRK2|NTRK3|ROS1,oncology,non-small cell lung cancer (NSCLC)
CN1CCN(c2ccc(C(=O)N=c3[nH][nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,"InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)",HAYYBYPASCDWEQ-UHFFFAOYSA-N,entrectinib,Launched,proto-oncogene tyrosine protein kinase inhibitor,ALK|NTRK1|NTRK2|NTRK3|ROS1,oncology,non-small cell lung cancer (NSCLC)
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,enzalutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,enzastaurin,Phase 3,PKC inhibitor,AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG,,
Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,"InChI=1S/C20H16BrClN2O/c1-12-4-2-3-5-15(12)20(25)16-8-7-14(11-17(16)22)24-19-9-6-13(21)10-18(19)23/h2-11,24H,23H2,1H3",HDCLCHNAEZNGNV-UHFFFAOYSA-N,eo-1428,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14,,
NS(=O)(=O)NCCN=c1[nH]onc1C(=NO)Nc1ccc(F)c(Br)c1,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,epacadostat,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
CC(=Cc1ccccc1)C=C1SC(=S)N(CC(=O)O)C1=O,"InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)",CHNUOJQWGUIOLD-UHFFFAOYSA-N,epalrestat,Launched,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy
CC(=O)NCC1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,"InChI=1S/C18H23FN4O5/c1-12(25)20-9-14-10-23(18(27)28-14)13-2-3-16(15(19)8-13)21-4-6-22(7-5-21)17(26)11-24/h2-3,8,14,24H,4-7,9-11H2,1H3,(H,20,25)",SIMWTRCFFSTNMG-UHFFFAOYSA-N,eperezolid,Phase 1,bacterial 30S ribosomal subunit inhibitor,,,
CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1,"InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3",SQUNAWUMZGQQJD-UHFFFAOYSA-N,eperisone,Launched,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury
NCC1OB(O)c2c(OCCCO)cccc21,"InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2",FXQIIDINBDJDKL-UHFFFAOYSA-N,epetraborole,Preclinical,leucyl-tRNA synthetase inhibitor,,,
CNC(C)C(O)c1ccccc1,"InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3",KWGRBVOPPLSCSI-UHFFFAOYSA-N,ephedrine,Launched,adrenergic receptor agonist,ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity
CNC(C)C(O)c1ccccc1,"InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3",KWGRBVOPPLSCSI-UHFFFAOYSA-N,ephedrine-(racemic),Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity
CC12CCC3C(CCC4CC(O)CCC43C)C1CCC2=O,"InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3",QGXBDMJGAMFCBF-UHFFFAOYSA-N,epiandrosterone,Preclinical,steroid,G6PD,,
O=C(OC1Cc2c(O)cc(O)cc2OC1c1ccc(O)c(O)c1)c1cc(O)c(O)c(O)c1,"InChI=1S/C22H18O10/c23-11-6-14(25)12-8-19(32-22(30)10-4-16(27)20(29)17(28)5-10)21(31-18(12)7-11)9-1-2-13(24)15(26)3-9/h1-7,19,21,23-29H,8H2",LSHVYAFMTMFKBA-UHFFFAOYSA-N,epicatechin-gallate-(-),Phase 2,bacterial DNA gyrase inhibitor,BACE1|FASN,,
CC12CCC3c4ccc(O)cc4CCC3C1CC(O)C2O,"InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3",PROQIPRRNZUXQM-UHFFFAOYSA-N,epiestriol,Preclinical,,,,
Oc1cc(O)c2c(c1)OC(c1cc(O)c(O)c(O)c1)C(O)C2,"InChI=1S/C15H14O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-4,12,15-21H,5H2",XMOCLSLCDHWDHP-UHFFFAOYSA-N,epigallocatechin-(-),Phase 2,,,,
O=C(OC1Cc2c(O)cc(O)cc2OC1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1,"InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2",WMBWREPUVVBILR-UHFFFAOYSA-N,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,ELANE|EP300|FASN|KAT2B|MMP14|MMP2,,
NC1=NCC2c3ccccc3Cc3ccccc3N12,"InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)",WHWZLSFABNNENI-UHFFFAOYSA-N,epinastine,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis
CNCC(O)c1ccc(O)c(O)c1,"InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3",UCTWMZQNUQWSLP-UHFFFAOYSA-N,epinephrine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma
CNCC(O)c1ccc(O)c(O)c1,"InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3",UCTWMZQNUQWSLP-UHFFFAOYSA-N,epinephrine,Launched,carbonic anhydrase activator,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma
CNCC(O)c1ccc(O)c(O)c1,"InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3",UCTWMZQNUQWSLP-UHFFFAOYSA-N,epinephrine,Launched,neurotransmitter,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma
COc1cc(C)nc(-n2nc(C)cc2OC)n1,"InChI=1S/C11H14N4O2/c1-7-5-9(16-3)13-11(12-7)15-10(17-4)6-8(2)14-15/h5-6H,1-4H3",RHAXSHUQNIEUEY-UHFFFAOYSA-N,epirizole,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(O)C(C)O1)CC(O)(C(=O)CO)C=4,"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,7,10,13,17,22,29,31-36H,6,8-9,28H2,1-2H3",OEMKXOUYUCIRSC-UHFFFAOYSA-N,epirubicin,Launched,topoisomerase inhibitor,CHD1|TOP2A,oncology,breast cancer
CC12CCC3C(CCC4CC5SC5CC43C)C1CCC2O,"InChI=1S/C19H30OS/c1-18-8-7-14-12(13(18)5-6-17(18)20)4-3-11-9-15-16(21-15)10-19(11,14)2/h11-17,20H,3-10H2,1-2H3",OBMLHUPNRURLOK-UHFFFAOYSA-N,epitiostanol,Launched,androgen receptor agonist,AR,oncology,breast cancer
COC(=O)C1=CC2CC(=O)CCC2(C)C23OC2CC2(C)C(CCC24CCC(=O)O4)C13,"InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h11,13,16-17,19H,4-10,12H2,1-3H3",NGPJYMSGYPTHBB-UHFFFAOYSA-N,eplerenone,Launched,cytochrome P450 inhibitor,NR3C2,cardiology,congestive heart failure|hypertension
CCCCCC(O)C=CC1C(O)CC2OC(=CCCCC(=O)O)CC21,"InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)",KAQKFAOMNZTLHT-UHFFFAOYSA-N,epoprostenol,Launched,prostacyclin analog,P2RY12|PTGER1|PTGER4|PTGIR|PTGIS,cardiology,hypertension
CC(=Cc1csc(C)n1)C1CC2OC2CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)O1,"InChI=1S/C26H39NO6S/c1-14-8-7-9-19-21(32-19)11-20(15(2)10-18-13-34-17(4)27-18)33-23(29)12-22(28)26(5,6)25(31)16(3)24(14)30/h10,13-14,16,19-22,24,28,30H,7-9,11-12H2,1-6H3",HESCAJZNRMSMJG-UHFFFAOYSA-N,epothilone-a,Preclinical,microtubule stabilizing agent,,,
CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)O1,"InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3",QXRSDHAAWVKZLJ-UHFFFAOYSA-N,epothilone-b,Phase 3,microtubule stabilizing agent,TUBB,,
CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)O1,"InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3",QXRSDHAAWVKZLJ-UHFFFAOYSA-N,epothilone-b,Phase 3,tubulin polymerization inhibitor,TUBB,,
CC1=CCC(C(C)=Cc2csc(C)n2)OC(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCC1,"InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3",XOZIUKBZLSUILX-UHFFFAOYSA-N,epothilone-d,Phase 2,microtubule stabilizing agent,TUBB,,
CC1=CCC(C(C)=Cc2csc(C)n2)OC(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCC1,"InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3",XOZIUKBZLSUILX-UHFFFAOYSA-N,epothilone-d,Phase 2,tubulin polymerization inhibitor,TUBB,,
CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(C(F)(F)F)c2)c1,"InChI=1S/C20H21F3N2O2/c1-2-27-16-7-5-6-15(13-16)24-19(26)14-8-9-18(25-10-3-4-11-25)17(12-14)20(21,22)23/h5-9,12-13H,2-4,10-11H2,1H3,(H,24,26)",KLFVWQCQUXXLOU-UHFFFAOYSA-N,epptb,Preclinical,trace amine associated receptor antagonist,TAAR1,,
CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1,"InChI=1S/C24H32N2O2/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22/h4-13,20,23H,3,14-19H2,1-2H3",BSHWLCACYCVCJE-UHFFFAOYSA-N,eprazinone,Launched,mucolytic agent,,pulmonary,bronchospasm
CCC(C)C1OC2(C=CC1C)CC1CC(CC=C(C)C(OC3CC(OC)C(OC4CC(OC)C(NC(C)=O)C(C)O4)C(C)O3)C(C)C=CC=C3COC4C(O)C(C)=CC(C(=O)O1)C34O)O2,"InChI=1S/C50H75NO14/c1-12-26(2)45-29(5)18-19-49(65-45)24-36-21-35(64-49)17-16-28(4)44(27(3)14-13-15-34-25-58-47-43(53)30(6)20-37(48(54)61-36)50(34,47)55)62-41-23-39(57-11)46(32(8)60-41)63-40-22-38(56-10)42(31(7)59-40)51-33(9)52/h13-16,18-20,26-27,29,31-32,35-47,53,55H,12,17,21-25H2,1-11H3,(H,51,52)",ZKWQQXZUCOBISE-UHFFFAOYSA-N,eprinomectin,Launched,benzodiazepine receptor agonist,,infectious disease,gastrointestinal roundworms|lungworms
CC(C)(C)NC(=O)C1CCC2C3C=CC4=CC(C(=O)O)CCC4(C)C3CCC12C,"InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6-7,14-15,17-20H,8-13H2,1-5H3,(H,26,27)(H,28,29)",RNFAQHDTIWCBAR-UHFFFAOYSA-N,epristeride,Preclinical,5 alpha reductase inhibitor,,,
O=C(NCCCN1CCOCC1)c1ccc(Cl)cc1,"InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18)",YYFGRAGNYHYWEZ-UHFFFAOYSA-N,eprobemide,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression
O=S(=O)(O)CCCS(=O)(=O)O,"InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)",MGNVWUDMMXZUDI-UHFFFAOYSA-N,eprodisate,Phase 3,amyloid protein inhibitor,SAA1,,
O=S(=O)(O)CCCS(=O)(=O)O,"InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)",MGNVWUDMMXZUDI-UHFFFAOYSA-N,eprodisate,Phase 3,antiamyloidogenic agent,SAA1,,
CCCC=c1ncc(=CC(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,"InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-12,14,18H,2-3,13,15H2,1H3,(H,26,27)(H,28,29)",OLWGWPVIWQZCDJ-UHFFFAOYSA-N,eprosartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
N=C(N)NCCCCC1NC(=O)CCSSCC(C(N)=O)NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(=O)O)NC(=O)CNC1=O,"InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)",CZKPOZZJODAYPZ-UHFFFAOYSA-N,eptifibatide,Launched,platelet aggregation inhibitor,ITGA2B|ITGB3,cardiology,acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)
CC(C)N(CC1OC(n2cnc3c(=N)[nH]cnc32)C(O)C1O)C1CC(CCc2nc3cc(C(C)(C)C)ccc3[nH]2)C1,"InChI=1S/C30H42N8O3/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33)",LXFOLMYKSYSZQS-UHFFFAOYSA-N,epz-5676,Phase 1,histone lysine methyltransferase inhibitor,DOT1L,,
CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)CC1OC(n2ccc3c(=N)[nH]cnc32)C(O)C1O,"InChI=1S/C28H41N7O4/c1-17(2)34(13-6-12-30-27(38)33-19-9-7-18(8-10-19)28(3,4)5)15-21-22(36)23(37)26(39-21)35-14-11-20-24(29)31-16-32-25(20)35/h7-11,14,16-17,21-23,26,36-37H,6,12-13,15H2,1-5H3,(H2,29,31,32)(H2,30,33,38)",WXRGFPHDRFQODR-UHFFFAOYSA-N,epz004777,Preclinical,histone lysine methyltransferase inhibitor,DOT1L,,
Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(CN4CCOCC4)cc3)cc3c2cnn3C2CCCC2)c(=O)[nH]1,"InChI=1S/C32H37N5O3/c1-21-15-22(2)35-32(39)28(21)18-33-31(38)27-16-25(17-30-29(27)19-34-37(30)26-5-3-4-6-26)24-9-7-23(8-10-24)20-36-11-13-40-14-12-36/h7-10,15-17,19,26H,3-6,11-14,18,20H2,1-2H3,(H,33,38)(H,35,39)",ZOIBZSZLMJDVDQ-UHFFFAOYSA-N,epz005687,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCN(c1cc(C#CCN2CCOCC2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCC(N(C)CCOC)CC1,"InChI=1S/C35H51N5O4/c1-7-40(30-12-10-29(11-13-30)38(5)15-18-43-6)33-23-28(9-8-14-39-16-19-44-20-17-39)22-31(27(33)4)34(41)36-24-32-25(2)21-26(3)37-35(32)42/h21-23,29-30H,7,10-20,24H2,1-6H3,(H,36,41)(H,37,42)",XQFINGFCBFHOPE-UHFFFAOYSA-N,epz011989,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=C(CNC(O)c1cc(=NC2COC2)[nH]cn1)CN1CCc2ccccc2C1,"InChI=1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16,20-21,27H,5-6,8-12H2,(H,22,23,24)",RTONCGPIJCWPSI-UHFFFAOYSA-N,epz015666,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,
CNCCN(C)Cc1c[nH]nc1-c1ccc(OC2CC(OCCC3CCOCC3)C2)cc1,"InChI=1S/C25H38N4O3/c1-26-10-11-29(2)18-21-17-27-28-25(21)20-3-5-22(6-4-20)32-24-15-23(16-24)31-14-9-19-7-12-30-13-8-19/h3-6,17,19,23-24,26H,7-16,18H2,1-2H3,(H,27,28)",QMDKVNSQXPVCRD-UHFFFAOYSA-N,epz020411,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT6,,
CC12CCC3C(=CCc4cc(O)ccc43)C1CCC2=O,"InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3",WKRLQDKEXYKHJB-UHFFFAOYSA-N,equilin,Preclinical,estrogen receptor agonist,HSD17B1,,
Oc1ccc(C2COc3cc(O)ccc3C2)cc1,"InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2",ADFCQWZHKCXPAJ-UHFFFAOYSA-N,equol,Launched,estrogen receptor agonist,ESR1|ESR2,,
Cc1ccc2c(=O)c3ccccc3n(CCCN)c2c1C,"InChI=1S/C18H20N2O/c1-12-8-9-15-17(13(12)2)20(11-5-10-19)16-7-4-3-6-14(16)18(15)21/h3-4,6-9H,5,10-11,19H2,1-2H3",CFPDEQBPNROZDC-UHFFFAOYSA-N,er-27319,Preclinical,mediator release inhibitor,SYK,,
Cc1ccc2c(=O)c3ccccc3n(CCCN)c2c1C,"InChI=1S/C18H20N2O/c1-12-8-9-15-17(13(12)2)20(11-5-10-19)16-7-4-3-6-14(16)18(15)21/h3-4,6-9H,5,10-11,19H2,1-2H3",CFPDEQBPNROZDC-UHFFFAOYSA-N,er-27319,Preclinical,SYK inhibitor,SYK,,
CC(C)c1cccc2c(-c3ccccc3)cc(-c3ccc(-c4ccc(C(=O)O)cc4)[nH]3)nc12,"InChI=1S/C29H24N2O2/c1-18(2)22-9-6-10-23-24(19-7-4-3-5-8-19)17-27(31-28(22)23)26-16-15-25(30-26)20-11-13-21(14-12-20)29(32)33/h3-18,30H,1-2H3,(H,32,33)",LSGNKLDHMQVTEK-UHFFFAOYSA-N,er-50891,Preclinical,retinoid receptor antagonist,RARA,,
CCOc1ccccc1-n1c(C(C)N2CCN(C(=O)COc3ccc(Cl)cc3)CC2)nc2ccccc2c1=O,"InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3",BKQFRNYHFIQEKN-UHFFFAOYSA-N,erastin,Preclinical,ion channel antagonist,VDAC2,,
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)c3c(cc4c(F)cc(NC(O)CN5CCCC5)c(O)c4c3O)CC12,"InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h7,9,13,16,19-20,30,33-35,40H,3-6,8,10H2,1-2H3,(H2,29,39)",UVLBVOSCXCUSGH-UHFFFAOYSA-N,eravacycline,Launched,antibacterial,,,
COC(=O)C=Cc1cc(O)ccc1O,"InChI=1S/C10H10O4/c1-14-10(13)5-2-7-6-8(11)3-4-9(7)12/h2-6,11-12H,1H3",BQCNSTFWSKOWMA-UHFFFAOYSA-N,erbstatin-analog,Preclinical,EGFR inhibitor,EGFR,,
COC(=O)C=Cc1cc(O)ccc1O,"InChI=1S/C10H10O4/c1-14-10(13)5-2-7-6-8(11)3-4-9(7)12/h2-6,11-12H,1H3",BQCNSTFWSKOWMA-UHFFFAOYSA-N,erbstatin-analog,Preclinical,tyrosine kinase inhibitor,EGFR,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC(C)C(C)(C)O)CC(O)CC1O,"InChI=1S/C28H44O3/c1-18(9-10-19(2)27(4,5)31)24-13-14-25-21(8-7-15-28(24,25)6)11-12-22-16-23(29)17-26(30)20(22)3/h9-12,18-19,23-26,29-31H,3,7-8,13-17H2,1-2,4-6H3",ZGLHBRQAEXKACO-UHFFFAOYSA-N,ercalcitriol,Phase 1,vitamin D receptor agonist,VDR,,
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,"InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3",OLAHOMJCDNXHFI-UHFFFAOYSA-N,erdafitinib,Launched,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4,,
O=C(O)CSCC(=O)NC1CCSC1=O,"InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)",QGFORSXNKQLDNO-UHFFFAOYSA-N,erdosteine,Launched,mucolytic agent,,pulmonary|infectious disease,bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections
C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)C=CC(C)C(C)C,"InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3",MECHNRXZTMCUDQ-UHFFFAOYSA-N,ergocalciferol,Launched,vitamin analog,VDR,endocrinology|orthopedics,hypoparathyroidism|rickets|hypophosphatemia
CC(CO)NC(=O)C1=CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,15,17,20,23H,7,9-10H2,1-2H3,(H,21,24)",KHLVYIOBOBGWML-UHFFFAOYSA-N,ergonovine,Launched,adrenergic receptor agonist,ADRA1A|HTR1E,hematology,postpartum hemorrhage (PPH)
CC(CO)NC(=O)C1=CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,15,17,20,23H,7,9-10H2,1-2H3,(H,21,24)",KHLVYIOBOBGWML-UHFFFAOYSA-N,ergonovine,Launched,serotonin receptor agonist,ADRA1A|HTR1E,hematology,postpartum hemorrhage (PPH)
CC(C)C(C)C=CC(C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC21C,"InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3",DNVPQKQSNYMLRS-UHFFFAOYSA-N,ergosterol,Preclinical,vitamin D precursor,,,
CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)=CC2c3cccc4[nH]cc(c34)CC21,"InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,23,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)",UDWYQEMSGZBOBQ-UHFFFAOYSA-N,ergotamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2,neurology/psychiatry,migraine headache
COc1cc(N2CCN(C)CC2)ccc1N=c1nc2c(c[nH]1)N(C)C(=O)c1ccccc1N2C,"InChI=1S/C25H29N7O2/c1-29-11-13-32(14-12-29)17-9-10-19(22(15-17)34-4)27-25-26-16-21-23(28-25)30(2)20-8-6-5-7-18(20)24(33)31(21)3/h5-10,15-16H,11-14H2,1-4H3,(H,26,27,28)",DDTPGANIPBKTNU-UHFFFAOYSA-N,erk5-in-1,Preclinical,MAP kinase inhibitor,MAPK7,,
C#Cc1cccc(N=c2[nH]cnc3cc(OCCOC)c(OCCOC)cc23)c1,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,erlotinib,Launched,EGFR inhibitor,EGFR|NR1I2,oncology,non-small cell lung cancer (NSCLC)|pancreatic cancer
CC(O)C1C(=O)N2C(C(=O)O)=C(SC3CNC(C(=O)Nc4cccc(C(=O)O)c4)C3)C(C)C12,"InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)",JUZNIMUFDBIJCM-UHFFFAOYSA-N,ertapenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,intra-abdominal infections|skin infections|pneumonia|urinary tract infections|gynecologic infections|postpartum endomyometritis
Oc1ccc(C2Oc3ccc(O)cc3C3CCCC32)cc1,"InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2",XIESSJVMWNJCGZ-UHFFFAOYSA-N,erteberel,Phase 2,estrogen receptor agonist,ESR1|ESR2,,
CCOc1ccc(Cc2cc(C34OCC(CO)(O3)C(O)C(O)C4O)ccc2Cl)cc1,"InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3",MCIACXAZCBVDEE-UHFFFAOYSA-N,ertugliflozin,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus
OCC(O)C(O)CO,"InChI=1S/C4H10O4/c5-1-3(7)4(8)2-6/h3-8H,1-2H2",UNXHWFMMPAWVPI-UHFFFAOYSA-N,erythritol,Launched,,,,
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O,"InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3",ULGZDMOVFRHVEP-UHFFFAOYSA-N,erythromycin,Launched,NFkB pathway inhibitor,MLNR,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
CCC(=O)OC1C(OC2C(C)C(OC3CC(C)(OC)C(O)C(C)O3)C(C)C(=O)OC(CC)C(C)(O)C(O)C(C)C(=O)C(C)CC2(C)O)OC(C)CC1N(C)C,"InChI=1S/C40H71NO14/c1-15-27-40(11,48)33(44)22(5)30(43)20(3)18-38(9,47)35(55-37-32(53-28(42)16-2)26(41(12)13)17-21(4)50-37)23(6)31(24(7)36(46)52-27)54-29-19-39(10,49-14)34(45)25(8)51-29/h20-27,29,31-35,37,44-45,47-48H,15-19H2,1-14H3",TYQXKHPOXXXCTP-UHFFFAOYSA-N,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
CCOC(=O)CCC(=O)OC1C(OC2C(C)C(OC3CC(C)(OC)C(O)C(C)O3)C(C)C(=O)OC(CC)C(C)(O)C(O)C(C)C(=O)C(C)CC2(C)O)OC(C)CC1N(C)C,"InChI=1S/C43H75NO16/c1-15-29-43(11,52)36(48)24(5)33(47)22(3)20-41(9,51)38(25(6)34(26(7)39(50)57-29)59-32-21-42(10,53-14)37(49)27(8)56-32)60-40-35(28(44(12)13)19-23(4)55-40)58-31(46)18-17-30(45)54-16-2/h22-29,32,34-38,40,48-49,51-52H,15-21H2,1-14H3",NSYZCCDSJNWWJL-UHFFFAOYSA-N,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
CCOC(=O)CCC(=O)OC1C(OC2C(C)C(OC3CC(C)(OC)C(O)C(C)O3)C(C)C(=O)OC(CC)C(C)(O)C(O)C(C)C(=O)C(C)CC2(C)O)OC(C)CC1N(C)C,"InChI=1S/C43H75NO16/c1-15-29-43(11,52)36(48)24(5)33(47)22(3)20-41(9,51)38(25(6)34(26(7)39(50)57-29)59-32-21-42(10,53-14)37(49)27(8)56-32)60-40-35(28(44(12)13)19-23(4)55-40)58-31(46)18-17-30(45)54-16-2/h22-29,32,34-38,40,48-49,51-52H,15-21H2,1-14H3",NSYZCCDSJNWWJL-UHFFFAOYSA-N,erythromycin-ethylsuccinate,Launched,protein synthesis inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma
O=C1OC2(c3ccccc31)c1cc(I)c(O)c(I)c1Oc1c2cc(I)c(O)c1I,"InChI=1S/C20H8I4O5/c21-11-5-9-17(13(23)15(11)25)28-18-10(6-12(22)16(26)14(18)24)20(9)8-4-2-1-3-7(8)19(27)29-20/h1-6,25-26H",OALHHIHQOFIMEF-UHFFFAOYSA-N,erythrosine,Preclinical,coloring agent,,,
O=C(CN1CCNCC1)NC1CCCCC1,"InChI=1S/C12H23N3O/c16-12(10-15-8-6-13-7-9-15)14-11-4-2-1-3-5-11/h11,13H,1-10H2,(H,14,16)",RTFADALJKSFJDZ-UHFFFAOYSA-N,esaprazole,Phase 2,,,,
Cc1c(C(=O)Nc2ccc(S(C)(=O)=O)cc2)cn(CCO)c1-c1ccccc1C(F)(F)F,"InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)",NOSNHVJANRODGR-UHFFFAOYSA-N,esaxerenone,Preclinical,mineralocorticoid receptor antagonist,,,
CC=C(C)C(=O)OC1C(OC(C)=O)C2(CO)C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(C(=O)O)C(OC7OC(CO)C(O)C(O)C7O)C(O)C6OC6OC(CO)C(O)C(O)C6O)C(C)(CO)C5CCC43C)C2CC1(C)C,"InChI=1S/C55H86O24/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)",AXNVHPCVMSNXNP-UHFFFAOYSA-N,escin,Launched,nitric oxide synthase stimulant,,dermatology,varicose veins
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,"InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3",WSEQXVZVJXJVFP-UHFFFAOYSA-N,escitalopram,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)
O=c1ccc2cc(OC3OC(CO)C(O)C(O)C3O)c(O)cc2o1,"InChI=1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2",XHCADAYNFIFUHF-UHFFFAOYSA-N,esculin,Phase 1,antioxidant,,,
CN1CCC2(C)c3cc(O)ccc3N(C)C12,"InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3",HKGWQUVGHPDEBZ-UHFFFAOYSA-N,eseroline-(-),Preclinical,acetylcholinesterase inhibitor,OPRD1|OPRM1,,
CC(C)(C)c1cc(C(=O)C(C#N)=NNc2cccc(Cl)c2)no1,"InChI=1S/C16H15ClN4O2/c1-16(2,3)14-8-12(21-23-14)15(22)13(9-18)20-19-11-6-4-5-10(17)7-11/h4-8,19H,1-3H3",DXEATJQGQHDURZ-UHFFFAOYSA-N,esi-09,Preclinical,EPAC inhibitor,RAPGEF3|RAPGEF4,,
CC(=O)OC1Cc2ccccc2N(C(N)=O)c2ccccc21,"InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)",QIALRBLEEWJACW-UHFFFAOYSA-N,eslicarbazepine-acetate,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,"InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3",AQNDDEOPVVGCPG-UHFFFAOYSA-N,esmolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,ventricular tachycardia (VT)|hypertension
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,"InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)",SUBDBMMJDZJVOS-UHFFFAOYSA-N,esomeprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)
CC(=O)SCC(CC(=O)c1ccc(C)cc1)C(=O)O,"InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18)",YRSSFEUQNAXQMX-UHFFFAOYSA-N,esonarimod,Preclinical,antirheumatic drug,,,
CC12CCC3c4ccc(O)cc4CCC3C1C(O)C(O)C2O,"InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3",AJIPIJNNOJSSQC-UHFFFAOYSA-N,estetrol,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,
CC12CCC3c4ccc(O)cc4CCC3C1CCC2O,"InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3",VOXZDWNPVJITMN-UHFFFAOYSA-N,estradiol,Launched,estrogen receptor agonist,ESR1|ESR2|GPER1|KCNMA1|NR1I2,endocrinology,contraceptive
CC12CCC3c4ccc(OS(N)(=O)=O)cc4CCC3C1CCC2O,"InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)",YXYXCSOJKUAPJI-UHFFFAOYSA-N,estradiol-3-o-sulfamate,Phase 2,steryl sulfatase inhibitor,,,
CC(=O)Oc1ccc2c(c1)CCC1C2CCC2(C)C(O)CCC12,"InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3",FHXBMXJMKMWVRG-UHFFFAOYSA-N,estradiol-acetate,Launched,estrogen receptor agonist,ESR1,endocrinology|obstetrics/gynecology,menopause|vaginal atrophy
CC12CCC3c4ccc(OC(=O)c5ccccc5)cc4CCC3C1CCC2O,"InChI=1S/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3",UYIFTLBWAOGQBI-UHFFFAOYSA-N,estradiol-benzoate,Preclinical,contraceptive agent,ESR1,,
CC12CCC3c4ccc(O)cc4CCC3C1CCC2OC(=O)CCC1CCCC1,"InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3",UOACKFBJUYNSLK-UHFFFAOYSA-N,estradiol-cypionate,Launched,estrogen receptor agonist,ESR1,endocrinology,hypoestrogenism|menopause
CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C,"InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3",RSEPBGGWRJCQGY-UHFFFAOYSA-N,estradiol-valerate,Launched,estrogen receptor agonist,ESR1,oncology|endocrinology|obstetrics/gynecology,prostate cancer|hypoestrogenism|menopause|vaginal atrophy
CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O,"InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3",FRPJXPJMRWBBIH-UHFFFAOYSA-N,estramustine,Launched,DNA alkylating agent,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer
CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O[PH](=O)(=O)O,"InChI=1S/C23H31Cl2NO6P/c1-23-9-8-18-17-5-3-16(31-22(27)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)32-33(28,29)30/h3,5,14,18-21H,2,4,6-13H2,1H3,(H,28,29,30)",AWZSOVOECGNMFX-UHFFFAOYSA-N,estramustine-phosphate,Launched,DNA synthesis inhibitor,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer
CC12CCC3c4ccc(OC(=O)N(CCCl)CCCl)cc4CCC3C1CCC2O[PH](=O)(=O)O,"InChI=1S/C23H31Cl2NO6P/c1-23-9-8-18-17-5-3-16(31-22(27)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)32-33(28,29)30/h3,5,14,18-21H,2,4,6-13H2,1H3,(H,28,29,30)",AWZSOVOECGNMFX-UHFFFAOYSA-N,estramustine-phosphate,Launched,microtubule inhibitor,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer
CC12CCC3c4ccc(O)cc4CCC3C1CC(O)C2O,"InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3",PROQIPRRNZUXQM-UHFFFAOYSA-N,estriol,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology|obstetrics/gynecology|infectious disease,menopause|vaginal atrophy|urinary tract infections
CC12CCC3c4ccc(O)cc4CCC3C1CCC2=O,"InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3",DNXHEGUUPJUMQT-UHFFFAOYSA-N,estrone,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology,menopause
CC12CCC3c4ccc(O)cc4CCC3C1CCC2=O,"InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3",DNXHEGUUPJUMQT-UHFFFAOYSA-N,estrone,Launched,estrogenic hormone,ESR1|ESR2,endocrinology,menopause
CC12CCC3c4ccc(OS(=O)(=O)O)cc4CCC3C1CCC2=O,"InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)",JKKFKPJIXZFSSB-UHFFFAOYSA-N,estropipate,Launched,estrogen receptor agonist,ESR1|ESR2,orthopedics|endocrinology|obstetrics/gynecology,osteoporosis|menopause|vaginal atrophy|hypoestrogenism
C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,"InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)",AVOLMBLBETYQHX-UHFFFAOYSA-N,etacrynic-acid,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|SLC12A1,cardiology|gastroenterology|nephrology|rheumatology,hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome
CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1,"InChI=1S/C21H27NO2/c1-3-22(4-2)16-17-24-21-13-9-8-12-19(21)20(23)15-14-18-10-6-5-7-11-18/h5-13H,3-4,14-17H2,1-2H3",OEGDFSLNGABBKJ-UHFFFAOYSA-N,etafenone,Launched,calcium channel blocker,,,
O=S(=O)(O)c1cc(O)ccc1O,"InChI=1S/C6H6O5S/c7-4-1-2-5(8)6(3-4)12(9,10)11/h1-3,7-8H,(H,9,10,11)",IKQCSJBQLWJEPU-UHFFFAOYSA-N,etamsylate,Launched,hemostatic agent,,hematology,hemorrhage
O=C(Cn1ccnc1[N+](=O)[O-])NCCO,"InChI=1S/C7H10N4O4/c12-4-2-8-6(13)5-10-3-1-9-7(10)11(14)15/h1,3,12H,2,4-5H2,(H,8,13)",WCDWBPCFGJXFJZ-UHFFFAOYSA-N,etanidazole,Phase 3,bacterial cell wall synthesis inhibitor,,,
CCOC(=O)c1c[nH]c2c(cnn2CC)c1=NN=C(C)C,"InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18)",OPQRBXUBWHDHPQ-UHFFFAOYSA-N,etazolate,Phase 2,phosphodiesterase inhibitor,GABRB3|PDE4A,,
Cn1c(=O)c2c(ncn2CC(=O)N=c2ccc(-c3ccccc3)n[nH]2)n(C)c1=O,"InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)",QTRXIFVSTWXRJJ-UHFFFAOYSA-N,etc-159,Phase 1,beta catenin inhibitor,PORCN,,
Cn1c(=O)c2c(ncn2CC(=O)N=c2ccc(-c3ccccc3)n[nH]2)n(C)c1=O,"InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)",QTRXIFVSTWXRJJ-UHFFFAOYSA-N,etc-159,Phase 1,porcupine inhibitor,PORCN,,
N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1,"InChI=1S/C25H20N4O2/c26-15-18-1-3-20(4-2-18)23-16-27-24-10-9-22(17-29(23)24)19-5-7-21(8-6-19)25(30)28-11-13-31-14-12-28/h1-10,16-17H,11-14H2",FWRFPHJSGLYXTD-UHFFFAOYSA-N,etc-206,Phase 1,MAPK-interacting kinase inhibitor,,,
CCN(CC)S(=O)(=O)c1ccc(C(=O)O)cc1,"InChI=1S/C11H15NO4S/c1-3-12(4-2)17(15,16)10-7-5-9(6-8-10)11(13)14/h5-8H,3-4H2,1-2H3,(H,13,14)",UACOQEQOBAQRDQ-UHFFFAOYSA-N,etebenecid,Preclinical,uricosuric blocker,,,
CCC1(c2ccccc2)C(=O)N(COC)C(=O)N(COC)C1=O,"InChI=1S/C16H20N2O5/c1-4-16(12-8-6-5-7-9-12)13(19)17(10-22-2)15(21)18(11-23-3)14(16)20/h5-9H,4,10-11H2,1-3H3",DACOQFZGGLCXMA-UHFFFAOYSA-N,eterobarb,Phase 2,anticonvulsant,,,
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN(CC)CC)c1ccccc1S2,"InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27)",PQXGNJKJMFUPPM-UHFFFAOYSA-N,ethacizin,Launched,anticonvulsant,,cardiology,ventricular tachycardia (VT)|Wolff-Parkinson-White Syndrome (WPW)
CCOc1ccc2[nH]c3cc(N)ccc3c(=N)c2c1,"InChI=1S/C15H15N3O/c1-2-19-10-4-6-13-12(8-10)15(17)11-5-3-9(16)7-14(11)18-13/h3-8H,2,16H2,1H3,(H2,17,18)",CIKWKGFPFXJVGW-UHFFFAOYSA-N,ethacridine-lactate-monohydrate,Preclinical,DNA intercalating agent,,,
CCC(CO)NCCNC(CC)CO,"InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3",AEUTYOVWOVBAKS-UHFFFAOYSA-N,ethambutol,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tuberculosis
CCN(CC)C(=O)c1ccc(O)c(OC)c1,"InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3",BQJODPIMMWWMFC-UHFFFAOYSA-N,ethamivan,Preclinical,respiratory stimulant,,,
CCCCCCCCC=CCCCCCCCC(=O)O,"InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)",ZQPPMHVWECSIRJ-UHFFFAOYSA-N,ethanolamine-oleate,Launched,immunostimulant,F12|FABP4|FFAR1|FFAR4|PLD2,gastroenterology,esophageal varices
CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,"InChI=1S/C24H29NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-12,14-16H,5-8,13H2,1-4H3",ZOWYFYXTIWQBEP-UHFFFAOYSA-N,ethaverine,Launched,calcium channel blocker,,neurology/psychiatry,muscle relaxant|spasms
CCOc1ccccc1C(N)=O,"InChI=1S/C9H11NO2/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3,(H2,10,11)",SBNKFTQSBPKMBZ-UHFFFAOYSA-N,ethenzamide,Launched,analgesic agent,,neurology/psychiatry|endocrinology|otolaryngology,headache|fever|common cold
CCn1cnc(C(=O)NC)c1C(=O)NC,"InChI=1S/C9H14N4O2/c1-4-13-5-12-6(8(14)10-2)7(13)9(15)11-3/h5H,4H2,1-3H3,(H,10,14)(H,11,15)",RYRFAMRQBZNEPX-UHFFFAOYSA-N,ethimizol,Phase 1,,,,
C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C,"InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3",BFPYWIDHMRZLRN-UHFFFAOYSA-N,ethinyl-estradiol,Launched,estrogen receptor agonist,ESR1|ESR2|NR1I2,endocrinology,contraceptive
C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C,"InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3",BFPYWIDHMRZLRN-UHFFFAOYSA-N,ethinyl-estradiol,Launched,estrogenic hormone,ESR1|ESR2|NR1I2,endocrinology,contraceptive
CCc1cc(C(N)=S)ccn1,"InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)",AEOCXXJPGCBFJA-UHFFFAOYSA-N,ethionamide,Launched,mycolic synthesis inhibitor,,infectious disease,tuberculosis
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C21H28O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,5,16-18,23H,6-13H2,2-3H3",UPKJTHPZSTZJNH-UHFFFAOYSA-N,ethisterone,Launched,progestogen hormone,TYR,endocrinology,amenorrhea
CCOc1cc(NC(C)=O)ccc1C(=O)OC,"InChI=1S/C12H15NO4/c1-4-17-11-7-9(13-8(2)14)5-6-10(11)12(15)16-3/h5-7H,4H2,1-3H3,(H,13,14)",GOVWOKSKFSBNGD-UHFFFAOYSA-N,ethopabate,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CCC1(C)CC(=O)NC1=O,"InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)",HAPOVYFOVVWLRS-UHFFFAOYSA-N,ethosuximide,Launched,succinimide antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,epilepsy
CCn1c(O)c(-c2ccccc2)[nH]c1=O,"InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,14H,2H2,1H3,(H,12,15)",DQTXWWZTPYDJTC-UHFFFAOYSA-N,ethotoin,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures
CCOc1ccc2c(c1)C(C)=CC(C)(C)N2,"InChI=1S/C14H19NO/c1-5-16-11-6-7-13-12(8-11)10(2)9-14(3,4)15-13/h6-9,15H,5H2,1-4H3",DECIPOUIJURFOJ-UHFFFAOYSA-N,ethoxyquin,Preclinical,antioxidant,,,
CCOc1ccc2nc(S(N)(=O)=O)sc2c1,"InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)",OUZWUKMCLIBBOG-UHFFFAOYSA-N,ethoxzolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9,ophthalmology|gastroenterology,glaucoma|duodenal ulcer disease
CCOC(=O)c1ccccc1OC(N)=O,"InChI=1S/C10H11NO4/c1-2-14-9(12)7-5-3-4-6-8(7)15-10(11)13/h3-6H,2H2,1H3,(H2,11,13)",JFMIIMPCFQKAAD-UHFFFAOYSA-N,ethyl-2-(carbamoyloxy)benzoate,Phase 1,,,,
CCOC(=O)c1ccc(O)cc1,"InChI=1S/C9H10O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3",NUVBSKCKDOMJSU-UHFFFAOYSA-N,ethyl-paraben,Preclinical,,,,
CCOC(=O)C(C)=O,"InChI=1S/C5H8O3/c1-3-8-5(7)4(2)6/h3H2,1-2H3",XXRCUYVCPSWGCC-UHFFFAOYSA-N,ethyl-pyruvate,Phase 2,tumor necrosis factor production inhibitor,,,
CCOc1cc(C=O)ccc1O,"InChI=1S/C9H10O3/c1-2-12-9-5-7(6-10)3-4-8(9)11/h3-6,11H,2H2,1H3",CBOQJANXLMLOSS-UHFFFAOYSA-N,ethyl-vanillin,Preclinical,,,,
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O,"InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)",KCXVZYZYPLLWCC-UHFFFAOYSA-N,ethylenediaminetetraacetic-acid,Launched,PKC inhibitor,,neurology/psychiatry,metal toxicity
CCC(N)C(O)c1ccc(O)c(O)c1,"InChI=1S/C10H15NO3/c1-2-7(11)10(14)6-3-4-8(12)9(13)5-6/h3-5,7,10,12-14H,2,11H2,1H3",LENNRXOJHWNHSD-UHFFFAOYSA-N,ethylnorepinephrine,Preclinical,bronchodilator,,,
C#CC1(OC(C)=O)CCC2C3CCC4=CC(OC(C)=O)CCC4C3CCC21C,"InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3",ONKUMRGIYFNPJW-UHFFFAOYSA-N,ethynodiol-diacetate,Launched,,ESR1|PGR,endocrinology,contraceptive
C#CC1(O)C(CO)OC(n2ccc(=N)[nH]c2=O)C1O,"InChI=1S/C11H13N3O5/c1-2-11(18)6(5-15)19-9(8(11)16)14-4-3-7(12)13-10(14)17/h1,3-4,6,8-9,15-16,18H,5H2,(H2,12,13,17)",JFIWEPHGRUDAJN-UHFFFAOYSA-N,ethynylcytidine,Preclinical,antimetabolite,,,
CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CC)c1O,"InChI=1S/C17H25ClN2O3/c1-4-11-9-13(18)16(23-3)14(15(11)21)17(22)19-10-12-7-6-8-20(12)5-2/h9,12,21H,4-8,10H2,1-3H3,(H,19,22)",AADCDMQTJNYOSS-UHFFFAOYSA-N,eticlopride,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,
CC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C2H6O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H,4,5,6)(H,7,8,9)",STSVWMYPAMHMEK-UHFFFAOYSA-N,etidronic-acid,Launched,bone resorption inhibitor,ATP6V1A|PTPRS,endocrinology|orthopedics,Paget's disease|heterotopic ossification
CCc1cccc(CC)c1NC(=O)CN(CC(=O)O)CC(=O)O,"InChI=1S/C16H22N2O5/c1-3-11-6-5-7-12(4-2)16(11)17-13(19)8-18(9-14(20)21)10-15(22)23/h5-7H,3-4,8-10H2,1-2H3,(H,17,19)(H,20,21)(H,22,23)",WNIDXAKKFOKNEF-UHFFFAOYSA-N,etifenin,Preclinical,renal function diagnostic agent,,,
CCN=C1Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,"InChI=1S/C17H17ClN2O/c1-3-19-16-20-15-10-9-13(18)11-14(15)17(2,21-16)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3,(H,19,20)",IBYCYJFUEJQSMK-UHFFFAOYSA-N,etifoxine,Launched,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,neurology/psychiatry,anxiety
CCNCC(O)c1cccc(O)c1,"InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3",SQVIAVUSQAWMKL-UHFFFAOYSA-N,etilefrine,Launched,adrenergic receptor agonist,ADRA1A|ADRB1,neurology/psychiatry|otolaryngology|endocrinology|pulmonary,headache|nasal congestion|fever|cough suppressant|common cold
CCOC(=O)C(N)Cc1ccc(O)c(O)c1,"InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3",NULMGOSOSZBEQL-UHFFFAOYSA-N,etilevodopa,Phase 3,dopamine receptor agonist,DRD3,,
CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,"InChI=1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3",VMZUTJCNQWMAGF-UHFFFAOYSA-N,etizolam,Launched,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,insomnia|anxiety
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,"InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)",NNYBQONXHNTVIJ-UHFFFAOYSA-N,etodolac,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
O=C(OCCOCCO)c1ccccc1Nc1cccc(C(F)(F)F)c1,"InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2",XILVEPYQJIOVNB-UHFFFAOYSA-N,etofenamate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,"InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3",XXRVYAFBUDSLJX-UHFFFAOYSA-N,etofibrate,Launched,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia
Cn1c(=O)c2c(ncn2CCO)n(C)c1=O,"InChI=1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3",NWPRCRWQMGIBOT-UHFFFAOYSA-N,etofylline,Launched,adenosine receptor antagonist,ADORA1,pulmonary,asthma|bronchitis
Cn1c(=O)c2c(ncn2CCOC(=O)C(C)(C)Oc2ccc(Cl)cc2)n(C)c1=O,"InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3",KYAKGJDISSNVPZ-UHFFFAOYSA-N,etofylline-clofibrate,Launched,platelet aggregation inhibitor,PPARA,endocrinology,hyperlipidemia
CCOC(=O)c1cncn1C(C)c1ccccc1,"InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3",NPUKDXXFDDZOKR-UHFFFAOYSA-N,etomidate,Launched,GABA receptor modulator,ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,general anaesthetic
CCOC(=O)C1(CCCCCCOc2ccc(Cl)cc2)CO1,"InChI=1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3",DZLOHEOHWICNIL-UHFFFAOYSA-N,etomoxir,Phase 2,carnitine palmitoyltransferase inhibitor,CPT1A,,
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3C(=C)CC21CC,"InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,6,17-20,24H,3-4,7-13H2,1H3",BOMXWTHINLWJIE-UHFFFAOYSA-N,etonogestrel,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,"InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3",VJJPUSNTGOMMGY-UHFFFAOYSA-N,etoposide,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,non-small cell lung cancer (NSCLC)
COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O[PH](=O)(=O)O,"InChI=1S/C29H32O16P/c1-11-38-9-20-27(42-11)23(30)24(31)29(43-20)44-25-14-7-17-16(40-10-41-17)6-13(14)21(22-15(25)8-39-28(22)32)12-4-18(36-2)26(19(5-12)37-3)45-46(33,34)35/h4-7,11,15,20-25,27,29-31H,8-10H2,1-3H3,(H,33,34,35)",XONJELLUBRSXGD-UHFFFAOYSA-N,etoposide-phosphate,Launched,topoisomerase inhibitor,TOP2A,oncology,testicular carcinoma|small cell lung cancer
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,"InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3",MNJVRJDLRVPLFE-UHFFFAOYSA-N,etoricoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis
CCOCCOc1ccccc1C(N)=O,"InChI=1S/C11H15NO3/c1-2-14-7-8-15-10-6-4-3-5-9(10)11(12)13/h3-6H,2,7-8H2,1H3,(H2,12,13)",XBNRCMFFZFCWMH-UHFFFAOYSA-N,etosalamide,Preclinical,anti-inflammatory agent,,,
O=C(CCCO)NCCO,"InChI=1S/C6H13NO3/c8-4-1-2-6(10)7-3-5-9/h8-9H,1-5H2,(H,7,10)",MFHPPMMWHSHDSI-UHFFFAOYSA-N,etoxybamide,Phase 2,,,,
Cn1ncc2c(N3CCOCC3)nc(-c3cccc(O)c3)nc21,"InChI=1S/C16H17N5O2/c1-20-15-13(10-17-20)16(21-5-7-23-8-6-21)19-14(18-15)11-3-2-4-12(22)9-11/h2-4,9-10,22H,5-8H2,1H3",BJVRNXSHJLDZJR-UHFFFAOYSA-N,etp-45658,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)(C#N)c1ccc(N2C(=O)OCc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)cc1,"InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3",DPLMXAYKJZOTKO-UHFFFAOYSA-N,etp-46464,Preclinical,ATR kinase inhibitor,,,
CNC1CCc2ncsc2C1,"InChI=1S/C8H12N2S/c1-9-6-2-3-7-8(4-6)11-5-10-7/h5-6,9H,2-4H2,1H3",YDSVAKPJAOSZJA-UHFFFAOYSA-N,etrabamine,Phase 2,dopamine receptor agonist,,,
O=C(O)CC1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,"InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)",MVGWUTBTXDYMND-UHFFFAOYSA-N,etrasimod,Phase 3,sphingosine 1-phosphate receptor antagonist,,,
Cc1cc(C#N)cc(C)c1Oc1[nH]c(=Nc2ccc(C#N)cc2)[nH]c(=N)c1Br,"InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)",PYGWGZALEOIKDF-UHFFFAOYSA-N,etravirine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP2C19|CYP2C9|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,"InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3",HQMNCQVAMBCHCO-UHFFFAOYSA-N,etretinate,Withdrawn,protein synthesis inhibitor,RARA|RXRG,,
CC12CCC(CC1)C(C)(C)O2,"InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3",WEEGYLXZBRQIMU-UHFFFAOYSA-N,eucalyptol,Launched,acetylcholinesterase inhibitor,ACHE,dental,gingivitis
CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)N1C,"InChI=1S/C17H25NO3/c1-12-10-14(11-17(2,3)18(12)4)21-16(20)15(19)13-8-6-5-7-9-13/h5-9,12,14-15,19H,10-11H2,1-4H3",QSAVEGSLJISCDF-UHFFFAOYSA-N,eucatropine,Preclinical,acetylcholine receptor antagonist,,,
C=CCc1ccc(O)c(OC)c1,"InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3",RRAFCDWBNXTKKO-UHFFFAOYSA-N,eugenol,Launched,androgen receptor antagonist,AR,dental,toothache
COc1cccc(C=NCCN=Cc2cccc(OC)c2O)c1O,"InChI=1S/C18H20N2O4/c1-23-15-7-3-5-13(17(15)21)11-19-9-10-20-12-14-6-4-8-16(24-2)18(14)22/h3-8,11-12,21-22H,9-10H2,1-2H3",POOCDAFRRKDABS-UHFFFAOYSA-N,euk-134,Preclinical,catalase stimulant,APP|SOD2,,
COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,"InChI=1S/C18H16O7/c1-22-12-5-4-9(6-14(12)23-2)13-7-10(19)16-15(25-13)8-11(20)18(24-3)17(16)21/h4-8,20-21H,1-3H3",DRRWBCNQOKKKOL-UHFFFAOYSA-N,eupatilin,Launched,mucus protecting agent,,,
Cc1cc(C)c2c(c1)C(N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2CC1CCC(C(=O)O)CC1,"InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)",IHIUGIVXARLYHP-UHFFFAOYSA-N,evacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
Cc1cc(-c2ccc(N=Nc3ccc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4c3O)c(C)c2)ccc1N=Nc1ccc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2c1O,"InChI=1S/C34H28N6O14S4/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",COXVTLYNGOIATD-UHFFFAOYSA-N,evans-blue,Launched,glutamate receptor negative allosteric modulator,GRIA1|PTPN1,,
CC(C)(C)c1ccc(CN(Cc2cccc(OCC(=O)O)c2)S(=O)(=O)c2cccnc2)cc1,"InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)",WOHRHWDYFNWPNG-UHFFFAOYSA-N,evatanepag,Phase 2,prostaglandin inhibitor,PTGER2|PTGER4,,
CCCCOc1cccc(CCNCC(=O)N(C)C)c1,"InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3",GRHBODILPPXVKN-UHFFFAOYSA-N,evenamide,Phase 2,voltage-gated sodium channel blocker,,,
COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,35-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3",SXIBUDLORNYMST-UHFFFAOYSA-N,everolimus,Launched,mTOR inhibitor,MTOR,oncology|neurology/psychiatry|genetics|urology,breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma
C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,"InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)",QUIWHXQETADMGN-UHFFFAOYSA-N,evobrutinib,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
CC(NC1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12,"InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)",RZNUIYPHQFXBAN-UHFFFAOYSA-N,evocalcet,Phase 3,calcium sensitizer,,,
CN1c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C21,"InChI=1S/C19H17N3O/c1-21-16-9-5-3-7-14(16)19(23)22-11-10-13-12-6-2-4-8-15(12)20-17(13)18(21)22/h2-9,18,20H,10-11H2,1H3",TXDUTHBFYKGSAH-UHFFFAOYSA-N,evodiamine,Preclinical,ATPase inhibitor,TRPV1,,
CN1c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C21,"InChI=1S/C19H17N3O/c1-21-16-9-5-3-7-14(16)19(23)22-11-10-13-12-6-2-4-8-15(12)20-17(13)18(21)22/h2-9,18,20H,10-11H2,1H3",TXDUTHBFYKGSAH-UHFFFAOYSA-N,evodiamine,Preclinical,TRPV agonist,TRPV1,,
O=C(NC1CN2CCC1CC2)c1cc2cccc(Cl)c2s1,"InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)",SSRDSYXGYPJKRR-UHFFFAOYSA-N,evp-6124,Phase 3,acetylcholine receptor agonist,CHRNA7,,
Nc1ccc2[nH]cnc(=NCCc3ccc(Oc4ccccc4)cc3)c2c1,"InChI=1S/C22H20N4O/c23-17-8-11-21-20(14-17)22(26-15-25-21)24-13-12-16-6-9-19(10-7-16)27-18-4-2-1-3-5-18/h1-11,14-15H,12-13,23H2,(H,24,25,26)",IBAKVEUZKHOWNG-UHFFFAOYSA-N,evp4593,Preclinical,NFkB pathway inhibitor,,,
Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,"InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)",FJCDSQATIJKQKA-UHFFFAOYSA-N,ew-7197,Phase 2,TGF beta receptor inhibitor,ACVR1B|TGFBR1,,
NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21,"InChI=1S/C13H13ClN2O/c14-7-4-5-11-10(6-7)8-2-1-3-9(13(15)17)12(8)16-11/h4-6,9,16H,1-3H2,(H2,15,17)",FUZYTVDVLBBXDL-UHFFFAOYSA-N,ex-527,Phase 2,SIRT inhibitor,SIRT1,,
CCCCCCOc1ccccc1C(N)=O,"InChI=1S/C13H19NO2/c1-2-3-4-7-10-16-12-9-6-5-8-11(12)13(14)15/h5-6,8-9H,2-4,7,10H2,1H3,(H2,14,15)",CKSJXOVLXUMMFF-UHFFFAOYSA-N,exalamide,Launched,membrane permeability inhibitor,,,
Cc1[nH]c2ccccc2c1CC(NC(=O)C(N)Cc1c[nH]cn1)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCCN)C(N)=O,"InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)",RVWNMGKSNGWLOL-UHFFFAOYSA-N,examorelin,Phase 2,growth hormone releasing factor agonist,GHRHR|GHSR,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2C(N)CC3,"InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3",ZVYVPGLRVWUPMP-UHFFFAOYSA-N,exatecan-mesylate,Phase 3,topoisomerase inhibitor,TOP1,,
C=C1CC2C(CCC3(C)C(=O)CCC23)C2(C)C=CC(=O)C=C12,"InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3",BFYIZQONLCFLEV-UHFFFAOYSA-N,exemestane,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(N)Cc1c[nH]cn1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O,"InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)",HTQBXNHDCUEHJF-UHFFFAOYSA-N,exenatide,Launched,GLP receptor agonist,GLP1R,endocrinology,diabetes mellitus
CC(=O)NC1CSSCC(C(N)=O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(Cc2c[nH]cn2)NC1=O,"InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)",FQVLRGLGWNWPSS-UHFFFAOYSA-N,exherin,Phase 2,cadherin antagonist,CDH2,,
O=C(c1cc(O)c(O)c(O)c1)c1ccc(O)c(O)c1O,"InChI=1S/C13H10O7/c14-7-2-1-6(11(18)13(7)20)10(17)5-3-8(15)12(19)9(16)4-5/h1-4,14-16,18-20H",XEDWWPGWIXPVRQ-UHFFFAOYSA-N,exifone,Withdrawn,nootropic agent,TYR,,
CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc(S(C)(=O)=O)cc1,"InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)",MVGSNCBCUWPVDA-UHFFFAOYSA-N,exisulind,Phase 3,phosphodiesterase inhibitor,PDE5A,,
COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1,"InChI=1S/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)",KIAPWMKFHIKQOZ-UHFFFAOYSA-N,exo-1,Preclinical,ARF inhibitor,,,
O=C(Nc1cccc2cccnc12)c1ccc(-n2c(O)c3c(c2O)C2C=CC3C2)cc1,"InChI=1S/C25H19N3O3/c29-23(27-19-5-1-3-14-4-2-12-26-22(14)19)15-8-10-18(11-9-15)28-24(30)20-16-6-7-17(13-16)21(20)25(28)31/h1-12,16-17,30-31H,13H2,(H,27,29)",OGYSABKWWQZOIU-UHFFFAOYSA-N,exo-iwr-1,Preclinical,WNT signaling inhibitor negative control,TNKS,,
CCOC(=O)C(N)CCC(=O)NC(CSCc1ccccc1)C(=O)NC(C(=O)OCC)c1ccccc1,"InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)",GWEJFLVSOGNLSS-UHFFFAOYSA-N,ezatiostat,Phase 2,glutathione transferase inhibitor,GSTP1,,
O=C1C(CCC(O)c2ccc(F)cc2)C(c2ccc(O)cc2)N1c1ccc(F)cc1,"InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2",OLNTVTPDXPETLC-UHFFFAOYSA-N,ezetimibe,Launched,cholesterol inhibitor,ANPEP|NPC1L1|SOAT1,endocrinology|metabolism,hyperlipidemia|hypercholesterolemia|sitosterolemia
O=C1C(CCC(O)c2ccc(F)cc2)C(c2ccc(O)cc2)N1c1ccc(F)cc1,"InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2",OLNTVTPDXPETLC-UHFFFAOYSA-N,ezetimibe,Launched,Niemann-Pick C1-like 1 protein antagonist,ANPEP|NPC1L1|SOAT1,endocrinology|metabolism,hyperlipidemia|hypercholesterolemia|sitosterolemia
CCN(CC)c1ccc(-n2nc3cc(C)c(N)cc3n2)cc1,"InChI=1S/C17H21N5/c1-4-21(5-2)13-6-8-14(9-7-13)22-19-16-10-12(3)15(18)11-17(16)20-22/h6-11H,4-5,18H2,1-3H3",WRIPKYOZKAJHRL-UHFFFAOYSA-N,ezutromid,Phase 2,utrophin enhancer,UTRN,,
Cn1c(=O)cnn(CCCCN2CCN(c3ncccn3)CC2)c1=O,"InChI=1S/C16H23N7O2/c1-20-14(24)13-19-23(16(20)25)8-3-2-7-21-9-11-22(12-10-21)15-17-5-4-6-18-15/h4-6,13H,2-3,7-12H2,1H3",NMYAHEULKSYAPP-UHFFFAOYSA-N,f-11440,Phase 2,serotonin receptor agonist,HTR1A,,
CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCc1cccnc1,"InChI=1S/C28H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23-28(30)31-26-27-22-21-24-29-25-27/h3-4,6-7,9-10,12-13,15-16,18-19,21-22,24-25H,2,5,8,11,14,17,20,23,26H2,1H3",BUWVEXMRBAWBPJ-UHFFFAOYSA-N,f-16915,Preclinical,,,,
Cc1ccc(=O)n(-c2ccc(O)cc2)c1,"InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3",NETTXQJYJRFTFS-UHFFFAOYSA-N,f351,Phase 2,TGF beta receptor inhibitor,TGFB1,,
N#Cc1ccc(C2CCCc3cncn32)cc1,"InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2",CLPFFLWZZBQMAO-UHFFFAOYSA-N,fadrozole,Launched,aromatase inhibitor,CYP11B1|CYP19A1,oncology,breast cancer
OCC1NCCC(O)C1O,"InChI=1S/C6H13NO3/c8-3-4-6(10)5(9)1-2-7-4/h4-10H,1-3H2",YZNNBIPIQWYLDM-UHFFFAOYSA-N,fagomine,Phase 2,glucosidase inhibitor,GLB1,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCCC(O)(C(F)(F)F)C(F)(F)F)CC(O)CC1O,"InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3",XPYGGHVSFMUHLH-UHFFFAOYSA-N,falecalcitriol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
CC(=O)OCC(CCn1cnc2c[nH]c(=N)nc21)COC(C)=O,"InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)",GGXKWVWZWMLJEH-UHFFFAOYSA-N,famciclovir,Launched,DNA polymerase inhibitor,,dental|infectious disease,cold sore|genitial herpes|shingles
N=C(N)N=c1[nH]c(CSCCC(=N)NS(N)(=O)=O)cs1,"InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)",XUFQPHANEAPEMJ-UHFFFAOYSA-N,famotidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn
CC(C)c1c(CN(C)C(C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O,"InChI=1S/C24H31N3O/c1-18(2)23-22(17-25(4)19(3)16-20-12-8-6-9-13-20)26(5)27(24(23)28)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3",GNUXVOXXWGNPIV-UHFFFAOYSA-N,famprofazone,Preclinical,cyclooxygenase inhibitor,,,
O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccc(F)cc2)CC1,"InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2",VGIGHGMPMUCLIQ-UHFFFAOYSA-N,fananserin,Phase 2,dopamine receptor antagonist,HTR2A,,
O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccc(F)cc2)CC1,"InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2",VGIGHGMPMUCLIQ-UHFFFAOYSA-N,fananserin,Phase 2,serotonin receptor antagonist,HTR2A,,
c1ccc(CCN=c2[nH]c(-c3ccccc3)cs2)cc1,"InChI=1S/C17H16N2S/c1-3-7-14(8-4-1)11-12-18-17-19-16(13-20-17)15-9-5-2-6-10-15/h1-10,13H,11-12H2,(H,18,19)",WEEYMMXMBFJUAI-UHFFFAOYSA-N,fanetizole,Phase 3,neutrophil superoxide production,,,
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)cn4ccccc34)cc2)cc1OC,"InChI=1S/C31H38N2O5S/c1-23(2)27-22-33-18-7-6-9-28(33)31(27)39(34,35)26-13-11-25(12-14-26)38-20-8-17-32(3)19-16-24-10-15-29(36-4)30(21-24)37-5/h6-7,9-15,18,21-23H,8,16-17,19-20H2,1-5H3",ITAMRBIZWGDOHW-UHFFFAOYSA-N,fantofarone,Preclinical,calcium channel blocker,,,
O=C(c1ccc2nonc2c1)N1CCCCC1,"InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2",XFVRBYKKGGDPAJ-UHFFFAOYSA-N,farampator,Preclinical,ionotropic glutamate receptor agonist,,,
CC(C)=CCCC(C)=CCCC(C)=CCSc1ccccc1C(N)=O,"InChI=1S/C22H31NOS/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H2,23,24)",GZTMFRUGZMZCRD-UHFFFAOYSA-N,farnesyl-thiosalicylic-acid-amide,Phase 1,Ras GTPase inhibitor,HRAS,,
CC(O)C1C(=O)N2C(C(=O)O)=C(C3CCCO3)SC12,"InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)",HGGAKXAHAYOLDJ-UHFFFAOYSA-N,faropenem,Launched,lactamase inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|skin infections|urinary tract infections|sinusitis
Cc1oc(=O)oc1COC(=O)C1=C(C2CCCO2)SC2C(C(C)O)C(=O)N12,"InChI=1S/C17H19NO8S/c1-7(19)11-14(20)18-12(13(27-15(11)18)9-4-3-5-23-9)16(21)24-6-10-8(2)25-17(22)26-10/h7,9,11,15,19H,3-6H2,1-2H3",JQBKWZPHJOEQAO-UHFFFAOYSA-N,faropenem-medoxomil,Launched,lactamase inhibitor,,otolaryngology|infectious disease|pulmonary,sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections
Oc1ccc(C(O)N2CCCCC2)[nH]1,"InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h4-5,10-11,13-14H,1-3,6-7H2",YOVHZHRBNQHJKE-UHFFFAOYSA-N,fasoracetam,Preclinical,GABA receptor antagonist,,,
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,"InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2",NGOGFTYYXHNFQH-UHFFFAOYSA-N,fasudil,Launched,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1|ROCK2,neurology/psychiatry,cerebral vasospasm
NC(=O)c1nc(F)c[nH]c1=O,"InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)",ZCGNOVWYSGBHAU-UHFFFAOYSA-N,favipiravir,Phase 3,RNA polymerase inhibitor,,,
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(=CNN=CN5CCCCC5)c(O)c4c3C2=O)=NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,45,50-54H,10-12,17-18H2,1-9H3",FNQXHJZILQDPGE-UHFFFAOYSA-N,fce-22250,Phase 1,DNA directed DNA polymerase inhibitor,,,
N=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1F,"InChI=1S/C9H12FN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)",IDYKCXHJJGMAEV-UHFFFAOYSA-N,fdcyd,Phase 2,DNA methyltransferase inhibitor,,,
CCCCOCC(O)COc1ccccc1,"InChI=1S/C13H20O3/c1-2-3-9-15-10-12(14)11-16-13-7-5-4-6-8-13/h4-8,12,14H,2-3,9-11H2,1H3",WBLXZPHICYCDGN-UHFFFAOYSA-N,febuprol,Launched,choleretic agent,,,
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,"InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)",BQSJTQLCZDPROO-UHFFFAOYSA-N,febuxostat,Launched,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia
Cc1c[nH]c(=Nc2ccc(OCCN3CCCC3)cc2)[nH]c1=Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,"InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)",JOOXLOJCABQBSG-UHFFFAOYSA-N,fedratinib,Launched,FLT3 inhibitor,BRD4|JAK1|JAK2|JAK3|TYK2,hematologic malignancy,myelofibrosis
Cc1c[nH]c(=Nc2ccc(OCCN3CCCC3)cc2)[nH]c1=Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,"InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)",JOOXLOJCABQBSG-UHFFFAOYSA-N,fedratinib,Launched,JAK inhibitor,BRD4|JAK1|JAK2|JAK3|TYK2,hematologic malignancy,myelofibrosis
NC(=O)OCC(COC(N)=O)c1ccccc1,"InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)",WKGXYQFOCVYPAC-UHFFFAOYSA-N,felbamate,Launched,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,neurology/psychiatry,epilepsy
O=C(O)Cc1ccc(-c2ccccc2)cc1,"InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)",QRZAKQDHEVVFRX-UHFFFAOYSA-N,felbinac,Launched,cyclooxygenase inhibitor,CTSL,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain
CCOC(=O)Cc1ccc(-c2ccccc2)cc1,"InChI=1S/C16H16O2/c1-2-18-16(17)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,2,12H2,1H3",NPPJLSILDPVHCM-UHFFFAOYSA-N,felbinac-ethyl,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1c1cccc(Cl)c1Cl,"InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,13,15H,5H2,1-4H3",HAQDEJPEAKWAAM-UHFFFAOYSA-N,felodipine,Launched,calcium channel blocker,CFTR,cardiology,hypertension
NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)",SFKQVVDKFKYTNA-UHFFFAOYSA-N,felypressin,Preclinical,vasopressin receptor agonist,,,
O=C(CCCl)NCCc1ccccc1,"InChI=1S/C11H14ClNO/c12-8-6-11(14)13-9-7-10-4-2-1-3-5-10/h1-5H,6-9H2,(H,13,14)",BITWVVLBVUMFHU-UHFFFAOYSA-N,fenaclon,Preclinical,,,,
COC(=O)N=c1[nH]c2ccc(Sc3ccccc3)cc2[nH]1,"InChI=1S/C15H13N3O2S/c1-20-15(19)18-14-16-12-8-7-11(9-13(12)17-14)21-10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)",HDDSHPAODJUKPD-UHFFFAOYSA-N,fenbendazole,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites|gastrointestinal roundworms
O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,"InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)",ZPAKPRAICRBAOD-UHFFFAOYSA-N,fenbufen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
NC(Cc1ccc(Cl)cc1)C(=O)O,"InChI=1S/C9H10ClNO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)",NIGWMJHCCYYCSF-UHFFFAOYSA-N,fenclonine-(+/-),Preclinical,tryptophan hydroxylase inhibitor,PAH|TPH1|TPH2,,
CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,"InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3",NMKSAYKQLCHXDK-UHFFFAOYSA-N,fendiline,Preclinical,calcium channel blocker,HTR2B,,
CC1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)[nH]c1,"InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)",WNEODWDFDXWOLU-UHFFFAOYSA-N,fenebrutinib,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
NCC(CC(=O)O)c1ccccc1,"InChI=1S/C10H13NO2/c11-7-9(6-10(12)13)8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)",DAFOCGYVTAOKAJ-UHFFFAOYSA-N,fenigam,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,neurology/psychiatry,posttraumatic stress disorder|anxiety|depression
CCCCC(O)c1ccccc1,"InChI=1S/C11H16O/c1-2-3-9-11(12)10-7-5-4-6-8-10/h4-8,11-12H,2-3,9H2,1H3",OVGORFFCBUIFIA-UHFFFAOYSA-N,fenipentol,Launched,choleretic agent,,gastroenterology,bile stimulation
Cn1cc(O)[nH]c1=NC(=O)Nc1cccc(Cl)c1,"InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-6,17H,1H3,(H2,13,14,15,18)",XSGFZVPHOUBKKN-UHFFFAOYSA-N,fenobam,Phase 2,glutamate receptor antagonist,GRM5,,
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,"InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",YMTINGFKWWXKFG-UHFFFAOYSA-N,fenofibrate,Launched,PPAR receptor agonist,MMP25|PPARA,endocrinology,hypercholesterolemia|hypertriglyceridemia
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,"InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)",MQOBSOSZFYZQOK-UHFFFAOYSA-N,fenofibric-acid,Launched,cytochrome P450 inhibitor,CLCN1|PPARA,cardiology,dyslipidemia
Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1,"InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2",TVURRHSHRRELCG-UHFFFAOYSA-N,fenoldopam,Launched,dopamine receptor agonist,DRD1|DRD4,cardiology,hypertension
CC(C(=O)O)c1cccc(Oc2ccccc2)c1,"InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)",RDJGLLICXDHJDY-UHFFFAOYSA-N,fenoprofen,Launched,prostaglandin inhibitor,PTGS1|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis
CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,"InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3",LSLYOANBFKQKPT-UHFFFAOYSA-N,fenoterol,Withdrawn,adrenergic receptor agonist,ADRB2,,
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21,"InChI=1S/C26H25N3O3S/c30-26(29-20-5-1-3-7-24(20)33-25-8-4-2-6-21(25)29)17-28-13-11-27(12-14-28)16-19-9-10-22-23(15-19)32-18-31-22/h1-10,15H,11-14,16-18H2",UBAJTZKNDCEGKL-UHFFFAOYSA-N,fenoverine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,spasms
CCOC(=O)C(C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1,"InChI=1S/C18H16ClNO5/c1-3-22-17(21)11(2)23-13-5-7-14(8-6-13)24-18-20-15-9-4-12(19)10-16(15)25-18/h4-11H,3H2,1-2H3",PQKBPHSEKWERTG-UHFFFAOYSA-N,fenoxaprop-p-ethyl,Preclinical,,NOS3,,
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)Nc1ccc(O)cc1,"InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)",AKJHMTWEGVYYSE-UHFFFAOYSA-N,fenretinide,Phase 3,apoptosis stimulant,RARA,,
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)Nc1ccc(O)cc1,"InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)",AKJHMTWEGVYYSE-UHFFFAOYSA-N,fenretinide,Phase 3,retinoid receptor agonist,RARA,,
O=C1NCC2(CCN(CCc3ccccc3)CC2)O1,"InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)",FVNFBBAOMBJTST-UHFFFAOYSA-N,fenspiride,Launched,bronchodilator,,pulmonary|otolaryngology,asthma|otitis|sinusitis|rhinopharyngitis|laryngitis
COP(=S)(OC)Oc1ccc(SC)c(C)c1,"InChI=1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3",PNVJTZOFSHSLTO-UHFFFAOYSA-N,fenthion,Launched,cholinesterase inhibitor,,,
O=C(O)Cc1sc(-c2ccccc2)nc1-c1ccc(Cl)cc1,"InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)",JIEKMACRVQTPRC-UHFFFAOYSA-N,fentiazac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain
Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1,"InChI=1S/C24H20Cl2N2OS/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20/h1-14,17,24H,15-16H2",ZCJYUTQZBAIHBS-UHFFFAOYSA-N,fenticonazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,vulvovaginal candidiasis
ON=Cc1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,"InChI=1S/C13H9ClFNO3/c14-12-9(3-1-8(6-16-19)13(12)18)7-2-4-11(17)10(15)5-7/h1-6,17-19H",LRRMQNGSYOUANY-UHFFFAOYSA-N,ferb-033,Preclinical,EGFR inhibitor,ERBB2,,
CN(C)CC1=CC=CC1CN=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C18H20ClN3/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18/h3-10,13H,11-12H2,1-2H3,(H,20,21)",CKOVXJOFLLSDBI-UHFFFAOYSA-N,ferroquine,Phase 2,antimalarial agent,,,
CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1,"InChI=1S/C15H22N2O2/c1-2-19-15(18)11-8-9-14(13(16)10-11)17-12-6-4-3-5-7-12/h8-10,12,17H,2-7,16H2,1H3",UJHBVMHOBZBWMX-UHFFFAOYSA-N,ferrostatin-1,Preclinical,ferroptosis inhibitor,,,
COc1cc(C=CC(=O)O)ccc1O,"InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)",KSEBMYQBYZTDHS-UHFFFAOYSA-N,ferulic-acid,Phase 2,antioxidant,CA1|CA12|CA14|CA2|CA4|CA6|CA9,,
CC(C)C(=O)Oc1ccc(CO)cc1C(CCN(C(C)C)C(C)C)c1ccccc1,"InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3",DCCSDBARQIPTGU-UHFFFAOYSA-N,fesoterodine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,"InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)",GFPPXZDRVCSVNR-UHFFFAOYSA-N,fevipiprant,Phase 2,prostaglandin inhibitor,,,
COC(=O)C=Cc1cccc(N(Cc2ccc(-c3ccc(N(C)C)cc3)cc2)C(=O)C2CCCCC2)c1,"InChI=1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3",VLQTUNDJHLEFEQ-UHFFFAOYSA-N,fexaramine,Preclinical,FXR agonist,NR1H4,,
CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1,"InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3",MIWWSGDADVMLTG-UHFFFAOYSA-N,fexinidazole,Phase 3,,,,
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)",RWTNPBWLLIMQHL-UHFFFAOYSA-N,fexofenadine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3C)n1,"InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3",PPSNFPASKFYPMN-UHFFFAOYSA-N,fezolinetant,Phase 2,neurokinin receptor antagonist,,,
O=C(O)CNC(=O)c1nc(Cl)c2ccccc2c1O,"InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17)",OUQVKRKGTAUJQA-UHFFFAOYSA-N,fg-2216,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|HIF1A,,
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,"InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)",YOZBGTLTNGAVFU-UHFFFAOYSA-N,fg-4592,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|EGLN3,,
CNC(=O)c1cc2c(cn1)[nH]c1ccccc12,"InChI=1S/C13H11N3O/c1-14-13(17)11-6-9-8-4-2-3-5-10(8)16-12(9)7-15-11/h2-7,16H,1H3,(H,14,17)",QMCOPDWHWYSJSA-UHFFFAOYSA-N,fg-7142,Preclinical,GABA benzodiazepine site receptor inverse agonist,,,
CCCCCCN(CCCCCC)C(=O)Cc1c(-c2ccc(F)cc2)[nH]c2ccccc12,"InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3",VUWXAQFLTSBUDB-UHFFFAOYSA-N,fgin-1-27,Preclinical,inositol monophosphatase inhibitor,TSPO,,
CCCCCCN(CCCCCC)C(=O)Cc1c(-c2ccc(Cl)cc2)[nH]c2ccc(Cl)cc12,"InChI=1S/C28H36Cl2N2O/c1-3-5-7-9-17-32(18-10-8-6-4-2)27(33)20-25-24-19-23(30)15-16-26(24)31-28(25)21-11-13-22(29)14-12-21/h11-16,19,31H,3-10,17-18,20H2,1-2H3",XTZUPNNVXIMWAR-UHFFFAOYSA-N,fgin-1-43,Preclinical,benzodiazepine receptor agonist,TSPO,,
Cc1cc([N+](=O)[O-])ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl,"InChI=1S/C13H10Cl2N2O4S/c1-8-6-10(17(18)19)3-5-12(8)16-22(20,21)13-7-9(14)2-4-11(13)15/h2-7,16H,1H3",AXNUEXXEQGQWPA-UHFFFAOYSA-N,fh-535,Preclinical,PPAR receptor antagonist,PPARD|PPARG,,
Cc1cc([N+](=O)[O-])ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl,"InChI=1S/C13H10Cl2N2O4S/c1-8-6-10(17(18)19)3-5-12(8)16-22(20,21)13-7-9(14)2-4-11(13)15/h2-7,16H,1H3",AXNUEXXEQGQWPA-UHFFFAOYSA-N,fh-535,Preclinical,WNT signaling inhibitor,PPARD|PPARG,,
CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1,"InChI=1S/C17H18N2O2/c1-12(20)18-16-7-3-14(4-8-16)11-15-5-9-17(10-6-15)19-13(2)21/h3-10H,11H2,1-2H3,(H,18,20)(H,19,21)",OEXMNSOPAKOPEF-UHFFFAOYSA-N,fh1,Preclinical,hepatocyte function enhancer,,,
N=c1[nH]c(=O)n(C2OC(CO)C(O)C2F)cc1I,"InChI=1S/C9H11FIN3O4/c10-5-6(16)4(2-15)18-8(5)14-1-3(11)7(12)13-9(14)17/h1,4-6,8,15-16H,2H2,(H2,12,13,17)",GIMSJJHKKXRFGV-UHFFFAOYSA-N,fiacitabine,Phase 2,DNA synthesis inhibitor,,,
NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1,"InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)",WAAPEIZFCHNLKK-UHFFFAOYSA-N,fidarestat,Phase 3,aldose reductase inhibitor,AKR1B1,,
CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)OC1C(C)OC(OCC2=CC=CCC(O)C(C)=CC(CC)C(OC3OC(C)(C)C(OC(=O)C(C)C)C(O)C3O)C(C)=CC(C)=CCC(C(C)O)OC2=O)C(OC)C1O,"InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3",ZVGNESXIJDCBKN-UHFFFAOYSA-N,fidaxomicin,Launched,RNA polymerase inhibitor,,gastroenterology,diarrhea
CON(C)C(=O)N1N=C(c2cc(F)ccc2F)SC1(CCCN)c1ccccc1,"InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3",LLXISKGBWFTGEI-UHFFFAOYSA-N,filanesib,Phase 3,kinesin inhibitor,KIF11,,
CON(C)C(=O)N1N=C(c2cc(F)ccc2F)SC1(CCCN)c1ccccc1,"InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3",LLXISKGBWFTGEI-UHFFFAOYSA-N,filanesib,Phase 3,kinesin-like spindle protein inhibitor,KIF11,,
O=C(N=c1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2[nH]1)C1CC1,"InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)",RIJLVEAXPNLDTC-UHFFFAOYSA-N,filgotinib,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)",AMEROGPZOLAFBN-UHFFFAOYSA-N,fimasartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure
N#Cc1c(N2CC3NCCOC3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,"InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)",FYMHQCNFKNMJAV-UHFFFAOYSA-N,finafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|pulmonary,intra-abdominal infections|chronic obstructive pulmonary disease (COPD)|cystic fibrosis
CC(C)(C)NC(=O)C1CCC2C3CCC4NC(=O)C=CC4(C)C3CCC12C,"InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)",DBEPLOCGEIEOCV-UHFFFAOYSA-N,finasteride,Launched,5 alpha reductase inhibitor,AKR1D1|SRD5A1|SRD5A2,endocrinology,androgenetic alopecia
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,"InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3",KKGQTZUTZRNORY-UHFFFAOYSA-N,fingolimod,Launched,immunosuppressant,S1PR1|S1PR5,neurology/psychiatry,multiple sclerosis
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,"InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3",KKGQTZUTZRNORY-UHFFFAOYSA-N,fingolimod,Launched,sphingosine 1-phosphate receptor agonist,S1PR1|S1PR5,neurology/psychiatry,multiple sclerosis
O=C(COc1ccc(Cl)cc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1,"InChI=1S/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2",BFUJHVVEMMWLHC-UHFFFAOYSA-N,fipexide,Withdrawn,psychoactive drug,,,
O=C(NCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1cc2cc(F)ccc2[nH]1,"InChI=1S/C23H24FN5O2/c24-16-5-6-18-15(13-16)14-20(26-18)22(30)25-9-12-28-10-7-17(8-11-28)29-21-4-2-1-3-19(21)27-23(29)31/h1-6,13-14,17,26H,7-12H2,(H,25,30)(H,27,31)",LHABRXRGDLASIH-UHFFFAOYSA-N,fipi,Preclinical,phospholipase inhibitor,PLD1|PLD2,,
N#Cc1[nH]n(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(=N)c1[S+]([O-])C(F)(F)F,"InChI=1S/C12H4Cl2F6N4OS/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)26(25)12(18,19)20/h1-2,22-23H",KDZAIKFHBUSULQ-UHFFFAOYSA-N,fipronil,Launched,chloride channel blocker,,infectious disease,flea control
N#Cc1[nH]n(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(=N)c1[S+]([O-])C(F)(F)F,"InChI=1S/C12H4Cl2F6N4OS/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)26(25)12(18,19)20/h1-2,22-23H",KDZAIKFHBUSULQ-UHFFFAOYSA-N,fipronil,Launched,GABA gated chloride channel blocker,,infectious disease,flea control
CCOCc1cc(OC)c(-c2ccc(CC(NC(=O)c3c(F)cccc3F)C(=O)O)cc2)c(OC)c1,"InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)",YLFZHHDVRSYTKT-UHFFFAOYSA-N,firategrast,Phase 2,integrin antagonist,ITGA4,,
CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(S(C)(=O)=O)cc1,"InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3",FULAPETWGIGNMT-UHFFFAOYSA-N,firocoxib,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis
COc1ccccc1C(Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1,"InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)",ZZWWXIBKLBMSCS-UHFFFAOYSA-N,firsocostat,Phase 2,acetyl-CoA carboxylase inhibitor,,,
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,"InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H",XHEFDIBZLJXQHF-UHFFFAOYSA-N,fisetin,Preclinical,Aurora kinase inhibitor,CDK6|FASN,,
C=CC(=O)NC1CCOCC1N=c1nc2ccc(-c3c(Cl)c(OC)cc(OC)c3Cl)cc2c[nH]1,"InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)",MGZKYOAQVGSSGC-UHFFFAOYSA-N,fisogatinib,Phase 1,fibroblast growth factor inhibitor,,,
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccc(N=C=S)cc2)CC1,"InChI=1S/C23H27N3OS/c1-2-23(27)26(21-6-4-3-5-7-21)22-13-16-25(17-14-22)15-12-19-8-10-20(11-9-19)24-18-28/h3-11,22H,2,12-17H2,1H3",VDKBIFPJULZUPU-UHFFFAOYSA-N,fit,Preclinical,opioid receptor agonist,OPRD1,,
CC(NC(=O)C(N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)C(Cc1ccccc1)C(=O)NC(CO)CC[S+](C)[O-],"InChI=1S/C29H41N5O7S/c1-19(32-28(39)24(30)15-21-9-11-23(36)12-10-21)27(38)31-17-26(37)34(2)25(16-20-7-5-4-6-8-20)29(40)33-22(18-35)13-14-42(3)41/h4-12,19,22,24-25,35-36H,13-18,30H2,1-3H3,(H,31,38)(H,32,39)(H,33,40)",HYZHONGSQNXMPH-UHFFFAOYSA-N,fk-33-824,Phase 2,opioid receptor agonist,OPRM1,,
CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,"InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3",DIIYLGZNZGPXRR-UHFFFAOYSA-N,fk-3311,Phase 2,cyclooxygenase inhibitor,PTGS2,,
CCC(=CC(=NO)C(N)=O)C(C)[N+](=O)[O-],"InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)",MZAGXDHQGXUDDX-UHFFFAOYSA-N,fk-409,Phase 2,guanylyl cyclase activator,,,
O=C(C=Cc1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,"InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)",KPBNHDGDUADAGP-UHFFFAOYSA-N,fk-866,Phase 2,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,
CN(Cc1ccccc1)C(=O)C(Cc1ccc2ccccc2c1)NC(=O)C1CC(O)CN1C(=O)c1cn(C)c2ccccc12,"InChI=1S/C36H36N4O4/c1-38-23-30(29-14-8-9-15-32(29)38)35(43)40-22-28(41)20-33(40)34(42)37-31(36(44)39(2)21-24-10-4-3-5-11-24)19-25-16-17-26-12-6-7-13-27(26)18-25/h3-18,23,28,31,33,41H,19-22H2,1-2H3,(H,37,42)",BFNKQTIJVFGCKQ-UHFFFAOYSA-N,fk-888,Phase 2,tachykinin antagonist,TACR1|TACR2,,
CC(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1,"InChI=1S/C14H17FN2O2/c1-10(18)17-8-6-13(7-9-17)16-14(19)11-2-4-12(15)5-3-11/h2-5,13H,6-9H2,1H3,(H,16,19)",VBHVOHJOTMCSBQ-UHFFFAOYSA-N,fk-962,Phase 2,somatostatin receptor agonist,,,
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(CC(O)C(O)C(O)CO[PH](=O)(=O)O[PH](=O)(=O)OCC3OC(n4cnc5c(=N)[nH]cnc54)C(O)C3O)c2cc1C,"InChI=1S/C27H31N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H2,28,29,30)(H,34,42,43)",JSHNEDVBYLKEBM-UHFFFAOYSA-N,flavin-adenine-dinucleotide,Preclinical,,ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH,,
Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,"InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3",SPIUTQOUKAMGCX-UHFFFAOYSA-N,flavoxate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2,urology,urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis
O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,"InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)",DJBNUMBKLMJRSA-UHFFFAOYSA-N,flecainide,Launched,sodium channel blocker,KCNA5|KCNA7|SCN5A,cardiology,ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1,"InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)",XBJBPGROQZJDOJ-UHFFFAOYSA-N,fleroxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease|gastroenterology,gonorrhea|enteritis|diarrhea|respiratory tract infections
CC1=C(C(=O)OC2CCCCC2)C(c2ccc([N+](=O)[O-])cc2)C2C(=O)CC(C)(C)CC2=N1,"InChI=1S/C25H30N2O5/c1-15-21(24(29)32-18-7-5-4-6-8-18)22(16-9-11-17(12-10-16)27(30)31)23-19(26-15)13-25(2,3)14-20(23)28/h9-12,18,22-23H,4-8,13-14H2,1-3H3",GSEWODUYOOBDMD-UHFFFAOYSA-N,fli-06,Preclinical,notch signaling inhibitor,,,
O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1,"InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)",PPRRDFIXUUSXRA-UHFFFAOYSA-N,flibanserin,Launched,serotonin receptor agonist,DRD4|HTR1A|HTR2A,neurology/psychiatry,hypoactive sexual desire disorder
COc1ccc(Cl)cc1C1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,"InChI=1S/C16H10ClF4NO2/c1-24-13-5-3-9(17)7-11(13)15(18)10-4-2-8(16(19,20)21)6-12(10)22-14(15)23/h2-7H,1H3,(H,22,23)",ULYONBAOIMCNEH-UHFFFAOYSA-N,flindokalner,Phase 3,potassium channel agonist,KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5,,
O=C(OCC(O)CO)c1ccccc1N=c1cc[nH]c2c(C(F)(F)F)cccc12,"InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)",APQPGQGAWABJLN-UHFFFAOYSA-N,floctafenine,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CCC(=O)c1c(O)cc(O)cc1O,"InChI=1S/C9H10O4/c1-2-6(11)9-7(12)3-5(10)4-8(9)13/h3-4,10,12-13H,2H2,1H3",PTHLEKANMPKYDB-UHFFFAOYSA-N,flopropione,Launched,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms
CS(=O)(=O)c1ccc(C(O)C(CF)NC(=O)C(Cl)Cl)cc1,"InChI=1S/C12H14Cl2FNO4S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-15)16-12(18)11(13)14/h2-5,9-11,17H,6H2,1H3,(H,16,18)",AYIRNRDRBQJXIF-UHFFFAOYSA-N,florfenicol,Launched,protein synthesis inhibitor,,pulmonary,bovine respiratory disease (BRD)
O=C(OCCN1CCCC1)c1ccccc1N=c1cc[nH]c2cc(C(F)(F)F)ccc12,"InChI=1S/C23H22F3N3O2/c24-23(25,26)16-7-8-17-20(9-10-27-21(17)15-16)28-19-6-2-1-5-18(19)22(30)31-14-13-29-11-3-4-12-29/h1-2,5-10,15H,3-4,11-14H2,(H,27,28)",DQOYUDHAZMAVLD-UHFFFAOYSA-N,florifenine,Preclinical,anti-inflammatory agent,,,
Cn1cc([S+](C)[O-])c(=O)c2ccc(F)cc21,"InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3",UYGONJYYUKVHDD-UHFFFAOYSA-N,flosequinan,Withdrawn,phosphodiesterase inhibitor,,,
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1F,"InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)",ODKNJVUHOIMIIZ-UHFFFAOYSA-N,floxuridine,Launched,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer
CCCN=c1[nH]c(=Nc2ccc(C#N)cc2)[nH]cc1C#CCCCNC(=O)C(C)N(C)C(=O)C=CCN(C)C,"InChI=1S/C29H38N8O2/c1-6-17-31-27-24(21-33-29(35-27)34-25-15-13-23(20-30)14-16-25)11-8-7-9-18-32-28(39)22(2)37(5)26(38)12-10-19-36(3)4/h10,12-16,21-22H,6-7,9,17-19H2,1-5H3,(H,32,39)(H2,31,33,34,35)",HJFSVYUFOXAVAA-UHFFFAOYSA-N,flt3-in-1,Preclinical,FLT3 inhibitor,,,
COC(=O)N=c1[nH]c2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1,"InChI=1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)",CPEUVMUXAHMANV-UHFFFAOYSA-N,flubendazole,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites
Cc1onc(-c2c(F)cccc2Cl)c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)",UIOFUWFRIANQPC-UHFFFAOYSA-N,flucloxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|dermatology|gastroenterology,gram-positive bacterial infections|tonsillitis|sinusitis|pneumonia|eczema|endocarditis|meningitis|enteritis|bacterial septicemia
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2",RFHAOTPXVQNOHP-UHFFFAOYSA-N,fluconazole,Launched,sterol demethylase inhibitor,CYP51A1,infectious disease,esophageal candidiasis|meningitis
N=c1[nH]c(=O)[nH]cc1F,"InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)",XRECTZIEBJDKEO-UHFFFAOYSA-N,flucytosine,Launched,other antifungal,DNMT1,infectious disease,bacterial septicemia|endocarditis|urinary tract infections|meningitis
N=c1[nH]c(F)nc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)",HBUBKKRHXORPQB-UHFFFAOYSA-N,fludarabine,Launched,ribonucleotide reductase inhibitor,ADA|DCK|POLA1|RRM1|RRM2,hematologic malignancy,chronic lymphocytic leukemia (CLL)
N=c1[nH]c(F)nc2c1ncn2C1OC(CO[PH](=O)(=O)O)C(O)C1O,"InChI=1S/C10H12FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H,19,20,21)",CAOWNCTTWGSKDO-UHFFFAOYSA-N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,chronic lymphocytic leukemia (CLL)
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3(F)C(O)CC21C,"InChI=1S/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h4,16-18,27,29H,5-12H2,1-3H3",CIGNZXWBHKAMIO-UHFFFAOYSA-N,fludrocortisone-acetate,Launched,,NR3C2,endocrinology,Addison's disease|adrenogenital syndrome
CC1(C)OC2CC3C4CC(F)=C5CC(=O)CCC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h13-14,17,19-20,26,28H,5-11H2,1-4H3",BCULYDRERATSCZ-UHFFFAOYSA-N,fludroxycortide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,infectious disease|dermatology,skin infections|psoriasis
O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,"InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)",LPEPZBJOKDYZAD-UHFFFAOYSA-N,flufenamic-acid,Preclinical,chloride channel blocker,AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5,,
Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1N=c1nc(-c2cccnc2)cc[nH]1,"InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)",BJCJYEYYYGBROF-UHFFFAOYSA-N,flumatinib,Phase 3,Bcr-Abl kinase inhibitor,ABL1|PDGFRB,,
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,"InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3",OFBIFZUFASYYRE-UHFFFAOYSA-N,flumazenil,Launched,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,sedative
CCC(O)(c1ccccc1)c1cccc(C(F)(F)F)c1,"InChI=1S/C16H15F3O/c1-2-15(20,12-7-4-3-5-8-12)13-9-6-10-14(11-13)16(17,18)19/h3-11,20H,2H2,1H3",DVASNQYQOZHAJN-UHFFFAOYSA-N,flumecinol,Launched,,,,
CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,"InChI=1S/C14H12FNO3/c1-7-2-3-8-4-9(15)5-10-12(8)16(7)6-11(13(10)17)14(18)19/h4-7H,2-3H2,1H3,(H,18,19)",DPSPPJIUMHPXMA-UHFFFAOYSA-N,flumequine,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
CC1CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO,"InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,11,13-14,17,25,27,29H,6-10H2,1-3H3",FWISRXLAJVUSOL-UHFFFAOYSA-N,flumethasone,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,otolaryngology|infectious disease|dermatology,otitis|ear infections|corticosteroid-responsive dermatoses
CC1CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COC(=O)C(C)(C)C,"InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,14,16-17,20,31,34H,9-13H2,1-6H3",BKNMGJRIIPQSAQ-UHFFFAOYSA-N,flumethasone-pivalate,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis
FC(F)(F)c1cccc(C2CNCCO2)c1,"InChI=1S/C11H12F3NO/c12-11(13,14)9-3-1-2-8(6-9)10-7-15-4-5-16-10/h1-3,6,10,15H,4-5,7H2",GXPYCYWPUGKQIJ-UHFFFAOYSA-N,flumexadol,Preclinical,,,,
Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,"InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2",SMANXXCATUTDDT-UHFFFAOYSA-N,flunarizine,Launched,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1,neurology/psychiatry|cardiology,migraine headache|vertigo|peripheral artery disease (PAD)
CC1(C)OC2CC3C4CC(F)=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-6,13-14,17,19-20,26,28H,7-11H2,1-4H3",WDPGUNUWRTWBQU-UHFFFAOYSA-N,flunisolide,Launched,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis
Cc1c(N=c2[nH]cccc2C(=O)O)cccc1C(F)(F)F,"InChI=1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21)",NOOCSNJCXJYGPE-UHFFFAOYSA-N,flunixin-meglumin,Launched,prostanoid receptor antagonist,,pulmonary,bovine respiratory disease (BRD)
CC1(C)OC2CC3C4CC(F)=C5CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-6,13-14,17,19,27,29H,7-11H2,1-4H3",DAHOOVZVJYWQKK-UHFFFAOYSA-N,fluocinolone-acetonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,dermatology,seborrheic dermatitis
CC(=O)OCC(=O)C12OC(C)(C)OC1CC1C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC12C,"InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-7,15-16,19,21,31H,8-12H2,1-5H3",KSHUWMONZRTTEG-UHFFFAOYSA-N,fluocinonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6|SMO,dermatology,seborrheic dermatitis|eczema
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,"InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H",GNBHRKFJIUUOQI-UHFFFAOYSA-N,fluorescein,Launched,,SLC22A6,ophthalmology,ophthalmology diagnostic
CC(=O)C1(O)CCC2C3CC(C)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,15,17-18,26-27H,6,8-11H2,1-4H3",ORJMOWYWYBXFBE-UHFFFAOYSA-N,fluorometholone,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation
CC(=O)OC1(C(C)=O)CCC2C3CC(C)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C24H31FO5/c1-13-10-19-17-7-9-23(14(2)26,30-15(3)27)22(17,5)12-20(29)24(19,25)21(4)8-6-16(28)11-18(13)21/h6,8,17,19-20,29H,7,9-12H2,1-5H3",YZABVDSJBDBKPD-UHFFFAOYSA-N,fluorometholone-acetate,Launched,,NR3C1,ophthalmology,eye inflammation
C[N+](C)(CF)CCO,"InChI=1S/C5H13FNO/c1-7(2,5-6)3-4-8/h8H,3-5H2,1-2H3/q+1",PBVFROWIWWGIFK-UHFFFAOYSA-N,fluoromethylcholine,Launched,,,,
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,"InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3",RTHCYVBBDHJXIQ-UHFFFAOYSA-N,fluoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),ANO1|HTR2B|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder
OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,"InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2",NJMYODHXAKYRHW-UHFFFAOYSA-N,flupentixol,Launched,dopamine receptor antagonist,ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A,neurology/psychiatry,schizophrenia|depression
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,"InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2",PLDUPXSUYLZYBN-UHFFFAOYSA-N,fluphenazine,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia
CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,"InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3",VIQCGTZFEYDQMR-UHFFFAOYSA-N,fluphenazine-decanoate,Launched,dopamine receptor antagonist,DRD2|HTR1B|HTR4,neurology/psychiatry,schizophrenia
CCOC(=O)Nc1ccc(=NCc2ccc(F)cc2)[nH]c1N,"InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)",JUUFBMODXQKSTD-UHFFFAOYSA-N,flupirtine,Launched,glutamate receptor antagonist,ADRA2A|KCNQ1|KCNQ2,neurology/psychiatry,pain relief
NC(=O)NCCN1CCN(c2cccc(C(F)(F)F)c2)CC1,"InChI=1S/C14H19F3N4O/c15-14(16,17)11-2-1-3-12(10-11)21-8-6-20(7-9-21)5-4-19-13(18)22/h1-3,10H,4-9H2,(H3,18,19,22)",CHQKHXJPWDSTPY-UHFFFAOYSA-N,fluprazine,Phase 1,serotonin receptor agonist,HTR1A|HTR1B,,
Cc1cc(C2=NOC(c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)ccc1C(=O)NCC(=O)NCC(F)(F)F,"InChI=1S/C22H17Cl2F6N3O3/c1-11-4-12(2-3-16(11)19(35)31-9-18(34)32-10-21(25,26)27)17-8-20(36-33-17,22(28,29)30)13-5-14(23)7-15(24)6-13/h2-7H,8-10H2,1H3,(H,31,35)(H,32,34)",MLBZKOGAMRTSKP-UHFFFAOYSA-N,fluralaner,Preclinical,GABA receptor antagonist,,,
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,"InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",SYTBZMRGLBWNTM-UHFFFAOYSA-N,flurbiprofen-(+/-),Launched,cyclooxygenase inhibitor,,rheumatology,rheumatoid arthritis|osteoarthritis
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,"InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",SYTBZMRGLBWNTM-UHFFFAOYSA-N,flurbiprofen-(s)-(+),Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,"InChI=1S/C19H19FO4/c1-12(19(22)24-14(3)23-13(2)21)16-9-10-17(18(20)11-16)15-7-5-4-6-8-15/h4-12,14H,1-3H3",ALIVXCSEERJYHU-UHFFFAOYSA-N,flurbiprofen-axetil,Launched,analgesic agent,,,
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,"InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)",SYTBZMRGLBWNTM-UHFFFAOYSA-N,flurizan,Phase 3,gamma secretase inhibitor,APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2,,
NP(N)(=O)NC(=O)c1ccc(F)cc1,"InChI=1S/C7H9FN3O2P/c8-6-3-1-5(2-4-6)7(12)11-14(9,10)13/h1-4H,(H5,9,10,11,12,13)",QWZFVMCWPLMLTL-UHFFFAOYSA-N,flurofamide,Preclinical,urease inhibitor,,,
FC(F)(F)COCC(F)(F)F,"InChI=1S/C4H4F6O/c5-3(6,7)1-11-2-4(8,9)10/h1-2H2",KGPPDNUWZNWPSI-UHFFFAOYSA-N,flurothyl,Preclinical,,,,
C=COCC(F)(F)F,"InChI=1S/C4H5F3O/c1-2-8-3-4(5,6)7/h2H,1,3H2",DLEGDLSLRSOURQ-UHFFFAOYSA-N,fluroxene,Preclinical,local anesthetic,,,
O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2,"InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)",QOYHHIBFXOOADH-UHFFFAOYSA-N,fluspirilene,Launched,dopamine receptor antagonist,CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,"InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)",MKXKFYHWDHIYRV-UHFFFAOYSA-N,flutamide,Launched,androgen receptor antagonist,AHR|AR,oncology,prostate cancer
CCC(=O)OC1(C(=O)SCF)C(C)CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,13,15-16,19,30H,5,8-12H2,1-4H3",MCSYMYUHCZRDGM-UHFFFAOYSA-N,fluticasone-propionate,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|PGR|PLA2G4A,dermatology,corticosteroid-responsive dermatoses
Fc1ccc(C(c2ccccc2)(c2ccccc2F)n2ccnc2)cc1,"InChI=1S/C22H16F2N2/c23-19-12-10-18(11-13-19)22(26-15-14-25-16-26,17-6-2-1-3-7-17)20-8-4-5-9-21(20)24/h1-16H",QHMWCHQXCUNUAK-UHFFFAOYSA-N,flutrimazole,Launched,sterol demethylase inhibitor,,infectious disease,mycosis
CC(C)n1c(C=CC(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,"InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)",FJLGEFLZQAZZCD-UHFFFAOYSA-N,fluvastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hypercholesterolemia|congenital heart defects
COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1,"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3",CJOFXWAVKWHTFT-UHFFFAOYSA-N,fluvoxamine,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD)
CC(C)CC(NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,"InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)",CBPJQFCAFFNICX-UHFFFAOYSA-N,fmoc-l-leucine,Phase 2,PPAR receptor agonist,,,
CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3N=c3[nH]cnc4[nH]ccc34)cc2)CC1,"InChI=1S/C22H25N9O/c1-30-8-10-31(11-9-30)13-15-2-4-16(5-3-15)27-22(32)19-18(12-26-29-19)28-21-17-6-7-23-20(17)24-14-25-21/h2-7,12,14H,8-11,13H2,1H3,(H,26,29)(H,27,32)(H2,23,24,25,28)",VXLAKHWYGRKCGI-UHFFFAOYSA-N,fn-1501,Phase 1,tyrosine kinase inhibitor,,,
N=c1[nH]c(=O)c2nc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,"InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)",OVBPIULPVIDEAO-UHFFFAOYSA-N,folic-acid,Launched,folate receptor ligand,FOLR2|FOLR3|SLC19A1|SLC46A1,hematology,megaloblastic anemia
Cc1cn[nH]c1,"InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)",RIKMMFOAQPJVMX-UHFFFAOYSA-N,fomepizole,Launched,alcohol dehydrogenase inhibitor,ADH1A|ADH1B|ADH1C|AKR1A1|CAT,critical care,poison antidote
c1ccc(OCc2ccc(CCCN3CCOCC3)cc2)cc1,"InChI=1S/C20H25NO2/c1-2-6-20(7-3-1)23-17-19-10-8-18(9-11-19)5-4-12-21-13-15-22-16-14-21/h1-3,6-11H,4-5,12-17H2",CVHGCWVMTZWGAY-UHFFFAOYSA-N,fomocaine,Launched,voltage-gated sodium channel modulator,,neurology/psychiatry,local anesthetic
COC1OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(COS(=O)(=O)O)C(OC4OC(C(=O)O)C(OC5OC(COS(=O)(=O)O)C(O)C(O)C5NS(=O)(=O)O)C(O)C4O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C(O)C1NS(=O)(=O)O,"InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)",KANJSNBRCNMZMV-UHFFFAOYSA-N,fondaparinux,Launched,coagulation factor inhibitor,F10|SERPINC1,hematology,deep vein thrombosis (DVT)
COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)",CXQHYVUVSFXTMY-UHFFFAOYSA-N,foretinib,Phase 2,VEGFR inhibitor,FLT1|FLT4|KDR|MET,,
CC12CCC3C(CCC4C(=O)C(=O)CCC43C)C1CCC2=O,"InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-14H,3-10H2,1-2H3",ZMEULISFKSVRLQ-UHFFFAOYSA-N,formestane,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
COc1ccc(-c2coc3cc(O)ccc3c2=O)cc1,"InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3",HKQYGTCOTHHOMP-UHFFFAOYSA-N,formononetin,Preclinical,alcohol dehydrogenase inhibitor,ADH1C|SLC5A2,,
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)",BPZSYCZIITTYBL-UHFFFAOYSA-N,formoterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
O=c1[nH]cnc2c(C3NC(CO)C(O)C3O)c[nH]c12,"InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)",IWKXDMQDITUYRK-UHFFFAOYSA-N,forodesine,Launched,purinergic receptor antagonist,PNP,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
CC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1,"InChI=1S/C28H40N4S/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22/h9-11,14-16,18-21H,12-13,17H2,1-8H3",VVBFISAUNSXQGZ-UHFFFAOYSA-N,foropafant,Phase 3,platelet activating factor receptor antagonist,PTAFR,,
C=CC1(C)CC(=O)C2(O)C(C)(O1)C(OC(C)=O)C(O)C1C(C)(C)CCC(O)C12C,"InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3",OHCQJHSOBUTRHG-UHFFFAOYSA-N,forskolin,Launched,adenylyl cyclase activator,ADCY2|ADCY5|GNAS,,
CC(C)CN(CC(O[PH](=O)(=O)O)C(Cc1ccccc1)NC(=O)OC1CCOC1)S(=O)(=O)c1ccc(N)cc1,"InChI=1S/C25H35N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H,30,31,32)",QQMSZCGPEQFVPJ-UHFFFAOYSA-N,fosamprenavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CC(OC1OCCN(Cc2nc(=O)n([PH](=O)(=O)O)[nH]2)C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C23H21F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H,36,37,38)",XUNLYHPFTFVIKV-UHFFFAOYSA-N,fosaprepitant-dimeglumine,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1O[PH](=O)(=O)O,"InChI=1S/C18H20O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H,19,20,21)",FWLWIJYTMGPYEM-UHFFFAOYSA-N,fosbretabulin,Phase 3,tubulin polymerization inhibitor,CDH5,,
COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1O[PH](=O)(=O)O,"InChI=1S/C18H20O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H,19,20,21)",FWLWIJYTMGPYEM-UHFFFAOYSA-N,fosbretabulin,Phase 3,VE-cadherin antagonist,CDH5,,
O=C(O)[PH](=O)(=O)O,"InChI=1S/CH2O5P/c2-1(3)7(4,5)6/h(H,2,3)(H,4,5,6)",YUXMLIOVDAUXGA-UHFFFAOYSA-N,foscarnet,Launched,DNA polymerase inhibitor,,infectious disease,cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)
CCC(=C(CC)c1ccc(O[PH](=O)(=O)O)cc1)c1ccc(O[PH](=O)(=O)O)cc1,"InChI=1S/C18H20O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H,19,20,21)(H,22,23,24)",DVYDJJBVOBOXTF-UHFFFAOYSA-N,fosfestrol,Launched,synthetic estrogen,ESR1|ESR2,oncology,prostate cancer
O=[PH](=O)(O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"InChI=1S/C13H12F2N6O4P/c14-10-1-2-11(12(15)3-10)13(25-26(22,23)24,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9H,4-5H2,(H,22,23,24)",LDHJDSQNUUOTRO-UHFFFAOYSA-N,fosfluconazole,Preclinical,other antifungal,,,
CC1OC1[PH](=O)(=O)O,"InChI=1S/C3H6O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H,4,5,6)",UJNUDOLLRRCQDH-UHFFFAOYSA-N,fosfomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections
O=C(O)c1ccccc1O[PH](=O)(=O)O,"InChI=1S/C7H6O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H,10,11,12)",MWVPRKFMEGIJDY-UHFFFAOYSA-N,fosfosal,Launched,phosphodiesterase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
O=C(C(O)CO[PH](=O)(=O)O)C(O)C(O)CO[PH](=O)(=O)O,"InChI=1S/C6H12O12P2/c7-3(1-17-19(11,12)13)5(9)6(10)4(8)2-18-20(14,15)16/h3-5,7-9H,1-2H2,(H,11,12,13)(H,14,15,16)",OBXWSGSGUWLHMS-UHFFFAOYSA-N,fosfructose,Phase 3,fructose diphosphate stimulant,,,
CCC(=O)OC(OP(=O)(CCCCc1ccccc1)CC(=O)N1CC(C2CCCCC2)CC1C(=O)O)C(C)C,"InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)",BIDNLKIUORFRQP-UHFFFAOYSA-N,fosinopril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
O=C(O)C1CC(C2CCCCC2)CN1C(=O)C[PH](=O)(=O)CCCCc1ccccc1,"InChI=1S/C23H33NO5P/c25-22(17-30(28,29)14-8-7-11-18-9-3-1-4-10-18)24-16-20(15-21(24)23(26)27)19-12-5-2-6-13-19/h1,3-4,9-10,19-21H,2,5-8,11-17H2,(H,26,27)",JHHCISWMTSVXES-UHFFFAOYSA-N,fosinoprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1CO[PH](=O)(=O)O,"InChI=1S/C16H14N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H,21,22,23)",KFODUDWNFSWFFD-UHFFFAOYSA-N,fosphenytoin,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,epilepsy|seizures
COc1cc(N=c2nc(N=c3ccc4c([nH]3)N(CO[PH](=O)(=O)O)C(=O)C(C)(C)O4)c(F)c[nH]2)cc(OC)c1OC,"InChI=1S/C23H25FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H,32,33,34)(H2,25,26,27,28,29)",BCPNSUHDMLFQPA-UHFFFAOYSA-N,fostamatinib,Launched,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP)
COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2CO[PH](=O)(=O)O,"InChI=1S/C25H25N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H,36,37,38)",FEEQFOBGGTXZBD-UHFFFAOYSA-N,fostemsavir,Phase 3,antiviral,,,
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)NO,"InChI=1S/C9H21ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8,12,15H,4-7H2,1-3H3,(H,11,14)",MOGVETSVTCBTEJ-UHFFFAOYSA-N,fotemustine,Launched,thioredoxin inhibitor,,oncology,melanoma
CSCCC(NC=O)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CS)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)O,"InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)",WFZPJYYCTSHDJI-UHFFFAOYSA-N,foxy-5,Phase 2,WNT5a peptide mimetic,WNT5A,,
NC(=S)NN=Cc1coc2ccccc2c1=O,"InChI=1S/C11H9N3O2S/c12-11(17)14-13-5-7-6-16-9-4-2-1-3-8(9)10(7)15/h1-6H,(H3,12,14,17)",YQOMHBIWKFONOC-UHFFFAOYSA-N,fpa-124,Preclinical,AKT inhibitor,,,
Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,"InChI=1S/C16H15ClF2N2O3S/c1-10-6-7-11(17)8-14(10)21(25(2,23)24)9-15(22)20-16-12(18)4-3-5-13(16)19/h3-8H,9H2,1-2H3,(H,20,22)",WAOBCCBUTHNTFO-UHFFFAOYSA-N,fph1-(brd-6125),Preclinical,hepatocyte function enhancer,,,
CC(N)(Cc1ccccc1)c1ccccc1,"InChI=1S/C15H17N/c1-15(16,14-10-6-3-7-11-14)12-13-8-4-2-5-9-13/h2-11H,12,16H2,1H3",JINQHBRSXWQJAZ-UHFFFAOYSA-N,fpl-12495,Phase 1,glutamate receptor antagonist,,,
CCCc1c(OCC(O)COc2ccc3c(=O)cc(C(=O)O)oc3c2CCC)ccc(C(C)=O)c1O,"InChI=1S/C27H30O9/c1-4-6-19-22(10-8-17(15(3)28)25(19)31)34-13-16(29)14-35-23-11-9-18-21(30)12-24(27(32)33)36-26(18)20(23)7-5-2/h8-12,16,29,31H,4-7,13-14H2,1-3H3,(H,32,33)",LMQBMWHHGVZWMR-UHFFFAOYSA-N,fpl-55712,Phase 1,leukotriene receptor antagonist,,,
COc1ccc(N=c2ccn(-c3ccccc3)[nH]2)cc1,"InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)",WKLGNFJHVJIZPK-UHFFFAOYSA-N,fpl-62064,Phase 2,cyclooxygenase inhibitor,,,
COc1ccc(N=c2ccn(-c3ccccc3)[nH]2)cc1,"InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)",WKLGNFJHVJIZPK-UHFFFAOYSA-N,fpl-62064,Phase 2,lipoxygenase inhibitor,,,
COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,"InChI=1S/C22H21NO3/c1-14-19(20(15(2)23-14)22(25)26-3)21(24)18-12-8-7-11-17(18)13-16-9-5-4-6-10-16/h4-12,23H,13H2,1-3H3",MDMWHKZANMNXTF-UHFFFAOYSA-N,fpl-64176,Preclinical,calcium channel activator,CACNA1C|CACNA1S,,
O=C(c1ccc(Cl)cc1)N(Cc1ccccc1)C1CCCCC1,"InChI=1S/C20H22ClNO/c21-18-13-11-17(12-14-18)20(23)22(19-9-5-2-6-10-19)15-16-7-3-1-4-8-16/h1,3-4,7-8,11-14,19H,2,5-6,9-10,15H2",XDFKWGIBQMHSOH-UHFFFAOYSA-N,fps-zm1,Preclinical,RAGE receptor antagonist,AGER,,
COc1ccc(-c2nc(C(=O)N3CCN(C)CC3)sc2-c2ccc(OC)cc2)cc1,"InChI=1S/C23H25N3O3S/c1-25-12-14-26(15-13-25)23(27)22-24-20(16-4-8-18(28-2)9-5-16)21(30-22)17-6-10-19(29-3)11-7-17/h4-11H,12-15H2,1-3H3",UBHKJRYGKOSQDJ-UHFFFAOYSA-N,fr-122047,Preclinical,cyclooxygenase inhibitor,,,
CC(C)CC(NC(=O)N1CCCCCC1)C(=O)NC(Cc1cn(C)c2ccccc12)C(=O)NC(Cc1ccccn1)C(=O)O,"InChI=1S/C33H44N6O5/c1-22(2)18-26(37-33(44)39-16-10-4-5-11-17-39)30(40)35-27(19-23-21-38(3)29-14-7-6-13-25(23)29)31(41)36-28(32(42)43)20-24-12-8-9-15-34-24/h6-9,12-15,21-22,26-28H,4-5,10-11,16-20H2,1-3H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)",LIOKMIQQPDDTNO-UHFFFAOYSA-N,fr-139317,Phase 1,endothelin receptor antagonist,EDNRA,,
N=c1[nH][nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12,"InChI=1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)",XVECMUKVOMUNLE-UHFFFAOYSA-N,fr-180204,Preclinical,MAP kinase inhibitor,MAPK1|MAPK3,,
CCn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c[nH]c(=Nc3ccc(N4CCNCC4)c(F)c3)nc21,"InChI=1S/C25H23Cl2FN6O/c1-2-34-23-15(11-19(24(34)35)18-5-3-16(26)12-20(18)27)14-30-25(32-23)31-17-4-6-22(21(28)13-17)33-9-7-29-8-10-33/h3-6,11-14,29H,2,7-10H2,1H3,(H,30,31,32)",DHKFOIHIUYFSOF-UHFFFAOYSA-N,frax486,Preclinical,serine/threonine kinase inhibitor,PAK1|PAK2|PAK3|PAK4,,
COc1ccc2[nH]c(=NC(=O)Nc3ccccc3)sc2c1,"InChI=1S/C15H13N3O2S/c1-20-11-7-8-12-13(9-11)21-15(17-12)18-14(19)16-10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)",JHBWYQRKOUBPCA-UHFFFAOYSA-N,frentizole,Phase 1,immunosuppressant,,,
CC(C)C(NC(=O)Cn1c(-c2ccccc2)ncc(N)c1=O)C(O)c1nnc(C(C)(C)C)o1,"InChI=1S/C23H30N6O4/c1-13(2)17(18(31)20-27-28-22(33-20)23(3,4)5)26-16(30)12-29-19(14-9-7-6-8-10-14)25-11-15(24)21(29)32/h6-11,13,17-18,31H,12,24H2,1-5H3,(H,26,30)",HMPQTEPEMQZWQH-UHFFFAOYSA-N,freselestat,Preclinical,elastase inhibitor,CELA1|ELANE,,
CNC1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,"InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)",XPSQPHWEGNHMSK-UHFFFAOYSA-N,frovatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,neurology/psychiatry,migraine headache
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,"InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)",BALLNEJQLSTPIO-UHFFFAOYSA-N,fruquintinib,Launched,VEGFR inhibitor,KDR,oncology,colorectal cancer
C#CCOc1ccc(C=CC(=O)Nc2ccccc2C(=O)O)cc1OC,"InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)",UIWZIDIJCUEOMT-UHFFFAOYSA-N,ft011,Preclinical,TGF beta receptor inhibitor,,,
Cc1cccc(C)c1NC(=O)c1ccccc1C(=O)O,"InChI=1S/C16H15NO3/c1-10-6-5-7-11(2)14(10)17-15(18)12-8-3-4-9-13(12)16(19)20/h3-9H,1-2H3,(H,17,18)(H,19,20)",LLECMGGNFBKPRH-UHFFFAOYSA-N,ftaxilide,Preclinical,,,,
O=c1[nH]c(=O)n(C2CCCO2)cc1F,"InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)",WFWLQNSHRPWKFK-UHFFFAOYSA-N,ftorafur,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer
CC(=O)OC1CC(C)(C)C(=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C(C)(O)C1,"InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3",SJWWTRQNNRNTPU-UHFFFAOYSA-N,fucoxanthin,Phase 2,anticancer agent,,,
NC(CSCCCO)C(=O)O,"InChI=1S/C6H13NO3S/c7-5(6(9)10)4-11-3-1-2-8/h5,8H,1-4,7H2,(H,9,10)",KINWYTAUPKOPCQ-UHFFFAOYSA-N,fudosteine,Launched,mucolytic agent,,pulmonary,chest congestion
CC12CCC3c4ccc(O)cc4CC(CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)C3C1CCC2O,"InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3",VWUXBMIQPBEWFH-UHFFFAOYSA-N,fulvestrant,Launched,estrogen receptor antagonist,ESR1|ESR2|GPER1,oncology,breast cancer
COC1C(OC(=O)C=CC=CC=CC=CC(=O)O)CCC2(CO2)C1C1(C)OC1CC=C(C)C,"InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)",NGGMYCMLYOUNGM-UHFFFAOYSA-N,fumagillin,Launched,methionine aminopeptidase inhibitor,METAP2,infectious disease,microsporidiosis
CCCCC(C)C(OC(=O)CC(CC(=O)O)C(=O)O)C(CC(C)CC(O)CCCCC(O)CC(O)C(C)N)OC(=O)CC(CC(=O)O)C(=O)O,"InChI=1S/C34H59NO15/c1-5-6-9-20(3)32(50-31(44)17-23(34(47)48)15-29(41)42)27(49-30(43)16-22(33(45)46)14-28(39)40)13-19(2)12-24(36)10-7-8-11-25(37)18-26(38)21(4)35/h19-27,32,36-38H,5-18,35H2,1-4H3,(H,39,40)(H,41,42)(H,45,46)(H,47,48)",UVBUBMSSQKOIBE-UHFFFAOYSA-N,fumonisin-b1,Preclinical,,CERS1,,
O=C1N(Cc2ccc(C(F)(F)F)o2)c2ccccc2C12COc1cc3c(cc12)OCO3,"InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2",NEBUOXBYNAHKFV-UHFFFAOYSA-N,funapide,Preclinical,sodium channel blocker,,,
O=c1[nH]c(O)cn1N=CC=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C10H8N4O5/c15-8-6-13(10(16)12-8)11-5-1-2-7-3-4-9(19-7)14(17)18/h1-6,15H,(H,12,16)",YERFNOHRYLZBTP-UHFFFAOYSA-N,furagin,Preclinical,antibacterial,,,
O=C1OC(CN2CCOCC2)CN1N=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C13H16N4O6/c18-13-16(14-7-10-1-2-12(22-10)17(19)20)9-11(23-13)8-15-3-5-21-6-4-15/h1-2,7,11H,3-6,8-9H2",YVQVOQKFMFRVGR-UHFFFAOYSA-N,furaltadone,Launched,bacterial DNA inhibitor,,infectious disease,gram-negative bacterial infections
N=C(N)c1ccc(-c2ccc(-c3ccc(C(=N)N)cc3)o2)cc1,"InChI=1S/C18H16N4O/c19-17(20)13-5-1-11(2-6-13)15-9-10-16(23-15)12-3-7-14(8-4-12)18(21)22/h1-10H,(H3,19,20)(H3,21,22)",ZJHZBDRZEZEDGB-UHFFFAOYSA-N,furamidine,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2",PLHJDBGFXBMTGZ-UHFFFAOYSA-N,furazolidone,Launched,bacterial DNA inhibitor,,gastroenterology|infectious disease,diarrhea|enteritis|cholera
O=C(O)c1cc2cc(Cc3cccnc3)ccc2o1,"InChI=1S/C15H11NO3/c17-15(18)14-8-12-7-10(3-4-13(12)19-14)6-11-2-1-5-16-9-11/h1-5,7-9H,6H2,(H,17,18)",VHWFITPGPFLBGT-UHFFFAOYSA-N,furegrelate,Phase 1,thromboxane synthase inhibitor,TBXAS1,,
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,"InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)",ZZUFCTLCJUWOSV-UHFFFAOYSA-N,furosemide,Launched,diuretic,CA2|GPR35|SLC12A1|SLC12A2,cardiology|rheumatology,edema|hypertension|congestive heart failure|nephrotic syndrome
CC(=C(CCO)SSCC1CCCO1)N(C=O)Cc1c[nH]c(C)nc1=N,"InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)",JTLXCMOFVBXEKD-UHFFFAOYSA-N,fursultiamine,Launched,vitamin B,,metabolism,thiamine deficiency
O=[N+]([O-])C(Br)=Cc1ccc(Br)o1,InChI=1S/C6H3Br2NO3/c7-5(9(10)11)3-4-1-2-6(8)12-4/h1-3H,MJPPGVVIDGQOQT-UHFFFAOYSA-N,furvina,Preclinical,quorum sensing signaling inhibitor,,,
CC(=O)OC1=C(C(CCC=C(C)C)C(=O)O)C2CC(O)C3C4(C)CCC(O)C(C)C4CCC3(C)C2(C)C1,"InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,20-24,27,33-34H,8,10-16H2,1-7H3,(H,35,36)",JMNCPTSDROGKTR-UHFFFAOYSA-N,fusidic-acid,Launched,bacterial 30S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV)
C=CC(=O)N1CCC(n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(=N)[nH]cnc32)C1,"InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)",KEIPNCCJPRMIAX-UHFFFAOYSA-N,futibatinib,Phase 3,FGFR inhibitor,,,
CC(=O)c1ccc2c(c1)C1C=CCC1C(c1cc3c(cc1Br)OCO3)N2,"InChI=1S/C21H18BrNO3/c1-11(24)12-5-6-18-15(7-12)13-3-2-4-14(13)21(23-18)16-8-19-20(9-17(16)22)26-10-25-19/h2-3,5-9,13-14,21,23H,4,10H2,1H3",VHSVKVWHYFBIFJ-UHFFFAOYSA-N,g-1,Preclinical,G protein-coupled receptor agonist,GPER1,,
Brc1cc2c(cc1C1Nc3ccccc3C3C=CCC31)OCO2,"InChI=1S/C19H16BrNO2/c20-15-9-18-17(22-10-23-18)8-14(15)19-13-6-3-5-11(13)12-4-1-2-7-16(12)21-19/h1-5,7-9,11,13,19,21H,6,10H2",YOLTZIVRJAPVPH-UHFFFAOYSA-N,g-15,Preclinical,estrogen receptor antagonist,GPER1,,
CN1CCC(N=c2[nH]c(=Nc3ccc(Oc4ccccc4)cc3)c3c(=O)[nH]cc(Br)c3[nH]2)CC1,"InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)",SXWMIXPJPNCXQQ-UHFFFAOYSA-N,g-749,Preclinical,tyrosine kinase inhibitor,,,
C=C1CCC=C(C)CCC2C1CC2(C)C,"InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3",NPNUFJAVOOONJE-UHFFFAOYSA-N,g-caryophyllene,Preclinical,acetylcholinesterase inhibitor,ACHE,,
CS(=O)(=O)c1ccc(-c2nnc(C=Cc3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1,"InChI=1S/C25H16ClN7O3S/c1-37(34,35)18-10-11-20(28-15-18)24-31-29-22(33(24)21-5-3-2-4-19(21)26)12-13-23-30-32-25(36-23)17-8-6-16(14-27)7-9-17/h2-13,15H,1H3",HIWVLHPKZNBSBE-UHFFFAOYSA-N,g007-lk,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
CCCCCC=CCC=CCCCCCCCC(=O)NCCCC(=O)O,"InChI=1S/C22H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-21(24)23-20-17-19-22(25)26/h6-7,9-10H,2-5,8,11-20H2,1H3,(H,23,24)(H,25,26)",YGFYZZQGVSUXJE-UHFFFAOYSA-N,gaba-linoleamide,Phase 2,benzodiazepine receptor agonist,,,
NCC1(CC(=O)O)CCCCC1,"InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)",UGJMXCAKCUNAIE-UHFFFAOYSA-N,gabapentin,Launched,calcium channel blocker,ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,infectious disease|neurology/psychiatry,virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome
CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,"InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)",TZDUHAJSIBHXDL-UHFFFAOYSA-N,gabapentin-enacarbil,Launched,adrenergic receptor agonist,CACNA1G,neurology/psychiatry,restless leg syndrome|postherpetic neuralgia
COc1ccc(-c2ccc(=N)n(CCCC(=O)O)n2)cc1,"InChI=1S/C15H17N3O3/c1-21-12-6-4-11(5-7-12)13-8-9-14(16)18(17-13)10-2-3-15(19)20/h4-9,16H,2-3,10H2,1H3,(H,19,20)",ACVGNKYJVGNLIL-UHFFFAOYSA-N,gabazine,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2,,
CCOC(=O)c1ccc(OC(=O)CCCCCN=C(N)N)cc1,"InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)",YKGYIDJEEQRWQH-UHFFFAOYSA-N,gabexate,Launched,serine protease inhibitor,PRSS1|TPSAB1,gastroenterology,pancreatitis
O=c1[nH]oc2c1CCNC2,"InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)",ZXRVKCBLGJOCEE-UHFFFAOYSA-N,gaboxadol,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3,,
O=C1CN2CCN3CCN(C(CO)C(O)CO)CCN(CC2)CC(=O)O[Gd](O1)OC(=O)C3,"InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3",ZPDFIIGFYAHNSK-UHFFFAOYSA-K,gadobutrol,Launched,radiopaque medium,,radiology,MRI contrast agent
CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C2)OC(=O)C1,"InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3",HZHFFEYYPYZMNU-UHFFFAOYSA-K,gadodiamide,Launched,radiopaque medium,,radiology,MRI contrast agent
O=C(O)CN1CCN2CCN(CC(=O)O)CC(=O)O[Gd](OC(=O)C2)OC(=O)C1,"InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3",IZOOGPBRAOKZFK-UHFFFAOYSA-K,gadopentetic-acid,Launched,contrast agent,PGD,radiology,contrast agent
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,"InChI=1S/C16H28N4O8/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)",WDLRUFUQRNWCPK-UHFFFAOYSA-N,gadoterate-meglumine,Launched,radiopaque medium,,radiology,MRI contrast agent
CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,"InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3",DPNNNPAKRZOSMO-UHFFFAOYSA-K,gadoteridol,Launched,radiopaque medium,,radiology,MRI contrast agent
CCCN=c1nc(N(C)OC)[nH]c(=NCCC)[nH]1,"InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16)",FJNLCHNQVJVCPY-UHFFFAOYSA-N,gal-021,Preclinical,calcium channel blocker,,,
COc1ccc2c3c1OC1CC(O)C=CC31CCN(C)C2,"InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3",ASUTZQLVASHGKV-UHFFFAOYSA-N,galantamine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG,neurology/psychiatry,senile dementia
CC12CCC(O)CC1=CCC1C2CCC2(C)C(n3cnc4ccccc43)=CCC12,"InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3",PAFKTGFSEFKSQG-UHFFFAOYSA-N,galeterone,Phase 3,androgen receptor modulator,AR|CYP17A1,,
N=c1[nH]cnc2c(C3NC(CO)C(O)C3O)c[nH]c12,"InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)",AMFDITJFBUXZQN-UHFFFAOYSA-N,galidesivir,Phase 1,antiviral,,,
CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,"InChI=1S/C30H60N3O3/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9/h19-21H,10-18,22-27H2,1-9H3/q+3",OZLPUNFFCJDMJD-UHFFFAOYSA-N,gallamine-triethiodide,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA1,neurology/psychiatry,muscle relaxant
O=C(O)c1cc(O)c(O)c(O)c1,"InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)",LNTHITQWFMADLM-UHFFFAOYSA-N,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor,CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP,,
O=C(O)c1cc(O)c(O)c(O)c1,"InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)",LNTHITQWFMADLM-UHFFFAOYSA-N,gallic-acid,Preclinical,PPAR receptor agonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP,,
Oc1cccc2cccnc12,"InChI=1S/C9H7NO/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11H",MCJGNVYPOGVAJF-UHFFFAOYSA-N,gallium-triquinolin-8-olate,Phase 1,,,,
COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,"InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3",XQLWNAFCTODIRK-UHFFFAOYSA-N,gallopamil,Launched,L-type calcium channel blocker,ATP2A2,cardiology,hypertension|cardiac arrythmia
CC(C)=CCCC1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)OC12C(=CC4CC1C(C)(C)OC2(C=CC(C)C(=O)O)C4=O)C3=O,"InChI=1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16-18,22-23,27,39H,9,12,15,19H2,1-8H3,(H,42,43)",CEEBBUFFTJLISP-UHFFFAOYSA-N,gambogic-acid,Phase 2,caspase activator,BCL2,,
CCCN1CC(C)C(O)C(C)(O)C(CC)OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC1C,"InChI=1S/C40H76N2O12/c1-15-17-42-21-22(3)33(44)40(11,48)29(16-2)52-36(46)26(7)32(53-30-20-39(10,49-14)34(45)27(8)51-30)25(6)35(38(9,47)19-23(42)4)54-37-31(43)28(41(12)13)18-24(5)50-37/h22-35,37,43-45,47-48H,15-21H2,1-14H3",VWAMTBXLZPEDQO-UHFFFAOYSA-N,gamithromycin,Preclinical,antibacterial ,,,
NCCCC(=O)O,"InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)",BTCSSZJGUNDROE-UHFFFAOYSA-N,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1,,
CCCCCC=CCC=CCC=CCCCCC(=O)O,"InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)",VZCCETWTMQHEPK-UHFFFAOYSA-N,gamma-linolenic-acid,Phase 2,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CCCCCC=CCC=CCC=CCCCCC(=O)O,"InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)",VZCCETWTMQHEPK-UHFFFAOYSA-N,gamma-linolenic-acid,Phase 2,prostanoid receptor agonist,PTGS1|PTGS2,,
CC(=O)C1CCC2C3CCC4CC(C)(O)CCC4(C)C3CCC12C,"InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3",PGTVWKLGGCQMBR-UHFFFAOYSA-N,ganaxolone,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,
N=c1[nH]c(=O)c2ncn(COC(CO)CO)c2[nH]1,"InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)",IRSCQMHQWWYFCW-UHFFFAOYSA-N,ganciclovir,Launched,DNA polymerase inhibitor,,infectious disease,cytomegalovirus (CMV)
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,"InChI=1S/C20H20N4O3/c1-11(2)14-9-15(18(26)10-17(14)25)19-21-22-20(27)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25-26H,1-3H3,(H,22,27)",RVAQIUULWULRNW-UHFFFAOYSA-N,ganetespib,Phase 3,HSP inhibitor,HSP90AA1,,
CC(CC(=O)CC(C)C1CC(O)C2(C)C3C(=O)CC4C(C)(C)C(=O)CCC4(C)C3C(=O)CC12C)C(=O)O,"InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18,21,23-25,35H,8-14H2,1-7H3,(H,36,37)",WRTHLDKBEDRUGJ-UHFFFAOYSA-N,ganoderic-acid-a,Preclinical,JAK inhibitor,,,
c1cc(-c2sc(-c3ccncc3)c(-c3ccncc3)c2-c2ccncc2)ccn1,InChI=1S/C24H16N4S/c1-9-25-10-2-17(1)21-22(18-3-11-26-12-4-18)24(20-7-15-28-16-8-20)29-23(21)19-5-13-27-14-6-19/h1-16H,USWLOKMMUTWFMD-UHFFFAOYSA-N,gant-58,Preclinical,GLI antagonist,GLI1,,
CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1,"InChI=1S/C27H35N5/c1-29(2)25-12-7-5-10-23(25)20-31-18-9-19-32(27(31)22-14-16-28-17-15-22)21-24-11-6-8-13-26(24)30(3)4/h5-8,10-17,27H,9,18-21H2,1-4H3",KVQOGDQTWWCZFX-UHFFFAOYSA-N,gant-61,Preclinical,GLI antagonist,GLI1|GLI2,,
CC1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21,"InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)",NJDRXTDGYFKORP-UHFFFAOYSA-N,garenoxacin,Launched,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections
OCc1ccc(OC2OC(CO)C(O)C(O)C2O)cc1,"InChI=1S/C13H18O7/c14-5-7-1-3-8(4-2-7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2",PUQSUZTXKPLAPR-UHFFFAOYSA-N,gastrodin,Phase 2,,,,
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,"InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)",XUBOMFCQGDBHNK-UHFFFAOYSA-N,gatifloxacin,Withdrawn,bacterial DNA gyrase inhibitor,,,
O=C(C=Cc1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12)Nc1ccccc1,"InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)",WZBNEZWCNKUOSM-UHFFFAOYSA-N,gavestinel,Phase 3,glutamate receptor antagonist,GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,,
C(=Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C28H32N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-17,28H,18-24H2",XFBDGHFDKJITGC-UHFFFAOYSA-N,gbr-12783,Preclinical,dopamine reuptake inhibitor,,,
c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2",RAQPOZGWANIDQT-UHFFFAOYSA-N,gbr-12935,Preclinical,dopamine reuptake inhibitor,AGTR1|SLC6A3,,
Fc1ccc(C(OCCN2CCN(CC=Cc3ccccc3)CC2)c2ccc(F)cc2)cc1,"InChI=1S/C28H30F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-15,28H,16-22H2",DASHZBBQOARCMQ-UHFFFAOYSA-N,gbr-13069,Preclinical,dopamine reuptake inhibitor,SLC6A3,,
CC(C)NCC(C(=O)N1CCN(c2ncnc3c2C(C)CC3O)CC1)c1ccc(Cl)cc1,"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3",GRZXWCHAXNAUHY-UHFFFAOYSA-N,gdc-0068,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3|PRKG1,,
CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OCC3C(F)F)nc1-2)C(N)=O,"InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)",SGEUNORSOZVTOL-UHFFFAOYSA-N,gdc-0077,Phase 1,PI3K inhibitor,,,
CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(=N)[nH]c3)nc12,"InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)",LGWACEZVCMBSKW-UHFFFAOYSA-N,gdc-0084,Phase 2,mTOR inhibitor,,,
CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(=N)[nH]c3)nc12,"InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)",LGWACEZVCMBSKW-UHFFFAOYSA-N,gdc-0084,Phase 2,PI3K inhibitor,,,
CNC(C)C(=O)NC(C(=O)N1CCCC1C(=O)N=c1s[nH]nc1-c1ccccc1)C1CCCCC1,"InChI=1S/C25H34N6O3S/c1-16(26-2)22(32)27-21(18-12-7-4-8-13-18)25(34)31-15-9-14-19(31)23(33)28-24-20(29-30-35-24)17-10-5-3-6-11-17/h3,5-6,10-11,16,18-19,21,26,30H,4,7-9,12-15H2,1-2H3,(H,27,32)",OXMFMXFBPUMYOH-UHFFFAOYSA-N,gdc-0152,Phase 1,XIAP inhibitor,BIRC2|BIRC3|BIRC7|XIAP,,
CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOCC4C)n2)CCN(C2COC2)C3)cc1,"InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7,16,19H,3,8-15H2,1-2H3,(H2,25,26,31)",RGJOJUGRHPQXGF-UHFFFAOYSA-N,gdc-0349,Phase 1,Pim kinase inhibitor,PIK3CA,,
NC1CCCN(c2c(Br)cnc3[nH]cc(NC(=O)C4CC4)c23)C1,"InChI=1S/C16H20BrN5O/c17-11-6-19-15-13(14(11)22-5-1-2-10(18)8-22)12(7-20-15)21-16(23)9-3-4-9/h6-7,9-10H,1-5,8,18H2,(H,19,20)(H,21,23)",BAZRWWGASYWYGB-UHFFFAOYSA-N,gdc-0575,Phase 1,CHK inhibitor,,,
O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F,"InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)",RFWVETIZUQEJEF-UHFFFAOYSA-N,gdc-0623,Phase 1,MEK inhibitor,,,
CCC(=C(c1ccc(C=CC(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,"InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)",BURHGPHDEVGCEZ-UHFFFAOYSA-N,gdc-0810,Phase 2,selective estrogen receptor destabilizer,ESR1,,
Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(=Nc2ccc(C3C(=O)N(C)CCN3C)cc2)[nH]1,"InChI=1S/C33H36N6O3S/c1-20-24(9-7-10-25(20)36-31(40)28-18-22-8-5-6-11-27(22)43-28)26-19-39(4)33(42)30(35-26)34-23-14-12-21(13-15-23)29-32(41)38(3)17-16-37(29)2/h7,9-10,12-15,18-19,29H,5-6,8,11,16-17H2,1-4H3,(H,34,35)(H,36,40)",CDOOFZZILLRUQH-UHFFFAOYSA-N,gdc-0834,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
OCCn1cc(-c2ccc3c(c2)CCC3=NO)c(-c2ccncc2)n1,"InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2",DEZZLWQELQORIU-UHFFFAOYSA-N,gdc-0879,Preclinical,RAF inhibitor,BRAF,,
CC1=C(c2cccc(O)c2)C(c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21,"InChI=1S/C28H28FNO4/c1-18-25-14-23(32)7-10-26(25)34-28(27(18)21-3-2-4-22(31)13-21)20-5-8-24(9-6-20)33-12-11-30-16-19(15-29)17-30/h2-10,13-14,19,28,31-32H,11-12,15-17H2,1H3",KJAAPZIFCQQQKX-UHFFFAOYSA-N,gdc-0927,Phase 1,estrogen receptor antagonist,,,
CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,gdc-0941,Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(=O)C(O)N1CCN(Cc2sc3c(N4CCOCC4)nc(-c4cnc(=N)[nH]c4)nc3c2C)CC1,"InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,22,33H,3-10,13H2,1-2H3,(H2,24,25,26)",DOJCJLXTCSYOGG-UHFFFAOYSA-N,gdc-0980,Phase 2,mTOR inhibitor,FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK,,
CC(=O)C(O)N1CCN(Cc2sc3c(N4CCOCC4)nc(-c4cnc(=N)[nH]c4)nc3c2C)CC1,"InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,22,33H,3-10,13H2,1-2H3,(H2,24,25,26)",DOJCJLXTCSYOGG-UHFFFAOYSA-N,gdc-0980,Phase 2,PI3K inhibitor,FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK,,
Cn1nccc1N=c1nc(-c2ccn(C(CO)c3ccc(Cl)c(F)c3)c(=O)c2)cc[nH]1,"InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)",RZUOCXOYPYGSKL-UHFFFAOYSA-N,gdc-0994,Phase 1,MAP kinase inhibitor,MAPK1|MAPK3,,
CC(=O)OC1CC2C(C)(C)C(=O)C=CC2(C)C2CCC3(C)C(c4ccoc4)OC(=O)C4OC43C12C,"InChI=1S/C28H34O7/c1-15(29)33-20-13-18-24(2,3)19(30)8-10-25(18,4)17-7-11-26(5)21(16-9-12-32-14-16)34-23(31)22-28(26,35-22)27(17,20)6/h8-10,12,14,17-18,20-22H,7,11,13H2,1-6H3",YJXDGWUNRYLINJ-UHFFFAOYSA-N,gedunin,Preclinical,HSP inhibitor,HSP90AA1,,
COc1cc(C(C)C)c(Oc2c[nH]c(=N)[nH]c2=N)cc1S(N)(=O)=O,"InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)",HLWURFKMDLAKOD-UHFFFAOYSA-N,gefapixant,Phase 3,purinergic receptor antagonist,,,
COc1cc2[nH]cnc(=Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,gefitinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
COC1=CC(C)=Cc2c(O)c(cc(O)c2OC)NC(=O)C(C)CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C1O,"InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8,10-14,16-17,22,24,26,32-34H,9H2,1-7H3,(H2,30,36)(H,31,35)",HGMSUJCQIUFZBJ-UHFFFAOYSA-N,geldanamycin,Preclinical,HSP inhibitor,HSP90AA1,,
CC(C)(CO)CCCCCCC(C)(C)CO,"InChI=1S/C14H30O2/c1-13(2,11-15)9-7-5-6-8-10-14(3,4)12-16/h15-16H,5-12H2,1-4H3",DJKWDKJYFYUEBQ-UHFFFAOYSA-N,gemcadiol,Phase 2,antilipemic,,,
N=c1ccn(C2OC(CO)C(O)C2(F)F)c(=O)[nH]1,"InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)",SDUQYLNIPVEERB-UHFFFAOYSA-N,gemcitabine,Launched,ribonucleotide reductase inhibitor,CMPK1|RRM1|RRM2|TYMS,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer
CCCCCCCCC=CCCCCCCCC(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(F)(F)C1O,"InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)",HESSNRGIEVBPRB-UHFFFAOYSA-N,gemcitabine-elaidate,Phase 1,apoptosis inhibitor,CMPK1|RRM1|TYMS,,
CCCCCCCCC=CCCCCCCCC(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(F)(F)C1O,"InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)",HESSNRGIEVBPRB-UHFFFAOYSA-N,gemcitabine-elaidate,Phase 1,DNA synthesis inhibitor,CMPK1|RRM1|TYMS,,
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,"InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)",HEMJJKBWTPKOJG-UHFFFAOYSA-N,gemfibrozil,Launched,lipoprotein lipase activator,LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1,endocrinology|cardiology,hyperlipidemia|coronary heart disease
CON=C1CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN,"InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)",ZRCVYEYHRGVLOC-UHFFFAOYSA-N,gemifloxacin,Launched,bacterial DNA gyrase inhibitor,,pulmonary|infectious disease,bronchitis|pneumonia
NC(CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,"InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2",ZWPRRQZNBDYKLH-UHFFFAOYSA-N,gemigliptin,Launched,dipeptidyl peptidase inhibitor,,,
COC(=O)C1=COC(O)C2C(CO)=CCC12,"InChI=1S/C11H14O5/c1-15-10(13)8-5-16-11(14)9-6(4-12)2-3-7(8)9/h2,5,7,9,11-12,14H,3-4H2,1H3",AZKVWQKMDGGDSV-UHFFFAOYSA-N,genipin,Preclinical,choleretic agent,,,
COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)C2C(CO)=CCC12,"InChI=1S/C17H24O10/c1-24-15(23)9-6-25-16(11-7(4-18)2-3-8(9)11)27-17-14(22)13(21)12(20)10(5-19)26-17/h2,6,8,10-14,16-22H,3-5H2,1H3",IBFYXTRXDNAPMM-UHFFFAOYSA-N,geniposide,Preclinical,GLP receptor agonist,GLP1R,,
O=C(O)C1=COC(OC2OC(CO)C(O)C(O)C2O)C2C(CO)=CCC12,"InChI=1S/C16H22O10/c17-3-6-1-2-7-8(14(22)23)5-24-15(10(6)7)26-16-13(21)12(20)11(19)9(4-18)25-16/h1,5,7,9-13,15-21H,2-4H2,(H,22,23)",ZJDOESGVOWAULF-UHFFFAOYSA-N,geniposidic-acid,Preclinical,cyclooxygenase inhibitor,,,
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H",TZBJGXHYKVUXJN-UHFFFAOYSA-N,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5,,
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,"InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3",CEAZRRDELHUEMR-UHFFFAOYSA-N,gentamycin,Launched,bacterial 50S ribosomal subunit inhibitor,HSPA8,infectious disease|critical care,bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis
C=CC1C2=CCOC(=O)C2=COC1OC1OC(CO)C(O)C(O)C1O,"InChI=1S/C16H20O9/c1-2-7-8-3-4-22-14(21)9(8)6-23-15(7)25-16-13(20)12(19)11(18)10(5-17)24-16/h2-3,6-7,10-13,15-20H,1,4-5H2",DUAGQYUORDTXOR-UHFFFAOYSA-N,gentiopicrin,Phase 3,glutamate receptor downregulator,GRIN2B,,
CCCCCCCCC(=O)NC(CN1CCCC1)C(O)c1ccc2c(c1)OCCO2,"InChI=1S/C24H38N2O4/c1-2-3-4-5-6-7-10-23(27)25-20(18-26-13-8-9-14-26)24(28)19-11-12-21-22(17-19)30-16-15-29-21/h11-12,17,20,24,28H,2-10,13-16,18H2,1H3,(H,25,27)",JMNXWOFCUJJYEO-UHFFFAOYSA-N,genz-123346,Preclinical,glucosylceramidase inhibitor,UGCG,,
CNCCn1c(=O)c2cc(OC)c(OC)cc2c2cnc3cc4c(cc3c21)OCO4,"InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3",BAORCAMWLWRZQG-UHFFFAOYSA-N,genz-644282,Phase 1,topoisomerase inhibitor,TOP1,,
CC(N)Cc1cccc(O)c1,"InChI=1S/C9H13NO/c1-7(10)5-8-3-2-4-9(11)6-8/h2-4,6-7,11H,5,10H2,1H3",WTDGMHYYGNJEKQ-UHFFFAOYSA-N,gepefrine,Launched,adrenergic receptor agonist,,cardiology,hypotension
CC(C)C(NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(N)C(C)O)C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)O,"InChI=1S/C74H132N26O27/c1-36(2)56(69(124)97-47(22-27-52(107)108)66(121)93-44(19-13-35-87-74(83)84)61(116)94-45(20-25-50(103)104)64(119)90-41(16-7-10-32-77)63(118)98-49(71(126)127)24-29-54(111)112)99-70(125)57(38(4)102)100-67(122)48(23-28-53(109)110)95-62(117)43(18-12-34-86-73(81)82)92-60(115)42(17-11-33-85-72(79)80)91-59(114)39(14-5-8-30-75)88-58(113)40(15-6-9-31-76)89-65(120)46(21-26-51(105)106)96-68(123)55(78)37(3)101/h36-49,55-57,101-102H,5-35,75-78H2,1-4H3,(H,88,113)(H,89,120)(H,90,119)(H,91,114)(H,92,115)(H,93,121)(H,94,116)(H,95,117)(H,96,123)(H,97,124)(H,98,118)(H,99,125)(H,100,122)(H,103,104)(H,105,106)(H,107,108)(H,109,110)(H,111,112)(H,126,127)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)",HTQONPPEZULJKY-UHFFFAOYSA-N,gepon,Phase 1,,,,
O=c1ccc2ncc(=O)n3c2n1CC3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1,"InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2",PZFAZQUREQIODZ-UHFFFAOYSA-N,gepotidacin,Phase 2,topoisomerase inhibitor,,,
CC(C)=CCCC(C)=CCCC(C)=CCCC(=O)OCC=C(C)CCC=C(C)C,"InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3",ZPACYDRSPFRDHO-UHFFFAOYSA-N,geranyl-farnesylacetate,Phase 2,mucin production enhancer,,,
C#CC1(O)C=CC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,10,12,16-19,23H,3,6-9,11,13H2,1H3",PCGOZSMTJRCWQF-UHFFFAOYSA-N,gestodene,Launched,contraceptive agent,,endocrinology,contraceptive
C#CC1(O)CCC2C3=C(C=CC21CC)C1=C(CC3)CC(=O)CC1,"InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,19,23H,3,5-8,10,12-13H2,1H3",DPCOYXQLLBXEGL-UHFFFAOYSA-N,gestrinone,Launched,progesterone receptor antagonist,AR|ESR1|PGR,obstetrics/gynecology,endometriosis
CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,"InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)",QMGUOJYZJKLOLH-UHFFFAOYSA-N,gf109203x,Preclinical,PKC inhibitor,PDPK1|PIM1|PRKCI|PRKCZ,,
COP(=O)(CCC(N)C(=O)O)Oc1cccc(CC(=O)O)c1,"InChI=1S/C13H18NO7P/c1-20-22(19,6-5-11(14)13(17)18)21-10-4-2-3-9(7-10)8-12(15)16/h2-4,7,11H,5-6,8,14H2,1H3,(H,15,16)(H,17,18)",NTFPDEDRMYYPAC-UHFFFAOYSA-N,ggstop,Preclinical,gamma glutamyltransferase Inhibitor,GGT1,,
COC(=O)C(CC(C)C)NC(=O)c1ccc(NCC(N)CS)cc1-c1cccc2ccccc12,"InChI=1S/C27H33N3O3S/c1-17(2)13-25(27(32)33-3)30-26(31)23-12-11-20(29-15-19(28)16-34)14-24(23)22-10-6-8-18-7-4-5-9-21(18)22/h4-12,14,17,19,25,29,34H,13,15-16,28H2,1-3H3,(H,30,31)",XVWPFYDMUFBHBF-UHFFFAOYSA-N,ggti-298,Preclinical,GGTase inhibitor,CDKN1A,,
CCc1nc(C(N)=O)c(=Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)[nH]c1NC1CCOCC1,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,gilteritinib,Launched,FLT3 inhibitor,FLT3,,
O=c1cc(O)[nH]cc1Cl,"InChI=1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)",ZPLQIPFOCGIIHV-UHFFFAOYSA-N,gimeracil,Launched,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma
CC1C(=O)OC2CC34C5CC(C(C)(C)C)C36C(=O)C(O)OC6OC4(C(=O)O5)C21O,"InChI=1S/C20H24O9/c1-7-12(22)26-10-6-17-9-5-8(16(2,3)4)18(17)11(21)13(23)28-15(18)29-20(17,14(24)27-9)19(7,10)25/h7-10,13,15,23,25H,5-6H2,1-4H3",RGIHELSHLHZURE-UHFFFAOYSA-N,ginkgolide-a,Preclinical,GABA receptor antagonist,GLRA1|GLRB,,
CC1C(=O)OC2C(O)C34C5CC(C(C)(C)C)C36C(=O)C(O)OC6OC4(C(=O)O5)C12O,"InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-9,11,13,15,21,24,26H,5H2,1-4H3",KUQCTOKTSAEORC-UHFFFAOYSA-N,ginkgolide-b,Phase 3,platelet activating factor receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,
CC(C)=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC12C,"InChI=1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3",FVIZARNDLVOMSU-UHFFFAOYSA-N,ginsenoside-c-k,Phase 1,NFkB pathway inhibitor,PTGS2,,
CC(C)=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC12C,"InChI=1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3",FVIZARNDLVOMSU-UHFFFAOYSA-N,ginsenoside-c-k,Phase 1,nitric oxide synthase inhibitor,PTGS2,,
CC(C)=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C1CCC2(C)C1C(O)CC1C3(C)CCC(OC4OC(CO)C(O)C(O)C4OC4OC(CO)C(O)C(O)C4O)C(C)(C)C3CCC12C,"InChI=1S/C48H82O18/c1-22(2)10-9-14-48(8,66-42-39(60)36(57)33(54)26(20-50)62-42)23-11-16-47(7)31(23)24(52)18-29-45(5)15-13-30(44(3,4)28(45)12-17-46(29,47)6)64-43-40(37(58)34(55)27(21-51)63-43)65-41-38(59)35(56)32(53)25(19-49)61-41/h10,23-43,49-60H,9,11-21H2,1-8H3",RLDVZILFNVRJTL-UHFFFAOYSA-N,ginsenoside-rd,Phase 3,calcium channel blocker,,,
CC(C)=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3C(OC3OC(CO)C(O)C(O)C3OC3OC(C)C(O)C(O)C3O)CC12C,"InChI=1S/C48H82O18/c1-21(2)11-10-14-48(9,66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4,5)40(45)25(18-47(28,46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11,22-43,49-60H,10,12-20H2,1-9H3",PWAOOJDMFUQOKB-UHFFFAOYSA-N,ginsenoside-re,Phase 1,anti-inflammatory agent,,,
CC(C)=CCCC(C)(O)C1CCC2(C)C1C(O)CC1C3(C)CCC(OC4OC(CO)C(O)C(O)C4OC4OC(CO)C(O)C(O)C4O)C(C)(C)C3CCC12C,"InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3",RWXIFXNRCLMQCD-UHFFFAOYSA-N,ginsenoside-re3,Launched,angiogenesis inhibitor,KCNH2,,
CC(C)=CCCC(C)(O)C1CCC2(C)C1C(O)CC1C3(C)CCC(OC4OC(CO)C(O)C(O)C4OC4OC(CO)C(O)C(O)C4O)C(C)(C)C3CCC12C,"InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3",RWXIFXNRCLMQCD-UHFFFAOYSA-N,ginsenoside-re3,Launched,apoptosis stimulant,KCNH2,,
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(O)=NO)cc3)ccc2c1,"InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)",YALNUENQHAQXEA-UHFFFAOYSA-N,givinostat,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
C(#Cc1nc2ncccc2nc1OCCN1CCCC1)c1ccccc1,"InChI=1S/C21H20N4O/c1-2-7-17(8-3-1)10-11-19-21(26-16-15-25-13-4-5-14-25)24-18-9-6-12-22-20(18)23-19/h1-3,6-9,12H,4-5,13-16H2",MNYJJHBAEYKXEG-UHFFFAOYSA-N,gk921,Preclinical,transglutaminase inhibitor,TGM2,,
COCC(C)Oc1cc(OC(C)Cc2ccccc2)cc(C(=O)N=c2ccc(C(=O)O)c[nH]2)c1,"InChI=1S/C26H28N2O6/c1-17(11-19-7-5-4-6-8-19)33-22-12-21(13-23(14-22)34-18(2)16-32-3)25(29)28-24-10-9-20(15-27-24)26(30)31/h4-10,12-15,17-18H,11,16H2,1-3H3,(H,30,31)(H,27,28,29)",OCBMECSFDVUYQN-UHFFFAOYSA-N,gka-50,Preclinical,glucokinase activator,GCK,,
CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1,"InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3",RGYQPQARIQKJKH-UHFFFAOYSA-N,gkt137831,Phase 2,NADPH oxidase inhibitor,NOX1|NOX4,,
O=C(OCC(O)CO)c1ccccc1N=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C19H17ClN2O4/c20-12-5-6-14-17(7-8-21-18(14)9-12)22-16-4-2-1-3-15(16)19(25)26-11-13(24)10-23/h1-9,13,23-24H,10-11H2,(H,21,22)",GWOFUCIGLDBNKM-UHFFFAOYSA-N,glafenine,Withdrawn,DeltaF508-CFTR Correctors,CFTR,,
CN1CCC(NC(=O)Nc2ccc(C#N)cc2)CC1c1nc2ccccc2[nH]1,"InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)",SFNSLLSYNZWZQG-UHFFFAOYSA-N,glasdegib,Launched,hedgehog pathway inhibitor,SMO,hematologic malignancy,acute myeloid leukemia (AML)
CC(C)(C)C1NC(=O)OC2CCCC2OCC=CC(F)(F)c2nc3ccccc3nc2OC2CC(C(=O)NC3(C(=O)NS(=O)(=O)C4(C)CC4)CC3C(F)F)N(C2)C1=O,"InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)",MLSQGNCUYAMAHD-UHFFFAOYSA-N,glecaprevir,Launched,serine protease inhibitor,,infectious disease,hepatitis C
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,"InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)",YRCHYHRCBXNYNU-UHFFFAOYSA-N,glesatinib,Phase 2,tyrosine kinase inhibitor,,,
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,"InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)",BOVGTQGAOIONJV-UHFFFAOYSA-N,gliclazide,Launched,ATP channel blocker,,endocrinology,diabetes mellitus
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,"InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)",BOVGTQGAOIONJV-UHFFFAOYSA-N,gliclazide,Launched,insulin secretagogue,,endocrinology,diabetes mellitus
CCc1c(C)cn(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)c1O,"InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,15-16,19,29H,4-6,9-10,13-14H2,1-3H3,(H,25,31)(H2,26,27,30)",GKNDIYRVXVKUNM-UHFFFAOYSA-N,glimepiride,Launched,insulin secretagogue,ABCC8|KCNJ1|KCNJ11,endocrinology,diabetes mellitus
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,"InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)",ZJJXGWJIGJFDTL-UHFFFAOYSA-N,glipizide,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus|hyperglycemia
COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C,"InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)",LLJFMFZYVVLQKT-UHFFFAOYSA-N,gliquidone,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ8,endocrinology,diabetes mellitus
COc1ccc2c3c1OC1CC(OC(=O)c4ccccc4)C=CC31CCN(C)C2,"InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3",JKVNJTYHRABHIY-UHFFFAOYSA-N,gln-1062,Preclinical,cholinesterase inhibitor,,,
COc1ccc(S(=O)(=O)NC(CN=c2[nH]c(C)nc(N3CCC(c4ccc5c(n4)NCCC5)CC3)c2C)C(=O)O)cc1,"InChI=1S/C29H37N7O5S/c1-18-26(31-17-25(29(37)38)35-42(39,40)23-9-7-22(41-3)8-10-23)32-19(2)33-28(18)36-15-12-20(13-16-36)24-11-6-21-5-4-14-30-27(21)34-24/h6-11,20,25,35H,4-5,12-17H2,1-3H3,(H,30,34)(H,37,38)(H,31,32,33)",CXHCNOMGODVIKB-UHFFFAOYSA-N,glpg0187,Phase 1,integrin antagonist,,,
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(CO)c1ccccc1,"InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3",VAJGULUVTFDTAS-UHFFFAOYSA-N,glpg0492,Phase 1,androgen receptor modulator,AR,,
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)C1(CO)c1ccccc1,"InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3",VAJGULUVTFDTAS-UHFFFAOYSA-N,glpg0492-r-enantiomer,Phase 1,androgen receptor modulator,AR,,
CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1,"InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22)",GHTGYZMBQPXTCQ-UHFFFAOYSA-N,glpg1837,Phase 2,CFTR channel potentiator,,,
O=C(C(=O)C(O)C(O)C(O)O)C(O)O,"InChI=1S/C6H10O8/c7-1(3(9)5(11)12)2(8)4(10)6(13)14/h1,3,5-7,9,11-14H",UVDLHGNYJJTBFT-UHFFFAOYSA-N,glucaric-acid,Phase 1,,,,
O=C1C(CO)OC(O)C(O)C1O,"InChI=1S/C6H10O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2,4-7,9-11H,1H2",XUXWOYRIGVQFMU-UHFFFAOYSA-N,gluconolactone,Launched,,LCT,,
NC1C(O)OC(CO)C(O)C1O,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2",MSWZFWKMSRAUBD-UHFFFAOYSA-N,glucosamine,Launched,glycosylated protein precursor,IL1B,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis|joint pain|backache
NC(CCC(=O)NC(CS)C(=O)NCC(=O)O)C(=O)O,"InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)",RWSXRVCMGQZWBV-UHFFFAOYSA-N,glutathione,Phase 3,antioxidant,ESD|GGT1|GLO1|GLRX|GLRX2|GPX1|GPX2|GPX3|GPX4|GPX5|GPX6|GPX7|GPX8|GSR|GSS|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GSTK1|GSTM1|GSTM2|GSTM3|GSTM4|GSTM5|GSTO1|GSTO2|GSTP1|GSTT1|GSTZ1|HAGH|HPGDS|LTC4S|MGST1|MGST2|MGST3|TXNDC12,,
CC(C)OC(=O)CNC(=O)C(CS)NC(=O)CCC(N)C(=O)O,"InChI=1S/C13H23N3O6S/c1-7(2)22-11(18)5-15-12(19)9(6-23)16-10(17)4-3-8(14)13(20)21/h7-9,23H,3-6,14H2,1-2H3,(H,15,19)(H,16,17)(H,20,21)",MVNCPACIPXNJIW-UHFFFAOYSA-N,glutathione-monoisopropyl-ester,Phase 2,lipid peroxidase inhibitor,,,
NCC(=O)NC(CCC(N)=O)C(=O)O,"InChI=1S/C7H13N3O4/c8-3-6(12)10-4(7(13)14)1-2-5(9)11/h4H,1-3,8H2,(H2,9,11)(H,10,12)(H,13,14)",PNMUAGGSDZXTHX-UHFFFAOYSA-N,gly-gln,Phase 2,,,,
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",ZNNLBTZKUZBEKO-UHFFFAOYSA-N,glyburide,Launched,ATP channel blocker,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",ZNNLBTZKUZBEKO-UHFFFAOYSA-N,glyburide,Launched,insulin secretagogue,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",ZNNLBTZKUZBEKO-UHFFFAOYSA-N,glyburide,Launched,sulfonylurea,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia
CCCCCCCCCCCC(=O)OCC(O)CO,"InChI=1S/C15H30O4/c1-2-3-4-5-6-7-8-9-10-11-15(18)19-13-14(17)12-16/h14,16-17H,2-13H2,1H3",ARIWANIATODDMH-UHFFFAOYSA-N,glycerol-monolaurate,Launched,beta lactamase inhibitor,,,
O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1,"InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2",ZSDBFLMJVAGKOU-UHFFFAOYSA-N,glycerol-phenylbutyrate,Phase 1,sigma receptor ligand,,,
COc1cc2c(=O)c(-c3ccc(O)cc3)coc2cc1O,"InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3",DXYUAIFZCFRPTH-UHFFFAOYSA-N,glycitein,Phase 3,tumor necrosis factor release inhibitor,TNF,,
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,"InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1",ANGKOCUUWGHLCE-UHFFFAOYSA-N,glycopyrrolate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD)
CCC(C)(C)C(=O)C(=O)N1CCCC1C(=O)O,"InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)",FOPALECPEUVCTL-UHFFFAOYSA-N,gm-1485,Preclinical,immunophilin ligand,FKBP1A,,
N#CN=C(N=c1cc[nH]cc1)NCCCCCCOc1ccc(Cl)cc1,"InChI=1S/C19H22ClN5O/c20-16-5-7-18(8-6-16)26-14-4-2-1-3-11-23-19(24-15-21)25-17-9-12-22-13-10-17/h5-10,12-13H,1-4,11,14H2,(H2,22,23,24,25)",BOIPLTNGIAPDBY-UHFFFAOYSA-N,gmx1778,Phase 1/Phase 2,NAMPT inhibitor,NAMPT,,
CCN=c1[nH]c(=Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)[nH]cc1C(F)(F)F,"InChI=1S/C19H21F4N5O3/c1-3-24-16-12(19(21,22)23)10-25-18(27-16)26-14-9-13(20)11(8-15(14)30-2)17(29)28-4-6-31-7-5-28/h8-10H,3-7H2,1-2H3,(H2,24,25,26,27)",XCFLWTZSJYBCPF-UHFFFAOYSA-N,gne-7915,Preclinical,leucine rich repeat kinase inhibitor,,,
NC(=O)c1cccc(-c2cc(=Nc3ccc(OC(F)(F)F)cc3)[nH]cn2)c1,"InChI=1S/C18H13F3N4O2/c19-18(20,21)27-14-6-4-13(5-7-14)25-16-9-15(23-10-24-16)11-2-1-3-12(8-11)17(22)26/h1-10H,(H2,22,26)(H,23,24,25)",WEVYNIUIFUYDGI-UHFFFAOYSA-N,gnf-2,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
O=C(NCCO)c1cccc(-c2cc(=Nc3ccc(OC(F)(F)F)cc3)[nH]cn2)c1,"InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)",IIQUYGWWHIHOCF-UHFFFAOYSA-N,gnf-5,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
Cc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1Nc1ccc2c(c1)=NC(=O)C=2Cc1ccc[nH]1,"InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-11,13-14,33-34H,12H2,1H3,(H2,35,37,39)",LNFZRMDSZJCZTG-UHFFFAOYSA-N,gnf-5837,Preclinical,growth factor receptor inhibitor,NTRK1|NTRK2|NTRK3,,
Cc1ccc(N=c2nc3c(c[nH]2)CN(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C(=O)N3C)cn1,"InChI=1S/C28H24F3N7O2/c1-16-7-9-21(34-25(39)18-5-4-6-20(11-18)28(29,30)31)12-23(16)38-15-19-13-33-26(36-24(19)37(3)27(38)40)35-22-10-8-17(2)32-14-22/h4-14H,15H2,1-3H3,(H,34,39)(H,33,35,36)",SZNYUUZOQHNEKB-UHFFFAOYSA-N,gnf-7,Preclinical,glucokinase inhibitor,GCK|TNK2,,
Cc1ccc(N=c2nc3c(c[nH]2)CN(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C(=O)N3C)cn1,"InChI=1S/C28H24F3N7O2/c1-16-7-9-21(34-25(39)18-5-4-6-20(11-18)28(29,30)31)12-23(16)38-15-19-13-33-26(36-24(19)37(3)27(38)40)35-22-10-8-17(2)32-14-22/h4-14H,15H2,1-3H3,(H,34,39)(H,33,35,36)",SZNYUUZOQHNEKB-UHFFFAOYSA-N,gnf-7,Preclinical,protein kinase inhibitor,GCK|TNK2,,
N=C(N)Nc1ccc2[nH]c3c(c2c1)CC1(O)C2Cc4ccc(O)c5c4C1(CCN2CC1CC1)C3O5,"InChI=1S/C27H29N5O3/c28-25(29)30-15-4-5-18-16(10-15)17-11-27(34)20-9-14-3-6-19(33)23-21(14)26(27,24(35-23)22(17)31-18)7-8-32(20)12-13-1-2-13/h3-6,10,13,20,24,31,33-34H,1-2,7-9,11-12H2,(H4,28,29,30)",VLNHDKDBGWXJEE-UHFFFAOYSA-N,gnti,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,
COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C,"InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5,7-10,13-15,27H,6,11-12H2,1-3H3,(H,28,31,32)",LLJJDLHGZUOMQP-UHFFFAOYSA-N,go-6983,Preclinical,protein kinase inhibitor,PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ,,
Fc1cc(F)c2c(c1)C1C=CCC1C(c1cccnc1)N2,"InChI=1S/C17H14F2N2/c18-11-7-14-12-4-1-5-13(12)16(10-3-2-6-20-9-10)21-17(14)15(19)8-11/h1-4,6-9,12-13,16,21H,5H2",NJZHEQOUHLZCOX-UHFFFAOYSA-N,golgicide-a,Preclinical,ARF inhibitor,GBF1,,
CN1CCN(C2CCN(C(=O)N=c3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)cc[nH]3)CC2)CC1,"InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)",UQRCJCNVNUFYDX-UHFFFAOYSA-N,golvatinib,Phase 2,VEGFR inhibitor,KDR|MET,,
CC(C)CC(NC(=O)CNC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,"InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)",XLXSAKCOAKORKW-UHFFFAOYSA-N,gonadorelin,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,obstetrics/gynecology,cystic ovaries|reproductive synchrony
CC(C)CC(NC(=O)C(COC(C)(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(N)=O,"InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)",BLCLNMBMMGCOAS-UHFFFAOYSA-N,goserelin-acetate,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR|LHCGR,oncology|obstetrics/gynecology,prostate cancer|breast cancer|endometriosis
Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,"InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3",QBKSWRVVCFFDOT-UHFFFAOYSA-N,gossypol,Phase 2,BCL inhibitor,BCL2,,
Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,"InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3",QBKSWRVVCFFDOT-UHFFFAOYSA-N,gossypol,Phase 2,MCL1 inhibitor,BCL2,,
Cc1ccc2c(c1)Cc1c(C(=O)NN3CCCCC3)nn(-c3ccc(Cl)cc3Cl)c1-2,"InChI=1S/C23H22Cl2N4O/c1-14-5-7-17-15(11-14)12-18-21(23(30)27-28-9-3-2-4-10-28)26-29(22(17)18)20-8-6-16(24)13-19(20)25/h5-8,11,13H,2-4,9-10,12H2,1H3,(H,27,30)",FNOMTMVRTBHRET-UHFFFAOYSA-N,gp1a,Preclinical,cannabinoid receptor agonist,CNR2,,
Cc1ccc2c(c1)Cc1c(C(=O)NC3CCCCC3)nn(-c3ccc(Cl)cc3Cl)c1-2,"InChI=1S/C24H23Cl2N3O/c1-14-7-9-18-15(11-14)12-19-22(24(30)27-17-5-3-2-4-6-17)28-29(23(18)19)21-10-8-16(25)13-20(21)26/h7-11,13,17H,2-6,12H2,1H3,(H,27,30)",SPEFJYZGXZENAF-UHFFFAOYSA-N,gp2a,Preclinical,cannabinoid receptor agonist,CNR2,,
O=C1COc2nccc(-c3ccccc3F)c2CN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C23H15F7N2O2/c24-19-4-2-1-3-17(19)16-5-6-31-21-18(16)11-32(20(33)12-34-21)10-13-7-14(22(25,26)27)9-15(8-13)23(28,29)30/h1-9H,10-12H2",ZIXNJVGTAXRKAP-UHFFFAOYSA-N,gpbar-a,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CCC(C)(C)C(=O)C(=O)N1CCCC1C(=O)OCCCc1cccnc1,"InChI=1S/C20H28N2O4/c1-4-20(2,3)17(23)18(24)22-12-6-10-16(22)19(25)26-13-7-9-15-8-5-11-21-14-15/h5,8,11,14,16H,4,6-7,9-10,12-13H2,1-3H3",OQAHHWOPVDDWHD-UHFFFAOYSA-N,gpi-1046,Preclinical,FKBP inhibitor,FKBP1A,,
O=C(NC1Cc2ccccc2N(CC(O)CO)C1=O)c1cc2cc(Cl)sc2[nH]1,"InChI=1S/C19H18ClN3O4S/c20-16-7-11-6-13(22-18(11)28-16)17(26)21-14-5-10-3-1-2-4-15(10)23(19(14)27)8-12(25)9-24/h1-4,6-7,12,14,22,24-25H,5,8-9H2,(H,21,26)",UICNBXVDHCBKCE-UHFFFAOYSA-N,gpi-688,Preclinical,glycogen phosphorylase inhibitor,,,
O=C(CCCCCCCn1cc(-c2cccnc2)nn1)Nc1ccccc1-c1ccccc1,"InChI=1S/C27H29N5O/c33-27(29-25-16-9-8-15-24(25)22-12-5-4-6-13-22)17-7-2-1-3-10-19-32-21-26(30-31-32)23-14-11-18-28-20-23/h4-6,8-9,11-16,18,20-21H,1-3,7,10,17,19H2,(H,29,33)",SJOLTIOPWDLDEB-UHFFFAOYSA-N,gpp-78,Preclinical,NAMPT inhibitor,NAMPT,,
Cc1cc(OCc2nc(-c3ccccc3Cl)cs2)ccc1OCC(=O)O,"InChI=1S/C19H16ClNO4S/c1-12-8-13(6-7-17(12)25-10-19(22)23)24-9-18-21-16(11-26-18)14-4-2-3-5-15(14)20/h2-8,11H,9-10H2,1H3,(H,22,23)",FONSSTYHKIFEBM-UHFFFAOYSA-N,gpr120-modulator-1,Preclinical,G protein-coupled receptor modulator,FFAR4,,
COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(C(C)=O)cc3)cc2)CC1,"InChI=1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35)",JARNORYOPMINDY-UHFFFAOYSA-N,gr-103691,Preclinical,dopamine receptor antagonist,DRD3,,
Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc21,"InChI=1S/C19H27N3O4S/c1-21-13-17(16-5-3-4-6-18(16)21)19(23)26-14-15-7-10-22(11-8-15)12-9-20-27(2,24)25/h3-6,13,15,20H,7-12,14H2,1-2H3",MOZPSIXKYJUTKI-UHFFFAOYSA-N,gr-113808,Preclinical,serotonin receptor antagonist,HTR4,,
COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1N1CCN(C)CC1,"InChI=1S/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)",YDBCEBYHYKAFRX-UHFFFAOYSA-N,gr-127935,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,
COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1,"InChI=1S/C14H17N3O3/c1-9(18)15-6-5-10-8-16-13-4-3-11(7-12(10)13)17-14(19)20-2/h3-4,7-8,16H,5-6H2,1-2H3,(H,15,18)(H,17,19)",MPZVHKLZCUEJFO-UHFFFAOYSA-N,gr-135531,Preclinical,melatonin receptor agonist,,,
N=C(N)c1ccc(N2CCN(C3CCN(CC(=O)O)CC3)CC2)cc1,"InChI=1S/C18H27N5O2/c19-18(20)14-1-3-15(4-2-14)22-9-11-23(12-10-22)16-5-7-21(8-6-16)13-17(24)25/h1-4,16H,5-13H2,(H3,19,20)(H,24,25)",QGEGSJUSWLLZLH-UHFFFAOYSA-N,gr-144053,Preclinical,integrin antagonist,ITGA2B|ITGB3,,
COC1(C[S+]([O-])c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,"InChI=1S/C23H27FN2O2S/c1-28-23(17-29(27)20-5-3-2-4-6-20)10-13-26(14-11-23)12-9-18-16-25-22-8-7-19(24)15-21(18)22/h2-8,15-16,25H,9-14,17H2,1H3",BANYJBHWTOJQDU-UHFFFAOYSA-N,gr-159897,Preclinical,tachykinin antagonist,TAC1|TACR2,,
CC=C1C(=O)CC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4-5,15,17-18H,6-12H2,1-3H3",IVLRQLIWEVLAQF-UHFFFAOYSA-N,gr-235,Launched,estrogen receptor agonist,NR1H4,,
CC=C1C(=O)CC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4-5,15,17-18H,6-12H2,1-3H3",IVLRQLIWEVLAQF-UHFFFAOYSA-N,gr-235,Launched,FXR antagonist,NR1H4,,
CC=C1C(=O)CC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4-5,15,17-18H,6-12H2,1-3H3",IVLRQLIWEVLAQF-UHFFFAOYSA-N,gr-235,Launched,progesterone receptor agonist,NR1H4,,
OCC1OC(n2cnc3c(=NC4CCCC4O)[nH]cnc32)C(O)C1O,"InChI=1S/C15H21N5O5/c21-4-9-11(23)12(24)15(25-9)20-6-18-10-13(16-5-17-14(10)20)19-7-2-1-3-8(7)22/h5-9,11-12,15,21-24H,1-4H2,(H,16,17,19)",GYWXTRVEUURNEW-UHFFFAOYSA-N,gr-79236,Phase 1,adenosine receptor agonist,ADORA1|ADORA2A,,
COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,"InChI=1S/C19H26FN3O5S/c1-27-18-17(15-11-14(20)3-4-16(15)22-18)19(24)28-12-13-5-8-23(9-6-13)10-7-21-29(2,25)26/h3-4,11,13,21-22H,5-10,12H2,1-2H3",SSPCCAYAIDNNJX-UHFFFAOYSA-N,gr125487,Preclinical,serotonin receptor antagonist,HTR4,,
COc1ccc(CNC(=O)C=Cc2ccc3[nH]cc(CCN(C)C)c3c2)cc1,"InChI=1S/C23H27N3O2/c1-26(2)13-12-19-16-24-22-10-6-17(14-21(19)22)7-11-23(27)25-15-18-4-8-20(28-3)9-5-18/h4-11,14,16,24H,12-13,15H2,1-3H3,(H,25,27)",LBVZWEWTNUDWNS-UHFFFAOYSA-N,gr46611,Preclinical,serotonin receptor agonist,HTR1D,,
CC(C)CC(NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(=O)NC(C)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCO)C(C)C)C(C)C)C(C)C,"InChI=1S/C99H140N20O17/c1-51(2)37-73(109-86(123)59(17)107-81(122)49-105-96(133)82(55(9)10)106-50-121)89(126)108-60(18)87(124)117-84(57(13)14)98(135)119-85(58(15)16)99(136)118-83(56(11)12)97(134)116-80(44-64-48-104-72-34-26-22-30-68(64)72)95(132)112-76(40-54(7)8)92(129)115-79(43-63-47-103-71-33-25-21-29-67(63)71)94(131)111-75(39-53(5)6)91(128)114-78(42-62-46-102-70-32-24-20-28-66(62)70)93(130)110-74(38-52(3)4)90(127)113-77(88(125)100-35-36-120)41-61-45-101-69-31-23-19-27-65(61)69/h19-34,45-48,50-60,73-80,82-85,101-104,120H,35-44,49H2,1-18H3,(H,100,125)(H,105,133)(H,106,121)(H,107,122)(H,108,126)(H,109,123)(H,110,130)(H,111,131)(H,112,132)(H,113,127)(H,114,128)(H,115,129)(H,116,134)(H,117,124)(H,118,136)(H,119,135)",ZWCXYZRRTRDGQE-UHFFFAOYSA-N,gramicidin,Launched,bacterial permeability inducer,,infectious disease,first-aid antibiotic
CN(C)Cc1c[nH]c2ccccc12,"InChI=1S/C11H14N2/c1-13(2)8-9-7-12-11-6-4-3-5-10(9)11/h3-7,12H,8H2,1-2H3",OCDGBSUVYYVKQZ-UHFFFAOYSA-N,gramine,Preclinical,norepinephrine reputake inhibitor,,,
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,"InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)",MFWNKCLOYSRHCJ-UHFFFAOYSA-N,granisetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,"InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)",HZVLFTCYCLXTGV-UHFFFAOYSA-N,grapiprant,Launched,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis
C=CC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OC1CC1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,"InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)",OBMNJSNZOWALQB-UHFFFAOYSA-N,grazoprevir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O,"InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3",DDUHZTYCFQRHIY-UHFFFAOYSA-N,griseofulvin,Launched,tubulin polymerization inhibitor,KRT12,infectious disease,ringworm|tinea pedis
O=C(O)c1ccc(-n2[nH]c(=Cc3ccccc3)c(=Cc3ccc(-c4ccccc4F)o3)c2=O)cc1,"InChI=1S/C28H19FN2O4/c29-24-9-5-4-8-22(24)26-15-14-21(35-26)17-23-25(16-18-6-2-1-3-7-18)30-31(27(23)32)20-12-10-19(11-13-20)28(33)34/h1-17,30H,(H,33,34)",ZNWLGWKJYHHHAY-UHFFFAOYSA-N,gs-143,Preclinical,ubiquitin ligase inhibitor,BTRC|NFKBIA,,
CSc1nc(=NC2CCCC2)c([N+](=O)[O-])c(NC2CCCC2)[nH]1,"InChI=1S/C15H23N5O2S/c1-23-15-18-13(16-10-6-2-3-7-10)12(20(21)22)14(19-15)17-11-8-4-5-9-11/h10-11H,2-9H2,1H3,(H2,16,17,18,19)",GSGVDKOCBKBMGG-UHFFFAOYSA-N,gs-39783,Preclinical,GABA receptor modulator,GABBR1,,
CCCn1c(=O)c2[nH]c(-c3cnn(Cc4cccc(C(F)(F)F)c4)c3)nc2n(CC)c1=O,"InChI=1S/C21H21F3N6O2/c1-3-8-30-19(31)16-18(29(4-2)20(30)32)27-17(26-16)14-10-25-28(12-14)11-13-6-5-7-15(9-13)21(22,23)24/h5-7,9-10,12H,3-4,8,11H2,1-2H3,(H,26,27)",KOYXXLLNCXWUNF-UHFFFAOYSA-N,gs-6201,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CCCCOc1nc(=N)c2c([nH]1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,"InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26)",VFOKSTCIRGDTBR-UHFFFAOYSA-N,gs-9620,Phase 2,toll-like receptor agonist,TLR7,,
FC(F)(F)Oc1ccc(-c2ccc3nnc(C(F)(F)F)n3c2)cc1,"InChI=1S/C14H7F6N3O/c15-13(16,17)12-22-21-11-6-3-9(7-23(11)12)8-1-4-10(5-2-8)24-14(18,19)20/h1-7H",FEVBKJITJDHASC-UHFFFAOYSA-N,gs-967,Preclinical,voltage-gated sodium channel blocker,,,
c1cn2cc(-c3ccc4c[nH]nc4c3)[nH]c(=Nc3ccc(N4CCOCC4)cc3)c2n1,"InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)",XSMSNFMDVXXHGJ-UHFFFAOYSA-N,gs-9973,Phase 2,SYK inhibitor,SYK,,
O=Nc1c(-c2c(O)[nH]c3cc(Br)ccc23)[nH]c2ccccc12,"InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18-19,21H",SAQUSDSPQYQNBG-UHFFFAOYSA-N,gsk-3-inhibitor-ix,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,
O=Nc1c(-c2c(O)[nH]c3cc(Br)ccc23)[nH]c2ccccc12,"InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18-19,21H",SAQUSDSPQYQNBG-UHFFFAOYSA-N,gsk-3-inhibitor-ix,Preclinical,lipoxygenase inhibitor,GSK3A|GSK3B,,
O=C(O)CCN=c1cc(N2CCc3ccccc3CC2)[nH]c(-c2ccccn2)n1,"InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)",AVZCPICCWKMZDT-UHFFFAOYSA-N,gsk-j1,Preclinical,histone demethylase inhibitor,KDM6B,,
O=C(O)CCN=c1cc(N2CCc3ccccc3CC2)[nH]c(-c2cccnc2)n1,"InChI=1S/C22H23N5O2/c28-21(29)7-11-24-19-14-20(26-22(25-19)18-6-3-10-23-15-18)27-12-8-16-4-1-2-5-17(16)9-13-27/h1-6,10,14-15H,7-9,11-13H2,(H,28,29)(H,24,25,26)",LJIFOCRGDDQFJF-UHFFFAOYSA-N,gsk-j2,Preclinical,histone demethylase inhibitor,,,
CCOC(=O)CCN=c1cc(N2CCc3ccccc3CC2)[nH]c(-c2ccccn2)n1,"InChI=1S/C24H27N5O2/c1-2-31-23(30)10-14-26-21-17-22(28-24(27-21)20-9-5-6-13-25-20)29-15-11-18-7-3-4-8-19(18)12-16-29/h3-9,13,17H,2,10-12,14-16H2,1H3,(H,26,27,28)",WBKCKEHGXNWYMO-UHFFFAOYSA-N,gsk-j4,Preclinical,histone lysine demethylase inhibitor,KDM6A|KDM6B,,
CCOC(=O)CCN=c1cc(N2CCc3ccccc3CC2)[nH]c(-c2cccnc2)n1,"InChI=1S/C24H27N5O2/c1-2-31-23(30)9-13-26-21-16-22(28-24(27-21)20-8-5-12-25-17-20)29-14-10-18-6-3-4-7-19(18)11-15-29/h3-8,12,16-17H,2,9-11,13-15H2,1H3,(H,26,27,28)",LQPGVGSKBNXQDU-UHFFFAOYSA-N,gsk-j5,Preclinical,histone demethylase control,,,
c1ccc(C2CC2NC2CCNCC2)cc1,"InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2",BASFYRLYJAZPPL-UHFFFAOYSA-N,gsk-lsd-1,Preclinical,histone lysine demethylase inhibitor,KDM1A,,
COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,"InChI=1S/C19H18N2O5S2/c1-25-16-12-14(20-13-6-4-3-5-7-13)8-9-15(16)21-28(23,24)17-10-11-27-18(17)19(22)26-2/h3-12,20-21H,1-2H3",NDFKBGWLUHKMFY-UHFFFAOYSA-N,gsk0660,Preclinical,PPAR receptor antagonist,PPARD,,
O=C1NC(=O)C(=Cc2ccc3nccc(-c4ccncc4)c3c2)S1,"InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)",QDITZBLZQQZVEE-UHFFFAOYSA-N,gsk1059615,Phase 1,PI3K inhibitor,PIK3CG,,
CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,"InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)",QTBWCSQGBMPECM-UHFFFAOYSA-N,gsk1070916,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC|CYP2D6|CYP3A4,,
CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1,"InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3",AYJRTVVIBJSSKN-UHFFFAOYSA-N,gsk1292263,Phase 2,glucose dependent insulinotropic receptor agonist,GRPR,,
CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1,"InChI=1S/C30H30Cl2N4O4/c1-34(28(37)17-36-25-14-23(31)24(32)15-27(25)40-18-29(36)38)26(16-35-11-2-3-12-35)20-9-7-19(8-10-20)21-5-4-6-22(13-21)30(33)39/h4-10,13-15,26H,2-3,11-12,16-18H2,1H3,(H2,33,39)",QDUMEBKFKOODFN-UHFFFAOYSA-N,gsk1562590,Preclinical,urotensin receptor antagonist,UTS2R,,
Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,"InChI=1S/C25H29N5O/c1-19-8-9-22-23(27-19)6-3-7-24(22)29-16-14-28(15-17-29)12-10-20-4-2-5-21(18-20)30-13-11-26-25(30)31/h2-9,18H,10-17H2,1H3,(H,26,31)",ANGUXJDGJCHGOG-UHFFFAOYSA-N,gsk163090,Phase 2,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D,,
CNC(=O)c1c(F)cccc1N=c1[nH]c(=Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)[nH]c2[nH]ccc12,"InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)",HZTYDQRUAWIZRE-UHFFFAOYSA-N,gsk1838705a,Preclinical,insulin growth factor receptor inhibitor,ALK|IGF1R|INSR|RPS6KA1,,
CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,"InChI=1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)",WROHEWWOCPRMIA-UHFFFAOYSA-N,gsk189254,Phase 2,histamine receptor antagonist,,,
CCc1cc(N=c2nc(-c3c(-c4ccc(OC)c(C(=O)Nc5c(F)cccc5F)c4)nc4ccccn34)cc[nH]2)c(OC)cc1N1CCC(N2CCN(S(C)(=O)=O)CC2)CC1,"InChI=1S/C44H47F2N9O5S/c1-5-28-26-35(38(60-3)27-36(28)53-19-15-30(16-20-53)52-21-23-54(24-22-52)61(4,57)58)49-44-47-17-14-34(48-44)42-40(50-39-11-6-7-18-55(39)42)29-12-13-37(59-2)31(25-29)43(56)51-41-32(45)9-8-10-33(41)46/h6-14,17-18,25-27,30H,5,15-16,19-24H2,1-4H3,(H,51,56)(H,47,48,49)",MOSKATHMXWSZTQ-UHFFFAOYSA-N,gsk1904529a,Preclinical,IGF-1 inhibitor,IGF1R|INSR,,
CCc1cc(N=c2nc(-c3c(-c4ccc(OC)c(C(=O)Nc5c(F)cccc5F)c4)nc4ccccn34)cc[nH]2)c(OC)cc1N1CCC(N2CCN(S(C)(=O)=O)CC2)CC1,"InChI=1S/C44H47F2N9O5S/c1-5-28-26-35(38(60-3)27-36(28)53-19-15-30(16-20-53)52-21-23-54(24-22-52)61(4,57)58)49-44-47-17-14-34(48-44)42-40(50-39-11-6-7-18-55(39)42)29-12-13-37(59-2)31(25-29)43(56)51-41-32(45)9-8-10-33(41)46/h6-14,17-18,25-27,30H,5,15-16,19-24H2,1-4H3,(H,51,56)(H,47,48,49)",MOSKATHMXWSZTQ-UHFFFAOYSA-N,gsk1904529a,Preclinical,insulin growth factor receptor inhibitor,IGF1R|INSR,,
CCc1cc(N=c2nc(-c3c(-c4ccc(OC)c(C(=O)Nc5c(F)cccc5F)c4)nc4ccccn34)cc[nH]2)c(OC)cc1N1CCC(N2CCN(S(C)(=O)=O)CC2)CC1,"InChI=1S/C44H47F2N9O5S/c1-5-28-26-35(38(60-3)27-36(28)53-19-15-30(16-20-53)52-21-23-54(24-22-52)61(4,57)58)49-44-47-17-14-34(48-44)42-40(50-39-11-6-7-18-55(39)42)29-12-13-37(59-2)31(25-29)43(56)51-41-32(45)9-8-10-33(41)46/h6-14,17-18,25-27,30H,5,15-16,19-24H2,1-4H3,(H,51,56)(H,47,48,49)",MOSKATHMXWSZTQ-UHFFFAOYSA-N,gsk1904529a,Preclinical,insulin receptor ligand,IGF1R|INSR,,
Cn1ncc(Cl)c1-c1cc(C(=O)NC(CN)Cc2cccc(F)c2)sc1Cl,"InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)",AFJRDFWMXUECEW-UHFFFAOYSA-N,gsk2110183,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,gsk2126458,Phase 1,mTOR inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,"InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3",CGBJSGAELGCMKE-UHFFFAOYSA-N,gsk2126458,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,"InChI=1S/C38H43N3O4S/c1-8-44-34-18-14-28(22-40-34)27-12-10-26(11-13-27)23-41-32-17-16-30(45-24-29-15-9-25(2)21-39-29)19-31(32)35(46-37(3,4)5)33(41)20-38(6,7)36(42)43/h9-19,21-22H,8,20,23-24H2,1-7H3,(H,42,43)",DFQGDHBGRSTTHX-UHFFFAOYSA-N,gsk2190915,Phase 2,lipoxygenase inhibitor,ALOX5AP,,
O=C(NC1(c2ccccc2)CC1)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2cccc(C(F)(F)F)c2)nc2cc(Br)ccc12,"InChI=1S/C37H38BrF3N4O/c38-28-12-13-30-32(23-28)42-34(25-8-7-11-27(22-25)37(39,40)41)31(24-44-20-14-29(15-21-44)45-18-5-2-6-19-45)33(30)35(46)43-36(16-17-36)26-9-3-1-4-10-26/h1,3-4,7-13,22-23,29H,2,5-6,14-21,24H2,(H,43,46)",UIVOZBSCHXCGPS-UHFFFAOYSA-N,gsk2193874,Preclinical,transient receptor potential channel antagonist,TRPV4,,
O=C(C1CC1)N1CCC(Cc2n[nH]c(=O)n2-c2ccc(-c3ccc4occc4c3)cc2)C1,"InChI=1S/C25H24N4O3/c30-24(18-1-2-18)28-11-9-16(15-28)13-23-26-27-25(31)29(23)21-6-3-17(4-7-21)19-5-8-22-20(14-19)10-12-32-22/h3-8,10,12,14,16,18H,1-2,9,11,13,15H2,(H,27,31)",AQTPWCUIYUOEMG-UHFFFAOYSA-N,gsk2194069,Preclinical,fatty acid synthase inhibitor,FASN,,
COc1cccc2c1c(=NS(=O)(=O)c1ccc(Cl)s1)[nH]n2Cc1cccc(CNC(=O)C(C)(C)O)c1,"InChI=1S/C24H25ClN4O5S2/c1-24(2,31)23(30)26-13-15-6-4-7-16(12-15)14-29-17-8-5-9-18(34-3)21(17)22(27-29)28-36(32,33)20-11-10-19(25)35-20/h4-12,31H,13-14H2,1-3H3,(H,26,30)(H,27,28)",YTEVTHHGQMUPHC-UHFFFAOYSA-N,gsk2239633a,Preclinical,CC chemokine receptor antagonist,,,
CONC(=O)c1ccccc1N=c1cc(N=c2cc(C)[nH]n2C(C)C)[nH]cc1Cl,"InChI=1S/C20H23ClN6O2/c1-12(2)27-19(9-13(3)25-27)24-18-10-17(15(21)11-22-18)23-16-8-6-5-7-14(16)20(28)26-29-4/h5-12,25H,1-4H3,(H,22,23)(H,26,28)",ATXGPXKETUSNKL-UHFFFAOYSA-N,gsk2256098,Phase 2,kinase inhibitor,,,
CN=c1[nH]c(C)nc(=NC2CCCC(C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)[nH]1,"InChI=1S/C21H24F3N7O/c1-12-28-19(26-2)31-20(29-12)30-16-5-3-4-14(9-16)18(32)27-11-15-7-6-13(10-25)8-17(15)21(22,23)24/h6-8,14,16H,3-5,9,11H2,1-2H3,(H,27,32)(H2,26,28,29,30,31)",LQHDJQIMETZMPH-UHFFFAOYSA-N,gsk2256294a,Phase 1,epoxide hydolase inhibitor,EPHX2,,
CCCCC1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2C(c2ccccc2)N1,"InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)",CZGVOBIGEBDYTP-UHFFFAOYSA-N,gsk2330672,Phase 2,bile acid transporter inhibitor,SLC10A2,,
CN=c1nc(-c2ccc3c(=N)[nH][nH]c3c2)cc(N2CC(C(=O)NC3CCCCC3)CCC2C)[nH]1,"InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)",QLPHOXTXAKOFMU-UHFFFAOYSA-N,gsk2334470,Preclinical,phosphoinositide dependent kinase inhibitor,AURKA|AURKB|PDPK1,,
O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,"InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2",YFRBKEVUUCQYOW-UHFFFAOYSA-N,gsk239512,Preclinical,histamine receptor antagonist,,,
COc1cccc(N=c2c(C(N)=O)c[nH]c3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,"InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)",JFHROPTYMMSOLG-UHFFFAOYSA-N,gsk256066,Phase 2,phosphodiesterase inhibitor,PDE4A,,
O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1,"InChI=1S/C24H18FN3O2/c25-23-14-19(10-12-27-23)18-8-9-22(30-16-17-5-2-1-3-6-17)21(13-18)24(29)28-20-7-4-11-26-15-20/h1-15H,16H2,(H,28,29)",WCIGMFCFPXZRMQ-UHFFFAOYSA-N,gsk2578215a,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(=N)[nH]cnc21,"InChI=1S/C24H20F3N5O/c1-31-12-18(21-22(28)29-13-30-23(21)31)15-5-6-19-16(11-15)7-8-32(19)20(33)10-14-3-2-4-17(9-14)24(25,26)27/h2-6,9,11-13H,7-8,10H2,1H3,(H2,28,29,30)",SIXVRXARNAVBTC-UHFFFAOYSA-N,gsk2606414,Preclinical,protein kinase inhibitor,EIF2AK3|MYLK2,,
Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,"InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)",XTKLTGBKIDQGQL-UHFFFAOYSA-N,gsk2636771,Phase 2,PI3K inhibitor,PIK3CB,,
Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4[nH]cnc(=N)c24)c3F)n1,"InChI=1S/C23H21FN6O/c1-13-4-3-5-14(28-13)10-19(31)30-9-8-16-18(30)7-6-15(21(16)24)17-11-29(2)23-20(17)22(25)26-12-27-23/h3-7,11-12H,8-10H2,1-2H3,(H2,25,26,27)",PRWSIEBRGXYXAJ-UHFFFAOYSA-N,gsk2656157,Preclinical,PERK inhibitor,,,
CCn1c(-c2no[nH]c2=N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21,"InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)",YOVNFNXUCOWYSG-UHFFFAOYSA-N,gsk269962,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CCCOc1ccn2c(C(C)=O)cc(-c3ccccc3S(C)(=O)=O)c2c1,"InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3",KHWCPNJRJCNVRI-UHFFFAOYSA-N,gsk2801,Preclinical,bromodomain inhibitor,BAZ2A|BAZ2B,,
CCC(C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21,"InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)",FKSFKBQGSFSOSM-UHFFFAOYSA-N,gsk2816126,Phase 1,histone lysine methyltransferase inhibitor,EZH2,,
Cc1ncc(Cl)cc1NCc1ccc(C(=O)NC(CC2CCCC2)C(=O)NC2CC2)s1,"InChI=1S/C23H29ClN4O2S/c1-14-19(11-16(24)12-25-14)26-13-18-8-9-21(31-18)23(30)28-20(10-15-4-2-3-5-15)22(29)27-17-6-7-17/h8-9,11-12,15,17,20,26H,2-7,10,13H2,1H3,(H,27,29)(H,28,30)",IVDUVEGCMXCMSO-UHFFFAOYSA-N,gsk2830371,Preclinical,protein phosphatase inhibitor,PPM1D,,
COc1ncc(-c2ccc3c(=Nc4cc(Oc5cc(F)cc(F)c5)cc(C(=O)O)c4)c(S(=O)(=O)NC4CC4)c[nH]c3c2)c(OC)n1,"InChI=1S/C31H25F2N5O7S/c1-43-29-25(14-35-31(37-29)44-2)16-3-6-24-26(9-16)34-15-27(46(41,42)38-20-4-5-20)28(24)36-21-7-17(30(39)40)8-22(13-21)45-23-11-18(32)10-19(33)12-23/h3,6-15,20,38H,4-5H2,1-2H3,(H,34,36)(H,39,40)",RZBCPMYJIARMGV-UHFFFAOYSA-N,gsk2837808a,Preclinical,lactate dehydrogenase inhibitor,LDHA,,
CC(C)C1=C2C3CCC4C5(C)CCC(OC(=O)CC(C)(C)C(=O)O)C(C)(C)C5CCC4(C)C3(C)CCC2(C(O)CN(CCN(C)C)Cc2ccc(Cl)cc2)CC1=O,"InChI=1S/C48H73ClN2O6/c1-30(2)40-34(52)26-48(37(53)29-51(25-24-50(10)11)28-31-12-14-32(49)15-13-31)23-22-46(8)33(41(40)48)16-17-36-45(7)20-19-38(57-39(54)27-43(3,4)42(55)56)44(5,6)35(45)18-21-47(36,46)9/h12-15,30,33,35-38,53H,16-29H2,1-11H3,(H,55,56)",MEOWKUXNVNJAMY-UHFFFAOYSA-N,gsk2838232,Phase 2,HIV gag inhibitor,,,
O=C(O)c1ccc(CN2CCC(CNC3CC3c3ccccc3)CC2)cc1,"InChI=1S/C23H28N2O2/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19/h1-9,17,21-22,24H,10-16H2,(H,26,27)",LRULVYSBRWUVGR-UHFFFAOYSA-N,gsk2879552,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,
CC(CS(C)(=O)=O)n1ccc2c(C(F)(F)F)c(C#N)ccc21,"InChI=1S/C14H13F3N2O2S/c1-9(8-22(2,20)21)19-6-5-11-12(19)4-3-10(7-18)13(11)14(15,16)17/h3-6,9H,8H2,1-2H3",SKDVMPZQJMZEAC-UHFFFAOYSA-N,gsk2881078,Phase 2,androgen receptor modulator,,,
CCc1ccc(N(CC(C)C)S(=O)(=O)c2ccc(OCC3CCOCC3)c(CO)c2)cc1,"InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3",LZLBRISQTJVZNP-UHFFFAOYSA-N,gsk2981278,Phase 1/Phase 2,ROR modulator,,,
CN1C(=O)C(NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21,"InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)",LYPAFUINURXJSG-UHFFFAOYSA-N,gsk2982772,Phase 2,RIPK inhibitor,,,
O=C(OC1CCCC1)C(NCc1ccc(CCC(O)=NO)nc1)C1CCCCC1,"InChI=1S/C22H33N3O4/c26-20(25-28)13-12-18-11-10-16(14-23-18)15-24-21(17-6-2-1-3-7-17)22(27)29-19-8-4-5-9-19/h10-11,14,17,19,21,24,28H,1-9,12-13,15H2,(H,25,26)",AFDPFLDWOXXHQM-UHFFFAOYSA-N,gsk3117391,Phase 1/Phase 2,HDAC inhibitor,,,
CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)N=c2cc(C(C)(C)C(F)(F)F)o[nH]2)c(F)c1,"InChI=1S/C22H21F4N3O4/c1-4-32-16-9-19(30)27-11-14(16)12-5-6-13(15(23)7-12)8-20(31)28-18-10-17(33-29-18)21(2,3)22(24,25)26/h5-7,9-11H,4,8H2,1-3H3,(H,27,30)(H,28,29,31)",IDXKJSSOUXWLDB-UHFFFAOYSA-N,gsk3179106,Phase 1,RET tyrosine kinase inhibitor,,,
CC(=O)N1CCC(N=c2cc(C(=O)NCC(O)CN3CCc4ccccc4C3)[nH]cn2)CC1,"InChI=1S/C24H32N6O3/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28)",JLCCNYVTIWRPIZ-UHFFFAOYSA-N,gsk3326595,Phase 1/Phase 2,protein arginine N-methyltransferase inhibitor,,,
CCn1ncc2c(=NC3CCOCC3)c(-c3nnc(Cc4sc(C)nc4C)o3)c[nH]c21,"InChI=1S/C21H25N7O2S/c1-4-28-20-15(11-23-28)19(25-14-5-7-29-8-6-14)16(10-22-20)21-27-26-18(30-21)9-17-12(2)24-13(3)31-17/h10-11,14H,4-9H2,1-3H3,(H,22,25)",AWDJJMXJUOHGLC-UHFFFAOYSA-N,gsk356278,Preclinical,phosphodiesterase inhibitor,,,
CC(C)(C)NCc1ccc(N=c2cc[nH]c3cc(Cl)ccc23)cc1O,"InChI=1S/C20H22ClN3O/c1-20(2,3)23-12-13-4-6-15(11-19(13)25)24-17-8-9-22-18-10-14(21)5-7-16(17)18/h4-11,23,25H,12H2,1-3H3,(H,22,24)",ZVMMVSSEAMUNGI-UHFFFAOYSA-N,gsk369796,Phase 1,potassium channel antagonist,,,
COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1,"InChI=1S/C16H19NO3S/c1-11-9-12(2)16(13(3)10-11)17-21(18,19)15-7-5-14(20-4)6-8-15/h5-10,17H,1-4H3",FQUAFMNPXPXOJE-UHFFFAOYSA-N,gsk37647,Preclinical,free fatty acid receptor agonist,FFAR4,,
O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1,"InChI=1S/C15H12ClF3N2O3S/c16-12-4-1-10(2-5-12)14(22)20-7-8-25(23,24)13-6-3-11(9-21-13)15(17,18)19/h1-6,9H,7-8H2,(H,20,22)",JFUIMTGOQCQTPF-UHFFFAOYSA-N,gsk3787,Preclinical,PPAR receptor antagonist,PPARD,,
CC1=NC(=O)CC(c2ccc(C(F)(F)F)cc2)C1C(=O)Nc1cc2c[nH]nc2cc1F,"InChI=1S/C21H16F4N4O2/c1-10-19(20(31)28-17-6-12-9-26-29-16(12)8-15(17)22)14(7-18(30)27-10)11-2-4-13(5-3-11)21(23,24)25/h2-6,8-9,14,19H,7H2,1H3,(H,26,29)(H,28,31)",OGZNAHUSFVMYPZ-UHFFFAOYSA-N,gsk429286a,Preclinical,rho associated kinase inhibitor,ROCK1,,
CC(Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,"InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)",ZHJGWYRLJUCMRT-UHFFFAOYSA-N,gsk461364,Phase 1,PLK inhibitor,PLK1,,
Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(N4CCN(C)CC4)nc3)cc3c2c(C)cn3C(C)C)c(=O)[nH]1,"InChI=1S/C31H38N6O2/c1-19(2)37-18-21(4)29-25(30(38)33-17-26-20(3)13-22(5)34-31(26)39)14-24(15-27(29)37)23-7-8-28(32-16-23)36-11-9-35(6)10-12-36/h7-8,13-16,18-19H,9-12,17H2,1-6H3,(H,33,38)(H,34,39)",HRDQQHUKUIKFHT-UHFFFAOYSA-N,gsk503,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccccc4)cc23)cc1C1CCCC1,"InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)",WVSBGSNVCDAMCF-UHFFFAOYSA-N,gsk650394,Preclinical,serum/glucocorticoid regulated kinase inhibitor,SGK1|SGK2,,
NCC1OB(O)c2c(OCCO)ccc(Cl)c21,"InChI=1S/C10H13BClNO4/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15/h1-2,8,14-15H,3-5,13H2",DJUOWOXTPXUHDQ-UHFFFAOYSA-N,gsk656,Preclinical,leucyl-tRNA synthetase inhibitor,,,
CCn1c(-c2no[nH]c2=N)nc2c(C#CC(C)(C)O)ncc(OCC3CCCNC3)c21,"InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)",KGPGFQWBCSZGEL-UHFFFAOYSA-N,gsk690693,Phase 1,AKT inhibitor,AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX,,
O=S(=O)(Cc1ccccc1)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,"InChI=1S/C27H19F4N3O2S/c28-21-7-10-23(11-8-21)34-26-13-6-19(14-20(26)16-32-34)24-12-9-22(15-25(24)27(29,30)31)33-37(35,36)17-18-4-2-1-3-5-18/h1-16,33H,17H2",DXBJGDVBQPEMOB-UHFFFAOYSA-N,gsk9027,Preclinical,glucocorticoid receptor agonist,NR3C1,,
CC(C)Oc1ccc(C(=O)NC(CNC(=O)CN(C)C)Cc2ccc(-c3cn4cccc(C(C)O)c4n3)cc2)cc1Cl,"InChI=1S/C32H38ClN5O4/c1-20(2)42-29-13-12-24(16-27(29)33)32(41)35-25(17-34-30(40)19-37(4)5)15-22-8-10-23(11-9-22)28-18-38-14-6-7-26(21(3)39)31(38)36-28/h6-14,16,18,20-21,25,39H,15,17,19H2,1-5H3,(H,34,40)(H,35,41)",WHMXDBPHBVLYRC-UHFFFAOYSA-N,gsk923295,Phase 1,centromere associated protein inhibitor,CENPE,,
c1ccc(-c2[nH]nc3c2oc2ccccc23)cc1,"InChI=1S/C15H10N2O/c1-2-6-10(7-3-1)13-15-14(17-16-13)11-8-4-5-9-12(11)18-15/h1-9H,(H,16,17)",DZQLVVLATXPWBK-UHFFFAOYSA-N,gtp-14564,Preclinical,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFRB,,
c1ccc(-c2[nH]nc3c2oc2ccccc23)cc1,"InChI=1S/C15H10N2O/c1-2-6-10(7-3-1)13-15-14(17-16-13)11-8-4-5-9-12(11)18-15/h1-9H,(H,16,17)",DZQLVVLATXPWBK-UHFFFAOYSA-N,gtp-14564,Preclinical,tyrosine kinase inhibitor,CSF1R|FLT3|KIT|PDGFRB,,
COc1ccc(C=C2CCCN=C2c2cccnc2)c(OC)c1,"InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3",RPYWXZCFYPVCNQ-UHFFFAOYSA-N,gts21,Phase 1/Phase 2,cholinergic receptor agonist,CHRNA7,,
COc1ccccc1OC(=O)c1ccccc1OC(C)=O,"InChI=1S/C16H14O5/c1-11(17)20-13-8-4-3-7-12(13)16(18)21-15-10-6-5-9-14(15)19-2/h3-10H,1-2H3",HSJFYRYGGKLQBT-UHFFFAOYSA-N,guacetisal,Launched,immunosuppressant,,pulmonary,cough suppressant
N=c1ncn(C2CC(O[PH](=O)(=O)OCC3OC(n4cnc5c(=O)[nH]c(=N)[nH]c54)CC3O)C(CO)O2)c(=O)[nH]1,"InChI=1S/C18H23N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H2,19,25,31)(H3,20,23,24,30)",CKWGVHOCHXVKIN-UHFFFAOYSA-N,guadecitabine,Phase 3,DNA methyltransferase inhibitor,,,
COc1ccccc1O,"InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3",LHGVFZTZFXWLCP-UHFFFAOYSA-N,guaiacol,Launched,local anesthetic,CA2,pulmonary,cough suppressant
COc1ccccc1OCC(O)CO,"InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3",HSRJKNPTNIJEKV-UHFFFAOYSA-N,guaifenesin,Launched,expectorant,,pulmonary,cough suppressant
N=C(N)NN=Cc1c(Cl)cccc1Cl,"InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)",WDZVGELJXXEGPV-UHFFFAOYSA-N,guanaben-acetate,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
N=C(N)NCC1COC2(CCCCC2)O1,"InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)",HPBNRIOWIXYZFK-UHFFFAOYSA-N,guanadrel,Launched,adrenergic inhibitor,,cardiology,hypertension
CCC(C)(C)N=C(N)NC#N,"InChI=1S/C7H14N4/c1-4-7(2,3)11-6(9)10-5-8/h4H2,1-3H3,(H3,9,10,11)",VZVGEDRCVUKSEL-UHFFFAOYSA-N,guancydine,Preclinical,antihypertensive agent,,,
N=C(N)NCCN1CCCCCCC1,"InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)",ACGDKVXYNVEAGU-UHFFFAOYSA-N,guanethidine,Launched,adrenergic inhibitor,SLC6A2,cardiology,hypertension
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,"InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)",INJOMKTZOLKMBF-UHFFFAOYSA-N,guanfacine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
N=C(N)N,"InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)",ZRALSGWEFCBTJO-UHFFFAOYSA-N,guanidine,Launched,HSP inhibitor,ALDH2|DLG4|GAMT|RNASE1,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS)
N=C(N)NCCSSCCN=C(N)N,"InChI=1S/C6H16N6S2/c7-5(8)11-1-3-13-14-4-2-12-6(9)10/h1-4H2,(H4,7,8,11)(H4,9,10,12)",IRMTXMJNHRISQH-UHFFFAOYSA-N,guanidinoethyldisulfide-bicarbonate,Phase 2,nitric oxide synthase inhibitor,NOS2,,
N=C(N)NCCC(=O)O,"InChI=1S/C4H9N3O2/c5-4(6)7-2-1-3(8)9/h1-2H2,(H,8,9)(H4,5,6,7)",KMXXSJLYVJEBHI-UHFFFAOYSA-N,guanidinopropionic-acid,Phase 2,creatine kinase inhibitor,CKM,,
N=c1[nH]c(=O)c2ncn(C3OC(CO)C(O)C3O)c2[nH]1,"InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)",NYHBQMYGNKIUIF-UHFFFAOYSA-N,guanosine,Preclinical,,PNP,,
CSc1nc2ccc3[nH]c(=NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1,"InChI=1S/C23H17N3OS3/c1-28-23-25-17-13-12-16-19(20(17)30-23)29-22(24-16)26-21(27)18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-13,18H,1H3,(H,24,26,27)",UFOBDFMYJABXGK-UHFFFAOYSA-N,gue-1654,Preclinical,oxoeicosanoid receptor modulator,OXER1,,
O=C(O)C1=CCCNC1,"InChI=1S/C6H9NO2/c8-6(9)5-2-1-3-7-4-5/h2,7H,1,3-4H2,(H,8,9)",QTDZOWFRBNTPQR-UHFFFAOYSA-N,guvacine,Preclinical,GABA uptake inhibitor,SLC6A1|SLC6A11|SLC6A12|SLC6A13,,
Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)c(F)c3)nc2C)ccc1OCC(=O)O,"InChI=1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)",HWVNEWGKWRGSRK-UHFFFAOYSA-N,gw-0742,Preclinical,PPAR receptor agonist,PPARD,,
CCOC(=O)c1ccc(-n2cc(Cc3cnc(OCC)nc3)c(=O)nc2SCc2ccc(F)cc2)cc1,"InChI=1S/C27H25FN4O4S/c1-3-35-25(34)20-7-11-23(12-8-20)32-16-21(13-19-14-29-26(30-15-19)36-4-2)24(33)31-27(32)37-17-18-5-9-22(28)10-6-18/h5-12,14-16H,3-4,13,17H2,1-2H3",PTPNCCWOTBBVJR-UHFFFAOYSA-N,gw-1100,Preclinical,G protein-coupled receptor agonist,FFAR1,,
CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1,"InChI=1S/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)",QTQMRBZOBKYXCG-UHFFFAOYSA-N,gw-1929,Preclinical,PPAR receptor agonist,PPARG,,
COc1ccc(COc2ccc(Cc3c[nH]c(=N)[nH]c3=N)cc2OC)cc1,"InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)",MYQAUKPBNJWPIE-UHFFFAOYSA-N,gw-2580,Preclinical,cFMS kinase inhibitor,CSF1R,,
CC(C)C1C(=O)N(S(C)(=O)=O)C2CCN(C(=O)C=CCN3CCCCC3)C12,"InChI=1S/C19H31N3O4S/c1-14(2)17-18-15(22(19(17)24)27(3,25)26)9-13-21(18)16(23)8-7-12-20-10-5-4-6-11-20/h7-8,14-15,17-18H,4-6,9-13H2,1-3H3",NDNKNUMSTIMSHQ-UHFFFAOYSA-N,gw-311616,Phase 1,elastase inhibitor,ELANE,,
CC(C)C1C(=O)N(S(C)(=O)=O)C2CCN(C(=O)C=CCN3CCCCC3)C12,"InChI=1S/C19H31N3O4S/c1-14(2)17-18-15(22(19(17)24)27(3,25)26)9-13-21(18)16(23)8-7-12-20-10-5-4-6-11-20/h7-8,14-15,17-18H,4-6,9-13H2,1-3H3",NDNKNUMSTIMSHQ-UHFFFAOYSA-N,gw-311616,Phase 1,leukocyte elastase inhibitor,ELANE,,
O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,"InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)",NAXSRXHZFIBFMI-UHFFFAOYSA-N,gw-3965,Preclinical,LXR agonist,NR1H2|NR1H3,,
COc1ccc2c(c1)c(CCN1CCOCC1)c(C)n2C(=O)c1cccc(Cl)c1Cl,"InChI=1S/C23H24Cl2N2O3/c1-15-17(8-9-26-10-12-30-13-11-26)19-14-16(29-2)6-7-21(19)27(15)23(28)18-4-3-5-20(24)22(18)25/h3-7,14H,8-13H2,1-2H3",FSFZRNZSZYDVLI-UHFFFAOYSA-N,gw-405833,Preclinical,cannabinoid receptor agonist,CNR2,,
CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(C=Cc2cccc(C(=O)O)c2)c(Cl)c1,"InChI=1S/C28H22Cl3NO4/c1-16(2)27-21(26(32-36-27)25-22(29)7-4-8-23(25)30)15-35-20-12-11-18(24(31)14-20)10-9-17-5-3-6-19(13-17)28(33)34/h3-14,16H,15H2,1-2H3,(H,33,34)",BYTNEISLBIENSA-UHFFFAOYSA-N,gw-4064,Preclinical,FXR agonist,NR1H4,,
O=C(N=c1[nH]c2ccccc2n1CCc1ccccc1)c1ccccc1,"InChI=1S/C22H19N3O/c26-21(18-11-5-2-6-12-18)24-22-23-19-13-7-8-14-20(19)25(22)16-15-17-9-3-1-4-10-17/h1-14H,15-16H2,(H,23,24,26)",CDUDZZGLFOFINU-UHFFFAOYSA-N,gw-438014a,Preclinical,neuropeptide receptor antagonist,NPY5R,,
Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21,"InChI=1S/C17H13N3O/c1-20-10-11(12-5-2-3-7-15(12)20)9-13-16-14(19-17(13)21)6-4-8-18-16/h2-10H,1H3,(H,19,21)",NXNQLECPAXXYTR-UHFFFAOYSA-N,gw-441756,Preclinical,growth factor receptor inhibitor,NTRK1,,
Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,"InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)",YDBLKRPLXZNVNB-UHFFFAOYSA-N,gw-501516,Phase 2,PPAR receptor agonist,PPARA|PPARD,,
O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1,"InChI=1S/C15H8Br2INO2/c16-11-4-7(5-12(17)14(11)20)3-10-9-6-8(18)1-2-13(9)19-15(10)21/h1-6,20H,(H,19,21)",LMXYVLFTZRPNRV-UHFFFAOYSA-N,gw-5074,Phase 1/Phase 2,leucine rich repeat kinase inhibitor,NTRK1|RAF1,,
O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1,"InChI=1S/C15H8Br2INO2/c16-11-4-7(5-12(17)14(11)20)3-10-9-6-8(18)1-2-13(9)19-15(10)21/h1-6,20H,(H,19,21)",LMXYVLFTZRPNRV-UHFFFAOYSA-N,gw-5074,Phase 1/Phase 2,RAF inhibitor,NTRK1|RAF1,,
COc1ccccc1NC(=O)OCC1CCN(C(=O)OC(C)(C)C)CC1,"InChI=1S/C19H28N2O5/c1-19(2,3)26-18(23)21-11-9-14(10-12-21)13-25-17(22)20-15-7-5-6-8-16(15)24-4/h5-8,14H,9-13H2,1-4H3,(H,20,22)",SAXGSDIZIYFNKD-UHFFFAOYSA-N,gw-542573x,Preclinical,calcium channel activator,KCNN1,,
CS(=O)(=O)CCNCc1nc(-c2ccc3[nH]cnc(=Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cs1,"InChI=1S/C28H25ClFN5O3S2/c1-40(36,37)10-9-31-14-27-35-25(16-39-27)19-5-7-24-22(12-19)28(33-17-32-24)34-21-6-8-26(23(29)13-21)38-15-18-3-2-4-20(30)11-18/h2-8,11-13,16-17,31H,9-10,14-15H2,1H3,(H,32,33,34)",MNNXRVSQOABRRP-UHFFFAOYSA-N,gw-583340,Preclinical,EGFR inhibitor,EGFR|ERBB2,,
CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)NS(=O)(=O)c3ccccc3)cc1)C2,"InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)",XREWXJVMYAXCJV-UHFFFAOYSA-N,gw-627368,Preclinical,prostanoid receptor antagonist,PTGER4,,
CCC(=O)NCC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)N=C(C)CC(=O)c1ccc(C(F)(F)F)cc1,"InChI=1S/C35H36F3N3O4/c1-4-33(43)39-22-29(40-23(2)20-32(42)26-12-14-28(15-13-26)35(36,37)38)21-25-10-16-30(17-11-25)44-19-18-31-24(3)45-34(41-31)27-8-6-5-7-9-27/h5-17,29H,4,18-22H2,1-3H3,(H,39,43)",GWOGKYGQZKGRED-UHFFFAOYSA-N,gw-6471,Preclinical,PPAR receptor antagonist,PPARA,,
CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(=O)O,"InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)",PKNYXWMTHFMHKD-UHFFFAOYSA-N,gw-7647,Preclinical,PPAR receptor agonist,PPARA,,
O=C(NC1CCOCC1)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1,"InChI=1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)",SAGZIBJAQGBRQA-UHFFFAOYSA-N,gw-788388,Preclinical,ALK tyrosine kinase receptor inhibitor,LCK|MAPK14|TGFBR1,,
COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1,"InChI=1S/C25H24ClN3O3S/c1-31-22-14-19(8-9-21(22)32-13-12-28-10-2-3-11-28)29-16-27-20-15-23(33-24(20)25(29)30)17-4-6-18(26)7-5-17/h4-9,14-16H,2-3,10-13H2,1H3",MWULMTACIBZPGN-UHFFFAOYSA-N,gw-803430,Phase 1,melanin inhibitor,KCNH2|MCHR1,,
O=C(NCC1CCOCC1)c1c[nH]c(=Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F,"InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27)",TWQYWUXBZHPIIV-UHFFFAOYSA-N,gw-842166,Phase 2,cannabinoid receptor agonist,CNR2,,
COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC,"InChI=1S/C22H18F3N3O4S/c1-30-16-7-14-15(8-17(16)31-2)28(11-27-14)19-9-18(20(33-19)21(26)29)32-10-12-5-3-4-6-13(12)22(23,24)25/h3-9,11H,10H2,1-2H3,(H2,26,29)",JSKUWFIZUALZLX-UHFFFAOYSA-N,gw-843682x,Preclinical,PLK inhibitor,PLK1|PLK3,,
O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,"InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)",DGENZVKCTGIDRZ-UHFFFAOYSA-N,gw-9508,Preclinical,free fatty acid receptor agonist,FFAR1|FFAR4,,
O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,"InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)",DGENZVKCTGIDRZ-UHFFFAOYSA-N,gw-9508,Preclinical,G protein-coupled receptor agonist,FFAR1|FFAR4,,
O=C(Nc1ccccc1)c1cc([N+](=O)[O-])ccc1Cl,"InChI=1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)",DNTSIBUQMRRYIU-UHFFFAOYSA-N,gw-9662,Preclinical,PPAR receptor antagonist,NCOA2|PPARG|RXRA,,
CC(=N)NCCSCCC(N)C(=O)O,"InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)",MOLOJNHYNHBPCW-UHFFFAOYSA-N,gw274150,Phase 2,nitric oxide synthase inhibitor,,,
CC1=NN=C(c2ccc(N)cc2)c2cc3c(cc2C1)OCO3,"InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3",LFBZZHVSGAHQPP-UHFFFAOYSA-N,gyki-52466,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
CC(C)=CCCC(C)(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C1CCC2(C)C1C(O)CC1C3(C)CCC(OC4OC(CO)C(O)C(O)C4O)C(C)(C)C3CCC12C,"InChI=1S/C47H80O17/c1-22(2)10-9-14-47(8,64-42-39(58)36(55)34(53)27(62-42)21-60-40-37(56)32(51)25(50)20-59-40)23-11-16-46(7)31(23)24(49)18-29-44(5)15-13-30(43(3,4)28(44)12-17-45(29,46)6)63-41-38(57)35(54)33(52)26(19-48)61-41/h10,23-42,48-58H,9,11-21H2,1-8H3",ZTQSADJAYQOCDD-UHFFFAOYSA-N,gynostemma-extract,Phase 2,calcium channel modulator,,,
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,"InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)",TZKBVRDEOITLRB-UHFFFAOYSA-N,gzd824,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,
CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1,"InChI=1S/C17H17N3O/c1-2-12-7-9-13(10-8-12)19-17(21)20-16-11-18-15-6-4-3-5-14(15)16/h3-11,18H,2H2,1H3,(H2,19,20,21)",UJZDIKVQFMCLBE-UHFFFAOYSA-N,h-151,Preclinical,STING antagonist,,,
O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12,"InChI=1S/C20H20BrN3O2S/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20/h1-10,12,15,22,24H,11,13-14H2",ZKZXNDJNWUTGDK-UHFFFAOYSA-N,h-89,Preclinical,PKA inhibitor,GSG2|PKIA|PRKACA,,
O=C(O)c1ccc2c(c1)C(=O)N(c1cccc(Oc3ccc([N+](=O)[O-])cc3)c1)C2=O,"InChI=1S/C21H12N2O7/c24-19-17-9-4-12(21(26)27)10-18(17)20(25)22(19)14-2-1-3-16(11-14)30-15-7-5-13(6-8-15)23(28)29/h1-11H,(H,26,27)",HFYPTENHTPNXGP-UHFFFAOYSA-N,h2l-5765834,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,
N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12,"InChI=1S/C12H15N5O2S/c13-12(14)16-6-7-17-20(18,19)11-3-1-2-9-8-15-5-4-10(9)11/h1-5,8,17H,6-7H2,(H4,13,14,16)",MZNDNBFMSVMUCX-UHFFFAOYSA-N,ha-1004,Phase 2,calcium channel blocker,,,
O=C1SC(=Cc2ccc(OCc3cccc(B(O)O)c3)cc2)C(=O)N1Cc1ccc(F)cc1,"InChI=1S/C24H19BFNO5S/c26-20-8-4-17(5-9-20)14-27-23(28)22(33-24(27)29)13-16-6-10-21(11-7-16)32-15-18-2-1-3-19(12-18)25(30)31/h1-13,30-31H,14-15H2",VTNKMYWFWQTEHE-UHFFFAOYSA-N,ha-130,Preclinical,autotaxin inhibitor,ENPP2,,
NC1CCN(O)C1=O,"InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2",HCKUBNLZMKAEIN-UHFFFAOYSA-N,ha-966-(r)-(+),Preclinical,glutamate receptor agonist,GRIA1,,
NC1CCN(O)C1=O,"InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2",HCKUBNLZMKAEIN-UHFFFAOYSA-N,ha-966-(s)-(-),Preclinical,glutamate receptor antagonist,GRIA1,,
CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(=N)C1C(=O)OCC,"InChI=1S/C17H17BrN2O5/c1-3-23-16(21)11(8-19)13-10-7-9(18)5-6-12(10)25-15(20)14(13)17(22)24-4-2/h5-7,11,13-14,20H,3-4H2,1-2H3",DMETXMZYCSYQHI-UHFFFAOYSA-N,ha14-1,Preclinical,BCL inhibitor,BCL2,,
O=C(O)c1ccc(S(=O)(=O)N(Cl)Cl)cc1,"InChI=1S/C7H5Cl2NO4S/c8-10(9)15(13,14)6-3-1-5(2-4-6)7(11)12/h1-4H,(H,11,12)",XPDVQPODLRGWPL-UHFFFAOYSA-N,halazone,Launched,,,infectious disease,disinfectant
CC1(C)OC2CC3C4CC=C5CC(=O)CCC5(C)C4(F)C(O)CC3(C)C2(C(=O)CCl)O1,"InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h5,15-17,19,28H,6-12H2,1-4H3",SRFSUDHTQQJJIN-UHFFFAOYSA-N,halcinonide,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCC(=O)OC1(C(=O)CCl)C(C)CC2C3CC(F)=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,13,15-16,19,30H,5,8-12H2,1-4H3",DTALYPLHSSTQEU-UHFFFAOYSA-N,halobetasol-propionate,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses
CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,"InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3",FOHHNHSLJDZUGQ-UHFFFAOYSA-N,halofantrine,Launched,antimalarial agent,KCNN4,infectious disease,malaria
O=C(CC1NCCCC1O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,"InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2",LVASCWIMLIKXLA-UHFFFAOYSA-N,halofuginone,Launched,collagenase inhibitor,COL1A1|MMP2,rheumatology,scleroderma
O=C(NCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1ccc(F)cc1,"InChI=1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)",NBHPRWLFLUBAIE-UHFFFAOYSA-N,halopemide,Phase 2,phospholipase inhibitor,PLD1|PLD2,,
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,"InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",LNEPOXFFQSENCJ-UHFFFAOYSA-N,haloperidol,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1,neurology/psychiatry,schizophrenia|Tourette's disorder
CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,"InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3",GUTXTARXLVFHDK-UHFFFAOYSA-N,haloperidol-decanoate,Launched,psychoactive drug,DRD2|DRD3|DRD4|HTR2A,neurology/psychiatry,schizophrenia
Clc1cc(Cl)c(OCC#CI)cc1Cl,"InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2",CTETYYAZBPJBHE-UHFFFAOYSA-N,haloprogin,Launched,other antifungal,,infectious disease,tinea pedis
FC(F)(F)C(Cl)Br,"InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H",BCQZXOMGPXTTIC-UHFFFAOYSA-N,halothane,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic
Cc1nccc2c1[nH]c1ccccc12,"InChI=1S/C12H10N2/c1-8-12-10(6-7-13-8)9-4-2-3-5-11(9)14-12/h2-7,14H,1H3",PSFDQSOCUJVVGF-UHFFFAOYSA-N,harmane,Preclinical,monoamine oxidase inhibitor,MAOA|MAOB,,
COC(=O)CC(O)(CCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,"InChI=1S/C28H37NO9/c1-26(2,32)8-9-28(33,15-22(30)35-4)25(31)38-24-21(34-3)14-27-7-5-10-29(27)11-6-17-12-19-20(37-16-36-19)13-18(17)23(24)27/h12-14,23-24,32-33H,5-11,15-16H2,1-4H3",HAVJATCHLFRDHY-UHFFFAOYSA-N,harringtonine,Phase 3,protein synthesis inhibitor,,,
O=C(O)CN(CCN(CC(=O)O)Cc1ccccc1O)Cc1ccccc1O,"InChI=1S/C20H24N2O6/c23-17-7-3-1-5-15(17)11-21(13-19(25)26)9-10-22(14-20(27)28)12-16-6-2-4-8-18(16)24/h1-8,23-24H,9-14H2,(H,25,26)(H,27,28)",GRUVVLWKPGIYEG-UHFFFAOYSA-N,hbed,Phase 3,chelating agent,,,
CC(C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,"InChI=1S/C18H21N5O3/c1-11(2)12-5-7-13(8-6-12)20-14(24)9-23-10-19-16-15(23)17(25)22(4)18(26)21(16)3/h5-8,10-11H,9H2,1-4H3,(H,20,24)",HEQDZPHDVAOBLN-UHFFFAOYSA-N,hc-030031,Phase 1,TRPA1 channel blocker,TRPA1,,
Cc1c(C(=O)Nc2cccc(C(F)(F)F)c2)cc(-c2ccccc2)n1CCCN1CCOCC1,"InChI=1S/C26H28F3N3O2/c1-19-23(25(33)30-22-10-5-9-21(17-22)26(27,28)29)18-24(20-7-3-2-4-8-20)32(19)12-6-11-31-13-15-34-16-14-31/h2-5,7-10,17-18H,6,11-16H2,1H3,(H,30,33)",NCZYSQOTAYFTNM-UHFFFAOYSA-N,hc-067047,Preclinical,transient receptor potential channel antagonist,TRPV4,,
Cn1c(=O)n(CCCO)c(=O)c2c1nc(Oc1cccc(Cl)c1)n2Cc1ccc(Cl)cc1,"InChI=1S/C22H20Cl2N4O4/c1-26-19-18(20(30)27(22(26)31)10-3-11-29)28(13-14-6-8-15(23)9-7-14)21(25-19)32-17-5-2-4-16(24)12-17/h2,4-9,12,29H,3,10-11,13H2,1H3",VYJPVPHNGWEIBT-UHFFFAOYSA-N,hc-070,Preclinical,transient receptor potential channel antagonist,,,
CCc1ccc(C=CC(=O)Nc2ccc(C(C)=O)cc2)o1,"InChI=1S/C17H17NO3/c1-3-15-8-9-16(21-15)10-11-17(20)18-14-6-4-13(5-7-14)12(2)19/h4-11H,3H2,1-2H3,(H,18,20)",SPTWXRJNCFIDRQ-UHFFFAOYSA-N,heclin,Preclinical,ubiquitin ligase inhibitor,NEDD4|SMURF2|WWP1,,
CCCCC#Cc1nc(=NC)c2ncn(C3OC(CO)C(O)C3O)c2[nH]1,"InChI=1S/C17H23N5O4/c1-3-4-5-6-7-11-20-15(18-2)12-16(21-11)22(9-19-12)17-14(25)13(24)10(8-23)26-17/h9-10,13-14,17,23-25H,3-5,8H2,1-2H3,(H,18,20,21)",KOCIMZNSNPOGOP-UHFFFAOYSA-N,hemado,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CC1=C(C(C)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5CCC(=O)O)c(CCC(=O)O)c4C)C(C(C)O)=C3C,"InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,35-36,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)",DWZDGMDDUHAIQA-UHFFFAOYSA-N,hematoporphyrin,Launched,,,neurology/psychiatry,depression|psychosis
Oc1cc2c(cc1O)C1c3ccc(O)c(O)c3OCC1(O)C2,"InChI=1S/C16H14O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,13,17-21H,5-6H2",WZUVPPKBWHMQCE-UHFFFAOYSA-N,hematoxylin,Preclinical,,,,
C=Cc1c(C)c2[nH]c1=Cc1c(C)c(CCC(=O)O)c3n1[Fe+]n1c(c(C=C)c(=C)c1=CC1=NC(=C3)C(CCC(=O)O)=C1C)C=2,"InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-3,9-12H2,4-6H3,(H5,35,36,37,38,39,40,41,42);/q;+3/p-2",BCAQMTCEIGYYQY-UHFFFAOYSA-L,hemin,Launched,enzyme inducer,,hematology|cardiology,acute intermittent porphyria (AIP)|hypertension|ventricular tachycardia (VT)
CC(C)=CCCC(C)(O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3C(O)CC12C,"InChI=1S/C30H52O4/c1-18(2)10-9-13-30(8,34)19-11-15-28(6)24(19)20(31)16-22-27(5)14-12-23(33)26(3,4)25(27)21(32)17-29(22,28)7/h10,19-25,31-34H,9,11-17H2,1-8H3",SHCBCKBYTHZQGZ-UHFFFAOYSA-N,hemomex-s,Launched,,PPARG,,
NS(=O)(=O)OCCCCCCCOS(N)(=O)=O,"InChI=1S/C7H18N2O6S2/c8-16(10,11)14-6-4-2-1-3-5-7-15-17(9,12)13/h1-7H2,(H2,8,10,11)(H2,9,12,13)",GOJJWDOZNKBUSR-UHFFFAOYSA-N,hepsulfam,Preclinical,DNA cross-linking,,,
CC(N)CCCC(C)(C)O,"InChI=1S/C8H19NO/c1-7(9)5-4-6-8(2,3)10/h7,10H,4-6,9H2,1-3H3",LREQLEBVOXIEOM-UHFFFAOYSA-N,heptaminol,Launched,vasoconstrictor,,cardiology,hypotension
Cc1cc(N=c2[nH]cnc3ccc(-c4ccc(CNCCS(C)(=O)=O)o4)cc23)ccc1Oc1ccn2ncnc2c1,"InChI=1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)",QVMNYGOVNWWFKF-UHFFFAOYSA-N,her2-inhibitor-1,Preclinical,EGFR inhibitor,,,
CCS(=O)(=O)Nc1ccc2[nH]c(O)c(C(=Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1,"InChI=1S/C29H32N4O3S/c1-2-37(35,36)32-24-15-16-26-25(19-24)27(29(34)31-26)28(22-9-5-3-6-10-22)30-23-13-11-21(12-14-23)20-33-17-7-4-8-18-33/h3,5-6,9-16,19,31-32,34H,2,4,7-8,17-18,20H2,1H3",HYHIYZMIFPJROG-UHFFFAOYSA-N,hesperadin,Preclinical,Aurora kinase inhibitor,AURKB,,
COc1ccc(C2CC(=O)c3c(O)cc(O)cc3O2)cc1O,"InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3",AIONOLUJZLIMTK-UHFFFAOYSA-N,hesperetin,Launched,ACAT inhibitor,DGAT1|MTTP|SOAT1|SOAT2,,
COc1ccc(C2CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2)cc1O,"InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3",QUQPHWDTPGMPEX-UHFFFAOYSA-N,hesperidin,Launched,flavanone glycoside,AURKB|CACNA1B,,
CC1(C)SC2C(N3C(=O)C(c4ccccc4)NC3(C)C)C(=O)N2C1C(=O)O,"InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)",DXVUYOAEDJXBPY-UHFFFAOYSA-N,hetacillin,Launched,bacterial cell wall synthesis inhibitor,,obstetrics/gynecology,mastitis
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,"InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2",ACGUYXCXAPNIKK-UHFFFAOYSA-N,hexachlorophene,Launched,potassium channel activator,GLUD1|SDHD,infectious disease,gram-positive bacterial infections
C[N+](C)(C)CCCCCC[N+](C)(C)C,"InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2",VZJFGSRCJCXDSG-UHFFFAOYSA-N,hexamethonium,Preclinical,cholinergic receptor antagonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6,,
CC(=O)NCCCCCCNC(C)=O,"InChI=1S/C10H20N2O2/c1-9(13)11-7-5-3-4-6-8-12-10(2)14/h3-8H2,1-2H3,(H,11,13)(H,12,14)",BNQSTAOJRULKNX-UHFFFAOYSA-N,hexamethylenebisacetamide,Phase 2,AKT inhibitor,AKT1,,
CC(=O)NCCCCCCNC(C)=O,"InChI=1S/C10H20N2O2/c1-9(13)11-7-5-3-4-6-8-12-10(2)14/h3-8H2,1-2H3,(H,11,13)(H,12,14)",BNQSTAOJRULKNX-UHFFFAOYSA-N,hexamethylenebisacetamide,Phase 2,differentiation inducer,AKT1,,
CC(=O)NCCCCCCNC(C)=O,"InChI=1S/C10H20N2O2/c1-9(13)11-7-5-3-4-6-8-12-10(2)14/h3-8H2,1-2H3,(H,11,13)(H,12,14)",BNQSTAOJRULKNX-UHFFFAOYSA-N,hexamethylenebisacetamide,Phase 2,NFKB pathway inhibitor,AKT1,,
CCCCCCOC(=O)CCC(=O)CN,"InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3",RYQOILLJDKPETL-UHFFFAOYSA-N,hexaminolevulinate,Launched,,,radiology,diagnostic agent
O=[PH](=O)(O)OC1C(O[PH](=O)(=O)O)C(O[PH](=O)(=O)O)C(O[PH](=O)(=O)O)C(O[PH](=O)(=O)O)C1O[PH](=O)(=O)O,"InChI=1S/C6H12O24P6/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15/h1-6H,(H,7,8,9)(H,10,11,12)(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)",JXLNWQURODGVRM-UHFFFAOYSA-N,hexasodium-phytate,Phase 2,,,,
CCC(c1ccc(O)cc1)C(CC)c1ccc(O)cc1,"InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3",PBBGSZCBWVPOOL-UHFFFAOYSA-N,hexestrol,Launched,synthetic estrogen,AKR1C1|ESR1|ESR2,endocrinology,hypoestrogenism
CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1,"InChI=1S/C21H45N3/c1-6-10-12-19(8-3)14-23-16-21(5,22)17-24(18-23)15-20(9-4)13-11-7-2/h19-20H,6-18,22H2,1-5H3",DTOUUUZOYKYHEP-UHFFFAOYSA-N,hexetidine,Launched,local anesthetic,,otolaryngology|infectious disease|dental|gastroenterology,pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis
O=C(C(O)C(O)O)C(O)C(O)CO,"InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-3,5-9,11-13H,1H2",UVZKQGXWWWXEKH-UHFFFAOYSA-N,hexonic-acid,Preclinical,,,,
Oc1ccc(C(O)CNCCCCCCNCC(O)c2ccc(O)c(O)c2)cc1O,"InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2",OXLZNBCNGJWPRV-UHFFFAOYSA-N,hexoprenaline,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
CC(CNC1CCCCC1)OC(=O)c1ccccc1,"InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3",DKLKMKYDWHYZTD-UHFFFAOYSA-N,hexylcaine,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,local anesthetic
CC(O)CC(C)(C)O,"InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3",SVTBMSDMJJWYQN-UHFFFAOYSA-N,hexylene-glycol,Preclinical,,AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP,,
CCCCCCc1ccc(O)cc1O,"InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3",WFJIVOKAWHGMBH-UHFFFAOYSA-N,hexylresorcinol,Launched,local anesthetic,TYR,infectious disease,skin infections|first-aid antiseptic
Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1,"InChI=1S/C16H17NO3/c18-12-3-1-10(2-4-12)7-14-13-9-16(20)15(19)8-11(13)5-6-17-14/h1-4,8-9,14,17-20H,5-7H2",WZRCQWQRFZITDX-UHFFFAOYSA-N,higenamine,Phase 1,adrenergic receptor agonist,ADRB2,,
O=C(O)CNC(=O)c1ccccc1,"InChI=1S/C9H9NO3/c11-8(12)6-10-9(13)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)(H,11,12)",QIAFMBKCNZACKA-UHFFFAOYSA-N,hippuric-acid,Preclinical,,,,
NCCc1c[nH]cn1,"InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)",NTYJJOPFIAHURM-UHFFFAOYSA-N,histamine,Launched,histamine receptor agonist,HRH1|HRH2|HRH3|HRH4,allergy,allergic rhinitis
Cc1cc(C)c(S(=O)(=O)n2cc(C)cc2C)c(C)c1,"InChI=1S/C15H19NO2S/c1-10-6-12(3)15(13(4)7-10)19(17,18)16-9-11(2)8-14(16)5/h6-9H,1-5H3",AFZWZVLPIMHLSE-UHFFFAOYSA-N,hjc-0350,Preclinical,GTPase inhibitor,RAPGEF4,,
CCOc1cc2[nH]cc(C#N)c(=Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,"InChI=1S/C31H29ClFN5O3/c1-4-40-29-16-26-24(15-27(29)37-30(39)9-6-12-38(2)3)31(21(17-34)18-35-26)36-23-10-11-28(25(32)14-23)41-19-20-7-5-8-22(33)13-20/h5-11,13-16,18H,4,12,19H2,1-3H3,(H,35,36)(H,37,39)",NERXPXBELDBEPZ-UHFFFAOYSA-N,hki-357,Phase 1,EGFR inhibitor,EGFR,,
CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc21,"InChI=1S/C23H24N2O/c1-3-25-21-10-6-5-9-19(21)20-14-17(12-13-22(20)25)15-24-16-18-8-4-7-11-23(18)26-2/h4-14,24H,3,15-16H2,1-2H3",FIOIJUCPVZEPFX-UHFFFAOYSA-N,hlcl-61,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,
COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2,"InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)",AHJUHHDDCJQACA-UHFFFAOYSA-N,hm-30181,Phase 1,P glycoprotein inhibitor,,,
COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2C=Cc2cc[n+]([O-])cc2)cc1,"InChI=1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3",OCKHRKSTDPOHEN-UHFFFAOYSA-N,hmn-214,Phase 1,PLK inhibitor,PLK1,,
CC(C)(C)NCC(O)c1ccc(O)cc1Cl,"InChI=1S/C12H18ClNO2/c1-12(2,3)14-7-11(16)9-5-4-8(15)6-10(9)13/h4-6,11,14-16H,7H2,1-3H3",LIXBJWRFCNRAPA-UHFFFAOYSA-N,hoku-81,Preclinical,bronchodilator,,,
CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21,"InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1",QTANTQQOYSUMLC-UHFFFAOYSA-O,homidium,Preclinical,,,,
CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C19H23ClN2/c1-21-12-5-13-22(15-14-21)19(16-6-3-2-4-7-16)17-8-10-18(20)11-9-17/h2-4,6-11,19H,5,12-15H2,1H3",WEUCDJCFJHYFRL-UHFFFAOYSA-N,homochlorcyclizine,Launched,antihistamine,HRH1,allergy,allergic rhinitis
COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCc2cc4c(cc2C13)OCO4,"InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3",HYFHYPWGAURHIV-UHFFFAOYSA-N,homoharringtonine,Launched,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML)
O=C(O)Cc1cccnc1C(=O)O,"InChI=1S/C8H7NO4/c10-6(11)4-5-2-1-3-9-7(5)8(12)13/h1-3H,4H2,(H,10,11)(H,12,13)",HQPMJFFEXJELOQ-UHFFFAOYSA-N,homoquinolinic-acid,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CC1CC(OC(=O)c2ccccc2O)CC(C)(C)C1,"InChI=1S/C16H22O3/c1-11-8-12(10-16(2,3)9-11)19-15(18)13-6-4-5-7-14(13)17/h4-7,11-12,17H,8-10H2,1-3H3",WSSJONWNBBTCMG-UHFFFAOYSA-N,homosalate,Preclinical,HSP inducer,,,
COc1ccc(CCN)cc1OC,"InChI=1S/C10H15NO2/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,7H,5-6,11H2,1-2H3",ANOUKFYBOAKOIR-UHFFFAOYSA-N,homoveratrylamine,Preclinical,monoamine oxidase inhibitor,,,
C=CCc1ccc(O)c(-c2ccc(O)c(CC=C)c2)c1,"InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2",FVYXIJYOAGAUQK-UHFFFAOYSA-N,honokiol,Phase 3,AKT inhibitor,ALOX5|PTGS1|PTGS2,,
CN(C)CCc1ccc(O)cc1,"InChI=1S/C10H15NO/c1-11(2)8-7-9-3-5-10(12)6-4-9/h3-6,12H,7-8H2,1-2H3",KUBCEEMXQZUPDQ-UHFFFAOYSA-N,hordenine,Preclinical,,,,
CCCCC(NC(C)=O)C(=O)NC(CCC(N)=O)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCN=C(N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O,"InChI=1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)",UHKZNDVUBSEJJO-UHFFFAOYSA-N,hp-228,Preclinical,nitric oxide synthase inhibitor,,,
CC(C)(O)c1nc(-c2cccc(CNC(=O)c3cnc(-c4ccccn4)nc3)c2)no1,"InChI=1S/C22H20N6O3/c1-22(2,30)21-27-18(28-31-21)15-7-5-6-14(10-15)11-26-20(29)16-12-24-19(25-13-16)17-8-3-4-9-23-17/h3-10,12-13,30H,11H2,1-2H3,(H,26,29)",VJCLAPUACUQZOV-UHFFFAOYSA-N,hpgds-in-1,Preclinical,prostaglandin inhibitor,,,
CC=c1c(C)c2[nH]c1=Cc1[nH]c3c(c1C)C(=O)CC3=c1[nH]c(c(C)c1CCC(=O)O)=Cc1[nH]c(c(C(C)OCCCCCC)c1C)C2,"InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h9,17-18,24,40-43H,8,10-16,19H2,1-7H3,(H,45,46)",ZITMPKZCCFIWNX-UHFFFAOYSA-N,hpph,Phase 2,photosensitizing agent,,,
CCC(C)(C)C(=O)O,"InChI=1S/C6H12O2/c1-4-6(2,3)5(7)8/h4H2,1-3H3,(H,7,8)",VUAXHMVRKOTJKP-UHFFFAOYSA-N,hqk-1001,Phase 2,,,,
O=C(N=c1nn[nH][nH]1)c1cncc(N2CCCC2)n1,"InChI=1S/C10H12N8O/c19-9(13-10-14-16-17-15-10)7-5-11-6-8(12-7)18-3-1-2-4-18/h5-6H,1-4H2,(H2,13,14,15,16,17,19)",LUJDHCXCWJFNOJ-UHFFFAOYSA-N,hsr6071,Preclinical,antiallergic agent,,,
O=C1C(=Nc2cccc(C(F)(F)F)c2)c2ccccc2N1c1ccccc1,"InChI=1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H",TXCGMRVPXUBHAL-UHFFFAOYSA-N,ht-2157,Phase 1/Phase 2,galanin receptor 3 antagonist,,,
Cc1[nH]c(=Nc2cnn(C3CCNCC3)c2)nc2c1N(C)C(=O)c1cc3ccccc3cc1N2C,"InChI=1S/C26H28N8O/c1-16-23-24(31-26(29-16)30-19-14-28-34(15-19)20-8-10-27-11-9-20)32(2)22-13-18-7-5-4-6-17(18)12-21(22)25(35)33(23)3/h4-7,12-15,20,27H,8-11H2,1-3H3,(H,29,30,31)",CHSDJDLAKKAWCI-UHFFFAOYSA-N,hth-01-015,Preclinical,protein kinase inhibitor,NUAK1,,
CCCCCCOc1cc(C)c(O)c(C)c1C,"InChI=1S/C15H24O2/c1-5-6-7-8-9-17-14-10-11(2)15(16)13(4)12(14)3/h10,16H,5-9H2,1-4H3",ATMNQRRJNBCQJO-UHFFFAOYSA-N,hthq,Preclinical,antioxidant,,,
CC(CCCCC(=O)Nc1ccc(C(F)(F)F)cc1)NCCc1c[nH]cn1,"InChI=1S/C19H25F3N4O/c1-14(24-11-10-17-12-23-13-25-17)4-2-3-5-18(27)26-16-8-6-15(7-9-16)19(20,21)22/h6-9,12-14,24H,2-5,10-11H2,1H3,(H,23,25)(H,26,27)",PMKJGGBYYNEYPA-UHFFFAOYSA-N,htmt,Preclinical,histamine receptor agonist,HRH4,,
CC=C1C2C=C(C)CC1(N)c1ccc(=O)[nH]c1C2,"InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)",ZRJBHWIHUMBLCN-UHFFFAOYSA-N,huperzine-a,Phase 2,acetylcholinesterase inhibitor,ACHE,,
CC(=O)NC1CC(O)C(CO)OC1OC1C(C(=O)O)OC(O)C(O)C1O,"InChI=1S/C14H23NO11/c1-4(17)15-5-2-6(18)7(3-16)24-14(5)26-10-8(19)9(20)13(23)25-11(10)12(21)22/h5-11,13-14,16,18-20,23H,2-3H2,1H3,(H,15,17)(H,21,22)",WCDDVEOXEIYWFB-UHFFFAOYSA-N,hyaluronic-acid,Launched,,C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN,rheumatology|urology,osteoarthritis|interstitial cystitis (IC)
CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12,"InChI=1S/C20H24N2O2S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20/h5-10,21,23H,3-4,11-13H2,1-2H3",MFZWMTSUNYWVBU-UHFFFAOYSA-N,hycanthone,Launched,RNA synthesis inhibitor,,infectious disease,schistosomiasis
NN=c1[nH]ncc2ccccc12,"InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)",RPTUSVTUFVMDQK-UHFFFAOYSA-N,hydralazine,Launched,vasodilator,,cardiology,hypertension
COc1ccc2c(c1OC)C(=O)OC2C1c2cc3c(cc2CCN1C)OCO3,"InChI=1S/C21H21NO6/c1-22-7-6-11-8-15-16(27-10-26-15)9-13(11)18(22)19-12-4-5-14(24-2)20(25-3)17(12)21(23)28-19/h4-5,8-9,18-19H,6-7,10H2,1-3H3",JZUTXVTYJDCMDU-UHFFFAOYSA-N,"hydrastine-(1r,9s)",Preclinical,tyrosine hydroxylase inhibitor,,,
C[N+]1=Cc2cc3c(cc2CC1)OCO3,"InChI=1S/C11H12NO2/c1-12-3-2-8-4-10-11(14-7-13-10)5-9(8)6-12/h4-6H,2-3,7H2,1H3/q+1",LGDCROILDUSHQX-UHFFFAOYSA-N,hydrastinine,Preclinical,hemostatic agent,,,
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,"InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",JZUFKLXOESDKRF-UHFFFAOYSA-N,hydrochlorothiazide,Launched,thiazide diuretic,CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3,cardiology,hypertension|congestive heart failure
CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3",JYGXADMDTFJGBT-UHFFFAOYSA-N,hydrocortisone,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR3C1|NR3C2,dermatology|neurology/psychiatry,eczema|psoriasis|seborrheic dermatitis|itching
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3C(O)CC21C,"InChI=1S/C23H32O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h4,16-18,20,26,28H,5-12H2,1-3H3",XNMUPDICNYMLBM-UHFFFAOYSA-N,hydrocortisone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCCC(=O)OC1(C(=O)CO)CCC2C3CC=C4CC(=O)CCC4(C)C3C(O)CC21C,"InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h6,17-19,22,26,28H,4-5,7-14H2,1-3H3",XKBHXDANGNWXFJ-UHFFFAOYSA-N,hydrocortisone-butyrate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses|eczema
CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)CCC(=O)O,"InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)",VWQWXZAWFPZJDA-UHFFFAOYSA-N,hydrocortisone-hemisuccinate,Phase 2/Phase 3,,,,
CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO[PH](=O)(=O)O,"InChI=1S/C21H30O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H,26,27,28)",SIDODWGKBCPEIP-UHFFFAOYSA-N,hydrocortisone-phosphate,Launched,,,pulmonary|gastroenterology|hematologic malignancy|ophthalmology,asthma|nausea|vomiting|multiple myeloma|contact dermatitis|enteritis|colitis
CCCCC(=O)OC1(C(=O)CO)CCC2C3CC=C4CC(=O)CCC4(C)C3C(O)CC21C,"InChI=1S/C26H38O6/c1-4-5-6-22(31)32-26(21(30)15-27)12-10-19-18-8-7-16-13-17(28)9-11-24(16,2)23(18)20(29)14-25(19,26)3/h7,18-20,23,27,29H,4-6,8-15H2,1-3H3",OMSIWXSUNPHFMK-UHFFFAOYSA-N,hydrocortisone-valerate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O,"InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)",DMDGGSIALPNSEE-UHFFFAOYSA-N,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension
CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,"InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3",LJOQGZACKSYWCH-UHFFFAOYSA-N,hydroquinidine,Launched,antiarrhythmic,,cardiology,cardiac arrythmia
Oc1ccc(O)cc1,"InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H",QIGBRXMKCJKVMJ-UHFFFAOYSA-N,hydroquinone,Launched,melanin inhibitor,TYR,dermatology,dyschromia
CC1=C2N=C(C=C3N=C(C(C)C4=NC(C(CC(N)=O)C4(C)CCC(=O)NCC(C)O[PH](=O)(=O)OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O,"InChI=1S/C62H89N13O14P/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56/h20-21,23,28,31-32,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)",BFOWVMZUKTYNPH-UHFFFAOYSA-N,hydroxocobalamin,Launched,vitamin B,,,
CC(N)Cc1ccc(O)cc1,"InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3",GIKNHHRFLCDOEU-UHFFFAOYSA-N,hydroxyamphetamine,Launched,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis
CCN(CCO)CCCC(C)N=c1cc[nH]c2cc(Cl)ccc12,"InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)",XXSMGPRMXLTPCZ-UHFFFAOYSA-N,hydroxychloroquine,Launched,antimalarial agent,TLR7|TLR9,infectious disease,malaria
O=c1[nH]ccc2c(S(=O)(=O)N3CCCNCC3)cccc12,"InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)",ZAVGJDAFCZAWSZ-UHFFFAOYSA-N,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1,,
CC(=O)C1(O)CCC2C3CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,16-18,24H,5-12H2,1-3H3",RCFJDVCRANOZEL-UHFFFAOYSA-N,hydroxyprogesterone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth
CC(=O)OC1(C(C)=O)CCC2C3CC=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C23H32O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h5,18-20H,6-13H2,1-4H3",QSIFVIZZEAETDY-UHFFFAOYSA-N,hydroxyprogesterone-acetate,Launched,progesterone receptor agonist,PGR,,
CC(O)COCC1OC2OC3C(COCC(C)O)OC(OC4C(COCC(C)O)OC(OC5C(COCC(C)O)OC(OC6C(COCC(C)O)OC(OC7C(COCC(C)O)OC(OC8C(COCC(C)O)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,"InChI=1S/C63H112O42/c1-22(64)8-85-15-29-50-36(71)43(78)57(92-29)100-51-30(16-86-9-23(2)65)94-59(45(80)38(51)73)102-53-32(18-88-11-25(4)67)96-61(47(82)40(53)75)104-55-34(20-90-13-27(6)69)98-63(49(84)42(55)77)105-56-35(21-91-14-28(7)70)97-62(48(83)41(56)76)103-54-33(19-89-12-26(5)68)95-60(46(81)39(54)74)101-52-31(17-87-10-24(3)66)93-58(99-50)44(79)37(52)72/h22-84H,8-21H2,1-7H3",ODLHGICHYURWBS-UHFFFAOYSA-N,hydroxypropyl-beta-cyclodextrin,Phase 2/Phase 3,,,,
O=C(C=Cc1ccc(O)cc1)C1C(=O)C(C2OC(CO)C(O)C(O)C2O)C(=O)C(O)(C2OC(CO)C(O)C(O)C2O)C1=O,"InChI=1S/C27H32O16/c28-7-12-16(32)19(35)21(37)23(42-12)15-18(34)14(11(31)6-3-9-1-4-10(30)5-2-9)24(39)27(41,25(15)40)26-22(38)20(36)17(33)13(8-29)43-26/h1-6,12-17,19-23,26,28-30,32-33,35-38,41H,7-8H2",DKEZDPGUJMMUCC-UHFFFAOYSA-N,hydroxysafflor-yellow-a,Preclinical,antitumor agent,,,
N=C(N)c1ccc(C=Cc2ccc(C(=N)N)cc2O)cc1,"InChI=1S/C16H16N4O/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21/h1-9,21H,(H3,17,18)(H3,19,20)",TUESWZZJYCLFNL-UHFFFAOYSA-N,hydroxystilbamidine,Launched,,,,
N=c1c2c([nH]c3ccccc13)CCCC2O,"InChI=1S/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)",HLVVITIHAZBPKB-UHFFFAOYSA-N,"hydroxytacrine-maleate-(r,s)",Preclinical,cholinesterase inhibitor,ACHE,,
Cc1cccc(C(=O)O)c1O,"InChI=1S/C8H8O3/c1-5-3-2-4-6(7(5)9)8(10)11/h2-4,9H,1H3,(H,10,11)",WHSXTWFYRGOBGO-UHFFFAOYSA-N,hydroxytoluic-acid,Preclinical,,,,
NC(O)=NO,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",VSNHCAURESNICA-UHFFFAOYSA-N,hydroxyurea,Launched,ribonucleotide reductase inhibitor,RRM1|RRM2|RRM2B,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2",ZQDWXGKKHFNSQK-UHFFFAOYSA-N,hydroxyzine,Launched,antihistamine,HRH1,neurology/psychiatry|allergy|dermatology,anxiety|urticaria|itching|dermatosis
CNC1CC(N)C(O)C(OC2OC(CO)C(O)C3OC4(OC(C(N)CO)C(O)C(O)C4O)OC23)C1O,"InChI=1S/C20H37N3O13/c1-23-7-2-5(21)9(26)15(10(7)27)33-19-17-16(11(28)8(4-25)32-19)35-20(36-17)18(31)13(30)12(29)14(34-20)6(22)3-24/h5-19,23-31H,2-4,21-22H2,1H3",GRRNUXAQVGOGFE-UHFFFAOYSA-N,hygromycin-b,Preclinical,polypeptide synthesis inhibitor,,,
Cc1cc(=O)oc2cc(O)ccc12,"InChI=1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3",HSHNITRMYYLLCV-UHFFFAOYSA-N,hymecromone,Phase 2,monoamine oxidase inhibitor,MAOA|MAOB,,
CC(CCC(=O)O)C1CCC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)",DGABKXLVXPYZII-UHFFFAOYSA-N,hyodeoxycholic-acid,Phase 1,atherosclerosis formation inhibitor,,,
CN1C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2,"InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3",RKUNBYITZUJHSG-UHFFFAOYSA-N,hyoscyamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology|urology|neurology/psychiatry|allergy,peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis
Cc1cc(=O)c2c(O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c65)c78,"InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31,33-36,38H,1-2H3",FIIAPJASQSDOKY-UHFFFAOYSA-N,hypericin,Phase 3,tyrosine kinase inhibitor,,,
O=c1c(OC2OC(CO)C(O)C(O)C2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2",OVSQVDMCBVZWGM-UHFFFAOYSA-N,hyperin,Preclinical,aldose reductase inhibitor,ACE|AKR1B1,,
C=C1C(=O)CC2CC3OC3(C)CCC3OC3(C)CC(OC(C)=O)C1C2(C)C,"InChI=1S/C22H32O5/c1-12-15(24)9-14-10-18-21(5,27-18)8-7-17-22(6,26-17)11-16(25-13(2)23)19(12)20(14,3)4/h14,16-19H,1,7-11H2,2-6H3",HNPAHGHFONBTLV-UHFFFAOYSA-N,hypoestoxide,Phase 1,IKK inhibitor,IKBKB|IL1B|TNF,,
O=c1[nH]cnc2[nH]cnc12,"InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",FDGQSTZJBFJUBT-UHFFFAOYSA-N,hypoxanthine,Preclinical,PARP inhibitor,PNP,,
CCNC(=O)CC1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21,"InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)",AAAQFGUYHFJNHI-UHFFFAOYSA-N,i-bet-762,Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,
COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccn3)c12,"InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)",VUVUVNZRUGEAHB-UHFFFAOYSA-N,i-bet151,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4,,
CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O,"InChI=1S/C22H22F3N3O3S2/c1-2-28-12-17(13-4-3-5-14(10-13)22(23,24)25)19-16(21(28)29)11-18(32-19)20(26)27-15-6-8-33(30,31)9-7-15/h3-5,10-12,15H,2,6-9H2,1H3,(H2,26,27)",WRUWGLUCNBMGPS-UHFFFAOYSA-N,i-brd9,Preclinical,bromodomain inhibitor,BRD9,,
CCN(CC)CCNC(=O)c1ccc(I)cc1,"InChI=1S/C13H19IN2O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10H2,1-2H3,(H,15,17)",HRVWCNMOEFNEON-UHFFFAOYSA-N,i-bza,Phase 2,,,,
CCN(CC)CCNC(=O)c1ccccc1I,"InChI=1S/C13H19IN2O/c1-3-16(4-2)10-9-15-13(17)11-7-5-6-8-12(11)14/h5-8H,3-4,9-10H2,1-2H3,(H,15,17)",WNSWOZIBBVUJBI-UHFFFAOYSA-N,i-bza2,Phase 3,,,,
CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OCC2CCCN(C)C2)C1,"InChI=1S/C27H36N2O5/c1-5-26(30)29-11-12-33-27-22(17-29)13-21(20-8-9-23(31-3)24(14-20)32-4)15-25(27)34-18-19-7-6-10-28(2)16-19/h8-9,13-15,19H,5-7,10-12,16-18H2,1-4H3",YKNAKDFZAWQEEO-UHFFFAOYSA-N,i-cbp-112,Preclinical,bromodomain inhibitor,CREBBP|EP300,,
Cc1nc(-c2nc(-c3ccc(OC(F)(F)F)cc3)no2)nn1Cc1cccc(N2CCC(S(C)(=O)=O)CC2)c1,"InChI=1S/C25H25F3N6O4S/c1-16-29-23(24-30-22(32-38-24)18-6-8-20(9-7-18)37-25(26,27)28)31-34(16)15-17-4-3-5-19(14-17)33-12-10-21(11-13-33)39(2,35)36/h3-9,14,21H,10-13,15H2,1-2H3",HWJWNWZJUYCGKV-UHFFFAOYSA-N,iacs-10759,Preclinical,mitochondrial complex I inhibitor,,,
CNC(=O)C1OC(n2cnc3c(=NCc4cccc(I)c4)[nH]cnc32)C(O)C1O,"InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)",HUJXGQILHAUCCV-UHFFFAOYSA-N,ib-meca,Phase 3,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CCCCCN(C)CCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C9H21NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H,12,13,14)(H,15,16,17)",QQJMCUYGZZJIAF-UHFFFAOYSA-N,ibandronate,Launched,bone resorption inhibitor,FDPS,orthopedics,osteoporosis
CC(C)n1nnc2cc(C(=O)O)ccc21,"InChI=1S/C10H11N3O2/c1-6(2)13-9-4-3-7(10(14)15)5-8(9)11-12-13/h3-6H,1-2H3,(H,14,15)",RUTVRAJKELSHCC-UHFFFAOYSA-N,ibc-293,Preclinical,hydroxycarboxylic acid receptor agonist,HCAR3,,
O=C1CCC(N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,"InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)",IXZOHGPZAQLIBH-UHFFFAOYSA-N,iberdomide,Preclinical,cereblon modulator,,,
CC(C)(NC(=O)OC1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1,"InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)",YFHRCLAKZBDRHN-UHFFFAOYSA-N,ibiglustat,Preclinical,glucosylceramidase inhibitor,,,
CC(C)Cn1c(=O)n(C)c(=O)c2[nH]cnc21,"InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)",APIXJSLKIYYUKG-UHFFFAOYSA-N,ibmx,Preclinical,phosphodiesterase inhibitor,ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A,,
NC(C(=O)O)c1cc(=O)[nH]o1,"InChI=1S/C5H6N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h1,4H,6H2,(H,7,8)(H,9,10)",IRJCBFDCFXCWGO-UHFFFAOYSA-N,ibotenic-acid,Preclinical,glutamate receptor agonist,GRIN1,,
CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,"InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)",KPRTURMJVWXURQ-UHFFFAOYSA-N,ibrolipim,Phase 2,lipoprotein lipase activator,LPL,,
C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(=N)[nH]cnc32)C1,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)",XYFPWWZEPKGCCK-UHFFFAOYSA-N,ibrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BLK|BMX|BTK,hematologic malignancy,chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)
CC(C)C(=O)c1c(C(C)C)nn2ccccc12,"InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3",ZJVFLBOZORBYFE-UHFFFAOYSA-N,ibudilast,Launched,leukotriene receptor antagonist,IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary|neurology/psychiatry,asthma|stroke
CC(C)C(=O)c1c(C(C)C)nn2ccccc12,"InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3",ZJVFLBOZORBYFE-UHFFFAOYSA-N,ibudilast,Launched,phosphodiesterase inhibitor,IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary|neurology/psychiatry,asthma|stroke
CC(C)Cc1ccc(C(C)C(=O)O)cc1,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",HEFNNWSXXWATRW-UHFFFAOYSA-N,ibuprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry|rheumatology|otolaryngology|obstetrics/gynecology|endocrinology|dental,headache|muscle pain|rheumatoid arthritis|backache|common cold|menstrual pain|fever|toothache
CC(C)Cc1ccc(C(C)C(=O)O)cc1,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",HEFNNWSXXWATRW-UHFFFAOYSA-N,ibuprofen-(s),Launched,cyclooxygenase inhibitor,ASIC1|PTGS1|PTGS2|SLC5A8,neurology/psychiatry,pain relief
CC(C)Cc1ccc(C(C)C(=O)O)cc1,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",HEFNNWSXXWATRW-UHFFFAOYSA-N,ibuprofen-lysine,Launched,cyclooxygenase inhibitor,,cardiology,patent ductus arteriosus (PDA)
CC(C)Cc1ccc(C(C)C(=O)OCc2ccccn2)cc1,"InChI=1S/C19H23NO2/c1-14(2)12-16-7-9-17(10-8-16)15(3)19(21)22-13-18-6-4-5-11-20-18/h4-11,14-15H,12-13H2,1-3H3",ACEWLPOYLGNNHV-UHFFFAOYSA-N,ibuprofen-piconol,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC(C)Cc1ccc(C(C)C(O)=NO)cc1,"InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)",BYPIURIATSUHDW-UHFFFAOYSA-N,ibuproxam,Launched,cyclooxygenase inhibitor,ALOX5,endocrinology|rheumatology|neurology/psychiatry,fever|joint inflammation|pain relief
CC(C)Cc1ccc(C(C)C(O)=NO)cc1,"InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)",BYPIURIATSUHDW-UHFFFAOYSA-N,ibuproxam,Launched,prostaglandin inhibitor,ALOX5,endocrinology|rheumatology|neurology/psychiatry,fever|joint inflammation|pain relief
CC(C)(N)C(=O)NC(COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12,"InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)",UMUPQWIGCOZEOY-UHFFFAOYSA-N,ibutamoren,Phase 2,growth hormone secretagogue receptor agonist,GHR|GHSR,,
CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,"InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3",ALOBUEHUHMBRLE-UHFFFAOYSA-N,ibutilide,Launched,potassium channel blocker,CACNA1C|KCNH2,cardiology,atrial fibrillation (AF)
COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1,"InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)",JBJYTZXCZDNOJW-UHFFFAOYSA-N,ic261,Preclinical,casein kinase inhibitor,CSNK1A1|CSNK1D|CSNK1E|CSNK1G2,,
O=C(Nc1cnc(Cl)nc1)c1ccc(F)c(F)c1,"InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)",IIBSHMFXVWTQSJ-UHFFFAOYSA-N,ica-069673,Preclinical,voltage-gated potassium channel activator,KCNQ2|KCNQ3,,
O=C(Nc1ccc(Cl)nc1)c1ccc(Cl)cc1,"InChI=1S/C12H8Cl2N2O/c13-9-3-1-8(2-4-9)12(17)16-10-5-6-11(14)15-7-10/h1-7H,(H,16,17)",FOYOGIUAMYSVIT-UHFFFAOYSA-N,ica-110381,Preclinical,voltage-gated potassium channel activator,KCNQ2,,
O=C(Nc1ccc(S(=O)(=O)N=c2[nH]ccs2)cc1)C(c1ccccc1)c1ccccc1,"InChI=1S/C23H19N3O3S2/c27-22(21(17-7-3-1-4-8-17)18-9-5-2-6-10-18)25-19-11-13-20(14-12-19)31(28,29)26-23-24-15-16-30-23/h1-16,21H,(H,24,26)(H,25,27)",URSQNPPONHUJDL-UHFFFAOYSA-N,ica-121431,Preclinical,sodium channel blocker,SCN1A|SCN3A,,
COc1ccc(-c2oc3c(CC=C(C)C)c(OC4OC(CO)C(O)C(O)C4O)cc(O)c3c(=O)c2OC2OC(C)C(O)C(O)C2O)cc1,"InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3",TZJALUIVHRYQQB-UHFFFAOYSA-N,icariin,Phase 3,phosphodiesterase inhibitor,PDE5A,,
COc1ccc(-c2oc3c(CC=C(C)C)c(O)cc(O)c3c(=O)c2O)cc1,"InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3",TUUXBSASAQJECY-UHFFFAOYSA-N,icaritin,Phase 3,PPAR receptor antagonist,PDE5A,,
N=C(N)NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)N1CC(O)CC1C(=O)NCC(=O)NC(Cc1cccs1)C(=O)NC(CO)C(=O)N1Cc2ccccc2CC1C(=O)N1C(C(=O)NC(CCCN=C(N)N)C(=O)O)CC2CCCCC21,"InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)",QURWXBZNHXJZBE-UHFFFAOYSA-N,icatibant-acetate,Launched,bradykinin receptor antagonist,BDKRB2,cardiology,angioedema
O=C1C(Cc2ccc(O)cc2)N2C(=O)CCN(C(=O)NCc3ccccc3)C2CN1Cc1cccc2ccccc12,"InChI=1S/C33H32N4O4/c38-27-15-13-23(14-16-27)19-29-32(40)35(21-26-11-6-10-25-9-4-5-12-28(25)26)22-30-36(18-17-31(39)37(29)30)33(41)34-20-24-7-2-1-3-8-24/h1-16,29-30,38H,17-22H2,(H,34,41)",HQWTUOLCGKIECB-UHFFFAOYSA-N,icg-001,Preclinical,beta-catenin inhibitor,CTNNB1,,
Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2,"InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3",VFIDUCMKNJIJTO-UHFFFAOYSA-N,"ici-118,551",Phase 2,adrenergic receptor antagonist,ADRB2|ADRB3,,
N=C(N=c1ccn(CCCCC(N)=O)[nH]1)NCC(F)(F)F,"InChI=1S/C11H17F3N6O/c12-11(13,14)7-17-10(16)18-9-4-6-20(19-9)5-2-1-3-8(15)21/h4,6H,1-3,5,7H2,(H2,15,21)(H3,16,17,18,19)",ALCSGJCIESECFD-UHFFFAOYSA-N,ici-162846,Phase 1,histamine receptor antagonist,HRH2,,
CN(C)CCSc1nc2ccccc2cc1-c1ccccc1,"InChI=1S/C19H20N2S/c1-21(2)12-13-22-19-17(15-8-4-3-5-9-15)14-16-10-6-7-11-18(16)20-19/h3-11,14H,12-13H2,1-2H3",HYOLQGVNMQNERE-UHFFFAOYSA-N,ici-169369,Phase 2,serotonin receptor antagonist,,,
O=C(O)CCCC=CCC1COC(C(F)(F)F)OC1c1ccccc1O,"InChI=1S/C18H21F3O5/c19-18(20,21)17-25-11-12(7-3-1-2-4-10-15(23)24)16(26-17)13-8-5-6-9-14(13)22/h1,3,5-6,8-9,12,16-17,22H,2,4,7,10-11H2,(H,23,24)",ZWAVGFSZMACJHA-UHFFFAOYSA-N,"ici-185,282",Phase 1,thromboxane receptor antagonist,,,
O=C(O)CCC=CCC1COC(c2ccccc2Cl)OC1c1ccccc1O,"InChI=1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)",WHUIENZXNGAHQI-UHFFFAOYSA-N,ici-192605,Phase 2,thromboxane receptor antagonist,TBXA2R,,
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccccc1,"InChI=1S/C21H24Cl2N2O/c1-24(21(26)14-16-9-10-18(22)19(23)13-16)20(15-25-11-5-6-12-25)17-7-3-2-4-8-17/h2-4,7-10,13,20H,5-6,11-12,14-15H2,1H3",AEJOEPSMZCEYJN-UHFFFAOYSA-N,ici-199441,Preclinical,opioid receptor agonist,CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R,,
O=C(O)COc1ccc(OCCNCC(O)COc2ccccc2)cc1,"InChI=1S/C19H23NO6/c21-15(13-25-16-4-2-1-3-5-16)12-20-10-11-24-17-6-8-18(9-7-17)26-14-19(22)23/h1-9,15,20-21H,10-14H2,(H,22,23)",MXWICZOXPUWAHY-UHFFFAOYSA-N,"ici-215,001",Preclinical,adrenergic receptor agonist,ADRB3,,
CCCn1c(=O)c(C)cn2[nH]c(=N)nc12,"InChI=1S/C9H13N5O/c1-3-4-13-7(15)6(2)5-14-9(13)11-8(10)12-14/h5H,3-4H2,1-2H3,(H2,10,12)",UQDVRVNMIJAGRK-UHFFFAOYSA-N,ici-63197,Preclinical,phosphodiesterase inhibitor,,,
N#Cc1ccccc1OCC(O)CNCCNC(=O)Nc1ccccc1,"InChI=1S/C19H22N4O3/c20-12-15-6-4-5-9-18(15)26-14-17(24)13-21-10-11-22-19(25)23-16-7-2-1-3-8-16/h1-9,17,21,24H,10-11,13-14H2,(H2,22,23,25)",HTLWRKRZKFAAAH-UHFFFAOYSA-N,ici-89406,Phase 1,adrenergic receptor antagonist,ADRB1|ADRB2,,
O=C1N=C(c2cccc([N+](=O)[O-])c2)CCN1c1ccccc1O,"InChI=1S/C16H13N3O4/c20-15-7-2-1-6-14(15)18-9-8-13(17-16(18)21)11-4-3-5-12(10-11)19(22)23/h1-7,10,20H,8-9H2",ZYVQBACKUWPODX-UHFFFAOYSA-N,icilin,Phase 1,TRPV agonist,TRPA1|TRPM8,,
COc1cc(Cc2c[nH]c(=N)[nH]c2=N)c2c(c1OC)OC(C1CC1)C=C2,"InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)",HWJPWWYTGBZDEG-UHFFFAOYSA-N,iclaprim,Phase 3,dihydrofolate reductase inhibitor,,,
CCCCCC(O)C=CC=CCC=CCC=CCCCC(=O)O,"InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)",JSFATNQSLKRBCI-UHFFFAOYSA-N,icomucret,Phase 3,mucin production enhancer,LTB4R2,,
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,"InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)",JAZBEHYOTPTENJ-UHFFFAOYSA-N,icosapent,Launched,platelet aggregation inhibitor,ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1,endocrinology,hypertriglyceridemia
C#Cc1cccc(N=c2[nH]cnc3cc4c(cc23)OCCOCCOCCO4)c1,"InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)",QQLKULDARVNMAL-UHFFFAOYSA-N,icotinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
C=c1c(=Cc2sc(=O)n(-c3ccccc3)c2O)cc(C)n1-c1cccnc1,"InChI=1S/C21H17N3O2S/c1-14-11-16(15(2)23(14)18-9-6-10-22-13-18)12-19-20(25)24(21(26)27-19)17-7-4-3-5-8-17/h3-13,25H,2H2,1H3",KECOCSARXDYPNN-UHFFFAOYSA-N,icrt-14,Preclinical,beta catenin inhibitor,CTNNB1|TCF4,,
C=c1c(=Cc2sc(=O)n(-c3ccccc3)c2O)cc(C)n1-c1cccnc1,"InChI=1S/C21H17N3O2S/c1-14-11-16(15(2)23(14)18-9-6-10-22-13-18)12-19-20(25)24(21(26)27-19)17-7-4-3-5-8-17/h3-13,25H,2H2,1H3",KECOCSARXDYPNN-UHFFFAOYSA-N,icrt-14,Preclinical,WNT signaling inhibitor,CTNNB1|TCF4,,
CC(O)C(C)C(N)C(=O)O,"InChI=1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)",OSCCDBFHNMXNME-UHFFFAOYSA-N,id-1101,Phase 1,insulin sensitizer,INS,,
COc1ccc(-n2c(C)c([N+](=O)[O-])c3ccc(O)cc32)cc1,"InChI=1S/C16H14N2O4/c1-10-16(18(20)21)14-8-5-12(19)9-15(14)17(10)11-3-6-13(22-2)7-4-11/h3-9,19H,1-2H3",VVZNWYXIOADGSW-UHFFFAOYSA-N,id-8,Preclinical,,,,
Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1,"InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2",YBAWYTYNMZWMMJ-UHFFFAOYSA-N,idalopirdine,Phase 3,serotonin receptor antagonist,HTR6,,
CC(=O)C1(O)C=C(OC2CC(N)C(O)C(C)O2)c2c(c(O)c3c(O)c4ccccc4c(O)c3c2O)C1,"InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,9-10,15,17,21,29-34H,7-8,27H2,1-2H3",FXOONYIMGKDSJO-UHFFFAOYSA-N,idarubicin,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML)
COc1cc(C(=O)O)ccc1NC(=O)C1NC(CC(C)(C)C)C(C#N)(c2ccc(Cl)cc2F)C1c1cccc(Cl)c1F,"InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)",TVTXCJFHQKSQQM-UHFFFAOYSA-N,idasanutlin,Phase 3,MDM inhibitor,MDM2|TP53,,
c1ccc2c(c1)OCC(C1=NCCN1)O2,"InChI=1S/C11H12N2O2/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,10H,5-7H2,(H,12,13)",HPMRFMKYPGXPEP-UHFFFAOYSA-N,idazoxan,Phase 3,adrenergic receptor antagonist,ADRA2A|PTGS2,,
COc1c(O)c(C)c(C=CCCCCCCCCO)c(O)c1OC,"InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h10,12,20-22H,4-9,11,13H2,1-3H3",DAIXANOXBPTONE-UHFFFAOYSA-N,idebenone,Launched,calcium channel modulator,,neurology/psychiatry|ophthalmology,Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)
CCC(N=c1[nH]cnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)",IFSDAJWBUCMOAH-UHFFFAOYSA-N,idelalisib,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,chronic lymphocytic leukemia (CLL)
CN1CCN(C(=O)COc2ccc(C34CC5CC(CC(C5)C3)C4)cc2)CC1,"InChI=1S/C23H32N2O2/c1-24-6-8-25(9-7-24)22(26)16-27-21-4-2-20(3-5-21)23-13-17-10-18(14-23)12-19(11-17)15-23/h2-5,17-19H,6-16H2,1H3",QGBBBLPWBSWERZ-UHFFFAOYSA-N,idf-11774,Preclinical,hypoxia inducible factor inhibitor,,,
Cc1cc(C(C)N=c2nc(N3C(=O)OCC3C(C)F)cc[nH]2)ncc1-c1ccnc(C(F)(F)F)c1,"InChI=1S/C23H22F4N6O2/c1-12-8-17(30-10-16(12)15-4-6-28-19(9-15)23(25,26)27)14(3)31-21-29-7-5-20(32-21)33-18(13(2)24)11-35-22(33)34/h4-10,13-14,18H,11H2,1-3H3,(H,29,31,32)",DCGDPJCUIKLTDU-UHFFFAOYSA-N,idh-305,Phase 2,isocitrate dehydrogenase inhibitor,,,
N=c1[nH]onc1C(=NO)Nc1ccc(F)c(Cl)c1,"InChI=1S/C9H7ClFN5O2/c10-5-3-4(1-2-6(5)11)13-9(14-17)7-8(12)16-18-15-7/h1-3,17H,(H2,12,16)(H,13,14)",HGXSLPIXNPASGZ-UHFFFAOYSA-N,ido5l,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1I,"InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)",XQFRJNBWHJMXHO-UHFFFAOYSA-N,idoxuridine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,virus herpes simplex (HSV)
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1I,"InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)",XQFRJNBWHJMXHO-UHFFFAOYSA-N,idoxuridine,Launched,DNA synthesis inhibitor,,infectious disease,virus herpes simplex (HSV)
CC1Nc2ccc(Cl)cc2S(=O)(=O)N1,"InChI=1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3",VZRNTCHTJRLTMU-UHFFFAOYSA-N,idra-21,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
O=C1C2CC3CC1CC(O)(C3)C2,"InChI=1S/C10H14O2/c11-9-7-1-6-2-8(9)5-10(12,3-6)4-7/h6-8,12H,1-5H2",TZBDEVBNMSLVKT-UHFFFAOYSA-N,idramantone,Preclinical,,,,
Oc1ccc(C2=COc3cc(O)ccc3C2)cc1,"InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8-9,16-17H,7H2",QCNUDDPWPNUALZ-UHFFFAOYSA-N,idronoxil,Phase 3,XIAP inhibitor,ENOX2|SPHK1,,
C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,"InChI=1S/C19H37N2/c1-21(2,3)8-6-4-5-7-20-15-19-12-16-9-17(13-19)11-18(10-16)14-19/h16-18,20H,4-15H2,1-3H3/q+1",IWYZMMIPAJDJBN-UHFFFAOYSA-N,iem1460,Preclinical,glutamate receptor antagonist,GRIA2,,
NCCCCCNCC12CC3CC(CC(C3)C1)C2,"InChI=1S/C16H30N2/c17-4-2-1-3-5-18-12-16-9-13-6-14(10-16)8-15(7-13)11-16/h13-15,18H,1-12,17H2",UWWMQHVWAYFCDT-UHFFFAOYSA-N,iem1754,Preclinical,glutamate receptor antagonist,GRIA1,,
CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,"InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3",UYNVMODNBIQBMV-UHFFFAOYSA-N,ifenprodil,Launched,adrenergic receptor antagonist,GRIN2B,,
CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,"InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3",UYNVMODNBIQBMV-UHFFFAOYSA-N,ifenprodil,Launched,glutamate receptor antagonist,GRIN2B,,
O=P1(NCCCl)OCCCN1CCCl,"InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)",HOMGKSMUEGBAAB-UHFFFAOYSA-N,ifosfamide,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1,oncology|urology,testicular carcinoma|hemorrhagic cystitis
CCC(CC=Cc1ccccc1)(c1ccccc1)N(C)CC1CC1,"InChI=1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3",VCZSWYIFCKGTJI-UHFFFAOYSA-N,igmesine,Phase 2,sigma receptor agonist,SIGMAR1,,
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,"InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)",ANMATWQYLIFGOK-UHFFFAOYSA-N,iguratimod,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,"InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)",ANMATWQYLIFGOK-UHFFFAOYSA-N,iguratimod,Launched,NFkB pathway inhibitor,PTGS2,rheumatology,rheumatoid arthritis
O=C(c1ccc(N=c2nc(-c3cc4ccccc4s3)cc[nH]2)cc1)N1CCC(N2CCCC2)CC1,"InChI=1S/C28H29N5OS/c34-27(33-17-12-23(13-18-33)32-15-3-4-16-32)20-7-9-22(10-8-20)30-28-29-14-11-24(31-28)26-19-21-5-1-2-6-25(21)35-26/h1-2,5-11,14,19,23H,3-4,12-13,15-18H2,(H,29,30,31)",BWZJBXAPRCVCKQ-UHFFFAOYSA-N,ikk-16,Preclinical,IKK inhibitor,IKBKB,,
NC(=O)c1sc(-c2ccsc2)cc1N,"InChI=1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H,10H2,(H2,11,12)",BMUACLADCKCNKZ-UHFFFAOYSA-N,ikk-2-inhibitor,Preclinical,IKK inhibitor,IKBKB,,
NC(=O)c1sc(-c2ccsc2)cc1N,"InChI=1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H,10H2,(H2,11,12)",BMUACLADCKCNKZ-UHFFFAOYSA-N,ikk-2-inhibitor,Preclinical,SYK inhibitor,IKBKB,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,"InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)",CHILCFMQWMQVAL-UHFFFAOYSA-N,ikk-2-inhibitor-v,Phase 1,IKK inhibitor,IKBKB,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,"InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)",CHILCFMQWMQVAL-UHFFFAOYSA-N,ikk-2-inhibitor-v,Phase 1,NFkB pathway inhibitor,IKBKB,,
COc1ccnc(C[S+]([O-])c2nc3cc(-n4cccc4)ccc3[nH]2)c1C,"InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)",HRRXCXABAPSOCP-UHFFFAOYSA-N,ilaprazole,Launched,proton pump inhibitor,,gastroenterology,gastroesophageal reflux disease (GERD)
O=C(C=Cc1ccc2c(c1)OCO2)N1CCCCC1,"InChI=1S/C15H17NO3/c17-15(16-8-2-1-3-9-16)7-5-12-4-6-13-14(10-12)19-11-18-13/h4-7,10H,1-3,8-9,11H2",BLPUOQGPBJPXRL-UHFFFAOYSA-N,ilepcimide,Phase 3,anticonvulsant,,,
CNC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CC(O)=NO)CC(C)C,"InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)",NITYDPDXAAFEIT-UHFFFAOYSA-N,ilomastat,Phase 3,matrix metalloprotease inhibitor,ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9,,
COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,"InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3",XMXHEBAFVSFQEX-UHFFFAOYSA-N,iloperidone,Launched,dopamine receptor antagonist,ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia
COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,"InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3",XMXHEBAFVSFQEX-UHFFFAOYSA-N,iloperidone,Launched,serotonin receptor antagonist,ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia
CC#CCC(C)C(O)C=CC1C(O)CC2CC(=CCCCC(=O)O)CC21,"InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)",HIFJCPQKFCZDDL-UHFFFAOYSA-N,iloprost,Launched,platelet aggregation inhibitor,PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R,pulmonary,pulmonary arterial hypertension (PAH)
CC#CCC(C)C(O)C=CC1C(O)CC2CC(=CCCCC(=O)O)CC21,"InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)",HIFJCPQKFCZDDL-UHFFFAOYSA-N,iloprost,Launched,prostanoid receptor agonist,PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R,pulmonary,pulmonary arterial hypertension (PAH)
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1nc(-c2cccnc2)cc[nH]1,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,Launched,Bcr-Abl kinase inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1nc(-c2cccnc2)cc[nH]1,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,Launched,KIT inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1nc(-c2cccnc2)cc[nH]1,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,imatinib,Launched,PDGFR tyrosine kinase receptor inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)
O=C1CCC(c2ccc(-n3ccnc3)cc2)=NN1,"InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)",VXMYWVMXSWJFCV-UHFFFAOYSA-N,imazodan,Phase 1,phosphodiesterase inhibitor,,,
CC1N=C(N(C)C)N=C(N)N1,"InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)",GFICWFZTBXUVIG-UHFFFAOYSA-N,imeglimin,Phase 2,gluconeogenesis inhibitor,,,
N=C(N)SCCc1c[nH]cn1,"InChI=1S/C6H10N4S/c7-6(8)11-2-1-5-3-9-4-10-5/h3-4H,1-2H2,(H3,7,8)(H,9,10)",PEHSVUKQDJULKE-UHFFFAOYSA-N,imetit,Preclinical,histamine receptor agonist,HRH3|HRH4,,
Nc1[nH]c(=O)n2c1C2,"InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h1,5H2,(H,6,8)",QBKIGBNGDYTHNG-UHFFFAOYSA-N,imexon,Phase 2,apoptosis stimulant,,,
Nc1[nH]c(=O)n2c1C2,"InChI=1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h1,5H2,(H,6,8)",QBKIGBNGDYTHNG-UHFFFAOYSA-N,imexon,Phase 2,ribonucleotide reductase inhibitor,,,
O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,"InChI=1S/C9H10ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-2,5H,3-4,6H2,(H,11,13)",YWTYJOPNNQFBPC-UHFFFAOYSA-N,imidacloprid,Launched,acetylcholine receptor antagonist,,,
Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,"InChI=1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24)",SQKXYSGRELMAAU-UHFFFAOYSA-N,imidafenacin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,neurology/psychiatry,spasms
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1C(=O)N(C)CC1C(=O)O,"InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)",KLZWOWYOHUKJIG-UHFFFAOYSA-N,imidapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure
CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23,"InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3",CUNDRHORZHFPLY-UHFFFAOYSA-N,imidazoacridinone,Preclinical,anticancer agent,,,
O=C(NCNC(=O)Nc1c(O)[nH]c(=O)n1CO)Nc1c(O)[nH]c(=O)n1CO,"InChI=1S/C11H16N8O8/c20-2-18-4(6(22)16-10(18)26)14-8(24)12-1-13-9(25)15-5-7(23)17-11(27)19(5)3-21/h20-23H,1-3H2,(H,16,26)(H,17,27)(H2,12,14,24)(H2,13,15,25)",XMNZTTKBFFCEPC-UHFFFAOYSA-N,imidurea,Preclinical,other antibiotic,,,
CCn1ccnc1CC1COc2ccccc2O1,"InChI=1S/C14H16N2O2/c1-2-16-8-7-15-14(16)9-11-10-17-12-5-3-4-6-13(12)18-11/h3-8,11H,2,9-10H2,1H3",UXABARREKCJULM-UHFFFAOYSA-N,imiloxan,Phase 1,adrenergic receptor antagonist,ADRA2A|ADRA2B,,
CC(O)C1C(=O)N2C(C(=O)O)=C(SCCN=CN)CC12,"InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)",ZSKVGTPCRGIANV-UHFFFAOYSA-N,imipenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections|endocarditis
CN(C)CCCN1c2ccccc2CCc2ccccc21,"InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3",BCGWQEUPMDMJNV-UHFFFAOYSA-N,imipramine,Launched,norepinephrine reputake inhibitor,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry|urology,depression|nocturnal enuresis
CN(C)CCCN1c2ccccc2CCc2ccccc21,"InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3",BCGWQEUPMDMJNV-UHFFFAOYSA-N,imipramine,Launched,serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry|urology,depression|nocturnal enuresis
CC(C)Cn1cnc2c(=N)[nH]c3ccccc3c21,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",DOUYETYNHWVLEO-UHFFFAOYSA-N,imiquimod,Launched,interferon inducer,TLR7|TLR8,dermatology|infectious disease|oncology,actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)
CC(C)Cn1cnc2c(=N)[nH]c3ccccc3c21,"InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)",DOUYETYNHWVLEO-UHFFFAOYSA-N,imiquimod,Launched,toll-like receptor agonist,TLR7|TLR8,dermatology|infectious disease|oncology,actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)
O=C1NC(=O)C2(N1)c1cc(F)ccc1-c1ccc(F)cc12,"InChI=1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)",QCCHBHSAIQIQGO-UHFFFAOYSA-N,imirestat,Preclinical,aldose reductase inhibitor,,,
c1cc2nc(c1)CNC1CCCCC1NCCNC1CCCCC1NC2,"InChI=1S/C21H35N5/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20/h5-7,18-25H,1-4,8-15H2",MTQZSJFDXWEENV-UHFFFAOYSA-N,imisopasem-manganese,Preclinical,superoxide dismutase mimetic,,,
c1nc(CC2CCNCC2)c[nH]1,"InChI=1S/C9H15N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h6-8,10H,1-5H2,(H,11,12)",MCNGUYXRBCIGOV-UHFFFAOYSA-N,immepip,Preclinical,histamine receptor agonist,HRH3|HRH4,,
c1cc(Cc2c[nH]cn2)ccn1,"InChI=1S/C9H9N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h1-4,6-7H,5H2,(H,11,12)",DFVSGZHJSIEEQQ-UHFFFAOYSA-N,immethridine,Phase 1,histamine receptor agonist,HRH3,,
NCCCCCc1c[nH]cn1,"InChI=1S/C8H15N3/c9-5-3-1-2-4-8-6-10-7-11-8/h6-7H,1-5,9H2,(H,10,11)",MZCJWLAXZRFUPI-UHFFFAOYSA-N,impentamine,Preclinical,histamine receptor antagonist,HRH3,,
NC(Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)O,"InChI=1S/C13H17N3O5/c14-10(5-8-1-3-9(17)4-2-8)13(21)16-6-11(18)15-7-12(19)20/h1-4,10,17H,5-7,14H2,(H,15,18)(H,16,21)(H,19,20)",HIINQLBHPIQYHN-UHFFFAOYSA-N,imreg-1,Phase 3,,,,
COC1C(OP(=O)(S)OCC2OC(n3cnc4c(=N)[nH]cnc43)CC2O)C(CO)OC1n1ccc(=O)[nH]c1=O,"InChI=1S/C20H26N7O10PS/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31)",LYMICVBGNUEHGE-UHFFFAOYSA-N,inarigivir,Phase 2,antiviral,,,
COC1C(OP(=O)(OCC2OC(n3cnc4c(=N)[nH]cnc43)CC2O)SCOC(=O)OC(C)C)C(CO)OC1n1ccc(=O)[nH]c1=O,"InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)",CJCYTUJOSMYXLE-UHFFFAOYSA-N,inarigivir-soproxil,Phase 2,antiviral,,,
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,inc-280,Phase 3,c-Met inhibitor,MET,,
Oc1ccc(O)c2c1c1c3ccccc3c2c2ccccc21,"InChI=1S/C20H12O2/c21-15-9-10-16(22)20-18-12-6-2-1-5-11(12)17(19(15)20)13-7-3-4-8-14(13)18/h1-10,21-22H",WVAVLTVUKMJAGJ-UHFFFAOYSA-N,inca-6,Preclinical,calcineurin inhibitor,NFATC1,,
COc1ccc(C2(O)CCC(N3CCC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,"InChI=1S/C26H31F3N4O4/c1-37-23-6-5-19(14-30-23)25(36)10-7-21(8-11-25)33-12-9-20(16-33)32-22(34)15-31-24(35)17-3-2-4-18(13-17)26(27,28)29/h2-6,13-14,20-21,36H,7-12,15-16H2,1H3,(H,31,35)(H,32,34)",NXZNYBUBXWWKCP-UHFFFAOYSA-N,incb-003284,Phase 2,CC chemokine receptor antagonist,,,
CN1C(=O)C(C)(C)Oc2c(-c3cn(C)c(=O)c4[nH]ccc34)cc(S(C)(=O)=O)cc21,"InChI=1S/C20H21N3O5S/c1-20(2)19(25)23(4)15-9-11(29(5,26)27)8-13(17(15)28-20)14-10-22(3)18(24)16-12(14)6-7-21-16/h6-10,21H,1-5H3",VZSAMEOETVNDQH-UHFFFAOYSA-N,incb-057643,Phase 1/Phase 2,bromodomain inhibitor,,,
COc1ccc(C2(O)CCC(N3CCC(NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,"InChI=1S/C26H31F3N4O4/c1-37-23-6-5-19(14-30-23)25(36)10-7-21(8-11-25)33-12-9-20(16-33)32-22(34)15-31-24(35)17-3-2-4-18(13-17)26(27,28)29/h2-6,13-14,20-21,36H,7-12,15-16H2,1H3,(H,31,35)(H,32,34)",NXZNYBUBXWWKCP-UHFFFAOYSA-N,incb-3284,Phase 2,CC chemokine receptor antagonist,CCR2,,
NC(=O)C1C(=O)CC2CC3Cc4cccc(O)c4C(=O)C3C(=O)C2(O)C1=O,"InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,13-14,21,27H,4-6H2,(H2,20,26)",MDYVZYDNBUAVCN-UHFFFAOYSA-N,incyclinide,Phase 2,matrix metalloprotease inhibitor,,,
CCc1cc2c(cc1CC)CC(NCC(O)c1ccc(O)c3[nH]c(=O)ccc13)C2,"InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)",QZZUEBNBZAPZLX-UHFFFAOYSA-N,indacaterol,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD)
c1ccc2c(CCC3CCNCC3)c[nH]c2c1,"InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2",SADQVAVFGNTEOD-UHFFFAOYSA-N,indalpine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),SLC6A4,,
CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,"InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)",NDDAHWYSQHTHNT-UHFFFAOYSA-N,indapamide,Launched,thiazide diuretic,CA2|HTR3A|KCNQ1,cardiology,hypertension|congestive heart failure
CNC1CC(c2ccc(Cl)c(Cl)c2)c2ccccc21,"InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3",SVFXPTLYMIXFRX-UHFFFAOYSA-N,indatraline,Preclinical,norepinephrine transporter inhibitor,MAOA|MAOB,,
COc1ccc(S(=O)(=O)n2cc(CCC(=O)O)c3cc(OC)ccc32)cc1,"InChI=1S/C19H19NO6S/c1-25-14-4-7-16(8-5-14)27(23,24)20-12-13(3-10-19(21)22)17-11-15(26-2)6-9-18(17)20/h4-9,11-12H,3,10H2,1-2H3,(H,21,22)",YMPALHOKRBVHOJ-UHFFFAOYSA-N,indeglitazar,Phase 2,PPAR receptor agonist,NCOA1|PPARA|PPARD|PPARG,,
C1=Cc2cccc(OCC3CNCCO3)c2C1,"InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2",MADRVGBADLFHMO-UHFFFAOYSA-N,indeloxazine,Withdrawn,norepinephrine reuptake inhibitor,,,
C1=Cc2cccc(OCC3CNCCO3)c2C1,"InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2",MADRVGBADLFHMO-UHFFFAOYSA-N,indeloxazine,Withdrawn,serotonin reuptake inhibitor,,,
O=C(N=c1cc[nH]cc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,"InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)",SOLIIYNRSAWTSQ-UHFFFAOYSA-N,indibulin,Phase 1/Phase 2,tubulin polymerization inhibitor,,,
CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O,"InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)",CBVCZFGXHXORBI-UHFFFAOYSA-N,indinavir,Launched,HIV protease inhibitor,CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,"InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3",CBIAWPMZSFFRGN-UHFFFAOYSA-N,indiplon,Phase 3,benzodiazepine receptor agonist,GABRA1,,
O=C1C(c2c(O)[nH]c3ccccc23)=Nc2ccccc21,"InChI=1S/C16H10N2O2/c19-15-10-6-2-4-8-12(10)17-14(15)13-9-5-1-3-7-11(9)18-16(13)20/h1-8,18,20H",JNLNPCNGMHKCKO-UHFFFAOYSA-N,indirubin,Phase 2/Phase 3,CDK inhibitor,CDK1|CDK5|GSK3A,,
O=C1C(c2c(O)[nH]c3ccccc23)=Nc2ccccc21,"InChI=1S/C16H10N2O2/c19-15-10-6-2-4-8-12(10)17-14(15)13-9-5-1-3-7-11(9)18-16(13)20/h1-8,18,20H",JNLNPCNGMHKCKO-UHFFFAOYSA-N,indirubin,Phase 2/Phase 3,glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3A,,
O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12,"InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17-18,20H",FQCPPVRJPILDIK-UHFFFAOYSA-N,indirubin-3-monoxime,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5|CDK5R1|GSK3B,,
O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12,"InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17-18,20H",FQCPPVRJPILDIK-UHFFFAOYSA-N,indirubin-3-monoxime,Preclinical,glycogen synthase kinase inhibitor,CDK1|CDK2|CDK5|CDK5R1|GSK3B,,
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,"InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)",SETFNECMODOHTO-UHFFFAOYSA-N,indisulam,Phase 2,CDK inhibitor,CA1|CA12|CA14|CA2|CA6|CA7|CA9,,
CC(C)O,"InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3",KFZMGEQAYNKOFK-UHFFFAOYSA-N,indium-tri(2-propanolate),Preclinical,,,,
CC(C)O,"InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3",KFZMGEQAYNKOFK-UHFFFAOYSA-N,indium(iii)-isopropoxide,Preclinical,,,,
CCC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,"InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)",AYDXAULLCROVIT-UHFFFAOYSA-N,indobufen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,hematology,thrombosis
CCC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,"InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)",AYDXAULLCROVIT-UHFFFAOYSA-N,indobufen,Launched,platelet aggregation inhibitor,PTGS1|PTGS2,hematology,thrombosis
CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(=O)(=O)O)c2ccc3ccccc3c21,"InChI=1S/C43H48N2O6S2/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51)/p+1",BDBMLMBYCXNVMC-UHFFFAOYSA-O,indocyanine-green,Launched,contrast agent,SLCO1B1,cardiology,vascular imaging agent
OCc1c[nH]c2ccccc12,"InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2",IVYPNXXAYMYVSP-UHFFFAOYSA-N,indole-3-carbinol,Phase 2/Phase 3,aryl hydrocarbon receptor agonist,AHR,,
OCc1c[nH]c2ccccc12,"InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2",IVYPNXXAYMYVSP-UHFFFAOYSA-N,indole-3-carbinol,Phase 2/Phase 3,"indoleamine 2,3-dioxygenase inhibitor",AHR,,
O=C(O)C(=O)Cc1c[nH]c2ccccc12,"InChI=1S/C11H9NO3/c13-10(11(14)15)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,12H,5H2,(H,14,15)",RSTKLPZEZYGQPY-UHFFFAOYSA-N,indole-3-pyrubate,Phase 2,melatonin receptor agonist,,,
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,"InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)",CGIGDMFJXJATDK-UHFFFAOYSA-N,indomethacin,Launched,cyclooxygenase inhibitor,GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1,rheumatology|orthopedics,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis
CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,"InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)",RJMIEHBSYVWVIN-UHFFFAOYSA-N,indoprofen,Withdrawn,cyclooxygenase inhibitor,CXCR1|CXCR2|PTGS1|PTGS2,,
CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,"InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)",RJMIEHBSYVWVIN-UHFFFAOYSA-N,indoprofen,Withdrawn,prostanoid receptor antagonist,CXCR1|CXCR2|PTGS1|PTGS2,,
O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,"InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)",JXZZEXZZKAWDSP-UHFFFAOYSA-N,indoramin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
Cn1cc(CC(N)C(=O)O)c2ccccc21,"InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)",ZADWXFSZEAPBJS-UHFFFAOYSA-N,indoximod,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
CC1=CC23C(=O)C(=CC(CO)C(O)C2(O)C1O)C1C(CC3C)C1(C)C,"InChI=1S/C20H28O5/c1-9-7-19-10(2)5-13-14(18(13,3)4)12(17(19)24)6-11(8-21)16(23)20(19,25)15(9)22/h6-7,10-11,13-16,21-23,25H,5,8H2,1-4H3",VYIKEBWUZLHWQK-UHFFFAOYSA-N,ingenol,Launched,PKC activator,PRKCD|PRKCE,dermatology,keratosis
CC=C(C)C(=O)OC1C(C)=CC23C(=O)C(=CC(CO)C(O)C12O)C1C(CC3C)C1(C)C,"InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14-15,17-19,21,26-27,30H,8,11H2,1-6H3",HULPONUAINYLQQ-UHFFFAOYSA-N,ingenol-mebutate,Launched,PKC activator,PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,dermatology,actinic keratosis (AK)
Cc1ccc(-c2csc(=NC(=O)c3ccccc3)[nH]2)c(C)c1,"InChI=1S/C18H16N2OS/c1-12-8-9-15(13(2)10-12)16-11-22-18(19-16)20-17(21)14-6-4-3-5-7-14/h3-11H,1-2H3,(H,19,20,21)",JPMOKRWIYQGMJL-UHFFFAOYSA-N,inh1,Preclinical,Hec1 inhibitor,NDC80,,
CSCC1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)O1,"InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3",SRQKTCXJCCHINN-UHFFFAOYSA-N,inimur,Launched,other antifungal,,,
NC(=O)c1ccc(I)c([N+](=O)[O-])c1,"InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)",MDOJTZQKHMAPBK-UHFFFAOYSA-N,iniparib,Phase 3,PARP inhibitor,PARP1,,
O=c1[nH]cnc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)",UGQMRVRMYYASKQ-UHFFFAOYSA-N,inosine,Launched,neurotrophic agent,PARP1|PNP,,
OC1C(O)C(O)C(O)C(O)C1O,InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H,CDAISMWEOUEBRE-UHFFFAOYSA-N,inositol,Launched,insulin sensitizer,CDIPT,obstetrics/gynecology,polycystic ovary syndrom (PCOS)
O=C(OC1C(OC(=O)c2cccnc2)C(OC(=O)c2cccnc2)C(OC(=O)c2cccnc2)C(OC(=O)c2cccnc2)C1OC(=O)c1cccnc1)c1cccnc1,"InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H",MFZCIDXOLLEMOO-UHFFFAOYSA-N,inositol-hexanicotinate,Launched,,,dermatology|cardiology|rheumatology|neurology/psychiatry,statis dermatitis|claudication|Raynaud's disease|hypertension|insomnia|atherosclerosis|restless leg syndrome|schizophrenia|psoriasis|acne vulgaris (AV)
O=c1ccn(C2OC(CO[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)O)C(O)C2O)c(=O)[nH]1,"InChI=1S/C9H12N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H,16,17,18)",OZBORWBHODBWKZ-UHFFFAOYSA-N,ins316,Phase 2,purinergic receptor antagonist,,,
CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,"InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)",ZXERDUOLZKYMJM-UHFFFAOYSA-N,int-747,Phase 3,FXR agonist,,,
CCC1C(O)C2C3CCC(C(C)CCOS(=O)(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,"InChI=1S/C25H44O6S/c1-5-17-21-14-16(26)8-11-25(21,4)20-9-12-24(3)18(6-7-19(24)22(20)23(17)27)15(2)10-13-31-32(28,29)30/h15-23,26-27H,5-14H2,1-4H3,(H,28,29,30)",XGIYOABXZNJOHV-UHFFFAOYSA-N,int-767,Phase 1,FXR agonist,GPBAR1,,
Cc1cc(C)n(-c2cccc(C(CC(=O)O)CN3CCC(CCc4ccc5c(n4)NCCC5)C3)c2)n1,"InChI=1S/C29H37N5O2/c1-20-15-21(2)34(32-20)27-7-3-5-24(16-27)25(17-28(35)36)19-33-14-12-22(18-33)8-10-26-11-9-23-6-4-13-30-29(23)31-26/h3,5,7,9,11,15-16,22,25H,4,6,8,10,12-14,17-19H2,1-2H3,(H,30,31)(H,35,36)",ZMXBIIQMSGOIRZ-UHFFFAOYSA-N,integrin-antagonist-1,Phase 1,integrin antagonist,ITGAV|ITGB6,,
COc1[nH]c(=N)nc2c1ncn2C1OC(COP(=O)(NC(C)C(=O)OCC(C)(C)C)Oc2cccc3ccccc23)C(O)C1(C)O,"InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)",YFXGICNMLCGLHJ-UHFFFAOYSA-N,inx-08189,Phase 2,antiviral,,,
N=C(N)NCc1cccc(I)c1,"InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)",PDWUPXJEEYOOTR-UHFFFAOYSA-N,iobenguane,Launched,antineoplastic agent,,oncology|cardiology|endocrinology,neuroblastoma|congestive heart failure|pheochromocytoma
CC(=O)N(CC(C)C(=O)O)c1c(I)cc(I)c(N)c1I,"InChI=1S/C12H13I3N2O3/c1-5(12(19)20)4-17(6(2)18)11-8(14)3-7(13)10(16)9(11)15/h3,5H,4,16H2,1-2H3,(H,19,20)",GSVQIUGOUKJHRC-UHFFFAOYSA-N,iocetamic-acid,Launched,radiopaque medium,,radiology,contrast agent
O=C(CCCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I,"InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)",FFINMCNLQNTKLU-UHFFFAOYSA-N,iodipamide,Launched,radiopaque medium,ALB,radiology,contrast agent
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,"InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)",NBQNWMBBSKPBAY-UHFFFAOYSA-N,iodixanol,Launched,radiopaque medium,,radiology,contrast agent
Cc1c(I)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C11H11IN2O/c1-8-10(12)11(15)14(13(8)2)9-6-4-3-5-7-9/h3-7H,1-2H3",ZZOBLCHCPLOXCE-UHFFFAOYSA-N,iodoantipyrine,Preclinical,,,,
O=C1CCC(c2ccccc2)(C2CCN(Cc3ccc(I)cc3)CC2)C(=O)N1,"InChI=1S/C23H25IN2O2/c24-20-8-6-17(7-9-20)16-26-14-11-19(12-15-26)23(18-4-2-1-3-5-18)13-10-21(27)25-22(23)28/h1-9,19H,10-16H2,(H,25,27,28)",WJLRTFJPHDSXAF-UHFFFAOYSA-N,iododexetimide,Phase 2,acetylcholine receptor antagonist,,,
N=C(NCCc1ccc(I)cc1)SCCCc1c[nH]cn1,"InChI=1S/C15H19IN4S/c16-13-5-3-12(4-6-13)7-8-19-15(17)21-9-1-2-14-10-18-11-20-14/h3-6,10-11H,1-2,7-9H2,(H2,17,19)(H,18,20)",UBHYDQAARZKHEZ-UHFFFAOYSA-N,iodophenpropit,Preclinical,histamine receptor antagonist,HRH3|HRH4,,
Oc1c(I)cc(I)c2cccnc12,"InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",UXZFQZANDVDGMM-UHFFFAOYSA-N,iodoquinol,Launched,antiseptic,,infectious disease,amebiasis
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,"InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)",NTHXOOBQLCIOLC-UHFFFAOYSA-N,iohexol,Launched,radiopaque medium,,radiology,contrast agent
CC(=O)C(O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,"InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h7-8,15,23-27,29H,2-5H2,1H3,(H,21,30)(H,22,31)",KTYOXAWCLRIWLU-UHFFFAOYSA-N,iopamidol,Launched,radiopaque medium,,radiology,contrast agent
CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O,"InChI=1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)",OIRFJRBSRORBCM-UHFFFAOYSA-N,iopanic-acid,Withdrawn,thyroid hormone inhibitor,,,
CN(C)C=Nc1c(I)cc(I)c(CCC(=O)O)c1I,"InChI=1S/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)",YQNFBOJPTAXAKV-UHFFFAOYSA-N,iopodic-acid,Launched,,,radiology,contrast agent
COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,"InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)",DGAIEPBNLOQYER-UHFFFAOYSA-N,iopromide,Launched,radiopaque medium,,radiology,contrast agent
CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I,"InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)",UXIGWFXRQKWHHA-UHFFFAOYSA-N,iothalamic-acid-d3,Preclinical,radiopaque medium,,,
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I,"InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)",AMDBBAQNWSUWGN-UHFFFAOYSA-N,ioversol,Launched,radiopaque medium,,radiology,contrast agent
O=C(NCc1ccc(Oc2ccccc2)cc1)c1nc(-c2cc(Br)c(O)c(Br)c2)no1,"InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)",DSFNLJXHXBIKDS-UHFFFAOYSA-N,iowh032,Phase 2,CFTR channel antagonist,CFTR,,
O=C(O)c1ccc(O)c2ncccc12,"InChI=1S/C10H7NO3/c12-8-4-3-7(10(13)14)6-2-1-5-11-9(6)8/h1-5,12H,(H,13,14)",JGRPKOGHYBAVMW-UHFFFAOYSA-N,iox1,Preclinical,histone demethylase inhibitor,EGLN1|KDM3A|KDM4C|KDM6B,,
O=C(O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,"InChI=1S/C19H16N2O5/c22-15(23)10-20-18(25)16-17(24)13-8-4-5-9-14(13)21(19(16)26)11-12-6-2-1-3-7-12/h1-9,24H,10-11H2,(H,20,25)(H,22,23)",CAOSCCRYLYQBES-UHFFFAOYSA-N,iox2,Preclinical,hypoxia inducible factor inhibitor,EGLN1|KDM2A|KDM5C,,
CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I,"InChI=1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)",TYYBFXNZMFNZJT-UHFFFAOYSA-N,ioxaglic-acid,Launched,radiopaque medium,,radiology,contrast agent
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I,"InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)",UUMLTINZBQPNGF-UHFFFAOYSA-N,ioxilan,Launched,radiopaque medium,,radiology,angiography
Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,"InChI=1S/C20H14O2S2/c21-17-11-9-13-5-1-3-7-15(13)19(17)23-24-20-16-8-4-2-6-14(16)10-12-18(20)22/h1-12,21-22H",RFAXLXKIAKIUDT-UHFFFAOYSA-N,ipa-3,Preclinical,p21 activated kinase inhibitor,PAK1,,
N=C(Nc1ccc(I)cc1)NC1C2CC3CC(C2)CC1C3,"InChI=1S/C17H22IN3/c18-14-1-3-15(4-2-14)20-17(19)21-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16H,5-9H2,(H3,19,20,21)",UUKPIWYXWLJPJF-UHFFFAOYSA-N,ipag,Preclinical,,,,
CC(NC(=O)c1c(=N)[nH]n2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,"InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)",XUMALORDVCFWKV-UHFFFAOYSA-N,ipi549,Phase 2,PI3K inhibitor,,,
N=c1c2c([nH]c3c1CCC3)CCCC2,"InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)",YLUSMKAJIQOXPV-UHFFFAOYSA-N,ipidacrine,Phase 3,acetylcholinesterase inhibitor,ACHE,,
OCC1OC(c2ccc(F)c(Cc3cc4ccccc4s3)c2)C(O)C(O)C1O,"InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2",AHFWIQIYAXSLBA-UHFFFAOYSA-N,ipragliflozin-l-proline,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus
CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,"InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3",SFBODOKJTYAUCM-UHFFFAOYSA-N,ipriflavone,Launched,bone resorption inhibitor,,orthopedics,osteoporosis
CC(C)NNC(=O)c1ccncc1,"InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)",NYMGNSNKLVNMIA-UHFFFAOYSA-N,iproniazid,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,,
O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1,"InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2",TZJUVVIWVWFLCD-UHFFFAOYSA-N,ipsapirone,Phase 3,serotonin receptor agonist,HTR1A,,
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",YOSHYTLCDANDAN-UHFFFAOYSA-N,irbesartan,Launched,angiotensin receptor antagonist,AGTR1|JUN|SLC10A1,cardiology|nephrology,hypertension|diabetic nephropathy
CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)(COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)COC(=O)CCc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc(C(C)(C)C)c1O,"InChI=1S/C73H108O12/c1-65(2,3)49-33-45(34-50(61(49)78)66(4,5)6)25-29-57(74)82-41-73(42-83-58(75)30-26-46-35-51(67(7,8)9)62(79)52(36-46)68(10,11)12,43-84-59(76)31-27-47-37-53(69(13,14)15)63(80)54(38-47)70(16,17)18)44-85-60(77)32-28-48-39-55(71(19,20)21)64(81)56(40-48)72(22,23)24/h33-40,78-81H,25-32,41-44H2,1-24H3",BGYHLZZASRKEJE-UHFFFAOYSA-N,irganox-1010,Preclinical,antioxidant,,,
N=C(N)NCCCC1NC(=O)C(N)CSSCC(C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C2CCCN2C(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)CNC1=O,"InChI=1S/C35H57N13O14S2/c36-8-2-1-5-18-30(57)42-14-25(50)48-10-4-7-23(48)33(60)46-21(12-27(53)54)32(59)47-22(34(61)62)16-64-63-15-17(37)28(55)44-19(6-3-9-40-35(38)39)29(56)41-13-24(49)43-20(11-26(51)52)31(58)45-18/h17-23H,1-16,36-37H2,(H,41,56)(H,42,57)(H,43,49)(H,44,55)(H,45,58)(H,46,60)(H,47,59)(H,51,52)(H,53,54)(H,61,62)(H4,38,39,40)",YHTTWXCDIRTOQX-UHFFFAOYSA-N,irgd-peptide,Preclinical,integrin signaling activator,,,
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,"InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3",UWKQSNNFCGGAFS-UHFFFAOYSA-N,irinotecan,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,colorectal cancer
Cc1cc(C)cc(C(=O)N(C)C(Cc2ccc(-c3ccccc3)cc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)O)c1,"InChI=1S/C36H35N3O4/c1-23-17-24(2)19-28(18-23)35(41)39(3)33(20-25-13-15-27(16-14-25)26-9-5-4-6-10-26)34(40)38-32(36(42)43)21-29-22-37-31-12-8-7-11-30(29)31/h4-19,22,32-33,37H,20-21H2,1-3H3,(H,38,40)(H,42,43)",UZDORQWMYRRLQV-UHFFFAOYSA-N,irl-2500,Preclinical,endothelin receptor antagonist,EDNRB,,
NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3,"InChI=1S/C14H15NO5S/c15-21(17,18)20-9-6-7-11-10-4-2-1-3-5-12(10)14(16)19-13(11)8-9/h6-8H,1-5H2,(H2,15,17,18)",DSLPMJSGSBLWRE-UHFFFAOYSA-N,irosustat,Phase 2,steroid sulfatase inhibitor,CA2|STS,,
N=c1nc(-c2cc(Cl)ccc2Cl)[nH]c(=N)[nH]1,"InChI=1S/C9H7Cl2N5/c10-4-1-2-6(11)5(3-4)7-14-8(12)16-9(13)15-7/h1-3H,(H4,12,13,14,15,16)",ATCGGEJZONJOCL-UHFFFAOYSA-N,irsogladine,Launched,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD)
CC(C)NCC(O)COc1ccccc1-n1cccc1,"InChI=1S/C16H22N2O2/c1-13(2)17-11-14(19)12-20-16-8-4-3-7-15(16)18-9-5-6-10-18/h3-10,13-14,17,19H,11-12H2,1-2H3",XVTVPGKWYHWYAD-UHFFFAOYSA-N,isamoltane,Phase 1,adrenergic receptor antagonist,HTR1A|HTR1B,,
CC(c1nc(-c2ccc(C#N)cc2)cs1)C(O)(Cn1cncn1)c1cc(F)ccc1F,"InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3",DDFOUSQFMYRUQK-UHFFFAOYSA-N,isavuconazole,Phase 3,cytochrome P450 inhibitor,CYP3A4,,
CC(C)N=c1nccc[nH]1,"InChI=1S/C7H11N3/c1-6(2)10-7-8-4-3-5-9-7/h3-6H,1-2H3,(H,8,9,10)",FTCYIGBVOHNHCD-UHFFFAOYSA-N,isaxonine,Withdrawn,nerve growth factor agonist,,,
CC(C)Cn1cnc2c1c(=O)n(C)c(=O)n2C,"InChI=1S/C11H16N4O2/c1-7(2)5-15-6-12-9-8(15)10(16)14(4)11(17)13(9)3/h6-7H,5H2,1-4H3",WHUWQSQEVISUMC-UHFFFAOYSA-N,isbufylline,Phase 2,phosphodiesterase inhibitor,,,
CNC1C(O)C(OC2C(NC(=O)C(O)CN)CC(N)C(OC3OC(CN)C(O)C(O)C3O)C2O)OCC1(C)O,"InChI=1S/C22H43N5O12/c1-22(35)6-36-20(15(33)18(22)26-2)39-17-8(27-19(34)9(28)4-23)3-7(25)16(14(17)32)38-21-13(31)12(30)11(29)10(5-24)37-21/h7-18,20-21,26,28-33,35H,3-6,23-25H2,1-2H3,(H,27,34)",UDIIBEDMEYAVNG-UHFFFAOYSA-N,isepamicin,Launched,protein synthesis inhibitor,,infectious disease,pneumonia|peritonitis
COC(=O)CC1CC(c2ccc(O)cc2)=NO1,"InChI=1S/C12H13NO4/c1-16-12(15)7-10-6-11(13-17-10)8-2-4-9(14)5-3-8/h2-5,10,14H,6-7H2,1H3",AIXMJTYHQHQJLU-UHFFFAOYSA-N,iso-1,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,
CC(C)COC(=O)c1ccc(N)cc1,"InChI=1S/C11H15NO2/c1-8(2)7-14-11(13)9-3-5-10(12)6-4-9/h3-6,8H,7,12H2,1-2H3",PUYOAVGNCWPANW-UHFFFAOYSA-N,isobutamben,Preclinical,local anesthetic,,,
CC(C)C(N)=O,"InChI=1S/C4H9NO/c1-3(2)4(5)6/h3H,1-2H3,(H2,5,6)",WFKAJVHLWXSISD-UHFFFAOYSA-N,isobutyramide,Phase 2,gene expression stimulant,HBE1|HBG1,,
Cc1cc(C(=O)NNCc2ccccc2)no1,"InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)",XKFPYPQQHFEXRZ-UHFFFAOYSA-N,isocarboxazid,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression
Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,"InChI=1S/C18H14Cl4N2O/c19-12-4-5-13(17(22)8-12)18(9-24-7-6-23-11-24)25-10-14-15(20)2-1-3-16(14)21/h1-8,11,18H,9-10H2",MPIPASJGOJYODL-UHFFFAOYSA-N,isoconazole,Launched,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections
O=C(O)CCCN1C(=O)c2cccc3cccc(c23)C1=O,"InChI=1S/C16H13NO4/c18-13(19)8-3-9-17-15(20)11-6-1-4-10-5-2-7-12(14(10)11)16(17)21/h1-2,4-7H,3,8-9H2,(H,18,19)",ZHXRDXTYPCPBTI-UHFFFAOYSA-N,isodibut,Phase 2,aldehyde reductase inhibitor,,,
CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,"InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3",HUYWAWARQUIQLE-UHFFFAOYSA-N,isoetharine,Launched,adrenergic receptor agonist,,pulmonary,bronchospasm|asthma
CC(C)c1ccc2c(c1)C(N1CCN(CCO)CC1)Cc1ccc(F)cc1S2,"InChI=1S/C23H29FN2OS/c1-16(2)17-4-6-22-20(13-17)21(26-9-7-25(8-10-26)11-12-27)14-18-3-5-19(24)15-23(18)28-22/h3-6,13,15-16,21,27H,7-12,14H2,1-2H3",XDBMBHVYXPBOPL-UHFFFAOYSA-N,isofloxythepin,Phase 2,dopamine receptor antagonist,,,
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC21C,"InChI=1S/C23H29FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h4,6,8,16-18,27,29H,5,7,9-12H2,1-3H3",KAJQOJBJABVIDU-UHFFFAOYSA-N,isoflupredone-acetate,Preclinical,,NR3C1,,
FC(F)OC(Cl)C(F)(F)F,"InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H",PIWKPBJCKXDKJR-UHFFFAOYSA-N,isoflurane,Launched,inhaled anaesthetic,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic
CC(C)OP(=O)(F)OC(C)C,"InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3",MUCZHBLJLSDCSD-UHFFFAOYSA-N,isoflurophate,Launched,cholinesterase inhibitor,ACHE|BCHE,ophthalmology,glaucoma
O=C(O)C1CC=NCC1,"InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h3,5H,1-2,4H2,(H,8,9)",RCOHJNRVNKFDFV-UHFFFAOYSA-N,isoguvacine,Preclinical,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,
CCC(C)C(N)C(=O)O,"InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)",AGPKZVBTJJNPAG-UHFFFAOYSA-N,isoleucine,Launched,,,,
O=C(C=Cc1ccc(O)cc1)c1ccc(O)cc1O,"InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H",DXDRHHKMWQZJHT-UHFFFAOYSA-N,isoliquiritigenin,Preclinical,guanylate cyclase activator,GABBR1,,
CNC(C)CCC=C(C)C,"InChI=1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3",XVQUOJBERHHONY-UHFFFAOYSA-N,isometheptene-mucate,Launched,,,neurology/psychiatry,headache
NNC(=O)c1ccncc1,"InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)",QRXWMOHMRWLFEY-UHFFFAOYSA-N,isoniazid,Launched,FABI inhibitor,CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4,infectious disease,tuberculosis
COc1ccc(C=CC(=O)OCCC(C)C)cc1,"InChI=1S/C15H20O3/c1-12(2)10-11-18-15(16)9-6-13-4-7-14(17-3)8-5-13/h4-9,12H,10-11H2,1-3H3",UBNYRXMKIIGMKK-UHFFFAOYSA-N,isopentyl-4-methoxycinnamate,Launched,,,dermatology,sunscreen lotion
CC(C)NCC(O)c1ccc(O)c(O)c1,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3",JWZZKOKVBUJMES-UHFFFAOYSA-N,isoprenaline,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,cardiology|pulmonary,bradycardia|heart block|asthma
CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,"InChI=1S/C23H32N2O/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26)/p+1",JTPUMZTWMWIVPA-UHFFFAOYSA-O,isopropamide-iodide,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)|gastrointestinal acidosis
CCCCCCCCCCCCCC(=O)OC(C)C,"InChI=1S/C17H34O2/c1-4-5-6-7-8-9-10-11-12-13-14-15-17(18)19-16(2)3/h16H,4-15H2,1-3H3",AXISYYRBXTVTFY-UHFFFAOYSA-N,isopropyl-myristate,Launched,,,dermatology,cosmetic
CCCCCCCCCCCCCCCC(=O)OC(C)C,"InChI=1S/C19H38O2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(20)21-18(2)3/h18H,4-17H2,1-3H3",XUGNVMKQXJXZCD-UHFFFAOYSA-N,isopropyl-palmitate,Launched,cosmetic moisturizer,,dermatology,cosmetic
O=c1c(OC2OC(CO)C(O)C(O)C2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2",OVSQVDMCBVZWGM-UHFFFAOYSA-N,isoquercitrin,Phase 2/Phase 3,antioxidant,,,
COc1cc2c(cc1OC)C(C)NCC2,"InChI=1S/C12H17NO2/c1-8-10-7-12(15-3)11(14-2)6-9(10)4-5-13-8/h6-8,13H,4-5H2,1-3H3",HMYJLVDKPJHJCF-UHFFFAOYSA-N,"isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,",Preclinical,,,,
OC1COC2C(O)COC12,"InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2",KLDXJTOLSGUMSJ-UHFFFAOYSA-N,isosorbide,Launched,nitric oxide stimulant,,cardiology,angina pectoris|coronary artery disease (CAD)
O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,"InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2",MOYKHGMNXAOIAT-UHFFFAOYSA-N,isosorbide-dinitrate,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1,cardiology,angina pectoris|coronary artery disease (CAD)
O=[N+]([O-])OC1COC2C(O)COC12,"InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2",YWXYYJSYQOXTPL-UHFFFAOYSA-N,isosorbide-mononitrate,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,angina pectoris|coronary artery disease (CAD)
CC12CCC3C(CCC4C(C)(C(=O)O)CCCC34C)(CC1=O)C2,"InChI=1S/C20H30O3/c1-17-9-5-14-18(2)7-4-8-19(3,16(22)23)13(18)6-10-20(14,12-17)11-15(17)21/h13-14H,4-12H2,1-3H3,(H,22,23)",KFVUFODCZDRVSS-UHFFFAOYSA-N,isosteviol,Phase 2,,,,
Cc1ccnc2c1CCCC2C(N)=S,"InChI=1S/C11H14N2S/c1-7-5-6-13-10-8(7)3-2-4-9(10)11(12)14/h5-6,9H,2-4H2,1H3,(H2,12,14)",PWPWEYFVLITGNU-UHFFFAOYSA-N,isotiquimide,Phase 1,,,,
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)",SHGAZHPCJJPHSC-UHFFFAOYSA-N,isotretinoin,Launched,retinoid receptor agonist,RARA|RARB|RARG,dermatology,acne vulgaris (AV)
CC(C)CC(N)=O,"InChI=1S/C5H11NO/c1-4(2)3-5(6)7/h4H,3H2,1-2H3,(H2,6,7)",SANOUVWGPVYVAV-UHFFFAOYSA-N,isovaleramide,Phase 2,alcohol dehydrogenase inhibitor,,,
O=C(O)Cc1ccc2c(c1)C(=O)c1ccccc1CO2,"InChI=1S/C16H12O4/c17-15(18)8-10-5-6-14-13(7-10)16(19)12-4-2-1-3-11(12)9-20-14/h1-7H,8-9H2,(H,17,18)",QFGMXJOBTNZHEL-UHFFFAOYSA-N,isoxepac,Phase 2,anti-inflammatory agent,,,
Cc1cc(=NC(=O)C2C(=O)c3ccccc3S(=O)(=O)N2C)[nH]o1,"InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,12H,1-2H3,(H,15,16,19)",SPTMROWPYQRZSX-UHFFFAOYSA-N,isoxicam,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1,"InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3",BMUKKTUHUDJSNZ-UHFFFAOYSA-N,isoxsuprine,Launched,adrenergic receptor agonist,ADRB2,rheumatology|cardiology,Raynaud's disease|arteriosclerosis|Buerger's disease
Cc1ccc(C(=O)N(CCCN)C(c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,"InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3",QJZRFPJCWMNVAV-UHFFFAOYSA-N,ispinesib,Phase 2,kinesin inhibitor,KIF11,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OC(C)C)C1c1cccc2nonc12,"InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,15-16H,1-5H3",CNXVIBRFWKALQW-UHFFFAOYSA-N,isradipine,Launched,calcium channel blocker,CACNA1D|CACNA1F|CACNA2D1,cardiology,hypertension
O=C(COc1ccc(Cl)cc1)NC1CCC(NC(=O)COc2ccc(Cl)cc2)CC1,"InChI=1S/C22H24Cl2N2O4/c23-15-1-9-19(10-2-15)29-13-21(27)25-17-5-7-18(8-6-17)26-22(28)14-30-20-11-3-16(24)4-12-20/h1-4,9-12,17-18H,5-8,13-14H2,(H,25,27)(H,26,28)",HJGMCDHQPXTGAV-UHFFFAOYSA-N,isrib,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2A|EIF2AK3,,
O=C(COc1ccc(Cl)cc1)NC1CCC(NC(=O)COc2ccc(Cl)cc2)CC1,"InChI=1S/C22H24Cl2N2O4/c23-15-1-9-19(10-2-15)29-13-21(27)25-17-5-7-18(8-6-17)26-22(28)14-30-20-11-3-16(24)4-12-20/h1-4,9-12,17-18H,5-8,13-14H2,(H,25,27)(H,26,28)",HJGMCDHQPXTGAV-UHFFFAOYSA-N,isrib,Preclinical,PERK inhibitor,EIF2A|EIF2AK3,,
CC12CCC3C(CC(=O)C4CC(=NOCCN)CCC43C)C1CCC2=O,"InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3",MPYLDWFDPHRTEG-UHFFFAOYSA-N,istaroxime,Phase 2,ATPase inhibitor,ATP1A1,,
CCn1c(=O)c2c(nc(C=Cc3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,"InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3",IQVRBWUUXZMOPW-UHFFFAOYSA-N,istradefylline,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,neurology/psychiatry,Parkinson's Disease|dyskinesia
O=C(NC1CC1)c1cc(-c2cccs2)on1,"InChI=1S/C11H10N2O2S/c14-11(12-7-3-4-7)8-6-9(15-13-8)10-2-1-5-16-10/h1-2,5-7H,3-4H2,(H,12,14)",SYENTKHGMVKGAQ-UHFFFAOYSA-N,isx-9,Preclinical,neural stem cell inducer,NEUROD1,,
CC1(C)CN2C(CSC(=NC3CCCCC3)NC3CCCCC3)=CSC2=N1,"InChI=1S/C21H34N4S2/c1-21(2)15-25-18(14-27-20(25)24-21)13-26-19(22-16-9-5-3-6-10-16)23-17-11-7-4-8-12-17/h14,16-17H,3-13,15H2,1-2H3,(H,22,23)",OOSUDWRRWZVFEB-UHFFFAOYSA-N,it1t,Preclinical,CC chemokine receptor antagonist,CXCR4,,
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,itacitinib,Phase 3,JAK inhibitor,JAK1,,
CCOC(=O)C1=C(C)N=C2CC(C)(C)CC(=O)C2C1c1ccc(-c2ccccc2)cc1,"InChI=1S/C27H29NO3/c1-5-31-26(30)23-17(2)28-21-15-27(3,4)16-22(29)25(21)24(23)20-13-11-19(12-14-20)18-9-7-6-8-10-18/h6-14,24-25H,5,15-16H2,1-4H3",NPCZTDPKZMXZAZ-UHFFFAOYSA-N,itd-1,Preclinical,TGF beta receptor inhibitor,TGFBR2,,
COC(=O)c1csc(C(=O)c2c[nH]c3ccccc23)n1,"InChI=1S/C14H10N2O3S/c1-19-14(18)11-7-20-13(16-11)12(17)9-6-15-10-5-3-2-4-8(9)10/h2-7,15H,1H3",KDDXOGDIPZSCTM-UHFFFAOYSA-N,ite,Preclinical,aryl hydrocarbon receptor agonist,AHR,,
CN1C(=O)c2c([nH]n(Cc3ccc(-c4cccc(F)n4)cc3)c2=Nc2ccccc2)N2C1=NC1CCCC12,"InChI=1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,34H,5,10-11,17H2,1H3",KHNHKUZKELHFGQ-UHFFFAOYSA-N,iti214,Phase 1/Phase 2,phosphodiesterase inhibitor,PDE1A,,
COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC,"InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)",QQQIECGTIMUVDS-UHFFFAOYSA-N,itopride,Launched,dopamine receptor antagonist,CHRM3|DRD2,gastroenterology|neurology/psychiatry,dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3",VHVPQPYKVGDNFY-UHFFFAOYSA-N,itraconazole,Launched,cytochrome P450 inhibitor,,infectious disease,onychomycosis|histoplasmosis|blastomycosis|aspergillosis
Cc1cc(C=c2sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1,"InChI=1S/C22H17N3OS/c1-14-12-16(15(2)24(14)17-8-4-3-5-9-17)13-20-21(26)25-19-11-7-6-10-18(19)23-22(25)27-20/h3-13H,1-2H3",SJMYMKPBODEZSH-UHFFFAOYSA-N,itx3,Preclinical,GEF inhibitor,TRIO,,
COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O,"InChI=1S/C30H37N3O7S/c1-30(2,3)20-18-24(28(38-4)25(19-20)32-41(5,36)37)31-29(35)27(34)23-10-11-26(22-9-7-6-8-21(22)23)40-17-14-33-12-15-39-16-13-33/h6-11,18-19,32H,12-17H2,1-5H3,(H,31,35)",UUROSJLZNDSXRF-UHFFFAOYSA-N,itx5061,Phase 1,SR-BI inhibitor,,,
Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1,"InChI=1S/C18H21FN2O/c1-13-11-17(18(22)12-20-9-3-4-10-20)14(2)21(13)16-7-5-15(19)6-8-16/h5-8,11H,3-4,9-10,12H2,1-2H3",JUWDSDKJBMFLHE-UHFFFAOYSA-N,iu1,Preclinical,ubiquitin C-terminal hydrolase inhibitor,USP14,,
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2,"InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3",ACRHBAYQBXXRTO-UHFFFAOYSA-N,ivabradine,Launched,HCN channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2,"InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3",ACRHBAYQBXXRTO-UHFFFAOYSA-N,ivabradine,Launched,potassium channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)CC1Cc3cc(OC)c(OC)cc31)CC2,"InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3",ACRHBAYQBXXRTO-UHFFFAOYSA-N,ivabradine,Launched,sodium channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris
CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,"InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)",PURKAOJPTOLRMP-UHFFFAOYSA-N,ivacaftor,Launched,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis
CCC(C)C1OC2(CCC1C)CC1CC(CC=C(C)C(OC3CC(OC)C(OC4CC(OC)C(O)C(C)O4)C(C)O3)C(C)C=CC=C3COC4C(O)C(C)=CC(C(=O)O1)C34O)O2,"InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3",AZSNMRSAGSSBNP-UHFFFAOYSA-N,ivermectin,Launched,benzodiazepine receptor agonist,CHRNA7|P2RX7,infectious disease,gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies
N#Cc1ccnc(N2C(=O)CCC2C(=O)N(c2cncc(F)c2)C(C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,"InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)",WIJZXSAJMHAVGX-UHFFFAOYSA-N,ivosidenib,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML)
O=C(CSc1nc2c(c(=O)n1-c1ccccc1)SCC2)N=c1ccc(-c2ccccc2)c[nH]1,"InChI=1S/C25H20N4O2S2/c30-22(28-21-12-11-18(15-26-21)17-7-3-1-4-8-17)16-33-25-27-20-13-14-32-23(20)24(31)29(25)19-9-5-2-6-10-19/h1-12,15H,13-14,16H2,(H,26,28,30)",QESQGTFWEQMCMH-UHFFFAOYSA-N,iwp-l6,Preclinical,porcupine inhibitor,PORCN,,
CC(=Cc1csc(C)n1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,"InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)",FABUFPQFXZVHFB-UHFFFAOYSA-N,ixabepilone,Launched,microtubule stabilizing agent,TUBB,oncology,breast cancer
CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)",MXAYKZJJDUDWDS-UHFFFAOYSA-N,ixazomib,Launched,proteasome inhibitor,,hematologic malignancy,multiple myeloma
CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(=O)O)(C(=O)O)O1,"InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)",YTXSYWAKVMZICI-UHFFFAOYSA-N,ixazomib-citrate,Launched,proteasome inhibitor,,hematologic malignancy,multiple myeloma
COc1cccc(C=NN(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1,"InChI=1S/C18H17F3N2O2/c1-12-7-8-16(13(2)9-12)23(17(24)18(19,20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H,1-3H3",HYMZAYGFKNNHDN-UHFFFAOYSA-N,j147,Phase 1,BDNF inducer,,,
C=CC(=O)c1ccc2ccccc2c1,"InChI=1S/C13H10O/c1-2-13(14)12-8-7-10-5-3-4-6-11(10)9-12/h2-9H,1H2",FOTCGZPFSUWZBN-UHFFFAOYSA-N,jak3-inhibitor-v,Preclinical,JAK inhibitor,JAK3,,
CC(C)C(N=C(NS(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1)C(N)=O,"InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)",GTCSIQFTNPTSLO-UHFFFAOYSA-N,jd-5037,Preclinical,cannabinoid receptor antagonist,,,
CC(C)C(CN1CCC(C)(c2cccc(O)c2)C(C)C1)NC(=O)C1Cc2ccc(O)cc2CN1,"InChI=1S/C28H39N3O3/c1-18(2)26(30-27(34)25-13-20-8-9-24(33)12-21(20)15-29-25)17-31-11-10-28(4,19(3)16-31)22-6-5-7-23(32)14-22/h5-9,12,14,18-19,25-26,29,32-33H,10-11,13,15-17H2,1-4H3,(H,30,34)",ZLVXBBHTMQJRSX-UHFFFAOYSA-N,jdtic,Phase 1,opioid receptor antagonist,OPRK1,,
CCCCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2,"InChI=1S/C24H29F2NO/c1-2-3-14-27-21-12-13-22(27)16-23(15-21)28-24(17-4-8-19(25)9-5-17)18-6-10-20(26)11-7-18/h4-11,21-24H,2-3,12-16H2,1H3",HZEVDVGPBUFIAW-UHFFFAOYSA-N,jhw-007,Preclinical,dopamine reuptake inhibitor,SLC6A3,,
COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1cc[nH]c(=N)c1,"InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)",ZXBFYBLSJMEBEP-UHFFFAOYSA-N,ji-101,Phase 1/Phase 2,kinase inhibitor,,,
Clc1ccc(=NN=C(c2ccccc2)c2ccccn2)[nH]c1,"InChI=1S/C17H13ClN4/c18-14-9-10-16(20-12-14)21-22-17(13-6-2-1-3-7-13)15-8-4-5-11-19-15/h1-12H,(H,20,21)",YHHFKWKMXWRVTJ-UHFFFAOYSA-N,jib04,Preclinical,histone lysine demethylase inhibitor,KDM4E,,
CCOc1ccc(N=c2[nH]c(-c3c(C)nc4ccccn34)cs2)cc1,"InChI=1S/C19H18N4OS/c1-3-24-15-9-7-14(8-10-15)21-19-22-16(12-25-19)18-13(2)20-17-6-4-5-11-23(17)18/h4-12H,3H2,1-2H3,(H,21,22)",ROYXIPOUVGDTAO-UHFFFAOYSA-N,jk-184,Preclinical,hedgehog pathway inhibitor,,,
COc1oc(=O)c2cc(N)ccc2c1Cl,"InChI=1S/C10H8ClNO3/c1-14-10-8(11)6-3-2-5(12)4-7(6)9(13)15-10/h2-4H,12H2,1H3",AMDGKLWVCUXONP-UHFFFAOYSA-N,jlk-6,Preclinical,gamma secretase inhibitor,PSEN1,,
CN1CCN(C(=O)c2nc3cc(Cl)ccc3[nH]2)CC1,"InChI=1S/C13H15ClN4O/c1-17-4-6-18(7-5-17)13(19)12-15-10-3-2-9(14)8-11(10)16-12/h2-3,8H,4-7H2,1H3,(H,15,16)",MOIWSUQWIOVGRH-UHFFFAOYSA-N,jnj-10191584,Preclinical,histamine receptor antagonist,HRH4,,
CC1(C)OCC(NC(=O)Nc2ccc(Br)cc2Br)C(c2ccccc2)O1,"InChI=1S/C19H20Br2N2O3/c1-19(2)25-11-16(17(26-19)12-6-4-3-5-7-12)23-18(24)22-15-9-8-13(20)10-14(15)21/h3-10,16-17H,11H2,1-2H3,(H2,22,23,24)",RBKIJGLHFFQHBE-UHFFFAOYSA-N,jnj-10397049,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
COC1CCC(C(=O)c2ccc3nc4c(cc3c2)CCCO4)CC1,"InChI=1S/C20H23NO3/c1-23-17-7-4-13(5-8-17)19(22)14-6-9-18-16(11-14)12-15-3-2-10-24-20(15)21-18/h6,9,11-13,17H,2-5,7-8,10H2,1H3",QOTAQTRFJWLFCR-UHFFFAOYSA-N,jnj-16259685,Preclinical,glutamate receptor antagonist,GRM1,,
O=C(Nc1ccccc1)N1CCN(c2nc(-c3ccccc3)ns2)CC1,"InChI=1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)",BHBOSTKQCZEAJM-UHFFFAOYSA-N,jnj-1661010,Preclinical,FAAH inhibitor,FAAH,,
O=C(N=c1ccc(C(F)(F)F)c[nH]1)N1CCN(c2ncccc2C(F)(F)F)CC1,"InChI=1S/C17H15F6N5O/c18-16(19,20)11-3-4-13(25-10-11)26-15(29)28-8-6-27(7-9-28)14-12(17(21,22)23)2-1-5-24-14/h1-5,10H,6-9H2,(H,25,26,29)",JFRYYGVYCWYIDQ-UHFFFAOYSA-N,jnj-17203212,Preclinical,TRPV antagonist,TRPV1,,
Cn1cc(CNCC2CCN(c3ncc(C(O)=NO)cn3)CC2)c2ccccc21,"InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)",PAWIYAYFNXQGAP-UHFFFAOYSA-N,jnj-26481585,Phase 2,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2,,
NS(=O)(=O)NCc1csc2ccccc12,"InChI=1S/C9H10N2O2S2/c10-15(12,13)11-5-7-6-14-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H2,10,12,13)",AWSKBQNOSRREEY-UHFFFAOYSA-N,jnj-26990990,Phase 2,anticonvulsant,,,
CCC(c1ccc(F)c(F)c1)n1c(C(=O)OC)c(-c2ccno2)[nH]c1=S,"InChI=1S/C17H15F2N3O3S/c1-3-12(9-4-5-10(18)11(19)8-9)22-15(16(23)24-2)14(21-17(22)26)13-6-7-20-25-13/h4-8,12H,3H2,1-2H3,(H,21,26)",SYARXICKXVXWNA-UHFFFAOYSA-N,jnj-27141491,Preclinical,CC chemokine receptor antagonist,CCR2,,
Fc1ccc(CN2CCC(N=c3ccc(C(F)(F)F)n[nH]3)CC2)cc1F,"InChI=1S/C17H17F5N4/c18-13-2-1-11(9-14(13)19)10-26-7-5-12(6-8-26)23-16-4-3-15(24-25-16)17(20,21)22/h1-4,9,12H,5-8,10H2,(H,23,25)",UVUYWJWYRLJHEN-UHFFFAOYSA-N,jnj-37822681,Phase 2,dopamine receptor antagonist,DRD2,,
Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,"InChI=1S/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3",JRWCBEOAFGHNNU-UHFFFAOYSA-N,jnj-38877605,Phase 1,tyrosine kinase inhibitor,MET,,
FC(F)(c1ccc2ncccc2c1)c1nnc2ccc(-c3ccncc3)nn12,"InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H",KOAWAWHSMVKCON-UHFFFAOYSA-N,jnj-38877618,Phase 1,c-Met inhibitor,,,
CC(C)c1cc(N2CCC(N)C2)[nH]c(=N)n1,"InChI=1S/C11H19N5/c1-7(2)9-5-10(15-11(13)14-9)16-4-3-8(12)6-16/h5,7-8H,3-4,6,12H2,1-2H3,(H2,13,14,15)",COOGVHJHSCBOQT-UHFFFAOYSA-N,jnj-39758979,Phase 2,histamine receptor antagonist,,,
CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O,"InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3",HYOGJHCDLQSAHX-UHFFFAOYSA-N,jnj-40411813,Phase 2,glutamate receptor positive allosteric modulator,GRM2,,
O=C(O)c1cnn(-c2nc3cc(Cl)c(OC(F)(F)F)cc3[nH]2)c1,"InChI=1S/C12H6ClF3N4O3/c13-6-1-7-8(2-9(6)23-12(14,15)16)19-11(18-7)20-4-5(3-17-20)10(21)22/h1-4H,(H,18,19)(H,21,22)",FXHHASJVTYRJHH-UHFFFAOYSA-N,jnj-42041935,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,,
O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,"InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)",YWGYNGCRVZLMCS-UHFFFAOYSA-N,jnj-42165279,Phase 2,FAAH inhibitor,FAAH,,
O=C(NCC1(N2CCN(c3ccccc3)CC2)CCOCC1)c1cccnc1Sc1ccccc1,"InChI=1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)",XREFXUCWSYMIOG-UHFFFAOYSA-N,jnj-47965567,Preclinical,purinergic receptor antagonist,P2RX7,,
CC1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,"InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3",CWFVVQFVGMFTBD-UHFFFAOYSA-N,jnj-54175446,Phase 1,purinergic receptor antagonist,,,
CC(NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1,"InChI=1S/C17H17ClN2O2/c1-12(13-6-3-2-4-7-13)20-16(21)11-19-17(22)14-8-5-9-15(18)10-14/h2-10,12H,11H2,1H3,(H,19,22)(H,20,21)",MWDVCHRYCKXEBY-UHFFFAOYSA-N,jnj-63533054,Preclinical,G protein-coupled receptor agonist,GPR139,,
N=c1[nH]c2cc(CCC3CC(n4ccc5c(=N)[nH]cnc54)C(O)C3O)ccc2cc1Br,"InChI=1S/C22H23BrN6O2/c23-15-8-12-3-1-11(7-16(12)28-21(15)25)2-4-13-9-17(19(31)18(13)30)29-6-5-14-20(24)26-10-27-22(14)29/h1,3,5-8,10,13,17-19,30-31H,2,4,9H2,(H2,25,28)(H2,24,26,27)",DBSMLQTUDJVICQ-UHFFFAOYSA-N,jnj-64619178,Phase 1,protein arginine N-methyltransferase inhibitor,,,
CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,"InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3",GTQTUABHRCWVLL-UHFFFAOYSA-N,jnj-678,Phase 1,RSV fusion inhibitor,,,
N=c1[nH]c(=Nc2ccc(S(N)(=O)=O)cc2)[nH]n1C(=O)c1c(F)cccc1F,"InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)",KDKUVYLMPJIGKA-UHFFFAOYSA-N,jnj-7706621,Preclinical,CDK inhibitor,AURKA|AURKB|CDK1|CDK2,,
CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1,"InChI=1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3",HUQJRYMLJBBEDO-UHFFFAOYSA-N,jnj-7777120,Preclinical,histamine receptor antagonist,HRH4,,
COC1C(OC(C)=O)CC(=O)OC(C)CC=CC=CC(O)C(C)CC(CC=O)C1OC1OC(C)C(OC2CC(C)(O)C(OC(=O)CC(C)C)C(C)O2)C(N(C)C)C1O,"InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3",XJSFLOJWULLJQS-UHFFFAOYSA-N,josamycin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bronchitis
Nc1cc(COc2c(Cl)cc(CC(N)C(=O)O)cc2Cl)c2oc(-c3ccccc3)nc2c1,"InChI=1S/C23H19Cl2N3O4/c24-16-6-12(8-18(27)23(29)30)7-17(25)21(16)31-11-14-9-15(26)10-19-20(14)32-22(28-19)13-4-2-1-3-5-13/h1-7,9-10,18H,8,11,26-27H2,(H,29,30)",XNRZJPQTMQZBCE-UHFFFAOYSA-N,jph203,Preclinical,solute carrier family member inhibitor,,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=NC(CC(=O)OC(C)(C)C)c1nnc(C)n1-2,"InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3",DNVXATUJJDPFDM-UHFFFAOYSA-N,jq1-(+),Preclinical,bromodomain inhibitor,BRD4|BRDT,,
CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3[nH]c(C)cc(=N)c3c2)cc1,"InChI=1S/C26H25N3O2/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30)",VTGBZWHPJFMTKS-UHFFFAOYSA-N,jtc-801,Phase 2,opioid receptor antagonist,OPRL1,,
Cc1nn(C)c2[nH]c(=NNC(=O)N=c3cc(Cl)[nH]c(Cl)c3)cc(C(C)C)c12,"InChI=1S/C17H19Cl2N7O/c1-8(2)11-7-14(22-16-15(11)9(3)25-26(16)4)23-24-17(27)20-10-5-12(18)21-13(19)6-10/h5-8H,1-4H3,(H,22,23)(H2,20,21,24,27)",RNSLRQNDXRSASX-UHFFFAOYSA-N,jte-013,Preclinical,lysophospholipid receptor antagonist,P2RY10|S1PR2,,
CCOC(=O)C(Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,"InChI=1S/C25H31Cl2N3O5/c1-3-34-25(33)20(15-17-7-5-4-6-8-17)28-24(32)18-16-19(26)23(21(27)22(18)31)35-14-13-30-11-9-29(2)10-12-30/h4-8,16,20,31H,3,9-15H2,1-2H3,(H,28,32)",IPSSXIMJJXSJQB-UHFFFAOYSA-N,jte-607,Phase 2,cytokine production inhibitor,IL10|IL1B|IL6|TNF,,
CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4c(c3)OCO4)c(=O)[nH]c12,"InChI=1S/C24H26N2O6/c1-3-4-5-10-30-22-19(29-2)9-7-16-12-17(24(28)26-21(16)22)23(27)25-13-15-6-8-18-20(11-15)32-14-31-18/h6-9,11-12H,3-5,10,13-14H2,1-2H3,(H,25,27)(H,26,28)",GRAJFFFXJYFVOC-UHFFFAOYSA-N,jte-907,Phase 1,cannabinoid receptor inverse agonist,CNR2,,
COc1ccc(C2(CNC(=O)c3ccc(NC(=O)c4ccco4)cc3)CCOCC2)cc1,"InChI=1S/C25H26N2O5/c1-30-21-10-6-19(7-11-21)25(12-15-31-16-13-25)17-26-23(28)18-4-8-20(9-5-18)27-24(29)22-3-2-14-32-22/h2-11,14H,12-13,15-17H2,1H3,(H,26,28)(H,27,29)",ZJZWZIXSGNFWQQ-UHFFFAOYSA-N,jw-55,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,"InChI=1S/C21H20F6N2O3/c22-20(23,24)18(21(25,26)27)32-19(30)29-11-9-28(10-12-29)14-15-5-4-8-17(13-15)31-16-6-2-1-3-7-16/h1-8,13,18H,9-12,14H2",AVSCNEOUWSVZEY-UHFFFAOYSA-N,jw-642,Preclinical,monoacylglycerol lipase inhibitor,MGLL,,
O=C1Nc2ccccc2C12OCC1(CO2)COC2(OC1)C(=O)Nc1ccccc12,"InChI=1S/C21H18N2O6/c24-17-20(13-5-1-3-7-15(13)22-17)26-9-19(10-27-20)11-28-21(29-12-19)14-6-2-4-8-16(14)23-18(21)25/h1-8H,9-12H2,(H,22,24)(H,23,25)",BTXRSHKJNDFHGA-UHFFFAOYSA-N,jw-67,Preclinical,WNT pathway inhibitor,APC|AXIN1|GSK3B,,
COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,"InChI=1S/C24H20N6O2S/c1-16-3-5-17(6-4-16)22-26-21(32-29-22)15-33-24-28-27-23(18-11-13-25-14-12-18)30(24)19-7-9-20(31-2)10-8-19/h3-14H,15H2,1-2H3",KRIKILRRJCIWNB-UHFFFAOYSA-N,jw-74,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,"InChI=1S/C24H20N6O2S/c1-16-3-5-17(6-4-16)22-26-21(32-29-22)15-33-24-28-27-23(18-11-13-25-14-12-18)30(24)19-7-9-20(31-2)10-8-19/h3-14H,15H2,1-2H3",KRIKILRRJCIWNB-UHFFFAOYSA-N,jw-74,Preclinical,WNT signaling inhibitor,TNKS|TNKS2,,
COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,"InChI=1S/C21H25NO2S/c1-24-20-15-18(25-2)8-9-19(20)21(23)22-12-10-17(11-13-22)14-16-6-4-3-5-7-16/h3-9,15,17H,10-14H2,1-2H3",OMGLGPKQUFSRNN-UHFFFAOYSA-N,jx-401,Preclinical,p38 MAPK inhibitor,MAPK14,,
O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,"InChI=1S/C27H24N2O9/c30-26(38-21-5-3-20(4-6-21)29(32)33)28-11-9-17(10-12-28)27(31,18-1-7-22-24(13-18)36-15-34-22)19-2-8-23-25(14-19)37-16-35-23/h1-8,13-14,17,31H,9-12,15-16H2",SEGYOKHGGFKMCX-UHFFFAOYSA-N,jzl-184,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,
O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,"InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2",QNYRAEKLMNDRFY-UHFFFAOYSA-N,jzl-195,Preclinical,FAAH inhibitor,FAAH|MGLL,,
O=C(Oc1ccc([N+](=O)[O-])cc1)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,"InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2",QNYRAEKLMNDRFY-UHFFFAOYSA-N,jzl-195,Preclinical,monoacylglycerol lipase inhibitor,FAAH|MGLL,,
O=C(O)c1ccc(NC2OC(CO)C(O)C2O)cc1,"InChI=1S/C12H15NO6/c14-5-8-9(15)10(16)11(19-8)13-7-3-1-6(2-4-7)12(17)18/h1-4,8-11,13-16H,5H2,(H,17,18)",QNUBRHYSSHJWDH-UHFFFAOYSA-N,k-247,Phase 1,,,,
CC(=O)N=C1NN(C(C)=O)C(C)(c2ccccc2)S1,"InChI=1S/C13H15N3O2S/c1-9(17)14-12-15-16(10(2)18)13(3,19-12)11-7-5-4-6-8-11/h4-8H,1-3H3,(H,14,15,17)",JEFVYQYZCAVNTP-UHFFFAOYSA-N,k-858,Preclinical,kinesin-like spindle protein inhibitor,KIF11,,
O=C(O)c1ccc(NC2OC(CO)C(O)C(O)C2O)cc1,"InChI=1S/C13H17NO7/c15-5-8-9(16)10(17)11(18)12(21-8)14-7-3-1-6(2-4-7)13(19)20/h1-4,8-12,14-18H,5H2,(H,19,20)",VXMVXDITZWJXJN-UHFFFAOYSA-N,k-map,Phase 2,,,,
C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,"InChI=1S/C15H17ClIN3O3/c1-2-14(22)19-3-5-20(6-4-19)15(23)9-18-12-8-11(17)10(16)7-13(12)21/h2,7-8,18,21H,1,3-6,9H2",JFIFBWVNHLXJFY-UHFFFAOYSA-N,k-ras(g12c)-inhibitor-12,Preclinical,K-Ras inhibitor,KRAS,,
O=C(CCCS)NC1CCN(C(=O)COc2ccc(Cl)cc2Cl)CC1,"InChI=1S/C17H22Cl2N2O3S/c18-12-3-4-15(14(19)10-12)24-11-17(23)21-7-5-13(6-8-21)20-16(22)2-1-9-25/h3-4,10,13,25H,1-2,5-9,11H2,(H,20,22)",ZPXCEHMKUTXHRZ-UHFFFAOYSA-N,k-ras(g12c)-inhibitor-6,Preclinical,K-Ras inhibitor,,,
CC12CCC3C(CCC4(O)CC(O)CCC34C=O)C1(O)CCC2c1coc(O)c1,"InChI=1S/C23H32O6/c1-20-6-3-17-18(4-8-22(27)11-15(25)2-7-21(17,22)13-24)23(20,28)9-5-16(20)14-10-19(26)29-12-14/h10,12-13,15-18,25-28H,2-9,11H2,1H3",KQPLQXODEAHPLH-UHFFFAOYSA-N,k-strophanthidin,Phase 2,ATPase inhibitor,ATP1A1,,
COc1cc(-c2cc(-c3cccc(O)c3)c[nH]c2=N)cc(OC)c1OC,"InChI=1S/C20H20N2O4/c1-24-17-9-13(10-18(25-2)19(17)26-3)16-8-14(11-22-20(16)21)12-5-4-6-15(23)7-12/h4-11,23H,1-3H3,(H2,21,22)",CJLMANFTWLNAKC-UHFFFAOYSA-N,k02288,Preclinical,bone morphogenic protein inhibitor,BMP1,,
CCCCOc1ccc(CC=Cc2sc(=O)n(CCN)c2O)cc1,"InChI=1S/C18H24N2O3S/c1-2-3-13-23-15-9-7-14(8-10-15)5-4-6-16-17(21)20(12-11-19)18(22)24-16/h4,6-10,21H,2-3,5,11-13,19H2,1H3",NMAQTMAHOPQGAN-UHFFFAOYSA-N,k145,Preclinical,sphingosine kinase inhibitor,SPHK2,,
O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H",IYRMWMYZSQPJKC-UHFFFAOYSA-N,kaempferol,Preclinical,bone resorption inhibitor,AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1,,
O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H",IYRMWMYZSQPJKC-UHFFFAOYSA-N,kaempferol,Preclinical,estrogen-related receptor inverse agonist,AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1,,
CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN,"InChI=1S/C22H23F2N5O/c1-22(2)21-27-19(14-3-5-15(23)6-4-14)20(26-17-9-7-16(24)8-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3",BUPRVECGWBHCQV-UHFFFAOYSA-N,kaf-156,Preclinical,antimalarial agent,,,
CC(C)=C1CNC(C(=O)O)C1CC(=O)O,"InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6,9,11H,3-4H2,1-2H3,(H,12,13)(H,14,15)",IJRRZSHVLKYPPU-UHFFFAOYSA-N,kainic-acid,Preclinical,kainate receptor agonist,GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5,,
O=c1c(-c2ccc(O)cc2)coc2c(C3OC(CO)C(O)C(O)C3O)c(O)ccc12,"InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2",HKEAFJYKMMKDOR-UHFFFAOYSA-N,kakonein,Phase 2,GABA receptor antagonist,,,
O=c1c(-c2ccc(O)cc2)coc2c(C3OC(CO)C(O)C(O)C3O)c(O)ccc12,"InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2",HKEAFJYKMMKDOR-UHFFFAOYSA-N,kakonein,Phase 2,serotonin receptor antagonist,,,
NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(O)C(O)C1O,"InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2",SBUJHOSQTJFQJX-UHFFFAOYSA-N,kanamycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CC[Si](C)(C)C,"InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3",POADTFBBIXOWFJ-UHFFFAOYSA-N,karenitecin,Phase 3,topoisomerase inhibitor,TOP1,,
O=C(O)c1ccccc1C(=O)Nc1ccc(-c2ccccc2)cc1,"InChI=1S/C20H15NO3/c22-19(17-8-4-5-9-18(17)20(23)24)21-16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13H,(H,21,22)(H,23,24)",SLUINPGXGFUMLL-UHFFFAOYSA-N,kartogenin,Preclinical,chondrocyte differentiation stimulator,FLNA,,
CC1OC(OC2C(O)C(O)C(O)C(O)C2O)C(N)CC1N=C(N)C(=O)O,"InChI=1S/C14H25N3O9/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24)",PVTHJAPFENJVNC-UHFFFAOYSA-N,kasugamycin,Preclinical,bacterial 30S ribosomal subunit inhibitor,,,
N=C(N)SCCc1ccc(OCc2ccc([N+](=O)[O-])cc2)cc1,"InChI=1S/C16H17N3O3S/c17-16(18)23-10-9-12-3-7-15(8-4-12)22-11-13-1-5-14(6-2-13)19(20)21/h1-8H,9-11H2,(H3,17,18)",UMJUNUMSJDTYTM-UHFFFAOYSA-N,kb-r7943,Preclinical,sodium/calcium exchange inhibitor,SLC8A1|TRPC3|TRPC5|TRPC6,,
N=c1[nH]cnc2c1c(-c1ccc(Cl)cc1)nn2-c1cccc(-c2cnnn2Cc2cccc(-c3ccccc3)c2)c1,"InChI=1S/C32H23ClN8/c33-26-14-12-23(13-15-26)30-29-31(34)35-20-36-32(29)41(38-30)27-11-5-10-25(17-27)28-18-37-39-40(28)19-21-6-4-9-24(16-21)22-7-2-1-3-8-22/h1-18,20H,19H2,(H2,34,35,36)",UHIZYQVRKSWIFO-UHFFFAOYSA-N,kb-src-4,Preclinical,SRC inhibitor,SRC,,
OC1OC2COC(c3ccccc3)OC2C(O)C1O,"InChI=1S/C13H16O6/c14-9-10(15)12(16)18-8-6-17-13(19-11(8)9)7-4-2-1-3-5-7/h1-5,8-16H,6H2",FOLRUCXBTYDAQK-UHFFFAOYSA-N,kbg,Phase 2,neprilysin inhibitor,MME,,
CCCCCCCCCCCCCCOc1ccc(C(=O)O)o1,"InChI=1S/C19H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22-18-15-14-17(23-18)19(20)21/h14-15H,2-13,16H2,1H3,(H,20,21)",CZRCFAOMWRAFIC-UHFFFAOYSA-N,kd-023,Phase 2,ACAT inhibitor,ACACA|ACACB,,
CC(C)NC(=O)COc1cccc(-c2nc(=Nc3ccc4[nH]ncc4c3)c3ccccc3[nH]2)c1,"InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)",GKHIVNAUVKXIIY-UHFFFAOYSA-N,kd025,Phase 2,rho associated kinase inhibitor,ROCK2,,
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,"InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20)",QQUXFYAWXPMDOE-UHFFFAOYSA-N,kenpaullone,Preclinical,CDK inhibitor,CCNB1|CDK1|CDK5|GSK3B,,
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,"InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20)",QQUXFYAWXPMDOE-UHFFFAOYSA-N,kenpaullone,Preclinical,glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,
O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,"InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)",FPCCSQOGAWCVBH-UHFFFAOYSA-N,ketanserin,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2,cardiology,hypertension
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3",XMAYWYJOQHXEEK-UHFFFAOYSA-N,ketoconazole,Launched,sterol demethylase inhibitor,KCNA10,dermatology,seborrheic dermatitis
CC1CCN1c1nc(N2CC3C(CC(=O)O)C3C2)cc(C(F)(F)F)n1,"InChI=1S/C16H19F3N4O2/c1-8-2-3-23(8)15-20-12(16(17,18)19)5-13(21-15)22-6-10-9(4-14(24)25)11(10)7-22/h5,8-11H,2-4,6-7H2,1H3,(H,24,25)",MDUYWDNWFXSMJJ-UHFFFAOYSA-N,ketohexokinase-inhibitor-1,Preclinical,kinase inhibitor,,,
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,"InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)",DKYWVDODHFEZIM-UHFFFAOYSA-N,ketoprofen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,"InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)",OZWKMVRBQXNZKK-UHFFFAOYSA-N,ketorolac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,"InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3",ZCVMWBYGMWKGHF-UHFFFAOYSA-N,ketotifen,Launched,histamine receptor agonist,HRH1,neurology/psychiatry,itching
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,"InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3",ZCVMWBYGMWKGHF-UHFFFAOYSA-N,ketotifen,Launched,leukotriene receptor antagonist,HRH1,neurology/psychiatry,itching
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,"InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3",ZCVMWBYGMWKGHF-UHFFFAOYSA-N,ketotifen,Launched,phosphodiesterase inhibitor,HRH1,neurology/psychiatry,itching
N#CCCCSC(=N)N,"InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8)",PRDJGNVQBVXXEO-UHFFFAOYSA-N,kevetrin,Phase 1,p53 activator,,,
COc1ccc(C2CC(c3c(O)cc(C)oc3=O)=NCCS2)c(OC)c1,"InChI=1S/C19H21NO5S/c1-11-8-15(21)18(19(22)25-11)14-10-17(26-7-6-20-14)13-5-4-12(23-2)9-16(13)24-3/h4-5,8-9,17,21H,6-7,10H2,1-3H3",NHFIAAAMCYVRIW-UHFFFAOYSA-N,kf-38789,Preclinical,P selectin inhibitor,SELP,,
CSc1nc(=N)cc(Oc2ccc(-c3nc(=Nc4cccc(C(F)(F)F)c4)[nH][nH]3)cc2)[nH]1,"InChI=1S/C20H16F3N7OS/c1-32-19-26-15(24)10-16(27-19)31-14-7-5-11(6-8-14)17-28-18(30-29-17)25-13-4-2-3-12(9-13)20(21,22)23/h2-10H,1H3,(H2,24,26,27)(H2,25,28,29,30)",CMYHZFCJPORPHY-UHFFFAOYSA-N,kg-5,Preclinical,RAF inhibitor,BRAF|FLT3|KIT|PDGFRB,,
CCOC(=O)c1c(C(C#N)C=N)c2ccc(Cl)c(Cl)c2n1C,"InChI=1S/C15H13Cl2N3O2/c1-3-22-15(21)14-11(8(6-18)7-19)9-4-5-10(16)12(17)13(9)20(14)2/h4-6,8,18H,3H2,1-2H3",DXZRBHUCOHBAHP-UHFFFAOYSA-N,kh-cb19,Preclinical,CDC inhibitor,CLK1|CLK3|DYRK1A,,
COc1c2occc2c(OC)c2c(=O)cc(C)oc12,"InChI=1S/C14H12O5/c1-7-6-9(15)10-11(16-2)8-4-5-18-12(8)14(17-3)13(10)19-7/h4-6H,1-3H3",HSMPDPBYAYSOBC-UHFFFAOYSA-N,khellin,Phase 2,vasodilator,,,
CSc1ccccc1N=c1[nH]c(N2CCNCC2)nc2c(=NCC3CC3)[nH]cnc12,"InChI=1S/C21H26N8S/c1-30-16-5-3-2-4-15(16)26-20-17-18(19(25-13-24-17)23-12-14-6-7-14)27-21(28-20)29-10-8-22-9-11-29/h2-5,13-14,22H,6-12H2,1H3,(H,23,24,25)(H,26,27,28)",HFLMLZKGLUEWBU-UHFFFAOYSA-N,khk-in-1,Preclinical,hexokinase inhibitor,KHK,,
CC(C)CN=c1cc[nH]c(=NCc2csc(-c3ccccc3)n2)[nH]1,"InChI=1S/C18H21N5S/c1-13(2)10-20-16-8-9-19-18(23-16)21-11-15-12-24-17(22-15)14-6-4-3-5-7-14/h3-9,12-13H,10-11H2,1-2H3,(H2,19,20,21,23)",DGRJOOOHPBSAHD-UHFFFAOYSA-N,khs-101,Preclinical,neural stem cell inducer,TACC3,,
Cc1noc(-c2ccc(CSCCC(=O)O)cc2)c1NC(=O)OC(C)c1ccccc1Cl,"InChI=1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)",LLIFMNUXGDHTRO-UHFFFAOYSA-N,ki-16425,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,
COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,"InChI=1S/C24H24N4O5S/c1-14(23-26-9-10-34-23)27-24(29)28-17-6-5-15(11-20(17)30-2)33-19-7-8-25-18-13-22(32-4)21(31-3)12-16(18)19/h5-14H,1-4H3,(H2,27,28,29)",SHPFDGWALWEPGS-UHFFFAOYSA-N,ki-20227,Preclinical,c-Fms inhibitor,CSF1R|KDR|KIT|PDGFRB,,
COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,"InChI=1S/C24H18F3N3O4/c1-32-22-11-15-20(12-23(22)33-2)28-8-7-21(15)34-14-4-6-19(17(27)10-14)30-24(31)29-18-5-3-13(25)9-16(18)26/h3-12H,1-2H3,(H2,29,30,31)",LFKQSJNCVRGFCC-UHFFFAOYSA-N,ki-8751,Preclinical,KIT inhibitor,KDR,,
COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,"InChI=1S/C24H18F3N3O4/c1-32-22-11-15-20(12-23(22)33-2)28-8-7-21(15)34-14-4-6-19(17(27)10-14)30-24(31)29-18-5-3-13(25)9-16(18)26/h3-12H,1-2H3,(H2,29,30,31)",LFKQSJNCVRGFCC-UHFFFAOYSA-N,ki-8751,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KDR,,
COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,"InChI=1S/C24H18F3N3O4/c1-32-22-11-15-20(12-23(22)33-2)28-8-7-21(15)34-14-4-6-19(17(27)10-14)30-24(31)29-18-5-3-13(25)9-16(18)26/h3-12H,1-2H3,(H2,29,30,31)",LFKQSJNCVRGFCC-UHFFFAOYSA-N,ki-8751,Preclinical,VEGFR inhibitor,KDR,,
COC(=O)CCSCc1ccc(-c2onc(C)c2NC(=O)OC(C)c2ccccc2Cl)cc1,"InChI=1S/C24H25ClN2O5S/c1-15-22(26-24(29)31-16(2)19-6-4-5-7-20(19)25)23(32-27-15)18-10-8-17(9-11-18)14-33-13-12-21(28)30-3/h4-11,16H,12-14H2,1-3H3,(H,26,29)",HHVJBROTJWPHHX-UHFFFAOYSA-N,ki16198,Preclinical,lipoprotein antagonist,LPA,,
O=C1NC2C(O)C(O)C(O)C(CO)N2C1=O,"InChI=1S/C8H12N2O6/c11-1-2-3(12)4(13)5(14)6-9-7(15)8(16)10(2)6/h2-6,11-14H,1H2,(H,9,15)",OIURYJWYVIAOCW-UHFFFAOYSA-N,kifunensine,Phase 1,mannosidase inhibitor,MAN1B1|MAN2A1,,
c1coc(CN=c2[nH]cnc3[nH]cnc23)c1,"InChI=1S/C10H9N5O/c1-2-7(16-3-1)4-11-9-8-10(13-5-12-8)15-6-14-9/h1-3,5-6H,4H2,(H2,11,12,13,14,15)",QANMHLXAZMSUEX-UHFFFAOYSA-N,kinetin,Launched,cell division inducer,,dermatology,sunburn
CS(=O)(=O)N(Cc1ccco1)CC(O)Cn1c2ccccc2c2ccccc21,"InChI=1S/C21H22N2O4S/c1-28(25,26)22(15-17-7-6-12-27-17)13-16(24)14-23-20-10-4-2-8-18(20)19-9-3-5-11-21(19)23/h2-12,16,24H,13-15H2,1H3",OQAFDLPAPSSOHY-UHFFFAOYSA-N,kl-001,Preclinical,proteasome inhibitor,CRY1|CRY2,,
CN(C)CCNC(=O)COc1c2cccc1Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1cccc(c1OCC(=O)NCCN(C)C)C2,"InChI=1S/C52H72N8O8/c1-57(2)25-21-53-45(61)33-65-49-37-13-9-14-38(49)30-40-16-11-18-42(51(40)67-35-47(63)55-23-27-59(5)6)32-44-20-12-19-43(52(44)68-36-48(64)56-24-28-60(7)8)31-41-17-10-15-39(29-37)50(41)66-34-46(62)54-22-26-58(3)4/h9-20H,21-36H2,1-8H3,(H,53,61)(H,54,62)(H,55,63)(H,56,64)",CQVAQQNDZCZBSU-UHFFFAOYSA-N,km-0118,Phase 1,anticancer agent,,,
CC(C)(C)c1cc(C=C2CCOC2=O)cc(C(C)(C)C)c1O,"InChI=1S/C19H26O3/c1-18(2,3)14-10-12(9-13-7-8-22-17(13)21)11-15(16(14)20)19(4,5)6/h9-11,20H,7-8H2,1-6H3",DFPYHQJPGCODSB-UHFFFAOYSA-N,kme-4,Preclinical,prostaglandin inhibitor,,,
O=C(OC(C(F)(F)F)C(F)(F)F)N1CCC(C(O)(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1,"InChI=1S/C24H21F6NO7/c25-23(26,27)20(24(28,29)30)38-21(32)31-7-5-13(6-8-31)22(33,14-1-3-16-18(9-14)36-11-34-16)15-2-4-17-19(10-15)37-12-35-17/h1-4,9-10,13,20,33H,5-8,11-12H2",SXHQLPHDBLTFPM-UHFFFAOYSA-N,kml29,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,
CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12,"InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3",RJVLFQBBRSMWHX-UHFFFAOYSA-N,kn-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1,,
CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12,"InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3",RJVLFQBBRSMWHX-UHFFFAOYSA-N,kn-62,Preclinical,purinergic receptor antagonist,AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1,,
COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)CC=Cc2ccc(Cl)cc2)cc1,"InChI=1S/C26H29ClN2O4S/c1-28(17-5-6-21-9-11-23(27)12-10-21)20-22-7-3-4-8-26(22)29(18-19-30)34(31,32)25-15-13-24(33-2)14-16-25/h3-16,30H,17-20H2,1-2H3",LLLQTDSSHZREGW-UHFFFAOYSA-N,kn-93,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,,
COc1ccc2c3c([nH]c2c1)C(CC(C)C)n1c(c(O)nc(CCC(O)OC(C)(C)C)c1=O)C3,"InChI=1S/C26H35N3O5/c1-14(2)11-20-23-17(16-8-7-15(33-6)12-19(16)27-23)13-21-24(31)28-18(25(32)29(20)21)9-10-22(30)34-26(3,4)5/h7-8,12,14,20,22,27,30-31H,9-11,13H2,1-6H3",UOKGKKCXQOAQGH-UHFFFAOYSA-N,ko143,Preclinical,BCRP inhibitor,ABCB1|ABCC1,,
NC1=NC(=O)N(C2CC(O)C(CO)O2)CN1,"InChI=1S/C8H14N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h4-6,13-14H,1-3H2,(H3,9,10,11,15)",LAOLDMMWVYDDID-UHFFFAOYSA-N,kp-1212,Phase 2,,,,
COc1cc(-c2ncn(C=CC(=O)OC(C)C)n2)cc(C(F)(F)F)c1,"InChI=1S/C16H16F3N3O3/c1-10(2)25-14(23)4-5-22-9-20-15(21-22)11-6-12(16(17,18)19)8-13(7-11)24-3/h4-10H,1-3H3",NLNGWFLRRRYNIL-UHFFFAOYSA-N,kpt-185,Preclinical,exportin antagonist,XPO1,,
O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)N1CC(F)(F)C1,"InChI=1S/C16H10F8N4O/c17-14(18)6-27(7-14)12(29)1-2-28-8-25-13(26-28)9-3-10(15(19,20)21)5-11(4-9)16(22,23)24/h1-5,8H,6-7H2",JCHAWRDHMUSLMM-UHFFFAOYSA-N,kpt-276,Preclinical,exportin antagonist,XPO1,,
N=c1ccc(C=CC(=O)NCc2cc3cc(-c4ccc(C(=O)N5CCC(F)(F)CC5)cc4)cc(-c4ccc(F)cc4)c3o2)c[nH]1,"InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)",MRFOPLWJZULAQD-UHFFFAOYSA-N,kpt-9274,Phase 1,NAMPT inhibitor,,,
O=C(CSc1ccc(Br)cc1)Nc1cn(CCc2ccccc2)nc1C(=O)O,"InChI=1S/C20H18BrN3O3S/c21-15-6-8-16(9-7-15)28-13-18(25)22-17-12-24(23-19(17)20(26)27)11-10-14-4-2-1-3-5-14/h1-9,12H,10-11,13H2,(H,22,25)(H,26,27)",ZRLJEHIUGYTTSZ-UHFFFAOYSA-N,kr-33494,Preclinical,cell death inhibitor ,,,
COc1cc(N2CCN(C(C)=O)CC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccc(N3CCN(C(C)=O)CC3)cc2OC)[nH]1,"InChI=1S/C30H37ClN8O4/c1-20(40)36-9-13-38(14-10-36)22-5-7-25(27(17-22)42-3)33-29-24(31)19-32-30(35-29)34-26-8-6-23(18-28(26)43-4)39-15-11-37(12-16-39)21(2)41/h5-8,17-19H,9-16H2,1-4H3,(H2,32,33,34,35)",TXDIRJCYNAWBOS-UHFFFAOYSA-N,krca-0008,Preclinical,ALK inihibitor,ALK,,
CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,"InChI=1S/C20H21ClN4O4/c1-4-7-22-20(26)25-15-6-5-12(8-14(15)21)29-19-13-9-17(27-2)18(28-3)10-16(13)23-11-24-19/h5-6,8-11H,4,7H2,1-3H3,(H2,22,25,26)",VPBYZLCHOKSGRX-UHFFFAOYSA-N,krn-633,Preclinical,VEGFR inhibitor,FLT1|FLT4|KDR,,
O=C(Nc1ccccc1C(=O)Nc1ccc(CCO)cc1)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C22H19N3O5/c26-14-13-15-5-9-17(10-6-15)23-22(28)19-3-1-2-4-20(19)24-21(27)16-7-11-18(12-8-16)25(29)30/h1-12,26H,13-14H2,(H,23,28)(H,24,27)",LTWQQWSXYYXVGA-UHFFFAOYSA-N,ks-176,Preclinical,BCRP inhibitor,ABCG2,,
CCc1oc2ccccc2c1C(=O)c1ccc(OCC(=O)O)cc1,"InChI=1S/C19H16O5/c1-2-15-18(14-5-3-4-6-16(14)24-15)19(22)12-7-9-13(10-8-12)23-11-17(20)21/h3-10H,2,11H2,1H3,(H,20,21)",XSDFWTIKVXKOGJ-UHFFFAOYSA-N,kt-433,Phase 2,uricosuric agent,,,
COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4CC(C)OC(C)C4)nc3n2)cc1CO,"InChI=1S/C25H31N5O4/c1-16-13-30(14-17(2)34-16)25-27-23-20(24(28-25)29-8-10-33-11-9-29)5-6-21(26-23)18-4-7-22(32-3)19(12-18)15-31/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3",RFSMUFRPPYDYRD-UHFFFAOYSA-N,ku-0063794,Preclinical,mTOR inhibitor,MTOR,,
O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1,"InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2",XRKYMMUGXMWDAO-UHFFFAOYSA-N,ku-55933,Preclinical,ATM kinase inhibitor,ATM|PRKDC,,
CC1CN(CC(=O)Nc2ccc3c(c2)Cc2cccc(-c4cc(=O)cc(N5CCOCC5)o4)c2S3)CC(C)O1,"InChI=1S/C30H33N3O5S/c1-19-16-32(17-20(2)37-19)18-28(35)31-23-6-7-27-22(13-23)12-21-4-3-5-25(30(21)39-27)26-14-24(34)15-29(38-26)33-8-10-36-11-9-33/h3-7,13-15,19-20H,8-12,16-18H2,1-2H3,(H,31,35)",SCELLOWTHJGVIC-UHFFFAOYSA-N,ku-60019,Preclinical,ATM kinase inhibitor,ATM,,
CCC1(c2ncc[nH]2)Cc2ccccc2O1,"InChI=1S/C13H14N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-8H,2,9H2,1H3,(H,14,15)",JCWVNNMJXQJVNC-UHFFFAOYSA-N,ku14r,Preclinical,imidazoline receptor antagonist,,,
OCC1OC(Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)C(O)C(O)C1O,"InChI=1S/C21H20O11/c22-7-16-17(27)18(28)19(29)21(32-16)31-15-6-10-12(25)4-9(23)5-14(10)30-20(15)8-1-2-11(24)13(26)3-8/h1-6,16-19,21-22,27-29H,7H2,(H3-,23,24,25,26)/p+1",RKWHWFONKJEUEF-UHFFFAOYSA-O,kuromanin,Preclinical,ribosyl cyclase inhibitor,CD38,,
O=C(c1ccc(C=Cc2[nH]nc3ccccc23)cc1)N1CCNCC1,"InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)",YYLKKYCXAOBSRM-UHFFFAOYSA-N,kw-2449,Phase 1,Abl kinase inhibitor,ABL1|AURKA|AURKB|FLT3,,
O=C(c1ccc(C=Cc2[nH]nc3ccccc23)cc1)N1CCNCC1,"InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)",YYLKKYCXAOBSRM-UHFFFAOYSA-N,kw-2449,Phase 1,Aurora kinase inhibitor,ABL1|AURKA|AURKB|FLT3,,
O=C(c1ccc(C=Cc2[nH]nc3ccccc23)cc1)N1CCNCC1,"InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)",YYLKKYCXAOBSRM-UHFFFAOYSA-N,kw-2449,Phase 1,FLT3 inhibitor,ABL1|AURKA|AURKB|FLT3,,
CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,"InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3",VFUXSYAXEKYYMB-UHFFFAOYSA-N,kw-2478,Phase 1/Phase 2,HSP inhibitor,,,
CCCn1c(=O)c2[nH]c(C34CC5CC(CC3C5)C4)nc2n(CCC)c1=O,"InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)",PJBFVWGQFLYWCB-UHFFFAOYSA-N,kw-3902,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,"InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)",HUNGUWOZPQBXGX-UHFFFAOYSA-N,kx2-391,Phase 3,SRC inhibitor,SRC,,
O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,"InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)",HUNGUWOZPQBXGX-UHFFFAOYSA-N,kx2-391,Phase 3,tubulin polymerization inhibitor,SRC,,
COc1ccc(CCC(=O)N=c2[nH]c3ccc(Cl)cc3s2)cc1OC,"InChI=1S/C18H17ClN2O3S/c1-23-14-7-3-11(9-15(14)24-2)4-8-17(22)21-18-20-13-6-5-12(19)10-16(13)25-18/h3,5-7,9-10H,4,8H2,1-2H3,(H,20,21,22)",LXFKEVQQSKQXPR-UHFFFAOYSA-N,ky02111,Preclinical,WNT pathway inhibitor,DKK1,,
O=C(O)c1cc(=O)c2ccccc2[nH]1,"InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)",HCZHHEIFKROPDY-UHFFFAOYSA-N,kynurenic-acid,Phase 1,glutamate receptor antagonist,GPR35|GRIN1|GRIN2A|GRIN2B,,
CC1OC(O)C(O)C(O)C1O,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3",SHZGCJCMOBCMKK-UHFFFAOYSA-N,l-(+)-rhamnose-monohydrate,Preclinical,,,,
CC1(C)C=C2Oc3ccccc3C(C3C(=O)CC(C)(C)CC3=O)C2C(=O)C1,"InChI=1S/C23H26O4/c1-22(2)9-14(24)20(15(25)10-22)19-13-7-5-6-8-17(13)27-18-12-23(3,4)11-16(26)21(18)19/h5-8,12,19-21H,9-11H2,1-4H3",TXIMRZYBBVKDIK-UHFFFAOYSA-N,l-152804,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(-c2ccccc2S(=O)(=O)NC(=O)c2sccc2C)cc1,"InChI=1S/C32H29F3N4O4S2/c1-3-4-13-28-36-39(26-11-7-6-10-25(26)32(33,34)35)31(41)38(28)20-22-14-16-23(17-15-22)24-9-5-8-12-27(24)45(42,43)37-30(40)29-21(2)18-19-44-29/h5-12,14-19H,3-4,13,20H2,1-2H3,(H,37,40)",MMDNKTXNUZFVKD-UHFFFAOYSA-N,l-161982,Preclinical,prostanoid receptor antagonist,PTGER4,,
CCCc1c(OCCCOc2ccc(OCC(=O)O)cc2)ccc(C(C)=O)c1O,"InChI=1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)",HBBVCKCCQCQCTJ-UHFFFAOYSA-N,l-165041,Preclinical,PPAR receptor agonist,PPARD,,
CCCOc1ccc(Br)cc1-c1cc(-c2ccc(Cl)cc2)[nH]c1-c1ccncc1,"InChI=1S/C24H20BrClN2O/c1-2-13-29-23-8-5-18(25)14-20(23)21-15-22(16-3-6-19(26)7-4-16)28-24(21)17-9-11-27-12-10-17/h3-12,14-15,28H,2,13H2,1H3",HHBOWXZOLYQFNY-UHFFFAOYSA-N,l-168049,Preclinical,glucagon receptor antagonist,GCGR,,
Cc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,"InChI=1S/C24H22N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h3-15,22H,1-2H3,(H2,25,27,30)",KDFQABSFVYLGPM-UHFFFAOYSA-N,l-365260,Phase 2,CCK receptor antagonist,CCKAR|CCKBR|KCNQ1,,
Cc1ccccc1N1CCN(S(=O)(=O)CC23CCC(CC2NC(=O)C(N)CCS(C)(=O)=O)C3(C)C)CC1,"InChI=1S/C26H42N4O5S2/c1-19-7-5-6-8-22(19)29-12-14-30(15-13-29)37(34,35)18-26-11-9-20(25(26,2)3)17-23(26)28-24(31)21(27)10-16-36(4,32)33/h5-8,20-21,23H,9-18,27H2,1-4H3,(H,28,31)",MWIASLNTAGRGGA-UHFFFAOYSA-N,l-368899,Phase 1,oxytocin receptor antagonist,AVPR1A|AVPR2|OXTR,,
CCOC(=O)c1ncn2c1C1CCCN1C(=O)c1cc(OC)ccc1-2,"InChI=1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3",YKYOQIXTECBVBB-UHFFFAOYSA-N,"l-655,708",Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRG2,,
Cc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,"InChI=1S/C21H21ClFNO2/c1-13-17-10-16(23)8-9-18(17)24(12-14-4-6-15(22)7-5-14)19(13)11-21(2,3)20(25)26/h4-10H,11-12H2,1-3H3,(H,25,26)",JLPYLHLUHJOPNL-UHFFFAOYSA-N,l-655240,Phase 1,thromboxane receptor antagonist,PTGES,,
CS(=O)(=O)c1ccc(Cn2c3c(c4cc(F)cc(F)c42)CCCC3CC(=O)O)cc1,"InChI=1S/C22H21F2NO4S/c1-30(28,29)16-7-5-13(6-8-16)12-25-21-14(9-20(26)27)3-2-4-17(21)18-10-15(23)11-19(24)22(18)25/h5-8,10-11,14H,2-4,9,12H2,1H3,(H,26,27)",GMJWAIMJHBTYPD-UHFFFAOYSA-N,l-670596,Preclinical,prostanoid receptor antagonist,,,
O=C(Nc1ccccc1)NC1CC(C(=O)O)Nc2cc(Cl)cc(Cl)c21,"InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)",UCKHICKHGAOGAP-UHFFFAOYSA-N,l-689560,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CC(Oc1ccc(O)cc1)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C8H10O8P2/c1-8(17(10,11)12,18(13,14)15)16-7-4-2-6(9)3-5-7/h2-5,9H,1H3,(H,10,11,12)(H,13,14,15)",LZJFNDUCIKGHBG-UHFFFAOYSA-N,l-690330,Preclinical,inositol monophosphatase inhibitor,IMPA1,,
c1ccc(CN2CCC3(CCc4ccccc43)CC2)cc1,"InChI=1S/C20H23N/c1-2-6-17(7-3-1)16-21-14-12-20(13-15-21)11-10-18-8-4-5-9-19(18)20/h1-9H,10-16H2",GSXJSGMDWKPVBY-UHFFFAOYSA-N,l-693403,Preclinical,sigma receptor agonist,DRD2|SIGMAR1,,
c1ccc(CN2CCC3(CCc4ccccc43)CC2)cc1,"InChI=1S/C20H23N/c1-2-6-17(7-3-1)16-21-14-12-20(13-15-21)11-10-18-8-4-5-9-19(18)20/h1-9H,10-16H2",GSXJSGMDWKPVBY-UHFFFAOYSA-N,l-693403,Preclinical,sigma receptor antagonist,DRD2|SIGMAR1,,
CS(=O)(=O)Nc1ccc(Cc2noc(-c3ccc4[nH]cc(CCN)c4c3)n2)cc1,"InChI=1S/C20H21N5O3S/c1-29(26,27)25-16-5-2-13(3-6-16)10-19-23-20(28-24-19)14-4-7-18-17(11-14)15(8-9-21)12-22-18/h2-7,11-12,22,25H,8-10,21H2,1H3",HKXMQLISPYELRD-UHFFFAOYSA-N,l-694247,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,,
O=C(c1c(O)[nH]c2cc(Cl)ccc2c1=O)C1CC1,"InChI=1S/C13H10ClNO3/c14-7-3-4-8-9(5-7)15-13(18)10(12(8)17)11(16)6-1-2-6/h3-6H,1-2H2,(H2,15,17,18)",MXEFWCFPCLDOOG-UHFFFAOYSA-N,l-701252,Preclinical,glutamate receptor antagonist,GRIN1,,
O=c1[nH]c2cc(Cl)ccc2c(O)c1-c1cccc(Oc2ccccc2)c1,"InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)",FLVRDMUHUXVRET-UHFFFAOYSA-N,l-701324,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)OCc1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C22H18F6N2O3/c1-12(31)30-19(8-14-10-29-18-5-3-2-4-17(14)18)20(32)33-11-13-6-15(21(23,24)25)9-16(7-13)22(26,27)28/h2-7,9-10,19,29H,8,11H2,1H3,(H,30,31)",BYYQYXVAWXAYQC-UHFFFAOYSA-N,"l-732,138",Preclinical,tachykinin antagonist,TACR1|TACR2,,
FC(F)(F)c1cc(COC2CCCNC2c2ccccc2)cc(C(F)(F)F)c1,"InChI=1S/C20H19F6NO/c21-19(22,23)15-9-13(10-16(11-15)20(24,25)26)12-28-17-7-4-8-27-18(17)14-5-2-1-3-6-14/h1-3,5-6,9-11,17-18,27H,4,7-8,12H2",FCDRFVCGMLUYPG-UHFFFAOYSA-N,l-733060,Preclinical,tachykinin antagonist,TACR1,,
Cc1c(C2CCN(CCc3ccccc3)CC2)noc1-c1ccc(Cl)cc1,"InChI=1S/C23H25ClN2O/c1-17-22(25-27-23(17)20-7-9-21(24)10-8-20)19-12-15-26(16-13-19)14-11-18-5-3-2-4-6-18/h2-10,19H,11-16H2,1H3",QDMAKDIDFJTXEL-UHFFFAOYSA-N,l-741742,Preclinical,dopamine receptor antagonist,DRD3|DRD4|SCN1A|SCN3A,,
Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,"InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)",OGJGQVFWEPNYSB-UHFFFAOYSA-N,l-745870,Preclinical,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7,,
CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNCC(O)COc3ccc(O)cc3)cc2)cc1,"InChI=1S/C30H40N4O6S/c1-2-3-4-5-19-32-30(37)33-24-10-16-29(17-11-24)41(38,39)34-25-8-6-23(7-9-25)18-20-31-21-27(36)22-40-28-14-12-26(35)13-15-28/h6-17,27,31,34-36H,2-5,18-22H2,1H3,(H2,32,33,37)",NYYJKMXNVNFOFQ-UHFFFAOYSA-N,l-755507,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,
CC(OC1OCCN(Cc2[nH]nnc2CN(C)C)C1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C26H28F7N5O2/c1-15(17-10-18(25(28,29)30)12-19(11-17)26(31,32)33)40-24-23(16-4-6-20(27)7-5-16)38(8-9-39-24)14-22-21(13-37(2)3)34-36-35-22/h4-7,10-12,15,23-24H,8-9,13-14H2,1-3H3,(H,34,35,36)",USRYEHHMJIRICK-UHFFFAOYSA-N,l-760735,Preclinical,tachykinin antagonist,TACR1,,
N#Cc1ccc(Cn2cncc2CN2CCN(c3cccc(Cl)c3)C(=O)C2)cc1,"InChI=1S/C22H20ClN5O/c23-19-2-1-3-20(10-19)28-9-8-26(15-22(28)29)14-21-12-25-16-27(21)13-18-6-4-17(11-24)5-7-18/h1-7,10,12,16H,8-9,13-15H2",JNUGFGAVPBYSHF-UHFFFAOYSA-N,l-778123,Phase 1,farnesyltransferase inhibitor,FNTA|FNTB|PGGT1B,,
COc1ccc(Br)cc1S(=O)(=O)NC(=O)C=Cc1ccccc1Cc1ccc2ccccc2c1,"InChI=1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)",ODTKFNUPVBULRJ-UHFFFAOYSA-N,l-798106,Preclinical,prostanoid receptor antagonist,PTGER3,,
Cn1ncnc1COc1nn2c(-c3cc(F)ccc3F)nnc2cc1C(C)(C)C,"InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3",BQDUNOMMYOKHEP-UHFFFAOYSA-N,l-838417,Preclinical,GABA receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CC(N)C(=O)O,"InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)",QNAYBMKLOCPYGJ-UHFFFAOYSA-N,l-alanine,Launched,,AARS|AARS2|ABAT|AGXT|AGXT2|GPRC6A|GPT|GPT2|KYNU|NFS1|PHYKPL|SLC1A4|SLC36A1|SLC7A8,,
N=C(N)NCCCC(N)C(=O)O,"InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)",ODKSFYDXXFIFQN-UHFFFAOYSA-N,l-arginine,Launched,nitric oxide precursor,ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4,cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology,congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold
CCCCCCCCCCCCCCCC(=O)OCC(O)c1oc(O)c(O)c1O,"InChI=1S/C22H38O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(24)28-16-17(23)21-19(25)20(26)22(27)29-21/h17,23,25-27H,2-16H2,1H3",FMCKLHPPSGUBEM-UHFFFAOYSA-N,l-ascorbyl-6-palmitate,Preclinical,,,,
NC(=O)CC(N)C(=O)O,"InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)",DCXYFEDJOCDNAF-UHFFFAOYSA-N,l-asparagine,Phase 3,,ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3,,
NC(CC(O)=NO)C(=O)O,"InChI=1S/C4H8N2O4/c5-2(4(8)9)1-3(7)6-10/h2,10H,1,5H2,(H,6,7)(H,8,9)",ZBYVTTSIVDYQSO-UHFFFAOYSA-N,l-asparagine-n-hydroxy,Preclinical,,,,
NC(CC(=O)O)C(=O)O,"InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)",CKLJMWTZIZZHCS-UHFFFAOYSA-N,l-aspartic-acid,Launched,metallic radical formation stimulant,ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13,,
NC(=O)NCCCC(N)C(=O)O,"InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)",RHGKLRLOHDJJDR-UHFFFAOYSA-N,l-citrulline,Launched,nitric oxide stimulant,ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6,cardiology|urology,hypertension|erectile dysfunction
NC(CS)C(=O)O,"InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)",XUJNEKJLAYXESH-UHFFFAOYSA-N,l-cysteine,Launched,,CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3,rheumatology,osteoarthritis|rheumatoid arthritis
NC(CS(=O)O)C(=O)O,"InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)",ADVPTQAUNPRNPO-UHFFFAOYSA-N,l-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2,,
NC(CSSCC(N)C(=O)O)C(=O)O,"InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)",LEVWYRKDKASIDU-UHFFFAOYSA-N,l-cystine,Launched,,CTNS|SLC3A1|SLC7A11|SLC7A9,,
C[N+](C)(C)C(Cc1c[nH]c(=S)[nH]1)C(=O)O,"InChI=1S/C9H15N3O2S/c1-12(2,3)7(8(13)14)4-6-5-10-9(15)11-6/h5,7H,4H2,1-3H3,(H2-,10,11,13,14,15)/p+1",SSISHJJTAXXQAX-UHFFFAOYSA-O,l-ergothioneine,Phase 3,free radical scavenger,,,
NC(CCC(=O)O)C(=O)O,"InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)",WHUUTDBJXJRKMK-UHFFFAOYSA-N,l-glutamic-acid,Launched,glutamate receptor agonist,AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT,,
NC(=O)CCC(N)C(=O)O,"InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)",ZDXPYRJPNDTMRX-UHFFFAOYSA-N,l-glutamine,Launched,,CTPS1|GLUL|GPRC6A|PPAT,gastroenterology|dental|neurology/psychiatry|rheumatology,diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia
O=C(O)C1CC(O)CN1,"InChI=1S/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)",PMMYEEVYMWASQN-UHFFFAOYSA-N,l-hydroxyproline,Launched,,,,
Nc1ccccc1C(=O)CC(N)C(=O)O,"InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)",YGPSJZOEDVAXAB-UHFFFAOYSA-N,l-kynurenine,Phase 1,aryl hydrocarbon receptor agonist,,,
CC(C)CC(N)C(=O)O,"InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)",ROHFNLRQFUQHCH-UHFFFAOYSA-N,l-leucine,Phase 3,,BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2,,
NCCCCC(N)C(=O)O,"InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)",KDXKERNSBIXSRK-UHFFFAOYSA-N,l-lysine,Phase 2,serotonin receptor agonist,GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4,,
CSCCC(N)C(=O)O,"InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)",FFEARJCKVFRZRR-UHFFFAOYSA-N,l-methionine,Launched,voltage-gated calcium channel ligand,BHMT|BHMT2|METAP2|MTR|MTRR,pulmonary|allergy|neurology/psychiatry,asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia
NC(Cn1ccc(=O)c(O)c1)C(=O)O,"InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)",WZNJWVWKTVETCG-UHFFFAOYSA-N,l-mimosine,Preclinical,dopamine beta hydroxylase inhibitor,DBH|EIF5A,,
NC(Cn1ccc(=O)c(O)c1)C(=O)O,"InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)",WZNJWVWKTVETCG-UHFFFAOYSA-N,l-mimosine,Preclinical,eukaryotic translation initiation factor inhibitor,DBH|EIF5A,,
CNC(CCCN=C(N)N)C(=O)O,"InChI=1S/C7H16N4O2/c1-10-5(6(12)13)3-2-4-11-7(8)9/h5,10H,2-4H2,1H3,(H,12,13)(H4,8,9,11)",NTWVQPHTOUKMDI-UHFFFAOYSA-N,l-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,NOS1|NOS2,,
COC(=O)C(N)CCCN=C(N)N[N+](=O)[O-],"InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)",KCWZGJVSDFYRIX-UHFFFAOYSA-N,l-name,Phase 2/Phase 3,nitric oxide synthase inhibitor,NOS3,,
CC(=N)NCCCCC(N)C(=O)O,"InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)",ONYFNWIHJBLQKE-UHFFFAOYSA-N,l-nil,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
CC(Cc1ccccc1)N=c1[nH]cnc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C19H23N5O4/c1-11(7-12-5-3-2-4-6-12)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h2-6,9-11,13,15-16,19,25-27H,7-8H2,1H3,(H,20,21,23)",RIRGCFBBHQEQQH-UHFFFAOYSA-N,l-phenylisopropyladenosine,Preclinical,,,,
O=C(O)C1CCCN1,"InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)",ONIBWKKTOPOVIA-UHFFFAOYSA-N,l-proline,Launched,glutamate receptor agonist,EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7,,
NC(Cn1oc(=O)[nH]c1=O)C(=O)O,"InChI=1S/C5H7N3O5/c6-2(3(9)10)1-8-4(11)7-5(12)13-8/h2H,1,6H2,(H,9,10)(H,7,11,12)",ASNFTDCKZKHJSW-UHFFFAOYSA-N,l-quisqualic-acid,Preclinical,glutamate receptor agonist,FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8,,
CCNC(=O)CCC(N)C(=O)O,"InChI=1S/C7H14N2O3/c1-2-9-6(10)4-3-5(8)7(11)12/h5H,2-4,8H2,1H3,(H,9,10)(H,11,12)",DATAGRPVKZEWHA-UHFFFAOYSA-N,l-theanine,Launched,glutamate receptor antagonist,,,
CC(=O)C(N)C(O)O,"InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h3-4,7-8H,5H2,1H3",FVIRKMTVCDDJNM-UHFFFAOYSA-N,l-threonine,Phase 2,,TARS|TARS2|THNSL1,,
CC(C)C(N)C(=O)O,"InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)",KZSNJWFQEVHDMF-UHFFFAOYSA-N,l-valine,Phase 2,,,,
CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,"InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)",SGUAFYQXFOLMHL-UHFFFAOYSA-N,labetalol,Launched,adrenergic receptor antagonist,ADRA1D|ADRB1|ADRB2,cardiology,hypertension
CCOC(=O)C1=C(C)N=C(C)C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,"InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,21,23H,8-9H2,1-7H3",BGYJFSXPRMOZJK-UHFFFAOYSA-N,lacidipine,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension
OCC(O)C(O)C(OC1OC(CO)C(O)C(O)C1O)C(O)CO,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2",VQHSOMBJVWLPSR-UHFFFAOYSA-N,lacitol,Launched,laxative,,gastroenterology,constipation
OCC1OC(OC2C(CO)OC(O)(CO)C2O)C(O)C(O)C1O,"InChI=1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2",JCQLYHFGKNRPGE-UHFFFAOYSA-N,lactulose,Launched,laxative,,gastroenterology,portal-systemic encephalopathy (PSE)
O=C(C[S+]([O-])Cc1ccco1)NCC=CCOc1cc(CN2CCCCC2)ccn1,"InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)",KMZQAVXSMUKBPD-UHFFFAOYSA-N,lafutidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|peptic ulcer disease (PUD)
N=c1ccn(C2CSC(CO)O2)c(=O)[nH]1,"InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)",JTEGQNOMFQHVDC-UHFFFAOYSA-N,lamivudine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)|hepatitis B
N=c1[nH]nc(-c2cccc(Cl)c2Cl)c(=N)[nH]1,"InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)",PYZRQGJRPPTADH-UHFFFAOYSA-N,lamotrigine,Launched,serotonin receptor antagonist,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|bipolar disorder
N=c1[nH]nc(-c2cccc(Cl)c2Cl)c(=N)[nH]1,"InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)",PYZRQGJRPPTADH-UHFFFAOYSA-N,lamotrigine,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|bipolar disorder
CC#Cc1cncc(-c2ccc3c(c2)C2(N=C(C)C(=N)N2)C2(CCC(OC)CC2)C3)c1,"InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)",WKDNQONLGXOZRG-UHFFFAOYSA-N,lanabecestat,Phase 3,beta secretase inhibitor,,,
CC(=O)OC1CC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(c7coc(O)c7)CCC65O)C4)OC3C)OC2C)OC(C)C1OC1OC(CO)C(O)C(O)C1O,"InChI=1S/C49H76O20/c1-21-43(67-38-17-32(53)44(22(2)62-38)68-39-18-33(64-24(4)51)45(23(3)63-39)69-46-42(58)41(57)40(56)34(19-50)66-46)31(52)16-37(61-21)65-27-9-11-47(5)26(14-27)7-8-29-30(47)15-35(54)48(6)28(10-12-49(29,48)59)25-13-36(55)60-20-25/h13,20-23,26-35,37-46,50,52-59H,7-12,14-19H2,1-6H3",HTTBBJKIRUVDEX-UHFFFAOYSA-N,lanatoside-c,Preclinical,cardiac glycoside,,,
CC1(C)OCC(COC(=O)CCc2ccc(OCC(O)CNCCNC(=O)N3CCOCC3)cc2)O1,"InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)",WMDSZGFJQKSLLH-UHFFFAOYSA-N,landiolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia
O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1,"InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)",OQDQIFQRNZIEEJ-UHFFFAOYSA-N,lanifibranor,Phase 2,PPAR receptor agonist,,,
N#CC(=C1SCC(c2ccccc2Cl)S1)n1ccnc1,"InChI=1S/C14H10ClN3S2/c15-11-4-2-1-3-10(11)13-8-19-14(20-13)12(7-16)18-6-5-17-9-18/h1-6,9,13H,8H2",ZRTQSJFIDWNVJW-UHFFFAOYSA-N,lanoconazole,Launched,sterol demethylase inhibitor,,infectious disease,fungal infection
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,"InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)",MJIHNNLFOKEZEW-UHFFFAOYSA-N,lansoprazole,Launched,ATPase inhibitor,ATP4A|ATP4B,gastroenterology,heartburn
CS(=O)(=O)CCNCc1ccc(-c2ccc3[nH]cnc(=Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,lapatinib,Launched,EGFR inhibitor,EGFR|ERBB2,oncology,breast cancer
CCN1CC2(OC(=O)c3ccccc3NC(C)=O)CCC(OC)C34C1C(CC23)C1(O)CC(OC)C2CC4C1(O)C2OC,"InChI=1S/C32H44N2O8/c1-6-34-16-29(42-28(36)18-9-7-8-10-21(18)33-17(2)35)12-11-25(40-4)31-23(29)14-20(26(31)34)30(37)15-22(39-3)19-13-24(31)32(30,38)27(19)41-5/h7-10,19-20,22-27,37-38H,6,11-16H2,1-5H3,(H,33,35)",NWBWCXBPKTTZNQ-UHFFFAOYSA-N,lappaconite,Phase 2,sodium channel blocker,,,
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,"InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3",GKWPCEFFIHSJOE-UHFFFAOYSA-N,laquinimod,Phase 3,immunosuppressant,CXCL2,,
CC(C)CC(NC(=O)C(NC(=O)CNC(=O)CN)C(C)C)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(=O)NCC(=O)O)C(C)C,"InChI=1S/C32H55N9O10/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46)",ORFLZNAGUTZRLQ-UHFFFAOYSA-N,larazotide-acetate,Phase 2,tight junction regulator,,,
CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)C(CC(=O)O)CC3,"InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)",NXFFJDQHYLNEJK-UHFFFAOYSA-N,laropiprant,Launched,prostanoid receptor antagonist,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R,cardiology,cholesterol
O=C(Nc1cnn2ccc(N3CCCC3c3cc(F)ccc3F)nc12)N1CCC(O)C1,"InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)",NYNZQNWKBKUAII-UHFFFAOYSA-N,larotrectinib,Launched,tropomyosin receptor kinase inhibitor,NTRK1|NTRK2|NTRK3,,
CCC(C(=O)C(C)C(O)C(C)CCc1ccc(C)c(O)c1C(=O)O)C1OC(CC)(C2CCC(O)(CC)C(C)O2)CC1C,"InChI=1S/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)",BBMULGJBVDDDNI-UHFFFAOYSA-N,lasalocid,Launched,bacterial permeability inducer,,infectious disease,coccidiosis
CN1CCC(C(=O)c2cccc(=NC(=O)c3c(F)cc(F)cc3F)[nH]2)CC1,"InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)",XEDHVZKDSYZQBF-UHFFFAOYSA-N,lasmiditan,Launched,serotonin receptor agonist,,,
Oc1ccc2c(c1)CCC(c1ccccc1)C2c1ccc(OCCN2CCCC2)cc1,"InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2",GXESHMAMLJKROZ-UHFFFAOYSA-N,lasofoxifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer
CC(C)OC(=O)CCCC=CCC1C(O)CC(O)C1CCC(O)CCc1ccccc1,"InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3",GGXICVAJURFBLW-UHFFFAOYSA-N,latanoprost,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma
Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1,"InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3",JNODQFNWMXFMEV-UHFFFAOYSA-N,latrepirdine,Phase 3,glutamate receptor antagonist,HRH1|HTR6,,
CC1=CC(=O)OC2CC(CCC(C)C=CCC1)OC(O)(C1CSC(=O)N1)C2,"InChI=1S/C20H29NO5S/c1-13-5-3-4-6-14(2)9-18(22)25-16-10-15(8-7-13)26-20(24,11-16)17-12-27-19(23)21-17/h3,5,9,13,15-17,24H,4,6-8,10-12H2,1-2H3,(H,21,23)",NSHPHXHGRHSMIK-UHFFFAOYSA-N,latrunculin-b,Phase 1,actin polymerization inhibitor,ACTA1|MKL1|SPIRE2,,
CCCCCCCCCCCC(=O)O,"InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)",POULHZVOKOAJMA-UHFFFAOYSA-N,lauric-acid,Phase 3,bacterial permeability inducer,GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4,,
CCCCCCCCCCCC(=O)N(CCO)CCO,"InChI=1S/C16H33NO3/c1-2-3-4-5-6-7-8-9-10-11-16(20)17(12-14-18)13-15-19/h18-19H,2-15H2,1H3",AOMUHOFOVNGZAN-UHFFFAOYSA-N,lauric-diethanolamide,Preclinical,,,,
CCCCCCCCCCCCN1CCCCCC1=O,"InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-13-16-19-17-14-11-12-15-18(19)20/h2-17H2,1H3",AXTGDCSMTYGJND-UHFFFAOYSA-N,laurocapram,Phase 3,,,,
NCCNC(=O)c1ccc(Cl)cn1,"InChI=1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)",JZXRLKWWVNUZRB-UHFFFAOYSA-N,lazabemide,Phase 3,monoamine oxidase inhibitor,MAOB,,
C=CC(=O)Nc1cc(N=c2nc(-n3cc(CN(C)C)c(-c4ccccc4)n3)cc[nH]2)c(OC)cc1N1CCOCC1,"InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)",RRMJMHOQSALEJJ-UHFFFAOYSA-N,lazertinib,Phase 1/Phase 2,tyrosine kinase inhibitor,,,
CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)O)CC1,"InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)",JUQMLSGOTNKJKI-UHFFFAOYSA-N,lb-100,Phase 2,protein phosphatase inhibitor,,,
O=C(c1cn(Cc2cncn2Cc2ccc(Br)cc2)cc1-c1cccc2ccccc12)N1CCOCC1,"InChI=1S/C30H27BrN4O2/c31-24-10-8-22(9-11-24)17-35-21-32-16-25(35)18-33-19-28(27-7-3-5-23-4-1-2-6-26(23)27)29(20-33)30(36)34-12-14-37-15-13-34/h1-11,16,19-21H,12-15,17-18H2",GUUIRIMAQGOLHT-UHFFFAOYSA-N,lb42708,Preclinical,farnesyltransferase inhibitor,,,
CNC(C)C(=O)NC(C(=O)N1CCCC1c1nc(C(=O)c2ccc(F)cc2)cs1)C1CCCCC1,"InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)",UFPFGVNKHCLJJO-UHFFFAOYSA-N,lcl-161,Phase 2,XIAP inhibitor,BIRC2|XIAP,,
O=C(O)CC1CCC(c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1,"InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)",GXALXAKNHIROPE-UHFFFAOYSA-N,lcq908,Phase 3,diacylglycerol O acyltransferase inhibitor,DGAT1,,
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)C(C(=O)O)C(C)C,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)",ACWBQPMHZXGDFX-UHFFFAOYSA-N,lcz696,Launched,angiotensin receptor antagonist,,cardiology,angioedema|hypotension
CCOc1cn(-c2ccc(F)cc2C)nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1,"InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)",ISPBCAXOSOLFME-UHFFFAOYSA-N,ldc1267,Preclinical,protein tyrosine kinase inhibitor,AXL|MERTK|TYRO3,,
COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1,"InChI=1S/C17H17ClN2OS/c1-21-12-4-6-16-14(10-12)17(22-8-2-7-19)13-9-11(18)3-5-15(13)20-16/h3-6,9-10H,2,7-8,19H2,1H3",XMMAOXMYUGQGJD-UHFFFAOYSA-N,ldn-209929,Preclinical,haspin kinase inhibitor,GSG2,,
c1cc(-c2cnn3cc(-c4ccc(N5CCNCC5)cc4)cnc23)c2cccnc2c1,"InChI=1S/C25H22N6/c1-3-21(22-4-2-10-27-24(22)5-1)23-16-29-31-17-19(15-28-25(23)31)18-6-8-20(9-7-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2",BBDGBGOVJPEFBT-UHFFFAOYSA-N,ldn-212854,Preclinical,bone morphogenic protein inhibitor,ABL1|ACVR1|RIPK2,,
NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1,"InChI=1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25)",WLBUICQBNZXIDJ-UHFFFAOYSA-N,ldn-27219,Preclinical,tissue transglutaminase inhibitor,TGM2,,
CC(=O)ON=C1C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc21,"InChI=1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3",OPQRFPHLZZPCCH-UHFFFAOYSA-N,ldn-57444,Preclinical,ubiquitin C-terminal hydrolase inhibitor,,,
c1ccc2c(-c3cnn4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1,"InChI=1S/C25H22N6/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2",CDOVNWNANFFLFJ-UHFFFAOYSA-N,ldn193189,Preclinical,bone morphogenic protein inhibitor,ACVR1|BMPR1A,,
CN1c2cc3c(cc2N=C(c2ccc(C(=O)O)cc2)c2ccccc21)C(C)(C)CCC3(C)C,"InChI=1S/C29H30N2O2/c1-28(2)14-15-29(3,4)22-17-25-23(16-21(22)28)30-26(18-10-12-19(13-11-18)27(32)33)20-8-6-7-9-24(20)31(25)5/h6-13,16-17H,14-15H2,1-5H3,(H,32,33)",YZZAIQOVMHVWBS-UHFFFAOYSA-N,le-135,Preclinical,retinoid receptor agonist,RARB,,
COC(=O)NC(C(=O)N1CC2(CC2)CC1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c(C6C7CCC(C7)N6C(=O)C(NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,"InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)",VRTWBAAJJOHBQU-UHFFFAOYSA-N,ledipasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",VHOGYURTWQBHIL-UHFFFAOYSA-N,leflunomide,Launched,dihydroorotate dehydrogenase inhibitor,AHR|DHODH|PTK2B,rheumatology,rheumatoid arthritis
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",VHOGYURTWQBHIL-UHFFFAOYSA-N,leflunomide,Launched,PDGFR tyrosine kinase receptor inhibitor,AHR|DHODH|PTK2B,rheumatology,rheumatoid arthritis
Cc1ncc(OCC2(c3cccc(F)c3)CC2C(=O)N=c2ccc(F)c[nH]2)c(C)n1,"InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)",MUGXRYIUWFITCP-UHFFFAOYSA-N,lemborexant,Launched,orexin receptor antagonist,HCRTR1|HCRTR2,,
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,lenalidomide,Launched,anticancer agent,TNF,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS)
CCC(=O)N1CCC(N=c2[nH]cnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,"InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)",MWKYMZXCGYXLPL-UHFFFAOYSA-N,leniolisib,Phase 2/Phase 3,PI3K inhibitor,,,
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,Launched,FGFR inhibitor,FLT4|KDR,oncology,thyroid cancer
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,Launched,KIT inhibitor,FLT4|KDR,oncology,thyroid cancer
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,Launched,PDGFR tyrosine kinase receptor inhibitor,FLT4|KDR,oncology,thyroid cancer
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,lenvatinib,Launched,VEGFR inhibitor,FLT4|KDR,oncology,thyroid cancer
COc1cc(C(=O)OCCCCN=C(N)N)cc(OC)c1O,"InChI=1S/C14H21N3O5/c1-20-10-7-9(8-11(21-2)12(10)18)13(19)22-6-4-3-5-17-14(15)16/h7-8,18H,3-6H2,1-2H3,(H4,15,16,17)",WNGSUWLDMZFYNZ-UHFFFAOYSA-N,leonurine,Preclinical,anti-inflammatory agent,,,
Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)C(C)C2)c1C,"InChI=1S/C25H32N6O/c1-17-16-30(11-12-31(17)23-15-26-22(14-27-23)25(4,5)32)24-19(3)18(2)21(28-29-24)13-20-9-7-6-8-10-20/h6-10,14-15,17,32H,11-13,16H2,1-5H3",POERAARDVFVDLO-UHFFFAOYSA-N,leq506,Phase 1,G protein signaling inhibitor,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,32-33H,20-21,23H2,1-6H3",PHOGQKDIVUJGMJ-UHFFFAOYSA-N,lercanidipine,Launched,calcium channel blocker,CACNA2D1,cardiology,hypertension
c1ccc(Cn2c(N3CCNCC3)nc3ccccc32)cc1,"InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2",PWWDCRQZITYKDV-UHFFFAOYSA-N,lerisetron,Phase 3,serotonin receptor antagonist,HTR3A,,
CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1,"InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3",MCPUZZJBAHRIPO-UHFFFAOYSA-N,lersivirine,Phase 2,non-nucleoside reverse transcriptase inhibitor,,,
O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,"InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)",FGQFOYHRJSUHMR-UHFFFAOYSA-N,lesinurad,Launched,uric acid diuretic,SLC22A12,rheumatology,gout
CC12OC(CC1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)",UIARLYUEJFELEN-UHFFFAOYSA-N,lestaurtinib,Phase 3,FLT3 inhibitor,FLT3|NTRK1,,
CC12OC(CC1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)",UIARLYUEJFELEN-UHFFFAOYSA-N,lestaurtinib,Phase 3,growth factor receptor inhibitor,FLT3|NTRK1,,
CC12OC(CC1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)",UIARLYUEJFELEN-UHFFFAOYSA-N,lestaurtinib,Phase 3,JAK inhibitor,FLT3|NTRK1,,
O=C(CCn1cnc2c(=O)[nH]cnc21)Nc1ccc(C(=O)O)cc1,"InChI=1S/C15H13N5O4/c21-11(19-10-3-1-9(2-4-10)15(23)24)5-6-20-8-18-12-13(20)16-7-17-14(12)22/h1-4,7-8H,5-6H2,(H,19,21)(H,23,24)(H,16,17,22)",JMPOIZCOJJMTHI-UHFFFAOYSA-N,leteprinim,Phase 2,nerve growth factor agonist,,,
COc1cccc(N2CCN(C3=Nc4c(F)cccc4C(CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,"InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)",FWYSMLBETOMXAG-UHFFFAOYSA-N,letermovir,Launched,CMV terminase inhibitor,,infectious disease,cytomegalovirus (CMV)
CCOC(=O)CSCCC1NC(C(=O)O)CS1,"InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14)",IKOCLISPVJZJEA-UHFFFAOYSA-N,letosteine,Launched,mucolytic agent,,pulmonary|infectious disease,bronchitis|pneumonia
N#CC(c1ccc(F)cc1)c1c(Cl)cc(-n2ncc(=O)[nH]c2=O)cc1Cl,"InChI=1S/C17H9Cl2FN4O2/c18-13-5-11(24-17(26)23-15(25)8-22-24)6-14(19)16(13)12(7-21)9-1-3-10(20)4-2-9/h1-6,8,12H,(H,23,25,26)",XQKYUBTUOHHNDV-UHFFFAOYSA-N,letrazuril,Phase 1,antiinfective drug,,,
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,"InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H",HPJKCIUCZWXJDR-UHFFFAOYSA-N,letrozole,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer
CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2,"InChI=1S/C16H19N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10,17H,1-4H3",QTWZICCBKBYHDM-UHFFFAOYSA-N,leucomethylene-blue,Phase 3,nitric oxide production inhibitor,MAPT,,
CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2,"InChI=1S/C16H19N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10,17H,1-4H3",QTWZICCBKBYHDM-UHFFFAOYSA-N,leucomethylene-blue,Phase 3,tau aggregation inhibitor,MAPT,,
N=c1[nH]c2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1)CN2,"InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)",VVIAGPKUTFNRDU-UHFFFAOYSA-N,leucovorin,Launched,folate receptor ligand,,oncology,osteosarcoma
COC(=O)C(CC(C)C)NC(=O)C(N)CC(C)C,"InChI=1S/C13H26N2O3/c1-8(2)6-10(14)12(16)15-11(7-9(3)4)13(17)18-5/h8-11H,6-7,14H2,1-5H3,(H,15,16)",AJMOLNFDYWTVQW-UHFFFAOYSA-N,leucylleucine-methyl-ester,Phase 2,,,,
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,"InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)",GFIJNRVAKGFPGQ-UHFFFAOYSA-N,leuprolide,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3",NDAUXUAQIAJITI-UHFFFAOYSA-N,levalbuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm
C=CCN1CCC23CCCCC2C1Cc1ccc(O)cc13,"InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2",OZYUPQUCAUTOBP-UHFFFAOYSA-N,levallorphan,Launched,opioid receptor antagonist,CHRNA2|OPRM1,pulmonary,respiratory depression
c1ccc(C2CN3CCSC3=N2)cc1,"InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2",HLFSDGLLUJUHTE-UHFFFAOYSA-N,levamisole,Withdrawn,acetylcholine receptor agonist,ALPL,,
CCOC(=O)C1=C(COCCN)N=C(C)C(C(=O)OC)C1c1ccccc1Cl,"InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,16-17H,4,9-11,22H2,1-3H3",YMDXSGBNCBQYGC-UHFFFAOYSA-N,levamlodipine,Launched,calcium channel blocker,,cardiology,hypertension
CC1(C)Oc2ccc(C#N)cc2C(N2CCCC2=O)C1O,"InChI=1S/C16H18N2O3/c1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h5-6,8,14-15,20H,3-4,7H2,1-2H3",TVZCRIROJQEVOT-UHFFFAOYSA-N,levcromakalim,Phase 3,potassium channel activator,KCNJ5,,
CCC(C(N)=O)N1CCCC1=O,"InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)",HPHUVLMMVZITSG-UHFFFAOYSA-N,levetiracetam,Launched,calcium channel blocker,CACNA1B|SCN1A|SV2A,neurology/psychiatry,seizures
CN1CC2CCCC(C1)C2OC(=O)C(O)(c1ccccc1)C1CCCC1,"InChI=1S/C22H31NO3/c1-23-14-16-8-7-9-17(15-23)20(16)26-21(24)22(25,19-12-5-6-13-19)18-10-3-2-4-11-18/h2-4,10-11,16-17,19-20,25H,5-9,12-15H2,1H3",ROZOEEGFKDFEFP-UHFFFAOYSA-N,levo-phencynonate,Launched,acetylcholine receptor antagonist,CHRM1,,
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,"InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3",NWIUTZDMDHAVTP-UHFFFAOYSA-N,levobetaxolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma
CC(C)(C)NCC(O)COc1cccc2c1CCCC2=O,"InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3",IXHBTMCLRNMKHZ-UHFFFAOYSA-N,levobunolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,glaucoma|ocular hypertension
CC(C)(C)NCC(O)COc1cccc2c1CCCC2=O,"InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3",IXHBTMCLRNMKHZ-UHFFFAOYSA-N,levobunolol-(+),Preclinical,adrenergic receptor antagonist,,,
CC(C)(C)NCC(O)COc1cccc2c1CCCC2=O,"InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3",IXHBTMCLRNMKHZ-UHFFFAOYSA-N,levobunolol-(+/-),Preclinical,adrenergic receptor antagonist,,,
CC1CN(C2CCC(C#N)(c3ccc(F)cc3)CC2)CCC1(C(=O)O)c1ccccc1,"InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)",ZCGOMHNNNFPNMX-UHFFFAOYSA-N,levocabastine,Launched,histamine receptor antagonist,HRH1|NTSR2,ophthalmology,conjunctivitis
C[N+](C)(C)CC(O)CC(=O)O,"InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/p+1",PHIQHXFUZVPYII-UHFFFAOYSA-O,levocarnitine,Launched,,CRAT|CROT,endocrinology,carnitine deficiency
CCC(=O)OC(CC(=O)O)C[N+](C)(C)C,"InChI=1S/C10H19NO4/c1-5-10(14)15-8(6-9(12)13)7-11(2,3)4/h8H,5-7H2,1-4H3/p+1",UFAHZIUFPNSHSL-UHFFFAOYSA-O,levocarnitine-propionate,Launched,carnitine palmitoyltransferase inhibitor,CRAT,neurology/psychiatry|endocrinology,peripheral neuropathy|carnitine deficiency
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)",ZKLPARSLTMPFCP-UHFFFAOYSA-N,levocetirizine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
NC(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)",WTDRDQBEARUVNC-UHFFFAOYSA-N,levodopa,Launched,dopamine precursor,DRD1|DRD2|DRD3|DRD4|DRD5|GPR143,neurology/psychiatry,Parkinson's Disease
OCC(O)CN1CCN(c2ccccc2)CC1,"InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2",PTVWPYVOOKLBCG-UHFFFAOYSA-N,levodropropizine,Launched,antitussive,,pulmonary,cough suppressant
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,"InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)",GSDSWSVVBLHKDQ-UHFFFAOYSA-N,levofloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|otolaryngology|pulmonary|urology,pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague
CC(C)=CCCC(C)(O)C1CC=C(C)CC1,"InChI=1S/C15H26O/c1-12(2)6-5-11-15(4,16)14-9-7-13(3)8-10-14/h6-7,14,16H,5,8-11H2,1-4H3",RGZSQWQPBWRIAQ-UHFFFAOYSA-N,levomenol,Launched,,,neurology/psychiatry|infectious disease,spasms|skin infections
CC1CCC(C(C)C)C(O)C1,"InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3",NOOLISFMXDJSKH-UHFFFAOYSA-N,levomenthol,Launched,,OPRK1|TRPA1|TRPM8|TRPV3,neurology/psychiatry,pain relief
COc1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2,"InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3",VRQVVMDWGGWHTJ-UHFFFAOYSA-N,levomepromazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C,neurology/psychiatry|gastroenterology,psychosis|schizophrenia|bipolar disorder|nausea|insomnia
c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,"InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2",HOKDBMAJZXIPGC-UHFFFAOYSA-N,levomequitazine,Phase 2,histamine receptor antagonist,HRH1,,
CC(N)C(O)c1ccc(O)c(O)c1,"InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3",GEFQWZLICWMTKF-UHFFFAOYSA-N,levonordefrin,Launched,vasodilator,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2,hematology,hemorrhage
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,16-19,23H,3,6-13H2,1H3",LYRBZVWRTAFWPO-UHFFFAOYSA-N,levonorgestrel,Launched,estrogen receptor agonist,PGR,endocrinology,contraceptive
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,16-19,23H,3,6-13H2,1H3",LYRBZVWRTAFWPO-UHFFFAOYSA-N,levonorgestrel,Launched,glucocorticoid receptor antagonist,PGR,endocrinology,contraceptive
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,16-19,23H,3,6-13H2,1H3",LYRBZVWRTAFWPO-UHFFFAOYSA-N,levonorgestrel,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,16-19,23H,3,6-13H2,1H3",LYRBZVWRTAFWPO-UHFFFAOYSA-N,levonorgestrel,Launched,progesterone receptor antagonist,PGR,endocrinology,contraceptive
CCC(=O)OC(Cc1ccccc1)(c1ccccc1)C(C)CN(C)C,"InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3",XLMALTXPSGQGBX-UHFFFAOYSA-N,levopropoxyphene,Launched,antitussive,,pulmonary,cough suppressant
CC1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,"InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)",WHXMKTBCFHIYNQ-UHFFFAOYSA-N,levosimendan,Launched,calcium sensitizer,KCNJ11|KCNJ8|PDE3A|TNNC1,cardiology,congestive heart failure
CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,"InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)",BGRJTUBHPOOWDU-UHFFFAOYSA-N,levosulpiride,Launched,dopamine receptor antagonist,CA1|CA12|CA7|DRD2|DRD3,neurology/psychiatry|gastroenterology|urology,schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)
NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,"InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)",XUIIKFGFIJCVMT-UHFFFAOYSA-N,levothyroxine,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,myxedema coma
CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,"InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,8H,1H3,(H,15,17)",BQLDGDMKDYAGNE-UHFFFAOYSA-N,lfm-a13,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1cc(C)c(-c2ccc(NC(=O)C(Cc3ccc(C(=O)NCCS(=O)(=O)O)cc3)c3ccc(-c4ccc(C(C)(C)C)cc4)cc3)cc2)c(C)c1,"InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)",HKJMCBYPVCGZFB-UHFFFAOYSA-N,lgd-6972,Phase 2,glucagon receptor antagonist,,,
Cc1cc(-c2ncc(CC(=O)N=c3ccc(-c4cnccn4)c[nH]3)cc2C)ccn1,"InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)",XXYGTCZJJLTAGH-UHFFFAOYSA-N,lgk-974,Phase 2,porcupine inhibitor,PORCN,,
Cc1cc2sc(=NC(=O)Cc3ccccc3)[nH]c2cc1Cl,"InChI=1S/C16H13ClN2OS/c1-10-7-14-13(9-12(10)17)18-16(21-14)19-15(20)8-11-5-3-2-4-6-11/h2-7,9H,8H2,1H3,(H,18,19,20)",DYHAMRNAHTWYKY-UHFFFAOYSA-N,lh846,Preclinical,casein kinase inhibitor,CSNK1D,,
Clc1cccc(C(c2ccc3[nH]cnc3c2)n2ccnc2)c1,"InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)",UGFHIPBXIWJXNA-UHFFFAOYSA-N,liarozole,Phase 2/Phase 3,cytochrome P450 inhibitor,CYP19A1|CYP26A1,,
NC(=O)N1c2ccccc2CC(O)c2ccccc21,"InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)",BMPDWHIDQYTSHX-UHFFFAOYSA-N,licarbazepine,Phase 3,voltage-gated sodium channel blocker,SCN5A,,
C=CC(C)(C)c1cc(C=CC(=O)c2ccc(O)cc2)c(OC)cc1O,"InChI=1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3",KAZSKMJFUPEHHW-UHFFFAOYSA-N,licochalcone-a,Phase 3,topoisomerase inhibitor,PTPN1,,
CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,"InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)",UAWXGRJVZSAUSZ-UHFFFAOYSA-N,licofelone,Phase 3,cyclooxygenase inhibitor,ALOX5|PLA2G2E|PTGS2,,
CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,"InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)",UAWXGRJVZSAUSZ-UHFFFAOYSA-N,licofelone,Phase 3,lipoxygenase inhibitor,ALOX5|PLA2G2E|PTGS2,,
CCc1ccc(C2OC(CO)C(O)C(O)C2O)cc1Cc1ccc2c(c1)OCCO2,"InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3",XFJAMQQAAMJFGB-UHFFFAOYSA-N,licogliflozin,Preclinical,sodium/glucose cotransporter inhibitor,,,
O=c1[nH]c2cc(Cl)c(Cl)c([N+](=O)[O-])c2[nH]c1=O,"InChI=1S/C8H3Cl2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15)",CHFSOFHQIZKQCR-UHFFFAOYSA-N,licostinel,Phase 1,NMDA receptor antagonist ,,,
CN=C(N)NC(=O)Nc1c(C)cccc1C,"InChI=1S/C11H16N4O/c1-7-5-4-6-8(2)9(7)14-11(16)15-10(12)13-3/h4-6H,1-3H3,(H4,12,13,14,15,16)",RRHJHSBDJDZUGL-UHFFFAOYSA-N,lidamidine,Launched,adrenergic receptor agonist,,gastroenterology,diarrhea
CCN(CC)CC(=O)Nc1c(C)cccc1C,"InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)",NNJVILVZKWQKPM-UHFFFAOYSA-N,lidocaine,Launched,histamine receptor agonist,EGFR|SCN10A|SCN5A|SCN9A,neurology/psychiatry|dermatology|hematology,itching|eczema|hemorrhage
Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)",ZBIAKUMOEKILTF-UHFFFAOYSA-N,lidoflazine,Launched,calcium channel blocker,SCN1A|SCN3A|SLC29A1,cardiology,coronary artery disease (CAD)
O=C1CCc2c(Oc3ccc4c(c3)C3C(O4)C3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1,"InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)",NGFFVZQXSRKHBM-UHFFFAOYSA-N,lifirafenib,Phase 1/Phase 2,RAF inhibitor,,,
CS(=O)(=O)c1cccc(CC(NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,"InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)",JFOZKMSJYSPYLN-UHFFFAOYSA-N,lifitegrast,Launched,lymphocyte function-associated antigen negative modulator,,ophthalmology,dry eye syndrome
CCC=Cc1oc(O)c2c1CCC=C2,"InChI=1S/C12H14O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h3,5,7-8,13H,2,4,6H2,1H3",KRSPMDOGSDBDBB-UHFFFAOYSA-N,ligustilide,Preclinical,tumor necrosis factor production inhibitor,TNF,,
CCCCC(C)CC(O)C=CC1C(O)CC(=O)C1CCCC=CCC(=O)O,"InChI=1S/C22H36O5/c1-3-4-9-16(2)14-17(23)12-13-19-18(20(24)15-21(19)25)10-7-5-6-8-11-22(26)27/h6,8,12-13,16-19,21,23,25H,3-5,7,9-11,14-15H2,1-2H3,(H,26,27)",SLFOYSYSXOAEES-UHFFFAOYSA-N,limaprost-alfadex,Launched,prostanoid receptor agonist,PTGER1,cardiology,claudication
CC(C)C(=O)N=c1[nH]cc(-c2cc(C(F)F)nn2-c2c(Cl)cccc2Cl)s1,"InChI=1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)",IVUGBSGLHRJSSP-UHFFFAOYSA-N,limki-3,Preclinical,LIM kinase inhibitor,LIMK1,,
CC1(C)OC2CC(=O)OCC23C1CC(=O)C1(C)C3CCC2(C)C(c3ccoc3)OC(=O)C3OC321,"InChI=1S/C26H30O8/c1-22(2)15-9-16(27)24(4)14(25(15)12-31-18(28)10-17(25)33-22)5-7-23(3)19(13-6-8-30-11-13)32-21(29)20-26(23,24)34-20/h6,8,11,14-15,17,19-20H,5,7,9-10,12H2,1-4H3",KBDSLGBFQAGHBE-UHFFFAOYSA-N,limonin,Preclinical,HIV protease inhibitor,,,
CC1NC(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C2CSSCC(N)C(=O)NC3CSSCC(NC1=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)O)CSSCC(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CCC(=O)O)NC3=O)C(=O)N2,"InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)",KXGCNMMJRFDFNR-UHFFFAOYSA-N,linaclotide,Launched,guanylate cyclase activator,GUCY2C,gastroenterology,irritable bowel syndrome|constipation
CC#CCn1c(N2CCCC(N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3",LTXREWYXXSTFRX-UHFFFAOYSA-N,linagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
C=CC(C)(O)CCC=C(C)C,"InChI=1S/C10H18O/c1-5-10(4,11)8-6-7-9(2)3/h5,7,11H,1,6,8H2,2-4H3",CDOSHBSSFJOMGT-UHFFFAOYSA-N,linalool,Phase 1,anticonvulsant,,,
Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,"InChI=1S/C21H26N4O2/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27)",GHVIMBCFLRTFHI-UHFFFAOYSA-N,linaprazan,Preclinical,ATP-sensitive potassium channel inhibitor,,,
CCCC1CC(C(=O)NC(C(C)O)C2OC(SC)C(O)C(O)C2O)N(C)C1,"InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)",OJMMVQQUTAEWLP-UHFFFAOYSA-N,lincomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,gastroenterology,enteritis
ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl,InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H,JLYXXMFPNIAWKQ-UHFFFAOYSA-N,lindane,Launched,,GABRB1|GLRA1|GLRA2|GLRA3|GLRB,infectious disease,scabies
CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,"InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)",TYZROVQLWOKYKF-UHFFFAOYSA-N,linezolid,Launched,bacterial 50S ribosomal subunit inhibitor,MAOA|MAOB,infectious disease,pneumonia|skin infections
Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH][nH]c(=N)c34)cc2)c1,"InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)",MPVGZUGXCQEXTM-UHFFFAOYSA-N,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK,,
Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH][nH]c(=N)c34)cc2)c1,"InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)",MPVGZUGXCQEXTM-UHFFFAOYSA-N,linifanib,Phase 3,VEGFR inhibitor,CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK,,
CCCCCC=CCC=CCCCCCCCC(=O)O,"InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)",OYHQOLUKZRVURQ-UHFFFAOYSA-N,linoleic-acid,Phase 3,oxidative stress inducer,FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8,,
O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,"InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2",YEJCDKJIEMIWRQ-UHFFFAOYSA-N,linopirdine,Phase 3,potassium channel blocker,KCNQ2|KCNQ3|KCNQ4|KCNQ5,,
N=c1c[n+](N2CCOCC2)[nH]o1,"InChI=1S/C6H11N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7-8H,1-4H2/q+1",NTBJYBVMMBXFRP-UHFFFAOYSA-N,linsidomine,Launched,nitric oxide donor,,urology,erectile dysfunction
CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(=N)[nH]ccn23)C1,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)",PKCDDUHJAFVJJB-UHFFFAOYSA-N,linsitinib,Phase 3,IGF-1 inhibitor,IGF1R|INSR|INSRR,,
CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C14H19ClN4O2/c1-3-19-5-4-17-13(19)8-18-14(20)9-6-10(15)11(16)7-12(9)21-2/h6-7H,3-5,8,16H2,1-2H3,(H,18,20)",MJCKISCWHDATBN-UHFFFAOYSA-N,lintopride,Preclinical,serotonin receptor antagonist,,,
NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,"InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)",AUYYCJSJGJYCDS-UHFFFAOYSA-N,liothyronine,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,hypothyroidism|myxedema coma
NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,"InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)",AUYYCJSJGJYCDS-UHFFFAOYSA-N,liothyronine-(isomer),Preclinical,,,,
NC(=O)CCCCC1CCSS1,"InChI=1S/C8H15NOS2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H2,9,10)",FCCDDURTIIUXBY-UHFFFAOYSA-N,lipoamide,Preclinical,,,,
O=C1CC(c2ccc(OC3OC(CO)C(O)C(O)C3O)cc2)Oc2cc(O)ccc21,"InChI=1S/C21H22O9/c22-9-17-18(25)19(26)20(27)21(30-17)28-12-4-1-10(2-5-12)15-8-14(24)13-6-3-11(23)7-16(13)29-15/h1-7,15,17-23,25-27H,8-9H2",DEMKZLAVQYISIA-UHFFFAOYSA-N,liquiritin,Preclinical,antioxidant,,,
CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1c[nH]cn1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O,"InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)",YSDQQAXHVYUZIW-UHFFFAOYSA-N,liraglutide,Launched,GLP receptor agonist,GLP1R,endocrinology,weight-loss aid|diabetes mellitus
COc1cccc(N(C)C(=S)Oc2ccc3c(c2)CCCC3)n1,"InChI=1S/C18H20N2O2S/c1-20(16-8-5-9-17(19-16)21-2)18(23)22-15-11-10-13-6-3-4-7-14(13)12-15/h5,8-12H,3-4,6-7H2,1-2H3",VPHPQNGOVQYUMG-UHFFFAOYSA-N,liranaftate,Launched,fungal squalene epoxidase inhibitor,,infectious disease,fungal infection
CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(C(=O)c3ccc(Cl)cc3Cl)oc2c1,"InChI=1S/C17H12Cl2N2O6S/c1-28(24,25)27-9-3-5-11-13(7-9)26-16(14(11)21-17(20)23)15(22)10-4-2-8(18)6-12(10)19/h2-7H,1H3,(H3,20,21,23)",YPFLFUJKZDAXRA-UHFFFAOYSA-N,lirimilast,Phase 2,phosphodiesterase inhibitor,,,
Nc1ccc(C(=O)OCC(O)CO)cc1,"InChI=1S/C10H13NO4/c11-8-3-1-7(2-4-8)10(14)15-6-9(13)5-12/h1-4,9,12-13H,5-6,11H2",WHQOKFZWSDOTQP-UHFFFAOYSA-N,lisadimate,Launched,topical sunscreen agent,,dermatology,sunscreen lotion
NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O,"InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)",RLAWWYSOJDYHDC-UHFFFAOYSA-N,lisinopril,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology|endocrinology,hypertension|congestive heart failure|diabetes mellitus
CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,"InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3",NSMXQKNUPPXBRG-UHFFFAOYSA-N,lisofylline,Phase 2,interleukin receptor antagonist,,,
CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,"InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3",NSMXQKNUPPXBRG-UHFFFAOYSA-N,lisofylline,Phase 2,STAT inhibitor,,,
CCN(CC)C(=O)NC1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)",BKRGVLQUQGGVSM-UHFFFAOYSA-N,lisuride,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6,neurology/psychiatry,Parkinson's Disease
CC(=O)CC(=O)O,"InChI=1S/C4H6O3/c1-3(5)2-4(6)7/h2H2,1H3,(H,6,7)",WDJHALXBUFZDSR-UHFFFAOYSA-N,lithium-acetoacetate,Preclinical,,FAH,,
O=C(O)CC(O)(CC(=O)O)C(=O)O,"InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",KRKNYBCHXYNGOX-UHFFFAOYSA-N,lithium-citrate,Launched,,,neurology/psychiatry,bipolar disorder|depression
CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)",SMEROWZSTRWXGI-UHFFFAOYSA-N,lithocholic-acid,Preclinical,FXR antagonist,GPBAR1|NR1H4|NR1I2|VDR,,
CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)",SMEROWZSTRWXGI-UHFFFAOYSA-N,lithocholic-acid,Preclinical,vitamin D receptor agonist,GPBAR1|NR1H4|NR1I2|VDR,,
CCNCCS(=O)(=O)NCC1(c2ccccc2)SC(=NC(=O)C(C)(C)C)NN1C(=O)C(C)(C)C,"InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)",YVAFBXLHPINSIK-UHFFFAOYSA-N,litronesib,Phase 2,kinesin-like spindle protein inhibitor,KIF11,,
Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1,"InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)",PPHTXRNHTVLQED-UHFFFAOYSA-N,lixivaptan,Phase 3,vasopressin receptor antagonist,AVPR2,,
O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1,"InChI=1S/C15H21N3O6/c19-4-1-16-13(22)10-7-11(14(23)17-2-5-20)9-12(8-10)15(24)18-3-6-21/h7-9,19-21H,1-6H2,(H,16,22)(H,17,23)(H,18,24)",RGWJKANXFYJKHN-UHFFFAOYSA-N,lm-22a4,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,
CCC(C)C(N)C(=O)NCCN1CCOCC1,"InChI=1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)",YNMUTYLWSRFTPX-UHFFFAOYSA-N,lm11a-31,Phase 1,neurotrophic agent,NGFR,,
CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1,"InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)",STWTUEAWRAIWJG-UHFFFAOYSA-N,lmi070,Phase 1/Phase 2,survival motor neuron protein modulator,SMN1,,
Cc1cc(C)cc(C(=O)NOCCCCCC(O)=NO)c1,"InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)",VRYZCEONIWEUAV-UHFFFAOYSA-N,lmk-235,Preclinical,HDAC inhibitor,HDAC4|HDAC5,,
CN1C(CC(=O)c2ccccc2)CCCC1CC(O)c1ccccc1,"InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3",MXYUKLILVYORSK-UHFFFAOYSA-N,lobeline,Launched,acetylcholine receptor antagonist,CHRNA10|CHRNA9|SLC18A2,neurology/psychiatry,smoking cessation
CCOC(=O)N=c1[nH]c2ccccc2[nH]1,"InChI=1S/C10H11N3O2/c1-2-15-10(14)13-9-11-7-5-3-4-6-8(7)12-9/h3-6H,2H2,1H3,(H2,11,12,13,14)",OKOVSTKGUBOSTB-UHFFFAOYSA-N,lobendazole,Preclinical,anthelmintic agent,,,
O=C(O)c1ccccc1Nc1cc(Cl)ccc1C(=O)O,"InChI=1S/C14H10ClNO4/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18/h1-7,16H,(H,17,18)(H,19,20)",UGDPYGKWIHHBMB-UHFFFAOYSA-N,lobenzarit,Launched,immunosuppressant,,rheumatology,rheumatoid arthritis
N=c1[nH]cnc2c1ncn2C1OC(CO)CC1F,"InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)",KBEMFSMODRNJHE-UHFFFAOYSA-N,lodenosine,Phase 2,antiretroviral ,,,
N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1,"InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)",RVGLGHVJXCETIO-UHFFFAOYSA-N,lodoxamide,Launched,histamine receptor antagonist,,ophthalmology,vernal keratoconjunctivitis (VKC)
Cc1[nH]cnc1-c1ccc(Cl)cc1,"InChI=1S/C10H9ClN2/c1-7-10(13-6-12-7)8-2-4-9(11)5-3-8/h2-6H,1H3,(H,12,13)",MBKWNJVQSFBLQI-UHFFFAOYSA-N,lofemizole,Phase 3,cyclooxygenase inhibitor,,,
CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,"InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3",SAPNXPWPAUFAJU-UHFFFAOYSA-N,lofepramine,Launched,norepinephrine reuptake inhibitor,HTR1A|SLC6A2|SLC6A4,neurology/psychiatry,depression
CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,"InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3",SAPNXPWPAUFAJU-UHFFFAOYSA-N,lofepramine,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),HTR1A|SLC6A2|SLC6A4,neurology/psychiatry,depression
CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,"InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)",KSMAGQUYOIHWFS-UHFFFAOYSA-N,lofexidine,Launched,adrenergic receptor agonist,,neurology/psychiatry,opioid withdrawal
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21,"InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)",ZEKZLJVOYLTDKK-UHFFFAOYSA-N,lomefloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,respiratory tract infections|urinary tract infections
N=c1nc(OCc2cc(Br)cs2)c2[nH]cnc2[nH]1,"InChI=1S/C10H8BrN5OS/c11-5-1-6(18-3-5)2-17-9-7-8(14-4-13-7)15-10(12)16-9/h1,3-4H,2H2,(H3,12,13,14,15,16)",JUJPKFNFCWJBCX-UHFFFAOYSA-N,lomeguatrib,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,
COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC,"InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3",JQSAYKKFZOSZGJ-UHFFFAOYSA-N,lomerizine,Launched,calcium channel blocker,CACNA1B|SCN5A,neurology/psychiatry,migraine headache
N=c1[nH]c2c(c(=O)[nH]1)CC(CCc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1)CN2,"InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)",ZUQBAQVRAURMCL-UHFFFAOYSA-N,lometrexol,Phase 2,glycinamide ribonucleotide formyltransferase inhibitor,GART,,
O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1,"InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)",MBBCVAKAJPKAKM-UHFFFAOYSA-N,lomitapide,Launched,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia
O=C(NC1CCCCC1)N(CCCl)NO,"InChI=1S/C9H18ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8,12,15H,1-7H2,(H,11,14)",BRLZAHPFQRALAO-UHFFFAOYSA-N,lomustine,Launched,DNA synthesis inhibitor,,hematologic malignancy|oncology,Hodgkin's lymphoma|brain tumors
NC(=O)N1CCC(CC(=O)N2CCC(C3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)",DHMTURDWPRKSOA-UHFFFAOYSA-N,lonafarnib,Phase 3,farnesyltransferase inhibitor,FNTA|HRAS|KRAS|NRAS,,
O=C(O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,"InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)",WDRYRZXSPDWGEB-UHFFFAOYSA-N,lonidamine,Launched,glucokinase inhibitor,GCK,,
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,"InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3",RDOIQAHITMMDAJ-UHFFFAOYSA-N,loperamide,Launched,opioid receptor agonist,CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC,gastroenterology,diarrhea
Cc1cccc(C)c1OCC(=O)NC(Cc1ccccc1)C(O)CC(Cc1ccccc1)NC(=O)C(C(C)C)N1CCCNC1=O,"InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)",KJHKTHWMRKYKJE-UHFFFAOYSA-N,lopinavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1,"InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)",JAPHQRWPEGVNBT-UHFFFAOYSA-N,loracarbef,Launched,bacterial cell wall synthesis inhibitor,,infectious disease|otolaryngology|pulmonary,ear infections|laryngitis|bronchitis|pneumonia|urinary tract infections|skin infections
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,"InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3",JCCNYMKQOSZNPW-UHFFFAOYSA-N,loratadine,Launched,histamine receptor antagonist,HRH1,allergy|neurology/psychiatry,allergic rhinitis|itching
ClC(=Cn1cncn1)c1ccc(Cl)cc1Cl,InChI=1S/C10H6Cl3N3/c11-7-1-2-8(9(12)3-7)10(13)4-16-6-14-5-15-16/h1-6H,XGLHZTBDUXXHOM-UHFFFAOYSA-N,loreclezole,Phase 2,benzodiazepine receptor agonist,GABRB2|GABRB3,,
CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F,"InChI=1S/C20H15FN4O2S/c1-12(26)24(2)17-10-13(5-6-15(17)21)16-7-8-22-20-14(11-23-25(16)20)19(27)18-4-3-9-28-18/h3-11H,1-2H3",NQPOCLFSADOXBR-UHFFFAOYSA-N,lorediplon,Phase 2,GABA receptor modulator,GABRA1,,
CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,"InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)",IEKOTSCYBBDIJC-UHFFFAOYSA-N,lorglumide,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,
CC1Oc2cc(c[nH]c2=N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)",IIXWYSCJSQVBQM-UHFFFAOYSA-N,lorlatinib,Launched,ALK tyrosine kinase receptor inhibitor,ALK,oncology,non-small cell lung cancer (NSCLC)
CN1C(C(=O)N=c2cccc[nH]2)C(=O)c2sc(Cl)cc2S1(=O)=O,"InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,10H,1H3,(H,15,16,19)",QOFQTBTZCJVITI-UHFFFAOYSA-N,lornoxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|neurology/psychiatry,osteoarthritis|sciata
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)",PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology|nephrology,hypertension|diabetic nephropathy|hypertension
Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,"InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)",KKYABQBFGDZVNQ-UHFFFAOYSA-N,losmapimod,Phase 3,p38 MAPK inhibitor,MAPK14,,
CN=c1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2[nH]1,"InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)",BBTFKAOFCSOZMB-UHFFFAOYSA-N,lotamilast,Preclinical,phosphodiesterase inhibitor,,,
CCOC(=O)OC1(C(=O)OCCl)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h5,7,9,16-19,27H,4,6,8,10-13H2,1-3H3",FBBYEJJQINKJNE-UHFFFAOYSA-N,loteprednol,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis
CCOC(=O)OC1(C(=O)OCCl)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h5,7,9,16-19,27H,4,6,8,10-13H2,1-3H3",FBBYEJJQINKJNE-UHFFFAOYSA-N,loteprednol,Launched,phospholipase inhibitor,NR3C1,ophthalmology,conjunctivitis
CCC(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,"InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3",PCZOHLXUXFIOCF-UHFFFAOYSA-N,lovastatin,Launched,HMGCR inhibitor,HDAC2|HMGCR|ITGAL|NR1I2,cardiology|endocrinology,coronary heart disease|myocardial infarction|hypercholesterolemia
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,"InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",XJGVXQDUIWGIRW-UHFFFAOYSA-N,loxapine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,schizophrenia
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,"InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3",XJGVXQDUIWGIRW-UHFFFAOYSA-N,loxapine,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,schizophrenia
CC(C)CCNC(=O)C(CC(C)C)NC(=O)C1OC1C(=O)O,"InChI=1S/C15H26N2O5/c1-8(2)5-6-16-13(18)10(7-9(3)4)17-14(19)11-12(22-11)15(20)21/h8-12H,5-7H2,1-4H3,(H,16,18)(H,17,19)(H,20,21)",SCMSYZJDIQPSDI-UHFFFAOYSA-N,loxistatin-acid,Preclinical,cysteine peptidase inhibitor,CTSB,,
CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,"InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)",YMBXTVYHTMGZDW-UHFFFAOYSA-N,loxoprofen,Launched,cyclooxygenase inhibitor,PTGS2,neurology/psychiatry,pain relief
CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,"InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)",YMBXTVYHTMGZDW-UHFFFAOYSA-N,loxoprofen,Launched,prostanoid receptor antagonist,PTGS2,neurology/psychiatry,pain relief
N=c1nc(-c2ccc(CC(N)C(=O)O)cc2)cc(OC(c2ccc(-c3cccc(F)c3)cc2)C(F)(F)F)[nH]1,"InChI=1S/C27H22F4N4O3/c28-20-3-1-2-19(13-20)16-8-10-18(11-9-16)24(27(29,30)31)38-23-14-22(34-26(33)35-23)17-6-4-15(5-7-17)12-21(32)25(36)37/h1-11,13-14,21,24H,12,32H2,(H,36,37)(H2,33,34,35)",JZWUKILTKYJLCN-UHFFFAOYSA-N,lp-533401,Preclinical,tryptophan hydroxylase inhibitor,,,
Cc1csc2c(=NC(C)CN3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)[nH]cnc12,"InChI=1S/C20H23Cl2N5O2S2/c1-13-11-30-19-18(13)23-12-24-20(19)25-14(2)10-26-5-7-27(8-6-26)31(28,29)15-3-4-16(21)17(22)9-15/h3-4,9,11-12,14H,5-8,10H2,1-2H3,(H,23,24,25)",BPRNMVDTWIHULJ-UHFFFAOYSA-N,lpa2-antagonist-1,Preclinical,lysophosphatidic acid receptor antagonist,LPAR2,,
COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1nc2c(c[nH]1)N(C)C(=O)c1ccccc1N2C,"InChI=1S/C31H38N8O3/c1-35-15-17-38(18-16-35)22-11-13-39(14-12-22)29(40)21-9-10-24(27(19-21)42-4)33-31-32-20-26-28(34-31)36(2)25-8-6-5-7-23(25)30(41)37(26)3/h5-10,19-20,22H,11-18H2,1-4H3,(H,32,33,34)",IWMCPJZTADUIFX-UHFFFAOYSA-N,lrrk2-in-1,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,
CC(C)NC(=O)c1ccc(C#Cc2ccncc2)cn1,"InChI=1S/C16H15N3O/c1-12(2)19-16(20)15-6-5-14(11-18-15)4-3-13-7-9-17-10-8-13/h5-12H,1-2H3,(H,19,20)",STAFRSGTRKNXHF-UHFFFAOYSA-N,lsn-2463359,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(C=CC(=O)O)cc1,"InChI=1S/C25H17F3O4S/c1-25(27,28)20-12-15(26)5-9-18(20)24-23(19-10-6-16(29)13-21(19)33-24)32-17-7-2-14(3-8-17)4-11-22(30)31/h2-13,29H,1H3,(H,30,31)",SJXNPGGVGZXKKI-UHFFFAOYSA-N,lsz-102,Phase 1,selective estrogen receptor modulator (SERM),,,
N=C(Nc1ccccc1)c1cccs1,"InChI=1S/C11H10N2S/c12-11(10-7-4-8-14-10)13-9-5-2-1-3-6-9/h1-8H,(H2,12,13)",RCORNHOUCUDCAC-UHFFFAOYSA-N,lta,Phase 2,,,,
CCCCCC=CCC(O)C=CC=CC=CC(O)CCCC(=O)O,"InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)",VNYSSYRCGWBHLG-UHFFFAOYSA-N,ltb4,Phase 2,leukocyte activator,LTB4R|LTB4R2,,
NCCCCC(N)C(=O)NC(CCCCN)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(=O)NC(CCCCN)C(N)=O)C(c1ccccc1)c1ccccc1,"InChI=1S/C78H106N18O9/c79-38-18-13-30-57(84)71(98)90-62(35-15-20-40-81)73(100)93-66(44-52-47-87-59-32-11-8-28-55(52)59)76(103)95-65(43-51-46-86-58-31-10-7-27-54(51)58)75(102)92-63(36-16-21-41-82)72(99)91-64(37-17-22-42-83)74(101)94-67(45-53-48-88-60-33-12-9-29-56(53)60)77(104)96-69(78(105)89-61(70(85)97)34-14-19-39-80)68(49-23-3-1-4-24-49)50-25-5-2-6-26-50/h1-12,23-29,31-33,46-48,57,61-69,86-88H,13-22,30,34-45,79-84H2,(H2,85,97)(H,89,105)(H,90,98)(H,91,99)(H,92,102)(H,93,100)(H,94,101)(H,95,103)(H,96,104)",GGAKLYWEFZCVIT-UHFFFAOYSA-N,ltx-315,Phase 2,anticancer agent,,,
CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)N=c2sccn2CO[PH](=O)(=O)O)cc1F,"InChI=1S/C17H19F2N3O6PS/c1-17(2,3)8-13(23)20-14-11(18)6-10(7-12(14)19)15(24)21-16-22(4-5-30-16)9-28-29(25,26)27/h4-7H,8-9H2,1-3H3,(H,20,23)(H,25,26,27)",KEZUEODLXGTAAM-UHFFFAOYSA-N,lu-aa-47070,Phase 2,adenosine receptor antagonist,ADORA2A,,
CCCCC(F)(F)C(=O)CCC1C(O)CC(=O)C1CCCCCCC(=O)O,"InChI=1S/C20H32F2O5/c1-2-3-12-20(21,22)18(25)11-10-15-14(16(23)13-17(15)24)8-6-4-5-7-9-19(26)27/h14-15,17,24H,2-13H2,1H3,(H,26,27)",DBVFKLAGQHYVGQ-UHFFFAOYSA-N,lubiprostone,Launched,chloride channel activator,CLCN2,gastroenterology,constipation|irritable bowel syndrome
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,"InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3",FBQPGGIHOFZRGH-UHFFFAOYSA-N,lucanthone,Phase 2,endonuclease inhibitor,APEX1|TOP1|TOP2A,,
CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)",CUDVHEFYRIWYQD-UHFFFAOYSA-N,lucitanib,Phase 2,FGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,
CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)",CUDVHEFYRIWYQD-UHFFFAOYSA-N,lucitanib,Phase 2,VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,
N#Cc1c(SCc2ncc[nH]2)[nH]c(=N)c(C#N)c1-c1ccc(O)cc1,"InChI=1S/C17H12N6OS/c18-7-12-15(10-1-3-11(24)4-2-10)13(8-19)17(23-16(12)20)25-9-14-21-5-6-22-14/h1-6,24H,9H2,(H2,20,23)(H,21,22)",OFHKDLYFKPBXER-UHFFFAOYSA-N,luf-5834,Preclinical,adenosine receptor agonist,ADORA2A|ADORA2B,,
O=C(NC(=O)c1c(F)cccc1F)Nc1cc(Cl)c(OC(F)(F)C(F)C(F)(F)F)cc1Cl,"InChI=1S/C17H8Cl2F8N2O3/c18-6-5-11(32-17(26,27)14(22)16(23,24)25)7(19)4-10(6)28-15(31)29-13(30)12-8(20)2-1-3-9(12)21/h1-5,14H,(H2,28,29,30,31)",PWPJGUXAGUPAHP-UHFFFAOYSA-N,lufenuron,Launched,chitin inhibitor,,infectious disease,flea control
N#CC(=C1SCC(c2ccc(Cl)cc2Cl)S1)n1ccnc1,"InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2",YTAOBBFIOAEMLL-UHFFFAOYSA-N,luliconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
Cc1ccc(=NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)[nH]c1-c1cccc(C(=O)O)c1,"InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)",UFSKUSARDNFIRC-UHFFFAOYSA-N,lumacaftor,Launched,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis
CN1CCN2c3c(cccc31)C1CN(CCCC(=O)c3ccc(F)cc3)CCC12,"InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3",HOIIHACBCFLJET-UHFFFAOYSA-N,lumateperone,Launched,dopamine receptor modulator,DRD2|HTR2A,,
CN1CCN2c3c(cccc31)C1CN(CCCC(=O)c3ccc(F)cc3)CCC12,"InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3",HOIIHACBCFLJET-UHFFFAOYSA-N,lumateperone,Launched,serotonin receptor antagonist,DRD2|HTR2A,,
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1C2=Cc1ccc(Cl)cc1,"InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3",DYLGFOYVTXJFJP-UHFFFAOYSA-N,lumefantrine,Launched,antimalarial agent,ATP1A1,infectious disease,malaria
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,"InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)",KHPKQFYUPIUARC-UHFFFAOYSA-N,lumiracoxib,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,
O=C1CCCC2C3CC(CN12)C1CCCCN1C3,"InChI=1S/C15H24N2O/c18-15-6-3-5-14-11-8-12(10-17(14)15)13-4-1-2-7-16(13)9-11/h11-14H,1-10H2",JYIJIIVLEOETIQ-UHFFFAOYSA-N,lupanine,Phase 1,sodium channel blocker,INS,,
Oc1c2c(c(O)n1CC1CCCCC1CN1CCN(c3nsc4ccccc34)CC1)C1CCC2C1,"InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,33-34H,1-2,5-6,9-17H2",XNAWUDONOGZGEH-UHFFFAOYSA-N,lurasidone,Launched,dopamine receptor antagonist,ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7,neurology/psychiatry,schizophrenia
Oc1c2c(c(O)n1CC1CCCCC1CN1CCN(c3nsc4ccccc34)CC1)C1CCC2C1,"InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,33-34H,1-2,5-6,9-17H2",XNAWUDONOGZGEH-UHFFFAOYSA-N,lurasidone,Launched,serotonin receptor antagonist,ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7,neurology/psychiatry,schizophrenia
Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1,"InChI=1S/C22H21N3O2/c1-15-16(22(26)25-11-5-4-8-21(25)23-15)9-12-24-13-10-20-18(14-24)17-6-2-3-7-19(17)27-20/h2-8,11H,9-10,12-14H2,1H3",ZYXHQIPQIKTEDI-UHFFFAOYSA-N,lusaperidone,Preclinical,adrenergic receptor antagonist,,,
CCCCCCOC(C)c1cccc(-c2csc(=NC(=O)c3cc(Cl)c(C=C(C)C(=O)O)c(Cl)c3)[nH]2)c1OC,"InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)",NOZIJMHMKORZBA-UHFFFAOYSA-N,lusutrombopag,Launched,thrombopoietin receptor agonist,,,
CC(C=CC=C(C)C=CC1=C(C)CC(O)CC1(C)C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CC(O)CC1(C)C,"InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-25,35-37,41-42H,26-28H2,1-10H3",KBPHJBAIARWVSC-UHFFFAOYSA-N,lutein,Launched,antioxidant,,ophthalmology,macular degeneration|cataracts|retinitis pigmentosa (RP)
O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H",IQPNAANSBPBGFQ-UHFFFAOYSA-N,luteolin,Phase 2,glucosidase inhibitor,TOP1,,
CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,"InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)",WVVXBPKOIZGVNS-UHFFFAOYSA-N,luzindole,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,
COc1cccc(-c2ccc(C(Oc3cc(-c4ccc(CC(N)C(=O)O)cc4)[nH]c(=N)n3)C(F)(F)F)cc2)c1,"InChI=1S/C28H25F3N4O4/c1-38-21-4-2-3-20(14-21)17-9-11-19(12-10-17)25(28(29,30)31)39-24-15-23(34-27(33)35-24)18-7-5-16(6-8-18)13-22(32)26(36)37/h2-12,14-15,22,25H,13,32H2,1H3,(H,36,37)(H2,33,34,35)",XNMUICFMGGQSMZ-UHFFFAOYSA-N,lx1031,Phase 2,tryptophan hydroxylase inhibitor,TPH1,,
Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12,"InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)",PWPNYABQEOGNNC-UHFFFAOYSA-N,lx7101,Phase 1/Phase 2,LIM kinase inhibitor,LIMK2|ROCK1|ROCK2,,
Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12,"InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)",PWPNYABQEOGNNC-UHFFFAOYSA-N,lx7101,Phase 1/Phase 2,rho associated kinase inhibitor,LIMK2|ROCK1|ROCK2,,
Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1,"InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)",UEPXBTCUIIGYCY-UHFFFAOYSA-N,lxh254,Phase 1,RAF inhibitor,,,
Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,"InChI=1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2",KYWWJENKIMRJBI-UHFFFAOYSA-N,lxr-623,Phase 1,LXR agonist,AR|NR1H2|NR1H3|NR1I2|NR3C1,,
CC1(N)CCN(c2ccc[nH]c2=NC(=O)c2nc(-c3ncccc3C(F)(F)F)c[nH]c2=N)CC1,"InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)",XXJXHXJWQSCNPX-UHFFFAOYSA-N,lxs196,Phase 1,PKC inhibitor,,,
O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,"InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)",HRJWTAWVFDCTGO-UHFFFAOYSA-N,ly2090314,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,
c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1,"InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2",IHLVSLOZUHKNMQ-UHFFFAOYSA-N,ly2109761,Preclinical,TGF beta receptor inhibitor,TGFBR1|TGFBR2,,
NC1(C(=O)O)CS(=O)(=O)C2C(C(=O)O)C21,"InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)",AVDUGNCTZRCAHH-UHFFFAOYSA-N,ly2140023,Phase 3,glutamate receptor agonist,GRM3,,
O=C(O)C1CC2CC(CCc3nn[nH]n3)CCC2CN1,"InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)",ZXFRFPSZAKNPQQ-UHFFFAOYSA-N,ly215490,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1,,
Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,"InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)",IVRXNBXKWIJUQB-UHFFFAOYSA-N,ly2157299,Phase 2/Phase 3,TGF beta receptor inhibitor,TGFBR1,,
CN(C)C(=O)n1nnnc1Cc1ccc(-c2ccccc2)cc1,"InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3",GZNIYOXWFCDBBJ-UHFFFAOYSA-N,ly2183240,Preclinical,FAAH inhibitor,FAAH,,
CN(C)C(=O)n1nnnc1Cc1ccc(-c2ccccc2)cc1,"InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3",GZNIYOXWFCDBBJ-UHFFFAOYSA-N,ly2183240,Preclinical,FAAH reuptake inhibitor,FAAH,,
CC(C)(C)Cn1c(=N)[nH]c2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21,"InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)",XPPBBJCBDOEXDN-UHFFFAOYSA-N,ly2228820,Phase 2,p38 MAPK inhibitor,MAPK14,,
COc1ccc(C=CCCCCOc2ccc(C(=O)c3cccc(C(=O)O)c3)cc2CCC(=O)O)cc1,"InChI=1S/C30H30O7/c1-36-26-14-10-21(11-15-26)7-4-2-3-5-18-37-27-16-12-24(19-22(27)13-17-28(31)32)29(33)23-8-6-9-25(20-23)30(34)35/h4,6-12,14-16,19-20H,2-3,5,13,17-18H2,1H3,(H,31,32)(H,34,35)",SYZSSLLFRVDRHL-UHFFFAOYSA-N,ly223982,Phase 2,leukotriene receptor antagonist,LTB4R,,
CC(C)Oc1cccc(-n2c(CCc3c[nH]c4ccc(Br)cc34)nc3ccccc3c2=O)c1,"InChI=1S/C27H24BrN3O2/c1-17(2)33-21-7-5-6-20(15-21)31-26(30-25-9-4-3-8-22(25)27(31)32)13-10-18-16-29-24-12-11-19(28)14-23(18)24/h3-9,11-12,14-17,29H,10,13H2,1-2H3",KUECXUACQOYKNB-UHFFFAOYSA-N,ly225910,Preclinical,CCK receptor antagonist,CCKBR,,
CCNCc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"InChI=1S/C17H29NO/c1-8-18-11-12-9-13(16(2,3)4)15(19)14(10-12)17(5,6)7/h9-10,18-19H,8,11H2,1-7H3",WQNYIWJBDGLKEB-UHFFFAOYSA-N,ly231617,Preclinical,lipid peroxidase inhibitor,,,
CCCC(CCC)C(=O)N=c1ccn(C2OC(CO)C(O)C2(F)F)c(=O)[nH]1,"InChI=1S/C17H25F2N3O5/c1-3-5-10(6-4-2)14(25)20-12-7-8-22(16(26)21-12)15-17(18,19)13(24)11(9-23)27-15/h7-8,10-11,13,15,23-24H,3-6,9H2,1-2H3,(H,20,21,25,26)",MEOYFIHNRBNEPI-UHFFFAOYSA-N,ly2334737,Phase 1,antitumor agent,,,
CCCC(CCC)C(=O)N=c1ccn(C2OC(CO)C(O)C2(F)F)c(=O)[nH]1,"InChI=1S/C17H25F2N3O5/c1-3-5-10(6-4-2)14(25)20-12-7-8-22(16(26)21-12)15-17(18,19)13(24)11(9-23)27-15/h7-8,10-11,13,15,23-24H,3-6,9H2,1-2H3,(H,20,21,25,26)",MEOYFIHNRBNEPI-UHFFFAOYSA-N,ly2334737,Phase 1,ribonucleotide reductase inhibitor,,,
CN(CCOc1ccc(-c2ccc3c(c2)OCO3)cc1C(C)(C)C)CC(=O)O,"InChI=1S/C22H27NO5/c1-22(2,3)17-11-15(16-6-8-19-20(12-16)28-14-27-19)5-7-18(17)26-10-9-23(4)13-21(24)25/h5-8,11-12H,9-10,13-14H2,1-4H3,(H,24,25)",FKPLJWGRBCQLTL-UHFFFAOYSA-N,ly2365109,Preclinical,glycine transporter inhibitor,SLC6A9,,
CC(C)OC(=O)NC1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,"InChI=1S/C22H22N4O2/c1-14(2)28-22(27)25-17-10-19-18-9-15(12-23)6-7-20(18)26(21(19)11-17)13-16-5-3-4-8-24-16/h3-9,14,17H,10-11,13H2,1-2H3,(H,25,27)",IHIWYQYVBNODSV-UHFFFAOYSA-N,ly2452473,Phase 2,androgen receptor modulator,AR,,
CC(C)NCCCCC(NC(=O)C1CCC(=O)NC(Cc2ccccc2)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(CCCCNC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC(Cc2ccc3ccccc3c2)C(=O)NCC(=O)N1)C(N)=O,"InChI=1S/C62H88N14O10/c1-38(2)66-30-12-10-19-46(55(63)80)72-59(84)49-28-29-53(78)71-51(34-40-15-6-5-7-16-40)60(85)76-52(35-41-23-26-45(77)27-24-41)61(86)74-47(20-11-13-31-67-39(3)4)57(82)73-48(21-14-32-68-62(64)65)58(83)75-50(56(81)69-37-54(79)70-49)36-42-22-25-43-17-8-9-18-44(43)33-42/h5-9,15-18,22-27,33,38-39,46-52,66-67,77H,10-14,19-21,28-32,34-37H2,1-4H3,(H2,63,80)(H,69,81)(H,70,79)(H,71,78)(H,72,84)(H,73,82)(H,74,86)(H,75,83)(H,76,85)(H4,64,65,68)",IJHWVENTEFSNBC-UHFFFAOYSA-N,ly2510924,Phase 2,CC chemokine receptor antagonist,,,
CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1,"InChI=1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)",WCGXJPFHTHQNJL-UHFFFAOYSA-N,ly255283,Preclinical,leukotriene receptor antagonist,LTB4R|LTB4R2,,
Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1,"InChI=1S/C21H19F4N7/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30)",FYXRSVDHGLUMHB-UHFFFAOYSA-N,ly2584702,Phase 1,ribosomal protein inhibitor,RPS6KB1,,
Cc1c[nH]c(=NC(=O)Nc2cc(Br)c(C)cc2OCC2CNCCO2)cn1,"InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)",SYYBDNPGDKKJDU-UHFFFAOYSA-N,ly2603618,Phase 2,CHK inhibitor,CHEK1,,
COc1cccc(OCCCN)c1-c1cc(=Nc2cnc(C#N)cn2)[nH][nH]1,"InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)",DOTGPNHGTYJDEP-UHFFFAOYSA-N,ly2606368,Phase 2,CHK inhibitor,CHEK1,,
O=C(N=c1[nH]cc(SCCN2CCCC2)s1)C1(c2ccc(S(=O)(=O)C3CC3)cc2)CC1C1CCCCC1,"InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)",QIIVJLHCZUTGSD-UHFFFAOYSA-N,ly2608204,Phase 2,glucokinase activator,GCK,,
COc1ccc(CC2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC,"InChI=1S/C21H23ClN2O2/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22/h4-7,10,17,23-24H,8-9,11H2,1-3H3",NJLHHCITDFZZSE-UHFFFAOYSA-N,ly266097,Preclinical,serotonin receptor antagonist,HTR2B,,
Cc1cc(=Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH][nH]1,"InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)",SQSZANZGUXWJEA-UHFFFAOYSA-N,ly2784544,Phase 2,JAK inhibitor,JAK2|JAK3,,
NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccnc3)cc2)c(Cl)c1,"InChI=1S/C23H22ClN3O2/c24-20-13-17(23(25)28)7-10-22(20)29-19-8-5-16(6-9-19)15-27-12-2-4-21(27)18-3-1-11-26-14-18/h1,3,5-11,13-14,21H,2,4,12,15H2,(H2,25,28)",LOOCZNLSXJHWTG-UHFFFAOYSA-N,ly2795050,Preclinical,opioid receptor antagonist,,,
Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,"InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)",QHADVLVFMKEIIP-UHFFFAOYSA-N,ly2801653,Phase 2,MET inhibitor,MET,,
CC1(c2cc(-c3cncnc3)c(F)cc2F)CCSC(=N)N1,"InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)",MJQMRGWYPNIERM-UHFFFAOYSA-N,ly2811376,Phase 1,beta-secretase inhibitor,BACE1,,
Cc1nc(N2CCN(C)CC2)c2nc(-c3ccccc3Cl)n(C3CCOCC3)c2n1,"InChI=1S/C22H27ClN6O/c1-15-24-21(28-11-9-27(2)10-12-28)19-22(25-15)29(16-7-13-30-14-8-16)20(26-19)17-5-3-4-6-18(17)23/h3-6,16H,7-14H2,1-2H3",UCMNDPDJRSEZPL-UHFFFAOYSA-N,ly2828360,Phase 2,cannabinoid receptor agonist,,,
CC(C)c1c2cc(-c3cc[nH]c(=NC4CCC(NC5CCOCC5)CC4)n3)ccc2nn1C,"InChI=1S/C26H36N6O/c1-17(2)25-22-16-18(4-9-24(22)31-32(25)3)23-10-13-27-26(30-23)29-20-7-5-19(6-8-20)28-21-11-14-33-15-12-21/h4,9-10,13,16-17,19-21,28H,5-8,11-12,14-15H2,1-3H3,(H,27,29,30)",LHIUZPIDLZYPRL-UHFFFAOYSA-N,ly2857785,Preclinical,CDK inhibitor,CDK9,,
CC(Oc1ccc2[nH]nc(C=Cc3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,"InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)",GKJCVYLDJWTWQU-UHFFFAOYSA-N,ly2874455,Phase 1,FGFR antagonist,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,
O=C1NN(C(=O)Nc2ccc(Br)cc2)C(c2ccccc2)C1c1ccccc1,"InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)",LMUQHXHWJWQXSD-UHFFFAOYSA-N,ly288513,Preclinical,CCK receptor antagonist,CCKBR,,
N=C1NC2(c3cc(NC(=O)c4ccc(F)cn4)ccc3F)COCC2CS1,"InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)",NIDRNVHMMDAAIK-UHFFFAOYSA-N,ly2886721,Phase 1/Phase 2,beta-secretase inhibitor,BACE1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2",CZQHHVNHHHRRDU-UHFFFAOYSA-N,ly294002,Preclinical,DNA dependent protein kinase inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2",CZQHHVNHHHRRDU-UHFFFAOYSA-N,ly294002,Preclinical,mTOR inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2",CZQHHVNHHHRRDU-UHFFFAOYSA-N,ly294002,Preclinical,phosphodiesterase inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2",CZQHHVNHHHRRDU-UHFFFAOYSA-N,ly294002,Preclinical,PI3K inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2",CZQHHVNHHHRRDU-UHFFFAOYSA-N,ly294002,Preclinical,PLK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,
CC(N)C(=O)NC1(C(=O)O)CC(Sc2nc[nH]n2)C2C(C(=O)O)C21,"InChI=1S/C13H17N5O5S/c1-4(14)9(19)17-13(11(22)23)2-5(24-12-15-3-16-18-12)6-7(8(6)13)10(20)21/h3-8H,2,14H2,1H3,(H,17,19)(H,20,21)(H,22,23)(H,15,16,18)",BBGHHIUQOKQCBW-UHFFFAOYSA-N,ly2979165,Phase 1,glutamate receptor agonist,GRM2,,
CNC(=O)OC1COc2ccc(N3CCN(C4COC4)CC3)cc2C1NC(=O)c1ccc(F)cc1,"InChI=1S/C25H29FN4O5/c1-27-25(32)35-22-15-34-21-7-6-18(29-8-10-30(11-9-29)19-13-33-14-19)12-20(21)23(22)28-24(31)16-2-4-17(26)5-3-16/h2-7,12,19,22-23H,8-11,13-15H2,1H3,(H,27,32)(H,28,31)",NDEBZCZEAVMSQF-UHFFFAOYSA-N,ly3000328,Phase 1,cathepsin inhibitor,CTSS,,
CN=c1nc2nc(C)c(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)cc2c[nH]1,"InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)",HHCBMISMPSAZBF-UHFFFAOYSA-N,ly3009120,Phase 1,RAF inhibitor,BRAF|RAF1,,
COC(C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,"InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3",ACCFLVVUVBJNGT-UHFFFAOYSA-N,ly3023414,Phase 2,mTOR inhibitor,MTOR,,
COC(C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,"InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3",ACCFLVVUVBJNGT-UHFFFAOYSA-N,ly3023414,Phase 2,PI3K inhibitor,MTOR,,
O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2",NGAGMBNBKCDCDJ-UHFFFAOYSA-N,ly303511,Preclinical,casein kinase inhibitor,BRD2|BRD3|BRD4,,
O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2",NGAGMBNBKCDCDJ-UHFFFAOYSA-N,ly303511,Preclinical,mTOR inhibitor,BRD2|BRD3|BRD4,,
O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12,"InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2",NGAGMBNBKCDCDJ-UHFFFAOYSA-N,ly303511,Preclinical,PI3K inhibitor,BRD2|BRD3|BRD4,,
CC1(C)C(=O)N(CCN2CCC(C(=O)c3ccc(F)cc3)CC2)c2ccccc21,"InChI=1S/C24H27FN2O2/c1-24(2)20-5-3-4-6-21(20)27(23(24)29)16-15-26-13-11-18(12-14-26)22(28)17-7-9-19(25)10-8-17/h3-10,18H,11-16H2,1-2H3",KDXISMANFPJVJY-UHFFFAOYSA-N,ly310762,Preclinical,serotonin receptor antagonist,HTR1D,,
CCc1c(CC(N)=O)c2cc(OCCC[PH](=O)(=O)O)ccc2n1Cc1ccccc1,"InChI=1S/C22H26N2O5P/c1-2-20-19(14-22(23)25)18-13-17(29-11-6-12-30(26,27)28)9-10-21(18)24(20)15-16-7-4-3-5-8-16/h3-5,7-10,13H,2,6,11-12,14-15H2,1H3,(H2,23,25)(H,26,27,28)",LSBPXYRFKNGKFS-UHFFFAOYSA-N,ly311727,Preclinical,phospholipase inhibitor,,,
CC(C)(O)c1cc(=Nc2cc(Oc3cn(C4CC4)nc3C3CCOCC3)ccn2)cc[nH]1,"InChI=1S/C24H29N5O3/c1-24(2,30)21-13-17(5-9-25-21)27-22-14-19(6-10-26-22)32-20-15-29(18-3-4-18)28-23(20)16-7-11-31-12-8-16/h5-6,9-10,13-16,18,30H,3-4,7-8,11-12H2,1-2H3,(H,25,26,27)",PNPFMWIDAKQFPY-UHFFFAOYSA-N,ly3200882,Phase 1,TGF beta receptor inhibitor,,,
COc1ccc(-c2oc3cc(OC)ccc3c2C(=O)c2ccc(C#N)cc2)cc1,"InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3",RYNSGDFWBJWWSZ-UHFFFAOYSA-N,ly320135,Preclinical,cannabinoid receptor antagonist,CNR1,,
Cn1nccc1N=c1nc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)cc[nH]1,"InChI=1S/C22H27N7O2S/c1-22(2)19-15(20(30)29(22)9-8-28-10-12-31-13-11-28)14-17(32-19)16-4-6-23-21(25-16)26-18-5-7-24-27(18)3/h4-7,14H,8-13H2,1-3H3,(H,23,25,26)",JNPRPMBJODOFEC-UHFFFAOYSA-N,ly3214996,Phase 1,ERK inhibitor,,,
Cc1cc(=Nc2ccc(F)c(CC3(C(=O)O)CCN(Cc4cccc(Cl)c4F)C(C)C3)n2)[nH][nH]1,"InChI=1S/C24H26ClF2N5O2/c1-14-10-21(31-30-14)29-20-7-6-18(26)19(28-20)12-24(23(33)34)8-9-32(15(2)11-24)13-16-4-3-5-17(25)22(16)27/h3-7,10,15H,8-9,11-13H2,1-2H3,(H,33,34)(H2,28,29,30,31)",YQQZZYYQTCPEAS-UHFFFAOYSA-N,ly3295668,Phase 1/Phase 2,Aurora kinase inhibitor,,,
CN1CCC(c2c[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc23)CC1,"InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)",MDMJLMDBRQXOOI-UHFFFAOYSA-N,ly334370,Preclinical,serotonin receptor agonist,,,
CN(C)C1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,"InChI=1S/C21H22FN3O/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26)",GKWHICIUSVVNGX-UHFFFAOYSA-N,ly344864,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7,,
c1ccc(-c2[nH]ncc2-c2ccnc3ccccc23)nc1,"InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)",IBCXZJCWDGCXQT-UHFFFAOYSA-N,ly364947,Preclinical,p38 MAPK inhibitor,TGFBR1,,
c1ccc(-c2[nH]ncc2-c2ccnc3ccccc23)nc1,"InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)",IBCXZJCWDGCXQT-UHFFFAOYSA-N,ly364947,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
CC(C)N1Cc2cc(S(C)(=O)=O)ccc2N(CCN2CC=C(c3c[nH]c4cc(F)ccc34)CC2)S1(=O)=O,"InChI=1S/C26H31FN4O4S2/c1-18(2)31-17-20-14-22(36(3,32)33)5-7-26(20)30(37(31,34)35)13-12-29-10-8-19(9-11-29)24-16-28-25-15-21(27)4-6-23(24)25/h4-8,14-16,18,28H,9-13,17H2,1-3H3",QUSLYAPLTMMCFE-UHFFFAOYSA-N,ly393558,Preclinical,serotonin receptor antagonist,HTR1B|HTR1D|HTR2A|HTR2B,,
CC(CNS(=O)(=O)C(C)C)c1ccc(-c2ccc(C#N)cc2)cc1,"InChI=1S/C19H22N2O2S/c1-14(2)24(22,23)21-13-15(3)17-8-10-19(11-9-17)18-6-4-16(12-20)5-7-18/h4-11,14-15,21H,13H2,1-3H3",HOQAVGZLYRYHSO-UHFFFAOYSA-N,ly404187,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
CC(NC(=O)C(=O)c1cc(F)cc(F)c1)C(=O)NC1c2ccccc2-c2ccccc2N(C)C1O,"InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22,26,35H,1-2H3,(H,29,34)(H,30,33)",HQPSKIGWRSEVPB-UHFFFAOYSA-N,ly411575,Preclinical,gamma secretase inhibitor,,,
CC(CNS(=O)(=O)C(C)C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1,"InChI=1S/C19H22F2N2O3S/c1-12(2)27(25,26)22-11-13(3)14-4-6-18(7-5-14)23-19(24)15-8-16(20)10-17(21)9-15/h4-10,12-13,22H,11H2,1-3H3,(H,23,24)",ACOXQYLJOQAHST-UHFFFAOYSA-N,ly450108,Phase 1,glutamate receptor modulator,,,
COc1ccc(N=c2[nH]cnc3ccc(OC)cc23)cc1,"InChI=1S/C16H15N3O2/c1-20-12-5-3-11(4-6-12)19-16-14-9-13(21-2)7-8-15(14)17-10-18-16/h3-10H,1-2H3,(H,17,18,19)",XPJOMFBGKIABQW-UHFFFAOYSA-N,ly456236,Preclinical,glutamate receptor antagonist,GRM1,,
CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C,"InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3",OAIJSZIZWZSQBC-UHFFFAOYSA-N,lycopene,Launched,free radical scavenger,,,
CC(C)c1ccc2c(c1)CCC1C(C)(CN)CCCC21C,"InChI=1S/C20H31N/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3",JVVXZOOGOGPDRZ-UHFFFAOYSA-N,lylamine,Preclinical,cannabinoid receptor agonist,CNR1,,
CN(C)C1C(=O)C(C(=O)NCNCCCCC(N)C(=O)O)C(=O)C2(O)C(=O)C3C(=O)c4c(O)cccc4C(C)(O)C3CC12,"InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,19-21,31,34,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)",DZTKAWPWXGIREW-UHFFFAOYSA-N,lymecycline,Launched,bacterial 50S ribosomal subunit inhibitor,,dermatology,acne vulgaris (AV)
C#CC1(O)CCC2C3CCC4=CCCCC4C3CCC21C,"InChI=1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3",YNVGQYHLRCDXFQ-UHFFFAOYSA-N,lynestrenol,Launched,progestogen hormone,,endocrinology,contraceptive
NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)",BJFIDCADFRDPIO-UHFFFAOYSA-N,lypressin,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2,endocrinology,central diabetes insipidus
CCCCCC(O)CCCC(=O)O,"InChI=1S/C10H20O3/c1-2-3-4-6-9(11)7-5-8-10(12)13/h9,11H,2-8H2,1H3,(H,12,13)",LMHJFKYQYDSOQO-UHFFFAOYSA-N,m-14157,Phase 2,ATP-sensitive potassium channel antagonist,KCNQ1,,
CCCC(CCC)C(=O)NCc1ccc2c(cnn2-c2ccccc2OC)c1,"InChI=1S/C23H29N3O2/c1-4-8-18(9-5-2)23(27)24-15-17-12-13-20-19(14-17)16-25-26(20)21-10-6-7-11-22(21)28-3/h6-7,10-14,16,18H,4-5,8-9,15H2,1-3H3,(H,24,27)",WATNXVHKRRTUFK-UHFFFAOYSA-N,m-25,Preclinical,smoothened receptor antagonist,DHH|IHH|SMO,,
CN(C)c1ccc(C(=O)NCCCCCCC(O)=NO)cc1,"InChI=1S/C16H25N3O3/c1-19(2)14-10-8-13(9-11-14)16(21)17-12-6-4-3-5-7-15(20)18-22/h8-11,22H,3-7,12H2,1-2H3,(H,17,21)(H,18,20)",MXWDSZWTBOCWBK-UHFFFAOYSA-N,m-344,Preclinical,HDAC inhibitor,HDAC8,,
Cc1cc(C)c(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c(C)c1,"InChI=1S/C16H16F3NO2S/c1-10-7-11(2)15(12(3)8-10)23(21,22)20-14-6-4-5-13(9-14)16(17,18)19/h4-9,20H,1-3H3",ZIIUUSVHCHPIQD-UHFFFAOYSA-N,m-3m3fbs,Preclinical,phospholipase activator,PLCB2|PLCB3|PLCD1|PLCG1|PLCG2,,
N=C(N)N=C(N)Nc1cccc(Cl)c1,"InChI=1S/C8H10ClN5/c9-5-2-1-3-6(4-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)",DIHXJZHAIHGSAW-UHFFFAOYSA-N,m-chlorophenylbiguanide,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2C=C4)C=C3)c1,"InChI=1S/C44H30N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-24,45-46,49-52H",XAEPFBXVLMACNN-UHFFFAOYSA-N,m-thp,Phase 1,,,,
COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1,"InChI=1S/C22H24N2O3S/c1-26-20-14-18(9-10-19(20)27-16-17-6-3-2-4-7-17)15-24(12-11-23)22(25)21-8-5-13-28-21/h2-10,13-14H,11-12,15-16,23H2,1H3",UOGGWHBYFVBUIY-UHFFFAOYSA-N,m8-b,Preclinical,transient receptor potential channel antagonist,TRPM8,,
CC(C)Cc1ccc(C(C)C(=O)NCCO)cc1,"InChI=1S/C15H23NO2/c1-11(2)10-13-4-6-14(7-5-13)12(3)15(18)16-8-9-17/h4-7,11-12,17H,8-10H2,1-3H3,(H,16,18)",JVGUNCHERKJFCM-UHFFFAOYSA-N,mabuprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
CC(C)(C)NCC(O)c1cc(Cl)c(N)c(C(F)(F)F)c1,"InChI=1S/C13H18ClF3N2O/c1-12(2,3)19-6-10(20)7-4-8(13(15,16)17)11(18)9(14)5-7/h4-5,10,19-20H,6,18H2,1-3H3",JSJCTEKTBOKRST-UHFFFAOYSA-N,mabuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
COc1cc(CC(C)C(C)Cc2ccc3c(c2)OCO3)ccc1O,"InChI=1S/C20H24O4/c1-13(8-15-4-6-17(21)19(10-15)22-3)14(2)9-16-5-7-18-20(11-16)24-12-23-18/h4-7,10-11,13-14,21H,8-9,12H2,1-3H3",QDDILOVMGWUNGD-UHFFFAOYSA-N,macelignan,Preclinical,anti-inflammatory agent,,,
COc1cc(CC(C)C(C)Cc2ccc3c(c2)OCO3)ccc1O,"InChI=1S/C20H24O4/c1-13(8-15-4-6-17(21)19(10-15)22-3)14(2)9-16-5-7-18-20(11-16)24-12-23-18/h4-7,10-11,13-14,21H,8-9,12H2,1-3H3",QDDILOVMGWUNGD-UHFFFAOYSA-N,macelignan,Preclinical,antioxidant,,,
CCCNS(=O)(=O)N=c1[nH]cnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,"InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)",JGCMEBMXRHSZKX-UHFFFAOYSA-N,macitentan,Launched,endothelin receptor antagonist,EDNRA|EDNRB,endocrinology,contraceptive
CCCCS(=O)(=O)N=c1[nH]cnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,"InChI=1S/C20H21Br2N5O4S/c1-2-3-10-32(28,29)27-18-17(14-4-6-15(21)7-5-14)19(26-13-25-18)30-8-9-31-20-23-11-16(22)12-24-20/h4-7,11-13H,2-3,8-10H2,1H3,(H,25,26,27)",OZBDTKLWBSATSN-UHFFFAOYSA-N,macitentan-n-butyl-analogue,Preclinical,endothelin receptor antagonist,,,
O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12,"InChI=1S/C20H23F3N4O3S/c21-20(22,23)14-10-15-17(16(11-14)27(29)30)31-19(24-18(15)28)26-8-6-25(7-9-26)12-13-4-2-1-3-5-13/h10-11,13H,1-9,12H2",BJDZBXGJNBMCAV-UHFFFAOYSA-N,macozinone,Preclinical,DPRE1 inhibitor,,,
CC1CCC2(C(=O)OC3OC(COC4OC(CO)C(OC5OC(C)C(O)C(O)C5O)C(O)C4O)C(O)C(O)C3O)CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(CO)C5C(O)CC43C)C2C1C,"InChI=1S/C48H78O20/c1-19-10-11-48(13-12-46(6)22(28(48)20(19)2)8-9-27-44(4)14-24(52)39(61)45(5,18-50)38(44)23(51)15-47(27,46)7)43(62)68-42-35(59)32(56)30(54)26(66-42)17-63-40-36(60)33(57)37(25(16-49)65-40)67-41-34(58)31(55)29(53)21(3)64-41/h8,19-21,23-42,49-61H,9-18H2,1-7H3",BNMGUJRJUUDLHW-UHFFFAOYSA-N,madecassoside,Preclinical,anti-inflammatory agent,,,
COc1ccc2c(C)[nH]c(=Nc3nc(=O)c(C)c(C)[nH]3)nc2c1,"InChI=1S/C16H17N5O2/c1-8-9(2)17-16(20-14(8)22)21-15-18-10(3)12-6-5-11(23-4)7-13(12)19-15/h5-7H,1-4H3,(H2,17,18,19,20,21,22)",QQJIYKXTEMDJFM-UHFFFAOYSA-N,madrasin,Preclinical,cell splicing inhibitor,,,
NCc1ccc(S(N)(=O)=O)cc1,"InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)",TYMRLRRVMHJFTF-UHFFFAOYSA-N,mafenide,Launched,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA4|CA6|CA9,infectious disease,first-aid antibiotic|skin infections
C=CCc1ccc(O)c(-c2cc(CC=C)ccc2O)c1,"InChI=1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2",VVOAZFWZEDHOOU-UHFFFAOYSA-N,magnolol,Preclinical,PPAR receptor agonist,GABRA1|PPARG,,
CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,"InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3",JXSJBGJIGXNWCI-UHFFFAOYSA-N,malathion,Launched,cholinesterase inhibitor,ACHE,infectious disease,lice
O=C(O)C(=O)CC(O)O,"InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h3,6-7H,1H2,(H,8,9)",CZVZLSFYXQUOSW-UHFFFAOYSA-N,malic-acid,Launched,,PKD2L1,,
CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1,"InChI=1S/C12H16O4S2/c1-7(2)15-10(13)9(11(14)16-8(3)4)12-17-5-6-18-12/h5-8H,1-4H3",YPIQVCUJEKAZCP-UHFFFAOYSA-N,malotilate,Launched,protein synthesis stimulant,,gastroenterology,hepatic cirrhosis
O=C(C(O)C(O)O)C(OC1OC(CO)C(O)C(O)C1O)C(O)CO,"InChI=1S/C12H22O12/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12/h3-6,8-17,19-22H,1-2H2",BKJDTLQNPIYPQT-UHFFFAOYSA-N,maltobionic-acid,Launched,matrix metalloprotease inhibitor,,dermatology,cosmetic
O=C(O)C(O)c1ccccc1,"InChI=1S/C8H8O3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7,9H,(H,10,11)",IWYDHOAUDWTVEP-UHFFFAOYSA-N,mandelic-acid,Launched,,,,
Cc1nc(CO[PH](=O)(=O)O)cc(CN(CCN(CC(=O)O)Cc2cc(CO[PH](=O)(=O)O)nc(C)c2O)CC(=O)O)c1O,"InChI=1S/C22H30N4O14P2/c1-13-21(31)15(5-17(23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-16-6-18(12-40-42(36,37)38)24-14(2)22(16)32/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H,33,34,35)(H,36,37,38)",IVBDKHIIDXFJDZ-UHFFFAOYSA-N,mangafodipir,Launched,contrast agent,,radiology,contrast agent
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,31-33H,17-22H2,1-3H3",PIRWHBVBBBZNKG-UHFFFAOYSA-N,manidipine,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension
C#CCCC(=O)C(C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,"InChI=1S/C15H11F3N2O2/c1-2-3-4-13(21)12(9-19)14(22)20-11-7-5-10(6-8-11)15(16,17)18/h1,5-8,12H,3-4H2,(H,20,22)",MYMWDZLPEPMSCN-UHFFFAOYSA-N,manitimus,Preclinical,dehydrogenase inhibitor,,,
OCC(O)C(O)C(O)C(O)CO,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2",FBPFZTCFMRRESA-UHFFFAOYSA-N,mannitol-d,Launched,diuretic,,neurology/psychiatry|ophthalmology|gastroenterology,intracranial pressure|intraocular pressure|constipation
CNCCCC12CCC(c3ccccc31)c1ccccc12,"InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3",QSLMDECMDJKHMQ-UHFFFAOYSA-N,maprotiline,Launched,norepinephrine reputake inhibitor,SLC6A2,neurology/psychiatry,depression|dysthymic disorder
CNCCCC12CCC(c3ccccc31)c1ccccc12,"InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3",QSLMDECMDJKHMQ-UHFFFAOYSA-N,maprotiline,Launched,tricyclic antidepressant,SLC6A2,neurology/psychiatry,depression|dysthymic disorder
Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)c1ccccc1,"InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)",GSNHKUDZZFZSJB-UHFFFAOYSA-N,maraviroc,Launched,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1)
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OCN4C)CC1,"InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)",BPFYOAJNDMUVBL-UHFFFAOYSA-N,marbofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
CC(C)N=c1[nH]c2cc(Cl)c(Cl)cc2n1C1OC(CO)C(O)C1O,"InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)",KJFBVJALEQWJBS-UHFFFAOYSA-N,maribavir,Phase 3,cytomegalovirus inhibitor,PYGM,,
CC(C)N=c1[nH]c2cc(Cl)c(Cl)cc2n1C1OC(CO)C(O)C1O,"InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)",KJFBVJALEQWJBS-UHFFFAOYSA-N,maribavir,Phase 3,protein kinase inhibitor,PYGM,,
CNC(=O)C(NC(=O)C(CC(C)C)C(O)C(O)=NO)C(C)(C)C,"InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)",OCSMOTCMPXTDND-UHFFFAOYSA-N,marimastat,Phase 3,matrix metalloprotease inhibitor,MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9,,
COc1ccc(C(C)(C)C)cc1CNC1C2CCN(CC2)C1C(c1ccccc1)c1ccccc1,"InChI=1S/C32H40N2O/c1-32(2,3)27-15-16-28(35-4)26(21-27)22-33-30-25-17-19-34(20-18-25)31(30)29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-16,21,25,29-31,33H,17-20,22H2,1-4H3",OMPCVMLFFSQFIX-UHFFFAOYSA-N,maropitant,Launched,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1[nH]c(-c2cccnc2)cs1,"InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)",WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,Launched,KIT inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1[nH]c(-c2cccnc2)cs1,"InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)",WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,Launched,PDGFR tyrosine kinase receptor inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N=c1[nH]c(-c2cccnc2)cs1,"InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)",WJEOLQLKVOPQFV-UHFFFAOYSA-N,masitinib,Launched,SRC inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma
CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,"InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3",HCZKYJDFEPMADG-UHFFFAOYSA-N,masoprocol,Launched,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK)
O=C1CCCC2C3CCCN4CCCC(CN12)C34,"InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2",ZSBXGIUJOOQZMP-UHFFFAOYSA-N,matrine,Phase 2,opioid receptor agonist,OPRK1,,
CC(Nc1cc(=O)n(C(C)C)c(=O)[nH]1)c1ccccc1,"InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)",RLCLASQCAPXVLM-UHFFFAOYSA-N,mavacamten,Phase 3,myosin inhibitor ,,,
CC(C)(O)c1ccccc1-c1ccc2[nH]c(C=Cc3ccc(C(F)(F)F)cc3)nc2c1,"InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)",ORDHXXHTBUZRCN-UHFFFAOYSA-N,mavatrep,Preclinical,transient receptor potential channel antagonist,,,
COC(=O)N1CCC2C1CCCC2(O)C#Cc1cccc(C)c1,"InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3",ZFPZEYHRWGMJCV-UHFFFAOYSA-N,mavoglurant,Phase 2,glutamate receptor antagonist,GRM5,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)OCCC(C)(C)O)CC(O)CC1O,"InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3",DTXXSJZBSTYZKE-UHFFFAOYSA-N,maxacalcitol,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism
COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)C)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,"InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)",OPQNCARIZFLNLF-UHFFFAOYSA-N,maytansinol-isobutyrate,Preclinical,,,,
CCc1cnc(N2CCC(c3nc(COc4ccc(-n5cnnn5)cc4)cs3)CC2)nc1,"InChI=1S/C22H24N8OS/c1-2-16-11-23-22(24-12-16)29-9-7-17(8-10-29)21-26-18(14-32-21)13-31-20-5-3-19(4-6-20)30-15-25-27-28-30/h3-6,11-12,14-15,17H,2,7-10,13H2,1H3",NFTMKHWBOINJGM-UHFFFAOYSA-N,mbx-2982,Phase 2,glucose dependent insulinotropic receptor agonist,GPR119,,
Cc1ncc(CO[PH](=O)(=O)O)c(C=O)c1O,"InChI=1S/C8H9NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H,12,13,14)",HEUHJQACTZEVDO-UHFFFAOYSA-N,mc-1,Phase 3,,AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1,,
Cn1c(C=CC(=O)c2cccc(F)c2)ccc1C=CC(O)=NO,"InChI=1S/C17H15FN2O3/c1-20-14(5-6-15(20)8-10-17(22)19-23)7-9-16(21)12-3-2-4-13(18)11-12/h2-11,23H,1H3,(H,19,22)",QQDIFLSJMFDTCQ-UHFFFAOYSA-N,mc1568,Preclinical,HDAC inhibitor,HDAC2,,
CC(C)(O)c1coc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)c1,"InChI=1S/C20H24N2O5S/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23)",HUUSXLKCTQDPGL-UHFFFAOYSA-N,mcc950,Preclinical,NOD like receptor inhibitor,NLRP3,,
CSc1ccc(C2CN3CCCC3c3ccccc32)cc1,"InChI=1S/C19H21NS/c1-21-15-10-8-14(9-11-15)18-13-20-12-4-7-19(20)17-6-3-2-5-16(17)18/h2-3,5-6,8-11,18-19H,4,7,12-13H2,1H3",YVKDUIAAPBKHMJ-UHFFFAOYSA-N,mcn-5652-(+/-),Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
CC1(N2CCC(n3c(C4CCCNC4)nc4ccccc43)CC2)CCCCCCC1,"InChI=1S/C26H40N4/c1-26(15-7-3-2-4-8-16-26)29-18-13-22(14-19-29)30-24-12-6-5-11-23(24)28-25(30)21-10-9-17-27-20-21/h5-6,11-12,21-22,27H,2-4,7-10,13-20H2,1H3",CYYNMPPFEJPBJD-UHFFFAOYSA-N,mcoppb,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,
Clc1cccc(N2CCNCC2)c1,"InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2",VHFVKMTVMIZMIK-UHFFFAOYSA-N,mcpp,Phase 2,serotonin receptor agonist,HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6,,
C=C1CC23CC1(O)CCC2C12C=CC(O)C(C)(C(=O)O1)C2C3C(=O)O,"InChI=1S/C19H22O6/c1-9-7-17-8-18(9,24)5-3-10(17)19-6-4-11(20)16(2,15(23)25-19)13(19)12(17)14(21)22/h4,6,10-13,20,24H,1,3,5,7-8H2,2H3,(H,21,22)",IXORZMNAPKEEDV-UHFFFAOYSA-N,md-920,Phase 1,NFkB pathway inhibitor,AADACL2,,
COc1cc(-n2c(=S)[nH]c3ccccc3c2=O)c(Cl)cc1Cl,"InChI=1S/C15H10Cl2N2O2S/c1-21-13-7-12(9(16)6-10(13)17)19-14(20)8-4-2-3-5-11(8)18-15(19)22/h2-7H,1H3,(H,18,22)",NZJKEVWTYMOYOR-UHFFFAOYSA-N,mdivi-1,Preclinical,dynamin inhibitor,DNM1,,
OC(c1ccccc1)C1CCN(CCc2ccccc2)CC1,"InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2",AXNGJCOYCMDPQG-UHFFFAOYSA-N,mdl-11939,Phase 2,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
Cn1c(-c2ccccc2)nnc1S(C)(=O)=O,"InChI=1S/C10H11N3O2S/c1-13-9(8-6-4-3-5-7-8)11-12-10(13)16(2,14)15/h3-7H,1-2H3",DPGDRICHXKQXEN-UHFFFAOYSA-N,mdl-27531,Preclinical,glycine receptor agonist,,,
O=C(O)CCc1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12,"InChI=1S/C12H9Cl2NO4/c13-5-3-7(14)10-6(1-2-9(16)17)11(12(18)19)15-8(10)4-5/h3-4,15H,1-2H2,(H,16,17)(H,18,19)",KNBSYZNKEAWABY-UHFFFAOYSA-N,mdl-29951,Preclinical,glutamate receptor antagonist,FBP1,,
O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,"InChI=1S/C22H30N2O4/c25-20-13-22(9-3-4-10-22)14-21(26)24(20)12-6-5-11-23-15-17-16-27-18-7-1-2-8-19(18)28-17/h1-2,7-8,17,23H,3-6,9-16H2",HCVRCHQFYYZPHT-UHFFFAOYSA-N,mdl-72832,Preclinical,serotonin receptor agonist,HTR1A,,
O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,"InChI=1S/C20H26N2O4/c23-18-11-20(7-3-4-8-20)12-19(24)22(18)10-9-21-13-15-14-25-16-5-1-2-6-17(16)26-15/h1-2,5-6,15,21H,3-4,7-14H2",BVMYCHKQPGEOSI-UHFFFAOYSA-N,mdl-73005ef,Phase 1,serotonin receptor antagonist,HTR1A,,
CS(=O)(=O)OCOS(C)(=O)=O,"InChI=1S/C3H8O6S2/c1-10(4,5)8-3-9-11(2,6)7/h3H2,1-2H3",IQLZWWDXNXZGPK-UHFFFAOYSA-N,mdms,Phase 2,DNA inhibitor,,,
CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,"InChI=1S/C19H19N3O2/c1-13(14-7-3-2-4-8-14)20-18(23)12-11-17-21-16-10-6-5-9-15(16)19(24)22-17/h2-10,13H,11-12H2,1H3,(H,20,23)(H,21,22,24)",QIHBWVVVRYYYRO-UHFFFAOYSA-N,me-0328,Preclinical,PPAR receptor antagonist,PARP3,,
CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,"InChI=1S/C19H19N3O2/c1-13(14-7-3-2-4-8-14)20-18(23)12-11-17-21-16-10-6-5-9-15(16)19(24)22-17/h2-10,13H,11-12H2,1H3,(H,20,23)(H,21,22,24)",QIHBWVVVRYYYRO-UHFFFAOYSA-N,me0328,Preclinical,PARP inhibitor,PARP3,,
COC(=O)N=c1[nH]c2ccc(C(=O)c3ccccc3)cc2[nH]1,"InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)",OPXLLQIJSORQAM-UHFFFAOYSA-N,mebendazole,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,pinworm|whipworm|hookworm|ascariasis
CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,"InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3",VYVKHNNGDFVQGA-UHFFFAOYSA-N,mebeverine,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome
CN1CCc2c(c3ccccc3n2Cc2ccccc2)C1,"InChI=1S/C19H20N2/c1-20-12-11-19-17(14-20)16-9-5-6-10-18(16)21(19)13-15-7-3-2-4-8-15/h2-10H,11-14H2,1H3",FQQIIPAOSKSOJM-UHFFFAOYSA-N,mebhydrolin,Launched,antihistamine,,allergy,allergic rhinitis|urticaria
CN1C(=O)N(C)C2C1N(C)C(=O)N2C,"InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3",XIUUSFJTJXFNGH-UHFFFAOYSA-N,mebicar,Launched,anxiolytic,,neurology/psychiatry,anxiety
Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,"InChI=1S/C15H19BrN2O5/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23)",MHPZZZZLAQGTHT-UHFFFAOYSA-N,mebrofenin,Launched,,,radiology,diagnostic agent
CNC1(C)C2CCC(C2)C1(C)C,"InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3",IMYZQPCYWPFTAG-UHFFFAOYSA-N,mecamylamine,Launched,acetylcholine receptor antagonist,CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4,cardiology,hypertension
CCOC(=O)c1c(C)n(C)c2ccc(O)cc12,"InChI=1S/C13H15NO3/c1-4-17-13(16)12-8(2)14(3)11-6-5-9(15)7-10(11)12/h5-7,15H,4H2,1-3H3",YTBNTDMBGXAOCG-UHFFFAOYSA-N,mecarbinate,Preclinical,,,,
COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12,"InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)",DYLJVOXRWLXDIG-UHFFFAOYSA-N,meclinertant,Phase 2/Phase 3,neurotensin receptor antagonist,NTSR1|NTSR2,,
Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,"InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3",OCJYIGYOJCODJL-UHFFFAOYSA-N,meclizine,Launched,constitutive androstane receptor (CAR) agonist,NR1I3,gastroenterology|neurology/psychiatry,nausea|vomiting|motion sickness
C=C1c2c(Cl)ccc(O)c2C(=O)C2C(=O)C3(O)C(=O)C(C(N)=O)C(=O)C(N(C)C)C3C(O)C12,"InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,12-15,17,26,28,33H,1H2,2-3H3,(H2,24,32)",YKYBWGJKLYMCFI-UHFFFAOYSA-N,meclocycline-sulfosalicylate,Launched,bacterial 50S ribosomal subunit inhibitor,,dermatology|infectious disease,acne vulgaris (AV)|skin infections
Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,"InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)",SBDNJUWAMKYJOX-UHFFFAOYSA-N,meclofenamic-acid,Launched,cyclooxygenase inhibitor,ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2,rheumatology|neurology/psychiatry|endocrinology,joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,"InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)",SBDNJUWAMKYJOX-UHFFFAOYSA-N,meclofenamic-acid,Launched,prostanoid receptor antagonist,ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2,rheumatology|neurology/psychiatry|endocrinology,joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)
CN(C)CCOC(=O)COc1ccc(Cl)cc1,"InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3",XZTYGFHCIAKPGJ-UHFFFAOYSA-N,meclofenoxate,Launched,nootropic agent,,neurology/psychiatry,senile dementia|Alzheimer's disease
COC(=O)C(N)CS,"InChI=1S/C4H9NO2S/c1-7-4(6)3(5)2-8/h3,8H,2,5H2,1H3",MCYHPZGUONZRGO-UHFFFAOYSA-N,mecysteine,Launched,analgesic agent,,pulmonary,chest congestion
Cc1cccc(C(C)c2c[nH]cn2)c1C,"InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)",CUHVIMMYOGQXCV-UHFFFAOYSA-N,medetomidine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative
CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O,"InChI=1S/C20H38O4/c1-19(2,15-17(21)22)13-11-9-7-5-6-8-10-12-14-20(3,4)16-18(23)24/h5-16H2,1-4H3,(H,21,22)(H,23,24)",HYSMCRNFENOHJH-UHFFFAOYSA-N,medica-16,Phase 2,ATP citrase lyase inhibitor,FFAR1,,
Cc1nccc2[nH]c(=O)ccc12,"InChI=1S/C9H8N2O/c1-6-7-2-3-9(12)11-8(7)4-5-10-6/h2-5H,1H3,(H,11,12)",OCCZJXAHSUCJSA-UHFFFAOYSA-N,medorinone,Phase 1,,,,
O=[PH](=O)(O)C[PH](=O)(=O)O,"InChI=1S/CH4O6P2/c2-8(3,4)1-9(5,6)7/h1H2,(H,2,3,4)(H,5,6,7)",QAQMNNPEAQBPQJ-UHFFFAOYSA-N,medronic-acid,Launched,bone resorption inhibitor,,radiology,skeletal imaging agent
CC(=O)C1(O)CCC2C3CC(C)=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h16-18,25H,5-12H2,1-4H3",QOVGIKUHSFCSIK-UHFFFAOYSA-N,medroxyprogesterone,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive
CC(=O)OC1(C(C)=O)CCC2C3CC(C)=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h18-20H,6-13H2,1-5H3",WYYCRMBIYYRAEW-UHFFFAOYSA-N,medroxyprogesterone-acetate,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
CC(=O)C1CCC2C3CC(C)=C4CC(=O)CCC4(C)C3C(O)CC12C,"InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h15-17,19-20,25H,5-11H2,1-4H3",PYBNSXOYOSNUHV-UHFFFAOYSA-N,medrysone,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis|episcleritis
Cc1cccc(Nc2ccccc2C(=O)O)c1C,"InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)",HYYBABOKPJLUIN-UHFFFAOYSA-N,mefenamic-acid,Launched,cyclooxygenase inhibitor,KCNQ1|PTGS1|PTGS2|TRPM3,endocrinology,primary dysmenorrhea (PD)
CCN(CC)CCNC(=O)COc1ccc(OC)cc1,"InChI=1S/C15H24N2O3/c1-4-17(5-2)11-10-16-15(18)12-20-14-8-6-13(19-3)7-9-14/h6-9H,4-5,10-12H2,1-3H3,(H,16,18)",HUNIPYLVUPMFCZ-UHFFFAOYSA-N,mefexamide,Preclinical,psychoactive drug,,,
OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,"InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2",XEEQGYMUWCZPDN-UHFFFAOYSA-N,mefloquine,Launched,adenosine receptor antagonist,,infectious disease,malaria
OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,"InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2",XEEQGYMUWCZPDN-UHFFFAOYSA-N,mefloquine,Launched,hemoglobin antagonist,,infectious disease,malaria
CC(=O)C1(O)CCC2C3=CC(C)=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11,17-18,25H,5-10,12H2,1-4H3",XFVQIVAAMLIGHF-UHFFFAOYSA-N,megestrol,Launched,progesterone receptor agonist,,oncology,breast cancer
CC(=O)OC1(C(C)=O)CCC2C3=CC(C)=C4CC(=O)CCC4(C)C3CCC21C,"InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12,19-20H,6-11,13H2,1-5H3",IMZOHRNGPZTCSG-UHFFFAOYSA-N,megestrol-acetate,Launched,progesterone receptor agonist,NR3C1|PGR,neurology/psychiatry|endocrinology,anorexia|cachexia
COc1ccc(Cl)cc1C(=O)NCCc1ccc(C(=O)O)cc1,"InChI=1S/C17H16ClNO4/c1-23-15-7-6-13(18)10-14(15)16(20)19-9-8-11-2-4-12(5-3-11)17(21)22/h2-7,10H,8-9H2,1H3,(H,19,20)(H,21,22)",SWLAMJPTOQZTAE-UHFFFAOYSA-N,meglitinide,Phase 2,potassium channel blocker,CCR2,,
CNCC(O)C(O)C(O)C(O)CO,"InChI=1S/C7H17NO5/c1-8-2-4(10)6(12)7(13)5(11)3-9/h4-13H,2-3H2,1H3",MBBZMMPHUWSWHV-UHFFFAOYSA-N,meglumine,Launched,excipient,,,
CC(O)(CC(=O)O)CC(=O)O,"InChI=1S/C6H10O5/c1-6(11,2-4(7)8)3-5(9)10/h11H,2-3H2,1H3,(H,7,8)(H,9,10)",NPOAOTPXWNWTSH-UHFFFAOYSA-N,meglutol,Launched,HMGCR inhibitor,HMGCR,,
Cn1c(O)c(C2=c3ccccc3=NC2=O)c2ccccc21,"InChI=1S/C17H12N2O2/c1-19-13-9-5-3-7-11(13)15(17(19)21)14-10-6-2-4-8-12(10)18-16(14)20/h2-9,21H,1H3",XZYXCQXTKOYHGK-UHFFFAOYSA-N,meisoindigo,Phase 3,STAT inhibitor,STAT3,,
N#CC(C(=N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F,"InChI=1S/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8,13,22H,21H2",XQRVCODIGHFXKQ-UHFFFAOYSA-N,mek1-2-inhibitor,Preclinical,MEK inhibitor,MAP2K2,,
CCCCC(NC(C)=O)C(=O)NC1CC(=O)NCCCCC(C(N)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CCCN=C(N)N)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC1=O,"InChI=1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)",JDKLPDJLXHXHNV-UHFFFAOYSA-N,melanotan-ii,Launched,melanocortin receptor agonist,,,
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,Launched,melatonin receptor agonist,ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB,neurology/psychiatry,sleep cycle support
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,"InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)",DRLFMBDRBRZALE-UHFFFAOYSA-N,melatonin,Launched,nitric oxide synthase inhibitor,ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB,neurology/psychiatry,sleep cycle support
C[N+](C)(C)NCCC(=O)O,"InChI=1S/C6H14N2O2/c1-8(2,3)7-5-4-6(9)10/h7H,4-5H2,1-3H3/p+1",PVBQYTCFVWZSJK-UHFFFAOYSA-O,meldonium,Launched,gamma butyrobetaine hydroxylase inhibitor,BBOX1,cardiology,coronary artery disease (CAD)
C=C1CC2C3=CC(C)=C4CC(=O)CCC4(C)C3CCC2(C)C1(OC(C)=O)C(C)=O,"InChI=1S/C25H32O4/c1-14-11-19-20(23(5)9-7-18(28)13-21(14)23)8-10-24(6)22(19)12-15(2)25(24,16(3)26)29-17(4)27/h11,20,22H,2,7-10,12-13H2,1,3-6H3",XYCYGSOKPXCMHX-UHFFFAOYSA-N,melengestrol-acetate,Preclinical,progesterone receptor agonist,,,
COC(=O)C(N)Cc1ccc(O)c(O)c1,"InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3",XBBDACCLCFWBSI-UHFFFAOYSA-N,melevodopa,Launched,dopamine precursor,DDC,neurology/psychiatry,Parkinson's Disease
COC(=O)C(N)Cc1ccc(O)c(O)c1,"InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3",XBBDACCLCFWBSI-UHFFFAOYSA-N,melevodopa,Launched,dopamine receptor agonist,DDC,neurology/psychiatry,Parkinson's Disease
Cc1c[nH]c(=NC(=O)C2C(=O)c3ccccc3S(=O)(=O)N2C)s1,"InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,11H,1-2H3,(H,15,16,19)",ZAHQBPYQBHTECE-UHFFFAOYSA-N,meloxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,"InChI=1S/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3",DKMFBWQBDIGMHM-UHFFFAOYSA-N,melperone,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,psychosis
CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,"InChI=1S/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3",DKMFBWQBDIGMHM-UHFFFAOYSA-N,melperone,Launched,serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,psychosis
NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,"InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)",SGDBTWWWUNNDEQ-UHFFFAOYSA-N,melphalan,Launched,DNA alkylating agent,,hematologic malignancy,multiple myeloma
NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,"InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)",SGDBTWWWUNNDEQ-UHFFFAOYSA-N,melphalan,Launched,DNA inhibitor,,hematologic malignancy,multiple myeloma
NC(Cc1ccc([N+]([O-])(CCCl)CCCl)cc1)C(=O)O,"InChI=1S/C13H18Cl2N2O3/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)",GSKQMLGAUOTSKT-UHFFFAOYSA-N,melphalan-n-oxide,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,
CC(C)(C)NCC(O)c1ccc(O)cc1Cl,"InChI=1S/C12H18ClNO2/c1-12(2,3)14-7-11(16)9-5-4-8(15)6-10(9)13/h4-6,11,14-16H,7H2,1-3H3",LIXBJWRFCNRAPA-UHFFFAOYSA-N,meluadrine,Preclinical,,,,
CC12CC3CC(C)(C1)CC(N)(C3)C2,"InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3",BUGYDGFZZOZRHP-UHFFFAOYSA-N,memantine,Launched,glutamate receptor antagonist,,neurology/psychiatry,Alzheimer's disease|senile dementia
CC1=CC(=O)c2ccccc2C1=O,"InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3",MJVAVZPDRWSRRC-UHFFFAOYSA-N,menadione,Launched,mitochondrial DNA polymerase inhibitor,AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1,gastroenterology|neurology/psychiatry|dermatology|rheumatology,ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
CC1=CC(=O)c2ccccc2C1=O,"InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3",MJVAVZPDRWSRRC-UHFFFAOYSA-N,menadione,Launched,phosphatase inhibitor,AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1,gastroenterology|neurology/psychiatry|dermatology|rheumatology,ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis
CC1(S(=O)(=O)O)CC(=O)c2ccccc2C1=O,"InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)",WIXFIQKTHUVFDI-UHFFFAOYSA-N,menadione-bisulfite,Phase 2,vitamin K,GGCX|VKORC1|VKORC1L1,,
CC(C)=CCCC(C)=CCCC(C)=CCC=C(C)C=Cc1c(C)c(O)c2ccccc2c1O,"InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16-21,32-33H,9-11,13,15H2,1-6H3",BEXALXUVUGWKPB-UHFFFAOYSA-N,menatetrenone,Launched,bone resorption inhibitor,,orthopedics,osteoporosis
COc1ccc(C(=O)CCC(=O)O)c2ccccc12,"InChI=1S/C15H14O4/c1-19-14-8-6-11(13(16)7-9-15(17)18)10-4-2-3-5-12(10)14/h2-6,8H,7,9H2,1H3,(H,17,18)",FHGJSJFIQNQBCK-UHFFFAOYSA-N,menbutone,Launched,,,gastroenterology,bile stimulation
CCN(CC)CCCC(C)N=c1c2ccc(Cl)cc2[nH]c2ccc(OC)cc12,"InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)",GPKJTRJOBQGKQK-UHFFFAOYSA-N,mepacrine,Launched,cytokine production inhibitor,PLA2G1B,infectious disease,giardiasis
CCN(CC)CCCC(C)N=c1c2ccc(Cl)cc2[nH]c2ccc(OC)cc12,"InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)",GPKJTRJOBQGKQK-UHFFFAOYSA-N,mepacrine,Launched,NFkB pathway inhibitor,PLA2G1B,infectious disease,giardiasis
CCN(CC)CCCC(C)N=c1c2ccc(Cl)cc2[nH]c2ccc(OC)cc12,"InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)",GPKJTRJOBQGKQK-UHFFFAOYSA-N,mepacrine,Launched,TP53 activator,PLA2G1B,infectious disease,giardiasis
C#CC(C)(O)CC,"InChI=1S/C6H10O/c1-4-6(3,7)5-2/h1,7H,5H2,2-3H3",QXLPXWSKPNOQLE-UHFFFAOYSA-N,meparfylon,Preclinical,,,,
CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,"InChI=1S/C19H22N2S/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21/h2-5,8-11,15H,6-7,12-14H2,1H3",CBHCDHNUZWWAPP-UHFFFAOYSA-N,mepazine,Phase 2,MALT1 inhibitor (JH),MALT1,,
C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1,"InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1",GKNPSSNBBWDAGH-UHFFFAOYSA-N,mepenzolate,Launched,acetylcholine receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
Cc1ccccc1OCC(O)CO,"InChI=1S/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3",JWDYCNIAQWPBHD-UHFFFAOYSA-N,mephenesin,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant
CNC(C)(C)Cc1ccccc1,"InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3",RXQCGGRTAILOIN-UHFFFAOYSA-N,mephentermine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3,cardiology,hypotension
CCC1(c2ccccc2)NC(=O)N(C)C1=O,"InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)",GMHKMTDVRCWUDX-UHFFFAOYSA-N,mephenytoin,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures
[O-][n+]1cccc(CO)c1,"InChI=1S/C6H7NO2/c8-5-6-2-1-3-7(9)4-6/h1-4,8H,5H2",LQYJAVWWKTWWKN-UHFFFAOYSA-N,mepiroxol,Preclinical,,,,
Cc1cccc(C)c1NC(=O)C1CCCCN1C,"InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)",INWLQCZOYSRPNW-UHFFFAOYSA-N,mepivacaine,Launched,potassium channel blocker,,neurology/psychiatry,local anesthetic
Cc1cccc(C)c1NC(=O)C1CCCCN1C,"InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)",INWLQCZOYSRPNW-UHFFFAOYSA-N,mepivacaine,Launched,sodium channel blocker,,neurology/psychiatry,local anesthetic
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3C(=O)CC2(C)C1(O)C(=O)CO,"InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h4,6-7,12,15-16,19,23,27H,5,8-11H2,1-3H3",MFMZCKHYODAASC-UHFFFAOYSA-N,meprednisone,Launched,,NR3C1,,
CCCNC(C)(C)COC(=O)c1ccccc1,"InChI=1S/C14H21NO2/c1-4-10-15-14(2,3)11-17-13(16)12-8-6-5-7-9-12/h5-9,15H,4,10-11H2,1-3H3",VXJABHHJLXLNMP-UHFFFAOYSA-N,meprylcaine,Preclinical,local anesthetic,,,
CCC1(c2cccc(O)c2)CCCCN(C)C1,"InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3",JLICHNCFTLFZJN-UHFFFAOYSA-N,meptazinol,Launched,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief
COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,"InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3",YECBIJXISLIIDS-UHFFFAOYSA-N,mepyramine,Launched,histamine receptor antagonist,HRH1,otolaryngology|obstetrics/gynecology,common cold|menstrual pain
COc1ccc(O)cc1,"InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3",NWVVVBRKAWDGAB-UHFFFAOYSA-N,mequinol,Launched,,TYR,dermatology,skin depigmentation
O=C(Nc1ccccc1)c1c(O)[nH]c(=S)[nH]c1=O,"InChI=1S/C11H9N3O3S/c15-8(12-6-4-2-1-3-5-6)7-9(16)13-11(18)14-10(7)17/h1-5H,(H,12,15)(H3,13,14,16,17,18)",GFYRZTLCYQQVHZ-UHFFFAOYSA-N,merbarone,Phase 2,topoisomerase inhibitor,TOP2A,,
O=C(O)c1ccccc1-c1c2cc(Br)c(=O)c([Hg+])c-2oc2cc(O)c(Br)cc12,"InChI=1S/C20H9Br2O5.Hg/c21-13-5-11-17(7-15(13)23)27-18-8-16(24)14(22)6-12(18)19(11)9-3-1-2-4-10(9)20(25)26;/h1-7,23H,(H,25,26);/q;+1",LPSLNCROJRNURQ-UHFFFAOYSA-N,merbromin,Launched,antiseptic,,infectious disease,first-aid antiseptic
S=c1[nH]cnc2[nH]cnc12,"InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",GLVAUDGFNGKCSF-UHFFFAOYSA-N,mercaptopurine,Launched,immunosuppressant,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL)
S=c1[nH]cnc2[nH]cnc12,"InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",GLVAUDGFNGKCSF-UHFFFAOYSA-N,mercaptopurine,Launched,protein synthesis inhibitor,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL)
S=c1[nH]cnc2[nH]cnc12,"InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)",GLVAUDGFNGKCSF-UHFFFAOYSA-N,mercaptopurine,Launched,purine antagonist,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL)
O=C(O)CC(S)C(=O)O,"InChI=1S/C4H6O4S/c5-3(6)1-2(9)4(7)8/h2,9H,1H2,(H,5,6)(H,7,8)",NJRXVEJTAYWCQJ-UHFFFAOYSA-N,mercaptosuccinic-acid,Launched,,,,
CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1,"InChI=1S/C19H17N3O2S/c1-12(23)21-15-7-4-13(5-8-15)19(24)22-17-11-14(6-9-16(17)20)18-3-2-10-25-18/h2-11H,20H2,1H3,(H,21,23)(H,22,24)",ABZSPJVXTTUFAA-UHFFFAOYSA-N,merck60,Preclinical,HDAC inhibitor,HDAC1|HDAC2,,
CC(C)C(=O)OCC1OC(n2ccc(=N)[nH]c2=O)C(C)(F)C1OC(=O)C(C)C,"InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)",MLESJYFEMSJZLZ-UHFFFAOYSA-N,mericitabine,Phase 2,HCV inhibitor,,,
COc1cc(NC(=O)Nc2cccc(CNC(=O)OC3CCOC3)c2)ccc1-c1cnco1,"InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)",JBPUGFODGPKTDW-UHFFFAOYSA-N,merimepodib,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,
CC(O)C1C(=O)N2C(C(=O)O)=C(SC3CNC(C(=O)N(C)C)C3)C(C)C12,"InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)",DMJNNHOOLUXYBV-UHFFFAOYSA-N,meropenem,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections|intra-abdominal infections|meningitis
COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCS)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2,"InChI=1S/C35H48ClN3O10S/c1-19-10-9-11-26(46-8)35(44)18-25(47-33(43)37-35)20(2)31-34(4,49-31)27(48-32(42)21(3)38(5)28(40)12-13-50)17-29(41)39(6)23-15-22(14-19)16-24(45-7)30(23)36/h9-11,15-16,20-21,25-27,31,44,50H,12-14,17-18H2,1-8H3,(H,37,43)",ANZJBCHSOXCCRQ-UHFFFAOYSA-N,mertansine,Phase 2,microtubule inhibitor,,,
Nc1ccc(O)c(C(=O)O)c1,"InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)",KBOPZPXVLCULAV-UHFFFAOYSA-N,mesalazine,Launched,cyclooxygenase inhibitor,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease
Nc1ccc(O)c(C(=O)O)c1,"InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)",KBOPZPXVLCULAV-UHFFFAOYSA-N,mesalazine,Launched,lipoxygenase inhibitor,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease
Nc1ccc(O)c(C(=O)O)c1,"InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)",KBOPZPXVLCULAV-UHFFFAOYSA-N,mesalazine,Launched,prostanoid receptor antagonist,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease
O=S(=O)(O)CCS,"InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)",ZNEWHQLOPFWXOF-UHFFFAOYSA-N,mesna,Launched,antioxidant,,urology,hemorrhagic cystitis
CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21,"InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",SLVMESMUVMCQIY-UHFFFAOYSA-N,mesoridazine,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
CN(C)C(=O)Oc1ccc[n+](C)c1,"InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1",RVOLLAQWKVFTGE-UHFFFAOYSA-N,mestinon,Launched,cholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis
C#CC1(O)CCC2C3CCc4cc(OC)ccc4C3CCC21C,"InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3",IMSSROKUHAOUJS-UHFFFAOYSA-N,mestranol,Launched,estrogen receptor agonist,ESR1,endocrinology,contraceptive
CN1CC(NS(=O)(=O)N(C)C)CC2c3cccc4c3c(cn4C)CC21,"InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3",JLVHTNZNKOSCNB-UHFFFAOYSA-N,mesulergine,Phase 2,dopamine receptor agonist,HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7,,
CC(=O)Oc1cccc(C)c1,"InChI=1S/C9H10O2/c1-7-4-3-5-9(6-7)11-8(2)10/h3-6H,1-2H3",OTGAHJPFNKQGAE-UHFFFAOYSA-N,meta-cresyl-acetate,Preclinical,,,,
CC(=O)Nc1cccc(O)c1,"InChI=1S/C8H9NO2/c1-6(10)9-7-3-2-4-8(11)5-7/h2-5,11H,1H3,(H,9,10)",QLNWXBAGRTUKKI-UHFFFAOYSA-N,metacetamol,Preclinical,analgesic agent,,,
Cc1cccc(O)c1,"InChI=1S/C7H8O/c1-6-3-2-4-7(8)5-6/h2-5,8H,1H3",RLSSMJSEOOYNOY-UHFFFAOYSA-N,metacresol,Launched,,INS,,
CN1c2c([nH]c(=N)[nH]c2=O)NCC1CNc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,"InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)",ZNOVTXRBGFNYRX-UHFFFAOYSA-N,metafolin,Launched,,,,
Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)",LVWZTYCIRDMTEY-UHFFFAOYSA-N,metamizole,Withdrawn,cyclooxygenase inhibitor,PTGS1,,
Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)",LVWZTYCIRDMTEY-UHFFFAOYSA-N,metamizole,Withdrawn,opioid receptor agonist,PTGS1,,
S=C=Nc1cccc(C2(N3CCCCC3)CCCCC2)c1,"InChI=1S/C18H24N2S/c21-15-19-17-9-7-8-16(14-17)18(10-3-1-4-11-18)20-12-5-2-6-13-20/h7-9,14H,1-6,10-13H2",FGSGBQAQSPSRJK-UHFFFAOYSA-N,metaphit,Preclinical,phencyclidine receptor acylator,,,
CC(C)NCC(O)c1cc(O)cc(O)c1,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8/h3-5,7,11-15H,6H2,1-2H3",LMOINURANNBYCM-UHFFFAOYSA-N,metaproterenol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|asthma|bronchitis|emphysema
CC(N)C(O)c1cccc(O)c1,"InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3",WXFIGDLSSYIKKV-UHFFFAOYSA-N,metaraminol,Launched,adrenergic receptor agonist,ADRA1A,cardiology,hypotension
N=c1[nH]ccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,"InChI=1S/C23H15ClF2N4O3/c24-20-19(7-8-29-22(20)27)33-18-6-5-14(9-17(18)26)30-23(32)16-11-28-10-15(21(16)31)12-1-3-13(25)4-2-12/h1-11H,(H2,27,29)(H,28,31)(H,30,32)",PDYXPCKITKHFOZ-UHFFFAOYSA-N,metatinib,Phase 1,Bcr-Abl kinase inhibitor,ABL1|BCR,,
Cc1cc(C)cc(OCC2CNC(=O)O2)c1,"InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)",IMWZZHHPURKASS-UHFFFAOYSA-N,metaxalone,Launched,muscle relaxant,,neurology/psychiatry,muscle pain
COc1cc2[nH]c(N3CCN(C(=O)C(C)OC)CC3)nc(=N)c2cc1OC,"InChI=1S/C18H25N5O4/c1-11(25-2)17(24)22-5-7-23(8-6-22)18-20-13-10-15(27-4)14(26-3)9-12(13)16(19)21-18/h9-11H,5-8H2,1-4H3,(H2,19,20,21)",YEOTYALSMRNXLJ-UHFFFAOYSA-N,metazosin,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)",YFGBQHOOROIVKG-UHFFFAOYSA-N,metenkephalin,Phase 2,immunostimulant,OPRD1,,
CN1CC(CNC(=O)OCc2ccccc2)CC2c3cccc4c3c(cn4C)CC21,"InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)",WZHJKEUHNJHDLS-UHFFFAOYSA-N,metergoline,Launched,dopamine receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry|endocrinology,seasonal affective disorder|anxiety|hyperprolactinemia
CN1CC(CNC(=O)OCc2ccccc2)CC2c3cccc4c3c(cn4C)CC21,"InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)",WZHJKEUHNJHDLS-UHFFFAOYSA-N,metergoline,Launched,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry|endocrinology,seasonal affective disorder|anxiety|hyperprolactinemia
CN(C)C(N)=NC(=N)N,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,metformin,Launched,insulin sensitizer,ACACB|PRKAB1,endocrinology,diabetes mellitus
CC(=O)OC(C)C[N+](C)(C)C,"InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1",NZWOPGCLSHLLPA-UHFFFAOYSA-N,methacholine,Launched,acetylcholine receptor agonist,CHRM2|CHRM4,pulmonary,bronchial hyperresponsiveness diagnostic
C=C1c2cccc(O)c2C(=O)C2C(=O)C3(O)C(=O)C(C(N)=O)C(=O)C(N(C)C)C3C(O)C12,"InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,12-15,17,25,27,32H,1H2,2-3H3,(H2,23,31)",QNJKSUYWBCNWFI-UHFFFAOYSA-N,methacycline,Preclinical,protein synthesis inhibitor,,pulmonary,bronchitis
CS(=O)(=O)F,"InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3",KNWQLFOXPQZGPX-UHFFFAOYSA-N,methanesulfonyl-fluoride,Phase 2,acetylcholinesterase inhibitor,ACHE,,
CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,"InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1",GZHFODJQISUKAY-UHFFFAOYSA-N,methantheline,Launched,acetylcholine receptor antagonist,CHRM1|HRH2,gastroenterology|neurology/psychiatry|urology,peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder
CN(C)CCN(Cc1cccs1)c1ccccn1,"InChI=1S/C14H19N3S/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14/h3-8,11H,9-10,12H2,1-2H3",HNJJXZKZRAWDPF-UHFFFAOYSA-N,methapyrilene,Withdrawn,histamine receptor antagonist,HRH1,,
CCC1(CC)C(=O)NC(=O)N(C)C1=O,"InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)",FWJKNZONDWOGMI-UHFFFAOYSA-N,metharbital,Launched,GABA receptor modulator,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,epilepsy
CC(=O)N=c1sc(S(N)(=O)=O)nn1C,"InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)",FLOSMHQXBMRNHR-UHFFFAOYSA-N,methazolamide,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,glaucoma|intraocular pressure
C1N2CN3CN1CN(C2)C3,InChI=1S/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2,VKYKSIONXSXAKP-UHFFFAOYSA-N,methenamine,Launched,bacterial DNA inhibitor,,infectious disease,urinary tract infections
COC(=O)N=c1[nH]c2ccc(SC(C)C)cc2[nH]1,"InChI=1S/C12H15N3O2S/c1-7(2)18-8-4-5-9-10(6-8)14-11(13-9)15-12(16)17-3/h4-7H,1-3H3,(H2,13,14,15,16)",SXJIZQPZESTWLD-UHFFFAOYSA-N,methiazole,Preclinical,anthelmintic agent,,,
COc1cccc(OC)c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)",RJQXTJLFIWVMTO-UHFFFAOYSA-N,methicillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cn1cc[nH]c1=S,"InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)",PMRYVIKBURPHAH-UHFFFAOYSA-N,methimazole,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism
CSCCC(N)C(=O)O,"InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)",FFEARJCKVFRZRR-UHFFFAOYSA-N,methionine,Launched,,METAP2,,
CC(=O)SCCC(=O)N1C(C)CCCC1C(=O)O,"InChI=1S/C12H19NO4S/c1-8-4-3-5-10(12(16)17)13(8)11(15)6-7-18-9(2)14/h8,10H,3-7H2,1-2H3,(H,16,17)",JHFOAISYWJRTIM-UHFFFAOYSA-N,methiopril,Phase 2,angiotensin converting enzyme inhibitor,ACE,,
COc1ccccc1OCC(O)COC(N)=O,"InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)",GNXFOGHNGIVQEH-UHFFFAOYSA-N,methocarbamol,Launched,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant
COC(C)(C)CCCC(C)C=CC=C(C)CC(=O)OC(C)C,"InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,10-11,15-16H,9,12-14H2,1-7H3",UPJMCYOGPGHMHO-UHFFFAOYSA-N,methoprene-(s),Preclinical,,,,
CN(Cc1cnc2[nH]c(=N)[nH]c(=N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)",FBOZXECLQNJBKD-UHFFFAOYSA-N,methotrexate,Launched,dihydrofolate reductase inhibitor,DHFR,oncology|hematologic malignancy|dermatology|rheumatology,gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis
COc1ccc(OC)c(C(O)C(C)N)c1,"InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3",WJAJPNHVVFWKKL-UHFFFAOYSA-N,methoxamine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,cardiology,hypotension
COc1c2occc2cc2ccc(=O)oc12,"InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3",QXKHYNVANLEOEG-UHFFFAOYSA-N,methoxsalen,Launched,DNA synthesis inhibitor,CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4,dermatology,psoriasis
CON,"InChI=1S/CH5NO/c1-3-2/h2H2,1H3",GMPKIPWJBDOURN-UHFFFAOYSA-N,methoxyamine,Phase 2,DNA repair enzyme inhibitor,APEX1,,
COC(F)(F)C(Cl)Cl,"InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3",RFKMCNOHBTXSMU-UHFFFAOYSA-N,methoxyflurane,Launched,membrane permeability inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1,neurology/psychiatry,general anaesthetic
CNC(C)Cc1ccccc1OC,"InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3",OEHAYUOVELTAPG-UHFFFAOYSA-N,methoxyphenamine,Launched,adrenergic receptor agonist,,pulmonary,asthma
C[N+]1(C)C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12,"InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1",LZCOQTDXKCNBEE-UHFFFAOYSA-N,methscopolamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,peptic ulcer disease (PUD)
CN1C(=O)CC(C)(c2ccccc2)C1=O,"InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3",AJXPJJZHWIXJCJ-UHFFFAOYSA-N,methsuximide,Launched,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures
CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,"InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)",CESYKOGBSMNBPD-UHFFFAOYSA-N,methyclothiazide,Launched,chloride reabsorption inhibitor,SLC12A1|SLC12A3,cardiology,hypertension|edema
COC(=O)CCC(=O)CN,"InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3",YUUAYBAIHCDHHD-UHFFFAOYSA-N,methyl-aminolevulinate,Launched,oxidizing agent,FCGR1A|FECH,dermatology,actinic keratosis (AK)
COC(=O)c1cccnc1,"InChI=1S/C7H7NO2/c1-10-7(9)6-3-2-4-8-5-6/h2-5H,1H3",YNBADRVTZLEFNH-UHFFFAOYSA-N,methyl-nicotinate,Phase 2,,,,
COC(=O)c1ccccc1O,"InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3",OSWPMRLSEDHDFF-UHFFFAOYSA-N,methyl-salicylate,Launched,,,endocrinology|neurology/psychiatry,fever|pain relief
C[N+]1(C)C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2,"InChI=1S/C18H26NO3/c1-19(2)14-8-9-15(19)11-16(10-14)22-18(21)17(12-20)13-6-4-3-5-7-13/h3-7,14-17,20H,8-12H2,1-2H3/q+1",PIPAJLPNWZMYQA-UHFFFAOYSA-N,methylatropine-nitrate,Preclinical,acetylcholine receptor antagonist,CHRM1,,
CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1,"InChI=1S/C21H28NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,24H,4-5,16-17H2,1-3H3/q+1",HDAMOICMOAXFLJ-UHFFFAOYSA-N,methylbenactyzium-bromide,Preclinical,cholinergic receptor antagonist,,,
Cc1cc(C(C)(C)CC(C)(C)C)ccc1OCCOCC[N+](C)(C)Cc1ccccc1,"InChI=1S/C28H44NO2/c1-23-20-25(28(5,6)22-27(2,3)4)14-15-26(23)31-19-18-30-17-16-29(7,8)21-24-12-10-9-11-13-24/h9-15,20H,16-19,21-22H2,1-8H3/q+1",UQOOPIMXBSPVJI-UHFFFAOYSA-N,methylbenzethonium-chloride,Preclinical,other antibiotic,,,
CC1=C2N=C(C=C3N=C(C(C)C4=NC(C(CC(N)=O)C4(C)CCC(=O)NCC(C)O[PH](=O)(=O)OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O,"InChI=1S/C62H89N13O14P/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56/h20-21,23,28,31-32,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)",BFOWVMZUKTYNPH-UHFFFAOYSA-N,methylcobalamin,Phase 3,vitamin B,,,
CC(N)(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)",CJCSPKMFHVPWAR-UHFFFAOYSA-N,methyldopa,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|DDC,cardiology,hypertension
CCOC(=O)C(C)(N)Cc1ccc(O)c(O)c1,"InChI=1S/C12H17NO4/c1-3-17-11(16)12(2,13)7-8-4-5-9(14)10(15)6-8/h4-6,14-15H,3,7,13H2,1-2H3",SVEBYYWCXTVYCR-UHFFFAOYSA-N,methyldopate,Launched,,,cardiology,hypertension
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1,"InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1",RBTBFTRPCNLSDE-UHFFFAOYSA-N,methylene-blue,Launched,guanylyl cyclase inhibitor,ACHE,hematology,methemoglobinemia
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1,"InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1",RBTBFTRPCNLSDE-UHFFFAOYSA-N,methylene-blue,Launched,nitric oxide production inhibitor,ACHE,hematology,methemoglobinemia
CCC(CO)NC(=O)C1=CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,14,16,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)",PEMKDARQKHHFQF-UHFFFAOYSA-N,methylergometrine,Launched,dopamine receptor antagonist,DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C,hematology|neurology/psychiatry,postpartum hemorrhage (PPH)|migraine headache
CCC(CO)NC(=O)C1=CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,14,16,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)",PEMKDARQKHHFQF-UHFFFAOYSA-N,methylergometrine,Launched,serotonin receptor antagonist,DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C,hematology|neurology/psychiatry,postpartum hemorrhage (PPH)|migraine headache
CCN1CC2(COC(=O)c3ccccc3-n3c(O)cc(C)c3O)CCC(OC)C34C5CC6C(OC)CC(O)(C5C6OC)C(O)(C(OC)C23)C14,"InChI=1S/C37H50N2O10/c1-7-38-17-34(18-49-32(42)20-10-8-9-11-23(20)39-26(40)14-19(2)31(39)41)13-12-25(46-4)36-22-15-21-24(45-3)16-35(43,27(22)28(21)47-5)37(44,33(36)38)30(48-6)29(34)36/h8-11,14,21-22,24-25,27-30,33,40-41,43-44H,7,12-13,15-18H2,1-6H3",HIQYFEBMHDFUID-UHFFFAOYSA-N,methyllycaconitine,Preclinical,acetylcholine receptor antagonist,CHRNA7,,
C[N+]1(CC2CC2)CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5,"InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1",JVLBPIPGETUEET-UHFFFAOYSA-O,methylnaltrexone,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,constipation
COC(=O)c1ccc(O)cc1,"InChI=1S/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H3",LXCFILQKKLGQFO-UHFFFAOYSA-N,methylparaben,Launched,other antifungal,,dermatology,cosmetic
CC1=C2CC(=O)C=CC2(C)C2C(O)CC3(C)C(CCC3(O)C(=O)CO)C2C1,"InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,14-15,17,19,23,25,27H,5,7-11H2,1-3H3",ZABDAGALHQDSEU-UHFFFAOYSA-N,methylprednisolone,Launched,glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology,hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis
CCC(=O)OC1(C(=O)COC(C)=O)CCC2C3CC(C)=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,18-19,21,24,30H,6,8,10-14H2,1-5H3",PVZGGWZECUNBJK-UHFFFAOYSA-N,methylprednisolone-aceponate,Launched,anti-inflammatory agent,NR3C1,endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology,congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia
CCC(=O)OC1(C(=O)COC(C)=O)CCC2C3CC(C)=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,18-19,21,24,30H,6,8,10-14H2,1-5H3",PVZGGWZECUNBJK-UHFFFAOYSA-N,methylprednisolone-aceponate,Launched,glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology,congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia
CC1=C2CC(=O)C=CC2(C)C2C(O)CC3(C)C(CCC3(O)C(=O)COC(=O)CCC(=O)O)C2C1,"InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,16-17,19,23,28,33H,4-5,7,9-13H2,1-3H3,(H,30,31)",USWORSUDJQKUJO-UHFFFAOYSA-N,methylprednisolone-sodium-succinate,Launched,glucocorticoid receptor agonist,,endocrinology|rheumatology|dermatology|pulmonary|allergy|infectious disease|ophthalmology|gastroenterology|hematology|neurology/psychiatry,hypercalcemia|thyroiditis|osteoarthritis|rheumatoid arthritis|seborrheic dermatitis|asthma|allergic rhinitis|shingles|conjunctivitis|ulcerative colitis|enteritis|anemia|multiple sclerosis|mycosis
Cc1cc(=O)[nH]c(=S)[nH]1,"InChI=1S/C5H6N2OS/c1-3-2-4(8)7-5(9)6-3/h2H,1H3,(H2,6,7,8,9)",HWGBHCRJGXAGEU-UHFFFAOYSA-N,methylthiouracil,Launched,,,endocrinology,hyperthyroidism
CCC(CO)NC(=O)C1=CC2c3cccc4c3c(cn4C)CC2N(C)C1,"InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,15,17,19,25H,4,9,11-12H2,1-3H3,(H,22,26)",ZROSHIYBPNXMJG-UHFFFAOYSA-N,methysergide,Launched,serotonin receptor antagonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry,headache
Cc1cc2c(cc1S(N)(=O)=O)S(=O)(=O)CCC2,"InChI=1S/C10H13NO4S2/c1-7-5-8-3-2-4-16(12,13)10(8)6-9(7)17(11,14)15/h5-6H,2-4H2,1H3,(H2,11,14,15)",FNQQBFNIYODEMB-UHFFFAOYSA-N,meticrane,Launched,diuretic,,cardiology,edema
CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C,"InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3",BQIPXWYNLPYNHW-UHFFFAOYSA-N,metipranolol,Withdrawn,adrenergic receptor antagonist,,,
CC(N)(Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)",NHTGHBARYWONDQ-UHFFFAOYSA-N,metirosine,Launched,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension
CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2,"InChI=1S/C20H24N2S2/c1-21-9-11-22(12-10-21)18-13-15-5-3-4-6-19(15)24-20-8-7-16(23-2)14-17(18)20/h3-8,14,18H,9-13H2,1-2H3",RLJFTICUTYVZDG-UHFFFAOYSA-N,metitepine,Preclinical,anti-HCVE2,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1,"InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3",MJFJKKXQDNNUJF-UHFFFAOYSA-N,metixene,Launched,acetylcholine receptor antagonist,CHRM5,neurology/psychiatry,Parkinson's Disease
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",TTWJBBZEZQICBI-UHFFFAOYSA-N,metoclopramide,Launched,dopamine receptor antagonist,CHRM1|DRD2|HTR3A|HTR3B|HTR4,gastroenterology,gastroparesis|nausea|vomiting
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",TTWJBBZEZQICBI-UHFFFAOYSA-N,metoclopramide,Launched,serotonin receptor antagonist,CHRM1|DRD2|HTR3A|HTR3B|HTR4,gastroenterology,gastroparesis|nausea|vomiting
COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)C3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1C(C2)[N+](C)(C)CC3,"InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2",JFXBEKISTKFVAB-UHFFFAOYSA-N,metocurine,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2,neurology/psychiatry,muscle relaxant
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C,"InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)",AQCHWTWZEMGIFD-UHFFFAOYSA-N,metolazone,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension
COCCc1ccc(OCC(O)CNC(C)C)cc1,"InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3",IUBSYMUCCVWXPE-UHFFFAOYSA-N,metoprolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,hypertension|angina pectoris|myocardial infarction
COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,"InChI=1S/C20H24O3/c1-14(2)13-16-9-11-17(12-10-16)15(3)20(21)23-19-8-6-5-7-18(19)22-4/h5-12,14-15H,13H2,1-4H3",FVRWRGBTEHAPDI-UHFFFAOYSA-N,metoxibutropate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
COP(=O)(OC)C(O)C(Cl)(Cl)Cl,"InChI=1S/C4H8Cl3O4P/c1-10-12(9,11-2)3(8)4(5,6)7/h3,8H,1-2H3",NFACJZMKEDPNKN-UHFFFAOYSA-N,metrifonate,Phase 3,acetylcholinesterase inhibitor,ACHE,,
CC(=O)Nc1c(I)c(C(=O)NC2C(O)OC(CO)C(O)C2O)c(I)c(N(C)C(C)=O)c1I,"InChI=1S/C18H22I3N3O8/c1-5(26)22-12-9(19)8(10(20)14(11(12)21)24(3)6(2)27)17(30)23-13-16(29)15(28)7(4-25)32-18(13)31/h7,13,15-16,18,25,28-29,31H,4H2,1-3H3,(H,22,26)(H,23,30)",BAQCROVBDNBEEB-UHFFFAOYSA-N,metrizamide,Launched,radiopaque medium,,radiology,contrast agent
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I,"InChI=1S/C12H11I3N2O4/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19/h1-3H3,(H,16,18)(H,20,21)",GGGDNPWHMNJRFN-UHFFFAOYSA-N,metrizoic-acid,Launched,radiopaque medium,,radiology,contrast agent
Cc1ncc([N+](=O)[O-])n1CCO,"InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3",VAOCPAMSLUNLGC-UHFFFAOYSA-N,metronidazole,Launched,DNA inhibitor,CYP2C9|CYP3A4,dermatology,rosacea
CC(C)(C(=O)c1cccnc1)c1cccnc1,"InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3",FJLBFSROUSIWMA-UHFFFAOYSA-N,metyrapone,Launched,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent
CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,"InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3",AJLFOPYRIVGYMJ-UHFFFAOYSA-N,mevastatin,Preclinical,HMGCR inhibitor,HMGCR,,
COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,"InChI=1S/C15H14O3/c1-10-3-5-11(6-4-10)15(17)13-8-7-12(18-2)9-14(13)16/h3-9,16H,1-2H3",MJVGBKJNTFCUJM-UHFFFAOYSA-N,mexeneone,Preclinical,,,,
Cc1cccc(C)c1OCC(C)N,"InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3",VLPIATFUUWWMKC-UHFFFAOYSA-N,mexiletine,Launched,sodium channel blocker,PLAU|SCN4A|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CC1(C)SC2C(NC(=O)C(NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)",YPBATNHYBCGSSN-UHFFFAOYSA-N,mezlocillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
O=C1CC(c2ccc(O)cc2)Oc2cc(O)ccc21,"InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2",FURUXTVZLHCCNA-UHFFFAOYSA-N,mf-101,Phase 3,estrogen receptor agonist,CYP19A1|XDH,,
CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1,"InChI=1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)",TZYWCYJVHRLUCT-UHFFFAOYSA-N,mg-132,Preclinical,proteasome inhibitor,PSMB1,,
CC[N+](CC)(CC)CCOc1ccc(C=Cc2ccccc2)cc1,"InChI=1S/C22H30NO/c1-4-23(5-2,6-3)18-19-24-22-16-14-21(15-17-22)13-12-20-10-8-7-9-11-20/h7-17H,4-6,18-19H2,1-3H3/q+1",YIMFXBPXUPTIEJ-UHFFFAOYSA-N,mg-624,Preclinical,acetylcholine receptor antagonist,CHRNA7,,
Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1,"InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)",UFICVEHDQUKCEA-UHFFFAOYSA-N,mgcd-265,Preclinical,VEGFR inhibitor,AXL|MET,,
CC(=O)NCCN=c1cc(Cl)[nH]n2c(-c3cccc(S(=O)(=O)N(C)C)c3)c(C)nc12,"InChI=1S/C19H23ClN6O3S/c1-12-18(14-6-5-7-15(10-14)30(28,29)25(3)4)26-19(23-12)16(11-17(20)24-26)22-9-8-21-13(2)27/h5-7,10-11,24H,8-9H2,1-4H3,(H,21,27)",DLWRDQXITCHVEU-UHFFFAOYSA-N,mi-14,Preclinical,PI4K inhibitor,PI4KB,,
CN1CCN2c3ccccc3Cc3ccccc3C2C1,"InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3",UEQUQVLFIPOEMF-UHFFFAOYSA-N,mianserin,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,depression
CC(CNS(=O)(=O)C(C)C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1,"InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3",ULRDYYKSPCRXAJ-UHFFFAOYSA-N,mibampator,Phase 2,glutamate receptor modulator,GRIA1,,
COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2C1C(C)C,"InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)",HBNPJJILLOYFJU-UHFFFAOYSA-N,mibefradil,Withdrawn,T-type calcium channel blocker,ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4,,
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(O)CC(N)=O)NC(=O)C(C(O)C(O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)cc3)no2)cc1,"InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)",PIEUQSKUWLMALL-UHFFFAOYSA-N,micafungin,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",,infectious disease,candidemia|peritonitis|esophageal candidiasis
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2",BYBLEWFAAKGYCD-UHFFFAOYSA-N,miconazole,Launched,bacterial cell wall synthesis inhibitor,TRPM2|TRPV5,infectious disease|neurology/psychiatry,yeast infection|itching
CNCC1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,"InChI=1S/C20H41N5O7/c1-20(28)8-29-19(14(27)17(20)25-3)32-16-12(23)6-11(22)15(13(16)26)31-18-10(21)5-4-9(30-18)7-24-2/h9-19,24-28H,4-8,21-23H2,1-3H3",DNYGXMICFMACRA-UHFFFAOYSA-N,micronomicin,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
O=C(O)C1CN(CC=C[PH](=O)(=O)O)CCN1,"InChI=1S/C8H14N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H,13,14,15)",HAOKVJGFHUOAOY-UHFFFAOYSA-N,midafotel,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CCC(=O)OC1CC(=O)OC(C)CC=CC=CC(O)C(C)CC(CC=O)C(OC2OC(C)C(OC3CC(C)(O)C(OC(=O)CC)C(C)O3)C(N(C)C)C2O)C1OC,"InChI=1S/C41H67NO15/c1-11-30(45)54-29-21-32(47)51-24(4)16-14-13-15-17-28(44)23(3)20-27(18-19-43)37(38(29)50-10)57-40-35(48)34(42(8)9)36(25(5)53-40)56-33-22-41(7,49)39(26(6)52-33)55-31(46)12-2/h13-15,17,19,23-29,33-40,44,48-49H,11-12,16,18,20-22H2,1-10H3",DMUAPQTXSSNEDD-UHFFFAOYSA-N,midecamycin,Launched,protein synthesis inhibitor,,infectious disease,respiratory tract infections|ear infections|skin infections
COc1ccc(OC)c(C(O)CNC(=O)CN)c1,"InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)",PTKSEFOSCHHMPD-UHFFFAOYSA-N,midodrine,Launched,adrenergic receptor agonist,,cardiology,hypotension
COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)",BMGQWWVMWDBQGC-UHFFFAOYSA-N,midostaurin,Launched,FLT3 inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML)
COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)",BMGQWWVMWDBQGC-UHFFFAOYSA-N,midostaurin,Launched,KIT inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML)
COC1C(N(C)C(=O)c2ccccc2)CC2OC1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)",BMGQWWVMWDBQGC-UHFFFAOYSA-N,midostaurin,Launched,PKC inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML)
CC#CC1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(c3ccc(N(C)C)cc3)CC21C,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,25-26,32H,8,11-14,16-18H2,1-4H3",BHZCGCMWEVHUBA-UHFFFAOYSA-N,mifepristone,Launched,glucocorticoid receptor antagonist,AR|NR1I2|NR3C1|PGR,endocrinology,hyperglycemia|diabetes mellitus
CC#CC1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(c3ccc(N(C)C)cc3)CC21C,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,25-26,32H,8,11-14,16-18H2,1-4H3",BHZCGCMWEVHUBA-UHFFFAOYSA-N,mifepristone,Launched,progesterone receptor antagonist,AR|NR1I2|NR3C1|PGR,endocrinology,hyperglycemia|diabetes mellitus
COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,"InChI=1S/C11H17ClO7P2/c1-15-20(13,16-2)11(19-21(14,17-3)18-4)9-5-7-10(12)8-6-9/h5-8,11H,1-4H3",VQHUQHAPWMNBLP-UHFFFAOYSA-N,mifobate,Phase 2,PPAR receptor antagonist,PPARG,,
OCCN1CC(O)C(O)C(O)C1CO,"InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2",IBAQFPQHRJAVAV-UHFFFAOYSA-N,miglitol,Launched,glucosidase inhibitor,GAA|GANAB|GANC|MGAM,endocrinology,diabetes mellitus
CCCCN1CC(O)C(O)C(O)C1CO,"InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3",UQRORFVVSGFNRO-UHFFFAOYSA-N,miglustat,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease
CCCCCNCC(N)=O,"InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)",GJNNXIYZWIZFRH-UHFFFAOYSA-N,milacemide,Phase 3,monoamine oxidase inhibitor,MAOB,,
CC1(C)CCC2(CC1)NC(C(=O)NC1CCC(C(N)=O)OC1)C(c1ccnc(Cl)c1F)C21C(=O)Nc2cc(Cl)ccc21,"InChI=1S/C30H34Cl2FN5O4/c1-28(2)8-10-29(11-9-28)30(18-5-3-15(31)13-19(18)37-27(30)41)21(17-7-12-35-24(32)22(17)33)23(38-29)26(40)36-16-4-6-20(25(34)39)42-14-16/h3,5,7,12-13,16,20-21,23,38H,4,6,8-11,14H2,1-2H3,(H2,34,39)(H,36,40)(H,37,41)",RYAYYVTWKAOAJF-UHFFFAOYSA-N,milademetan,Phase 1,MDM inhibitor,,,
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,"InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3",GJJFMKBJSRMPLA-UHFFFAOYSA-N,milnacipran,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,rheumatology,fibromyalgia
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,"InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)",PZRHRDRVRGEVNW-UHFFFAOYSA-N,milrinone,Launched,phosphodiesterase inhibitor,PDE2A|PDE3A|PDE3B|PDE5A,cardiology,congestive heart failure
CCCCCCCCCCCCCCCCO[PH](=O)(=O)OCC[N+](C)(C)C,"InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3/q+1",BXWQEWMMVOSWKW-UHFFFAOYSA-N,miltefosine,Launched,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis
NC(Cn1ccc(=O)c(O)c1)C(=O)O,"InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)",WZNJWVWKTVETCG-UHFFFAOYSA-N,mimosine,Preclinical,DNA replication inhibitor,CCL2|SHMT1|SHMT2|TYR,,
Cc1cc(-c2ccccc2)n[nH]c1=NCCN1CCOCC1,"InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)",LDMWSLGGVTVJPG-UHFFFAOYSA-N,minaprine,Withdrawn,serotonin reuptake inhibitor,ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4,,
CCCCCCCCC=CCCCCCCC(=O)C(O)O,"InChI=1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,18,20-21H,2-8,11-16H2,1H3",XPSHIGAXIBDMRO-UHFFFAOYSA-N,minerval,Phase 1/Phase 2,FAAH inhibitor,,,
CN(C)c1ccc(O)c2c1CC1CC3C(N(C)C)C(=O)C(C(N)=O)C(=O)C3(O)C(=O)C1C2=O,"InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,14,16-17,27,33H,7-8H2,1-4H3,(H2,24,32)",ZZZRUAITSXLWBH-UHFFFAOYSA-N,minocycline,Launched,bacterial 30S ribosomal subunit inhibitor,,endocrinology|infectious disease|ophthalmology|urology,fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|tularemia|cholera|brucellosis
O=[PH](=O)(O)C(O)(Cc1cnc2ccccn12)[PH](=O)(=O)O,"InChI=1S/C9H10N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H,13,14,15)(H,16,17,18)",JVWDENNMNWMPJW-UHFFFAOYSA-N,minodronic-acid,Launched,bone resorption inhibitor,FDPS|GGPS1,orthopedics,osteoporosis
N=c1[nH]c(N2CCCCC2)cc(N)[n+]1[O-],"InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12)",ZFMITUMMTDLWHR-UHFFFAOYSA-N,minoxidil,Launched,KATP activator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia
N=c1[nH]c(N2CCCCC2)cc(N)[n+]1[O-],"InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12)",ZFMITUMMTDLWHR-UHFFFAOYSA-N,minoxidil,Launched,Kir6 channel (KATP) activator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia
N=c1[nH]c(N2CCCCC2)cc(N)[n+]1[O-],"InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12)",ZFMITUMMTDLWHR-UHFFFAOYSA-N,minoxidil,Launched,vasodilator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia
CCC(=O)OC1CC(=O)OC(C)CC=CC=CC(OC(C)=O)C(C)CC(CC=O)C(OC2OC(C)C(OC3CC(C)(OC(C)=O)C(OC(=O)CC)C(C)O3)C(N(C)C)C2O)C1OC,"InChI=1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3",GQNZGCARKRHPOH-UHFFFAOYSA-N,miocamycin,Launched,other antibiotic,,infectious disease,urinary tract infections|chlamydia
CCC(=O)OCN1C(=O)C=CC1=O,"InChI=1S/C8H9NO4/c1-2-8(12)13-5-9-6(10)3-4-7(9)11/h3-4H,2,5H2,1H3",YXEWPGYLMHXLPS-UHFFFAOYSA-N,mira-1,Preclinical,apoptosis stimulant,,,
N=c1[nH]c(CC(=O)Nc2ccc(CCNCC(O)c3ccccc3)cc2)cs1,"InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)",PBAPPPCECJKMCM-UHFFFAOYSA-N,mirabegron,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,urology,urinary incontinence
O=C(O)C1CCCN1C(=O)CCCCC(=O)N1CCCC1C(=O)O,"InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)",HZLAWYIBLZNRFZ-UHFFFAOYSA-N,miridesap,Preclinical,amyloid protein inhibitor,,,
N=C1NC(=O)C(=Cc2ccc(O)cc2)S1,"InChI=1S/C10H8N2O2S/c11-10-12-9(14)8(15-10)5-6-1-3-7(13)4-2-6/h1-5,13H,(H2,11,12,14)",YBHQCJILTOVLHD-UHFFFAOYSA-N,mirin,Preclinical,MRE11A exonuclease inhibitor,MRE11A,,
CCCCCCCCCCCCCC(=O)O,"InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)",TUNFSRHWOTWDNC-UHFFFAOYSA-N,miriplatin,Launched,DNA synthesis inhibitor,,oncology,hepatocellular carcinoma (HCC)
CCCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc(=O)c2c([nH]1)c(CCC)cn2CC,"InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)",MIJFNYMSCFYZNY-UHFFFAOYSA-N,mirodenafil,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction
CCC1=CC2C(C1)CC2(CN)CC(=O)O,"InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)",FTBQORVNHOIASH-UHFFFAOYSA-N,mirogabalin-besylate,Preclinical,calcium channel antagonist,,,
CN1CCN2c3ncccc3Cc3ccccc3C2C1,"InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3",RONZAEMNMFQXRA-UHFFFAOYSA-N,mirtazapine,Launched,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C,neurology/psychiatry,depression
CN1CCN2c3ncccc3Cc3ccccc3C2C1,"InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3",RONZAEMNMFQXRA-UHFFFAOYSA-N,mirtazapine,Launched,serotonin receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C,neurology/psychiatry,depression
COCC(O)Cn1ccnc1[N+](=O)[O-],"InChI=1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3",OBBCSXFCDPPXOL-UHFFFAOYSA-N,misonidazole,Phase 3,,,,
CCCCC(C)(O)CC=CC1C(O)CC(=O)C1CCCCCCC(=O)OC,"InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3",OJLOPKGSLYJEMD-UHFFFAOYSA-N,misoprostol,Launched,prostanoid receptor agonist,PTGER2|PTGER3|PTGER4|PTGIR,gastroenterology,duodenal ulcer disease
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1,"InChI=1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2",XAYGBKHKBBXDAK-UHFFFAOYSA-N,mitapivat,Preclinical,pyruvate kinase isozyme activator,,,
O=C(O)C(CC(=O)N1CC2CCCCC2C1)Cc1ccccc1,"InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)",WPGGHFDDFPHPOB-UHFFFAOYSA-N,mitiglinide,Launched,insulin secretagogue,ABCC8|KCNJ10|PPARG,endocrinology,diabetes mellitus
O=C(O)Cc1cccc2c(=O)cc(-c3ccccc3)oc12,"InChI=1S/C17H12O4/c18-14-10-15(11-5-2-1-3-6-11)21-17-12(9-16(19)20)7-4-8-13(14)17/h1-8,10H,9H2,(H,19,20)",TZZNWMJZDWYJAZ-UHFFFAOYSA-N,mitoflaxone,Phase 2,antitumor agent,VWF,,
COC12C(=COC(N)=O)c3c(O)c(N)c(C)c(O)c3N1CC1NC12,"InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h4,7,13,18,20-21H,3,16H2,1-2H3,(H2,17,22)",DZFQLAHFWAYDSR-UHFFFAOYSA-N,mitomycin-c,Launched,DNA alkylating agent,,oncology,pancreatic cancer|gastric adenocarcinoma
COC12C(=COC(N)=O)c3c(O)c(N)c(C)c(O)c3N1CC1NC12,"InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h4,7,13,18,20-21H,3,16H2,1-2H3,(H2,17,22)",DZFQLAHFWAYDSR-UHFFFAOYSA-N,mitomycin-c,Launched,DNA synthesis inhibitor,,oncology,pancreatic cancer|gastric adenocarcinoma
COc1c(O)c(C)c(C=CCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)c(O)c1OC,"InChI=1S/C37H43O4P/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32/h10-19,21-27H,4-9,20,28H2,1-3H3,(H-,38,39)/p+1",NGQALAHDDVTDHQ-UHFFFAOYSA-O,mitoquinone,Launched,antioxidant,,,
Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1,"InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H",JWBOIMRXGHLCPP-UHFFFAOYSA-N,mitotane,Launched,antineoplastic agent,CYP11A1|CYP11B1|ESR1,oncology,adrenal cortical carcinoma
OCCN=CCNc1ccc(NCCNCCO)c2c(O)c3c(O)ccc(O)c3c(O)c12,"InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-5,24-32H,6-12H2",YYJKSCIIZGQWEE-UHFFFAOYSA-N,mitoxantrone,Launched,topoisomerase inhibitor,TOP2A,neurology/psychiatry|oncology|hematologic malignancy,multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)
COc1cc2c(cc1OC)C(Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CCC=CCCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3C1Cc1cc(OC)c(OC)c(OC)c1)CC2,"InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2",ILVYCEVXHALBSC-UHFFFAOYSA-N,mivacurium,Launched,acetylcholine receptor antagonist,CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(-c2cn(C)c(=O)c3[nH]ccc23)c1,"InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3",RDONXGFGWSSFMY-UHFFFAOYSA-N,mivebresib,Phase 1,bromodomain inhibitor,,,
CCOC(O)N=c1cc2nc(C)c(-c3ccccc3)nc2c(N)[nH]1,"InChI=1S/C17H19N5O2/c1-3-24-17(23)21-13-9-12-15(16(18)20-13)22-14(10(2)19-12)11-7-5-4-6-8-11/h4-9,17,23H,3H2,1-2H3,(H3,18,20,21)",XEVLFXKFJGKHJY-UHFFFAOYSA-N,mivobulin,Phase 2,microtubule inhibitor,,,
N=c1[nH]cnc2c1ncn2C1OC2COP(=O)(S)OC3C(O)C(COP(=O)(S)OC2C1O)OC3n1cnc2c(=N)[nH]cnc21,"InChI=1S/C20H24N10O10P2S2/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26)",IZJJFUQKKZFVLH-UHFFFAOYSA-N,miw-815,Preclinical,interferon inducer,,,
CN(c1nc(=O)cc[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,"InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)",PVLJETXTTWAYEW-UHFFFAOYSA-N,mizolastine,Launched,histamine receptor antagonist,HRH1,allergy,urticaria|allergic rhinitis
NC(=O)c1ncn(C2OC(CO)C(O)C2O)c1O,"InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)",HZQDCMWJEBCWBR-UHFFFAOYSA-N,mizoribine,Launched,immunosuppressant,IMPDH1,transplant|rheumatology,organ rejection|nephrotic syndrome
NC(=O)c1ncn(C2OC(CO)C(O)C2O)c1O,"InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)",HZQDCMWJEBCWBR-UHFFFAOYSA-N,mizoribine,Launched,inosine monophosphate dehydrogenase inhibitor,IMPDH1,transplant|rheumatology,organ rejection|nephrotic syndrome
Cc1c(C(=O)NCc2cccnc2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"InChI=1S/C23H17Cl3N4O/c1-14-21(23(31)28-13-15-3-2-10-27-12-15)29-30(20-9-8-18(25)11-19(20)26)22(14)16-4-6-17(24)7-5-16/h2-12H,13H2,1H3,(H,28,31)",PJEIKJFNEFJFLA-UHFFFAOYSA-N,mj-15,Preclinical,cannabinoid receptor antagonist,CNR1,,
C1Cc2[nH]nc(-c3nn[nH]n3)c2C1,"InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13)",LTQYSJKGRPGMPO-UHFFFAOYSA-N,mk-0354,Phase 2,niacin receptor agonist,HCAR2|HCAR3,,
O=C1OC2(CCC(C(=O)N=c3ccn(-c4ccccc4F)[nH]3)CC2)c2cnccc21,"InChI=1S/C22H19FN4O3/c23-17-3-1-2-4-18(17)27-12-8-19(26-27)25-20(28)14-5-9-22(10-6-14)16-13-24-11-7-15(16)21(29)30-22/h1-4,7-8,11-14H,5-6,9-10H2,(H,25,26,28)",RMYZIRFUCOMQRH-UHFFFAOYSA-N,mk-0557,Phase 3,neuropeptide receptor antagonist,,,
CC1(O)C(O)C(CO)OC1n1ccc2c(=N)[nH]cnc21,"InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)",IRZRJANZDIOOIF-UHFFFAOYSA-N,mk-0608,Phase 1,antiviral,,,
O=C(O)CCC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1,"InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)",XCGJIFAKUZNNOR-UHFFFAOYSA-N,mk-0752,Phase 1/Phase 2,gamma secretase inhibitor,,,
CN1C(=O)C(F)=CC2(C)C3CCC4(C)C(C(=O)NCc5nc6cccnc6[nH]5)CCC4C3CCC12,"InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)",GBEUKTWTUSPHEE-UHFFFAOYSA-N,mk-0773,Phase 2,androgen receptor modulator,AR,,
COC1COCCC1NC1CCC(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1,"InChI=1S/C24H34F3N3O3/c1-15(2)23(7-4-18(11-23)29-20-6-9-33-14-21(20)32-3)22(31)30-8-5-19-16(13-30)10-17(12-28-19)24(25,26)27/h10,12,15,18,20-21,29H,4-9,11,13-14H2,1-3H3",MTMDXAIUENDNDL-UHFFFAOYSA-N,mk-0812,Phase 2,CC chemokine receptor antagonist,CCR2,,
COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3C(C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,"InChI=1S/C32H27Cl2N3O4/c1-19(20-3-5-21(6-4-20)32(40)35-12-11-31(38)39)37-30(18-29(36-37)25-14-26(33)17-27(34)15-25)24-8-7-23-16-28(41-2)10-9-22(23)13-24/h3-10,13-19H,11-12H2,1-2H3,(H,35,40)(H,38,39)",DNTVJEMGHBIUMW-UHFFFAOYSA-N,mk-0893,Phase 2,glucagon receptor antagonist,GCGR,,
COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC,"InChI=1S/C24H20ClN5O3/c1-32-21-7-6-18(30-24(21)33-2)14-29-23(31)19-10-16(15-9-17(25)13-26-11-15)12-28-22(19)20-5-3-4-8-27-20/h3-13H,14H2,1-2H3,(H,29,31)",CKTWQGHVNRYNCM-UHFFFAOYSA-N,mk-1064,Phase 1,orexin receptor antagonist,,,
C=CCn1c(=O)c2c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,"InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)",BKWJAKQVGHWELA-UHFFFAOYSA-N,mk-1775,Phase 2,WEE1 kinase inhibitor,WEE1,,
O=C(O)c1[nH]nc2c1CC1CC21,"InChI=1S/C8H8N2O2/c11-8(12)7-5-2-3-1-4(3)6(5)9-10-7/h3-4H,1-2H2,(H,9,10)(H,11,12)",CUTZNERBKDMLAP-UHFFFAOYSA-N,mk-1903,Phase 2,niacin receptor agonist,,,
CCN1CC(C)n2c(c(O)c3c(=O)n(Cc4ccc(F)c(Cl)c4)nc(C(=O)NC)c32)C1=O,"InChI=1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,29H,4,8-9H2,1-3H3,(H,24,30)",JSRREMIKIHJGAA-UHFFFAOYSA-N,mk-2048,Preclinical,HIV integrase inhibitor,,,
NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)",ULDXWLCXEDXJGE-UHFFFAOYSA-N,mk-2206,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
FC(F)(F)c1ccc(N=c2[nH]cnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,"InChI=1S/C21H12F6N4/c22-20(23,24)13-4-6-14(7-5-13)31-19-15-8-3-12(10-17(15)29-11-30-19)18-16(21(25,26)27)2-1-9-28-18/h1-11H,(H,29,30,31)",VTANGSDRFFLTSQ-UHFFFAOYSA-N,mk-2295,Phase 2,TRPV antagonist,TRPV1,,
CN(CC1COCCO1)S(=O)(=O)N=c1ccc2ccc3[nH]cc(-c4cnn(C)c4)cc3c(=O)c2c1,"InChI=1S/C24H25N5O5S/c1-28-13-18(12-26-28)17-9-22-23(25-11-17)6-4-16-3-5-19(10-21(16)24(22)30)27-35(31,32)29(2)14-20-15-33-7-8-34-20/h3-6,9-13,20,25H,7-8,14-15H2,1-2H3",AHHRTKFNTWZUAH-UHFFFAOYSA-N,mk-2461,Phase 1/Phase 2,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB,,
CN(CC1COCCO1)S(=O)(=O)N=c1ccc2ccc3[nH]cc(-c4cnn(C)c4)cc3c(=O)c2c1,"InChI=1S/C24H25N5O5S/c1-28-13-18(12-26-28)17-9-22-23(25-11-17)6-4-16-3-5-19(10-21(16)24(22)30)27-35(31,32)29(2)14-20-15-33-7-8-34-20/h3-6,9-13,20,25H,7-8,14-15H2,1-2H3",AHHRTKFNTWZUAH-UHFFFAOYSA-N,mk-2461,Phase 1/Phase 2,VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB,,
Cc1sc(C)c(C(=O)NC2(c3ccc(C(=O)O)cc3)CC2)c1Cc1ccc(C(F)(F)F)cc1,"InChI=1S/C25H22F3NO3S/c1-14-20(13-16-3-7-19(8-4-16)25(26,27)28)21(15(2)33-14)22(30)29-24(11-12-24)18-9-5-17(6-10-18)23(31)32/h3-10H,11-13H2,1-2H3,(H,29,30)(H,31,32)",QJZQFVRFJCGDKF-UHFFFAOYSA-N,mk-2894,Preclinical,prostaglandin inhibitor,PTGER4,,
O=C(CN1C(=O)C2(CCCC2)NCC1c1cc(F)cc(F)c1)Nc1ccc2c(c1)CC1(C2)C(=O)Nc2ncccc21,"InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)",AZAANWYREOQRFB-UHFFFAOYSA-N,mk-3207,Phase 2,calcitonin antagonist,CALCA,,
COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,"InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)",VSOUDUXMPUHJEU-UHFFFAOYSA-N,mk-3697,Phase 2,orexin receptor antagonist,HCRTR2,,
COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2cc(-c4cncc(C(=O)O)c4)ccc2O3)cc2c1c(C)cn2C1CC1,"InChI=1S/C33H31N3O6/c1-19-18-36(24-4-5-24)26-13-21(14-29(41-2)30(19)26)31(38)35-9-7-33(8-10-35)15-27(37)25-12-20(3-6-28(25)42-33)22-11-23(32(39)40)17-34-16-22/h3,6,11-14,16-18,24H,4-5,7-10,15H2,1-2H3,(H,39,40)",WDBNGXLHMZSUEI-UHFFFAOYSA-N,mk-4074,Phase 1,acetyl-CoA carboxylase inhibitor,,,
OC(Cc1nc(CC2(C(F)(F)F)CC2)c[nH]1)(c1ccc(-n2cccn2)cc1)C(F)(F)F,"InChI=1S/C20H18F6N4O/c21-19(22,23)17(6-7-17)10-14-12-27-16(29-14)11-18(31,20(24,25)26)13-2-4-15(5-3-13)30-9-1-8-28-30/h1-5,8-9,12,31H,6-7,10-11H2,(H,27,29)",UJINBEQCDMOAHM-UHFFFAOYSA-N,mk-5046,Preclinical,bombesin receptor agonist,BRS3|GRPR|NMBR,,
O=C(O)C1(Cc2cccc(=Nc3nccs3)[nH]2)CCC(Oc2cccc(Cl)c2F)CC1,"InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)",LCVIRAZGMYMNNT-UHFFFAOYSA-N,mk-5108,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CN(C)C(=O)CCSC(SCCC(=O)O)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,"InChI=1S/C26H27ClN2O3S2/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32)",AXUZQJFHDNNPFG-UHFFFAOYSA-N,mk-571,Phase 2,leukotriene receptor antagonist,ABCC2|CYSLTR1,,
Cc1ccc(-c2ncccn2)c(C(=O)N2CC(COc3ccc(F)cn3)CCC2C)c1,"InChI=1S/C24H25FN4O2/c1-16-4-8-20(23-26-10-3-11-27-23)21(12-16)24(30)29-14-18(6-5-17(29)2)15-31-22-9-7-19(25)13-28-22/h3-4,7-13,17-18H,5-6,14-15H2,1-2H3",NPFDWHQSDBWQLH-UHFFFAOYSA-N,mk-6096,Phase 2,orexin receptor antagonist,HCRTR1|HCRTR2,,
CN(C1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,"InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-21(25)26)17-4-2-3-5-19(17)24(20)13-15/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)",JTCAGRAKUAAYDY-UHFFFAOYSA-N,mk-7246,Preclinical,CRTH receptor antagonist,,,
Cc1ccc(Cc2cc3c(=O)n(C4CCCCC4O)cnc3c3ccccc23)cn1,"InChI=1S/C25H25N3O2/c1-16-10-11-17(14-26-16)12-18-13-21-24(20-7-3-2-6-19(18)20)27-15-28(25(21)30)22-8-4-5-9-23(22)29/h2-3,6-7,10-11,13-15,22-23,29H,4-5,8-9,12H2,1H3",JUVQLZBJFOGEEO-UHFFFAOYSA-N,mk-7622,Phase 2,cholinergic receptor agonist,,,
Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,"InChI=1S/C25H21N5O3S/c1-30-15-20(13-28-30)19-11-23-24(27-12-19)8-7-18-6-5-17(10-22(18)25(23)31)16-34(32,33)29-14-21-4-2-3-9-26-21/h2-13,15,29H,14,16H2,1H3",VMJFTOSOFDEKTM-UHFFFAOYSA-N,mk-8033,Phase 1,c-Met inhibitor,MET,,
O=C(O)Cn1nnc(-c2cc(N3CCC(Oc4cc(F)ccc4Br)CC3)no2)n1,"InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)",UJEAABFSXKCSGI-UHFFFAOYSA-N,mk-8245,Phase 2,stearoyl-CoA desaturase inhibitor,SCD,,
COc1ccc(C(NC(=O)c2c[nH]c(-c3cccnn3)nc2=O)c2ccc(OC)cc2)cc1,"InChI=1S/C24H21N5O4/c1-32-17-9-5-15(6-10-17)21(16-7-11-18(33-2)12-8-16)27-23(30)19-14-25-22(28-24(19)31)20-4-3-13-26-29-20/h3-14,21H,1-2H3,(H,27,30)(H,25,28,31)",WXLPERVDMILVIF-UHFFFAOYSA-N,mk-8617,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
O=C(c1cccc(Cl)c1F)N1CCN(Cc2cccc(=Nc3nccs3)[nH]2)CC1,"InChI=1S/C20H19ClFN5OS/c21-16-5-2-4-15(18(16)22)19(28)27-10-8-26(9-11-27)13-14-3-1-6-17(24-14)25-20-23-7-12-29-20/h1-7,12H,8-11,13H2,(H,23,24,25)",YCRFPWKUUNKNDN-UHFFFAOYSA-N,mk-8745,Preclinical,Aurora kinase inhibitor,AURKA,,
CC(C)c1ccc2c(c1)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,"InChI=1S/C27H34ClNO2S/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18/h8-14,17H,15-16H2,1-7H3,(H,30,31)",QAOAOVKBIIKRNL-UHFFFAOYSA-N,mk-886,Preclinical,lipoxygenase inhibitor,,,
CC(C)c1ccc(CC(=O)NC(C)c2ccc(OCC(F)(F)F)cn2)cc1,"InChI=1S/C20H23F3N2O2/c1-13(2)16-6-4-15(5-7-16)10-19(26)25-14(3)18-9-8-17(11-24-18)27-12-20(21,22)23/h4-9,11,13-14H,10,12H2,1-3H3,(H,25,26)",IQIKXZMPPBEWAD-UHFFFAOYSA-N,mk-8998,Phase 2,T-type calcium channel blocker,,,
O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1,"InChI=1S/C27H25ClN4O2/c28-21-6-4-20(5-7-21)25-12-13-26(34-25)27(33)32(19-22-3-1-2-14-30-22)24-10-8-23(9-11-24)31-17-15-29-16-18-31/h1-14,29H,15-19H2",LIPNXDIBECKOMJ-UHFFFAOYSA-N,mk2-in-1,Preclinical,MAP kinase inhibitor,MAPKAPK2,,
CCn1c(=Cc2cccc[n+]2CC)sc(=C2Sc3ccccc3N2C)c1=O,"InChI=1S/C21H22N3OS2/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21/h6-14H,4-5H2,1-3H3/q+1",QLYHOWIZHHZGPV-UHFFFAOYSA-N,mkt-077,Phase 1,HSP inhibitor,,,
COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1,"InChI=1S/C15H21ClN2O3/c1-20-14-10-13(17)12(16)9-11(14)15(19)21-8-7-18-5-3-2-4-6-18/h9-10H,2-8,17H2,1H3",RVFIAQAAZUEPPE-UHFFFAOYSA-N,ml10302,Preclinical,serotonin receptor partial agonist,HTR3A|HTR3B|HTR4,,
Cc1ccc(S(=O)(=O)n2c(=N)[nH]c3ccccc32)cc1,"InChI=1S/C14H13N3O2S/c1-10-6-8-11(9-7-10)20(18,19)17-13-5-3-2-4-12(13)16-14(17)15/h2-9H,1H3,(H2,15,16)",SRFABRWQVPCPRG-UHFFFAOYSA-N,ml130,Preclinical,NOD1 inhibitor,,,
COc1ccc(CNCc2cccc3ccccc23)cc1,"InChI=1S/C19H19NO/c1-21-18-11-9-15(10-12-18)13-20-14-17-7-4-6-16-5-2-3-8-19(16)17/h2-12,20H,13-14H2,1H3",GIFYKGIODMXYNT-UHFFFAOYSA-N,ml133,Preclinical,potassium channel blocker,,,
COc1ccc(C2CC(c3ccccc3)=NN2c2ccc(S(N)(=O)=O)cc2)cc1,"InChI=1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)",QBNZBMVRFYREHK-UHFFFAOYSA-N,ml141,Preclinical,GTPase inhibitor,CDC42,,
CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1,"InChI=1S/C17H17BrN2O2/c1-2-6-16(21)19-12-7-5-8-13(11-12)20-17(22)14-9-3-4-10-15(14)18/h3-5,7-11H,2,6H2,1H3,(H,19,21)(H,20,22)",DFOVLSMXPWPCFH-UHFFFAOYSA-N,ml161,Preclinical,protease-activated receptor inhibitor,,,
Cc1ccc(CN=c2[nH]cnc3ccc(-c4ccc(CO)o4)cc23)o1,"InChI=1S/C19H17N3O3/c1-12-2-4-14(24-12)9-20-19-16-8-13(3-6-17(16)21-11-22-19)18-7-5-15(10-23)25-18/h2-8,11,23H,9-10H2,1H3,(H,20,21,22)",ROCFOIBAEVAOLQ-UHFFFAOYSA-N,ml167,Preclinical,CLK inhibitor,CLK4|DYRK1B,,
Cc1ccc(CN=c2[nH]cnc3ccc(-c4ccc(CO)o4)cc23)o1,"InChI=1S/C19H17N3O3/c1-12-2-4-14(24-12)9-20-19-16-8-13(3-6-17(16)21-11-22-19)18-7-5-15(10-23)25-18/h2-8,11,23H,9-10H2,1H3,(H,20,21,22)",ROCFOIBAEVAOLQ-UHFFFAOYSA-N,ml167,Preclinical,DYRK inhibitor,CLK4|DYRK1B,,
O=c1cc(N2CCN(c3cccc(C(F)(F)F)c3)CC2)[nH]c(=O)n1C1CCCCC1,"InChI=1S/C21H25F3N4O2/c22-21(23,24)15-5-4-8-17(13-15)26-9-11-27(12-10-26)18-14-19(29)28(20(30)25-18)16-6-2-1-3-7-16/h4-5,8,13-14,16H,1-3,6-7,9-12H2,(H,25,30)",MFABFKUNLDYKGH-UHFFFAOYSA-N,ml179,Preclinical,liver receptor homolog inverse agonist,NR5A2,,
Cc1cc(C)c2nc(-c3ccccn3)cc(C(=O)Nc3ccc(S(=O)(=O)N=c4o[nH]c(C)c4C)cc3)c2c1,"InChI=1S/C28H25N5O4S/c1-16-13-17(2)26-22(14-16)23(15-25(31-26)24-7-5-6-12-29-24)27(34)30-20-8-10-21(11-9-20)38(35,36)33-28-18(3)19(4)32-37-28/h5-15,32H,1-4H3,(H,30,34)",AGNWVEJTZJIJIM-UHFFFAOYSA-N,ml193,Preclinical,G protein-coupled receptor antagonist,GPR55,,
Cc1cc(N2CCCCC2)nc2ccccc12,"InChI=1S/C15H18N2/c1-12-11-15(17-9-5-2-6-10-17)16-14-8-4-3-7-13(12)14/h3-4,7-8,11H,2,5-6,9-10H2,1H3",USYRQXDHKXGTCK-UHFFFAOYSA-N,ml204,Preclinical,transient receptor potential channel antagonist,TRPC4|TRPC5,,
Cc1cc(C)c(NC(=O)C2CC3CCC2C3)c(C)c1,"InChI=1S/C17H23NO/c1-10-6-11(2)16(12(3)7-10)18-17(19)15-9-13-4-5-14(15)8-13/h6-7,13-15H,4-5,8-9H2,1-3H3,(H,18,19)",SIQGKPGBLYKQBB-UHFFFAOYSA-N,ml213,Preclinical,potassium channel activator,KCNQ4,,
CC(C)(C)CCN1CC2C(CNC(=O)c3cc(Cl)cc(Cl)c3)C2C1,"InChI=1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)",GSJIGYLGKSBYBC-UHFFFAOYSA-N,ml218,Preclinical,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,
c1ccc(-c2ccc(CN=c3[nH]c(-c4ccccn4)nnc3-c3ccccc3)cc2)cc1,"InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32)",QNRODODTMXCRKU-UHFFFAOYSA-N,ml228,Preclinical,hypoxia inducible factor activator,HIF1A,,
COc1ccc(-c2csc(=NC(=O)C3CCCCN3S(=O)(=O)c3ccc(C)cc3)[nH]2)cc1,"InChI=1S/C23H25N3O4S2/c1-16-6-12-19(13-7-16)32(28,29)26-14-4-3-5-21(26)22(27)25-23-24-20(15-31-23)17-8-10-18(30-2)11-9-17/h6-13,15,21H,3-5,14H2,1-2H3,(H,24,25,27)",OXQNLLVUVDAEHC-UHFFFAOYSA-N,ml277,Preclinical,potassium channel activator,KCNQ1,,
CC(C)c1ccc(NC(=O)c2cccs2)c(-c2nc3ccccc3[nH]c2=O)c1,"InChI=1S/C22H19N3O2S/c1-13(2)14-9-10-16(24-21(26)19-8-5-11-28-19)15(12-14)20-22(27)25-18-7-4-3-6-17(18)23-20/h3-13H,1-2H3,(H,24,26)(H,25,27)",HWOYIOLMBQSTQS-UHFFFAOYSA-N,ml281,Preclinical,serine/threonine kinase inhibitor,STK33,,
Cc1cc(=NC(=O)Nc2ccc(F)c(F)c2)n(-c2ccccc2)[nH]1,"InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10,22H,1H3,(H,20,24)",TZCSXRWOFSIXLG-UHFFFAOYSA-N,ml297,Preclinical,inward rectifier potassium channel activator,KCNJ3,,
O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1,"InChI=1S/C22H23F3N4O2/c23-16-2-1-3-17(13-16)29-14-27-21(31)22(29)6-9-28(10-7-22)11-8-26-20(30)15-4-5-18(24)19(25)12-15/h1-5,12-13H,6-11,14H2,(H,26,30)(H,27,31)",XAPVAKKLQGLNOY-UHFFFAOYSA-N,ml298,Preclinical,phospholipase inhibitor,PLD2,,
COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC,"InChI=1S/C24H28N4O3/c1-29-20-7-5-4-6-19(20)27-10-12-28(13-11-27)24-17-14-21(30-2)22(31-3)15-18(17)25-23(26-24)16-8-9-16/h4-7,14-16H,8-13H2,1-3H3",SWEOAXMICIJCQC-UHFFFAOYSA-N,ml314,Preclinical,neurotensin agonist,NTSR1,,
Cc1c[nH]c(-c2ccccc2C(C)C)nc1=NCc1ccc(-n2ccnn2)cc1,"InChI=1S/C23H24N6/c1-16(2)20-6-4-5-7-21(20)23-24-14-17(3)22(27-23)25-15-18-8-10-19(11-9-18)29-13-12-26-28-29/h4-14,16H,15H2,1-3H3,(H,24,25,27)",VUIRVWPJNKZOSS-UHFFFAOYSA-N,ml323,Preclinical,ubiquitin specific protease inhibitor,USP1,,
CN(C)CCCNC(=O)c1ccc(-c2cc(O)c3ncccc3c2)cc1,"InChI=1S/C21H23N3O2/c1-24(2)12-4-11-23-21(26)16-8-6-15(7-9-16)18-13-17-5-3-10-22-20(17)19(25)14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,23,26)",QDBVSOZTVKXUES-UHFFFAOYSA-N,ml324,Preclinical,histone lysine demethylase inhibitor,KDM4A,,
CSc1nc(-c2cc[nH]c(=NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,"InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)",VXPWQNBKEIVYIS-UHFFFAOYSA-N,ml3403,Preclinical,MAP kinase inhibitor,CYP3A4|MAPK11|MAPK12|MAPK14,,
COc1ccc(-c2cnc3c(-c4cccc5ncccc45)cnn3c2)cc1,"InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3",FVRYPYDPKSZGNS-UHFFFAOYSA-N,ml347,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1|ACVRL1|BMPR1A,,
O=C(CN1CCN(C(=O)c2ccco2)CC1)Nc1cc(C(F)(F)F)ccc1Cl,"InChI=1S/C18H17ClF3N3O3/c19-13-4-3-12(18(20,21)22)10-14(13)23-16(26)11-24-5-7-25(8-6-24)17(27)15-2-1-9-28-15/h1-4,9-10H,5-8,11H2,(H,23,26)",OXKNHBBDOIMFFQ-UHFFFAOYSA-N,ml348,Preclinical,lysophospholipase inhibitor,LYPLA1,,
COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1,"InChI=1S/C22H20N2O3/c1-15-7-5-8-16(13-15)21(25)23-17-9-6-10-18(14-17)24-22(26)19-11-3-4-12-20(19)27-2/h3-14H,1-2H3,(H,23,25)(H,24,26)",UTAJHKSGYJSZBR-UHFFFAOYSA-N,ml365,Preclinical,potassium channel blocker,KCNK3|KCNK9,,
CC(C)(N)c1cc(C(=O)NC2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,"InChI=1S/C29H29F3N4O3/c1-28(2,33)19-11-18(12-20(15-19)29(30,31)32)27(38)35-21-5-3-16-4-6-22(14-17(16)13-21)39-24-9-10-34-26-23(24)7-8-25(37)36-26/h4,6,9-12,14-15,21H,3,5,7-8,13,33H2,1-2H3,(H,35,38)(H,34,36,37)",GXEGTVQATHKFDH-UHFFFAOYSA-N,ml786,Preclinical,RAF inhibitor,BRAF|RAF1,,
O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1,"InChI=1S/C15H17ClN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2",OZSMSRIUUDGTEP-UHFFFAOYSA-N,ml9,Preclinical,myosin light chain kinase inhibitor,TRPC6,,
CC(C)n1nc(-c2ccc3oc(=N)[nH]c3c2)c2c(=N)[nH]cnc21,"InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)",GYLDXIAOMVERTK-UHFFFAOYSA-N,mln0128,Phase 2,mTOR inhibitor,MTOR|PIK3CA|PIK3CD|PIK3CG,,
N=c1[nH]c2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,"InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)",BLGWHBSBBJNKJO-UHFFFAOYSA-N,mln1117,Phase 2,PI3K inhibitor,PIK3CA,,
CC(NC(=O)c1[nH]cnc(=N)c1Cl)c1ncc(C(=O)N=c2cc(C(F)(F)F)c(Cl)c[nH]2)s1,"InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)",VWMJHAFYPMOMGF-UHFFFAOYSA-N,mln2480,Phase 1/Phase 2,RAF inhibitor,,,
O=C(O)c1ccc(N=c2nc3c(c[nH]2)CN=C(c2c(F)cccc2F)c2cc(Cl)ccc2-3)cc1,"InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)",HHFBDROWDBDFBR-UHFFFAOYSA-N,mln8054,Phase 1,Aurora kinase inhibitor,AURKA,,
CC(C)CC(NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,"InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)",MBOMYENWWXQSNW-UHFFFAOYSA-N,mln9708,Phase 3,proteasome inhibitor,,,
CCC(CC)(NC(=O)C(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC1(C(=O)NC(c2ccc(F)cc2)c2ccc(F)cc2)CCCC1,"InChI=1S/C35H49F2N7O4/c1-5-34(6-2,43-29(45)22(3)4)31(47)41-27(10-9-21-40-33(38)39)30(46)44-35(19-7-8-20-35)32(48)42-28(23-11-15-25(36)16-12-23)24-13-17-26(37)18-14-24/h11-18,22,27-28H,5-10,19-21H2,1-4H3,(H,41,47)(H,42,48)(H,43,45)(H,44,46)(H4,38,39,40)",RZKSQRIPRKWVBU-UHFFFAOYSA-N,mm-102,Preclinical,WDR5/MLL interaction inhibitor,,,
CC1(C)CCC(C)(C)c2cc(C3(c4ccc5cc(C(=O)O)ccc5c4)SCCS3)ccc21,"InChI=1S/C28H30O2S2/c1-26(2)11-12-27(3,4)24-17-22(9-10-23(24)26)28(31-13-14-32-28)21-8-7-18-15-20(25(29)30)6-5-19(18)16-21/h5-10,15-17H,11-14H2,1-4H3,(H,29,30)",DPVGXUNWCVEIGT-UHFFFAOYSA-N,mm-11253,Preclinical,retinoid receptor antagonist,RARG,,
O=S(=O)(Nc1cc(Sc2ccccc2)c(O)c2ccccc12)c1c(F)c(F)c(F)c(F)c1F,"InChI=1S/C22H12F5NO3S2/c23-16-17(24)19(26)22(20(27)18(16)25)33(30,31)28-14-10-15(32-11-6-2-1-3-7-11)21(29)13-9-5-4-8-12(13)14/h1-10,28-29H",ZXJHEANDHXHGMV-UHFFFAOYSA-N,mm-206,Preclinical,STAT inhibitor,,,
COc1ccccc1N1CCN(CCCCn2c(O)ccc2O)CC1,"InChI=1S/C19H27N3O3/c1-25-17-7-3-2-6-16(17)21-14-12-20(13-15-21)10-4-5-11-22-18(23)8-9-19(22)24/h2-3,6-9,23-24H,4-5,10-15H2,1H3",DVIZJFOAZVEWCF-UHFFFAOYSA-N,mm77,Preclinical,serotonin receptor antagonist,HTR1A,,
COCc1nc2c(=O)n(C)c(=O)n(CC(C)C)c2[nH]1,"InChI=1S/C12H18N4O3/c1-7(2)5-16-10-9(11(17)15(3)12(16)18)13-8(14-10)6-19-4/h7H,5-6H2,1-4H3,(H,13,14)",NBLBCGUCPBXKOV-UHFFFAOYSA-N,mmpx,Preclinical,phosphodiesterase inhibitor,,,
CS(=O)(=O)c1ccc(-c2c[nH]c(=N)c(-c3ccc(C(F)(F)F)nc3)c2)cc1,"InChI=1S/C18H14F3N3O2S/c1-27(25,26)14-5-2-11(3-6-14)13-8-15(17(22)24-10-13)12-4-7-16(23-9-12)18(19,20)21/h2-10H,1H3,(H2,22,24)",RTJQABCNNLMCJF-UHFFFAOYSA-N,mmv-390048,Preclinical,PI4K inhibitor,,,
CC(C)c1ccc(-c2cc(=O)c3ccccc3o2)cc1,"InChI=1S/C18H16O2/c1-12(2)13-7-9-14(10-8-13)18-11-16(19)15-5-3-4-6-17(15)20-18/h3-12H,1-2H3",PYTOHIUBXSJKQH-UHFFFAOYSA-N,mn-64,Preclinical,tankyrase inhibitor,TNKS,,
Cn1cnnc1Sc1c([N+](=O)[O-])ncn1C,"InChI=1S/C7H8N6O2S/c1-11-3-8-5(13(14)15)6(11)16-7-10-9-4-12(7)2/h3-4H,1-2H3",NMBDIMPYACLUDE-UHFFFAOYSA-N,mnitmt,Preclinical,lymphocyte inhibitor,,,
Nc1ccccc1NC(=O)c1ccc(CN=c2nc(-c3cccnc3)cc[nH]2)cc1,"InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)",HRNLUBSXIHFDHP-UHFFFAOYSA-N,mocetinostat,Phase 2,HDAC inhibitor,HDAC1|HDAC11|HDAC2|HDAC3,,
O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,"InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)",YHXISWVBGDMDLQ-UHFFFAOYSA-N,moclobemide,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression|anxiety
Cc1nccnc1N1CCCCC1,"InChI=1S/C10H15N3/c1-9-10(12-6-5-11-9)13-7-3-2-4-8-13/h5-6H,2-4,7-8H2,1H3",BJHCGMHPEKLROM-UHFFFAOYSA-N,modaline,Preclinical,,,,
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1Cc2cc(OC)c(OC)cc2CC1C(=O)O,"InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)",UWWDHYUMIORJTA-UHFFFAOYSA-N,moexipril,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology,hypertension
NCC(=CF)CCc1ccc(F)cc1,"InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2",VXLBSYHAEKDUSU-UHFFFAOYSA-N,mofegiline,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB,,
COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1,"InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)",DJEIHHYCDCTAAH-UHFFFAOYSA-N,mofezolac,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology|orthopedics,rheumatoid arthritis|osteoporosis
CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC,"InChI=1S/C16H21NO5S/c1-3-21-16(19)10-14(18)17-8-9-23-15(17)11-22-13-7-5-4-6-12(13)20-2/h4-7,15H,3,8-11H2,1-2H3",WSYVIAQNTFPTBI-UHFFFAOYSA-N,moguisteine,Phase 2,ATP-sensitive potassium channel inhibitor,,,
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1,"InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2",IJMBOKOTALXLKS-UHFFFAOYSA-N,molidustat,Phase 3,hypoxia inducible factor inhibitor,EGLN2,,
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,"InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3",KLPWJLBORRMFGK-UHFFFAOYSA-N,molindone,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia
CCOC(=O)N=c1c[n+](N2CCOCC2)[nH]o1,"InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3/p+1",XLFWDASMENKTKL-UHFFFAOYSA-O,molsidomine,Launched,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD)
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CCl,"InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h4,6-7,12,15-17,26,28H,5,8-11H2,1-3H3",ADDZRWYKTHEDLJ-UHFFFAOYSA-N,mometasone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC1CC2C3CC=C4CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl,"InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-6,8-10,15,18-19,21,31H,7,11-14H2,1-3H3",DQTQVEGUWIUSSO-UHFFFAOYSA-N,mometasone-furoate,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CCOC(=O)C1C(C)=NC(=S)NC1c1cccc(O)c1,"InChI=1S/C14H16N2O3S/c1-3-19-13(18)11-8(2)15-14(20)16-12(11)9-5-4-6-10(17)7-9/h4-7,11-12,17H,3H2,1-2H3,(H,16,20)",PSKVISJISBFCKP-UHFFFAOYSA-N,monastrol,Preclinical,kinesin inhibitor,KIF11,,
CCC1(C2OC(C3OC(O)(CO)C(C)CC3C)CC2C)CCC(C2(C)CCC3(CC(O)C(C)C(C(C)C(OC)C(C)C(=O)O)O3)O2)O1,"InChI=1S/C36H62O11/c1-10-34(31-20(3)16-26(43-31)28-19(2)15-21(4)36(41,18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31,37-38,41H,10-18H2,1-9H3,(H,39,40)",GAOZTHIDHYLHMS-UHFFFAOYSA-N,monensin,Launched,bacterial permeability inducer,,infectious disease,gastrointestinal parasites
CC(C#N)(COc1cc(C#N)ccc1C(F)(F)F)NC(=O)c1ccc(SC(F)(F)F)cc1,"InChI=1S/C20H13F6N3O2S/c1-18(10-28,11-31-16-8-12(9-27)2-7-15(16)19(21,22)23)29-17(30)13-3-5-14(6-4-13)32-20(24,25)26/h2-8H,11H2,1H3,(H,29,30)",WTERNLDOAPYGJD-UHFFFAOYSA-N,monepantel,Preclinical,mTOR inhibitor,,,
Oc1ccc(OCc2ccccc2)cc1,"InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2",VYQNWZOUAUKGHI-UHFFFAOYSA-N,monobenzone,Launched,melanin inhibitor,TYR,dermatology,skin depigmentation
CC1C(=O)OC2CCN3CC=C(COC(=O)C(C)(O)C1(C)O)C23,"InChI=1S/C16H23NO6/c1-9-13(18)23-11-5-7-17-6-4-10(12(11)17)8-22-14(19)16(3,21)15(9,2)20/h4,9,11-12,20-21H,5-8H2,1-3H3",QVCMHGGNRFRMAD-UHFFFAOYSA-N,monocrotaline,Preclinical,antitumor agent,,,
CCCCCCCC(=O)OCC(O)CO,"InChI=1S/C11H22O4/c1-2-3-4-5-6-7-11(14)15-9-10(13)8-12/h10,12-13H,2-9H2,1H3",GHBFNMLVSPCDGN-UHFFFAOYSA-N,monoctanoin,Launched,,,gastroenterology,gallstones
COC(=O)C=CC(=O)O,"InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)",NKHAVTQWNUWKEO-UHFFFAOYSA-N,monomethyl-fumarate,Launched,,,neurology/psychiatry,multiple sclerosis
Nc1cccc2c(=O)[nH][nH]c(=O)c12,"InChI=1S/C8H7N3O2/c9-5-3-1-2-4-6(5)8(13)11-10-7(4)12/h1-3H,9H2,(H,10,12)(H,11,13)",HWYHZTIRURJOHG-UHFFFAOYSA-N,monosodium-alpha-luminol,Launched,,,,
CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO,"InChI=1S/C21H42O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h20,22-23H,2-19H2,1H3",VBICKXHEKHSIBG-UHFFFAOYSA-N,monostearin,Preclinical,,,,
CC(C)(O)c1ccccc1CCC(SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,"InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)",UCHDWCPVSPXUMX-UHFFFAOYSA-N,montelukast,Launched,leukotriene receptor antagonist,ALOX5|CYSLTR1,pulmonary|allergy,asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)
COc1ccccc1OCC(O)CNC(C)C,"InChI=1S/C13H21NO3/c1-10(2)14-8-11(15)9-17-13-7-5-4-6-12(13)16-3/h4-7,10-11,14-15H,8-9H2,1-3H3",LFTFGCDECFPSQD-UHFFFAOYSA-N,moprolol,Launched,adrenergic receptor antagonist,,cardiology|ophthalmology|neurology/psychiatry,hypertension|glaucoma|anxiety
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,"InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)",FUBVWMNBEHXPSU-UHFFFAOYSA-N,moracizine,Withdrawn,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias
Cc1ccsc1C=CC1=NCCCN1C,"InChI=1S/C12H16N2S/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2/h4-6,9H,3,7-8H2,1-2H3",NVEPPWDVLBMNMB-UHFFFAOYSA-N,morantel,Launched,acetylcholine receptor agonist,,infectious disease,tapeworm
O=c1c(O)c(-c2ccc(O)cc2O)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H",YXOLAZRVSSWPPT-UHFFFAOYSA-N,morin,Preclinical,cytochrome P450 inhibitor,ADORA2A|ESR2|FASN|MCL1|SLC22A12,,
Cc1ncc([N+](=O)[O-])n1CC(O)CN1CCOCC1,"InChI=1S/C11H18N4O4/c1-9-12-6-11(15(17)18)14(9)8-10(16)7-13-2-4-19-5-3-13/h6,10,16H,2-5,7-8H2,1H3",GAZGHCHCYRSPIV-UHFFFAOYSA-N,morinidazole,Launched,other antibiotic,CYP51A1,,
O=C(OCCN1CCOCC1)c1ccc[nH]c1=Nc1cccc(C(F)(F)F)c1,"InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)",LDXSPUSKBDTEKA-UHFFFAOYSA-N,morniflumate,Launched,anti-inflammatory agent,,neurology/psychiatry,pain relief
N=C(N)N=C(N)N1CCOCC1,"InChI=1S/C6H13N5O/c7-5(8)10-6(9)11-1-3-12-4-2-11/h1-4H2,(H5,7,8,9,10)",KJHOZAZQWVKILO-UHFFFAOYSA-N,moroxydine,Launched,antiviral,,infectious disease,influenza A virus infection
CCOC(=O)C1C(CN2CCOCC2)=NC(c2nccs2)=NC1c1ccc(F)cc1Br,"InChI=1S/C21H22BrFN4O3S/c1-2-30-21(28)17-16(12-27-6-8-29-9-7-27)25-19(20-24-5-10-31-20)26-18(17)14-4-3-13(23)11-15(14)22/h3-5,10-11,17-18H,2,6-9,12H2,1H3",MJXJQJGKHURKAX-UHFFFAOYSA-N,morphothiadin,Preclinical,antiinfective drug,,,
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,"InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)",YPELFRMCRYSPKZ-UHFFFAOYSA-N,mosapride,Launched,serotonin receptor agonist,HTR4,gastroenterology,hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome
CC1CC(=O)NN=C1c1cc(-n2ccnc2)cs1,"InChI=1S/C12H12N4OS/c1-8-4-11(17)14-15-12(8)10-5-9(6-18-10)16-3-2-13-7-16/h2-3,5-8H,4H2,1H3,(H,14,17)",NPFVRBCDMFKOPY-UHFFFAOYSA-N,motapizone,Preclinical,phosphodiesterase inhibitor,,,
CC1(C)CNc2cc(NC(=O)c3ccc[nH]c3=NCc3ccncc3)ccc21,"InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)",RAHBGWKEPAQNFF-UHFFFAOYSA-N,motesanib,Phase 3,KIT inhibitor,FLT1|FLT4|KDR|KIT,,
CC1(C)CNc2cc(NC(=O)c3ccc[nH]c3=NCc3ccncc3)ccc21,"InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)",RAHBGWKEPAQNFF-UHFFFAOYSA-N,motesanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,FLT1|FLT4|KDR|KIT,,
CC1(C)CNc2cc(NC(=O)c3ccc[nH]c3=NCc3ccncc3)ccc21,"InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)",RAHBGWKEPAQNFF-UHFFFAOYSA-N,motesanib,Phase 3,VEGFR inhibitor,FLT1|FLT4|KDR|KIT,,
CCCN(CCC)C(=O)C1C=c2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2=NC(=N)C1,"InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18,24,29H,3-6,13-16,19H2,1-2H3",DFTIJIITKGLYIH-UHFFFAOYSA-N,motolimod,Phase 2,toll-like receptor agonist,TLR8,,
COC1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)COC21,"InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)",JWCSIUVGFCSJCK-UHFFFAOYSA-N,moxalactam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections|gram-negative bacterial infections|skin infections|bone and joint infections|pneumonia|urinary tract infections|meningitis
CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1,"InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3",MYCMTMIGRXJNSO-UHFFFAOYSA-N,moxaverine,Launched,phosphodiesterase inhibitor,,neurology/psychiatry,spasms
CON=C1CC2(CC3CC(CC=C(C)CC(C)C=CC=C4COC5C(O)C(C)=CC(C(=O)O3)C45O)O2)OC(C(C)=CC(C)C)C1C,"InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3",YZBLFMPOMVTDJY-UHFFFAOYSA-N,moxidectin,Launched,chloride channel antagonist,,infectious disease,gastrointestinal parasites
COc1c(N2CC3CCCNC3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,"InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)",FABPRXSRWADJSP-UHFFFAOYSA-N,moxifloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology|pulmonary|infectious disease,sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections
CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,"InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3",VRYMTAVOXVTQEF-UHFFFAOYSA-N,moxisylyte,Withdrawn,adrenergic receptor antagonist,,,
COC1=NC(C)=NC(Cl)C1N=c1[nH]cc[nH]1,"InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4,6-7H,1-2H3,(H2,11,12,15)",NSIUCUILQKEQTB-UHFFFAOYSA-N,moxonidine,Launched,imidazoline receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1,"InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)",WRNXUQJJCIZICJ-UHFFFAOYSA-N,mozavaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2,endocrinology,hyponatremia
Cc1cccc(C#Cc2ccccc2)n1,"InChI=1S/C14H11N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-9H,1H3",NEWKHUASLBMWRE-UHFFFAOYSA-N,mpep,Preclinical,glutamate receptor antagonist,GRM1|GRM4|GRM5,,
Cc1cc(N2CCOCC2)ccc1N=c1[nH]c(=NC2CCCCC2)c2[nH]cnc2[nH]1,"InChI=1S/C22H29N7O/c1-15-13-17(29-9-11-30-12-10-29)7-8-18(15)26-22-27-20-19(23-14-24-20)21(28-22)25-16-5-3-2-4-6-16/h7-8,13-14,16H,2-6,9-12H2,1H3,(H3,23,24,25,26,27,28)",OVJBNYKNHXJGSA-UHFFFAOYSA-N,mpi-0479605,Preclinical,mitotic kinase inhibitor,TTK,,
CC(C)CN=c1[nH]c(-c2cccc3ncccc23)cn2c(-c3ccc(C(=O)NC4CC4)cc3)cnc12,"InChI=1S/C29H28N6O/c1-18(2)15-31-27-28-32-16-26(19-8-10-20(11-9-19)29(36)33-21-12-13-21)35(28)17-25(34-27)23-5-3-7-24-22(23)6-4-14-30-24/h3-11,14,16-18,21H,12-13,15H2,1-2H3,(H,31,34)(H,33,36)",MDYKTGNHXNTATG-UHFFFAOYSA-N,mps-bay-2a,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
COc1cc(N2CCC(O)CC2)ccc1N=c1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2[nH]1,"InChI=1S/C28H33N5O4S/c1-18(2)38(35,36)26-7-5-4-6-23(26)30-24-17-27(32-28-21(24)10-13-29-28)31-22-9-8-19(16-25(22)37-3)33-14-11-20(34)12-15-33/h4-10,13,16-18,20,34H,11-12,14-15H2,1-3H3,(H3,29,30,31,32)",NMJMRSQTDLRCRQ-UHFFFAOYSA-N,mps1-in-1,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
COc1cc(S(C)(=O)=O)ccc1N=c1nc2ccc(-c3ccc(NC(=O)C(C)c4ccc(F)cc4)cc3)cn2[nH]1,"InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)",NRJKIOCCERLIDG-UHFFFAOYSA-N,mps1-in-5,Phase 1,protein kinase inhibitor,,,
O=C(NCCCN1CCCCCC1)C(c1ccccc1)C1CCCCC1,"InChI=1S/C23H36N2O/c26-23(24-16-11-19-25-17-9-1-2-10-18-25)22(20-12-5-3-6-13-20)21-14-7-4-8-15-21/h3,5-6,12-13,21-22H,1-2,4,7-11,14-19H2,(H,24,26)",AGKAAJMNNVUNDK-UHFFFAOYSA-N,mr-16728,Preclinical,acetylcholine release enhancer,,,
OCCc1ccc(OCCn2ccnc2)cc1,"InChI=1S/C13H16N2O2/c16-9-5-12-1-3-13(4-2-12)17-10-8-15-7-6-14-11-15/h1-4,6-7,11,16H,5,8-10H2",LQQIZTXSZOYPPS-UHFFFAOYSA-N,mr-948,Phase 1,thromboxane synthase inhibitor,TBXAS1,,
Cc1cc(-c2nncc3c(C(C)(C)C)c(OCc4ncnn4C)nn23)no1,"InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3",QYSYOGCIDRANAR-UHFFFAOYSA-N,mrk-016,Phase 1,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
Cn1ncnc1COc1nn2c(-c3c(F)cccc3F)nnc2cc1C1CCC1,"InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3",GOIFCXRIFSYPFG-UHFFFAOYSA-N,mrk-409,Phase 1,benzodiazepine receptor agonist,,,
O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,"InChI=1S/C19H17ClF5NO4S2/c20-12-1-4-15(5-2-12)31(27,28)18(16-11-13(21)3-6-17(16)22)9-7-14(8-10-18)26-32(29,30)19(23,24)25/h1-6,11,14,26H,7-10H2",WDZVWDXOIGQJIO-UHFFFAOYSA-N,mrk-560,Preclinical,gamma secretase inhibitor,APP,,
O=C(Cc1ccccc1)N=c1[nH]c2ccc(Cl)cc2c2nc(-c3ccco3)nn12,"InChI=1S/C21H14ClN5O2/c22-14-8-9-16-15(12-14)20-25-19(17-7-4-10-29-17)26-27(20)21(23-16)24-18(28)11-13-5-2-1-3-6-13/h1-10,12H,11H2,(H,23,24,28)",TWWFAXQOKNBUCR-UHFFFAOYSA-N,mrs-1220,Preclinical,adenosine receptor antagonist,ADORA2B|ADORA3,,
CCOC(=O)C1=C(C)N=C(c2ccccc2)C(C(=O)OCc2ccc([N+](=O)[O-])cc2)C1C#Cc1ccccc1,"InChI=1S/C31H26N2O6/c1-3-38-30(34)27-21(2)32-29(24-12-8-5-9-13-24)28(26(27)19-16-22-10-6-4-7-11-22)31(35)39-20-23-14-17-25(18-15-23)33(36)37/h4-15,17-18,26,28H,3,20H2,1-2H3",LRTNJIWAQJAWGO-UHFFFAOYSA-N,mrs-1334,Preclinical,adenosine receptor antagonist,ADORA3,,
C#CCN1C(C)=C(C(=O)OC)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OCC)=C1C,"InChI=1S/C21H22N2O6/c1-6-11-22-13(3)17(20(24)28-5)19(18(14(22)4)21(25)29-7-2)15-9-8-10-16(12-15)23(26)27/h1,8-10,12,19H,7,11H2,2-5H3",BITHABUTZRAUGT-UHFFFAOYSA-N,mrs-1845,Preclinical,calcium channel blocker,,,
S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(N=C=S)c2)c1,"InChI=1S/C20H20N6S4/c27-13-23-15-5-3-7-17(11-15)25-19(29)21-9-1-2-10-22-20(30)26-18-8-4-6-16(12-18)24-14-28/h3-8,11-12H,1-2,9-10H2,(H2,21,25,29)(H2,22,26,30)",QOHNRGHTJPFMSL-UHFFFAOYSA-N,mrs-2578,Preclinical,purinergic receptor antagonist,P2RY6,,
c1ccc(Oc2nc(=NC3CCCCC3)c3[nH]cnc3[nH]2)cc1,"InChI=1S/C17H19N5O/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)21-17(22-16)23-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H2,18,19,20,21,22)",OGCQBCHLFMBCCE-UHFFFAOYSA-N,mrs-3777,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CN1CCN(Cc2ccc(-c3cn(C4CCC(O)CC4)c4[nH]c(=NCCC5CC5)ncc34)cc2)CC1,"InChI=1S/C29H40N6O/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21/h4-7,18,20-21,24-25,36H,2-3,8-17,19H2,1H3,(H,30,31,32)",LBEJYFVJIPQSNX-UHFFFAOYSA-N,mrx-2843,Phase 1,MER tyrosine kinase inhibitor,,,
CC1CC=NN1C(=O)c1cccnc1,"InChI=1S/C10H11N3O/c1-8-4-6-12-13(8)10(14)9-3-2-5-11-7-9/h2-3,5-8H,4H2,1H3",KKMMIKKVFRCZBO-UHFFFAOYSA-N,ms-424,Phase 2,glutamate transporter modulator,,,
CCc1ccc(C(=O)COc2ccc(Cc3sc(=O)[nH]c3O)cc2)nc1,"InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,23H,2,9,11H2,1H3,(H,21,24)",SJOXOZFIJKNJKJ-UHFFFAOYSA-N,msdc-0160,Phase 2,insulin sensitizer,,,
COc1cccc(C(=O)COc2ccc(Cc3sc(=O)[nH]c3O)cc2)c1,"InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,22H,9,11H2,1H3,(H,20,23)",JIJXYXYLGRAIGV-UHFFFAOYSA-N,msdc-0602k,Phase 2,mitochondrial pyruvate carrier modulator,,,
c1cnc(=NCc2ccc(CN=c3nccc[nH]3)cc2)[nH]c1,"InChI=1S/C16H16N6/c1-7-17-15(18-8-1)21-11-13-3-5-14(6-4-13)12-22-16-19-9-2-10-20-16/h1-10H,11-12H2,(H,17,18,21)(H,19,20,22)",PXZXYRKDDXKDTK-UHFFFAOYSA-N,msx-122,Phase 2,CC chemokine receptor antagonist,CXCR4,,
CC(N)(C(=O)O)c1ccc(-c2nn[nH]n2)cc1,"InChI=1S/C10H11N5O2/c1-10(11,9(16)17)7-4-2-6(3-5-7)8-12-14-15-13-8/h2-5H,11H2,1H3,(H,16,17)(H,12,13,14,15)",OZBFBAYESADVDX-UHFFFAOYSA-N,mtpg,Preclinical,glutamate receptor antagonist,GRM2|GRM3,,
FC(F)(F)c1ccc(C=Cc2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,"InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2",ZTFBIUXIQYRUNT-UHFFFAOYSA-N,mubritinib,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,
CC(=CC(=O)OCCCCCCCCC(=O)O)CC1OCC(CC2OC2C(C)C(C)O)C(O)C1O,"InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)",MINDHVHHQZYEEK-UHFFFAOYSA-N,mupirocin,Launched,isoleucyl-tRNA synthetase inhibitor,,infectious disease,impetigo
NCc1cc(=O)[nH]o1,"InChI=1S/C4H6N2O2/c5-2-3-1-4(7)6-8-3/h1H,2,5H2,(H,6,7)",ZJQHPWUVQPJPQT-UHFFFAOYSA-N,muscimol,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,
CCc1cc(O)c(Oc2ccc(C(N)=O)cc2F)cc1F,"InChI=1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)",QUHARGDBJJUOEB-UHFFFAOYSA-N,mut056399,Phase 1,FABI inhibitor,,,
Clc1cccc(N=c2[nH]nc(-c3ccccc3)c3ccccc23)c1,"InChI=1S/C20H14ClN3/c21-15-9-6-10-16(13-15)22-20-18-12-5-4-11-17(18)19(23-24-20)14-7-2-1-3-8-14/h1-13H,(H,22,24)",CEHQLKSLMFIHBF-UHFFFAOYSA-N,my-5445,Preclinical,phosphodiesterase inhibitor,PDE5A,,
Clc1cccc(N=c2[nH]nc(-c3ccccc3)c3ccccc23)c1,"InChI=1S/C20H14ClN3/c21-15-9-6-10-16(13-15)22-20-18-12-5-4-11-17(18)19(23-24-20)14-7-2-1-3-8-14/h1-13H,(H,22,24)",CEHQLKSLMFIHBF-UHFFFAOYSA-N,my-5445,Preclinical,platelet aggregation inhibitor,PDE5A,,
COc1c(CC=C(C)CCC(=O)OCCN2CCOCC2)c(O)c2c(O)occ2c1C,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,14,26-27H,5-13H2,1-3H3",PGPPCCZSDRAQKA-UHFFFAOYSA-N,mycophenolate-mofetil,Launched,dehydrogenase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
COc1c(CC=C(C)CCC(=O)OCCN2CCOCC2)c(O)c2c(O)occ2c1C,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,14,26-27H,5-13H2,1-3H3",PGPPCCZSDRAQKA-UHFFFAOYSA-N,mycophenolate-mofetil,Launched,inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
COc1c(CC=C(C)CCC(=O)O)c(O)c2c(O)occ2c1C,"InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,8,20-21H,5-7H2,1-3H3,(H,18,19)",LTBQFJVKVMGOEG-UHFFFAOYSA-N,mycophenolic-acid,Launched,dehydrogenase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
COc1c(CC=C(C)CCC(=O)O)c(O)c2c(O)occ2c1C,"InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,8,20-21H,5-7H2,1-3H3,(H,18,19)",LTBQFJVKVMGOEG-UHFFFAOYSA-N,mycophenolic-acid,Launched,inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection
O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H",IKMDFBPHZNJCSN-UHFFFAOYSA-N,myricetin,Preclinical,androgen receptor agonist,PIK3CG,,
O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H",IKMDFBPHZNJCSN-UHFFFAOYSA-N,myricetin,Preclinical,cytochrome P450 inhibitor,PIK3CG,,
CC1OC(Oc2c(-c3cc(O)c(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C1O,"InChI=1S/C21H20O12/c1-6-14(26)17(29)18(30)21(31-6)33-20-16(28)13-9(23)4-8(22)5-12(13)32-19(20)7-2-10(24)15(27)11(25)3-7/h2-6,14,17-18,21-27,29-30H,1H3",DCYOADKBABEMIQ-UHFFFAOYSA-N,myricitrin,Preclinical,PKC inhibitor,NOS1|PRKCA,,
CCCCCCCCCCCCCCOC(=O)c1cccnc1,"InChI=1S/C20H33NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-23-20(22)19-15-14-16-21-18-19/h14-16,18H,2-13,17H2,1H3",TVGLGJWCZSCAEM-UHFFFAOYSA-N,myristyl-nicotinate,Phase 1,topical sunscreen agent,,,
CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1,"InChI=1S/C15H15ClN6S2/c1-10(12-7-4-5-9-17-12)19-21-15(24)22-20-14(23)18-13-8-3-2-6-11(13)16/h2-9H,1H3,(H2,18,20,23)(H2,21,22,24)",YYLKOELWSMRYHV-UHFFFAOYSA-N,n-(2-chlorophenyl)-2-({(2e)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide,Preclinical,,,,
CCCCCc1ccc(C=CC(=O)Nc2ccccc2C(=O)O)cc1,"InChI=1S/C21H23NO3/c1-2-3-4-7-16-10-12-17(13-11-16)14-15-20(23)22-19-9-6-5-8-18(19)21(24)25/h5-6,8-15H,2-4,7H2,1H3,(H,22,23)(H,24,25)",GAMRBCZMOOMBSQ-UHFFFAOYSA-N,n-(p-amylcinnamoyl)-anthranilic-acid,Preclinical,phospholipase inhibitor,,,
O=C(NCCN1CCCCC1)c1ccc(I)cc1,"InChI=1S/C14H19IN2O/c15-13-6-4-12(5-7-13)14(18)16-8-11-17-9-2-1-3-10-17/h4-7H,1-3,8-11H2,(H,16,18)",WCMWVYQHPUQKHW-UHFFFAOYSA-N,n-[2-(piperidinylamino)ethyl]-4-iodobenzamide,Preclinical,sigma receptor ligand,,,
CC(=O)NC(C=O)C(O)C(O)C(O)CO,"InChI=1S/C8H15NO6/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11/h2,5-8,11,13-15H,3H2,1H3,(H,9,12)",MBLBDJOUHNCFQT-UHFFFAOYSA-N,n-acetyl-d-glucosamine,Phase 2/Phase 3,,B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP,,
CC(=O)NC(Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C11H13NO4/c1-7(13)12-10(11(15)16)6-8-2-4-9(14)5-3-8/h2-5,10,14H,6H2,1H3,(H,12,13)(H,15,16)",CAHKINHBCWCHCF-UHFFFAOYSA-N,n-acetyl-tyrosine,Launched,,,,
CC(=O)NCCC(=O)NC(Cc1c[nH]cn1)C(=O)O,"InChI=1S/C11H16N4O4/c1-7(16)13-3-2-10(17)15-9(11(18)19)4-8-5-12-6-14-8/h5-6,9H,2-4H2,1H3,(H,12,14)(H,13,16)(H,15,17)(H,18,19)",BKAYIFDRRZZKNF-UHFFFAOYSA-N,n-acetylcarnosine,Launched,,,,
CC(=O)NCC(=O)NC(CCC(=O)O)C(=O)O,"InChI=1S/C9H14N2O6/c1-5(12)10-4-7(13)11-6(9(16)17)2-3-8(14)15/h6H,2-4H2,1H3,(H,10,12)(H,11,13)(H,14,15)(H,16,17)",CQTYJLQESPLSOP-UHFFFAOYSA-N,n-acetylglycyl-d-glutamic-acid,Preclinical,glutamate receptor agonist,,,
CC(=O)NC1C(O)OC(CO)C(O)C1O,"InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)",OVRNDRQMDRJTHS-UHFFFAOYSA-N,n-acetylmannosamine,Phase 2,,,,
CC(=O)NCCc1c[nH]c2ccccc12,"InChI=1S/C12H14N2O/c1-9(15)13-7-6-10-8-14-12-5-3-2-4-11(10)12/h2-5,8,14H,6-7H2,1H3,(H,13,15)",NVUGEQAEQJTCIX-UHFFFAOYSA-N,n-acetyltryptamine,Preclinical,melatonin receptor agonist,,,
CNCCc1c[nH]cn1,"InChI=1S/C6H11N3/c1-7-3-2-6-4-8-5-9-6/h4-5,7H,2-3H2,1H3,(H,8,9)",PHSPJQZRQAJPPF-UHFFFAOYSA-N,n-alpha-methylhistamine-dihydrochloride,Phase 3,histamine receptor agonist,HRH4,,
Oc1ccc2c3c1OC1c4c(c5ccccc5n4Cc4ccccc4)CC4(O)C(C2)N(CC2CC2)CCC314,"InChI=1S/C33H32N2O3/c36-26-13-12-22-16-27-33(37)17-24-23-8-4-5-9-25(23)35(19-20-6-2-1-3-7-20)29(24)31-32(33,28(22)30(26)38-31)14-15-34(27)18-21-10-11-21/h1-9,12-13,21,27,31,36-37H,10-11,14-19H2",PSPANKCQVWSVHM-UHFFFAOYSA-N,n-benzylnaltrindole,Preclinical,opioid receptor antagonist,,,
c1ccc2sc(SNC3CCCCC3)nc2c1,"InChI=1S/C13H16N2S2/c1-2-6-10(7-3-1)15-17-13-14-11-8-4-5-9-12(11)16-13/h4-5,8-10,15H,1-3,6-7H2",DEQZTKGFXNUBJL-UHFFFAOYSA-N,n-cyclohexyl-2-benzothiazolesulfenamide,Preclinical,,,,
ON=C(O)c1cccnc1,"InChI=1S/C6H6N2O2/c9-6(8-10)5-2-1-3-7-4-5/h1-4,10H,(H,8,9)",IYCHDNQCHLMLJZ-UHFFFAOYSA-N,n-hydroxynicotinamide,Preclinical,,,,
CC(C(O)c1ccccc1)N(C)C,"InChI=1S/C11H17NO/c1-9(12(2)3)11(13)10-7-5-4-6-8-10/h4-9,11,13H,1-3H3",FMCGSUUBYTWNDP-UHFFFAOYSA-N,"n-methyl-(-)ephedrine-[1r,2s]",Preclinical,,,,
CNC=O,"InChI=1S/C2H5NO/c1-3-2-4/h2H,1H3,(H,3,4)",ATHHXGZTWNVVOU-UHFFFAOYSA-N,n-methylformamide,Phase 2,,,,
CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,"InChI=1S/C15H24N2O/c1-6-17(5,7-2)11-14(18)16-15-12(3)9-8-10-13(15)4/h8-10H,6-7,11H2,1-5H3/p+1",HFRFLLYLVAKRMZ-UHFFFAOYSA-O,n-methyllidocaine-iodide,Preclinical,antiarrhythmic medication,,,
CN1CCCC1=O,"InChI=1S/C5H9NO/c1-6-4-2-3-5(6)7/h2-4H2,1H3",SECXISVLQFMRJM-UHFFFAOYSA-N,n-methylpyrrolidone,Phase 1,,,,
CN1CCN(c2ccc3ccccc3n2)CC1,"InChI=1S/C14H17N3/c1-16-8-10-17(11-9-16)14-7-6-12-4-2-3-5-13(12)15-14/h2-7H,8-11H2,1H3",HOMWNUXPSJQSSU-UHFFFAOYSA-N,n-methylquipazine,Preclinical,serotonin receptor agonist,,,
CN(C(=O)Cc1ccccc1)C(CN1CCCC1)c1ccccc1,"InChI=1S/C21H26N2O/c1-22(21(24)16-18-10-4-2-5-11-18)20(17-23-14-8-9-15-23)19-12-6-3-7-13-19/h2-7,10-13,20H,8-9,14-17H2,1H3",OVZWUDZIAAHNFG-UHFFFAOYSA-N,n-mppp,Preclinical,opioid receptor agonist,,,
c1ccc2sc(SN3CCOCC3)nc2c1,"InChI=1S/C11H12N2OS2/c1-2-4-10-9(3-1)12-11(15-10)16-13-5-7-14-8-6-13/h1-4H,5-8H2",MHKLKWCYGIBEQF-UHFFFAOYSA-N,n-oxydiethylenebenzothiazole-2-sulfenamide,Preclinical,,,,
O=C(Nc1ccc(O)cc1)c1ccccc1O,"InChI=1S/C13H11NO3/c15-10-7-5-9(6-8-10)14-13(17)11-3-1-2-4-12(11)16/h1-8,15-16H,(H,14,17)",LGCMKPRGGJRYGM-UHFFFAOYSA-N,n-salicoylaminophenol,Phase 1/Phase 2,ribonucleotide reductase inhibitor,,,
NC(=O)CNCCC(c1ccccc1)c1ccccc1,"InChI=1S/C17H20N2O/c18-17(20)13-19-12-11-16(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-10,16,19H,11-13H2,(H2,18,20)",BYGXICRJQZKUPA-UHFFFAOYSA-N,n20c,Preclinical,glutamate receptor antagonist,,,
OCC1OC(n2cnc3c(=NC4CCCC4)[nH]cnc32)C(O)C1O,"InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)",SQMWSBKSHWARHU-UHFFFAOYSA-N,n6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1,,
CN=c1[nH]cnc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C11H15N5O4/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(19)7(18)5(2-17)20-11/h3-5,7-8,11,17-19H,2H2,1H3,(H,12,13,14)",VQAYFKKCNSOZKM-UHFFFAOYSA-N,n6-methyladenosine,Preclinical,,,,
Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1,"InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30)",YVPGZQLRPAGKLA-UHFFFAOYSA-N,n6022,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,ADH5,,
Cc1ccc(C)c(-n2cnc3cc(C(=O)NCc4ccccc4Cl)ccc32)c1,"InChI=1S/C23H20ClN3O/c1-15-7-8-16(2)22(11-15)27-14-26-20-12-17(9-10-21(20)27)23(28)25-13-18-5-3-4-6-19(18)24/h3-12,14H,13H2,1-2H3,(H,25,28)",CZSLEMCYYGEGKP-UHFFFAOYSA-N,nab-2,Preclinical,ubiquitin ligase transport promoter,NEDD4,,
COc1ccc2cc(CCC(C)=O)ccc2c1,"InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3",BLXXJMDCKKHMKV-UHFFFAOYSA-N,nabumetone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)OCC2OC([n+]3cccc(C(N)=O)c3)C(O)C2O)C(O)C1O,"InChI=1S/C21H25N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H3-,22,23,24,25,33)/p+1",CGHCNTDXMOIQQK-UHFFFAOYSA-O,nadide,Launched,free radical scavenger,AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2,,
CC1CCc2c(N3CCC(O)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,"InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)",JYJTVFIEFKZWCJ-UHFFFAOYSA-N,nadifloxacin,Launched,bacterial DNA gyrase inhibitor,,dermatology|infectious disease,acne vulgaris (AV)|skin infections
CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2,"InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3",VWPOSFSPZNDTMJ-UHFFFAOYSA-N,nadolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|hypertension
N=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O[PH](=O)(=O)OCC2OC(N3C=CCC(C(N)=O)=C3)C(O)C2O)C(O)C1O[PH](=O)(=O)O,"InChI=1S/C21H27N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H2,22,24,25)(H,33,34,35)",QRUJDAIIUGIBFG-UHFFFAOYSA-N,nadph,Preclinical,,DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C,,
CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC,"InChI=1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)",IDZASIQMRGPBCQ-UHFFFAOYSA-N,nafadotride,Preclinical,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,
N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1,"InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)",MQQNFDZXWVTQEH-UHFFFAOYSA-N,nafamostat,Launched,serine protease inhibitor,ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7,cardiology,anticoagulent
CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)",GPXLMGHLHQJAGZ-UHFFFAOYSA-N,nafcillin,Launched,bacterial cell wall synthesis inhibitor,CYP1A2|CYP3A4|SLC22A6,infectious disease,gram-positive bacterial infections
CCN(CC)CCOC(=O)C(Cc1cccc2ccccc12)CC1CCCO1,"InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3",KBAFPSLPKGSANY-UHFFFAOYSA-N,naftidrofuryl,Launched,adrenergic receptor antagonist,,cardiology,claudication
CN(CC=Cc1ccccc1)Cc1cccc2ccccc12,"InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3",OZGNYLLQHRPOBR-UHFFFAOYSA-N,naftifine,Launched,fungal squalene epoxidase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,"InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3",HRRBJVNMSRJFHQ-UHFFFAOYSA-N,naftopidil,Launched,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH)
Oc1ccc2c3c1OC1C(O)CCC4(O)C(C2)N(CC2CCC2)CCC314,"InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2",NETZHAKZCGBWSS-UHFFFAOYSA-N,nalbuphine,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,neurology/psychiatry,pain relief
Oc1ccc2c3c1OC1C(O)CCC4(O)C(C2)N(CC2CCC2)CCC314,"InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2",NETZHAKZCGBWSS-UHFFFAOYSA-N,nalbuphine,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,neurology/psychiatry,pain relief
CN(C(=O)C=Cc1ccoc1)C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5,"InChI=1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3",XGZZHZMWIXFATA-UHFFFAOYSA-N,nalfurafine,Launched,opioid receptor agonist,OPRK1|OPRM1,nephrology,uremic pruritus
CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21,"InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)",MHWLWQUZZRMNGJ-UHFFFAOYSA-N,nalidixic-acid,Launched,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections
C=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5,"InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2",WJBLNOPPDWQMCH-UHFFFAOYSA-N,nalmefene,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,pulmonary,respiratory depression
C=CCN1CCC23c4c5ccc(O)c4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5,"InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3",XNKCCCKFOQNXKV-UHFFFAOYSA-N,naloxegol,Launched,opioid receptor antagonist,OPRM1,gastroenterology,constipation
C=CCN1CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5,"InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2",UZHSEJADLWPNLE-UHFFFAOYSA-N,naloxone,Launched,opioid receptor antagonist,CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4,pulmonary,respiratory depression
C=CCN1CCC23c4c5ccc(O)c4OC2C(=NNC(=O)c2ccccc2)CCC3(O)C1C5,"InChI=1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)",AKXCFAYOTIEFOH-UHFFFAOYSA-N,naloxone-benzoylhydrazone,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,
O=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5,"InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2",DQCKKXVULJGBQN-UHFFFAOYSA-N,naltrexone,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1|SIGMAR1,neurology/psychiatry,abstinence from alcohol
Oc1ccc2c3c1OC1c4oc5ccccc5c4CC4(O)C(C2)N(CC2CC2)CCC314,"InChI=1S/C26H25NO4/c28-18-8-7-15-11-20-26(29)12-17-16-3-1-2-4-19(16)30-22(17)24-25(26,21(15)23(18)31-24)9-10-27(20)13-14-5-6-14/h1-4,7-8,14,20,24,28-29H,5-6,9-13H2",ZHVWWEYETMPAMX-UHFFFAOYSA-N,naltriben,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
Oc1ccc2c3c1OC1c4[nH]c5ccccc5c4CC4(O)C(C2)N(CC2CC2)CCC314,"InChI=1S/C26H26N2O3/c29-19-8-7-15-11-20-26(30)12-17-16-3-1-2-4-18(16)27-22(17)24-25(26,21(15)23(19)31-24)9-10-28(20)13-14-5-6-14/h1-4,7-8,14,20,24,27,29-30H,5-6,9-13H2",WIYUZYBFCWCCQJ-UHFFFAOYSA-N,naltrindole,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CC(C)(O)CS(=O)(=O)Nc1ccc2c(c1)CCN(C(=O)COc1cccnc1)C2,"InChI=1S/C20H25N3O5S/c1-20(2,25)14-29(26,27)22-17-6-5-16-12-23(9-7-15(16)10-17)19(24)13-28-18-4-3-8-21-11-18/h3-6,8,10-11,22,25H,7,9,12-14H2,1-2H3",QHHSCLARESIWBH-UHFFFAOYSA-N,nampt-in-1,Preclinical,,,,
COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,"InChI=1S/C23H27N3O3/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28/h2-5,8-11H,6-7,12-17H2,1H3",SJDOMIRMMUGQQK-UHFFFAOYSA-N,nan-190,Preclinical,serotonin receptor agonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F,,
COC1CCC(OC2CC(C3(C)CCC4(CC(O)C(C)C(C(C)=CC(C)C(=O)C(C)CC(C)C(=O)O)O4)O3)OC3(OC(C4OC(O)(CO)C(C)CC4C)CC3C)C2C)OC1C,"InChI=1S/C47H78O14/c1-24(40(50)25(2)18-28(5)43(51)52)17-26(3)41-31(8)34(49)22-45(59-41)16-15-44(11,61-45)38-21-36(56-39-14-13-35(54-12)33(10)55-39)32(9)47(58-38)30(7)20-37(57-47)42-27(4)19-29(6)46(53,23-48)60-42/h17,24-25,27-39,41-42,48-49,53H,13-16,18-23H2,1-12H3,(H,51,52)",LCVCBBIXPRAPRJ-UHFFFAOYSA-N,nanchangmycin,Preclinical,other antibiotic,,,
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,"InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3",DPHUWDIXHNQOSY-UHFFFAOYSA-N,napabucasin,Phase 3,STAT inhibitor,STAT3,,
C1=C(CC2=NCCN2)CCc2ccccc21,"InChI=1S/C14H16N2/c1-2-4-13-9-11(5-6-12(13)3-1)10-14-15-7-8-16-14/h1-4,9H,5-8,10H2,(H,15,16)",WETRBJOSGIDJHQ-UHFFFAOYSA-N,napamezole,Preclinical,adrenergic receptor antagonist,,,
C1=C(CC2=NCCN2)CCc2ccccc21,"InChI=1S/C14H16N2/c1-2-4-13-9-11(5-6-12(13)3-1)10-14-15-7-8-16-14/h1-4,9H,5-8,10H2,(H,15,16)",WETRBJOSGIDJHQ-UHFFFAOYSA-N,napamezole,Preclinical,monoamine reuptake inhibitor,,,
c1ccc2c(CC3=NCCN3)cccc2c1,"InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)",CNIIGCLFLJGOGP-UHFFFAOYSA-N,naphazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,ophthalmology,eye irritation
CC(C)(C)NCc1cc(N=c2cc[nH]c3cc(Cl)ccc23)c2c(c1O)CCCC2,"InChI=1S/C24H28ClN3O/c1-24(2,3)27-14-15-12-22(17-6-4-5-7-18(17)23(15)29)28-20-10-11-26-21-13-16(25)8-9-19(20)21/h8-13,27,29H,4-7,14H2,1-3H3,(H,26,28)",VEVMYTDOWUQLGI-UHFFFAOYSA-N,naphthoquine-phosphate,Launched,antimalarial agent,,infectious disease,malaria
Cn1cc(C(=O)c2cccc3ccccc23)cc1C(=O)O,"InChI=1S/C17H13NO3/c1-18-10-12(9-15(18)17(20)21)16(19)14-8-4-6-11-5-2-3-7-13(11)14/h2-10H,1H3,(H,20,21)",CNUPQURTHORUGH-UHFFFAOYSA-N,napirimus,Phase 1,immunosuppressant,,,
COc1ccc2cc(C(C)C(=O)O)ccc2c1,"InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)",CMWTZPSULFXXJA-UHFFFAOYSA-N,naproxen,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology,pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever
C=CC(=O)N1CCC(Oc2[nH]c(=Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,"InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)",QKDCLUARMDUUKN-UHFFFAOYSA-N,naquotinib,Phase 3,EGFR inhibitor,,,
CCC(C(=O)O)C1OC(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)C(C)CC1C,"InChI=1S/C43H72O11/c1-12-30(35(46)27(8)34(45)28(9)36-23(4)21-24(5)37(51-36)31(13-2)39(47)48)38-25(6)22-26(7)42(52-38)18-15-32(44)43(54-42)20-19-40(11,53-43)33-16-17-41(49,14-3)29(10)50-33/h15,18,23-34,36-38,44-45,49H,12-14,16-17,19-22H2,1-11H3,(H,47,48)",VHKXXVVRRDYCIK-UHFFFAOYSA-N,narasin,Launched,antiprotozoal agent,,infectious disease,coccidiosis
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,"InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3",AMKVXSZCKVJAGH-UHFFFAOYSA-N,naratriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21,"InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2",FTVWIRXFELQLPI-UHFFFAOYSA-N,naringenin,Phase 1,aromatase inhibitor,CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1,,
O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21,"InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2",FTVWIRXFELQLPI-UHFFFAOYSA-N,naringenin,Phase 1,TRPV antagonist,CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1,,
O=C(O)C=Cc1ccc(O)cc1,"InChI=1S/C9H8O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6,10H,(H,11,12)",NGSWKAQJJWESNS-UHFFFAOYSA-N,naringeninic-acid,Phase 1,,HCAR2|PTGR1,,
CC1OC(OC2C(Oc3cc(O)c4c(c3)OC(c3ccc(O)cc3)CC4=O)OC(CO)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3",DFPMSGMNTNDNHN-UHFFFAOYSA-N,naringin,Preclinical,cytochrome P450 inhibitor,SLCO1A2,,
CC1OC(OC2C(Oc3cc(O)c(C(=O)CCc4ccc(O)cc4)c(O)c3)OC(CO)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C27H34O14/c1-11-20(33)22(35)24(37)26(38-11)41-25-23(36)21(34)18(10-28)40-27(25)39-14-8-16(31)19(17(32)9-14)15(30)7-4-12-2-5-13(29)6-3-12/h2-3,5-6,8-9,11,18,20-29,31-37H,4,7,10H2,1H3",CWBZAESOUBENAP-UHFFFAOYSA-N,naringin-dihydrochalcone,Preclinical,cytochrome P450 inhibitor,,,
CCCCC(NC(=O)C1C2C(CN1C(=O)C(NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,"InChI=1S/C36H61N5O7S/c1-10-11-15-24(27(42)30(44)37-22-16-17-22)38-29(43)26-25-23(35(25,8)9)20-41(26)31(45)28(33(2,3)4)39-32(46)40-36(18-13-12-14-19-36)21-49(47,48)34(5,6)7/h22-26,28H,10-21H2,1-9H3,(H,37,44)(H,38,43)(H2,39,40,46)",RICZEKWVNZFTNZ-UHFFFAOYSA-N,narlaprevir,Phase 3,HCV inhibitor,,,
C1=C(CN2CCOCC2)COc2c1cccc2OCC1CNCCO1,"InChI=1S/C19H26N2O4/c1-2-16-10-15(12-21-5-8-22-9-6-21)13-25-19(16)18(3-1)24-14-17-11-20-4-7-23-17/h1-3,10,17,20H,4-9,11-14H2",RTKDBEOSPDFLGD-UHFFFAOYSA-N,nas-181,Preclinical,serotonin receptor antagonist,HTR1B,,
CC(C)(C)C(=O)CN1C(=O)C(NC(=O)Nc2cccc(C(=O)O)c2)CN(C2CCCCC2)c2ccccc21,"InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)",VIJCCFFEBCOOIE-UHFFFAOYSA-N,nastorazepide,Phase 2,CCK receptor antagonist,CCKBR,,
CC1CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC3OC3=CCC(=O)O1)CC(O)C2C(=O)O,"InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-12,18-22,24-25,27-30,32,35-36,38-39,42H,10,13-17,34H2,1-2H3,(H,40,41)",YYQGNGYORJFKQS-UHFFFAOYSA-N,natamycin,Launched,fungal ergosterol inhibitor,,ophthalmology|infectious disease,conjunctivitis|fungal keratosis|blepharitis
CC(C)C1CCC(C(=O)NC(Cc2ccccc2)C(=O)O)CC1,"InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)",OELFLUMRDSZNSF-UHFFFAOYSA-N,nateglinide,Launched,insulin secretagogue,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus
O=C(NCc1ccc(OC(F)(F)F)cc1)c1c2ccccc2c(O)n1C1CCOCC1,"InChI=1S/C22H21F3N2O4/c23-22(24,25)31-16-7-5-14(6-8-16)13-26-20(28)19-17-3-1-2-4-18(17)21(29)27(19)15-9-11-30-12-10-15/h1-8,15,29H,9-13H2,(H,26,28)",PUJRKTXCTGFOFF-UHFFFAOYSA-N,nav-26,Preclinical,voltage-gated sodium channel blocker,SCN9A,,
CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,"InChI=1S/C21H23N3O5/c1-5-13(15-10-9-11(2)29-15)22-16-17(20(27)19(16)26)23-14-8-6-7-12(18(14)25)21(28)24(3)4/h6-10,13,22-23,25H,5H2,1-4H3",RXIUEIPPLAFSDF-UHFFFAOYSA-N,navarixin,Phase 2,CC chemokine receptor antagonist,CXCR1|CXCR2,,
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC(CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,"InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)",JLYAXFNOILIKPP-UHFFFAOYSA-N,navitoclax,Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,
CCCN1CCOC2c3cc(O)ccc3CCC21,"InChI=1S/C15H21NO2/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16/h3,5,10,14-15,17H,2,4,6-9H2,1H3",JCSREICEMHWFAY-UHFFFAOYSA-N,naxagolide,Phase 3,dopamine receptor agonist,,,
N=c1[nH]cnc2c1ncn2CCNCCCCCO,"InChI=1S/C12H20N6O/c13-11-10-12(16-8-15-11)18(9-17-10)6-5-14-4-2-1-3-7-19/h8-9,14,19H,1-7H2,(H2,13,15,16)",CVPTTZZCRDVGSU-UHFFFAOYSA-N,nb-001,Preclinical,antiviral,,,
CCCN(CC1CC1)c1[nH]c(C)nc(=Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,"InChI=1S/C18H20Cl4N4/c1-3-6-26(9-11-4-5-11)18-15(22)17(23-10(2)24-18)25-16-13(20)7-12(19)8-14(16)21/h7-8,11H,3-6,9H2,1-2H3,(H,23,24,25)",KNADXBVKFAUMCR-UHFFFAOYSA-N,nbi-27914,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
CCOc1ccc(-n2c(C(C)N(Cc3cccnc3)C(=O)Cc3ccc(F)c(C(F)(F)F)c3)nc3ncccc3c2=O)cc1,"InChI=1S/C32H27F4N5O3/c1-3-44-24-11-9-23(10-12-24)41-30(39-29-25(31(41)43)7-5-15-38-29)20(2)40(19-22-6-4-14-37-18-22)28(42)17-21-8-13-27(33)26(16-21)32(34,35)36/h4-16,18,20H,3,17,19H2,1-2H3",XMRGQUDUVGRCBS-UHFFFAOYSA-N,nbi-74330-(+/-),Preclinical,CC chemokine receptor antagonist,CXCR3,,
COc1cc2c(cc1OC)C1CC(O)C(CC(C)C)CN1CC2,"InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3",WEQLWGNDNRARGE-UHFFFAOYSA-N,nbi-98782,Preclinical,vesicular monoamine transporter inhibitor,,,
NS(=O)(=O)c1cccc2c1c([N+](=O)[O-])cc1[nH]c(=O)c(=O)[nH]c12,"InChI=1S/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22)",UQNAFPHGVPVTAL-UHFFFAOYSA-N,nbqx,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B,,
O=C(O)CC1CCCc2ccccc2C1=O,"InChI=1S/C13H14O3/c14-12(15)8-10-6-3-5-9-4-1-2-7-11(9)13(10)16/h1-2,4,7,10H,3,5-6,8H2,(H,14,15)",PYYIEBMODWJEII-UHFFFAOYSA-N,ncs-382,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|SLC52A2,,
CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)c1ccc(CO[N+](=O)[O-])cc1,"InChI=1S/C29H33NO9/c1-27-11-9-20(31)13-19(27)7-8-21-22-10-12-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-17(4-6-18)15-39-30(36)37/h3-6,9,11,13,21-23,25,32,35H,7-8,10,12,14-16H2,1-2H3",MJHYBJOMJPGNMM-UHFFFAOYSA-N,ncx-1015,Preclinical,interleukin sythesis stimulator,,,
Cc1nccn1Cc1ccccn1,"InChI=1S/C10H11N3/c1-9-11-6-7-13(9)8-10-4-2-3-5-12-10/h2-7H,8H2,1H3",CTUICISGLKIJLG-UHFFFAOYSA-N,ndd-094,Preclinical,,,,
CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)OCO2)Cc1ccc2c(c1)OCO2,"InChI=1S/C36H35N3O4/c1-2-3-18-39-30(35(28-10-6-4-7-11-28)37-36(39)29-12-8-5-9-13-29)23-38(21-26-14-16-31-33(19-26)42-24-40-31)22-27-15-17-32-34(20-27)43-25-41-32/h4-17,19-20H,2-3,18,21-25H2,1H3",ITACCRHKSPSKKL-UHFFFAOYSA-N,ndt-9513727,Preclinical,complement antagonist,C5AR1,,
CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,"InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3",YBLIQJGXRLZBCZ-UHFFFAOYSA-N,ne-100,Phase 2,sigma receptor antagonist,SIGMAR1,,
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,"InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2",KOHIRBRYDXPAMZ-UHFFFAOYSA-N,nebivolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
NCC1CC(=O)N(Cc2ccccc2)C1,"InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2",LCAFGJGYCUMTGS-UHFFFAOYSA-N,nebracetam,Phase 3,acetylcholine receptor agonist,CHRM1,,
CCNC(=O)C1OC(n2cnc3c(=N)[nH]cnc32)C(O)C1O,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)",JADDQZYHOWSFJD-UHFFFAOYSA-N,neca,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
Cn1c(O)c(Cc2c[nH]c3ccccc23)[nH]c1=S,"InChI=1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,14,17H,6H2,1H3,(H,15,18)",BPUNDQLKPUIGBR-UHFFFAOYSA-N,necrostatin-1,Preclinical,RIPK inhibitor,RIPK1,,
Cn1c(O)c(Cc2c[nH]c3c(Cl)cccc23)[nH]c1=O,"InChI=1S/C13H12ClN3O2/c1-17-12(18)10(16-13(17)19)5-7-6-15-11-8(7)3-2-4-9(11)14/h2-4,6,15,18H,5H2,1H3,(H,16,19)",DTXKPPCECSHDBD-UHFFFAOYSA-N,necrostatin-2,Preclinical,necroptosis inhibitor,RIPK2,,
Cn1c(O)c(Cc2c[nH]c3c(Cl)cccc23)[nH]c1=O,"InChI=1S/C13H12ClN3O2/c1-17-12(18)10(16-13(17)19)5-7-6-15-11-8(7)3-2-4-9(11)14/h2-4,6,15,18H,5H2,1H3,(H,16,19)",DTXKPPCECSHDBD-UHFFFAOYSA-N,necrostatin-2,Preclinical,RIPK inhibitor,RIPK2,,
O=C(O)CO,"InChI=1S/C2H4O3/c3-1-2(4)5/h3H,1H2,(H,4,5)",AEMRFAOFKBGASW-UHFFFAOYSA-N,nedaplatin,Launched,DNA inhibitor,,oncology,non-small cell lung cancer (NSCLC)|small cell lung cancer|esophageal cancer
CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12,"InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)",RQTOOFIXOKYGAN-UHFFFAOYSA-N,nedocromil,Launched,histamine receptor antagonist,CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR,neurology/psychiatry|ophthalmology,itching|conjunctivitis
CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",VRBKIVRKKCLPHA-UHFFFAOYSA-N,nefazodone,Withdrawn,adrenergic inhibitor,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,,
CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",VRBKIVRKKCLPHA-UHFFFAOYSA-N,nefazodone,Withdrawn,norepinephrine reuptake inhibitor,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,,
CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",VRBKIVRKKCLPHA-UHFFFAOYSA-N,nefazodone,Withdrawn,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,,
CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",VRBKIVRKKCLPHA-UHFFFAOYSA-N,nefazodone,Withdrawn,serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,,
Cc1cccc(C)c1NC(=O)CN1CCCC1=O,"InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)",NGHTXZCKLWZPGK-UHFFFAOYSA-N,nefiracetam,Phase 3,acetylcholine receptor agonist,CHRM1,,
Cc1cccc(C)c1NC(=O)CN1CCCC1=O,"InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)",NGHTXZCKLWZPGK-UHFFFAOYSA-N,nefiracetam,Phase 3,benzodiazepine receptor agonist,CHRM1,,
CN1CCOC(c2ccccc2)c2ccccc2C1,"InChI=1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3",RGPDEAGGEXEMMM-UHFFFAOYSA-N,nefopam,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
COc1[nH]c(=N)nc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)",IXOXBSCIXZEQEQ-UHFFFAOYSA-N,nelarabine,Launched,DNA synthesis inhibitor,POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL)
COc1[nH]c(=N)nc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)",IXOXBSCIXZEQEQ-UHFFFAOYSA-N,nelarabine,Launched,T cell inhibitor,POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL)
Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,"InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)",QAGYKUNXZHXKMR-UHFFFAOYSA-N,nelfinavir,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
COC(=O)Nc1c(N)[nH]c(-c2nn(Cc3ccccc3F)c3ncccc23)nc1=N,"InChI=1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)",FTQHGWIXJSSWOY-UHFFFAOYSA-N,nelociguat,Preclinical,guanylate cyclase stimulant,,,
COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C,"InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)",COSPVUFTLGQDQL-UHFFFAOYSA-N,nelotanserin,Phase 2,serotonin receptor inverse agonist,,,
Nc1c(Cl)cc(CC2=NCCN2)cc1Cl,"InChI=1S/C10H11Cl2N3/c11-7-3-6(4-8(12)10(7)13)5-9-14-1-2-15-9/h3-4H,1-2,5,13H2,(H,14,15)",FXNNRWAIGIEAST-UHFFFAOYSA-N,nemazoline,Phase 2,adrenergic receptor agonist,,,
Nc1c(Cl)cc(CC2=NCCN2)cc1Cl,"InChI=1S/C10H11Cl2N3/c11-7-3-6(4-8(12)10(7)13)5-9-14-1-2-15-9/h3-4H,1-2,5,13H2,(H,14,15)",FXNNRWAIGIEAST-UHFFFAOYSA-N,nemazoline,Phase 2,adrenergic receptor antagonist,,,
CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,"InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)",MCIDWGZGWVSZMK-UHFFFAOYSA-N,nemiralisib,Phase 2,,,,
CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl,"InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)",KRVOJOCLBAAKSJ-UHFFFAOYSA-N,nemonapride,Launched,dopamine receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia
COc1ccc(-n2nccn2)c(C(=O)N2CCCC2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1,"InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)",NBGABHGMJVIVBW-UHFFFAOYSA-N,nemorexant,Preclinical,orexin receptor antagonist,,,
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)C(OC1CC(N2CCOC(OC)C2)C(O)C(C)O1)=CC(O)(C(=O)CO)C4,"InChI=1S/C32H37NO13/c1-14-27(36)17(33-7-8-44-22(12-33)43-3)9-21(45-14)46-19-11-32(41,20(35)13-34)10-16-24(19)31(40)26-25(29(16)38)28(37)15-5-4-6-18(42-2)23(15)30(26)39/h4-6,11,14,17,21-22,27,34,36-41H,7-10,12-13H2,1-3H3",XFPHSOSADXIJEC-UHFFFAOYSA-N,nemorubicin,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,
CCC[N+]12C(O)C(CC)C3CC1C1N(C)c4ccccc4C14CC2C3C4O,"InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1",UAUHEPXILIZYCU-UHFFFAOYSA-N,neo-gilurytmal,Launched,,,cardiology,cardiac arrythmia
COc1ccc(C2CC(=O)c3c(O)cc(OC4OC(CO)C(O)C(O)C4OC4OC(C)C(O)C(O)C4O)cc3O2)cc1O,"InChI=1S/C28H34O15/c1-10-21(33)23(35)25(37)27(39-10)43-26-24(36)22(34)19(9-29)42-28(26)40-12-6-14(31)20-15(32)8-17(41-18(20)7-12)11-3-4-16(38-2)13(30)5-11/h3-7,10,17,19,21-31,33-37H,8-9H2,1-2H3",ARGKVCXINMKCAZ-UHFFFAOYSA-N,neohesperidin,Preclinical,,,,
COc1ccc(CCC(=O)c2c(O)cc(OC3OC(CO)C(O)C(O)C3OC3OC(C)C(O)C(O)C3O)cc2O)cc1O,"InChI=1S/C28H36O15/c1-11-21(34)23(36)25(38)27(40-11)43-26-24(37)22(35)19(10-29)42-28(26)41-13-8-16(32)20(17(33)9-13)14(30)5-3-12-4-6-18(39-2)15(31)7-12/h4,6-9,11,19,21-29,31-38H,3,5,10H2,1-2H3",ITVGXXMINPYUHD-UHFFFAOYSA-N,neohesperidin-dihydrochalcone,Preclinical,,,,
NCC1OC(OC2C(CO)OC(OC3C(O)C(N)CC(N)C3OC3OC(CN)C(O)C(O)C3N)C2O)C(N)C(O)C1O,"InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2",PGBHMTALBVVCIT-UHFFFAOYSA-N,neomycin,Launched,bacterial 30S ribosomal subunit inhibitor,CXCR4,infectious disease|gastroenterology,first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,"InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1",ALWKGYPQUAPLQC-UHFFFAOYSA-N,neostigmine,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,"InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)",QEFAQIPZVLVERP-UHFFFAOYSA-N,nepafenac,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,ophthalmology,eye inflammation
NCc1c[nH]c(=S)n1C1CCc2c(F)cc(F)cc2C1,"InChI=1S/C14H15F2N3S/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20/h3,5,7,10H,1-2,4,6,17H2,(H,18,20)",YZZVIKDAOTXDEB-UHFFFAOYSA-N,nepicastat,Phase 2,dopamine beta hydroxylase inhibitor,DBH,,
CCOc1cc2[nH]cc(C#N)c(=Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)",JWNPDZNEKVCWMY-UHFFFAOYSA-N,neratinib,Launched,EGFR inhibitor,EGFR|ERBB2|KDR,oncology,breast cancer
Cc1oncc1C(=O)N1CCCCC1,"InChI=1S/C10H14N2O2/c1-8-9(7-11-14-8)10(13)12-5-3-2-4-6-12/h7H,2-6H2,1H3",ZWNGSOLJLMBZFZ-UHFFFAOYSA-N,nerbacadol,Phase 3,cyclooxygenase inhibitor,,,
NCCCCCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C6H15NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H,9,10,11)(H,12,13,14)",JLGQKDVACLRIBP-UHFFFAOYSA-N,neridronic-acid,Launched,bone resorption inhibitor,FDPS,endocrinology,brittle bone disease|Paget's disease
CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(CCO)S(C)(=O)=O)c(C3CC3)cc12,"InChI=1S/C22H23FN2O5S/c1-24-22(27)20-17-11-16(13-3-4-13)18(25(9-10-26)31(2,28)29)12-19(17)30-21(20)14-5-7-15(23)8-6-14/h5-8,11-13,26H,3-4,9-10H2,1-2H3,(H,24,27)",WTDWVLJJJOTABN-UHFFFAOYSA-N,nesbuvir,Phase 2,RNA polymerase inhibitor,,,
CCNC1CC(N)C(OC2OC(CN)=CCC2N)C(O)C1OC1OCC(C)(O)C(NC)C1O,"InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3",CIDUJQMULVCIBT-UHFFFAOYSA-N,netilmicin,Launched,protein synthesis inhibitor,,infectious disease,gram-negative bacterial infections
Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3",WAXQNWCZJDTGBU-UHFFFAOYSA-N,netupitant,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting
O=C(O)c1cc(NCc2c(F)c(F)c(C(F)(F)F)c(F)c2F)ccc1O,"InChI=1S/C15H8F7NO3/c16-10-7(11(17)13(19)9(12(10)18)15(20,21)22)4-23-5-1-2-8(24)6(3-5)14(25)26/h1-3,23-24H,4H2,(H,25,26)",HABROHXUHNHQMY-UHFFFAOYSA-N,neu2000,Phase 2,ionotropic glutamate receptor antagonist,,,
COc1ccc(-c2nc(-c3ccc(-c4cccc(Cl)c4)o3)[nH]c2-c2ccc(OC)cc2)cc1,"InChI=1S/C27H21ClN2O3/c1-31-21-10-6-17(7-11-21)25-26(18-8-12-22(32-2)13-9-18)30-27(29-25)24-15-14-23(33-24)19-4-3-5-20(28)16-19/h3-16H,1-2H3,(H,29,30)",FEEOFPAEDSMOTO-UHFFFAOYSA-N,neurodazine,Preclinical,neurogenesis of non-pluripotent C2C12 myoblast inducer,,,
CCOC(=O)c1ccc(N(C)c2csc(-c3ccccc3)n2)cc1,"InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3",MGKYEWWFHSESJN-UHFFFAOYSA-N,neuropathiazol,Preclinical,neural stem cell inducer,BMP2|LIF,,
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5,infectious disease,human immunodeficiency virus (HIV-1)
CCCCN(Cc1ccc(C(O)=NO)cc1)C(=O)Nc1ccccc1,"InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)",JZWXMCPARMXZQV-UHFFFAOYSA-N,nexturastat-a,Preclinical,HDAC inhibitor,HDAC1|HDAC6,,
Cc1ccc(NCCCc2ccccc2)c(N)c1,"InChI=1S/C16H20N2/c1-13-9-10-16(15(17)12-13)18-11-5-8-14-6-3-2-4-7-14/h2-4,6-7,9-10,12,18H,5,8,11,17H2,1H3",YMFNPBSZFWXMAD-UHFFFAOYSA-N,nfkb-activation-inhibitor-ii,Preclinical,NFkB pathway inhibitor,RELA,,
N=C(NCCCC(N)C(=O)O)N[N+](=O)[O-],"InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)",MRAUNPAHJZDYCK-UHFFFAOYSA-N,ng-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,
O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2,"InChI=1S/C28H29Cl2N3O/c29-25-8-5-9-26(27(25)30)33-16-14-32(15-17-33)13-4-3-12-31-28(34)21-10-11-24-22(19-21)18-20-6-1-2-7-23(20)24/h1-2,5-11,19H,3-4,12-18H2,(H,31,34)",YJPWVCIGSHWNON-UHFFFAOYSA-N,ngb-2904,Preclinical,dopamine receptor antagonist,DRD3,,
c1ccc(-c2nc(CN3CCN(c4ncccn4)CC3)c[nH]2)cc1,"InChI=1S/C18H20N6/c1-2-5-15(6-3-1)17-21-13-16(22-17)14-23-9-11-24(12-10-23)18-19-7-4-8-20-18/h1-8,13H,9-12,14H2,(H,21,22)",OTVQCHUIPJYASM-UHFFFAOYSA-N,ngd-94-1,Phase 1,dopamine receptor antagonist,DRD4,,
CCC(CC)N=c1[nH]c(C)c(-c2ccc(OC(F)(F)F)cc2OC)nc1OC,"InChI=1S/C19H24F3N3O3/c1-6-12(7-2)24-17-18(27-5)25-16(11(3)23-17)14-9-8-13(10-15(14)26-4)28-19(20,21)22/h8-10,12H,6-7H2,1-5H3,(H,23,24)",PSUFQBRCUSJTDO-UHFFFAOYSA-N,ngd-98-2,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,
CCc1cc(N=c2[nH]c(-c3ccc(-n4cnc(C)c4)c(F)c3)cs2)c(C)cc1C,"InChI=1S/C23H23FN4S/c1-5-17-10-20(15(3)8-14(17)2)26-23-27-21(12-29-23)18-6-7-22(19(24)9-18)28-11-16(4)25-13-28/h6-13H,5H2,1-4H3,(H,26,27)",WDEKUGNKKOGFOA-UHFFFAOYSA-N,ngp555,Phase 1,gamma secretase modulator,,,
CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C,"InChI=1S/C27H45N2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-28-23-24-29(26(28)2)25-27-20-17-16-18-21-27/h16-18,20-21,23-24H,3-15,19,22,25H2,1-2H3/q+1",ZZXUNAFAKNKXFW-UHFFFAOYSA-N,nh125,Preclinical,eukaryotic translation elongation factor 2 inhibitor,,,
COC(=O)c1cc2c(C(F)(F)F)cc(-c3ccccc3)cc2n1O,"InChI=1S/C17H12F3NO3/c1-24-16(22)15-9-12-13(17(18,19)20)7-11(8-14(12)21(15)23)10-5-3-2-4-6-10/h2-9,23H,1H3",YPPFWRWCZNXINO-UHFFFAOYSA-N,nhi-2,Preclinical,lactate dehydrogenase inhibitor,LDHA,,
COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,"InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3",UEMQPCYDWCSVCU-UHFFFAOYSA-N,ni-57,Preclinical,bromodomain inhibitor,BRD1|BRPF1|BRPF3,,
O=C(O)c1cccnc1,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",PVNIIMVLHYAWGP-UHFFFAOYSA-N,niacin,Launched,NAD precursor,DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT,endocrinology,hypertriglyceridemia
O=C(O)c1cccnc1,"InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)",PVNIIMVLHYAWGP-UHFFFAOYSA-N,niacin,Launched,vitamin B,DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT,endocrinology,hypertriglyceridemia
O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,"InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)",NOIIUHRQUVNIDD-UHFFFAOYSA-N,nialamide,Withdrawn,monoamine oxidase inhibitor,COMT|MAOA|MAOB,,
CCN(CC)CCCCC(NC(=O)c1ccc([N+](=O)[O-])cc1)c1ccccc1,"InChI=1S/C22H29N3O3/c1-3-24(4-2)17-9-8-12-21(18-10-6-5-7-11-18)23-22(26)19-13-15-20(16-14-19)25(27)28/h5-7,10-11,13-16,21H,3-4,8-9,12,17H2,1-2H3,(H,23,26)",YRFYIORBFFGPPZ-UHFFFAOYSA-N,nibentan,Phase 2,potassium channel blocker,,,
CC(C)NCC(O)COc1cccc2c1N(C(=O)c1cccnc1)CCC2,"InChI=1S/C21H27N3O3/c1-15(2)23-13-18(25)14-27-19-9-3-6-16-8-5-11-24(20(16)19)21(26)17-7-4-10-22-12-17/h3-4,6-7,9-10,12,15,18,23,25H,5,8,11,13-14H2,1-2H3",AUIHHZBJBKRDIE-UHFFFAOYSA-N,nicainoprol,Preclinical,angiotensin converting enzyme inhibitor,,,
CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1,"InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)",KTXBOOWDLPUROC-UHFFFAOYSA-N,nicaraven,Phase 3,free radical scavenger,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,23-24H,13-14,16H2,1-4H3",UXVSDVSUISWXKD-UHFFFAOYSA-N,nicardipine,Launched,calcium channel blocker,ADORA3,cardiology,chronic stable angina|hypertension
COC12CC(COC(=O)c3cncc(Br)c3)CN(C)C1Cc1cn(C)c3cccc2c13,"InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3",YSEXMKHXIOCEJA-UHFFFAOYSA-N,nicergoline,Launched,adrenergic receptor antagonist,ADRA1A,rheumatology|neurology/psychiatry|cardiology|hematology,Raynaud's disease|migraine headache|atherosclerosis|thrombosis
O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1,"InChI=1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2",KUEUWHJGRZKESU-UHFFFAOYSA-N,niceritrol,Launched,NAD precursor,,endocrinology,hyperlipidemia
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,"InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)",RJMUSRYZPJIFPJ-UHFFFAOYSA-N,niclosamide,Launched,DNA replication inhibitor,STAT3,infectious disease,tapeworm
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,"InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)",RJMUSRYZPJIFPJ-UHFFFAOYSA-N,niclosamide,Launched,STAT inhibitor,STAT3,infectious disease,tapeworm
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)NCCNC(=O)c1cccnc1,"InChI=1S/C28H39N3O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-27(32)30-23-24-31-28(33)26-20-19-22-29-25-26/h3-4,6-7,9-10,12-13,15-16,19-20,22,25H,2,5,8,11,14,17-18,21,23-24H2,1H3,(H,30,32)(H,31,33)",YYQALOWPCKMFDQ-UHFFFAOYSA-N,nicodicosapent,Preclinical,sterol regulatory element binding protein (SREBP) inhibitor,,,
O=C(NCCO[N+](=O)[O-])c1cccnc1,"InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)",LBHIOVVIQHSOQN-UHFFFAOYSA-N,nicorandil,Launched,nitric oxide donor,KCNJ11,cardiology,angina pectoris
O=C(NCCO[N+](=O)[O-])c1cccnc1,"InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)",LBHIOVVIQHSOQN-UHFFFAOYSA-N,nicorandil,Launched,potassium channel activator,KCNJ11,cardiology,angina pectoris
NC(=O)c1cccnc1,"InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)",DFPAKSUCGFBDDF-UHFFFAOYSA-N,nicotinamide,Launched,protein synthesis stimulant,BST1|LDHA|PARP1|SIRT5,dermatology,acne vulgaris (AV)
CN1CCCC1c1cccnc1,"InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3",SNICXCGAKADSCV-UHFFFAOYSA-N,nicotine,Launched,acetylcholine receptor agonist,CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1,neurology/psychiatry,smoking cessation
OCc1cccnc1,"InChI=1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2",MVQVNTPHUGQQHK-UHFFFAOYSA-N,nicotinyl-alcohol-tartrate,Launched,,,cardiology|neurology/psychiatry,vascular spasm|vertigo
COc1ccc(-c2c(C)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1,"InChI=1S/C23H24Cl2N4O2/c1-15-21(23(30)27-28-12-4-3-5-13-28)26-29(20-11-8-17(24)14-19(20)25)22(15)16-6-9-18(31-2)10-7-16/h6-11,14H,3-5,12-13H2,1-2H3,(H,27,30)",KWDBQJRWPWTGPF-UHFFFAOYSA-N,nida-41020,Preclinical,cannabinoid receptor antagonist,CNR1,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,13,15H,1-4H3",OSUCQKNXQBPLDG-UHFFFAOYSA-N,nifedipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3,cardiology,vasospastic angina|chronic stable angina
Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O,"InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3",OEBPANQZQGQPHF-UHFFFAOYSA-N,nifekalant,Launched,potassium channel blocker,,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CC(C)NCC(O)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C11H16N2O3/c1-8(2)12-7-11(14)9-3-5-10(6-4-9)13(15)16/h3-6,8,11-12,14H,7H2,1-2H3",UAORFCGRZIGNCI-UHFFFAOYSA-N,nifenalol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,,
Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C17H16N4O2/c1-12-15(19-16(22)13-7-6-10-18-11-13)17(23)21(20(12)2)14-8-4-3-5-9-14/h3-11H,1-2H3,(H,19,22)",BRZANEXCSZCZCI-UHFFFAOYSA-N,nifenazone,Launched,analgesic agent,,neurology/psychiatry,pain relief
O=C(O)c1ccc[nH]c1=Nc1cccc(C(F)(F)F)c1,"InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)",JZFPYUNJRRFVQU-UHFFFAOYSA-N,niflumic-acid,Launched,cyclooxygenase inhibitor,ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9,rheumatology|neurology/psychiatry,joint pain|muscle pain
O=C(NN=Cc1ccc([N+](=O)[O-])o1)c1ccc(O)cc1,"InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)",YCWSUKQGVSGXJO-UHFFFAOYSA-N,nifuroxazide,Launched,bacterial DNA inhibitor,,gastroenterology,colitis|diarrhea
O=C(NN=Cc1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O,"InChI=1S/C12H7N5O9/c18-11-8(3-6(15(20)21)4-9(11)16(22)23)12(19)14-13-5-7-1-2-10(26-7)17(24)25/h1-5,18H,(H,14,19)",XXUXXCZCUGIGPP-UHFFFAOYSA-N,nifursol,Launched,bacterial DNA inhibitor,,,
CC1CS(=O)(=O)CCN1N=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3",ARFHIAQFJWUCFH-UHFFFAOYSA-N,nifurtimox,Launched,DNA inhibitor,,infectious disease,Chagas disease|African trypanosomiasis
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,32-33H,11,18-23H2,1-3H3",DCOAXFMVFWUZET-UHFFFAOYSA-N,niguldipine-(r)-(-),Preclinical,,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,32-33H,11,18-23H2,1-3H3",DCOAXFMVFWUZET-UHFFFAOYSA-N,niguldipine-(s)-(+),Preclinical,adrenergic receptor antagonist,ADRA1A,,
CCN(CC)C(=O)c1cccnc1,"InChI=1S/C10H14N2O/c1-3-12(4-2)10(13)9-6-5-7-11-8-9/h5-8H,3-4H2,1-2H3",NCYVXEGFNDZQCU-UHFFFAOYSA-N,nikethamide,Withdrawn,immunostimulant,,,
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N=c4nc(-c5cccnc5)cc[nH]4)c3)cc(C(F)(F)F)c2)cn1,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,nilotinib,Launched,Abl kinase inhibitor,ABL1|KIT,hematologic malignancy,chronic myeloid leukemia (CML)
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N=c4nc(-c5cccnc5)cc[nH]4)c3)cc(C(F)(F)F)c2)cn1,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,nilotinib,Launched,Bcr-Abl kinase inhibitor,ABL1|KIT,hematologic malignancy,chronic myeloid leukemia (CML)
CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,"InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)",XWXYUMMDTVBTOU-UHFFFAOYSA-N,nilutamide,Launched,androgen receptor antagonist,AR,oncology,prostate cancer
COC(=O)C1=C(C#N)N=C(C)C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,15-16H,1-4H3",KJWGEXJCWCYEMI-UHFFFAOYSA-N,nilvadipine,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension|cerebral artery occlusion
CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(C(C)CC)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,"InChI=1S/C62H111N11O12/c1-25-28-29-40(15)52(75)51-56(79)65-43(27-3)58(81)67(18)33-47(74)71(22)50(39(14)26-2)55(78)66-48(37(10)11)61(84)68(19)44(30-34(4)5)54(77)63-41(16)53(76)64-42(17)57(80)69(20)45(31-35(6)7)59(82)70(21)46(32-36(8)9)60(83)72(23)49(38(12)13)62(85)73(51)24/h25,28,34-46,48-52,75H,26-27,29-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)",RPJPZDVUUKWPGT-UHFFFAOYSA-N,nim811,Phase 2,mitochondrial permeability transition inhibitor,,,
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,"InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3",HYWYRSMBCFDLJT-UHFFFAOYSA-N,nimesulide,Launched,cyclooxygenase inhibitor,LTF|PLA2G2E|PTGS1|PTGS2,rheumatology|obstetrics/gynecology,osteoarthritis|menstrual pain
COCCOC(=O)C1=C(C)N=C(C)C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,18-19H,9-10H2,1-5H3",SVMHYHIZWOJKDL-UHFFFAOYSA-N,nimodipine,Launched,calcium channel blocker,CFTR|NR3C2,hematology,hemorrhage
O=[N+]([O-])c1cncn1CCN1CCOCC1,"InChI=1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2",MDJFHRLTPRPZLY-UHFFFAOYSA-N,nimorazole,Launched,bacterial DNA inhibitor,,oncology,head and neck squamous cell carcinoma (HNSCC)
Cc1nc(=N)c(CNC(=O)N(CCCl)NO)c[nH]1,"InChI=1S/C9H15ClN6O2/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10/h4,15,18H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14)",KDFKNUYVBPFKHA-UHFFFAOYSA-N,nimustine,Launched,DNA alkylating agent,,,
Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)",VQYYQSZNRVQLIS-UHFFFAOYSA-N,ningetinib-tosylate,Preclinical,protein tyrosine kinase inhibitor,,,
COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3",CPMDPSXJELVGJG-UHFFFAOYSA-N,nintedanib,Launched,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF)
COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3",CPMDPSXJELVGJG-UHFFFAOYSA-N,nintedanib,Launched,PDGFR tyrosine kinase receptor inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF)
COC(=O)c1ccc2c(C(=Nc3ccc(N(C)C(=O)CN4CCN(C)CC4)cc3)c3ccccc3)c(O)[nH]c2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3",CPMDPSXJELVGJG-UHFFFAOYSA-N,nintedanib,Launched,VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF)
NC(=O)c1cccc2cn(-c3ccc(C4CCCNC4)cc3)nc12,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)",PCHKPVIQAHNQLW-UHFFFAOYSA-N,niraparib,Launched,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC)
O=C1NCCN1c1ncc([N+](=O)[O-])s1,"InChI=1S/C6H6N4O3S/c11-5-7-1-2-9(5)6-8-3-4(14-6)10(12)13/h3H,1-2H2,(H,7,11)",RDXLYGJSWZYTFJ-UHFFFAOYSA-N,niridazole,Launched,phosphofructokinase inhibitor,,infectious disease,schistosomiasis
CCC(=NC(=O)C(N)C(C)CC)C(=O)NC1CSCC(C(=O)NC2C(=O)N3CCCC3C(=O)NCC(=O)NC(C(=O)NC(CCCCN)C(=O)NC3C(=O)NCC(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NCC(=O)NC(C(=O)NC(CC(N)=O)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC4C(=O)NC(C)C(=O)NC5C(=O)NC(CSC4C)C(=O)NC(Cc4c[nH]cn4)C(=O)NC(C(=O)NC(CO)C(=O)NC(C(=O)NC(Cc4c[nH]cn4)C(=O)NC(C(=O)N=C(C)C(=O)NC(CCCCN)C(=O)O)C(C)C)C(C)CC)CSC5C)CSC3C)CSC2C)NC(=O)C(CC(C)C)NC(=O)C(C)=NC(=O)C(C(C)CC)NC1=O,"InChI=1S/C143H230N42O37S7/c1-24-69(11)105(148)135(213)162-82(27-4)118(196)174-94-58-225-59-95(175-123(201)89(48-67(7)8)169-115(193)74(16)158-138(216)107(70(12)25-2)180-132(94)210)133(211)184-112-79(21)229-61-96(160-104(190)56-152-134(212)100-38-34-44-185(100)142(112)220)128(206)164-84(36-29-32-42-145)120(198)182-109-76(18)226-60-97(161-103(189)55-151-117(195)85(39-45-223-22)165-122(200)88(47-66(5)6)168-113(191)72(14)156-102(188)54-153-136(109)214)129(207)171-92(51-101(147)187)125(203)166-86(40-46-224-23)119(197)163-83(35-28-31-41-144)121(199)183-110-77(19)228-63-99-130(208)170-90(49-80-52-149-64-154-80)124(202)176-98(62-227-78(20)111(141(219)177-99)181-116(194)75(17)159-140(110)218)131(209)173-93(57-186)127(205)179-108(71(13)26-3)139(217)172-91(50-81-53-150-65-155-81)126(204)178-106(68(9)10)137(215)157-73(15)114(192)167-87(143(221)222)37-30-33-43-146/h52-53,64-72,75-79,83-100,105-112,186H,24-51,54-63,144-146,148H2,1-23H3,(H2,147,187)(H,149,154)(H,150,155)(H,151,195)(H,152,212)(H,153,214)(H,156,188)(H,159,218)(H,160,190)(H,161,189)(H,163,197)(H,164,206)(H,165,200)(H,166,203)(H,167,192)(H,168,191)(H,169,193)(H,170,208)(H,171,207)(H,172,217)(H,173,209)(H,174,196)(H,175,201)(H,176,202)(H,177,219)(H,178,204)(H,179,205)(H,180,210)(H,181,194)(H,182,198)(H,183,199)(H,184,211)(H,221,222)",FBWYNNFRJLMFNG-UHFFFAOYSA-N,nisin,Phase 1,bacterial cell wall synthesis inhibitor,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],"InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,17-18H,10H2,1-5H3",PKICUDXEAPMDNG-UHFFFAOYSA-N,nisoldipine,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension
CNCCC(Oc1ccccc1OC)c1ccccc1,"InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3",ITJNARMNRKSWTA-UHFFFAOYSA-N,nisoxetine,Phase 1,norepinephrine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,,
O=[N+]([O-])c1ccc([As](=O)(O)O)cc1,"InChI=1S/C6H6AsNO5/c9-7(10,11)5-1-3-6(4-2-5)8(12)13/h1-4H,(H2,9,10,11)",FUUFQLXAIUOWML-UHFFFAOYSA-N,nitarsone,Launched,,,dermatology,blackhead disease
CC(=O)Oc1ccccc1C(=O)N=c1[nH]cc([N+](=O)[O-])s1,"InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)",YQNQNVDNTFHQSW-UHFFFAOYSA-N,nitazoxanide,Launched,pyruvate ferredoxin oxidoreductase inhibitor,,gastroenterology,diarrhea
CC(=O)C(=Cc1cc(O)c(O)c([N+](=O)[O-])c1)C(C)=O,"InChI=1S/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3",UPMRZALMHVUCIN-UHFFFAOYSA-N,nitecapone,Phase 2,catechol O methyltransferase inhibitor,COMT,,
CCN(Cc1ccc(Cl)nc1)C(C[N+](=O)[O-])=NC,"InChI=1S/C11H15ClN4O2/c1-3-15(11(13-2)8-16(17)18)7-9-4-5-10(12)14-6-9/h4-6H,3,7-8H2,1-2H3",VLLBCTKFTIILHS-UHFFFAOYSA-N,nitenpyram,Launched,,,infectious disease,flea control
CC(=O)N=c1[nH]cc([N+](=O)[O-])s1,"InChI=1S/C5H5N3O3S/c1-3(9)7-5-6-2-4(12-5)8(10)11/h2H,1H3,(H,6,7,9)",UJRRDDHEMZLWFI-UHFFFAOYSA-N,nithiamide,Preclinical,bacterial DNA inhibitor,,,
O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],"InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2",OUBCNLGXQFSTLU-UHFFFAOYSA-N,nitisinone,Launched,hydroxyphenylpyruvate dioxygenase inhibitor,,metabolism,tyrosinemia
CCOC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,14,16H,5H2,1-4H3",VVTJQHCRBOHFTD-UHFFFAOYSA-N,nitrendipine,Launched,calcium channel blocker,CACNA1D|CACNA2D1|KCNN4,cardiology,hypertension
CCN(CC)CCOC(=O)C1(c2ccc([N+](=O)[O-])cc2)CCCC1,"InChI=1S/C18H26N2O4/c1-3-19(4-2)13-14-24-17(21)18(11-5-6-12-18)15-7-9-16(10-8-15)20(22)23/h7-10H,3-6,11-14H2,1-2H3",NSHMVLOWOAQFTP-UHFFFAOYSA-N,nitrocaramiphen,Preclinical,cholinergic receptor antagonist,CHRM1,,
CC(C(=O)OCCCCO[N+](=O)[O-])c1ccc(-c2ccccc2)c(F)c1,"InChI=1S/C19H20FNO5/c1-14(19(22)25-11-5-6-12-26-21(23)24)16-9-10-17(18(20)13-16)15-7-3-2-4-8-15/h2-4,7-10,13-14H,5-6,11-12H2,1H3",DLWSRGHNJVLJAH-UHFFFAOYSA-N,nitroflurbiprofen,Preclinical,cyclooxygenase inhibitor,,,
O=c1[nH]c(O)cn1N=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-4,13H,(H,10,14)",ZSPWEUZMDXEYMX-UHFFFAOYSA-N,nitrofurantoin,Launched,DNA inhibitor,,infectious disease,urinary tract infections|pyelonephritis
NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,"InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)",IAIWVQXQOWNYOU-UHFFFAOYSA-N,nitrofurazone,Launched,bacterial DNA inhibitor,,infectious disease,first-aid antibiotic
NC(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1,"InChI=1S/C7H5N3O5/c8-7(11)4-1-5(9(12)13)3-6(2-4)10(14)15/h1-3H,(H2,8,11)",UUKWKUSGGZNXGA-UHFFFAOYSA-N,nitromide,Launched,,,infectious disease,coccidiosis
CNC(=O)N(C)NO,"InChI=1S/C3H9N3O2/c1-4-3(7)6(2)5-8/h5,8H,1-2H3,(H,4,7)",IXPMBHCGGBEFRU-UHFFFAOYSA-N,nitrosodimethylurea,Preclinical,DNA synthesis inhibitor,,,
O=[N+]([O-])c1ccc(O)c2ncccc12,"InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H",RJIWZDNTCBHXAL-UHFFFAOYSA-N,nitroxoline,Launched,cathepsin inhibitor,METAP2,infectious disease,urinary tract infections
CN=C(C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,"InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h9H,4-8H2,1-3H3,(H,13,14)",XPZQPVYGEOEOKS-UHFFFAOYSA-N,nizatidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)
CCN(CC)Cc1nccn1-c1ccc([N+](=O)[O-])cc1C(=O)c1ccccc1Cl,"InChI=1S/C21H21ClN4O3/c1-3-24(4-2)14-20-23-11-12-25(20)19-10-9-15(26(28)29)13-17(19)21(27)16-7-5-6-8-18(16)22/h5-13H,3-4,14H2,1-2H3",WZGBZLHGOVJDET-UHFFFAOYSA-N,nizofenone,Launched,ion channel antagonist,,neurology/psychiatry,stroke
O=C(N=c1[nH]nc(-c2ccco2)o1)NCc1ccccn1,"InChI=1S/C13H11N5O3/c19-12(15-8-9-4-1-2-6-14-9)16-13-18-17-11(21-13)10-5-3-7-20-10/h1-7H,8H2,(H2,15,16,18,19)",FNSCFQXZZNCDAI-UHFFFAOYSA-N,nk-252,Preclinical,nuclear factor erythroid derived,NFE2L2,,
O=C(N=c1[nH]nc(-c2ccco2)o1)NCc1ccccn1,"InChI=1S/C13H11N5O3/c19-12(15-8-9-4-1-2-6-14-9)16-13-18-17-11(21-13)10-5-3-7-20-10/h1-7H,8H2,(H2,15,16,18,19)",FNSCFQXZZNCDAI-UHFFFAOYSA-N,nk-252,Preclinical,like (NRF2) activator,NFE2L2,,
c1ccc2[nH][n+]([Ru+7][n+]3cc4ccccc4[nH]3)cc2c1,"InChI=1S/2C7H6N2.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;/h2*1-5H,(H,8,9);/q;;+9",HHIPVEGSSASWOD-UHFFFAOYSA-N,nkp-1339,Phase 1,HSP inhibitor,,,
N=c1nc2c(c[nH]1)C(=O)CC(c1ccco1)C2,"InChI=1S/C12H11N3O2/c13-12-14-6-8-9(15-12)4-7(5-10(8)16)11-2-1-3-17-11/h1-3,6-7H,4-5H2,(H2,13,14,15)",SOJUSNIBPPMLCC-UHFFFAOYSA-N,nky-80,Preclinical,adenylyl cyclase inhibitor,ADCY5,,
OC(CC1c2ccccc2-c2cncn21)C1CCCCC1,"InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2",YTRRAUACYORZLX-UHFFFAOYSA-N,nlg919,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,
CC1(O)C(O)C(CO)OC1n1ccc(=N)[nH]c1=O,"InChI=1S/C10H15N3O5/c1-10(17)7(15)5(4-14)18-8(10)13-3-2-6(11)12-9(13)16/h2-3,5,7-8,14-15,17H,4H2,1H3,(H2,11,12,16)",PPUDLEUZKVJXSZ-UHFFFAOYSA-N,nm107,Phase 2,RNA polymerase inhibitor,,,
CNC(CC(=O)O)C(=O)O,"InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)",HOKKHZGPKSLGJE-UHFFFAOYSA-N,nmda,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
CN1CCN(c2ccc(OC(F)(F)F)c(N=c3nc4c(c[nH]3)CCc3c(C(N)=O)nn(CCO)c3-4)c2)CC1,"InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)",QHLVBNKYJGBCQJ-UHFFFAOYSA-N,nms-1286937,Phase 2,PLK inhibitor,FLT3|PLK1|PLK2|PLK3,,
Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(S(C)(=O)=O)cc1,"InChI=1S/C27H28N4O3S2/c1-19-16-22(11-14-25(19)20-9-12-24(13-10-20)36(2,32)33)34-18-26-29-30-27(35-23-7-3-4-8-23)31(26)21-6-5-15-28-17-21/h5-6,9-17,23H,3-4,7-8,18H2,1-2H3",UJGTUKMAJVCBIS-UHFFFAOYSA-N,nms-873,Preclinical,ATPase inhibitor,VCP,,
CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1,"InChI=1S/C22H22N4O7/c1-25-8-6-13(7-9-25)23-22(29)17-12-20(33-24-17)21-18(28)10-15(27)11-19(21)32-16-4-2-14(3-5-16)26(30)31/h2-5,10-13,27-28H,6-9H2,1H3,(H,23,29)",YLQODGGPIHWTHR-UHFFFAOYSA-N,nms-e973,Preclinical,HSP inhibitor,,,
CCc1cccc(CC)c1NC(=O)c1nn(C)c2c1CCc1c[nH]c(=Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC(F)(F)F)nc1-2,"InChI=1S/C35H39F3N8O3/c1-5-20-8-7-9-21(6-2)28(20)42-33(48)30-25-12-10-23-19-39-34(43-29(23)31(25)46(4)44-30)41-26-13-11-22(18-27(26)49-35(36,37)38)32(47)40-24-14-16-45(3)17-15-24/h7-9,11,13,18-19,24H,5-6,10,12,14-17H2,1-4H3,(H,40,47)(H,42,48)(H,39,41,43)",JFOAJUGFHDCBJJ-UHFFFAOYSA-N,nms-p715,Preclinical,protein kinase inhibitor,,,
CCCCCCCCCN1CC(O)C(O)C(O)C1CO,"InChI=1S/C15H31NO4/c1-2-3-4-5-6-7-8-9-16-10-13(18)15(20)14(19)12(16)11-17/h12-15,17-20H,2-11H2,1H3",FTSCEGKYKXESFF-UHFFFAOYSA-N,nn-dnj,Preclinical,glucosidase inhibitor,GBA,,
COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc32)CC1,"InChI=1S/C27H30N2O2/c1-31-26-14-7-4-11-23(26)27(30)15-19-28(20-16-27)17-8-18-29-24-12-5-2-9-21(24)22-10-3-6-13-25(22)29/h2-7,9-14,30H,8,15-20H2,1H3",XZZYCJOGZYEPPW-UHFFFAOYSA-N,nnc-05-2090,Preclinical,GABA uptake inhibitor,SLC6A12,,
COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc32)CC1,"InChI=1S/C27H30N2O2/c1-31-26-14-7-4-11-23(26)27(30)15-19-28(20-16-27)17-8-18-29-24-12-5-2-9-21(24)22-10-3-6-13-25(22)29/h2-7,9-14,30H,8,15-20H2,1H3",XZZYCJOGZYEPPW-UHFFFAOYSA-N,nnc-05-2090,Preclinical,GAT inhibitor,SLC6A12,,
CC(C)C1c2ccc(F)cc2CCC1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,"InChI=1S/C30H38FN3O2/c1-20(2)28-24-13-12-23(31)19-22(24)14-15-30(28,36-29(35)21-10-11-21)16-18-34(3)17-6-9-27-32-25-7-4-5-8-26(25)33-27/h4-5,7-8,12-13,19-21,28H,6,9-11,14-18H2,1-3H3,(H,32,33)",VHHVPDKNKPNKHY-UHFFFAOYSA-N,nnc-55-0396,Preclinical,T-type calcium channel blocker,CATSPER1|CATSPER2|CATSPER3|CATSPER4,,
COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,"InChI=1S/C27H29N3O3/c1-33-25(31)19-29-20-30(23-11-3-2-4-12-23)27(26(29)32)14-16-28(17-15-27)18-22-10-7-9-21-8-5-6-13-24(21)22/h2-13H,14-20H2,1H3",AQMPIDSGLFVVPL-UHFFFAOYSA-N,nnc-63-0532,Preclinical,opioid receptor agonist,OPRL1,,
O=C(O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,"InChI=1S/C21H22N2O3/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-6,8-12H,7,13-16H2,(H,24,25)",NGNALWDRPKNJGR-UHFFFAOYSA-N,nnc-711,Preclinical,GABA uptake inhibitor,SIGMAR1|SLC6A1,,
CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+](=O)[O-])c1,"InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3",IOJUJUOXKXMJNF-UHFFFAOYSA-N,no-asa,Phase 2,cyclooxygenase inhibitor,PTGS2,,
COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1OC,"InChI=1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3",MRIAQLRQZPPODS-UHFFFAOYSA-N,nobiletin,Preclinical,MEK inhibitor,MAP2K1,,
COC(=O)N=c1[nH]c2ccc(C(=O)c3cccs3)cc2[nH]1,"InChI=1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19)",KYRVNWMVYQXFEU-UHFFFAOYSA-N,nocodazole,Preclinical,tubulin polymerization inhibitor,HPGDS,,
Cc1ccc2[nH]c(=N)[nH]c(=O)c2c1Sc1ccncc1,"InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)",XHWRWCSCBDLOLM-UHFFFAOYSA-N,nolatrexed,Phase 3,thymidylate synthase inhibitor,TYMS,,
CC(=O)OC1(C(C)=O)CCC2C3=CC(C)=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11,17-18,21H,5-10,12H2,1-4H3",TTXRYAMBSXFTEJ-UHFFFAOYSA-N,nomegestrol-acetate,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive
CN1Cc2c(N)cccc2C(c2ccccc2)C1,"InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3",XXPANQJNYNUNES-UHFFFAOYSA-N,nomifensine,Withdrawn,dopamine reuptake inhibitor,DRD2|SLC6A2|SLC6A3,,
CN1Cc2c(N)cccc2C(c2ccccc2)C1,"InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3",XXPANQJNYNUNES-UHFFFAOYSA-N,nomifensine,Withdrawn,noradrenaline uptake inhibitor,DRD2|SLC6A2|SLC6A3,,
CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,"InChI=1S/C17H27NO3/c1-3-4-5-6-7-8-9-17(20)18-13-14-10-11-15(19)16(12-14)21-2/h10-12,19H,3-9,13H2,1-2H3,(H,18,20)",RGOVYLWUIBMPGK-UHFFFAOYSA-N,nonivamide,Launched,TRPV agonist,TRPV1,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain
CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1,"InChI=1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3",FBWNMEQMRUMQSO-UHFFFAOYSA-N,nonoxynol-9,Launched,membrane integrity inhibitor,,endocrinology,contraceptive
Oc1ccc2c3c1OC1c4[nH]c5c(c4CC4(O)C(C2)N(CC2CC2)CCC314)CC1(O)C2Cc3ccc(O)c4c3C1(CCN2CC1CC1)C5O4,"InChI=1S/C40H43N3O6/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2",APSUXPSYBJVPPS-UHFFFAOYSA-N,nor-binaltorphimine,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,
CNCCC=C1c2ccccc2C=Cc2ccccc21,"InChI=1S/C19H19N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-13,20H,6,14H2,1H3",XECQQDXTQRYYBH-UHFFFAOYSA-N,norcyclobenzaprine,Preclinical,adrenergic receptor agonist,,,
CNCCC=C1c2ccccc2C=Cc2ccccc21,"InChI=1S/C19H19N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-13,20H,6,14H2,1H3",XECQQDXTQRYYBH-UHFFFAOYSA-N,norcyclobenzaprine,Preclinical,serotonin receptor antagonist,,,
C#CC1(O)CCC2C3CCC4=CC(=NO)CCC4C3CCC21CC,"InChI=1S/C21H29NO2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23-24H,3,5-12H2,1H3",ISHXLNHNDMZNMC-UHFFFAOYSA-N,norelgestromin,Launched,,PGR,endocrinology,contraceptive
NCC(O)c1ccc(O)c(O)c1,"InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2",SFLSHLFXELFNJZ-UHFFFAOYSA-N,norepinephrine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2,cardiology|allergy|neurology/psychiatry,hypertension|urticaria|headache|seasonal affective disorder
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,4,15-18,22H,5-12H2,2H3",QGQUHXSBTSDAML-UHFFFAOYSA-N,norethindrone,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis
C#CC1(OC(C)=O)CCC2C3CC=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,5,17-20H,6-13H2,2-3H3",KDYGOTULHKNOFI-UHFFFAOYSA-N,norethindrone-acetate,Launched,progesterone receptor agonist,PGR,endocrinology|orthopedics|obstetrics/gynecology,menopause|osteoporosis|vaginal atrophy
C#CC1(OC(=O)CCCCCC)CCC2C3CC=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,10,21-24H,4,6-9,11-18H2,1,3H3",ZYEOLMDPAUHXEQ-UHFFFAOYSA-N,norethisterone-enanthate,Launched,contraceptive agent,,endocrinology,contraceptive
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,4,15-18,22H,5-12H2,2H3",QGQUHXSBTSDAML-UHFFFAOYSA-N,noretynodrel,Launched,progestogen hormone,PGR,endocrinology,contraceptive
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,"InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)",OGJPXUAPXNRGGI-UHFFFAOYSA-N,norfloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,urinary tract infections|gonorrhea|prostatitis
NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,"InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2",WIQRCHMSJFFONW-UHFFFAOYSA-N,norfluoxetine,Phase 1,selective serotonin reuptake inhibitor (SSRI),HTR2B,,
C#CC1(OC(C)=O)CCC2C3CCC4=CC(=NO)CCC4C3CCC21CC,"InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3",KIQQMECNKUGGKA-UHFFFAOYSA-N,norgestimate,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive
C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,5,16-19,23H,3,6-13H2,1H3",LYRBZVWRTAFWPO-UHFFFAOYSA-N,norgestrel,Launched,progesterone receptor agonist,AR|ESR1|PGR|SRD5A1,endocrinology,contraceptive
c1cncc(C2CCCN2)c1,"InChI=1S/C9H12N2/c1-3-8(7-10-5-1)9-4-2-6-11-9/h1,3,5,7,9,11H,2,4,6H2",MYKUKUCHPMASKF-UHFFFAOYSA-N,nornicotine,Preclinical,acetylcholine receptor agonist,,,
CNCCC=C1c2ccccc2CCc2ccccc21,"InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3",PHVGLTMQBUFIQQ-UHFFFAOYSA-N,nortriptyline,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression
CC(C)CC(N)C(=O)Nc1c(O)[nH]c(CC(N)O)c(O)[nH]c2c3cc(c(OC4OC(CO)C(O)C(O)C4OC4CC(C)(N)C(O)C(C)O4)c(c3)oc3ccc(cc3Cl)c1=O)Oc1ccc(cc1Cl)C(O)c1[nH]c(O)c(c3ccc(O)c(c3)c3c(O)cc(O)cc3c(=C(O)O)[nH]c1O)NC=2O,"InChI=1S/C65H73Cl2N9O24/c1-22(2)11-33(68)57(87)75-48-50(82)25-6-9-37(31(66)13-25)96-39-15-27-16-40(54(39)100-64-55(53(85)52(84)41(21-77)98-64)99-43-20-65(4,70)56(86)23(3)95-43)97-38-10-7-26(14-32(38)67)51(83)49-62(92)74-47(63(93)94)30-17-28(78)18-36(80)44(30)29-12-24(5-8-35(29)79)45(59(89)76-49)73-60(90)46(27)72-58(88)34(19-42(69)81)71-61(48)91/h5-10,12-18,22-23,33,41-43,51-53,55-56,64,71-74,76-81,83-86,88-94H,11,19-21,68-70H2,1-4H3,(H,75,87)",KHWVKRZPRLZUIL-UHFFFAOYSA-N,norvancomycin,Preclinical,,,,
COc1ccc2c(c1OC)C(=O)OC2C1c2c(cc3c(c2OC)OCO3)CCN1C,"InChI=1S/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3",AKNNEGZIBPJZJG-UHFFFAOYSA-N,noscapine,Launched,bradykinin receptor antagonist,SIGMAR1,pulmonary,cough suppressant
COc1ccc2c(c1OC)C(=O)OC2C1c2c(cc3c(c2OC)OCO3)CCN1C,"InChI=1S/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3",AKNNEGZIBPJZJG-UHFFFAOYSA-N,noscapine,Launched,tubulin polymerization inhibitor,SIGMAR1,pulmonary,cough suppressant
NC(CCC(=O)NC(CSSCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O,"InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)",YPZRWBKMTBYPTK-UHFFFAOYSA-N,nov-002,Phase 3,,GSR,,
COC1C(OC(N)=O)C(O)C(Oc2ccc3c(=O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(O)oc3c2C)OC1(C)C,"InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34,36,38H,8H2,1-6H3,(H2,32,39)(H,33,37)",DYYIUCVAQGRACE-UHFFFAOYSA-N,novobiocin,Launched,bacterial DNA gyrase inhibitor,,obstetrics/gynecology,mastitis
CC12CC(O)C3C(CC=C4CC(=O)CCC43C)C1CCC2=O,"InChI=1S/C19H26O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h3,13-15,17,21H,4-10H2,1-2H3",KNZBHPIVYMGACT-UHFFFAOYSA-N,npc-01,Phase 3,steroid,,,
CC(C)CC(NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,"InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)",CBPJQFCAFFNICX-UHFFFAOYSA-N,npc-15199,Phase 2,ICAM1 antagonist,PPARG,,
O=C(O)c1cc([N+](=O)[O-])ccc1NCCCc1ccccc1,"InChI=1S/C16H16N2O4/c19-16(20)14-11-13(18(21)22)8-9-15(14)17-10-4-7-12-5-2-1-3-6-12/h1-3,5-6,8-9,11,17H,4,7,10H2,(H,19,20)",WBSMIPAMAXNXFS-UHFFFAOYSA-N,nppb,Preclinical,chloride channel blocker,ANO1|CLCN2|CLCN7|TRPA1,,
CC(C)(Cc1ccc2ccccc2c1)NCC(O)COc1cccc(Cl)c1C#N,"InChI=1S/C24H25ClN2O2/c1-24(2,13-17-10-11-18-6-3-4-7-19(18)12-17)27-15-20(28)16-29-23-9-5-8-22(25)21(23)14-26/h3-12,20,27-28H,13,15-16H2,1-2H3",PZUJQWHTIRWCID-UHFFFAOYSA-N,nps-2143,Preclinical,calcium receptor antagonist,CASR,,
CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1,"InChI=1S/C19H19N3O/c1-19(2,12-14-8-4-3-5-9-14)22-18(23)17-13-20-15-10-6-7-11-16(15)21-17/h3-11,13H,12H2,1-2H3,(H,22,23)",DQEWVIJXZPUPQA-UHFFFAOYSA-N,nps-2407,Preclinical,glutamate receptor antagonist,,,
Cc1c(NC(=O)N2CCOCC2)ccc2c1c1ccccc1n2C(C)C,"InChI=1S/C21H25N3O2/c1-14(2)24-18-7-5-4-6-16(18)20-15(3)17(8-9-19(20)24)22-21(25)23-10-12-26-13-11-23/h4-9,14H,10-13H2,1-3H3,(H,22,25)",ZNFMHLDBJPAFEQ-UHFFFAOYSA-N,npy-5ra972,Preclinical,neuropeptide receptor antagonist,NPY5R,,
CCOC(=O)c1c2c3c(cccc3[nH]c1=O)C(=O)c1ccccc1-2,"InChI=1S/C19H13NO4/c1-2-24-19(23)16-15-10-6-3-4-7-11(10)17(21)12-8-5-9-13(14(12)15)20-18(16)22/h3-9H,2H2,1H3,(H,20,22)",UFJGFNHRMPMALC-UHFFFAOYSA-N,nqdi-1,Preclinical,caspase inhibitor,CASP3,,
CC(N=c1cc(-c2cnn(C)c2)cc(N=c2cncc[nH]2)[nH]1)c1ccc(F)cc1,"InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)",UQTPDWDAYHAZNT-UHFFFAOYSA-N,ns-018,Phase 1/Phase 2,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,
FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(C(F)(F)F)c1,"InChI=1S/C16H9BrF6N6S/c17-9-1-2-12(11(6-9)13-26-28-29-27-13)25-14(30)24-10-4-7(15(18,19)20)3-8(5-10)16(21,22)23/h1-6H,(H2,24,25,30)(H,26,27,28,29)",MDKAFDIKYQMOMF-UHFFFAOYSA-N,ns-11021,Preclinical,calcium-activated potassium channel activator,KCNMA1,,
CC(C)(O)c1ccc2c(c1)ncn2-c1cccc(-c2ccccc2C#N)c1,"InChI=1S/C23H19N3O/c1-23(2,27)18-10-11-22-21(13-18)25-15-26(22)19-8-5-7-16(12-19)20-9-4-3-6-17(20)14-24/h3-13,15,27H,1-2H3",HLKYSQGBIIIQJN-UHFFFAOYSA-N,ns-11394,Preclinical,GABA receptor agonist,,,
O=C(Nc1cc(C(F)(F)F)ccc1O)Nc1cc(C(F)(F)F)ccc1O,"InChI=1S/C15H10F6N2O3/c16-14(17,18)7-1-3-11(24)9(5-7)22-13(26)23-10-6-8(15(19,20)21)2-4-12(10)25/h1-6,24-25H,(H2,22,23,26)",NJFVQMRYJZHGME-UHFFFAOYSA-N,ns-1643,Preclinical,voltage-gated potassium channel activator,KCNH2|KCNH6|KCNMA1,,
N=c1[nH]cc(Cc2ccc(Br)cc2)s1,"InChI=1S/C10H9BrN2S/c11-8-3-1-7(2-4-8)5-9-6-13-10(12)14-9/h1-4,6H,5H2,(H2,12,13)",HGWLTZOMQZIUBW-UHFFFAOYSA-N,ns-19504,Preclinical,calcium-activated potassium channel activator,KCNMA1,,
O=Nc1c(O)[nH]c2c(Cl)c(Cl)ccc12,"InChI=1S/C8H4Cl2N2O2/c9-4-2-1-3-6(5(4)10)11-8(13)7(3)12-14/h1-2,11,13H",ROBYKNONIPZMTK-UHFFFAOYSA-N,ns-309,Preclinical,calcium-activated potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,
O=C(Nc1cccc(C(F)(F)F)c1)Nc1ccc(Br)cc1-c1nn[nH]n1,"InChI=1S/C15H10BrF3N6O/c16-9-4-5-12(11(7-9)13-22-24-25-23-13)21-14(26)20-10-3-1-2-8(6-10)15(17,18)19/h1-7H,(H2,20,21,26)(H,22,23,24,25)",JXPULDIATMTIIN-UHFFFAOYSA-N,ns-3623,Preclinical,voltage-gated potassium channel activator,KCNH2,,
CN1C2C=C(c3sccc3Br)CC1CC2,"InChI=1S/C12H14BrNS/c1-14-9-2-3-10(14)7-8(6-9)12-11(13)4-5-15-12/h4-6,9-10H,2-3,7H2,1H3",ZJCNRVHZJADROC-UHFFFAOYSA-N,ns-3861,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNB4,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)Nc1c(Br)cc(Br)cc1-c1nn[nH]n1,"InChI=1S/C16H8Br2F6N6O/c17-8-4-10(13-27-29-30-28-13)12(11(18)5-8)26-14(31)25-9-2-6(15(19,20)21)1-7(3-9)16(22,23)24/h1-5H,(H2,25,26,31)(H,27,28,29,30)",UZWJWROOLOOCPQ-UHFFFAOYSA-N,ns-5806,Preclinical,voltage-gated potassium channel activator,KCND3,,
Cc1c(-c2ccccc2F)[nH]c(N)c1C#N,"InChI=1S/C12H10FN3/c1-7-9(6-14)12(15)16-11(7)8-4-2-3-5-10(8)13/h2-5,16H,15H2,1H3",KVDWOQGDMAEJLM-UHFFFAOYSA-N,ns-8,Phase 2,potassium channel agonist,KCNMA1,,
c1ccc2c(c1)CCCC2N=c1[nH]c2ccccc2[nH]1,"InChI=1S/C17H17N3/c1-2-8-13-12(6-1)7-5-11-14(13)18-17-19-15-9-3-4-10-16(15)20-17/h1-4,6,8-10,14H,5,7,11H2,(H2,18,19,20)",XZIZUQSOFMLIIR-UHFFFAOYSA-N,ns-8593,Preclinical,calcium-activated potassium channel modulator,KCNN1|KCNN2|KCNN3,,
N#Cc1cccc(-c2nc(-c3cccnc3)no2)c1,"InChI=1S/C14H8N4O/c15-8-10-3-1-4-11(7-10)14-17-13(18-19-14)12-5-2-6-16-9-12/h1-7,9H",HGFXDSQLRSWUBO-UHFFFAOYSA-N,ns-9283,Preclinical,acetylcholine receptor allosteric modulator,CHRNA4,,
CCN(CC)CCCC(C)N=c1[nH]c(C)cc(=Nc2ccc3[nH]c(C)cc(=N)c3c2)[nH]1,"InChI=1S/C24H35N7/c1-6-31(7-2)12-8-9-16(3)27-24-28-18(5)14-23(30-24)29-19-10-11-22-20(15-19)21(25)13-17(4)26-22/h10-11,13-16H,6-9,12H2,1-5H3,(H2,25,26)(H2,27,28,29,30)",DEFBCZWQLILOJF-UHFFFAOYSA-N,nsc-23766,Preclinical,Ras GTPase inhibitor,,,
CC(=NNC(=S)N1CCC1)c1ccccn1,"InChI=1S/C11H14N4S/c1-9(10-5-2-3-6-12-10)13-14-11(16)15-7-4-8-15/h2-3,5-6H,4,7-8H2,1H3,(H,14,16)",XDHBUMNIQRLHGO-UHFFFAOYSA-N,nsc-319726,Preclinical,p53 activator,,,
O=Nc1ccc(O)c2ncccc12,"InChI=1S/C9H6N2O2/c12-8-4-3-7(11-13)6-2-1-5-10-9(6)8/h1-5,12H",RZWRYPGAUIOOMK-UHFFFAOYSA-N,nsc-3852,Preclinical,HDAC inhibitor,HDAC1,,
CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1,"InChI=1S/C12H15Cl2NO/c1-3-4-8(2)15-12(16)9-5-6-10(13)11(14)7-9/h5-8H,3-4H2,1-2H3,(H,15,16)",ARDYECYBETXQFD-UHFFFAOYSA-N,nsc-405020,Preclinical,matrix metalloprotease inhibitor,MMP1,,
C=C(C)C1CCC2(CO)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C12,"InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3",FVWJYYTZTCVBKE-UHFFFAOYSA-N,nsc-4644,Phase 2,ACAT inhibitor,PYGM,,
C=C(C)C1CCC2(CO)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C12,"InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3",FVWJYYTZTCVBKE-UHFFFAOYSA-N,nsc-4644,Phase 2,sterol regulatory element binding protein (SREBP) inhibitor,PYGM,,
Clc1ccc2c(=NCCN=c3cc[nH]c4cc(Cl)ccc34)cc[nH]c2c1,"InChI=1S/C20H16Cl2N4/c21-13-1-3-15-17(5-7-23-19(15)11-13)25-9-10-26-18-6-8-24-20-12-14(22)2-4-16(18)20/h1-8,11-12H,9-10H2,(H,23,25)(H,24,26)",SSXYXSMMVMVYEV-UHFFFAOYSA-N,nsc-5844,Preclinical,CC chemokine receptor agonist,CCR1,,
COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12,"InChI=1S/C15H13NO2S/c1-17-11-7-8-12(18-2)14-13(11)15(19)9-5-3-4-6-10(9)16-14/h3-8H,1-2H3,(H,16,19)",KFAKESMKRPNZTM-UHFFFAOYSA-N,nsc-625987,Preclinical,CDK inhibitor,CDK2|CDK4,,
Cc1ccc(C=C2CNCC(=Cc3ccc(C)cc3)C2=O)cc1,"InChI=1S/C21H21NO/c1-15-3-7-17(8-4-15)11-19-13-22-14-20(21(19)23)12-18-9-5-16(2)6-10-18/h3-12,22H,13-14H2,1-2H3",PKCYYPHSCUSQDK-UHFFFAOYSA-N,nsc-632839,Preclinical,ubiquitin specific protease inhibitor,SENP2|USP1|USP2|USP7,,
O=[N+]([O-])c1cc([N+](=O)[O-])c(C=Cc2ccc(Cl)c(Cl)c2)cc1C=Cc1ccc(Cl)c(Cl)c1,InChI=1S/C22H12Cl4N2O4/c23-17-7-3-13(9-19(17)25)1-5-15-11-16(22(28(31)32)12-21(15)27(29)30)6-2-14-4-8-18(24)20(26)10-14/h1-12H,YYZPXBXVBQSBDG-UHFFFAOYSA-N,nsc-636819,Preclinical,histone demethylase inhibitor,KDM4A|KDM4B,,
O=C1C(=NCCN2CCOCC2)C(Cl)C(=O)c2cccnc21,"InChI=1S/C15H16ClN3O3/c16-11-13(18-4-5-19-6-8-22-9-7-19)15(21)12-10(14(11)20)2-1-3-17-12/h1-3,11H,4-9H2",DUKQPWDVIZDABV-UHFFFAOYSA-N,nsc-663284,Preclinical,CDC inhibitor,CDC25A|CDC25B|CDC25C,,
Cc1ccc(S(=O)(=O)c2ccc([N+](=O)[O-])o2)cc1,"InChI=1S/C11H9NO5S/c1-8-2-4-9(5-3-8)18(15,16)11-7-6-10(17-11)12(13)14/h2-7H,1H3",GAUHIPWCDXOLCZ-UHFFFAOYSA-N,nsc-697923,Preclinical,ubiquitin-conjugating enzyme inhibitor,UBE2N,,
O=C1C(SCCO)=C(SCCO)C(=O)c2ccccc21,"InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2",MAASHDQFQDDECQ-UHFFFAOYSA-N,nsc-95397,Preclinical,CDC inhibitor,CDC25A|CDC25B,,
COC1CC=C2CCN3CCC4=C(CC(=O)OC4)C23C1,"InChI=1S/C16H21NO3/c1-19-13-3-2-12-5-7-17-6-4-11-10-20-15(18)8-14(11)16(12,17)9-13/h2,13H,3-10H2,1H3",ALSKYCOJJPXPFS-UHFFFAOYSA-N,nsc-9965,Preclinical,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,
CC(C)CCN=c1[nH]cccc1C(=O)N1CCN(Cc2ccccc2)CC1,"InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)",DYTOQURYRYYNOR-UHFFFAOYSA-N,nsi-189,Phase 2,neurotrophic agent,,,
CC1CC(=O)NN=C1c1ccc(N=C2CCC(=O)C2C)cc1,"InChI=1S/C17H19N3O2/c1-10-9-16(22)19-20-17(10)12-3-5-13(6-4-12)18-14-7-8-15(21)11(14)2/h3-6,10-11H,7-9H2,1-2H3,(H,19,22)",YHCXDPICTBVYQD-UHFFFAOYSA-N,nsp-805,Preclinical,phosphodiesterase inhibitor,,,
Oc1cc(CNC(=S)C=Cc2cc(O)c(O)c(Br)c2)cc(O)c1O,"InChI=1S/C16H14BrNO5S/c17-10-3-8(4-11(19)15(10)22)1-2-14(24)18-7-9-5-12(20)16(23)13(21)6-9/h1-6,19-23H,7H2,(H,18,24)",NIPUPOUEGOSAAO-UHFFFAOYSA-N,nt157,Preclinical,IGF-1 inhibitor,IGF1R,,
O=[N+]([O-])c1ccccc1S(=O)(=O)NCC1CCC(CNCC2CCc3ccccc3C2)CC1,"InChI=1S/C25H33N3O4S/c29-28(30)24-7-3-4-8-25(24)33(31,32)27-18-20-11-9-19(10-12-20)16-26-17-21-13-14-22-5-1-2-6-23(22)15-21/h1-8,19-21,26-27H,9-18H2",ISSSVYKMIIAPTH-UHFFFAOYSA-N,ntncb,Preclinical,neuropeptide receptor antagonist,NPY5R,,
Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)c(C(=O)C(F)(F)F)cn3CC(=O)NC(CC(C)C)C(=O)O)cc1,"InChI=1S/C25H26F3N3O6S/c1-14(2)10-20(24(34)35)29-22(32)13-31-12-19(23(33)25(26,27)28)18-11-16(6-9-21(18)31)30-38(36,37)17-7-4-15(3)5-8-17/h4-9,11-12,14,20,30H,10,13H2,1-3H3,(H,29,32)(H,34,35)",SOOLLEBJNGCDOZ-UHFFFAOYSA-N,ntrc-824,Preclinical,neurotensin receptor antagonist,NTSR2,,
O=C(O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1,"InChI=1S/C22H15Cl2NO2S/c23-15-8-6-14(7-9-15)13-25-19-11-10-16(24)12-18(19)21(20(25)22(26)27)28-17-4-2-1-3-5-17/h1-12H,13H2,(H,26,27)",VUPOTURDKDMIGQ-UHFFFAOYSA-N,ntzdpa,Preclinical,PPAR receptor agonist,PPARG,,
Cc1nc(=O)c2cccc(O)c2[nH]1,"InChI=1S/C9H8N2O2/c1-5-10-8-6(9(13)11-5)3-2-4-7(8)12/h2-4,12H,1H3,(H,10,11,13)",YJDAOHJWLUNFLX-UHFFFAOYSA-N,nu-1025,Preclinical,PARP inhibitor,PARP1,,
N=c1nc(OCC2CCCCC2)c2[nH]cnc2[nH]1,"InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17)",MWGXGTJJAOZBNW-UHFFFAOYSA-N,nu-2058,Preclinical,cyclin D inhibitor,CCNA2|CDK2,,
N=c1[nH]c(OCC2CCCCC2)c(N=O)c(=N)[nH]1,"InChI=1S/C11H17N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h7H,1-6H2,(H4,12,13,14,15)",DGWXOLHKVGDQLN-UHFFFAOYSA-N,nu-6027,Preclinical,CDK inhibitor,CCNA2|CDK2,,
O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,"InChI=1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2",KKTZALUTXUZPSN-UHFFFAOYSA-N,nu-7026,Preclinical,DNA dependent protein kinase inhibitor,PRKDC,,
O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,"InChI=1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2",KKTZALUTXUZPSN-UHFFFAOYSA-N,nu-7026,Preclinical,mTOR inhibitor,PRKDC,,
O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,"InChI=1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2",KKTZALUTXUZPSN-UHFFFAOYSA-N,nu-7026,Preclinical,PI3K inhibitor,PRKDC,,
O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12,"InChI=1S/C25H19NO3S/c27-21-15-23(26-11-13-28-14-12-26)29-24-17(6-3-9-20(21)24)19-8-4-7-18-16-5-1-2-10-22(16)30-25(18)19/h1-10,15H,11-14H2",JAMULYFATHSZJM-UHFFFAOYSA-N,nu-7441,Preclinical,DNA dependent protein kinase inhibitor,PRKDC,,
O=c1c(Cc2ccc(Cl)cc2)c(O)nc2n1CCS2,"InChI=1S/C13H11ClN2O2S/c14-9-3-1-8(2-4-9)7-10-11(17)15-13-16(12(10)18)5-6-19-13/h1-4,17H,5-7H2",RDZSGZAIZQMLMI-UHFFFAOYSA-N,nuclomedone,Phase 3,immunosuppressant,,,
COc1ccc(C2=NC(c3ccc(Cl)cc3)C(c3ccc(Cl)cc3)N2C(=O)N2CCNC(=O)C2)c(OC(C)C)c1,"InChI=1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)",BDUHCSBCVGXTJM-UHFFFAOYSA-N,nutlin-3,Preclinical,MDM inhibitor,MDM2|TP53,,
CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1,"InChI=1S/C19H20N4O2/c1-22-11-8-13(9-12-22)19(25)23-16-7-3-2-6-15(16)21-18(24)14-5-4-10-20-17(14)23/h2-7,10,13H,8-9,11-12H2,1H3,(H,21,24)",HPKYRXAEGNUARA-UHFFFAOYSA-N,nuvenzepine,Preclinical,acetylcholine receptor antagonist,,,
O=C(N=c1[nH]c2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1,"InChI=1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)",MVSSJPGNLQPWSW-UHFFFAOYSA-N,nvp-231,Preclinical,ceramidase inhibitor,CERK,,
N=c1[nH]cnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1,"InChI=1S/C28H31N5O/c29-27-26-25(22-9-6-10-24(15-22)34-18-20-7-2-1-3-8-20)17-33(28(26)31-19-30-27)23-13-21(14-23)16-32-11-4-5-12-32/h1-3,6-10,15,17,19,21,23H,4-5,11-14,16,18H2,(H2,29,30,31)",LSFLAQVDISHMNB-UHFFFAOYSA-N,nvp-adw742,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,
N=c1[nH]cnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCC2)C1,"InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)",AECDBHGVIIRMOI-UHFFFAOYSA-N,nvp-aew541,Preclinical,IGF-1 inhibitor,IGF1R|INSR,,
CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,nvp-auy922,Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,
Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,nvp-bez235,Phase 3,mTOR inhibitor,ATR|MTOR|PIK3CA|PIK3CD|PIK3CG,,
Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,nvp-bez235,Phase 3,PI3K inhibitor,ATR|MTOR|PIK3CA|PIK3CD|PIK3CG,,
CCN1CCN(c2ccc(N=c3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)[nH]cn3)cc2)CC1,"InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)",QADPYRIHXKWUSV-UHFFFAOYSA-N,nvp-bgj398,Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,
Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1N=c1[nH]c(-c2cccnc2)nc2c1cnn2C,"InChI=1S/C26H20F3N7O/c1-15-8-9-16(25(37)32-19-7-3-6-18(12-19)26(27,28)29)11-21(15)33-23-20-14-31-36(2)24(20)35-22(34-23)17-5-4-10-30-13-17/h3-14H,1-2H3,(H,32,37)(H,33,34,35)",ZCCPLJOKGAACRT-UHFFFAOYSA-N,nvp-bhg712,Preclinical,ephrin inhibitor,EPHB4,,
Fc1cc(-c2cccc3ncc(-c4cnn(C5CCNCC5)c4)nc23)cc(F)c1CN1CCOCC1,"InChI=1S/C27H28F2N6O/c28-23-12-18(13-24(29)22(23)17-34-8-10-36-11-9-34)21-2-1-3-25-27(21)33-26(15-31-25)19-14-32-35(16-19)20-4-6-30-7-5-20/h1-3,12-16,20,30H,4-11,17H2",IBPVXAOOVUAOKJ-UHFFFAOYSA-N,nvp-bsk805,Preclinical,JAK inhibitor,JAK2,,
Cn1cc(-c2ccc3ncc(Cc4ccc5ncccc5c4)n3n2)cn1,"InChI=1S/C20H16N6/c1-25-13-16(11-23-25)19-6-7-20-22-12-17(26(20)24-19)10-14-4-5-18-15(9-14)3-2-8-21-18/h2-9,11-13H,10H2,1H3",RNCNPRCUHHDYPC-UHFFFAOYSA-N,nvp-bvu972,Preclinical,MET inhibitor,MET,,
N#Cc1ccc(=NCCNCC(=O)N2CCCC2C#N)[nH]c1,"InChI=1S/C15H18N6O/c16-8-12-3-4-14(20-10-12)19-6-5-18-11-15(22)21-7-1-2-13(21)9-17/h3-4,10,13,18H,1-2,5-7,11H2,(H,19,20)",VFFZWMWTUSXDCB-UHFFFAOYSA-N,nvp-dpp728,Phase 2,dipeptidyl peptidase inhibitor,DPP4,,
COc1cccc(-c2cc(F)ccc2C2Cc3[nH]c(=N)nc(C)c3C(=O)N2)n1,"InChI=1S/C20H18FN5O2/c1-10-18-16(26-20(22)23-10)9-15(25-19(18)27)12-7-6-11(21)8-13(12)14-4-3-5-17(24-14)28-2/h3-8,15H,9H2,1-2H3,(H,25,27)(H2,22,23,26)",WSMQUUGTQYPVPD-UHFFFAOYSA-N,nvp-hsp990,Phase 1,HSP inhibitor,HSP90AA1|HSP90AB1,,
CNC(=O)c1ccccc1N=c1[nH]c(=Nc2ccc(N3CCOCC3)cc2OC)[nH]cc1Cl,"InChI=1S/C23H25ClN6O3/c1-25-22(31)16-5-3-4-6-18(16)27-21-17(24)14-26-23(29-21)28-19-8-7-15(13-20(19)32-2)30-9-11-33-12-10-30/h3-8,13-14H,9-12H2,1-2H3,(H,25,31)(H2,26,27,28,29)",UYJNQQDJUOUFQJ-UHFFFAOYSA-N,nvp-tae226,Preclinical,protein tyrosine kinase inhibitor,PTK2,,
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1[nH]cc(Cl)c(=Nc2ccccc2S(=O)(=O)C(C)C)[nH]1,"InChI=1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)",QQWUGDVOUVUTOY-UHFFFAOYSA-N,nvp-tae684,Preclinical,ALK tyrosine kinase receptor inhibitor,ALK|INSR,,
COc1ccc(C(=O)C2CCN(CC(=O)N(Cc3nc(=O)c4c([nH]3)CCOC4)CC3CC3)CC2)cc1,"InChI=1S/C27H34N4O5/c1-35-21-6-4-19(5-7-21)26(33)20-8-11-30(12-9-20)16-25(32)31(14-18-2-3-18)15-24-28-23-10-13-36-17-22(23)27(34)29-24/h4-7,18,20H,2-3,8-17H2,1H3,(H,28,29,34)",DYGBNAYFDZEYBA-UHFFFAOYSA-N,nvp-tnks656,Preclinical,tankyrase inhibitor,TNKS2,,
CC(C)NC(=O)N1CCC(N=C2Nc3cc(F)ccc3N(CC(F)F)c3ccc(Cl)cc32)C1,"InChI=1S/C23H25ClF3N5O/c1-13(2)28-23(33)31-8-7-16(11-31)29-22-17-9-14(24)3-5-19(17)32(12-21(26)27)20-6-4-15(25)10-18(20)30-22/h3-6,9-10,13,16,21H,7-8,11-12H2,1-2H3,(H,28,33)(H,29,30)",OINGHOPGNMYCAB-UHFFFAOYSA-N,nvs-pak1-1,Preclinical,p21 activated kinase inhibitor,PAK1,,
CC(C)(C)[N+]([O-])=Cc1ccc(S(=O)(=O)O)cc1S(=O)(=O)O,"InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)",OVTCHWSLKGENKP-UHFFFAOYSA-N,nxy-059,Phase 3,free radical scavenger,,,
CC1C=CC=CCCC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,"InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)",VQOXZBDYSJBXMA-UHFFFAOYSA-N,nystatin,Launched,fungal ergosterol inhibitor,,infectious disease,esophageal candidiasis|skin infections|yeast infection
C=C(C)C1CCC(C)=CC1c1c(OC)cc(C)cc1OC,"InChI=1S/C19H26O2/c1-12(2)15-8-7-13(3)9-16(15)19-17(20-5)10-14(4)11-18(19)21-6/h9-11,15-16H,1,7-8H2,2-6H3",ICHJMVMWPKLUKT-UHFFFAOYSA-N,o-1918,Preclinical,cannabinoid receptor antagonist,,,
O=C(N=c1[nH]c(=O)n(Cc2ccc(Cl)cc2)s1)c1ccc(Cl)cc1,"InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23)",WEDWLYRQKUTOAX-UHFFFAOYSA-N,o-304,Preclinical,AMPK activator,,,
Cc1cc(C)c(S(=O)(=O)Nc2ccccc2C(F)(F)F)c(C)c1,"InChI=1S/C16H16F3NO2S/c1-10-8-11(2)15(12(3)9-10)23(21,22)20-14-7-5-4-6-13(14)16(17,18)19/h4-9,20H,1-3H3",SKJJIFRWCCSXGL-UHFFFAOYSA-N,o-3m3fbs,Preclinical,phospholipase activator,,,
CC(=O)OCC(N)C(=O)O,"InChI=1S/C5H9NO4/c1-3(7)10-2-4(6)5(8)9/h4H,2,6H2,1H3,(H,8,9)",VZXPDPZARILFQX-UHFFFAOYSA-N,o-acetyl-l-serine,Preclinical,,PTGS1,,
O=C(O)c1ccccc1S,"InChI=1S/C7H6O2S/c8-7(9)5-3-1-2-4-6(5)10/h1-4,10H,(H,8,9)",NBOMNTLFRHMDEZ-UHFFFAOYSA-N,o-mercapto-benzoic-acid,Preclinical,,,,
COc1ccc(COc2ccc(CC#N)cc2)cc1,"InChI=1S/C16H15NO2/c1-18-15-6-4-14(5-7-15)12-19-16-8-2-13(3-9-16)10-11-17/h2-9H,10,12H2,1H3",QJEJLARVLKHYFW-UHFFFAOYSA-N,o4i1,Preclinical,Oct inducer,POU5F1,,
N=c1nc(OCc2ccccc2)c2[nH]cnc2[nH]1,"InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)",KRWMERLEINMZFT-UHFFFAOYSA-N,o6-benzylguanine,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,
O=C(N=c1cc2cc[nH]c2c[nH]1)c1ccccc1,"InChI=1S/C14H11N3O/c18-14(10-4-2-1-3-5-10)17-13-8-11-6-7-15-12(11)9-16-13/h1-9,15H,(H,16,17,18)",HWJRIFZDXJKJJN-UHFFFAOYSA-N,oac1,Preclinical,Oct activator,,,
O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1,"InChI=1S/C15H12N2O/c18-15(11-4-2-1-3-5-11)17-13-6-7-14-12(10-13)8-9-16-14/h1-10,16H,(H,17,18)",JCAFGYWSIWYMOX-UHFFFAOYSA-N,oac2,Preclinical,Oct activator,POU5F1,,
C=c1cc(C)c(=Cc2[nH]c(-c3cc4ccccc4[nH]3)cc2OC)[nH]1,"InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21-23H,2H2,1,3H3",BELKGVZAXTUUHW-UHFFFAOYSA-N,obatoclax,Phase 3,BCL inhibitor,BCL2,,
CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,"InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)",ZXERDUOLZKYMJM-UHFFFAOYSA-N,obeticholic-acid,Launched,FXR agonist,NR1H4,gastroenterology,primary biliary cholangitis
ON=Cc1cc[n+](COC[n+]2ccc(C=NO)cc2)cc1,"InChI=1S/C14H14N4O3/c19-15-9-13-1-5-17(6-2-13)11-21-12-18-7-3-14(4-8-18)10-16-20/h1-10H,11-12H2/p+2",HIGRLDNHDGYWQJ-UHFFFAOYSA-P,obidoxime,Launched,cholinesterase reactivator,ACHE,critical care|neurology/psychiatry,poison antidote|nerve gas poisoning
Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O,"InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)",FATGTHLOZSXOBC-UHFFFAOYSA-N,oc000459,Phase 2,CRTH receptor antagonist,PTGDR2,,
Cc1nc2c(C)cccn2c(=O)c1CCN1CCC(c2noc3cc(F)ccc23)CC1,"InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3",ZZQNEJILGNNOEP-UHFFFAOYSA-N,ocaperidone,Preclinical,serotonin receptor antagonist,,,
Cc1cc(O)c2c(ccc3c(O)c4c(O)cccc4c(O)c32)c1,"InChI=1S/C19H14O4/c1-9-7-10-5-6-12-17(15(10)14(21)8-9)19(23)11-3-2-4-13(20)16(11)18(12)22/h2-8,20-23H,1H3",HTLACEZDKVHAAD-UHFFFAOYSA-N,ochromycinone,Phase 1,STAT inhibitor,STAT3,,
O=C(c1ccccn1)c1cnn2c(-c3ccncc3)ccnc12,InChI=1S/C17H11N5O/c23-16(14-3-1-2-7-19-14)13-11-21-22-15(6-10-20-17(13)22)12-4-8-18-9-5-12/h1-11H,OQJFBUOFGHPMSR-UHFFFAOYSA-N,ocinaplon,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,,
CC(C)c1ccc(C(=O)NCCOc2ccc(C(=O)O)cc2)cc1,"InChI=1S/C19H21NO4/c1-13(2)14-3-5-15(6-4-14)18(21)20-11-12-24-17-9-7-16(8-10-17)19(22)23/h3-10,13H,11-12H2,1-2H3,(H,20,21)(H,22,23)",ODLDHXPJRGNTPC-UHFFFAOYSA-N,oco-1112,Phase 2,cholesterol inhibitor,,,
CCCCCCCCCCCCCCCCCCO,"InChI=1S/C18H38O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h19H,2-18H2,1H3",GLDOVTGHNKAZLK-UHFFFAOYSA-N,octadecan-1-ol,Preclinical,,,,
C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,"InChI=1S/C8H24O2Si3/c1-11(2,3)9-13(7,8)10-12(4,5)6/h1-8H3",CXQXSVUQTKDNFP-UHFFFAOYSA-N,octamethyltrisiloxane,Preclinical,,,,
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1,"InChI=1S/C36H62N4/c1-3-5-7-9-15-19-27-37-35-23-31-39(32-24-35)29-21-17-13-11-12-14-18-22-30-40-33-25-36(26-34-40)38-28-20-16-10-8-6-4-2/h23-26,31-34H,3-22,27-30H2,1-2H3",ZVXNYZWXUADSRV-UHFFFAOYSA-N,octenidine,Launched,membrane integrity inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CCCCC(CC)COC(=O)C=Cc1ccc(OC)cc1,"InChI=1S/C18H26O3/c1-4-6-7-15(5-2)14-21-18(19)13-10-16-8-11-17(20-3)12-9-16/h8-13,15H,4-7,14H2,1-3H3",YBGZDTIWKVFICR-UHFFFAOYSA-N,octinoxate,Launched,,,dermatology,sunscreen lotion
CCCCC(CC)COC(=O)c1ccccc1O,"InChI=1S/C15H22O3/c1-3-5-8-12(4-2)11-18-15(17)13-9-6-7-10-14(13)16/h6-7,9-10,12,16H,3-5,8,11H2,1-2H3",FMRHJJZUHUTGKE-UHFFFAOYSA-N,octisalate,Launched,,,dermatology,sunscreen lotion
CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1,"InChI=1S/C24H27NO2/c1-3-5-12-19(4-2)18-27-24(26)22(17-25)23(20-13-8-6-9-14-20)21-15-10-7-11-16-21/h6-11,13-16,19H,3-5,12,18H2,1-2H3",FMJSMJQBSVNSBF-UHFFFAOYSA-N,octocrylene,Launched,,,dermatology,sunscreen lotion
CC(C)CCCC(C)N,"InChI=1S/C8H19N/c1-7(2)5-4-6-8(3)9/h7-8H,4-6,9H2,1-3H3",QNIVIMYXGGFTAK-UHFFFAOYSA-N,octodrine,Preclinical,antitumor agent,,,
NCC(O)c1ccc(O)cc1,"InChI=1S/C8H11NO2/c9-5-8(11)6-1-3-7(10)4-2-6/h1-4,8,10-11H,5,9H2",QHGUCRYDKWKLMG-UHFFFAOYSA-N,octopamine,Preclinical,trace amine associated receptor agonist,F10|TAAR1,,
CC(=O)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)C(N)Cc2ccccc2)CSSCC(C(=O)NC(CO)C(C)O)NC1O,"InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28,34,36-42,49,52,58,60-61,69H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,59,64)",JDKKNQACNITFEA-UHFFFAOYSA-N,octreotide,Launched,somatostatin receptor agonist,SSTR2|SSTR3|SSTR5,gastroenterology|endocrinology|oncology,diarrhea|acromegaly|carcinoid tumors
CC(C)(F)CC(NC(c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,"InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)",FWIVDMJALNEADT-UHFFFAOYSA-N,odanacatib,Phase 3,cathepsin inhibitor,CTSK,,
O=c1onc2cnc3ccccc3n12,InChI=1S/C9H5N3O2/c13-9-12-7-4-2-1-3-6(7)10-5-8(12)11-14-9/h1-5H,LZMHWZHOZLVYDL-UHFFFAOYSA-N,odq,Preclinical,guanylyl cyclase inhibitor,GUCY1A2|GUCY1A3|GUCY1B3,,
COc1cc2c(cc1NS(=O)(=O)c1ccc(Br)cc1C)n(C)c(=O)n2C,"InChI=1S/C17H18BrN3O4S/c1-10-7-11(18)5-6-16(10)26(23,24)19-12-8-13-14(9-15(12)25-4)21(3)17(22)20(13)2/h5-9,19H,1-4H3",YUNQZQREIHWDQT-UHFFFAOYSA-N,of-1,Preclinical,bromodomain inhibitor,BRD1,,
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,"InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)",GSDSWSVVBLHKDQ-UHFFFAOYSA-N,ofloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|otolaryngology|gastroenterology|endocrinology,respiratory tract infections|sinusitis|skin infections|bone and joint infections|intra-abdominal infections|diarrhea|fever|urinary tract infections
NC1CC1c1ccc(-c2cccc(O)c2)cc1,"InChI=1S/C15H15NO/c16-15-9-14(15)11-6-4-10(5-7-11)12-2-1-3-13(17)8-12/h1-8,14-15,17H,9,16H2",DSOJSZXQRJGBCW-UHFFFAOYSA-N,og-l002,Preclinical,histone lysine demethylase inhibitor,KDM1A,,
N=c1[nH]c(-c2ccccc2CO)nc(=NCc2ccccc2)[nH]1,"InChI=1S/C17H17N5O/c18-16-20-15(14-9-5-4-8-13(14)11-23)21-17(22-16)19-10-12-6-2-1-3-7-12/h1-9,23H,10-11H2,(H3,18,19,20,21,22)",MDGIEDNDSFMSLP-UHFFFAOYSA-N,ogerin,Preclinical,G protein-coupled receptor modulator,,,
CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)N=c4c(Cl)c[nH]cc4Cl)c3c2c1,"InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)",OKFDRAHPFKMAJH-UHFFFAOYSA-N,oglemilast,Phase 2,phosphodiesterase inhibitor,,,
NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)O,"InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)",LLEUXCDZPQOJMY-UHFFFAOYSA-N,oglufanide,Phase 2,VEGF antagonist,,,
CN1CCN(c2ccc(-c3cccc(CN4CCOCC4)c3)cc2NC(=O)c2c[nH]c(=O)cc2C(F)(F)F)CC1,"InChI=1S/C29H32F3N5O3/c1-35-7-9-37(10-8-35)26-6-5-22(21-4-2-3-20(15-21)19-36-11-13-40-14-12-36)16-25(26)34-28(39)23-18-33-27(38)17-24(23)29(30,31)32/h2-6,15-18H,7-14,19H2,1H3,(H,33,38)(H,34,39)",DJOVLOYCGXNVPI-UHFFFAOYSA-N,oicr-9429,Preclinical,WDR5/MLL interaction inhibitor,WDR5,,
Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,18H,7-10H2,1-2H3",WXPNDRBBWZMPQG-UHFFFAOYSA-N,olanzapine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder
Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1,"InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,18H,7-10H2,1-2H3",WXPNDRBBWZMPQG-UHFFFAOYSA-N,olanzapine,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,olaparib,Launched,PARP inhibitor,PARP1|PARP2,oncology,ovarian cancer
CCCCCCCCC=CCCCCCCCC(=O)NCCc1ccc(O)c(O)c1,"InChI=1S/C26H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(30)27-21-20-23-18-19-24(28)25(29)22-23/h9-10,18-19,22,28-29H,2-8,11-17,20-21H2,1H3,(H,27,30)",QQBPLXNESPTPNU-UHFFFAOYSA-N,olda,Preclinical,TRPV agonist,GPR119,,
CCCCCCCCC=CCCCCCCCC(N)=O,"InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)",FATBGEAMYMYZAF-UHFFFAOYSA-N,oleamide,Preclinical,cannabinoid receptor agonist,HTR7|PLA2G2A,,
COC1CC(OC2CCC3(C)C(CCC4C3CCC3(C)C(c5coc(O)c5)C(OC(C)=O)CC43O)C2)OC(C)C1O,"InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,16-17,20-25,27-29,34-36H,6-11,13-15H2,1-5H3",WEGJXXVDTSUKRM-UHFFFAOYSA-N,oleandrin,Phase 1,Na/K-ATPase inhibitor,,,
CC1(C)CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1,"InChI=1S/C30H48O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)",MIJYXULNPSFWEK-UHFFFAOYSA-N,oleanolic-acid,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CCCCCCCCC=CCCCCCCCC(=O)NCCO,"InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)",BOWVQLFMWHZBEF-UHFFFAOYSA-N,oleoylethanolamide,Preclinical,cannabinoid receptor agonist,CNR1|GPR119|GPR55|PPARA,,
CCCCCCCCC=CCCCCCCCC(=O)NCCO,"InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)",BOWVQLFMWHZBEF-UHFFFAOYSA-N,oleoylethanolamide,Preclinical,glucose dependent insulinotropic receptor agonist,CNR1|GPR119|GPR55|PPARA,,
CCCCCCCCC=CCCCCCCCC(=O)NCCO,"InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)",BOWVQLFMWHZBEF-UHFFFAOYSA-N,oleoylethanolamide,Preclinical,potassium channel blocker,CNR1|GPR119|GPR55|PPARA,,
CCCCCCCCC=CCCCCCCCC(=O)NCCO,"InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)",BOWVQLFMWHZBEF-UHFFFAOYSA-N,oleoylethanolamide,Preclinical,PPAR receptor agonist,CNR1|GPR119|GPR55|PPARA,,
CC(C)CCCC(C)C1CCC2C3CCC4=CC(=NO)CCC4(C)C3CCC12C,"InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3",QNTASHOAVRSLMD-UHFFFAOYSA-N,olesoxime,Phase 2/Phase 3,apoptosis stimulant,,,
CC=C1C(OC2OC(CO)C(O)C(O)C2O)OC=C(C(=O)OC)C1CC(=O)OCCc1ccc(O)c(O)c1,"InChI=1S/C25H32O13/c1-3-13-14(9-19(29)35-7-6-12-4-5-16(27)17(28)8-12)15(23(33)34-2)11-36-24(13)38-25-22(32)21(31)20(30)18(10-26)37-25/h3-5,8,11,14,18,20-22,24-28,30-32H,6-7,9-10H2,1-2H3",RFWGABANNQMHMZ-UHFFFAOYSA-N,oleuropein,Phase 2,estrogen receptor agonist,GPER1,,
CCC1C=CC=CCC(C)C(O)C(C)(O)C(=O)C(C)C(O)C(C)C(=O)C(C)C(O)C(C)=CCC(=O)OC2C(C)C(CC1)OC1(CCC(C)C(CC(C)O)O1)C2C,"InChI=1S/C45H74O11/c1-12-34-17-15-13-14-16-27(4)42(51)44(11,53)43(52)32(9)40(50)31(8)39(49)30(7)38(48)26(3)18-21-37(47)54-41-29(6)35(20-19-34)55-45(33(41)10)23-22-25(2)36(56-45)24-28(5)46/h13-15,17-18,25,27-36,38,40-42,46,48,50-51,53H,12,16,19-24H2,1-11H3",YDLGNYLLRWZBEZ-UHFFFAOYSA-N,oligomycin-a,Preclinical,ATP synthase inhibitor,ATP5A1,,
CCC1C=CC=CCC(C)C(O)C(C)(O)C(=O)C(C)C(O)C(C)C(=O)C(C)C(O)C(C)=CCC(=O)OC2C(C)C(CC1)OC1(CCC(C)C(CC(C)O)O1)C2C,"InChI=1S/C45H74O11/c1-12-34-17-15-13-14-16-27(4)42(51)44(11,53)43(52)32(9)40(50)31(8)39(49)30(7)38(48)26(3)18-21-37(47)54-41-29(6)35(20-19-34)55-45(33(41)10)23-22-25(2)36(56-45)24-28(5)46/h13-15,17-18,25,27-36,38,40-42,46,48,50-51,53H,12,16,19-24H2,1-11H3",YDLGNYLLRWZBEZ-UHFFFAOYSA-N,oligomycin-a,Preclinical,ATPase inhibitor,ATP5A1,,
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)",VTRAEEWXHOVJFV-UHFFFAOYSA-N,olmesartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)",UQGKUQLKSCSZGY-UHFFFAOYSA-N,olmesartan-medoxomil,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension
C=CC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,"InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)",FDMQDKQUTRLUBU-UHFFFAOYSA-N,olmutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BTK|EGFR,oncology,non-small cell lung cancer (NSCLC)
C=CC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,"InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)",FDMQDKQUTRLUBU-UHFFFAOYSA-N,olmutinib,Launched,EGFR inhibitor,BTK|EGFR,oncology,non-small cell lung cancer (NSCLC)
COc1ccc2c(c1OCc1ccccc1)CC(C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2,"InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)",GHBCIXGRCZIPNQ-UHFFFAOYSA-N,olodanrigan,Phase 2,angiotensin antagonist,,,
Cn1cnc2c(=NCc3ccccc3)[nH]c(=NCCO)[nH]c21,"InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)",GTVPOLSIJWJJNY-UHFFFAOYSA-N,olomoucine,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5|MAPK1,,
CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,"InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)",JBIMVDZLSHOPLA-UHFFFAOYSA-N,olopatadine,Launched,histamine receptor antagonist,HRH1|S100A1|S100A12|S100A13|S100A2|S100B,ophthalmology,conjunctivitis
Cc1[nH]c(=O)c(C#N)cc1-c1ccc2nccn2c1,"InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)",JPAWFIIYTJQOKW-UHFFFAOYSA-N,olprinone,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
O=C(O)c1cc(N=Nc2ccc(O)c(C(=O)O)c2)ccc1O,"InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)",QQBDLJCYGRGAKP-UHFFFAOYSA-N,olsalazine,Launched,cyclooxygenase inhibitor,IFNG|TPMT,gastroenterology,ulcerative colitis
Cc1c(-c2cnccn2)ssc1=S,"InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3",CKNAQFVBEHDJQV-UHFFFAOYSA-N,oltipraz,Phase 3,nuclear factor erythroid derived,ANG,,
Cc1c(-c2cnccn2)ssc1=S,"InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3",CKNAQFVBEHDJQV-UHFFFAOYSA-N,oltipraz,Phase 3,like (NRF2) activator,ANG,,
CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1,"InChI=1S/C26H43NO7/c1-4-6-7-8-9-10-11-12-13-14-15-16-19-32-25-18-17-22(34-25)26(30)33-21-23(28)27(3)20-24(29)31-5-2/h17-18H,4-16,19-21H2,1-3H3",FYJLDICZGDFWKP-UHFFFAOYSA-N,olumacostat-glasaretil,Phase 3,acetyl-CoA carboxylase inhibitor,,,
CCCCCCCCC=CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,"InChI=1S/C26H43NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26(29)27-22-23-19-20-24(28)25(21-23)30-2/h10-11,19-21,28H,3-9,12-18,22H2,1-2H3,(H,27,29)",OPZKBPQVWDSATI-UHFFFAOYSA-N,olvanil,Preclinical,TRPV agonist,CNR1|GPR119|TRPV1,,
CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1CC1CC3C(N(C)C)C(=O)C(C(N)=O)C(=O)C3(O)C(=O)C1C2=O,"InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,18,20-21,31,34,40H,8-9,11-12H2,1-7H3,(H2,30,39)",OVIWLBQFYMOVOF-UHFFFAOYSA-N,omadacycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,pneumonia
O=C(NC1CCSC2CCCC(C(=O)O)N2C1=O)C(S)Cc1ccccc1,"InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)",LVRLSYPNFFBYCZ-UHFFFAOYSA-N,omapatrilat,Preclinical,metalloproteinase inhibitor,ACE|MME,,
CS(=O)(=O)n1cc2c(n1)CN(C1COC(c3cc(F)ccc3F)C(N)C1)C2,"InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3",MKMPWKUAHLTIBJ-UHFFFAOYSA-N,omarigliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
COC(=O)NC(C(=O)N1CCCC1C(=O)Nc1ccc(C2CCC(c3ccc(NC(=O)C4CCCN4C(=O)C(NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C,"InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)",PIDFDZJZLOTZTM-UHFFFAOYSA-N,ombitasvir,Launched,HCV inhibitor,,infectious disease,hepatitis C
COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1NC(=O)C(N)CO,"InChI=1S/C21H26N2O6/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3/h5-11,15,24H,12,22H2,1-4H3,(H,23,25)",IXWNTLSTOZFSCM-UHFFFAOYSA-N,ombrabulin,Phase 3,tubulin polymerization inhibitor,,,
CCCCCCCCC=CCCCCCCCC(=O)NC(CO)Cc1ccc(O)cc1,"InChI=1S/C27H45NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(31)28-25(23-29)22-24-18-20-26(30)21-19-24/h9-10,18-21,25,29-30H,2-8,11-17,22-23H2,1H3,(H,28,31)",ICDMLAQPOAVWNH-UHFFFAOYSA-N,omdm-2,Preclinical,FAAH inhibitor,GPR119,,
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,"InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)",RFUBTTPMWSKEIW-UHFFFAOYSA-N,omecamtiv-mecarbil,Phase 3,cardiac myosin activator,MYBPC3,,
O=C(O)CCCCCCCCCCCCCCc1ccc(I)cc1,"InChI=1S/C21H33IO2/c22-20-17-15-19(16-18-20)13-11-9-7-5-3-1-2-4-6-8-10-12-14-21(23)24/h15-18H,1-14H2,(H,23,24)",YAONEUNUMVOKNQ-UHFFFAOYSA-N,omega-(4-iodophenyl)pentadecanoic-acid,Preclinical,,,,
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC,"InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3",SSQPWTVBQMWLSZ-UHFFFAOYSA-N,omega-3-acid-esters,Launched,cholesterol inhibitor,,,
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,"InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)",SUBDBMMJDZJVOS-UHFFFAOYSA-N,omeprazole,Launched,ATPase inhibitor,ATP4A|CLCN2,gastroenterology,heartburn
COc1ccc2c(c1)nc([S+]([O-])Cc1ncc(C)c(OC)c1C)n2[Mg]n1c([S+]([O-])Cc2ncc(C)c(OC)c2C)nc2cc(OC)ccc21,"InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2",KWORUUGOSLYAGD-UHFFFAOYSA-N,omeprazole-magnesium,Launched,proton pump inhibitor,ATP4A|ATP4B,gastroenterology,gastroesophageal reflux disease (GERD)|heartburn
COc1ccc2[nH]c(SCc3ncc(C)c(OC)c3C)nc2c1,"InChI=1S/C17H19N3O2S/c1-10-8-18-15(11(2)16(10)22-4)9-23-17-19-13-6-5-12(21-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)",XURCIPRUUASYLR-UHFFFAOYSA-N,omeprazole-sulfide,Phase 1,ATPase inhibitor,,,
CC(C)C12OC1C1OC13C1(C)CCc4c(coc4O)C1CC1OC13C2OC(=O)CCC(=O)O,"InChI=1S/C24H28O9/c1-10(2)22-17(32-22)18-24(33-18)21(3)7-6-11-12(9-29-19(11)28)13(21)8-14-23(24,31-14)20(22)30-16(27)5-4-15(25)26/h9-10,13-14,17-18,20,28H,4-8H2,1-3H3,(H,25,26)",GGMMZTVNHUQGTH-UHFFFAOYSA-N,omtriptolide,Preclinical,ERK1 and ERK2 phosphorylation inhibitor,,,
COc1cc(OC)c(C=CS(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1,"InChI=1S/C19H23NO6S/c1-23-14-10-18(25-3)15(19(11-14)26-4)7-8-27(21,22)12-13-5-6-17(24-2)16(20)9-13/h5-11H,12,20H2,1-4H3",KUTAVMCJCVADGZ-UHFFFAOYSA-N,on-01500,Preclinical,apoptosis stimulant,,,
CN1CCN(c2ccc(N=c3nc4c(c[nH]3)cc(C#N)c(=O)n4C3CCCC3)cc2)CC1,"InChI=1S/C24H27N7O/c1-29-10-12-30(13-11-29)20-8-6-19(7-9-20)27-24-26-16-18-14-17(15-25)23(32)31(22(18)28-24)21-4-2-3-5-21/h6-9,14,16,21H,2-5,10-13H2,1H3,(H,26,27,28)",VADOZMZXXRBXNY-UHFFFAOYSA-N,on123300,Preclinical,CDK inhibitor,CDK4|NUAK1|PDGFRB,,
Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,"InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3",VLULRUCCHYVXOH-UHFFFAOYSA-N,onc201,Phase 2,AKT inhibitor,TNFSF10,,
Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,"InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3",VLULRUCCHYVXOH-UHFFFAOYSA-N,onc201,Phase 2,MAP kinase inhibitor,TNFSF10,,
O=Cc1cn(Cc2ccc(Cl)cc2)c2ccccc12,"InChI=1S/C16H12ClNO/c17-14-7-5-12(6-8-14)9-18-10-13(11-19)15-3-1-2-4-16(15)18/h1-8,10-11H,9H2",ZDRQMXCSSAPUMM-UHFFFAOYSA-N,oncrasin-1,Preclinical,apoptosis stimulant,,,
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,ondansetron,Launched,serotonin receptor antagonist,HTR3A|HTR3B,gastroenterology,nausea|vomiting
CC#CC(=O)N1CCC(n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(=N)[nH]cnc32)C1,"InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)",SEJLPXCPMNSRAM-UHFFFAOYSA-N,ono-4059,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
CCOCOCC(CC(C)C(O)=NO)NC(=O)c1ccc(Oc2ccccc2)cc1,"InChI=1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)",HDWWQELUBWGQGA-UHFFFAOYSA-N,ono-4817,Phase 1,matrix metalloprotease inhibitor,MMP8,,
Cc1csc(S(=O)(=O)N(CC(C)C)c2cc3c(cc2OCc2ccc(C(=O)O)cc2)CCC3)n1,"InChI=1S/C25H28N2O5S2/c1-16(2)13-27(34(30,31)25-26-17(3)15-33-25)22-11-20-5-4-6-21(20)12-23(22)32-14-18-7-9-19(10-8-18)24(28)29/h7-12,15-16H,4-6,13-14H2,1-3H3,(H,28,29)",IOXMDBQCUCDLAF-UHFFFAOYSA-N,ono-8130,Preclinical,prostanoid receptor antagonist,PTGER1,,
CC(C(=O)Nc1cc(C#N)ccc1CCCC(=O)O)c1ccc(F)c2ccccc12,"InChI=1S/C24H21FN2O3/c1-15(18-11-12-21(25)20-7-3-2-6-19(18)20)24(30)27-22-13-16(14-26)9-10-17(22)5-4-8-23(28)29/h2-3,6-7,9-13,15H,4-5,8H2,1H3,(H,27,30)(H,28,29)",MTDIMKNAJUQTIO-UHFFFAOYSA-N,ono-ae3-208,Preclinical,prostanoid receptor antagonist,PTGER4,,
COc1ccc(CC(NC(=O)C(C)NC(=O)CN2CCOCC2)C(=O)NC(Cc2ccccc2)C(=O)C2(C)CO2)cc1,"InChI=1S/C31H40N4O7/c1-21(32-27(36)19-35-13-15-41-16-14-35)29(38)34-26(18-23-9-11-24(40-3)12-10-23)30(39)33-25(28(37)31(2)20-42-31)17-22-7-5-4-6-8-22/h4-12,21,25-26H,13-20H2,1-3H3,(H,32,36)(H,33,39)(H,34,38)",WQAVPPWWLLVGFK-UHFFFAOYSA-N,onx-0914,Preclinical,proteasome inhibitor,,,
NCCONC(=O)C1CCC2CN1C(=O)N2OS(=O)(=O)O,"InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)",RSBPYSTVZQAADE-UHFFFAOYSA-N,op-0595,Preclinical,beta lactamase inhibitor,,,
CC(=O)NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4ccccc43)CC2)cc1,"InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)",KSNUCNRMDYJBKT-UHFFFAOYSA-N,opc-21268,Phase 1,vasopressin receptor antagonist,AVPR1A|AVPR2|OXTR,,
Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1,"InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3",ASOADIZOVZTJSR-UHFFFAOYSA-N,opicapone,Phase 3,catechol O methyltransferase inhibitor,COMT,,
OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,"InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2",YNZFUWZUGRBMHL-UHFFFAOYSA-N,opipramol,Launched,sigma receptor agonist,,neurology/psychiatry,generalized anxiety disorder (GAD)
COCC(NC(=O)c1cnc(C)s1)C(=O)NC(COC)C(=O)NC(Cc1ccccc1)C(=O)C1(C)CO1,"InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)",SWZXEVABPLUDIO-UHFFFAOYSA-N,oprozomib,Phase 1/Phase 2,proteasome inhibitor,,,
O=[N+]([O-])c1cc(O)c(O)c([N+](=O)[O-])c1,"InChI=1S/C6H4N2O6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H",VDCDWNDTNSWDFJ-UHFFFAOYSA-N,or-486,Preclinical,catechol O methyltransferase inhibitor,COMT,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccccc23)c(C)c1CCC(=O)O,"InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19-20,23H,2,7-8H2,1H3,(H,21,22)",GMROZDPZEUVIGD-UHFFFAOYSA-N,orantinib,Phase 3,FGFR inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccccc23)c(C)c1CCC(=O)O,"InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19-20,23H,2,7-8H2,1H3,(H,21,22)",GMROZDPZEUVIGD-UHFFFAOYSA-N,orantinib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccccc23)c(C)c1CCC(=O)O,"InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19-20,23H,2,7-8H2,1H3,(H,21,22)",GMROZDPZEUVIGD-UHFFFAOYSA-N,orantinib,Phase 3,VEGFR inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,,
CC1CN(c2c(F)c(F)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1,"InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)",QIPQASLPWJVQMH-UHFFFAOYSA-N,orbifloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,urinary tract infections
CC(C)CC(NC(Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(=O)O)C(=O)O,"InChI=1S/C19H23Cl2N3O4/c1-11(2)3-16(18(25)26)23-17(19(27)28)7-15-8-22-10-24(15)9-12-4-13(20)6-14(21)5-12/h4-6,8,10-11,16-17,23H,3,7,9H2,1-2H3,(H,25,26)(H,27,28)",NTCCRGGIJNDEAB-UHFFFAOYSA-N,ore1001,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,ACE2,,
FC(F)(F)c1ccc(N2CCNCC2)nc1Cl,"InChI=1S/C10H11ClF3N3/c11-9-7(10(12,13)14)1-2-8(16-9)17-5-3-15-4-6-17/h1-2,15H,3-6H2",QZYYPQAYSFBKPW-UHFFFAOYSA-N,org-12962,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
COc1cc(C(=O)NCC2(N(C)C)CCCC2)cc(OC)c1OCc1ccccc1,"InChI=1S/C24H32N2O4/c1-26(2)24(12-8-9-13-24)17-25-23(27)19-14-20(28-3)22(21(15-19)29-4)30-16-18-10-6-5-7-11-18/h5-7,10-11,14-15H,8-9,12-13,16-17H2,1-4H3,(H,25,27)",ZCYOBMASPXQBSZ-UHFFFAOYSA-N,org-25543,Preclinical,glycine transporter inhibitor,GLRB|SLC6A5,,
O=C1c2cccnc2OCC2CCCN12,"InChI=1S/C11H12N2O2/c14-11-9-4-1-5-12-10(9)15-7-8-3-2-6-13(8)11/h1,4-5,8H,2-3,6-7H2",FIKUEZUFASUKAH-UHFFFAOYSA-N,org-26576,Phase 2,glutamate receptor modulator,,,
CCc1c(C(=O)NCCc2ccc(N3CCCCC3)cc2)[nH]c2ccc(Cl)cc12,"InChI=1S/C24H28ClN3O/c1-2-20-21-16-18(25)8-11-22(21)27-23(20)24(29)26-13-12-17-6-9-19(10-7-17)28-14-4-3-5-15-28/h6-11,16,27H,2-5,12-15H2,1H3,(H,26,29)",AHFZDNYNXFMRFQ-UHFFFAOYSA-N,org-27569,Preclinical,cannabinoid receptor modulator,CNR1,,
CC1(CN)Cc2ccccc2C1,"InChI=1S/C11H15N/c1-11(8-12)6-9-4-2-3-5-10(9)7-11/h2-5H,6-8,12H2,1H3",JOLKQWPKJFRPOU-UHFFFAOYSA-N,org-9768,Phase 1,adrenergic receptor antagonist,ADRA2A,,
C=C1C(=O)C23C(O)C1CCC2C12COC3(O)C(O)C1C(C)(C)CCC2O,"InChI=1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3",SDHTXBWLVGWJFT-UHFFFAOYSA-N,oridonin,Preclinical,BCL inhibitor,BCL2,,
CNC(CC(C)C)C(=O)Nc1c(O)[nH]c(CC(N)O)c(O)[nH]c2c3cc(c(OC4OC(CO)C(O)C(O)C4OC4CC(C)(NCc5ccc(-c6ccc(Cl)cc6)cc5)C(O)C(C)O4)c(c3)oc3ccc(cc3Cl)c1=O)Oc1ccc(cc1Cl)C(OC1CC(C)(N)C(O)C(C)O1)c1[nH]c(O)c(c3ccc(O)c(c3)c3c(O)cc(O)cc3c(=C(O)O)[nH]c1O)NC=2O,"InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51,59-62,70-72,74-76,84,92-97,99-104,106-109,111-117H,22,30-34,90-91H2,1-7H3,(H,98,110)",IWWOHVCLXHJZRV-UHFFFAOYSA-N,oritavancin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,skin infections
CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O,"InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)",AHLBNYSZXLDEJQ-UHFFFAOYSA-N,orlistat,Launched,lipase inhibitor,CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP,endocrinology,weight-loss aid
COc1ccc2c(c1)OC(C)(C)C(c1ccccc1)C2c1ccc(OCCN2CCCC2)cc1,"InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3",XZEUAXYWNKYKPL-UHFFFAOYSA-N,ormeloxifene,Launched,selective estrogen receptor modulator (SERM),,endocrinology,contraceptive
Cc1ncc([N+](=O)[O-])n1CC(O)CCl,"InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3",IPWKIXLWTCNBKN-UHFFFAOYSA-N,ornidazole,Launched,antiprotozoal agent,,infectious disease,protozoan infection
NCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C45H63N13O12S2/c46-16-4-8-28(39(64)51-21-37(50)62)53-44(69)34-9-5-17-58(34)45(70)33-23-72-71-22-27(47)38(63)54-30(19-25-10-12-26(59)13-11-25)42(67)55-31(18-24-6-2-1-3-7-24)41(66)52-29(14-15-35(48)60)40(65)56-32(20-36(49)61)43(68)57-33/h1-3,6-7,10-13,27-34,59H,4-5,8-9,14-23,46-47H2,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,69)(H,54,63)(H,55,67)(H,56,65)(H,57,68)",MUNMIGOEDGHVLE-UHFFFAOYSA-N,ornipressin,Preclinical,vasoconstrictor,,,
NCCCC(N)C(=O)O,"InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)",AHLPHDHHMVZTML-UHFFFAOYSA-N,ornithine,Launched,NFkB pathway modulator,GPRC6A,,
O=C(O)c1cc(=O)[nH]c(=O)[nH]1,"InChI=1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11)",PXQPEWDEAKTCGB-UHFFFAOYSA-N,orotic-acid,Phase 2,,DHODH,,
CC(C)CC(NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccccc1)C(C)O)C(=O)NC(C)C(=O)NC(CC(N)=O)C(=O)NC(CCC(N)=O)C(=O)O,"InChI=1S/C79H129N27O22/c1-41(2)33-54(72(122)95-44(5)66(116)103-56(36-59(84)110)73(123)102-53(77(127)128)27-28-58(83)109)104-70(120)49(23-13-15-29-80)100-69(119)52(26-18-32-90-79(87)88)99-65(115)43(4)96-75(125)57(40-107)105-71(121)50(24-14-16-30-81)101-68(118)51(25-17-31-89-78(85)86)98-64(114)42(3)94-61(112)39-93-76(126)63(45(6)108)106-74(124)55(35-47-21-11-8-12-22-47)97-62(113)38-91-60(111)37-92-67(117)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,107-108H,13-18,23-40,80-82H2,1-6H3,(H2,83,109)(H2,84,110)(H,91,111)(H,92,117)(H,93,126)(H,94,112)(H,95,122)(H,96,125)(H,97,113)(H,98,114)(H,99,115)(H,100,119)(H,101,118)(H,102,123)(H,103,116)(H,104,120)(H,105,121)(H,106,124)(H,127,128)(H4,85,86,89)(H4,87,88,90)",PULGYDLMFSFVBL-UHFFFAOYSA-N,orphanin-fq,Phase 1,opioid receptor agonist,OPRL1|OPRM1,,
Cc1ccccc1C(OCCN(C)C)c1ccccc1,"InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3",QVYRGXJJSLMXQH-UHFFFAOYSA-N,orphenadrine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,muscle pain
CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1,"InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)",OZPFIJIOIVJZMN-UHFFFAOYSA-N,orteronel,Phase 3,androgen biosynthesis inhibitor,CYP17A1,,
CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1,"InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)",OZPFIJIOIVJZMN-UHFFFAOYSA-N,orteronel,Phase 3,androgen receptor antagonist,CYP17A1,,
CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1,"InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)",OZPFIJIOIVJZMN-UHFFFAOYSA-N,orteronel,Phase 3,cytochrome P450 inhibitor,CYP17A1,,
NC1CCC(NC2CC2c2ccccc2)CC1,"InChI=1S/C15H22N2/c16-12-6-8-13(9-7-12)17-15-10-14(15)11-4-2-1-3-5-11/h1-5,12-15,17H,6-10,16H2",ALHBJBCQLJZYON-UHFFFAOYSA-N,ory-1001,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,
CCC(CC)OC1=CC(C(=O)O)CC(N)C1NC(C)=O,"InChI=1S/C14H24N2O4/c1-4-10(5-2)20-12-7-9(14(18)19)6-11(15)13(12)16-8(3)17/h7,9-11,13H,4-6,15H2,1-3H3,(H,16,17)(H,18,19)",UIAYAXYLNIEFGV-UHFFFAOYSA-N,oseltamivir-carboxylate,Launched,neuraminidase inhibitor,,infectious disease,influenza A virus infection
CCOC(=O)C1=CC(OC(CC)CC)C(NC(C)=O)C(N)C1,"InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)",VSZGPKBBMSAYNT-UHFFFAOYSA-N,oseltamivir-phosphate,Launched,neuraminidase inhibitor,CES1|NEU1|NEU2,infectious disease,influenza A virus infection
c1ccc2c(c1)OCC(CNCCCOc1ccc3c(c1)OCO3)O2,"InChI=1S/C19H21NO5/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17/h1-2,4-7,10,15,20H,3,8-9,11-13H2",MEEQBDCQPIZMLY-UHFFFAOYSA-N,osemozotan,Phase 2/Phase 3,serotonin receptor agonist,HTR1A,,
COc1cccc2cc(-c3nc(C4CCC(C(=O)O)CC4)n4[nH]cnc(=N)c34)[nH]c12,"InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)",JROFGZPOBKIAEW-UHFFFAOYSA-N,osi-027,Phase 1,mTOR inhibitor,MTOR,,
C#Cc1cccc(N=c2[nH]cnc3cc(OCCOC)c(OCCO)cc23)c1,"InChI=1S/C21H21N3O4/c1-3-15-5-4-6-16(11-15)24-21-17-12-19(27-8-7-25)20(28-10-9-26-2)13-18(17)22-14-23-21/h1,4-6,11-14,25H,7-10H2,2H3,(H,22,23,24)",KOQIAZNBAWFSQM-UHFFFAOYSA-N,osi-420,Preclinical,EGFR inhibitor,EGFR,,
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,"InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)",FGTCROZDHDSNIO-UHFFFAOYSA-N,osi-930,Phase 1,KIT inhibitor,FLT1|KDR|KIT,,
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,"InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)",FGTCROZDHDSNIO-UHFFFAOYSA-N,osi-930,Phase 1,VEGFR inhibitor,FLT1|KDR|KIT,,
N#Cc1ccc(C2CCc3cncn32)c(F)c1,"InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2",USUZGMWDZDXMDG-UHFFFAOYSA-N,osilodrostat,Launched,cytochrome P450 inhibitor,,,
C=CC(=O)Nc1cc(N=c2nc(-c3cn(C)c4ccccc34)cc[nH]2)c(OC)cc1N(C)CCN(C)C,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,osimertinib,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC)
OCCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,"InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2",LUMKNAVTFCDUIE-UHFFFAOYSA-N,ospemifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,obstetrics/gynecology|endocrinology,vaginal atrophy|dyspareunia|menopause
CC(O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,"InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)",JNGVJMBLXIUVRD-UHFFFAOYSA-N,ostarine,Phase 3,androgen receptor modulator,AR,,
COc1ccc2ccc(=O)oc2c1CC=C(C)C,"InChI=1S/C15H16O3/c1-10(2)4-7-12-13(17-3)8-5-11-6-9-14(16)18-15(11)12/h4-6,8-9H,7H2,1-3H3",MBRLOUHOWLUMFF-UHFFFAOYSA-N,osthol,Preclinical,calcium channel blocker,,,
CON=C1CC(C(=O)NCC(O)c2ccccc2)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1,"InChI=1S/C28H29N3O4/c1-19-8-6-7-11-24(19)20-12-14-22(15-13-20)28(34)31-18-23(30-35-2)16-25(31)27(33)29-17-26(32)21-9-4-3-5-10-21/h3-15,25-26,32H,16-18H2,1-2H3,(H,29,33)",IBXGJPAYWMFXSF-UHFFFAOYSA-N,ot-r-antagonist-1,Preclinical,oxytocin receptor antagonist,AVPR1A|OXTR,,
COC(=O)C(Cc1cccc(C(=N)N)c1)C(C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,"InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)",PFGVNLZDWRZPJW-UHFFFAOYSA-N,otamixaban,Phase 3,coagulation factor inhibitor,F10,,
CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc21,"InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)",UBRKDAVQCKZSPO-UHFFFAOYSA-N,otenzepad,Phase 3,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,
CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1,"InChI=1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1",NQHNLNLJPDMBFN-UHFFFAOYSA-O,otilonium,Launched,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome
CC(=O)c1c[nH]c2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1=NC1CCC(CN(C)C)CC1,"InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)",DKZYXHCYPUVGAF-UHFFFAOYSA-N,ots167,Phase 1/Phase 2,maternal embryonic leucine zipper kinase inhibitor,MELK,,
Cc1cc(O)c(-c2ccc(C(C)CN)cc2)c2c1[nH]c(=O)c1sccc12,"InChI=1S/C21H20N2O2S/c1-11-9-16(24)17(14-5-3-13(4-6-14)12(2)10-22)18-15-7-8-26-20(15)21(25)23-19(11)18/h3-9,12,24H,10,22H2,1-2H3,(H,23,25)",OETLNMOJNONWOY-UHFFFAOYSA-N,ots514,Preclinical,TOPK inhibitor,,,
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=NC(CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,"InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)",GNMUEVRJHCWKTO-UHFFFAOYSA-N,otx015,Phase 1/Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,
CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(c6coc(O)c6)CCC5(O)C4CCC3(O)C2)C(O)C(O)C1O,"InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,11,13,15-19,21-25,30-38H,3-6,8-10,12H2,1-2H3",ZCOAKPWIZHZTPH-UHFFFAOYSA-N,ouabain,Launched,ATPase inhibitor,ATP1A1,cardiology,hypertension|cardiac arrythmia
Fc1ccccc1CNCc1ccc(-c2ccnc3[nH]ccc23)cc1,"InChI=1S/C21H18FN3/c22-20-4-2-1-3-17(20)14-23-13-15-5-7-16(8-6-15)18-9-11-24-21-19(18)10-12-25-21/h1-12,23H,13-14H2,(H,24,25)",XUIUXXQVHPEQNM-UHFFFAOYSA-N,oxa-06,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CC(=O)N1CC(O)CC1C(=O)O,"InChI=1S/C7H11NO4/c1-4(9)8-3-5(10)2-6(8)7(11)12/h5-6,10H,2-3H2,1H3,(H,11,12)",BAPRUDZDYCKSOQ-UHFFFAOYSA-N,oxaceprol,Preclinical,anti-inflammatory agent,,,
Cc1onc(-c2ccccc2)c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)",UWYHMGVUTGAWSP-UHFFFAOYSA-N,oxacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,staphylococcal infections
O=C1CCCCCCCCCCCCCCO1,InChI=1S/C15H28O2/c16-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-17-15/h1-14H2,FKUPPRZPSYCDRS-UHFFFAOYSA-N,oxacyclohexadecan-2-one,Preclinical,protein kinase inhibitor,,,
NC1CCCCC1N,"InChI=1S/C6H14N2/c7-5-3-1-2-4-6(5)8/h5-6H,1-4,7-8H2",SSJXIUAHEKJCMH-UHFFFAOYSA-N,oxaliplatin,Launched,DNA inhibitor,,oncology,colorectal cancer
O=C(O)CC(=O)C(=O)O,"InChI=1S/C4H4O5/c5-2(4(8)9)1-3(6)7/h1H2,(H,6,7)(H,8,9)",KHPXUQMNIQBQEV-UHFFFAOYSA-N,oxaloacetate,Phase 2/Phase 3,glutamate release inhibitor,,,
CN1CCCN=C1C=Cc1cccc(O)c1,"InChI=1S/C13H16N2O/c1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h2,4-7,10,16H,3,8-9H2,1H3",VRYKTHBAWRESFI-UHFFFAOYSA-N,oxantel,Launched,anthelmintic agent,,infectious disease,gastrointestinal parasites
O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,"InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)",OFPXSFXSNFPTHF-UHFFFAOYSA-N,oxaprozin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)",BAINIUMDFURPJM-UHFFFAOYSA-N,oxatomide,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
NC(=O)N1c2ccccc2CC(=O)c2ccccc21,"InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)",CTRLABGOLIVAIY-UHFFFAOYSA-N,oxcarbazepine,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,"InChI=1S/C20H33NO3/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4/h9-13H,5-8,14-17H2,1-4H3",IQADUMSPOQKAAO-UHFFFAOYSA-N,oxelaidin,Launched,antitussive,,pulmonary,cough suppressant
CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1,"InChI=1S/C28H41N3O3/c1-27(2,19-23-13-9-7-10-14-23)29(5)25(33)21-31(17-18-32)22-26(34)30(6)28(3,4)20-24-15-11-8-12-16-24/h7-16,32H,17-22H2,1-6H3",FTLDJPRFCGDUFH-UHFFFAOYSA-N,oxethazaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
Cc1noc(C)c1-c1cc(O)cc(C(O)c2ccccc2)c1,"InChI=1S/C18H17NO3/c1-11-17(12(2)22-19-11)14-8-15(10-16(20)9-14)18(21)13-6-4-3-5-7-13/h3-10,18,20-21H,1-2H3",FEQUIPXIENTMJN-UHFFFAOYSA-N,oxf-bd-02,Preclinical,bromodomain inhibitor,BRD4,,
COC(=O)N=c1[nH]c2ccc([S+]([O-])c3ccccc3)cc2[nH]1,"InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)",BEZZFPOZAYTVHN-UHFFFAOYSA-N,oxfendazole,Launched,anthelmintic agent,,infectious disease,lungworms|tapeworm|gastrointestinal roundworms
NC(C(=O)O)c1ccc(O)cc1,"InChI=1S/C8H9NO3/c9-7(8(11)12)5-1-3-6(10)4-2-5/h1-4,7,10H,9H2,(H,11,12)",LJCWONGJFPCTTL-UHFFFAOYSA-N,oxfenicine,Phase 1,carnitine palmitoyltransferase inhibitor,CPT1A|CPT1B,,
CCCOc1ccc2[nH]c(=NC(=O)OC)[nH]c2c1,"InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)",RAOCRURYZCVHMG-UHFFFAOYSA-N,oxibendazole,Launched,tubulin polymerization inhibitor,TUBB|TUBB4B,infectious disease,strongyles
Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2",QRJJEGAJXVEBNE-UHFFFAOYSA-N,oxiconazole,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
NCCc1cc(O)c(O)cc1O,"InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2",DIVDFFZHCJEHGG-UHFFFAOYSA-N,oxidopamine,Preclinical,neurotoxin,,,
O=C(O)c1ccc[n+]([O-])c1,"InChI=1S/C6H5NO3/c8-6(9)5-2-1-3-7(10)4-5/h1-4H,(H,8,9)",FJCFFCXMEXZEIM-UHFFFAOYSA-N,oxiniacic-acid,Preclinical,,,,
O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1,"InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)",NVDBBGBUTKLRSN-UHFFFAOYSA-N,oxiperomide,Phase 2,dopamine receptor antagonist,,,
NC(=O)CN1CC(O)CC1=O,"InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10)",IHLAQQPQKRMGSS-UHFFFAOYSA-N,oxiracetam,Launched,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia
CCN(CC)CCc1nc(-c2ccccc2)no1,"InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3",IDCHQQSVJAAUQQ-UHFFFAOYSA-N,oxolamine,Launched,antitussive,,pulmonary,cough suppressant
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3,"InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)",KYGZCKSPAKDVKC-UHFFFAOYSA-N,oxolinic-acid,Preclinical,bacterial DNA gyrase inhibitor,,,
O=C(O)c1nc(=O)[nH]c(=O)[nH]1,"InChI=1S/C4H3N3O4/c8-2(9)1-5-3(10)7-4(11)6-1/h(H,8,9)(H2,5,6,7,10,11)",RYYCJUAHISIHTL-UHFFFAOYSA-N,oxonic-acid,Preclinical,uricase inhibitor,,,
C[N+](C)(C)CC#CCN1CCCC1=O,"InChI=1S/C11H19N2O/c1-13(2,3)10-5-4-8-12-9-6-7-11(12)14/h6-10H2,1-3H3/q+1",CANZROMYQDHYHR-UHFFFAOYSA-N,oxotremorine-m,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
O=C1CCCN1CC#CCN1CCCC1,"InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2",RSDOPYMFZBJHRL-UHFFFAOYSA-N,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,
C=CCOc1ccccc1OCC(O)CNC(C)C,"InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3",CEMAWMOMDPGJMB-UHFFFAOYSA-N,oxprenolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,angina pectoris|hypertension|cardiac arrythmia
COc1ccc(C(=O)c2ccccc2)c(O)c1,"InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3",DXGLGDHPHMLXJC-UHFFFAOYSA-N,oxybenzone,Launched,lipase inhibitor,LIPE,dermatology,sunscreen lotion
CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N,"InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3",CMHHMUWAYWTMGS-UHFFFAOYSA-N,oxybuprocaine,Launched,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,"InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3",XIQVNETUBQGFHX-UHFFFAOYSA-N,oxybutynin,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,urology,urinary incontinence
O=C(Nc1cc(Cl)cc(Cl)c1O)c1c(O)c(Cl)cc(Cl)c1Cl,"InChI=1S/C13H6Cl5NO3/c14-4-1-6(16)11(20)8(2-4)19-13(22)9-10(18)5(15)3-7(17)12(9)21/h1-3,20-21H,(H,19,22)",JYWIYHUXVMAGLG-UHFFFAOYSA-N,oxyclozanide,Launched,,,infectious disease,fascioliasis
COc1cccc(C(=O)CCNC(C)C(O)c2ccccc2)c1,"InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3",GDYUVHBMFVMBAF-UHFFFAOYSA-N,oxyfedrine,Launched,adrenergic receptor agonist,,cardiology,angina pectoris
O=C1CCCC2C3CCC[N+]4([O-])CCCC(CN12)C34,"InChI=1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2",XVPBINOPNYFXID-UHFFFAOYSA-N,oxymatrine,Launched,,,,
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,"InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)",WYWIFABBXFUGLM-UHFFFAOYSA-N,oxymetazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C,otolaryngology,nasal congestion
CCCCc1c(O)n(-c2ccc(O)cc2)n(-c2ccccc2)c1=O,"InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,22,24H,2-3,9H2,1H3",GFMGHHYHOFNBHB-UHFFFAOYSA-N,oxyphenbutazone,Withdrawn,cyclooxygenase inhibitor,,,
CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1,"InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3",DUDKAZCAISNGQN-UHFFFAOYSA-N,oxyphencyclimine,Launched,cholinergic receptor antagonist,,gastroenterology,peptic ulcer disease (PUD)
CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,"InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1",GFRUPHOKLBPHTQ-UHFFFAOYSA-N,oxyphenonium,Launched,cholinergic receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD)
O=c1[nH]c(=O)c2c[nH]nc2[nH]1,"InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)",HXNFUBHNUDHIGC-UHFFFAOYSA-N,oxypurinol,Phase 2/Phase 3,xanthine oxidase inhibitor,XDH,,
Oc1cccc2cccnc12,"InChI=1S/C9H7NO/c11-8-5-1-3-7-4-2-6-10-9(7)8/h1-6,11H",MCJGNVYPOGVAJF-UHFFFAOYSA-N,oxyquinoline,Launched,chelating agent,METAP2,dermatology,cosmetic
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)C3C(=O)c4c(O)cccc4C(C)(O)C3C(O)C12,"InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,10-14,17,25,28,32-33H,1-3H3,(H2,23,31)",TUEWQXNXQFRUTK-UHFFFAOYSA-N,oxytetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease|urology,chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease
CCC(C)C1NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC1=O,"InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)",XNOPRXBHLZRZKH-UHFFFAOYSA-N,oxytocin,Launched,oxytocin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,obstetrics/gynecology,labor induction
O=C(O)C=Cc1ccc(Cn2ccnc2)cc1,"InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)",SHZKQBHERIJWAO-UHFFFAOYSA-N,ozagrel,Launched,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CCC4NCCO)no2)cc1C#N,"InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3",XRVDGNKRPOAQTN-UHFFFAOYSA-N,ozanimod,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,
CN=c1[nH]cc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C,"InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)",XPIJWUTXQAGSLK-UHFFFAOYSA-N,ozenoxacin,Phase 3,antiinfective drug,,,
CN1C(=O)C(N2CCCCC2)SC1=CC(=O)O,"InChI=1S/C11H16N2O3S/c1-12-8(7-9(14)15)17-11(10(12)16)13-5-3-2-4-6-13/h7,11H,2-6H2,1H3,(H,14,15)",NQFBZYYUAFJYNS-UHFFFAOYSA-N,ozolinone,Phase 3,diuretic,,,
CCCCCOC(=O)c1ccc(N(C)C)cc1,"InChI=1S/C14H21NO2/c1-4-5-6-11-17-14(16)12-7-9-13(10-8-12)15(2)3/h7-10H,4-6,11H2,1-3H3",LXTZRIBXKVRLOA-UHFFFAOYSA-N,p-dimethylinamyl-benzoate,Preclinical,,,,
CC(=O)c1cc([N+](=O)[O-])c(Sc2ccc(F)cc2F)s1,"InChI=1S/C12H7F2NO3S2/c1-6(16)11-5-9(15(17)18)12(20-11)19-10-3-2-7(13)4-8(10)14/h2-5H,1H3",RMAMGGNACJHXHO-UHFFFAOYSA-N,p22077,Preclinical,ubiquitin specific protease inhibitor,USP7,,
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3",QLUYMIVVAYRECT-UHFFFAOYSA-N,p276-00,Phase 2,CDK inhibitor,CDK1|CDK4|CDK9,,
CC(=O)c1cc([N+](=O)[O-])c(Sc2cccc(Cl)c2Cl)s1,"InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3",LKZLGMAAKNEGCH-UHFFFAOYSA-N,p5091,Preclinical,ubiquitin specific protease inhibitor,USP7,,
OC(CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,"InChI=1S/C21H18Br2N2O/c22-14-6-8-20-18(10-14)19-11-15(23)7-9-21(19)25(20)13-17(26)12-24-16-4-2-1-3-5-16/h1-11,17,24,26H,12-13H2",FZHHRERIIVOATI-UHFFFAOYSA-N,p7c3,Preclinical,NAMPT inhibitor,NAMPT,,
CCCCCCOc1cc2c(cc1N(C)c1ncc(C(=O)O)cn1)C(C)(C)CCC2(C)C,"InChI=1S/C26H37N3O3/c1-7-8-9-10-13-32-22-15-20-19(25(2,3)11-12-26(20,4)5)14-21(22)29(6)24-27-16-18(17-28-24)23(30)31/h14-17H,7-13H2,1-6H3,(H,30,31)",JJUUTJCZMGZJDZ-UHFFFAOYSA-N,pa-452,Preclinical,retinoid receptor antagonist,RXRA,,
C=CCc1cccc(C=NNC(=O)CN2CCN(Cc3ccccc3)CC2)c1O,"InChI=1S/C23H28N4O2/c1-2-7-20-10-6-11-21(23(20)29)16-24-25-22(28)18-27-14-12-26(13-15-27)17-19-8-4-3-5-9-19/h2-6,8-11,16,29H,1,7,12-15,17-18H2,(H,25,28)",YQNRVGJCPCNMKT-UHFFFAOYSA-N,pac-1,Phase 1,caspase activator,CASP3,,
CC(=O)OC1=C2C(C)C(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)CC(O)(C(OC(=O)c3ccccc3)C3C4(OC(C)=O)COC4CC(O)C3(C)C1=O)C2(C)C,"InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,25,31-33,35-36,38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)",NDUAXKHGCJIYEQ-UHFFFAOYSA-N,paclitaxel,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)
CCCCCCCCCCCCCCCC(=O)C(F)(F)F,"InChI=1S/C17H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(21)17(18,19)20/h2-15H2,1H3",MAHYXYTYTLCTQD-UHFFFAOYSA-N,pacocf3,Preclinical,phospholipase inhibitor,PLA2G4A,,
C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,"InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)",HWXVIOGONBBTBY-UHFFFAOYSA-N,pacritinib,Phase 3,FLT3 inhibitor,FLT3|JAK1|JAK2|JAK3,,
C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,"InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)",HWXVIOGONBBTBY-UHFFFAOYSA-N,pacritinib,Phase 3,JAK inhibitor,FLT3|JAK1|JAK2|JAK3,,
COCc1nn2c(CN3CC(CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,"InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3",DCXFIOLWWRXEQH-UHFFFAOYSA-N,padsevonil,Phase 3,antiepileptic,,,
CC12CC3(O)OC(O1)C1(COC(=O)c4ccccc4)C3CC21OC1OC(CO)C(O)C(O)C1O,"InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3",YKRGDOXKVOZESV-UHFFFAOYSA-N,paeoniflorin,Preclinical,anticonvulsant,,,
COc1ccc(C(C)=O)c(O)c1,"InChI=1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3",UILPJVPSNHJFIK-UHFFFAOYSA-N,paeonol,Preclinical,anti-inflammatory agent,,,
CON=C(N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1,"InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24)",UKOQVLAXCBRRGH-UHFFFAOYSA-N,pafuramidine,Phase 3,DNA synthesis inhibitor,,,
CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,"InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3",HIUPRQPBWVEQJJ-UHFFFAOYSA-N,pagoclone,Phase 2/Phase 3,GABA receptor agonist,,,
CC(=O)c1c(C)c2c[nH]c(=Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,palbociclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
O=[PH](=O)(NCCCl)NCCCl,"InChI=1S/C4H10Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H2,7,8,9,10)",HAMIHZLXXAZNLI-UHFFFAOYSA-N,palifosfamide,Phase 3,DNA alkylating agent,,,
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,"InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3",PMXMIIMHBWHSKN-UHFFFAOYSA-N,paliperidone,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,"InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3",PMXMIIMHBWHSKN-UHFFFAOYSA-N,paliperidone,Launched,serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia
COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2,"InChI=1S/C21H22NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,9-12H,7-8H2,1-4H3/q+1",QUCQEUCGKKTEBI-UHFFFAOYSA-N,palmatine-chloride,Preclinical,dopamine synthesis inhibitor,CYP3A4,,
CCCCCCC=CCCCCCCCC(=O)O,"InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h7-8H,2-6,9-15H2,1H3,(H,17,18)",SECPZKHBENQXJG-UHFFFAOYSA-N,palmitoleic-acid,Preclinical,,,,
CCCCCCCCCCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C,"InChI=1S/C23H45NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(27)28-21(19-22(25)26)20-24(2,3)4/h21H,5-20H2,1-4H3/p+1",XOMRRQXKHMYMOC-UHFFFAOYSA-O,palmitoylcarnitine,Preclinical,protein kinase inhibitor,,,
CCCCCCCCCCCCCCCC(=O)NCCO,"InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)",HXYVTAGFYLMHSO-UHFFFAOYSA-N,palmitoylethanolamide,Launched,cannabinoid receptor agonist,CNR2|GPR119|GPR55,,
COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1,"InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3",YEAHTLOYHVWAKW-UHFFFAOYSA-N,palomid-529,Phase 1,AKT inhibitor,MTOR,,
COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1,"InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3",YEAHTLOYHVWAKW-UHFFFAOYSA-N,palomid-529,Phase 1,mTOR inhibitor,MTOR,,
O=C1c2cccc3c2C(CCC3)CN1C1CN2CCC1CC2,"InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2",CPZBLNMUGSZIPR-UHFFFAOYSA-N,palonosetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting
Cc1cc(=NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2[nH]1,"InChI=1S/C25H30N4O2/c1-19-17-23(21-9-5-6-10-22(21)27-19)28-24(30)26-13-16-29-14-11-25(31,12-15-29)18-20-7-3-2-4-8-20/h2-10,17,31H,11-16,18H2,1H3,(H2,26,27,28,30)",WYJCYXOCHXWTHG-UHFFFAOYSA-N,palosuran,Phase 2,urotensin receptor antagonist,UTS2R,,
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(C=Cc3ccc(C(=O)O)cc3)cc21,"InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)",YTFHCXIPDIHOIA-UHFFFAOYSA-N,palovarotene,Phase 3,retinoid receptor agonist,RARG,,
Cn1c(=O)c2[nH]c(Br)nc2n(C)c1=O,"InChI=1S/C7H7BrN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)",SKTFQHRVFFOHTQ-UHFFFAOYSA-N,pamabrom,Launched,diuretic,,gastroenterology,bloating
NCCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,"InChI=1S/C3H9NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H,6,7,8)(H,9,10,11)",ZDNFRAXSAKZHLL-UHFFFAOYSA-N,pamidronate,Launched,bone resorption inhibitor,FDPS,endocrinology|oncology|hematologic malignancy,hypercalcemia|Paget's disease|breast cancer|multiple myeloma
CC12CCCN1C=c1[nH][nH]c(=O)c3cc(F)cc4[nH]c2c1c43,"InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-7,18-19H,2-4H2,1H3,(H,20,22)",OBWVEPQPQCSOPR-UHFFFAOYSA-N,pamiparib,Phase 3,PARP inhibitor,,,
CC(=O)OC1CC2CCC3C(CCC4(C)C3CC([N+]3(C)CCCCC3)C4OC(C)=O)C2(C)CC1[N+]1(C)CCCCC1,"InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2",GVEAYVLWDAFXET-UHFFFAOYSA-N,pancuronium,Launched,acetylcholine receptor antagonist,CHRM2|CHRM3|CHRNA1|CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant
CC(=N)N1CCC(SC2=C(C(=O)O)N3C(=O)C(C(C)O)C3C2)C1,"InChI=1S/C15H21N3O4S/c1-7(19)12-10-5-11(13(15(21)22)18(10)14(12)20)23-9-3-4-17(6-9)8(2)16/h7,9-10,12,16,19H,3-6H2,1-2H3,(H,21,22)",TYMABNNERDVXID-UHFFFAOYSA-N,panipenem,Preclinical,antibacterial ,,,
Cc1[nH]c2ccccc2c1CCNCc1ccc(C=CC(O)=NO)cc1,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)",FPOHNWQLNRZRFC-UHFFFAOYSA-N,panobinostat,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,multiple myeloma
CC(C)(CO)C(=O)C(O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO,"InChI=1S/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17,20,26-28,31,34H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)",CKISLMYLRMCWDU-UHFFFAOYSA-N,pantethine,Launched,coenzyme A precursor,,,
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)",IQPSEEYGBUAQFF-UHFFFAOYSA-N,pantoprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome
CC(C)(CO)C(=O)C(O)NCCC(=O)O,"InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h8,10-11,15H,3-5H2,1-2H3,(H,12,13)",QSPIFYOFUKWPGV-UHFFFAOYSA-N,pantothenic-acid,Launched,coenzyme A precursor,,,
NC(=O)CN1CCC(NC(=O)C2CCCN2)C1=O,"InChI=1S/C11H18N4O3/c12-9(16)6-15-5-3-8(11(15)18)14-10(17)7-2-1-4-13-7/h7-8,13H,1-6H2,(H2,12,16)(H,14,17)",QXHVGEXNEZRSGG-UHFFFAOYSA-N,paopa,Preclinical,dopamine receptor modulator,DRD2,,
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,"InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3",XQYZDYMELSJDRZ-UHFFFAOYSA-N,papaverine,Launched,phosphodiesterase inhibitor,PDE10A|PDE4B|PDE5A,cardiology|hematology|gastroenterology,myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm
CCc1cccc2c1c(=O)c(C(=O)N(CC)c1ccccc1)c(O)n2C,"InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,25H,4-5H2,1-3H3",UURQLTORRWBQQE-UHFFFAOYSA-N,paquinimod,Phase 2,S100A9 inhibitor,,,
Cc1ccc(S(N)(=O)=O)cc1,"InChI=1S/C7H9NO2S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H3,(H2,8,9,10)",LMYRWZFENFIFIT-UHFFFAOYSA-N,para-toluenesulfonamide,Phase 3,,CA12|CA2|CA6|CA9,,
CC(=O)Nc1ccc(O)cc1,"InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)",RZVAJINKPMORJF-UHFFFAOYSA-N,paracetamol,Launched,cyclooxygenase inhibitor,FAAH|PTGS1|PTGS2|TRPV1,neurology/psychiatry|endocrinology,pain relief|fever
Oc1ccc(Cl)cc1,"InChI=1S/C6H5ClO/c7-5-1-3-6(8)4-2-5/h1-4,8H",WXNZTHHGJRFXKQ-UHFFFAOYSA-N,parachlorophenol,Launched,antiinfective drug,,infectious disease,first-aid antiseptic
CCC1(C)OC(=O)N(C)C1=O,"InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3",VQASKUSHBVDKGU-UHFFFAOYSA-N,paramethadione,Launched,anticonvulsant,CACNA1G,neurology/psychiatry,seizures
Cn1c(=O)[nH]c2ncn(C)c2c1=O,"InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)11(2)7(13)9-5/h3H,1-2H3,(H,9,13)",QUNWUDVFRNGTCO-UHFFFAOYSA-N,paraxanthine,Phase 1,adenosine receptor antagonist,,,
CCCCc1ccc2[nH]c(=NC(=O)OC)[nH]c2c1,"InChI=1S/C13H17N3O2/c1-3-4-5-9-6-7-10-11(8-9)15-12(14-10)16-13(17)18-2/h6-8H,3-5H2,1-2H3,(H2,14,15,16,17)",YRWLZFXJFBZBEY-UHFFFAOYSA-N,parbendazole,Preclinical,tubulin polymerization inhibitor,TUBB,,
CC(=O)Nc1ccc(OC2(C)OC(=O)c3ccccc3O2)cc1,"InChI=1S/C17H15NO5/c1-11(19)18-12-7-9-13(10-8-12)21-17(2)22-15-6-4-3-5-14(15)16(20)23-17/h3-10H,1-2H3,(H,18,19)",ZAPRLADYRFPQSH-UHFFFAOYSA-N,parcetasal,Preclinical,anti-inflammatory agent,,,
CN1CCN(c2cccc3[nH]c(=O)oc23)CC1,"InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)",YVPUUUDAZYFFQT-UHFFFAOYSA-N,pardoprunox,Phase 3,dopamine receptor agonist,DRD2|DRD3|DRD4|HTR1A|HTR7,,
CN1CCN(c2cccc3[nH]c(=O)oc23)CC1,"InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)",YVPUUUDAZYFFQT-UHFFFAOYSA-N,pardoprunox,Phase 3,serotonin receptor agonist,DRD2|DRD3|DRD4|HTR1A|HTR7,,
CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,"InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)",TZRHLKRLEZJVIJ-UHFFFAOYSA-N,parecoxib,Launched,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief
CCOc1ccc(C(=O)OCCN(CC)CC)cc1,"InChI=1S/C15H23NO3/c1-4-16(5-2)11-12-19-15(17)13-7-9-14(10-8-13)18-6-3/h7-10H,4-6,11-12H2,1-3H3",OWWVHQUOYSPNNE-UHFFFAOYSA-N,parethoxycaine,Preclinical,local anesthetic,,,
C#CCN(C)Cc1ccccc1,"InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3",DPWPWRLQFGFJFI-UHFFFAOYSA-N,pargyline,Launched,monoamine oxidase inhibitor,MAOA|MAOB,cardiology,hypertension
CC(C=CC(C)C(C)(C)O)C1CCC2C(=CC=C3CC(O)CC(O)C3)CCCC21C,"InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3",BPKAHTKRCLCHEA-UHFFFAOYSA-N,paricalcitol,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperthyroidism
Cc1cnc(C(=O)NC2CCCCCC=CC3CC3(C(=O)NS(=O)(=O)C3CC3)NC(=O)C3CC(Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,"InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)",UAUIUKWPKRJZJV-UHFFFAOYSA-N,paritaprevir,Launched,HCV inhibitor,,infectious disease,hepatitis C
NCC1OC(OC2C(CO)OC(OC3C(O)C(N)CC(N)C3OC3OC(CO)C(O)C(O)C3N)C2O)C(N)C(O)C1O,"InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2",UOZODPSAJZTQNH-UHFFFAOYSA-N,paromomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,amebiasis
Fc1ccc(C2CCNCC2COc2ccc3c(c2)OCO3)cc1,"InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2",AHOUBRCZNHFOSL-UHFFFAOYSA-N,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder
CCC(=O)c1ccc(O)cc1,"InChI=1S/C9H10O2/c1-2-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3",RARSHUDCJQSEFJ-UHFFFAOYSA-N,paroxypropione,Launched,gonadotropin inhibitor,,,
CCOc1c(C(C)n2nc(C)c3c(=N)[nH]cnc32)cc(Cl)c(F)c1C1CNC(=O)C1,"InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)",ZQPDJCIXJHUERQ-UHFFFAOYSA-N,parsaclisib,Phase 2,PI3K inhibitor,,,
C=C1C(=O)OC2C1CCC(C)=CCCC1(C)OC21,"InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3",KTEXNACQROZXEV-UHFFFAOYSA-N,parthenolide,Phase 1,NFkB pathway inhibitor,,,
C=C1C(=O)OC2C1CCC(C)=CCCC1(C)OC21,"InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3",KTEXNACQROZXEV-UHFFFAOYSA-N,parthenolide-(-),Preclinical,NFkB pathway inhibitor,HDAC1,,
C=C1C(=O)OC2C1CCC(C)=CCCC1(C)OC21,"InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3",KTEXNACQROZXEV-UHFFFAOYSA-N,parthenolide-(alternate-stereo),Preclinical,NFkB pathway inhibitor,IKBKB|RELA,,
NCCCCC1NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(c2ccccc2)NC(=O)C2CC(OC(=O)NCCN)CN2C(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(OCc3ccccc3)cc2)NC1=O,"InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)",VMZMNAABQBOLAK-UHFFFAOYSA-N,pasireotide,Launched,somatostatin receptor agonist,SSTR1|SSTR2|SSTR3|SSTR5,endocrinology,Cushing's syndrome|acromegaly
NCc1cc(Oc2cccc(C(=O)N3CC(O)C(F)C3)c2)nc(C(F)(F)F)c1,"InChI=1S/C18H17F4N3O3/c19-13-8-25(9-14(13)26)17(27)11-2-1-3-12(6-11)28-16-5-10(7-23)4-15(24-16)18(20,21)22/h1-6,13-14,26H,7-9,23H2",ODGXXYXJORZPHE-UHFFFAOYSA-N,pat-1251,Phase 1,lysyl oxidase inhibitor,,,
CCC(NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,"InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)",QYTBBBAHNIWFOD-UHFFFAOYSA-N,pavinetant,Phase 2,neurokinin receptor antagonist,,,
Cc1ccc(N=c2nc(N(C)c3ccc4c(C)n(C)nc4c3)cc[nH]2)cc1S(N)(=O)=O,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,Launched,KIT inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
Cc1ccc(N=c2nc(N(C)c3ccc4c(C)n(C)nc4c3)cc[nH]2)cc1S(N)(=O)=O,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,Launched,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
Cc1ccc(N=c2nc(N(C)c3ccc4c(C)n(C)nc4c3)cc[nH]2)cc1S(N)(=O)=O,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,pazopanib,Launched,VEGFR inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS)
CC1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,"InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)",XAGMUUZPGZWTRP-UHFFFAOYSA-N,pazufloxacin,Launched,topoisomerase inhibitor,,infectious disease,pneumonia|peritonitis|bacterial septicemia
CCCCCc1cccc(CC(=O)O)c1,"InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)",PEGQOIGYZLJMIB-UHFFFAOYSA-N,pbi-4050,Phase 2/Phase 3,free fatty acid receptor agonist,,,
CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,"InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3",YZPOQCQXOSEMAZ-UHFFFAOYSA-N,pbt-1033,Preclinical,chelating agent,,,
COC(=O)C1=C(C)N=C(C)C(C(=O)OCCSc2ccccc2)C1C,"InChI=1S/C19H23NO4S/c1-12-16(18(21)23-4)13(2)20-14(3)17(12)19(22)24-10-11-25-15-8-6-5-7-9-15/h5-9,12,17H,10-11H2,1-4H3",MHKRWJRATDRSDY-UHFFFAOYSA-N,pca-4248,Phase 1,platelet activating factor receptor antagonist,PTAFR,,
CN(C)Cc1c(C(=O)NCCOc2ccc(C(O)=NO)cc2)oc2ccccc12,"InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)",MAUCONCHVWBMHK-UHFFFAOYSA-N,pci-24781,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6,,
N=C(N)c1ccc2[nH]c(-c3cc(CC(=O)NC(CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)nc2c1,"InChI=1S/C26H24N6O9S/c27-24(28)12-1-3-17-18(8-12)32-25(31-17)16-6-11(7-21(34)30-19(26(38)39)10-22(35)36)5-15(23(16)37)14-9-13(42(29,40)41)2-4-20(14)33/h1-6,8-9,19,33,37H,7,10H2,(H3,27,28)(H,30,34)(H,31,32)(H,35,36)(H,38,39)(H2,29,40,41)",WDJHHCAKBRKCLW-UHFFFAOYSA-N,pci-27483,Phase 2,ERK1 and ERK2 phosphorylation inhibitor,,,
N=c1[nH]cnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCC1,"InChI=1S/C22H21N5O/c23-21-19-20(26-27(16-6-4-5-7-16)22(19)25-14-24-21)15-10-12-18(13-11-15)28-17-8-2-1-3-9-17/h1-3,8-14,16H,4-7H2,(H2,23,24,25)",GMJUPMONHWAZCP-UHFFFAOYSA-N,pci-29732,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
COc1ccc(Cn2ccc3ccc(C(O)=NO)cc32)cc1,"InChI=1S/C17H16N2O3/c1-22-15-6-2-12(3-7-15)11-19-9-8-13-4-5-14(10-16(13)19)17(20)18-21/h2-10,21H,11H2,1H3,(H,18,20)",AJRGHIGYPXNABY-UHFFFAOYSA-N,pci-34051,Preclinical,HDAC inhibitor,HDAC1|HDAC10|HDAC6|HDAC8,,
CC1(C)Oc2ccc(C#N)cc2C(OC2=CC(=O)CC2)C1O,"InChI=1S/C17H17NO4/c1-17(2)16(20)15(21-12-5-4-11(19)8-12)13-7-10(9-18)3-6-14(13)22-17/h3,6-8,15-16,20H,4-5H2,1-2H3",WJBHHTPFTVKZCV-UHFFFAOYSA-N,pco-400,Phase 1,potassium channel activator,KCNJ8,,
O=C(NOCC(O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,"InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)",SUDAHWBOROXANE-UHFFFAOYSA-N,pd-0325901,Phase 2,MEK inhibitor,MAP2K1,,
CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3,"InChI=1S/C23H24N2O4/c1-4-28-23(26)20-13(2)24-18-7-8-19-17(21(18)20)12-25-10-9-14-11-15(27-3)5-6-16(14)22(25)29-19/h5-8,11,22,24H,4,9-10,12H2,1-3H3",VDDUJINYXKGZLV-UHFFFAOYSA-N,pd-102807,Preclinical,acetylcholine receptor antagonist,CHRM4,,
O=C(O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1,"InChI=1S/C21H17Cl2NO2/c22-18-12-9-15(13-19(18)23)6-5-14-7-10-16(11-8-14)24-20-4-2-1-3-17(20)21(25)26/h1-4,7-13,24H,5-6H2,(H,25,26)",ZCQOSCDABPVAFB-UHFFFAOYSA-N,pd-118057,Preclinical,potassium channel activator,KCNH2,,
Cc1cc(Cn2cnc3c2CC(C(=O)O)N(C(=O)C(c2ccccc2)c2ccccc2)C3)ccc1N(C)C,"InChI=1S/C31H32N4O3/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38)",YSTVFDAKLDMYCR-UHFFFAOYSA-N,pd-123319,Phase 1,angiotensin antagonist,AGTR2,,
CCCN1CCOC2c3cc(O)ccc3OCC21,"InChI=1S/C14H19NO3/c1-2-5-15-6-7-17-14-11-8-10(16)3-4-13(11)18-9-12(14)15/h3-4,8,12,14,16H,2,5-7,9H2,1H3",YOILXOMTHPUMRG-UHFFFAOYSA-N,pd-128907,Preclinical,dopamine receptor agonist,DRD2|DRD3,,
COc1cc2[nH]cnc(=Nc3cccc(Br)c3)c2cc1OC,"InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)",LSPANGZZENHZNJ-UHFFFAOYSA-N,pd-153035,Phase 1,EGFR inhibitor,EGFR|KDR,,
COc1ccc(C(=O)C(=Cc2cc(OC)c(OC)c(OC)c2)C(C(=O)O)c2ccc3c(c2)OCO3)cc1,"InChI=1S/C28H26O9/c1-32-19-8-5-17(6-9-19)26(29)20(11-16-12-23(33-2)27(35-4)24(13-16)34-3)25(28(30)31)18-7-10-21-22(14-18)37-15-36-21/h5-14,25H,15H2,1-4H3,(H,30,31)",PLNDINDFIGGYPN-UHFFFAOYSA-N,pd-156707,Preclinical,endothelin receptor antagonist,EDNRA|EDNRB,,
CN=c1cc2c(=Nc3cccc(Br)c3)[nH]cnc2c[nH]1,"InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)",KFHMLBXBRCITHF-UHFFFAOYSA-N,pd-158780,Preclinical,EGFR inhibitor,EGFR,,
CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+](=O)[O-],"InChI=1S/C18H17N3O4S/c1-11(2)12-6-3-4-8-15(12)26(24,25)16-10-14(19)17-13(7-5-9-20-17)18(16)21(22)23/h3-11H,19H2,1-2H3",YUVNGBZROXQYQH-UHFFFAOYSA-N,pd-160170,Preclinical,neuropeptide receptor antagonist,NPY1R,,
CCN(CC)CCCCN=c1nc2[nH]c(=NC(=O)NC(C)(C)C)c(-c3c(Cl)cccc3Cl)cc2c[nH]1,"InChI=1S/C26H35Cl2N7O/c1-6-35(7-2)14-9-8-13-29-24-30-16-17-15-18(21-19(27)11-10-12-20(21)28)23(31-22(17)32-24)33-25(36)34-26(3,4)5/h10-12,15-16H,6-9,13-14H2,1-5H3,(H3,29,30,31,32,33,34,36)",MKVMEJKNLUWFSQ-UHFFFAOYSA-N,pd-161570,Preclinical,FGFR inhibitor,FGFR1,,
CCN(CC)CCOc1ccc(N=c2nc3c(c[nH]2)cc(-c2c(Cl)cccc2Cl)c(=O)n3C)cc1,"InChI=1S/C26H27Cl2N5O2/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31)",IFPPYSWJNWHOLQ-UHFFFAOYSA-N,pd-166285,Preclinical,SRC inhibitor,EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1,,
CC(C)C(NS(=O)(=O)c1ccc(-c2ccc(Br)cc2)cc1)C(=O)O,"InChI=1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)",GJOCABIDMCKCEG-UHFFFAOYSA-N,pd-166793,Preclinical,collagenase inhibitor,MMP13|MMP2|MMP3,,
CC(C)C(NS(=O)(=O)c1ccc(-c2ccc(Br)cc2)cc1)C(=O)O,"InChI=1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)",GJOCABIDMCKCEG-UHFFFAOYSA-N,pd-166793,Preclinical,metalloproteinase inhibitor,MMP13|MMP2|MMP3,,
Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1,"InChI=1S/C20H22N4O/c1-16-5-4-7-17(13-16)20(25)22-15-23-9-11-24(12-10-23)19-8-3-2-6-18(19)14-21/h2-8,13H,9-12,15H2,1H3,(H,22,25)",DNULYRGWTFLJQL-UHFFFAOYSA-N,pd-168077,Preclinical,dopamine receptor agonist,DRD2,,
C=CC(=O)Nc1ccc2[nH]cnc(=Nc3cccc(Br)c3)c2c1,"InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)",HTUBKQUPEREOGA-UHFFFAOYSA-N,pd-168393,Preclinical,EGFR inhibitor,EGFR|ERBB2|SRC,,
Cc1ccc(N2CCN(CCC3NC(=O)c4ccccc43)CC2)cc1C,"InChI=1S/C22H27N3O/c1-16-7-8-18(15-17(16)2)25-13-11-24(12-14-25)10-9-21-19-5-3-4-6-20(19)22(26)23-21/h3-8,15,21H,9-14H2,1-2H3,(H,23,26)",WQEPZBNLBWDIRZ-UHFFFAOYSA-N,pd-168568,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,
CCN(CC)CCCCN=c1nc2[nH]c(=NC(=O)NC(C)(C)C)c(-c3cc(OC)cc(OC)c3)cc2c[nH]1,"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)",DXCUKNQANPLTEJ-UHFFFAOYSA-N,pd-173074,Preclinical,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,,
CCN(CC)CCCCN=c1nc2[nH]c(=NC(=O)NC(C)(C)C)c(-c3cc(OC)cc(OC)c3)cc2c[nH]1,"InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)",DXCUKNQANPLTEJ-UHFFFAOYSA-N,pd-173074,Preclinical,VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,,
CC(C)CC(C(=O)NC(Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C)N(C)Cc1ccc(C(C)(C)C)cc1,"InChI=1S/C38H53N3O3/c1-27(2)23-34(41(9)25-29-15-19-31(20-16-29)37(3,4)5)36(43)39-33(35(42)40-38(6,7)8)24-28-17-21-32(22-18-28)44-26-30-13-11-10-12-14-30/h10-22,27,33-34H,23-26H2,1-9H3,(H,39,43)(H,40,42)",GCDHMGROXQUFNR-UHFFFAOYSA-N,pd-173212,Preclinical,calcium channel blocker,CACNA1B,,
O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)",GFMMXOIFOQCCGU-UHFFFAOYSA-N,pd-184352,Phase 2,MEK inhibitor,MAP2K1|MAP3K1|MAP3K2,,
Cc1cc(I)ccc1Nc1c(C(=O)NOCC2CC2)cc(F)c(F)c1F,"InChI=1S/C18H16F3IN2O2/c1-9-6-11(22)4-5-14(9)23-17-12(7-13(19)15(20)16(17)21)18(25)24-26-8-10-2-3-10/h4-7,10,23H,2-3,8H2,1H3,(H,24,25)",UHAXDAKQGVISBZ-UHFFFAOYSA-N,pd-198306,Preclinical,MAP kinase inhibitor,MAP2K1|MAP2K2,,
Cc1cc(I)ccc1Nc1c(C(=O)NOCC2CC2)cc(F)c(F)c1F,"InChI=1S/C18H16F3IN2O2/c1-9-6-11(22)4-5-14(9)23-17-12(7-13(19)15(20)16(17)21)18(25)24-26-8-10-2-3-10/h4-7,10,23H,2-3,8H2,1H3,(H,24,25)",UHAXDAKQGVISBZ-UHFFFAOYSA-N,pd-198306,Preclinical,MEK inhibitor,MAP2K1|MAP2K2,,
O=C(NOCC(O)CO)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,"InChI=1S/C16H13BrF3IN2O4/c17-10-4-9(16(26)23-27-6-8(25)5-24)15(14(20)13(10)19)22-12-2-1-7(21)3-11(12)18/h1-4,8,22,24-25H,5-6H2,(H,23,26)",XXSSGBYXSKOLAM-UHFFFAOYSA-N,pd-318088,Preclinical,MEK inhibitor,,,
O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21,"InChI=1S/C20H12N2O3/c23-11-6-7-14-13(8-11)16-15(21-14)9-12(10-4-2-1-3-5-10)17-18(16)20(25)22-19(17)24/h1-9,21,23H,(H,22,24,25)",IAUZTOZLTFSMIE-UHFFFAOYSA-N,pd-407824,Preclinical,PKC inhibitor,WEE1,,
Cc1sc(N)c(C(=O)c2cccc(C(F)(F)F)c2)c1C,"InChI=1S/C14H12F3NOS/c1-7-8(2)20-13(18)11(7)12(19)9-4-3-5-10(6-9)14(15,16)17/h3-6H,18H2,1-2H3",KKDKAWKYGCUOGR-UHFFFAOYSA-N,pd-81723,Preclinical,adenosine receptor agonist,ADORA1,,
COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,"InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3",QFWCYNPOPKQOKV-UHFFFAOYSA-N,pd-98059,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,
COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCCC1C(=O)O,"InChI=1S/C29H33NO5/c1-20-22(12-9-13-24(20)21-10-5-4-6-11-21)19-35-23-16-27(33-2)25(28(17-23)34-3)18-30-15-8-7-14-26(30)29(31)32/h4-6,9-13,16-17,26H,7-8,14-15,18-19H2,1-3H3,(H,31,32)",ZBOYJODMIAUJHH-UHFFFAOYSA-N,pd1-pdl-inhibitor-1,Preclinical,programmed death ligand inhibitor,CD274,,
Cc1cc(Cn2c(=O)n(Cc3cnc(C)s3)c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc32)n(C)n1,"InChI=1S/C23H26N6O4S2/c1-14-9-16(27(4)25-14)12-28-20-6-5-18(35(32,33)26-23(3)7-8-23)10-19(20)21(30)29(22(28)31)13-17-11-24-15(2)34-17/h5-6,9-11,26H,7-8,12-13H2,1-4H3",IFWUBRBMMNTBRZ-UHFFFAOYSA-N,pdd-00017273,Preclinical,PARG inhibitor,,,
Cc1ncc(C)n2nc(C3CC3c3nc4c5cccnc5ccn4c3C)nc12,"InChI=1S/C21H19N7/c1-11-10-23-12(2)20-25-19(26-28(11)20)16-9-15(16)18-13(3)27-8-6-17-14(21(27)24-18)5-4-7-22-17/h4-8,10,15-16H,9H2,1-3H3",ZLHNYULRKIEGAY-UHFFFAOYSA-N,pde10-in-1,Preclinical,phosphodiesterase inhibitor,PDE10A,,
CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1,"InChI=1S/C25H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-23-17-15-18-24(21-23)29-22-25(28)26-19-20-27/h15,17-18,21,27H,2-14,16,19-20,22H2,1H3,(H,26,28)",BIOVSNWTCKRADD-UHFFFAOYSA-N,pdp-ea,Preclinical,FAAH activator,FAAH,,
NC(=O)c1c[nH]c2[nH]ccc2c1=NC1C2CC3CC1CC(O)(C3)C2,"InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)",DREIJXJRTLTGJC-UHFFFAOYSA-N,peficitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis
CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,"InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)",FHFYDNQZQSQIAI-UHFFFAOYSA-N,pefloxacin,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,gastrointestinal infections|urethritis|gonorrhea|urinary tract infections
O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(c2ccccc2)CC1,"InChI=1S/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)",WPKPLSFHHBBLRY-UHFFFAOYSA-N,pelanserin,Phase 2,serotonin receptor antagonist,HTR2A,,
CCOc1cc2[nH]cc(C#N)c(=Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C,"InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)",WVUNYSQLFKLYNI-UHFFFAOYSA-N,pelitinib,Phase 2,EGFR inhibitor,EGFR,,
Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1,"InChI=1S/C12H11N5O/c1-8-16-11(10(5-13)12(18)17-8)15-7-9-3-2-4-14-6-9/h2-4,6H,7H2,1H3,(H2,15,16,17,18)",NZXHFDXOCVIYLO-UHFFFAOYSA-N,pelrinone,Phase 2,phosphodiesterase inhibitor,,,
CCC(Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,"InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)",ZHKNLJLMDFQVHJ-UHFFFAOYSA-N,pemafibrate,Phase 3,PPAR receptor agonist,,,
N=c1[nH]c(=O)c2c(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)",WBXPDJSOTKVWSJ-UHFFFAOYSA-N,pemetrexed,Launched,dihydrofolate reductase inhibitor,ATIC|DHFR|GART|TYMS,oncology,non-small cell lung cancer (NSCLC)|mesothelioma
N=c1[nH]c(=O)c2c(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)",WBXPDJSOTKVWSJ-UHFFFAOYSA-N,pemetrexed,Launched,thymidylate synthase inhibitor,ATIC|DHFR|GART|TYMS,oncology,non-small cell lung cancer (NSCLC)|mesothelioma
Cc1cccn2c(=O)c(-c3nn[nH]n3)cnc12,"InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)",HIANJWSAHKJQTH-UHFFFAOYSA-N,pemirolast,Launched,mediator release inhibitor,HRH1,pulmonary,asthma
CN1C(C)(C)CCCC1(C)C,"InChI=1S/C10H21N/c1-9(2)7-6-8-10(3,4)11(9)5/h6-8H2,1-5H3",XULIXFLCVXWHRF-UHFFFAOYSA-N,pempidine,Launched,ganglionic blocker,,cardiology,hypertension
CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,"InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3",KQXKVJAGOJTNJS-UHFFFAOYSA-N,penbutolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR1B,cardiology,hypertension
N=c1[nH]c(=O)c2ncn(CCC(CO)CO)c2[nH]1,"InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)",JNTOCHDNEULJHD-UHFFFAOYSA-N,penciclovir,Launched,DNA directed DNA polymerase inhibitor,,dental,cold sore
OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2",MDLAAYDRRZXJIF-UHFFFAOYSA-N,penfluridol,Launched,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia
CC(C)(S)C(N)C(=O)O,"InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)",VVNCNSJFMMFHPL-UHFFFAOYSA-N,penicillamine-(d),Launched,chelating agent,,metabolism|rheumatology|nephrology,Wilson's disease|rheumatoid arthritis|cystinuria
CC(C)(S)C(N)C(=O)O,"InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)",VVNCNSJFMMFHPL-UHFFFAOYSA-N,penicillamine-(racemic),Launched,,,,
CC1(C)SC2C(NC(=O)COc3ccccc3)C(=O)N2C1C(=O)O,"InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)",BPLBGHOLXOTWMN-UHFFFAOYSA-N,penicillin-v-potassium,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,pneumonia|ear infections|skin infections|throat infections|cholera|scarlet fever
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,"InChI=1S/C25H50O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25(26)27/h2-24H2,1H3,(H,26,27)",MWMPEAHGUXCSMY-UHFFFAOYSA-N,pentacosanoic-acid,Preclinical,,,,
CSCCC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O,"InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)",NEYNJQRKHLUJRU-UHFFFAOYSA-N,pentagastrin,Launched,CCK receptor agonist,CCKBR,gastroenterology,anacidity diagnostic|gastric hypersecretion diagnostic
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,"InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)",XDRYMKDFEDOLFX-UHFFFAOYSA-N,pentamidine,Launched,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O,"InChI=1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)",QPCDCPDFJACHGM-UHFFFAOYSA-N,pentetic-acid,Phase 2,chelating agent,,,
C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,"InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2",XSBSKEQEUFOSDD-UHFFFAOYSA-N,pentolinium,Launched,cholinergic receptor antagonist,CHRNA10|CHRNA3|CHRNA4|CHRNB4,cardiology,hypertension
OCC1OC(n2cnc3c2N=CNCC3O)CC1O,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)",FPVKHBSQESCIEP-UHFFFAOYSA-N,pentostatin,Launched,adenosine deaminase inhibitor,ADA,hematologic malignancy,hairy cell leukemia
OCC1OC(n2cnc3c2N=CNCC3O)CC1O,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)",FPVKHBSQESCIEP-UHFFFAOYSA-N,pentostatin,Launched,ribonucleotide reductase inhibitor,ADA,hematologic malignancy,hairy cell leukemia
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,"InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3",BYPFEZZEUUWMEJ-UHFFFAOYSA-N,pentoxifylline,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF,cardiology,claudication
C1CCc2nnnn2CC1,InChI=1S/C6H10N4/c1-2-4-6-7-8-9-10(6)5-3-1/h1-5H2,CWRVKFFCRWGWCS-UHFFFAOYSA-N,pentylenetetrazol,Withdrawn,GABA receptor antagonist,,,
COc1ccc(C(O)c2cc(-c3ncnc4cc(N5CCOCC5)ccc34)c(F)cc2Cl)nn1,"InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3",MOWXJLUYGFNTAL-UHFFFAOYSA-N,peposertib,Phase 1/Phase 2,DNA dependent protein kinase inhibitor,,,
CC(C)CC(=O)NC(C(=O)NC(C(=O)NC(CC(C)C)C(O)CC(=O)NC(C)C(=O)NC(CC(C)C)C(O)CC(=O)O)C(C)C)C(C)C,"InChI=1S/C34H63N5O9/c1-17(2)12-23(37-33(47)31(21(9)10)39-34(48)30(20(7)8)38-27(42)14-19(5)6)25(40)15-28(43)35-22(11)32(46)36-24(13-18(3)4)26(41)16-29(44)45/h17-26,30-31,40-41H,12-16H2,1-11H3,(H,35,43)(H,36,46)(H,37,47)(H,38,42)(H,39,48)(H,44,45)",FAXGPCHRFPCXOO-UHFFFAOYSA-N,pepstatin,Preclinical,aspartic protease inhibitor,CTSB|CTSD|CTSL|REN,,
CCC(CC)C(NC(C)=O)C1C(N=C(N)N)CC(C(=O)O)C1O,"InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)",XRQDFNLINLXZLB-UHFFFAOYSA-N,peramivir,Launched,neuraminidase inhibitor,,infectious disease,influenza A virus infection
NC(=S)NN=Cc1ccncc1,"InChI=1S/C7H8N4S/c8-7(12)11-10-5-6-1-3-9-4-2-6/h1-5H,(H3,8,11,12)",QTSJJDIDTYFLFC-UHFFFAOYSA-N,perchlozone,Launched,,,infectious disease,tuberculosis
CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC(=O)O,"InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)",UUBHZHZSIKRVIV-UHFFFAOYSA-N,peretinoin,Phase 3,retinoid receptor agonist,RXRA,,
FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F,"InChI=1S/C9F21N/c10-1(11,4(16,17)18)7(25,26)31(8(27,28)2(12,13)5(19,20)21)9(29,30)3(14,15)6(22,23)24",JAJLKEVKNDUJBG-UHFFFAOYSA-N,perfluamine,Launched,,,,
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,"InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26",WTWWXOGTJWMJHI-UHFFFAOYSA-N,perflubron,Launched,contrast agent,,radiology,contrast agent
FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F,"InChI=1S/C10F18/c11-1-2(12,5(17,18)9(25,26)7(21,22)3(1,13)14)6(19,20)10(27,28)8(23,24)4(1,15)16",UWEYRJFJVCLAGH-UHFFFAOYSA-N,perfluorodecalin,Launched,,,dermatology,cosmetic
CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,"InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3",WRYIIOKOQSICTB-UHFFFAOYSA-N,perfluorohexyloctane,Launched,,,,
CCCN1CC(CSC)CC2c3cccc4[nH]cc(c34)CC21,"InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3",YEHCICAEULNIGD-UHFFFAOYSA-N,pergolide,Withdrawn,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,,
C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,"InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2",CYXKNKQEMFBLER-UHFFFAOYSA-N,perhexiline,Launched,carnitine palmitoyltransferase inhibitor,CPT1A,cardiology,angina pectoris
CCCCCCCCCCCCCCCCCCO[PH](=O)(=O)OC1CC[N+](C)(C)CC1,"InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3/q+1",XEEHOTYCMWLXRQ-UHFFFAOYSA-N,perifosine,Phase 3,AKT inhibitor,AKT1,,
C=C(C)C1CC=C(CO)CC1,"InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3",NDTYTMIUWGWIMO-UHFFFAOYSA-N,perillyl-alcohol,Phase 2,apoptosis stimulant,FNTA,,
C=C(C)C1CC=C(CO)CC1,"InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3",NDTYTMIUWGWIMO-UHFFFAOYSA-N,perillyl-alcohol,Phase 2,farnesyltransferase inhibitor,FNTA,,
CCCC(NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21)C(=O)OCC,"InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)",IPVQLZZIHOAWMC-UHFFFAOYSA-N,perindopril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction|coronary artery disease (CAD)
CCCC(NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21)C(=O)O,"InChI=1S/C17H28N2O5/c1-3-6-12(16(21)22)18-10(2)15(20)19-13-8-5-4-7-11(13)9-14(19)17(23)24/h10-14,18H,3-9H2,1-2H3,(H,21,22)(H,23,24)",ODAIHABQVKJNIY-UHFFFAOYSA-N,perindoprilat,Phase 2,angiotensin converting enzyme inhibitor,ACE,,
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1,"InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3",RLLPVAHGXHCWKJ-UHFFFAOYSA-N,permethrin,Launched,,,infectious disease,lice
Oc1c2c(c(O)n1CCCCN1CCN(c3nsc4ccccc34)CC1)CCCC2,"InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,28-29H,1-2,5-8,11-16H2",GRZAUXJKSWFZCU-UHFFFAOYSA-N,perospirone,Launched,dopamine receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia|bipolar disorder
Oc1c2c(c(O)n1CCCCN1CCN(c3nsc4ccccc34)CC1)CCCC2,"InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,28-29H,1-2,5-8,11-16H2",GRZAUXJKSWFZCU-UHFFFAOYSA-N,perospirone,Launched,serotonin receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia|bipolar disorder
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2",RGCVKNLCSQQDEP-UHFFFAOYSA-N,perphenazine,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry|gastroenterology,schizophrenia|nausea|vomiting
COC1C(O)C(C)OC(OC2CCC3(C=O)C(CCC4C3CCC3(C)C(c5coc(O)c5)CCC43O)C2)C1O,"InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,14-16,18-22,24-27,32-35H,4-11,13H2,1-3H3",PCQKDOBQOUEZQO-UHFFFAOYSA-N,peruvoside,Phase 1,cardiac glycoside,,,
O=c1c2c(c1=O)N(CC[PH](=O)(=O)O)CCCN2,"InChI=1S/C9H12N2O5P/c12-8-6-7(9(8)13)11(3-1-2-10-6)4-5-17(14,15)16/h10H,1-5H2,(H,14,15,16)",ZAWKLRBELVMFSJ-UHFFFAOYSA-N,perzinfotel,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B,,
OC(Cc1ccncc1)C(Cl)(Cl)Cl,"InChI=1S/C8H8Cl3NO/c9-8(10,11)7(13)5-6-1-3-12-4-2-6/h1-4,7,13H,5H2",NGTDJJKTGRNNAU-UHFFFAOYSA-N,petcm,Preclinical,caspase activator,CASP3,,
NS(=O)(=O)OCC1CC(n2ccc3c(=NC4CCc5ccccc54)[nH]cnc32)CC1O,"InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)",MPUQHZXIXSTTDU-UHFFFAOYSA-N,pevonedistat,Phase 3,nedd activating enzyme inhibitor,NAE1|UBA3,,
FC(F)(F)c1ccc(CN=c2ccc(Cc3c[nH]c4ncc(Cl)cc34)c[nH]2)cn1,"InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)",JGWRKYUXBBNENE-UHFFFAOYSA-N,pexidartinib,Launched,tyrosine kinase inhibitor,CSF1R|FLT3|KIT,,
Cc1ccc(-n2[nH]c(C(C)(C)C)cc2=NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,"InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,36,39H,13-14,18H2,1-4H3,(H,33,40)",SQZMVSMPSJAHQX-UHFFFAOYSA-N,pexmetinib,Phase 1,MAP kinase inhibitor,MAPK14|TEK,,
Cc1ccc(-n2[nH]c(C(C)(C)C)cc2=NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,"InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,36,39H,13-14,18H2,1-4H3,(H,33,40)",SQZMVSMPSJAHQX-UHFFFAOYSA-N,pexmetinib,Phase 1,TIE tyrosine kinase inhibitor,MAPK14|TEK,,
Cc1cc(Oc2c(C3CC3)nn(CS(C)(=O)=O)c2C)cc(C)c1C#N,"InChI=1S/C18H21N3O3S/c1-11-7-15(8-12(2)16(11)9-19)24-18-13(3)21(10-25(4,22)23)20-17(18)14-5-6-14/h7-8,14H,5-6,10H2,1-4H3",QSFGZNVRVZHUGV-UHFFFAOYSA-N,pf-02413873,Phase 1,progesterone receptor antagonist,,,
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,"InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3",AZEXWHKOMMASPA-UHFFFAOYSA-N,pf-02545920,Phase 2,phosphodiesterase inhibitor,PDE10A,,
CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,"InChI=1S/C24H32N6O4/c1-3-13-34-14-11-30-21-15-19(18-4-5-22(33-2)26-16-18)25-17-20(21)27-23(24(30)32)29-8-6-28(7-9-29)10-12-31/h4-5,15-17,31H,3,6-14H2,1-2H3",MNLNAGRCHNMKKJ-UHFFFAOYSA-N,pf-03049423,Phase 2,phosphodiesterase inhibitor,PDE5A,,
CCCC(NC1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,"InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)",VFCRKLWBYMDAED-UHFFFAOYSA-N,pf-03084014,Phase 3,gamma secretase inhibitor,,,
Cc1nc(=Nc2[nH]nc3c2CN(C(=O)NC(CN(C)C)c2ccccc2)C3(C)C)c2sccc2[nH]1,"InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)",AYCPARAPKDAOEN-UHFFFAOYSA-N,pf-03758309,Phase 1,p21 activated kinase inhibitor,PAK4,,
CC(=O)NCC(=O)N1C2CCC1c1cc(N=c3[nH]cc(C(F)(F)F)c(=NC4CCC4)[nH]3)ccc12,"InChI=1S/C23H25F3N6O2/c1-12(33)27-11-20(34)32-18-7-8-19(32)16-9-14(5-6-15(16)18)30-22-28-10-17(23(24,25)26)21(31-22)29-13-3-2-4-13/h5-6,9-10,13,18-19H,2-4,7-8,11H2,1H3,(H,27,33)(H2,28,29,30,31)",RYYNGWLOYLRZLK-UHFFFAOYSA-N,pf-03814735,Phase 1,Aurora kinase inhibitor,AURKA|AURKB,,
N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CCC3C2C2CCCC2)cc1Cl,"InChI=1S/C24H22ClN3O2/c25-21-12-18(8-5-17(21)13-26)28-23(14-3-1-2-4-14)20-10-6-15-11-16(24(29)30)7-9-19(15)22(20)27-28/h5,7-9,11-12,14,20,23H,1-4,6,10H2,(H,29,30)",XNULRSOGWPFPBL-UHFFFAOYSA-N,pf-03882845,Phase 1,mineralocorticoid receptor antagonist,,,
O=C(NCC(=O)N1CCC(NC2CCC(O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,"InChI=1S/C29H31F3N6O3/c30-29(31,32)21-4-1-3-19(15-21)27(40)36-17-25(39)38-14-9-23(18-38)37-22-7-10-28(41,11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6,12-13,15-16,22-23,37,41H,7-11,14,17-18H2,(H,36,40)",ZNSVOHSYDRPBGI-UHFFFAOYSA-N,pf-04136309,Phase 2,CC chemokine receptor antagonist,,,
OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,"InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2",PDMUGYOXRHVNMO-UHFFFAOYSA-N,pf-04217903,Phase 1,c-Met inhibitor,MET,,
COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1,"InChI=1S/C23H20FNO5/c1-29-19-8-4-17-11-20(9-5-16(17)10-19)30-14-23(22(27)28)12-25(13-23)21(26)15-2-6-18(24)7-3-15/h2-11H,12-14H2,1H3,(H,27,28)",LWJGMYMNSNVCEM-UHFFFAOYSA-N,pf-04418948,Phase 1,prostaglandin inhibitor,PTGER2,,
CC1CN(Cc2ncccn2)CC1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1,"InChI=1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)",IWXUVYOOUMLUTQ-UHFFFAOYSA-N,pf-04447943,Phase 2,phosphodiesterase inhibitor,PDE9A,,
O=C(N=c1cccn[nH]1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,"InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)",BATCTBJIJJEPHM-UHFFFAOYSA-N,pf-04457845,Phase 2,FAAH inhibitor,FAAH,,
N=c1[nH]cnc2c1C(=O)N(c1ccc(C3CCC(CC(=O)O)CC3)cc1)CCO2,"InChI=1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)",GEVVQZHMFVFGLN-UHFFFAOYSA-N,pf-04620110,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,
COc1ccc(-c2cc3c(C)[nH]c(=N)nc3n(C3CCC(OCCO)CC3)c2=O)cn1,"InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)",XDLYKKIQACFMJG-UHFFFAOYSA-N,pf-04691502,Phase 2,mTOR inhibitor,MTOR|PIK3CA,,
COc1ccc(-c2cc3c(C)[nH]c(=N)nc3n(C3CCC(OCCO)CC3)c2=O)cn1,"InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)",XDLYKKIQACFMJG-UHFFFAOYSA-N,pf-04691502,Phase 2,PI3K inhibitor,MTOR|PIK3CA,,
CC(C)(N)c1nc(-c2ccc(OC(F)(F)F)cc2)c[nH]1,"InChI=1S/C13H14F3N3O/c1-12(2,17)11-18-7-10(19-11)8-3-5-9(6-4-8)20-13(14,15)16/h3-7H,17H2,1-2H3,(H,18,19)",AGORGFNWYAUYSU-UHFFFAOYSA-N,pf-04885614,Preclinical,voltage-gated sodium channel blocker,SCN10A,,
Cc1c[nH]c(=NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1,"InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)",MASKQITXHVYVFL-UHFFFAOYSA-N,pf-04937319,Phase 2,glucokinase activator,GCK,,
OC1(CN2CCC(COc3noc4cccc(OC5CCOC5)c34)CC2)CCOCC1,"InChI=1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2",WLLOFQROROXOMO-UHFFFAOYSA-N,pf-04995274,Phase 1,serotonin receptor agonist,,,
N=c1[nH][nH]cc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,"InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)",ZYSCOUXLBXGGIM-UHFFFAOYSA-N,pf-05089771,Preclinical,sodium channel blocker,,,
Cc1nc2cc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)ccc2[nH]1,"InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)",BDXXSFOJPYSYOC-UHFFFAOYSA-N,pf-05175157,Phase 2,acetyl-CoA carboxylase inhibitor,,,
Cc1nc(-c2cnn(C)c2-c2ccc(C(F)(F)F)cn2)c2c(N3CCC3)ncnn12,"InChI=1S/C19H17F3N8/c1-11-27-15(17-18(29-6-3-7-29)24-10-26-30(11)17)13-9-25-28(2)16(13)14-5-4-12(8-23-14)19(20,21)22/h4-5,8-10H,3,6-7H2,1-2H3",CLGCHUKGBICQTE-UHFFFAOYSA-N,pf-05180999,Phase 1,phosphodiesterase inhibitor,,,
Cc1cc(-c2ccc3c(c2)CCC3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1,"InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3",ZIUDADZJCKGWKR-UHFFFAOYSA-N,pf-05190457,Phase 2,growth hormone secretagogue receptor inverse agonist,GHSR,,
CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,"InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)",DWZAEMINVBZMHQ-UHFFFAOYSA-N,pf-05212384,Phase 2,mTOR inhibitor,MTOR|PIK3CA,,
CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,"InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)",DWZAEMINVBZMHQ-UHFFFAOYSA-N,pf-05212384,Phase 2,PI3K inhibitor,MTOR|PIK3CA,,
CC1CNS(=O)(=O)N(c2ccc3c(C#N)nccc3c2)C1,"InChI=1S/C14H14N4O2S/c1-10-8-17-21(19,20)18(9-10)12-2-3-13-11(6-12)4-5-16-14(13)7-15/h2-6,10,17H,8-9H2,1H3",ZKAVFOXYJCREBQ-UHFFFAOYSA-N,pf-06260414,Phase 1,androgen receptor modulator,,,
CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2c[nH]c(=N)nc21,"InChI=1S/C23H22ClN7O3/c1-23(2,12-32)31-11-18(17-10-28-22(25)30-21(17)31)20(34)13-5-16(9-26-7-13)29-19(33)6-15-4-3-14(24)8-27-15/h3-5,7-11,32H,6,12H2,1-2H3,(H,29,33)(H2,25,28,30)",BPIWZDNVMQQBQX-UHFFFAOYSA-N,pf-06273340,Phase 1,tyrosine kinase receptor inhibitor,,,
COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O,"InChI=1S/C13H12ClN3O3S/c1-20-10-3-2-7(14)4-8(10)9-5-12(19)16-13(21)17(9)6-11(15)18/h2-5H,6H2,1H3,(H2,15,18)(H,16,19,21)",ICYNYWFGIDGBRD-UHFFFAOYSA-N,pf-06282999,Phase 1,myeloperoxidase inhibitor,,,
CC(C(N)=O)C(N)c1nc2cc(C(C)(C)C)ccc2[nH]1,"InChI=1S/C15H22N4O/c1-8(13(17)20)12(16)14-18-10-6-5-9(15(2,3)4)7-11(10)19-14/h5-8,12H,16H2,1-4H3,(H2,17,20)(H,18,19)",APWZIFIAVVFPNT-UHFFFAOYSA-N,pf-06305591,Phase 1,sodium channel blocker,,,
O=C(O)c1c[nH]c2cc(Cl)c(-c3ccc(C4(O)CCC4)cc3)cc12,"InChI=1S/C19H16ClNO3/c20-16-9-17-14(15(10-21-17)18(22)23)8-13(16)11-2-4-12(5-3-11)19(24)6-1-7-19/h2-5,8-10,21,24H,1,6-7H2,(H,22,23)",FHQXLWCFSUSXBF-UHFFFAOYSA-N,pf-06409577,Phase 1,protein kinase activator,,,
Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C,"InChI=1S/C19H17N5O/c1-11-8-14(25-19-16-9-23-24-17(16)6-7-20-19)4-5-15(11)18-12(2)21-10-22-13(18)3/h4-10H,1-3H3,(H,23,24)",IDIUJOHYYBNCPC-UHFFFAOYSA-N,pf-06412562,Phase 1,dopamine receptor partial agonist,,,
N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1,"InChI=1S/C17H15N5O/c18-9-12-2-1-3-13(8-12)14-10-19-16-15(14)17(21-11-20-16)22-4-6-23-7-5-22/h1-3,8,10-11H,4-7H2,(H,19,20,21)",BHTWDJBVZQBRKP-UHFFFAOYSA-N,pf-06447475,Preclinical,serine/threonine kinase inhibitor,LRRK2,,
C=CC(=O)N1CC(COc2[nH]c(=Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C(OC)C1,"InChI=1S/C19H22ClN7O3/c1-4-15(28)27-7-11(14(9-27)29-3)10-30-18-16-13(20)6-21-17(16)24-19(25-18)23-12-5-22-26(2)8-12/h4-6,8,11,14H,1,7,9-10H2,2-3H3,(H2,21,23,24,25)",ODMXWZROLKITMS-UHFFFAOYSA-N,pf-06459988,Phase 2,receptor tyrosine protein kinase inhibitor,,,
CC1Oc2cc(c[nH]c2=N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)",IIXWYSCJSQVBQM-UHFFFAOYSA-N,pf-06463922,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FES|ROS1,oncology,non-small cell lung cancer (NSCLC)
CCC1C(COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)C1F,"InChI=1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)",JKDGKIBAOAFRPJ-UHFFFAOYSA-N,pf-06650833,Phase 1,kinase inhibitor,,,
C=CC(=O)N1CC(N=c2[nH]cnc3[nH]ccc23)CCC1C,"InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)",CBRJPFGIXUFMTM-UHFFFAOYSA-N,pf-06651600,Phase 2/Phase 3,JAK inhibitor,,,
C=CC(=O)NC1CN(c2nc(=Nc3cn(C)nc3OC)c3ncn(C)c3[nH]2)CC1F,"InChI=1S/C18H22FN9O2/c1-5-13(29)21-11-8-28(6-10(11)19)18-23-15(14-16(24-18)26(2)9-20-14)22-12-7-27(3)25-17(12)30-4/h5,7,9-11H,1,6,8H2,2-4H3,(H,21,29)(H,22,23,24)",JYIUNVOCEFIUIU-UHFFFAOYSA-N,pf-06747775,Phase 2,EGFR inhibitor,,,
CC1CC2CSC(=N)NC2(c2nc(NC(=O)c3ccc(OC(F)F)cn3)cs2)CO1,"InChI=1S/C18H19F2N5O3S2/c1-9-4-10-6-30-17(21)25-18(10,8-27-9)15-24-13(7-29-15)23-14(26)12-3-2-11(5-22-12)28-16(19)20/h2-3,5,7,9-10,16H,4,6,8H2,1H3,(H2,21,25)(H,23,26)",ZLZUHACSRMOLLV-UHFFFAOYSA-N,pf-06751979,Phase 1,beta secretase inhibitor,,,
Oc1cc(-c2c[nH]c3ccc(F)cc23)c(O)[nH]1,"InChI=1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-5,14-17H",HUYXRGHLIDWZBX-UHFFFAOYSA-N,pf-06840003,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",,,
CC1(O)CCCC1n1c(=O)c(C(F)F)cc2c[nH]c(=NC3CCN(S(C)(=O)=O)CC3)nc21,"InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)",QIEKHLDZKRQLLN-UHFFFAOYSA-N,pf-06873600,Phase 2,CDK inhibitor,,,
O=C(NC1CCCCC1C(=O)O)c1c[nH]n2c(=O)cc(-c3ccccc3)nc12,"InChI=1S/C20H20N4O4/c25-17-10-16(12-6-2-1-3-7-12)22-18-14(11-21-24(17)18)19(26)23-15-9-5-4-8-13(15)20(27)28/h1-3,6-7,10-11,13,15,21H,4-5,8-9H2,(H,23,26)(H,27,28)",WGQGCLHXUPGUSZ-UHFFFAOYSA-N,pf-06928215,Preclinical,cyclic GMP-AMP synthase inhibitor,,,
COCc1nnc(N2CC(Oc3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,"InChI=1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3",HNIFCPBQMKPRCX-UHFFFAOYSA-N,pf-3274167,Phase 2,oxytocin receptor antagonist,AVPR1A|OXTR,,
O=C(Nc1cccnc1)N1CCC(Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,"InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32)",NBOJHRYUGLRASX-UHFFFAOYSA-N,pf-3845,Preclinical,FAAH inhibitor,FAAH,,
Cn1nccc1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1,"InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)",DVNQWYLVSNPCJZ-UHFFFAOYSA-N,pf-4191834,Preclinical,lipoxygenase inhibitor,,,
CCN(CC)Cc1ccc(C(=O)N(CCc2ccccc2OC)C2CCNC2)cc1,"InChI=1S/C25H35N3O2/c1-4-27(5-2)19-20-10-12-22(13-11-20)25(29)28(23-14-16-26-18-23)17-15-21-8-6-7-9-24(21)30-3/h6-13,23,26H,4-5,14-19H2,1-3H3",XKPJTOHUPQWSOJ-UHFFFAOYSA-N,pf-429242,Preclinical,SREBP inhibitor,MBTPS1,,
CN(c1ccccc1CN=c1[nH]c(=Nc2ccc3[nH]c(O)cc3c2)[nH]cc1C(F)(F)F)S(C)(=O)=O,"InChI=1S/C22H21F3N6O3S/c1-31(35(2,33)34)18-6-4-3-5-13(18)11-26-20-16(22(23,24)25)12-27-21(30-20)28-15-7-8-17-14(9-15)10-19(32)29-17/h3-10,12,29,32H,11H2,1-2H3,(H2,26,27,28,30)",GQXSULRYFDAMOO-UHFFFAOYSA-N,pf-431396,Preclinical,focal adhesion kinase inhibitor,PTK2|PTK2B,,
CCc1cncnc1N1CCN(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)CC1,"InChI=1S/C19H21F3N6/c1-2-13-10-23-12-24-18(13)28-7-5-27(6-8-28)11-17-25-15-4-3-14(19(20,21)22)9-16(15)26-17/h3-4,9-10,12H,2,5-8,11H2,1H3,(H,25,26)",FBLPQCAQRNSVHB-UHFFFAOYSA-N,pf-4708671,Preclinical,ribosomal protein inhibitor,RPS6KB1,,
Cn1cc(-c2nc3cc(=NC(O)C(N)C4CCCCC4)cc4c(=O)[nH]ncc2c34)cn1,"InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,22,31H,2-6,23H2,1H3,(H,28,30)",BPUJSTYCIQYLIZ-UHFFFAOYSA-N,pf-477736,Phase 1,CHK inhibitor,CHEK1|CHEK2,,
N=c1[nH]cnc2c1c(COc1cccc(Cl)c1)nn2C1CCOCC1,"InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)",AUMDBEHGJRZSOO-UHFFFAOYSA-N,pf-4800567,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,
Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CCC(N6CCCCC6)C5)c34)cnn2C)cc1,"InChI=1S/C26H32N8/c1-18-7-9-19(10-8-18)24-21(15-29-31(24)2)23-22-25(32(3)30-23)27-17-28-26(22)34-14-11-20(16-34)33-12-5-4-6-13-33/h7-10,15,17,20H,4-6,11-14,16H2,1-3H3",WDWIMDKOXZZYHH-UHFFFAOYSA-N,pf-4981517,Preclinical,cytochrome P450 inhibitor,CYP3A4,,
CC(F)(F)CN1CCOc2c(nn(-c3ccccc3Cl)c2-c2ccc(Cl)cc2)C1=O,"InChI=1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3",FJMQJSUOOGOWBD-UHFFFAOYSA-N,pf-514273,Preclinical,cannabinoid receptor antagonist,,,
Cc1cnc(-c2cc(N3CCN(C(=O)CCS(C)(=O)=O)CC3)ncc2Cl)c(C)c1,"InChI=1S/C20H25ClN4O3S/c1-14-10-15(2)20(23-12-14)16-11-18(22-13-17(16)21)24-5-7-25(8-6-24)19(26)4-9-29(3,27)28/h10-13H,4-9H2,1-3H3",BBVNTTZIOTWDSV-UHFFFAOYSA-N,pf-5274857,Preclinical,smoothened receptor antagonist,SMO,,
CN(c1ncccc1CN=c1[nH]c(=Nc2ccc3[nH]c(O)cc3c2)[nH]cc1C(F)(F)F)S(C)(=O)=O,"InChI=1S/C21H20F3N7O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16/h3-9,11,29,32H,10H2,1-2H3,(H2,26,27,28,30)",SACKFBGRWYSCQK-UHFFFAOYSA-N,pf-562271,Phase 1,focal adhesion kinase inhibitor,PTK2|PTK2B,,
CS(=O)(=O)c1cccc(CN=c2[nH]c(=Nc3ccc4c(c3)CCC(=O)N4)[nH]cc2C(F)(F)F)c1,"InChI=1S/C22H20F3N5O3S/c1-34(32,33)16-4-2-3-13(9-16)11-26-20-17(22(23,24)25)12-27-21(30-20)28-15-6-7-18-14(10-15)5-8-19(31)29-18/h2-4,6-7,9-10,12H,5,8,11H2,1H3,(H,29,31)(H2,26,27,28,30)",HESLKTSGTIBHJU-UHFFFAOYSA-N,pf-573228,Preclinical,focal adhesion kinase inhibitor,CDK1|CDK2|CDK7|GSK3B|IKBKB,,
N=c1nc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)cc[nH]1,"InChI=1S/C19H20FN5/c20-14-8-6-13(7-9-14)17-18(16-10-11-22-19(21)24-16)25(12-23-17)15-4-2-1-3-5-15/h6-12,15H,1-5H2,(H2,21,22,24)",WUDBUIUHVNECTM-UHFFFAOYSA-N,pf-670462,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,
O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1,"InChI=1S/C22H23N3O/c26-22(24-20-7-2-1-3-8-20)25-12-10-17(11-13-25)14-18-15-19-6-4-5-9-21(19)23-16-18/h1-9,15-17H,10-14H2,(H,24,26)",BIODYGOZWZNCAG-UHFFFAOYSA-N,pf-750,Preclinical,FAAH inhibitor,FAAH,,
O=C(CCN1CCN(C(=O)OCc2cc(Cl)cc(Cl)c2)CC1)c1ccc2[nH]c(=O)oc2c1,"InChI=1S/C22H21Cl2N3O5/c23-16-9-14(10-17(24)12-16)13-31-22(30)27-7-5-26(6-8-27)4-3-19(28)15-1-2-18-20(11-15)32-21(29)25-18/h1-2,9-12H,3-8,13H2,(H,25,29)",JMSUDQYHPSNBSN-UHFFFAOYSA-N,pf-8380,Preclinical,autotaxin inhibitor,ENPP2,,
N#Cc1ccc(-c2ccc(S(=O)(=O)N=c3cccc(N)[nH]3)cc2)cc1,"InChI=1S/C18H14N4O2S/c19-12-13-4-6-14(7-5-13)15-8-10-16(11-9-15)25(23,24)22-18-3-1-2-17(20)21-18/h1-11H,(H3,20,21,22)",ZESFDAKNYJQYKO-UHFFFAOYSA-N,pf-915275,Phase 1,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,,
COc1ccccc1S(=O)(=O)Nc1ccc2c(c1)CN(C)C(=O)N2,"InChI=1S/C16H17N3O4S/c1-19-10-11-9-12(7-8-13(11)17-16(19)20)18-24(21,22)15-6-4-3-5-14(15)23-2/h3-9,18H,10H2,1-2H3,(H,17,20)",TXZPMHLMPKIUGK-UHFFFAOYSA-N,pfi-1,Preclinical,bromodomain inhibitor,BRD4,,
O=C(C=CN1CC2CC1CN2c1ccccn1)c1ccccc1O,"InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2",INAICWLVUAKEPB-UHFFFAOYSA-N,pfi-3,Preclinical,bromodomain inhibitor,PBRM1|SMARCA4,,
COc1ccccc1C(=O)Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,"InChI=1S/C21H24N4O3/c1-23-17-12-15(22-20(26)14-8-4-5-9-19(14)28-3)16(25-10-6-7-11-25)13-18(17)24(2)21(23)27/h4-5,8-9,12-13H,6-7,10-11H2,1-3H3,(H,22,26)",QCIJLRJBZDBVDB-UHFFFAOYSA-N,pfi-4,Preclinical,bromodomain inhibitor,BRPF1,,
O=C(C=Cc1ccc2ccccc2n1)c1ccncc1,InChI=1S/C17H12N2O/c20-17(14-9-11-18-12-10-14)8-7-15-6-5-13-3-1-2-4-16(13)19-15/h1-12H,UJJUKZPBUMCSJZ-UHFFFAOYSA-N,pfk-015,Phase 1,phosphofructokinase inhibitor,PFKFB3,,
O=C(C=Cc1ccc2ccc(C(F)(F)F)cc2n1)c1ccncc1,"InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H",IAJOMYABKVAZCN-UHFFFAOYSA-N,pfk-158,Phase 1,phosphofructokinase inhibitor,PFKFB3,,
CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,"InChI=1S/C17H22BrNO2/c1-11(12-3-5-13(18)6-4-12)17(20)21-16-9-14-7-8-15(10-16)19(14)2/h3-6,11,14-16H,7-10H2,1-2H3",GHDWIFTUSXQYGK-UHFFFAOYSA-N,pg-9,Preclinical,acetylcholine receptor agonist,,,
N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1,"InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2",XCPPIJCBCWUBNT-UHFFFAOYSA-N,pgl5001,Phase 2,JNK inhibitor,MAPK10|MAPK8|MAPK9,,
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,"InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28)",KCAJXIDMCNPGHZ-UHFFFAOYSA-N,ph-797804,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK14,,
O=C(NC1CN2CCC1CC2)c1cc2ccoc2cn1,"InChI=1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19)",IPKZCLGGYKRDES-UHFFFAOYSA-N,pha-543613,Preclinical,nicotinic receptor agonist,,,
O=C(NC1CN2CCC1CC2)c1ccc2c(c1)OCCO2,"InChI=1S/C16H20N2O3/c19-16(17-13-10-18-5-3-11(13)4-6-18)12-1-2-14-15(9-12)21-8-7-20-14/h1-2,9,11,13H,3-8,10H2,(H,17,19)",LUVXHMJTVXZFPD-UHFFFAOYSA-N,pha-568487,Preclinical,nicotinic receptor agonist,CHRNA7,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc23)c(C)c1C(=O)N1CCCC1CN1CCCC1,"InChI=1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35-36,39H,2-4,6-7,12-14,17-18H2,1H3",WRRYQNBXGWABMV-UHFFFAOYSA-N,pha-665752,Preclinical,c-Met inhibitor,MET,,
CCc1cccc(CC)c1NC(=O)n1cc2[nH][nH]c(=NC(O)c3ccc(N4CCN(C)CC4)cc3)c2c1,"InChI=1S/C28H35N7O2/c1-4-19-7-6-8-20(5-2)25(19)29-28(37)35-17-23-24(18-35)31-32-26(23)30-27(36)21-9-11-22(12-10-21)34-15-13-33(3)14-16-34/h6-12,17-18,27,31,36H,4-5,13-16H2,1-3H3,(H,29,37)(H,30,32)",JRBAYKVRMGVZCX-UHFFFAOYSA-N,pha-680632,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
O=c1[nH]ccc2[nH]c(C3=CC=NCC3)cc12,"InChI=1S/C12H11N3O/c16-12-9-7-11(8-1-4-13-5-2-8)15-10(9)3-6-14-12/h1,3-4,6-7,15H,2,5H2,(H,14,16)",BBPQGPSOLIIXNW-UHFFFAOYSA-N,pha-767491,Preclinical,CDC inhibitor,CDK1|RPS6KB1,,
CC(C)CC(=O)N=c1[nH][nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,"InChI=1S/C19H31N5O2/c1-12(2)10-15(25)20-17-14-11-24(19(3,4)16(14)21-22-17)18(26)13-6-8-23(5)9-7-13/h12-13H,6-11H2,1-5H3,(H2,20,21,22,25)",HUXYBQXJVXOMKX-UHFFFAOYSA-N,pha-793887,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK7|CDK9,,
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,"InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)",RXZMYLDMFYNEIM-UHFFFAOYSA-N,pha-848125,Phase 2,CDK inhibitor,CDK2|CDK4|CDK7|NTRK1,,
CNC(=O)c1nn(C)c2c1C(C)(C)Cc1c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,"InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)",RXZMYLDMFYNEIM-UHFFFAOYSA-N,pha-848125,Phase 2,growth factor receptor inhibitor,CDK2|CDK4|CDK7|NTRK1,,
O=C(Nc1ccccc1)C12CC1C(=NO)c1ccccc1O2,"InChI=1S/C17H14N2O3/c20-16(18-11-6-2-1-3-7-11)17-10-13(17)15(19-21)12-8-4-5-9-14(12)22-17/h1-9,13,21H,10H2,(H,18,20)",FPXPIEZPAXSELW-UHFFFAOYSA-N,phccc,Preclinical,glutamate receptor agonist,GRM1|GRM4,,
CCOc1ccc(N=C(C)Nc2ccc(OCC)cc2)cc1,"InChI=1S/C18H22N2O2/c1-4-21-17-10-6-15(7-11-17)19-14(3)20-16-8-12-18(13-9-16)22-5-2/h6-13H,4-5H2,1-3H3,(H,19,20)",QXDAEKSDNVPFJG-UHFFFAOYSA-N,phenacaine,Launched,local anesthetic,,neurology/psychiatry,local anesthetic
NC(=O)NC(=O)Cc1ccccc1,"InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)",XPFRXWCVYUEORT-UHFFFAOYSA-N,phenacemide,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures
CCOc1ccc(NC(C)=O)cc1,"InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)",CPJSUEIXXCENMM-UHFFFAOYSA-N,phenacetin,Withdrawn,cyclooxygenase inhibitor,PTGS1,,
Cc1cc(=O)n(-c2ccccc2)n1C,"InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3",VEQOALNAAJBPNY-UHFFFAOYSA-N,phenazone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
N=c1[nH]c(N)ccc1N=Nc1ccccc1,"InChI=1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)",QPFYXYFORQJZEC-UHFFFAOYSA-N,phenazopyridine,Launched,local anesthetic,SCN1A,infectious disease,urinary tract infections
NNCCc1ccccc1,"InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2",RMUCZJUITONUFY-UHFFFAOYSA-N,phenelzine,Launched,monoamine oxidase inhibitor,ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
CC(Oc1ccccc1)C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,"InChI=1S/C17H20N2O5S/c1-9(24-10-7-5-4-6-8-10)13(20)18-11-14(21)19-12(16(22)23)17(2,3)25-15(11)19/h4-9,11-12,15H,1-3H3,(H,18,20)(H,22,23)",NONJJLVGHLVQQM-UHFFFAOYSA-N,phenethicillin,Launched,bacterial cell wall synthesis inhibitor,,,
S=C=NCCc1ccccc1,"InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2",IZJDOKYDEWTZSO-UHFFFAOYSA-N,phenethyl-isothiocyanate,Phase 2,anticancer agent,CYP2E1,,
N=C(N)N=C(N)NCCc1ccccc1,"InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)",ICFJFFQQTFMIBG-UHFFFAOYSA-N,phenformin,Withdrawn,AMPK activator,KCNJ8|PRKAA1,,
CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12,"InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3",ISFHAYSTHMVOJR-UHFFFAOYSA-N,phenindamine,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold
O=C1c2ccccc2C(=O)C1c1ccccc1,"InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H",NFBAXHOPROOJAW-UHFFFAOYSA-N,phenindione,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT)
CN(C)CCC(c1ccccc1)c1ccccn1,"InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3",IJHNSHDBIRRJRN-UHFFFAOYSA-N,pheniramine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria
Oc1ccccc1,"InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H",ISWSIDIOOBJBQZ-UHFFFAOYSA-N,phenol,Preclinical,,CA1|CA12|CA14|CA2|CA4|CA9,otolaryngology,pharyngitis
O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,"InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H",KJFMBFZCATUALV-UHFFFAOYSA-N,phenolphthalein,Withdrawn,indicator dye,UGT1A9,,
O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,"InChI=1S/C19H14O5S/c20-15-9-5-13(6-10-15)19(14-7-11-16(21)12-8-14)17-3-1-2-4-18(17)25(22,23)24-19/h1-12,20-21H",BELBBZDIHDAJOR-UHFFFAOYSA-N,phenolsulfonphthalein,Launched,,,,
c1ccc2c(c1)Nc1ccccc1S2,"InChI=1S/C12H9NS/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-8,13H",WJFKNYWRSNBZNX-UHFFFAOYSA-N,phenothiazine,Preclinical,dopamine receptor antagonist,,,
CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C,"InChI=1S/C23H26O3/c1-16(2)13-20-21(23(20,3)4)22(24)25-15-17-9-8-12-19(14-17)26-18-10-6-5-7-11-18/h5-14,20-21H,15H2,1-4H3",SBNFWQZLDJGRLK-UHFFFAOYSA-N,phenothrin,Launched,,,infectious disease,lice
CC(COc1ccccc1)N(CCCl)Cc1ccccc1,"InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3",QZVCTJOXCFMACW-UHFFFAOYSA-N,phenoxybenzamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|endocrinology,hypertension|pheochromocytoma
NC(=O)OCCCc1ccccc1,"InChI=1S/C10H13NO2/c11-10(12)13-8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H2,11,12)",CAMYKONBWHRPDD-UHFFFAOYSA-N,phenprobamate,Launched,muscle relaxant,,neurology/psychiatry,anxiety|muscle relaxant
CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,"InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3",DQDAYGNAKTZFIW-UHFFFAOYSA-N,phenprocoumon,Launched,vitamin K antagonist,VKORC1,hematology,thrombosis|pulmonary embolism (PE)
CN1CCC2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)C12,"InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)",PBHFNBQPZCRWQP-UHFFFAOYSA-N,phenserine,Phase 3,acetylcholinesterase inhibitor,ACHE|BCHE,,
CN1CCC2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)C12,"InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)",PBHFNBQPZCRWQP-UHFFFAOYSA-N,phenserine,Phase 3,beta amyloid synthesis inhibitor,ACHE|BCHE,,
Cn1c(O)cc(-c2ccccc2)c1O,"InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-7,13-14H,1H3",HKISVIYTVBXSEX-UHFFFAOYSA-N,phensuximide,Launched,succinimide antiepileptic,,neurology/psychiatry,seizures
Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,"InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)",MRBDMNSDAVCSSF-UHFFFAOYSA-N,phentolamine,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,endocrinology|cardiology,pheochromocytoma|hypertension
Nc1ccc(C(=O)Oc2ccccc2)c(O)c1,"InChI=1S/C13H11NO3/c14-9-6-7-11(12(15)8-9)13(16)17-10-4-2-1-3-5-10/h1-8,15H,14H2",DNVVZWSVACQWJE-UHFFFAOYSA-N,phenyl-aminosalicylate,Launched,,,infectious disease,tuberculosis
O=C(Oc1ccccc1)c1ccccc1O,"InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H",ZQBAKBUEJOMQEX-UHFFFAOYSA-N,phenyl-salicylate,Launched,antiseptic,,urology,interstitial cystitis (IC)
NC(=O)CCC(NC(=O)Cc1ccccc1)C(=O)O,"InChI=1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)",JFLIEFSWGNOPJJ-UHFFFAOYSA-N,phenylacetylglutamine,Phase 2,DNA methylase inhibitor,,,
NC(=O)CCC(NC(=O)Cc1ccccc1)C(=O)O,"InChI=1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)",JFLIEFSWGNOPJJ-UHFFFAOYSA-N,phenylacetylglutamine,Phase 2,protein synthesis inhibitor,,,
O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1,"InChI=1S/C13H10N2O3S/c16-19(17,18)10-6-7-11-12(8-10)15-13(14-11)9-4-2-1-3-5-9/h1-8H,(H,14,15)(H,16,17,18)",UVCJGUGAGLDPAA-UHFFFAOYSA-N,phenylbenzimidazole-sulfonic-acid,Launched,,,dermatology,sunscreen lotion
CCCCc1c(O)n(-c2ccccc2)n(-c2ccccc2)c1=O,"InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,22H,2-3,14H2,1H3",PKYKNPLSFOKASK-UHFFFAOYSA-N,phenylbutazone,Withdrawn,cyclooxygenase inhibitor,PTGIS|PTGS1|PTGS2,,
CCCCc1c(O)n(-c2ccccc2)n(-c2ccccc2)c1=O,"InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,22H,2-3,14H2,1H3",PKYKNPLSFOKASK-UHFFFAOYSA-N,phenylbutazone,Withdrawn,prostanoid receptor antagonist,PTGIS|PTGS1|PTGS2,,
O=C(O)CCCc1ccccc1,"InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)",OBKXEAXTFZPCHS-UHFFFAOYSA-N,phenylbutyrate,Launched,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders
CNCC(O)c1cccc(O)c1,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3",SONNWYBIRXJNDC-UHFFFAOYSA-N,phenylephrine,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,otolaryngology|gastroenterology|cardiology,nasal congestion|hemorrhoids|hypotension
OCCc1ccccc1,"InChI=1S/C8H10O/c9-7-6-8-4-2-1-3-5-8/h1-5,9H,6-7H2",WRMNZCZEMHIOCP-UHFFFAOYSA-N,phenylethyl-alcohol,Preclinical,,,,
[Hg+]c1ccccc1,InChI=1S/C6H5.Hg/c1-2-4-6-5-3-1;/h1-5H;/q;+1,BODKAQWWZBLGOU-UHFFFAOYSA-N,phenylmercuric-acetate,Preclinical,other antifungal,,,
O=S(=O)(F)Cc1ccccc1,"InChI=1S/C7H7FO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2",YBYRMVIVWMBXKQ-UHFFFAOYSA-N,phenylmethylsulfonyl-fluoride,Preclinical,serine protease inhibitor,,,
NC(=O)CN1CC(c2ccccc2)CC1=O,"InChI=1S/C12H14N2O2/c13-11(15)8-14-7-10(6-12(14)16)9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,13,15)",LYONXVJRBWWGQO-UHFFFAOYSA-N,phenylpiracetam,Launched,noradrenaline uptake inhibitor,,neurology/psychiatry,anxiety|fatigue|depression
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,"InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)",CXOFVDLJLONNDW-UHFFFAOYSA-N,phenytoin,Launched,hydantoin antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CCn1c2ccccc2c2cc(CNC)ccc21,"InChI=1S/C16H18N2/c1-3-18-15-7-5-4-6-13(15)14-10-12(11-17-2)8-9-16(14)18/h4-10,17H,3,11H2,1-2H3",LBPNOEAFWYTTEB-UHFFFAOYSA-N,phikan-083,Preclinical,p53 stabilizing agent,TP53,,
O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O,"InChI=1S/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H2",VGEREEWJJVICBM-UHFFFAOYSA-N,phloretin,Launched,sodium/glucose cotransporter inhibitor,AQP9|CLCN3|SLC23A1,,
O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1OC1OC(CO)C(O)C(O)C1O,"InChI=1S/C21H24O10/c22-9-16-18(27)19(28)20(29)21(31-16)30-15-8-12(24)7-14(26)17(15)13(25)6-3-10-1-4-11(23)5-2-10/h1-2,4-5,7-8,16,18-24,26-29H,3,6,9H2",IOUVKUPGCMBWBT-UHFFFAOYSA-N,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A11|SLC5A2|SLC5A3,,
Oc1cc(O)cc(O)c1,"InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H",QCDYQQDYXPDABM-UHFFFAOYSA-N,phloroglucin,Launched,,,neurology/psychiatry,spasms
Cc1cc(-c2nc3cc(F)ccc3s2)ccc1NC(=O)C(N)CCCCN,"InChI=1S/C20H23FN4OS/c1-12-10-13(20-25-17-11-14(21)6-8-18(17)27-20)5-7-16(12)24-19(26)15(23)4-2-3-9-22/h5-8,10-11,15H,2-4,9,22-23H2,1H3,(H,24,26)",LFDOEFHQLNGBQQ-UHFFFAOYSA-N,phortress,Phase 1,aryl hydrocarbon receptor ligand,AHR,,
CCCCCC=CCC=CCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCC)CO[PH](=O)(=O)OCC[N+](C)(C)C,"InChI=1S/C42H80NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h14,16,20-21,40H,6-13,15,17-19,22-39H2,1-5H3/q+1",RCAMZTBQMGPDPM-UHFFFAOYSA-N,phosphatidylcholine,Launched,,,infectious disease|dermatology|gastroenterology|cardiology|obstetrics/gynecology,hepatitis B|hepatitis C|eczema|gallbladder disease|cholesterol|premenstrual syndrome
On1ncc(C2CCNCC2)c1-c1cccc(-c2ccccc2)c1,"InChI=1S/C20H21N3O/c24-23-20(19(14-22-23)16-9-11-21-12-10-16)18-8-4-7-17(13-18)15-5-2-1-3-6-15/h1-8,13-14,16,21,24H,9-12H2",UHEYIOPHTBWBQN-UHFFFAOYSA-N,php-501,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,
CCCCCCCCCCCCc1ccc(S(=O)(=O)N=c2[nH]ncs2)cc1,"InChI=1S/C20H31N3O2S2/c1-2-3-4-5-6-7-8-9-10-11-12-18-13-15-19(16-14-18)27(24,25)23-20-22-21-17-26-20/h13-17H,2-12H2,1H3,(H,22,23)",BYWWNRBKPCPJMG-UHFFFAOYSA-N,pht-427,Preclinical,AKT inhibitor,AKT2|PDPK1,,
CCCCCCCCCCCCc1ccc(S(=O)(=O)N=c2[nH]ncs2)cc1,"InChI=1S/C20H31N3O2S2/c1-2-3-4-5-6-7-8-9-10-11-12-18-13-15-19(16-14-18)27(24,25)23-20-22-21-17-26-20/h13-17H,2-12H2,1H3,(H,22,23)",BYWWNRBKPCPJMG-UHFFFAOYSA-N,pht-427,Preclinical,pyruvate dehydrogenase inhibitor,AKT2|PDPK1,,
CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(=O)O)cc1,"InChI=1S/C16H14N2O6S/c1-10(19)18-25(23,24)12-8-6-11(7-9-12)17-15(20)13-4-2-3-5-14(13)16(21)22/h2-9H,1H3,(H,17,20)(H,18,19)(H,21,22)",SNWQKAWITMVCQW-UHFFFAOYSA-N,phthalylsulfacetamide,Preclinical,,,,
O=C(O)c1ccccc1C(=O)Nc1ccc(S(=O)(=O)N=c2[nH]ccs2)cc1,"InChI=1S/C17H13N3O5S2/c21-15(13-3-1-2-4-14(13)16(22)23)19-11-5-7-12(8-6-11)27(24,25)20-17-18-9-10-26-17/h1-10H,(H,18,20)(H,19,21)(H,22,23)",PBMSWVPMRUJMPE-UHFFFAOYSA-N,phthalylsulfathiazole,Launched,dihydropteroate synthetase inhibitor,,infectious disease|gastroenterology,dysentry|colitis
Oc1ccc(-c2c(-c3ccccc3)nn3c(C(F)(F)F)cc(C(F)(F)F)nc23)cc1,"InChI=1S/C20H11F6N3O/c21-19(22,23)14-10-15(20(24,25)26)29-18(27-14)16(11-6-8-13(30)9-7-11)17(28-29)12-4-2-1-3-5-12/h1-10,30H",AEZPAUSGTAHLOQ-UHFFFAOYSA-N,phtpp,Preclinical,estrogen receptor antagonist,ESR2,,
CNC(=O)Oc1ccc2c(c1)C1(C)CCN(C)C1N2C,"InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)",PIJVFDBKTWXHHD-UHFFFAOYSA-N,physostigmine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,cardiology|neurology/psychiatry|ophthalmology|gastroenterology,hypotension|Alzheimer's disease|glaucoma|gastroparesis
CNC(=O)Oc1ccc2c(c1)C1(C)CCN(C)C1N2C,"InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)",PIJVFDBKTWXHHD-UHFFFAOYSA-N,physostigmine,Launched,cholinesterase inhibitor,ACHE|BCHE,cardiology|neurology/psychiatry|ophthalmology|gastroenterology,hypotension|Alzheimer's disease|glaucoma|gastroparesis
CC(C=Cc1c(C)c(O)c2ccccc2c1O)=CCCC(C)CCCC(C)CCCC(C)C,"InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,17-24,32-33H,9-16H2,1-6H3",LLVIVPAPYJXADK-UHFFFAOYSA-N,phytonadione,Launched,,BGLAP|GGCX,hematology,vitamin K deficiency|anticoagulation reversal
CCCCCCCCCCCCCCC(O)C(O)C(N)CO,"InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3",AERBNCYCJBRYDG-UHFFFAOYSA-N,phytosphingosine,Phase 1,,,,
Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2",TUVCWJQQGGETHL-UHFFFAOYSA-N,pi-103,Preclinical,mTOR inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1,"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2",TUVCWJQQGGETHL-UHFFFAOYSA-N,pi-103,Preclinical,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)cc1,"InChI=1S/C19H18N2O3/c20-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)21-8-10-23-11-9-21/h1-7,12H,8-11,20H2",WUKMIBOGGXMBAC-UHFFFAOYSA-N,pi-828,Preclinical,PI3K inhibitor,,,
N=c1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c[nH]1,"InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)",ADGGYDAFIHSYFI-UHFFFAOYSA-N,pi3k-in-2,Phase 2,PI3K inhibitor,,,
COc1ncc(-c2nc(N3CCOCC3)nc3c(CN4CCC(C(C)(C)O)CC4)cc(F)cc23)cc1NS(C)(=O)=O,"InChI=1S/C28H37FN6O5S/c1-28(2,36)20-5-7-34(8-6-20)17-19-13-21(29)15-22-24(31-27(32-25(19)22)35-9-11-40-12-10-35)18-14-23(33-41(4,37)38)26(39-3)30-16-18/h13-16,20,33,36H,5-12,17H2,1-4H3",NVWKNQGHVMMAJW-UHFFFAOYSA-N,pi3kd-in-2,Preclinical,PI3K inhibitor,,,
COc1ccc(-c2sc(=NC(=O)C(C)(C)C)[nH]c2C)cc1S(=O)(=O)Nc1ccc(O)cc1,"InChI=1S/C22H25N3O5S2/c1-13-19(31-21(23-13)24-20(27)22(2,3)4)14-6-11-17(30-5)18(12-14)32(28,29)25-15-7-9-16(26)10-8-15/h6-12,25-26H,1-5H3,(H,23,24,27)",PLUYFBRIGUAKBR-UHFFFAOYSA-N,pi4kiii-beta-inhibitor-1,Preclinical,PI4K inhibitor,PI4K2B,,
CN1CCN(c2ccc3[nH]c(-c4ccc5[nH]c(-c6ccc(O)cc6)nc5c4)nc3c2)CC1,"InChI=1S/C25H24N6O/c1-30-10-12-31(13-11-30)18-5-9-21-23(15-18)29-25(27-21)17-4-8-20-22(14-17)28-24(26-20)16-2-6-19(32)7-3-16/h2-9,14-15,32H,10-13H2,1H3,(H,26,28)(H,27,29)",INAAIJLSXJJHOZ-UHFFFAOYSA-N,pibenzimol,Phase 2,DNA inhibitor,,,
CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1,"InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)",KVCSJPATKXABRQ-UHFFFAOYSA-N,piboserod,Phase 2,serotonin receptor antagonist,HTR2B|HTR4,,
CNC(=S)C1(c2ccccn2)CCCS1,"InChI=1S/C11H14N2S2/c1-12-10(14)11(6-4-8-15-11)9-5-2-3-7-13-9/h2-3,5,7H,4,6,8H2,1H3,(H,12,14)",ITNLONMDUMHEOK-UHFFFAOYSA-N,picartamide,Phase 2,H+/K+-ATPase inhibitor,ATP4A,,
Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1,"InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H",CDRPUGZCRXZLFL-UHFFFAOYSA-N,piceatannol,Preclinical,SYK inhibitor,ATP5A1|ATP5B|ATP5C1|IRF3,,
COc1ccc(C(=O)N=c2c(Cl)c[nH]cc2Cl)cc1OC1CCCC1,"InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)",RRRUXBQSQLKHEL-UHFFFAOYSA-N,piclamilast,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,
NCc1cccnc1,"InChI=1S/C6H8N2/c7-4-6-2-1-3-8-5-6/h1-3,5H,4,7H2",HDOUGSFASVGDCS-UHFFFAOYSA-N,picolamine,Preclinical,,,,
O=C(O)c1ccccn1,"InChI=1S/C6H5NO2/c8-6(9)5-3-1-2-4-7-5/h1-4H,(H,8,9)",SIOXPEMLGUPBBT-UHFFFAOYSA-N,picolinic-acid,Phase 2,chelating agent,,,
OCc1ccccn1,"InChI=1S/C6H7NO/c8-5-6-3-1-2-4-7-6/h1-4,8H,5H2",SHNUBALDGXWUJI-UHFFFAOYSA-N,piconol,Preclinical,,,,
COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1,"InChI=1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27)",KYWCWBXGRWWINE-UHFFFAOYSA-N,picotamide,Launched,thromboxane receptor antagonist,TBXA2R,hematology,thrombosis
COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1,"InChI=1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27)",KYWCWBXGRWWINE-UHFFFAOYSA-N,picotamide,Launched,thromboxane synthase inhibitor,TBXA2R,hematology,thrombosis
CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC34C(=O)OC2C14C,"InChI=1S/C15H18O7/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9/h5-9,18-19H,4H2,1-3H3",RYEFFICCPKWYML-UHFFFAOYSA-N,picrotin,Phase 2,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB,,
C=C(C)C1C2OC(=O)C1C1(O)CC3OC34C(=O)OC2C14C,"InChI=1S/C15H16O6/c1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h6-10,18H,1,4H2,2-3H3",PIMZUZSSNYHVCU-UHFFFAOYSA-N,picrotoxinin,Preclinical,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,
Oc1ccc(C(O)O)[nH]1,"InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h1-2,5-9H",GUUGZPSUOTWOMD-UHFFFAOYSA-N,pidolic-acid,Launched,,ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA,dermatology,xerosis cutis
O=C(O)C1CSCN1C(O)c1ccc(O)[nH]1,"InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h1-2,6,8,10,12-13H,3-4H2,(H,14,15)",LGLDHRVRBOXAPS-UHFFFAOYSA-N,pidotimod,Launched,interferon receptor agonist,,infectious disease,immune adjuvant
O=C(O)C1CSCN1C(O)c1ccc(O)[nH]1,"InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h1-2,6,8,10,12-13H,3-4H2,(H,14,15)",LGLDHRVRBOXAPS-UHFFFAOYSA-N,pidotimod,Launched,interleukin receptor agonist,,infectious disease,immune adjuvant
Cc1ccc(C(=O)Cn2c3c(sc2=N)CCCC3)cc1,"InChI=1S/C16H18N2OS/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17/h6-9,17H,2-5,10H2,1H3",OLTZHXYLLRJLST-UHFFFAOYSA-N,pifithrin-alpha,Preclinical,TP53 inhibitor,TP53,,
Cc1ccc(-c2cn3c4c(sc3n2)CCCC4)cc1,"InChI=1S/C16H16N2S/c1-11-6-8-12(9-7-11)13-10-18-14-4-2-3-5-15(14)19-16(18)17-13/h6-10H,2-5H2,1H3",IMUKUMUNZJILCG-UHFFFAOYSA-N,pifithrin-cyclic,Preclinical,TP53 inhibitor,TP53,,
NS(=O)(=O)C#Cc1ccccc1,"InChI=1S/C8H7NO2S/c9-12(10,11)7-6-8-4-2-1-3-5-8/h1-5H,(H2,9,10,11)",ZZUZYEMRHCMVTB-UHFFFAOYSA-N,pifithrin-mu,Preclinical,HSP inhibitor,HSPA1A|TP53,,
Cc1ccccc1-n1c(Cn2ncc3c(=N)[nH]cnc32)nc2cccc(C)c2c1=O,"InChI=1S/C22H19N7O/c1-13-6-3-4-9-17(13)29-18(27-16-8-5-7-14(2)19(16)22(29)30)11-28-21-15(10-26-28)20(23)24-12-25-21/h3-10,12H,11H2,1-2H3,(H2,23,24,25)",KQDBVHKNIYROHU-UHFFFAOYSA-N,pik-293,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(=N)[nH]cnc32)nc2cccc(C)c2c1=O,"InChI=1S/C28H23N7O2/c1-16-7-3-4-12-21(16)35-22(32-20-11-5-8-17(2)23(20)28(35)37)14-34-27-24(26(29)30-15-31-27)25(33-34)18-9-6-10-19(36)13-18/h3-13,15,36H,14H2,1-2H3,(H2,29,30,31)",WFSLJOPRIJSOJR-UHFFFAOYSA-N,pik-294,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)N=Cc1cnc2ccc(Br)cn12,"InChI=1S/C16H14BrN5O4S/c1-11-3-5-13(22(23)24)7-15(11)27(25,26)20(2)19-9-14-8-18-16-6-4-12(17)10-21(14)16/h3-10H,1-2H3",QTHCAAFKVUWAFI-UHFFFAOYSA-N,pik-75,Preclinical,DNA protein kinase inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)N=Cc1cnc2ccc(Br)cn12,"InChI=1S/C16H14BrN5O4S/c1-11-3-5-13(22(23)24)7-15(11)27(25,26)20(2)19-9-14-8-18-16-6-4-12(17)10-21(14)16/h3-10H,1-2H3",QTHCAAFKVUWAFI-UHFFFAOYSA-N,pik-75,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,
CC(=O)N=c1[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1,"InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)",JFVNFXCESCXMBC-UHFFFAOYSA-N,pik-93,Preclinical,PI3K inhibitor,PI4KB|PIK3C3|PIK3CG,,
O=C(O)CCCNC(=O)c1cccnc1,"InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)",NAJVRARAUNYNDX-UHFFFAOYSA-N,pikamilone,Phase 1,,,,
Cc1cc[nH]c(=NC(=O)C(C)c2cccc(C(=O)c3ccccc3)c2)c1,"InChI=1S/C22H20N2O2/c1-15-11-12-23-20(13-15)24-22(26)16(2)18-9-6-10-19(14-18)21(25)17-7-4-3-5-8-17/h3-14,16H,1-2H3,(H,23,24,26)",ASFKKFRSMGBFRO-UHFFFAOYSA-N,piketoprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
COc1ccc(Cl)c(N=c2[nH]c3ccccc3[nH]c2=NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,pilaralisib,Phase 2,PI3K inhibitor,,,
CCC1C(=O)OCC1Cc1cncn1C,"InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3",QCHFTSOMWOSFHM-UHFFFAOYSA-N,pilocarpine,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology|cardiology,glaucoma|hypertension
Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,"InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)",BCQTVJKBTWGHCX-UHFFFAOYSA-N,pilsicainide,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia
N=c1nc(-c2ccc3noc(-c4ccc(Cl)cc4)c3c2)cc[nH]1,"InChI=1S/C17H11ClN4O/c18-12-4-1-10(2-5-12)16-13-9-11(3-6-15(13)22-23-16)14-7-8-20-17(19)21-14/h1-9H,(H2,19,20,21)",AQVFETGXIRKVAQ-UHFFFAOYSA-N,pim-1-inhibitor-2,Preclinical,Pim kinase inhibitor,PIM1,,
CC1CC(N)CC(c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,"InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)",VRQXRVAKPDCRCI-UHFFFAOYSA-N,pim-447,Phase 1,Pim kinase inhibitor,,,
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,"InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)",RKEWSXXUOLRFBX-UHFFFAOYSA-N,pimavanserin,Launched,serotonin receptor inverse agonist,DRD2|HTR2A,neurology/psychiatry,Parkinson's Disease
CCC1=CC(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(Cl)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,"InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,24-25,27-29,31-33,35-39,46,51H,10-17,19,21-23H2,1-9H3",QQXZSKLNJZQNSA-UHFFFAOYSA-N,pimecrolimus,Launched,calcineurin inhibitor,,dermatology,eczema
CN1CCC(=C2c3ccccc3Sc3ccccc32)CC1,"InChI=1S/C19H19NS/c1-20-12-10-14(11-13-20)19-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)19/h2-9H,10-13H2,1H3",NZLVRVYNQYGMAB-UHFFFAOYSA-N,pimethixene,Launched,antihistamine,,neurology/psychiatry|allergy,attention-deficit/hyperactivity disorder (ADHD)|anxiety|sleep cycle support|allergic rhinitis
COc1ccc(-c2nc3cc(C4=NNC(=O)CC4C)ccc3[nH]2)cc1,"InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)",GLBJJMFZWDBELO-UHFFFAOYSA-N,pimobendan,Launched,calcium sensitizer,PDE3A,cardiology,congestive heart failure
COc1ccc(-c2nc3cc(C4=NNC(=O)CC4C)ccc3[nH]2)cc1,"InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)",GLBJJMFZWDBELO-UHFFFAOYSA-N,pimobendan,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure
O=C(O)C1C2CCC(CC2)C1N=c1[nH]c(-c2c[nH]c3ncc(F)cc23)ncc1F,"InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)",JGPXDNKSIXAZEQ-UHFFFAOYSA-N,pimodivir,Phase 3,antiviral,,,
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,"InChI=1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2",WVWOOAYQYLJEFD-UHFFFAOYSA-N,pimonidazole,Phase 3,,,,
O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)",YVUQSNJEYSNKRX-UHFFFAOYSA-N,pimozide,Launched,dopamine receptor antagonist,CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2,neurology/psychiatry,Tourette's disorder
CC(N=C(N=c1cc[nH]cc1)NC#N)C(C)(C)C,"InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)",IVVNZDGDKPTYHK-UHFFFAOYSA-N,pinacidil,Launched,ATP channel activator,ABCC8|ABCC9,cardiology,hypertension
CC(N=C(N=c1cc[nH]cc1)NC#N)C(C)(C)C,"InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)",IVVNZDGDKPTYHK-UHFFFAOYSA-N,pinacidil,Launched,potassium channel activator,ABCC8|ABCC9,cardiology,hypertension
CC1(C)C2CC(O)C(C)(O)C1C2,"InChI=1S/C10H18O2/c1-9(2)6-4-7(9)10(3,12)8(11)5-6/h6-8,11-12H,4-5H2,1-3H3",MOILFCKRQFQVFS-UHFFFAOYSA-N,pinanediol,Preclinical,,,,
COc1cc(Br)c(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)cc1OC,"InChI=1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1",DDHUTBKXLWCZCO-UHFFFAOYSA-N,pinaverium,Launched,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome
Cc1cccc(C)c1NC(=O)CN1CCCCCC1,"InChI=1S/C16H24N2O/c1-13-8-7-9-14(2)16(13)17-15(19)12-18-10-5-3-4-6-11-18/h7-9H,3-6,10-12H2,1-2H3,(H,17,19)",RJOUHGWLHPOQSA-UHFFFAOYSA-N,pincainide,Phase 1,antiarrhythmic,,,
CC(C)NCC(O)COc1cccc2[nH]ccc12,"InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",JZQKKSLKJUAGIC-UHFFFAOYSA-N,pindolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR2A|HTR2B,cardiology,hypertension
CC(C)NCC(O)COc1cccc2[nH]ccc12,"InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",JZQKKSLKJUAGIC-UHFFFAOYSA-N,pindolol-(-),Phase 2,adrenergic receptor antagonist,HTR1A,,
CC(C)NCC(O)COc1cccc2[nH]ccc12,"InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",JZQKKSLKJUAGIC-UHFFFAOYSA-N,pindolol-(-),Phase 2,serotonin receptor antagonist,HTR1A,,
COC1C(O)C(O)C(O)C(O)C1O,"InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3",DSCFFEYYQKSRSV-UHFFFAOYSA-N,pinitol,Phase 2,gamma secretase inhibitor,,,
O=C1CC(c2ccccc2)Oc2cc(O)cc(O)c21,"InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2",URFCJEUYXNAHFI-UHFFFAOYSA-N,pinocembrin,Phase 2,cytochrome P450 inhibitor,CYP1B1,,
CCc1ccc(CCOc2ccc(Cc3sc(=O)[nH]c3O)cc2)nc1,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,22H,2,9-11H2,1H3,(H,21,23)",IYYGBZJXHJSLEV-UHFFFAOYSA-N,pioglitazone,Launched,insulin sensitizer,PPARG|TRPM3,endocrinology,diabetes mellitus
CCc1ccc(CCOc2ccc(Cc3sc(=O)[nH]c3O)cc2)nc1,"InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,22H,2,9-11H2,1H3,(H,21,23)",IYYGBZJXHJSLEV-UHFFFAOYSA-N,pioglitazone,Launched,PPAR receptor agonist,PPARG|TRPM3,endocrinology,diabetes mellitus
NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,"InChI=1S/C21H30FN3O2/c22-18-8-6-17(7-9-18)19(26)5-4-12-24-15-10-21(11-16-24,20(23)27)25-13-2-1-3-14-25/h6-9H,1-5,10-16H2,(H2,23,27)",AXKPFOAXAHJUAG-UHFFFAOYSA-N,pipamperone,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A,neurology/psychiatry,schizophrenia
CC(=O)OC1CC2CCC3C(CCC4(C)C3CC(N3CC[N+](C)(C)CC3)C4OC(C)=O)C2(C)CC1N1CC[N+](C)(C)CC1,"InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2",OWWLUIWOFHMHOQ-UHFFFAOYSA-N,pipecuronium,Launched,neuromuscular blocker,CHRM2|CHRM3|CHRNA2,neurology/psychiatry,anesthetic
CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21,"InChI=1S/C14H17N5O3/c1-2-18-8-10(13(21)22)11(20)9-7-16-14(17-12(9)18)19-5-3-15-4-6-19/h7-8,15H,2-6H2,1H3,(H,21,22)",JOHZPMXAZQZXHR-UHFFFAOYSA-N,pipemidic-acid,Launched,topoisomerase inhibitor,,infectious disease,gram-negative bacterial infections
CC[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1,"InChI=1S/C22H28NO3/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3/q+1",WPUKUEMZZRVAKZ-UHFFFAOYSA-N,pipenzolate,Launched,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms
CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2,"InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3",BTFMCMVEUCGQDX-UHFFFAOYSA-N,piperacetazine,Launched,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia
CCN1CCN(C(=O)NC(C(=O)NC2C(=O)N3C2SC(C)(C)C3C(=O)O)c2ccccc2)C(=O)C1=O,"InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)",IVBHGBMCVLDMKU-UHFFFAOYSA-N,piperacillin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,"InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2",UCRHFBCYFMIWHC-UHFFFAOYSA-N,piperaquine-phosphate,Launched,antimalarial agent,,infectious disease,malaria
C1CNCCN1,"InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2",GLUUGHFHXGJENI-UHFFFAOYSA-N,piperazine,Launched,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms
O=C1CNC(=O)CN1,"InChI=1S/C4H6N2O2/c7-3-1-5-4(8)2-6-3/h1-2H2,(H,5,8)(H,6,7)",BXRNXXXXHLBUKK-UHFFFAOYSA-N,piperazinedione,Phase 2,DNA synthesis inhibitor,,,
CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1,"InChI=1S/C21H25NO2/c1-2-22-15-9-14-19(16-22)24-21(23)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19-20H,2,9,14-16H2,1H3",KTHVBAZBLKXIHZ-UHFFFAOYSA-N,piperidolate,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms
O=C(C=CC=Cc1ccc2c(c1)OCO2)N1CCCCC1,"InChI=1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2",MXXWOMGUGJBKIW-UHFFFAOYSA-N,piperine,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB|TRPV1,,
CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2,"InChI=1S/C19H30O5/c1-3-5-7-20-8-9-21-10-11-22-14-17-13-19-18(23-15-24-19)12-16(17)6-4-2/h12-13H,3-11,14-15H2,1-2H3",FIPWRIJSWJWJAI-UHFFFAOYSA-N,piperonyl-butoxide,Launched,cytochrome P450 inhibitor,,infectious disease,lice
O=C(CCBr)N1CCN(C(=O)CCBr)CC1,InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2,NJBFOOCLYDNZJN-UHFFFAOYSA-N,pipobroman,Launched,DNA alkylating agent,,hematology,polycythemia vera|thrombocythemia
CN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1,"InChI=1S/C16H19N5O/c1-19-7-9-21(10-8-19)15-11-13-16(18-17-15)22-14-6-4-3-5-12(14)20(13)2/h3-6,11H,7-10H2,1-2H3",SDYYIRPAZHJOLM-UHFFFAOYSA-N,pipofezine,Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
CN(C)S(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2,"InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3",JOMHSQGEWSNUKU-UHFFFAOYSA-N,pipotiazine,Launched,dopamine receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,"InChI=1S/C40H63N3O4S2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-22-40(44)47-32-27-34-25-30-42(31-26-34)28-19-29-43-36-20-17-18-21-38(36)48-39-24-23-35(33-37(39)43)49(45,46)41(2)3/h17-18,20-21,23-24,33-34H,4-16,19,22,25-32H2,1-3H3",KTOYYUONFQWSMW-UHFFFAOYSA-N,pipotiazine-palmitate,Launched,dopamine receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,"InChI=1S/C40H63N3O4S2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-22-40(44)47-32-27-34-25-30-42(31-26-34)28-19-29-43-36-20-17-18-21-38(36)48-39-24-23-35(33-37(39)43)49(45,46)41(2)3/h17-18,20-21,23-24,33-34H,4-16,19,22,25-32H2,1-3H3",KTOYYUONFQWSMW-UHFFFAOYSA-N,pipotiazine-palmitate,Launched,serotonin receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
NC(=O)CN1CCCC1=O,"InChI=1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)",GMZVRMREEHBGGF-UHFFFAOYSA-N,piracetam,Launched,acetylcholine receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,neurology/psychiatry,senile dementia
COc1cccc2c(O)c3c(O)c4c(c(O)c3c(O)c12)=C(OC1CC(N)C(OC2CCCCO2)C(C)O1)CC(O)(C(=O)CO)C=4,"InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,11,14,17,21-22,31,34,36-40H,3-4,8-10,12-13,33H2,1-2H3",MLNXYRCHUAIOQD-UHFFFAOYSA-N,pirarubicin,Launched,topoisomerase inhibitor,TOP2A,oncology,breast cancer
O=C(O)c1cc(=O)c2c3nc4ccccc4oc-3cc(=O)c2[nH]1,"InChI=1S/C16H8N2O5/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12/h1-6H,(H,18,19)(H,21,22)",OKPNYGAWTYOBFZ-UHFFFAOYSA-N,pirenoxine,Launched,AGE inhibitor,,ophthalmology,cataracts
Cc1nc2ccccn2c(=O)c1CCN1CCC(C(=O)c2ccc(F)cc2)CC1,"InChI=1S/C23H24FN3O2/c1-16-20(23(29)27-12-3-2-4-21(27)25-16)11-15-26-13-9-18(10-14-26)22(28)17-5-7-19(24)8-6-17/h2-8,12,18H,9-11,13-15H2,1H3",HXCNRYXBZNHDNE-UHFFFAOYSA-N,pirenperone,Preclinical,serotonin receptor antagonist,HTR2A|HTR7,,
CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,"InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)",RMHMFHUVIITRHF-UHFFFAOYSA-N,pirenzepine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD)
NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc1ccccc1,"InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)",UJEWTUDSLQGTOA-UHFFFAOYSA-N,piretanide,Launched,glucocorticoid receptor agonist,SLC12A1|SLC12A2,cardiology,hypertension|edema
Cc1ccc(=O)n(-c2ccccc2)c1,"InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3",ISWRGOKTTBVCFA-UHFFFAOYSA-N,pirfenidone,Launched,TGF beta receptor inhibitor,FURIN|TNF,pulmonary,idiopathic pulmonary fibrosis (IPF)
c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1,"InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2",OQDPVLVUJFGPGQ-UHFFFAOYSA-N,piribedil,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B,neurology/psychiatry,Parkinson's Disease|dizziness
CC12CCC(C(=O)N(CCCCN3CCN(c4ccccn4)CC3)C1=O)C2(C)C,"InChI=1S/C23H34N4O2/c1-22(2)18-9-10-23(22,3)21(29)27(20(18)28)13-7-6-12-25-14-16-26(17-15-25)19-8-4-5-11-24-19/h4-5,8,11,18H,6-7,9-10,12-17H2,1-3H3",NCMIPRCQUMYAEC-UHFFFAOYSA-N,piricapiron,Phase 2,dopamine receptor antagonist,HTR2A,,
CC12CCC(C(=O)N(CCCCN3CCN(c4ccccn4)CC3)C1=O)C2(C)C,"InChI=1S/C23H34N4O2/c1-22(2)18-9-10-23(22,3)21(29)27(20(18)28)13-7-6-12-25-14-16-26(17-15-25)19-8-4-5-11-24-19/h4-5,8,11,18H,6-7,9-10,12-17H2,1-3H3",NCMIPRCQUMYAEC-UHFFFAOYSA-N,piricapiron,Phase 2,serotonin receptor antagonist,HTR2A,,
Cc1cccc(N=c2cc(Cl)[nH]c(SCC(=O)O)n2)c1C,"InChI=1S/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)",SZRPDCCEHVWOJX-UHFFFAOYSA-N,pirinixic-acid,Preclinical,PPAR receptor agonist,PPARA,,
Cc1ccc2c(c1)c1c3n2CCNC3CCC1,"InChI=1S/C15H18N2/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13/h5-6,9,13,16H,2-4,7-8H2,1H3",IWVRVEIKCBFZNF-UHFFFAOYSA-N,pirlindole,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression
CC1CCCC(C)N1CCCC(O)(c1ccccc1)c1ccccn1,"InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3",APUDBKTWDCXQJA-UHFFFAOYSA-N,pirmenol,Preclinical,acetylcholine receptor inhibitor,,,
Cc1cc(CC(C)CC(C)(C)C)n(O)c(=O)c1,"InChI=1S/C14H23NO2/c1-10-6-12(15(17)13(16)8-10)7-11(2)9-14(3,4)5/h6,8,11,17H,7,9H2,1-5H3",OIQJEQLSYJSNDS-UHFFFAOYSA-N,piroctone-olamine,Launched,,,infectious disease,fungal infection
CCOC(=O)c1ccc(OCCC2CCN(c3ccc(C)nn3)CC2)cc1,"InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3",KCHIOGFOPPOUJC-UHFFFAOYSA-N,pirodavir,Phase 2,,,,
CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21,"InChI=1S/C14H16N4O3/c1-2-17-8-10(13(20)21)11(19)9-7-15-14(16-12(9)17)18-5-3-4-6-18/h7-8H,2-6H2,1H3,(H,20,21)",RCIMBBZXSXFZBV-UHFFFAOYSA-N,piromidic-acid,Phase 2,bacterial DNA gyrase inhibitor,,,
CN1C(C(=O)N=c2cccc[nH]2)C(=O)c2ccccc2S1(=O)=O,"InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,13H,1H3,(H,16,17,20)",MNSCVRXKDINXEY-UHFFFAOYSA-N,piroxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1,"InChI=1S/C11H11N3O2/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7/h3-6H,2H2,1H3,(H2,13,14,16)",OQGWJZOWLHWFME-UHFFFAOYSA-N,piroximone,Phase 2,phosphodiesterase inhibitor,PDE3A,,
COc1cc(C(=O)OCc2cccc(COC(=O)c3cc(OC)c(OC)c(OC)c3)n2)cc(OC)c1OC,"InChI=1S/C27H29NO10/c1-31-20-10-16(11-21(32-2)24(20)35-5)26(29)37-14-18-8-7-9-19(28-18)15-38-27(30)17-12-22(33-3)25(36-6)23(13-17)34-4/h7-13H,14-15H2,1-6H3",DIIBXMIIOQXTHW-UHFFFAOYSA-N,pirozadil,Preclinical,hypolipidemic,,,
O=c1[nH]c2ccccc2c2cc(CO)nn12,"InChI=1S/C11H9N3O2/c15-6-7-5-10-8-3-1-2-4-9(8)12-11(16)14(10)13-7/h1-5,15H,6H2,(H,12,16)",XLUKOGNIEDDIMV-UHFFFAOYSA-N,pirquinozol,Phase 1,histamine release inhibitor,,,
O=C1C(c2ccccn2)=[N+]([O-])c2ccccc21,InChI=1S/C13H8N2O2/c16-13-9-5-1-2-7-11(9)15(17)12(13)10-6-3-4-8-14-10/h1-8H,LXEZPPZLNVOLDI-UHFFFAOYSA-N,pit,Preclinical,purinergic receptor antagonist,P2RY1,,
O=C(O)CC(O)CC(O)C=Cc1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,"InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)",VGYFMXBACGZSIL-UHFFFAOYSA-N,pitavastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia
Clc1ccc(CCCOCCCN2CCCCC2)cc1,"InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2",NNACHAUCXXVJSP-UHFFFAOYSA-N,pitolisant,Launched,histamine receptor antagonist,HRH3,,
CC(C)(C)C(=O)NCCCC(=O)O,"InChI=1S/C9H17NO3/c1-9(2,3)8(13)10-6-4-5-7(11)12/h4-6H2,1-3H3,(H,10,13)(H,11,12)",SRPNQDXRVRCTNK-UHFFFAOYSA-N,pivagabine,Launched,corticotropin releasing factor receptor antagonist,CRHR1|CRHR2,neurology/psychiatry,depression
CC(C)(C)C(=O)OCOC(=O)C1N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1(C)C,"InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)",ZEMIJUDPLILVNQ-UHFFFAOYSA-N,pivampicillin,Launched,bacterial cell wall synthesis inhibitor,,pulmonary|infectious disease,bronchitis|pneumonia|gynecologic infections
CCCC(=O)OCOC(=O)C(C)(C)C,"InChI=1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3",GYKLFBYWXZYSOW-UHFFFAOYSA-N,pivanex,Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CC(C)(C)C(=O)OCOC(=O)C1N2C(=O)C(N=CN3CCCCCC3)C2SC1(C)C,"InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3",NPGNOVNWUSPMDP-UHFFFAOYSA-N,pivmecillinam,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,urinary tract infections|gram-negative bacterial infections
N=CCN=c1ccc(NCCN)c2c(O)c3cc[nH]cc3c(O)c12,"InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,5-6,9,19-21,23-24H,4,7-8,18H2",GQCUSCJVHOZNJP-UHFFFAOYSA-N,pixantrone,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,non-Hodgkin lymphoma (NHL)
CN1CCC(=C2c3ccccc3CCc3sccc32)CC1,"InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3",FIADGNVRKBPQEU-UHFFFAOYSA-N,pizotifen,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C,neurology/psychiatry,migraine headache
CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,"InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22)",UYJZZVDLGDDTCL-UHFFFAOYSA-N,pj-34,Preclinical,PARP inhibitor,EEF2|PARP1|PARP15|PARP3,,
CCC(C)N(C)C(=O)c1cc2ccccc2c(-c2ccccc2Cl)n1,"InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3",RAVIZVQZGXBOQO-UHFFFAOYSA-N,pk-11195,Phase 1,benzodiazepine receptor antagonist,TSPO,,
NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1[nH]nc2c(F)c(F)ccc12,"InChI=1S/C17H16F5N7O/c18-10-2-1-9-11(24-26-15(9)14(10)19)5-8(23)6-13(30)28-3-4-29-12(7-28)25-27-16(29)17(20,21)22/h1-2,8H,3-7,23H2,(H,24,26)",LIPWZZYFIVYJSI-UHFFFAOYSA-N,pk-44,Preclinical,dipeptidyl peptidase inhibitor,DPP4,,
CCCC(=O)C1CCN(c2ncnc3c2CN(C(=O)c2ccc(-c4ccccc4)cc2)CC3)CC1,"InChI=1S/C29H32N4O2/c1-2-6-27(34)23-13-16-32(17-14-23)28-25-19-33(18-15-26(25)30-20-31-28)29(35)24-11-9-22(10-12-24)21-7-4-3-5-8-21/h3-5,7-12,20,23H,2,6,13-19H2,1H3",CJZGRIRZVHNUSM-UHFFFAOYSA-N,pk-thpp,Preclinical,potassium channel blocker,KCNK9,,
CC(N=c1[nH]cnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,"InChI=1S/C20H18N4O/c1-13(14-5-3-2-4-6-14)23-19-17-11-18(24-20(17)22-12-21-19)15-7-9-16(25)10-8-15/h2-13,25H,1H3,(H2,21,22,23,24)",XRYJULCDUUATMC-UHFFFAOYSA-N,pki-166,Phase 1,EGFR inhibitor,EGFR,,
O=C(N=c1cc[nH]cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,"InChI=1S/C25H28N8O3/c34-25(28-19-7-9-26-10-8-19)27-18-3-1-17(2-4-18)22-29-23(32-11-13-35-14-12-32)31-24(30-22)33-20-5-6-21(33)16-36-15-20/h1-4,7-10,20-21H,5-6,11-16H2,(H2,26,27,28,34)",WXUUCRLKXQMWRY-UHFFFAOYSA-N,pki-179,Phase 1,mTOR inhibitor,MTOR,,
O=C(N=c1cc[nH]cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,"InChI=1S/C25H28N8O3/c34-25(28-19-7-9-26-10-8-19)27-18-3-1-17(2-4-18)22-29-23(32-11-13-35-14-12-32)31-24(30-22)33-20-5-6-21(33)16-36-15-20/h1-4,7-10,20-21H,5-6,11-16H2,(H2,26,27,28,34)",WXUUCRLKXQMWRY-UHFFFAOYSA-N,pki-179,Phase 1,PI3K inhibitor,MTOR,,
Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,"InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3",KQOXLKOJHVFTRN-UHFFFAOYSA-N,pleconaril,Phase 3,,,,
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,"InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2",YIQPUIGJQJDJOS-UHFFFAOYSA-N,plerixafor,Launched,CC chemokine receptor antagonist,ACKR3|CCR4|CXCR4,hematologic malignancy,non-Hodgkin lymphoma (NHL)|multiple myeloma
COC(C(=O)C(O)C(C)O)C1Cc2cc3cc(OC4CC(OC5CC(O)C(O)C(C)O5)C(O)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC1CC(OC2CC(OC3CC(C)(O)C(O)C(C)O3)C(O)C(C)O2)C(O)C(C)O1,"InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3",CFCUWKMKBJTWLW-UHFFFAOYSA-N,plicamycin,Launched,alcohol dehydrogenase inhibitor,,oncology|endocrinology,testicular carcinoma|Paget's disease|hypercalcemia
CC(C)(C)c1[nH]cnc1C=c1[nH]c(=O)c(=Cc2ccccc2)[nH]c1=O,"InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)",UNRCMCRRFYFGFX-UHFFFAOYSA-N,plinabulin,Phase 3,tubulin polymerization inhibitor,,,
NC(Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)",OUYCCCASQSFEME-UHFFFAOYSA-N,plovamer-acetate,Phase 2,,TAT|TH|YARS|YARS2,,
CC1=CC(=O)c2c(O)cccc2C1=O,"InChI=1S/C11H8O3/c1-6-5-9(13)10-7(11(6)14)3-2-4-8(10)12/h2-5,12H,1H3",VCMMXZQDRFWYSE-UHFFFAOYSA-N,plumbagin,Preclinical,anticancer agent,,,
O=C(NNc1ccccc1)c1ccncc1,"InChI=1S/C12H11N3O/c16-12(10-6-8-13-9-7-10)15-14-11-4-2-1-3-5-11/h1-9,14H,(H,15,16)",HUDWXDLBWRHCKO-UHFFFAOYSA-N,plurisin-1,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,"InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)",YZDJQTHVDDOVHR-UHFFFAOYSA-N,plx4720,Preclinical,RAF inhibitor,BRAF|KDR,,
Cc1noc(C)c1-c1cnc2c(-c3ccc(C(=O)O)cc3)cn(C(C)c3ccccn3)c2c1,"InChI=1S/C26H22N4O3/c1-15-24(17(3)33-29-15)20-12-23-25(28-13-20)21(18-7-9-19(10-8-18)26(31)32)14-30(23)16(2)22-6-4-5-11-27-22/h4-14,16H,1-3H3,(H,31,32)",AMSUHYUVOVCWTP-UHFFFAOYSA-N,plx51107,Phase 1,bromodomain inhibitor,,,
FC(F)(F)c1ccc(CN=c2ccc(Cc3c[nH]c4ncccc34)c[nH]2)cc1,"InChI=1S/C21H17F3N4/c22-21(23,24)17-6-3-14(4-7-17)11-26-19-8-5-15(12-27-19)10-16-13-28-20-18(16)2-1-9-25-20/h1-9,12-13H,10-11H2,(H,25,28)(H,26,27)",NODCQQSEMCESEC-UHFFFAOYSA-N,plx647,Preclinical,receptor tyrosine protein kinase inhibitor,CSF1R|KIT,,
O=C(c1c(F)ccc(NS(=O)(=O)N2CCC(F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12,"InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)",YYACLQUDUDXAPA-UHFFFAOYSA-N,plx8394,Phase 1/Phase 2,serine/threonine kinase inhibitor,BRAF,,
O=C(O)CCC(C[PH](=O)(=O)O)C(=O)O,"InChI=1S/C6H10O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H,11,12,13)",SNWHWMDURJMUID-UHFFFAOYSA-N,pmpa,Preclinical,glutamate receptor antagonist,FOLH1,,
COc1cc(OC)c(NC(=O)N=c2cc(C)o[nH]2)cc1Cl,"InChI=1S/C13H14ClN3O4/c1-7-4-12(17-21-7)16-13(18)15-9-5-8(14)10(19-2)6-11(9)20-3/h4-6H,1-3H3,(H2,15,16,17,18)",CEIIEALEIHQDBX-UHFFFAOYSA-N,pnu-120596,Preclinical,acetylcholine receptor agonist,CHRNA7,,
CNC(=O)c1ccc2c(c1)CCOC2CCN1CCN(c2ccc(C(N)=O)cc2)CC1,"InChI=1S/C24H30N4O3/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30)",PNTVCCRNJOGKGA-UHFFFAOYSA-N,pnu-142633,Phase 2,serotonin receptor agonist,HTR1D,,
CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1,"InChI=1S/C18H21F3N2O3S/c1-2-12-22-13-11-14-3-5-15(6-4-14)23-27(24,25)17-9-7-16(8-10-17)26-18(19,20)21/h3-10,22-23H,2,11-13H2,1H3",JGGQWSXZZQPZTR-UHFFFAOYSA-N,pnu-177864,Preclinical,dopamine receptor antagonist,DRD3,,
Cn1c2c(c3ccccc31)CCNCC2,"InChI=1S/C13H16N2/c1-15-12-5-3-2-4-10(12)11-6-8-14-9-7-13(11)15/h2-5,14H,6-9H2,1H3",ZBXDOQWPGBISAR-UHFFFAOYSA-N,pnu-22394,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C|MAOA|MAOB,,
O=C(NC1CN2CCC1CC2)c1ccc(Cl)cc1,"InChI=1S/C14H17ClN2O/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17/h1-4,10,13H,5-9H2,(H,16,18)",WECKJONDRAUFDD-UHFFFAOYSA-N,pnu-282987,Preclinical,cholinergic receptor agonist,CHRNA7,,
C1CCC(N=C(NC23CC4CC(CC(C4)C2)C3)N2CCOCC2)CC1,"InChI=1S/C21H35N3O/c1-2-4-19(5-3-1)22-20(24-6-8-25-9-7-24)23-21-13-16-10-17(14-21)12-18(11-16)15-21/h16-19H,1-15H2,(H,22,23)",GKCGWXNLOYTUNC-UHFFFAOYSA-N,pnu-37883,Preclinical,ATP-sensitive potassium channel antagonist,,,
Cc1ccc(C=NNC(=O)c2ccccc2Oc2ccccc2)o1,"InChI=1S/C19H16N2O3/c1-14-11-12-16(23-14)13-20-21-19(22)17-9-5-6-10-18(17)24-15-7-3-2-4-8-15/h2-13H,1H3,(H,21,22)",JJEDWBQZCRESJL-UHFFFAOYSA-N,pnu-74654,Preclinical,beta-catenin inhibitor,CTNNB1|TCF4,,
Cc1cc2c(N3CCCC3)nc(N3CCCC3)nc2n1C,"InChI=1S/C16H23N5/c1-12-11-13-14(19(12)2)17-16(21-9-5-6-10-21)18-15(13)20-7-3-4-8-20/h11H,3-10H2,1-2H3",UADIKEUOAMACNA-UHFFFAOYSA-N,pnu-89843,Preclinical,benzodiazepine receptor agonist,GABBR1,,
COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1,"InChI=1S/C21H17Cl3O3/c1-25-16-9-10-20(19(24)11-16)26-12-14-5-7-15(8-6-14)13-27-21-17(22)3-2-4-18(21)23/h2-11H,12-13H2,1H3",XXMDDBVNWRWNCW-UHFFFAOYSA-N,pocapavir,Preclinical,Enterovirus capsid inhibitor,,,
COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC,"InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3",YJGVMLPVUAXIQN-UHFFFAOYSA-N,podophyllotoxin,Launched,microtubule inhibitor,IGF1R|TOP2A|TUBA4A|TUBB,infectious disease,genital warts
COc1cc(C2c3cc4c(cc3C(O)C3COC(=O)C23)OCO4)cc(OC)c1OC,"InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3",YJGVMLPVUAXIQN-UHFFFAOYSA-N,podophyllotoxin,Launched,tubulin polymerization inhibitor,IGF1R|TOP2A|TUBA4A|TUBB,infectious disease,genital warts
NCCC(=O)NC(Cc1c[nH]cn1)C(=O)O,"InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)",CQOVPNPJLQNMDC-UHFFFAOYSA-N,polaprezinc,Preclinical,chelating agent,,,
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,"InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3",ONJQDTZCDSESIW-UHFFFAOYSA-N,polidocanol,Launched,local anesthetic,,dermatology,varicose veins
OCC1OC(Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)C(O)C(O)C1O,"InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2",HSTZMXCBWJGKHG-UHFFFAOYSA-N,polydatin,Phase 2,ICAM1 expression inhibitor,ICAM1,,
O=c1[nH]cnc2c1ncn2C1OC(CO[PH](=O)(=O)O)C(O)C1O,"InChI=1S/C10H12N4O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H,18,19,20)",XIDDESHOKKUXHH-UHFFFAOYSA-N,polyinosine,Preclinical,immunostimulant,HPRT1|IMPDH2|PYGM,,
CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O,"InChI=1S/C56H98N16O13/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80)",WQVJHHACXVLGBL-UHFFFAOYSA-N,polymyxin-b-sulfate,Launched,bacterial permeability inducer,,ophthalmology,eye infection
CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,"InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)",CYLWJCABXYDINA-UHFFFAOYSA-N,polythiazide,Launched,sodium/chloride cotransporter inhibitor,SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,Launched,angiogenesis inhibitor,,hematologic malignancy,multiple myeloma
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,"InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)",UVSMNLNDYGZFPF-UHFFFAOYSA-N,pomalidomide,Launched,tumor necrosis factor production inhibitor,,hematologic malignancy,multiple myeloma
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,Launched,Bcr-Abl kinase inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,Launched,FLT3 inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)",PHXJVRSECIGDHY-UHFFFAOYSA-N,ponatinib,Launched,PDGFR tyrosine kinase receptor inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)
CCCN=C1SC(=Cc2ccc(OCC(O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,"InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3",LPAUOXUZGSBGDU-UHFFFAOYSA-N,ponesimod,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,
CCC(C(C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,"InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3",RAGOYPUPXAKGKH-UHFFFAOYSA-N,posaconazole,Launched,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis
CC12CCC(=O)C=C1C=CC1C2CCC2(C)C1CCC2(O)CCC(=O)O,"InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)",PBKZPPIHUVSDNM-UHFFFAOYSA-N,potassium-canrenoate,Launched,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema
I,InChI=1S/HI/h1H,XMBWDFGMSWQBCA-UHFFFAOYSA-N,potassium-iodide,Launched,,,pulmonary,asthma|bronchitis|emphysema
Nc1ccc(C(=O)O)cc1,"InChI=1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)",ALYNCZNDIQEVRV-UHFFFAOYSA-N,potassium-p-aminobenzoate,Launched,,,rheumatology|urology,scleroderma|dermatomyositis|Peyronie's disease
Cc1ncccc1OCC1CCCN1,"InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3",YRVIKLBSVVNSHF-UHFFFAOYSA-N,pozanicline,Phase 2,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,
C=CC(=O)N1CCC(Oc2cc3c(=Nc4ccc(Cl)c(Cl)c4F)[nH]cnc3cc2OC)CC1,"InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)",LPFWVDIFUFFKJU-UHFFFAOYSA-N,poziotinib,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB4,,
Cc1ccc(-c2nn(C(C)(C)C)c3[nH]cnc(=N)c23)cc1,"InChI=1S/C16H19N5/c1-10-5-7-11(8-6-10)13-12-14(17)18-9-19-15(12)21(20-13)16(2,3)4/h5-9H,1-4H3,(H2,17,18,19)",ZVPDNRVYHLRXLX-UHFFFAOYSA-N,pp-1,Preclinical,SRC inhibitor,HCK|RET,,
N=c1[nH]cnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,"InChI=1S/C17H17N7/c18-15-13-14(11-7-10-5-6-19-16(10)20-8-11)23-24(12-3-1-2-4-12)17(13)22-9-21-15/h5-9,12H,1-4H2,(H,19,20)(H2,18,21,22)",NVRXTLZYXZNATH-UHFFFAOYSA-N,pp-121,Preclinical,protein tyrosine kinase inhibitor,ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC,,
CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(=N)[nH]cnc21,"InChI=1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)",PBBRWFOVCUAONR-UHFFFAOYSA-N,pp-2,Preclinical,SRC inhibitor,ABL1|LCK|RIPK2|SRC,,
CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(=N)[nH]cnc21,"InChI=1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)",MFAQYJIYDMLAIM-UHFFFAOYSA-N,pp242,Preclinical,mTOR inhibitor,MTOR|PASK,,
CCCc1c(-c2ccc(O)cc2)nn(-c2ccc(O)cc2)c1-c1ccc(O)cc1,"InChI=1S/C24H22N2O3/c1-2-3-22-23(16-4-10-19(27)11-5-16)25-26(18-8-14-21(29)15-9-18)24(22)17-6-12-20(28)13-7-17/h4-15,27-29H,2-3H2,1H3",IOTXSIGGFRQYKW-UHFFFAOYSA-N,ppt,Preclinical,estrogen receptor agonist,ESR1,,
COc1ccccc1-c1c[nH]c2ncc(-c3cncc(C(=O)N(C)C)c3)cc12,"InChI=1S/C22H20N4O2/c1-26(2)22(27)16-8-14(10-23-11-16)15-9-18-19(13-25-21(18)24-12-15)17-6-4-5-7-20(17)28-3/h4-13H,1-3H3,(H,24,25)",GYQRHHQPEMOLKH-UHFFFAOYSA-N,ppy-a,Preclinical,Abl kinase inhibitor,ABL1|BCR,,
COc1ccc(Cl)cc1NC(=O)N=c1cc(C)[nH]c2ccccc12,"InChI=1S/C18H16ClN3O2/c1-11-9-15(13-5-3-4-6-14(13)20-11)21-18(23)22-16-10-12(19)7-8-17(16)24-2/h3-10H,1-2H3,(H2,20,21,22,23)",YBLWOZUPHDKFOT-UHFFFAOYSA-N,pq-401,Preclinical,IGF-1 inhibitor,IGF1R,,
N#CSc1cc(SC#N)c(=N)[nH]c1N,"InChI=1S/C7H5N5S2/c8-2-13-4-1-5(14-3-9)7(11)12-6(4)10/h1H,(H4,10,11,12)",ZXOBLNBVNROVLC-UHFFFAOYSA-N,pr-619,Preclinical,DUB inhibitor,,,
CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1,"InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)",DURULFYMVIFBIR-UHFFFAOYSA-N,practolol,Withdrawn,adrenergic receptor antagonist,ADRB1,,
N=c1[nH]cnc2c1ncn2CCOCP1(=O)OCCC(c2cccc(Cl)c2)O1,"InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)",GWNHAOBXDGOXRR-UHFFFAOYSA-N,pradefovir,Phase 2,cytochrome P450 activator,,,
C#CCC(Cc1cnc2[nH]c(=N)[nH]c(=N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1,"InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)",OGSBUKJUDHAQEA-UHFFFAOYSA-N,pralatrexate,Launched,dihydrofolate reductase inhibitor,DHFR,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
C[n+]1ccccc1C=NO,"InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1",JBKPUQTUERUYQE-UHFFFAOYSA-O,pralidoxime,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,critical care,organophosphate poisoning
C[n+]1ccccc1C=NO,"InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1",JBKPUQTUERUYQE-UHFFFAOYSA-O,pralidoxime-chloride,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,pulmonary,respiratory depression
CC(N)C(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCCN)C(N)=O,"InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)",HRNLPPBUBKMZMT-UHFFFAOYSA-N,pralmorelin,Launched,growth hormone releasing peptide ligand agonist,,,
CCCNC1CCc2[nH]c(=N)sc2C1,"InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)",FASDKYOPVNHBLU-UHFFFAOYSA-N,pramipexole,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease
CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,"InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)",ZULJGOSFKWFVRX-UHFFFAOYSA-N,pramiracetam,Launched,acetylcholine receptor agonist,,neurology/psychiatry,senile dementia
CCCCOc1ccc(OCCCN2CCOCC2)cc1,"InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3",DQKXQSGTHWVTAD-UHFFFAOYSA-N,pramoxine,Launched,topical anesthetic,,dermatology,corticosteroid-responsive dermatoses
COC(=O)C1=C(C)N=C(C)C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,22-23H,14H2,1-3H3",ISBYPYUIOMMYGS-UHFFFAOYSA-N,pranidipine,Phase 2,calcium channel blocker,CACNA1C,,
O=C(Nc1cccc2c(=O)cc(-c3nn[nH]n3)oc12)c1ccc(OCCCCc2ccccc2)cc1,"InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)",NBQKINXMPLXUET-UHFFFAOYSA-N,pranlukast,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF,pulmonary,bronchospasm|asthma
CC(C(=O)O)c1ccc2c(c1)Cc1cccnc1O2,"InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)",TVQZAMVBTVNYLA-UHFFFAOYSA-N,pranoprofen,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,pain relief
CC(=O)OC1CCC2(C)C(=CCC3C4CCC(=O)C4(C)CCC32)C1,"InChI=1S/C21H30O3/c1-13(22)24-15-8-10-20(2)14(12-15)4-5-16-17-6-7-19(23)21(17,3)11-9-18(16)20/h4,15-18H,5-12H2,1-3H3",NCMZQTLCXHGLOK-UHFFFAOYSA-N,prasterone-acetate,Preclinical,,,,
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,"InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3",DTGLZDAWLRGWQN-UHFFFAOYSA-N,prasugrel,Launched,purinergic receptor antagonist,P2RY12,cardiology,myocardial infarction|acute coronary syndrome (ACS)
COc1ccc(C(=O)c2c(C)n(CCN3CCOCC3)c3ccccc23)cc1,"InChI=1S/C23H26N2O3/c1-17-22(23(26)18-7-9-19(27-2)10-8-18)20-5-3-4-6-21(20)25(17)12-11-24-13-15-28-16-14-24/h3-10H,11-16H2,1-2H3",MEUQWHZOUDZXHH-UHFFFAOYSA-N,pravadoline,Preclinical,cyclooxygenase inhibitor,CNR1|CNR2,,
CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,"InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)",TUZYXOIXSAXUGO-UHFFFAOYSA-N,pravastatin,Launched,HMGCR inhibitor,HMGCR|SLCO1B1,endocrinology|cardiology,hypercholesterolemia|myocardial infarction|hyperlipidemia
O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,"InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2",FSVJFNAIGNNGKK-UHFFFAOYSA-N,praziquantel,Launched,anthelmintic agent,,infectious disease,gastrointestinal parasites|cystic hydatid disease|schistosomiasis
COc1cc2[nH]c(N3CCN(C(=O)c4ccco4)CC3)nc(=N)c2cc1OC,"InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)",IENZQIKPVFGBNW-UHFFFAOYSA-N,prazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7,cardiology,hypertension
O=C(OCCN1CCOCC1)C1(c2ccccc2)CCCCC1,"InChI=1S/C19H27NO3/c21-18(23-16-13-20-11-14-22-15-12-20)19(9-5-2-6-10-19)17-7-3-1-4-8-17/h1,3-4,7-8H,2,5-6,9-16H2",RQHKZUBCUZVZEF-UHFFFAOYSA-N,pre-084,Preclinical,sigma receptor agonist,SIGMAR1,,
CCCN1CCCC(c2cccc(O)c2)C1,"InChI=1S/C14H21NO/c1-2-8-15-9-4-6-13(11-15)12-5-3-7-14(16)10-12/h3,5,7,10,13,16H,2,4,6,8-9,11H2,1H3",HTSNFXAICLXZMA-UHFFFAOYSA-N,preclamol,Phase 2,dopamine receptor agonist,DRD2,,
CCOC(=O)OC1(C(=O)COC(=O)CC)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h7,9,11,18-20,23,29H,5-6,8,10,12-15H2,1-4H3",FIVPIQADCOIIHF-UHFFFAOYSA-N,prednicarbate,Launched,phospholipase activator,PLA2G1B,dermatology|ophthalmology|neurology/psychiatry,eczema|contact dermatitis|itching
CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,"InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3",OIGNJSKKLXVSLS-UHFFFAOYSA-N,prednisolone,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|SERPINA6,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h4,6,8,16-18,20,26,28H,5,7,9-12H2,1-3H3",DKHHQUXEXCKMMT-UHFFFAOYSA-N,prednisolone-acetate,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis
CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)CCC(=O)O,"InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)",APGDTXUMTIZLCJ-UHFFFAOYSA-N,prednisolone-hemisuccinate,Preclinical,glucocorticoid receptor agonist,NR3C1,,
CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO[PH](=O)(=O)O,"InChI=1S/C21H28O8P/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19/h5,7,9,14-16,18,23,25H,3-4,6,8,10-11H2,1-2H3,(H,26,27,28)",HJIZNZDDWGOOHK-UHFFFAOYSA-N,prednisolone-sodium-phosphate,Launched,glucocorticoid receptor agonist,NR3C1,allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology,allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis
CC(C)(C)CC(=O)OCC(=O)C1(O)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h6,8,10,18-20,23,29,32H,7,9,11-15H2,1-5H3",AEQGYUJKXATLBW-UHFFFAOYSA-N,prednisolone-tebutate,Launched,anti-inflammatory agent,,,
CC12C=CC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3",XOFYZVNMUHMLCC-UHFFFAOYSA-N,prednisone,Launched,glucocorticoid receptor agonist,HSD11B1|NR3C1,endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry,congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis
CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3",ORNBQBCIOKFOEO-UHFFFAOYSA-N,pregnenolone,Launched,glutamate receptor modulator,SULT2B1,rheumatology,rheumatoid arthritis
CC(=O)C1CCC2C3CC=C4CC(OC(=O)CCC(=O)O)CCC4(C)C3CCC12C,"InChI=1S/C25H36O5/c1-15(26)19-6-7-20-18-5-4-16-14-17(30-23(29)9-8-22(27)28)10-12-24(16,2)21(18)11-13-25(19,20)3/h4,17-21H,5-14H2,1-3H3,(H,27,28)",OZZAYJQNMKMUSD-UHFFFAOYSA-N,pregnenolone-succinate,Preclinical,GABA receptor negative allosteric modulator,CYP17A1,,
COCCOc1ccc(N2CCN(CCn3[nH]cc4c3nc(=N)n3nc(-c5ccco5)nc43)CC2)cc1,"InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17,26-27H,8-13,15-16H2,1H3",OGHUQXNBDJXYLA-UHFFFAOYSA-N,preladenant,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,"InChI=1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3",IFFPICMESYHZPQ-UHFFFAOYSA-N,prenylamine,Withdrawn,calcium channel blocker,,,
Cc1cn2nc(C3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CCC(N)C1,"InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3",GOFXWTVKPWJNGD-UHFFFAOYSA-N,presatovir,Phase 2,RSV fusion inhibitor,,,
O=[N+]([O-])c1cn2c(n1)OCC(OCc1ccc(OC(F)(F)F)cc1)C2,"InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2",ZLHZLMOSPGACSZ-UHFFFAOYSA-N,pretomanid,Launched,nitric oxide donor,FASN,,
OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,"InChI=1S/C20H25NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1-2,4-7,10-13,22H,3,8-9,14-17H2",RQXCLMGKHJWMOA-UHFFFAOYSA-N,pridinol,Launched,muscle relaxant,,neurology/psychiatry,muscle relaxant
CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1,"InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3",YGKUEOZJFIXDGI-UHFFFAOYSA-N,pridopidine,Phase 2,dopamine receptor antagonist,,,
CCCNC(C)C(=O)Nc1ccccc1C,"InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)",MVFGUOIZUNYYSO-UHFFFAOYSA-N,prilocaine,Launched,local anesthetic,SCN5A,neurology/psychiatry,anesthetic
O=C1C2CCN(CC2)C1(CO)CO,"InChI=1S/C9H15NO3/c11-5-9(6-12)8(13)7-1-3-10(9)4-2-7/h7,11-12H,1-6H2",RFBVBRVVOPAAFS-UHFFFAOYSA-N,prima1,Preclinical,TP53 inhibitor,ACHE,,
COc1cc(NC(C)CCCN)c2ncccc2c1,"InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3",INDBQLZJXZLFIT-UHFFFAOYSA-N,primaquine,Launched,antimalarial agent,,infectious disease,malaria
COc1cc(NC(C)CCCN)c2ncccc2c1,"InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3",INDBQLZJXZLFIT-UHFFFAOYSA-N,primaquine,Launched,DNA inhibitor,,infectious disease,malaria
CCC1(c2ccccc2)C(=O)NCNC1=O,"InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)",DQMZLTXERSFNPB-UHFFFAOYSA-N,primidone,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12,"InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2",MQIMZDXIAHJKQP-UHFFFAOYSA-N,prinaberel,Phase 2,estrogen receptor agonist,ESR2|NCOA1,,
CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)C1C(O)=NO,"InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)",YKPYIPVDTNNYCN-UHFFFAOYSA-N,prinomastat,Phase 3,matrix metalloprotease inhibitor,,,
CC(NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,"InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)",BHJIBOFHEFDSAU-UHFFFAOYSA-N,priralfinamide,Phase 3,sodium channel blocker,CACNA1B,,
CC(C)NC(C)Cc1ccc(O)cn1,"InChI=1S/C11H18N2O/c1-8(2)13-9(3)6-10-4-5-11(14)7-12-10/h4-5,7-9,13-14H,6H2,1-3H3",WQRPBKUCJBWQRT-UHFFFAOYSA-N,prisotinol,Phase 2,,,,
Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O,"InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)",IVZKZONQVYTCKC-UHFFFAOYSA-N,pritelivir,Phase 2,helicase primase inhibitor,,,
CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O,"InChI=1S/C21H24N4O2/c1-2-27-19-10-6-5-9-18(19)25-20(15-24-13-11-22-12-14-24)23-17-8-4-3-7-16(17)21(25)26/h3-10,22H,2,11-15H2,1H3",OBWOSMGNXYUDFB-UHFFFAOYSA-N,prlx-93936,Phase 1/Phase 2,voltage-dependent anion selective channel protein inhibitor,,,
CC(C)(C=C(C#N)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(=N)[nH]cnc32)C1)N1CCN(C2COC2)CC1,"InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)",LCFFREMLXLZNHE-UHFFFAOYSA-N,prn1008,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,,,
C=CC(=O)N1CCN(CCCn2c(=O)c(-c3c(Cl)c(OC)cc(OC)c3Cl)cc3c[nH]c(=NC)nc32)CC1,"InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)",PUIXMSRTTHLNKI-UHFFFAOYSA-N,prn1371,Phase 1,protein tyrosine kinase inhibitor,,,
COCc1c[n+]([O-])c(C)cn1,"InChI=1S/C7H10N2O2/c1-6-3-8-7(5-11-2)4-9(6)10/h3-4H,5H2,1-2H3",KKKHJYGCTVKQEM-UHFFFAOYSA-N,proacipimox,Phase 1,cholesterol inhibitor,,,
CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,"InChI=1S/C23H31NO2/c1-4-17-23(20-13-9-7-10-14-20,21-15-11-8-12-16-21)22(25)26-19-18-24(5-2)6-3/h7-16H,4-6,17-19H2,1-3H3",SNTQPLDRUZOSDP-UHFFFAOYSA-N,proadifen,Preclinical,nitric oxide synthase inhibitor,NOS1,,
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,"InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)",DBABZHXKTCFAPX-UHFFFAOYSA-N,probenecid,Launched,uricosuric blocker,PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1,nephrology|rheumatology,hyperuricemia|gout
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3",FYPMFJGVHOHGLL-UHFFFAOYSA-N,probucol,Launched,atherogenesis inhibitor,ABCA1|ABCB11|CES1,cardiology,coronary artery disease (CAD)
CCN(CC)CCNC(=O)c1ccc(N)cc1,"InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)",REQCZEXYDRLIBE-UHFFFAOYSA-N,procainamide,Launched,sodium channel blocker,DNMT1|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT)
CCN(CC)CCOC(=O)c1ccc(N)cc1,"InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3",MFDFERRIHVXMIY-UHFFFAOYSA-N,procaine,Launched,HMGCR inhibitor,CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3,neurology/psychiatry,anesthetic
CNNCc1ccc(C(=O)NC(C)C)cc1,"InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)",CPTBDICYNRMXFX-UHFFFAOYSA-N,procarbazine,Launched,monoamine oxidase inhibitor,,hematologic malignancy,Hodgkin's lymphoma
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)",FKNXQNWAXFXVNW-UHFFFAOYSA-N,procaterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3",WIKYUJGCLQQFNW-UHFFFAOYSA-N,prochlorperazine,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4,gastroenterology,nausea|vomiting
O=C(O)CCc1nc2ccccc2[nH]1,"InChI=1S/C10H10N2O2/c13-10(14)6-5-9-11-7-3-1-2-4-8(7)12-9/h1-4H,5-6H2,(H,11,12)(H,13,14)",XYWJNTOURDMTPI-UHFFFAOYSA-N,procodazole,Preclinical,immunostimulant,,,
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2c1c(O)cc(O)c2c1OC(c1ccc(O)c(O)c1)C(O)C2,"InChI=1S/C30H26O12/c31-13-7-20(37)24-23(8-13)41-29(12-2-4-16(33)19(36)6-12)27(40)26(24)25-21(38)10-17(34)14-9-22(39)28(42-30(14)25)11-1-3-15(32)18(35)5-11/h1-8,10,22,26-29,31-40H,9H2",XFZJEEAOWLFHDH-UHFFFAOYSA-N,procyanidin-b-2,Phase 2,,,,
COc1cc(NC(C)CCCN)c2ncccc2c1,"InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3",INDBQLZJXZLFIT-UHFFFAOYSA-N,procyclidine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,parkinsonism|Parkinson's Disease|akathisia|dystonia
O=c1[nH]c(C(O)O)cs1,"InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h1,3,6-7H,(H,5,8)",WIPLQCGXEUQNNF-UHFFFAOYSA-N,procysteine,Phase 3,glutathione synthase stimulant,,,
CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21,"InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3",CDOZDBSBBXSXLB-UHFFFAOYSA-N,profenamine,Launched,butyrylcholinesterase inhibitor,CHRM1,neurology/psychiatry,Parkinson's Disease
CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21,"InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3",CDOZDBSBBXSXLB-UHFFFAOYSA-N,profenamine,Launched,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,Parkinson's Disease
Nc1ccc2cc3ccc(N)cc3nc2c1,"InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2",WDVSHHCDHLJJJR-UHFFFAOYSA-N,proflavine-hemisulfate,Phase 2,topical anesthetic,F2,,
CC(=O)C1CCC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,"InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,16-19H,5-12H2,1-3H3",MNRHZPCIEGLWGK-UHFFFAOYSA-N,progesterone,Launched,progesterone receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5,obstetrics/gynecology|endocrinology,infertility|amenorrhea
CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1,"InChI=1S/C46H58ClN5O8/c1-5-21-51(22-6-2)46(57)40(48-44(55)34-11-8-7-9-12-34)18-20-42(53)59-29-10-23-49-24-26-50(27-25-49)28-30-60-43(54)32-38-33(3)52(41-19-17-37(58-4)31-39(38)41)45(56)35-13-15-36(47)16-14-35/h7-9,11-17,19,31,40H,5-6,10,18,20-30,32H2,1-4H3,(H,48,55)",PTXGHCGBYMQQIG-UHFFFAOYSA-N,proglumetacin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1,"InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)",DGMKFQYCZXERLX-UHFFFAOYSA-N,proglumide,Withdrawn,CCK receptor antagonist,CCKAR|CCKBR,,
CC(C)N=C(N)N=C(N)Nc1ccc(Cl)cc1,"InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)",SSOLNOMRVKKSON-UHFFFAOYSA-N,proguanil,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria
CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O,"InChI=1S/C13H24N4O3/c1-8(2)6-10(12(19)16-7-11(14)18)17-13(20)9-4-3-5-15-9/h8-10,15H,3-7H2,1-2H3,(H2,14,18)(H,16,19)(H,17,20)",NOOJLZTTWSNHOX-UHFFFAOYSA-N,prolylleucylglycinamide,Phase 2,melanocyte-stimulating hormone release inhibitor,,,
CN(C)CCCN1c2ccccc2Sc2ccccc21,"InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3",ZGUGWUXLJSTTMA-UHFFFAOYSA-N,promazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C,neurology/psychiatry,schizophrenia
CCCOc1ccc2c(c1)CCC1C2CCC2(C)C(OC)CCC12,"InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3",IUWKNLFTJBHTSD-UHFFFAOYSA-N,promestriene,Launched,estrogen receptor agonist,ESR1,endocrinology,androgenetic alopecia
CC(CN1c2ccccc2Sc2ccccc21)N(C)C,"InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3",PWWVAXIEGOYWEE-UHFFFAOYSA-N,promethazine,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|allergy,sedative|allergic rhinitis
CC(C)NCC(O)c1ccc2ccccc2c1,"InChI=1S/C15H19NO/c1-11(2)16-10-15(17)14-8-7-12-5-3-4-6-13(12)9-14/h3-9,11,15-17H,10H2,1-2H3",HRSANNODOVBCST-UHFFFAOYSA-N,pronethalol,Withdrawn,adrenergic receptor antagonist,,,
CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,"InChI=1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)",QTGAJCQTLIRCFL-UHFFFAOYSA-N,propacetamol,Launched,cyclooxygenase inhibitor,PTGS2,endocrinology|neurology/psychiatry,fever|pain relief
CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,"InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3",JWHAUXFOSRPERK-UHFFFAOYSA-N,propafenone,Launched,antiarrhythmic,ADRB1|ADRB2|KCNA5|KCNH2,cardiology,atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias
O=C(O)CC[Ge](=O)O[Ge](=O)CCC(=O)O,"InChI=1S/C6H10Ge2O7/c9-5(10)1-3-7(13)15-8(14)4-2-6(11)12/h1-4H2,(H,9,10)(H,11,12)",XEABSBMNTNXEJM-UHFFFAOYSA-N,propagermanium,Launched,CCR agonist,CCR2,infectious disease,hepatitis B
O=C(O)CC[Ge](=O)O[Ge](=O)CCC(=O)O,"InChI=1S/C6H10Ge2O7/c9-5(10)1-3-7(13)15-8(14)4-2-6(11)12/h1-4H2,(H,9,10)(H,11,12)",XEABSBMNTNXEJM-UHFFFAOYSA-N,propagermanium,Launched,interferon receptor agonist,CCR2,infectious disease,hepatitis B
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C,"InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1",VVWYOYDLCMFIEM-UHFFFAOYSA-N,propantheline,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)
CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],"InChI=1S/C6H11N3O9/c1-2-6(3-16-7(10)11,4-17-8(12)13)5-18-9(14)15/h2-5H2,1H3",YZZCJYJBCUJISI-UHFFFAOYSA-N,propatylnitrate,Launched,,,cardiology,angina pectoris
CCCn1cnc2c1c(=O)n(CCCCC(C)=O)c(=O)n2C,"InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3",RBQOQRRFDPXAGN-UHFFFAOYSA-N,propentofylline,Launched,adenosine reuptake inhibitor,PDE1A,neurology/psychiatry,stroke
CCCn1cnc2c1c(=O)n(CCCCC(C)=O)c(=O)n2C,"InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3",RBQOQRRFDPXAGN-UHFFFAOYSA-N,propentofylline,Launched,phosphodiesterase inhibitor,PDE1A,neurology/psychiatry,stroke
CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21,"InChI=1S/C27H33N4/c1-4-31(3,5-2)17-9-16-30-26-19-22(29)13-15-24(26)23-14-12-21(28)18-25(23)27(30)20-10-7-6-8-11-20/h6-8,10-15,18-19,29H,4-5,9,16-17,28H2,1-3H3/q+1/p+1",ZDWVWKDAWBGPDN-UHFFFAOYSA-O,propidium-iodide,Preclinical,,ACHE,,
O=C1CCO1,InChI=1S/C3H4O2/c4-3-1-2-5-3/h1-2H2,VEZXCJBBBCKRPI-UHFFFAOYSA-N,propiolactone,Launched,,,infectious disease,antiseptic
CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,"InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3",QPCVHQBVMYCJOM-UHFFFAOYSA-N,propiverine,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence
CC(C)c1cccc(C(C)C)c1O,"InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3",OLBCVFGFOZPWHH-UHFFFAOYSA-N,propofol,Launched,benzodiazepine receptor agonist,FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A,neurology/psychiatry,anesthetic
CNC(=O)Oc1ccccc1OC(C)C,"InChI=1S/C11H15NO3/c1-8(2)14-9-6-4-5-7-10(9)15-11(13)12-3/h4-8H,1-3H3,(H,12,13)",ISRUGXGCCGIOQO-UHFFFAOYSA-N,propoxur,Launched,,,infectious disease,flea control
CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,"InChI=1S/C16H26N2O3/c1-4-10-20-15-12-13(17)7-8-14(15)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3",CAJIGINSTLKQMM-UHFFFAOYSA-N,propoxycaine,Launched,local anesthetic,,neurology/psychiatry,anesthetic
CC(C)NCC(O)COc1cccc2ccccc12,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,propranolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology|neurology/psychiatry,hypertension|angina pectoris|migraine headache
CC(C)NCC(O)COc1cccc2ccccc12,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,propranolol-(r),Preclinical,adrenergic receptor antagonist,ADRB2|ADRB3,,
CC(C)NCC(O)COc1cccc2ccccc12,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,propranolol-(s),Preclinical,adrenergic receptor antagonist,ADRB1|HTR1A|HTR5A|SLC10A1,,
CCCOC(=O)c1ccccc1,"InChI=1S/C10H12O2/c1-2-8-12-10(11)9-6-4-3-5-7-9/h3-7H,2,8H2,1H3",UDEWPOVQBGFNGE-UHFFFAOYSA-N,propyl-benzoate,Launched,,,,
CC(O)CO,"InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3",DNIAPMSPPWPWGF-UHFFFAOYSA-N,propylene-glycol,Launched,,,,
CNC(C)CC1CCCCC1,"InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3",JCRIVQIOJSSCQD-UHFFFAOYSA-N,propylhexedrine,Launched,adrenergic receptor agonist,,otolaryngology|endocrinology|allergy,nasal congestion|fever|allergic rhinitis
CCCOC(=O)c1ccc(O)cc1,"InChI=1S/C10H12O3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11H,2,7H2,1H3",QELSKZZBTMNZEB-UHFFFAOYSA-N,propylparaben,Launched,,,,
CCCc1cc(=O)[nH]c(=S)[nH]1,"InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)",KNAHARQHSZJURB-UHFFFAOYSA-N,propylthiouracil,Launched,thyroid peroxidase inhibitor,DIO1|TPO,endocrinology,hyperthyroidism|Grave's disease|goiter
Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3",PXWLVJLKJGVOKE-UHFFFAOYSA-N,propyphenazone,Preclinical,anti-inflammatory agent,,,
Cc1ccc2c(-c3ccccc3)nc(=O)n(C(C)C)c2c1,"InChI=1S/C18H18N2O/c1-12(2)20-16-11-13(3)9-10-15(16)17(19-18(20)21)14-7-5-4-6-8-14/h4-12H,1-3H3",JTIGKVIOEQASGT-UHFFFAOYSA-N,proquazone,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief
CC1OC(OC2C=C3CCC4C(CCC5(C)C(c6ccc(=O)oc6)CCC45O)C3(C)CC2)C(O)C(O)C1O,"InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3",MYEJFUXQJGHEQK-UHFFFAOYSA-N,proscillaridin-a,Launched,,,cardiology,congestive heart failure|cardiac arrythmia
CCCc1cc(C(N)=S)ccn1,"InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)",VRDIULHPQTYCLN-UHFFFAOYSA-N,protionamide,Launched,,,infectious disease,tuberculosis
NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(O)c1ccc(O)[nH]1,"InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h3-4,7-8,11-12,15,20-21,23,25H,1-2,5-6H2,(H2,17,24)(H,18,19)",QYHFILLIFQOIIA-UHFFFAOYSA-N,protirelin,Launched,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic
C=Cc1c(C)c2[nH]c1=Cc1[nH]c(c(C=CC(=O)O)c1C)C=c1[nH]c(c(C)c1C=CC(=O)O)=Cc1[nH]c(c(CC)c1C)C=2,"InChI=1S/C34H34N4O4/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25/h8-16,35-38H,2,7H2,1,3-6H3,(H,39,40)(H,41,42)",PDKFOJSLCWWIFZ-UHFFFAOYSA-N,protoporphyrin-ix,Preclinical,heme oxygenase inhibitor,HMOX1,,
CNCCCC1c2ccccc2C=Cc2ccccc21,"InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3",BWPIARFWQZKAIA-UHFFFAOYSA-N,protriptyline,Launched,tricyclic antidepressant,SLC6A2|SLC6A4,neurology/psychiatry,depression
Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1,"InChI=1S/C17H25N3O4/c1-12-19-16(24-20-12)11-23-15-8-6-5-7-14(15)22-10-13(21)9-18-17(2,3)4/h5-8,13,18,21H,9-11H2,1-4H3",CEDZURSVVKNCSL-UHFFFAOYSA-N,proxodolol,Launched,adrenergic receptor antagonist,,,
c1ccc(COCCCc2c[nH]cn2)cc1,"InChI=1S/C13H16N2O/c1-2-5-12(6-3-1)10-16-8-4-7-13-9-14-11-15-13/h1-3,5-6,9,11H,4,7-8,10H2,(H,14,15)",WNWALBVQAAIULR-UHFFFAOYSA-N,proxyfan,Preclinical,histamine receptor modulator,HRH3,,
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,"InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3",KCLANYCVBBTKTO-UHFFFAOYSA-N,proxymetacaine,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,anesthetic
CC(O)Cn1cnc2c1c(=O)n(C)c(=O)n2C,"InChI=1S/C10H14N4O3/c1-6(15)4-14-5-11-8-7(14)9(16)13(3)10(17)12(8)2/h5-6,15H,4H2,1-3H3",KYHQZNGJUGFTGR-UHFFFAOYSA-N,proxyphylline,Launched,,,pulmonary,asthma
CCS(=O)(=O)N1CCN(c2ccc(N=c3[nH]cc(C(N)=O)c(=NC4CC4)[nH]3)cc2)CC1,"InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)",BGLPECHZZQDNCD-UHFFFAOYSA-N,prt062070,Phase 2/Phase 3,JAK inhibitor,SYK,,
CCS(=O)(=O)N1CCN(c2ccc(N=c3[nH]cc(C(N)=O)c(=NC4CC4)[nH]3)cc2)CC1,"InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)",BGLPECHZZQDNCD-UHFFFAOYSA-N,prt062070,Phase 2/Phase 3,SYK inhibitor,SYK,,
NC(=O)c1c[nH]c(=NC2CCCCC2N)[nH]c1=Nc1cccc(-n2nccn2)c1,"InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)",TXGKRVFSSHPBAJ-UHFFFAOYSA-N,prt062607,Phase 2,SYK inhibitor,FGR|MAP3K9|SYK,,
O=C1C(=Cc2cccnc2)C(=O)c2ccccc21,InChI=1S/C15H9NO2/c17-14-11-5-1-2-6-12(11)15(18)13(14)8-10-4-3-7-16-9-10/h1-9H,OMHZFEWYVFWVLI-UHFFFAOYSA-N,prt4165,Preclinical,polycomb repressive complex inhibitor,PRC1,,
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,"InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)",ZPMNHBXQOOVQJL-UHFFFAOYSA-N,prucalopride,Launched,serotonin receptor agonist,HTR4,gastroenterology,constipation
Cc1oc(=O)oc1CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)c2n3C(C)S2)CC1,"InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)",PWNMXPDKBYZCOO-UHFFFAOYSA-N,prulifloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease|pulmonary|gastroenterology,urinary tract infections|bronchitis|diarrhea
N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,"InChI=1S/C22H21FN4O/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20/h1-7,15,25H,8-13H2",AQRLDDAFYYAIJP-UHFFFAOYSA-N,pruvanserin,Phase 2,serotonin receptor antagonist,HTR2A|HTR2C,,
COc1cc(Cl)cc(C(C)Nc2cc(N3CCNCC3)ccc2S(C)(=O)=O)c1OC,"InChI=1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3",BSLXKMCHXRCBIH-UHFFFAOYSA-N,prx-07034,Phase 1,serotonin receptor antagonist,,,
N#Cc1cc(CN2CCC(N=c3[nH]cnc4sc(Cl)cc34)CC2)ccc1F,"InChI=1S/C19H17ClFN5S/c20-17-8-15-18(23-11-24-19(15)27-17)25-14-3-5-26(6-4-14)10-12-1-2-16(21)13(7-12)9-22/h1-2,7-8,11,14H,3-6,10H2,(H,23,24,25)",IENZFHBNCRQMNP-UHFFFAOYSA-N,prx-08066,Phase 2,serotonin receptor antagonist,HTR2B,,
Cc1c(-n2c(O)c3n(c2=O)CCC3O)ccc(C#N)c1Cl,"InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,19-20H,4-5H2,1H3",ZHVQJONIPYDBTP-UHFFFAOYSA-N,ps178990,Phase 1,androgen receptor modulator,AR,,
Nc1c(S(=O)(=O)O)cc(Nc2cccc3ccccc23)c2c1C(=O)c1ccccc1C2=O,"InChI=1S/C24H16N2O5S/c25-22-19(32(29,30)31)12-18(26-17-11-5-7-13-6-1-2-8-14(13)17)20-21(22)24(28)16-10-4-3-9-15(16)23(20)27/h1-12,26H,25H2,(H,29,30,31)",ZHQRPIRGSWEALJ-UHFFFAOYSA-N,psb-06126,Preclinical,NTPDase inhibitor,ENTPD3,,
CCC1CN2C(=O)N(C)c3[nH]c(-c4ccccc4)nc3C2=N1,"InChI=1S/C16H17N5O/c1-3-11-9-21-15(17-11)12-14(20(2)16(21)22)19-13(18-12)10-7-5-4-6-8-10/h4-8,11H,3,9H2,1-2H3,(H,18,19)",RGDHRCXUMURWBJ-UHFFFAOYSA-N,psb-11,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA3,,
CCCn1c(=O)[nH]c2[nH]c(-c3ccc(S(=O)(=O)O)cc3)nc2c1=O,"InChI=1S/C14H14N4O5S/c1-2-7-18-13(19)10-12(17-14(18)20)16-11(15-10)8-3-5-9(6-4-8)24(21,22)23/h3-6H,2,7H2,1H3,(H,15,16)(H,17,20)(H,21,22,23)",UYDRRQPGDSIMNU-UHFFFAOYSA-N,psb-1115,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,
CCCn1c(=O)[nH]c2[nH]c(-c3ccc(S(=O)(=O)N4CCN(c5ccc(Cl)cc5)CC4)cc3)nc2c1=O,"InChI=1S/C24H25ClN6O4S/c1-2-11-31-23(32)20-22(28-24(31)33)27-21(26-20)16-3-9-19(10-4-16)36(34,35)30-14-12-29(13-15-30)18-7-5-17(25)6-8-18/h3-10H,2,11-15H2,1H3,(H,26,27)(H,28,33)",OVHCTHHFOHMNFV-UHFFFAOYSA-N,psb-603,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CC1(F)C(O)C(CO)OC1n1ccc(=N)[nH]c1=O,"InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)",NYPIRLYMDJMKGW-UHFFFAOYSA-N,psi-6130,Phase 1,RNA polymerase inhibitor,,,
O=C(O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3c(ccc12)CCCC3,"InChI=1S/C21H18ClNO3/c22-14-8-5-12(6-9-14)11-17-20(24)18(21(25)26)16-10-7-13-3-1-2-4-15(13)19(16)23-17/h5-10,24H,1-4,11H2,(H,25,26)",DIEPFYNZGUUVHD-UHFFFAOYSA-N,psi-697,Phase 1,P selectin inhibitor,,,
CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)",TTZHDVOVKQGIBA-UHFFFAOYSA-N,psi-7976,Preclinical,HCV inhibitor,,,
CCCCC1CCC(c2nc(-c3ccncc3)no2)CC1,"InChI=1S/C17H23N3O/c1-2-3-4-13-5-7-15(8-6-13)17-19-16(20-21-17)14-9-11-18-12-10-14/h9-13,15H,2-8H2,1H3",OAVLEYPTWABFLF-UHFFFAOYSA-N,psn-375963,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,
O=C(Nc1ccc(Cl)cc1)Nc1cccc(-c2cccc(N3CCCC3)n2)c1,"InChI=1S/C22H21ClN4O/c23-17-9-11-18(12-10-17)24-22(28)25-19-6-3-5-16(15-19)20-7-4-8-21(26-20)27-13-1-2-14-27/h3-12,15H,1-2,13-14H2,(H2,24,25,28)",HDAYFSFWIPRJSO-UHFFFAOYSA-N,psncbam-1,Preclinical,cannabinoid receptor modulator,CNR1,,
O=c1ccc2cc3ccoc3cc2o1,InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H,ZCCUUQDIBDJBTK-UHFFFAOYSA-N,psoralen,Launched,,MAOA|MAOB,dermatology,psoriasis|eczema|vitiligo
CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(O)C(F)(F)C2,"InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3",ONBSHRSJOPSEGS-UHFFFAOYSA-N,pt-2385,Phase 1,hypoxia inducible factor inhibitor,EPAS1,,
Cc1nc2cc(F)c(F)cc2n1-c1cncc(=Nc2ccc(C(F)(F)F)cc2)[nH]1,"InChI=1S/C19H12F5N5/c1-10-26-15-6-13(20)14(21)7-16(15)29(10)18-9-25-8-17(28-18)27-12-4-2-11(3-5-12)19(22,23)24/h2-9H,1H3,(H,27,28)",JEZGPBWIZWPDHP-UHFFFAOYSA-N,ptc-028,Preclinical,BMI-1 inhibitor,,,
COc1cc(Br)c(N=c2[nH]c(-c3c(C)nc4ncccn34)cs2)c(Br)c1,"InChI=1S/C17H13Br2N5OS/c1-9-15(24-5-3-4-20-16(24)21-9)13-8-26-17(22-13)23-14-11(18)6-10(25-2)7-12(14)19/h3-8H,1-2H3,(H,22,23)",XVOOCQSWCCRVDY-UHFFFAOYSA-N,ptc-209,Preclinical,BMI-1 inhibitor,,,
COc1cc(C=Cc2ccc(O)cc2)cc(OC)c1,"InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3",VLEUZFDZJKSGMX-UHFFFAOYSA-N,pterostilbene,Phase 2/Phase 3,cyclooxygenase inhibitor,PTGS2,,
COc1cc(C=Cc2ccc(O)cc2)cc(OC)c1,"InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3",VLEUZFDZJKSGMX-UHFFFAOYSA-N,pterostilbene,Phase 2/Phase 3,PPAR receptor agonist,PTGS2,,
CC(C)NCCCn1c(Sc2cc3c(cc2I)OCO3)nc2c(=N)[nH]cnc21,"InChI=1S/C18H21IN6O2S/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23)",SUPVGFZUWFMATN-UHFFFAOYSA-N,pu-h71,Phase 1,HSP inhibitor,HSP90AA1,,
O=c1c(-c2ccc(O)cc2)coc2c(C3OC(CO)C(O)C(O)C3O)c(O)ccc12,"InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2",HKEAFJYKMMKDOR-UHFFFAOYSA-N,puerarin,Phase 2,serotonin receptor antagonist,,,
O=C(NC1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,"InChI=1S/C15H17N3O2S/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20)",AFUWQWYPPZFWCO-UHFFFAOYSA-N,pumosetrag,Phase 2,serotonin receptor agonist,HTR3A|HTR4,,
c1ccc2c(Oc3nc(=Nc4ccc(N5CCOCC5)cc4)c4ncn(C5CCCCC5)c4[nH]3)cccc2c1,"InChI=1S/C31H32N6O2/c1-2-9-25(10-3-1)37-21-32-28-29(33-23-13-15-24(16-14-23)36-17-19-38-20-18-36)34-31(35-30(28)37)39-27-12-6-8-22-7-4-5-11-26(22)27/h4-8,11-16,21,25H,1-3,9-10,17-20H2,(H,33,34,35)",FYBHCRQFSFYWPY-UHFFFAOYSA-N,purmorphamine,Preclinical,smoothened receptor agonist,SMO,,
COc1ccc(CC(N)C(=O)NC2C(CO)OC(n3cnc4c(N(C)C)ncnc43)C2O)cc1,"InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)",RXWNCPJZOCPEPQ-UHFFFAOYSA-N,puromycin,Preclinical,protein synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,
CC(C)C(CO)N=c1[nH]c(=Nc2cccc(Cl)c2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)",PMXCMJLOPOFPBT-UHFFFAOYSA-N,purvalanol-a,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC,,
CC(C)C(CO)N=c1[nH]c(=Nc2ccc(C(=O)O)c(Cl)c2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)",ZKDXRFMOHZVXSG-UHFFFAOYSA-N,purvalanol-b,Preclinical,tyrosine kinase inhibitor,CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2,,
NCCCCN,InChI=1S/C4H12N2/c5-3-1-2-4-6/h1-6H2,KIDHWZJUCRJVML-UHFFFAOYSA-N,putrescine,Phase 2,tissue transglutaminase inhibitor,AMD1|KCNJ4|ODC1,,
CCC(C)SSc1ncc[nH]1,"InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)",BPBPYQWMFCTCNG-UHFFFAOYSA-N,px-12,Phase 2,thioredoxin inhibitor,CNR1|TXN,,
NC(Cc1ccc([N+]([O-])(CCCl)CCCl)cc1)C(=O)O,"InChI=1S/C13H18Cl2N2O3/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)",GSKQMLGAUOTSKT-UHFFFAOYSA-N,px-478,Phase 1,hypoxia inducible factor inhibitor,,,
CC1CCC2(OC1)OC1CC3C4CCC5CC(O)CCC5(C)C4CCC3(C)C1C2C,"InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3",GMBQZIIUCVWOCD-UHFFFAOYSA-N,pym50028,Phase 2,neurotrophic agent,,,
CCOC(=O)c1ccc(N2NC(=O)C(=Cc3ccc([N+](=O)[O-])o3)C2=O)cc1,"InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21)",ARGIPZKQJGFSGQ-UHFFFAOYSA-N,pyr-41,Preclinical,ubiquitin activating enzyme inhibitor,,,
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,"InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)",WLJNZVDCPSBLRP-UHFFFAOYSA-N,pyrantel,Launched,acetylcholine receptor agonist,,infectious disease,gastrointestinal roundworms
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,"InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)",WLJNZVDCPSBLRP-UHFFFAOYSA-N,pyrantel,Launched,nicotinic receptor agonist,,infectious disease,gastrointestinal roundworms
CN1CCCN=C1C=Cc1cccs1,"InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3",YSAUAVHXTIETRK-UHFFFAOYSA-N,pyrantel-pamoate,Launched,neuromuscular blocker,,infectious disease,hookworm|tapeworm
NC(=O)c1cnccn1,"InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)",IPEHBUMCGVEMRF-UHFFFAOYSA-N,pyrazinamide,Launched,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis
N=C(N)NC(=O)c1cnccn1,"InChI=1S/C6H7N5O/c7-6(8)11-5(12)4-3-9-1-2-10-4/h1-3H,(H4,7,8,11,12)",WNBSDCKJFDZMHT-UHFFFAOYSA-N,pyrazinoylguanidine,Phase 1,diuretic,,,
Oc1c2ccccc2c2c3c(cccc13)N=N2,"InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7,17H",KRIUNPBAQZGFQA-UHFFFAOYSA-N,pyrazolanthrone,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK,,
COc1ccc2c(c1)-c1nn(CCCN(C)C)c3ccc([N+](=O)[O-])c(c13)N2,"InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3",HZCWPKGYTCJSEB-UHFFFAOYSA-N,pyrazoloacridine,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,
C=CC=CCC1=C(C)C(OC(=O)C2C(C=C(C)C)C2(C)C)CC1=O,"InChI=1S/C21H28O3/c1-7-8-9-10-15-14(4)18(12-17(15)22)24-20(23)19-16(11-13(2)3)21(19,5)6/h7-9,11,16,18-19H,1,10,12H2,2-6H3",ROVGZAWFACYCSP-UHFFFAOYSA-N,pyrethrins,Launched,,,infectious disease,flea control
Cc1ncc(CO)c(C=O)c1O,"InChI=1S/C8H9NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,4,10,12H,3H2,1H3",RADKZDMFGJYCBB-UHFFFAOYSA-N,pyridoxal,Launched,,PDXK,neurology/psychiatry,epilepsy
C=c1[nH]cc(CO)c(=CNNC(=O)c2ccncc2)c1=O,"InChI=1S/C14H14N4O3/c1-9-13(20)12(11(8-19)6-16-9)7-17-18-14(21)10-2-4-15-5-3-10/h2-7,16-17,19H,1,8H2,(H,18,21)",AHLAVTICAUSHAX-UHFFFAOYSA-N,pyridoxal-isonicotinoyl-hydrazone,Phase 2,apoptosis stimulant,,,
Cc1ncc(CO)c(CN)c1O,"InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3",NHZMQXZHNVQTQA-UHFFFAOYSA-N,pyridoxamine,Phase 3,AGE inhibitor,,,
Cc1ncc(CO)c(CO)c1O,"InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3",LXNHXLLTXMVWPM-UHFFFAOYSA-N,pyridoxine,Launched,vitamin B,DDC|PDXK,metabolism,vitamin B6 deficiency
CCc1[nH]c(=N)[nH]c(=N)c1-c1ccc(Cl)cc1,"InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)",WKSAUQYGYAYLPV-UHFFFAOYSA-N,pyrimethamine,Launched,dihydrofolate reductase inhibitor,DHFR|SLC47A1,infectious disease,malaria
O=S(=O)(NCC1CC1)c1ccc(N=c2nc(N3CCCc4cc(O)ccc43)cc[nH]2)cc1,"InChI=1S/C23H25N5O3S/c29-19-7-10-21-17(14-19)2-1-13-28(21)22-11-12-24-23(27-22)26-18-5-8-20(9-6-18)32(30,31)25-15-16-3-4-16/h5-12,14,16,25,29H,1-4,13,15H2,(H,24,26,27)",QRJTZIJWDLJKQO-UHFFFAOYSA-N,pyrintegrin,Preclinical,integrin signaling activator,,,
On1ccccc1=S,"InChI=1S/C5H5NOS/c7-6-4-2-1-3-5(6)8/h1-4,7H",YBBJKCMMCRQZMA-UHFFFAOYSA-N,pyrithione-zinc,Launched,ATP synthase inhibitor,KCNQ1|KCNQ2|KCNQ4|KCNQ5,dermatology,dandruff|cosmetic
CCC1(CC)C(=O)CC=NC1=O,"InChI=1S/C9H13NO2/c1-3-9(4-2)7(11)5-6-10-8(9)12/h6H,3-5H2,1-2H3",PXOUWIIMEOTTMM-UHFFFAOYSA-N,pyrithyldione,Withdrawn,psychoactive drug,,,
Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,"InChI=1S/C16H20N2O4S2/c1-9-15(21)13(5-19)11(3-17-9)7-23-24-8-12-4-18-10(2)16(22)14(12)6-20/h3-4,19-22H,5-8H2,1-2H3",SIXLXDIJGIWWFU-UHFFFAOYSA-N,pyritinol,Launched,,,rheumatology|neurology/psychiatry,rheumatoid arthritis|senile dementia
COc1ccc2[nH]c3cc(Cl)ccc3c(=Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1,"InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)",DJUFPMUQJKWIJB-UHFFFAOYSA-N,pyronaridine,Phase 3,antimalarial agent,,,
CCOc1cc2[nH]cc(C#N)c(=Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CC1CCCN1C,"InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)",SADXACCFNXBCFY-UHFFFAOYSA-N,pyrotinib,Phase 3,kinase inhibitor,,,
O=C(CCCCCCC(O)=NO)Nc1cccnc1,"InChI=1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)",PTJGLFIIZFVFJV-UHFFFAOYSA-N,pyroxamide,Phase 1,HDAC inhibitor,HDAC1,,
S=C(S)N1CCCC1,"InChI=1S/C5H9NS2/c7-5(8)6-3-1-2-4-6/h1-4H2,(H,7,8)",VSWDORGPIHIGNW-UHFFFAOYSA-N,pyrrolidine-dithiocarbamate,Preclinical,NFkB pathway inhibitor,HSD11B1|RELA,,
Cc1cc(C=Cc2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,"InChI=1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1",QMHSXPLYMTVAMK-UHFFFAOYSA-N,pyrvinium-pamoate,Launched,androgen receptor antagonist,AR,infectious disease,pinworm
CC(C)c1ccc(CC(=O)N2CCN(c3ccc(C#N)nn3)CC2)cc1,"InChI=1S/C20H23N5O/c1-15(2)17-5-3-16(4-6-17)13-20(26)25-11-9-24(10-12-25)19-8-7-18(14-21)22-23-19/h3-8,15H,9-13H2,1-2H3",LGWDVWIZDPGCFG-UHFFFAOYSA-N,pz-2891,Preclinical,pantothenate kinase activator,,,
CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1,"InChI=1S/C29H28ClF3N4O2/c1-2-25-27(37-18-22(30)7-12-26(37)35-25)28(38)34-17-19-3-8-23(9-4-19)36-15-13-21(14-16-36)20-5-10-24(11-6-20)39-29(31,32)33/h3-12,18,21H,2,13-17H2,1H3,(H,34,38)",OJICYBSWSZGRFB-UHFFFAOYSA-N,q-203,Phase 2,ATP synthase inhibitor,,,
Cc1c(O)nc2n1Cc1c(Cl)cccc1N2,"InChI=1S/C11H10ClN3O/c1-6-10(16)14-11-13-9-4-2-3-8(12)7(9)5-15(6)11/h2-4,16H,5H2,1H3,(H,13,14)",XIXXNJFWPAVKFR-UHFFFAOYSA-N,quazinone,Phase 2,phosphodiesterase inhibitor,PDE3A|PDE3B,,
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H",REFJWTPEDVJJIY-UHFFFAOYSA-N,quercetin,Launched,polar auxin transport inhibitor,ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1,neurology/psychiatry|allergy,fatigue|allergic rhinitis|drowsiness
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2",URKOMYMAXPYINW-UHFFFAOYSA-N,quetiapine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2,neurology/psychiatry,schizophrenia|bipolar disorder
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2",URKOMYMAXPYINW-UHFFFAOYSA-N,quetiapine,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2,neurology/psychiatry,schizophrenia|bipolar disorder
CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,"InChI=1S/C34H35ClN2O3S/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39/h6-18H,19-21H2,1-5H3,(H,38,39)",NZOONKHCNQFYCI-UHFFFAOYSA-N,quiflapon,Phase 2,leukotriene synthesis inhibitor,ALOX5|ALOX5AP,,
CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21,"InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3",GDFGTRDCCWFXTG-UHFFFAOYSA-N,quinagolide,Launched,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1Cc2ccccc2CC1C(=O)O,"InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)",JSDRRTOADPPCHY-UHFFFAOYSA-N,quinapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|angioedema
CC(NC(CCc1ccccc1)C(=O)O)C(=O)N1Cc2ccccc2CC1C(=O)O,"InChI=1S/C23H26N2O5/c1-15(24-19(22(27)28)12-11-16-7-3-2-4-8-16)21(26)25-14-18-10-6-5-9-17(18)13-20(25)23(29)30/h2-10,15,19-20,24H,11-14H2,1H3,(H,27,28)(H,29,30)",FLSLEGPOVLMJMN-UHFFFAOYSA-N,quinaprilat,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|angioedema
CCCN1CCCC2Cc3[nH]c(=N)ncc3CC21,"InChI=1S/C14H22N4/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12/h9-10,13H,2-8H2,1H3,(H2,15,16,17)",TUFADSGTJUOBEH-UHFFFAOYSA-N,quinelorane,Phase 3,dopamine receptor agonist,DRD2|DRD3,,
C#CC1(O)CCC2C3CCc4cc(OC5CCCC5)ccc4C3CCC21C,"InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3",PWZUUYSISTUNDW-UHFFFAOYSA-N,quinestrol,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology,menopause
CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1,"InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)",AGMMTXLNIQSRCG-UHFFFAOYSA-N,quinethazone,Launched,thiazide diuretic,,cardiology,hypertension
C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3",LOUPRKONTZGTKE-UHFFFAOYSA-N,quinidine,Launched,sodium channel blocker,KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4,infectious disease|cardiology,malaria|atrial fibrillation (AF)|ventricular arrhythmias
C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,"InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3",LOUPRKONTZGTKE-UHFFFAOYSA-N,quinine,Launched,hemozoin biocrystallization inhibitor,GP9|KCNB2|KCNN4|SLC29A4,infectious disease,malaria
C=CC1CN2CCC1CC2C(OC(=O)OCC)c1ccnc2ccc(OC)cc12,"InChI=1S/C23H28N2O4/c1-4-15-14-25-11-9-16(15)12-21(25)22(29-23(26)28-5-2)18-8-10-24-20-7-6-17(27-3)13-19(18)20/h4,6-8,10,13,15-16,21-22H,1,5,9,11-12,14H2,2-3H3",NSBRKSWSLRQPJW-UHFFFAOYSA-N,quinine-ethyl-carbonate,Launched,,,infectious disease,malaria
O=C(O)c1cccnc1C(=O)O,"InChI=1S/C7H5NO4/c9-6(10)4-2-1-3-8-5(4)7(11)12/h1-3H,(H,9,10)(H,11,12)",GJAWHXHKYYXBSV-UHFFFAOYSA-N,quinolinic-acid,Preclinical,glutamate receptor agonist,,,
CCCN1CCCC2Cc3[nH]ncc3CC21,"InChI=1S/C13H21N3/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12/h9-10,13H,2-8H2,1H3,(H,14,15)",FTSUPYGMFAPCFZ-UHFFFAOYSA-N,quinpirol-(-),Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C,,
c1ccc2nc(N3CCNCC3)ccc2c1,"InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2",XRXDAJYKGWNHTQ-UHFFFAOYSA-N,quipazine,Preclinical,serotonin receptor agonist,HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4,,
CC(C)(C)c1cc(=NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)[nH]o1,"InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)",CVWXJKQAOSCOAB-UHFFFAOYSA-N,quizartinib,Phase 3,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET,,
Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,"InChI=1S/C13H20N2O/c1-10-7-6-8-11(2)13(10)14-12(16)9-15(3,4)5/h6-8H,9H2,1-5H3/p+1",QYUXPWDVDMSTKR-UHFFFAOYSA-O,qx-222,Preclinical,sodium channel blocker,,,
CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,"InChI=1S/C16H26N2O/c1-6-18(7-2,8-3)12-15(19)17-16-13(4)10-9-11-14(16)5/h9-11H,6-8,12H2,1-5H3/p+1",PYEBKOFMWAMBFV-UHFFFAOYSA-O,qx-314,Preclinical,sodium channel blocker,MAPK14|TGFBR1,,
CCCN(CCC)c1cc(C)nc2c(-c3cnc(N(C)C)cc3C)c(C)nn12,"InChI=1S/C22H32N6/c1-8-10-27(11-9-2)20-13-16(4)24-22-21(17(5)25-28(20)22)18-14-23-19(26(6)7)12-15(18)3/h12-14H,8-11H2,1-7H3",ANNRUWYFVIGKHA-UHFFFAOYSA-N,r-121919,Preclinical,CRF receptor antagonist,,,
[N-]=[N+]=NC1(CO)OC(n2ccc(=N)[nH]c2=O)C(O)C1O,"InChI=1S/C9H12N6O5/c10-4-1-2-15(8(19)12-4)7-5(17)6(18)9(3-16,20-7)13-14-11/h1-2,5-7,16-18H,3H2,(H2,10,12,19)",ODLGMSQBFONGNG-UHFFFAOYSA-N,r-1479,Phase 1,HCV inhibitor,,,
O=S(=O)(c1ccccc1F)N1CCOc2c(N3CCNCC3)cccc21,"InChI=1S/C18H20FN3O3S/c19-14-4-1-2-7-17(14)26(23,24)22-12-13-25-18-15(5-3-6-16(18)22)21-10-8-20-9-11-21/h1-7,20H,8-13H2",UPROBLPRPWYJGN-UHFFFAOYSA-N,r-1485,Phase 1,serotonin receptor antagonist,HTR6,,
Cn1c(=O)c(Oc2ccc(F)cc2F)cc2c[nH]c(=NC3CCOCC3)nc21,"InChI=1S/C19H18F2N4O3/c1-25-17-11(10-22-19(24-17)23-13-4-6-27-7-5-13)8-16(18(25)26)28-15-3-2-12(20)9-14(15)21/h2-3,8-10,13H,4-7H2,1H3,(H,22,23,24)",KKKRKRMVJRHDMG-UHFFFAOYSA-N,r-1487,Phase 1,p38 MAPK inhibitor,,,
Cc1cccc(-c2[nH]ncc2-c2ccc(F)c(-c3cnn(CCO)c3)c2)n1,"InChI=1S/C20H18FN5O/c1-13-3-2-4-19(24-13)20-17(11-22-25-20)14-5-6-18(21)16(9-14)15-10-23-26(12-15)7-8-27/h2-6,9-12,27H,7-8H2,1H3,(H,22,25)",JQGOCCALXFSRHZ-UHFFFAOYSA-N,r-268712,Preclinical,serine/threonine kinase inhibitor,TGFBR1,,
N=c1[nH]c(=Nc2ccc3c(c2)CCC(N2CCCC2)CC3)[nH]n1-c1cc2c(nn1)-c1ccccc1CCC2,"InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)",KXMZDGSRSGHMMK-UHFFFAOYSA-N,r-428,Phase 2,AXL kinase inhibitor,AXL,,
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,"InChI=1S/C27H26FN3OS/c1-19-24(26(32)31-17-18-33-27(31)29-19)13-16-30-14-11-22(12-15-30)25(20-5-3-2-4-6-20)21-7-9-23(28)10-8-21/h2-10,17-18H,11-16H2,1H3",MFVJXLPANKSLLD-UHFFFAOYSA-N,r-59022,Preclinical,diacylglycerol kinase inhibitor,DGKA,,
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1,"InChI=1S/C27H26FN3OS/c1-19-24(26(32)31-17-18-33-27(31)29-19)13-16-30-14-11-22(12-15-30)25(20-5-3-2-4-6-20)21-7-9-23(28)10-8-21/h2-10,17-18H,11-16H2,1H3",MFVJXLPANKSLLD-UHFFFAOYSA-N,r-59022,Preclinical,protein kinase inhibitor,DGKA,,
COc1cccc(CCc2ccccc2OCCC2CC(O)CN2C)c1,"InChI=1S/C22H29NO3/c1-23-16-20(24)15-19(23)12-13-26-22-9-4-3-7-18(22)11-10-17-6-5-8-21(14-17)25-2/h3-9,14,19-20,24H,10-13,15-16H2,1-2H3",AFZLABYDOCWQBQ-UHFFFAOYSA-N,r-96544,Preclinical,serotonin receptor antagonist,HTR2A,,
Oc1cccc(N=c2[nH]cc(F)c(=Nc3cccc(O)c3)[nH]2)c1,"InChI=1S/C16H13FN4O2/c17-14-9-18-16(20-11-4-2-6-13(23)8-11)21-15(14)19-10-3-1-5-12(22)7-10/h1-9,22-23H,(H2,18,19,20,21)",TVKGTSHBQZEFEE-UHFFFAOYSA-N,r112,Phase 1,SYK inhibitor,SYK,,
O=S(=O)(c1ccc2ccccc2c1)N1CCN(c2ncc(C(O)=NO)cn2)CC1,"InChI=1S/C19H19N5O4S/c25-18(22-26)16-12-20-19(21-13-16)23-7-9-24(10-8-23)29(27,28)17-6-5-14-3-1-2-4-15(14)11-17/h1-6,11-13,26H,7-10H2,(H,22,25)",MUTBJZVSRNUIHA-UHFFFAOYSA-N,r306465,Phase 1,HDAC inhibitor,,,
COc1cc(N=c2nc(N=c3ccc4c([nH]3)NC(=O)C(C)(C)O4)c(F)c[nH]2)cc(OC)c1OC,"InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)",NHHQJBCNYHBUSI-UHFFFAOYSA-N,r406,Phase 1,SYK inhibitor,RET|SYK,,
COc1ccc(F)c(F)c1C(=O)c1c[nH]c(=NC2CCN(S(C)(=O)=O)CC2)[nH]c1=N,"InChI=1S/C18H21F2N5O4S/c1-29-13-4-3-12(19)15(20)14(13)16(26)11-9-22-18(24-17(11)21)23-10-5-7-25(8-6-10)30(2,27)28/h3-4,9-10H,5-8H2,1-2H3,(H3,21,22,23,24)",JRNJNYBQQYBCLE-UHFFFAOYSA-N,r547,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK7,,
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,"InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)",YREYEVIYCVEVJK-UHFFFAOYSA-N,rabeprazole,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,"InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)",YREYEVIYCVEVJK-UHFFFAOYSA-N,rabeprazole,Launched,gastrin inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome
CC(C)(C)c1cc(C(C)(C)C)c2c(c1)C(O)(C(F)(F)F)C(=O)O2,"InChI=1S/C17H21F3O3/c1-14(2,3)9-7-10(15(4,5)6)12-11(8-9)16(22,13(21)23-12)17(18,19)20/h7-8,22H,1-6H3",RVNOANDLZIIFHB-UHFFFAOYSA-N,rac-bhff,Preclinical,GABA receptor positive allosteric modulator,GABBR1,,
CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,"InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25)",ODUOJXZPIYUATO-UHFFFAOYSA-N,racecadotril,Launched,enkephalinase inhibitor,MME,gastroenterology,diarrhea
CCN1CCCC1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,"InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)",WAOQONBSWFLFPE-UHFFFAOYSA-N,raclopride,Launched,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,
CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1,"InChI=1S/C18H23NO3/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15/h4-11,13,18-22H,2-3,12H2,1H3",YJQZYXCXBBCEAQ-UHFFFAOYSA-N,ractopamine,Launched,adrenergic receptor agonist,,endocrinology,weight-gain aid
Cc1c(NC(c2nnc(-c3ccc(C#N)cc3)o2)C(C)O)ccc(C#N)c1Cl,"InChI=1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3",XMBUPPIEVAFYHO-UHFFFAOYSA-N,rad140,Phase 1,androgen receptor modulator,,,
CC1NC(C)(C)COC1(O)c1cccc(Cl)c1,"InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3",RCOBKSKAZMVBHT-UHFFFAOYSA-N,radafaxine,Phase 2,dopamine-norepinephrine reuptake inhibitor,SLC6A3,,
CC(=O)NCC1CN(c2ccc(-c3ccc(CNCc4c[nH]nn4)cc3)c(F)c2)C(=O)O1,"InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)",BTTNOGHPGJANSW-UHFFFAOYSA-N,radezolid,Phase 2,bacterial 30S ribosomal subunit inhibitor,,,
CC(=O)NCC1CN(c2ccc(-c3ccc(CNCc4c[nH]nn4)cc3)c(F)c2)C(=O)O1,"InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)",BTTNOGHPGJANSW-UHFFFAOYSA-N,radezolid,Phase 2,bacterial 50S ribosomal subunit inhibitor,,,
O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,"InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)",GKGRZLGAQZPEHO-UHFFFAOYSA-N,radiprodil,Phase 2,acetylcholine receptor antagonist,,,
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N=c4nc(-c5cnccn5)cc[nH]4)c3)cc(C(F)(F)F)c2)cn1,"InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)",DUPWHXBITIZIKZ-UHFFFAOYSA-N,radotinib,Phase 3,Bcr-Abl kinase inhibitor,,,
Cn1c(=Nc2ccc(C(F)(F)F)cc2)[nH]c2cc(Oc3ccnc(-c4nc(C(F)(F)F)c[nH]4)c3)ccc21,"InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)",YABJJWZLRMPFSI-UHFFFAOYSA-N,raf265,Phase 2,RAF inhibitor,BRAF,,
Cn1c(=Nc2ccc(C(F)(F)F)cc2)[nH]c2cc(Oc3ccnc(-c4nc(C(F)(F)F)c[nH]4)c3)ccc21,"InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)",YABJJWZLRMPFSI-UHFFFAOYSA-N,raf265,Phase 2,VEGFR inhibitor,BRAF,,
Cc1ncc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1cnc(OC2CCOCC2)c(N2CCOCC2)c1,"InChI=1S/C28H29F3N4O4/c1-18-24(15-22(17-32-18)34-26(36)19-3-2-4-21(13-19)28(29,30)31)20-14-25(35-7-11-38-12-8-35)27(33-16-20)39-23-5-9-37-10-6-23/h2-4,13-17,23H,5-12H2,1H3,(H,34,36)",FYNMINFUAIDIFL-UHFFFAOYSA-N,raf709,Preclinical,RAF inhibitor,,,
O=C(O)COCC1CCC(COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1,"InChI=1S/C23H26ClNO5/c24-19-10-12-21(13-11-19)25(20-4-2-1-3-5-20)23(28)30-15-18-8-6-17(7-9-18)14-29-16-22(26)27/h1-5,10-13,17-18H,6-9,14-16H2,(H,26,27)",NPDKXVKJRHPDQT-UHFFFAOYSA-N,ralinepag,Phase 3,IP1 prostacyclin receptor agonist,,,
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,"InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2",GZUITABIAKMVPG-UHFFFAOYSA-N,raloxifene,Launched,estrogen receptor antagonist,ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,"InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2",GZUITABIAKMVPG-UHFFFAOYSA-N,raloxifene,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,"InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)",CZFFBEXEKNGXKS-UHFFFAOYSA-N,raltegravir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)NC(CCC(=O)O)C(=O)O)s3)ccc2[nH]1,"InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)",IVTVGDXNLFLDRM-UHFFFAOYSA-N,raltitrexed,Launched,thymidylate synthase inhibitor,FPGS|TYMS,oncology,mesothelioma
O=C(O)CCn1c2c(c3ccccc31)CC(NS(=O)(=O)c1ccc(F)cc1)CC2,"InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)",LDXDSHIEDAPSSA-UHFFFAOYSA-N,ramatroban,Launched,prostanoid receptor antagonist,PTGDR2|TBXA2R,cardiology|pulmonary,coronary artery disease (CAD)|asthma
CCC(=O)NCCC1CCc2ccc3c(c21)CCO3,"InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)",YLXDSYKOBKBWJQ-UHFFFAOYSA-N,ramelteon,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,insomnia
Cc1c(NC(C)C)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C14H19N3O/c1-10(2)15-13-11(3)16(4)17(14(13)18)12-8-6-5-7-9-12/h5-10,15H,1-4H3",XOZLRRYPUKAKMU-UHFFFAOYSA-N,ramifenazone,Launched,cyclooxygenase inhibitor,,neurology/psychiatry|endocrinology,pain relief|fever
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1C(C(=O)O)CC2CCCC21,"InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)",HDACQVRGBOVJII-UHFFFAOYSA-N,ramipril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
Cn1cc(C(=O)C2CCc3[nH]cnc3C2)c2ccccc21,"InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)",NTHPAPBPFQJABD-UHFFFAOYSA-N,ramosetron,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting|irritable bowel syndrome
O=C1CC2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12,"InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)",QCVNMNYRNIMDKV-UHFFFAOYSA-N,ranirestat,Phase 3,aldose reductase inhibitor,AKR1B1,,
CN=C(C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,"InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5H,6-10H2,1-3H3,(H,14,15)",SYNOVMDJYWJCON-UHFFFAOYSA-N,ranitidine,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,"InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)",XKLMZUWKNUAPSZ-UHFFFAOYSA-N,ranolazine,Launched,sodium channel blocker,SCN10A|SCN9A,cardiology,chronic stable angina
CC(=O)C(N)C(O)N1CCCC1C(=O)N1CCCC1C(=O)NC(C(C)=O)C(N)O,"InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h11-15,18,26,29H,3-8,19-20H2,1-2H3,(H,21,27)",VHEMRFZQTVVPGP-UHFFFAOYSA-N,rapastinel,Phase 2,glutamate receptor agonist,,,
C#CCNC1CCc2ccccc21,"InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2",RUOKEQAAGRXIBM-UHFFFAOYSA-N,rasagiline,Launched,monoamine oxidase inhibitor,BCL2|MAOB,neurology/psychiatry,Parkinson's Disease
COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,"InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3",BLGXFZZNTVWLAY-UHFFFAOYSA-N,rauwolscine,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B,,
Cn1nccc1N=c1nc(-c2ccn(C(CO)c3ccc(Cl)c(F)c3)c(=O)c2)cc[nH]1,"InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)",RZUOCXOYPYGSKL-UHFFFAOYSA-N,ravoxertinib,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,MAPK1|MAPK3,,
CC(c1nc(-c2ccc(C#N)cc2)cs1)C(O)(Cn1cncn1)c1ccc(F)cc1F,"InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3",OPAHEYNNJWPQPX-UHFFFAOYSA-N,ravuconazole,Phase 2,sterol demethylase inhibitor,,,
COc1ccc(OC)c(C2c3c(-c4ccc5ccccc5c4)n[nH]c3OC(=N)C2C#N)c1,"InChI=1S/C25H20N4O3/c1-30-17-9-10-20(31-2)18(12-17)21-19(13-26)24(27)32-25-22(21)23(28-29-25)16-8-7-14-5-3-4-6-15(14)11-16/h3-12,19,21,27H,1-2H3,(H,28,29)",RFEAEBNMNYRJFD-UHFFFAOYSA-N,rbc8,Preclinical,Ral GTPase inhibitor,RALA|RALB,,
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,"InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)",ALLWOAVDORUJLA-UHFFFAOYSA-N,rebamipide,Launched,free radical scavenger,FPR1,gastroenterology,peptic ulcer disease (PUD)|gastritis
CNC(=O)c1cc(Oc2ccc(NC(=O)N=c3cc(C(C)(C)C)[nH]n3-c3ccc4ncccc4c3)c(F)c2)ccn1,"InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17,37H,1-4H3,(H,32,39)(H,35,40)",IMFPENOEXPBPQM-UHFFFAOYSA-N,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,,
CNC(=O)c1cc(Oc2ccc(NC(=O)N=c3cc(C(C)(C)C)[nH]n3-c3ccc4ncccc4c3)c(F)c2)ccn1,"InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17,37H,1-4H3,(H,32,39)(H,35,40)",IMFPENOEXPBPQM-UHFFFAOYSA-N,rebastinib,Phase 1/Phase 2,TIE tyrosine kinase inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,,
CNC(=O)c1cc(Oc2ccc(NC(=O)N=c3cc(C(C)(C)C)[nH]n3-c3ccc4ncccc4c3)c(F)c2)ccn1,"InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17,37H,1-4H3,(H,32,39)(H,35,40)",IMFPENOEXPBPQM-UHFFFAOYSA-N,rebastinib,Phase 1/Phase 2,VEGFR inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,,
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1,"InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3",CBQGYUDMJHNJBX-UHFFFAOYSA-N,reboxetine,Launched,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression
COc1cc2[nH]c(N3CCN(C(=O)COc4c(OC)cccc4C(C)C)CC3)nc(=N)c2cc1OC,"InChI=1S/C26H33N5O5/c1-16(2)17-7-6-8-20(33-3)24(17)36-15-23(32)30-9-11-31(12-10-30)26-28-19-14-22(35-5)21(34-4)13-18(19)25(27)29-26/h6-8,13-14,16H,9-12,15H2,1-5H3,(H2,27,28,29)",ZZMFJJDBKSYGRM-UHFFFAOYSA-N,rec-15/2615,Phase 2,adrenergic receptor antagonist,ADRA1A,,
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(CC(O)CO)CC1,"InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3",RDSACQWTXKSHJT-UHFFFAOYSA-N,refametinib,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,
CNC(=O)c1cnn(-c2nc(=N)c3ncn(C4OC(CO)C(O)C4O)c3[nH]2)c1,"InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)",LZPZPHGJDAGEJZ-UHFFFAOYSA-N,regadenoson,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,radiology,myocardial perfusion imaging (MPI)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,FGFR inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,KIT inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,PDGFR tyrosine kinase receptor inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,RAF inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,RET tyrosine kinase inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,regorafenib,Launched,VEGFR inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST)
COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3C(O)(c3ccccc3Cl)C2C(=O)N2CCCC2C(N)=O)cc1OC,"InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)",CEBYCSRFKCEUSW-UHFFFAOYSA-N,relcovaptan,Phase 2,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,,
O=C(NC1CCNCC1)C1CCC2CN1C(=O)N2OS(=O)(=O)O,"InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)",SMOBCLHAZXOKDQ-UHFFFAOYSA-N,relebactam,Launched,beta lactamase inhibitor,,,
CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,"InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)",AOMXMOCNKJTRQP-UHFFFAOYSA-N,relugolix,Phase 3,gonadotropin releasing factor hormone receptor antagonist,,,
CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,"InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)",YSGASDXSLKIKOD-UHFFFAOYSA-N,remacemide,Phase 3,glutamate receptor antagonist,GRIN1,,
COC(=O)c1ccc(OC(=O)CCCCCCC(O)=NO)cc1,"InChI=1S/C16H21NO6/c1-22-16(20)12-8-10-13(11-9-12)23-15(19)7-5-3-2-4-6-14(18)17-21/h8-11,21H,2-7H2,1H3,(H,17,18)",XDZAHHULFQIBFE-UHFFFAOYSA-N,remetinostat,Phase 2,HDAC inhibitor,,,
COC(=O)CCC1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,"InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3",CYHWMBVXXDIZNZ-UHFFFAOYSA-N,remimazolam,Phase 3,benzodiazepine receptor agonist,GABBR1,,
N#Cc1ccc(-c2csc(=NN=C3CCCC3)[nH]2)cc1,"InChI=1S/C15H14N4S/c16-9-11-5-7-12(8-6-11)14-10-20-15(17-14)19-18-13-3-1-2-4-13/h5-8,10H,1-4H2,(H,17,19)",XAEJIFARBQJLML-UHFFFAOYSA-N,remodelin,Preclinical,transferase inhibitor,NAT10,,
CCN1CCCC1CNC(=O)c1c(OC)ccc(Br)c1OC,"InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)",GUJRSXAPGDDABA-UHFFFAOYSA-N,remoxipride,Withdrawn,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR2A|SIGMAR1,,
CCOc1cc(CC(=O)NC(CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,"InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)",FAEKWTJYAYMJKF-UHFFFAOYSA-N,repaglinide,Launched,insulin secretagogue,ABCC8|KCNJ11|PPARG,endocrinology,diabetes mellitus
CC(C)Cc1ccc(C(C)C(=O)NS(C)(=O)=O)cc1,"InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)",KQDRVXQXKZXMHP-UHFFFAOYSA-N,reparixin,Phase 3,CC chemokine receptor antagonist,CXCR1|CXCR2,,
CC1CNC(=O)c2cnn3ccc(nc23)NC(C)c2cc(F)ccc2O1,"InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)",FIKPXCOQUIZNHB-UHFFFAOYSA-N,repotrectinib,Phase 1/Phase 2,receptor tyrosine protein kinase inhibitor,,,
Cc1cccc(-c2[nH]ncc2-c2ccc3ncccc3n2)n1,"InChI=1S/C17H13N5/c1-11-4-2-5-16(20-11)17-12(10-19-22-17)13-7-8-14-15(21-13)6-3-9-18-14/h2-10H,1H3,(H,19,22)",LBPKYPYHDKKRFS-UHFFFAOYSA-N,repsox,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
CCOC(=O)C1=CCCCC1S(=O)(=O)Nc1ccc(F)cc1Cl,"InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3",LEEIJTHMHDMWLJ-UHFFFAOYSA-N,resatorvid,Phase 3,toll-like receptor inhibitor,TLR4,,
COC(=O)C1C2CC3c4[nH]c5cc(OC)ccc5c4CCN3CC2CC(OC(=O)c2cc(OC)c(OC)c(OC)c2)C1OC,"InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3",QEVHRUUCFGRFIF-UHFFFAOYSA-N,reserpine,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,cardiology,hypertension
CC12CCC(O)CC1CCC1C2CCC2(C)C(c3ccc(=O)oc3)CC3OC312,"InChI=1S/C24H32O4/c1-22-9-7-16(25)11-15(22)4-5-18-17(22)8-10-23(2)19(12-20-24(18,23)28-20)14-3-6-21(26)27-13-14/h3,6,13,15-20,25H,4-5,7-12H2,1-2H3",ATLJNLYIJOCWJE-UHFFFAOYSA-N,resibufogenin,Phase 2,Na/K-ATPase inhibitor,,,
CCOCc1nc2c(=N)[nH]c3ccccc3c2n1CC(C)(C)O,"InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)",BXNMTOQRYBFHNZ-UHFFFAOYSA-N,resiquimod,Phase 3,toll-like receptor agonist,TLR7|TLR8,,
CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O,"InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)",FDBYIYFVSAHJLY-UHFFFAOYSA-N,resmetirom,Phase 3,thyroid hormone receptor agonist,,,
CN(C)Cc1ccc(S(=O)(=O)n2ccc(C=CC(O)=NO)c2)cc1,"InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)",FECGNJPYVFEKOD-UHFFFAOYSA-N,resminostat,Phase 2,HDAC inhibitor,HDAC1|HDAC3|HDAC6|HDAC8,,
Oc1cccc(O)c1,"InChI=1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H",GHMLBKRAJCXXBS-UHFFFAOYSA-N,resorcinol,Launched,phosphodiesterase inhibitor,CA12|CA14|CA2|PTGS1,dermatology,acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis
CC(=O)Oc1cccc(O)c1,"InChI=1S/C8H8O3/c1-6(9)11-8-4-2-3-7(10)5-8/h2-5,10H,1H3",ZZPKZRHERLGEKA-UHFFFAOYSA-N,resorcinol-monoacetate,Launched,antiseptic,,,
Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1,"InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H",LUKBXSAWLPMMSZ-UHFFFAOYSA-N,resveratrol,Launched,cytochrome P450 inhibitor,CSNK2A1|NQO2|PTGS1|PTGS2,,
Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1,"InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H",LUKBXSAWLPMMSZ-UHFFFAOYSA-N,resveratrol,Launched,SIRT activator,CSNK2A1|NQO2|PTGS1|PTGS2,,
COC(=O)c1nc(C(F)(F)F)n2c1CN(C(=O)CC(N)Cc1cc(F)c(F)cc1F)CC2,"InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3",WIIAMRXFUJLYEF-UHFFFAOYSA-N,retagliptin,Phase 1,dipeptidyl peptidase inhibitor,,,
C=CC1(C)CC(OC(=O)CSC2CC3CCC(C2)N3C)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O,"InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3",STZYTFJPGGDRJD-UHFFFAOYSA-N,retapamulin,Launched,protein synthesis inhibitor,,infectious disease,impetigo
CCC=Nc1c(O)cc2c(O)c1C=C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)C=CCC(C)C(=O)N2,"InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h9,11-13,15-16,18-19,24-25,27,29,35-37H,8,10,14H2,1-7H3,(H2,32,39)(H,34,38)",LNLROEQOEUUFON-UHFFFAOYSA-N,retaspimycin,Phase 3,HSP inhibitor,HSP90AA1,,
CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=O,"InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3",NCYCYZXNIZJOKI-UHFFFAOYSA-N,retinaldehyde,Launched,,,dermatology,cosmetic
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CCO,"InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3",FPIPGXGPPPQFEQ-UHFFFAOYSA-N,retinol,Launched,retinoid receptor ligand,ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG,dermatology,cosmetic|acne vulgaris (AV)|keratosis
CC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,"InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3",QGNJRVVDBSJHIZ-UHFFFAOYSA-N,retinyl-acetate,Launched,,,,
CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,"InChI=1S/C36H60O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-25-35(37)38-30-28-32(3)23-20-22-31(2)26-27-34-33(4)24-21-29-36(34,5)6/h20,22-23,26-28H,7-19,21,24-25,29-30H2,1-6H3",VYGQUTWHTHXGQB-UHFFFAOYSA-N,retinyl-palmitate,Launched,,,,
CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,"InChI=1S/C22H25NO2/c1-2-3-4-12-22(24)18-9-7-10-20(15-18)25-16-19-14-13-17-8-5-6-11-21(17)23-19/h5-11,13-15,22,24H,2-4,12,16H2,1H3",JRLOEMCOOZSCQP-UHFFFAOYSA-N,rev-5901,Phase 2,leukotriene receptor antagonist,ALOX5,,
CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,"InChI=1S/C22H25NO2/c1-2-3-4-12-22(24)18-9-7-10-20(15-18)25-16-19-14-13-17-8-5-6-11-21(17)23-19/h5-11,13-15,22,24H,2-4,12,16H2,1H3",JRLOEMCOOZSCQP-UHFFFAOYSA-N,rev-5901,Phase 2,lipoxygenase inhibitor,ALOX5,,
Cc1[nH]c(=Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C,"InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)",LECZXZOBEZITCL-UHFFFAOYSA-N,revaprazan,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,gastritis
CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1,"InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)",FYDWDCIFZSGNBU-UHFFFAOYSA-N,revefenacin,Launched,cholinergic receptor antagonist,,,
O=C(NCCCN1CCOCC1)c1cnn2c(-c3ccccc3)cc(-c3ccccc3)nc12,"InChI=1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32)",JTRXWCLQFAZHGP-UHFFFAOYSA-N,reversan,Preclinical,MRP inhibitor,ABCC1,,
c1nc2[nH]c(=Nc3ccc(N4CCOCC4)cc3)[nH]c(=NC3CCCCC3)c2[nH]1,"InChI=1S/C21H27N7O/c1-2-4-15(5-3-1)24-20-18-19(23-14-22-18)26-21(27-20)25-16-6-8-17(9-7-16)28-10-12-29-13-11-28/h6-9,14-15H,1-5,10-13H2,(H3,22,23,24,25,26,27)",ZFLJHSQHILSNCM-UHFFFAOYSA-N,reversine,Preclinical,Aurora kinase inhibitor,AURKB|INCENP|MAP2K1,,
O=c1c(OC2OCC(O)C(O)C2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"InChI=1S/C20H18O11/c21-8-4-11(24)14-13(5-8)30-18(7-1-2-9(22)10(23)3-7)19(16(14)27)31-20-17(28)15(26)12(25)6-29-20/h1-5,12,15,17,20-26,28H,6H2",PZZRDJXEMZMZFD-UHFFFAOYSA-N,reynoutrin,Preclinical,antioxidant,,,
O=C(O)C(Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,"InChI=1S/C19H14N2O4/c22-17-13-6-1-2-7-14(13)18(23)21(17)16(19(24)25)9-11-10-20-15-8-4-3-5-12(11)15/h1-8,10,16,20H,9H2,(H,24,25)",HPTXLHAHLXOAKV-UHFFFAOYSA-N,rg108,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3B,,
COc1cc2c(cc1F)C(c1ccccc1Cl)N=c1c(C)n[nH]c1=N2,"InChI=1S/C18H14ClFN4O/c1-9-16-18(24-23-9)21-14-8-15(25-2)13(20)7-11(14)17(22-16)10-5-3-4-6-12(10)19/h3-8,17H,1-2H3,(H,21,24)",QUTGNUMOFZDLSB-UHFFFAOYSA-N,rg1530,Phase 1,FGFR inhibitor,FGFR1|FGFR2,,
COc1cc2c(cc1F)C(c1ccccc1Cl)N=c1c(C)n[nH]c1=N2,"InChI=1S/C18H14ClFN4O/c1-9-16-18(24-23-9)21-14-8-15(25-2)13(20)7-11(14)17(22-16)10-5-3-4-6-12(10)19/h3-8,17H,1-2H3,(H,21,24)",QUTGNUMOFZDLSB-UHFFFAOYSA-N,rg1530,Phase 1,PDGFR tyrosine kinase receptor inhibitor,FGFR1|FGFR2,,
COc1cc2c(cc1F)C(c1ccccc1Cl)N=c1c(C)n[nH]c1=N2,"InChI=1S/C18H14ClFN4O/c1-9-16-18(24-23-9)21-14-8-15(25-2)13(20)7-11(14)17(22-16)10-5-3-4-6-12(10)19/h3-8,17H,1-2H3,(H,21,24)",QUTGNUMOFZDLSB-UHFFFAOYSA-N,rg1530,Phase 1,VEGFR inhibitor,FGFR1|FGFR2,,
Cc1ccc(C(=O)NCCCCCC(=O)Nc2ccccc2N)cc1,"InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24)",VOPDXHFYDJAYNS-UHFFFAOYSA-N,rg2833,Phase 1,HDAC inhibitor,HDAC1|HDAC3,,
CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)NC1C(=O)Nc2ccccc2-c2ccccc21,"InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)",OJPLJFIFUQPSJR-UHFFFAOYSA-N,rg4733,Phase 2,gamma secretase inhibitor,PSEN1,,
CCOc1cc(C(C)(C)C)ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(c2ccc(Cl)cc2)N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1,"InChI=1S/C38H48Cl2N4O4S/c1-8-48-33-26-29(36(2,3)4)14-19-32(33)34-41-37(5,27-10-15-30(39)16-11-27)38(6,28-12-17-31(40)18-13-28)44(34)35(45)43-23-21-42(22-24-43)20-9-25-49(7,46)47/h10-19,26H,8-9,20-25H2,1-7H3",QBGKPEROWUKSBK-UHFFFAOYSA-N,rg7112,Phase 1,MDM inhibitor,MDM2,,
CCc1nc(C)cn2nc(-c3cc(=O)n4cc(C5CCN(C)CC5)cc(C)c4n3)cc12,"InChI=1S/C24H28N6O/c1-5-19-22-11-21(27-30(22)13-16(3)25-19)20-12-23(31)29-14-18(10-15(2)24(29)26-20)17-6-8-28(4)9-7-17/h10-14,17H,5-9H2,1-4H3",GYFRQCMDLBNZSF-UHFFFAOYSA-N,rg7800,Preclinical,RNA splicing modifier,,,
COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1C(C(C)C)C2,"InChI=1S/C22H27NO6/c1-13(2)17-8-14-9-21(29-7-5-6-27-3)20(28-4)10-15(14)18-11-19(24)16(22(25)26)12-23(17)18/h9-13,17H,5-8H2,1-4H3,(H,25,26)",KBXLMOYQNDMHQT-UHFFFAOYSA-N,rg7834,Preclinical,antiviral,,,
COCCN1CCN(Cc2ccc(-c3[nH]nc4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,"InChI=1S/C29H35N7O4/c1-39-16-13-34-9-11-35(12-10-34)19-20-5-7-21(8-6-20)26-25-27(32-31-26)22-3-2-4-23(24(22)28(25)37)30-29(38)33-36-14-17-40-18-15-36/h2-8H,9-19H2,1H3,(H,31,32)(H2,30,33,38)",XLSYZSRXVVCHLS-UHFFFAOYSA-N,rgb-286638,Phase 1,CDK inhibitor,CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9,,
Nc1cc(F)ccc1NC(=O)C=Cc1cnn(CC=Cc2ccccc2)c1,"InChI=1S/C21H19FN4O/c22-18-9-10-20(19(23)13-18)25-21(27)11-8-17-14-24-26(15-17)12-4-7-16-5-2-1-3-6-16/h1-11,13-15H,12,23H2,(H,25,27)",BLVQHYHDYFTPDV-UHFFFAOYSA-N,rgfp966,Preclinical,HDAC inhibitor,HDAC3,,
CC(CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,"InChI=1S/C34H33ClF3NO3/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41)",ZLJZDYOBXVOTSA-UHFFFAOYSA-N,rgx-104,Phase 1,LXR agonist,,,
O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,"InChI=1S/C20H34N4O4/c25-19(27-23-17-11-5-3-6-12-17)21-15-9-1-2-10-16-22-20(26)28-24-18-13-7-4-8-14-18/h1-16H2,(H,21,25)(H,22,26)",RXSVYGIGWRDVQC-UHFFFAOYSA-N,rhc-80267,Preclinical,triacylglycerol lipase inhibitor,DAGLA|DAGLB,,
O=C(O)c1cc(O)c2c(c1)C(=O)c1cccc(O)c1C2=O,"InChI=1S/C15H8O6/c16-9-3-1-2-7-11(9)14(19)12-8(13(7)18)4-6(15(20)21)5-10(12)17/h1-5,16-17H,(H,20,21)",FCDLCPWAQCPTKC-UHFFFAOYSA-N,rhein,Phase 1,,HSP90AA1,,
COc1cc(O)c2c(c1)C(=O)c1cc(C)cc(O)c1C2=O,"InChI=1S/C16H12O5/c1-7-3-9-13(11(17)4-7)16(20)14-10(15(9)19)5-8(21-2)6-12(14)18/h3-6,17-18H,1-2H3",FFWOKTFYGVYKIR-UHFFFAOYSA-N,rheochrysidin,Preclinical,protein tyrosine kinase inhibitor,PTPN1,,
COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12,"InChI=1S/C21H17N2O3/c1-25-21(24)15-5-3-2-4-14(15)20-16-8-6-12(22)10-18(16)26-19-11-13(23)7-9-17(19)20/h2-11H,22-23H2,1H3/q+1",ZWODABSNRKVFCK-UHFFFAOYSA-N,rhodamine-123,Phase 1,,,,
O=C1C(Cl)=C(N2CCOCC2)C(=O)N1c1ccc(Cl)c(Cl)c1,"InChI=1S/C14H11Cl3N2O3/c15-9-2-1-8(7-10(9)16)19-13(20)11(17)12(14(19)21)18-3-5-22-6-4-18/h1-2,7H,3-6H2",MWSUIZKGNWELRF-UHFFFAOYSA-N,ri-1,Preclinical,,RAD51,,
NC(=O)c1ncn(C2OC(CO)C(O)C2O)n1,"InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)",IWUCXVSUMQZMFG-UHFFFAOYSA-N,ribavirin,Launched,antiviral,ADK|ENPP1|IMPDH1|IMPDH2|NT5C2,infectious disease,hepatitis C
OCC(O)C(O)C(O)CO,"InChI=1S/C5H12O5/c6-1-3(8)5(10)4(9)2-7/h3-10H,1-2H2",HEBKCHPVOIAQTA-UHFFFAOYSA-N,ribitol,Preclinical,,,,
CN(C)C(=O)c1cc2c[nH]c(=Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,ribociclib,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(CC(O)C(O)C(O)CO)c2cc1C,"InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)",AUNGANRZJHBGPY-UHFFFAOYSA-N,riboflavin,Launched,vitamin B,BLVRB|RFK,gastroenterology,jaundice
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(CC(O)C(O)C(O)CO[PH](=O)(=O)O)c2cc1C,"InChI=1S/C17H20N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H,27,28,29)",QJEFVOVCMNSTPX-UHFFFAOYSA-N,riboflavin-5-phosphate-sodium,Launched,,BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1,,
CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(Cn1c2nc(=O)[nH]c(=O)c-2nc2cc(C)c(C)cc21)OC(=O)CCC,"InChI=1S/C33H44N4O10/c1-7-11-25(38)44-18-24(46-27(40)13-9-3)30(47-28(41)14-10-4)23(45-26(39)12-8-2)17-37-22-16-20(6)19(5)15-21(22)34-29-31(37)35-33(43)36-32(29)42/h15-16,23-24,30H,7-14,17-18H2,1-6H3,(H,36,42,43)",MJNIWUJSIGSWKK-UHFFFAOYSA-N,riboflavin-tetrabutyrate,Preclinical,antioxidant,,,
NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O,"InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2",NSKGQURZWSPSBC-UHFFFAOYSA-N,ribostamycin,Launched,bacterial 30S ribosomal subunit inhibitor,P4HB,infectious disease,human immunodeficiency virus (HIV-1)
NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O,"InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2",NSKGQURZWSPSBC-UHFFFAOYSA-N,ribostamycin-sulfate,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
CCCCCCC(O)CC=CCCCCCCCC(=O)O,"InChI=1S/C18H34O3/c1-2-3-4-11-14-17(19)15-12-9-7-5-6-8-10-13-16-18(20)21/h9,12,17,19H,2-8,10-11,13-16H2,1H3,(H,20,21)",WBHHMMIMDMUBKC-UHFFFAOYSA-N,ricinoleic-acid,Launched,prostanoid receptor agonist,PTGER3,,
c1cc(-c2nc3cc(-c4ccc5[nH]c(-c6ccncc6)nc5c4)ccc3[nH]2)ccn1,"InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)",UHQFBTAJFNVZIV-UHFFFAOYSA-N,ridinilazole,Phase 3,antibacterial,,,
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,52-55H,16-19,21H2,1-11H3,(H,47,57)",AZFBLLCNOQPJGJ-UHFFFAOYSA-N,rifabutin,Launched,protein synthesis inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(=CNN5CCN(C)CC5)c(O)c4c3C2=O)=NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,44,49-53H,15-18H2,1-10H3",QHOUDEZPFKDYIG-UHFFFAOYSA-N,rifampin,Launched,RNA polymerase inhibitor,NR1I2|SLCO1A2|SLCO1B1|SLCO1B3,infectious disease,tuberculosis|meningitis
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)",HJYYPODYNSCCOU-UHFFFAOYSA-N,rifamycin,Launched,DNA directed RNA polymerase inhibitor,SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1,infectious disease,tuberculosis|leprosy
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)",HJYYPODYNSCCOU-UHFFFAOYSA-N,rifamycin-sv,Phase 3,RNA synthesis inhibitor,,,
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(=CNN5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)=NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,48,53-57H,10-11,15-16,18-21H2,1-9H3",RQIIXJNHOGWQKH-UHFFFAOYSA-N,rifapentine,Launched,RNA polymerase inhibitor,CYP2C8|CYP2C9|CYP3A4,infectious disease,tuberculosis
COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C,"InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)",NZCRJKRKKOLAOJ-UHFFFAOYSA-N,rifaximin,Launched,RNA synthesis inhibitor,,gastroenterology,diarrhea|irritable bowel syndrome|hepatic encephalopathy (HE)
COc1cc(OC)c(C=CS(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,"InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)",OWBFCJROIKNMGD-UHFFFAOYSA-N,rigosertib,Phase 3,cell cycle inhibitor,PLK1,,
COc1cc(OC)c(C=CS(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,"InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)",OWBFCJROIKNMGD-UHFFFAOYSA-N,rigosertib,Phase 3,PLK inhibitor,PLK1,,
COCCN1CCC(N(Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C(=O)Cn2c(SCc3cccc(F)c3F)cc(=O)c3ccccc32)CC1,"InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3",NNBGCSGCRSCFEA-UHFFFAOYSA-N,rilapladib,Phase 2,phospholipase inhibitor,,,
C1COC(=NC(C2CC2)C2CC2)N1,"InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)",CQXADFVORZEARL-UHFFFAOYSA-N,rilmenidine,Launched,adrenergic receptor agonist,ADRA2A,cardiology,hypertension
C1COC(=NC(C2CC2)C2CC2)N1,"InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)",CQXADFVORZEARL-UHFFFAOYSA-N,rilmenidine,Launched,imidazoline receptor agonist,ADRA2A,cardiology,hypertension
Cc1cc(C=CC#N)cc(C)c1N=c1cc[nH]c(=Nc2ccc(C#N)cc2)[nH]1,"InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)",YIBOMRUWOWDFLG-UHFFFAOYSA-N,rilpivirine,Launched,non-nucleoside reverse transcriptase inhibitor,NR1I2|SCN10A,infectious disease,human immunodeficiency virus (HIV-1)
N=c1[nH]c2ccc(OC(F)(F)F)cc2s1,"InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)",FTALBRSUTCGOEG-UHFFFAOYSA-N,riluzole,Launched,glutamate inhibitor,KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)
CC(N)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3",UBCHPRBFMUDMNC-UHFFFAOYSA-N,rimantadine,Launched,antiviral,,infectious disease,influenza A virus infection
CC(N)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3",UBCHPRBFMUDMNC-UHFFFAOYSA-N,rimantadine,Launched,RNA synthesis inhibitor,,infectious disease,influenza A virus infection
CC1CN(CCCn2c3ccccc3c3ccccc32)CC(C)N1,"InChI=1S/C21H27N3/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3",GUDVQJXODNJRIJ-UHFFFAOYSA-N,rimcazole,Phase 1,sigma receptor antagonist,SIGMAR1,,
NC1c2cccnc2C(OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CCC1c1cccc(F)c1F,"InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)",KRNAOFGYEFKHPB-UHFFFAOYSA-N,rimegepant,Launched,calcitonin antagonist,CALCA,,
Cc1cc(S(C)(=O)=O)c(S(C)(=O)=O)cc1C(=O)N=C(N)N,"InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15)",GROMEQPXDKRRIE-UHFFFAOYSA-N,rimeporide,Phase 1,sodium/hydrogen exchanger inhibitor,,,
CCC(=O)C1(C)C(C)CC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,"InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h7,9-10,14,17-19,21,26H,6,8,11-13H2,1-5H3",WJRIHWQHXZEYMP-UHFFFAOYSA-N,rimexolone,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,ophthalmology,anterior uveitis
Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,"InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)",JZCPYUJPEARBJL-UHFFFAOYSA-N,rimonabant,Withdrawn,cannabinoid receptor antagonist,CNR1|GPR55,,
COC(=O)N(C)c1c(N)[nH]c(-c2nn(Cc3ccccc3F)c3ncccc23)nc1=N,"InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)",WXXSNCNJFUAIDG-UHFFFAOYSA-N,riociguat,Launched,guanylate cyclase stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,hypertension
COC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1c1ccccc1OC(F)F,"InChI=1S/C18H19F2NO5/c1-9-13(16(22)24-3)15(14(10(2)21-9)17(23)25-4)11-7-5-6-8-12(11)26-18(19)20/h5-8,13,15,18H,1-4H3",XSEHDLCUCAKVSS-UHFFFAOYSA-N,riodipine,Phase 2,calcium channel blocker,,,
Oc1c(I)cc(I)c(O)c1I,"InChI=1S/C6H3I3O2/c7-2-1-3(8)6(11)4(9)5(2)10/h1,10-11H",XKFZYVWWXHCHIX-UHFFFAOYSA-N,riodoxol,Launched,other antibiotic,,,
CC1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,"InChI=1S/C15H18FN3O2S/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14/h2,4-5,9-11,17H,3,6-8H2,1H3",QSKQVZWVLOIIEV-UHFFFAOYSA-N,ripasudil,Launched,rho associated kinase inhibitor,ROCK1|ROCK2,ophthalmology,glaucoma|ocular hypertension
CCn1nc(C)c2c1=C(c1ccccc1)NCC(=O)N=2,"InChI=1S/C15H16N4O/c1-3-19-15-13(10(2)18-19)17-12(20)9-16-14(15)11-7-5-4-6-8-11/h4-8,16H,3,9H2,1-2H3",KCQRPNZDIDUWGK-UHFFFAOYSA-N,ripazepam,Phase 2,benzodiazepine receptor agonist,GABRA1,,
CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2c[nH]c(=NC)cc21,"InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)",CEFJVGZHQAGLHS-UHFFFAOYSA-N,ripretinib,Phase 3,receptor tyrosine protein kinase inhibitor,,,
Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1,"InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3",ASKZRYGFUPSJPN-UHFFFAOYSA-N,risdiplam,Phase 2/Phase 3,RNA splicing inhibitor,,,
O=[PH](=O)(O)C(O)(Cc1cccnc1)[PH](=O)(=O)O,"InChI=1S/C7H9NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H,10,11,12)(H,13,14,15)",BVPYUOGGVTWBOM-UHFFFAOYSA-N,risedronate,Launched,osteoclast inhibitor,FDPS,orthopedics|endocrinology,osteoporosis|Paget's disease
Cc1ccc(COC(=O)N2CCC(CN=c3nccc[nH]3)C(F)C2)cc1,"InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)",RECBFDWSXWAXHY-UHFFFAOYSA-N,rislenemdaz,Preclinical,ionotropic glutamate receptor antagonist,,,
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3",RAPZEAPATHNIPO-UHFFFAOYSA-N,risperidone,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder|irritability
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,"InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3",RAPZEAPATHNIPO-UHFFFAOYSA-N,risperidone,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder|irritability
OCc1ccc(-c2ccc(-c3ccc(CO)s3)o2)s1,"InChI=1S/C14H12O3S2/c15-7-9-1-5-13(18-9)11-3-4-12(17-11)14-6-2-10(8-16)19-14/h1-6,15-16H,7-8H2",KZENBFUSKMWCJF-UHFFFAOYSA-N,rita,Preclinical,MDM inhibitor,MDM2,,
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3",JUQLTPCYUFPYKE-UHFFFAOYSA-N,ritanserin,Phase 3,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,
CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1,"InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3",IOVGROKTTNBUGK-UHFFFAOYSA-N,ritodrine,Withdrawn,adrenergic receptor agonist,,obstetrics/gynecology,premature labor
CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)",NCDNCNXCDXHOMX-UHFFFAOYSA-N,ritonavir,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1)
CNCCC=Cc1cccnc1,"InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3",JUOSGGQXEBBCJB-UHFFFAOYSA-N,rivanicline,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2|CXCL8,,
O=C(NCC1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)",KGFYHTZWPPHNLQ-UHFFFAOYSA-N,rivaroxaban,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)
CCN(C)C(=O)Oc1cccc(C(C)N(C)C)c1,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3",XSVMFMHYUFZWBK-UHFFFAOYSA-N,rivastigmine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease|Parkinson's Disease|senile dementia
CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,"InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3",ULFRLSNUDGIQQP-UHFFFAOYSA-N,rizatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
O=C(N=c1[nH]c(-c2ccncc2)cs1)NCc1cccc(O)c1,"InChI=1S/C16H14N4O2S/c21-13-3-1-2-11(8-13)9-18-15(22)20-16-19-14(10-23-16)12-4-6-17-7-5-12/h1-8,10,21H,9H2,(H2,18,19,20,22)",GDVRVPIXWXOKQO-UHFFFAOYSA-N,rki-1447,Preclinical,rho associated kinase inhibitor,CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2,,
O=c1c2ccccc2nc2n1CCCCC2,"InChI=1S/C13H14N2O/c16-13-10-6-3-4-7-11(10)14-12-8-2-1-5-9-15(12)13/h3-4,6-7H,1-2,5,8-9H2",HTLIIBRHXAULMB-UHFFFAOYSA-N,rlx,Preclinical,,,,
Cc1nc(N2CCC3(CC2)COC(C)C3N)c(CO)nc1-c1cccc(Cl)c1Cl,"InChI=1S/C21H26Cl2N4O2/c1-12-18(14-4-3-5-15(22)17(14)23)26-16(10-28)20(25-12)27-8-6-21(7-9-27)11-29-13(2)19(21)24/h3-5,13,19,28H,6-11,24H2,1-2H3",IKUYEYLZXGGCRD-UHFFFAOYSA-N,rmc-4550,Preclinical,SHIP2 phosphatase inhibitor,,,
CN1CCN(C(=O)CNC2CC2c2ccc(OCc3ccccc3)cc2)CC1,"InChI=1S/C23H29N3O2/c1-25-11-13-26(14-12-25)23(27)16-24-22-15-21(22)19-7-9-20(10-8-19)28-17-18-5-3-2-4-6-18/h2-10,21-22,24H,11-17H2,1H3",YAMSXCOVJUUMCT-UHFFFAOYSA-N,rn-1,Preclinical,histone demethylase inhibitor,KDM1A,,
CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,"InChI=1S/C14H22Cl2N2O2S/c1-10(2)17-7-8-18(11(3)4)21(19,20)14-6-5-12(15)9-13(14)16/h5-6,9-11,17H,7-8H2,1-4H3",IHYZMEAZAIFMTN-UHFFFAOYSA-N,rn-1734,Preclinical,TRPV antagonist,TRPV4,,
O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,"InChI=1S/C17H18ClN3O4S/c18-15-6-7-17(16(12-15)21(22)23)26(24,25)20-10-8-19(9-11-20)13-14-4-2-1-3-5-14/h1-7,12H,8-11,13H2",ZNLVYSJQUMALEO-UHFFFAOYSA-N,rn-1747,Preclinical,TRPV agonist,TRPV4,,
COc1cc2c(cc1O)C(CCc1ccc(Cl)cc1)N(C)CC2,"InChI=1S/C19H22ClNO2/c1-21-10-9-14-11-19(23-2)18(22)12-16(14)17(21)8-5-13-3-6-15(20)7-4-13/h3-4,6-7,11-12,17,22H,5,8-10H2,1-2H3",DSTWURHEHMZWEI-UHFFFAOYSA-N,ro-04-5595,Preclinical,glutamate receptor antagonist,GRIN2B,,
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C)c2cc1C=O,"InChI=1S/C13H10N4O3/c1-6-3-8-9(4-7(6)5-18)17(2)11-10(14-8)12(19)16-13(20)15-11/h3-5H,1-2H3,(H,16,19,20)",JDEMVNYMYPJJIM-UHFFFAOYSA-N,ro-08-2750,Preclinical,NGF binding inhibitor,NGF|NGFR,,
Cc1nc(=N)c(CN2CC=C(c3ccccc3)CC2)c[nH]1,"InChI=1S/C17H20N4/c1-13-19-11-16(17(18)20-13)12-21-9-7-15(8-10-21)14-5-3-2-4-6-14/h2-7,11H,8-10,12H2,1H3,(H2,18,19,20)",KABDATZAOUSYES-UHFFFAOYSA-N,ro-10-5824,Preclinical,dopamine receptor agonist,DRD4,,
[O-][S+](c1ccccc1)c1ccc2nnnn2n1,InChI=1S/C10H7N5OS/c16-17(8-4-2-1-3-5-8)10-7-6-9-11-13-14-15(9)12-10/h1-7H,JFSXSNSCPNFCDM-UHFFFAOYSA-N,ro-106-9920,Preclinical,NFkB pathway inhibitor,,,
CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1,"InChI=1S/C19H23N3O/c1-14(2)23-18-9-5-16(6-10-18)13-15-3-7-17(8-4-15)22-19-20-11-12-21-19/h3-10,14H,11-13H2,1-2H3,(H2,20,21,22)",GYYRMJMXXLJZAB-UHFFFAOYSA-N,ro-1138452,Preclinical,prostanoid receptor antagonist,PTGIR,,
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(N=[N+]=[N-])ccc1-2,"InChI=1S/C15H14N6O3/c1-3-24-15(23)13-12-7-20(2)14(22)10-6-9(18-19-16)4-5-11(10)21(12)8-17-13/h4-6,8H,3,7H2,1-2H3",CFSOJZTUTOQNIA-UHFFFAOYSA-N,ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,
CN1Cc2c(C(=O)OC(C)(C)C)ncn2-c2ccsc2C1=O,"InChI=1S/C15H17N3O3S/c1-15(2,3)21-14(20)11-10-7-17(4)13(19)12-9(5-6-22-12)18(10)8-16-11/h5-6,8H,7H2,1-4H3",ZIGMMUKDYCABPW-UHFFFAOYSA-N,ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,"InChI=1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)",PDMUULPVBYQBBK-UHFFFAOYSA-N,ro-20-1724,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE4A|PDE4B|PDE4C|PDE4D,,
CC(CN1CCC(Cc2ccccc2)CC1)C(O)c1ccc(O)cc1,"InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3",WVZSEUPGUDIELE-UHFFFAOYSA-N,ro-25-6981,Preclinical,glutamate receptor antagonist,GRIN2B,,
CC(CN1CCC(Cc2ccccc2)CC1)C(O)c1ccc(O)cc1,"InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3",WVZSEUPGUDIELE-UHFFFAOYSA-N,ro-25-6981,Preclinical,monamine transporter modulator,GRIN2B,,
CS(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)N=c2[nH]ccs2)cc1,"InChI=1S/C18H22N2O3S2/c1-25(22,23)15-8-6-14(7-9-15)16(12-13-4-2-3-5-13)17(21)20-18-19-10-11-24-18/h6-11,13,16H,2-5,12H2,1H3,(H,19,20,21)",NEQSWPCDHDQINX-UHFFFAOYSA-N,ro-28-1675,Preclinical,glucokinase activator,GCK,,
COc1cc(Cc2c[nH]c(=N)[nH]c2=N)c(C(C)C)cc1OC,"InChI=1S/C16H22N4O2/c1-9(2)12-7-14(22-4)13(21-3)6-10(12)5-11-8-19-16(18)20-15(11)17/h6-9H,5H2,1-4H3,(H4,17,18,19,20)",PYNPWUIBJMVRIG-UHFFFAOYSA-N,ro-3,Preclinical,purinergic receptor antagonist,P2RX3,,
O=C1N=C(NCc2cccs2)SC1=Cc1ccc2ncccc2c1,"InChI=1S/C18H13N3OS2/c22-17-16(24-18(21-17)20-11-14-4-2-8-23-14)10-12-5-6-15-13(9-12)3-1-7-19-15/h1-10H,11H2,(H,20,21,22)",XOLMRFUGOINFDQ-UHFFFAOYSA-N,ro-3306,Preclinical,CDK inhibitor,CDK1,,
CCCN(CCC)Cc1nc(-c2ncn3c2CN(C)C(=O)c2cc(F)ccc2-3)no1,"InChI=1S/C21H25FN6O2/c1-4-8-27(9-5-2)12-18-24-20(25-30-18)19-17-11-26(3)21(29)15-10-14(22)6-7-16(15)28(17)13-23-19/h6-7,10,13H,4-5,8-9,11-12H2,1-3H3",NOQIYRGMEFBZTI-UHFFFAOYSA-N,ro-48-6791,Preclinical,GABA receptor modulator,,,
C=CCN(C)CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1,"InChI=1S/C23H27BrFNO2/c1-3-14-26(2)15-6-4-5-7-16-28-20-12-13-21(22(25)17-20)23(27)18-8-10-19(24)11-9-18/h3,8-13,17H,1,4-7,14-16H2,2H3",CMYCCJYVZIMDFU-UHFFFAOYSA-N,ro-48-8071,Preclinical,oxidosqualene cyclase inhibitor,LSS,,
O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,"InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)",FIMYFEGKMOCQKT-UHFFFAOYSA-N,ro-4987655,Phase 1,MEK inhibitor,MAP2K1,,
CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc23)c2ccc(Cl)cc21,"InChI=1S/C25H28ClN3O2/c1-27(2)13-14-29-16-21(20-8-7-19(26)15-23(20)29)24(30)28-11-9-25(10-12-28)22-6-4-3-5-18(22)17-31-25/h3-8,15-16H,9-14,17H2,1-2H3",QZXVLRCMAHJVIP-UHFFFAOYSA-N,ro-5028442,Phase 1,vasopressin receptor antagonist,,,
CNS(=O)(=O)N=c1[nH]ccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,"InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)",LMMJFBMMJUMSJS-UHFFFAOYSA-N,ro-5126766,Phase 1,MEK inhibitor,BRAF|MAP2K1|MAP2K2|RAF1,,
CNS(=O)(=O)N=c1[nH]ccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,"InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)",LMMJFBMMJUMSJS-UHFFFAOYSA-N,ro-5126766,Phase 1,RAF inhibitor,BRAF|MAP2K1|MAP2K2|RAF1,,
Cc1c(F)cccc1C1COC(=N)N1,"InChI=1S/C10H11FN2O/c1-6-7(3-2-4-8(6)11)9-5-14-10(12)13-9/h2-4,9H,5H2,1H3,(H2,12,13)",IOHOUWIYOVWGHV-UHFFFAOYSA-N,ro-5263397,Preclinical,trace amine associated receptor agonist,,,
CC(N)Cn1ccc2cc(F)c(Cl)cc21,"InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3",XJJZQXUGLLXTHO-UHFFFAOYSA-N,ro-60-0175,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,
COc1ccc(S(=O)(=O)N=c2[nH]c(-c3cccc([N+](=O)[O-])c3)cs2)cc1OC,"InChI=1S/C17H15N3O6S2/c1-25-15-7-6-13(9-16(15)26-2)28(23,24)19-17-18-14(10-27-17)11-4-3-5-12(8-11)20(21)22/h3-10H,1-2H3,(H,18,19)",NDPBMCKQJOZAQX-UHFFFAOYSA-N,ro-61-8048,Preclinical,kynurenine 3-monooxygenase inhibitor,KMO,,
Cc1ccc(S(=O)(=O)N2CCCC2c2ccc(F)cc2)cc1,"InChI=1S/C17H18FNO2S/c1-13-4-10-16(11-5-13)22(20,21)19-12-2-3-17(19)14-6-8-15(18)9-7-14/h4-11,17H,2-3,12H2,1H3",DAEHFYNGSSBGSS-UHFFFAOYSA-N,ro-67-7476,Preclinical,glutamate receptor positive allosteric modulator,GRM1,,
Nc1ccc(-c2nc3cc(-c4nc5cc(N)ccc5[nH]4)ccc3[nH]2)cc1,"InChI=1S/C20H16N6/c21-13-4-1-11(2-5-13)19-23-15-7-3-12(9-17(15)25-19)20-24-16-8-6-14(22)10-18(16)26-20/h1-10H,21-22H2,(H,23,25)(H,24,26)",PAGZCEHLFCJSPV-UHFFFAOYSA-N,ro-90-7501,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,
[N-]=[N+]=NC1(CO)OC(n2ccc(=N)[nH]c2=O)C(O)C1O,"InChI=1S/C9H12N6O5/c10-4-1-2-15(8(19)12-4)7-5(17)6(18)9(3-16,20-7)13-14-11/h1-2,5-7,16-18H,3H2,(H2,10,12,19)",ODLGMSQBFONGNG-UHFFFAOYSA-N,ro-9187,Preclinical,HCV inhibitor,,,
NC(=O)c1ccc(F)c2c1CC(N(C1CCC1)C1CCC1)CO2,"InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)",MQTUXRKNJYPMCG-UHFFFAOYSA-N,robalzotan,Phase 2,serotonin receptor antagonist,HTR1A,,
COCCN=c1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)[nH]cc1C#N,"InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)",BHKDKKZMPODMIQ-UHFFFAOYSA-N,roblitinib,Preclinical,FGFR inhibitor,,,
C=CC(=O)Nc1cccc(N=c2[nH]c(=Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)[nH]cc2C(F)(F)F)c1,"InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)",HUFOZJXAKZVRNJ-UHFFFAOYSA-N,rociletinib,Phase 3,EGFR inhibitor,EGFR,,
C=CC[N+]1(C2CC3C4CCC5CC(O)C(N6CCOCC6)CC5(C)C4CCC3(C)C2OC(C)=O)CCCC1,"InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1",YXRDKMPIGHSVRX-UHFFFAOYSA-N,rocuronium,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2|HTR3A,neurology/psychiatry,anesthetic
CS(=O)(=O)c1ccc(-c2coc(O)c2-c2ccccc2)cc1,"InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-11,18H,1H3",MRHFQRMJFYDYBV-UHFFFAOYSA-N,rofecoxib,Withdrawn,cyclooxygenase inhibitor,ELN|PTGS2,,
O=C(N=c1c(Cl)c[nH]cc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,"InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)",MNDBXUUTURYVHR-UHFFFAOYSA-N,roflumilast,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis
COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(=N)[nH]cnn2c1CN1CCNC(=O)C1,"InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)",HNLRRJSKGXOYNO-UHFFFAOYSA-N,rogaratinib,Phase 2/Phase 3,FGFR inhibitor,,,
CC(OCC1(c2ccccc2)CCC2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)",FIVSJYGQAIEMOC-UHFFFAOYSA-N,rolapitant,Phase 3,neurokinin receptor antagonist,,,
COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,"InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)",HJORMJIFDVBMOB-UHFFFAOYSA-N,rolipram,Phase 3,phosphodiesterase inhibitor,,,
CN(C)C1C(=O)C(C(=O)NCN2CCCC2)C(=O)C2(O)C(=O)C3C(=O)c4c(O)cccc4C(C)(O)C3CC12,"InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,18-20,31,37-38H,4-5,9-12H2,1-3H3,(H,28,36)",PLDZOHPIBZVDLQ-UHFFFAOYSA-N,rolitetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
O=C(CN1CCC(CN2Cc3ccccc3C2=O)CC1)c1ccc(F)cc1,"InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2",RNRYULFRLCBRQS-UHFFFAOYSA-N,roluperidone,Phase 2,,,,
O=C1CCC2CCC(=O)N12,"InChI=1S/C7H9NO2/c9-6-3-1-5-2-4-7(10)8(5)6/h5H,1-4H2",IEZDOKQWPWZVQF-UHFFFAOYSA-N,rolziracetam,Phase 2,,,,
CCC1=NC(=O)C2CSSCCC=CC(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,"InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h7,9,13-15,17,19-20H,6,8,10-12H2,1-5H3,(H,26,32)(H,27,29)(H,28,30)",SOOPLNPQGWJZHY-UHFFFAOYSA-N,romidepsin,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
Cn1c([N+](=O)[O-])cnc1COC(N)=O,"InChI=1S/C6H8N4O4/c1-9-4(3-14-6(7)11)8-2-5(9)10(12)13/h2H,3H2,1H3,(H2,7,11)",PQFRTXSWDXZRRS-UHFFFAOYSA-N,ronidazole,Launched,antiprotozoal agent,,infectious disease,histomoniasis|dysentry
CCCN(CCC)CCc1cccc2[nH]c(O)cc12,"InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7,12,17,19H,3-4,8-11H2,1-2H3",FBYFJOVKHROJSY-UHFFFAOYSA-N,ropinirole,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease|restless leg syndrome
CCCN1CCCCC1C(=O)Nc1c(C)cccc1C,"InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)",ZKMNUMMKYBVTFN-UHFFFAOYSA-N,ropivacaine,Launched,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic
CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,"InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3",SGOOQMRIPALTEL-UHFFFAOYSA-N,roquinimex,Phase 3,angiogenesis inhibitor,,,
CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,"InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3",SGOOQMRIPALTEL-UHFFFAOYSA-N,roquinimex,Phase 3,tumor necrosis factor production inhibitor,,,
CCC1OC(=O)CC(O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(CC=O)CC(C)C(=O)C=CC2(C)OC2C1C,"InChI=1S/C31H51NO9/c1-9-25-20(5)29-31(6,41-29)12-10-23(34)17(2)14-21(11-13-33)28(19(4)24(35)16-26(36)39-25)40-30-27(37)22(32(7)8)15-18(3)38-30/h10,12-13,17-22,24-25,27-30,35,37H,9,11,14-16H2,1-8H3",IUPCWCLVECYZRV-UHFFFAOYSA-N,rosamicin,Phase 2,protein synthesis inhibitor,,,
CCC(CO)N=c1[nH]c(=NCc2ccccc2)c2ncn(C(C)C)c2[nH]1,"InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)",BTIHMVBBUGXLCJ-UHFFFAOYSA-N,roscovitine,Phase 2,CDK inhibitor,CDK2|CDK9,,
O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c(O)c(I)cc12,"InChI=1S/C20H4Cl4I4O5/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28/h1-2,29H,(H,31,32)",VDNLFJGJEQUWRB-UHFFFAOYSA-N,rose-bengal,Launched,contrast agent,,radiology,diagnostic agent
O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(=O)c(I)c-2oc2c(I)c(O)c(I)cc12,"InChI=1S/C20H4Cl4I4O5/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28/h1-2,29H,(H,31,32)",VDNLFJGJEQUWRB-UHFFFAOYSA-N,rose-bengal,Launched,immunostimulant,,radiology,diagnostic agent
O=C1OC2(c3cc(I)c(O)c(I)c3Oc3c2cc(I)c(O)c3I)c2c(Cl)c(Cl)c(Cl)c(Cl)c21,"InChI=1S/C20H4Cl4I4O5/c21-9-7-8(10(22)12(24)11(9)23)20(33-19(7)31)3-1-5(25)15(29)13(27)17(3)32-18-4(20)2-6(26)16(30)14(18)28/h1-2,29-30H",IICCLYANAQEHCI-UHFFFAOYSA-N,rose-bengal-lactone,Launched,coloring agent,,ophthalmology,staining agent
CN(CCOc1ccc(Cc2sc(=O)[nH]c2O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,22H,10-12H2,1H3,(H,20,23)",FLDPBMANMDLQTH-UHFFFAOYSA-N,rosiglitazone,Withdrawn,insulin sensitizer,FFAR1|PPARG|TRPC5|TRPM3,,
CN(CCOc1ccc(Cc2sc(=O)[nH]c2O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,22H,10-12H2,1H3,(H,20,23)",FLDPBMANMDLQTH-UHFFFAOYSA-N,rosiglitazone,Withdrawn,PPAR receptor agonist,FFAR1|PPARG|TRPC5|TRPM3,,
C=C1CCC2C(CN)C(C3(C)CCC(O)CC3CO)CCC12C,"InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3",MDEJTPWQNNMAQF-UHFFFAOYSA-N,rosiptor,Phase 2,SHIP1 phosphatase activator,,,
O=C(C=Cc1ccc(O)c(O)c1)OC(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C18H16O8/c19-12-4-1-10(7-14(12)21)3-6-17(23)26-16(18(24)25)9-11-2-5-13(20)15(22)8-11/h1-8,16,19-22H,9H2,(H,24,25)",DOUMFZQKYFQNTF-UHFFFAOYSA-N,rosmarinic-acid,Launched,GABA transaminase inhibitor,MCL1|TYR,,
CCn1cc(C(=O)O)c(=O)c2ccc(-c3ccncc3)cc21,"InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)",XBPZXDSZHPDXQU-UHFFFAOYSA-N,rosoxacin,Launched,topoisomerase inhibitor,,infectious disease,urinary tract infections
CC12CCC(O)CC1CCC1C2CCC2(C)C(O)(c3ccoc3)CCC12O,"InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3",AEAPORIZZWBIEX-UHFFFAOYSA-N,rostafuroxine,Phase 2,ATPase inhibitor,ATP1A1,,
CC(C)=c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1=CCC(O)CC(O)CC(=O)O,"InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-8,10,16-17,27-28H,9,11-12H2,1-4H3,(H,29,30)",DRLXVNRHGMULCY-UHFFFAOYSA-N,rosuvastatin,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis
CCCN(CCc1cccs1)C1CCc2c(O)cccc2C1,"InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3",KFQYTPMOWPVWEJ-UHFFFAOYSA-N,rotigotine,Launched,dopamine receptor agonist,ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A,neurology/psychiatry,Parkinson's Disease|restless leg syndrome
COc1cc2c(cc1OC)C1Cc3ccc(OC)c(OC)c3CN1CC2,"InChI=1S/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3",AEQDJSLRWYMAQI-UHFFFAOYSA-N,rotundine,Launched,serotonin receptor agonist,DRD1|DRD2|DRD3|HTR1A,neurology/psychiatry,anxiety|sedative
CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,"InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3",ZUMNJDGBYXHASJ-UHFFFAOYSA-N,rovazolac,Preclinical,LXR agonist,,,
O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O,"InChI=1S/C6H6AsNO6/c9-6-2-1-4(7(10,11)12)3-5(6)8(13)14/h1-3,9H,(H2,10,11,12)",XMVJITFPVVRMHC-UHFFFAOYSA-N,roxarsone,Launched,antiprotozoal agent,,endocrinology,weight-gain aid
CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,"InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)",SMTZFNFIKUPEJC-UHFFFAOYSA-N,roxatidine-acetate,Launched,histamine receptor antagonist,HRH2,gastroenterology,Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=NOCOCCOC)C(C)C(O)C1(C)O,"InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3",RXZBMPWDPOLZGW-UHFFFAOYSA-N,roxithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,respiratory tract infections|urinary tract infections|skin infections
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CCC4NCCC(=O)O)no2)cc1C#N,"InChI=1S/C24H24N4O4/c1-14(2)31-21-9-6-15(12-16(21)13-25)24-27-23(28-32-24)19-5-3-4-18-17(19)7-8-20(18)26-11-10-22(29)30/h3-6,9,12,14,20,26H,7-8,10-11H2,1-2H3,(H,29,30)",WNDDDFYFTSGSEC-UHFFFAOYSA-N,rp-001,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
COc1ccccc1CC(=N)N1CC2C(=O)CCC(c3ccccc3)(c3ccccc3)C2C1,"InChI=1S/C29H30N2O2/c1-33-27-15-9-8-10-21(27)18-28(30)31-19-24-25(20-31)29(17-16-26(24)32,22-11-4-2-5-12-22)23-13-6-3-7-14-23/h2-15,24-25,30H,16-20H2,1H3",VWBOQFANCXZMAU-UHFFFAOYSA-N,rp67580,Preclinical,,,,
O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc(C(F)(F)F)cc2Cl)cc1,"InChI=1S/C21H13ClF6N2O5S/c22-17-9-14(20(23,24)25)10-29-18(17)30(11-12-1-5-15(6-2-12)35-21(26,27)28)36(33,34)16-7-3-13(4-8-16)19(31)32/h1-10H,11H2,(H,31,32)",IJGQFZYYEHCCIZ-UHFFFAOYSA-N,rq-00203078,Preclinical,transient receptor potential channel antagonist,TRPM8,,
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1,"InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2",JODKFOVZURLVTG-UHFFFAOYSA-N,rrx-001,Phase 3,glucose 6-phosphate dehydrogenase inhibitor,G6PD,,
CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1,"InChI=1S/C19H20N2O2S/c1-14(15-8-4-2-5-9-15)20-18(22)17-12-24-13-21(17)19(23)16-10-6-3-7-11-16/h2-11,14,17H,12-13H2,1H3,(H,20,22)",MEXWLVVJOPSWLN-UHFFFAOYSA-N,rs-0481,Phase 2,immunostimulant,,,
Cc1c[nH]c(=O)n(CCCN2CCN(c3ccccc3OCC(F)(F)F)CC2)c1=O,"InChI=1S/C20H25F3N4O3/c1-15-13-24-19(29)27(18(15)28)8-4-7-25-9-11-26(12-10-25)16-5-2-3-6-17(16)30-14-20(21,22)23/h2-3,5-6,13H,4,7-12,14H2,1H3,(H,24,29)",RCOBWVAGWYRNHZ-UHFFFAOYSA-N,rs-100329,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,
COc1cc(OC)c(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1,"InChI=1S/C27H31F3N4O7S/c1-40-22-16-23(41-2)20(33-42(38,39)18-8-6-17(7-9-18)27(28,29)30)15-19(22)21(35)5-3-4-12-34-13-10-26(11-14-34)24(36)31-25(37)32-26/h6-9,15-16,33H,3-5,10-14H2,1-2H3,(H2,31,32,36,37)",HZZZZODVDSHQRG-UHFFFAOYSA-N,rs-102221,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
O=C1Nc2ccccc2C2(CCN(CCc3ccc(C(F)(F)F)cc3)CC2)O1,"InChI=1S/C21H21F3N2O2/c22-21(23,24)16-7-5-15(6-8-16)9-12-26-13-10-20(11-14-26)17-3-1-2-4-18(17)25-19(27)28-20/h1-8H,9-14H2,(H,25,27)",HIDWEYPGMLIQSN-UHFFFAOYSA-N,rs-102895,Preclinical,CCR antagonist,CCR2,,
CC(C)c1cc(-c2ccc(F)c3ccccc23)[nH]c(=N)n1,"InChI=1S/C17H16FN3/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13/h3-10H,1-2H3,(H2,19,20,21)",ZZZQXCUPAJFVBN-UHFFFAOYSA-N,rs-127445,Phase 1,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
CC(C)n1cnc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21,"InChI=1S/C18H23ClN4O/c1-11(2)23-10-20-17-14(7-13(19)8-16(17)23)18(24)21-15-9-22-5-3-12(15)4-6-22/h7-8,10-12,15H,3-6,9H2,1-2H3,(H,21,24)",OGXMGJGFLBSEJW-UHFFFAOYSA-N,rs-16566,Preclinical,serotonin receptor antagonist,,,
CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,"InChI=1S/C24H29ClN2O2/c1-24(2,14-18-15-26-21-10-9-19(25)13-20(18)21)27-11-12-28-22-5-3-4-6-23(22)29-16-17-7-8-17/h3-6,9-10,13,15,17,26-27H,7-8,11-12,14,16H2,1-2H3",XLZHXAXXJVKTFM-UHFFFAOYSA-N,rs-17053,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,
COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,"InChI=1S/C16H23ClN2O3/c1-21-15-11-14(18)13(17)10-12(15)16(20)22-9-5-8-19-6-3-2-4-7-19/h10-11H,2-9,18H2,1H3",RLSGBCUXLRMTPF-UHFFFAOYSA-N,rs-23597-190,Preclinical,serotonin receptor antagonist,HTR4,,
COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,"InChI=1S/C26H36ClN3O6S/c1-34-20-12-19(13-21(14-20)35-2)17-36-26-16-24(28)23(27)15-22(26)25(31)5-4-18-6-9-30(10-7-18)11-8-29-37(3,32)33/h12-16,18,29H,4-11,17,28H2,1-3H3",BKVIWGRFRKLFIO-UHFFFAOYSA-N,rs-39604,Preclinical,serotonin receptor antagonist,HTR4,,
Clc1cccc2c1CN(C1=NCCN1)C2,"InChI=1S/C11H12ClN3/c12-10-3-1-2-8-6-15(7-9(8)10)11-13-4-5-14-11/h1-3H,4-7H2,(H,13,14)",IVCMOOBKRRDNHX-UHFFFAOYSA-N,rs-45041-190,Preclinical,imidazoline receptor agonist,,,
Cc1ccc2c(c1)C1(CCN(CCc3nc(-c4ccccc4)oc3C)CC1)OC(=O)N2,"InChI=1S/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29)",ODNICNWASXKNNQ-UHFFFAOYSA-N,rs-504393,Preclinical,CC chemokine receptor antagonist,CCL2|CCR2,,
Cn1cc(C(=O)C(=O)NC2CN3CCC2CC3)c2ccccc21,"InChI=1S/C18H21N3O2/c1-20-10-14(13-4-2-3-5-16(13)20)17(22)18(23)19-15-11-21-8-6-12(15)7-9-21/h2-5,10,12,15H,6-9,11H2,1H3,(H,19,23)",ZNAPADWWBWFMCQ-UHFFFAOYSA-N,rs-56812,Preclinical,serotonin receptor partial agonist,HTR3A,,
CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,"InChI=1S/C19H29ClN2O2/c1-3-4-9-22-10-7-14(8-11-22)5-6-18(23)15-12-16(20)17(21)13-19(15)24-2/h12-14H,3-11,21H2,1-2H3",JBHLYIVFFLNISJ-UHFFFAOYSA-N,rs-67333,Preclinical,serotonin receptor partial agonist,HTR4,,
COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,"InChI=1S/C18H28ClN3O4S/c1-26-18-12-16(20)15(19)11-14(18)17(23)4-3-13-5-8-22(9-6-13)10-7-21-27(2,24)25/h11-13,21H,3-10,20H2,1-2H3",UATDVRSFFGFTAI-UHFFFAOYSA-N,rs-67506,Preclinical,serotonin receptor partial agonist,HTR4,,
CCS(=O)(=O)N1CCCC2CN3CCc4cc(OC)ccc4C3CC21,"InChI=1S/C19H28N2O3S/c1-3-25(22,23)21-9-4-5-15-13-20-10-8-14-11-16(24-2)6-7-17(14)19(20)12-18(15)21/h6-7,11,15,18-19H,3-5,8-10,12-13H2,1-2H3",UMGBFFAJXFXOIL-UHFFFAOYSA-N,rs-79948,Preclinical,adrenergic receptor antagonist,ADRA2A,,
O=C(N=C1NC(c2ccccc2)c2ccccc2NC1=O)Nc1ccccc1F,"InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,19H,(H,24,28)(H2,25,26,27,29)",AOAJKOPXVSAPCE-UHFFFAOYSA-N,rsv604,Phase 2,RSV replication inhibitor,,,
CC1(C)CCC2(NC(=O)C(C)(F)F)CCC3(C)C(C(=O)C=C4C5(C)C=C(C#N)C(=O)C(C)(C)C5CCC43C)C2C1,"InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)",RJCWBNBKOKFWNY-UHFFFAOYSA-N,rta-408,Phase 2,nitric oxide production inhibitor,NFE2L2,,
COc1ccc2[nH]cc(C3=CCNCC3)c2c1,"InChI=1S/C14H16N2O/c1-17-11-2-3-14-12(8-11)13(9-16-14)10-4-6-15-7-5-10/h2-4,8-9,15-16H,5-7H2,1H3",KRVMLPUDAOWOGN-UHFFFAOYSA-N,ru-24969,Phase 1,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6,,
CCCC1C=C2CC(=O)CCC2(C)C2CCC3(C)C(CCC3(O)CCC(=O)O)C12,"InChI=1S/C25H38O4/c1-4-5-16-14-17-15-18(26)6-10-23(17,2)19-7-11-24(3)20(22(16)19)8-12-25(24,29)13-9-21(27)28/h14,16,19-20,22,29H,4-13,15H2,1-3H3,(H,27,28)",LEKDLFUBQWXQTG-UHFFFAOYSA-N,ru-28318,Phase 2,cytochrome P450 inhibitor,NR3C2,,
CC(C)NC1CCn2c(=O)[nH]c3cccc(c32)C1O,"InChI=1S/C14H19N3O2/c1-8(2)15-11-6-7-17-12-9(13(11)18)4-3-5-10(12)16-14(17)19/h3-5,8,11,13,15,18H,6-7H2,1-2H3,(H,16,19)",ZSTCZWJCLIRCOJ-UHFFFAOYSA-N,ru-42173,Phase 2,adrenergic receptor agonist,ADRB2,,
CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCCCO,"InChI=1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3",ARBYGDBJECGMGA-UHFFFAOYSA-N,ru-58841,Phase 2,androgen receptor antagonist,AR,,
CCC(C)CNCC(=O)N1CCc2sccc2C1COc1cccc(C)c1,"InChI=1S/C22H30N2O2S/c1-4-16(2)13-23-14-22(25)24-10-8-21-19(9-11-27-21)20(24)15-26-18-7-5-6-17(3)12-18/h5-7,9,11-12,16,20,23H,4,8,10,13-15H2,1-3H3",AEENEMOEBJOKGN-UHFFFAOYSA-N,ru-ski-43,Preclinical,hedgehog pathway inhibitor,HHAT,,
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,"InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3",VHXNKPBCCMUMSW-UHFFFAOYSA-N,rubitecan,Phase 3,topoisomerase inhibitor,TOP1,,
CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,"InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)",ZCBUQCWBWNUWSU-UHFFFAOYSA-N,ruboxistaurin,Phase 3,PKC inhibitor,,,
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,rucaparib,Phase 3,PARP inhibitor,PARP1|PARP2,,
CCCCc1ccc(O)cc1O,"InChI=1S/C10H14O2/c1-2-3-4-8-5-6-9(11)7-10(8)12/h5-7,11-12H,2-4H2,1H3",CSHZYWUPJWVTMQ-UHFFFAOYSA-N,rucinol,Phase 1,tyrosinase inhibitor,TYR,,
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,"InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)",POGQSBRIGCQNEG-UHFFFAOYSA-N,rufinamide,Launched,voltage-gated sodium channel blocker,GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures
CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2SCC4)CC1,"InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)",NJCJBUHJQLFDSW-UHFFFAOYSA-N,rufloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,"InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3",WUZYKBABMWJHDL-UHFFFAOYSA-N,rupatadine,Launched,histamine receptor antagonist,HRH1|PTAFR,allergy,allergic rhinitis|urticaria
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,"InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3",WUZYKBABMWJHDL-UHFFFAOYSA-N,rupatadine,Launched,platelet activating factor receptor antagonist,HRH1|PTAFR,allergy,allergic rhinitis|urticaria
O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,"InChI=1S/C18H13N3O/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19H,9-10H2",ACVGWSKVRYFWRP-UHFFFAOYSA-N,rutaecarpine,Preclinical,cyclooxygenase inhibitor,PTGS2,,
CC1OC(OCC2OC(Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3",IKGXIBQEEMLURG-UHFFFAOYSA-N,rutin,Launched,antioxidant,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis
CC1OC(OCC2OC(Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3",IKGXIBQEEMLURG-UHFFFAOYSA-N,rutin,Launched,capillary stabilizing agent,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis
CC1OC(OCC2OC(Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3",IKGXIBQEEMLURG-UHFFFAOYSA-N,rutin,Launched,nitric oxide scavenger,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis
N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)",HFNKQEVNSGCOJV-UHFFFAOYSA-N,ruxolitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,hematologic malignancy|hematology,myelofibrosis|polycythemia vera
N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)",HFNKQEVNSGCOJV-UHFFFAOYSA-N,ruxolitinib-(s),Preclinical,JAK inhibitor,JAK1|JAK2,,
COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(=N)[nH]cnc43)n(Cc3ccccc3Cl)c(=O)c12,"InChI=1S/C39H39ClN8O5/c1-52-20-18-46(19-21-53-2)33(50)17-5-3-4-10-26-12-9-16-31-34(26)39(51)47(23-28-11-6-7-15-30(28)40)32(44-31)24-48-38-35(37(41)42-25-43-38)36(45-48)27-13-8-14-29(49)22-27/h6-9,11-16,22,25,49H,3,5,17-21,23-24H2,1-2H3,(H2,41,42,43)",UBLOHCIYTDRGJH-UHFFFAOYSA-N,rv1729,Phase 1,PI3K inhibitor,,,
C=CCn1c(=O)n(C2OC(CO)C(O)C2O)c2[nH]c(=N)[nH]c(=O)c21,"InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)",VDCRFBBZFHHYGT-UHFFFAOYSA-N,rwj-21757,Phase 2,toll-like receptor agonist,TLR7,,
Cc1c(C(=O)NCCCO)cnn1-c1nc(-c2cccc(C(F)(F)F)c2)cs1,"InChI=1S/C18H17F3N4O2S/c1-11-14(16(27)22-6-3-7-26)9-23-25(11)17-24-15(10-28-17)12-4-2-5-13(8-12)18(19,20)21/h2,4-5,8-10,26H,3,6-7H2,1H3,(H,22,27)",HOFGTYCLOKDAES-UHFFFAOYSA-N,rwj-50271,Preclinical,integrin inhibitor,ICAM1,,
OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1,"InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2",QSUSKMBNZQHHPA-UHFFFAOYSA-N,rwj-67657,Phase 1,MAP kinase inhibitor,MAPK14|PTGS2,,
N=c1ccn(C2C(F)=C(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C10H12FN3O4/c11-6-4(3-15)8(16)9(17)7(6)14-2-1-5(12)13-10(14)18/h1-2,7-9,15-17H,3H2,(H2,12,13,18)",QLLGKCJUPWYJON-UHFFFAOYSA-N,rx-3117,Phase 1/Phase 2,CDK inhibitor,CDK2|DNMT1,,
N=c1ccn(C2C(F)=C(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C10H12FN3O4/c11-6-4(3-15)8(16)9(17)7(6)14-2-1-5(12)13-10(14)18/h1-2,7-9,15-17H,3H2,(H2,12,13,18)",QLLGKCJUPWYJON-UHFFFAOYSA-N,rx-3117,Phase 1/Phase 2,DNA synthesis inhibitor,CDK2|DNMT1,,
COC1(C2=NCCN2)COc2ccccc2O1,"InChI=1S/C12H14N2O3/c1-15-12(11-13-6-7-14-11)8-16-9-4-2-3-5-10(9)17-12/h2-5H,6-8H2,1H3,(H,13,14)",HQGWKNGAKBPTBX-UHFFFAOYSA-N,rx-821002,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,,
Cc1ccc(N=C2CC(=O)c3sc(C)nc3C2=O)cc1,"InChI=1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-6H,7H2,1-2H3",CANBMWXJDLUDFF-UHFFFAOYSA-N,ryuvidine,Preclinical,histone lysine methyltransferase inhibitor,CDK2|CDK4,,
Cc1oc2ccccc2c1CNC(=O)NCc1cccs1,"InChI=1S/C16H16N2O2S/c1-11-14(13-6-2-3-7-15(13)20-11)10-18-16(19)17-9-12-5-4-8-21-12/h2-8H,9-10H2,1H3,(H2,17,18,19)",UITFWLJMEZPXOF-UHFFFAOYSA-N,s-07662,Preclinical,CAR antagonist,NR1I3,,
CC(C)=CCCC(C)(O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC12C,"InChI=1S/C30H52O3/c1-19(2)10-9-14-30(8,33)20-11-16-29(7)25(20)21(31)18-23-27(5)15-13-24(32)26(3,4)22(27)12-17-28(23,29)6/h10,20-25,31-33H,9,11-18H2,1-8H3",PYXFVCFISTUSOO-UHFFFAOYSA-N,s-111,Phase 2,PARP inhibitor,PARP1,,
COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,"InChI=1S/C24H26FN3O2/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19/h2-10,17H,11-16H2,1H3,(H,26,29)",IFMQODYDAUKKEN-UHFFFAOYSA-N,s-14506,Preclinical,serotonin receptor agonist,HTR1A,,
O=C(C1CC2CCCCC2N1C(=O)C1CC1c1ccccc1)N1CCSC1,"InChI=1S/C22H28N2O2S/c25-21(18-13-17(18)15-6-2-1-3-7-15)24-19-9-5-4-8-16(19)12-20(24)22(26)23-10-11-27-14-23/h1-3,6-7,16-20H,4-5,8-14H2",NXSXRIHXEQSYEZ-UHFFFAOYSA-N,s-17092,Preclinical,prolyl endopeptidase inhibitor,,,
Cc1ccc(C#Cc2ccc(S(=O)(=O)NC(Cc3c[nH]c4ccccc34)C(=O)O)s2)cc1,"InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)",YWCLDDLVLSQGSZ-UHFFFAOYSA-N,s-3304,Phase 1/Phase 2,matrix metalloprotease inhibitor,,,
NC(=O)c1ccc(OCCCN2CC3CCCC3C2)cc1,"InChI=1S/C17H24N2O2/c18-17(20)13-5-7-16(8-6-13)21-10-2-9-19-11-14-3-1-4-15(14)12-19/h5-8,14-15H,1-4,9-12H2,(H2,18,20)",MRNMYWNBLVJWKG-UHFFFAOYSA-N,s-38093,Preclinical,histamine receptor antagonist,,,
CC(C)SC(=N)N,"InChI=1S/C4H10N2S/c1-3(2)7-4(5)6/h3H,1-2H3,(H3,5,6)",XSSNABKEYXKKMK-UHFFFAOYSA-N,s-isopropylisothiourea,Preclinical,nitric oxide synthase inhibitor,NOS3,,
CSCC(N)C(=O)O,"InChI=1S/C4H9NO2S/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)",IDIDJDIHTAOVLG-UHFFFAOYSA-N,s-methylcysteine,Phase 1,,CTSD|MGMT,,
NC(CCC(=O)NC(CS[N+][O-])C(=O)NCC(=O)O)C(=O)O,"InChI=1S/C10H16N4O7S/c11-5(10(19)20)1-2-7(15)13-6(4-22-14-21)9(18)12-3-8(16)17/h5-6H,1-4,11H2,(H,12,18)(H,13,15)(H,16,17)(H,19,20)",HYHSBSXUHZOYLX-UHFFFAOYSA-N,s-nitrosoglutathione,Phase 1,nitric oxide stimulant,PTPN1,,
NC(CSS(=O)(=O)O)C(=O)O,"InChI=1S/C3H7NO5S2/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)",NOKPBJYHPHHWAN-UHFFFAOYSA-N,s-sulfo-l-cysteine,Preclinical,glutamate receptor agonist,,,
NC(CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O,"InChI=1S/C22H21NO2S/c23-20(21(24)25)16-26-22(17-10-4-1-5-11-17,18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15,20H,16,23H2,(H,24,25)",DLMYFMLKORXJPO-UHFFFAOYSA-N,s-trityl-l-cysteine,Preclinical,mitotic kinesin inhibitor,,,
c1ccc2c(c1)CC(N1CCN(c3cccc4c3OCCO4)CC1)C2,"InChI=1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2",QJPPEMXOOWNICQ-UHFFFAOYSA-N,s15535,Preclinical,serotonin receptor agonist,,,
O=S1(=O)NC2CCCN2c2ccccc21,"InChI=1S/C10H12N2O2S/c13-15(14)9-5-2-1-4-8(9)12-7-3-6-10(12)11-15/h1-2,4-5,10-11H,3,6-7H2",MNTIJYGEITVWHU-UHFFFAOYSA-N,s18986,Phase 2,glutamate receptor modulator,GRIA1|GRIA2|GRIA3|GRIA4,,
COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1,"InChI=1S/C21H16F3N3O3/c1-30-18-9-10-25-12-16(18)19(28)27-20(29)26-14-7-8-15(13-5-3-2-4-6-13)17(11-14)21(22,23)24/h2-12H,1H3,(H2,26,27,28,29)",MLDQTQOMWDNTNN-UHFFFAOYSA-N,s1p1-agonist-iii,Preclinical,sphingosine kinase inhibitor,S1PR1,,
COC(=O)C(Cc1ccc(OCCn2c(=O)sc3cc(C(=O)c4ccccc4)ccc32)cc1)C(=O)OC,"InChI=1S/C28H25NO7S/c1-34-26(31)22(27(32)35-2)16-18-8-11-21(12-9-18)36-15-14-29-23-13-10-20(17-24(23)37-28(29)33)25(30)19-6-4-3-5-7-19/h3-13,17,22H,14-16H2,1-2H3",NSMJEHGOMXSLCW-UHFFFAOYSA-N,s26948,Preclinical,PPAR receptor agonist,PPARG,,
Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1,"InChI=1S/C15H17N3O4S/c1-10-7-11(2)9-13(8-10)18-15(19)17-12-3-5-14(6-4-12)22-23(16,20)21/h3-9H,1-2H3,(H2,16,20,21)(H2,17,18,19)",HGVHSNXRZYOTPD-UHFFFAOYSA-N,s4,Preclinical,carbonic anhydrase inhibitor,CA12|CA9,,
O=C1N=c2ccc(=Cn3c(O)csc3=O)cc2C1Cc1cc(CN2CCOCC2)c[nH]1,"InChI=1S/C22H22N4O4S/c27-20-13-31-22(29)26(20)12-14-1-2-19-17(8-14)18(21(28)24-19)9-16-7-15(10-23-16)11-25-3-5-30-6-4-25/h1-2,7-8,10,12-13,18,23,27H,3-6,9,11H2",RSUJQTWPGMFECL-UHFFFAOYSA-N,s49076,Preclinical,tyrosine kinase inhibitor,,,
Cc1c(-c2c(-c3ccc(F)o3)sc3ncnc(OC(Cc4ccccc4OCc4ccnn4CC(F)(F)F)C(=O)O)c23)ccc(OCCN2CCN(C)CC2)c1Cl,"InChI=1S/C39H37ClF4N6O6S/c1-23-26(7-8-28(34(23)40)53-18-17-49-15-13-48(2)14-16-49)32-33-36(45-22-46-37(33)57-35(32)29-9-10-31(41)55-29)56-30(38(51)52)19-24-5-3-4-6-27(24)54-20-25-11-12-47-50(25)21-39(42,43)44/h3-12,22,30H,13-21H2,1-2H3,(H,51,52)",ZFBHXVOCZBPADE-UHFFFAOYSA-N,s63845,Preclinical,MCL1 inhibitor,,,
CNC(=O)COC(=O)NCCC1CCN(c2cccc(C)n2)CC1,"InChI=1S/C17H26N4O3/c1-13-4-3-5-15(20-13)21-10-7-14(8-11-21)6-9-19-17(23)24-12-16(22)18-2/h3-5,14H,6-12H2,1-2H3,(H,18,22)(H,19,23)",HSYCMGWPPRTNKH-UHFFFAOYSA-N,sa-47,Preclinical,FAAH inhibitor,FAAH,,
O=C1NS(=O)(=O)c2ccccc21,"InChI=1S/C7H5NO3S/c9-7-5-3-1-2-4-6(5)12(10,11)8-7/h1-4H,(H,8,9)",CVHZOJJKTDOEJC-UHFFFAOYSA-N,saccharin,Launched,DNA polymerase inhibitor,CA1|CA12|CA2|CA9,,
NCC(CS(=O)(=O)O)c1ccc(Cl)cc1,"InChI=1S/C9H12ClNO3S/c10-9-3-1-7(2-4-9)8(5-11)6-15(12,13)14/h1-4,8H,5-6,11H2,(H,12,13,14)",JYLNVJYYQQXNEK-UHFFFAOYSA-N,saclofen,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,
CCOC(=O)C(C)CC(Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,"InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)",PYNXFZCZUAOOQC-UHFFFAOYSA-N,sacubitril,Launched,neprilysin inhibitor,MME,cardiology,congestive heart failure
CC(CC(Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O)C(=O)O,"InChI=1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)",DOBNVUFHFMVMDB-UHFFFAOYSA-N,sacubitrilat,Preclinical,neprilysin inhibitor,,,
O=C(C=Cc1ccc(O)cc1)C1C(=O)C(=CC2C(=O)C(C(=O)C=Cc3ccc(O)cc3)C(=O)C(O)(C3OC(CO)C(O)C(O)C3O)C2=O)C(=O)C(O)(C2OC(CO)C(O)C(O)C2O)C1=O,"InChI=1S/C43H42O22/c44-14-24-30(52)32(54)34(56)40(64-24)42(62)36(58)20(28(50)26(38(42)60)22(48)11-5-16-1-7-18(46)8-2-16)13-21-29(51)27(23(49)12-6-17-3-9-19(47)10-4-17)39(61)43(63,37(21)59)41-35(57)33(55)31(53)25(15-45)65-41/h1-13,20,24-27,30-35,40-41,44-47,52-57,62-63H,14-15H2",UHZGYDZTDCTJBO-UHFFFAOYSA-N,safflower-yellow,Preclinical,anti-inflammatory agent,,,
CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,"InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)",NEMGRZFTLSKBAP-UHFFFAOYSA-N,safinamide,Launched,dopamine reuptake inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease
CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,"InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)",NEMGRZFTLSKBAP-UHFFFAOYSA-N,safinamide,Launched,glutamate inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease
CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,"InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)",NEMGRZFTLSKBAP-UHFFFAOYSA-N,safinamide,Launched,monoamine oxidase inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease
CCCCCCCCCCCCCCCC(O)C(N)CO,"InChI=1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3",OTKJDMGTUTTYMP-UHFFFAOYSA-N,safingol,Phase 1,PKC inhibitor,TRPM3,,
CC1=C(C=O)C(C)(C)CC=C1,"InChI=1S/C10H14O/c1-8-5-4-6-10(2,3)9(8)7-11/h4-5,7H,6H2,1-3H3",SGAWOGXMMPSZPB-UHFFFAOYSA-N,safranal,Phase 2,benzodiazepine receptor agonist,GABBR1,,
CNC1CCC(N(Cc2cccc(-c3ccncc3)c2)C(=O)c2sc3ccccc3c2Cl)CC1,"InChI=1S/C28H28ClN3OS/c1-30-22-9-11-23(12-10-22)32(28(33)27-26(29)24-7-2-3-8-25(24)34-27)18-19-5-4-6-21(17-19)20-13-15-31-16-14-20/h2-8,13-17,22-23,30H,9-12,18H2,1H3",VFSUUTYAEQOIMW-UHFFFAOYSA-N,sag,Preclinical,smoothened receptor agonist,SMO|TRPC6,,
O=C(C=Cc1ccccc1)NC(NC(=S)Nc1ccc(Cl)cc1)C(Cl)(Cl)Cl,"InChI=1S/C18H15Cl4N3OS/c19-13-7-9-14(10-8-13)23-17(27)25-16(18(20,21)22)24-15(26)11-6-12-4-2-1-3-5-12/h1-11,16H,(H,24,26)(H2,23,25,27)",TVNBASWNLOIQML-UHFFFAOYSA-N,sal003,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2A,,
COc1ccc(=NS(=O)(=O)c2ccc(N=Nc3ccc(O)c(C(=O)O)c3)cc2)[nH]n1,"InChI=1S/C18H15N5O6S/c1-29-17-9-8-16(21-22-17)23-30(27,28)13-5-2-11(3-6-13)19-20-12-4-7-15(24)14(10-12)18(25)26/h2-10,24H,1H3,(H,21,23)(H,25,26)",YFUATOCFMCWUEH-UHFFFAOYSA-N,salazodine,Phase 2,,,,
OCc1ccccc1OC1OC(CO)C(O)C(O)C1O,"InChI=1S/C13H18O7/c14-5-7-3-1-2-4-8(7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2",NGFMICBWJRZIBI-UHFFFAOYSA-N,salicin,Phase 1,anti-inflammatory agent,,,
OCc1ccccc1O,"InChI=1S/C7H8O2/c8-5-6-3-1-2-4-7(6)9/h1-4,8-9H,5H2",CQRYARSYNCAZFO-UHFFFAOYSA-N,salicyl-alcohol,Preclinical,,,,
NC(=O)c1ccccc1O,"InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)",SKZKKFZAGNVIMN-UHFFFAOYSA-N,salicylamide,Launched,analgesic agent,,neurology/psychiatry|endocrinology,pain relief|fever
O=C(Nc1ccccc1)c1ccccc1O,"InChI=1S/C13H11NO2/c15-12-9-5-4-8-11(12)13(16)14-10-6-2-1-3-7-10/h1-9,15H,(H,14,16)",WKEDVNSFRWHDNR-UHFFFAOYSA-N,salicylanilide,Preclinical,other antibiotic,,,
O=C(O)c1ccccc1O,"InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",YGSDEFSMJLZEOE-UHFFFAOYSA-N,salicylic-acid,Launched,cyclooxygenase inhibitor,AKR1C1|ASIC3|PTGS1|PTGS2,dermatology|endocrinology|neurology/psychiatry,acne vulgaris (AV)|fever|pain relief
O=C(O)c1ccccc1O,"InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)",YGSDEFSMJLZEOE-UHFFFAOYSA-N,salicylic-acid,Launched,prostanoid receptor antagonist,AKR1C1|ASIC3|PTGS1|PTGS2,dermatology|endocrinology|neurology/psychiatry,acne vulgaris (AV)|fever|pain relief
OCC1OC(OCCc2ccc(O)cc2)C(O)C(O)C1O,"InChI=1S/C14H20O7/c15-7-10-11(17)12(18)13(19)14(21-10)20-6-5-8-1-3-9(16)4-2-8/h1-4,10-19H,5-7H2",ILRCGYURZSFMEG-UHFFFAOYSA-N,salidroside,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,
CCC(C(=O)O)C1CCC(C)C(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)O1,"InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)",KQXDHUJYNAXLNZ-UHFFFAOYSA-N,salinomycin,Launched,,,infectious disease,coccidiosis
CC(C)=CCCC(C)=CCCC(C)=CCSc1ccccc1C(=O)O,"InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)",WUILNKCFCLNXOK-UHFFFAOYSA-N,salirasib,Phase 2,mTOR inhibitor,TRPA1,,
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,"InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2",GIIZNNXWQWCKIB-UHFFFAOYSA-N,salmeterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm
CC1(C(=O)O)NCCc2cc(O)c(O)cc21,"InChI=1S/C11H13NO4/c1-11(10(15)16)7-5-9(14)8(13)4-6(7)2-3-12-11/h4-5,12-14H,2-3H2,1H3,(H,15,16)",XHGLVMDBZZZXDP-UHFFFAOYSA-N,salsolinol-1-carboxylic-acid,Preclinical,,,,
O=C(C=Cc1ccccc1)NC(NC(=S)Nc1cccc2cccnc12)C(Cl)(Cl)Cl,"InChI=1S/C21H17Cl3N4OS/c22-21(23,24)19(27-17(29)12-11-14-6-2-1-3-7-14)28-20(30)26-16-10-4-8-15-9-5-13-25-18(15)16/h1-13,19H,(H,27,29)(H2,26,28,30)",LCOIAYJMPKXARU-UHFFFAOYSA-N,salubrinal,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2S1,,
O=C(C=Cc1ccc(O)c(O)c1C=Cc1ccc(O)c(O)c1)OC(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)",YMGFTDKNIWPMGF-UHFFFAOYSA-N,salvianolic-acid-a,Phase 1,matrix metalloprotease inhibitor,,,
O=C(C=Cc1ccc(O)c2c1C(C(=O)OC(Cc1ccc(O)c(O)c1)C(=O)O)C(c1ccc(O)c(O)c1)O2)OC(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)",SNKFFCBZYFGCQN-UHFFFAOYSA-N,salvianolic-acid-b,Phase 2,EGFR inhibitor,MMP9,,
O=C(C=Cc1ccc(O)c2c1C(C(=O)OC(Cc1ccc(O)c(O)c1)C(=O)O)C(c1ccc(O)c(O)c1)O2)OC(Cc1ccc(O)c(O)c1)C(=O)O,"InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)",SNKFFCBZYFGCQN-UHFFFAOYSA-N,salvianolic-acid-b,Phase 2,metalloproteinase inhibitor,MMP9,,
COC(=O)C1CC(OC(C)=O)C(=O)C2C1(C)CCC1C(=O)OC(c3ccoc3)CC12C,"InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3",OBSYBRPAKCASQB-UHFFFAOYSA-N,salvinorin-a,Phase 1,opioid receptor agonist,OPRD1|OPRK1|OPRM1,,
O=S(=O)(c1cccc2ccccc12)c1[nH]nc2ccc(N3CCNCC3)cc12,"InChI=1S/C21H20N4O2S/c26-28(27,20-7-3-5-15-4-1-2-6-17(15)20)21-18-14-16(8-9-19(18)23-24-21)25-12-10-22-11-13-25/h1-9,14,22H,10-13H2,(H,23,24)",FYOVZCDHYOEKDE-UHFFFAOYSA-N,sam-315,Preclinical,serotonin receptor antagonist,,,
CCCCCCN1CCC(C(=O)N(C)CC)(c2ccccc2)CC1,"InChI=1S/C21H34N2O/c1-4-6-7-11-16-23-17-14-21(15-18-23,20(24)22(3)5-2)19-12-9-8-10-13-19/h8-10,12-13H,4-7,11,14-18H2,1-3H3",TYWUGCGYWNSRPS-UHFFFAOYSA-N,sameridine,Preclinical,opioid receptor modulator,,,
COCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"InChI=1S/C7H11N5O4/c1-16-3-2-8-6(13)4-11-5-9-7(10-11)12(14)15/h5H,2-4H2,1H3,(H,8,13)",YKDRHKCETNMLHL-UHFFFAOYSA-N,sanazole,Phase 1,,,,
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)C3C(=O)c4c(O)cccc4CC3CC12,"InChI=1S/C21H22N2O7/c1-23(2)15-10-7-9-6-8-4-3-5-11(24)12(8)16(25)13(9)18(27)21(10,30)19(28)14(17(15)26)20(22)29/h3-5,9-10,13-15,24,30H,6-7H2,1-2H3,(H2,22,29)",CRNIKQQPTHSPBA-UHFFFAOYSA-N,sancycline,Preclinical,antitumor agent,,,
N=c1[nH]cnc2c1c(C(N)=O)cn2C1OC(CO)C(O)C1O,"InChI=1S/C12H15N5O5/c13-9-6-4(10(14)21)1-17(11(6)16-3-15-9)12-8(20)7(19)5(2-18)22-12/h1,3,5,7-8,12,18-20H,2H2,(H2,14,21)(H2,13,15,16)",OBZJZDHRXBKKTJ-UHFFFAOYSA-N,sangivamycin,Phase 1,DNA inhibitor,,,
C[n+]1cc2c3c(ccc2c2ccc4cc5c(cc4c21)OCO5)OCO3,"InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1",INVGWHRKADIJHF-UHFFFAOYSA-N,sanguinarium-chloride,Phase 1,apoptosis stimulant,CASP3,,
Cc1nn(-c2ccccc2)c(C)c1C=NN1CCN(Cc2ccccc2)CC1,"InChI=1S/C23H27N5/c1-19-23(20(2)28(25-19)22-11-7-4-8-12-22)17-24-27-15-13-26(14-16-27)18-21-9-5-3-6-10-21/h3-12,17H,13-16,18H2,1-2H3",FOORCIAZMIWALX-UHFFFAOYSA-N,sant-1,Preclinical,smoothened receptor antagonist,SHH|SMO,,
CCOc1cc(C(=O)Nc2ccc(Cl)c(-c3nc4ccccc4[nH]3)c2)cc(OCC)c1OCC,"InChI=1S/C26H26ClN3O4/c1-4-32-22-13-16(14-23(33-5-2)24(22)34-6-3)26(31)28-17-11-12-19(27)18(15-17)25-29-20-9-7-8-10-21(20)30-25/h7-15H,4-6H2,1-3H3,(H,28,31)(H,29,30)",VQOJFGFKIVFMDH-UHFFFAOYSA-N,sant-2,Preclinical,smoothened receptor antagonist,SHH|SMO,,
CCCCCCCCCCCCCCCC(=O)N=c1ccn(C2OC(CO)C(O)C2C#N)c(=O)[nH]1,"InChI=1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)",LBGFKUUHOPIEMA-UHFFFAOYSA-N,sapacitabine,Phase 3,DNA synthesis inhibitor,,,
CC(O)C(O)C1CNc2[nH]c(=N)[nH]c(=O)c2N1,"InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)",FNKQXYHWGSIFBK-UHFFFAOYSA-N,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,NOS3|PAH|TH|TPH1,metabolism,hyperphenylalaninemia (HPA)
CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(=O)C(Cc1ccccc1)NC(=O)C(CC(N)O)NC(=O)c1ccc2ccccc2n1,"InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-32,34,46H,7-8,14-15,19-23,39H2,1-3H3,(H,41,48)(H,42,47)(H,43,49)",CKABLRDEWGBLBV-UHFFFAOYSA-N,saquinavir,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1)
COc1cc(N=c2[nH]c3ccccc3[nH]c2=NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,"InChI=1S/C31H29N5O6S/c1-19-9-10-20(15-28(19)42-4)31(37)33-21-11-13-25(14-12-21)43(38,39)36-30-29(34-26-7-5-6-8-27(26)35-30)32-22-16-23(40-2)18-24(17-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36)",HJSSPYJVWLTYHG-UHFFFAOYSA-N,sar-245409,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CG,,
CCn1c(N)c(C(=O)NC)c(=O)c2ccc(C#CC(C)(O)COC)nc21,"InChI=1S/C18H22N4O4/c1-5-22-15(19)13(17(24)20-3)14(23)12-7-6-11(21-16(12)22)8-9-18(2,25)10-26-4/h6-7,25H,5,10,19H2,1-4H3,(H,20,24)",PFMPOBVAYMTUOX-UHFFFAOYSA-N,sar131675,Preclinical,VEGFR inhibitor,FLT4,,
CC1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)C(C(F)(F)F)CC2,"InChI=1S/C19H21ClF3N5O2/c1-12-11-30-5-4-26(12)16-7-17(29)27-3-2-15(19(21,22)23)28(18(27)25-16)10-13-6-14(20)9-24-8-13/h6-9,12,15H,2-5,10-11H2,1H3",SPDQRCUBFSRAFI-UHFFFAOYSA-N,sar405,Preclinical,PI3K inhibitor,PIK3C3,,
CC(C)(C)CC1NC(C(=O)NC2CCC(O)CC2)C(c2cccc(Cl)c2F)C12C(=O)Nc1cc(Cl)ccc12,"InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)",IDKAKZRYYDCJDU-UHFFFAOYSA-N,sar405838,Phase 1,MDM inhibitor,MDM2,,
O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,"InChI=1S/C14H16N2O2/c17-14-13-2-1-12(9-10(13)3-8-16-14)18-11-4-6-15-7-5-11/h1-3,8-9,11,15H,4-7H2,(H,16,17)",IPEXHQGMTHOKQV-UHFFFAOYSA-N,sar407899,Phase 2,rho associated kinase inhibitor,ROCK1,,
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(=Nc4c(Cl)ccc5c4OCO5)[nH]cnc3c2)CC1,"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)",OUKYUETWWIPKQR-UHFFFAOYSA-N,saracatinib,Phase 2/Phase 3,SRC inhibitor,ABL1|LCK|SRC|YES1,,
O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O,"InChI=1S/C20H17F2N3O3/c21-12-1-3-13(4-2-12)25-11-15(20(27)28)19(26)14-9-16(22)18(10-17(14)25)24-7-5-23-6-8-24/h1-4,9-11,23H,5-8H2,(H,27,28)",XBHBWNFJWIASRO-UHFFFAOYSA-N,sarafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CNCC(=O)O,"InChI=1S/C3H7NO2/c1-4-2-3(5)6/h4H,2H2,1H3,(H,5,6)",FSYKKLYZXJSNPZ-UHFFFAOYSA-N,sarcosine,Phase 2,glycine transporter inhibitor,SLC6A9,,
N=C(N)NN=C1CCc2c(C(=N)N)cccc21,"InChI=1S/C11H14N6/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17)",CYPGNVSXMAUSJY-UHFFFAOYSA-N,sardomozide,Preclinical,S-adenosylmethionine decarboxylase inhibitor,,,
CCc1noc(C)c1-c1[nH]c2ccccc2c1C(O)CN(C)C,"InChI=1S/C18H23N3O2/c1-5-13-16(11(2)23-20-13)18-17(15(22)10-21(3)4)12-8-6-7-9-14(12)19-18/h6-9,15,19,22H,5,10H2,1-4H3",GMGOZCSXMVXXRS-UHFFFAOYSA-N,sari-59-801,Phase 1,,,,
CCOC(Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O,"InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)",MRWFZSLZNUJVQW-UHFFFAOYSA-N,saroglitazar,Launched,PPAR receptor agonist,PPARA|PPARG,endocrinology|cardiology|gastroenterology,diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,"InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)",FFYNAVGJSYHHFO-UHFFFAOYSA-N,sarpogrelate,Launched,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,endocrinology|cardiology|rheumatology,diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,"InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)",WVYADZUPLLSGPU-UHFFFAOYSA-N,sasapyrine,Launched,NFkB pathway inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis
NC1CCCCC1,"InChI=1S/C6H13N/c7-6-4-2-1-3-5-6/h6H,1-5,7H2",PAFZNILMFXTMIY-UHFFFAOYSA-N,satraplatin,Phase 3,DNA alkylating agent,,,
CC(c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,"InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3",XYDNMOZJKOGZLS-UHFFFAOYSA-N,savolitinib,Phase 3,c-Met inhibitor,MET,,
N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2,"InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2",QGJUIPDUBHWZPV-UHFFFAOYSA-N,saxagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc21,"InChI=1S/C15H14N4O/c1-19-8-6-11-9-12(4-5-14(11)19)17-15(20)18-13-3-2-7-16-10-13/h2-10H,1H3,(H2,17,18,20)",OJZZJTLBYXHUSJ-UHFFFAOYSA-N,sb-200646,Preclinical,serotonin receptor antagonist,HTR2B|HTR2C,,
Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,"InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)",QHKYPYXTTXKZST-UHFFFAOYSA-N,sb-202190,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,
O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,"InChI=1S/C16H20N2O2/c19-16(20-11-10-18-8-4-1-5-9-18)14-12-17-15-7-3-2-6-13(14)15/h2-3,6-7,12,17H,1,4-5,8-11H2",YGKPIROTKVQCCU-UHFFFAOYSA-N,sb-203186,Preclinical,serotonin receptor antagonist,HTR4,,
C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,"InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)",CDMGBJANTYXAIV-UHFFFAOYSA-N,sb-203580,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF,,
CC#CCOC(=O)c1c(C)[nH]c2sc3c(c2c1=N)CCC(O)C3,"InChI=1S/C17H18N2O3S/c1-3-4-7-22-17(21)13-9(2)19-16-14(15(13)18)11-6-5-10(20)8-12(11)23-16/h10,20H,5-8H2,1-2H3,(H2,18,19)",JDTZAGLGBRRCJT-UHFFFAOYSA-N,sb-205384,Preclinical,GABA receptor modulator,GABRA3|GABRA5|GABRA6,,
Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1,"InChI=1S/C17H16N4O/c1-20-7-4-12-10-16-13(9-15(12)20)5-8-21(16)17(22)19-14-3-2-6-18-11-14/h2-4,6-7,9-11H,5,8H2,1H3,(H,19,22)",QJQORSLQNXDVGE-UHFFFAOYSA-N,sb-206553,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1OCCN(C)C,"InChI=1S/C28H30N4O4/c1-18-16-22(27-29-19(2)36-31-27)10-12-24(18)20-6-8-21(9-7-20)28(33)30-23-11-13-25(34-5)26(17-23)35-15-14-32(3)4/h6-13,16-17H,14-15H2,1-5H3,(H,30,33)",JRNUKVFYILMMLX-UHFFFAOYSA-N,sb-216641,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,,
Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21,"InChI=1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)",JCSGFHVFHSKIJH-UHFFFAOYSA-N,sb-216763,Preclinical,glycogen synthase kinase inhibitor,CCNA2|CDK2|GSK3A|GSK3B,,
O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,"InChI=1S/C24H15N3O3/c28-23-19-17-11-5-1-3-7-13(11)26-15-9-10-16(30-15)27-14-8-4-2-6-12(14)18(22(27)21(17)26)20(19)24(29)25-23/h1-8,15-16H,9-10H2,(H,25,28,29)",OTPNDVKVEAIXTI-UHFFFAOYSA-N,sb-218078,Preclinical,CHK inhibitor,CHEK1,,
COC(=O)C(NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1,"InChI=1S/C25H20N2O3/c1-30-25(29)23(18-12-6-3-7-13-18)27-24(28)20-16-22(17-10-4-2-5-11-17)26-21-15-9-8-14-19(20)21/h2-16,23H,1H3,(H,27,28)",IUMQXQJZIHWLIN-UHFFFAOYSA-N,sb-218795,Preclinical,tachykinin antagonist,TACR3,,
CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2,"InChI=1S/C16H14F3N3OS/c1-24-14-7-10-4-6-22(13(10)8-12(14)16(17,18)19)15(23)21-11-3-2-5-20-9-11/h2-3,5,7-9H,4,6H2,1H3,(H,21,23)",OQZOXHCRSXYSPM-UHFFFAOYSA-N,sb-221284,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
CCC(NC(=O)c1c(C)c(-c2ccccc2)nc2ccccc12)c1ccccc1,"InChI=1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)",MQNYRKWJSMQECI-UHFFFAOYSA-N,sb-222200,Preclinical,tachykinin antagonist,TACR3,,
O=C(Nc1ccc([N+](=O)[O-])cc1O)Nc1ccccc1Br,"InChI=1S/C13H10BrN3O4/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17(20)21)7-12(11)18/h1-7,18H,(H2,15,16,19)",MQBZVUNNWUIPMK-UHFFFAOYSA-N,sb-225002,Preclinical,CC chemokine receptor antagonist,CXCR2,,
COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2,"InChI=1S/C22H17F4N3O2/c1-31-20-9-13-4-6-29(19(13)11-18(20)22(24,25)26)21(30)28-17-8-15(7-16(23)10-17)14-3-2-5-27-12-14/h2-3,5,7-12H,4,6H2,1H3,(H,28,30)",RRJLJKRFFRZRAF-UHFFFAOYSA-N,sb-228357,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
Cc1nc2c(-c3cnc(=N)[nH]c3)nc(N3CCOCC3)nc2n1C(C)C,"InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)",QYBGBLQCOOISAR-UHFFFAOYSA-N,sb-2343,Phase 1,mTOR inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
Cc1nc2c(-c3cnc(=N)[nH]c3)nc(N3CCOCC3)nc2n1C(C)C,"InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)",QYBGBLQCOOISAR-UHFFFAOYSA-N,sb-2343,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1,"InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3",ZQUSFAUAYSEREK-UHFFFAOYSA-N,sb-239063,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14|PTGS2,,
COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1,"InChI=1S/C19H20FN5O/c1-26-19-22-11-8-16(24-19)18-17(13-2-4-14(20)5-3-13)23-12-25(18)15-6-9-21-10-7-15/h2-5,8,11-12,15,21H,6-7,9-10H2,1H3",PDTYLGXVBIWRIM-UHFFFAOYSA-N,sb-242235,Phase 1,p38 MAPK inhibitor,HSPB1|MAPK14,,
Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2,"InChI=1S/C22H19F3N4O2/c1-13-10-15-7-9-29(18(15)11-17(13)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-19-4-3-8-26-14(19)2/h3-6,8,10-12H,7,9H2,1-2H3,(H,28,30)",ZETBBVYSBABLHL-UHFFFAOYSA-N,sb-243213,Phase 1,serotonin receptor inverse agonist,HTR2A|HTR2B|HTR2C|HTR6,,
COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,"InChI=1S/C18H22IN3O3S/c1-21-9-11-22(12-10-21)17-13-15(5-8-18(17)25-2)20-26(23,24)16-6-3-14(19)4-7-16/h3-8,13,20H,9-12H2,1-2H3",BDHMSYNBSBZCAF-UHFFFAOYSA-N,sb-258585,Preclinical,serotonin receptor antagonist,HTR6,,
Cc1ccccc1N(C)C(=O)c1ccc([S+]([O-])c2nccs2)c([N+](=O)[O-])c1,"InChI=1S/C18H15N3O4S2/c1-12-5-3-4-6-14(12)20(2)17(22)13-7-8-16(15(11-13)21(23)24)27(25)18-19-9-10-26-18/h3-11H,1-2H3",YXHLPJQQPOMPGE-UHFFFAOYSA-N,sb-268262,Preclinical,calcitonin antagonist,CALCA,,
CC1CCN(CCC2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,"InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3",HWKROQUZSKPIKQ-UHFFFAOYSA-N,sb-269970,Preclinical,serotonin receptor antagonist,HTR7,,
COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,"InChI=1S/C20H22ClN3O3S2/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24/h3-6,11-12,22-23H,7-10H2,1-2H3",LOCQRDBFWSXQQI-UHFFFAOYSA-N,sb-271046,Phase 1,serotonin receptor antagonist,HTR6,,
CCOC(=O)C(Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1ccccc1,"InChI=1S/C18H18N2O5/c1-2-25-18(22)16(19-17(21)14-6-4-3-5-7-14)12-13-8-10-15(11-9-13)20(23)24/h3-11,16H,2,12H2,1H3,(H,19,21)",BEZXGSZPWXRHIN-UHFFFAOYSA-N,sb-297006,Preclinical,CC chemokine receptor antagonist,CCR3,,
COC(=O)C(Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1cccc2ccccc12,"InChI=1S/C21H18N2O5/c1-28-21(25)19(13-14-9-11-16(12-10-14)23(26)27)22-20(24)18-8-4-6-15-5-2-3-7-17(15)18/h2-12,19H,13H2,1H3,(H,22,24)",VMFGCGRAIBLAFY-UHFFFAOYSA-N,sb-328437,Preclinical,CCR antagonist,,,
Cc1nc2ccc(NC(=O)N=c3cc[nH]c4cccnc34)cc2o1,"InChI=1S/C17H13N5O2/c1-10-20-12-5-4-11(9-15(12)24-10)21-17(23)22-14-6-8-18-13-3-2-7-19-16(13)14/h2-9H,1H3,(H2,18,21,22,23)",AKMNUCBQGHFICM-UHFFFAOYSA-N,sb-334867,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
COc1cccc(NC(=O)C=Cc2ccc(Cl)cc2)c1,"InChI=1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)",RYAMDQKWNKKFHD-UHFFFAOYSA-N,sb-366791,Preclinical,TRPV antagonist,TRPV1,,
COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1N1CCNCC1,"InChI=1S/C18H21Cl2N3O4S/c1-26-17-4-3-13(11-16(17)23-7-5-21-6-8-23)28(24,25)22-15-10-12(19)9-14(20)18(15)27-2/h3-4,9-11,21-22H,5-8H2,1-2H3",ATKZKAYWARYLBW-UHFFFAOYSA-N,sb-399885,Preclinical,serotonin receptor antagonist,HTR6,,
Cc1cc(=NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2[nH]1,"InChI=1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26)",JTARFZSNUAGHRB-UHFFFAOYSA-N,sb-408124,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,
O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])C1=Nc1ccc(O)c(Cl)c1,"InChI=1S/C16H10ClN3O5/c17-10-7-8(5-6-12(10)21)18-14-13(15(22)19-16(14)23)9-3-1-2-4-11(9)20(24)25/h1-7,13,21H,(H,19,22,23)",PIWVARUFOMADFY-UHFFFAOYSA-N,sb-415286,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B|RPS6KB1,,
NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCO4)c(-c3ccccn3)[nH]2)cc1,"InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)",FHYUGAJXYORMHI-UHFFFAOYSA-N,sb-431542,Preclinical,TGF beta receptor inhibitor,ACVR1C|TGFBR1,,
CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1,"InChI=1S/C18H22BrN3O/c1-3-22(15-8-6-7-14(2)13-15)12-11-20-18(23)21-17-10-5-4-9-16(17)19/h4-10,13H,3,11-12H2,1-2H3,(H2,20,21,23)",IFJYEGJUQIBBQV-UHFFFAOYSA-N,sb-452533,Preclinical,TRPV antagonist,TRPV1,,
Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1,"InChI=1S/C20H21N3O2/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2,3)4)13-8-9-15-16(10-13)25-11-24-15/h5-10H,11H2,1-4H3,(H,22,23)",WGZOTBUYUFBEPZ-UHFFFAOYSA-N,sb-505124,Preclinical,ALK tyrosine kinase receptor inhibitor,TGFBR1,,
Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3nccnc3c2)n1,"InChI=1S/C21H21N5/c1-13-6-5-7-16(24-13)19-18(25-20(26-19)21(2,3)4)14-8-9-15-17(12-14)23-11-10-22-15/h5-12H,1-4H3,(H,25,26)",DKPQHFZUICCZHF-UHFFFAOYSA-N,sb-525334,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
CN(C)CCOc1ccc(-c2nc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)[nH]2)cc1,"InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,33H,6,10,15-16H2,1-2H3,(H,29,30)",MLSAQOINCGAULQ-UHFFFAOYSA-N,sb-590885,Preclinical,RAF inhibitor,BRAF,,
Cc1cccc2c1CCC(CN1CCC(c3c(Cl)cccc3Cl)CC1)CC2O,"InChI=1S/C24H29Cl2NO/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26/h2-7,17-18,23,28H,8-15H2,1H3",OHRDCQFCAWLDBP-UHFFFAOYSA-N,sb-612111,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,
Cc1nc(C(=O)N2CCCCC2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1,"InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)",ZJXIUGNEAIHSBI-UHFFFAOYSA-N,sb-649868,Phase 2,orexin receptor antagonist,,,
COc1cc(Br)c(S(=O)(=O)Nc2ccc(Cl)c(OC3CCN(C)C3)c2)cc1OC,"InChI=1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3",KQCZCINJGIRLCD-UHFFFAOYSA-N,sb-657510,Preclinical,urotensin receptor antagonist,UTS2R,,
COc1cccc(OC)c1-c1ccc(CC(NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,"InChI=1S/C24H21Cl2NO5/c1-31-19-7-4-8-20(32-2)21(19)15-11-9-14(10-12-15)13-18(24(29)30)27-23(28)22-16(25)5-3-6-17(22)26/h3-12,18H,13H2,1-2H3,(H,27,28)(H,29,30)",DRSJLVGDSNWQBI-UHFFFAOYSA-N,sb-683698,Phase 1,integrin antagonist,ITGA4|ITGAV|ITGB1|ITGB7,,
O=C(Nc1ccccc1Br)NC1CCN(c2ccc(C(F)(F)F)cn2)C1,"InChI=1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)",JYILLRHXRVTRSH-UHFFFAOYSA-N,sb-705498,Phase 2,TRPV antagonist,TRPV1,,
COc1cc(Br)c(S(=O)(=O)Nc2ccc(C(F)(F)F)c(OC3CCN(C)C3)c2)cc1OC,"InChI=1S/C20H22BrF3N2O5S/c1-26-7-6-13(11-26)31-16-8-12(4-5-14(16)20(22,23)24)25-32(27,28)19-10-18(30-3)17(29-2)9-15(19)21/h4-5,8-10,13,25H,6-7,11H2,1-3H3",BPOWQJYAMDEAFF-UHFFFAOYSA-N,sb-706375,Preclinical,urotensin receptor antagonist,UTS2R,,
O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1,"InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2",JJZFWROHYSMCMU-UHFFFAOYSA-N,sb-742457,Phase 3,serotonin receptor antagonist,HTR6,,
Cc1ccc(C(=O)N(CCCN)C(c2oc3cc(Cl)ccc3c(=O)c2Cc2ccccc2)C(C)C)cc1,"InChI=1S/C31H33ClN2O3/c1-20(2)28(34(17-7-16-33)31(36)23-12-10-21(3)11-13-23)30-26(18-22-8-5-4-6-9-22)29(35)25-15-14-24(32)19-27(25)37-30/h4-6,8-15,19-20,28H,7,16-18,33H2,1-3H3",PGXYIBJJCLWJST-UHFFFAOYSA-N,sb-743921,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,KIF11,,
CCn1c(-c2no[nH]c2=N)nc2cncc(CNC3CCNCC3)c21,"InChI=1S/C16H22N8O/c1-2-24-14-10(8-20-11-3-5-18-6-4-11)7-19-9-12(14)21-16(24)13-15(17)23-25-22-13/h7,9,11,18,20H,2-6,8H2,1H3,(H2,17,23)",MBCJUIJWPYUEBX-UHFFFAOYSA-N,sb-747651a,Preclinical,kinase inhibitor,AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1,,
COc1ccc(S(=O)(=O)N2CCCN(S(=O)(=O)c3ccc(OC)c(OC)c3)CC2)cc1OC,"InChI=1S/C21H28N2O8S2/c1-28-18-8-6-16(14-20(18)30-3)32(24,25)22-10-5-11-23(13-12-22)33(26,27)17-7-9-19(29-2)21(15-17)31-4/h6-9,14-15H,5,10-13H2,1-4H3",GJUFPAZNBPFNRI-UHFFFAOYSA-N,sb-756050,Phase 1,G protein-coupled receptor agonist,GPBAR1,,
CCn1c(-c2no[nH]c2=N)nc2cncc(C(=O)N3CCC(N)C3)c21,"InChI=1S/C15H18N8O2/c1-2-23-12-9(15(24)22-4-3-8(16)7-22)5-18-6-10(12)19-14(23)11-13(17)21-25-20-11/h5-6,8H,2-4,7,16H2,1H3,(H2,17,21)",PHWHNHYZZNJPLB-UHFFFAOYSA-N,sb-772077b,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,
CCCCc1nc2cc(C=CC(O)=NO)ccc2n1CCN(CC)CC,"InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)",JHDKZFFAIZKUCU-UHFFFAOYSA-N,sb-939,Phase 3,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9,,
COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC,"InChI=1S/C24H27ClN2O4/c1-28-20-7-4-17(12-22(20)29-2)10-11-26-14-18-5-8-21(23(13-18)30-3)31-16-19-6-9-24(25)27-15-19/h4-9,12-13,15,26H,10-11,14,16H2,1-3H3",XNPRQBVQOJZMMA-UHFFFAOYSA-N,sbe-13,Preclinical,PLK inhibitor,PLK1,,
ON=C(O)CCCCCCC(O)=NO,"InChI=1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)",IDQPVOFTURLJPT-UHFFFAOYSA-N,sbha,Preclinical,HDAC inhibitor,HDAC1|HDAC3,,
CCS(=O)(=O)c1ncc(Cl)c(C(=O)Oc2cccc(C)c2)n1,"InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3",IJPXOPBVXVPPEW-UHFFFAOYSA-N,sbi-115,Preclinical,G protein-coupled receptor antagonist,,,
CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,"InChI=1S/C17H22ClNO2S/c1-2-3-4-5-6-13-19-22(20,21)17-12-8-9-14-15(17)10-7-11-16(14)18/h7-12,19H,2-6,13H2,1H3",MJMJERJFCHYXEM-UHFFFAOYSA-N,sc-10,Preclinical,protein kinase activator,PRKCA,,
COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1,"InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)",XPRDUGXOWVXZLL-UHFFFAOYSA-N,sc-12267,Phase 2,dihydroorotate dehydrogenase inhibitor,IL17A,,
O=C(NN=c1[nH]c2cc(F)ccc2n2cccc12)c1cnccn1,"InChI=1S/C16H11FN6O/c17-10-3-4-13-11(8-10)20-15(14-2-1-7-23(13)14)21-22-16(24)12-9-18-5-6-19-12/h1-9H,(H,20,21)(H,22,24)",UEADAWQSJOWXBK-UHFFFAOYSA-N,sc-144,Preclinical,P glycoprotein inhibitor,,,
CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,"InChI=1S/C16H14ClN3O3/c1-10(21)18-19-16(22)20-9-11-4-2-3-5-14(11)23-15-7-6-12(17)8-13(15)20/h2-8H,9H2,1H3,(H,18,21)(H,19,22)",KNURFLJTOUGOOQ-UHFFFAOYSA-N,sc-19220,Preclinical,prostanoid receptor antagonist,PTGER1,,
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,"InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)",NSQNZEUFHPTJME-UHFFFAOYSA-N,sc-236,Preclinical,cyclooxygenase inhibitor,PTGS2,,
O=C(CCc1ccncc1)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc21,"InChI=1S/C22H19ClN4O3/c23-17-6-7-20-18(13-17)27(14-16-3-1-2-4-19(16)30-20)22(29)26-25-21(28)8-5-15-9-11-24-12-10-15/h1-4,6-7,9-13H,5,8,14H2,(H,25,28)(H,26,29)",XDJPQOUDGROSEU-UHFFFAOYSA-N,sc-51089,Preclinical,prostanoid receptor antagonist,PTGER1,,
COc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,"InChI=1S/C17H12ClF3N2O/c1-24-14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3",PQUGCKBLVKJMNT-UHFFFAOYSA-N,sc-560,Preclinical,cyclooxygenase inhibitor,PTGS1,,
O=S(=O)(NCCCCCCc1ccccc1)c1cccc2c(Cl)cccc12,"InChI=1S/C22H24ClNO2S/c23-21-15-8-14-20-19(21)13-9-16-22(20)27(25,26)24-17-7-2-1-4-10-18-11-5-3-6-12-18/h3,5-6,8-9,11-16,24H,1-2,4,7,10,17H2",YUXMTDYHFPRPLG-UHFFFAOYSA-N,sc-9,Preclinical,protein tyrosine kinase activator,PRKCA,,
C=C1C(=O)OC2C=C(C)Cc3cc(c(O)o3)CC(OC(=O)C(C)=CC)C12,"InChI=1S/C20H22O6/c1-5-11(3)18(21)25-16-9-13-8-14(24-20(13)23)6-10(2)7-15-17(16)12(4)19(22)26-15/h5,7-8,15-17,23H,4,6,9H2,1-3H3",OMPAVQLPJYCMRB-UHFFFAOYSA-N,scabertopin,Preclinical,anticancer agent,,,
CN=c1nc(-c2ccccc2)n(-c2ccccc2)s1,"InChI=1S/C15H13N3S/c1-16-15-17-14(12-8-4-2-5-9-12)18(19-15)13-10-6-3-7-11-13/h2-11H,1H3",FFUBTEITUNMMOK-UHFFFAOYSA-N,sch-202676,Preclinical,G protein-coupled receptor modulator,CHRM1|CHRM2|DRD1|DRD2,,
Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2,"InChI=1S/C28H31NO/c1-20-10-6-8-14-25(20)27(26-15-9-7-11-21(26)2)29-23-16-17-24(29)19-28(30,18-23)22-12-4-3-5-13-22/h3-15,23-24,27,30H,16-19H2,1-2H3",LOSJNRBXNQTUNT-UHFFFAOYSA-N,sch-221510,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,
CN1CCc2cc(Cl)c(O)cc2C(c2ccccc2)C1,"InChI=1S/C17H18ClNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3",GOTMKOSCLKVOGG-UHFFFAOYSA-N,sch-23390,Preclinical,dopamine receptor antagonist,DRD1|DRD5|HTR2C|KCNJ4|KCNJ6,,
Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,"InChI=1S/C17H15N3O/c1-13-15(9-10-18)20-11-5-8-16(17(20)19-13)21-12-14-6-3-2-4-7-14/h2-8,11H,9,12H2,1H3",PYKJFEPAUKAXNN-UHFFFAOYSA-N,sch-28080,Phase 1,ATPase inhibitor,ATP4A,,
COc1ccc2[nH]c3[nH]nc(C)c3c(=NCCOCCO)c2c1,"InChI=1S/C16H20N4O3/c1-10-14-15(17-5-7-23-8-6-21)12-9-11(22-2)3-4-13(12)18-16(14)20-19-10/h3-4,9,21H,5-8H2,1-2H3,(H2,17,18,19,20)",YWEGXZZAORIRQR-UHFFFAOYSA-N,sch-51344,Preclinical,MTH1 inhibitor,NUDT1,,
N=c1[nH]c2c(cnn2CCc2ccccc2)c2nc(-c3ccco3)nn12,"InChI=1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22)",UTLPKQYUXOEJIL-UHFFFAOYSA-N,sch-58261,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
Cn1cc(-c2c[nH]n3c(=N)c(Br)c(C4CCCNC4)nc23)cn1,"InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,17-18,20H,2-5H2,1H3",KUFDZBFFAKTDQE-UHFFFAOYSA-N,sch-900776,Phase 2,CHK inhibitor,CDK2|CHEK1,,
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)CC(C)C(C)C2,"InChI=1S/C23H28O6/c1-12-7-14-9-16(24-3)20(25-4)22(26-5)18(14)19-15(8-13(12)2)10-17-21(23(19)27-6)29-11-28-17/h9-10,12-13H,7-8,11H2,1-6H3",RTZKSTLPRTWFEV-UHFFFAOYSA-N,schisandrin-b,Preclinical,antioxidant,ATR,,
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)CC(C)C(C)(O)C2,"InChI=1S/C23H28O7/c1-12-7-13-8-16-20(30-11-29-16)22(28-6)17(13)18-14(10-23(12,2)24)9-15(25-3)19(26-4)21(18)27-5/h8-9,12,24H,7,10-11H2,1-6H3",ZWRRJEICIPUPHZ-UHFFFAOYSA-N,schisandrol-b,Phase 3,lipid peroxidase inhibitor,,,
C=CC(C)(O)CCC1C(C)(O)CCC2C(C)(C)CCCC21C,"InChI=1S/C20H36O2/c1-7-18(4,21)13-9-16-19(5)12-8-11-17(2,3)15(19)10-14-20(16,6)22/h7,15-16,21-22H,1,8-14H2,2-6H3",XVULBTBTFGYVRC-UHFFFAOYSA-N,sclareol,Preclinical,,,,
CC1(C)CCCC2(C)C1CCC1(C)OC(=O)CC12,"InChI=1S/C16H26O2/c1-14(2)7-5-8-15(3)11(14)6-9-16(4)12(15)10-13(17)18-16/h11-12H,5-10H2,1-4H3",IMKJGXCIJJXALX-UHFFFAOYSA-N,sclareolide,Launched,other antifungal,,,
NC(CSCC(=O)O)C(=O)O,"InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)",GBFLZEXEOZUWRN-UHFFFAOYSA-N,scmc-lys,Launched,mucolytic agent,GSTP1,pulmonary,chronic obstructive pulmonary disease (COPD)
CN1C2CC(O)CC1C1OC12,"InChI=1S/C8H13NO2/c1-9-5-2-4(10)3-6(9)8-7(5)11-8/h4-8,10H,2-3H2,1H3",FIMXSEMBHGTNKT-UHFFFAOYSA-N,scopine,Launched,,,,
CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12,"InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3",STECJAGHUSJQJN-UHFFFAOYSA-N,scopolamine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI,neurology/psychiatry|gastroenterology,motion sickness|vomiting|nausea
O=C(CN1C(=O)c2ccccc2S1(=O)=O)Nc1ccc(O)cc1,"InChI=1S/C15H12N2O5S/c18-11-7-5-10(6-8-11)16-14(19)9-17-15(20)12-3-1-2-4-13(12)23(17,21)22/h1-8,18H,9H2,(H,16,19)",PUPNJSIFIXXJCH-UHFFFAOYSA-N,scp-1,Phase 1,analgesic agent,,,
O=C1c2cccc3cccc(c23)C(=O)N1CCCCCC(O)=NO,"InChI=1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)",JTDYUFSDZATMKU-UHFFFAOYSA-N,scriptaid,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
O=C(NN=Cc1ccccc1O)c1ccccc1O,"InChI=1S/C14H12N2O3/c17-12-7-3-1-5-10(12)9-15-16-14(19)11-6-2-4-8-13(11)18/h1-9,17-18H,(H,16,19)",OMCYEZUIYGPHDJ-UHFFFAOYSA-N,scs,Preclinical,,,,
O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1,"InChI=1S/C20H20ClN5O2/c21-15-3-1-13(2-4-15)19-18(16-5-8-22-12-23-16)20(25-24-19)14-6-9-26(10-7-14)17(28)11-27/h1-5,8,12,14,27H,6-7,9-11H2,(H,24,25)",CATQHDWESBRRQA-UHFFFAOYSA-N,sd-0006,Phase 2,p38 MAPK inhibitor,,,
NC(=O)c1ccc2[nH]ccc2c1,"InChI=1S/C9H8N2O/c10-9(12)7-1-2-8-6(5-7)3-4-11-8/h1-5,11H,(H2,10,12)",GQMYQEAXTITUAE-UHFFFAOYSA-N,sd-169,Preclinical,p38 MAPK inhibitor,MAPK14,,
Fc1ccc(Cl)cc1-c1nc(=Nc2ccncc2)c2nccnc2[nH]1,"InChI=1S/C17H10ClFN6/c18-10-1-2-13(19)12(9-10)15-24-16-14(21-7-8-22-16)17(25-15)23-11-3-5-20-6-4-11/h1-9H,(H,20,22,23,24,25)",BERLXWPRSBJFHO-UHFFFAOYSA-N,sd-208,Preclinical,TGF beta receptor inhibitor,TGFBR1,,
COCCN1CCC(C(O)=NO)(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CC1,"InChI=1S/C22H25F3N2O7S/c1-32-15-14-27-12-10-21(11-13-27,20(28)26-29)35(30,31)19-8-6-17(7-9-19)33-16-2-4-18(5-3-16)34-22(23,24)25/h2-9,29H,10-15H2,1H3,(H,26,28)",NXUHVWMBPOFLMA-UHFFFAOYSA-N,sd-2590,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2,,
CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C14H21ClN2O3/c1-4-17(5-2)6-7-20-14(18)10-8-11(15)12(16)9-13(10)19-3/h8-9H,4-7,16H2,1-3H3",FFNWMBDISAYHDC-UHFFFAOYSA-N,sdz-205-557,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,"InChI=1S/C19H28N2O4/c1-12(2)25-18(23)16-9-14-15(21-16)7-6-8-17(14)24-11-13(22)10-20-19(3,4)5/h6-9,12-13,20-22H,10-11H2,1-5H3",SJYFDORQYYEJLB-UHFFFAOYSA-N,sdz-21009,Preclinical,adrenergic receptor antagonist,HTR1A|HTR1B,,
CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,"InChI=1S/C19H28N2O4/c1-12(2)25-18(23)16-9-14-15(21-16)7-6-8-17(14)24-11-13(22)10-20-19(3,4)5/h6-9,12-13,20-22H,10-11H2,1-5H3",SJYFDORQYYEJLB-UHFFFAOYSA-N,sdz-21009,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B,,
NC(Cc1cc(-c2ccc(Cl)cc2Cl)cc(C[PH](=O)(=O)O)c1O)C(=O)O,"InChI=1S/C16H15Cl2NO6P/c17-11-1-2-12(13(18)6-11)8-3-9(5-14(19)16(21)22)15(20)10(4-8)7-26(23,24)25/h1-4,6,14,20H,5,7,19H2,(H,21,22)(H,23,24,25)",ZGJUTXLOEHFKOL-UHFFFAOYSA-N,sdz-220-040,Preclinical,glutamate receptor antagonist,GRIN1,,
NC(Cc1cc(C[PH](=O)(=O)O)cc(-c2ccccc2Cl)c1)C(=O)O,"InChI=1S/C16H16ClNO5P/c17-14-4-2-1-3-13(14)12-6-10(8-15(18)16(19)20)5-11(7-12)9-24(21,22)23/h1-7,15H,8-9,18H2,(H,19,20)(H,21,22,23)",FFGKCQDYEZUEFV-UHFFFAOYSA-N,sdz-220-581,Preclinical,glutamate receptor antagonist,GRIN1,,
CN(Cc1ccccc1)C(=O)C(Cc1ccc2ccccc2c1)NC(=O)C1CCCN1C(=O)Nc1ccccc1[N+](=O)[O-],"InChI=1S/C33H33N5O5/c1-36(22-23-10-3-2-4-11-23)32(40)28(21-24-17-18-25-12-5-6-13-26(25)20-24)34-31(39)30-16-9-19-37(30)33(41)35-27-14-7-8-15-29(27)38(42)43/h2-8,10-15,17-18,20,28,30H,9,16,19,21-22H2,1H3,(H,34,39)(H,35,41)",PCVSIMQAFWRUEC-UHFFFAOYSA-N,sdz-nkt-343,Phase 1,tachykinin antagonist,TACR1,,
CN1CCC2CN3CCc4cccc(c43)C2C1,"InChI=1S/C15H20N2/c1-16-7-5-12-9-17-8-6-11-3-2-4-13(15(11)17)14(12)10-16/h2-4,12,14H,5-10H2,1H3",YASBOGFWAMXINH-UHFFFAOYSA-N,sdz-ser-082,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,
COC1C(O)C(CO)OC1n1cnc2c(=NC3CCCCC3)[nH]cnc21,"InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)",JAKAFSGZUXCHLF-UHFFFAOYSA-N,sdz-wag-994,Phase 2,adenosine receptor agonist,ADORA1,,
C[Se]CC(N)C(=O)O,"InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)",XDSSPSLGNGIIHP-UHFFFAOYSA-N,se-methylselenocysteine,Phase 2,,,,
C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)CCC(O)C(C)(C)O,"InChI=1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3",FCKJYANJHNLEEP-UHFFFAOYSA-N,secalciferol,Launched,vitamin D receptor agonist,VDR,critical care,bone fracture
O=C1c2cc(Cl)ccc2OC2CCON12,"InChI=1S/C10H8ClNO3/c11-6-1-2-8-7(5-6)10(13)12-9(15-8)3-4-14-12/h1-2,5,9H,3-4H2",XWXVKXXKKLBDDJ-UHFFFAOYSA-N,seclazone,Phase 1,anti-inflammatory agent,,,
CC(=NNC(=O)c1cccc(S(=O)(=O)N2CCN(C)CC2)c1)c1cc(Cl)ccc1O,"InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)",MVSQDUZRRVBYLA-UHFFFAOYSA-N,seclidemstat,Phase 1,histone demethylase inhibitor,,,
Cc1ncc([N+](=O)[O-])n1CC(C)O,"InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3",KPQZUUQMTUIKBP-UHFFFAOYSA-N,secnidazole,Launched,acetylcholinesterase inhibitor,,infectious disease,protozoan infection
Cc1ncc([N+](=O)[O-])n1CC(C)O,"InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3",KPQZUUQMTUIKBP-UHFFFAOYSA-N,secnidazole,Launched,microtubule inhibitor,,infectious disease,protozoan infection
COc1cc(CC(CO)C(CO)Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C20H26O6/c1-25-19-9-13(3-5-17(19)23)7-15(11-21)16(12-22)8-14-4-6-18(24)20(10-14)26-2/h3-6,9-10,15-16,21-24H,7-8,11-12H2,1-2H3",PUETUDUXMCLALY-UHFFFAOYSA-N,secoisolariciresinol-(-),Phase 2,,,,
COc1cc(CC(COC2OC(CO)C(O)C(O)C2O)C(COC2OC(CO)C(O)C(O)C2O)Cc2ccc(O)c(OC)c2)ccc1O,"InChI=1S/C32H46O16/c1-43-21-9-15(3-5-19(21)35)7-17(13-45-31-29(41)27(39)25(37)23(11-33)47-31)18(8-16-4-6-20(36)22(10-16)44-2)14-46-32-30(42)28(40)26(38)24(12-34)48-32/h3-6,9-10,17-18,23-42H,7-8,11-14H2,1-2H3",SBVBJPHMDABKJV-UHFFFAOYSA-N,secoisolariciresinol-diglucoside,Phase 2,antioxidant,,,
O=C1C=C2C=CC3CC2(O1)C1CCCCN31,"InChI=1S/C13H15NO2/c15-12-7-9-4-5-10-8-13(9,16-12)11-3-1-2-6-14(10)11/h4-5,7,10-11H,1-3,6,8H2",SWZMSZQQJRKFBP-UHFFFAOYSA-N,securinine,Preclinical,GABA receptor antagonist,GABRA1,,
O=C1C=C2C=CC3CC2(O1)C1CCCCN31,"InChI=1S/C13H15NO2/c15-12-7-9-4-5-10-8-13(9,16-12)11-3-1-2-6-14(10)11/h4-5,7,10-11H,1-3,6,8H2",SWZMSZQQJRKFBP-UHFFFAOYSA-N,securinine,Preclinical,TP53 activator,GABRA1,,
C=C1CC2C3CC=C4CC(=O)CCC4C3CCC2(C)C1(OC(C)=O)C(C)=O,"InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h5,18-21H,1,6-12H2,2-4H3",GSPVJNNQYBLBBW-UHFFFAOYSA-N,segesterone-acetate,Launched,progesterone receptor agonist,PGR,,
CCOC(COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1,"InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)",JWHYSEDOYMYMNM-UHFFFAOYSA-N,seladelpar,Phase 3,PPAR receptor agonist,,,
COC1CC(OC2C(C)=CCC3CC(CC4(CCC(C)C(C5CCCCC5)O4)O3)OC(=O)C3=CC(C)C(=NO)C4OCC(=CC=CC2C)C34O)OC(C)C1O,"InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26-29,31-32,34-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3",WDXAISOBFTWPEE-UHFFFAOYSA-N,selamectin,Launched,nematocide,,infectious disease,flea control
C#CCN(C)C(C)Cc1ccccc1,"InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3",MEZLKOACVSPNER-UHFFFAOYSA-N,selegiline,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,Parkinson's Disease
C[Se]CCC(N)C(=O)O,"InChI=1S/C5H11NO2Se/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)",RJFAYQIBOAGBLC-UHFFFAOYSA-N,selenomethionine,Launched,,,,
[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2C(N=c2[nH]cnc3cccnc23)C(F)(F)F)c1,"InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)",LNLJHGXOFYUARS-UHFFFAOYSA-N,seletalisib,Preclinical,PI3K inhibitor,,,
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,"InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)",QXWZQTURMXZVHJ-UHFFFAOYSA-N,selexipag,Launched,IP1 prostacyclin receptor agonist,PTGIR,pulmonary,pulmonary arterial hypertension (PAH)
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,"InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)",QXWZQTURMXZVHJ-UHFFFAOYSA-N,selexipag,Launched,platelet aggregation inhibitor,PTGIR,pulmonary,pulmonary arterial hypertension (PAH)
O=C(O)C1CC(C[PH](=O)(=O)O)CCN1,"InChI=1S/C7H13NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H,11,12,13)",SLHISZNPHHGKAE-UHFFFAOYSA-N,selfotel,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NN=c1cncc[nH]1,"InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)",DEVSOMFAQLZNKR-UHFFFAOYSA-N,selinexor,Launched,exportin antagonist,XPO1,hematologic malignancy,multiple myeloma
CC1CCc2ncc(F)cc2C2CCCN2c2ccn3ncc(c3n2)C(=O)N1,"InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)",OEBIHOVSAMBXIB-UHFFFAOYSA-N,selitrectinib,Phase 1/Phase 2,protein tyrosine kinase inhibitor,,,
Cc1cc(F)c(C(=O)N=c2cccc(-c3nncn3C(C)C)[nH]2)cc1-n1cnc(C2CC2)c1,"InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)",YIDDLAAKOYYGJG-UHFFFAOYSA-N,selonsertib,Phase 2,MAP kinase activator,,,
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,selumetinib,Phase 3,MEK inhibitor,MAP2K1,,
CC(C)C(=O)C(=O)NC(C)C(=O)NC1c2ccccc2CCN(C)C1O,"InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15,19,26H,9-10H2,1-4H3,(H,20,25)(H,21,24)",BNMLDKAQNJFMMR-UHFFFAOYSA-N,semagacestat,Phase 3,gamma secretase inhibitor,PSEN1,,
CC(=NN=C(N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(C(C)=NN=C(N)N)cc(C(C)=NN=C(N)N)c2)cc(C(C)=NN=C(N)N)c1,"InChI=1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)",PWDYHMBTPGXCSN-UHFFFAOYSA-N,semapimod,Phase 2,cytokine production inhibitor,MAPK14,,
CC(=NN=C(N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(C(C)=NN=C(N)N)cc(C(C)=NN=C(N)N)c2)cc(C(C)=NN=C(N)N)c1,"InChI=1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)",PWDYHMBTPGXCSN-UHFFFAOYSA-N,semapimod,Phase 2,p38 MAPK inhibitor,MAPK14,,
C=c1cc(C)[nH]c1=Cc1c(O)[nH]c2ccccc12,"InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16-18H,1H2,2H3",JGIFSQPBZMIFQM-UHFFFAOYSA-N,semaxanib,Phase 3,VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,
CC1CCC(NC(=O)N(CCCl)NO)CC1,"InChI=1S/C10H20ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9,13,16H,2-7H2,1H3,(H,12,15)",PXDZKUOYOBYJPB-UHFFFAOYSA-N,semustine,Phase 3,DNA alkylating agent,,,
CN(C)c1cccc(Oc2cnc(=Nc3cccc(O)c3)[nH]c2)c1,"InChI=1S/C18H18N4O2/c1-22(2)14-6-4-8-16(10-14)24-17-11-19-18(20-12-17)21-13-5-3-7-15(23)9-13/h3-12,23H,1-2H3,(H,19,20,21)",MFPAAKZZUIRMKR-UHFFFAOYSA-N,sen-1269,Preclinical,beta amyloid inhibitor,APP,,
NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,"InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)",SCTZUZTYRMOMKT-UHFFFAOYSA-N,senicapoc,Phase 3,intermediate conductance potassium channel blocker,KCNN4,,
O=C(O)c1cc(O)c2c(O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc3c(-c3c4cc(C(=O)O)cc(O)c4c(O)c4c(OC5OC(CO)C(O)C(O)C5O)cccc34)c2c1,"InChI=1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-24,31-32,35-38,41-54H,11-12H2,(H,55,56)(H,57,58)",QFJIQUOMKJNYLI-UHFFFAOYSA-N,sennoside-a,Launched,glycoside agonist,,gastroenterology,constipation
O=C(O)c1cc(O)c2c(O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc3c(-c3c4cc(C(=O)O)cc(O)c4c(O)c4c(OC5OC(CO)C(O)C(O)C5O)cccc34)c2c1,"InChI=1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-24,31-32,35-38,41-54H,11-12H2,(H,55,56)(H,57,58)",QFJIQUOMKJNYLI-UHFFFAOYSA-N,sennoside-protonated,Preclinical,,,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)C=CC=CC(O)(CC)CC)CC(O)CC1O,"InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3",LVLLALCJVJNGQQ-UHFFFAOYSA-N,seocalcitol,Phase 3,vitamin D receptor agonist,VDR,,
O=C(O)c1cc2occc2[nH]1,"InChI=1S/C7H5NO3/c9-7(10)5-3-6-4(8-5)1-2-11-6/h1-3,8H,(H,9,10)",MMAIBGHDBYQYDI-UHFFFAOYSA-N,sep-227900,Phase 1,D-amino acid oxidase Inhibitor,DAO,,
Cc1c(C)c(O)c(C(=CCCCCC(=O)O)c2ccccc2)c(C)c1O,"InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-12,25-26H,5,8-9,13H2,1-3H3,(H,23,24)",RADRBZBLNXVQEU-UHFFFAOYSA-N,seratrodast,Launched,prostanoid receptor antagonist,TBXA2R,pulmonary,asthma
c1ccc2c(CCNc3ccc(N=c4cc[nH]cc4)cc3)c[nH]c2c1,"InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)",CEGSUKYESLWKJP-UHFFFAOYSA-N,serdemetan,Phase 1,MDM inhibitor,MDM2,,
NCCc1c[nH]c2ccc(O)cc12,"InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2",QZAYGJVTTNCVMB-UHFFFAOYSA-N,serotonin,Launched,growth factor receptor activator,DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1,neurology/psychiatry,anxiety|depression|sleeplessness
Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,"InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2",JLGKQTAYUIMGRK-UHFFFAOYSA-N,sertaconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis
O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,"InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",GZKLJWGUPQBVJQ-UHFFFAOYSA-N,sertindole,Withdrawn,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2,,
O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,"InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",GZKLJWGUPQBVJQ-UHFFFAOYSA-N,sertindole,Withdrawn,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2,,
CNC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21,"InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3",VGKDLMBJGBXTGI-UHFFFAOYSA-N,sertraline,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A3|SLC6A4,neurology/psychiatry|obstetrics/gynecology,depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder
c1cc2c(cc1C1OCC3C(c4ccc5c(c4)OCO5)OCC13)OCO2,"InChI=1S/C20H18O6/c1-3-15-17(25-9-23-15)5-11(1)19-13-7-22-20(14(13)8-21-19)12-2-4-16-18(6-12)26-10-24-16/h1-6,13-14,19-20H,7-10H2",PEYUIKBAABKQKQ-UHFFFAOYSA-N,sesamin,Preclinical,NFkB pathway inhibitor,,,
O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2,"InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)",IHAXLPDVOWLUOS-UHFFFAOYSA-N,setipiprant,Phase 3,prostaglandin inhibitor,PTGDR2,,
CN1CCC2=C(C1)c1ccccc1Cc1ccccc12,"InChI=1S/C19H19N/c1-20-11-10-18-16-8-4-2-6-14(16)12-15-7-3-5-9-17(15)19(18)13-20/h2-9H,10-13H2,1H3",GVPIXRLYKVFFMK-UHFFFAOYSA-N,setiptiline,Launched,adrenergic receptor antagonist,HRH1|HTR2A|HTR2C,neurology/psychiatry,depression
CC(=O)NC(CCCN=C(N)N)C(=O)NC1CSSCC(C(N)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CCCN=C(N)N)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(C)NC1=O,"InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)",HDHDTKMUACZDAA-UHFFFAOYSA-N,setmelanotide,Phase 3,melanocortin receptor agonist,,,
FCOC(C(F)(F)F)C(F)(F)F,"InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2",DFEYYRMXOJXZRJ-UHFFFAOYSA-N,sevoflurane,Launched,membrane integrity inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1,neurology/psychiatry,anesthetic
FC(F)(F)c1cccc(-c2noc(-c3cc(-c4ccccc4)c(C(F)(F)F)s3)n2)c1,"InChI=1S/C20H10F6N2OS/c21-19(22,23)13-8-4-7-12(9-13)17-27-18(29-28-17)15-10-14(11-5-2-1-3-6-11)16(30-15)20(24,25)26/h1-10H",OYMNPJXKQVTQTR-UHFFFAOYSA-N,sew-2871,Preclinical,lysophospholipid receptor agonist,S1PR1,,
CCOc1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C27H30N2O2S/c1-2-31-25-15-13-24(14-16-25)28-26(32)29-19-17-23(18-20-29)27(30,21-9-5-3-6-10-21)22-11-7-4-8-12-22/h3-16,23,30H,2,17-20H2,1H3,(H,28,32)",PMEQBGAGFZDWQX-UHFFFAOYSA-N,sf-11,Preclinical,neuropeptide receptor antagonist,MCOLN3|NPY2R,,
CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)CC1OC(n2cc(Br)c3c(=N)[nH]cnc32)C(O)C1O,"InChI=1S/C28H40BrN7O4/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3,4)5)14-20-22(37)23(38)26(40-20)36-13-19(29)21-24(30)32-15-33-25(21)36/h7-10,13,15-16,20,22-23,26,37-38H,6,11-12,14H2,1-5H3,(H2,30,32,33)(H2,31,34,39)",IQCKJUKAQJINMK-UHFFFAOYSA-N,sgc-0946,Preclinical,histone lysine methyltransferase inhibitor,,,
O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,"InChI=1S/C16H18N4O2/c21-15(20-7-1-2-8-20)11-18-16(22)19-14-4-3-13-10-17-6-5-12(13)9-14/h3-6,9-10H,1-2,7-8,11H2,(H2,18,19,22)",DMIDPTCQPIJYFE-UHFFFAOYSA-N,sgc-707,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,
COc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2CC(C)N2CCOCC2)cc1Cl,"InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3",GEPYBHCJBORHCE-UHFFFAOYSA-N,sgc-cbp30,Preclinical,bromodomain inhibitor,CREBBP|EP300,,
Cc1cc(=Nc2ccc(NC(=O)c3ccc(N=c4cc[nH]c5ccccc45)cc3)cc2)[nH]c(=N)[nH]1,"InChI=1S/C27H23N7O/c1-17-16-25(34-27(28)30-17)32-20-10-12-21(13-11-20)33-26(35)18-6-8-19(9-7-18)31-24-14-15-29-23-5-3-2-4-22(23)24/h2-16H,1H3,(H,29,31)(H,33,35)(H3,28,30,32,34)",QSYLKMKIVWJAAK-UHFFFAOYSA-N,sgi-1027,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3A|DNMT3B,,
CN1CCC(CN=c2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3[nH]2)CC1,"InChI=1S/C20H22F3N5O/c1-27-9-7-14(8-10-27)12-24-18-5-6-19-25-13-17(28(19)26-18)15-3-2-4-16(11-15)29-20(21,22)23/h2-6,11,13-14H,7-10,12H2,1H3,(H,24,26)",MHXGEROHKGDZGO-UHFFFAOYSA-N,sgi-1776,Phase 1,Pim kinase inhibitor,FLT3|PIM1|PIM2|PIM3,,
CCCC[PH](=O)(=O)CCCN,"InChI=1S/C7H17NO2P/c1-2-3-6-11(9,10)7-4-5-8/h2-8H2,1H3",VWJUTUNLQWMFRC-UHFFFAOYSA-N,sgs-742,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,
Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,"InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3",BCZUAADEACICHN-UHFFFAOYSA-N,sgx523,Phase 1,hepatocyte growth factor receptor inhibitor,MET,,
O=C(NCc1ccc(F)cc1)N1CCN2C(=O)OC(c3ccccc3)(c3ccccc3)C2C1,"InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)",SFRQIPRTNYHJHP-UHFFFAOYSA-N,sha-68,Preclinical,neuropeptide receptor antagonist,NPSR1,,
O=C(O)C1CC(=O)C(O)C(O)C1,"InChI=1S/C7H10O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h3-4,6,8,10H,1-2H2,(H,11,12)",DWRJQFGWIHQEOC-UHFFFAOYSA-N,shikimic-acid,Preclinical,,,,
CC1(N)CCN(c2cnc(-c3cccc(Cl)c3Cl)c(=N)[nH]2)CC1,"InChI=1S/C16H19Cl2N5/c1-16(20)5-7-23(8-6-16)12-9-21-14(15(19)22-12)10-3-2-4-11(17)13(10)18/h2-4,9H,5-8,20H2,1H3,(H2,19,22)",YGUFCDOEKKVKJK-UHFFFAOYSA-N,shp099,Preclinical,protein tyrosine kinase inhibitor,PTPN11,,
CN1CCCC1CCSc1ccc(O)cc1,"InChI=1S/C13H19NOS/c1-14-9-2-3-11(14)8-10-16-13-6-4-12(15)5-7-13/h4-7,11,15H,2-3,8-10H2,1H3",NVZGJSVPOOILDI-UHFFFAOYSA-N,sib-1553a,Phase 2,acetylcholine receptor agonist,CHRNB4,,
Cc1ccc(O)c(N=Nc2ccccc2)n1,"InChI=1S/C12H11N3O/c1-9-7-8-11(16)12(13-9)15-14-10-5-3-2-4-6-10/h2-8,16H,1H3",LOCPVWIREQIGNQ-UHFFFAOYSA-N,sib-1757,Preclinical,glutamate receptor antagonist,GRM5,,
Cc1cccc(C=Cc2ccccc2)n1,"InChI=1S/C14H13N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-11H,1H3",SISOFUCTXZKSOQ-UHFFFAOYSA-N,sib-1893,Preclinical,glutamate receptor antagonist,GRM4|GRM5,,
CCOC(=O)C(C)Oc1cccc2c(=O)n(CC(=O)Nc3ccc4c(c3)OCCO4)ccc12,"InChI=1S/C24H24N2O7/c1-3-30-24(29)15(2)33-19-6-4-5-18-17(19)9-10-26(23(18)28)14-22(27)25-16-7-8-20-21(13-16)32-12-11-31-20/h4-10,13,15H,3,11-12,14H2,1-2H3,(H,25,27)",KWMBIIQCLUIHDI-UHFFFAOYSA-N,sid-7969543,Preclinical,steroidogenic factor antagonist,NR5A1,,
CN=C(NC#N)Nc1ccc(C2=NNC(=O)CC2C)cc1,"InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)",NUHPODZZKHQQET-UHFFFAOYSA-N,siguazodan,Phase 1,phosphodiesterase inhibitor,PDE3A,,
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,"InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)",BNRNXUUZRGQAQC-UHFFFAOYSA-N,sildenafil,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3,urology,erectile dysfunction
COc1cc(C2Oc3cc(C4Oc5cc(O)cc(O)c5C(=O)C4O)ccc3OC2CO)ccc1O,"InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3",SEBFKMXJBCUCAI-UHFFFAOYSA-N,silibinin,Launched,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis
CC(Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,"InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)",PNCPYILNMDWPEY-UHFFFAOYSA-N,silodosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH)
Nc1ccc(S(=O)(=O)N=c2nccc[nH]2)cc1,"InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)",SEEPANYCNGTZFQ-UHFFFAOYSA-N,silver-sulfadiazine,Launched,PABA antagonist,,critical care,sepsis
COc1cc(C2Oc3ccc(C4Oc5cc(O)cc(O)c5C(=O)C4O)cc3OC2CO)ccc1O,"InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-18-7-12(3-5-16(18)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3",FDQAOULAVFHKBX-UHFFFAOYSA-N,silymarin,Launched,,,,
COc1ccc2c(OC3CC4C(=O)NC5(C(=O)NS(=O)(=O)C6CC6)CC5C=CCCCCN(C)C(=O)C4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,"InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)",JTZZSQYMACOLNN-UHFFFAOYSA-N,simeprevir,Launched,HCV inhibitor,CYP1A2|CYP3A4,infectious disease,hepatitis C
Cc1[nH]ncc1-c1cc2[nH]c(C3CC4CCN3CC4)nc(=O)c2s1,"InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)",XGVXKJKTISMIOW-UHFFFAOYSA-N,simurosertib,Preclinical,kinase inhibitor,,,
CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3",RYMZZMVNJRMUDD-UHFFFAOYSA-N,simvastatin,Launched,HMGCR inhibitor,HMGCR|ITGB2,endocrinology|cardiology|neurology/psychiatry,hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia
CSCCC(NC(=O)C(Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)C(N)CC(=O)O)C(=O)NCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O,"InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)",IZTQOLKUZKXIRV-UHFFFAOYSA-N,sincalide,Preclinical,cholecystokinin agonist,,,
N=c1[nH]cnc2c1ncn2C1OC(CC(N)CCC(N)C(=O)O)C(O)C1O,"InChI=1S/C15H23N7O5/c16-6(1-2-7(17)15(25)26)3-8-10(23)11(24)14(27-8)22-5-21-9-12(18)19-4-20-13(9)22/h4-8,10-11,14,23-24H,1-3,16-17H2,(H,25,26)(H2,18,19,20)",LMXOHSDXUQEUSF-UHFFFAOYSA-N,sinefungin,Preclinical,DNA methyltransferase inhibitor,CARM1,,
N=c1[nH]cnc2c1ncn2C1OC(CC(N)CCC(N)C(=O)O)C(O)C1O,"InChI=1S/C15H23N7O5/c16-6(1-2-7(17)15(25)26)3-8-10(23)11(24)14(27-8)22-5-21-9-12(18)19-4-20-13(9)22/h4-8,10-11,14,23-24H,1-3,16-17H2,(H,25,26)(H2,18,19,20)",LMXOHSDXUQEUSF-UHFFFAOYSA-N,sinefungin,Preclinical,RNA synthesis inhibitor,CARM1,,
COC1=CC2C3Cc4ccc(OC)c(O)c4C2(CCN3C)CC1=O,"InChI=1S/C19H23NO4/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9,12-13,22H,6-8,10H2,1-3H3",INYYVPJSBIVGPH-UHFFFAOYSA-N,sinomenine,Preclinical,angiogenesis inhibitor,,,
CN1CCN(c2nc(=N)c(-c3cc(Cl)cc(Cl)c3Cl)c[nH]2)CC1,"InChI=1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)",PDOCBJADCWMDGL-UHFFFAOYSA-N,sipatrigine,Phase 2,voltage-gated sodium channel blocker,CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A,,
CCc1cc(C(C)=NOCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1,"InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)",KIHYPELVXPAIDH-UHFFFAOYSA-N,siponimod,Launched,sphingosine 1-phosphate receptor modulator,S1PR1,neurology/psychiatry,multiple sclerosis
Fc1ccc(-n2cc(CCCCN3CCC4(CC3)OCc3ccccc34)c3ccccc32)cc1,"InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2",XWAONOGAGZNUSF-UHFFFAOYSA-N,siramesine,Phase 2,sigma receptor antagonist,ADRA1A|ADRA1B|ADRA1D,,
COc1ncc(-c2nc3c(n2C(C)C)C(c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1,"InChI=1S/C26H24Cl2N6O4/c1-13(2)33-21-19(30-22(33)17-11-29-26(38-5)31-23(17)37-4)25(36)34(18-10-16(28)12-32(3)24(18)35)20(21)14-6-8-15(27)9-7-14/h6-13,20H,1-5H3",AGBSXNCBIWWLHD-UHFFFAOYSA-N,siremadlin,Preclinical,MDM inhibitor,,,
COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,33-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3",DVSZTYJRXBBIFA-UHFFFAOYSA-N,sirolimus,Launched,mTOR inhibitor,FKBP1A|MTOR,transplant|pulmonary,organ rejection|lymphangioleiomyomatosis
Cc1cc(C)nc(SCC(=O)N=c2[nH]cc(Cc3cccc4ccccc34)s2)n1,"InChI=1S/C22H20N4OS2/c1-14-10-15(2)25-22(24-14)28-13-20(27)26-21-23-12-18(29-21)11-17-8-5-7-16-6-3-4-9-19(16)17/h3-10,12H,11,13H2,1-2H3,(H,23,26,27)",MENNDDDTIIZDDN-UHFFFAOYSA-N,sirreal-2,Preclinical,SIRT inhibitor,SIRT2,,
CC(NC(=O)c1ccccc1N=Cc1c(O)ccc2ccccc12)c1ccccc1,"InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)",UXJFDYIHRJGPFS-UHFFFAOYSA-N,sirtinol,Preclinical,SIRT inhibitor,SIRT1|SIRT2,,
COc1cc2c(cc1OC)CN(C(=O)C=Cc1c(-c3ccccc3)n(C)c3ncccc13)CC2,"InChI=1S/C28H27N3O3/c1-30-27(19-8-5-4-6-9-19)22(23-10-7-14-29-28(23)30)11-12-26(32)31-15-13-20-16-24(33-2)25(34-3)17-21(20)18-31/h4-12,14,16-17H,13,15,18H2,1-3H3",IJYPHMXWKKKHGT-UHFFFAOYSA-N,sis3,Preclinical,serine/threonine kinase inhibitor,SMAD3|TGFBR1,,
CNC1C(O)C(OC2C(N)CC(N)C(OC3OC(CN)=CCC3N)C2O)OCC1(C)O,"InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3",URWAJWIAIPFPJE-UHFFFAOYSA-N,sisomicin,Launched,protein synthesis inhibitor,,ophthalmology,conjunctivitis|punctate keratitis
CNC1C(O)C(OC2C(N)CC(N)C(OC3OC(CN)=CCC3N)C2O)OCC1(C)O,"InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3",URWAJWIAIPFPJE-UHFFFAOYSA-N,sisomicin-sulfate,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,gram-negative bacterial infections
NC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4F)c3c2Cl)CC12CC2,"InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)",PNUZDKCDAWUEGK-UHFFFAOYSA-N,sitafloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,buruli ulcer
NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2",MFFMDFFZMYYVKS-UHFFFAOYSA-N,sitagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)N=c1o[nH]c(C)c1Cl)OCO2,"InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,20H,6,8H2,1-2H3",RDEGIROIGSZXBA-UHFFFAOYSA-N,sitaxentan,Withdrawn,endothelin receptor antagonist,EDNRA|EDNRB,,
CCC(CCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C,"InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3",KZJWDPNRJALLNS-UHFFFAOYSA-N,sitosterol,Preclinical,,,,
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1,"InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)",WLAVZAAODLTUSW-UHFFFAOYSA-N,sitravatinib,Phase 3,receptor tyrosine protein kinase inhibitor,,,
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,"InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)",BTGNGJJLZOIYID-UHFFFAOYSA-N,sivelestat,Launched,elastase inhibitor,CELA1|ELANE,pulmonary,acute lung injury
C=c1[nH]n(-c2ccccc2)c(=O)c1=Cc1cc(Cl)c(OCC(=O)OC)c(OCC)c1,"InChI=1S/C22H21ClN2O5/c1-4-29-19-12-15(11-18(23)21(19)30-13-20(26)28-3)10-17-14(2)24-25(22(17)27)16-8-6-5-7-9-16/h5-12,24H,2,4,13H2,1,3H3",YYGAKNYNVTYPSV-UHFFFAOYSA-N,sj-172550,Preclinical,MDM inhibitor,MDM4,,
N#Cc1cc(NC(=O)C2c3ccccc3C(=O)N(CC(F)(F)F)C2c2cccnc2)ccc1F,"InChI=1S/C24H16F4N4O2/c25-19-8-7-16(10-15(19)11-29)31-22(33)20-17-5-1-2-6-18(17)23(34)32(13-24(26,27)28)21(20)14-4-3-9-30-12-14/h1-10,12,20-21H,13H2,(H,31,33)",VKCPFWKTFZAOTO-UHFFFAOYSA-N,sj-733,Phase 1,ATPase inhibitor,,,
C=C1CC2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)CC4C=N5)c(OC)cc3C(=O)N2C1,"InChI=1S/C31H32N4O6/c1-18-8-20-14-32-24-12-28(26(38-3)10-22(24)30(36)34(20)16-18)40-6-5-7-41-29-13-25-23(11-27(29)39-4)31(37)35-17-19(2)9-21(35)15-33-25/h10-15,20-21H,1-2,5-9,16-17H2,3-4H3",RWZVMMQNDHPRQD-UHFFFAOYSA-N,sjg-136,Phase 2,DNA intercalating agent,,,
C=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,"InChI=1S/C17H23NO/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17/h4-6,11-12,16,19H,1,7-10H2,2-3H3",LGQCVMYAEFTEFN-UHFFFAOYSA-N,sk&f-10047-(+),Phase 1,sigma receptor agonist,SIGMAR1,,
N=c1[nH]c2c(ccc3ccccc32)s1,"InChI=1S/C11H8N2S/c12-11-13-10-8-4-2-1-3-7(8)5-6-9(10)14-11/h1-6H,(H2,12,13)",FECQXVPRUCCUIL-UHFFFAOYSA-N,ska-31,Preclinical,potassium channel activator,KCNN4,,
O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCC(O)CO)cc21,"InChI=1S/C24H21F2NO4/c25-16-4-8-23(22(26)10-16)27-17-5-7-20-15(9-17)2-1-14-3-6-19(11-21(14)24(20)30)31-13-18(29)12-28/h3-11,18,27-29H,1-2,12-13H2",HXMGCTFLLWPVFM-UHFFFAOYSA-N,skepinone-l,Preclinical,p38 MAPK inhibitor,MAPK14,,
Oc1cc2c(cc1O)C(c1ccccc1)CNCC2,"InChI=1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2",JUDKOGFHZYMDMF-UHFFFAOYSA-N,skf-38393,Preclinical,dopamine receptor agonist,CALY|DRD1|DRD5,,
C=CCN1CCc2cc(O)c(O)cc2C(c2ccccc2)C1,"InChI=1S/C19H21NO2/c1-2-9-20-10-8-15-11-18(21)19(22)12-16(15)17(13-20)14-6-4-3-5-7-14/h2-7,11-12,17,21-22H,1,8-10,13H2",QBUVZVXIRYFENV-UHFFFAOYSA-N,skf-77434,Preclinical,dopamine receptor agonist,DRD1,,
Oc1cc2c(c(Cl)c1O)CCNCC2c1ccccc1,"InChI=1S/C16H16ClNO2/c17-15-11-6-7-18-9-13(10-4-2-1-3-5-10)12(11)8-14(19)16(15)20/h1-5,8,13,18-20H,6-7,9H2",GHWJEDJMOVUXEC-UHFFFAOYSA-N,skf-81297,Preclinical,dopamine receptor agonist,DRD1|DRD5,,
CN1CCc2cc(Br)c(O)cc2C(c2ccccc2)C1,"InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3",XFTVOHWWEQGXLS-UHFFFAOYSA-N,skf-83566,Preclinical,dopamine receptor antagonist,DRD1|DRD5,,
Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1,"InChI=1S/C16H12FN3S/c17-13-3-1-11(2-4-13)14-15(12-5-7-18-8-6-12)20-9-10-21-16(20)19-14/h1-8H,9-10H2",YOELZIQOLWZLQC-UHFFFAOYSA-N,skf-86002,Preclinical,p38 MAPK inhibitor,ALOX5|MAPK14,,
O=C(O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,"InChI=1S/C22H25NO2/c24-22(25)20-13-7-15-23(17-20)16-8-14-21(18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-6,9-12,14,20H,7-8,13,15-17H2,(H,24,25)",TXQKSMSLZVKQBI-UHFFFAOYSA-N,skf-89976a,Preclinical,GABA uptake inhibitor,SLC6A1,,
CN(C)CCCCSC(=N)N,"InChI=1S/C7H17N3S/c1-10(2)5-3-4-6-11-7(8)9/h3-6H2,1-2H3,(H3,8,9)",UFYJLJINUGVUHO-UHFFFAOYSA-N,skf-91488,Preclinical,histamine N-methyltransferase inhibitor,HNMT,,
COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,"InChI=1S/C22H26N2O3/c1-25-20-9-5-18(6-10-20)4-3-15-27-22(16-24-14-13-23-17-24)19-7-11-21(26-2)12-8-19/h5-14,17,22H,3-4,15-16H2,1-2H3",HLMBXBGDBBCYII-UHFFFAOYSA-N,skf-96365,Preclinical,calcium channel blocker,CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2,,
Oc1ccc(N=c2[nH]c(-c3ccc(Cl)cc3)cs2)cc1,"InChI=1S/C15H11ClN2OS/c16-11-3-1-10(2-4-11)14-9-20-15(18-14)17-12-5-7-13(19)8-6-12/h1-9,19H,(H,17,18)",ZFGXZJKLOFCECI-UHFFFAOYSA-N,ski-ii,Preclinical,sphingosine kinase inhibitor,SPHK1,,
CC(C)n1c(=Nc2cccnc2)[nH]c2c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc21,"InChI=1S/C24H29N9/c1-17(2)33-22-21(29-24(33)28-19-5-4-10-25-15-19)16-26-23(30-22)27-18-6-8-20(9-7-18)32-13-11-31(3)12-14-32/h4-10,15-17H,11-14H2,1-3H3,(H,28,29)(H,26,27,30)",WSOHOUHPUOAXIN-UHFFFAOYSA-N,sklb-1028,Preclinical,Abl kinase inhibitor,,,
CC(C)n1c(=Nc2cccnc2)[nH]c2c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc21,"InChI=1S/C24H29N9/c1-17(2)33-22-21(29-24(33)28-19-5-4-10-25-15-19)16-26-23(30-22)27-18-6-8-20(9-7-18)32-13-11-31(3)12-14-32/h4-10,15-17H,11-14H2,1-3H3,(H,28,29)(H,26,27,30)",WSOHOUHPUOAXIN-UHFFFAOYSA-N,sklb-1028,Preclinical,EGFR inhibitor,,,
CC(C)n1c(=Nc2cccnc2)[nH]c2c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc21,"InChI=1S/C24H29N9/c1-17(2)33-22-21(29-24(33)28-19-5-4-10-25-15-19)16-26-23(30-22)27-18-6-8-20(9-7-18)32-13-11-31(3)12-14-32/h4-10,15-17H,11-14H2,1-3H3,(H,28,29)(H,26,27,30)",WSOHOUHPUOAXIN-UHFFFAOYSA-N,sklb-1028,Preclinical,FLT3 inhibitor,,,
COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,"InChI=1S/C13H12N4O2S2/c1-7-16-17-13(20-7)21-12-8-4-10(18-2)11(19-3)5-9(8)14-6-15-12/h4-6H,1-3H3",RQVGFDBMONQTBC-UHFFFAOYSA-N,sklb1002,Preclinical,VEGFR inhibitor,KDR,,
CN=C(NS(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1,"InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)",AXJQVVLKUYCICH-UHFFFAOYSA-N,slv-319-(+/-),Phase 2,cannabinoid receptor antagonist,CNR1|DRD2|HTR1A,,
OC1CCC(N=c2[nH]c(-c3ccccc3)nc3[nH]ccc23)CC1,"InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)",RBZNJGHIKXAKQE-UHFFFAOYSA-N,slv-320,Phase 2,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
NC(=O)c1[nH]cnc1O,"InChI=1S/C4H5N3O2/c5-3(8)2-4(9)7-1-6-2/h1,9H,(H2,5,8)(H,6,7)",UEWSIIBPZOBMBL-UHFFFAOYSA-N,sm-108,Phase 2,,,,
CNC(C)C(=O)NC1CCCCC2CCC(C(=O)NC(c3ccccc3)c3cn(CCCCc4ccc(CCCCn5cc(C(NC(=O)C6CCC7CCCCC(NC(=O)C(C)NC)C(=O)N76)c6ccccc6)nn5)cc4)nn3)N2C1=O,"InChI=1S/C62H84N14O6/c1-41(63-3)57(77)65-49-27-13-11-25-47-33-35-53(75(47)61(49)81)59(79)67-55(45-21-7-5-8-22-45)51-39-73(71-69-51)37-17-15-19-43-29-31-44(32-30-43)20-16-18-38-74-40-52(70-72-74)56(46-23-9-6-10-24-46)68-60(80)54-36-34-48-26-12-14-28-50(62(82)76(48)54)66-58(78)42(2)64-4/h5-10,21-24,29-32,39-42,47-50,53-56,63-64H,11-20,25-28,33-38H2,1-4H3,(H,65,77)(H,66,78)(H,67,79)(H,68,80)",LGYDZXNSSLRFJS-UHFFFAOYSA-N,sm-164,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,
CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C,"InChI=1S/C18H24ClNO3/c1-3-17(22-15-8-4-12(19)5-9-15)18(21)23-16-10-13-6-7-14(11-16)20(13)2/h4-5,8-9,13-14,16-17H,3,6-7,10-11H2,1-2H3",WTPAXDRULIZRDJ-UHFFFAOYSA-N,sm-21,Preclinical,sigma receptor antagonist,PGRMC1,,
C=CCN=c1[nH]cnc2ccc(Br)cc12,"InChI=1S/C11H10BrN3/c1-2-5-13-11-9-6-8(12)3-4-10(9)14-7-15-11/h2-4,6-7H,1,5H2,(H,13,14,15)",BCPOLXUSCUFDGE-UHFFFAOYSA-N,smer-28,Preclinical,autophagy inducer,SNCA,,
O=C1NC(=O)C(=Cc2cccc(C(F)(F)F)c2)S1,"InChI=1S/C11H6F3NO2S/c12-11(13,14)7-3-1-2-6(4-7)5-8-9(16)15-10(17)18-8/h1-5H,(H,15,16,17)",NGJLOFCOEOHFKQ-UHFFFAOYSA-N,smi-4a,Preclinical,Pim kinase inhibitor,PIM1,,
Cc1cc(C)c(C2=NOC3C4CCC(C4)C23)c(C)c1,"InChI=1S/C17H21NO/c1-9-6-10(2)14(11(3)7-9)16-15-12-4-5-13(8-12)17(15)19-18-16/h6-7,12-13,15,17H,4-5,8H2,1-3H3",WKLZNTYMDOPBSE-UHFFFAOYSA-N,sn-2,Preclinical,transient receptor potential channel agonist,MCOLN3,,
CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC,"InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3",FJHBVJOVLFPMQE-UHFFFAOYSA-N,sn-38,Launched,topoisomerase inhibitor,TOP1,oncology,colorectal cancer
CCOC(=O)C1CSC(Cc2ccc(OCc3ccc([N+](=O)[O-])cc3)cc2)N1,"InChI=1S/C20H22N2O5S/c1-2-26-20(23)18-13-28-19(21-18)11-14-5-9-17(10-6-14)27-12-15-3-7-16(8-4-15)22(24)25/h3-10,18-19,21H,2,11-13H2,1H3",ZVYIJXLMBWCGHP-UHFFFAOYSA-N,sn-6,Preclinical,sodium/calcium exchange inhibitor,,,
CC(=O)NC(C(=O)O)C(C)(C)SNO,"InChI=1S/C7H14N2O4S/c1-4(10)8-5(6(11)12)7(2,3)14-9-13/h5,9,13H,1-3H3,(H,8,10)(H,11,12)",DKBCGIRXIKTDKA-UHFFFAOYSA-N,snap,Phase 2,nitric oxide donor,PTPN1,,
COC(=O)C1=C(C)N=C(C)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1,"InChI=1S/C36H40N4O5/c1-25-31(33(32(26(2)38-25)35(42)45-3)27-15-17-30(18-16-27)40(43)44)34(41)37-21-10-22-39-23-19-36(20-24-39,28-11-6-4-7-12-28)29-13-8-5-9-14-29/h4-9,11-18,31,33H,10,19-24H2,1-3H3,(H,37,41)",YOVAOKIOUGAIJE-UHFFFAOYSA-N,snap-5089,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D,,
Cc1ccc(NC(=O)C(C)C)cc1C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,"InChI=1S/C29H32F2N2O2/c1-19(2)29(34)32-23-7-4-20(3)26(16-23)22-12-14-33(15-13-22)18-21-5-8-24(9-6-21)35-25-10-11-27(30)28(31)17-25/h4-11,16-17,19,22H,12-15,18H2,1-3H3,(H,32,34)",VMLZFUVIKCGATC-UHFFFAOYSA-N,snap-94847,Preclinical,,ADRA1A|DRD2,,
C=CCN1CC(C)N(C(c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)CC1C,"InChI=1S/C28H39N3O2/c1-7-17-30-19-22(5)31(20-21(30)4)27(25-11-10-12-26(18-25)33-6)23-13-15-24(16-14-23)28(32)29(8-2)9-3/h7,10-16,18,21-22,27H,1,8-9,17,19-20H2,2-6H3",KQWVAUSXZDRQPZ-UHFFFAOYSA-N,snc-80,Preclinical,,OPRD1,,
CC(C)=CCc1c(O)cc(O)c2c(=O)c(O)c(-c3ccc(C(F)(F)F)cc3)oc12,"InChI=1S/C21H17F3O5/c1-10(2)3-8-13-14(25)9-15(26)16-17(27)18(28)19(29-20(13)16)11-4-6-12(7-5-11)21(22,23)24/h3-7,9,25-26,28H,8H2,1-2H3",OXHMDMVBLQNMGP-UHFFFAOYSA-N,sng-1153,Preclinical,selective estrogen receptor modulator (SERM),ESR1,,
O=C(N=c1[nH]cc(CCN=c2[nH]cnc3ccsc23)s1)Nc1cccc(Cl)c1,"InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)",FAYAUAZLLLJJGH-UHFFFAOYSA-N,sns-314,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(NC4CCC(O)CC4)c3)c2C1,"InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)",ZFVRYNYOPQZKDG-UHFFFAOYSA-N,snx-2112,Phase 1,HSP inhibitor,,,
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(NC4CCC(OC(=O)CN)CC4)c3)c2C1,"InChI=1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)",AVDSOVJPJZVBTC-UHFFFAOYSA-N,snx-5422,Phase 1/Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,
Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1,"InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)",QNAZTOHXCZPOSA-UHFFFAOYSA-N,sobetirome,Phase 1/Phase 2,thyroid hormone receptor agonist,THRA|THRB,,
CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C,"InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)",DZMVCVHATYROOS-UHFFFAOYSA-N,soblidotin,Phase 2,microtubule inhibitor,,,
CC1=CCC(C(C)(C)O)CC1O,"InChI=1S/C10H18O2/c1-7-4-5-8(6-9(7)11)10(2,3)12/h4,8-9,11-12H,5-6H2,1-3H3",OMDMTHRBGUBUCO-UHFFFAOYSA-N,sobrepin,Launched,mucolytic agent,,pulmonary,chest congestion
CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O,"InChI=1S/C22H34N4O10/c1-15(2)11-33-21(31)35-13-25-17(27)7-23(8-18(25)28)5-6-24-9-19(29)26(20(30)10-24)14-36-22(32)34-12-16(3)4/h15-16H,5-14H2,1-4H3",OCOKWVBYZHBHLU-UHFFFAOYSA-N,sobuzoxane,Launched,topoisomerase inhibitor,,hematologic malignancy,peripheral T-cell lymphoma (PTCL)
O=C1C(O)C(O)OC1C(O)CO,"InChI=1S/C6H10O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,4-8,10-11H,1H2",KYDVLNNTBWQYOK-UHFFFAOYSA-N,sodium-ascorbate,Launched,,,,
CCCC(=O)O,"InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)",FERIUCNNQQJTOY-UHFFFAOYSA-N,sodium-butyrate,Phase 2,HDAC inhibitor,BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8,,
O=C(Cc1ccc(O)c(O)c1)C(O)O,"InChI=1S/C9H10O5/c10-6-2-1-5(3-7(6)11)4-8(12)9(13)14/h1-3,9-11,13-14H,4H2",PTVBAOGVIGOALV-UHFFFAOYSA-N,sodium-danshensu,Preclinical,,,,
CCCCCCCCCCCCOS(=O)(=O)O,"InChI=1S/C12H26O4S/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H,13,14,15)",MOTZDAYCYVMXPC-UHFFFAOYSA-N,sodium-dodecyl-sulfate,Launched,,ALB,,
O=C(C(O)C(O)O)C(O)C(O)CO,"InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-3,5-9,11-13H,1H2",UVZKQGXWWWXEKH-UHFFFAOYSA-N,sodium-gluconate,Launched,,,,
Cc1cc(S(=O)(=O)O)c2c(C)ccc(C(C)C)cc1-2,"InChI=1S/C15H18O3S/c1-9(2)12-6-5-10(3)15-13(8-12)11(4)7-14(15)19(16,17)18/h5-9H,1-4H3,(H,16,17,18)",VIZXMHCBZLGUET-UHFFFAOYSA-N,sodium-gualenate,Launched,antacid,,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|pharyngitis
O=[PH](=O)(O)F,"InChI=1S/FHO3P/c1-5(2,3)4/h(H,2,3,4)",QKNZASPUMVFSDA-UHFFFAOYSA-N,sodium-monofluorophosphate,Launched,,PYGM,dental,cavities
ONO,InChI=1S/H3NO2/c2-1-3/h1-3H,AMEDKBHURXXSQO-UHFFFAOYSA-N,sodium-nitrite,Launched,nitric oxide donor,,critical care,poison antidote|cyanide poisoning
[N]O,InChI=1S/HNO/c1-2/h2H,JSGZKHJWRITPII-UHFFFAOYSA-N,sodium-nitroprusside,Launched,nitric oxide donor,,cardiology,hypertension|congestive heart failure
O,InChI=1S/H2O/h1H2,XLYOFNOQVPJJNP-UHFFFAOYSA-N,sodium-orthovanadate,Preclinical,,,,
O=S(=O)(O)Oc1ccc(C(c2ccc(OS(=O)(=O)O)cc2)c2ccccn2)cc1,"InChI=1S/C18H15NO8S2/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)",UJIDKYTZIQTXPM-UHFFFAOYSA-N,sodium-picosulfate,Launched,,,gastroenterology,constipation
O=C(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(=O)O)C(O3)C(C(O)CO)O4)OC(C(O)CO)C1O2,"InChI=1S/2C6H9O7.2H2O.O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;/h2*2-5,7-8H,1H2,(H,12,13);2*1H2;;;/q2*-3;;;;2*+4/p-2",RPOBPHCDIPHDQL-UHFFFAOYSA-L,sodium-stibogluconate,Launched,tyrosine phosphatase inhibitor,PTPN6,infectious disease,leishmaniasis
Cc1c(S(=O)(=O)O)oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,"InChI=1S/C19H18O6S/c1-9-13-15(20)16(21)14-10-5-4-8-19(2,3)12(10)7-6-11(14)17(13)25-18(9)26(22,23)24/h6-7H,4-5,8H2,1-3H3,(H,22,23,24)",UJCACMLMPLLRGW-UHFFFAOYSA-N,sodium-tanshinone-ii-a-sulfonate,Phase 2,potassium channel activator,,,
CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)O,"InChI=1S/C14H30O4S/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17/h12-14H,5-11H2,1-4H3,(H,15,16,17)",GROJOWHVXQYQGN-UHFFFAOYSA-N,sodium-tetradecyl-sulfate,Launched,,PROC,dermatology,varicose veins
CC(C)=CCOc1ccc(C=CC(=O)c2ccc(OCC=C(C)C)cc2OCC(=O)O)cc1,"InChI=1S/C27H30O6/c1-19(2)13-15-31-22-8-5-21(6-9-22)7-12-25(28)24-11-10-23(32-16-14-20(3)4)17-26(24)33-18-27(29)30/h5-14,17H,15-16,18H2,1-4H3,(H,29,30)",GFWRVVCDTLRWPK-UHFFFAOYSA-N,sofalcone,Launched,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD)
CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(F)C1O)Oc1ccccc1,"InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)",TTZHDVOVKQGIBA-UHFFFAOYSA-N,sofosbuvir,Launched,HCV inhibitor,,infectious disease,hepatitis C|hepatitis C
CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(O)C1O)Oc1ccccc1,"InChI=1S/C22H30N3O10P/c1-13(2)33-19(28)14(3)24-36(31,35-15-8-6-5-7-9-15)32-12-16-18(27)22(4,30)20(34-16)25-11-10-17(26)23-21(25)29/h5-11,13-14,16,18,20,27,30H,12H2,1-4H3,(H,24,31)(H,23,26,29)",WAKQLZVLNOKKHE-UHFFFAOYSA-N,sofosbuvir-impurity-m,Preclinical,antiviral,,,
CNc1cccc(NC(=O)NC2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1,"InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)",YDZYKNJZCVIKPP-UHFFFAOYSA-N,sograzepide,Phase 2,gastrin inhibitor,,,
CC1CCC2(NC1)OC1CC3C4CC=C5CC(OC6OC(CO)C(OC7OC(C)C(O)C(O)C7O)C(O)C6OC6OC(C)C(O)C(O)C6O)CCC5(C)C4CCC3(C)C1C2C,"InChI=1S/C45H73NO15/c1-19-9-14-45(46-17-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(53)34(51)32(49)22(4)56-41)37(54)38(29(18-47)58-42)59-40-35(52)33(50)31(48)21(3)55-40/h7,19-22,24-42,46-54H,8-18H2,1-6H3",MBWUSSKCCUMJHO-UHFFFAOYSA-N,solamargine,Phase 3,apoptosis inhibitor,,,
CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(=NC(=O)C5CC5)[nH]n34)cc2)C1,"InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)",MPYACSQFXVMWNO-UHFFFAOYSA-N,solcitinib,Phase 1,JAK inhibitor,JAK1,,
O=C(OC1CN2CCC1CC2)N1CCc2ccccc2C1c1ccccc1,"InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2",FBOUYBDGKBSUES-UHFFFAOYSA-N,solifenacin-succinate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency
CCC1OC(=O)C(C)(F)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)OC12C,"InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3",IXXFZUPTQVDPPK-UHFFFAOYSA-N,solithromycin,Phase 3,protein synthesis inhibitor,,,
NC(=O)OCC(N)Cc1ccccc1,"InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)",UCTRAOBQFUDCSR-UHFFFAOYSA-N,solriamfetol,Launched,dopamine reuptake inhibitor,,neurology/psychiatry,narcolepsy
CC(C)(N)CC12CC3CC(CC(C3)C1)C2,"InChI=1S/C14H25N/c1-13(2,15)9-14-6-10-3-11(7-14)5-12(4-10)8-14/h10-12H,3-9,15H2,1-2H3",OWKXRDQRMTVCEX-UHFFFAOYSA-N,somantadine,Phase 1,antiviral,,,
CC(N)C(=O)NCC(=O)NC1CSSCC(C(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(Cc2ccccc2)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC1=O,"InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)",NHXLMOGPVYXJNR-UHFFFAOYSA-N,somatostatin,Launched,somatostatin receptor agonist,OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5,hematology,hemorrhage
NS(=O)(=O)c1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1,"InChI=1S/C21H27N3O3S/c22-28(25,26)19-7-5-18(6-8-19)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-27-21/h1-8,21H,9-16H2,(H2,22,25,26)",WNUQCGWXPNGORO-UHFFFAOYSA-N,sonepiprazole,Phase 2,dopamine receptor antagonist,,,
Cc1c(C(=O)Nc2ccc(N3CC(C)OC(C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,"InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)",VZZJRYRQSPEMTK-UHFFFAOYSA-N,sonidegib,Launched,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC)
O=C1C=CCC2C3CCCN4CCCC(CN12)C34,"InChI=1S/C15H22N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h1,7,11-13,15H,2-6,8-10H2",AAGFPTSOPGCENQ-UHFFFAOYSA-N,sophocarpine,Phase 3,,,,
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,FLT3 inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,KIT inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,PDGFR tyrosine kinase receptor inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,RAF inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,RET tyrosine kinase inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,sorafenib,Launched,VEGFR inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)
COCCOC1c2ccn3c(C)c(C)nc3c2NC(c2ccccc2)C1O,"InChI=1S/C21H25N3O3/c1-13-14(2)24-10-9-16-18(21(24)22-13)23-17(15-7-5-4-6-8-15)19(25)20(16)27-12-11-26-3/h4-10,17,19-20,23,25H,11-12H2,1-3H3",PWILYDZRJORZDR-UHFFFAOYSA-N,soraprazan,Preclinical,proton pump inhibitor,,,
CC=CC=CC(=O)O,"InChI=1S/C6H8O2/c1-2-3-4-5-6(7)8/h2-5H,1H3,(H,7,8)",WSWCOQWTEOXDQX-UHFFFAOYSA-N,sorbic-acid,Launched,,,,
O=C1NC(=O)C2(CCOc3ccc(F)cc32)N1,"InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)",LXANPKRCLVQAOG-UHFFFAOYSA-N,sorbinil,Phase 3,aldose reductase inhibitor,AKR1B1,,
CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O,"InChI=1S/C24H46O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(27)29-19-21(26)24-23(28)20(25)18-30-24/h20-21,23-26,28H,2-19H2,1H3",HVUMOYIDDBPOLL-UHFFFAOYSA-N,sorbitan-monostearate,Preclinical,,,,
OCC(O)C(O)C(O)C(O)CO,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2",FBPFZTCFMRRESA-UHFFFAOYSA-N,sorbitol,Launched,mucolytic agent,,gastroenterology,constipation
CCOc1ccc(Cc2cc(C3OC(SC)C(O)C(O)C3O)ccc2Cl)cc1,"InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3",QKDRXGFQVGOQKS-UHFFFAOYSA-N,sotagliflozin,Phase 3,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,,
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,"InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3",ZBMZVLHSJCTVON-UHFFFAOYSA-N,sotalol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|KCNH2,cardiology,atrial fibrillation (AF)|ventricular arrhythmias
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,"InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)",OAVGBZOFDPFGPJ-UHFFFAOYSA-N,sotrastaurin,Phase 2,PKC inhibitor,PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ,,
O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1C(F)(F)F,"InChI=1S/C14H5ClF9N3O/c15-11-25-4-8(9(27-11)14(22,23)24)10(28)26-7-2-5(12(16,17)18)1-6(3-7)13(19,20)21/h1-4H,(H,26,28)",GHMKQBWHPQMXSH-UHFFFAOYSA-N,sp-100030,Preclinical,NFkB pathway inhibitor,JUN|NFKB1,,
COc1ccc2[nH]c3c(-c4cccc5ccccc45)nccc3c2c1,"InChI=1S/C22H16N2O/c1-25-15-9-10-20-19(13-15)18-11-12-23-21(22(18)24-20)17-8-4-6-14-5-2-3-7-16(14)17/h2-13,24H,1H3",AABFWJDLCCDJJN-UHFFFAOYSA-N,sp-141,Preclinical,ubiquitin ligase inhibitor,MDM2,,
COCCOCCOc1ccc(C2=NC(C)(C(=O)O)CS2)c(O)c1,"InChI=1S/C16H21NO6S/c1-16(15(19)20)10-24-14(17-16)12-4-3-11(9-13(12)18)23-8-7-22-6-5-21-2/h3-4,9,18H,5-8,10H2,1-2H3,(H,19,20)",YASYAEVZKXPYIZ-UHFFFAOYSA-N,sp-420,Phase 1,,,,
CC(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)O,"InChI=1S/C11H16N2O8/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21)",OPVPGKGADVGKTG-UHFFFAOYSA-N,spaglumic-acid,Launched,glutamate receptor antagonist,GRM3,allergy,allergic conjunctivitis|allergic rhinitis
CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1,"InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)",DZZWHBIBMUVIIW-UHFFFAOYSA-N,sparfloxacin,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,,
O=C(O)CC(NC(=O)C[PH](=O)(=O)O)C(=O)O,"InChI=1S/C6H9NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H,13,14,15)",XMKWPJVVFOVQHC-UHFFFAOYSA-N,sparfosate,Phase 3,aspartate carbamoyltransferase inhibitor,CA2|CA4,,
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)N=c2[nH]oc(C)c2C)c(COCC)c1,"InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)",WRFHGDPIDHPWIQ-UHFFFAOYSA-N,sparsentan,Phase 3,angiotensin receptor antagonist,,,
C1CCN2CC3CC(CN4CCCCC34)C2C1,"InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2",SLRCCWJSBJZJBV-UHFFFAOYSA-N,sparteine-(-),Launched,,,,
C1CCN2CC3CC(CN4CCCCC34)C2C1,"InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2",SLRCCWJSBJZJBV-UHFFFAOYSA-N,sparteine-(+),Launched,,,,
C1CCN2CC3CC(CN4CCCCC34)C2C1,"InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2",SLRCCWJSBJZJBV-UHFFFAOYSA-N,sparteine-sulfate,Launched,,,,
Fc1ccc(CN=c2[nH]cnc3ccc(F)cc23)cc1,"InChI=1S/C15H11F2N3/c16-11-3-1-10(2-4-11)8-18-15-13-7-12(17)5-6-14(13)19-9-20-15/h1-7,9H,8H2,(H,18,19,20)",AWIVHRPYFSSVOG-UHFFFAOYSA-N,spautin-1,Preclinical,deubiquitinase inhibitor,USP10|USP13,,
CNC1C(O)C(NC)C2OC3(O)C(=O)CC(C)OC3OC2C1O,"InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3",UNFWWIHTNXNPBV-UHFFFAOYSA-N,spectinomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,pulmonary,airsacculitis|chronic respiratory disease
NCCCCNCCCN,"InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2",ATHGHQPFGPMSJY-UHFFFAOYSA-N,spermidine,Preclinical,glutamate receptor modulator,KCNJ4|TXNRD1,,
NCCCNCCCCNCCCN,"InChI=1S/C10H26N4/c11-5-3-9-13-7-1-2-8-14-10-4-6-12/h13-14H,1-12H2",PFNFFQXMRSDOHW-UHFFFAOYSA-N,spermine,Preclinical,,CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5,,
CCCCCCCCCCCCCC=CC(O)C(N)CO[PH](=O)(=O)OCC[N+](C)(C)C,"InChI=1S/C23H49N2O5P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(26)22(24)21-30-31(27,28)29-20-19-25(2,3)4/h17-18,22-23,26H,5-16,19-21,24H2,1-4H3/q+1",ZPWNIQPHSBQUBA-UHFFFAOYSA-N,sphingosylphosphorylcholine,Preclinical,gene expression stimulant,GPR12,,
O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1,"InChI=1S/C23H26FN3O2/c24-19-10-8-18(9-11-19)21(28)7-4-14-26-15-12-23(13-16-26)22(29)25-17-27(23)20-5-2-1-3-6-20/h1-3,5-6,8-11H,4,7,12-17H2,(H,25,29)",DKGZKTPJOSAWFA-UHFFFAOYSA-N,spiperone,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1,"InChI=1S/C22H30Cl2N2O2/c1-25(21(27)14-16-5-6-17(23)18(24)13-16)19-7-9-22(8-4-12-28-22)15-20(19)26-10-2-3-11-26/h5-6,13,19-20H,2-4,7-12,14-15H2,1H3",NYKCGQQJNVPOLU-UHFFFAOYSA-N,spiradoline,Phase 2,opioid receptor agonist,OPRK1,,
COC1C(O)CC(=O)OC(C)CC=CC=CC(OC2CCC(N(C)C)C(C)O2)C(C)CC(CC=O)C1OC1OC(C)C(OC2CC(C)(O)C(O)C(C)O2)C(N(C)C)C1O,"InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3",ACTOXUHEUCPTEW-UHFFFAOYSA-N,spiramycin,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,toxoplasmosis|soft tissue infection
O=C(CCBr)N1CC[N+]2(CC1)CC[N+]1(CCN(C(=O)CCBr)CC1)CC2,InChI=1S/C18H32Br2N4O2/c19-3-1-17(25)21-5-9-23(10-6-21)13-15-24(16-14-23)11-7-22(8-12-24)18(26)2-4-20/h1-16H2/q+2,JXEICPOBKSQAIU-UHFFFAOYSA-N,spirobromin,Phase 1,,,,
CC(=O)SC1C=C2CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12,"InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h13,17-19,21H,4-12H2,1-3H3",RRQQBPFUONLKTL-UHFFFAOYSA-N,spironolactone,Launched,mineralocorticoid receptor antagonist,AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG,endocrinology|cardiology|gastroenterology|rheumatology,hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia
O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2,"InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26)",JVGBTTIJPBFLTE-UHFFFAOYSA-N,spiroxatrine,Preclinical,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B,,
CC(=O)c1ccc2c(c1)C(=O)C1(CC1)O2,"InChI=1S/C12H10O3/c1-7(13)8-2-3-10-9(6-8)11(14)12(15-10)4-5-12/h2-3,6H,4-5H2,1H3",SETMGIIITGNLAS-UHFFFAOYSA-N,spizofurone,Withdrawn,,,,
O=C1CCc2c(ccc3ccccc23)O1,"InChI=1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2",ISFPDBUKMJDAJH-UHFFFAOYSA-N,splitomycin,Preclinical,SIRT inhibitor,SIRT1,,
COc1ccccc1Oc1c(OC)[nH]c(-c2ccncc2)nc1=NS(=O)(=O)c1ccc(C)cn1,"InChI=1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)",YBWLTKFZAOSWSM-UHFFFAOYSA-N,spp301,Phase 3,endothelin receptor antagonist,EDNRA,,
CC(C)n1nc(C#Cc2ccccc2)c2c(=N)[nH]cnc21,"InChI=1S/C16H15N5/c1-11(2)21-16-14(15(17)18-10-19-16)13(20-21)9-8-12-6-4-3-5-7-12/h3-7,10-11H,1-2H3,(H2,17,18,19)",JQOIRTDBHMDWMT-UHFFFAOYSA-N,spp86,Preclinical,receptor tyrosine protein kinase inhibitor,RET,,
CC(C)=CCCC(C)=CCNCCNC1C2CC3CC(C2)CC1C3,"InChI=1S/C22H38N2/c1-16(2)5-4-6-17(3)7-8-23-9-10-24-22-20-12-18-11-19(14-20)15-21(22)13-18/h5,7,18-24H,4,6,8-15H2,1-3H3",JFIBVDBTCDTBRH-UHFFFAOYSA-N,sq-109,Phase 3,bacterial cell wall synthesis inhibitor,FDFT1,,
N=c1[nH]cnc2c1ncn2C1CCCO1,"InChI=1S/C9H11N5O/c10-8-7-9(12-4-11-8)14(5-13-7)6-2-1-3-15-6/h4-6H,1-3H2,(H2,10,11,12)",UKHMZCMKHPHFOT-UHFFFAOYSA-N,sq-22536,Preclinical,adenylyl cyclase inhibitor,ADCY1,,
CC(C)C(CCC(C)C1CCC2C3C(O)CC4CC(NCCCNCCCCN)CCC4(C)C3CCC12C)OS(=O)(=O)O,"InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)",UIRKNQLZZXALBI-UHFFFAOYSA-N,squalamine,Phase 3,antiviral,,,
CCCCOc1c(OCCCC)c(=O)c1=O,"InChI=1S/C12H18O4/c1-3-5-7-15-11-9(13)10(14)12(11)16-8-6-4-2/h3-8H2,1-2H3",XBRWELTXMQSEIN-UHFFFAOYSA-N,squaric-acid-dibutyl-ester,Preclinical,oxidative stress inducer,,,
O=C(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccc(C(F)(F)F)cc1,"InChI=1S/C17H10F9NO2/c18-15(19,20)11-3-1-9(2-4-11)13(28)27-12-7-5-10(6-8-12)14(29,16(21,22)23)17(24,25)26/h1-8,29H,(H,27,28)",DUXWIYXHHGNUJU-UHFFFAOYSA-N,sr-1078,Preclinical,retinoid receptor agonist,RORA|RORC,,
CC(C=CC=C(C=CC1=C(C)CCCC1(C)C)c1ccc(C)cc1)=CC(=O)O,"InChI=1S/C26H32O2/c1-19-11-13-23(14-12-19)22(10-6-8-20(2)18-25(27)28)15-16-24-21(3)9-7-17-26(24,4)5/h6,8,10-16,18H,7,9,17H2,1-5H3,(H,27,28)",RQANARBNMTXCDM-UHFFFAOYSA-N,sr-11302,Preclinical,,,,
CC(C)Oc1cccc(CC(=O)N2CCCC(CC[N+]34CCC(c5ccccc5)(CC3)CC4)(c3ccc(Cl)c(Cl)c3)C2)c1,"InChI=1S/C37H45Cl2N2O2/c1-28(2)43-32-11-6-8-29(24-32)25-35(42)40-19-7-14-37(27-40,31-12-13-33(38)34(39)26-31)18-23-41-20-15-36(16-21-41,17-22-41)30-9-4-3-5-10-30/h3-6,8-13,24,26,28H,7,14-23,25,27H2,1-2H3/q+1",RPDFDSQFBCJTDY-UHFFFAOYSA-N,sr-140333,Phase 2,neurokinin receptor antagonist,TACR1,,
Cc1c(C)n(Cc2ccc(-c3ccccc3C(=O)O)cc2)c2ccc(C(=O)NC(C)c3ccc([N+](=O)[O-])cc3)cc12,"InChI=1S/C33H29N3O5/c1-20-22(3)35(19-23-8-10-25(11-9-23)28-6-4-5-7-29(28)33(38)39)31-17-14-26(18-30(20)31)32(37)34-21(2)24-12-15-27(16-13-24)36(40)41/h4-18,21H,19H2,1-3H3,(H,34,37)(H,38,39)",IIJDFXNUWZTHIM-UHFFFAOYSA-N,sr-1664,Preclinical,PPAR receptor ligand,PPARG,,
OC(c1ccc(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)c(F)c1)(C(F)(F)F)C(F)(F)F,"InChI=1S/C26H24F7N3O/c27-23-15-21(24(37,25(28,29)30)26(31,32)33)5-6-22(23)20-3-1-18(2-4-20)16-35-11-13-36(14-12-35)17-19-7-9-34-10-8-19/h1-10,15,37H,11-14,16-17H2",KVHKWAZUPPBMLL-UHFFFAOYSA-N,sr-2211,Preclinical,retinoid receptor inverse agonist,RORC,,
O=C(O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1,"InChI=1S/C23H18N2O3/c26-23(27)20-9-2-4-11-22(20)24-17-7-5-8-19(14-17)28-15-18-13-12-16-6-1-3-10-21(16)25-18/h1-14,24H,15H2,(H,26,27)",LMPZHLXYBWGGNT-UHFFFAOYSA-N,sr-2640,Phase 2,leukotriene receptor antagonist,CYSLTR1,,
O=C(O)Cn1c(C(=O)N=c2[nH]c(-c3ccccc3Cl)cs2)cc2ccccc21,"InChI=1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27)",ILNRQFBVVQUOLP-UHFFFAOYSA-N,sr-27897,Phase 2,CCK receptor antagonist,CCKAR,,
Cc1ccc(-c2ncn(-c3ccc(N=c4nc(-c5cccc(N6CCOCC6)c5)cc[nH]4)cc3)n2)cn1,"InChI=1S/C28H26N8O/c1-20-5-6-22(18-30-20)27-31-19-36(34-27)24-9-7-23(8-10-24)32-28-29-12-11-26(33-28)21-3-2-4-25(17-21)35-13-15-37-16-14-35/h2-12,17-19H,13-16H2,1H3,(H,29,32,33)",QDMXVKKPYBGIAS-UHFFFAOYSA-N,sr-3306,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK9,,
COc1ccc(CCN(C)CCCOc2ccc(S(=O)(=O)c3c(C(C)C)c4ccccc4n3C)cc2)cc1OC,"InChI=1S/C32H40N2O5S/c1-23(2)31-27-10-7-8-11-28(27)34(4)32(31)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3",GCVFQRRBTCHIPK-UHFFFAOYSA-N,sr-33805,Phase 1,calcium channel blocker,,,
COc1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4cccc(C)c4)cn3)c2)cc(OC)c1OC,"InChI=1S/C27H27N5O5/c1-17-7-5-9-19(11-17)30-27(34)31-21-15-28-32(16-21)22-10-6-8-18(12-22)26(33)29-20-13-23(35-2)25(37-4)24(14-20)36-3/h5-16H,1-4H3,(H,29,33)(H2,30,31,34)",MTFAYLZZDJGFGV-UHFFFAOYSA-N,sr-3576,Preclinical,JNK inhibitor,MAPK10,,
CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,"InChI=1S/C22H24N4O4/c1-26(2)9-10-28-20-11-15(16-12-23-24-13-16)7-8-17(20)25-22(27)21-14-29-18-5-3-4-6-19(18)30-21/h3-8,11-13,21H,9-10,14H2,1-2H3,(H,23,24)(H,25,27)",OQWZIAVXCYIZNN-UHFFFAOYSA-N,sr-3677,Preclinical,rho associated kinase inhibitor,ROCK2,,
NC1CCN(c2cccc(Cl)n2)CC1,"InChI=1S/C10H14ClN3/c11-9-2-1-3-10(13-9)14-6-4-8(12)5-7-14/h1-3,8H,4-7,12H2",WPVVMKYQOMJPIN-UHFFFAOYSA-N,sr-57227a,Phase 2,serotonin receptor agonist,HTR3A,,
CCc1ccccc1OCC(O)CNC1CCCc2ccccc21,"InChI=1S/C21H27NO2/c1-2-16-8-4-6-13-21(16)24-15-18(23)14-22-20-12-7-10-17-9-3-5-11-19(17)20/h3-6,8-9,11,13,18,20,22-23H,2,7,10,12,14-15H2,1H3",VFDHMSXXELYMRW-UHFFFAOYSA-N,sr-59230a,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
c1ccc2c(c1)CCCc1cc(=NCCN3CCOCC3)[nH]nc1-2,"InChI=1S/C19H24N4O/c1-2-7-17-15(4-1)5-3-6-16-14-18(21-22-19(16)17)20-8-9-23-10-12-24-13-11-23/h1-2,4,7,14H,3,5-6,8-13H2,(H,20,21)",RUTYAHFAKWVMNH-UHFFFAOYSA-N,sr-95639a,Preclinical,acetylcholine receptor agonist,CHRM1,,
COc1cc2[nH]cnc(=Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,"InChI=1S/C22H19N3O3/c1-26-20-12-18-19(13-21(20)27-2)23-14-24-22(18)25-15-8-10-17(11-9-15)28-16-6-4-3-5-7-16/h3-14H,1-2H3,(H,23,24,25)",DMWVGXGXHPOEPT-UHFFFAOYSA-N,src-kinase-inhibitor-i,Preclinical,SRC inhibitor,CSK|LCK|RIPK2,,
O=C(Nc1cc(C(F)(F)F)ccc1N1CCCCC1)c1ccncc1,"InChI=1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)",DWFGGOFPIISJIT-UHFFFAOYSA-N,srpin340,Preclinical,serine arginine protein kinase inhibitor,SRPK1|SRPK2,,
O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,"InChI=1S/C25H23N7OS/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31/h1-8,13,15-16,26H,9-12,14H2,(H,29,33)",IASPBORHOMBZMY-UHFFFAOYSA-N,srt1720,Preclinical,SIRT activator,SIRT1,,
Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1,"InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)",LAMQVIQMVKWXOC-UHFFFAOYSA-N,srt2104,Phase 2,SIRT activator,SIRT1,,
CC(N=c1cc(NS(=O)(=O)N2CCC2)[nH]c(SCc2cccc(F)c2F)n1)C(O)CO,"InChI=1S/C18H23F2N5O4S2/c1-11(14(27)9-26)21-15-8-16(24-31(28,29)25-6-3-7-25)23-18(22-15)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,26-27H,3,6-7,9-10H2,1H3,(H2,21,22,23,24)",QVKPEMXUBULFBM-UHFFFAOYSA-N,srt3190,Preclinical,CC chemokine receptor antagonist,,,
COc1c(C)c(C(=O)c2ccc(N)c(C(=O)O)c2)n2ccccc12,"InChI=1S/C18H16N2O4/c1-10-15(20-8-4-3-5-14(20)17(10)24-2)16(21)11-6-7-13(19)12(9-11)18(22)23/h3-9H,19H2,1-2H3,(H,22,23)",SNMCWIDCSPHZRD-UHFFFAOYSA-N,ssr128129e,Preclinical,,,,
O=C(Oc1ccc(Br)cc1)N1CCN2CCC1CC2,"InChI=1S/C14H17BrN2O2/c15-11-1-3-13(4-2-11)19-14(18)17-10-9-16-7-5-12(17)6-8-16/h1-4,12H,5-10H2",RXLOZRCLQMJJLC-UHFFFAOYSA-N,ssr180711,Phase 2,acetylcholine receptor agonist,CHRNA7,,
COc1ccc2cc(S(=O)(=O)NC(CC(=O)NC(Cc3ccc(CN4C(C)CCCC4C)cc3)C(=O)N(C)C(C)C)c3ccc4c(c3)OCO4)ccc2c1,"InChI=1S/C42H52N4O7S/c1-27(2)45(5)42(48)38(20-30-10-12-31(13-11-30)25-46-28(3)8-7-9-29(46)4)43-41(47)24-37(34-16-19-39-40(23-34)53-26-52-39)44-54(49,50)36-18-15-32-21-35(51-6)17-14-33(32)22-36/h10-19,21-23,27-29,37-38,44H,7-9,20,24-26H2,1-6H3,(H,43,47)",QGWIQIAWOCJRPI-UHFFFAOYSA-N,ssr240612,Preclinical,bradykinin receptor antagonist,,,
CCCCc1nc(=N)c2nc(-n3nccn3)n(C)c2[nH]1,"InChI=1S/C12H16N8/c1-3-4-5-8-16-10(13)9-11(17-8)19(2)12(18-9)20-14-6-7-15-20/h6-7H,3-5H2,1-2H3,(H2,13,16,17)",CYYQMAWUIRPCNW-UHFFFAOYSA-N,st-1535,Preclinical,adenosine receptor antagonist,,,
Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12,"InChI=1S/C21H16O2/c22-20-11-9-14-5-1-3-7-16(14)18(20)13-19-17-8-4-2-6-15(17)10-12-21(19)23/h1-12,22-23H,13H2",ZPANWZBSGMDWON-UHFFFAOYSA-N,st-1859,Phase 1,antiamyloidogenic agent,,,
NC(=O)C1CCSC2CC3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N21,"InChI=1S/C27H28Cl2N4O5S/c28-17-4-7-21(19(29)13-17)38-15-22(34)31-18-5-2-16(3-6-18)12-23(35)32-10-1-9-27(32)14-24-33(26(27)37)20(25(30)36)8-11-39-24/h2-7,13,20,24H,1,8-12,14-15H2,(H2,30,36)(H,31,34)",HBLHLJXFIPCEMW-UHFFFAOYSA-N,st-2825,Preclinical,myeloid differentiation primary response inhibitor,MYD88,,
CCc1cccc(CC)c1NC1=NCCN1,"InChI=1S/C13H19N3/c1-3-10-6-5-7-11(4-2)12(10)16-13-14-8-9-15-13/h5-7H,3-4,8-9H2,1-2H3,(H2,14,15,16)",IALHTUPVRAQZFI-UHFFFAOYSA-N,st-91,Preclinical,adrenergic receptor agonist,,,
Cc1cccc(C=NN=c2cc(N3CCOCC3)[nH]c(OCCc3ccccn3)n2)c1,"InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)",HSKAZIJJKRAJAV-UHFFFAOYSA-N,sta-5326,Phase 2,interleukin synthesis inhibitor,IL12A,,
Cc1ccc(S(=O)(=O)OCC(=O)Nc2ccc(C(=O)O)c(O)c2)cc1,"InChI=1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)",HWNUSGNZBAISFM-UHFFFAOYSA-N,stat3-inhibitor-vi,Preclinical,STAT inhibitor,STAT3,,
O=C(O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12,"InChI=1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23)",LKBFFDOJUKLQNY-UHFFFAOYSA-N,statil,Preclinical,aldose reductase inhibitor,,,
O=[N+]([O-])c1ccc2c(c1)S(=O)(=O)C=C2,"InChI=1S/C8H5NO4S/c10-9(11)7-2-1-6-3-4-14(12,13)8(6)5-7/h1-5H",ZRRGOUHITGRLBA-UHFFFAOYSA-N,stattic,Preclinical,,,,
Cc1cn(C2C=CC(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)",XNKLLVCARDGLGL-UHFFFAOYSA-N,stavudine,Launched,DNA directed DNA polymerase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
Cc1cn(C2C=CC(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)",XNKLLVCARDGLGL-UHFFFAOYSA-N,stavudine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CC(C)n1cnc2c(=NCCc3ccc(O)cc3)[nH]c(-c3csc4ccccc34)nc21,"InChI=1S/C24H23N5OS/c1-15(2)29-14-26-21-23(25-12-11-16-7-9-17(30)10-8-16)27-22(28-24(21)29)19-13-31-20-6-4-3-5-18(19)20/h3-10,13-15,30H,11-12H2,1-2H3,(H,25,27,28)",BGFHMYJZJZLMHW-UHFFFAOYSA-N,stemregenin-1,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,
CC(SC(=O)c1cccs1)C(=O)NCC(=O)O,"InChI=1S/C10H11NO4S2/c1-6(9(14)11-5-8(12)13)17-10(15)7-3-2-4-16-7/h2-4,6H,5H2,1H3,(H,11,14)(H,12,13)",JNYSEDHQJCOWQU-UHFFFAOYSA-N,stepronin,Launched,mucolytic agent,,,
CC(=O)C1CCC2C3CC=C4CC(=O)CCC4(C)C3C(O)CC12C,"InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h4,15-19,24H,5-11H2,1-3H3",AADGIVANXMJZCW-UHFFFAOYSA-N,stetaderm,Launched,,,,
O=S(=O)(N=Cc1c(O)ccc2ccccc12)c1cccs1,"InChI=1S/C15H11NO3S2/c17-14-8-7-11-4-1-2-5-12(11)13(14)10-16-21(18,19)15-6-3-9-20-15/h1-10,17H",TVIVJHZHPKNDAQ-UHFFFAOYSA-N,stf-083010,Preclinical,serine/threonine kinase inhibitor,ERN1,,
Cc1ccc(S(=O)(=O)Cc2nc(-c3ccc(C(=O)NCc4cccnc4)cc3)oc2C)cc1,"InChI=1S/C25H23N3O4S/c1-17-5-11-22(12-6-17)33(30,31)16-23-18(2)32-25(28-23)21-9-7-20(8-10-21)24(29)27-15-19-4-3-13-26-14-19/h3-14H,15-16H2,1-2H3,(H,27,29)",DLFCEZOMHBPDGI-UHFFFAOYSA-N,stf-118804,Preclinical,NAMPT inhibitor,NAMPT,,
CC(C)(C)c1ccc(S(=O)(=O)NCc2ccc(C(=O)Nc3cccnc3)cc2)cc1,"InChI=1S/C23H25N3O3S/c1-23(2,3)19-10-12-21(13-11-19)30(28,29)25-15-17-6-8-18(9-7-17)22(27)26-20-5-4-14-24-16-20/h4-14,16,25H,15H2,1-3H3,(H,26,27)",NGQPRVWTFNBUHA-UHFFFAOYSA-N,stf-31,Preclinical,NAMPT inhibitor,NAMPT|SLC2A1,,
Cc1cccc(N=c2[nH]c(-c3ccncc3)cs2)c1,"InChI=1S/C15H13N3S/c1-11-3-2-4-13(9-11)17-15-18-14(10-19-15)12-5-7-16-8-6-12/h2-10H,1H3,(H,17,18)",KATNUHQNJGNLPW-UHFFFAOYSA-N,stf-62247,Preclinical,autophagy inducer,,,
CCC(C=CC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C,"InChI=1S/C29H48O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-10,19-21,23-27,30H,7,11-18H2,1-6H3",HCXVJBMSMIARIN-UHFFFAOYSA-N,stigmasterol,Preclinical,,,,
CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,"InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3",IBLNKMRFIPWSOY-UHFFFAOYSA-N,stiripentol,Launched,GABA uptake inhibitor,GABRA3,neurology/psychiatry,epilepsy
Cc1ccc2c(c1)C1CN(C)CCC1N2,"InChI=1S/C13H18N2/c1-9-3-4-12-10(7-9)11-8-15(2)6-5-13(11)14-12/h3-4,7,11,13-14H,5-6,8H2,1-2H3",CYJQCYXRNNCURD-UHFFFAOYSA-N,stobadine,Phase 2,adrenergic receptor antagonist,ADRA1A,,
CNC1C(OC2C(OC3C(O)C(O)C(N=C(N)N)C(O)C3N=C(N)N)OC(C)C2(O)C=O)OC(CO)C(O)C1O,"InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)",UCSJYZPVAKXKNQ-UHFFFAOYSA-N,streptomycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,tuberculosis
CN(NO)C(=O)NC1C(O)OC(CO)C(O)C1O,"InChI=1S/C8H17N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,10,12-15,17H,2H2,1H3,(H,9,16)",LUNQAAUVSFIVKD-UHFFFAOYSA-N,streptozotocin,Launched,DNA alkylating agent,,oncology,pancreatic cancer
N#Cc1c(N(CC(=O)O)CC(=O)O)sc(C(=O)O)c1CC(=O)O,"InChI=1S/C12H10N2O8S/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22)",DJSXNILVACEBLP-UHFFFAOYSA-N,strontium-ranelate,Launched,bone formation stimulant,CASR,orthopedics|rheumatology,osteoporosis|osteoarthritis
N#Cc1c(N(CC(=O)O)CC(=O)O)sc(C(=O)O)c1CC(=O)O,"InChI=1S/C12H10N2O8S/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22)",DJSXNILVACEBLP-UHFFFAOYSA-N,strontium-ranelate,Launched,bone resorption inhibitor,CASR,orthopedics|rheumatology,osteoporosis|osteoarthritis
O=C1CC2OCC=C3CN4CCC56c7ccccc7N1C5C2C3CC46,"InChI=1S/C21H22N2O2/c24-18-10-16-19-13-9-17-21(6-7-22(17)11-12(13)5-8-25-16)14-3-1-2-4-15(14)23(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2",QMGVPVSNSZLJIA-UHFFFAOYSA-N,strychnine,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA10|CHRNA9|GLRA1|GLRA2|GLRA3|GLRB,,
Cc1[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c(C)c1C(=O)NCC(=O)CN1CCOCC1,"InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9,26-27,30H,5-8,10-12H2,1-2H3,(H,25,31)",QFMPTBUYMZFRIP-UHFFFAOYSA-N,su014813,Phase 2,PDGFR tyrosine kinase receptor inhibitor,KDR,,
Cc1[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c(C)c1C(=O)NCC(=O)CN1CCOCC1,"InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9,26-27,30H,5-8,10-12H2,1-2H3,(H,25,31)",QFMPTBUYMZFRIP-UHFFFAOYSA-N,su014813,Phase 2,VEGFR inhibitor,KDR,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc23)c(C)c1C(=O)N1CCN(C)CC1,"InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30-31,35H,2,10-13H2,1,3-4H3",YTYGVVYTPPUYRI-UHFFFAOYSA-N,su11274,Preclinical,hepatocyte growth factor receptor inhibitor,MET,,
C=c1[nH]c(=Cc2c(O)[nH]c3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc23)c(C)c1C(=O)N1CCN(C)CC1,"InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30-31,35H,2,10-13H2,1,3-4H3",YTYGVVYTPPUYRI-UHFFFAOYSA-N,su11274,Preclinical,tyrosine kinase inhibitor,MET,,
C=c1[nH]c(=Cc2c(O)[nH]c3cc(-c4ccccc4)ccc23)c(C)c1CCC(=O)O,"InChI=1S/C24H22N2O3/c1-14-18(10-11-23(27)28)15(2)25-21(14)13-20-19-9-8-17(12-22(19)26-24(20)29)16-6-4-3-5-7-16/h3-9,12-13,25-26,29H,2,10-11H2,1H3,(H,27,28)",WZQCIRXONVBVHN-UHFFFAOYSA-N,su16f,Preclinical,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,,
N=c1[nH]nc(Sc2ncc([N+](=O)[O-])s2)s1,"InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8)",NQQBNZBOOHHVQP-UHFFFAOYSA-N,su3327,Preclinical,JNK inhibitor,MAPK8,,
CN(C)c1ccc(C=C2C(=O)Nc3ccccc32)cc1,"InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)",UAKWLVYMKBWHMX-UHFFFAOYSA-N,su4312,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KDR|PDGFRB,,
CN(C)c1ccc(C=C2C(=O)Nc3ccccc32)cc1,"InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)",UAKWLVYMKBWHMX-UHFFFAOYSA-N,su4312,Preclinical,tyrosine kinase inhibitor,KDR|PDGFRB,,
CN(C)c1ccc(C=C2C(=O)Nc3ccccc32)cc1,"InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)",UAKWLVYMKBWHMX-UHFFFAOYSA-N,su4312,Preclinical,VEGFR inhibitor,KDR|PDGFRB,,
COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2,"InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)",QNUKRWAIZMBVCU-UHFFFAOYSA-N,su9516,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5,,
CSCCC(NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(Cc1ccccc1)NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C1CCCN1C(=O)C(N)CCCN=C(N)N)C(N)=O,"InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)",ADNPLDHMAVUMIW-UHFFFAOYSA-N,substance-p,Phase 1,neurokinin receptor antagonist,TACR1|TACR2|TACR3,,
O=C(O)CCC(=O)O,"InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)",KDYFGRWQOYBRFD-UHFFFAOYSA-N,succinic-acid,Launched,,ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE,,
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OC(=O)CCC(=O)O)c(C(C)(C)C)c1,"InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)",RKSMVPNZHBRNNS-UHFFFAOYSA-N,succinobucol,Phase 2/Phase 3,antioxidant,VCAM1,,
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,"InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2",AXOIZCJOOAYSMI-UHFFFAOYSA-N,succinylcholine-chloride,Launched,,CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10,neurology/psychiatry,muscle relaxant
O=C(O)CCC(=O)Nc1ccc(S(=O)(=O)N=c2[nH]ccs2)cc1,"InChI=1S/C13H13N3O5S2/c17-11(5-6-12(18)19)15-9-1-3-10(4-2-9)23(20,21)16-13-14-7-8-22-13/h1-4,7-8H,5-6H2,(H,14,16)(H,15,17)(H,18,19)",SKVLYVHULOWXTD-UHFFFAOYSA-N,succinylsulfathiazole,Phase 2,dihydrofolate reductase inhibitor,DHFR,,
O=S(=O)(O)OCC1OC(OC2(COS(=O)(=O)O)OC(COS(=O)(=O)O)C(OS(=O)(=O)O)C2OS(=O)(=O)O)C(OS(=O)(=O)O)C(OS(=O)(=O)O)C1OS(=O)(=O)O,"InChI=1S/C12H22O35S8/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36)",WEPNHBQBLCNOBB-UHFFFAOYSA-N,sucralfate,Launched,antacid,,gastroenterology,duodenal ulcer disease
OCC1OC(OC2(CCl)OC(CCl)C(O)C2O)C(O)C(O)C1Cl,"InChI=1S/C12H19Cl3O8/c13-1-4-7(17)10(20)12(3-14,22-4)23-11-9(19)8(18)6(15)5(2-16)21-11/h4-11,16-20H,1-3H2",BAQAVOSOZGMPRM-UHFFFAOYSA-N,sucralose,Launched,,,,
OCC1OC(OC2(CO)OC(CO)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2",CZMRCDWAGMRECN-UHFFFAOYSA-N,sucrose,Launched,,ACTA1|ATOX1|C22orf28|LYZ,,
CC(=O)OCC1OC(OC2(COC(C)=O)OC(COC(C)=O)C(OC(C)=O)C2OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O,"InChI=1S/C28H38O19/c1-12(29)37-9-20-22(40-15(4)32)24(42-17(6)34)25(43-18(7)35)27(45-20)47-28(11-39-14(3)31)26(44-19(8)36)23(41-16(5)33)21(46-28)10-38-13(2)30/h20-27H,9-11H2,1-8H3",ZIJKGAXBCRWEOL-UHFFFAOYSA-N,sucrose-octaacetate,Preclinical,,,,
Cc1ccccc1N=Nc1ccc(N=Nc2c(O)ccc3ccccc23)c(C)c1,"InChI=1S/C24H20N4O/c1-16-7-3-6-10-21(16)26-25-19-12-13-22(17(2)15-19)27-28-24-20-9-5-4-8-18(20)11-14-23(24)29/h3-15,29H,1-2H3",RCTGMCJBQGBLKT-UHFFFAOYSA-N,sudan-iv,Preclinical,,,,
CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1,"InChI=1S/C36H31F2N5O4S/c1-41(20-23-10-5-3-6-11-23)21-28-31-33(44)43(26-12-7-4-8-13-26)36(46)42(22-27-29(37)14-9-15-30(27)38)34(31)48-32(28)24-16-18-25(19-17-24)39-35(45)40-47-2/h3-19H,20-22H2,1-2H3,(H2,39,40,45)",UCQSBGOFELXYIN-UHFFFAOYSA-N,sufugolix,Preclinical,gonadotropin releasing factor hormone receptor antagonist,,,
O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,"InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)",WHRODDIHRRDWEW-UHFFFAOYSA-N,sugammadex,Launched,neuromuscular blockade reversal agent,,,
CC1(C)C(C(=O)O)N2C(=O)CC2S1(=O)=O,"InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)",FKENQMMABCRJMK-UHFFFAOYSA-N,sulbactam,Launched,beta lactamase inhibitor,,infectious disease,skin infections|intra-abdominal infections|gynecologic infections
CC(C)(C)C(=O)OCOC(=O)C1N2C(=O)CC2S(=O)(=O)C1(C)C,"InChI=1S/C14H21NO7S/c1-13(2,3)12(18)22-7-21-11(17)10-14(4,5)23(19,20)9-6-8(16)15(9)10/h9-10H,6-7H2,1-5H3",OHPVYKXTRACOSQ-UHFFFAOYSA-N,sulbactam-pivoxil,Launched,beta lactamase inhibitor,,infectious disease,skin infections
S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,"InChI=1S/C17H18N2S2/c20-17-19(12-16-9-5-2-6-10-16)13-18(14-21-17)11-15-7-3-1-4-8-15/h1-10H,11-14H2",QFVAWNPSRQWSDU-UHFFFAOYSA-N,sulbentine,Preclinical,other antifungal,,,
CC(=C(CCOC(=O)C(C)C)SSC(CCOC(=O)C(C)C)=C(C)N(C=O)Cc1c[nH]c(C)nc1=N)N(C=O)Cc1c[nH]c(C)nc1=N,"InChI=1S/C32H46N8O6S2/c1-19(2)31(43)45-11-9-27(21(5)39(17-41)15-25-13-35-23(7)37-29(25)33)47-48-28(10-12-46-32(44)20(3)4)22(6)40(18-42)16-26-14-36-24(8)38-30(26)34/h13-14,17-20H,9-12,15-16H2,1-8H3,(H2,33,35,37)(H2,34,36,38)",CKHJPWQVLKHBIH-UHFFFAOYSA-N,sulbutiamine,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,asthenia
Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"InChI=1S/C18H15Cl3N2S/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2",AFNXATANNDIXLG-UHFFFAOYSA-N,sulconazole,Launched,sterol demethylase inhibitor,,infectious disease,tinea pedis|tinea cruris|tinea corporis
Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1,"InChI=1S/C13H12N2O3S/c14-11-6-8-12(9-7-11)19(17,18)15-13(16)10-4-2-1-3-5-10/h1-9H,14H2,(H,15,16)",PBCZLFBEBARBBI-UHFFFAOYSA-N,sulfabenzamide,Launched,bacterial antifolate,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
NC(=O)NS(=O)(=O)c1ccc(N)cc1,"InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11)",WVAKABMNNSMCDK-UHFFFAOYSA-N,sulfacarbamide,Withdrawn,,,,
CC(=O)NS(=O)(=O)c1ccc(N)cc1,"InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)",SKIVFJLNDNKQPD-UHFFFAOYSA-N,sulfacetamide,Launched,PABA antagonist,,ophthalmology,conjunctivitis
Nc1ccc(S(=O)(=O)N=c2ccc(Cl)n[nH]2)cc1,"InChI=1S/C10H9ClN4O2S/c11-9-5-6-10(14-13-9)15-18(16,17)8-3-1-7(12)2-4-8/h1-6H,12H2,(H,14,15)",XOXHILFPRYWFOD-UHFFFAOYSA-N,sulfachlorpyridazine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Nc1ccc(S(=O)(=O)N=c2nccc[nH]2)cc1,"InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)",SEEPANYCNGTZFQ-UHFFFAOYSA-N,sulfadiazine,Launched,bacterial antifolate,,infectious disease|ophthalmology,malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid
COc1[nH]cnc(=NS(=O)(=O)c2ccc(N)cc2)c1OC,"InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",PJSFRIWCGOHTNF-UHFFFAOYSA-N,sulfadoxine,Launched,dihydropteroate synthase inhibitor,,infectious disease,malaria
Cc1[nH]oc(=NS(=O)(=O)c2ccc(N)cc2)c1C,"InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,13H,12H2,1-2H3",SGWYOFPLCPFUKP-UHFFFAOYSA-N,sulfafurazole,Launched,bacterial antifolate,,infectious disease,urinary tract infections
N=C(N)NS(=O)(=O)c1ccc(N)cc1,"InChI=1S/C7H10N4O2S/c8-5-1-3-6(4-2-5)14(12,13)11-7(9)10/h1-4H,8H2,(H4,9,10,11)",BRBKOPJOKNSWSG-UHFFFAOYSA-N,sulfaguanidine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1cc[nH]c(=NS(=O)(=O)c2ccc(N)cc2)n1,"InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)",QPPBRPIAZZHUNT-UHFFFAOYSA-N,sulfamerazine,Launched,bacterial antifolate,,infectious disease,coccidiosis|cholera
COc1cnc(=NS(=O)(=O)c2ccc(N)cc2)[nH]c1,"InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)",GPTONYMQFTZPKC-UHFFFAOYSA-N,sulfameter,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections
Cc1cc(C)[nH]c(=NS(=O)(=O)c2ccc(N)cc2)n1,"InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)",ASWVTGNCAZCNNR-UHFFFAOYSA-N,sulfamethazine,Launched,PABA antagonist,,gastroenterology,enteritis
Cc1n[nH]c(=NS(=O)(=O)c2ccc(N)cc2)s1,"InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)",VACCAVUAMIDAGB-UHFFFAOYSA-N,sulfamethizole,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1cc(=NS(=O)(=O)c2ccc(N)cc2)[nH]o1,"InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)",JLKIGFTWXXRPMT-UHFFFAOYSA-N,sulfamethoxazole,Launched,PABA antagonist,,infectious disease|gastroenterology,pneumonia|enteritis|urinary tract infections
COc1ccc(=NS(=O)(=O)c2ccc(N)cc2)[nH]n1,"InChI=1S/C11H12N4O3S/c1-18-11-7-6-10(13-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)",VLYWMPOKSSWJAL-UHFFFAOYSA-N,sulfamethoxypyridazine,Withdrawn,bacterial antifolate,,,
COc1ncc[nH]c1=NS(=O)(=O)c1ccc(N)cc1,"InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)",KXRZBTAEDBELFD-UHFFFAOYSA-N,sulfametopyrazine,Launched,PABA antagonist,,infectious disease,malaria|urinary tract infections|respiratory tract infections
COc1cc(=NS(=O)(=O)c2ccc(N)cc2)[nH]cn1,"InChI=1S/C11H12N4O3S/c1-18-11-6-10(13-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,14,15)",WMPXPUYPYQKQCX-UHFFFAOYSA-N,sulfamonomethoxine,Launched,bacterial antifolate,,infectious disease,urinary tract infections
Cc1[nH]c(=NS(=O)(=O)c2ccc(N)cc2)oc1C,"InChI=1S/C11H13N3O3S/c1-7-8(2)17-11(13-7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6H,12H2,1-2H3,(H,13,14)",CYFLXLSBHQBMFT-UHFFFAOYSA-N,sulfamoxole,Launched,PABA antagonist,,infectious disease,urinary tract infections
Nc1ccc(S(N)(=O)=O)cc1,"InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)",FDDDEECHVMSUSB-UHFFFAOYSA-N,sulfanilamide,Launched,carbonic anhydrase inhibitor,CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4,infectious disease,vulvovaginal candidiasis
Nc1ccc(S(=O)(=O)O)cc1,"InChI=1S/C6H7NO3S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H,8,9,10)",HVBSAKJJOYLTQU-UHFFFAOYSA-N,sulfanilate-zinc,Preclinical,,,,
CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc([N+](=O)[O-])cc2)cc1,"InChI=1S/C14H13N3O5S/c1-10(18)15-11-4-8-14(9-5-11)23(21,22)16-12-2-6-13(7-3-12)17(19)20/h2-9,16H,1H3,(H,15,18)",GWBPFRGXNGPPMF-UHFFFAOYSA-N,sulfanitran,Launched,,,infectious disease,coccidiosis
Nc1ccc(S(=O)(=O)N=c2cc[nH]n2-c2ccccc2)cc1,"InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,17H,16H2",OVLRICZMNOIGCE-UHFFFAOYSA-N,sulfaphenazole,Launched,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections
Nc1ccc(S(=O)(=O)N=c2cccc[nH]2)cc1,"InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)",GECHUMIMRBOMGK-UHFFFAOYSA-N,sulfapyridine,Launched,PABA antagonist,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Nc1ccc(S(=O)(=O)N=c2cnc3ccccc3[nH]2)cc1,"InChI=1S/C14H12N4O2S/c15-10-5-7-11(8-6-10)21(19,20)18-14-9-16-12-3-1-2-4-13(12)17-14/h1-9H,15H2,(H,17,18)",NHZLNPMOSADWGC-UHFFFAOYSA-N,sulfaquinoxaline,Launched,vitamin K antagonist,,infectious disease,coccidiosis
O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)N=c3cccc[nH]3)cc2)ccc1O,"InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)",NCEXYHBECQHGNR-UHFFFAOYSA-N,sulfasalazine,Launched,cyclooxygenase inhibitor,ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1,gastroenterology,ulcerative colitis
Nc1ccc(S(=O)(=O)N=c2[nH]ccs2)cc1,"InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)",JNMRHUJNCSQMMB-UHFFFAOYSA-N,sulfathiazole,Launched,dihydropteroate synthase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
Cc1cc2cc(Oc3cc[nH]c(=Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1,"InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)",TTZSNFLLYPYKIL-UHFFFAOYSA-N,sulfatinib,Phase 1,tyrosine kinase inhibitor,,,
O=c1c(CC[S+]([O-])c2ccccc2)c(O)n(-c2ccccc2)n1-c1ccccc1,"InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,26H,16-17H2",AUMHDRMJJNZTPB-UHFFFAOYSA-N,sulfinpyrazone,Launched,uricosuric blocker,ABCC1|FPR1|SLC22A12,rheumatology,gout
Cc1cc(=NS(=O)(=O)c2ccc(N)cc2)[nH]c(C)n1,"InChI=1S/C12H14N4O2S/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)",YZMCKZRAOLZXAZ-UHFFFAOYSA-N,sulfisomidin,Preclinical,antibacterial,,,
CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1,"InChI=1S/C13H15N3O4S/c1-8-9(2)15-20-13(8)16(10(3)17)21(18,19)12-6-4-11(14)5-7-12/h4-7H,14H2,1-3H3",JFNWFXVFBDDWCX-UHFFFAOYSA-N,sulfisoxazole-acetyl,Launched,folic acid antagonist,,infectious disease|otolaryngology,meningitis|urinary tract infections|otitis|trachoma
C[S+]([O-])CCCCN=C=S,"InChI=1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3",SUVMJBTUFCVSAD-UHFFFAOYSA-N,sulforaphane,Phase 2,anticancer agent,NFE2L2,,
C[S+]([O-])CCCCN=C=S,"InChI=1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3",SUVMJBTUFCVSAD-UHFFFAOYSA-N,sulforaphane,Phase 2,aryl hydrocarbon receptor antagonist,NFE2L2,,
CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc([S+](C)[O-])cc1,"InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)",MLKXDPUZXIRXEP-UHFFFAOYSA-N,sulindac,Launched,cyclooxygenase inhibitor,AKR1B1,rheumatology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis
COc1cc(O)c(C(=O)c2ccccc2)cc1S(=O)(=O)O,"InChI=1S/C14H12O6S/c1-20-12-8-11(15)10(7-13(12)21(17,18)19)14(16)9-5-3-2-4-6-9/h2-8,15H,1H3,(H,17,18,19)",CXVGEDCSTKKODG-UHFFFAOYSA-N,sulisobenzone,Launched,,,dermatology,sunscreen lotion
COc1cc([S+](C)[O-])ccc1-c1nc2cccnc2[nH]1,"InChI=1S/C14H13N3O2S/c1-19-12-8-9(20(2)18)5-6-10(12)13-16-11-4-3-7-15-14(11)17-13/h3-8H,1-2H3,(H,15,16,17)",XMFCOYRWYYXZMY-UHFFFAOYSA-N,sulmazole,Phase 1,adenosine receptor antagonist,,,
COc1cc(C(=S)N2CCOCC2)cc(OC)c1OC,"InChI=1S/C14H19NO4S/c1-16-11-8-10(9-12(17-2)13(11)18-3)14(20)15-4-6-19-7-5-15/h8-9H,4-7H2,1-3H3",MVOUIYUWRXPNKD-UHFFFAOYSA-N,sulmetozine,Launched,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD)
CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,"InChI=1S/C20H35NOS/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3/h11-14,16-17,20-22H,5-10,15H2,1-4H3",BFCDFTHTSVTWOG-UHFFFAOYSA-N,suloctidil,Withdrawn,adrenergic receptor antagonist,,,
CC(O)C1C(=O)N2C(C(=O)O)=C(SC3CC[S+]([O-])C3)SC12,"InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)",FLSUCZWOEMTFAQ-UHFFFAOYSA-N,sulopenem,Phase 3,antibacterial,,,
COc1cc(=NS(=O)(=O)c2ccc(N)cc2)[nH]c(OC)n1,"InChI=1S/C12H14N4O4S/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",ZZORFUFYDOWNEF-UHFFFAOYSA-N,sulphadimethoxine,Launched,dihydropteroate synthetase inhibitor,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,"InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)",BGRJTUBHPOOWDU-UHFFFAOYSA-N,sulpiride,Launched,dopamine receptor antagonist,,neurology/psychiatry,schizophrenia
CC1(C)SC2C(NC(=O)C(N)c3ccccc3)C(=O)N2C1C(=O)OCOC(=O)C1N2C(=O)CC2S(=O)(=O)C1(C)C,"InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)",OPYGFNJSCUDTBT-UHFFFAOYSA-N,sultamicillin,Launched,antibacterial ,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,"InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)",HMHVCUVYZFYAJI-UHFFFAOYSA-N,sultiame,Phase 3,carbonic anhydrase inhibitor,CA2,,
CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC,"InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)",UNRHXEPDKXPRTM-UHFFFAOYSA-N,sultopride,Preclinical,dopamine receptor antagonist,,,
CNC1Cc2cccc3[nH]c(=O)n(c23)C1,"InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)",RKZSNTNMEFVBDT-UHFFFAOYSA-N,sumanirole,Phase 3,dopamine receptor agonist,DRD2,,
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,"InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3",KQKPFRSPSRPDEB-UHFFFAOYSA-N,sumatriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7,neurology/psychiatry,migraine headache
Cc1c(C)c(NCC(=O)N(C)C2CCN(Cc3ccc(C(N)=O)cc3)CC2)c(C)c(C)c1N,"InChI=1S/C26H37N5O2/c1-16-18(3)25(19(4)17(2)24(16)27)29-14-23(32)30(5)22-10-12-31(13-11-22)15-20-6-8-21(9-7-20)26(28)33/h6-9,22,29H,10-15,27H2,1-5H3,(H2,28,33)",KCODNOOPOPTZMO-UHFFFAOYSA-N,sun-11602,Preclinical,fibroblast growth factor mimetic,FGFR1,,
CC(=Nc1ccccc1N)c1c(C)cc(=O)n(O)c1O,"InChI=1S/C14H15N3O3/c1-8-7-12(18)17(20)14(19)13(8)9(2)16-11-6-4-3-5-10(11)15/h3-7,19-20H,15H2,1-2H3",SGJLINMLDNLWOS-UHFFFAOYSA-N,sun-b-8155,Preclinical,calcitonin agonist,CALCR,,
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-9,11,25-26,28H,5-6,10,12H2,1-4H3",ALVHFWNGOPERPY-UHFFFAOYSA-N,sunitinib,Launched,FLT3 inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-9,11,25-26,28H,5-6,10,12H2,1-4H3",ALVHFWNGOPERPY-UHFFFAOYSA-N,sunitinib,Launched,KIT inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-9,11,25-26,28H,5-6,10,12H2,1-4H3",ALVHFWNGOPERPY-UHFFFAOYSA-N,sunitinib,Launched,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-9,11,25-26,28H,5-6,10,12H2,1-4H3",ALVHFWNGOPERPY-UHFFFAOYSA-N,sunitinib,Launched,RET tyrosine kinase inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCN(CC)CC=NC(=O)c1c(C)[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-9,11,25-26,28H,5-6,10,12H2,1-4H3",ALVHFWNGOPERPY-UHFFFAOYSA-N,sunitinib,Launched,VEGFR inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)
CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1,"InChI=1S/C16H25NO4S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3/h5-8,14,18H,4,9-12H2,1-3H3/p+1",DYZJXZOQQRXDLE-UHFFFAOYSA-O,suplatast,Launched,histamine release inhibitor,,rheumatology,Kimura's disease
CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1,"InChI=1S/C16H25NO4S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3/h5-8,14,18H,4,9-12H2,1-3H3/p+1",DYZJXZOQQRXDLE-UHFFFAOYSA-O,suplatast,Launched,immunoglobulin inhibitor,,rheumatology,Kimura's disease
CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,"InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)",MDKGKXOCJGEUJW-UHFFFAOYSA-N,suprofen,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,
Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,"InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)",FIAFUQMPZJWCLV-UHFFFAOYSA-N,suramin,Launched,DNA synthesis inhibitor,F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5,infectious disease,African trypanosomiasis|onchocerciasis
Cn1nc(-c2cccc(F)c2)n(C)c1=S,"InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3",IWDUZEHNLHFBRZ-UHFFFAOYSA-N,suritozole,Phase 2,GABA receptor inverse agonist,GABBR1,,
CC(=O)NCC1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,"InChI=1S/C16H20FN3O3S/c1-11(21)18-9-13-10-20(16(22)23-13)12-2-3-15(14(17)8-12)19-4-6-24-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)",FNDDDNOJWPQCBZ-UHFFFAOYSA-N,sutezolid,Phase 2,protein synthesis inhibitor,,,
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,"InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)",ONWXNHPOAGOMTG-UHFFFAOYSA-N,suxibuzone,Launched,cyclooxygenase inhibitor,,rheumatology|neurology/psychiatry,joint pain|muscle pain
OC1CN2CCCC(O)C2C1O,"InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2",FXUAIOOAOAVCGD-UHFFFAOYSA-N,swainsonine,Phase 2,alpha mannosidase inhibitor,MAN2A1,,
CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc12,"InChI=1S/C26H27ClFN3O3/c1-29(2)26(34)24(32)21-15-30(3)23-14-22(27)20(13-19(21)23)25(33)31-10-8-17(9-11-31)12-16-4-6-18(28)7-5-16/h4-7,13-15,17H,8-12H2,1-3H3",GUTYHDCSDBBMGW-UHFFFAOYSA-N,sx-011,Preclinical,MAP kinase inhibitor,MAPK14,,
CC(=O)N(C)Cc1ccc2c(c1)OCO2,"InChI=1S/C11H13NO3/c1-8(13)12(2)6-9-3-4-10-11(5-9)15-7-14-10/h3-5H,6-7H2,1-2H3",JIWDGIYBLGMPRV-UHFFFAOYSA-N,sy-640,Phase 2,,,,
CC(CC(N)C(=O)O)C(=O)O,"InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)",KRKRAOXTGDJWNI-UHFFFAOYSA-N,sym-2081,Preclinical,kainate receptor antagonist,GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2,,
CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C1C)OCO3,"InChI=1S/C20H22N4O3/c1-3-8-22-20(25)24-12(2)15-9-17-18(27-11-26-17)10-16(15)19(23-24)13-4-6-14(21)7-5-13/h4-7,9-10,12H,3,8,11,21H2,1-2H3,(H,22,25)",OFUDZKKOKPGXOH-UHFFFAOYSA-N,sym-2206,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
O=c1n(Cl)c(=O)n(Cl)c(=O)n1Cl,InChI=1S/C3Cl3N3O3/c4-7-1(10)8(5)3(12)9(6)2(7)11,YRIZYWQGELRKNT-UHFFFAOYSA-N,symclosene,Preclinical,,,,
CNCC(O)c1ccc(O)cc1,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-2-4-8(11)5-3-7/h2-5,9-12H,6H2,1H3",YRCWQPVGYLYSOX-UHFFFAOYSA-N,synephrine,Launched,adrenergic receptor agonist,ADRA1A,otolaryngology,sinusitis
O=C(N=c1cc[nH]cc1)c1cc([N+](=O)[O-])ccc1Cl,"InChI=1S/C12H8ClN3O3/c13-11-2-1-9(16(18)19)7-10(11)12(17)15-8-3-5-14-6-4-8/h1-7H,(H,14,15,17)",FRPJSHKMZHWJBE-UHFFFAOYSA-N,t-0070907,Preclinical,PPAR receptor antagonist,PPARG,,
COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,"InChI=1S/C31H29N5O7/c1-18-13-19(7-11-32-18)16-36-27(31(38)42-5)25(20-14-22(39-2)28(41-4)23(15-20)40-3)21-8-12-35-29(26(21)30(36)37)43-17-24-33-9-6-10-34-24/h6-15H,16-17H2,1-5H3",JEMJAABFSYOLAP-UHFFFAOYSA-N,t-0156,Preclinical,phosphodiesterase inhibitor,PDE5A,,
CN=c1[nH]c(=NCc2ncccn2)c2c(-c3ccc4ncccc4c3)c[nH]c2[nH]1,"InChI=1S/C21H18N8/c1-22-21-28-19-18(20(29-21)27-12-17-24-8-3-9-25-17)15(11-26-19)13-5-6-16-14(10-13)4-2-7-23-16/h2-11H,12H2,1H3,(H3,22,26,27,28,29)",PMWVYONICYRLNY-UHFFFAOYSA-N,t-025,Preclinical,CLK inhibitor,,,
O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,"InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2",SGIWFELWJPNFDH-UHFFFAOYSA-N,t-0901317,Preclinical,LXR agonist,NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB,,
COC(=O)OCC1OC(Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)C(O)C(O)C1O,"InChI=1S/C26H28O11/c1-13-9-17(28)21(16(27)5-3-14-4-6-18-15(11-14)7-8-34-18)19(10-13)36-25-24(31)23(30)22(29)20(37-25)12-35-26(32)33-2/h4,6-11,20,22-25,28-31H,3,5,12H2,1-2H3",BXNCIERBDJYIQT-UHFFFAOYSA-N,t-1095,Preclinical,sodium/glucose cotransporter inhibitor,,,
O=C(O)CCc1cc(C(=O)c2ccc(OC3CCCC3)cc2O)ccc1OCc1ccc2c(=O)[nH]oc2c1,"InChI=1S/C29H27NO8/c31-24-15-21(37-20-3-1-2-4-20)8-10-22(24)28(34)19-6-11-25(18(14-19)7-12-27(32)33)36-16-17-5-9-23-26(13-17)38-30-29(23)35/h5-6,8-11,13-15,20,31H,1-4,7,12,16H2,(H,30,35)(H,32,33)",DALCQQSLNPLQFZ-UHFFFAOYSA-N,t-5224,Phase 2,AP inhibitor,JUN,,
Cc1cc(C(=O)Nc2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)on1,"InChI=1S/C19H14F3N3O3/c1-11-8-16(28-25-11)18(27)24-14-6-2-4-12(9-14)17(26)23-15-7-3-5-13(10-15)19(20,21)22/h2-10H,1H3,(H,23,26)(H,24,27)",XVOKFRPKSAWELK-UHFFFAOYSA-N,t-5601640,Preclinical,LIM kinase inhibitor,LIMK2,,
Nc1sc2c(c1C(=O)c1ccc(Cl)cc1)CCCC2,"InChI=1S/C15H14ClNOS/c16-10-7-5-9(6-8-10)14(18)13-11-3-1-2-4-12(11)19-15(13)17/h5-8H,1-4,17H2",OTZVBZFYMFTYKH-UHFFFAOYSA-N,t-62,Phase 2,adenosine receptor modulator,ADORA2A,,
Fc1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1,"InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H",GETAAWDSFUCLBS-UHFFFAOYSA-N,t-807,Phase 2,PET radiotracer,,,
Fc1ccc(-c2[nH]c(-c3c(F)cccc3F)nc2-c2ccncc2)cc1,"InChI=1S/C20H12F3N3/c21-14-6-4-12(5-7-14)18-19(13-8-10-24-11-9-13)26-20(25-18)17-15(22)2-1-3-16(17)23/h1-11H,(H,25,26)",TWPJJJZCYVFUOA-UHFFFAOYSA-N,ta-01,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E|MAPK14,,
Fc1ccc(-c2[nH]c(-c3c(F)cccc3F)nc2-c2ccncc2)cc1,"InChI=1S/C20H12F3N3/c21-14-6-4-12(5-7-14)18-19(13-8-10-24-11-9-13)26-20(25-18)17-15(22)2-1-3-16(17)23/h1-11H,(H,25,26)",TWPJJJZCYVFUOA-UHFFFAOYSA-N,ta-01,Preclinical,MAP kinase inhibitor,CSNK1D|CSNK1E|MAPK14,,
CNC(=O)C(Cc1ccccc1)N(C)C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)C=CCC(C)(C)N,"InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)",WURGZWOTGMLDJP-UHFFFAOYSA-N,tabimorelin,Phase 2,growth hormone secretagogue receptor agonist,GHSR,,
C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCC(O)C(C)C)CC(O)CC1O,"InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3",BJYLYJCXYAMOFT-UHFFFAOYSA-N,tacalcitol,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis|chapped lips
CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,"InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)",VAZAPHZUAVEOMC-UHFFFAOYSA-N,tacedinaline,Phase 3,HDAC inhibitor,HDAC1,,
N=c1c2c([nH]c3ccccc13)CCCC2,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,tacrine,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease
C=CCC1=CC(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,"InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,25-26,28-30,32-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3",SLUYGGAVUSVJOT-UHFFFAOYSA-N,tacrolimus,Launched,calcineurin inhibitor,FKBP1A,transplant,organ rejection
CN1CC(=O)N2C(Cc3c([nH]c4ccccc34)C2c2ccc3c(c2)OCO3)C1=O,"InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3",WOXKDUGGOYFFRN-UHFFFAOYSA-N,tadalafil,Launched,phosphodiesterase inhibitor,PDE11A|PDE5A,urology,erectile dysfunction
O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,"InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)",TXEIIPDJKFWEEC-UHFFFAOYSA-N,tafamidis-meglumine,Launched,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP)
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1,"InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3",LBHLFPGPEGDCJG-UHFFFAOYSA-N,tafenoquine,Launched,antimalarial agent,,infectious disease,malaria
CC(C)OC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(F)(F)COc1ccccc1,"InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3",WSNODXPBBALQOF-UHFFFAOYSA-N,tafluprost,Launched,prostaglandin inhibitor,PTGFR,ophthalmology,glaucoma|ocular hypertension
O=C(C(O)CO)C(O)C(O)CO,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-5,7-11H,1-2H2",DWJZKGYQNOQQEZ-UHFFFAOYSA-N,tagatose,Launched,phosphorylase inhibitor,PYGL,,
COc1cn(-c2ccc(-n3cccn3)cc2F)nc(-c2ccnn2-c2ccccc2)c1=O,"InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3",KVHRYLNQDWXAGI-UHFFFAOYSA-N,tak-063,Phase 2,phosphodiesterase inhibitor,PDE10A,,
CC(=O)N1CCC(C(=O)N(CCCN2CCC(Cc3ccc(C(N)=O)cc3)CC2)c2ccc(C)c(Cl)c2)CC1,"InChI=1S/C31H41ClN4O3/c1-22-4-9-28(21-29(22)32)36(31(39)27-12-18-35(19-13-27)23(2)37)15-3-14-34-16-10-25(11-17-34)20-24-5-7-26(8-6-24)30(33)38/h4-9,21,25,27H,3,10-20H2,1-2H3,(H2,33,38)",ASSJTMUEFHUKMJ-UHFFFAOYSA-N,tak-220,Phase 1,CC chemokine receptor antagonist,CCR5,,
NS(=O)(=O)OCC1CC(N=c2cc[nH]c3cc(-c4cccc(SC(F)(F)F)c4)nn23)C(O)C1O,"InChI=1S/C19H20F3N5O5S2/c20-19(21,22)33-12-3-1-2-10(6-12)13-8-16-24-5-4-15(27(16)26-13)25-14-7-11(17(28)18(14)29)9-32-34(23,30)31/h1-6,8,11,14,17-18,24,28-29H,7,9H2,(H2,23,30,31)",VBEKXIGVIUZCNE-UHFFFAOYSA-N,tak-243,Phase 1,ubiquitin activating enzyme inhibitor,,,
CC(C)(O)CC(=O)NCCn1ccc2[nH]cnc(=Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34)",ZYQXEVJIFYIBHZ-UHFFFAOYSA-N,tak-285,Phase 1,EGFR inhibitor,ERBB2,,
Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,"InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)",DZFZXPPHBWCXPQ-UHFFFAOYSA-N,tak-593,Phase 1,VEGFR inhibitor,PDGFRA,,
N#Cc1c(Oc2ccc(F)c(NC(=O)Cc3cccc(C(F)(F)F)c3)c2)ccc2[nH]c(=NC(=O)C3CC3)sc12,"InChI=1S/C27H18F4N4O3S/c28-19-7-6-17(12-21(19)33-23(36)11-14-2-1-3-16(10-14)27(29,30)31)38-22-9-8-20-24(18(22)13-32)39-26(34-20)35-25(37)15-4-5-15/h1-3,6-10,12,15H,4-5,11H2,(H,33,36)(H,34,35,37)",OJFKUJDRGJSAQB-UHFFFAOYSA-N,tak-632,Preclinical,RAF inhibitor,BRAF,,
Cn1cc(-c2nc(NC3CCCCC3N)c(F)c3c[nH]c(O)c23)cn1,"InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6-8,11-12,20,22,25H,2-5,19H2,1H3",JHXFDSRHJRKBTE-UHFFFAOYSA-N,tak-659,Phase 2,spleen associated tyrosine kinase inhibitor,,,
CCc1nc(-c2cccc(C)c2)c(-c2cc[nH]c(=NC(=O)c3ccccc3)c2)s1,"InChI=1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28)",HEKAIDKUDLCBRU-UHFFFAOYSA-N,tak-715,Phase 2,p38 MAPK inhibitor,MAPK14,,
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(CC(O)CO)cnc21,"InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3",RCLQNICOARASSR-UHFFFAOYSA-N,tak-733,Phase 1,MEK inhibitor,MAP2K1,,
Cc1ccc(-c2ccc3c(c2)C=C(C(=O)Nc2ccc(C[N+](C)(C)C4CCOCC4)cc2)CCC3)cc1,"InChI=1S/C33H38N2O2/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2,3)32-17-19-37-20-18-32/h7-16,21-22,32H,4-6,17-20,23H2,1-3H3/p+1",XNHZXMPLVSJQFK-UHFFFAOYSA-O,tak-779,Preclinical,CC chemokine receptor antagonist,,,
Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OCC3CC(=O)O)c1,"InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)",BZCALJIHZVNMGJ-UHFFFAOYSA-N,tak-875,Phase 3,insulin secretagogue,FFAR1,,
CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,"InChI=1S/C28H32N4O3S/c1-5-36(34,35)21-8-6-7-19(14-21)23-15-22(28(33)30-20-9-11-32(4)12-10-20)18(3)26-25(23)24-13-17(2)16-29-27(24)31-26/h6-8,13-16,20H,5,9-12H2,1-4H3,(H,29,31)(H,30,33)",WKDACQVEJIVHMZ-UHFFFAOYSA-N,tak-901,Phase 1,Aurora kinase inhibitor,AURKB,,
COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1N=c1nc2c(c[nH]1)N(C)C(=O)C(F)(F)CN2C1CCCC1,"InChI=1S/C27H34F3N7O3/c1-35-10-8-16(9-11-35)32-24(38)18-12-22(40-3)20(13-19(18)28)33-26-31-14-21-23(34-26)37(17-6-4-5-7-17)15-27(29,30)25(39)36(21)2/h12-14,16-17H,4-11,15H2,1-3H3,(H,32,38)(H,31,33,34)",GWRSATNRNFYMDI-UHFFFAOYSA-N,tak-960,Phase 1,PLK inhibitor,PLK1,,
CC(C)C(N)C(=O)N1CCCC1B(O)O,"InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3",FKCMADOPPWWGNZ-UHFFFAOYSA-N,talabostat,Phase 3,dipeptidyl peptidase inhibitor,DPP4,,
CC(C)C(N)C(=O)N1CCCC1B(O)O,"InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3",FKCMADOPPWWGNZ-UHFFFAOYSA-N,talabostat,Phase 3,fibroblast activation protein inhibitor,DPP4,,
CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1,"InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3",SZBGQDXLNMELTB-UHFFFAOYSA-N,taladegib,Phase 2,smoothened receptor antagonist,DHH|IHH|SMO,,
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2CC1C)OCO3,"InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3",JACAAXNEHGBPOQ-UHFFFAOYSA-N,talampanel,Phase 2,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,
CC=c1c(C)c2[nH]c1=Cc1[nH]c(c(C(=O)O)c1C)C(CC(=O)N=C(CC(=O)O)C(=O)O)c1[nH]c(c(C)c1CCC(=O)O)C=c1[nH]c(c(CC)c1C)=C2,"InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h8,12-14,23,39-40,42-43H,7,9-11,15H2,1-6H3,(H,45,46)(H,47,48)(H,49,50)(H,51,52)",JGEJRWLURAYYGH-UHFFFAOYSA-N,talaporfin,Phase 3,photosensitizing agent,,,
CCC(CC)C(c1ccc(N=c2[nH]c3ccccc3s2)cc1)n1cncn1,"InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)",SNFYYXUGUBUECJ-UHFFFAOYSA-N,talarozole,Phase 2,cytochrome P450 inhibitor,CYP26A1,,
CN1NCNC1=c1c(-c2ccc(F)cc2)nc2cc(F)cc3c(=O)[nH]nc1c23,"InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-7,22-23H,8H2,1H3,(H,26,28)",YGMOBDCMAASSKC-UHFFFAOYSA-N,talazoparib,Launched,PARP inhibitor,PARP2,oncology,breast cancer
CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,"InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)",MXFWWQICDIZSOA-UHFFFAOYSA-N,talinolol,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension
C=CCN1CCc2[nH]c(=N)sc2CC1,"InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)",DHSSDEDRBUKTQY-UHFFFAOYSA-N,talipexole,Launched,adrenergic receptor agonist,ADRA2A|DRD2|HTR3A,infectious disease,genitial herpes
C=CCN1CCc2[nH]c(=N)sc2CC1,"InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)",DHSSDEDRBUKTQY-UHFFFAOYSA-N,talipexole,Launched,dopamine receptor agonist,ADRA2A|DRD2|HTR3A,infectious disease,genitial herpes
CC1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)C(C)CN1Cc1ccc(F)cc1,"InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3",ZMELOYOKMZBMRB-UHFFFAOYSA-N,talmapimod,Phase 2,p38 MAPK inhibitor,IL1B|MAPK11|MAPK14|MT-CO2|TNF,,
CCC(NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,"InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)",BIAVGWDGIJKWRM-UHFFFAOYSA-N,talnetant,Phase 2,tachykinin antagonist,TACR2|TACR3,,
O=C1OC(OC(=O)c2ccc[nH]c2=Nc2cccc(C(F)(F)F)c2)c2ccccc21,"InChI=1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)",ANMLJLFWUCQGKZ-UHFFFAOYSA-N,talniflumate,Launched,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief
CNCCCC1(c2ccccc2)OC(C)(C)c2ccccc21,"InChI=1S/C20H25NO/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16/h4-8,10-13,21H,9,14-15H2,1-3H3",LJBBMCNHIUJBDU-UHFFFAOYSA-N,talopram,Phase 2,adrenergic inhibitor,SLC6A2,,
C#CCOC1CN2CCC1CC2,"InChI=1S/C10H15NO/c1-2-7-12-10-8-11-5-3-9(10)4-6-11/h1,9-10H,3-8H2",XVFJONKUSLSKSW-UHFFFAOYSA-N,talsaclidine,Phase 2/Phase 3,acetylcholine receptor agonist,,,
Cn1c(=O)cc(C(=O)NC(Cc2c[nH]cn2)C(O)N2CCCC2C(N)=O)[nH]c1=O,"InChI=1S/C17H23N7O5/c1-23-13(25)6-10(22-17(23)29)15(27)21-11(5-9-7-19-8-20-9)16(28)24-4-2-3-12(24)14(18)26/h6-8,11-12,16,28H,2-5H2,1H3,(H2,18,26)(H,19,20)(H,21,27)(H,22,29)",ZFPKQDYTSNSALD-UHFFFAOYSA-N,taltirelin,Launched,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia
CNC(C(=O)NC(C(=O)N(C)C(=CC(C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1,"InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-18,21-22,28H,1-10H3,(H,29,31)(H,33,34)",PNBQDOVOFVVZTG-UHFFFAOYSA-N,taltobulin,Phase 1,tubulin polymerization inhibitor,,,
COC(=O)C(CCCN=C(N)N)NS(=O)(=O)c1ccc(C)cc1,"InChI=1S/C14H22N4O4S/c1-10-5-7-11(8-6-10)23(20,21)18-12(13(19)22-2)4-3-9-17-14(15)16/h5-8,12,18H,3-4,9H2,1-2H3,(H4,15,16,17)",FKMJXALNHKIDOD-UHFFFAOYSA-N,tame,Preclinical,,,,
CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,"InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",MUTNCGKQJGXKEM-UHFFFAOYSA-N,tamibarotene,Launched,retinoid receptor agonist,RARA|RARB,hematologic malignancy,acute promyelocytic leukemia (APL)
N=c1[nH]c(-n2cccn2)nc(-n2cccn2)c1Br,"InChI=1S/C10H8BrN7/c11-7-8(12)15-10(18-6-2-4-14-18)16-9(7)17-5-1-3-13-17/h1-6H,(H2,12,15,16)",ATFXVNUWQOXRRU-UHFFFAOYSA-N,taminadenant,Phase 1/Phase 2,adenosine receptor antagonist,,,
CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3",NKANXQFJJICGDU-UHFFFAOYSA-N,tamoxifen,Launched,estrogen receptor antagonist,EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ,oncology,breast cancer
CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3",NKANXQFJJICGDU-UHFFFAOYSA-N,tamoxifen,Launched,selective estrogen receptor modulator (SERM),EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ,oncology,breast cancer
CCOc1ccccc1OCCNC(C)Cc1ccc(OC)c(S(N)(=O)=O)c1,"InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)",DRHKJLXJIQTDTD-UHFFFAOYSA-N,tamsulosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH)
Cn1c(C#N)ccc1-c1ccc2c(c1)C(C)(C)OC(=S)N2,"InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)",PYVFWTPEBMRKSR-UHFFFAOYSA-N,tanaproget,Phase 2,progesterone receptor agonist,PGR,,
Oc1c2c(c(O)n1CCCCN1CCN(c3ncccn3)CC1)C1CCC2C1,"InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-16,27-28H,1-2,4-5,8-14H2",XCISMQWGDMQWLH-UHFFFAOYSA-N,tandospirone,Launched,serotonin receptor agonist,HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)|dysthymic disorder
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,"InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)",UXXQOJXBIDBUAC-UHFFFAOYSA-N,tandutinib,Phase 2,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,,
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,"InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)",UXXQOJXBIDBUAC-UHFFFAOYSA-N,tandutinib,Phase 2,KIT inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,,
COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,"InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)",UXXQOJXBIDBUAC-UHFFFAOYSA-N,tandutinib,Phase 2,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,,
CCC=Nc1c(O)cc2c(O)c1C=C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)=CC=CC(C)C(=O)N2,"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h9-13,15-16,18-19,25,27,29,35-37H,8,14H2,1-7H3,(H2,32,39)(H,34,38)",SJHRVDFSSOGKDR-UHFFFAOYSA-N,tanespimycin,Phase 3,HSP inhibitor,HSP90AA1,,
COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,"InChI=1S/C20H20O7/c1-22-12-8-6-11(7-9-12)14-10-13(21)15-16(23-2)18(24-3)20(26-5)19(25-4)17(15)27-14/h6-10H,1-5H3",ULSUXBXHSYSGDT-UHFFFAOYSA-N,tangeritin,Preclinical,cell cycle inhibitor,,,
O=C(OCC1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,"InChI=1S/C76H52O46/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26/h1-20,52,63-65,76-101H,21H2",LRBQNJMCXXYXIU-UHFFFAOYSA-N,tannic-acid,Launched,PARG inhibitor,ANO1,gastroenterology,constipation
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,"InChI=1S/C18H12O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-8H,1-2H3",AIGAZQPHXLWMOJ-UHFFFAOYSA-N,tanshinone-i,Phase 2,AP inhibitor,IFNG,,
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,"InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3",HYXITZLLTYIPOF-UHFFFAOYSA-N,tanshinone-iia,Phase 2/Phase 3,anti-inflammatory agent,IL1B|NR1I2|TNF,,
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,"InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3",HYXITZLLTYIPOF-UHFFFAOYSA-N,tanshinone-iia,Phase 2/Phase 3,interleukin inhibitor,IL1B|NR1I2|TNF,,
CC(C)c1c(O)cc(C=Cc2ccccc2)cc1O,"InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3",ZISJNXNHJRQYJO-UHFFFAOYSA-N,tapinarof,Phase 3,aryl hydrocarbon receptor agonist,,,
O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1,"InChI=1S/C24H22N4O5S/c29-24(30)18-33-22-5-1-4-20(14-22)17-27(34(31,32)23-6-2-11-25-15-23)16-19-7-9-21(10-8-19)28-13-3-12-26-28/h1-15H,16-18H2,(H,29,30)",MFFBXYNKZHTCEY-UHFFFAOYSA-N,taprenepag,Phase 2,prostaglandin receptor agonist,PTGER2,,
O=C(OC1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1,"InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2",UXZDMXYRRQJIBJ-UHFFFAOYSA-N,tarafenacin,Phase 2,acetylcholine receptor antagonist,CHRM3,,
CC(NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)C(Cc1ccc(Cl)cc1)c1cccc(C#N)c1,"InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)",QLYKJCMUNUWAGO-UHFFFAOYSA-N,taranabant,Phase 3,cannabinoid receptor inverse agonist,CNR1,,
CN=C(N)NCCCC(N)C(=O)O,"InChI=1S/C7H16N4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11)",NTNWOCRCBQPEKQ-UHFFFAOYSA-N,targinine,Phase 3,nitric oxide synthase inhibitor,NOS3,,
COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,"InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)",LGGHDPFKSSRQNS-UHFFFAOYSA-N,tariquidar,Phase 3,P glycoprotein inhibitor,ABCB1,,
O=C(C(=O)C(O)O)C(O)O,"InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h3-4,7-10H",CDNLAQOKAXRAOM-UHFFFAOYSA-N,tartaric-acid,Launched,antioxidant,,,
CN(C)CCN=c1[nH]c2cc(O)ccc2c2c1C(=O)c1ccccc1-2,"InChI=1S/C20H19N3O2/c1-23(2)10-9-21-20-18-17(13-5-3-4-6-14(13)19(18)25)15-8-7-12(24)11-16(15)22-20/h3-8,11,24H,9-10H2,1-2H3,(H,21,22)",ROWSTIYZUWEOMM-UHFFFAOYSA-N,tas-103,Phase 1,topoisomerase inhibitor,TOP1,,
Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,"InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)",BEUQXVWXFDOSAQ-UHFFFAOYSA-N,taselisib,Phase 3,PI3K inhibitor,PIK3CA,,
CCC(=O)NCC1CC1c1cccc2c1CCO2,"InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)",PTOIAAWZLUQTIO-UHFFFAOYSA-N,tasimelteon,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,"InChI=1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)",WWONFUQGBVOKOF-UHFFFAOYSA-N,tasisulam,Phase 3,apoptosis stimulant,,,
COc1cccc2c1c(=O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(O)n2C,"InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,28H,1-3H3",UNRWIPNEFZWESY-UHFFFAOYSA-N,tasquinimod,Phase 3,angiogenesis inhibitor,HDAC4,,
COc1cccc2c1c(=O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(O)n2C,"InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,28H,1-3H3",UNRWIPNEFZWESY-UHFFFAOYSA-N,tasquinimod,Phase 3,S100A9 inhibitor,HDAC4,,
c1cnc(SCc2cccnc2)nc1,"InChI=1S/C10H9N3S/c1-3-9(7-11-4-1)8-14-10-12-5-2-6-13-10/h1-7H,8H2",HMCTXMOKMWELFJ-UHFFFAOYSA-N,tasuldine,Phase 3,mucolytic agent,,,
NCCS(=O)(=O)O,"InChI=1S/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)",XOAAWQZATWQOTB-UHFFFAOYSA-N,taurine,Launched,antioxidant,,neurology/psychiatry,anxiety|irritability|sleeplessness
CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,"InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)",WBWWGRHZICKQGZ-UHFFFAOYSA-N,taurocholate,Phase 1,G protein-coupled receptor agonist,CEL|FABP6|SLCO1C1,,
CC(CCC(=O)NCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C,"InChI=1S/C28H48N2O8S/c1-16(4-7-24(34)30-15-25(35)29-10-11-39(36,37)38)19-5-6-20-26-21(14-23(33)28(19,20)3)27(2)9-8-18(31)12-17(27)13-22(26)32/h16-23,26,31-33H,4-15H2,1-3H3,(H,29,35)(H,30,34)(H,36,37,38)",URJQSMIFSMHWSP-UHFFFAOYSA-N,tauroglycocholate,Preclinical,membrane permeability enhancer,,,
O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1,"InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2",AJKIRUJIDFJUKJ-UHFFFAOYSA-N,taurolidine,Launched,apoptosis stimulant,,infectious disease,catheter-related bloodstream infection
OB1OCc2cc(F)ccc21,"InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2",LFQDNHWZDQTITF-UHFFFAOYSA-N,tavaborole,Launched,leucyl-tRNA synthetase inhibitor,,infectious disease,onychomycosis
NCCCCC1NC(=O)C(CCC(=O)O)NC(=O)c2cc([N+](=O)[O-])ccc2OCCC(C(=O)NCC(=O)O)NC1=O,"InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)",DVJXNXPFYJIACK-UHFFFAOYSA-N,tavilermide,Phase 3,tyrosine kinase partial agonist,,,
O=C1C(O)c2c(O)cc(O)cc2OC1c1ccc(O)c(O)c1,"InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,13,15-20H",BYVWXQRJRYELNP-UHFFFAOYSA-N,taxifolin,Phase 2,opioid receptor antagonist,ADIPOR2,,
CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,"InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3",OGQICQVSFDPSEI-UHFFFAOYSA-N,tazarotene,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRB,dermatology,cosmetic|sunscreen lotion
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,"InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)",NSQSAUGJQHDYNO-UHFFFAOYSA-N,tazemetostat,Launched,histone lysine methyltransferase inhibitor,EZH2,,
CC1(Cn2ccnn2)C(C(=O)O)N2C(=O)CC2S1(=O)=O,"InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)",LPQZKKCYTLCDGQ-UHFFFAOYSA-N,tazobactam,Launched,beta lactamase inhibitor,,infectious disease,pneumonia
O=[N+]([O-])c1cn2c(n1)OCC(OCc1ccc(-c3ccc(OC(F)(F)F)cc3)nc1)C2,"InChI=1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2",ZXSGSFMORAILEY-UHFFFAOYSA-N,tba-354,Phase 1,,,,
NC(C(=O)O)C(OCc1ccccc1)C(=O)O,"InChI=1S/C11H13NO5/c12-8(10(13)14)9(11(15)16)17-6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)",BYOBCYXURWDEDS-UHFFFAOYSA-N,tboa-(dl),Preclinical,excitatory amino acid transporter inhibitor,SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7,,
Cc1cc(=Nc2cc(C)c(C#N)c(=NC(C)CCCC(C)(C)O)[nH]2)[nH][nH]1,"InChI=1S/C19H28N6O/c1-12-9-16(22-17-10-14(3)24-25-17)23-18(15(12)11-20)21-13(2)7-6-8-19(4,5)26/h9-10,13,26H,6-8H2,1-5H3,(H3,21,22,23,24,25)",XHHRGYCOEVNAKV-UHFFFAOYSA-N,tc-a-2317,Preclinical,Aurora kinase inhibitor,AURKA,,
CC(C)(C)c1ccc(C(=O)Nc2cn3cc(-n4ccnc4)ccc3n2)cc1,"InChI=1S/C21H21N5O/c1-21(2,3)16-6-4-15(5-7-16)20(27)24-18-13-26-12-17(8-9-19(26)23-18)25-11-10-22-14-25/h4-14H,1-3H3,(H,24,27)",SMJAMOAYGIVKRI-UHFFFAOYSA-N,tc-ask-10,Preclinical,MAP kinase inhibitor,MAP3K5|MAP3K6,,
O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1,"InChI=1S/C15H27NO4/c17-14(16(20)12-11-15(18)19)8-6-4-2-1-3-5-7-13-9-10-13/h13,20H,1-12H2,(H,18,19)",NEHSERYKENINRH-UHFFFAOYSA-N,tc-e-5002,Preclinical,histone demethylase inhibitor,KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8,,
CC1CCN(C(c2ccc(F)cc2)c2ccc(C(C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1,"InChI=1S/C29H29F4NO2/c1-18-13-15-34(16-14-18)27(21-5-10-24(30)11-6-21)25-12-7-22(19(2)28(35)36)17-26(25)20-3-8-23(9-4-20)29(31,32)33/h3-12,17-19,27H,13-16H2,1-2H3,(H,35,36)",ONYWALXTZFPKAS-UHFFFAOYSA-N,tc-e-5006,Preclinical,gamma secretase modulator,APP,,
CCn1c(=O)n(C2CCCN(c3nccc(-c4cc5ccccc5o4)n3)C2)c2ccccc21,"InChI=1S/C26H25N5O2/c1-2-30-21-10-4-5-11-22(21)31(26(30)32)19-9-7-15-29(17-19)25-27-14-13-20(28-25)24-16-18-8-3-6-12-23(18)33-24/h3-6,8,10-14,16,19H,2,7,9,15,17H2,1H3",NXTBLPPTZRPJCA-UHFFFAOYSA-N,tc-f-2,Preclinical,FAAH inhibitor,FAAH,,
CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C,"InChI=1S/C20H21ClN4O2/c1-13(2)18-17(23-20(27)22-15-11-9-14(21)10-12-15)19(26)25(24(18)3)16-7-5-4-6-8-16/h4-13H,1-3H3,(H2,22,23,27)",PAEBEUZTAPIOIO-UHFFFAOYSA-N,tc-fpr-43,Preclinical,formyl peptide receptor agonist,FPR2,,
Cc1sc(C)c2c1CCC=C2c1c[nH]cn1,"InChI=1S/C13H14N2S/c1-8-10-4-3-5-11(12-6-14-7-15-12)13(10)9(2)16-8/h5-7H,3-4H2,1-2H3,(H,14,15)",RLKWQKZPCMICPS-UHFFFAOYSA-N,tc-g-1000,Preclinical,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,,
COC1CCN(c2cccc(-c3cc(=NC(C)=O)[nH]c(-n4nc(C)cc4C)n3)n2)CC1,"InChI=1S/C22H27N7O2/c1-14-12-15(2)29(27-14)22-25-19(13-20(26-22)23-16(3)30)18-6-5-7-21(24-18)28-10-8-17(31-4)9-11-28/h5-7,12-13,17H,8-11H2,1-4H3,(H,23,25,26,30)",JENSDTKXNVHSSN-UHFFFAOYSA-N,tc-g-1004,Preclinical,adenosine receptor antagonist,ADORA2A,,
Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc32)c1,"InChI=1S/C25H25N3O2/c1-17-7-8-18(2)24(15-17)30-23-11-12-26-16-20(23)25(29)28-14-13-27(19-9-10-19)21-5-3-4-6-22(21)28/h3-8,11-12,15-16,19H,9-10,13-14H2,1-2H3",JQULIQJSYPZQMA-UHFFFAOYSA-N,tc-g-1005,Preclinical,G protein-coupled receptor agonist,GPBAR1,,
CN=c1[nH]c(-c2ccccn2)cc(=NCc2ccc(NS(C)(=O)=O)cc2Cl)[nH]1,"InChI=1S/C18H19ClN6O2S/c1-20-18-23-16(15-5-3-4-8-21-15)10-17(24-18)22-11-12-6-7-13(9-14(12)19)25-28(2,26)27/h3-10,25H,11H2,1-2H3,(H2,20,22,23,24)",DRSZMILOMUPIBJ-UHFFFAOYSA-N,tc-g-1008,Preclinical,G protein-coupled receptor agonist,GPR39,,
Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1,"InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)",WTKBRPXPNAKVEQ-UHFFFAOYSA-N,tc-h-106,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CC1(C)SCN(S(=O)(=O)c2ccccc2)C1C(=O)NC(CNC(=O)NCc1ccccc1)C(=O)O,"InChI=1S/C23H28N4O6S2/c1-23(2)19(27(15-34-23)35(32,33)17-11-7-4-8-12-17)20(28)26-18(21(29)30)14-25-22(31)24-13-16-9-5-3-6-10-16/h3-12,18-19H,13-15H2,1-2H3,(H,26,28)(H,29,30)(H2,24,25,31)",XKLHCUGVLCGKKX-UHFFFAOYSA-N,tc-i-15,Preclinical,integrin inhibitor,ITGA2|ITGB1,,
O=C(Nc1ccc(F)cc1)N1CCc2ccccc2C1c1ccc(C(F)(F)F)cc1,"InChI=1S/C23H18F4N2O/c24-18-9-11-19(12-10-18)28-22(30)29-14-13-15-3-1-2-4-20(15)21(29)16-5-7-17(8-6-16)23(25,26)27/h1-12,21H,13-14H2,(H,28,30)",ADCDUDFEGFKKQH-UHFFFAOYSA-N,tc-i-2000,Preclinical,transient receptor potential channel antagonist,TRPM8,,
FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1,"InChI=1S/C23H19F6N3O/c24-22(25,26)15-7-3-2-6-14(15)13-10-16(23(27,28)29)19-17(11-13)30-20(31-19)18-12-21(33-32-18)8-4-1-5-9-21/h2-3,6-7,10-11H,1,4-5,8-9,12H2,(H,30,31)",VSMFCZZEKTVDHM-UHFFFAOYSA-N,tc-i-2014,Preclinical,transient receptor potential channel antagonist,TRPM8,,
COc1cccc(-n2nc(C(=O)O)cc2-c2ccc(C3CCCCC3)c(Cl)c2)c1,"InChI=1S/C23H23ClN2O3/c1-29-18-9-5-8-17(13-18)26-22(14-21(25-26)23(27)28)16-10-11-19(20(24)12-16)15-6-3-2-4-7-15/h5,8-15H,2-4,6-7H2,1H3,(H,27,28)",BNALUYKEGYUHQC-UHFFFAOYSA-N,tc-lpa5-4,Preclinical,lysophosphatidic acid receptor antagonist,LPAR5,,
CC(C)(C)N=c1[nH]c(Nc2ccc(C(N)=O)cc2)cc(N)c1C#N,"InChI=1S/C17H20N6O/c1-17(2,3)23-16-12(9-18)13(19)8-14(22-16)21-11-6-4-10(5-7-11)15(20)24/h4-8H,1-3H3,(H2,20,24)(H4,19,21,22,23)",XDEFNAWAKYQBQY-UHFFFAOYSA-N,tc-mps1-12,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,
CC(=O)Nc1cccc(N=c2nc(N3CCC(OCc4ccc(OC(F)(F)F)cc4)CC3)nc[nH]2)c1C,"InChI=1S/C25H27F3N6O3/c1-16-21(31-17(2)35)4-3-5-22(16)32-23-29-15-30-24(33-23)34-12-10-19(11-13-34)36-14-18-6-8-20(9-7-18)37-25(26,27)28/h3-9,15,19H,10-14H2,1-2H3,(H,31,35)(H,29,30,32,33)",QLKAFHZJICDACE-UHFFFAOYSA-N,tc-n-1752,Preclinical,sodium channel blocker,SCN9A,,
COc1cccc(OC)c1-c1cc(C(=O)NC(CC(C)C)C(=O)O)nn1-c1ccnc2cc(Cl)ccc12,"InChI=1S/C27H27ClN4O5/c1-15(2)12-20(27(34)35)30-26(33)19-14-22(25-23(36-3)6-5-7-24(25)37-4)32(31-19)21-10-11-29-18-13-16(28)8-9-17(18)21/h5-11,13-15,20H,12H2,1-4H3,(H,30,33)(H,34,35)",ZQUSYVORYNBGLG-UHFFFAOYSA-N,tc-ntr1-17,Preclinical,neurotensin agonist,NTSR1,,
COc1cc(OC)cc(C(=O)NNC(=O)Nc2cccc3ccccc23)c1,"InChI=1S/C20H19N3O4/c1-26-15-10-14(11-16(12-15)27-2)19(24)22-23-20(25)21-18-9-5-7-13-6-3-4-8-17(13)18/h3-12H,1-2H3,(H,22,24)(H2,21,23,25)",KPTMSQHTGZMEFU-UHFFFAOYSA-N,tc-o-9311,Preclinical,G protein-coupled receptor agonist,GPR139,,
Cc1cc(C(=O)N2Cc3cnn(C)c3Nc3ccccc32)ccc1CNC(=O)N1CCCC1C(=S)N1CCCN(C)CC1,"InChI=1S/C32H40N8O2S/c1-22-18-23(30(41)40-21-25-20-34-37(3)29(25)35-26-8-4-5-9-27(26)40)11-12-24(22)19-33-32(42)39-15-6-10-28(39)31(43)38-14-7-13-36(2)16-17-38/h4-5,8-9,11-12,18,20,28,35H,6-7,10,13-17,19,21H2,1-3H3,(H,33,42)",KSNHHKZYKYNBEI-UHFFFAOYSA-N,tc-ot-39,Preclinical,oxytocin receptor agonist,AVPR1A|OXT,,
Cc1cc(C(=O)N2Cc3cnn(C)c3Nc3ccccc32)ccc1CNC(=O)N1CCCC1C(=S)N1CCCN(C)CC1,"InChI=1S/C32H40N8O2S/c1-22-18-23(30(41)40-21-25-20-34-37(3)29(25)35-26-8-4-5-9-27(26)40)11-12-24(22)19-33-32(42)39-15-6-10-28(39)31(43)38-14-7-13-36(2)16-17-38/h4-5,8-9,11-12,18,20,28,35H,6-7,10,13-17,19,21H2,1-3H3,(H,33,42)",KSNHHKZYKYNBEI-UHFFFAOYSA-N,tc-ot-39,Preclinical,vasopressin receptor agonist,AVPR1A|OXT,,
Cc1cccc(C)c1-n1c(=O)c2c[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)nc2n2c3ccccc3nc12,"InChI=1S/C31H30N8O/c1-20-7-6-8-21(2)27(20)39-29(40)24-19-32-30(35-28(24)38-26-10-5-4-9-25(26)34-31(38)39)33-22-11-13-23(14-12-22)37-17-15-36(3)16-18-37/h4-14,19H,15-18H2,1-3H3,(H,32,33,35)",BHJJWVDKNXABFS-UHFFFAOYSA-N,tc-s-7003,Preclinical,SRC inhibitor,LCK,,
COc1ncc2cc(C(=O)Nc3cc(C(=O)NCc4cccc(Cl)c4)ccc3Cl)c(=O)[nH]c2n1,"InChI=1S/C23H17Cl2N5O4/c1-34-23-27-11-14-8-16(22(33)29-19(14)30-23)21(32)28-18-9-13(5-6-17(18)25)20(31)26-10-12-3-2-4-15(24)7-12/h2-9,11H,10H2,1H3,(H,26,31)(H,28,32)(H,27,29,30,33)",CQKBSRPVZZLCJE-UHFFFAOYSA-N,tc-s-7004,Preclinical,DYRK inhibitor,DYRK1A|DYRK1B,,
CC(N=c1cc2c(-c3ccc4c(c3)OCO4)noc2c[nH]1)c1ccccc1,"InChI=1S/C21H17N3O3/c1-13(14-5-3-2-4-6-14)23-20-10-16-19(11-22-20)27-24-21(16)15-7-8-17-18(9-15)26-12-25-17/h2-11,13H,12H2,1H3,(H,22,23)",DAAGOCSHXCDWDY-UHFFFAOYSA-N,tc-s-7005,Preclinical,PLK inhibitor,PLK2,,
N#Cc1c[nH]c2c[nH]c(=NCc3cccnc3)cc2c1=Nc1ccc(F)c(Cl)c1,"InChI=1S/C21H14ClFN6/c22-17-6-15(3-4-18(17)23)29-21-14(8-24)11-26-19-12-28-20(7-16(19)21)27-10-13-2-1-5-25-9-13/h1-7,9,11-12H,10H2,(H,26,29)(H,27,28)",NMEUKWOOQOHUNA-UHFFFAOYSA-N,tc-s-7006,Preclinical,MAP kinase inhibitor,MAP3K8,,
O=[N+]([O-])c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12,"InChI=1S/C12H6ClFN4O3/c13-6-3-7(14)5-8(4-6)15-10-2-1-9-11(17-21-16-9)12(10)18(19)20/h1-5,15H",CDQUJZKBRAFWNG-UHFFFAOYSA-N,tc-s-7009,Preclinical,hypoxia inducible factor inhibitor,EPAS1,,
O=C(O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1,"InChI=1S/C25H20F2N2O2S/c26-20-4-2-1-3-17(20)9-15-6-8-23-22(11-15)28-24(32-23)19-7-5-16(10-21(19)27)12-29-13-18(14-29)25(30)31/h1-8,10-11,18H,9,12-14H2,(H,30,31)",GVXGVDIXINMAAL-UHFFFAOYSA-N,tc-sp-14,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,
OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1,"InChI=1S/C19H20FNO/c20-9-3-1-2-8(6-9)4-5-21-18-14-10-7-11-13-12(10)15(18)17(13)19(21,22)16(11)14/h1-3,6,10-18,22H,4-5,7H2",FYGREZKTJIXWIH-UHFFFAOYSA-N,tc1,Preclinical,beta-secretase inhibitor,BACE1,,
CCOc1cncc(C=CCCNC)c1,"InChI=1S/C12H18N2O/c1-3-15-12-8-11(9-14-10-12)6-4-5-7-13-2/h4,6,8-10,13H,3,5,7H2,1-2H3",HFZDMKMXPGRKCK-UHFFFAOYSA-N,tc2559,Preclinical,acetylcholine receptor agonist,CHRNA4,,
O=C1CC(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c21,InChI=1S/C9H2Cl4O2/c10-6-4-2(14)1-3(15)5(4)7(11)9(13)8(6)12/h1H2,IDLAOWFFKWRNHB-UHFFFAOYSA-N,tcid,Preclinical,,,,
O=C(NNC(=O)c1ccc(CNS(=O)(=O)c2ccc(F)c(Cl)c2)cc1)c1ccccc1,"InChI=1S/C21H17ClFN3O4S/c22-18-12-17(10-11-19(18)23)31(29,30)24-13-14-6-8-16(9-7-14)21(28)26-25-20(27)15-4-2-1-3-5-15/h1-12,24H,13H2,(H,25,27)(H,26,28)",FYIBXBFDXNPBSF-UHFFFAOYSA-N,tcn201,Preclinical,glutamate receptor antagonist,GRIN2A,,
N=c1nc(C=Cc2ccccc2)cc[nH]1,"InChI=1S/C12H11N3/c13-12-14-9-8-11(15-12)7-6-10-4-2-1-3-5-10/h1-9H,(H2,13,14,15)",LNUXNUNUGIHCPA-UHFFFAOYSA-N,tcn238,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
Cc1nnc(-c2ccc3occ(-c4ccc([S+](C)[O-])cc4)c3c2)o1,"InChI=1S/C18H14N2O3S/c1-11-19-20-18(23-11)13-5-8-17-15(9-13)16(10-22-17)12-3-6-14(7-4-12)24(2)21/h3-10H,1-2H3",RCKYSTKYIVULEK-UHFFFAOYSA-N,tcs-2002,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,
CC(C)(O)C(=O)N1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1,"InChI=1S/C27H25F3N4O4/c1-26(2,38)25(37)34-11-9-33(10-12-34)15-7-8-19(27(28,29)30)17(13-15)21-22(24(36)32-23(21)35)18-14-31-20-6-4-3-5-16(18)20/h3-8,13-14,31,38H,9-12H2,1-2H3,(H,32,35,36)",CLGRAWDGLMENOD-UHFFFAOYSA-N,tcs-21311,Preclinical,JAK inhibitor,JAK3,,
O=c1[nH]c2ccc(C(O)=NO)cc2nc1CCCc1ccccc1,"InChI=1S/C18H17N3O3/c22-17(21-24)13-9-10-14-16(11-13)19-15(18(23)20-14)8-4-7-12-5-2-1-3-6-12/h1-3,5-6,9-11,24H,4,7-8H2,(H,20,23)(H,21,22)",ZOFZKGFBKISZRI-UHFFFAOYSA-N,tcs-2210,Preclinical,neural stem cell inducer,,,
Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOCC2C(=O)N2CCC(CC(=O)O)CC2)cc1,"InChI=1S/C28H34N4O6/c1-19-4-2-3-5-23(19)30-28(37)29-22-8-6-20(7-9-22)16-25(33)32-14-15-38-18-24(32)27(36)31-12-10-21(11-13-31)17-26(34)35/h2-9,21,24H,10-18H2,1H3,(H,34,35)(H2,29,30,37)",ITXAAOWFOURIHK-UHFFFAOYSA-N,tcs-2314,Preclinical,integrin inhibitor,ITGA4|ITGB1,,
O=C(O)COc1ccc(C=C2SC(=O)NC2=O)cc1,"InChI=1S/C12H9NO5S/c14-10(15)6-18-8-3-1-7(2-4-8)5-9-11(16)13-12(17)19-9/h1-5H,6H2,(H,14,15)(H,13,16,17)",WXMCOLGPDOYHNK-UHFFFAOYSA-N,tcs-3035,Preclinical,G protein-coupled receptor agonist,GPR35,,
COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC,"InChI=1S/C18H20N2O4S/c1-23-12-8-7-10(9-13(12)24-2)17(22)20-18-15(16(19)21)11-5-3-4-6-14(11)25-18/h7-9H,3-6H2,1-2H3,(H2,19,21)(H,20,22)",FSPQCTGGIANIJZ-UHFFFAOYSA-N,tcs-359,Preclinical,FLT3 inhibitor,FLT3,,
CCC(C)c1ccc(NC(=O)Cn2cnc3c2c(=O)n(C)c(=O)n3C)cc1,"InChI=1S/C19H23N5O3/c1-5-12(2)13-6-8-14(9-7-13)21-15(25)10-24-11-20-17-16(24)18(26)23(4)19(27)22(17)3/h6-9,11-12H,5,10H2,1-4H3,(H,21,25)",ZUTUWJYMCADJHD-UHFFFAOYSA-N,tcs-5861528,Preclinical,transient receptor potential channel antagonist,TRPA1,,
CC(C)C(=O)SCCCCCC(NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2,"InChI=1S/C26H44N2O4S/c1-17(2)23(30)33-10-8-6-7-9-21(27-24(31)32-25(3,4)5)22(29)28-26-14-18-11-19(15-26)13-20(12-18)16-26/h17-21H,6-16H2,1-5H3,(H,27,31)(H,28,29)",DQZMLPMCOMRJOR-UHFFFAOYSA-N,tcs-hdac6-20b,Preclinical,HDAC inhibitor,HDAC6,,
COc1cc2c(cc1OC)CN(C(=O)C(NCc1ccncc1)C(C)(C)C)CC2,"InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3",COFVZFLCAOUMJT-UHFFFAOYSA-N,tcs-ox2-29,Preclinical,orexin receptor antagonist,HCRTR2,,
N#Cc1c(-c2ccccc2)cc(-c2cc(Br)ccc2O)[nH]c1=O,"InChI=1S/C18H11BrN2O2/c19-12-6-7-17(22)14(8-12)16-9-13(11-4-2-1-3-5-11)15(10-20)18(23)21-16/h1-9,22H,(H,21,23)",SVSYJTYGPLVUOZ-UHFFFAOYSA-N,tcs-pim-1-1,Preclinical,Pim kinase inhibitor,PIM1,,
CCC[n+]1cc(Br)cc(C(=O)N(CCC(=O)NCCOC(=O)N2CCc3ccccc3C2)c2ccccc2)c1,"InChI=1S/C30H33BrN4O4/c1-2-15-33-20-25(19-26(31)22-33)29(37)35(27-10-4-3-5-11-27)17-13-28(36)32-14-18-39-30(38)34-16-12-23-8-6-7-9-24(23)21-34/h3-11,19-20,22H,2,12-18,21H2,1H3/p+1",NWWZMECSQFUIGC-UHFFFAOYSA-O,tcv-309,Preclinical,platelet activating factor receptor antagonist,,,
OCC1OC(SC2OC(CO)C(O)C(n3cc(-c4cccc(F)c4)nn3)C2O)C(O)C(n2cc(-c3cccc(F)c3)nn2)C1O,"InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2",YGIDGBAHDZEYMT-UHFFFAOYSA-N,td139,Phase 2,anti-inflammatory agent,,,
CC(O)C1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(SC3CN(C4=NCCS4)C3)C(C)C12,"InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3",SNUDIPVBUUXCDG-UHFFFAOYSA-N,tebipenem,Launched,bacterial cell wall synthesis inhibitor,CNR1,infectious disease|otolaryngology,pneumonia|otitis
OCC1OC(n2cnc3c(=NC4CCOC4)[nH]cnc32)C(O)C1O,"InChI=1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)",OESBDSFYJMDRJY-UHFFFAOYSA-N,tecadenoson,Phase 2,adenosine receptor agonist,ADORA1,,
COc1cccc(C(C)NCCCc2ccccc2Cl)c1,"InChI=1S/C18H22ClNO/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3",ZVQUCWXZCKWZBP-UHFFFAOYSA-N,tecalcet,Phase 2,calcium-sensing receptor agonist,CASR,,
Fc1ccc(Cn2c(=NC3CCNCC3)[nH]c3ccccc32)cc1,"InChI=1S/C19H21FN4/c20-15-7-5-14(6-8-15)13-24-18-4-2-1-3-17(18)23-19(24)22-16-9-11-21-12-10-16/h1-8,16,21H,9-13H2,(H,22,23)",SFOVDSLXFUGAIV-UHFFFAOYSA-N,tecastemizole,Phase 3,histamine receptor antagonist,KCNH2,,
O=C(Nn1c(O)c2c(c1O)C1C=CC2C2CC12)c1ccc(C(F)(F)F)cc1,"InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-13,26-27H,7H2,(H,23,25)",PFTCYSLXMGONAY-UHFFFAOYSA-N,tecovirimat,Launched,orthopoxvirus egress inhibitor,,infectious disease,smallpox
Cn1nnc(-c2ccc(-c3ccc(N4CC(CO)OC4=O)cc3F)cn2)n1,"InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3",XFALPSLJIHVRKE-UHFFFAOYSA-N,tedizolid,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,skin infections
Cn1nnc(-c2ccc(-c3ccc(N4CC(CO[PH](=O)(=O)O)OC4=O)cc3F)cn2)n1,"InChI=1S/C17H15FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H,26,27,28)",ZZEMPAYSEHOMNO-UHFFFAOYSA-N,tedizolid-phosphate,Launched,protein synthesis inhibitor,,infectious disease,skin infections
CCCCCN=C(N)NN=Cc1c[nH]c2ccc(OC)cc12,"InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)",IKBKZGMPCYNSLU-UHFFFAOYSA-N,tegaserod,Withdrawn,serotonin receptor partial agonist,HTR2A|HTR2B|HTR2C|HTR4,,
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1,"InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2",XBEQSQDCBSKCHJ-UHFFFAOYSA-N,tegobuvir,Phase 3,HCV inhibitor,,,
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1,"InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2",XBEQSQDCBSKCHJ-UHFFFAOYSA-N,tegobuvir,Phase 3,protease inhibitor,,,
CCCCCCCCCC(=O)NC1C(Oc2c3cc4cc2Oc2ccc(cc2Cl)C(OC2OC(CO)C(O)C(O)C2NC(C)=O)c2[nH]c(O)c(c5ccc(O)c(c5)c5c(OC6OC(CO)C(O)C(O)C6O)cc(O)cc5c(=C(O)O)[nH]c2O)NC(=O)C4NC(=O)C2NC(=O)C(Cc4ccc(c(Cl)c4)O3)NC(=O)C(N)c3ccc(O)c(c3)Oc3cc(O)cc2c3)OC(CO)C(O)C1O,"InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62,64-65,67-68,70-77,86-88,98-102,104-107,109-115,118,121-123H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)",RAXMVMGVQGYZCD-UHFFFAOYSA-N,teicoplanin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CCCCCC=CCCC(=O)NC1C(Oc2c3cc4cc2Oc2ccc(cc2Cl)C(OC2OC(CO)C(O)C(O)C2NC(C)=O)c2[nH]c(O)c(c5ccc(O)c(c5)c5c(OC6OC(CO)C(O)C(O)C6O)cc(O)cc5c(=C(O)O)[nH]c2O)NC(=O)C4NC(=O)C2NC(=O)C(Cc4ccc(c(Cl)c4)O3)NC(=O)C(N)c3ccc(O)c(c3)Oc3cc(O)cc2c3)OC(CO)C(O)C1O,"InChI=1S/C88H95Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h7-8,11-19,21-30,48,57-59,62,64-65,67-68,70-77,86-88,98-102,104-107,109-115,118,121-123H,3-6,9-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)",LOUVESMXBKJVJH-UHFFFAOYSA-N,teicoplanin-a2-1,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
CC(=O)NC1C(OC2c3ccc(c(Cl)c3)Oc3cc4cc(c3OC3OC(CO)C(O)C(O)C3NC(=O)CCCCCCCC(C)C)Oc3ccc(cc3Cl)CC3NC(=O)C(N)c5ccc(O)c(c5)Oc5cc(O)cc(c5)C(NC3=O)C(=O)NC4C(=O)Nc3c(O)[nH]c2c(O)[nH]c(=C(O)O)c2cc(O)cc(OC4OC(CO)C(O)C(O)C4O)c2c2cc3ccc2O)OC(CO)C(O)C1O,"InChI=1S/C89H99Cl2N9O33/c1-34(2)9-7-5-4-6-8-10-61(109)95-69-75(114)72(111)59(32-102)130-88(69)133-79-56-26-41-27-57(79)127-53-18-14-39(24-48(53)91)78(132-87-68(93-35(3)104)74(113)71(110)58(31-101)129-87)70-85(122)99-67(86(123)124)46-29-43(106)30-55(128-89-77(116)76(115)73(112)60(33-103)131-89)62(46)45-23-38(13-15-50(45)107)64(82(119)100-70)97-84(121)66(41)98-83(120)65-40-21-42(105)28-44(22-40)125-54-25-37(12-16-51(54)108)63(92)81(118)94-49(80(117)96-65)20-36-11-17-52(126-56)47(90)19-36/h11-19,21-30,34,49,58-60,63,65-66,68-69,71-78,87-89,99-103,105-108,110-116,119,122-124H,4-10,20,31-33,92H2,1-3H3,(H,93,104)(H,94,118)(H,95,109)(H,96,117)(H,97,121)(H,98,120)",UEFCQVYZPMSWCP-UHFFFAOYSA-N,teicoplanin-a2-3,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,gram-positive bacterial infections
O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccc(Cl)cc2)C1,"InChI=1S/C21H21ClF3N3O2/c22-17-6-4-14(5-7-17)12-28-9-8-18(13-28)27-19(29)11-26-20(30)15-2-1-3-16(10-15)21(23,24)25/h1-7,10,18H,8-9,11-13H2,(H,26,30)(H,27,29)",BAOQJSULMWXFRK-UHFFFAOYSA-N,teijin-compound-1,Preclinical,CC chemokine receptor antagonist,CCR2,,
CCCC(NC(=O)C1C2CCCC2CN1C(=O)C(NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,"InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)",BBAWEDCPNXPBQM-UHFFFAOYSA-N,telaprevir,Launched,HCV inhibitor,CTSA|PGR,infectious disease,hepatitis C
CNC(=O)c1cc(COc2n[nH]c(=Nc3ccc(Cl)cc3)c3ccoc23)ccn1,"InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)",QFCXANHHBCGMAS-UHFFFAOYSA-N,telatinib,Phase 2,KIT inhibitor,KDR,,
CNC(=O)c1cc(COc2n[nH]c(=Nc3ccc(Cl)cc3)c3ccoc23)ccn1,"InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)",QFCXANHHBCGMAS-UHFFFAOYSA-N,telatinib,Phase 2,PDGFR tyrosine kinase receptor inhibitor,KDR,,
CNC(=O)c1cc(COc2n[nH]c(=Nc3ccc(Cl)cc3)c3ccoc23)ccn1,"InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)",QFCXANHHBCGMAS-UHFFFAOYSA-N,telatinib,Phase 2,VEGFR inhibitor,KDR,,
Cc1cn(C2CC(O)C(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)",IQFYYKKMVGJFEH-UHFFFAOYSA-N,telbivudine,Launched,DNA polymerase inhibitor,,infectious disease,hepatitis B
O=C(NC1CCC(c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,"InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)",CGDZXLJGHVKVIE-UHFFFAOYSA-N,telcagepant,Phase 3,calcitonin antagonist,CALCRL|RAMP1,,
Cc1scc2c1N(C(=O)CN1CCN(C)CC1)c1ccccc1NC2=O,"InChI=1S/C19H22N4O2S/c1-13-18-14(12-26-13)19(25)20-15-5-3-4-6-16(15)23(18)17(24)11-22-9-7-21(2)8-10-22/h3-6,12H,7-11H2,1-2H3,(H,20,25)",VSWPGAIWKHPTKX-UHFFFAOYSA-N,telenzepine,Phase 3,acetylcholine receptor antagonist,CHRM1,,
CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)OC12C,"InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3",LJVAJPDWBABPEJ-UHFFFAOYSA-N,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor,CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7,infectious disease,pneumonia
CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)OC12C,"InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3",LJVAJPDWBABPEJ-UHFFFAOYSA-N,telithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7,infectious disease,pneumonia
CCOC(=O)N1CSCC1C(=O)O,"InChI=1S/C7H11NO4S/c1-2-12-7(11)8-4-13-3-5(8)6(9)10/h5H,2-4H2,1H3,(H,9,10)",XBJWOGLKABXFJE-UHFFFAOYSA-N,telmesteine,Launched,mucolytic agent,,pulmonary,cough suppressant
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",RMMXLENWKUUMAY-UHFFFAOYSA-N,telmisartan,Launched,angiotensin receptor antagonist,AGTR1|PPARG,cardiology,hypertension
Cc1ccn(-c2cc(Cl)ccc2C(Oc2cc(-c3ccc(CC(N)C(=O)O)cc3)[nH]c(=N)n2)C(F)(F)F)n1,"InChI=1S/C25H22ClF3N6O3/c1-13-8-9-35(34-13)20-11-16(26)6-7-17(20)22(25(27,28)29)38-21-12-19(32-24(31)33-21)15-4-2-14(3-5-15)10-18(30)23(36)37/h2-9,11-12,18,22H,10,30H2,1H3,(H,36,37)(H2,31,32,33)",NCLGDOBQAWBXRA-UHFFFAOYSA-N,telotristat,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea
CCOC(=O)C(N)Cc1ccc(-c2cc(OC(c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)[nH]c(=N)n2)cc1,"InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)",MDSQOJYHHZBZKA-UHFFFAOYSA-N,telotristat-ethyl,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea
CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(=N)[nH]c3ccccc3c21,"InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42)",RRTPWQXEERTRRK-UHFFFAOYSA-N,telratolimod,Preclinical,toll-like receptor agonist,,,
COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1,"InChI=1S/C24H28N4O4/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28/h3-9,16-17H,10-15H2,1-2H3,(H,26,29)",ZEOQUKRCASTCFR-UHFFFAOYSA-N,temanogrel,Preclinical,serotonin receptor antagonist,,,
COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1,"InChI=1S/C16H20O6P2S3/c1-17-23(25,18-2)21-13-5-9-15(10-6-13)27-16-11-7-14(8-12-16)22-24(26,19-3)20-4/h5-12H,1-4H3",WWJZWCUNLNYYAU-UHFFFAOYSA-N,temefos,Launched,cholinesterase inhibitor,,,
CCOC(=O)C(CCc1ccccc1)NC1CSC(c2cccs2)CN(CC(=O)O)C1=O,"InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)",FIQOFIRCTOWDOW-UHFFFAOYSA-N,temocapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology|nephrology,hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)
Oc1cccc(C2=c3ccc([nH]3)=C(c3cccc(O)c3)c3ccc([nH]3)C(c3cccc(O)c3)=c3ccc([nH]3)=C(c3cccc(O)c3)c3ccc2[nH]3)c1,"InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-24,45-52H",HCNNZWKIHZUMHS-UHFFFAOYSA-N,temoporfin,Launched,radical formation stimulant,,oncology,head and neck squamous cell carcinoma (HNSCC)
Cn1nnc2c(C(N)=O)ncn2c1=O,"InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)",BPEGJWRSRHCHSN-UHFFFAOYSA-N,temozolomide,Launched,DNA alkylating agent,MGMT,oncology,glioblastoma|astrocytoma
CC1(C)CC(O)CC(C)(C)N1O,"InChI=1S/C9H19NO2/c1-8(2)5-7(11)6-9(3,4)10(8)12/h7,11-12H,5-6H2,1-4H3",CSGAUKGQUCHWDP-UHFFFAOYSA-N,tempol,Phase 2,free radical scavenger,,,
COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,36-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3",ZWYQUVBAZLHTHP-UHFFFAOYSA-N,temsirolimus,Launched,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC)
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=NC(CC(=O)NCCCN1CCN(C)CC1)c1nnc(C)n1-2,"InChI=1S/C27H34ClN7OS/c1-17-18(2)37-27-24(17)25(20-6-8-21(28)9-7-20)30-22(26-32-31-19(3)35(26)27)16-23(36)29-10-5-11-34-14-12-33(4)13-15-34/h6-9,22H,5,10-16H2,1-4H3,(H,29,36)",PKQXLRYFPSZKDU-UHFFFAOYSA-N,ten-010,Preclinical,bromodomain inhibitor,,,
CCC(N=c1[nH]cnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,"InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)",HDXDQPRPFRKGKZ-UHFFFAOYSA-N,tenalisib,Phase 2,PI3K inhibitor,,,
CN1Cc2c(Cl)cc(Cl)cc2C(c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc(C4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1,"InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)",DNHPDWGIXIMXSA-UHFFFAOYSA-N,tenapanor,Launched,sodium/hydrogen exchanger inhibitor,,,
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2n1,"InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20)",ZBFDAUIVDSSISP-UHFFFAOYSA-N,tenatoprazole,Phase 2,ATPase inhibitor,IDO1,,
Cc1cc(N2CCN(C3CNC(C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,"InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3",WGRQANOPCQRCME-UHFFFAOYSA-N,teneligliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21,"InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20)",IZSFDUMVCVVWKW-UHFFFAOYSA-N,tenidap,Phase 3,cyclooxygenase inhibitor,KCNJ4|PTGS1,,
O=C1NCCNC1c1cccs1,"InChI=1S/C8H10N2OS/c11-8-7(9-3-4-10-8)6-2-1-5-12-6/h1-2,5,7,9H,3-4H2,(H,10,11)",BBACKDMGYMXYLE-UHFFFAOYSA-N,tenilsetam,Phase 3,AGE inhibitor,,,
COc1cc(C2c3cc4c(cc3C(OC3OC5COC(c6cccs6)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O,"InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3",NRUKOCRGYNPUPR-UHFFFAOYSA-N,teniposide,Launched,topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute lymphoblastic leukemia (ALL)
CC(Cn1cnc2c(=N)[nH]cnc21)OC[PH](=O)(=O)O,"InChI=1S/C9H13N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H,15,16,17)",WUCSXTDWYHOFKK-UHFFFAOYSA-N,tenofovir,Launched,HIV integrase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B
CC(Cn1cnc2c(=N)[nH]cnc21)OC[PH](=O)(=O)O,"InChI=1S/C9H13N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H,15,16,17)",WUCSXTDWYHOFKK-UHFFFAOYSA-N,tenofovir,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B
CC(C)OC(=O)C(C)NP(=O)(COC(C)Cn1cnc2c(=N)[nH]cnc21)Oc1ccccc1,"InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)",LDEKQSIMHVQZJK-UHFFFAOYSA-N,tenofovir-alafenamide,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,hepatitis B
CC(C)OC(=O)OCOP(=O)(COC(C)Cn1cnc2c(=N)[nH]cnc21)OCOC(=O)OC(C)C,"InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)",JFVZFKDSXNQEJW-UHFFFAOYSA-N,tenofovir-disoproxil,Launched,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B
CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(C(C)(C)C)cc2)cc1,"InChI=1S/C20H23N3O2S/c1-13(24)21-16-9-11-17(12-10-16)22-19(26)23-18(25)14-5-7-15(8-6-14)20(2,3)4/h5-12H,1-4H3,(H,21,24)(H2,22,23,25,26)",WOWJIWFCOPZFGV-UHFFFAOYSA-N,tenovin-1,Preclinical,SIRT inhibitor,SIRT1,,
CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(C(C)(C)C)cc2)cc1,"InChI=1S/C20H23N3O2S/c1-13(24)21-16-9-11-17(12-10-16)22-19(26)23-18(25)14-5-7-15(8-6-14)20(2,3)4/h5-12H,1-4H3,(H,21,24)(H2,22,23,25,26)",WOWJIWFCOPZFGV-UHFFFAOYSA-N,tenovin-1,Preclinical,TP53 activator,SIRT1,,
CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(C(C)(C)C)cc2)cc1,"InChI=1S/C25H34N4O2S/c1-25(2,3)19-11-9-18(10-12-19)23(31)28-24(32)27-21-15-13-20(14-16-21)26-22(30)8-6-7-17-29(4)5/h9-16H,6-8,17H2,1-5H3,(H,26,30)(H2,27,28,31,32)",BVJSXSQRIUSRCO-UHFFFAOYSA-N,tenovin-6,Preclinical,SIRT inhibitor,SIRT1|SIRT2|SIRT3,,
CN1C(C(=O)N=c2cccc[nH]2)C(=O)c2sccc2S1(=O)=O,"InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,10H,1H3,(H,14,15,18)",OTGJPAOGHQFBMI-UHFFFAOYSA-N,tenoxicam,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|orthopedics,rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis
O=C1C(=Cc2cccs2)CCCC1=Cc1cccs1,"InChI=1S/C16H14OS2/c17-16-12(10-14-6-2-8-18-14)4-1-5-13(16)11-15-7-3-9-19-15/h2-3,6-11H,1,4-5H2",KHXBULXCCPIELT-UHFFFAOYSA-N,tenylidone,Preclinical,,,,
COc1ccc(-n2nc(CCC(=O)N(C)O)cc2-c2ccc(Cl)cc2)cc1,"InChI=1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3",XYKWNRUXCOIMFZ-UHFFFAOYSA-N,tepoxalin,Launched,cyclooxygenase inhibitor,ALOX5,rheumatology|orthopedics,rheumatoid arthritis|hip dysplasia
COc1ccc(-n2nc(CCC(=O)N(C)O)cc2-c2ccc(Cl)cc2)cc1,"InChI=1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3",XYKWNRUXCOIMFZ-UHFFFAOYSA-N,tepoxalin,Launched,lipoxygenase inhibitor,ALOX5,rheumatology|orthopedics,rheumatoid arthritis|hip dysplasia
Cn1c2cc([S+](C)[O-])sc2c2cnn(Cc3cccc(N)c3)c(=O)c21,"InChI=1S/C17H16N4O2S2/c1-20-13-7-14(25(2)23)24-16(13)12-8-19-21(17(22)15(12)20)9-10-4-3-5-11(18)6-10/h3-8H,9,18H2,1-2H3",ZWKJWVSEDISQIS-UHFFFAOYSA-N,tepp-46,Preclinical,pyruvate kinase isozyme activator,PKM,,
CC(=O)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,"InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3",HUCXKZBETONXFO-UHFFFAOYSA-N,teprenone,Launched,mucus protecting agent,,dermatology,cosmetic
COc1ccc(CC(C)C(C)Cc2ccc(OC)c(OC)c2)cc1OC,"InChI=1S/C22H30O4/c1-15(11-17-7-9-19(23-3)21(13-17)25-5)16(2)12-18-8-10-20(24-4)22(14-18)26-6/h7-10,13-16H,11-12H2,1-6H3",ORQFDHFZSMXRLM-UHFFFAOYSA-N,terameprocol,Phase 1/Phase 2,lipoxygenase inhibitor,BIRC5|CDK1,,
COc1cc2[nH]c(N3CCN(C(=O)C4CCCO4)CC3)nc(=N)c2cc1OC,"InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)",VCKUSRYTPJJLNI-UHFFFAOYSA-N,terazosin,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension
CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,"InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3",DOMXUEMWDBAQBQ-UHFFFAOYSA-N,terbinafine,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,"InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3",XWTYSIMOBUGWOL-UHFFFAOYSA-N,terbutaline,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|bronchitis|emphysema
C#CC1(OCC(O)CN2CCN(c3cccc(C(F)(F)F)c3)CC2)CCCCC1,"InChI=1S/C22H29F3N2O2/c1-2-21(9-4-3-5-10-21)29-17-20(28)16-26-11-13-27(14-12-26)19-8-6-7-18(15-19)22(23,24)25/h1,6-8,15,20,28H,3-5,9-14,16-17H2",SDKXUWMRKYQIFU-UHFFFAOYSA-N,terciprazine,Phase 1,,,,
CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3",BLSQLHNBWJLIBQ-UHFFFAOYSA-N,terconazole,Launched,sterol demethylase inhibitor,,infectious disease,vulvovaginal candidiasis
CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,"InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3",GUGOEEXESWIERI-UHFFFAOYSA-N,terfenadine,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,,
CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)",JOAHPSVPXZTVEP-UHFFFAOYSA-N,terguride,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease
CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,"InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)",JOAHPSVPXZTVEP-UHFFFAOYSA-N,terguride,Launched,serotonin receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease
CC(=O)C(C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,"InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,10H,1H3,(H,17,19)",NABQBYDEMLGCEO-UHFFFAOYSA-N,teriflunomide,Launched,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis
NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)",BENFXAYNYRLAIU-UHFFFAOYSA-N,terlipressin,Launched,vasopressin receptor agonist,AVPR1A,cardiology,hypotension
CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,"InChI=1S/C20H27N/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19,21H,15H2,1-4H3",UISARWKNNNHPGI-UHFFFAOYSA-N,terodiline,Withdrawn,cholinergic receptor antagonist,,,
O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,"InChI=1S/C12H15N3O6/c16-10-13(1-7-4-19-7)11(17)15(3-9-6-21-9)12(18)14(10)2-8-5-20-8/h7-9H,1-6H2",OUPZKGBUJRBPGC-UHFFFAOYSA-N,teroxirone,Phase 1,DNA inhibitor,,,
CC1(O)CCC(C(C)(C)O)CC1,"InChI=1S/C10H20O2/c1-9(2,11)8-4-6-10(3,12)7-5-8/h8,11-12H,4-7H2,1-3H3",RBNWAMSGVWEHFP-UHFFFAOYSA-N,terpene,Preclinical,,,,
Cc1c(O)c(O)c2c(c1O)O2,"InChI=1S/C7H6O4/c1-2-3(8)5(10)7-6(11-7)4(2)9/h8-10H,1H3",KDDDKUDGIQOQGM-UHFFFAOYSA-N,terreic-acid-(-),Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,
Cc1ccc2c(c1CCC(=O)O)CCC(NS(=O)(=O)c1ccc(Cl)cc1)C2,"InChI=1S/C20H22ClNO4S/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24)",HWEOXFSBSQIWSY-UHFFFAOYSA-N,terutroban,Phase 3,prostanoid receptor antagonist,TBXA2R,,
CCOC(Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,"InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)",CXGTZJYQWSUFET-UHFFFAOYSA-N,tesaglitazar,Phase 3,insulin sensitizer,PPARA|PPARG,,
CCOC(Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,"InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)",CXGTZJYQWSUFET-UHFFFAOYSA-N,tesaglitazar,Phase 3,PPAR receptor agonist,PPARA|PPARG,,
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,"InChI=1S/C19H18N2O4S/c1-3-24-16-9-8-12(10-17(16)25-4-2)18-21-15(11-26-18)13-6-5-7-14(20-13)19(22)23/h5-11H,3-4H2,1-2H3,(H,22,23)",XDBHURGONHZNJF-UHFFFAOYSA-N,tetomilast,Phase 2,phosphodiesterase inhibitor,PDE4D,,
COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2,"InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3",MKJIEFSOBYUXJB-UHFFFAOYSA-N,tetrabenazine,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,infectious disease|neurology/psychiatry,cholera|Huntington's disease
CCCCNc1ccc(C(=O)OCCN(C)C)cc1,"InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3",GKCBAIGFKIBETG-UHFFFAOYSA-N,tetracaine,Launched,membrane integrity inhibitor,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,anesthetic
CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)C3C(=O)c4c(O)cccc4C(C)(O)C3CC12,"InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,13-15,25,31-32H,7H2,1-3H3,(H2,23,30)",MUHBBHLZPHKTTR-UHFFFAOYSA-N,tetracycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease|dermatology,respiratory tract infections|pneumonia|skin infections|urinary tract infections|acne vulgaris (AV)|plague|psittacosis
CCCCCCCCCCCCCCSCC(=O)O,"InChI=1S/C16H32O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-15-16(17)18/h2-15H2,1H3,(H,17,18)",IPBCWPPBAWQYOO-UHFFFAOYSA-N,tetradecylthioacetic-acid,Phase 2,lipid peroxidase inhibitor,,,
NCCNCCNCCNCCN,"InChI=1S/C8H23N5/c9-1-3-11-5-7-13-8-6-12-4-2-10/h11-13H,1-10H2",FAGUFWYHJQFNRV-UHFFFAOYSA-N,tetraethylenepentamine,Phase 2/Phase 3,superoxide dismutase inhibitor,SOD1|SOD2,,
N=c1[nH]c2c(c(=O)[nH]1)NC(CNc1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1)CN2,"InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)",MSTNYGQPCMXVAQ-UHFFFAOYSA-N,tetrahydrofolic-acid,Launched,,FOLR2,,
COc1ccc(CC2NCCc3cc(OC)c(OC)cc32)cc1OC,"InChI=1S/C20H25NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-6,10-12,16,21H,7-9H2,1-4H3",YXWQTVWJNHKSCC-UHFFFAOYSA-N,tetrahydropapaverine,Preclinical,,,,
O=C1NC(O)CCN1C1OC(CO)C(O)C1O,"InChI=1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)",UCKYOOZPSJFJIZ-UHFFFAOYSA-N,tetrahydrouridine,Phase 2,cytidine deaminase inhibitor,CDA,,
c1ccc2c(c1)CCCC2C1=NCCN1,"InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)",BYJAVTDNIXVSPW-UHFFFAOYSA-N,tetrahydrozoline,Launched,adrenergic receptor agonist,,ophthalmology,eye irritation
CN(C)C(=S)SC(=S)N(C)C,InChI=1S/C6H12N2S3/c1-7(2)5(9)11-6(10)8(3)4/h1-4H3,REQPQFUJGGOFQL-UHFFFAOYSA-N,tetramethylthiuram-monosulfide,Preclinical,,,,
c1ccc(C2CN3CCSC3=N2)cc1,"InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2",HLFSDGLLUJUHTE-UHFFFAOYSA-N,tetramisole,Launched,immunostimulant,ALPPL2|CHRNA3,infectious disease,gastrointestinal parasites
COc1ccc2cc1Oc1ccc(cc1)CC1c3cc(c(OC)cc3CCN1C)Oc1c(OC)c(OC)cc3c1C(C2)N(C)CC3,"InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3",WVTKBKWTSCPRNU-UHFFFAOYSA-N,tetrandrine,Preclinical,calcium channel blocker,SLC6A3,,
NC(C(=O)O)c1nn[nH]n1,"InChI=1S/C3H5N5O2/c4-1(3(9)10)2-5-7-8-6-2/h1H,4H2,(H,9,10)(H,5,6,7,8)",UKBRUIZWQZHXFL-UHFFFAOYSA-N,tetrazol-5-yl-glycine-(rs),Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,
c1cc2c(cc1C1CCCCC1)c1c3n2CCNC3CCC1,"InChI=1S/C20H26N2/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18/h9-10,13-14,18,21H,1-8,11-12H2",AUXCHYJDVJZEPG-UHFFFAOYSA-N,tetrindole,Phase 3,monoamine oxidase inhibitor,MAOA,,
O=C1C(O)=C(O)C(=O)C(O)=C1O,"InChI=1S/C6H4O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h7-8,11-12H",DGQOCLATAPFASR-UHFFFAOYSA-N,tetroquinone,Preclinical,,,,
CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1CC(O)CO,"InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)",MJUVRTYWUMPBTR-UHFFFAOYSA-N,tezacaftor,Launched,CFTR channel agonist,,pulmonary,cystic fibrosis
O=C(Nc1ccc(N2CCC(C(=O)N3CCOCC3)CC2)cc1)c1cnc(Oc2ccccc2)nc1,"InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33)",NLSSUSRERAMBTA-UHFFFAOYSA-N,tfc-007,Preclinical,prostaglandin inhibitor,HPGDS,,
CCN1C(=CC(C)=O)Sc2ccc(OC)cc21,"InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3",BGVLELSCIHASRV-UHFFFAOYSA-N,tg-003,Preclinical,CLK inhibitor,CLK1|CLK4|DYRK1A|DYRK1B,,
CN1CC=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,"InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)",VXBAJLGYBMTJCY-UHFFFAOYSA-N,tg-02,Phase 1/Phase 2,CDK inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,,
CN1CC=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,"InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)",VXBAJLGYBMTJCY-UHFFFAOYSA-N,tg-02,Phase 1/Phase 2,FLT3 inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,,
CN1CC=CCCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,"InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)",VXBAJLGYBMTJCY-UHFFFAOYSA-N,tg-02,Phase 1/Phase 2,JAK inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,,
Cc1cc(-c2cc(O)ccc2Cl)cc2n[nH]c(=Nc3ccc(OCCN4CCCC4)cc3)nc12,"InChI=1S/C26H26ClN5O2/c1-17-14-18(22-16-20(33)6-9-23(22)27)15-24-25(17)29-26(31-30-24)28-19-4-7-21(8-5-19)34-13-12-32-10-2-3-11-32/h4-9,14-16,33H,2-3,10-13H2,1H3,(H,28,29,31)",AQSSMEORRLJZLU-UHFFFAOYSA-N,tg-100572,Preclinical,SRC inhibitor,KDR|SRC,,
Cc1cc(-c2cc(O)ccc2Cl)cc2n[nH]c(=Nc3ccc(OCCN4CCCC4)cc3)nc12,"InChI=1S/C26H26ClN5O2/c1-17-14-18(22-16-20(33)6-9-23(22)27)15-24-25(17)29-26(31-30-24)28-19-4-7-21(8-5-19)34-13-12-32-10-2-3-11-32/h4-9,14-16,33H,2-3,10-13H2,1H3,(H,28,29,31)",AQSSMEORRLJZLU-UHFFFAOYSA-N,tg-100572,Preclinical,VEGFR inhibitor,KDR|SRC,,
N=c1[nH]c(=N)c2nc(-c3cccc(O)c3)cnc2[nH]1,"InChI=1S/C12H10N6O/c13-10-9-11(18-12(14)17-10)15-5-8(16-9)6-2-1-3-7(19)4-6/h1-5,19H,(H4,13,14,15,17,18)",UOORQSPLBHUQDQ-UHFFFAOYSA-N,tg-100713,Preclinical,PI3K inhibitor,,,
Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2n[nH]c(=Nc3ccc(OCCN4CCCC4)cc3)nc12,"InChI=1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)",JMGXJHWTVBGOKG-UHFFFAOYSA-N,tg-100801,Phase 2,SRC inhibitor,CSK|FGFR1|FLT1|FLT4|KDR|SRC,,
Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2n[nH]c(=Nc3ccc(OCCN4CCCC4)cc3)nc12,"InChI=1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)",JMGXJHWTVBGOKG-UHFFFAOYSA-N,tg-100801,Phase 2,VEGFR inhibitor,CSK|FGFR1|FLT1|FLT4|KDR|SRC,,
Cc1c[nH]c(=Nc2ccc(N3CCN(C)CC3)cc2)[nH]c1=Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,"InChI=1S/C26H35N7O2S/c1-19-18-27-25(29-20-9-11-22(12-10-20)33-15-13-32(5)14-16-33)30-24(19)28-21-7-6-8-23(17-21)36(34,35)31-26(2,3)4/h6-12,17-18,31H,13-16H2,1-5H3,(H2,27,28,29,30)",JVDOKQYTTYUYDV-UHFFFAOYSA-N,tg-101209,Preclinical,JAK inhibitor,JAK2|JAK3,,
N=c1[nH]c(=N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2[nH]1,"InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)",UJIAQDJKSXQLIT-UHFFFAOYSA-N,tg100-115,Phase 1/Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,
CC(C)Oc1ccc(-c2nn(C(C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3[nH]cnc(=N)c23)cc1F,"InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)",IUVCFHHAEHNCFT-UHFFFAOYSA-N,tgr-1202,Phase 3,PI3K inhibitor,,,
Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1,"InChI=1S/C21H24N4O2/c1-15-12-18(16(2)22-17-6-4-3-5-7-17)21-23-19(13-20(26)25(21)14-15)24-8-10-27-11-9-24/h3-7,12-14,16,22H,8-11H2,1-2H3",CPRAGQJXBLMUEL-UHFFFAOYSA-N,tgx-221,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD,,
Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+](=O)[O-],"InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)",UGJWRPJDTDGERK-UHFFFAOYSA-N,th-302,Phase 3,DNA alkylating agent,,,
N=c1[nH]c(-c2cccc(Cl)c2Cl)cc(=NC2CC2)[nH]1,"InChI=1S/C13H12Cl2N4/c14-9-3-1-2-8(12(9)15)10-6-11(17-7-4-5-7)19-13(16)18-10/h1-3,6-7H,4-5H2,(H3,16,17,18,19)",PNMYJIOQIAEYQL-UHFFFAOYSA-N,th-588,Preclinical,MTH1 inhibitor,NUDT1,,
COc1cc(CC2c3cc(OC)c(OC)cc3CCN2C)c(Oc2cc3c(cc2OC)-c2c(OC)c(OC)cc4c2C(C3)N(C)CC4)cc1OC,"InChI=1S/C41H48N2O8/c1-42-12-10-23-16-32(44-3)34(46-5)20-27(23)29(42)15-26-19-33(45-4)36(48-7)22-31(26)51-37-18-25-14-30-39-24(11-13-43(30)2)17-38(49-8)41(50-9)40(39)28(25)21-35(37)47-6/h16-22,29-30H,10-15H2,1-9H3",ZCTJIMXXSXQXRI-UHFFFAOYSA-N,thaliblastine,Phase 2,DNA inhibitor,,,
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,thalidomide,Launched,tumor necrosis factor production inhibitor,TNF,oncology,myeloma
O=c1c(O)cc(C2Oc3cc(O)cc(O)c3CC2O)cc2c(C3Oc4cc(O)cc(O)c4CC3O)cc(O)c(O)c12,"InChI=1S/C29H24O12/c30-11-3-17(32)15-8-21(36)28(40-23(15)5-11)10-1-13-14(7-20(35)27(39)25(13)26(38)19(34)2-10)29-22(37)9-16-18(33)4-12(31)6-24(16)41-29/h1-7,21-22,28-33,35-37,39H,8-9H2,(H,34,38)",IPMYMEWFZKHGAX-UHFFFAOYSA-N,theaflavin,Preclinical,antiviral,,,
Cn1cnc2c1c(=O)[nH]c(=O)n2C,"InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)",YAPQBXQYLJRXSA-UHFFFAOYSA-N,theobromine,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|PDE4B,,
CCN=C1NC2C(OC(CO)C(O)C2O)S1,"InChI=1S/C9H16N2O4S/c1-2-10-9-11-5-7(14)6(13)4(3-12)15-8(5)16-9/h4-8,12-14H,2-3H2,1H3,(H,10,11)",PPAIMZHKIXDJRN-UHFFFAOYSA-N,thiamet-g,Preclinical,GLCNAC phosphotransferase inhibitor,MGEA5,,
Cc1nc(=N)c(C[n+]2csc(CCO)c2C)c[nH]1,"InChI=1S/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1",JZRWCGZRTZMZEH-UHFFFAOYSA-N,thiamine,Launched,vitamin B,SLC19A2|SLC19A3|TPK1,metabolism,thiamine deficiency
Cc1nc(=N)c(C[n+]2csc(CCO[PH](=O)(=O)O[PH](=O)(=O)O)c2C)c[nH]1,"InChI=1S/C12H17N4O7P2S/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H2,13,14,15)(H,17,18,19)/q+1",XWGNDHBWCQCPLM-UHFFFAOYSA-N,thiamine-pyrophosphate,Launched,,,hematology,anemia
CS(=O)(=O)c1ccc(C(O)C(CO)NC(=O)C(Cl)Cl)cc1,"InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)",OTVAEFIXJLOWRX-UHFFFAOYSA-N,thiamphenicol,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease,pelvic inflammatory disease
C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O,"InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)",XLOMZPUITCYLMJ-UHFFFAOYSA-N,thiamylal,Launched,glutamate receptor antagonist,GABRA1,neurology/psychiatry,sedative
O=C(NCc1ccccc1)c1csc(=Nc2ccncn2)[nH]1,"InChI=1S/C15H13N5OS/c21-14(17-8-11-4-2-1-3-5-11)12-9-22-15(19-12)20-13-6-7-16-10-18-13/h1-7,9-10H,8H2,(H,17,21)(H,16,18,19,20)",DOBKQCZBPPCLEG-UHFFFAOYSA-N,thiazovivin,Preclinical,rho associated kinase inhibitor,,,
CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2,"InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3",XCTYLCDETUVOIP-UHFFFAOYSA-N,thiethylperazine,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD4,gastroenterology,nausea
COc1c(OC2OC(CO)C(O)C(O)C2O)cc2c(c1OC)-c1ccc(SC)c(=O)cc1C(NC(C)=O)CC2,"InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)",LEQAKWQJCITZNK-UHFFFAOYSA-N,thiocolchicoside,Launched,GABA receptor antagonist,GABRA1|GABRB2|GABRG2|GLRA1|GLRB,neurology/psychiatry,muscle relaxant
O=C(O)CCCCC1CCSS1,"InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)",AGBQKNBQESQNJD-UHFFFAOYSA-N,thioctic-acid,Launched,reducing agent,ACHE|PTGS2,nephrology,diabetic nephropathy
OCCSCCO,"InChI=1S/C4H10O2S/c5-1-3-7-4-2-6/h5-6H,1-4H2",YODZTKMDCQEPHD-UHFFFAOYSA-N,thiodiglycol,Preclinical,,,,
N=c1[nH]c(=S)c2[nH]cnc2[nH]1,"InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)",WYWHKKSPHMUBEB-UHFFFAOYSA-N,thioguanine,Launched,purine antagonist,IMPDH1|IMPDH2,hematologic malignancy,acute myeloid leukemia (AML)
CC[Hg]Sc1ccccc1C(=O)O,"InChI=1S/C7H6O2S.C2H5.Hg/c8-7(9)5-3-1-2-4-6(5)10;1-2;/h1-4,10H,(H,8,9);1H2,2H3;/q;;+1/p-1",HXQVQGWHFRNKMS-UHFFFAOYSA-M,thiomersal,Launched,other antibiotic,OXCT1,infectious disease,preservative
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,"InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",IUJDSEJGGMCXSG-UHFFFAOYSA-N,thiopental,Launched,GABA receptor antagonist,FAAH,neurology/psychiatry,anesthetic
S=C(NC1CCCCC1)N1CCC(c2c[nH]cn2)CC1,"InChI=1S/C15H24N4S/c20-15(18-13-4-2-1-3-5-13)19-8-6-12(7-9-19)14-10-16-11-17-14/h10-13H,1-9H2,(H,16,17)(H,18,20)",QKDDJDBFONZGBW-UHFFFAOYSA-N,thioperamide,Preclinical,histamine receptor antagonist,HRH3|HRH4,,
COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC,"InChI=1S/C12H14N4O4S2/c1-19-11(17)15-9(21)13-7-5-3-4-6-8(7)14-10(22)16-12(18)20-2/h3-6H,1-2H3,(H2,13,15,17,21)(H2,14,16,18,22)",QGHREAKMXXNCOA-UHFFFAOYSA-N,thiophanate,Preclinical,,,,
CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,"InChI=1S/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3",VZYCZNZBPPHOFY-UHFFFAOYSA-N,thioproperazine,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia
CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,"InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",KLBQZWRITKRQQV-UHFFFAOYSA-N,thioridazine,Withdrawn,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7,,
O=C(O)CNC(=O)C(CS)Cc1ccccc1,"InChI=1S/C12H15NO3S/c14-11(15)7-13-12(16)10(8-17)6-9-4-2-1-3-5-9/h1-5,10,17H,6-8H2,(H,13,16)(H,14,15)",LJJKNPQAGWVLDQ-UHFFFAOYSA-N,thiorphan,Phase 1,membrane metalloendopeptidase inhibitor,MME,,
C=C(NC(=O)C(=C)NC(=O)c1csc(C2=NC3c4csc(n4)C4NC(=O)c5csc(n5)C(C(C)(O)C(C)O)NC(=O)C5CSC(=N5)C(=CC)NC(=O)C(C(C)O)NC(=O)c5csc(n5)C3(CC2)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)Nc2ccc3c(c2O)NC(=CC3C(C)O)C(=O)OC4C)n1)C(N)=O,"InChI=1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,37,45,47-49,52-53,79-80,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)",UTBOEBCWXGDOGI-UHFFFAOYSA-N,thiostrepton,Launched,FOXM1 inhibitor,FOXM1,obstetrics/gynecology,mastitis
C=C(NC(=O)C(=C)NC(=O)c1csc(C2=NC3c4csc(n4)C4NC(=O)c5csc(n5)C(C(C)(O)C(C)O)NC(=O)C5CSC(=N5)C(=CC)NC(=O)C(C(C)O)NC(=O)c5csc(n5)C3(CC2)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)Nc2ccc3c(c2O)NC(=CC3C(C)O)C(=O)OC4C)n1)C(N)=O,"InChI=1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,37,45,47-49,52-53,79-80,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)",UTBOEBCWXGDOGI-UHFFFAOYSA-N,thiostrepton,Launched,protein synthesis inhibitor,FOXM1,obstetrics/gynecology,mastitis
S=P(N1CC1)(N1CC1)N1CC1,"InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2",FOCVUCIESVLUNU-UHFFFAOYSA-N,thiotepa,Launched,cytochrome P450 inhibitor,CYP2B6|CYP3A4,oncology,breast cancer|ovarian cancer|bladder cancer
CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,"InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3",GFBKORZTTCHDGY-UHFFFAOYSA-N,thiothixene,Launched,dopamine receptor antagonist,DRD1|DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia
CN(C)C(=S)SSC(=S)N(C)C,InChI=1S/C6H12N2S4/c1-7(2)5(9)11-12-6(10)8(3)4/h1-4H3,KUAZQDVKQLNFPE-UHFFFAOYSA-N,thiram,Launched,,JAK2,ophthalmology,contact dermatitis
CN=c1ccc(-c2ccc3cc(OCC(O)CF)ccc3n2)c[nH]1,"InChI=1S/C18H18FN3O2/c1-20-18-7-3-13(10-21-18)17-5-2-12-8-15(4-6-16(12)22-17)24-11-14(23)9-19/h2-8,10,14,23H,9,11H2,1H3,(H,20,21)",DLVXFZWSPCOWSN-UHFFFAOYSA-N,thk5351,Phase 2,PET radiotracer ,,,
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1,"InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1",IOYZYMQFUSNATM-UHFFFAOYSA-N,thonzonium,Launched,ATPase inhibitor,,infectious disease,ear infections
COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,"InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3",GULNIHOSWFYMRN-UHFFFAOYSA-N,thonzylamine,Launched,antihistamine,,neurology/psychiatry,itching
CC(O)(C(=O)O)C(CC(=O)O)C(=O)O,"InChI=1S/C7H10O7/c1-7(14,6(12)13)3(5(10)11)2-4(8)9/h3,14H,2H2,1H3,(H,8,9)(H,10,11)(H,12,13)",HHKPKXCSHMJWCF-UHFFFAOYSA-N,threo-2-methylisocitrate-(dl),Preclinical,isocitrate lyase substrate,,,
CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(C)=O)C(C)C)C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(N)=O)C(=O)O)C(C)C)C(C)C)C(C)O)C(C)O,"InChI=1S/C129H215N33O55/c1-18-59(10)98(159-114(201)76(36-42-91(181)182)146-120(207)83(53-164)154-121(208)84(54-165)155-127(214)99(63(14)166)160-118(205)80(51-94(187)188)152-123(210)95(56(4)5)156-104(191)62(13)135-102(189)60(11)137-115(202)78(49-92(183)184)151-119(206)82(52-163)138-66(17)169)125(212)161-101(65(16)168)128(215)162-100(64(15)167)126(213)147-70(30-22-26-46-133)109(196)150-79(50-93(185)186)117(204)149-77(47-55(2)3)116(203)142-69(29-21-25-45-132)108(195)144-73(33-39-88(175)176)110(197)141-67(27-19-23-43-130)106(193)140-68(28-20-24-44-131)107(194)145-75(35-41-90(179)180)113(200)157-97(58(8)9)124(211)158-96(57(6)7)122(209)148-74(34-40-89(177)178)111(198)143-71(31-37-86(171)172)105(192)136-61(12)103(190)139-72(32-38-87(173)174)112(199)153-81(129(216)217)48-85(134)170/h55-65,67-84,95-101,163-168H,18-54,130-133H2,1-17H3,(H2,134,170)(H,135,189)(H,136,192)(H,137,202)(H,138,169)(H,139,190)(H,140,193)(H,141,197)(H,142,203)(H,143,198)(H,144,195)(H,145,194)(H,146,207)(H,147,213)(H,148,209)(H,149,204)(H,150,196)(H,151,206)(H,152,210)(H,153,199)(H,154,208)(H,155,214)(H,156,191)(H,157,200)(H,158,211)(H,159,201)(H,160,205)(H,161,212)(H,162,215)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,216,217)",NZVYCXVTEHPMHE-UHFFFAOYSA-N,thymalfasin,Launched,immune response modulator,,infectious disease,hepatitis B|hepatitis C
Cc1ccc(C(C)C)c(O)c1,"InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3",MGSRCZKZVOBKFT-UHFFFAOYSA-N,thymol,Launched,GABA receptor positive allosteric modulator,TRPA1,infectious disease,ringworm|antiseptic
Cc1cc(OI)c(C(C)C)cc1-c1cc(C(C)C)c(OI)cc1C,"InChI=1S/C20H24I2O2/c1-11(2)15-9-17(13(5)7-19(15)23-21)18-10-16(12(3)4)20(24-22)8-14(18)6/h7-12H,1-6H3",SHOKWSLXDAIZPP-UHFFFAOYSA-N,thymol-iodide,Preclinical,,,,
CC(C)C(NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(N)CCCN=C(N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)",PSWFFKRAVBDQEG-UHFFFAOYSA-N,thymopentin,Launched,immune response stimulator,,,
CN(C)C=CCC(=O)Nc1ccc(C(=O)Nc2cccc(N=c3nc(-c4c[nH]c5ccccc45)c(Cl)c[nH]3)c2)cc1,"InChI=1S/C31H28ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-10,12-19,33H,11H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)",NJSVYIXLKIJTAN-UHFFFAOYSA-N,thz1,Preclinical,CDK inhibitor,CDK7,,
CN(C)CCCC(=O)Nc1ccc(C(=O)Nc2cccc(N=c3nc(-c4c[nH]c5ccccc45)c(Cl)c[nH]3)c2)cc1,"InChI=1S/C31H30ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-5,7-10,12-15,17-19,33H,6,11,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)",TUERFPPIPKZNKE-UHFFFAOYSA-N,thz1-r,Preclinical,CDK inhibitor,CDK7,,
CN(C)C=CCC(=O)Nc1cccc(C(=O)Nc2cccc(N=c3nc(-c4c[nH]c5ccccc45)c(Cl)c[nH]3)c2)c1,"InChI=1S/C31H28ClN7O2/c1-39(2)15-7-14-28(40)35-21-9-5-8-20(16-21)30(41)36-22-10-6-11-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-13-4-3-12-24(25)27/h3-13,15-19,33H,14H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)",FJBAMBVFKFYDKU-UHFFFAOYSA-N,thz2,Preclinical,CDK inhibitor,CDK7,,
c1ccc2[nH]c(-c3cscn3)nc2c1,"InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)",WJCNZQLZVWNLKY-UHFFFAOYSA-N,tiabendazole,Launched,angiogenesis inhibitor,,infectious disease,gastrointestinal roundworms|hookworm
Cc1ccsc1C(=CCCN1CCCC(C(=O)O)C1)c1sccc1C,"InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)",PBJUNZJWGZTSKL-UHFFFAOYSA-N,tiagabine,Launched,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures
CN1c2ccccc2C(NCCCCCCC(=O)O)c2ccc(Cl)cc2S1(=O)=O,"InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)",JICJBGPOMZQUBB-UHFFFAOYSA-N,tianeptine,Launched,selective serotonin reuptake enhancer (SSRE),OPRD1|OPRK1|OPRM1,neurology/psychiatry|pulmonary|gastroenterology,depression|asthma|irritable bowel syndrome
CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,"InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)",JTVPZMFULRWINT-UHFFFAOYSA-N,tiapride,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,dyskinesia|abstinence from alcohol|psychosis
CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1,"InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)",GUHPRPJDBZHYCJ-UHFFFAOYSA-N,tiaprofenic-acid,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis
O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,"InChI=1S/C15H18ClN3O3S/c16-11-1-2-13-12(9-11)19(15(22)23-13)10-14(21)18-5-3-17(4-6-18)7-8-20/h1-2,9,20H,3-8,10H2",HTJXMOGUGMSZOG-UHFFFAOYSA-N,tiaramide,Launched,anti-inflammatory agent,,pulmonary,asthma
C#CC1(O)CCC2C3C(C)C=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,11,13,16-19,23H,5-10,12H2,2-3H3",AMSBRQDLADKBGS-UHFFFAOYSA-N,tibolone,Launched,androgen receptor agonist,ESR1,obstetrics/gynecology,endometriosis
C#CC1(O)CCC2C3C(C)C=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,11,13,16-19,23H,5-10,12H2,2-3H3",AMSBRQDLADKBGS-UHFFFAOYSA-N,tibolone,Launched,estrogen receptor agonist,ESR1,obstetrics/gynecology,endometriosis
C#CC1(O)CCC2C3C(C)C=C4CC(=O)CCC4C3CCC21C,"InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,11,13,16-19,23H,5-10,12H2,2-3H3",AMSBRQDLADKBGS-UHFFFAOYSA-N,tibolone,Launched,progesterone receptor agonist,ESR1,obstetrics/gynecology,endometriosis
Cc1ccccc1CN1C2=CCN(Cc3ccccc3)CC2C(=O)N2CCN=C21,"InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-22-11-13-26(15-19-8-3-2-4-9-19)17-21(22)23(29)27-14-12-25-24(27)28/h2-11,21H,12-17H2,1H3",OWOUIGIVGMODJP-UHFFFAOYSA-N,tic10,Phase 2,AKT inhibitor,AKT1|MAPK1,,
Cc1ccccc1CN1C2=CCN(Cc3ccccc3)CC2C(=O)N2CCN=C21,"InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-22-11-13-26(15-19-8-3-2-4-9-19)17-21(22)23(29)27-14-12-25-24(27)28/h2-11,21H,12-17H2,1H3",OWOUIGIVGMODJP-UHFFFAOYSA-N,tic10,Phase 2,TRAIL modulator,AKT1|MAPK1,,
CCCSc1nc(=NC2CC2c2ccc(F)c(F)c2)c2nnn(C3CC(OCCO)C(O)C3O)c2[nH]1,"InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)",OEKWJQXRCDYSHL-UHFFFAOYSA-N,ticagrelor,Launched,purinergic receptor antagonist,P2RY12,cardiology,acute coronary syndrome (ACS)|myocardial infarction
CC1(C)SC2C(NC(=O)C(C(=O)O)c3ccsc3)C(=O)N2C1C(=O)O,"InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)",OHKOGUYZJXTSFX-UHFFFAOYSA-N,ticarcillin,Launched,lactamase inhibitor,,infectious disease,gram-negative bacterial infections
Clc1ccccc1CN1CCc2sccc2C1,"InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2",PHWBOXQYWZNQIN-UHFFFAOYSA-N,ticlopidine,Launched,purinergic receptor antagonist,P2RY12,hematology|neurology/psychiatry,thrombosis|stroke
O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,"InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2",PMJIHLSCWIDGMD-UHFFFAOYSA-N,tideglusib,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,
COc1ccc2cc(-c3[nH]c(-c4ccc([S+](C)[O-])cc4)nc3-c3ccncc3)ccc2c1,"InChI=1S/C26H21N3O2S/c1-31-22-8-5-19-15-21(4-3-20(19)16-22)25-24(17-11-13-27-14-12-17)28-26(29-25)18-6-9-23(10-7-18)32(2)30/h3-16H,1-2H3,(H,28,29)",SINQIEAULQKUPD-UHFFFAOYSA-N,tie2-kinase-inhibitor,Preclinical,TIE tyrosine kinase inhibitor,KDR|MAPK14,,
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,"InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)",AGHANLSBXUWXTB-UHFFFAOYSA-N,tienilic-acid,Withdrawn,cytochrome P450 inhibitor,CYP2C9|SLC12A1,,
O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,"InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)",AGHANLSBXUWXTB-UHFFFAOYSA-N,tienilic-acid,Withdrawn,sodium/potassium/chloride transporter inhibitor,CYP2C9|SLC12A1,,
CC1(NC2=NS(=O)(=O)c3sc(Cl)cc3N2)CC1,"InChI=1S/C9H10ClN3O2S2/c1-9(2-3-9)12-8-11-5-4-6(10)16-7(5)17(14,15)13-8/h4H,2-3H2,1H3,(H2,11,12,13)",KYSFUHHFTIGRJN-UHFFFAOYSA-N,tifenazoxide,Phase 1,ATP-sensitive potassium channel agonist,ABCC8|KCNJ11,,
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c(O)c3c(cc12)CC1C(N(C)C)C(=O)C(C(N)=O)C(=O)C1(O)C3O,"InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h8,10,14,20-21,25,31,36-37,39,42H,9,11H2,1-7H3,(H2,30,41)(H,32,35)",HFGTWXXQCHUAMV-UHFFFAOYSA-N,tigecycline,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,skin infections|pneumonia|intra-abdominal infections
CCC1OC(=O)CC(O)C(C)C(OC2OC(C)C(O)C(N(C)C)C2O)C(CCN2CC(C)CC(C)C2)CC(C)C(=O)C=CC(C)=CC1COC1OC(C)C(O)C(OC)C1OC,"InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3",JTSDBFGMPLKDCD-UHFFFAOYSA-N,tilmicosin,Launched,bacterial 50S ribosomal subunit inhibitor,,pulmonary,bovine respiratory disease (BRD)
CCN(CC)CCOc1ccc2c(c1)C(=O)c1cc(OCCN(CC)CC)ccc1-2,"InChI=1S/C25H34N2O3/c1-5-26(6-2)13-15-29-19-9-11-21-22-12-10-20(30-16-14-27(7-3)8-4)18-24(22)25(28)23(21)17-19/h9-12,17-18H,5-8,13-16H2,1-4H3",MPMFCABZENCRHV-UHFFFAOYSA-N,tilorone,Launched,interferon inducer,,infectious disease|gastroenterology|neurology/psychiatry,influenza A virus infection|diarrhea|hepatitis B|multiple sclerosis|urinary tract infections|virus herpes simplex (HSV)|hepatitis C
O=[PH](=O)(O)C(Sc1ccc(Cl)cc1)[PH](=O)(=O)O,"InChI=1S/C7H7ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H,9,10,11)(H,12,13,14)",YJPVNWRCJRDXEZ-UHFFFAOYSA-N,tiludronate,Launched,bone resorption inhibitor,ATP6V1A|MMP2|PTPN1,orthopedics,navicular syndrome
O=[PH](=O)(O)C(Sc1ccc(Cl)cc1)[PH](=O)(=O)O,"InChI=1S/C7H7ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H,9,10,11)(H,12,13,14)",YJPVNWRCJRDXEZ-UHFFFAOYSA-N,tiludronate,Launched,osteoclast inhibitor,ATP6V1A|MMP2|PTPN1,orthopedics,navicular syndrome
CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(=O)O,"InChI=1S/C14H16ClNO4S/c1-14(2,20-10-5-3-9(15)4-6-10)13(19)16-8-21-7-11(16)12(17)18/h3-6,11H,7-8H2,1-2H3,(H,17,18)",QSNOWCXXECLALL-UHFFFAOYSA-N,timofibrate,Phase 2,cholesterol inhibitor,LPL,,
CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(=O)O,"InChI=1S/C14H16ClNO4S/c1-14(2,20-10-5-3-9(15)4-6-10)13(19)16-8-21-7-11(16)12(17)18/h3-6,11H,7-8H2,1-2H3,(H,17,18)",QSNOWCXXECLALL-UHFFFAOYSA-N,timofibrate,Phase 2,lipase clearing factor inhibitor,LPL,,
CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3",BLJRIMJGRPQVNF-UHFFFAOYSA-N,timolol,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,ocular hypertension|glaucoma
O=C(O)C1CSCN1,"InChI=1S/C4H7NO2S/c6-4(7)3-1-8-2-5-3/h3,5H,1-2H2,(H,6,7)",DZLNHFMRPBPULJ-UHFFFAOYSA-N,timonacic,Launched,antioxidant,,,
c1ccc2c(SC3=NCCN3)c[nH]c2c1,"InChI=1S/C11H11N3S/c1-2-4-9-8(3-1)10(7-14-9)15-11-12-5-6-13-11/h1-4,7,14H,5-6H2,(H,12,13)",JENBDJGHNIOHAJ-UHFFFAOYSA-N,tinazoline,Launched,adrenergic receptor agonist,,,
CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,"InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3",HJLSLZFTEKNLFI-UHFFFAOYSA-N,tinidazole,Launched,antiprotozoal agent,,infectious disease|obstetrics/gynecology,giardiasis|amebiasis|bacterial vaginosis|trichomoniasis
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2,"InChI=1S/C17H20N2O2S/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12/h3-7H,2,8-11,18H2,1H3",PFENFDGYVLAFBR-UHFFFAOYSA-N,tinoridine,Launched,anti-inflammatory agent,,neurology/psychiatry,pain relief
Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,"InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2",QXHHHPZILQDDPS-UHFFFAOYSA-N,tioconazole,Launched,sterol demethylase inhibitor,,infectious disease,yeast infection
N=c1[nH]c(=S)c2ncn(C3OC(CO)C(O)C3O)c2[nH]1,"InChI=1S/C10H13N5O4S/c11-10-13-7-4(8(20)14-10)12-2-15(7)9-6(18)5(17)3(1-16)19-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,20)",OTDJAMXESTUWLO-UHFFFAOYSA-N,tioguanine,Launched,purine antagonist,,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)
CC(S)C(=O)NCC(=O)O,"InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)",YTGJWQPHMWSCST-UHFFFAOYSA-N,tiopronin,Launched,chelating agent,,urology,kidney stones
CC(S)C(=O)NCC(=O)O,"InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)",YTGJWQPHMWSCST-UHFFFAOYSA-N,tiopronin,Launched,reducing agent,,urology,kidney stones
CN=C(NC#N)NCCSCc1csc(=NC(=N)N)[nH]1,"InChI=1S/C10H16N8S2/c1-14-9(16-6-11)15-2-3-19-4-7-5-20-10(17-7)18-8(12)13/h5H,2-4H2,1H3,(H2,14,15,16)(H4,12,13,17,18)",YDDXVAXDYKBWDX-UHFFFAOYSA-N,tiotidine,Phase 2,histamine receptor antagonist,HRH2,,
C[N+]1(C)C2CC(OC(=O)C(O)(c3cccs3)c3cccs3)CC1C1OC12,"InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1",LERNTVKEWCAPOY-UHFFFAOYSA-N,tiotropium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
O=c1oc2cc(O)ccc2s1,"InChI=1S/C7H4O3S/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3,8H",SLYPOVJCSQHITR-UHFFFAOYSA-N,tioxolone,Preclinical,carbonic anhydrase inhibitor,CA2,,
CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O,"InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)",KPWYNAGOBXLMSE-UHFFFAOYSA-N,tipelukast,Phase 2,leukotriene receptor antagonist,,,
Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3",PLHJCIYEEKOWNM-UHFFFAOYSA-N,tipifarnib,Phase 3,farnesyltransferase inhibitor,FNTA|FNTB,,
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,"InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)",QQHMKNYGKVVGCZ-UHFFFAOYSA-N,tipiracil,Launched,thymidine phosphorylase inhibitor,,oncology,colorectal cancer
O=C(O)C(=O)c1cn(Cc2ccccc2)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc12,"InChI=1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)",ODXQFEWQSHNQNI-UHFFFAOYSA-N,tiplaxtinin,Phase 1,plasminogen activator inhibitor,SERPINE1,,
CCCC1(CCc2ccccc2)CC(=O)C(C(CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,"InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,28,36H,3-4,15-17,19H2,1-2H3",MYXACKZCYFKMTE-UHFFFAOYSA-N,tipranavir,Launched,HIV protease inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CSc1ccccc1OCC(O)CNC(C)C,"InChI=1S/C13H21NO2S/c1-10(2)14-8-11(15)9-16-12-6-4-5-7-13(12)17-3/h4-7,10-11,14-15H,8-9H2,1-3H3",CSUNLSYSEQIDMO-UHFFFAOYSA-N,tiprenolol,Phase 2,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
C[N+]12CCCCC1CCC(=C(c1cccs1)c1cccs1)C2,"InChI=1S/C19H24NS2/c1-20-11-3-2-6-16(20)10-9-15(14-20)19(17-7-4-12-21-17)18-8-5-13-22-18/h4-5,7-8,12-13,16H,2-3,6,9-11,14H2,1H3/q+1",ZGSDGGRVFIYKKE-UHFFFAOYSA-N,tiquizium,Launched,acetylcholine receptor antagonist,,neurology/psychiatry,spasms
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(C)C)c1ccccc1CC2,"InChI=1S/C21H25N3O3/c1-4-27-21(26)22-17-12-11-16-10-9-15-7-5-6-8-18(15)24(19(16)13-17)20(25)14-23(2)3/h5-8,11-13H,4,9-10,14H2,1-3H3,(H,22,26)",KJAMZCVTJDTESW-UHFFFAOYSA-N,tiracizine,Withdrawn,sodium channel blocker,SCN5A,,
N=c1[nH][n+]([O-])c2ccccc2[n+]1[O-],"InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)",ORYDPOVDJJZGHQ-UHFFFAOYSA-N,tirapazamine,Phase 3,DNA inhibitor,,,
C#Cc1cnc2[nH]c(=O)n(C(CC)CC)c2n1,"InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17)",RSQGZEAXODVTOL-UHFFFAOYSA-N,tirasemtiv,Phase 2,troponin activator,,,
O=C(O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,"InChI=1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)",UOWZUVNAGUAEQC-UHFFFAOYSA-N,tiratricol,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,Refetoff syndrome
CCCCS(=O)(=O)NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,"InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)",COKMIXFXJJXBQG-UHFFFAOYSA-N,tirofiban,Launched,platelet aggregation inhibitor,ITGA2B|ITGB3,cardiology,myocardial infarction|refactory angina
CCCCS(=O)(=O)NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,"InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)",COKMIXFXJJXBQG-UHFFFAOYSA-N,tirofiban,Launched,structural glycoprotein antagonist,ITGA2B|ITGB3,cardiology,myocardial infarction|refactory angina
C1=CCC=C1,"InChI=1S/C5H6/c1-2-4-5-3-1/h1-4H,5H2",ZSWFCLXCOIISFI-UHFFFAOYSA-N,titanocene-dichloride,Phase 2,apoptosis stimulant,,,
Oc1[nH]c(O)c(-c2cn3c4c(cccc24)CCC3)c1-c1c[nH]c2ccccc12,"InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,24-25,27-28H,4,6,10H2",SPBRERBTQCKOBN-UHFFFAOYSA-N,tivantinib,Phase 3,tyrosine kinase inhibitor,MET,,
COc1cc2nccc(Oc3ccc(NC(=O)N=c4cc(C)o[nH]4)c(Cl)c3)c2cc1OC,"InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",SPMVMDHWKHCIDT-UHFFFAOYSA-N,tivozanib,Launched,VEGFR inhibitor,FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB,oncology,renal cell carcinoma (RCC)
Clc1ccc2nsnc2c1NC1=NCCN1,"InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)",XFYDIVBRZNQMJC-UHFFFAOYSA-N,tizanidine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|NISCH,neurology/psychiatry,spasms
Cc1ccc(CCCO)c(NCc2ccc3[nH]c(=NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,"InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)",DKORMNNYNRPTBJ-UHFFFAOYSA-N,tmc-353121,Phase 2,RSV fusion inhibitor,,,
COc1ccc2c(c1)C=C1Cn3c-2c(C2CCCCC2)c2ccc(cc23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O,"InChI=1S/C32H38N4O6S/c1-34-13-15-42-16-14-35(2)43(39,40)33-31(37)22-9-11-27-28(19-22)36-20-24(32(34)38)17-23-18-25(41-3)10-12-26(23)30(36)29(27)21-7-5-4-6-8-21/h9-12,17-19,21H,4-8,13-16,20H2,1-3H3,(H,33,37)",UOBYJVFBFSLCTQ-UHFFFAOYSA-N,tmc647055,Phase 2,RNA polymerase inhibitor,,,
O=C(NC(=O)c1c(F)cccc1Cl)NC1c2ccccc2-c2ccccc21,"InChI=1S/C21H14ClFN2O2/c22-16-10-5-11-17(23)18(16)20(26)25-21(27)24-19-14-8-3-1-6-12(14)13-7-2-4-9-15(13)19/h1-11,19H,(H2,24,25,26,27)",SFNLLCUAISZNRV-UHFFFAOYSA-N,tmn-355,Preclinical,cyclophilin inhibitor,PPIA,,
CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1,"InChI=1S/C16H31NO2/c1-6-7-8-9-10-14(18)19-13-11-15(2,3)17-16(4,5)12-13/h13,17H,6-12H2,1-5H3",PWWKJRFUJIFGGD-UHFFFAOYSA-N,tmph,Preclinical,,,,
COc1cc(C=Cc2ccc(OC)cc2OC)cc(OC)c1,"InChI=1S/C18H20O4/c1-19-15-8-7-14(18(12-15)22-4)6-5-13-9-16(20-2)11-17(10-13)21-3/h5-12H,1-4H3",JDBCWSHYEQUBLW-UHFFFAOYSA-N,tms,Preclinical,,,,
COC1C(OC(=O)NC(=O)CCl)CCC2(CO2)C1C1(C)OC1CC=C(C)C,"InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)",MSHZHSPISPJWHW-UHFFFAOYSA-N,tnp-470,Phase 2,methionine aminopeptidase inhibitor,METAP2,,
NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O,"InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2",NLVFBUXFDBBNBW-UHFFFAOYSA-N,tobramycin,Launched,bacterial 30S ribosomal subunit inhibitor,,infectious disease,bacterial septicemia|respiratory tract infections|meningitis|skin infections|urinary tract infections
Cc1cccc(C)c1NC(=O)C(C)N,"InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)",BUJAGSGYPOAWEI-UHFFFAOYSA-N,tocainide,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia
Cc1[nH]c(Cc2c(O)[nH]c3ccc(F)cc23)c(C)c1C(=O)N=CCN1CCCC1,"InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-7,11,25-26,28H,3-4,8-10,12H2,1-2H3",GZEHPNWWXZEWLN-UHFFFAOYSA-N,toceranib,Launched,protein tyrosine kinase inhibitor,FLT1|FLT3|KDR|PDGFRA|PDGFRB,oncology,cutaneous mast cell tumors
Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)OCCO)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C35H58O6/c1-24(2)12-9-13-25(3)14-10-15-26(4)16-11-20-35(8)21-19-30-29(7)33(27(5)28(6)34(30)41-35)40-32(38)18-17-31(37)39-23-22-36/h24-26,36H,9-23H2,1-8H3",AOBORMOPSGHCAX-UHFFFAOYSA-N,tocofersolan,Launched,antioxidant,,cardiology,cerebral cholesterosis
CCOC(=O)NN=c1[nH]ncc2ccccc12,"InChI=1S/C11H12N4O2/c1-2-17-11(16)15-14-10-9-6-4-3-5-8(9)7-12-13-10/h3-7H,2H2,1H3,(H,13,14)(H,15,16)",WGZDBVOTUVNQFP-UHFFFAOYSA-N,todralazine,Launched,antihypertensive agent,,cardiology,hypertension
CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)",UJLAWZDWDVHWOW-UHFFFAOYSA-N,tofacitinib,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis
CCC1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,"InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3",RUJBDQSFYCKFAA-UHFFFAOYSA-N,tofisopam,Launched,cytochrome P450 inhibitor,CYP3A4,neurology/psychiatry,anxiety|abstinence from alcohol
CCC1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21,"InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3",RUJBDQSFYCKFAA-UHFFFAOYSA-N,tofisopam,Launched,phosphodiesterase inhibitor,CYP3A4,neurology/psychiatry,anxiety|abstinence from alcohol
CCc1ccc(Cc2ccc3c(c2)C2(OC3)OC(CO)C(O)C(O)C2O)cc1,"InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3",VWVKUNOPTJGDOB-UHFFFAOYSA-N,tofogliflozin,Launched,sodium/glucose cotransporter inhibitor,GCK,endocrinology,diabetes mellitus
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1,"InChI=1S/C19H24N2O4/c1-14-4-2-3-5-18(14)25-13-16(22)12-21-10-11-24-17-8-6-15(7-9-17)19(20)23/h2-9,16,21-22H,10-13H2,1H3,(H2,20,23)",SKQDKFOTIPJUSV-UHFFFAOYSA-N,tolamolol,Phase 3,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,
Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1,"InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)",OUDSBRTVNLOZBN-UHFFFAOYSA-N,tolazamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus
c1ccc(CC2=NCCN2)cc1,"InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)",JIVZKJJQOZQXQB-UHFFFAOYSA-N,tolazoline,Launched,adrenergic receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2,neurology/psychiatry,reverse sedative
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,"InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)",JLRGJRBPOGGCBT-UHFFFAOYSA-N,tolbutamide,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ11|KCNJ8,endocrinology,diabetes mellitus
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,"InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3",MIQPIUSUKVNLNT-UHFFFAOYSA-N,tolcapone,Withdrawn,catechol O methyltransferase inhibitor,COMT,,
Cc1c(Cl)cccc1Nc1ccccc1C(=O)O,"InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)",YEZNLOUZAIOMLT-UHFFFAOYSA-N,tolfenamic-acid,Launched,cyclooxygenase inhibitor,,neurology/psychiatry,migraine headache
Cc1c(Cl)cccc1Nc1ccccc1C(=O)O,"InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)",YEZNLOUZAIOMLT-UHFFFAOYSA-N,tolfenamic-acid,Launched,prostanoid receptor antagonist,,neurology/psychiatry,migraine headache
Cc1cccc(Oc2cnc(=O)[nH]c2)c1,"InChI=1S/C11H10N2O2/c1-8-3-2-4-9(5-8)15-10-6-12-11(14)13-7-10/h2-7H,1H3,(H,12,13,14)",HJQILFPVRNHTIG-UHFFFAOYSA-N,tolimidone,Phase 2,SRC activator,LYN|SRC,,
Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,"InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)",UPSPUYADGBWSHF-UHFFFAOYSA-N,tolmetin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis
Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1,"InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3",FUSNMLFNXJSCDI-UHFFFAOYSA-N,tolnaftate,Launched,fungal squalene epoxidase inhibitor,,infectious disease,tinea pedis|tinea corporis
Cc1ccc(NC2=NCCN2)c(Cl)c1,"InChI=1S/C10H12ClN3/c1-7-2-3-9(8(11)6-7)14-10-12-4-5-13-10/h2-3,6H,4-5H2,1H3,(H2,12,13,14)",KWBTZIFLQYYPTH-UHFFFAOYSA-N,tolonidine,Launched,adrenergic receptor antagonist,ADRA2A,,
Cc1cc2nc3ccc(=[N+](C)C)cc-3sc2cc1N,"InChI=1S/C15H15N3S/c1-9-6-13-15(8-11(9)16)19-14-7-10(18(2)3)4-5-12(14)17-13/h4-8,16H,1-3H3/p+1",KZEUBCUXBNEMSQ-UHFFFAOYSA-O,tolonium,Launched,,,hematology,methemoglobinemia
Cc1cccc(N2CC(CO)OC2=O)c1,"InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3",MXUNKHLAEDCYJL-UHFFFAOYSA-N,toloxatone,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression
Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1,"InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3",FSKFPVLPFLJRQB-UHFFFAOYSA-N,tolperisone,Launched,voltage-gated sodium channel blocker,CYP2C19|CYP2D6,neurology/psychiatry|infectious disease|rheumatology|cardiology,muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease
COc1ccc2c(C(=S)N(C)CC(=O)O)cccc2c1C(F)(F)F,"InChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)",LUBHDINQXIHVLS-UHFFFAOYSA-N,tolrestat,Withdrawn,aldose reductase inhibitor,AKR1A1|AKR1B1|AKR1B10,,
Cc1ccc(O)c(C(CCN(C(C)C)C(C)C)c2ccccc2)c1,"InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3",OOGJQPCLVADCPB-UHFFFAOYSA-N,tolterodine,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency
Cc1cc(-n2c(=O)[nH]c(=O)n(C)c2=O)ccc1Oc1ccc(SC(F)(F)F)cc1,"InChI=1S/C18H14F3N3O4S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)28-12-4-6-13(7-5-12)29-18(19,20)21/h3-9H,1-2H3,(H,22,25,26)",OCINXEZVIIVXFU-UHFFFAOYSA-N,toltrazuril,Launched,antiprotozoal agent,,infectious disease,coccidiosis
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",GYHCTFXIZSNGJT-UHFFFAOYSA-N,tolvaptan,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology|cardiology|gastroenterology,hyponatremia|congestive heart failure|hepatic cirrhosis
CN(C)c1cccc2c(S(=O)(=O)Nc3ccc(NC(=O)C(C)(C)CO)cc3)cccc12,"InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)",OSQAKHSYTKBSPB-UHFFFAOYSA-N,tomeglovir,Preclinical,antiviral,,,
CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O,"InChI=1S/C16H22N4O3/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15/h8-9,22H,3-7,10H2,1-2H3,(H,17,18,19,20)",MWYHLEQJTQJHSS-UHFFFAOYSA-N,tomelukast,Phase 3,leukotriene receptor antagonist,CYSLTR1,,
Cc1cc(N=c2cc(N)[nH]cn2)c(=O)n2c1C(=O)NC21CCCCC1,"InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)",HKTBYUWLRDZAJK-UHFFFAOYSA-N,tomivosertib,Phase 2,MAPK-interacting kinase inhibitor,,,
CC(=O)c1ccc2c(c1)C(NC(=O)c1ccc(F)c(Cl)c1)C(O)C(C)(C)O2,"InChI=1S/C20H19ClFNO4/c1-10(24)11-5-7-16-13(8-11)17(18(25)20(2,3)27-16)23-19(26)12-4-6-15(22)14(21)9-12/h4-9,17-18,25H,1-3H3,(H,23,26)",XLIIRNOPGJTBJD-UHFFFAOYSA-N,tonabersat,Phase 2,gap junction modulator,,,
CC(=O)c1ccc2c(c1)C(NC(=O)c1ccc(F)c(Cl)c1)C(O)C(C)(C)O2,"InChI=1S/C20H19ClFNO4/c1-10(24)11-5-7-16-13(8-11)17(18(25)20(2,3)27-16)23-19(26)12-4-6-15(22)14(21)9-12/h4-9,17-18,25H,1-3H3,(H,23,26)",XLIIRNOPGJTBJD-UHFFFAOYSA-N,tonabersat,Phase 2,nitric oxide production inhibitor,,,
CC(O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,"InChI=1S/C13H11F6N3O5/c1-11(25,5-20-10(24)13(17,18)19)9(23)21-6-2-3-8(22(26)27)7(4-6)12(14,15)16/h2-4,25H,5H2,1H3,(H,20,24)(H,21,23)",YCNCRLKXSLARFT-UHFFFAOYSA-N,topilutamide,Preclinical,androgen receptor antagonist,,,
CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1,"InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)",KJADKKWYZYXHBB-UHFFFAOYSA-N,topiramate,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache
CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1,"InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)",KJADKKWYZYXHBB-UHFFFAOYSA-N,topiramate,Launched,glutamate receptor antagonist,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache
CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1,"InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)",KJADKKWYZYXHBB-UHFFFAOYSA-N,topiramate,Launched,kainate receptor antagonist,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache
N#Cc1cc(-c2n[nH]c(-c3ccncc3)n2)ccn1,"InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)",UBVZQGOVTLIHLH-UHFFFAOYSA-N,topiroxostat,Launched,xanthine oxidase inhibitor,XDH,rheumatology|nephrology,gout|hyperuricemia
CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,"InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3",UCFGDBYHRUNTLO-UHFFFAOYSA-N,topotecan,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,small cell lung cancer|cervical cancer
Cc1cccc(N=c2cc[nH]cc2S(=O)(=O)NC(=O)NC(C)C)c1,"InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)",NGBFQHCMQULJNZ-UHFFFAOYSA-N,torasemide,Launched,electrolyte reabsorption inhibitor,SLC12A1,cardiology,edema|congestive heart failure|hypertension
Cc1cccc(N=c2cc[nH]cc2S(=O)(=O)NC(=O)NC(C)C)c1,"InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)",NGBFQHCMQULJNZ-UHFFFAOYSA-N,torasemide,Launched,thromboxane receptor antagonist,SLC12A1,cardiology,edema|congestive heart failure|hypertension
CCOC(=O)N1c2ccc(C(F)(F)F)cc2C(N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)CC1CC,"InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3",CMSGWTNRGKRWGS-UHFFFAOYSA-N,torcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,
N=c1ccn(C2CC(O)C(CO)O2)c(=O)[nH]1,"InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)",CKTSBUTUHBMZGZ-UHFFFAOYSA-N,torcitabine,Phase 2,DNA polymerase inhibitor,DCK|TK2,,
CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,"InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3",XFCLJVABOIYOMF-UHFFFAOYSA-N,toremifene,Launched,estrogen receptor antagonist,ESR1,oncology,breast cancer
CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,"InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3",XFCLJVABOIYOMF-UHFFFAOYSA-N,toremifene,Launched,selective estrogen receptor modulator (SERM),ESR1,oncology,breast cancer
CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1,"InChI=1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3",AKCRNFFTGXBONI-UHFFFAOYSA-N,torin-1,Preclinical,mTOR inhibitor,MTOR,,
N=c1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)c[nH]1,"InChI=1S/C24H15F3N4O/c25-24(26,27)17-2-1-3-18(11-17)31-22(32)9-6-16-13-29-20-7-4-14(10-19(20)23(16)31)15-5-8-21(28)30-12-15/h1-13H,(H2,28,30)",GUXXEUUYCAYESJ-UHFFFAOYSA-N,torin-2,Preclinical,mTOR inhibitor,MTOR,,
CC(C)CC(C(=O)C(O)=NO)C(O)NC(C(=O)OC1CCCC1)c1ccccc1,"InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-17,19,22,25,28H,6-7,10-12H2,1-2H3,(H,23,26)",ZRQGYARGZXJPPR-UHFFFAOYSA-N,tosedostat,Phase 2,peptidase inhibitor,ANPEP|LAP3|NPEPPS,,
NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1,"InChI=1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)",WUWFMDMBOJLQIV-UHFFFAOYSA-N,tosufloxacin,Launched,bacterial DNA gyrase inhibitor,,infectious disease,gram-negative bacterial infections
N#Cc1cn(C2OC(CO)C(O)C2O)c2[nH]cnc(=N)c12,"InChI=1S/C12H13N5O4/c13-1-5-2-17(11-7(5)10(14)15-4-16-11)12-9(20)8(19)6(3-18)21-12/h2,4,6,8-9,12,18-20H,3H2,(H2,14,15,16)",XOKJUSAYZUAMGJ-UHFFFAOYSA-N,toyocamycin,Phase 1,serine/threonine kinase inhibitor,ERN1,,
COc1ccc(N2CCOCC2)c2sc(=NC(=O)N3CCC(C)(O)CC3)[nH]c12,"InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)",XNBRWUQWSKXMPW-UHFFFAOYSA-N,tozadenant,Phase 3,adenosine receptor antagonist,ADORA2A,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)[nH][nH]1,"InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)",GCIKSSRWRFVXBI-UHFFFAOYSA-N,tozasertib,Phase 2,Aurora kinase inhibitor,AURKA|AURKB|AURKC|LCK,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)[nH][nH]1,"InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)",GCIKSSRWRFVXBI-UHFFFAOYSA-N,tozasertib,Phase 2,Bcr-Abl kinase inhibitor,AURKA|AURKB|AURKC|LCK,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)[nH][nH]1,"InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)",GCIKSSRWRFVXBI-UHFFFAOYSA-N,tozasertib,Phase 2,FLT3 inhibitor,AURKA|AURKB|AURKC|LCK,,
Cc1cc(=Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)[nH][nH]1,"InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)",GCIKSSRWRFVXBI-UHFFFAOYSA-N,tozasertib,Phase 2,JAK inhibitor,AURKA|AURKB|AURKC|LCK,,
CC(C)(O)c1ccn2c(-c3ccc(F)c(-c4ccc(F)cc4C#N)c3)cnc2c1F,"InChI=1S/C23H16F3N3O/c1-23(2,30)18-7-8-29-20(12-28-22(29)21(18)26)13-3-6-19(25)17(10-13)16-5-4-15(24)9-14(16)11-27/h3-10,12,30H,1-2H3",SJMMDWXJSSJHOQ-UHFFFAOYSA-N,tp-003,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CN1CCN(Cc2ccc(N=c3[nH]cc(Cl)c(=Nc4ccccc4S(=O)(=O)N(C)C)[nH]3)cc2)CC1,"InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)",YUAALFPUEOYPNX-UHFFFAOYSA-N,tp-0903,Phase 1/Phase 2,AXL kinase inhibitor,AXL,,
CC(C)(O)C1CCC(N=c2ccc3ncc(-c4cccc(C(F)(F)F)c4)n3[nH]2)CC1,"InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)",XRNVABDYQLHODA-UHFFFAOYSA-N,tp-3654,Phase 1,"1,4,5-trisphosphate inhibitor",,,
NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O,"InChI=1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18)",SAYGKHKXGCPTLX-UHFFFAOYSA-N,tpca-1,Preclinical,IKK inhibitor,IKBKB,,
O=S(=O)(O)c1ccc(-c2c3nc(c(-c4ccc(S(=O)(=O)O)cc4)c4ccc([nH]4)c(-c4ccc(S(=O)(=O)O)cc4)c4ccc([nH]4)c(-c4ccc(S(=O)(=O)O)cc4)c4nc2C=C4)C=C3)cc1,"InChI=1S/C44H30N4O12S4/c49-61(50,51)29-9-1-25(2-10-29)41-33-17-19-35(45-33)42(26-3-11-30(12-4-26)62(52,53)54)37-21-23-39(47-37)44(28-7-15-32(16-8-28)64(58,59)60)40-24-22-38(48-40)43(36-20-18-34(41)46-36)27-5-13-31(14-6-27)63(55,56)57/h1-24,45-46H,(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)",YAVMDSYMZGJNES-UHFFFAOYSA-N,tpps4,Phase 1,,,,
O=[N+]([O-])OCC1OC(n2cnc3c(=NC4CCCC4)[nH]cnc32)C(O)C1O,"InChI=1S/C15H20N6O6/c22-11-9(5-26-21(24)25)27-15(12(11)23)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,22-23H,1-5H2,(H,16,17,19)",AQLVRTWKJDTWQQ-UHFFFAOYSA-N,trabodenoson,Phase 3,adenosine receptor agonist,,,
CCCCN=c1c(C(=O)OCC)c(C)[nH]c2c1cnn2CC,"InChI=1S/C16H24N4O2/c1-5-8-9-17-14-12-10-18-20(6-2)15(12)19-11(4)13(14)16(21)22-7-3/h10H,5-9H2,1-4H3,(H,17,19)",PCTRYMLLRKWXGF-UHFFFAOYSA-N,tracazolate,Phase 2,GABA receptor modulator,GABRA1,,
O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1,"InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2",CAVRKWRKTNINFF-UHFFFAOYSA-N,tradipitant,Phase 3,neurokinin receptor antagonist,,,
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1,"InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H",KBFUQFVFYYBHBT-UHFFFAOYSA-N,tram-34,Preclinical,potassium channel antagonist,KCNN4,,
N#CC(c1ccccc1)(c1ccccc1)c1ccccc1Cl,"InChI=1S/C20H14ClN/c21-19-14-8-7-13-18(19)20(15-22,16-9-3-1-4-10-16)17-11-5-2-6-12-17/h1-14H",JHNRTPKGSCVKKC-UHFFFAOYSA-N,tram-39,Preclinical,calcium-activated potassium channel activator,KCNN4,,
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,trametinib,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma
NCCCS(=O)(=O)O,"InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)",SNKZJIOFVMKAOJ-UHFFFAOYSA-N,tramiprosate,Phase 3,beta amyloid protein neurotoxicity inhibitor,APP,,
CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21,"InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)",VXFJYXUZANRPDJ-UHFFFAOYSA-N,trandolapril,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction
NCC1CCC(C(=O)O)CC1,"InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)",GYDJEQRTZSCIOI-UHFFFAOYSA-N,tranexamic-acid,Launched,antifibrinolytic,PLG,hematology,hemophilia
NCC1CCC(C(=O)O)CC1,"InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)",GYDJEQRTZSCIOI-UHFFFAOYSA-N,tranexamic-acid,Launched,plasminogen activator inhibitor,PLG,hematology,hemophilia
COc1ccc(C=CC(=O)Nc2ccccc2C(=O)O)cc1OC,"InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)",NZHGWWWHIYHZNX-UHFFFAOYSA-N,tranilast,Launched,angiogenesis inhibitor,HPGDS|HRH1,pulmonary,asthma
CCCCCC=CC=CCCCCCCCCC(=O)O,"InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-9H,2-5,10-17H2,1H3,(H,19,20)",GKJZMAHZJGSBKD-UHFFFAOYSA-N,"trans-10,cis-12-conjugated-linoleic-acid",Launched,,,,
CCCCCCCC=CCC(=O)O,"InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h8-9H,2-7,10H2,1H3,(H,12,13)",OQDNPLAISLNBNS-UHFFFAOYSA-N,trans-2-undecenoic-acid,Preclinical,,,,
O=C(O)C1CCC(c2cc3cccnc3c(-c3cccc(F)c3)n2)CC1,"InChI=1S/C21H19FN2O2/c22-17-5-1-3-15(11-17)20-19-16(4-2-10-23-19)12-18(24-20)13-6-8-14(9-7-13)21(25)26/h1-5,10-14H,6-9H2,(H,25,26)",XWVBOPKUSVZZPJ-UHFFFAOYSA-N,"trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",Preclinical,,,,
O=CCCC(=O)O,"InChI=1S/C4H6O3/c5-3-1-2-4(6)7/h3H,1-2H2,(H,6,7)",UIUJIQZEACWQSV-UHFFFAOYSA-N,trans-4-hydroxycrotonic-acid,Preclinical,gamma hydroxybutyric acid ligand,,,
COc1ccc(C=CC(=O)O)cc1,"InChI=1S/C10H10O3/c1-13-9-5-2-8(3-6-9)4-7-10(11)12/h2-7H,1H3,(H,11,12)",AFDXODALSZRGIH-UHFFFAOYSA-N,trans-4-methoxycinnamic-acid,Preclinical,,,,
CC(C=CC=C(C)C(=O)O)=CC=CC=C(C)C=CC=C(C)C(=O)O,"InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)",PANKHBYNKQNAHN-UHFFFAOYSA-N,transcrocetinate,Preclinical,glutamate receptor antagonist,,,
NC1CC1c1ccccc1,"InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2",AELCINSCMGFISI-UHFFFAOYSA-N,tranylcypromine,Launched,monoamine oxidase inhibitor,KDM1A|MAOA|MAOB,neurology/psychiatry,depression
CCn1c(=O)n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c2ccccc21,"InChI=1S/C24H35N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19,28H,2-7,10-11,14-18H2,1H3",DCRGHMJXEBSRQG-UHFFFAOYSA-N,trap-101,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,
CCn1c(=O)n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c2ccccc21,"InChI=1S/C24H35N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19,28H,2-7,10-11,14-18H2,1H3",DCRGHMJXEBSRQG-UHFFFAOYSA-N,trap-101,Preclinical,opioid receptor antagonist,OPRL1,,
CCN(CC)c1cc(C)nc2ncnn12,"InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3",GSNOZLZNQMLSKJ-UHFFFAOYSA-N,trapidil,Launched,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD)
CC(C)OC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(O)COc1cccc(C(F)(F)F)c1,"InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3",MKPLKVHSHYCHOC-UHFFFAOYSA-N,travoprost,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma
CC(C(O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,"InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3",QEMSVZNTSXPFJA-UHFFFAOYSA-N,traxoprodil,Phase 2,glutamate receptor antagonist,GRIN2B,,
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,"InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",PHLBKPHSAVXXEF-UHFFFAOYSA-N,trazodone,Launched,adrenergic receptor antagonist,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,"InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",PHLBKPHSAVXXEF-UHFFFAOYSA-N,trazodone,Launched,serotonin receptor antagonist,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,"InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",PHLBKPHSAVXXEF-UHFFFAOYSA-N,trazodone,Launched,serotonin reuptake inhibitor,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression
CC1Oc2ccccc2CC1N(C)C,"InChI=1S/C12H17NO/c1-9-11(13(2)3)8-10-6-4-5-7-12(10)14-9/h4-7,9,11H,8H2,1-3H3",FDJAKSHVOONYHX-UHFFFAOYSA-N,trebenzomine,Phase 2,,,,
Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O,"InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3",IWYJYHUNXVAVAA-UHFFFAOYSA-N,trelagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
C(#CCN1CCCC1)CN1CCCC1,"InChI=1S/C12H20N2/c1-2-8-13(7-1)11-5-6-12-14-9-3-4-10-14/h1-4,7-12H2",JSUAJTLKVREZHV-UHFFFAOYSA-N,tremorine,Preclinical,acetylcholine receptor agonist,,,
CS(=O)(=O)OCC(O)C(O)COS(C)(=O)=O,"InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3",YCPOZVAOBBQLRI-UHFFFAOYSA-N,treosulfan,Launched,DNA synthesis inhibitor,,oncology,ovarian cancer
CCOc1cc(OCC)c(C(=O)CCC(=O)O)cc1OCC,"InChI=1S/C16H22O6/c1-4-20-13-10-15(22-6-3)14(21-5-2)9-11(13)12(17)7-8-16(18)19/h9-10H,4-8H2,1-3H3,(H,18,19)",YPTFHLJNWSJXKG-UHFFFAOYSA-N,trepibutone,Launched,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,irritable bowel syndrome
CCCCCC(O)CCC1C(O)CC2Cc3c(cccc3OCC(=O)O)CC21,"InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)",PAJMKGZZBBTTOY-UHFFFAOYSA-N,treprostinil,Launched,prostanoid receptor agonist,P2RY12|PPARD|PTGIR,pulmonary,pulmonary arterial hypertension (PAH)
COc1cc2c(cc1OC)-c1cc(=Nc3c(C)cc(C)cc3C)n(C)c(=O)n1CC2,"InChI=1S/C24H27N3O3/c1-14-9-15(2)23(16(3)10-14)25-22-13-19-18-12-21(30-6)20(29-5)11-17(18)7-8-27(19)24(28)26(22)4/h9-13H,7-8H2,1-6H3",MCMSJVMUSBZUCN-UHFFFAOYSA-N,trequinsin,Phase 1,phosphodiesterase inhibitor,PDE5A,,
NC(=O)c1cc(N2CC2)c([N+](=O)[O-])cc1[N+](=O)[O-],"InChI=1S/C9H8N4O5/c10-9(14)5-3-7(11-1-2-11)8(13(17)18)4-6(5)12(15)16/h3-4H,1-2H2,(H2,10,14)",WOCXQMCIOTUMJV-UHFFFAOYSA-N,tretazicar,Phase 2,DNA replication inhibitor,NQO2,,
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)",SHGAZHPCJJPHSC-UHFFFAOYSA-N,tretinoin,Launched,retinoid receptor agonist,ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG,hematologic malignancy,acute promyelocytic leukemia (APL)
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,"InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)",SHGAZHPCJJPHSC-UHFFFAOYSA-N,tretinoin,Launched,retinoid receptor ligand,ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG,hematologic malignancy,acute promyelocytic leukemia (APL)
CC(=O)OCC(COC(C)=O)OC(C)=O,"InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3",URAYPUMNDPQOKB-UHFFFAOYSA-N,triacetin,Launched,,,,
CC12C=CC(=O)C=C1CCC1C3CC(O)C(O)(C(=O)CO)C3(C)CC(O)C12F,"InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3",GFNANZIMVAIWHM-UHFFFAOYSA-N,triamcinolone,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses
CC1(C)OC2CC3C4CC=C5CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h5,7-8,15-17,19,26,28H,6,9-12H2,1-4H3",AIPSXDXZFKITIG-UHFFFAOYSA-N,triamcinolone-acetonide,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses
CC1(C)OC2CC3C4CC=C5CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1,"InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h5,7-8,15-17,19,26,28H,6,9-12H2,1-4H3",AIPSXDXZFKITIG-UHFFFAOYSA-N,triamcinolone-acetonide,Launched,immunosuppressant,NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses
CC(C)(C)CC(=O)OCC(=O)C12OC(C)(C)OC1CC1C3CC=C4CC(=O)C=CC4(C)C3(F)C(O)CC12C,"InChI=1S/C30H41FO7/c1-25(2,3)15-24(35)36-16-22(34)30-23(37-26(4,5)38-30)13-20-19-9-8-17-12-18(32)10-11-27(17,6)29(19,31)21(33)14-28(20,30)7/h8,10-11,19-21,23,33H,9,12-16H2,1-7H3",BJOHUNZQBNULNC-UHFFFAOYSA-N,triamcinolone-hexacetonide,Launched,anti-inflammatory agent,,,
N=c1[nH]c(=N)c2nc(-c3ccccc3)c(=N)[nH]c2[nH]1,"InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)",FNYLWPVRPXGIIP-UHFFFAOYSA-N,triamterene,Launched,sodium channel blocker,SCNN1A|SCNN1B|SCNN1D|SCNN1G,endocrinology|cardiology,hypokalemia|hypertension|edema
NC(=S)NN=Cc1ncccc1N,"InChI=1S/C7H9N5S/c8-5-2-1-3-10-6(5)4-11-12-7(9)13/h1-4H,8H2,(H3,9,12,13)",XMYKNCNAZKMVQN-UHFFFAOYSA-N,triapine,Phase 2,ribonucleotide reductase inhibitor,RRM1|RRM2,,
CCOC1OC(C(COCc2ccccc2)OCc2ccccc2)C(OCc2ccccc2)C1O,"InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3",ULLNJSBQMBKOJH-UHFFFAOYSA-N,tribenoside,Launched,anti-inflammatory agent,,,
CCOC1OC(C(COCc2ccccc2)OCc2ccccc2)C(OCc2ccccc2)C1O,"InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3",ULLNJSBQMBKOJH-UHFFFAOYSA-N,tribenoside,Launched,capillary stabilizing agent,,,
O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O,"InChI=1S/C13H8Br3NO2/c14-7-1-3-9(4-2-7)17-13(19)10-5-8(15)6-11(16)12(10)18/h1-6,18H,(H,17,19)",KVSKGMLNBAPGKH-UHFFFAOYSA-N,tribomsalan,Preclinical,,,,
OCC(Br)(Br)Br,"InChI=1S/C2H3Br3O/c3-2(4,5)1-6/h6H,1H2",YFDSDPIBEUFTMI-UHFFFAOYSA-N,tribromoethanol,Preclinical,analgesic agent,,,
CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC,"InChI=1S/C15H26O6/c1-4-7-13(16)19-10-12(21-15(18)9-6-3)11-20-14(17)8-5-2/h12H,4-11H2,1-3H3",UYXTWWCETRIEDR-UHFFFAOYSA-N,tributyrin,Phase 1,HDAC inhibitor,,,
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,"InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3",VLPFTAMPNXLGLX-UHFFFAOYSA-N,tricaprylin,Launched,,,dermatology,cosmetic
NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O,"InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)",LMJSLTNSBFUCMU-UHFFFAOYSA-N,trichlormethiazide,Launched,chloride channel blocker,PTGS1|PTGS2|SLC12A1,cardiology,hypertension|edema
O=C(O)C(Cl)(Cl)Cl,"InChI=1S/C2HCl3O2/c3-2(4,5)1(6)7/h(H,6,7)",YNJBWRMUSHSURL-UHFFFAOYSA-N,trichloroacetic-acid,Launched,,,dermatology,warts
ClC=C(Cl)Cl,InChI=1S/C2HCl3/c3-1-2(4)5/h1H,XSTXAVWGXDQKEL-UHFFFAOYSA-N,trichloroethylene,Preclinical,,,,
CC(=CC(C)C=CC(O)=NO)C(=O)c1ccc(N(C)C)cc1,"InChI=1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-12,22H,1-4H3,(H,18,20)",ALCVRKZFLFWUAZ-UHFFFAOYSA-N,trichostatin-a,Phase 1,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,
CN1N=C(N)c2cn(C3OC(CO)C(O)C3O)c3ncnc1c23,"InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)",HOGVTUZUJGHKPL-UHFFFAOYSA-N,triciribine,Phase 1/Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
CN1N=C(N)c2cn(C3OC(CO[PH](=O)(=O)O)C(O)C3O)c3ncnc1c23,"InChI=1S/C13H16N6O7P/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(21)8(20)6(26-13)3-25-27(22,23)24/h2,4,6,8-9,13,20-21H,3H2,1H3,(H2,14,17)(H,22,23,24)",QFRVXOPVQXDLHS-UHFFFAOYSA-N,triciribine-phosphate,Phase 1/Phase 2,AKT inhibitor,,,
CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,"InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)",NQPDXQQQCQDHHW-UHFFFAOYSA-N,triclabendazole,Launched,microtubule inhibitor,DNMT1,infectious disease,tapeworm
O=C(Nc1ccc(Cl)cc1)Nc1ccc(Cl)c(Cl)c1,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-9(4-2-8)17-13(19)18-10-5-6-11(15)12(16)7-10/h1-7H,(H2,17,18,19)",ICUTUKXCWQYESQ-UHFFFAOYSA-N,triclocarban,Launched,other antibiotic,,infectious disease,first-aid antiseptic
Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,"InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H",XEFQLINVKFYRCS-UHFFFAOYSA-N,triclosan,Launched,antibacterial agent,DNMT1,infectious disease,first-aid antiseptic
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1,"InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1",NPRHVSBSZMAEIN-UHFFFAOYSA-N,tridihexethyl,Launched,acetylcholine receptor antagonist,,gastroenterology|ophthalmology,peptic ulcer disease (PUD)|nystagmus
NCCNCCNCCN,"InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2",VILCJCGEZXAXTO-UHFFFAOYSA-N,trientine,Launched,chelating agent,CA14,metabolism,Wilson's disease
CON=C(C(=O)OC)c1ccccc1CON=C(C)c1cccc(C(F)(F)F)c1,"InChI=1S/C20H19F3N2O4/c1-13(14-8-6-9-16(11-14)20(21,22)23)24-29-12-15-7-4-5-10-17(15)18(25-28-3)19(26)27-2/h4-11H,12H2,1-3H3",ONCZDRURRATYFI-UHFFFAOYSA-N,trifloxystrobin,Preclinical,mitochondrial electron transport inhibitor,,,
CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,"InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3",ZEWQUBUPAILYHI-UHFFFAOYSA-N,trifluoperazine,Launched,dopamine receptor antagonist,ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1,neurology/psychiatry,schizophrenia
CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21,"InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3",XSCGXQMFQXDFCW-UHFFFAOYSA-N,triflupromazine,Launched,dopamine receptor antagonist,CHRM1|CHRM2|DRD1|DRD2|HTR2B,neurology/psychiatry|gastroenterology,psychosis|nausea|vomiting
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1C(F)(F)F,"InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)",VSQQQLOSPVPRAZ-UHFFFAOYSA-N,trifluridine,Launched,DNA directed DNA polymerase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV)
O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1C(F)(F)F,"InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)",VSQQQLOSPVPRAZ-UHFFFAOYSA-N,trifluridine,Launched,thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV)
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O,"InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)",RMWVZGDJPAKBDE-UHFFFAOYSA-N,triflusal,Launched,cyclooxygenase inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF)
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O,"InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)",RMWVZGDJPAKBDE-UHFFFAOYSA-N,triflusal,Launched,platelet aggregation inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF)
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O,"InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)",RMWVZGDJPAKBDE-UHFFFAOYSA-N,triflusal,Launched,thromboxane synthase inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF)
C[n+]1cccc(C(=O)O)c1,"InChI=1S/C7H7NO2/c1-8-4-2-3-6(5-8)7(9)10/h2-5H,1H3/p+1",WWNNZCOKKKDOPX-UHFFFAOYSA-O,trigonelline,Phase 1,,,,
OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1,"InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2",HWHLPVGTWGOCJO-UHFFFAOYSA-N,trihexyphenidyl,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,parkinsonism
CN1CCN(c2ccc(N=c3nc4c(c[nH]3)cc3n4C4(CCCCC4)CNC3=O)nc2)CC1,"InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)",PDGKHKMBHVFCMG-UHFFFAOYSA-N,trilaciclib,Phase 2,CDK inhibitor,,,
CC12CCC3C(CCC45OC4C(=O)C(C#N)CC35C)C1CCC2O,"InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h11-15,17,22H,3-9H2,1-2H3",RLQVKDVIBJCQGE-UHFFFAOYSA-N,trilostane,Launched,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,,endocrinology,Cushing's syndrome
FC(F)(F)c1ccccc1-n1ccnc1,"InChI=1S/C10H7F3N2/c11-10(12,13)8-3-1-2-4-9(8)15-6-5-14-7-15/h1-7H",WZBWBNCQUTXYEL-UHFFFAOYSA-N,trim,Preclinical,,,,
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,"InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3",LORDFXWUHHSAQU-UHFFFAOYSA-N,trimebutine,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome
COc1ccc(CN2CCNCC2)c(OC)c1OC,"InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3",UHWVSEOVJBQKBE-UHFFFAOYSA-N,trimetazidine,Launched,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris
CN1C(=O)OC(C)(C)C1=O,InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3,IRYJRGCIQBGHIV-UHFFFAOYSA-N,trimethadione,Launched,oxazolidine antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures
COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC,"InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)",FEZBIKUBAYAZIU-UHFFFAOYSA-N,trimethobenzamide,Launched,histamine receptor antagonist,DRD2,gastroenterology,vomiting|nausea|gastroenteritis
COc1cc(Cc2c[nH]c(=N)[nH]c2=N)cc(OC)c1OC,"InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)",IEDVJHCEMCRBQM-UHFFFAOYSA-N,trimethoprim,Launched,dihydrofolate reductase inhibitor,DHFR|TYMS,infectious disease|gastroenterology,urinary tract infections|ear infections|diarrhea
COc1cc(CC2NCCc3cc(O)c(O)cc32)cc(OC)c1OC,"InChI=1S/C19H23NO5/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14/h7-10,14,20-22H,4-6H2,1-3H3",RGVPOXRFEPSFGH-UHFFFAOYSA-N,trimethoquinol,Launched,adrenergic receptor antagonist,ADRB2|ADRB3,pulmonary,asthma
C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C,"InChI=1S/C15H20O6/c1-5-12(16)19-9-15(8-4,10-20-13(17)6-2)11-21-14(18)7-3/h5-7H,1-3,8-11H2,4H3",DAKWPKUUDNSNPN-UHFFFAOYSA-N,trimethylolpropane-triacrylate,Preclinical,,,,
COc1cc(C(=O)N2CCOCC2)cc(OC)c1OC,"InChI=1S/C14H19NO5/c1-17-11-8-10(9-12(18-2)13(11)19-3)14(16)15-4-6-20-7-5-15/h8-9H,4-7H2,1-3H3",XWVOEFLBOSSYGM-UHFFFAOYSA-N,trimetozine,Launched,sedative,,neurology/psychiatry,sedative
COc1cc(NCc2ccc3[nH]c(=N)[nH]c(=N)c3c2C)cc(OC)c1OC,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,trimetrexate,Phase 3,dihydrofolate reductase inhibitor,DHFR,,
CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,"InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3",ZSCDBOWYZJWBIY-UHFFFAOYSA-N,trimipramine,Launched,norepinephrine reputake inhibitor,SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,"InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3",ZSCDBOWYZJWBIY-UHFFFAOYSA-N,trimipramine,Launched,tricyclic antidepressant,SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression
Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,"InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3",FMHHVULEAZTJMA-UHFFFAOYSA-N,trioxsalen,Launched,DNA synthesis inhibitor,,dermatology,vitiligo|eczema
CN(C)CCN(Cc1ccccc1)c1ccccn1,"InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3",UFLGIAIHIAPJJC-UHFFFAOYSA-N,tripelennamine,Launched,histamine receptor antagonist,HRH1,pulmonary|allergy,asthma|allergic rhinitis|urticaria
Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,"InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3",CBEQULMOCCWAQT-UHFFFAOYSA-N,triprolidine,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis
CC(C)C(C)(C)C,"InChI=1S/C7H16/c1-6(2)7(3,4)5/h6H,1-5H3",ZISSAWUMDACLOM-UHFFFAOYSA-N,triptan,Phase 1,serotonin receptor agonist,HTR1B|HTR1D,,
CC(C)C12OC1C1OC13C1(C)CCc4c(coc4O)C1CC1OC13C2O,"InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h7-8,11-14,16,21-22H,4-6H2,1-3H3",ALFGUYQNTDROJK-UHFFFAOYSA-N,triptolide,Phase 3,RNA polymerase inhibitor,RELA,,
CC(C)CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,"InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)",VXKHXGOKWPXYNA-UHFFFAOYSA-N,triptorelin,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology|endocrinology|obstetrics/gynecology,prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria
O=c1[nH]c(=O)n(Cl)c(=O)n1Cl,"InChI=1S/C3HCl2N3O3/c4-7-1(9)6-2(10)8(5)3(7)11/h(H,6,9,10)",CEJLBZWIKQJOAT-UHFFFAOYSA-N,troclosene,Launched,,,,
CC(C)C(CCC(C)C1CCC2C3C(O)CC4CC(NCCCNCCCCNCCCN)CCC4(C)C3CCC12C)OS(=O)(=O)O,"InChI=1S/C37H72N4O5S/c1-26(2)34(46-47(43,44)45)13-10-27(3)30-11-12-31-35-32(15-17-37(30,31)5)36(4)16-14-29(24-28(36)25-33(35)42)41-23-9-22-40-20-7-6-19-39-21-8-18-38/h26-35,39-42H,6-25,38H2,1-5H3,(H,43,44,45)",WUJVPODXELZABP-UHFFFAOYSA-N,trodusquemine,Phase 1,tyrosine phosphatase inhibitor,,,
NCC(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)O,"InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)",JJGBXTYGTKWGAT-UHFFFAOYSA-N,trofinetide,Phase 2,cytokine production inhibitor,IFNG|IL6|TNF,,
O=P1(N(CCCl)CCCl)OCCCN1CCCl,"InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2",UMKFEPPTGMDVMI-UHFFFAOYSA-N,trofosfamide,Launched,DNA alkylating agent,,oncology,medulloblastoma
Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(Cc3sc(=O)[nH]c3O)cc1)O2,"InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,26-27H,9-12H2,1-4H3,(H,25,28)",BJWJSFCBOIUATF-UHFFFAOYSA-N,troglitazone,Withdrawn,insulin sensitizer,CYP2C8|PPARG|TRPM3,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(Cc3sc(=O)[nH]c3O)cc1)O2,"InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,26-27H,9-12H2,1-4H3,(H,25,28)",BJWJSFCBOIUATF-UHFFFAOYSA-N,troglitazone,Withdrawn,PPAR receptor agonist,CYP2C8|PPARG|TRPM3,,
COC1CC(OC2C(C)C(=O)OC(C)C(C)C(OC(C)=O)C(C)C(=O)C3(CO3)CC(C)C(OC3OC(C)CC(N(C)C)C3OC(C)=O)C2C)OC(C)C1OC(C)=O,"InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3",LQCLVBQBTUVCEQ-UHFFFAOYSA-N,troleandomycin,Launched,protein synthesis inhibitor,,infectious disease|pulmonary|otolaryngology,pneumonia|bronchitis|tonsillitis|sinusitis
Cc1c(C)c2c(c(C)c1O)CCC(C)(C(=O)O)O2,"InChI=1S/C14H18O4/c1-7-8(2)12-10(9(3)11(7)15)5-6-14(4,18-12)13(16)17/h15H,5-6H2,1-4H3,(H,16,17)",GLEVLJDDWXEYCO-UHFFFAOYSA-N,trolox,Launched,antioxidant,,,
O=C(O)c1ccccc1NCCc1ccccc1,"InChI=1S/C15H15NO2/c17-15(18)13-8-4-5-9-14(13)16-11-10-12-6-2-1-3-7-12/h1-9,16H,10-11H2,(H,17,18)",HLNLBEFKHHCAMV-UHFFFAOYSA-N,tromaril,Launched,prostanoid receptor antagonist,,ophthalmology,eye inflammation
NC(CO)(CO)CO,"InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2",LENZDBCJOHFCAS-UHFFFAOYSA-N,trometamol,Launched,,AMD1|CANT1|DCN|NEIL1|VEGFA,,
Cc1cc(C)cc(C(=O)OC2CC3CCC(C2)N3C)c1,"InChI=1S/C17H23NO2/c1-11-6-12(2)8-13(7-11)17(19)20-16-9-14-4-5-15(10-16)18(14)3/h6-8,14-16H,4-5,9-10H2,1-3H3",HDDNYFLPWFSBLN-UHFFFAOYSA-N,"tropanyl-3,5-dimethylbenzoate",Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
COc1ccc2c(c1)c(CC(=O)OCC(C(=O)O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,"InChI=1S/C28H24ClNO6/c1-17-22(15-26(31)36-16-24(28(33)34)18-6-4-3-5-7-18)23-14-21(35-2)12-13-25(23)30(17)27(32)19-8-10-20(29)11-9-19/h3-14,24H,15-16H2,1-2H3,(H,33,34)",UCCJWNPWWPJKGL-UHFFFAOYSA-N,tropesin,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,
CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,"InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3",BGDKAVGWHJFAGW-UHFFFAOYSA-N,tropicamide,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,ophthalmology,mydriasis diagnostic|cycloplegia diagnostic
O=C(O)c1cc(F)c2nc(N3C4CCC3CC(OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1,"InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)",VYLOOGHLKSNNEK-UHFFFAOYSA-N,tropifexor,Phase 2,FXR agonist,,,
CN1C2CCC1CC(OC(=O)c1c[nH]c3ccccc13)C2,"InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3",ZNRGQMMCGHDTEI-UHFFFAOYSA-N,tropisetron,Launched,serotonin receptor antagonist,GLRA1|GLRA2|GLRB|HTR3A|HTR4,gastroenterology,nausea|vomiting
O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1,"InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1",OYYDSUSKLWTMMQ-UHFFFAOYSA-N,trospium,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence|urinary frequency
NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12,"InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)",WVPSKSLAZQPAKQ-UHFFFAOYSA-N,trovafloxacin,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,,
CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1,"InChI=1S/C20H30NO3/c1-4-20(14-22,15-8-6-5-7-9-15)19(23)24-18-12-16-10-11-17(13-18)21(16,2)3/h5-9,16-18,22H,4,10-14H2,1-3H3/q+1",QFWSRMACUIYPGS-UHFFFAOYSA-N,troventol,Phase 1,,,,
S=C(N=c1ccc(Br)c[nH]1)NCCc1ccccn1,"InChI=1S/C13H13BrN4S/c14-10-4-5-12(17-9-10)18-13(19)16-8-6-11-3-1-2-7-15-11/h1-5,7,9H,6,8H2,(H2,16,17,18,19)",HOCFDYZWQYGULA-UHFFFAOYSA-N,trovirdine,Phase 1,non-nucleoside reverse transcriptase inhibitor,,,
CC1OC(OCC2OC(Oc3c(-c4ccc(OCCO)c(OCCO)c4)oc4cc(OCCO)cc(O)c4c3=O)C(O)C(O)C2O)C(O)C(O)C1O,"InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3",IYVFNTXFRYQLRP-UHFFFAOYSA-N,troxerutin,Launched,antioxidant,,,
COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC,"InChI=1S/C15H22N2O4/c1-19-12-7-10(8-13(20-2)14(12)21-3)15(18)17-11-5-4-6-16-9-11/h7-8,11,16H,4-6,9H2,1-3H3,(H,17,18)",YSIITVVESCNIPR-UHFFFAOYSA-N,troxipide,Launched,glucosamine synthetase stimulant,,gastroenterology,gastroesophageal reflux disease (GERD)
COc1ccsc1CNCCC1(c2ccccn2)CCOC2(CCCC2)C1,"InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3",DMNOVGJWPASQDL-UHFFFAOYSA-N,trv130,Phase 3,opioid receptor agonist,OPRM1,,
O=C1c2ccccc2-n2c1nc1ccccc1c2=O,InChI=1S/C15H8N2O2/c18-13-10-6-2-4-8-12(10)17-14(13)16-11-7-3-1-5-9(11)15(17)19/h1-8H,VQQVWGVXDIPORV-UHFFFAOYSA-N,tryptanthrin,Preclinical,cyclooxygenase inhibitor,IDO1,,
NC(Cc1c[nH]c2ccccc12)C(=O)O,"InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)",QIVBCDIJIAJPQS-UHFFFAOYSA-N,tryptophan,Launched,serotonin receptor partial agonist,CASR|IDO1|SLC36A1|WARS|WARS2,neurology/psychiatry|gastroenterology,anxiety|bloating|constipation|fatigue|sleeplessness
[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1,"InChI=1S/C11H14ClN3O2/c12-10-7-9(13-8-14-16)1-2-11(10)15-3-5-17-6-4-15/h1-2,7,13H,3-6,8H2",CQMCOBQPZDLWIX-UHFFFAOYSA-N,ts-011,Preclinical,delayed vasospasm antagonist,,,
CC(=Cc1ccc(C(=O)O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C,"InChI=1S/C24H28O2/c1-16(14-17-6-8-18(9-7-17)22(25)26)19-10-11-20-21(15-19)24(4,5)13-12-23(20,2)3/h6-11,14-15H,12-13H2,1-5H3,(H,25,26)",FOIVPCKZDPCJJY-UHFFFAOYSA-N,ttnpb,Phase 1,retinoid receptor agonist,RARA|RARB|RARG,,
Cc1ccc(-c2csc3ncnc(SCCC(=O)O)c23)cc1,"InChI=1S/C16H14N2O2S2/c1-10-2-4-11(5-3-10)12-8-22-16-14(12)15(17-9-18-16)21-7-6-13(19)20/h2-5,8-9H,6-7H2,1H3,(H,19,20)",RAOULLCLLOGTDA-UHFFFAOYSA-N,ttp-22,Preclinical,casein kinase inhibitor,CSNK2A1,,
CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,"InChI=1S/C27H32O8/c1-3-32-26(30)20-14-10-12-16-22(20)34-24(28)18-8-6-5-7-9-19-25(29)35-23-17-13-11-15-21(23)27(31)33-4-2/h10-17H,3-9,18-19H2,1-2H3",LIBAUACOIKWWKP-UHFFFAOYSA-N,tu-2100,Phase 2,,,,
CCCCCC(C)N,"InChI=1S/C7H17N/c1-3-4-5-6-7(2)8/h7H,3-6,8H2,1-2H3",VSRBKQFNFZQRBM-UHFFFAOYSA-N,tuaminoheptane,Launched,,,otolaryngology,nasal congestion
CN1CCc2c(c3ccccc3n2Cc2ccc(C(O)=NO)cc2)C1,"InChI=1S/C20H21N3O2/c1-22-11-10-19-17(13-22)16-4-2-3-5-18(16)23(19)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24)",GOVYBPLHWIEHEJ-UHFFFAOYSA-N,tubastatin-a,Preclinical,HDAC inhibitor,HDAC6,,
COc1cc2c3cc1Oc1cc(ccc1O)CC1c4c(cc(OC)c(O)c4Oc4ccc(cc4)CC3N(C)CC2)CC[N+]1(C)C,"InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1",JFJZZMVDLULRGK-UHFFFAOYSA-O,tubocurarine,Launched,acetylcholine receptor antagonist,ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN,neurology/psychiatry,anesthetic
Cc1cc(N=c2[nH]cnc3ccc(N=C4NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,"InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)",SDEAXTCZPQIFQM-UHFFFAOYSA-N,tucatinib,Phase 3,EGFR inhibitor,ERBB2,,
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)C=Cc2cccnc2)cc1,"InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)",SZMJVTADHFNAIS-UHFFFAOYSA-N,tucidinostat,Phase 3,HDAC inhibitor,,,
CC(=O)C(N)C(O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)O,"InChI=1S/C21H40N8O6/c1-12(30)16(23)18(32)27-13(6-2-3-9-22)19(33)29-11-5-8-15(29)17(31)28-14(20(34)35)7-4-10-26-21(24)25/h13-16,18,27,32H,2-11,22-23H2,1H3,(H,28,31)(H,34,35)(H4,24,25,26)",XXPGTVHWORQQRW-UHFFFAOYSA-N,tuftsin,Preclinical,macrophage activator,,,
N#CCc1ccccc1C#Cc1ccc(CCC(=O)O)c(F)c1,"InChI=1S/C19H14FNO2/c20-18-13-14(6-8-17(18)9-10-19(22)23)5-7-15-3-1-2-4-16(15)11-12-21/h1-4,6,8,13H,9-11H2,(H,22,23)",KIZUBVPJNPVIIN-UHFFFAOYSA-N,tug-770,Preclinical,free fatty acid receptor agonist,FFAR1,,
Cc1ccc(-c2ccc(F)cc2COc2ccc(CCC(=O)O)cc2)cc1,"InChI=1S/C23H21FO3/c1-16-2-7-18(8-3-16)22-12-9-20(24)14-19(22)15-27-21-10-4-17(5-11-21)6-13-23(25)26/h2-5,7-12,14H,6,13,15H2,1H3,(H,25,26)",LPGBXHWIQNZEJB-UHFFFAOYSA-N,tug-891,Preclinical,free fatty acid receptor agonist,FFAR4,,
CC(C)(C)NCC(O)c1ccccc1Cl,"InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3",YREYLAVBNPACJM-UHFFFAOYSA-N,tulobuterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma
O=C1c2cc3nnn(CCc4cccc(F)c4)c(=O)c3cc2OCN1C1CC1,"InChI=1S/C20H17FN4O3/c21-13-3-1-2-12(8-13)6-7-25-20(27)15-10-18-16(9-17(15)22-23-25)19(26)24(11-28-18)14-4-5-14/h1-3,8-10,14H,4-7,11H2",JHCFQXNWYDLBOG-UHFFFAOYSA-N,tulrampator,Phase 2,antidepressant ,,,
CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,"InChI=1S/C33H35NO6S/c1-20(2)25-11-7-6-10-21(25)18-22-19-26(30(36)31(37)29(22)35)32(38)34-23-14-16-24(17-15-23)41(39,40)28-13-9-8-12-27(28)33(3,4)5/h6-17,19-20,35-37H,18H2,1-5H3,(H,34,38)",PQAPVTKIEGUPRN-UHFFFAOYSA-N,tw-37,Preclinical,BCL inhibitor,BCL2|BCL2L1|MCL1,,
Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1,"InChI=1S/C18H14N4O2/c19-12-4-1-3-11(7-12)16-9-15-17(22-16)20-10-21-18(15)24-14-6-2-5-13(23)8-14/h1-10,23H,19H2,(H,20,21,22)",VPVLEBIVXZSOMQ-UHFFFAOYSA-N,tws-119,Preclinical,glycogen synthase kinase inhibitor,GSK3B|JUN|MYC,,
CCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(N)CC(=O)O)C(C)C)C(=O)NC(Cc1c[nH]cn1)C(=O)N1CCCC1C(=O)O,"InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)",PVHLMTREZMEJCG-UHFFFAOYSA-N,txa127,Phase 2,angiotensin receptor agonist,,,
CC(C)(C)C(=O)C(=NNc1ccc(Cl)cc1)Nc1ccc(Cl)cc1,"InChI=1S/C18H19Cl2N3O/c1-18(2,3)16(24)17(21-14-8-4-12(19)5-9-14)23-22-15-10-6-13(20)7-11-15/h4-11,22H,1-3H3,(H,21,23)",XONRRGIRSGNWFP-UHFFFAOYSA-N,ty-52156,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR3,,
CCC1OC(=O)CC(O)C(C)C(OC2OC(C)C(OC3CC(C)(O)C(O)C(C)O3)C(N(C)C)C2O)C(CC=O)CC(C)C(=O)C=CC(C)=CC1COC1OC(C)C(O)C(OC)C1OC,"InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3",WBPYTXDJUQJLPQ-UHFFFAOYSA-N,tylosin,Launched,protein synthesis inhibitor,,infectious disease|gastroenterology,gram-positive bacterial infections|colitis
Cc1ccc(C(C)C)c(OCC2=NCCN2)c1,"InChI=1S/C14H20N2O/c1-10(2)12-5-4-11(3)8-13(12)17-9-14-15-6-7-16-14/h4-5,8,10H,6-7,9H2,1-3H3,(H,15,16)",QRORCRWSRPKEHR-UHFFFAOYSA-N,tymazoline,Launched,,,allergy,allergic rhinitis
CC(C)(C)c1cc(C=C(C#N)C#N)cc(C(C)(C)C)c1O,"InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3",MZOPWQKISXCCTP-UHFFFAOYSA-N,tyrphostin-a9,Preclinical,protein tyrosine kinase inhibitor,,,
CC(C)(C)c1cc(C=C(C#N)C#N)cc(C(C)(C)C)c1O,"InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3",MZOPWQKISXCCTP-UHFFFAOYSA-N,tyrphostin-a9,Preclinical,tyrosine kinase inhibitor,,,
COc1cc2ncc(-c3ccccc3)nc2cc1OC,"InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3",QNOXYUNHIGOWNY-UHFFFAOYSA-N,tyrphostin-ag-1296,Preclinical,FLT3 inhibitor,FLT3,,
COc1cc2[nH]cnc(=Nc3cccc(Cl)c3)c2cc1OC,"InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)",GFNNBHLJANVSQV-UHFFFAOYSA-N,tyrphostin-ag-1478,Preclinical,EGFR inhibitor,EGFR|MAPK14,,
N#CC(C#N)=Cc1ccc(O)c(O)c1,"InChI=1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H",VTJXFTPMFYAJJU-UHFFFAOYSA-N,tyrphostin-ag-18,Preclinical,EGFR inhibitor,EGFR,,
N#CC(C#N)=Cc1ccc(O)c(O)c1,"InChI=1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H",VTJXFTPMFYAJJU-UHFFFAOYSA-N,tyrphostin-ag-18,Preclinical,tyrosine kinase inhibitor,EGFR,,
N#CC(=Cc1ccc(O)c(O)c1)C(=O)Nc1ccccc1,"InChI=1S/C16H12N2O3/c17-10-12(8-11-6-7-14(19)15(20)9-11)16(21)18-13-4-2-1-3-5-13/h1-9,19-20H,(H,18,21)",HKHOVJYOELRGMV-UHFFFAOYSA-N,tyrphostin-ag-494,Preclinical,EGFR inhibitor,EGFR,,
COc1cc(C=C(C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,"InChI=1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)",KXDONFLNGBQLTN-UHFFFAOYSA-N,tyrphostin-ag-825,Preclinical,protein tyrosine kinase inhibitor,ERBB2,,
CC(NC(=O)C(C#N)=Cc1ccc(O)c(O)c1)c1ccccc1,"InChI=1S/C18H16N2O3/c1-12(14-5-3-2-4-6-14)20-18(23)15(11-19)9-13-7-8-16(21)17(22)10-13/h2-10,12,21-22H,1H3,(H,20,23)",UMGQVUWXNOJOSJ-UHFFFAOYSA-N,tyrphostin-ag-835,Preclinical,protein tyrosine kinase inhibitor,EGFR,,
CC(C)(C)c1cc(C=C(C#N)C(N)=S)cc(C(C)(C)C)c1O,"InChI=1S/C18H24N2OS/c1-17(2,3)13-8-11(7-12(10-19)16(20)22)9-14(15(13)21)18(4,5)6/h7-9,21H,1-6H3,(H2,20,22)",XRZYELWZLNAXGE-UHFFFAOYSA-N,tyrphostin-ag-879,Preclinical,tyrosine kinase inhibitor,ERBB2|KDR|NTRK1,,
N#CC(=Cc1ccc(O)c(O)c1)C(N)=O,"InChI=1S/C10H8N2O3/c11-5-7(10(12)15)3-6-1-2-8(13)9(14)4-6/h1-4,13-14H,(H2,12,15)",USOXQZNJFMKTKJ-UHFFFAOYSA-N,tyrphostin-ag-99,Preclinical,tyrosine kinase inhibitor,EGFR,,
CSC(=N)C(C#N)C(C#N)C(=N)SC,"InChI=1S/C8H10N4S2/c1-13-7(11)5(3-9)6(4-10)8(12)14-2/h5-6,11-12H,1-2H3",GXGXSVFKGDVBMD-UHFFFAOYSA-N,u-0124,Preclinical,MEK inhibitor,,,
N#CC(C(=N)Sc1ccccc1N)C(C#N)C(=N)Sc1ccccc1N,"InChI=1S/C18H16N6S2/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22/h1-8,11-12,23-24H,21-22H2",ZCHZSBUNJOCWCW-UHFFFAOYSA-N,u-0126,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,
CC(C)C(=O)c1ccc(O)c(O)c1,"InChI=1S/C10H12O3/c1-6(2)10(13)7-3-4-8(11)9(12)5-7/h3-6,11-12H,1-2H3",VDQLKIBLTMPAHI-UHFFFAOYSA-N,u-0521,Preclinical,catechol O methyltransferase inhibitor,COMT,,
NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,"InChI=1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)",YJQZNWPYLCNRLP-UHFFFAOYSA-N,u-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA9,,
CCN(CC)CCOC1CCC2(C)C(=CCC3C4CCC(=O)C4(C)CCC32)C1,"InChI=1S/C25H41NO2/c1-5-26(6-2)15-16-28-19-11-13-24(3)18(17-19)7-8-20-21-9-10-23(27)25(21,4)14-12-22(20)24/h7,19-22H,5-6,8-17H2,1-4H3",DMZCCFMMPHJWQY-UHFFFAOYSA-N,u-18666a,Preclinical,oxidosqualene cyclase inhibitor,,,
CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCCCC1N1CCCC1,"InChI=1S/C19H26Cl2N2O/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23/h8-9,12,17-18H,2-7,10-11,13H2,1H3",VQLPLYSROCPWFF-UHFFFAOYSA-N,u-50488-(-),Preclinical,opioid receptor agonist,OPRK1,,
CN(C(=O)c1ccc(Cl)c(Cl)c1)C1CCCCC1N1CCCC1,"InChI=1S/C18H24Cl2N2O/c1-21(18(23)13-8-9-14(19)15(20)12-13)16-6-2-3-7-17(16)22-10-4-5-11-22/h8-9,12,16-17H,2-7,10-11H2,1H3",JUBNVWGVNWIXMB-UHFFFAOYSA-N,u-54494a,Preclinical,opioid receptor agonist,OPRK1,,
CC(NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(N)Cc1c[nH]cn1)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCCN)C(N)=O,"InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)",WZHKXNSOCOQYQX-UHFFFAOYSA-N,u-75799e,Phase 1,growth hormone releasing factor agonist,GHSR,,
CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,"InChI=1S/C17H27NO2/c1-5-7-18(8-6-2)15-9-13-11-16(19-3)17(20-4)12-14(13)10-15/h11-12,15H,5-10H2,1-4H3",UOLJKAPABHXFRE-UHFFFAOYSA-N,u-99194,Preclinical,dopamine receptor antagonist,DRD3,,
NC(CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1,"InChI=1S/C16H24ClN3O/c17-14-6-4-13(5-7-14)12-19-9-8-15(18)16(21)20-10-2-1-3-11-20/h4-7,15,19H,1-3,8-12,18H2",DNVZYSMOLXCOLY-UHFFFAOYSA-N,uamc-00039,Preclinical,dipeptidyl peptidase inhibitor,DPP4|DPP7,,
CC(C)CC(NC(=O)C(O)C(N)Cc1ccccc1)C(=O)O,"InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)",VGGGPCQERPFHOB-UHFFFAOYSA-N,ubenimex,Launched,leukotriene synthesis inhibitor,LTA4H|RNPEP,hematologic malignancy,acute myeloid leukemia (AML)
NC(Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,"InChI=1S/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)",UUIYULWYHDSXHL-UHFFFAOYSA-N,ubp-296,Preclinical,glutamate receptor antagonist,GRIK1,,
NC(Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,"InChI=1S/C15H15N3O6/c16-11(14(22)23)8-17-6-5-12(19)18(15(17)24)7-9-3-1-2-4-10(9)13(20)21/h1-6,11H,7-8,16H2,(H,20,21)(H,22,23)",UUIYULWYHDSXHL-UHFFFAOYSA-N,ubp-302,Preclinical,glutamate receptor antagonist,GRIK1,,
Cc1cn(CC(N)C(=O)O)c(=O)n(Cc2ccsc2C(=O)O)c1=O,"InChI=1S/C14H15N3O6S/c1-7-4-16(6-9(15)12(19)20)14(23)17(11(7)18)5-8-2-3-24-10(8)13(21)22/h2-4,9H,5-6,15H2,1H3,(H,19,20)(H,21,22)",ZTAZUCRXCRXNSU-UHFFFAOYSA-N,ubp-310,Preclinical,glutamate receptor antagonist,GRIK1|GRIK5,,
Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12,"InChI=1S/C22H24N2O2/c25-22-18(14-24-11-4-5-12-24)13-19(20-9-6-10-23-21(20)22)16-26-15-17-7-2-1-3-8-17/h1-3,6-10,13,25H,4-5,11-12,14-16H2",LTGLGIQQZXSLLF-UHFFFAOYSA-N,uc-112,Preclinical,XIAP inhibitor,XIAP,,
c1ccc(C(NCc2cccnc2)(c2ccccc2)c2ccccc2)cc1,"InChI=1S/C25H22N2/c1-4-12-22(13-5-1)25(23-14-6-2-7-15-23,24-16-8-3-9-17-24)27-20-21-11-10-18-26-19-21/h1-19,27H,20H2",PQFNWDHABGBCHB-UHFFFAOYSA-N,ucl-2077,Preclinical,slow afterhyperpolarization channel blocker,,,
CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc(=O)c2c([nH]1)c(CCC)nn2C,"InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)",IYFNEFQTYQPVOC-UHFFFAOYSA-N,udenafil,Launched,phosphodiesterase inhibitor,,urology,erectile dysfunction
CCCCNNC(=O)c1ccc(Br)cc1,"InChI=1S/C11H15BrN2O/c1-2-3-8-13-14-11(15)9-4-6-10(12)7-5-9/h4-7,13H,2-3,8H2,1H3,(H,14,15)",BVQCFCYPFJOOAV-UHFFFAOYSA-N,uf-010,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,
CCCCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1,"InChI=1S/C18H18F3NO2/c1-2-3-11-24-17(23)15-9-4-5-10-16(15)22-14-8-6-7-13(12-14)18(19,20)21/h4-10,12,22H,2-3,11H2,1H3",JDLSRXWHEBFHNC-UHFFFAOYSA-N,ufenamate,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,dermatology,eczema|dermatitis
CCCN(CCC)C1CCc2c(OC)cccc2C1C,"InChI=1S/C18H29NO/c1-5-12-19(13-6-2)17-11-10-16-15(14(17)3)8-7-9-18(16)20-4/h7-9,14,17H,5-6,10-13H2,1-4H3",BTOJYCTUJJHANF-UHFFFAOYSA-N,uh-232-(+),Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR1A,,
Cc1cc(CCCC(CC(O)=NO)C(=O)NC(C(=O)NC(C)c2ccccc2)C(C)(C)C)ccc1-c1ccccc1,"InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)",JJHRUUKMPWUYIB-UHFFFAOYSA-N,uk-356618,Preclinical,metalloproteinase inhibitor,MMP13|MMP14|MMP2|MMP3|MMP9,,
NC(=O)c1noc(C(CCCC2CCCCC2)CC(O)=NO)n1,"InChI=1S/C15H24N4O4/c16-13(21)14-17-15(23-19-14)11(9-12(20)18-22)8-4-7-10-5-2-1-3-6-10/h10-11,22H,1-9H2,(H2,16,21)(H,18,20)",ARJCBSRIPGJMAD-UHFFFAOYSA-N,uk-383367,Phase 1,procollagen C-endopeptidase inhibitor,BMP1,,
N#CC(=Cc1cn(-c2ccccc2)c2ccccc12)C(=O)O,"InChI=1S/C18H12N2O2/c19-11-13(18(21)22)10-14-12-20(15-6-2-1-3-7-15)17-9-5-4-8-16(14)17/h1-10,12H,(H,21,22)",BIZNHCWFGNKBBZ-UHFFFAOYSA-N,uk-5099,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,
CCOC(=O)N1CCN(C(=O)C(Cc2cccc(C(=N)N)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1,"InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)",ISJSHQTWOHGCMM-UHFFFAOYSA-N,uki-1,Preclinical,urokinase inhibitor,,,
CC1Sc2c(C(=O)O)c(=O)c3cc(F)c(N4CCNCC4)cc3n21,"InChI=1S/C16H16FN3O3S/c1-8-20-11-7-12(19-4-2-18-3-5-19)10(17)6-9(11)14(21)13(16(22)23)15(20)24-8/h6-8,18H,2-5H2,1H3,(H,22,23)",SUXQDLLXIBLQHW-UHFFFAOYSA-N,ulifloxacin,Launched,,,infectious disease,gram-negative bacterial infections|gram-positive bacterial infections
CC(=O)OC1(C(C)=O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(c3ccc(N(C)C)cc3)CC21C,"InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,26-27H,8,11-17H2,1-5H3",NSCGCTPLPUDDHL-UHFFFAOYSA-N,ulipristal,Launched,progesterone receptor antagonist,PGR,endocrinology,contraceptive
OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,"InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1",FVTWTVQXNAJTQP-UHFFFAOYSA-N,umeclidinium,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema
CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(c23)C1=O,"InChI=1S/C17H18N4O3/c1-20(2)6-7-21-15(22)12-5-3-4-10-8-11(19-17(18)24)9-13(14(10)12)16(21)23/h3-5,8-9H,6-7H2,1-2H3,(H3,18,19,24)",WCKZRLOUKYFJDY-UHFFFAOYSA-N,unbs-5162,Phase 1,CC chemokine receptor antagonist,,,
COc1cc2c(=NC3CCN(C)CC3)[nH]c(N3CCCN(C)CC3)nc2cc1OCCCN(C)C,"InChI=1S/C26H43N7O2/c1-30(2)10-7-17-35-24-19-22-21(18-23(24)34-5)25(27-20-8-13-32(4)14-9-20)29-26(28-22)33-12-6-11-31(3)15-16-33/h18-20H,6-17H2,1-5H3,(H,27,28,29)",XIVUGRBSBIXXJE-UHFFFAOYSA-N,unc0224,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(=NC3CCN(C)CC3)[nH]c(N3CCCN(C)CC3)nc2cc1OCCOCCN(C)C,"InChI=1S/C27H45N7O3/c1-31(2)15-16-36-17-18-37-25-20-23-22(19-24(25)35-5)26(28-21-7-11-33(4)12-8-21)30-27(29-23)34-10-6-9-32(3)13-14-34/h19-21H,6-18H2,1-5H3,(H,28,29,30)",AULLUGALUBVBDD-UHFFFAOYSA-N,unc0321,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(=NC3CCN(CC4CCCCC4)CC3)[nH]c(N3CCCN(C(C)C)CC3)nc2cc1OCCCN1CCCCC1,"InChI=1S/C37H61N7O2/c1-29(2)43-19-10-20-44(24-23-43)37-39-33-27-35(46-25-11-18-41-16-8-5-9-17-41)34(45-3)26-32(33)36(40-37)38-31-14-21-42(22-15-31)28-30-12-6-4-7-13-30/h26-27,29-31H,4-25,28H2,1-3H3,(H,38,39,40)",XFAXSWXKPQWHDW-UHFFFAOYSA-N,unc0631,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(=NC3CCN(C(C)C)CC3)[nH]c(C3CCCCC3)nc2cc1OCCCN1CCCC1,"InChI=1S/C30H47N5O2/c1-22(2)35-17-12-24(13-18-35)31-30-25-20-27(36-3)28(37-19-9-16-34-14-7-8-15-34)21-26(25)32-29(33-30)23-10-5-4-6-11-23/h20-24H,4-19H2,1-3H3,(H,31,32,33)",QOECJCJVIMVJGX-UHFFFAOYSA-N,unc0638,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(=NC3CCN(C(C)C)CC3)[nH]c(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,"InChI=1S/C29H44F2N6O2/c1-21(2)36-14-7-22(8-15-36)32-27-23-19-25(38-3)26(39-18-6-13-35-11-4-5-12-35)20-24(23)33-28(34-27)37-16-9-29(30,31)10-17-37/h19-22H,4-18H2,1-3H3,(H,32,33,34)",RNAMYOYQYRYFQY-UHFFFAOYSA-N,unc0642,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
COc1cc2c(=NC3CCN(C4CCCCC4)CC3)[nH]c(N3CCCN(C(C)C)CC3)nc2cc1OCCCN1CCCCC1,"InChI=1S/C36H59N7O2/c1-28(2)41-19-10-20-43(24-23-41)36-38-32-27-34(45-25-11-18-40-16-8-5-9-17-40)33(44-3)26-31(32)35(39-36)37-29-14-21-42(22-15-29)30-12-6-4-7-13-30/h26-30H,4-25H2,1-3H3,(H,37,38,39)",OUKWLRHRXOPODD-UHFFFAOYSA-N,unc0646,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,
COc1cc2c(N(C)C3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,"InChI=1S/C31H49N5O2/c1-23(2)36-18-13-25(14-19-36)34(3)31-26-21-28(37-4)29(38-20-10-17-35-15-8-9-16-35)22-27(26)32-30(33-31)24-11-6-5-7-12-24/h21-25H,5-20H2,1-4H3",ATORKVYCKKBNTF-UHFFFAOYSA-N,unc0737,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,
O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1,"InChI=1S/C32H43N5O2/c38-31(36-20-12-27(13-21-36)34-16-4-5-17-34)25-10-11-29(30(24-25)33-26-8-2-1-3-9-26)32(39)37-22-14-28(15-23-37)35-18-6-7-19-35/h1-3,8-11,24,27-28,33H,4-7,12-23H2",PQOOIERVZAXHBP-UHFFFAOYSA-N,unc1215,Preclinical,L3MBTL antagonist,L3MBTL3,,
CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,"InChI=1S/C33H43N7O2/c1-7-8-24-15-23(6)37-33(42)28(24)19-35-32(41)27-16-26(17-30-29(27)20-36-40(30)22(4)5)25-9-10-31(34-18-25)39-13-11-38(12-14-39)21(2)3/h9-10,15-18,20-22H,7-8,11-14,19H2,1-6H3,(H,35,41)(H,37,42)",DPJNKUOXBZSZAI-UHFFFAOYSA-N,unc1999,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,
CCCCN=c1nc2c(c[nH]1)c(-c1ccc(CN3CCN(C)CC3)cc1)cn2C1CCC(O)CC1,"InChI=1S/C28H40N6O/c1-3-4-13-29-28-30-18-25-26(20-34(27(25)31-28)23-9-11-24(35)12-10-23)22-7-5-21(6-8-22)19-33-16-14-32(2)15-17-33/h5-8,18,20,23-24,35H,3-4,9-17,19H2,1-2H3,(H,29,30,31)",MJSHVHLADKXCML-UHFFFAOYSA-N,unc2025,Preclinical,FLT3 inhibitor,FLT3|MERTK,,
CCCCN=c1nc2c(c[nH]1)c(-c1ccc(CN3CCN(C)CC3)cc1)cn2C1CCC(O)CC1,"InChI=1S/C28H40N6O/c1-3-4-13-29-28-30-18-25-26(20-34(27(25)31-28)23-9-11-24(35)12-10-23)22-7-5-21(6-8-22)19-33-16-14-32(2)15-17-33/h5-8,18,20,23-24,35H,3-4,9-17,19H2,1-2H3,(H,29,30,31)",MJSHVHLADKXCML-UHFFFAOYSA-N,unc2025,Preclinical,MER tyrosine kinase inhibitor,FLT3|MERTK,,
CCCCN=c1[nH]cc(-c2ccc(CN3CCOCC3)cn2)c(=NC2CCC(O)CC2)[nH]1,"InChI=1S/C24H36N6O2/c1-2-3-10-25-24-27-16-21(23(29-24)28-19-5-7-20(31)8-6-19)22-9-4-18(15-26-22)17-30-11-13-32-14-12-30/h4,9,15-16,19-20,31H,2-3,5-8,10-14,17H2,1H3,(H2,25,27,28,29)",HSYSSKFCQHXOBP-UHFFFAOYSA-N,unc2250,Preclinical,MER tyrosine kinase inhibitor,MERTK,,
O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1,"InChI=1S/C14H17N5O2S/c20-13(19-6-2-1-3-7-19)9-15-14(21)16-10-4-5-11-12(8-10)22-18-17-11/h4-5,8H,1-3,6-7,9H2,(H2,15,16,21)",MYTRGTBDVGKKRO-UHFFFAOYSA-N,unc2327,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,
NC(=O)c1[nH]c(=Nc2ccccc2)sc1NC(=O)C1CCCCC1,"InChI=1S/C17H20N4O2S/c18-14(22)13-16(21-15(23)11-7-3-1-4-8-11)24-17(20-13)19-12-9-5-2-6-10-12/h2,5-6,9-11H,1,3-4,7-8H2,(H2,18,22)(H,19,20)(H,21,23)",RZCNASHHHSKTGP-UHFFFAOYSA-N,unc3230,Preclinical,phosphatidyl-inositol activator,PIP5K1C,,
O=C(c1cncc(Br)c1)N1CCC(N2CCCC2)CC1,"InChI=1S/C15H20BrN3O/c16-13-9-12(10-17-11-13)15(20)19-7-3-14(4-8-19)18-5-1-2-6-18/h9-11,14H,1-8H2",CQERVFFAOOUFEQ-UHFFFAOYSA-N,unc669,Preclinical,L3MBTL antagonist,L3MBTL1,,
O=C(c1cccc(Br)c1)N1CCC(N2CCCC2)CC1,"InChI=1S/C16H21BrN2O/c17-14-5-3-4-13(12-14)16(20)19-10-6-15(7-11-19)18-8-1-2-9-18/h3-5,12,15H,1-2,6-11H2",OWGLFIKZKQOYHZ-UHFFFAOYSA-N,unc926,Preclinical,MBT inhibitor,L3MBTL1,,
C=CCCCCCCCCC(=O)O,"InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)",FRPZMMHWLSIFAZ-UHFFFAOYSA-N,undecylenic-acid,Launched,other antifungal,,infectious disease,tinea pedis|tinea corporis
CCC1CN(C(=O)NCC(F)(F)F)CC1c1cnc2cnc3[nH]ccc3n12,"InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)",WYQFJHHDOKWSHR-UHFFFAOYSA-N,upadacitinib,Launched,JAK inhibitor,,,
CCOC(=O)N1CCN(C(=O)C(Cc2cccc(C(N)=NO)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1,"InChI=1S/C32H47N5O6S/c1-8-43-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34-40)35-44(41,42)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35,40H,8,12-15,17H2,1-7H3,(H2,33,34)",HUASEDVYRABWCV-UHFFFAOYSA-N,upamostat,Phase 2,serine protease inhibitor,,,
O=C(COc1cccc2c(=O)[nH]ccc12)c1ccccc1,"InChI=1S/C17H13NO3/c19-15(12-5-2-1-3-6-12)11-21-16-8-4-7-14-13(16)9-10-18-17(14)20/h1-10H,11H2,(H,18,20)",JJWMRRNGWSITSQ-UHFFFAOYSA-N,upf-1069,Preclinical,PARP inhibitor,PARP2,,
CC(C)OC(=O)C(C)NP(=O)(OCC1OC(n2ccc(=O)[nH]c2=O)C(C)(Cl)C1O)Oc1ccccc1,"InChI=1S/C22H29ClN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)",SFPFZQKYPOWCSI-UHFFFAOYSA-N,uprifosbuvir,Preclinical,antiviral,,,
Cn1ncc(Cl)c1-c1cc(C(=O)NC(CN)Cc2ccc(F)c(F)c2)oc1Cl,"InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)",AXTAPYRUEKNRBA-UHFFFAOYSA-N,uprosertib,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,
O=c1cc[nH]c(=O)[nH]1,"InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)",ISAKRJDGNUQOIC-UHFFFAOYSA-N,uracil,Launched,,DPYD|UCKL1,,
O=c1[nH]cc(N(CCCl)CCCl)c(=O)[nH]1,"InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)",IDPUKCWIGUEADI-UHFFFAOYSA-N,uracil-mustard,Launched,DNA synthesis inhibitor,,hematologic malignancy,non-Hodgkin lymphoma (NHL)
COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,"InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3",ICMGLRUYEQNHPF-UHFFFAOYSA-N,urapidil,Launched,adrenergic receptor antagonist,HTR1A,cardiology,hypertension
NC(=O)c1cccc(-c2cccc(OC(=O)NC3CCCCC3)c2)c1,"InChI=1S/C20H22N2O3/c21-19(23)16-8-4-6-14(12-16)15-7-5-11-18(13-15)25-20(24)22-17-9-2-1-3-10-17/h4-8,11-13,17H,1-3,9-10H2,(H2,21,23)(H,22,24)",ROFVXGGUISEHAM-UHFFFAOYSA-N,urb597,Phase 1,FAAH inhibitor,FAAH|FAAH2|TRPA1,,
NC(N)=O,"InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)",XSQUKJJJFZCRTK-UHFFFAOYSA-N,urea,Launched,hydroxy radical formation stimulant,ARG1|CA2|CTNNB1,dermatology,psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis
CCOC(N)=O,"InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)",JOYRKODLDBILNP-UHFFFAOYSA-N,urethane,Preclinical,local anesthetic,,,
O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1,"InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)",LEHOTFFKMJEONL-UHFFFAOYSA-N,uric-acid,Phase 3,,PYGL,,
O=c1ccn(C2OC(CO)C(O)C2O)c(=O)[nH]1,"InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)",DRTQHJPVMGBUCF-UHFFFAOYSA-N,uridine,Phase 2,dopamine receptor agonist,LSM6|TYMP,,
O=c1ccn(C2OC(CO[PH](=O)(=O)O[PH](=O)(=O)O[PH](=O)(=O)O)C(O)C2O)c(=O)[nH]1,"InChI=1S/C9H12N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H,16,17,18)",OZBORWBHODBWKZ-UHFFFAOYSA-N,uridine-5'-triphosphate,Launched,purinergic receptor activator,P2RY11|P2RY2|P2RY4|P2RY6|UCK2,,
CC(=O)OCC1OC(n2ccc(=O)[nH]c2=O)C(OC(C)=O)C1OC(C)=O,"InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)",AUFUWRKPQLGTGF-UHFFFAOYSA-N,uridine-triacetate,Launched,,,nephrology,orotic aciduria
CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,"InChI=1S/C27H27N5/c1-31-10-12-32(13-11-31)18-19-2-4-20(5-3-19)23-15-24-25(17-30-27(24)29-16-23)21-6-7-26-22(14-21)8-9-28-26/h2-9,14-17,28H,10-13,18H2,1H3,(H,29,30)",QKKIWEILHCXECO-UHFFFAOYSA-N,urmc-099,Preclinical,mixed lineage kinase inhibitor,CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2,,
O=c1oc2cc(O)ccc2c2ccc(O)cc12,"InChI=1S/C13H8O4/c14-7-1-3-9-10-4-2-8(15)6-12(10)17-13(16)11(9)5-7/h1-6,14-15H",RIUPLDUFZCXCHM-UHFFFAOYSA-N,urolithin-a,Phase 3,antioxidant,,,
CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)",BHTRKEVKTKCXOH-UHFFFAOYSA-N,ursodeoxycholyltaurine,Phase 3,cholesterol inhibitor,,,
CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)",RUDATBOHQWOJDD-UHFFFAOYSA-N,ursodiol,Launched,nuclear factor erythroid derived,AKR1C2|NR1H4,gastroenterology,gallstones
CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,"InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)",RUDATBOHQWOJDD-UHFFFAOYSA-N,ursodiol,Launched,like (NRF2) activator,AKR1C2|NR1H4,gastroenterology,gallstones
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1C,"InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)",WCGUUGGRBIKTOS-UHFFFAOYSA-N,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,,
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1C,"InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)",WCGUUGGRBIKTOS-UHFFFAOYSA-N,ursolic-acid,Phase 2/Phase 3,NFkB pathway inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,,
CC1CCC2(C(=O)O)CCC3(C)C(=CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1C,"InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)",WCGUUGGRBIKTOS-UHFFFAOYSA-N,ursolic-acid,Phase 2/Phase 3,STAT inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,,
CC(=O)c1c(O)c(C)c(O)c2c1OC1=CC(=O)C(C(C)=O)C(=O)C12C,"InChI=1S/C18H16O7/c1-6-14(22)12(8(3)20)16-13(15(6)23)18(4)10(25-16)5-9(21)11(7(2)19)17(18)24/h5,11,22-23H,1-4H3",CUCUKLJLRRAKFN-UHFFFAOYSA-N,usniacin-(+),Preclinical,MAP kinase activator,PTPN1,,
COc1cc(CN2CCN(c3ccc(F)cc3)CC2)cc(OC)c1OC,"InChI=1S/C20H25FN2O3/c1-24-18-12-15(13-19(25-2)20(18)26-3)14-22-8-10-23(11-9-22)17-6-4-16(21)5-7-17/h4-7,12-13H,8-11,14H2,1-3H3",KKCOGNFFBYOKMA-UHFFFAOYSA-N,v-51,Phase 1,adrenergic receptor antagonist,,,
O=C(O)CC1CCC(NC(=O)Cc2cccs2)B(O)O1,"InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)",IOOWNWLVCOUUEX-UHFFFAOYSA-N,vaborbactam,Launched,beta lactamase inhibitor,,,
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,"InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)",JGRXMPYUTJLTKT-UHFFFAOYSA-N,vadadustat,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,,,
CC(C)C(N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O,"InChI=1S/C14H20N2O4/c1-8(2)12(15)13(18)16-11(14(19)20)7-9-3-5-10(17)6-4-9/h3-6,8,11-12,17H,7,15H2,1-2H3,(H,16,18)(H,19,20)",VEYJKJORLPYVLO-UHFFFAOYSA-N,val-tyr,Preclinical,angiotensin converting enzyme inhibitor,,,
CC(C)C(N)C(=O)OCCOCn1cnc2c(=O)[nH]c(=N)[nH]c21,"InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)",HDOVUKNUBWVHOX-UHFFFAOYSA-N,valaciclovir,Launched,DNA polymerase inhibitor,,infectious disease,shingles|virus herpes simplex (HSV)
COc1cc2c(cc1OC)C1CC(OC(=O)C(N)C(C)C)C(CC(C)C)CN1CC2,"InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3",GEJDGVNQKABXKG-UHFFFAOYSA-N,valbenazine,Launched,vesicular monoamine transporter inhibitor,,neurology/psychiatry,dyskinesia
Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,"InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)",LNPDTQAFDNKSHK-UHFFFAOYSA-N,valdecoxib,Withdrawn,cyclooxygenase inhibitor,CA12|PTGS2,,
CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,"InChI=1S/C19H32NO2/c1-6-16(4)18(17-12-10-9-11-13-17)19(21)22-15-14-20(5,7-2)8-3/h9-13,16,18H,6-8,14-15H2,1-5H3/q+1",UPPMZCXMQRVMME-UHFFFAOYSA-N,valethamate,Launched,acetylcholine receptor antagonist,CHRM1|CHRM4|CHRM5,obstetrics/gynecology,labor induction
CC(C)C(N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(=N)[nH]c21,"InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)",WPVFJKSGQUFQAP-UHFFFAOYSA-N,valganciclovir,Launched,DNA synthesis inhibitor,,infectious disease,cytomegalovirus (CMV)
C=CC1(C)CC(OC(=O)CSC(C)(C)CNC(=O)C(N)C(C)C)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O,"InChI=1S/C31H52N2O5S/c1-10-29(8)15-22(38-23(35)16-39-28(6,7)17-33-27(37)24(32)18(2)3)30(9)19(4)11-13-31(20(5)26(29)36)14-12-21(34)25(30)31/h10,18-20,22,24-26,36H,1,11-17,32H2,2-9H3,(H,33,37)",LLYYNOVSVPBRGV-UHFFFAOYSA-N,valnemulin,Launched,bacterial 50S ribosomal subunit inhibitor,,infectious disease|gastroenterology,dysentry|colitis|pneumonia
CCC(C)C(CC)C(N)=O,"InChI=1S/C8H17NO/c1-4-6(3)7(5-2)8(9)10/h6-7H,4-5H2,1-3H3,(H2,9,10)",QRCJOCOSPZMDJY-UHFFFAOYSA-N,valnoctamide,Launched,arachidonic acid acylation inhibitor,,neurology/psychiatry,sleeplessness
CCC(C)C(CC)C(N)=O,"InChI=1S/C8H17NO/c1-4-6(3)7(5-2)8(9)10/h6-7H,4-5H2,1-3H3,(H2,9,10)",QRCJOCOSPZMDJY-UHFFFAOYSA-N,valnoctamide,Launched,benzodiazepine receptor agonist,,neurology/psychiatry,sleeplessness
CCCC(CCC)C(=O)O,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,valproic-acid,Launched,benzodiazepine receptor agonist,ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures|seizures
CCCC(CCC)C(=O)O,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,valproic-acid,Launched,HDAC inhibitor,ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures|seizures
CCCC(CCC)C(N)=O,"InChI=1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)",OMOMUFTZPTXCHP-UHFFFAOYSA-N,valpromide,Launched,epoxide hydolase inhibitor,,neurology/psychiatry,epilepsy
CCCC(CCC)C(=O)NCC(N)=O,"InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)",RALGCAOVRLYSMA-UHFFFAOYSA-N,valrocemide,Phase 2,,,,
CCCCC(=O)OCC(=O)C1(O)C=C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)c2c(c(O)c3c(O)c4cccc(OC)c4c(O)c3c2O)C1,"InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,12,14,17,22,27,41-45,47H,4-5,9-11,13H2,1-3H3,(H,38,46)",TWNRWNXYVFLAMA-UHFFFAOYSA-N,valrubicin,Launched,DNA inhibitor,TOP2A,oncology,bladder cancer
CCCCC(=O)OCC(=O)C1(O)C=C(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)c2c(c(O)c3c(O)c4cccc(OC)c4c(O)c3c2O)C1,"InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,12,14,17,22,27,41-45,47H,4-5,9-11,13H2,1-3H3,(H,38,46)",TWNRWNXYVFLAMA-UHFFFAOYSA-N,valrubicin,Launched,topoisomerase inhibitor,TOP2A,oncology,bladder cancer
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)C(C(=O)O)C(C)C,"InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)",ACWBQPMHZXGDFX-UHFFFAOYSA-N,valsartan,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure|congestive heart failure
CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,"InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)",YJDYDFNKCBANTM-UHFFFAOYSA-N,valspodar,Phase 3,P glycoprotein inhibitor,ABCB1,,
CNC(CC(C)C)C(=O)Nc1c(O)[nH]c(CC(N)O)c(O)[nH]c2c3cc(c(OC4OC(CO)C(O)C(O)C4OC4CC(C)(N)C(O)C(C)O4)c(c3)oc3ccc(cc3Cl)c1=O)Oc1ccc(cc1Cl)C(O)c1[nH]c(O)c(c3ccc(O)c(c3)c3c(O)cc(O)cc3c(=C(O)O)[nH]c1O)NC=2O,"InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34,42-44,52-54,56-57,65,71-75,77-82,84-87,89-95H,12,20-22,69-70H2,1-5H3,(H,76,88)",NVGAOKACLXYVQR-UHFFFAOYSA-N,vancomycin,Launched,bacterial cell wall synthesis inhibitor,,infectious disease,endocarditis
COc1cc2c(=Nc3ccc(Br)cc3F)[nH]cnc2cc1OCC1CCN(C)CC1,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,vandetanib,Launched,EGFR inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC)
COc1cc2c(=Nc3ccc(Br)cc3F)[nH]cnc2cc1OCC1CCN(C)CC1,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,vandetanib,Launched,RET tyrosine kinase inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC)
COc1cc2c(=Nc3ccc(Br)cc3F)[nH]cnc2cc1OCC1CCN(C)CC1,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,vandetanib,Launched,VEGFR inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC)
COc1cc(C=O)ccc1O,"InChI=1S/C8H8O3/c1-11-8-4-6(5-9)2-3-7(8)10/h2-5,10H,1H3",MWOOGOJBHIARFG-UHFFFAOYSA-N,vanillin,Preclinical,,ABAT|ALDH5A1,,
COc1cc(CCC(C)=O)ccc1O,"InChI=1S/C11H14O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h5-7,13H,3-4H2,1-2H3",OJYLAHXKWMRDGS-UHFFFAOYSA-N,vanillylacetone,Preclinical,,,,
CCC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1,"InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)",KUQWGLQLLVFLSM-UHFFFAOYSA-N,vaniprevir,Phase 3,serine protease inhibitor,,,
COc1cc(C(=S)N2CCOCC2)ccc1O,"InChI=1S/C12H15NO3S/c1-15-11-8-9(2-3-10(11)14)12(17)13-4-6-16-7-5-13/h2-3,8,14H,4-7H2,1H3",WQYRHRAZNNRDIA-UHFFFAOYSA-N,vanitiolide,Preclinical,,,,
Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,"InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2",NAUWTFJOPJWYOT-UHFFFAOYSA-N,vanoxerine,Phase 3,dopamine reuptake inhibitor,SLC6A3,,
CCOc1noc2cc(OCCC3CCN(c4ccc(C)nn4)CC3)ccc12,"InChI=1S/C21H26N4O3/c1-3-26-21-18-6-5-17(14-19(18)28-24-21)27-13-10-16-8-11-25(12-9-16)20-7-4-15(2)22-23-20/h4-7,14,16H,3,8-13H2,1-2H3",DKSVBVKHUICELN-UHFFFAOYSA-N,vapendavir,Phase 2,antiviral,,,
CCCc1nc(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12,"InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)",SECKRCOLJRRGGV-UHFFFAOYSA-N,vardenafil,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H,urology,erectile dysfunction
c1cnc2cc3c(cc2n1)C1CNCC3C1,"InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2",JQSHBVHOMNKWFT-UHFFFAOYSA-N,varenicline,Launched,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNA6|CHRNA7,neurology/psychiatry,smoking cessation
CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1,"InChI=1S/C21H20N2O5/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25)",BHLXTPHDSZUFHR-UHFFFAOYSA-N,varespladib,Phase 3,secretory phospholipase inhibitor,PLA2G2A,,
N=C(N)NCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)",KBZOIRJILGZLEJ-UHFFFAOYSA-N,vasopressin,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,gastroenterology,abdominal distension
Clc1ccc(N=c2[nH]nc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,vatalanib,Phase 3,KIT inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,,
Clc1ccc(N=c2[nH]nc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,vatalanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,,
Clc1ccc(N=c2[nH]nc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,vatalanib,Phase 3,VEGFR inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,,
CS(=O)(=O)NCCN1C(=O)NCC12CCN1CCc3c(oc4ccccc34)C1C2,"InChI=1S/C20H26N4O4S/c1-29(26,27)22-8-11-24-19(25)21-13-20(24)7-10-23-9-6-15-14-4-2-3-5-17(14)28-18(15)16(23)12-20/h2-5,16,22H,6-13H2,1H3,(H,21,25)",GTBKISRCRQUFNL-UHFFFAOYSA-N,vatinoxan,Preclinical,adrenergic receptor antagonist,,,
CCC(NC(=O)C(CS(=O)(=O)CC1CC1)NC(c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1,"InChI=1S/C23H29F4N3O5S/c1-2-17(19(31)22(33)28-16-9-10-16)30-21(32)18(12-36(34,35)11-13-3-4-13)29-20(23(25,26)27)14-5-7-15(24)8-6-14/h5-8,13,16-18,20,29H,2-4,9-12H2,1H3,(H,28,33)(H,30,32)",PPUXXDKQNAHHON-UHFFFAOYSA-N,vby-825,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSS,,
COC1CCC(N(C(=O)C2CCC(C)CC2)c2cc(C3=CCCCC3)sc2C(=O)O)CC1,"InChI=1S/C26H37NO4S/c1-17-8-10-19(11-9-17)25(28)27(20-12-14-21(31-2)15-13-20)22-16-23(32-24(22)26(29)30)18-6-4-3-5-7-18/h6,16-17,19-21H,3-5,7-15H2,1-2H3,(H,29,30)",LNYKGELUODVSNS-UHFFFAOYSA-N,vch-916,Phase 1,HCV inhibitor,,,
CS(=O)(=O)c1ccc(-c2c[nH]c(=N)c(C(=O)Nc3ccccc3)n2)cc1,"InChI=1S/C18H16N4O3S/c1-26(24,25)14-9-7-12(8-10-14)15-11-20-17(19)16(22-15)18(23)21-13-5-3-2-4-6-13/h2-11H,1H3,(H2,19,20)(H,21,23)",DUIHHZKTCSNTGM-UHFFFAOYSA-N,ve-821,Preclinical,ATR kinase inhibitor,ATR,,
CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)c[nH]c3=N)on2)cc1,"InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)",JZCWLJDSIRUGIN-UHFFFAOYSA-N,ve-822,Phase 2,ATR kinase inhibitor,ATM|ATR|MTOR|PIK3CG,,
N=c1[nH]cnc(N2CCC(C(N)=O)C(N3CCCC(Nc4cc(Cl)cc(C(F)(F)F)c4)C3=O)C2)c1F,"InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)",QLRRJMOBVVGXEJ-UHFFFAOYSA-N,vecabrutinib,Phase 1/Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,,,
CC(=O)OC1CC2CCC3C(CCC4(C)C3CC([N+]3(C)CCCCC3)C4OC(C)=O)C2(C)CC1N1CCCCC1,"InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1",BGSZAXLLHYERSY-UHFFFAOYSA-N,vecuronium,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant
CC(C(=O)O)c1ccc(C2CCCCC2)c2ccccc12,"InChI=1S/C19H22O2/c1-13(19(20)21)15-11-12-16(14-7-3-2-4-8-14)18-10-6-5-9-17(15)18/h5-6,9-14H,2-4,7-8H2,1H3,(H,20,21)",VZUGVMQFWFVFBX-UHFFFAOYSA-N,vedaprofen,Launched,anti-inflammatory agent,PTGS2,neurology/psychiatry|endocrinology,pain relief|fever
O=Cc1c(O)cccc1OCCCCC(=O)O,"InChI=1S/C12H14O5/c13-8-9-10(14)4-3-5-11(9)17-7-2-1-6-12(15)16/h3-5,8,14H,1-2,6-7H2,(H,15,16)",NSUDGNLOXMLAEB-UHFFFAOYSA-N,velaresol,Preclinical,,,,
CCCC(N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C,"InChI=1S/C27H38N2O3/c1-9-12-24(27(5,6)7)29(26(31)20-16-18(3)15-19(4)17-20)28-25(30)22-13-11-14-23(32-8)21(22)10-2/h11,13-17,24H,9-10,12H2,1-8H3,(H,28,30)",LZWZPGLVHLSWQX-UHFFFAOYSA-N,veledimex,Phase 2,cytochrome P450 inhibitor,,,
O=C(O)C(c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1,"InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)",ZEYYDOLCHFETHQ-UHFFFAOYSA-N,veliflapon,Phase 3,leukotriene synthesis inhibitor,ALOX5AP,,
CC1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1,"InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)",JNAHVYVRKWKWKQ-UHFFFAOYSA-N,veliparib,Phase 3,PARP inhibitor,PARP1|PARP2,,
CC(C)(C)S(=O)(=O)NC1CCC(C(=O)N=c2ccc(C(F)(F)F)c[nH]2)CC1,"InChI=1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)",WGEWUYACXPEFPO-UHFFFAOYSA-N,velneperit,Phase 2,neuropeptide receptor antagonist,NPY5R,,
COCC1CC(c2nc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c(C7CCC(C)N7C(=O)C(NC(=O)OC)C(C)C)nc65)cc3-4)c[nH]2)N(C(=O)C(NC(=O)OC)c2ccccc2)C1,"InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)",FHCUMDQMBHQXKK-UHFFFAOYSA-N,velpatasvir,Launched,antiviral,,infectious disease,hepatitis C
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,vemurafenib,Launched,RAF inhibitor,BRAF|RAF1,oncology,melanoma
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,venetoclax,Launched,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL)
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,"InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",PNVNVHUZROJLTJ-UHFFFAOYSA-N,venlafaxine,Launched,adrenergic inhibitor,SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,"InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",PNVNVHUZROJLTJ-UHFFFAOYSA-N,venlafaxine,Launched,norepinephrine reuptake inhibitor,SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,"InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",PNVNVHUZROJLTJ-UHFFFAOYSA-N,venlafaxine,Launched,serotoninnorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder
N#Cc1ccc(COCC2OC(n3c(=NCc4ccc(Cl)c(Cl)c4)[nH]c4c(=N)[nH]cnc43)C(O)C2O)cc1,"InChI=1S/C25H23Cl2N7O4/c26-16-6-5-15(7-17(16)27)9-30-25-33-19-22(29)31-12-32-23(19)34(25)24-21(36)20(35)18(38-24)11-37-10-14-3-1-13(8-28)2-4-14/h1-7,12,18,20-21,24,35-36H,9-11H2,(H,30,33)(H2,29,31,32)",ZXGGCBQORXDVTE-UHFFFAOYSA-N,ver-155008,Preclinical,HSP inhibitor,HSPA1A,,
CCNC(=O)c1[nH]nc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1,"InChI=1S/C19H18ClN3O4/c1-3-21-19(26)18-16(10-4-6-11(27-2)7-5-10)17(22-23-18)12-8-13(20)15(25)9-14(12)24/h4-9,24-25H,3H2,1-2H3,(H,21,26)(H,22,23)",HUNAOTXNHVALTN-UHFFFAOYSA-N,ver-49009,Preclinical,HSP inhibitor,HSP90AA1,,
C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC,"InChI=1S/C17H25N3O5S/c1-4-7-20-8-5-6-12(20)11-19-17(21)14-9-13(26(18,22)23)10-15(24-2)16(14)25-3/h4,9-10,12H,1,5-8,11H2,2-3H3,(H,19,21)(H2,18,22,23)",RYJXBGGBZJGVQF-UHFFFAOYSA-N,veralipride,Preclinical,dopamine receptor antagonist,,,
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3",SGTNSNPWRIOYBX-UHFFFAOYSA-N,verapamil,Launched,calcium channel blocker,CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4,cardiology,hypertension
CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(CO)C2OC(=O)C=Cc2ccc(O)c(O)c2)C(O)C(O)C1O,"InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3",FBSKJMQYURKNSU-UHFFFAOYSA-N,verbascoside,Phase 2/Phase 3,NFkB pathway inhibitor,,,
CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(CO)C2OC(=O)C=Cc2ccc(O)c(O)c2)C(O)C(O)C1O,"InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3",FBSKJMQYURKNSU-UHFFFAOYSA-N,verbascoside,Phase 2/Phase 3,PKC inhibitor,,,
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,"InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3",JRWROCIMSDXGOZ-UHFFFAOYSA-N,vercirnon,Phase 3,CC chemokine receptor antagonist,CCR9,,
O=C(C=Cn1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NN=c1cccc[nH]1,"InChI=1S/C18H12F6N6O/c19-17(20,21)12-7-11(8-13(9-12)18(22,23)24)16-26-10-30(29-16)6-4-15(31)28-27-14-3-1-2-5-25-14/h1-10H,(H,25,27)(H,28,31)",OPAKEJZFFCECPN-UHFFFAOYSA-N,verdinexor,Preclinical,exportin antagonist,,,
CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21,"InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17)",FVJCUZCRPIMVLB-UHFFFAOYSA-N,verdiperstat,Phase 3,myeloperoxidase inhibitor,,,
COC(=O)Nc1c(N)[nH]c(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1=N,"InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)",QZFHIXARHDBPBY-UHFFFAOYSA-N,vericiguat,Phase 3,guanylate cyclase stimulant,,,
CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O,"InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)",YYBOLPLTQDKXPM-UHFFFAOYSA-N,verinurad,Phase 2,urate transporter inhibitor,SLC22A12,,
COc1ccc(CCOC2CCCCC2N2CCC(O)C2)cc1OC,"InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3",VBHQKCBVWWUUKN-UHFFFAOYSA-N,vernakalant,Launched,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF)
CC=c1c(C)c2[nH]c1=Cc1[nH]c(c(=CCC(=O)O)c1C)=Cc1[nH]c(c(C)c1C=CC(=O)OC)C=C1N=C(C2)C2=CC=C(C(=O)OC)C(C(=O)OC)C12C,"InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-13,15-16,18-19,38,42-44H,14,17H2,1-8H3,(H,46,47)",QCMRUEAXYQGLGA-UHFFFAOYSA-N,verteporfin,Launched,photosensitizing agent,,ophthalmology,macular degeneration
CN1C(N)=NC(C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O,"InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)",YHYKUSGACIYRML-UHFFFAOYSA-N,verubecestat,Phase 3,beta secretase inhibitor,,,
COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,"InChI=1S/C17H17N3O/c1-12-18-16-7-5-4-6-15(16)17(19-12)20(2)13-8-10-14(21-3)11-9-13/h4-11H,1-3H3",SNHCRNMVYDHVDT-UHFFFAOYSA-N,verubulin,Phase 2,tubulin polymerization inhibitor,TUBB,,
CCC(N=c1cc(C)[nH]c2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1,"InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,23H,7H2,1-6H3",FWMVRKRAOBPTGV-UHFFFAOYSA-N,verucerfont,Phase 2,corticotropin releasing factor receptor antagonist,,,
OC1CCCCC1N1CCC(c2ccccc2)CC1,"InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2",YSSBJODGIYRAMI-UHFFFAOYSA-N,vesamicol,Preclinical,acetylcholinesterase inhibitor,SLC18A3,,
COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,"InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)",ZVNYJIZDIRKMBF-UHFFFAOYSA-N,vesnarinone,Launched,phosphodiesterase inhibitor,KCNH2|PDE3A,cardiology,congestive heart failure
O=C(O)CC1CC(c2ccccc2)=NO1,"InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)",MUFJHYRCIHHATF-UHFFFAOYSA-N,vgx-1027,Phase 1,tumor necrosis factor receptor antagonist,TLR4,,
COCC(c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)CC1C,"InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3",CNPVJJQCETWNEU-UHFFFAOYSA-N,vicriviroc,Phase 3,CC chemokine receptor antagonist,CCR5,,
N=c1[nH]cnc2c1ncn2C1OC(CO)C(O)C1O,"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)",OIRDTQYFTABQOQ-UHFFFAOYSA-N,vidarabine,Launched,antiviral,ADA,infectious disease,virus herpes simplex (HSV)|varicella-zoster virus (VZV)
C=CC(N)CCC(=O)O,"InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)",PJDFLNIOAUIZSL-UHFFFAOYSA-N,vigabatrin,Launched,GABA aminotransferase inhibitor,ABAT|SLC32A1,neurology/psychiatry,seizures|spasms
OCc1cc(C(O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,"InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2",DAFYYTQWSAWIGS-UHFFFAOYSA-N,vilanterol,Launched,adrenergic receptor agonist,ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD)
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,"InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)",SGEGOXDYSFKCPT-UHFFFAOYSA-N,vilazodone,Launched,serotonin reuptake inhibitor,DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4,neurology/psychiatry,depression
N#CC1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,"InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2",SYOKIDBDQMKNDQ-UHFFFAOYSA-N,vildagliptin,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus
CCOc1ccccc1OCC1CNCCO1,"InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3",YWPHCCPCQOJSGZ-UHFFFAOYSA-N,viloxazine,Launched,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression
CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,"InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3",JXLYSJRDGCGARV-UHFFFAOYSA-N,vinblastine,Launched,microtubule inhibitor,JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1,hematologic malignancy|infectious disease|oncology,Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,"InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3",JXLYSJRDGCGARV-UHFFFAOYSA-N,vinblastine,Launched,tubulin polymerization inhibitor,JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1,hematologic malignancy|infectious disease|oncology,Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma
CCC12CCCN3CCc4c(n(c5ccccc45)C(=O)C1)C32,"InChI=1S/C19H22N2O/c1-2-19-9-5-10-20-11-8-14-13-6-3-4-7-15(13)21(16(22)12-19)17(14)18(19)20/h3-4,6-7,18H,2,5,8-12H2,1H3",WYJAPUKIYAZSEM-UHFFFAOYSA-N,vinburnine,Launched,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,stroke
CCC12CCCN3CCc4c(n(c5ccccc45)C(O)(C(=O)OC)C1)C32,"InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3",RXPRRQLKFXBCSJ-UHFFFAOYSA-N,vincamine,Withdrawn,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,,
CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1,"InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3",OGWKCGZFUXNPDA-UHFFFAOYSA-N,vincristine,Launched,tubulin polymerization inhibitor,TUBA4A|TUBB,hematologic malignancy,acute lymphoblastic leukemia (ALL)
CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3cc4c(cc3OC)N(C)C3C(O)(C(N)=O)C(O)C5(CC)C=CCN6CCC43C65)C2)C1,"InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)",HHJUWIANJFBDHT-UHFFFAOYSA-N,vindesine,Launched,tubulin polymerization inhibitor,TUBB|TUBB1,oncology,breast cancer|non-small cell lung cancer (NSCLC)|melanoma
CCC12C=CCN3CCC4(c5cc(C6(C(=O)OC)CC7CC(C(C)(F)F)CN(CCc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)C4C(O)(C(=O)OC)C1OC(C)=O)C32,"InChI=1S/C46H56F2N4O8/c1-8-43-15-11-17-52-19-16-44(37(43)52)31-21-32(35(57-5)22-34(31)50(4)38(44)46(56,41(55)59-7)39(43)60-26(2)53)45(40(54)58-6)23-27-20-28(42(3,47)48)25-51(24-27)18-14-30-29-12-9-10-13-33(29)49-36(30)45/h9-13,15,21-22,27-28,37-39,49,56H,8,14,16-20,23-25H2,1-7H3",NOSAJPUYIASWEH-UHFFFAOYSA-N,vinflunine,Launched,microtubule inhibitor,,oncology,bladder cancer
CCC1=CC2CN(C1)Cc1c([nH]c3ccccc13)C(C(=O)OC)(c1cc3c(cc1OC)N(C)C1C(O)(C(=O)OC)C(OC(C)=O)C4(CC)C=CCN5CCC31C54)C2,"InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3",GBABOYUKABKIAF-UHFFFAOYSA-N,vinorelbine,Launched,tubulin polymerization inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,non-small cell lung cancer (NSCLC)
CCOC(=O)C1=CC2(CC)CCCN3CCc4c(n1c1ccccc41)C32,"InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3",DDNCQMVWWZOMLN-UHFFFAOYSA-N,vinpocetine,Launched,phosphodiesterase inhibitor,PDE1A|PDE1C,neurology/psychiatry,stroke|senile dementia
CCOC(=O)C1=CC2(CC)CCCN3CCc4c(n1c1ccccc41)C32,"InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3",DDNCQMVWWZOMLN-UHFFFAOYSA-N,vinpocetine,Launched,sodium channel blocker,PDE1A|PDE1C,neurology/psychiatry,stroke|senile dementia
NCCCC(N)CC(=O)NC1CNC(=O)C(C2CC(O)N=C(N)N2)NC(=O)C(C=NC(N)=O)NC(=O)C(CO)NC(=O)C(CO)NC1=O,"InChI=1S/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H2,29,48)(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)",NSWGELWYFNCPHU-UHFFFAOYSA-N,viomycin,Launched,protein synthesis inhibitor,,infectious disease,tuberculosis
Cc1cc(Cn2nnc3c(-c4ccco4)[nH]c(=N)nc32)ccc1N,"InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)",HQSBCDPYXDGTCL-UHFFFAOYSA-N,vipadenant,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",BPQMGSKTAYIVFO-UHFFFAOYSA-N,vismodegib,Launched,hedgehog pathway inhibitor,SMO,oncology,basal cell carcinoma (BCC)
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",BPQMGSKTAYIVFO-UHFFFAOYSA-N,vismodegib,Launched,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC)
Cc1c(O)cc(C=CCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)c(O)c1C,"InChI=1S/C36H41O2P/c1-29-30(2)36(38)31(28-35(29)37)20-12-7-5-3-4-6-8-19-27-39(32-21-13-9-14-22-32,33-23-15-10-16-24-33)34-25-17-11-18-26-34/h9-18,20-26,28H,3-8,19,27H2,1-2H3,(H-,37,38)/p+1",BZLWLZQETLMDHE-UHFFFAOYSA-O,visomitin,Preclinical,antioxidant,,,
CC1=C2N=C(C=C3N=C(C(C)C4=NC(C(CC(N)=O)C4(C)CCC(=O)NCC(C)O[PH](=O)(=O)OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O,"InChI=1S/C62H89N13O14P/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56/h20-21,23,28,31-32,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)",BFOWVMZUKTYNPH-UHFFFAOYSA-N,vitamin-b12,Launched,,,hematology,megaloblastic anemia
Cc1c(C)c2c(c(C)c1O)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3",GVJHHUAWPYXKBD-UHFFFAOYSA-N,vitamin-e,Launched,LDL oxidation inhibitor,ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4,,
Cc1c(C)c2c(c(C)c1O)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,"InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3",GVJHHUAWPYXKBD-UHFFFAOYSA-N,vitamin-e,Launched,PKC inhibitor,ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4,,
NC(=O)C1CCC(c2ccc(OCc3ccccc3F)cc2)N1,"InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)",JESCETIFNOFKEU-UHFFFAOYSA-N,vixotrigine,Phase 2,sodium channel blocker,,,
Cc1ncsc1-c1ccc(CNC(=O)C2CC(O)CN2C(=O)C(C(C)C)N2Cc3ccccc3C2=O)cc1,"InChI=1S/C29H32N4O4S/c1-17(2)25(33-14-21-6-4-5-7-23(21)28(33)36)29(37)32-15-22(34)12-24(32)27(35)30-13-19-8-10-20(11-9-19)26-18(3)31-16-38-26/h4-11,16-17,22,24-25,34H,12-15H2,1-3H3,(H,30,35)",HEDFFPYRFJKXQP-UHFFFAOYSA-N,vl285,Preclinical,PROTAC,,,
C=CC(=O)N1CCC(=Cc2ccc(F)c([N+](=O)[O-])c2)C(=O)C(=Cc2ccc(F)c([N+](=O)[O-])c2)C1,"InChI=1S/C23H17F2N3O6/c1-2-22(29)26-8-7-16(9-14-3-5-18(24)20(11-14)27(31)32)23(30)17(13-26)10-15-4-6-19(25)21(12-15)28(33)34/h2-6,9-12H,1,7-8,13H2",SCKXBVLYWLLALY-UHFFFAOYSA-N,vlx1570,Phase 1/Phase 2,deubiquitinase inhibitor,,,
CC(=NN=c1nc2[nH]c3c(C)cccc3c2n[nH]1)c1ccccn1,"InChI=1S/C17H15N7/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13/h3-9H,1-2H3,(H2,19,20,23,24)",UQOSBPRTQFFUOA-UHFFFAOYSA-N,vlx600,Phase 1,antitumor agent,TP53|USP14,,
CC(=NN=c1nc2[nH]c3c(C)cccc3c2n[nH]1)c1ccccn1,"InChI=1S/C17H15N7/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13/h3-9H,1-2H3,(H2,19,20,23,24)",UQOSBPRTQFFUOA-UHFFFAOYSA-N,vlx600,Phase 1,ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,
C=CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,"InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)",BICRTLVBTLFLRD-UHFFFAOYSA-N,voclosporin,Phase 3,calcineurin inhibitor,,,
OCC(CO)NC1CC(O)(CO)C(O)C(O)C1O,"InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2",FZNCGRZWXLXZSZ-UHFFFAOYSA-N,voglibose,Launched,glucosidase inhibitor,MGAM,endocrinology,diabetes mellitus|hyperglycemia
CCC1C(=O)N(C)c2c[nH]c(=Nc3ccc(C(=O)NC4CCC(N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)",SXNJFOWDRLKDSF-UHFFFAOYSA-N,volasertib,Phase 3,PLK inhibitor,PLK1,,
COc1cccc(C(O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,"InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3",HXTGXYRHXAGCFP-UHFFFAOYSA-N,volinanserin,Phase 3,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|KCNH2,,
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,"InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3",BFDBKMOZYNOTPK-UHFFFAOYSA-N,vonoprazan,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD)
CCOC(=O)NC1CCC2C(C1)CC1C(=O)OC(C)C1C2C=Cc1ccc(-c2cccc(F)c2)cn1,"InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)",ZBGXUVOIWDMMJE-UHFFFAOYSA-N,vorapaxar,Launched,thrombin inhibitor,F2R,cardiology,myocardial infarction|peripheral artery disease (PAD)
CC(N=c1nc(-c2cccc(Cl)n2)[nH]c(=NC(C)C(F)(F)F)[nH]1)C(F)(F)F,"InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)",QCZAWDGAVJMPTA-UHFFFAOYSA-N,vorasidenib,Preclinical,isocitrate dehydrogenase inhibitor,,,
CNC1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)CC1OC,"InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)",XZAFZXJXZHRNAQ-UHFFFAOYSA-N,voreloxin,Phase 3,topoisomerase inhibitor,TOP2A,,
CC(c1ncncc1F)C(O)(Cn1cncn1)c1ccc(F)cc1F,"InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3",BCEHBSKCWLPMDN-UHFFFAOYSA-N,voriconazole,Launched,cytochrome P450 inhibitor,CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1,infectious disease,esophageal candidiasis|aspergillosis|skin infections
O=C(CCCCCCC(O)=NO)Nc1ccccc1,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,vorinostat,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL)
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,"InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3",YQNWZWMKLDQSAC-UHFFFAOYSA-N,vortioxetine,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4,neurology/psychiatry,depression
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,"InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3",YQNWZWMKLDQSAC-UHFFFAOYSA-N,vortioxetine,Launched,serotonin receptor antagonist,HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4,neurology/psychiatry,depression
CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)C1CO,"InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3",MRPGRAKIAJJGMM-UHFFFAOYSA-N,voruciclib,Phase 1,CDK9 inhibitor,,,
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,"InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3",FWCVZAQENIZVMY-UHFFFAOYSA-N,voxelotor,Launched,hemoglobin modulator,,,
CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)[nH]c(=N)nc21,"InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)",RGHYDLZMTYDBDT-UHFFFAOYSA-N,voxtalisib,Phase 2,mTOR inhibitor,MTOR|PIK3CA,,
CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)[nH]c(=N)nc21,"InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)",RGHYDLZMTYDBDT-UHFFFAOYSA-N,voxtalisib,Phase 2,PI3K inhibitor,MTOR|PIK3CA,,
O=C(O)CCc1c[nH]c2ccccc12,"InChI=1S/C11H11NO2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6H2,(H,13,14)",GOLXRNDWAUTYKT-UHFFFAOYSA-N,vp-20629,Phase 1,beta amyloid antagonist,PLA2G2E|SLC36A1,,
CNC(=O)c1ccccc1N=c1cc(Nc2ccc(N3CCOCC3)cc2OC)[nH]cc1C(F)(F)F,"InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32)",IGUBBWJDMLCRIK-UHFFFAOYSA-N,vs-4718,Phase 1,focal adhesion kinase inhibitor,,,
CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,"InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)",ZBRAJOQFSNYJMF-UHFFFAOYSA-N,vt-464,Phase 2,cytochrome P450 inhibitor,CYP17A1,,
CNC(CNC(=O)N1CCCC(C(OCCNC(=O)OC)c2cccc(Cl)c2)C1)CC1CCCOC1,"InChI=1S/C26H41ClN4O5/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32)",NXWASIVXQMMPLM-UHFFFAOYSA-N,vtp-27999,Phase 1,renin inhibitor,REN,,
CC(CN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)NC(=O)c1ccc2ccccc2c1,"InChI=1S/C26H27ClN4O2/c1-17(28-25(32)20-7-6-18-4-2-3-5-19(18)14-20)16-30-12-10-22(11-13-30)31-24-9-8-21(27)15-23(24)29-26(31)33/h2-9,14-15,17,22H,10-13,16H2,1H3,(H,28,32)(H,29,33)",DRIMIUYGTDAQOX-UHFFFAOYSA-N,vu0155069,Preclinical,phospholipase inhibitor,PLD1,,
COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc32)cc1,"InChI=1S/C17H12F3NO4/c1-24-11-4-2-10(3-5-11)9-21-14-7-6-12(25-17(18,19)20)8-13(14)15(22)16(21)23/h2-8H,9H2,1H3",CKLGZXFOLMHCMC-UHFFFAOYSA-N,vu0238429,Preclinical,acetylcholine receptor allosteric modulator,CHRM5,,
Cc1csc(=NC(=O)CSc2ccc(-c3ccccc3)nn2)[nH]1,"InChI=1S/C16H14N4OS2/c1-11-9-23-16(17-11)18-14(21)10-22-15-8-7-13(19-20-15)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,17,18,21)",WJRWSLORVIHRNX-UHFFFAOYSA-N,vu0240551,Preclinical,potassium/chloride cotransporter inhibitor,SLC12A5,,
CCCCOc1ccc(C(=O)Nc2ccc(F)cc2F)cc1,"InChI=1S/C17H17F2NO2/c1-2-3-10-22-14-7-4-12(5-8-14)17(21)20-16-9-6-13(18)11-15(16)19/h4-9,11H,2-3,10H2,1H3,(H,20,21)",AHCYOTLTLQTPSU-UHFFFAOYSA-N,vu0357121,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
O=C(NC1CCC1)c1ccc(C#Cc2cccc(F)c2)nc1,"InChI=1S/C18H15FN2O/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22)",NEMHWVUKNWAKTM-UHFFFAOYSA-N,vu0360172,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
COc1cc(NC(=O)c2ccccn2)ccc1Cl,"InChI=1S/C13H11ClN2O2/c1-18-12-8-9(5-6-10(12)14)16-13(17)11-4-2-3-7-15-11/h2-8H,1H3,(H,16,17)",ARYUXFNGXHNNDM-UHFFFAOYSA-N,vu0361737,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2Cl)c(Cl)c1)c1ccccn1,"InChI=1S/C18H13Cl2N3O3S/c19-13-5-1-2-6-15(13)23-27(25,26)17-9-8-12(11-14(17)20)22-18(24)16-7-3-4-10-21-16/h1-11,23H,(H,22,24)",IXHCGJXBIHHIEF-UHFFFAOYSA-N,vu0364439,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc2ccccc2c1,"InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-18-29-25(33)26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)",MSTXJJGAXXJCBY-UHFFFAOYSA-N,vu0364739,Preclinical,phospholipase inhibitor,PLD2,,
O=C(Nc1cccc(Cl)c1)c1ccccn1,"InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)",SUYUTNCKIOLMAJ-UHFFFAOYSA-N,vu0364770,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,
O=C(Nc1ccc(Oc2ccc(Cl)cn2)c(Cl)c1)c1ccccn1,"InChI=1S/C17H11Cl2N3O2/c18-11-4-7-16(21-10-11)24-15-6-5-12(9-13(15)19)22-17(23)14-3-1-2-8-20-14/h1-10H,(H,22,23)",MZRLPXFGQKQHST-UHFFFAOYSA-N,vu0422288,Preclinical,glutamate receptor positive allosteric modulator,GRM3,,
Cc1cc(C)c2c(N)c(C(=O)NCc3ccc(Cl)cc3)sc2n1,"InChI=1S/C17H16ClN3OS/c1-9-7-10(2)21-17-13(9)14(19)15(23-17)16(22)20-8-11-3-5-12(18)6-4-11/h3-7H,8,19H2,1-2H3,(H,20,22)",FPRULFHDSFKYBV-UHFFFAOYSA-N,vu10010,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,
COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,"InChI=1S/C18H19N3O2S/c1-10-8-11(2)21-18-14(10)15(19)16(24-18)17(22)20-9-12-4-6-13(23-3)7-5-12/h4-8H,9,19H2,1-3H3,(H,20,22)",MDNWGCQSCGNTKH-UHFFFAOYSA-N,vu152100,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,
O=C(N=c1cc(-c2ccccc2)[nH]n1-c1ccccc1F)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C22H15FN4O3/c23-18-8-4-5-9-20(18)26-21(14-19(25-26)15-6-2-1-3-7-15)24-22(28)16-10-12-17(13-11-16)27(29)30/h1-14,25H",WLNYCWJYGGAFRA-UHFFFAOYSA-N,vu1545,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,
O=C(N=c1cc(-c2ccccc2)[nH]n1-c1ccccc1)c1ccc([N+](=O)[O-])cc1,"InChI=1S/C22H16N4O3/c27-22(17-11-13-19(14-12-17)26(28)29)23-21-15-20(16-7-3-1-4-8-16)24-25(21)18-9-5-2-6-10-18/h1-15,24H",JJHSQXKADVEMOL-UHFFFAOYSA-N,vu29,Preclinical,glutamate receptor potentiator,GRM5,,
O=[N+]([O-])c1ccc2[nH]c(COCc3nc4cc([N+](=O)[O-])ccc4[nH]3)nc2c1,"InChI=1S/C16H12N6O5/c23-21(24)9-1-3-11-13(5-9)19-15(17-11)7-27-8-16-18-12-4-2-10(22(25)26)6-14(12)20-16/h1-6H,7-8H2,(H,17,19)(H,18,20)",ZQPXNYLXYNRFNP-UHFFFAOYSA-N,vu591,Preclinical,potassium channel blocker,KCNJ1,,
CN1CCN(c2nc3ccccc3nc2Cl)CC1,"InChI=1S/C13H15ClN4/c1-17-6-8-18(9-7-17)13-12(14)15-10-4-2-3-5-11(10)16-13/h2-5H,6-9H2,1H3",FFXVTQDGTKEXHF-UHFFFAOYSA-N,vuf10166,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,
CN1CCN(c2cc(-c3ccccc3)[nH]c(=N)n2)CC1,"InChI=1S/C15H19N5/c1-19-7-9-20(10-8-19)14-11-13(17-15(16)18-14)12-5-3-2-4-6-12/h2-6,11H,7-10H2,1H3,(H2,16,17,18)",NIJGWJIOMPHDBP-UHFFFAOYSA-N,vuf10460,Preclinical,histamine receptor agonist,HRH4,,
COc1cc(C(=O)N(CCC2CCCN2C)CC(C)=Cc2ccccc2F)cc(OC)c1OC,"InChI=1S/C27H35FN2O4/c1-19(15-20-9-6-7-11-23(20)28)18-30(14-12-22-10-8-13-29(22)2)27(31)21-16-24(32-3)26(34-5)25(17-21)33-4/h6-7,9,11,15-17,22H,8,10,12-14,18H2,1-5H3",JVRRRKAXHMGUHZ-UHFFFAOYSA-N,vuf11207,Preclinical,CC chemokine receptor agonist,ACKR3,,
Cc1c[nH]c(=Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)NC(CO)c2cccc(Cl)c2)c1,"InChI=1S/C24H20Cl2FN5O2/c1-13-10-29-24(31-19-6-5-17(27)9-18(19)26)32-22(13)15-8-20(28-11-15)23(34)30-21(12-33)14-3-2-4-16(25)7-14/h2-11,21,28,33H,12H2,1H3,(H,30,34)(H,29,31,32)",WUTVMXLIGHTZJC-UHFFFAOYSA-N,vx-11e,Preclinical,MAP kinase inhibitor,MAPK1,,
CC1CCC(C(=O)N(c2cc(C#CC(C)(C)C)sc2C(=O)O)C2CCC(O)CC2)CC1,"InChI=1S/C25H35NO4S/c1-16-5-7-17(8-6-16)23(28)26(18-9-11-19(27)12-10-18)21-15-20(13-14-25(2,3)4)31-22(21)24(29)30/h15-19,27H,5-12H2,1-4H3,(H,29,30)",WPMJNLCLKAKMLA-UHFFFAOYSA-N,vx-222,Phase 2,HCV inhibitor,,,
NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,"InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)",FYSRKRZDBHOFAY-UHFFFAOYSA-N,vx-702,Phase 2,p38 MAPK inhibitor,IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF,,
O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H,VEPKQEUBKLEPRA-UHFFFAOYSA-N,vx-745,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK14,,
CCOC1OC(=O)CC1NC(=O)C1CCCN1C(=O)C(NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,"InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)",SJDDOCKBXFJEJB-UHFFFAOYSA-N,vx-765,Phase 2,caspase inhibitor,CASP1,,
COc1ccc2c(c1)C(C(=O)N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)CCC2,"InChI=1S/C30H36N2O2/c1-21(2)23-11-16-26(17-12-23)32(20-22-9-14-25(15-10-22)31(3)4)30(33)28-8-6-7-24-13-18-27(34-5)19-29(24)28/h9-19,21,28H,6-8,20H2,1-5H3",DVYASSBBADJRAS-UHFFFAOYSA-N,w-54011,Preclinical,anaphylatoxin chemotactic receptor antagonist,C5AR1,,
Cn1nc(-c2ccc(C(F)(F)F)cc2)nc2c(=O)n(C)c(=O)nc1-2,"InChI=1S/C14H10F3N5O2/c1-21-12(23)9-11(19-13(21)24)22(2)20-10(18-9)7-3-5-8(6-4-7)14(15,16)17/h3-6H,1-2H3",XRVMPTWWKLKLPB-UHFFFAOYSA-N,walrycin-b,Preclinical,transcriptional regulatory protein WalR,,,
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,"InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3",PJVWKTKQMONHTI-UHFFFAOYSA-N,warfarin,Launched,vitamin K antagonist,VKORC1,hematology|cardiology,deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction
COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,"InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3",SBPRIAGPYFYCRT-UHFFFAOYSA-N,way-100635,Phase 1,serotonin receptor antagonist,HTR1A,,
O=C1Nc2cc(Cl)c(Cl)cc2N2CCNCC12,"InChI=1S/C11H11Cl2N3O/c12-6-3-8-9(4-7(6)13)16-2-1-14-5-10(16)11(17)15-8/h3-4,10,14H,1-2,5H2,(H,15,17)",PHGWDAICBXUJDU-UHFFFAOYSA-N,way-161503,Preclinical,serotonin receptor agonist,HTR2C,,
Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(C(O)=NO)c1,"InChI=1S/C33H31N3O7S/c1-22-18-23(2)31(28(19-22)32(37)35-39)36(21-24-8-4-3-5-9-24)44(40,41)27-14-12-26(13-15-27)42-17-16-34-33(38)30-20-25-10-6-7-11-29(25)43-30/h3-15,18-20,39H,16-17,21H2,1-2H3,(H,34,38)(H,35,37)",FARMEEAGJWMFSZ-UHFFFAOYSA-N,way-170523,Preclinical,metalloproteinase inhibitor,MMP13,,
Oc1ccc(-c2nc3cc(O)cc(Br)c3o2)cc1,"InChI=1S/C13H8BrNO3/c14-10-5-9(17)6-11-12(10)18-13(15-11)7-1-3-8(16)4-2-7/h1-6,16-17H",BAAILVWEAXFTSF-UHFFFAOYSA-N,way-200070,Preclinical,estrogen receptor agonist,ERBB2|ERBB3|ERBB4|ESR2,,
CC(C)(C)c1ccc(-c2nc3c(N4CCN(Cc5ccc6nccnc6c5)CC4)cccc3[nH]2)cc1,"InChI=1S/C30H32N6/c1-30(2,3)23-10-8-22(9-11-23)29-33-25-5-4-6-27(28(25)34-29)36-17-15-35(16-18-36)20-21-7-12-24-26(19-21)32-14-13-31-24/h4-14,19H,15-18,20H2,1-3H3,(H,33,34)",AVEVJMZJJJDOCI-UHFFFAOYSA-N,way-207024,Preclinical,gonadotropin releasing factor hormone receptor antagonist,GNRHR|HRH2|TACR2,,
CN(C)CCn1cc(S(=O)(=O)c2cccc(F)c2)c2cccnc21,"InChI=1S/C17H18FN3O2S/c1-20(2)9-10-21-12-16(15-7-4-8-19-17(15)21)24(22,23)14-6-3-5-13(18)11-14/h3-8,11-12H,9-10H2,1-2H3",SFSFIDVAEMDPIP-UHFFFAOYSA-N,way-208466,Preclinical,serotonin receptor agonist,DRD2|HTR2A|HTR2C|HTR6|HTR7,,
NC(CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(=O)O,"InChI=1S/C16H13BrF2N2O4/c17-10-5-11(18)12(19)6-14(10)25-9-3-1-8(2-4-9)21-15(22)7-13(20)16(23)24/h1-6,13H,7,20H2,(H,21,22)(H,23,24)",BNYDDAAZMBUFRG-UHFFFAOYSA-N,way-213613,Preclinical,glutamate inhibitor,SLC1A2,,
Cn1c(C#N)ccc1-c1cc(F)c2c(c1)C(C)(C)C(=O)N2,"InChI=1S/C16H14FN3O/c1-16(2)11-6-9(7-12(17)14(11)19-15(16)21)13-5-4-10(8-18)20(13)3/h4-7H,1-3H3,(H,19,21)",KIOOLNRTWPFVHX-UHFFFAOYSA-N,way-255348,Preclinical,progesterone receptor antagonist,,,
O=S(=O)(NC1CCNCC1)c1cc(S(=O)(=O)c2ccccc2)ccc1C(F)(F)F,"InChI=1S/C18H19F3N2O4S2/c19-18(20,21)16-7-6-15(28(24,25)14-4-2-1-3-5-14)12-17(16)29(26,27)23-13-8-10-22-11-9-13/h1-7,12-13,22-23H,8-11H2",ITBGJNVZJBVPLJ-UHFFFAOYSA-N,way-316606,Preclinical,secreted frizzled related protein inhibitor,SFRP1,,
CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,"InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3",INASOKQDNHHMRE-UHFFFAOYSA-N,way-362450,Phase 1,FXR agonist,NR1H4,,
c1cncc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)c1,"InChI=1S/C28H30N8O/c1-2-20(17-29-8-1)19-34-10-6-23(7-11-34)36-28-24(18-31-36)27(35-12-14-37-15-13-35)32-26(33-28)22-3-4-25-21(16-22)5-9-30-25/h1-5,8-9,16-18,23,30H,6-7,10-15,19H2",FPEIJQLXFHKLJV-UHFFFAOYSA-N,way-600,Preclinical,mTOR inhibitor,MTOR,,
c1cc2c3c(c1)c1c(n3CCNC2)CCCC1,"InChI=1S/C15H18N2/c1-2-7-14-12(5-1)13-6-3-4-11-10-16-8-9-17(14)15(11)13/h3-4,6,16H,1-2,5,7-10H2",OIGHTPDWPMLMGT-UHFFFAOYSA-N,way-629,Preclinical,serotonin receptor agonist,HTR2C,,
COc1cccc(OC)c1OCCNCC1COc2ccccc2O1,"InChI=1S/C19H23NO5/c1-21-17-8-5-9-18(22-2)19(17)23-11-10-20-12-14-13-24-15-6-3-4-7-16(15)25-14/h3-9,14,20H,10-13H2,1-2H3",GYSZUJHYXCZAKI-UHFFFAOYSA-N,wb-4101,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A,,
COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1,"InChI=1S/C21H25N3O4/c1-23-9-11-24(12-10-23)19-8-7-16(21(26)28-3)14-18(19)22-20(25)15-5-4-6-17(13-15)27-2/h4-8,13-14H,9-12H2,1-3H3,(H,22,25)",ZPLBXOVTSNRBFB-UHFFFAOYSA-N,wdr5-0103,Preclinical,histone lysine methyltransferase inhibitor,WDR5,,
Cc1ccc(-c2nn(C(C)(C)CNC(=O)c3ncccc3C)c3[nH]cnc(=N)c23)cc1,"InChI=1S/C23H25N7O/c1-14-7-9-16(10-8-14)19-17-20(24)27-13-28-21(17)30(29-19)23(3,4)12-26-22(31)18-15(2)6-5-11-25-18/h5-11,13H,12H2,1-4H3,(H,26,31)(H2,24,27,28)",ZCZGSEXBXXYQQC-UHFFFAOYSA-N,wehi-345-analog,Preclinical,SRC inhibitor,,,
COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2cc[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)n2)c(OC)c1,"InChI=1S/C32H36N6O4/c1-22-7-6-8-23(2)30(22)42-32(39)38(27-14-13-26(40-4)21-28(27)41-5)29-15-16-33-31(35-29)34-24-9-11-25(12-10-24)37-19-17-36(3)18-20-37/h6-16,21H,17-20H2,1-5H3,(H,33,34,35)",NBTNHSGBRGTFJS-UHFFFAOYSA-N,wh-4-023,Preclinical,SRC inhibitor,LCK|SRC,,
COc1cc2[nH]cnc(=Nc3ccc(O)c(Br)c3)c2cc1OC,"InChI=1S/C16H14BrN3O3/c1-22-14-6-10-12(7-15(14)23-2)18-8-19-16(10)20-9-3-4-13(21)11(17)5-9/h3-8,21H,1-2H3,(H,18,19,20)",CBIAKDAYHRWZCU-UHFFFAOYSA-N,whi-p154,Preclinical,JAK inhibitor,EGFR|JAK1|JAK2|JAK3,,
COc1ccc(-n2c(SCCCN3C(=O)c4cccc5cccc(c45)C3=O)nnc2-c2ccncc2)cc1,"InChI=1S/C29H23N5O3S/c1-37-22-11-9-21(10-12-22)34-26(20-13-15-30-16-14-20)31-32-29(34)38-18-4-17-33-27(35)23-7-2-5-19-6-3-8-24(25(19)23)28(33)36/h2-3,5-16H,4,17-18H2,1H3",RNUXIZKXJOGYQP-UHFFFAOYSA-N,wiki4,Preclinical,tankyrase inhibitor,TNKS2,,
COc1ccc(-n2c(SCCCN3C(=O)c4cccc5cccc(c45)C3=O)nnc2-c2ccncc2)cc1,"InChI=1S/C29H23N5O3S/c1-37-22-11-9-21(10-12-22)34-26(20-13-15-30-16-14-20)31-32-29(34)38-18-4-17-33-27(35)23-7-2-5-19-6-3-8-24(25(19)23)28(33)36/h2-3,5-16H,4,17-18H2,1H3",RNUXIZKXJOGYQP-UHFFFAOYSA-N,wiki4,Preclinical,WNT pathway inhibitor,TNKS2,,
O=C(NCCCCCCCCNC(=O)C(Cl)Cl)C(Cl)Cl,"InChI=1S/C12H20Cl4N2O2/c13-9(14)11(19)17-7-5-3-1-2-4-6-8-18-12(20)10(15)16/h9-10H,1-8H2,(H,17,19)(H,18,20)",FAOMZVDZARKPFJ-UHFFFAOYSA-N,win-18446,Preclinical,aldehyde dehydrogenase inhibitor,ALDH1A2,,
CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)C(Cc2ccc3ccccc3c2)N=C(NC2CCCCC2)NC2CCCCC2)cc1,"InChI=1S/C45H67N4OP/c1-4-7-30-51(31-8-5-2,32-9-6-3)35-36-25-28-42(29-26-36)46-44(50)43(34-37-24-27-38-18-16-17-19-39(38)33-37)49-45(47-40-20-12-10-13-21-40)48-41-22-14-11-15-23-41/h16-19,24-29,33,40-41,43H,4-15,20-23,30-32,34-35H2,1-3H3,(H2-,46,47,48,49,50)/p+1",UKMJWGFHXMGRNG-UHFFFAOYSA-O,win-64338,Preclinical,bradykinin receptor antagonist,BDKRB2,,
CN(C)CC(O)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,"InChI=1S/C17H18Br2N2O/c1-20(2)9-13(22)10-21-16-5-3-11(18)7-14(16)15-8-12(19)4-6-17(15)21/h3-8,13,22H,9-10H2,1-2H3",XUBJEDZHBUPBKL-UHFFFAOYSA-N,wiskostatin,Preclinical,actin related protein inhibitor,WASL,,
CN(C)CC(O)Cn1c2ccc(Br)cc2c2cc(Br)ccc21,"InChI=1S/C17H18Br2N2O/c1-20(2)9-13(22)10-21-16-5-3-11(18)7-14(16)15-8-12(19)4-6-17(15)21/h3-8,13,22H,9-10H2,1-2H3",XUBJEDZHBUPBKL-UHFFFAOYSA-N,wiskostatin,Preclinical,neural Wiskott-Aldrich syndrome protein inhibitor,WASL,,
Cc1cc(-c2ccc(CC(=O)Nc3ccc(-c4cccnc4)cc3)cc2)ccn1,"InChI=1S/C25H21N3O/c1-18-15-22(12-14-27-18)20-6-4-19(5-7-20)16-25(29)28-24-10-8-21(9-11-24)23-3-2-13-26-17-23/h2-15,17H,16H2,1H3,(H,28,29)",KHZOJCQBHJUJFY-UHFFFAOYSA-N,wnt-c59,Preclinical,porcupine inhibitor,PORCN,,
COCC1OC(=O)c2coc3c2C1(C)C1=C(C3=O)C2CCC(=O)C2(C)CC1OC(C)=O,"InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3",QDLHCMPXEPAAMD-UHFFFAOYSA-N,wortmannin,Preclinical,PI3K inhibitor,PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC,,
CC(NC(=O)C(C#N)=Cc1cccc(Br)n1)c1ccccc1,"InChI=1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)",VFUAJMPDXIRPKO-UHFFFAOYSA-N,wp1066,Phase 1,STAT inhibitor,STAT3,,
CCCC(NC(=O)C(C#N)=Cc1cccc(Br)n1)c1ccccc1,"InChI=1S/C19H18BrN3O/c1-2-7-17(14-8-4-3-5-9-14)23-19(24)15(13-21)12-16-10-6-11-18(20)22-16/h3-6,8-12,17H,2,7H2,1H3,(H,23,24)",LIDOPKHSVQTSJY-UHFFFAOYSA-N,wp1130,Preclinical,deubiquitinase inhibitor,JAK2|UCHL5|USP14|USP9X,,
O=C(O)Cn1nnnc1-c1ccsc1,"InChI=1S/C7H6N4O2S/c12-6(13)3-11-7(8-9-10-11)5-1-2-14-4-5/h1-2,4H,3H2,(H,12,13)",DDVAZOPRCKAYOV-UHFFFAOYSA-N,wp921,Preclinical,,,,
CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl,"InChI=1S/C14H18Cl3N5O2/c1-14(2)21-12(18)20-13(19)22(14)24-5-3-4-23-11-7-9(16)8(15)6-10(11)17/h6-7H,3-5H2,1-2H3,(H4,18,19,20,21)",MJZJYWCQPMNPRM-UHFFFAOYSA-N,wr99210,Preclinical,dihydrofolate reductase inhibitor,TYMS,infectious disease,malaria
CCOC(=O)c1ccc(-c2ccc(OC(=O)N(C)Cc3cccc(-c4ccncc4)c3)cc2)cc1,"InChI=1S/C29H26N2O4/c1-3-34-28(32)25-9-7-22(8-10-25)23-11-13-27(14-12-23)35-29(33)31(2)20-21-5-4-6-26(19-21)24-15-17-30-18-16-24/h4-19H,3,20H2,1-2H3",AKIIPHDGVCFVCC-UHFFFAOYSA-N,wwl-113,Preclinical,carboxylesterase inhibitor,CES3,,
CN(Cc1cccc(-c2ccccc2)c1)C(=O)Oc1ccc(-c2ccc(C(N)=O)cc2)cc1,"InChI=1S/C28H24N2O3/c1-30(19-20-6-5-9-25(18-20)21-7-3-2-4-8-21)28(32)33-26-16-14-23(15-17-26)22-10-12-24(13-11-22)27(29)31/h2-18H,19H2,1H3,(H2,29,31)",UUJGYRHAOHORFC-UHFFFAOYSA-N,wwl-123,Preclinical,monoacylglycerol lipase inhibitor,ABHD6,,
CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O,"InChI=1S/C12H14N2O5/c1-3-19-12(17)11(16)14-7-5-4-6-8(18-2)9(7)10(13)15/h4-6H,3H2,1-2H3,(H2,13,15)(H,14,16)",GGLRYZACPLNCKB-UHFFFAOYSA-N,wy-16922,Phase 1,histamine release inhibitor,,,
CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1,"InChI=1S/C27H33N7O4/c1-28-26(35)30-18-4-2-17(3-5-18)23-31-24(33-15-20-6-7-21(16-33)38-20)22-14-29-34(25(22)32-23)19-8-10-27(11-9-19)36-12-13-37-27/h2-5,14,19-21H,6-13,15-16H2,1H3,(H2,28,30,35)",QLHHRYZMBGPBJG-UHFFFAOYSA-N,wye-125132,Preclinical,mTOR inhibitor,MTOR,,
COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,"InChI=1S/C24H29N7O5/c1-34-23(32)26-17-5-3-16(4-6-17)20-27-21(29-11-13-36-14-12-29)19-15-25-31(22(19)28-20)18-7-9-30(10-8-18)24(33)35-2/h3-6,15,18H,7-14H2,1-2H3,(H,26,32)",IMXHGCRIEAKIBU-UHFFFAOYSA-N,wye-354,Preclinical,mTOR inhibitor,MTOR,,
COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1,"InChI=1S/C28H32N8O3/c1-38-28(37)31-22-6-4-21(5-7-22)25-32-26(35-13-15-39-16-14-35)24-18-30-36(27(24)33-25)23-8-11-34(12-9-23)19-20-3-2-10-29-17-20/h2-7,10,17-18,23H,8-9,11-16,19H2,1H3,(H,31,37)",VDOCQQKGPJENHJ-UHFFFAOYSA-N,wye-687,Preclinical,mTOR inhibitor,MTOR,,
C=CC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1,"InChI=1S/C24H25ClN6O2/c1-3-22(32)27-18-5-4-6-20(15-18)33-23-21(25)16-26-24(29-23)28-17-7-9-19(10-8-17)31-13-11-30(2)12-14-31/h3-10,15-16H,1,11-14H2,2H3,(H,27,32)(H,26,28,29)",APHGZZPEOCCYNO-UHFFFAOYSA-N,wz-3146,Preclinical,EGFR inhibitor,EGFR,,
C=CC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,"InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30)",ITTRLTNMFYIYPA-UHFFFAOYSA-N,wz-4002,Preclinical,EGFR inhibitor,EGFR|ERBB2,,
CCC(=O)Nc1cccc(Oc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,"InChI=1S/C25H29ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30)",SDGJBAUIGHSMRI-UHFFFAOYSA-N,wz4003,Preclinical,AMPK inhibitor,NUAK1|NUAK2,,
C=CC(=O)Nc1cccc(Sc2[nH]c(=Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1,"InChI=1S/C24H25ClN6OS/c1-3-22(32)27-18-5-4-6-20(15-18)33-23-21(25)16-26-24(29-23)28-17-7-9-19(10-8-17)31-13-11-30(2)12-14-31/h3-10,15-16H,1,11-14H2,2H3,(H,27,32)(H,26,28,29)",KIISCIGBPUVZBF-UHFFFAOYSA-N,wz8040,Preclinical,EGFR inhibitor,EGFR,,
c1ccc(=NCc2ccc(CN=c3cccc[nH]3)cc2)[nH]c1,"InChI=1S/C18H18N4/c1-3-11-19-17(5-1)21-13-15-7-9-16(10-8-15)14-22-18-6-2-4-12-20-18/h1-12H,13-14H2,(H,19,21)(H,20,22)",KBVFRXIGQQRMEF-UHFFFAOYSA-N,wz811,Preclinical,CC chemokine receptor antagonist,CXCR4,,
FC(F)(F)c1cccc(C2=CCN(CCc3ccc4ccccc4c3)CC2)c1,"InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2",WJJYZXPHLSLMGE-UHFFFAOYSA-N,xaliproden,Phase 3,serotonin receptor agonist,HTR1A,,
O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1,"InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)",DXPOSRCHIDYWHW-UHFFFAOYSA-N,xamoterol,Phase 3,adrenergic receptor agonist,ADRB1,,
CCCCCCOc1nsnc1C1=CCCN(C)C1,"InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3",JOLJIIDDOBNFHW-UHFFFAOYSA-N,xanomeline,Phase 3,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7,,
O=c1c2ccccc2oc2ccccc12,InChI=1S/C13H8O2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H,JNELGWHKGNBSMD-UHFFFAOYSA-N,xanthone,Preclinical,antimalarial agent,,,
O=c1[nH]c(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2,"InChI=1S/C14H11F3N2OS/c15-14(16,17)9-3-1-8(2-4-9)12-18-11-5-6-21-7-10(11)13(20)19-12/h1-4H,5-7H2,(H,18,19,20)",KLGQSVMIPOVQAX-UHFFFAOYSA-N,xav-939,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,
CCN(Cc1ccccc1)C(=O)Cn1c(=O)n(C)c2cnc(-c3ccccc3)nc21,"InChI=1S/C23H23N5O2/c1-3-27(15-17-10-6-4-7-11-17)20(29)16-28-22-19(26(2)23(28)30)14-24-21(25-22)18-12-8-5-9-13-18/h4-14H,3,15-16H2,1-2H3",NBMBIEOUVBHEBM-UHFFFAOYSA-N,xbd173,Phase 2,benzodiazepine receptor ligand,TSPO,,
CCc1c(C(=O)Nc2cc(S(=O)(=O)N(CC)CC)ccc2O)[nH]c(C)c1C(C)=O,"InChI=1S/C20H27N3O5S/c1-6-15-18(13(5)24)12(4)21-19(15)20(26)22-16-11-14(9-10-17(16)25)29(27,28)23(7-2)8-3/h9-11,21,25H,6-8H2,1-5H3,(H,22,26)",DPBKLIVPNYGQQG-UHFFFAOYSA-N,xd-14,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4|BRDT,,
O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21,"InChI=1S/C26H20N2O/c29-25-21-5-1-3-7-23(21)26(17-19-9-13-27-14-10-19,18-20-11-15-28-16-12-20)24-8-4-2-6-22(24)25/h1-16H,17-18H2",KHJFBUUFMUBONL-UHFFFAOYSA-N,xe-991,Preclinical,potassium channel blocker,KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5,,
O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1,"InChI=1S/C14H9F3O2/c15-14(16,17)10-7-5-9(6-8-10)11-3-1-2-4-12(11)13(18)19/h1-8H,(H,18,19)",IQOMYCGTGFGDFN-UHFFFAOYSA-N,xenalipin,Phase 2,,,,
Cc1cccc(OCC(O)CNC(C)(C)C)c1C,"InChI=1S/C15H25NO2/c1-11-7-6-8-14(12(11)2)18-10-13(17)9-16-15(3,4)5/h6-8,13,16-17H,9-10H2,1-5H3",RKUQLAPSGZJLGP-UHFFFAOYSA-N,xibenolol,Phase 3,adrenergic receptor antagonist,,,
Cc1cccc(C)c1NC(=O)N=C1CCCN1C,"InChI=1S/C14H19N3O/c1-10-6-4-7-11(2)13(10)16-14(18)15-12-8-5-9-17(12)3/h4,6-7H,5,8-9H2,1-3H3,(H,16,18)",PAXRPWSXCPTPCA-UHFFFAOYSA-N,xilobam,Phase 1,,,,
Cc1cccc(C)c1NC(=O)c1cc(S(N)(=O)=O)c(Cl)cc1O,"InChI=1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)",MTZBBNMLMNBNJL-UHFFFAOYSA-N,xipamide,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension
O=C(Nc1ccc(-c2cc[nH]c(=Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,"InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)",ISOCDPQFIXDIMS-UHFFFAOYSA-N,xl019,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,
CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,"InChI=1S/C29H28Cl2F2N2O4S/c1-28(2,26-19(30)7-6-8-20(26)31)27-34-25(29(3,4)37)14-35(27)23-10-9-16(11-22(23)33)17-12-21(32)18(15-36)24(13-17)40(5,38)39/h6-14,36-37H,15H2,1-5H3",HNAJDMYOTDNOBK-UHFFFAOYSA-N,xl041,Preclinical,LXR agonist,,,
Cc1ccc(S(=O)(=O)N=c2[nH]c3ccccc3[nH]c2=Nc2ccc3nsnc3c2)cc1,"InChI=1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)",MQMKRQLTIWPEDM-UHFFFAOYSA-N,xl147,Phase 2,PI3K inhibitor,PIK3CA|PIK3CD|PIK3CG,,
CC(C)c1cc(CN=c2nc(N3CCN(C)CC3)cc(N=c3cc(C4CC4)[nH][nH]3)[nH]2)on1,"InChI=1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28)",ALKJNCZNEOTEMP-UHFFFAOYSA-N,xl228,Phase 1,Abl kinase inhibitor,IGF1R|SRC,,
CC(C)c1cc(CN=c2nc(N3CCN(C)CC3)cc(N=c3cc(C4CC4)[nH][nH]3)[nH]2)on1,"InChI=1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28)",ALKJNCZNEOTEMP-UHFFFAOYSA-N,xl228,Phase 1,insulin growth factor receptor inhibitor,IGF1R|SRC,,
CC(C)c1cc(CN=c2nc(N3CCN(C)CC3)cc(N=c3cc(C4CC4)[nH][nH]3)[nH]2)on1,"InChI=1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28)",ALKJNCZNEOTEMP-UHFFFAOYSA-N,xl228,Phase 1,SRC inhibitor,IGF1R|SRC,,
Cc1c(C(=O)N2CCOc3ccc(-c4ccc(=N)[nH]c4)cc3C2)ccc(S(C)(=O)=O)c1F,"InChI=1S/C23H22FN3O4S/c1-14-18(5-7-20(22(14)24)32(2,29)30)23(28)27-9-10-31-19-6-3-15(11-17(19)13-27)16-4-8-21(25)26-12-16/h3-8,11-12H,9-10,13H2,1-2H3,(H2,25,26)",LNFBAYSBVQBKFR-UHFFFAOYSA-N,xl388,Preclinical,mTOR inhibitor,MTOR,,
COc1cc2c(=Nc3ccc(Cl)c(Cl)c3F)[nH]cnc2cc1OCC1CC2CN(C)CC2C1,"InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)",HVXKQKFEHMGHSL-UHFFFAOYSA-N,xl647,Phase 3,EGFR inhibitor,EGFR|EPHB4|ERBB2|FLT4|KDR,,
COc1cc2c(=Nc3ccc(Cl)c(Cl)c3F)[nH]cnc2cc1OCC1CC2CN(C)CC2C1,"InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)",HVXKQKFEHMGHSL-UHFFFAOYSA-N,xl647,Phase 3,VEGFR inhibitor,EGFR|EPHB4|ERBB2|FLT4|KDR,,
CCC(C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(C(=O)C3CC3)cn2)c(C)cc1C(N)=O,"InChI=1S/C29H37N5O3/c1-4-17(3)32-25-14-23(16(2)11-24(25)28(30)36)29(37)33-20-12-21-8-9-22(13-20)34(21)26-10-7-19(15-31-26)27(35)18-5-6-18/h7,10-11,14-15,17-18,20-22,32H,4-6,8-9,12-13H2,1-3H3,(H2,30,36)(H,33,37)",LHGWWAFKVCIILM-UHFFFAOYSA-N,xl888,Phase 1,HSP inhibitor,,,
CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1N=c1nc2c(c[nH]1)N(C)C(=O)c1ccccc1N2C1CCCC1,"InChI=1S/C36H46N8O3/c1-4-47-32-23-25(34(45)43-17-15-26(16-18-43)42-21-19-40(2)20-22-42)13-14-29(32)38-36-37-24-31-33(39-36)44(27-9-5-6-10-27)30-12-8-7-11-28(30)35(46)41(31)3/h7-8,11-14,23-24,26-27H,4-6,9-10,15-22H2,1-3H3,(H,37,38,39)",XVBGRTMNFNMINE-UHFFFAOYSA-N,xmd17-109,Preclinical,MAP kinase inhibitor,MAPK7,,
CCOc1cc(N2CCC(O)CC2)ccc1N=c1nc2c(c[nH]1)N(C)C(=O)c1ccccc1N2C,"InChI=1S/C26H30N6O3/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29)",QAPAJIZPZGWAND-UHFFFAOYSA-N,xmd8-92,Preclinical,MAP kinase inhibitor,DCLK2|MAPK7|PLK4|TNK1,,
Cc1cccc(C)c1N=C1NCCCS1,"InChI=1S/C12H16N2S/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12/h3,5-6H,4,7-8H2,1-2H3,(H,13,14)",BPICBUSOMSTKRF-UHFFFAOYSA-N,xylazine,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,anesthetic
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,"InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)",HUCJFAOMUPXHDK-UHFFFAOYSA-N,xylometazoline,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,otolaryngology|allergy,nasal congestion|allergic rhinitis
O=C(C(O)CO)C(O)CO,"InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h3-4,6-9H,1-2H2",WXYXERHRDKEISL-UHFFFAOYSA-N,xylose,Launched,,,,
OCC[N+]12CN3CN(CN(C3)C1)C2,"InChI=1S/C8H17N4O/c13-2-1-12-6-9-3-10(7-12)5-11(4-9)8-12/h13H,1-8H2/q+1",SQWGHMPVSMSPNY-UHFFFAOYSA-N,y-11,Preclinical,focal adhesion kinase inhibitor,PTK2,,
CC(C)N1CCN(c2ccc(C(=O)c3c(-c4ccc(O)cc4)sc4cc(O)ccc34)cc2)CC1,"InChI=1S/C28H28N2O3S/c1-18(2)29-13-15-30(16-14-29)21-7-3-19(4-8-21)27(33)26-24-12-11-23(32)17-25(24)34-28(26)20-5-9-22(31)10-6-20/h3-12,17-18,31-32H,13-16H2,1-2H3",LQEOPHGPHCWOAC-UHFFFAOYSA-N,y-134,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,
CC(=O)N(O)C1c2cc(C#N)ccc2OC(C)(C)C1O,"InChI=1S/C14H16N2O4/c1-8(17)16(19)12-10-6-9(7-15)4-5-11(10)20-14(2,3)13(12)18/h4-6,12-13,18-19H,1-3H3",IWTCFIIOUXJOOV-UHFFFAOYSA-N,y-26763,Phase 1,potassium channel activator,KCNJ8,,
CC(=O)N(OCc1ccccc1)C1c2cc(C#N)ccc2OC(C)(C)C1O,"InChI=1S/C21H22N2O4/c1-14(24)23(26-13-15-7-5-4-6-8-15)19-17-11-16(12-22)9-10-18(17)27-21(2,3)20(19)25/h4-11,19-20,25H,13H2,1-3H3",RHFUXPCCELGMFC-UHFFFAOYSA-N,y-27152,Phase 1,potassium channel activator,KCNJ8,,
CC(N)C1CCC(C(=O)N=c2cc[nH]cc2)CC1,"InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)",IYOZTVGMEWJPKR-UHFFFAOYSA-N,y-27632,Preclinical,rho associated kinase inhibitor,PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2,,
CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1,"InChI=1S/C23H34N2OS2/c1-18(2)20-14-13-19(22(26)21-12-11-17-27-21)23(24-20)28-16-10-8-6-5-7-9-15-25(3)4/h11-14,17-18H,5-10,15-16H2,1-4H3",HAGHKJDWBDSFKC-UHFFFAOYSA-N,y-29794,Preclinical,prolyl endopeptidase inhibitor,PREP,,
Cc1c(C(=O)Nc2ccc(N3CCC(N4CCOCC4)CC3)c(C#N)c2)cnn1-c1ccc(Cl)cc1,"InChI=1S/C27H29ClN6O2/c1-19-25(18-30-34(19)24-5-2-21(28)3-6-24)27(35)31-22-4-7-26(20(16-22)17-29)33-10-8-23(9-11-33)32-12-14-36-15-13-32/h2-7,16,18,23H,8-15H2,1H3,(H,31,35)",BWZNJVZTAWBIFG-UHFFFAOYSA-N,y-320,Preclinical,interleukin inhibitor,IL17A,,
CC(N)c1ccc(C(=O)N=c2cc[nH]c3[nH]ccc23)cc1,"InChI=1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)",JTVBXQAYBIJXRP-UHFFFAOYSA-N,y-39983,Phase 2,rho associated kinase inhibitor,ROCK1|ROCK2,,
Cc1cccc(COc2cccc(C=C3C(=O)NN(c4ccccc4)C3=O)c2)c1,"InChI=1S/C24H20N2O3/c1-17-7-5-9-19(13-17)16-29-21-12-6-8-18(14-21)15-22-23(27)25-26(24(22)28)20-10-3-2-4-11-20/h2-15H,16H2,1H3,(H,25,27)",ITMLWGWTDWJSRZ-UHFFFAOYSA-N,y16,Preclinical,rho associated kinase inhibitor,RHOA,,
OCc1ccc(-c2nn(Cc3ccccc3)c3ccccc23)o1,"InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2",OQQVFCKUDYMWGV-UHFFFAOYSA-N,yc-1,Preclinical,guanylyl cyclase activator,GUCY1A2|GUCY1A3|GUCY1B3|HIF1A,,
Cc1nc2ccc(Oc3ccc(F)cc3)cc2c(=O)n1CC1CCCN(C(C)C)C1,"InChI=1S/C24H28FN3O2/c1-16(2)27-12-4-5-18(14-27)15-28-17(3)26-23-11-10-21(13-22(23)24(28)29)30-20-8-6-19(25)7-9-20/h6-11,13,16,18H,4-5,12,14-15H2,1-3H3",FRKXOBMDEXCHHD-UHFFFAOYSA-N,yil-781,Preclinical,ghrelin receptor antagonist,GHSR,,
COc1ccc(C(=O)CC2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)cc1,"InChI=1S/C17H13Cl2NO4/c1-24-10-4-2-9(3-5-10)13(21)8-17(23)14-11(18)6-7-12(19)15(14)20-16(17)22/h2-7,23H,8H2,1H3,(H,20,22)",HLXSCTYHLQHQDJ-UHFFFAOYSA-N,yk-4-279,Preclinical,apoptosis inhibitor,EWSR1|FLI1,,
O=c1ccccn1CC1(O)CCN(Cc2ccccc2)CC1,"InChI=1S/C18H22N2O2/c21-17-8-4-5-11-20(17)15-18(22)9-12-19(13-10-18)14-16-6-2-1-3-7-16/h1-8,11,22H,9-10,12-15H2",BGMVOROUOUVVRV-UHFFFAOYSA-N,yl0919,Preclinical,selective serotonin reuptake inhibitor (SSRI),,,
Cc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,"InChI=1S/C32H28N4O3/c1-21-11-10-15-24(19-21)33-32(39)35-30-31(38)36(20-28(37)25-16-7-6-12-22(25)2)27-18-9-8-17-26(27)29(34-30)23-13-4-3-5-14-23/h3-19,30H,20H2,1-2H3,(H2,33,35,39)",YCXFHPUBGMMWJQ-UHFFFAOYSA-N,ym-022,Phase 2,CCK receptor antagonist,CCKBR,,
COCCn1c2c([n+](Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O,"InChI=1S/C20H19N4O3/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25/h3-8,11H,9-10,12H2,1-2H3/q+1",OTSOOHRUMBRSHZ-UHFFFAOYSA-N,ym-155,Phase 2,survivin inhibitor,BIRC5,,
N=c1ccc(C(=O)Nc2cccc(-c3nc(N4CCOCC4)c4oc5ncccc5c4n3)c2)c[nH]1,"InChI=1S/C25H21N7O3/c26-19-7-6-16(14-28-19)24(33)29-17-4-1-3-15(13-17)22-30-20-18-5-2-8-27-25(18)35-21(20)23(31-22)32-9-11-34-12-10-32/h1-8,13-14H,9-12H2,(H2,26,28)(H,29,33)",YBPIBGNBHHGLEB-UHFFFAOYSA-N,ym-201636,Preclinical,PI3K inhibitor,,,
Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1,"InChI=1S/C26H22FN3O3/c27-21-5-1-4-19(13-21)17-32-23-8-10-24(11-9-23)33-25-12-7-20(16-29-25)26(31)30-15-18-3-2-6-22(28)14-18/h1-14,16H,15,17,28H2,(H,30,31)",JZMLHJRKSJXARY-UHFFFAOYSA-N,ym-244769,Preclinical,sodium/calcium exchange inhibitor,,,
Cc1c(C(=O)N(C)C2CCCCC2)sc2nc3ccc(N)cc3n12,"InChI=1S/C18H22N4OS/c1-11-16(17(23)21(2)13-6-4-3-5-7-13)24-18-20-14-9-8-12(19)10-15(14)22(11)18/h8-10,13H,3-7,19H2,1-2H3",KCBXOMYXOBVLED-UHFFFAOYSA-N,ym-298198,Preclinical,glutamate receptor antagonist,GRM1,,
Cc1c(C(=O)NC2CCCCC2)sc2nc3ccc(N)cc3n12,"InChI=1S/C17H20N4OS/c1-10-15(16(22)19-12-5-3-2-4-6-12)23-17-20-13-8-7-11(18)9-14(13)21(10)17/h7-9,12H,2-6,18H2,1H3,(H,19,22)",VWOMTTIMBHBPBI-UHFFFAOYSA-N,ym-298198-desmethyl,Preclinical,glutamate receptor antagonist,GRM1,,
N#Cc1ccc(N(Cc2ccc(Br)cc2)n2cnnc2)cc1,"InChI=1S/C16H12BrN5/c17-15-5-1-14(2-6-15)10-22(21-11-19-20-12-21)16-7-3-13(9-18)4-8-16/h1-8,11-12H,10H2",GGPPBTSXFROGAE-UHFFFAOYSA-N,ym-511,Phase 2,aromatase inhibitor,CYP19A1,,
Cc1nnsc1C(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2C(F)(F)F)cc1,"InChI=1S/C15H9F6N5OS/c1-7-12(28-25-23-7)13(27)22-8-2-4-9(5-3-8)26-11(15(19,20)21)6-10(24-26)14(16,17)18/h2-6H,1H3,(H,22,27)",XPRZIORDEVHURQ-UHFFFAOYSA-N,ym-58483,Preclinical,calcium channel blocker,TRPC3|TRPC5|TRPM4,,
Cc1cc(C)c(NC(=O)N(Cc2ccc3c(c2)Cc2ccccc2-3)C2CCCCCC2)c(C)c1,"InChI=1S/C31H36N2O/c1-21-16-22(2)30(23(3)17-21)32-31(34)33(27-11-6-4-5-7-12-27)20-24-14-15-29-26(18-24)19-25-10-8-9-13-28(25)29/h8-10,13-18,27H,4-7,11-12,19-20H2,1-3H3,(H,32,34)",FMLJREWZCZHGGW-UHFFFAOYSA-N,ym-750,Phase 1,ACAT inhibitor,SOAT1,,
COc1cc2c(cc1OC)-c1cc3nc4ccccc4nc3n1C(C)(C)C2,"InChI=1S/C22H21N3O2/c1-22(2)12-13-9-19(26-3)20(27-4)10-14(13)18-11-17-21(25(18)22)24-16-8-6-5-7-15(16)23-17/h5-11H,12H2,1-4H3",HIXSPVQXXDULHS-UHFFFAOYSA-N,ym-90709,Preclinical,IL5 inhibitor,CSF2RB|IL5RA,,
CCc1ccc2c(-c3cccc(Cl)c3)nc(=O)n(CC)c2n1,"InChI=1S/C17H16ClN3O/c1-3-13-8-9-14-15(11-6-5-7-12(18)10-11)20-17(22)21(4-2)16(14)19-13/h5-10H,3-4H2,1-2H3",MNHXYNNKDDXKNP-UHFFFAOYSA-N,ym-976,Phase 1,phosphodiesterase inhibitor,PDE4A,,
CC(NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC1C(=O)N(C)c2ccccc2-c2ccccc21,"InChI=1S/C26H23F2N3O3/c1-15(29-23(32)13-16-11-17(27)14-18(28)12-16)25(33)30-24-21-9-4-3-7-19(21)20-8-5-6-10-22(20)31(2)26(24)34/h3-12,14-15,24H,13H2,1-2H3,(H,29,32)(H,30,33)",QSHGISMANBKLQL-UHFFFAOYSA-N,yo-01027,Preclinical,gamma secretase inhibitor,,,
Clc1cccc(Cl)c1CSc1nnc(-c2cnccn2)s1,"InChI=1S/C13H8Cl2N4S2/c14-9-2-1-3-10(15)8(9)7-20-13-19-18-12(21-13)11-6-16-4-5-17-11/h1-6H,7H2",BQNXBSYSQXSXPT-UHFFFAOYSA-N,yoda-1,Preclinical,piezo channel activator,PIEZO1,,
COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,"InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3",BLGXFZZNTVWLAY-UHFFFAOYSA-N,yohimbine,Launched,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8,cardiology,cardiac arrythmia|bradycardia
COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,"InChI=1S/C21H29NO4/c1-22(12-10-16-6-8-18(23-2)20(14-16)25-4)13-11-17-7-9-19(24-3)21(15-17)26-5/h6-9,14-15H,10-13H2,1-5H3",OXZMQFKVNVQMLI-UHFFFAOYSA-N,ys-035,Preclinical,calcium channel blocker,,,
CCOC(=O)C1=C(C)N=C(C)C(C(=O)OCCN2CCCCC2)C1c1cccc([N+](=O)[O-])c1,"InChI=1S/C24H31N3O6/c1-4-32-23(28)20-16(2)25-17(3)21(22(20)18-9-8-10-19(15-18)27(30)31)24(29)33-14-13-26-11-6-5-7-12-26/h8-10,15,21-22H,4-7,11-14H2,1-3H3",WISXRBQDKZPIAN-UHFFFAOYSA-N,ys-201,Preclinical,calcium receptor antagonist,,,
CCOC(=O)c1cc2ccc(O)cc2oc1=O,"InChI=1S/C12H10O5/c1-2-16-11(14)9-5-7-3-4-8(13)6-10(7)17-12(9)15/h3-6,13H,2H2,1H3",IETDBZQIWIJQJG-UHFFFAOYSA-N,yz9,Preclinical,phosphofructokinase inhibitor,MIF|PFKFB3,,
O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1,"InChI=1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2",VCPMZDWBEWTGNW-UHFFFAOYSA-N,z160,Phase 2,N-type calcium channel blocker,CACNA2D1,,
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,"InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)",YEEZWCHGZNKEEK-UHFFFAOYSA-N,zafirlukast,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2,pulmonary,asthma
N=c1ccn(C2CCC(CO)O2)c(=O)[nH]1,"InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)",WREGKURFCTUGRC-UHFFFAOYSA-N,zalcitabine,Launched,nucleoside reverse transcriptase inhibitor,,infectious disease,human immunodeficiency virus (HIV-1)
CC1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21,"InChI=1S/C26H28N4O2/c1-26(24-11-6-14-29(24)22-9-4-2-7-19(22)17-32-26)18-28-15-12-20(13-16-28)30-23-10-5-3-8-21(23)27-25(30)31/h2-11,14,20H,12-13,15-18H2,1H3,(H,27,31)",HTGCJAAPDHZCHL-UHFFFAOYSA-N,zaldaride,Phase 3,calmodulin antagonist,CALM1,,
Cc1nc(-c2csc(=NC(=N)N)[nH]2)c[nH]1,"InChI=1S/C8H10N6S/c1-4-11-2-5(12-4)6-3-15-8(13-6)14-7(9)10/h2-3H,1H3,(H,11,12)(H4,9,10,13,14)",GIMNAEMRNXUAQP-UHFFFAOYSA-N,zaltidine,Phase 3,histamine receptor antagonist,HRH2,,
CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,"InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)",MUXFZBHBYYYLTH-UHFFFAOYSA-N,zaltoprofen,Launched,cyclooxygenase inhibitor,,endocrinology|neurology/psychiatry,fever|pain relief
CCC(O)=NO,"InChI=1S/C3H7NO2/c1-2-3(5)4-6/h6H,2H2,1H3,(H,4,5)",RSIPQHOWTCNEBI-UHFFFAOYSA-N,zami-633,Phase 3,urease inhibitor,,,
c1ccc(C(OC2CCCN(CCc3ccc4c(c3)OCO4)C2)c2ccccc2)cc1,"InChI=1S/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2",BDNFQGRSKSQXRI-UHFFFAOYSA-N,zamifenacin,Phase 3,acetylcholine receptor antagonist,CHRM3,,
CC(=O)Nc1c(C(O)C(O)CO)oc(C(O)O)cc1=NC(N)N,"InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,6,9,11-12,17,19-22H,3,13-14H2,1H3,(H,15,18)",QAJJNWFGGAXZNK-UHFFFAOYSA-N,zanamivir,Launched,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection
C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)",RNOAOAWBMHREKO-UHFFFAOYSA-N,zanubrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,,,
N=C(N)SC=CC(=O)O,"InChI=1S/C4H6N2O2S/c5-4(6)9-2-1-3(7)8/h1-2H,(H3,5,6)(H,7,8)",QEYNZJBVNYDZKZ-UHFFFAOYSA-N,zapa,Preclinical,,,,
CCCOc1ccccc1-c1nc(=O)c2[nH]nnc2[nH]1,"InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)",REZGGXNDEMKIQB-UHFFFAOYSA-N,zaprinast,Phase 2,phosphodiesterase inhibitor,GPR35|PDE1A|PDE4D|PDE5A|PDE9A,,
COc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F,"InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)",HJMQDJPMQIHLPB-UHFFFAOYSA-N,zardaverine,Phase 2,phosphodiesterase inhibitor,PDE4D,,
COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,"InChI=1S/C26H36N2O5/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29/h7-8,15-17H,6,9-14,18H2,1-5H3",KEDQCFRVSHYKLR-UHFFFAOYSA-N,zatebradine,Phase 3,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,
Cc1cc(C)[nH]c(=NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1,"InChI=1S/C21H19BrClN5O4S2/c1-12-9-13(2)25-20(24-12)28-34(30,31)16-6-4-15(5-7-16)26-21(33)27-19(29)11-32-18-8-3-14(22)10-17(18)23/h3-10H,11H2,1-2H3,(H,24,25,28)(H2,26,27,29,33)",XKZDWYDHEBCGCG-UHFFFAOYSA-N,zcl-278,Preclinical,CDC inhibitor,CDC42,,
N#Cc1cccc(C2C=C(C(F)(F)F)N=C3CCCC(=O)C32)c1,"InChI=1S/C17H13F3N2O/c18-17(19,20)15-8-12(11-4-1-3-10(7-11)9-21)16-13(22-15)5-2-6-14(16)23/h1,3-4,7-8,12,16H,2,5-6H2",BULVGMUVVMMGGD-UHFFFAOYSA-N,zd-0947,Preclinical,potassium channel activator,,,
O=C(O)Cc1ccc(OCCNCC(O)c2ccccc2)cc1,"InChI=1S/C18H21NO4/c20-17(15-4-2-1-3-5-15)13-19-10-11-23-16-8-6-14(7-9-16)12-18(21)22/h1-9,17,19-20H,10-13H2,(H,21,22)",SRBPKVWITYPHQR-UHFFFAOYSA-N,zd-2079,Phase 2,adrenergic receptor agonist,ADRB3,,
COCCNC(=O)COc1ccc(OCCNCC(O)COc2ccccc2)cc1,"InChI=1S/C22H30N2O6/c1-27-13-12-24-22(26)17-30-21-9-7-20(8-10-21)28-14-11-23-15-18(25)16-29-19-5-3-2-4-6-19/h2-10,18,23,25H,11-17H2,1H3,(H,24,26)",RVMBDLSFFNKKLG-UHFFFAOYSA-N,zd-7114,Phase 1,adrenergic receptor agonist,ADRB3,,
CCc1cc2c(c(CC)n1)CCC(=O)N2Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,"InChI=1S/C26H26N6O/c1-3-19-15-24-22(23(4-2)27-19)13-14-25(33)32(24)16-17-9-11-18(12-10-17)20-7-5-6-8-21(20)26-28-30-31-29-26/h5-12,15H,3-4,13-14,16H2,1-2H3,(H,28,29,30,31)",BFVNEYDCFJNLGN-UHFFFAOYSA-N,zd-7155,Preclinical,angiotensin receptor antagonist,AGTR1,,
CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1,"InChI=1S/C15H20N4/c1-5-19(13-9-7-6-8-10-13)15-11-14(16-3)18(4)12(2)17-15/h6-11H,5H2,1-4H3",JABSKGQQWUDVRU-UHFFFAOYSA-N,zd-7288,Phase 2,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,
CC(=CCN=c1[nH]cnc2[nH]cnc12)CO,"InChI=1S/C10H13N5O/c1-7(4-16)2-3-11-9-8-10(13-5-12-8)15-6-14-9/h2,5-6,16H,3-4H2,1H3,(H2,11,12,13,14,15)",UZKQTCBAMSWPJD-UHFFFAOYSA-N,zeatin,Phase 1,,,,
O=c1ncccn1C1OC(CO)C(O)C1O,"InChI=1S/C9H12N2O5/c12-4-5-6(13)7(14)8(16-5)11-3-1-2-10-9(11)15/h1-3,5-8,12-14H,4H2",RPQZTTQVRYEKCR-UHFFFAOYSA-N,zebularine,Preclinical,DNA methyltransferase inhibitor,CDA|DNMT1,,
COc1nc(C)c[nH]c1=NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,"InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)",FJHHZXWJVIEFGJ-UHFFFAOYSA-N,zibotentan,Phase 3,endothelin receptor antagonist,EDNRA,,
Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O,"InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)",HBOMLICNUCNMMY-UHFFFAOYSA-N,zidovudine,Launched,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)
CC(c1cc2ccccc2s1)N(O)C(N)=O,"InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)",MWLSOWXNZPKENC-UHFFFAOYSA-N,zileuton,Launched,leukotriene synthesis inhibitor,ALOX5,pulmonary,asthma
CC(c1cc2ccccc2s1)N(O)C(N)=O,"InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)",MWLSOWXNZPKENC-UHFFFAOYSA-N,zileuton,Launched,lipoxygenase inhibitor,ALOX5,pulmonary,asthma
CC(C)NC1CCn2c(=O)[nH]c3cccc(c32)C1O,"InChI=1S/C14H19N3O2/c1-8(2)15-11-6-7-17-12-9(13(11)18)4-3-5-10(12)16-14(17)19/h3-5,8,11,13,15,18H,6-7H2,1-2H3,(H,16,19)",ZSTCZWJCLIRCOJ-UHFFFAOYSA-N,zilpaterol,Launched,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid
CN(C)CC=C(c1ccc(Br)cc1)c1cccnc1,"InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3",OYPPVKRFBIWMSX-UHFFFAOYSA-N,zimelidine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),MAOA|MAOB|SLC6A4,,
C=CCCCCCCCCC(=O)O,"InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)",FRPZMMHWLSIFAZ-UHFFFAOYSA-N,zinc-undecylenate,Launched,other antifungal,,infectious disease,tinea pedis
Cc1cc(N2CCCCC2)nn2cnnc12,"InChI=1S/C11H15N5/c1-9-7-10(15-5-3-2-4-6-15)14-16-8-12-13-11(9)16/h7-8H,2-6H2,1H3",YYHWOTFWBVRTQD-UHFFFAOYSA-N,zindotrine,Phase 2,phosphodiesterase inhibitor,,,
Oc1cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2[nH]1,"InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11-13,23,27H,5-10H2",CARRCRVKWDEWCD-UHFFFAOYSA-N,ziprasidone,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4,neurology/psychiatry,schizophrenia|bipolar disorder
Oc1cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2[nH]1,"InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11-13,23,27H,5-10H2",CARRCRVKWDEWCD-UHFFFAOYSA-N,ziprasidone,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4,neurology/psychiatry,schizophrenia|bipolar disorder
CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,"InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3",REQQVBGILUTQNN-UHFFFAOYSA-N,ziritaxestat,Phase 3,autotaxin inhibitor,,,
CCCCCS(=O)(=O)CCCCCCCCCCn1c(-c2ccc(O)cc2)c(C)c2cc(O)ccc21,"InChI=1S/C30H43NO4S/c1-3-4-12-21-36(34,35)22-13-10-8-6-5-7-9-11-20-31-29-19-18-27(33)23-28(29)24(2)30(31)25-14-16-26(32)17-15-25/h14-19,23,32-33H,3-13,20-22H2,1-2H3",LYJSJVYJLZOMCD-UHFFFAOYSA-N,zk-164015,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,
O=c1[nH]c2cc(C(F)(F)F)c(N3CCOCC3)cc2n(C[PH](=O)(=O)O)c1=O,"InChI=1S/C14H14F3N3O6P/c15-14(16,17)8-5-9-11(6-10(8)19-1-3-26-4-2-19)20(7-27(23,24)25)13(22)12(21)18-9/h5-6H,1-4,7H2,(H,18,21)(H,23,24,25)",IPODDIOOEOCLTA-UHFFFAOYSA-N,zk-200775,Phase 2,kainate receptor antagonist,,,
CC1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,"InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)",XQYASZNUFDVMFH-UHFFFAOYSA-N,zk-811752,Phase 2,CC chemokine receptor antagonist,CCR1,,
CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,"InChI=1S/C23H22N2O4/c1-3-28-23(26)22-18(14-27-2)21-17-11-16(29-13-15-7-5-4-6-8-15)9-10-19(17)25-20(21)12-24-22/h4-12,25H,3,13-14H2,1-2H3",ALBKMJDFBZVHAK-UHFFFAOYSA-N,zk-93423,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,
CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,"InChI=1S/C18H20N2O3/c1-5-22-18(21)17-11(4)15-13(9-19-17)20-12-7-6-8-14(16(12)15)23-10(2)3/h6-10,20H,5H2,1-4H3",VMDUABMKBUKKPG-UHFFFAOYSA-N,zk-93426,Phase 1,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA5,,
CC(C)(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,"InChI=1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)",LQUNNCQSFFKSSK-UHFFFAOYSA-N,zln005,Preclinical,,,,
Cc1ccc(OCCSc2ncccn2)c(Br)c1,"InChI=1S/C13H13BrN2OS/c1-10-3-4-12(11(14)9-10)17-7-8-18-13-15-5-2-6-16-13/h2-6,9H,7-8H2,1H3",KWJRSHZSULRJHE-UHFFFAOYSA-N,zln024,Preclinical,AMPK activator,PRKAA1|PRKAB1|PRKAG1,,
CC(O)(C(=O)Nc1ccc(S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,"InChI=1S/C16H14F3NO4S/c1-15(22,16(17,18)19)14(21)20-11-7-9-13(10-8-11)25(23,24)12-5-3-2-4-6-12/h2-10,22H,1H3,(H,20,21)",LJLXQHHFAKVTNP-UHFFFAOYSA-N,zm-226600,Preclinical,Kir6 channel (KATP) activator,,,
N=c1[nH]c(=NCCc2ccc(O)cc2)nc2[nH]c(-c3ccco3)nn12,"InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)",PWTBZOIUWZOPFT-UHFFFAOYSA-N,zm-241385,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,
COc1cc2[nH]cnc(=Nc3ccc(Cl)cc3F)c2cc1OC,"InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)",YHUIUSRCUKUUQA-UHFFFAOYSA-N,zm-306416,Preclinical,Abl kinase inhibitor,EGFR|FLT1|FLT4|KDR,,
COc1cc2[nH]cnc(=Nc3ccc(Cl)cc3F)c2cc1OC,"InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)",YHUIUSRCUKUUQA-UHFFFAOYSA-N,zm-306416,Preclinical,SRC inhibitor,EGFR|FLT1|FLT4|KDR,,
COc1cc2[nH]cnc(=Nc3ccc(Cl)cc3F)c2cc1OC,"InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)",YHUIUSRCUKUUQA-UHFFFAOYSA-N,zm-306416,Preclinical,VEGFR inhibitor,EGFR|FLT1|FLT4|KDR,,
Cc1cc(F)c(N=c2[nH]cnc3cc(OCc4ccccc4)ccc23)cc1O,"InChI=1S/C22H18FN3O2/c1-14-9-18(23)20(11-21(14)27)26-22-17-8-7-16(10-19(17)24-13-25-22)28-12-15-5-3-2-4-6-15/h2-11,13,27H,12H2,1H3,(H,24,25,26)",NVBNDZZLJRYRPD-UHFFFAOYSA-N,zm-323881,Preclinical,VEGFR inhibitor,KDR,,
Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1,"InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)",PYEFPDQFAZNXLI-UHFFFAOYSA-N,zm-336372,Preclinical,RAF inhibitor,BRAF|LCK|MAPK14|RAF1,,
CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1,"InChI=1S/C23H25NO/c1-18(2)24(17-19-8-4-3-5-9-19)15-14-23(25)22-13-12-20-10-6-7-11-21(20)16-22/h3-13,16,18H,14-15,17H2,1-2H3",JSASWRWALCMOQP-UHFFFAOYSA-N,zm-39923,Preclinical,JAK inhibitor,JAK1|JAK3,,
COc1cc2c(=Nc3ccc(NC(=O)c4ccccc4)cc3)[nH]cnc2cc1OCCCN1CCOCC1,"InChI=1S/C29H31N5O4/c1-36-26-18-24-25(19-27(26)38-15-5-12-34-13-16-37-17-14-34)30-20-31-28(24)32-22-8-10-23(11-9-22)33-29(35)21-6-3-2-4-7-21/h2-4,6-11,18-20H,5,12-17H2,1H3,(H,33,35)(H,30,31,32)",OGNYUTNQZVRGMN-UHFFFAOYSA-N,zm-447439,Preclinical,Aurora kinase inhibitor,AURKA|AURKB,,
CC(CSC(=O)c1ccccc1)C(=O)N1CC(Sc2ccccc2)CC1C(=O)O,"InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)",IAIDUHCBNLFXEF-UHFFFAOYSA-N,zofenopril-calcium,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension
c1cc(CN2CCCCC2)cc(OCCCN=c2[nH]c3ccccc3s2)c1,"InChI=1S/C22H27N3OS/c1-4-13-25(14-5-1)17-18-8-6-9-19(16-18)26-15-7-12-23-22-24-20-10-2-3-11-21(20)27-22/h2-3,6,8-11,16H,1,4-5,7,12-15,17H2,(H,23,24)",KUBONGDXTUOOLM-UHFFFAOYSA-N,zolantidine,Preclinical,histamine receptor antagonist,,,
O=[PH](=O)(O)C(O)(Cn1ccnc1)[PH](=O)(=O)O,"InChI=1S/C5H8N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H,9,10,11)(H,12,13,14)",VVTFUCQBNYYCPM-UHFFFAOYSA-N,zoledronic-acid,Launched,bone resorption inhibitor,FDPS|GGPS1,endocrinology,Paget's disease
CC1CN2c3c(cc4c(N5C(=O)OCC5C)noc4c3F)CC3(C(=O)NC(=O)NC3=O)C2C(C)O1,"InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)",ZSWMIFNWDQEXDT-UHFFFAOYSA-N,zoliflodacin,Phase 3,antibacterial ,,,
CS(=O)(=O)c1ccc(-c2cn3ccccc3n2)cc1,"InChI=1S/C14H12N2O2S/c1-19(17,18)12-7-5-11(6-8-12)13-10-16-9-3-2-4-14(16)15-13/h2-10H,1H3",VSLIUWLPFRVCDL-UHFFFAOYSA-N,zolimidine,Launched,mucus protecting agent,,gastroenterology,peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)
CN(C)CCc1c[nH]c2ccc(CC3COC(=O)N3)cc12,"InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)",ULSDMUVEXKOYBU-UHFFFAOYSA-N,zolmitriptan,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache
Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,"InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)",ZXVNMYWKKDOREA-UHFFFAOYSA-N,zomepirac,Withdrawn,prostaglandin synthesis inhibitor,PTGDR2,,
Cc1nn(C)c2c1=C(c1cccc(Cl)c1)NCCN=2,"InChI=1S/C14H15ClN4/c1-9-12-13(10-4-3-5-11(15)8-10)16-6-7-17-14(12)19(2)18-9/h3-5,8,16H,6-7H2,1-2H3",HDKFLYGGZYBXNN-UHFFFAOYSA-N,zometapine,Phase 2,,,,
N=C(N)NC(=O)c1cnn(-c2cccc3ncccc23)c1C1CC1,"InChI=1S/C17H16N6O/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13/h1-5,8-10H,6-7H2,(H4,18,19,22,24)",GDXBRVCQGGKXJY-UHFFFAOYSA-N,zoniporide,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,
NS(=O)(=O)Cc1noc2ccccc12,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",UBQNRHZMVUUOMG-UHFFFAOYSA-N,zonisamide,Launched,sodium channel blocker,CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures|epilepsy
NS(=O)(=O)Cc1noc2ccccc12,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",UBQNRHZMVUUOMG-UHFFFAOYSA-N,zonisamide,Launched,T-type calcium channel blocker,CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures|epilepsy
O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2ccccc12,"InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)",BCSVCWVQNOXFGL-UHFFFAOYSA-N,zopolrestat,Phase 2,,AKR1B1|AKR1B10,,
OC(COc1cccc2ncccc12)CN1CCN(C2c3ccccc3C3C(c4ccccc42)C3(F)F)CC1,"InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2",IHOVFYSQUDPMCN-UHFFFAOYSA-N,zosuquidar,Phase 3,P glycoprotein inhibitor,ABCB1|ABCB4,,
COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(n3cnnn3)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C,"InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,34-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3",UOZZDEYFDFKHQS-UHFFFAOYSA-N,zotarolimus,Launched,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,"InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3",HDOZVRUNCMBHFH-UHFFFAOYSA-N,zotepine,Launched,dopamine receptor antagonist,ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4,neurology/psychiatry,schizophrenia
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,"InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3",HDOZVRUNCMBHFH-UHFFFAOYSA-N,zotepine,Launched,serotonin receptor antagonist,ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4,neurology/psychiatry,schizophrenia
N=c1[nH]c2cc(Cl)ccc2o1,"InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)",YGCODSQDUUUKIV-UHFFFAOYSA-N,zoxazolamine,Phase 2,myorelaxant,,,
O=C1N=C2C=CC=CN2C12Cc1ccccc1C2,"InChI=1S/C15H12N2O/c18-14-15(17-8-4-3-7-13(17)16-14)9-11-5-1-2-6-12(11)10-15/h1-8H,9-10H2",QZWYXEBIQWJXAR-UHFFFAOYSA-N,zset1446,Preclinical,nicotinic receptor agonist,,,
FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,"InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2",HGVNLRPZOWWDKD-UHFFFAOYSA-N,zstk-474,Phase 1/Phase 2,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,
OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(Cl)cc32)CC1,"InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2",WFPIAZLQTJBIFN-UHFFFAOYSA-N,zuclopenthixol,Launched,dopamine receptor antagonist,ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder
CC1(O)CCC2C(CCC3C2CCC2(C)C(C(=O)Cn4cc(C#N)cn4)CCC32)C1,"InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3",HARRKNSQXBRBGZ-UHFFFAOYSA-N,zuranolone,Phase 3,GABA receptor agonist,,,
